<SEC-DOCUMENT>0001121404-24-000016.txt : 20240725
<SEC-HEADER>0001121404-24-000016.hdr.sgml : 20240725
<ACCEPTANCE-DATETIME>20240725102648
ACCESSION NUMBER:		0001121404-24-000016
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		122
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240725
DATE AS OF CHANGE:		20240725

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		241140327

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>sny-20240630.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a012fc2d-d3ff-4c6a-950e-09cafe0bb60f,g:e711d38b-47f1-4329-bc58-181a62b743af,d:3d5998289d7f47c8af486862bada0cec-->
<html xmlns:srt="http://fasb.org/srt/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:sny="http://www.sanofi.com/20240630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sny-20240630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-3">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-4">0001121404</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-5">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-month-day-year" id="f-6">6/30/2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-7">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-8">Q2</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sny-20240630.xsd"/></ix:references><ix:resources><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="eurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="proceeding"><xbrli:measure>sny:proceeding</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>sny:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-07</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-07</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-07</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-07</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:TR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AssetsAcquisitionAxis">sny:AssetsAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AssetsAcquisitionAxis">sny:AssetsAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:OtherIntangibleAssetsExcludingSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:NovavaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:VaccinesCoExclusiveLicensingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:OtherIntangibleAssetsExcludingSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-10</xbrli:startDate><xbrli:endDate>2024-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:MCMVaccineBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:ShareProgramAxis">sny:ShareRepurchase2023ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-25</xbrli:startDate><xbrli:endDate>2023-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:ShareProgramAxis">sny:ShareRepurchase2023ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:ShareProgramAxis">sny:ShareRepurchase2024ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-30</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithoutMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sny:ExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sny:ExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024AdditionalSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:EquityInstrumentsIncludedInFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:EquityInstrumentsIncludedInFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:EquityInstrumentsIncludedInFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:ForeignCurrencyTranslationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:ForeignCurrencyTranslationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AmortizedCostNettingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AdjustmentToDebtMeasuredAtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:NonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:NonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondMaturingApril2024Redeemed2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:SyndicatedCreditFacilityOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtMarketValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtMarketValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInCanadianDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInCanadianDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInHungarianFlorintMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInHungarianFlorintMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarUSBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarUSBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ContingentConsiderationArisingFromAcquisitionOfAmunixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ContingentConsiderationArisingFromAcquisitionOfAmunixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ContingentConsiderationArisingFromAcquisitionOfAmunixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:UKZONEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:EUROZONEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:NovavaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-10</xbrli:startDate><xbrli:endDate>2024-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:FulcrumTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-13</xbrli:startDate><xbrli:endDate>2024-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:TaxotereProductLitigationInTheUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:ZantacProductLitigationInTheUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:GoldBondProductLitigationInTheUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:PlavixAttorneyGeneralActionInHawaiiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-22</xbrli:startDate><xbrli:endDate>2024-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:OthersCounterpartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:OthersCounterpartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:OthersCounterpartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:InterestRateAndCurrencyDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:InterestRateAndCurrencyDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:InterestRateAndCurrencyDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaLaunchesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaLaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaLaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaLaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaLaunchesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaLaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaLaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaLaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EnjaymoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EnjaymoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EnjaymoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EnjaymoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EnjaymoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EnjaymoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EnjaymoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EnjaymoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SeasonalSymptomsAndPainReliefMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SeasonalSymptomsAndPainReliefMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:WellnessBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:WellnessBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OthersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OthersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-657"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-659"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-670"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-684"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-698"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CertainWholesalersInTheUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-237 f-238 f-239 f-288 f-289 f-290 f-349 f-350 f-351 f-356 f-357 f-358 f-359 f-360 f-361" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-259 f-260 f-261 f-262" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-392 f-393 f-394" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-3" order="3"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-398 f-399 f-400" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="4"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-407 f-408 f-409" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-5" order="5"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-425 f-426 f-427" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-6" order="6"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-431 f-432 f-433" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-7" order="7"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-437 f-438 f-439" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-8" order="8"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-470 f-471 f-472" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-9" order="9"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-548 f-549 f-550 f-551 f-572 f-573 f-574 f-575" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-10" order="10"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-580 f-581 f-582 f-583" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-11" order="11"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-620 f-621 f-622" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-12" order="12"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-623 f-624 f-625" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-13" order="13"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-626 f-627 f-628" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-14" order="14"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-720" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-15" order="15"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-723 f-727" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-16" order="16"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-725" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-17" order="17"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-814 f-815 f-816" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-18" order="18"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-823 f-824 f-825" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-19" order="19"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-832 f-833 f-834" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-20" order="20"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-863 f-864" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-21" order="21"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-898 f-899 f-900 f-901 f-902" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-22" order="22"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-913" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-23" order="23"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1071" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-24" order="24"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1079" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-25" order="25"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1079" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-26" order="26"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1193 f-1198 f-1203 f-1208 f-1213 f-1218 f-1219 f-1220" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-27" order="27"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1199 f-1200 f-1201 f-1202 f-1203" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-28" order="28"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1236 f-1237 f-1238" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-29" order="29"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1251 f-1256 f-1261" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-30" order="30"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1266 f-1267 f-1268 f-1269 f-1270" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-31" order="31"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1295" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-32" order="32"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1296" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-33" order="33"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1358 f-1359 f-1360" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-34" order="34"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1376 f-1377 f-1378" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-35" order="35"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1379 f-1380 f-1381" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-36" order="36"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1388 f-1389 f-1390" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-37" order="37"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1400 f-1401 f-1402" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-38" order="38"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1436 f-1437 f-1439 f-1440 f-1442 f-1443 f-1445 f-1446 f-1448 f-1449 f-1451 f-1452 f-1454 f-1455" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-39" order="39"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1439 f-1440 f-1441" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-40" order="40"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1442 f-1443 f-1444" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-41" order="41"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1451 f-1452 f-1453" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-42" order="42"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1638 f-1642 f-1646 f-1650 f-1654 f-1658 f-1662 f-1666 f-1670" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-43" order="43"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1674 f-1678 f-1682 f-1686 f-1690 f-1694 f-1698 f-1702 f-1706" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-44" order="44"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1710 f-1714 f-1718 f-1722 f-1726 f-1730 f-1734 f-1738 f-1742" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-45" order="45"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1748 f-1749 f-1750" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-46" order="46"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1751 f-1752 f-1753" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-47" order="47"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1754 f-1755 f-1756" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-48" order="48"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1760 f-1761 f-1762" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-49" order="49"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1763 f-1764 f-1765" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-50" order="50"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1766 f-1767 f-1768" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-51" order="51"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1784 f-1785 f-1786" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-52" order="52"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1793 f-1794 f-1795" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-53" order="53"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-1802 f-1803 f-1804" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-54" order="54"/></ix:resources></ix:header></div><div id="i3d5998289d7f47c8af486862bada0cec_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">6-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE&#160;13a-16&#160;OR&#160;15d-16</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the month of July 2024</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number:&#160;001-31368</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-2">SANOFI</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Translation of registrant&#8217;s name into English)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">46 avenue de la Grande Arm&#233;e &#8211; 75017 Paris</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F&#160;or Form&#160;40-F.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form 20-F&#160;&#160;&#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form&#160;40-F&#160;&#160;&#9744;</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, Sanofi issued the financial statements and half year management report attached hereto as Exhibit 99.1 and 99.2 which are incorporated herein by reference.</span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div id="i3d5998289d7f47c8af486862bada0cec_4"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">2024 HALF-YEAR FINANCIAL REPORT</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"/><td style="width:2.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.368%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.681%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4a7ebb;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#4a7ebb;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#4a7ebb;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3d5998289d7f47c8af486862bada0cec_10">CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#4a7ebb;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CONSOLIDATED BALANCE SHEETS &#8211; ASSETS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CONSOLIDATED BALANCE SHEETS &#8212; SHAREHOLDERS&#8217; EQUITY AND LIABILITIES</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CONSOLIDATED INCOME STATEMENTS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOTES TO THE CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE&#160;30, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INTRODUCTION</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A/ Basis of preparation of the half-year financial statements and accounting policies</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B/ Significant information for the first half of 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C/ Events subsequent to June 30, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4a7ebb;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4a7ebb;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HALF-YEAR MANAGEMENT REPORT</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#4a7ebb;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A/ Significant events of the first half of 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B/ Progress on implementation of the Corporate Social Responsibility strategy</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C/ Events subsequent to June 30, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D/ Consolidated financial statements for the first half of 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E/ Risk factors and related party transactions</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F/ Outlook</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">G/ Appendix &#8211; Research and Development Pipeline</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4a7ebb;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4a7ebb;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">STATUTORY AUDITORS&#8217; REPORT</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#4a7ebb;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4a7ebb;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4a7ebb;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RESPONSIBILITY STATEMENT OF THE CERTIFYING OFFICER &#8211; HALF-YEAR FINANCIAL REPORT</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#4a7ebb;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div><span><br/></span></div><div id="i3d5998289d7f47c8af486862bada0cec_7"></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:60.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed half-year consolidated financial statements for 2024</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 99.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Half-year management report, Statutory Auditors&#8217; Report and Responsibility Statement</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.635%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: July&#160;25, 2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SANOFI</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Alexandra Roger</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexandra Roger</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Head of Securities Law and Capital Markets</span></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>sny-20240630_d2.htm
<DESCRIPTION>EX-99.1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a012fc2d-d3ff-4c6a-950e-09cafe0bb60f,g:e711d38b-47f1-4329-bc58-181a62b743af,d:3ef621f573d04e32b436c2b3b98c6331-->
<html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:sny="http://www.sanofi.com/20240630" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2023" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sny-20240630_d2</title></head><body><div id="i3ef621f573d04e32b436c2b3b98c6331_4"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.403%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:2.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.307%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.942%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">1.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_7">CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_7">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_10">CONSOLIDATED BALANCE SHEETS &#8211; ASSETS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_10">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_13">CONSOLIDATED BALANCE SHEETS &#8212; SHAREHOLDERS&#8217; EQUITY AND LIABILITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_16">CONSOLIDATED INCOME STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_16">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_19">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_22">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_25">CONSOLIDATED STATEMENTS OF CASH FLOWS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_25">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_28">NOTES TO THE CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE&#160;30, </a>2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_28">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_31">INTRODUCTION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_31">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_34">A/ Basis of preparation of the half-year financial statements and accounting policies</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_34">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_37">B/ Significant information for the first half of </a>2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_37">14</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_100">C/ Events subsequent to June 30, </a>2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_100">35</a></span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div></div></div><div id="i3ef621f573d04e32b436c2b3b98c6331_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:3pt double #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:26pt;font-style:italic;font-weight:400;line-height:120%">1. CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_10"></div><div><span><br/></span></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">CONSOLIDATED BALANCE SHEETS &#8211; ASSETS</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:65.313%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Note</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Property, plant and equipment owned</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.2.</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-9">10,264</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-10">10,160</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Right-of-use assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-11">1,616</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-12">1,654</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.3.</span></td><td colspan="2" style="background-color:#E8EAF6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-13">50,080</ix:nonFraction>&#160;</span></td><td style="background-color:#E8EAF6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-14">49,404</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.3.</span></td><td colspan="2" style="background-color:#E8EAF6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-15">26,653</ix:nonFraction>&#160;</span></td><td style="background-color:#E8EAF6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-16">24,319</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.5.</span></td><td colspan="2" style="background-color:#E8EAF6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-17">315</ix:nonFraction>&#160;</span></td><td style="background-color:#E8EAF6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-18">424</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="2" style="background-color:#E8EAF6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-19">3,333</ix:nonFraction>&#160;</span></td><td style="background-color:#E8EAF6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-20">3,218</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current income tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#E8EAF6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentTaxAssetsNoncurrent" scale="6" id="f-21">129</ix:nonFraction>&#160;</span></td><td style="background-color:#E8EAF6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentTaxAssetsNoncurrent" scale="6" id="f-22">188</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#E8EAF6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="f-23">7,284</ix:nonFraction>&#160;</span></td><td style="background-color:#E8EAF6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="f-24">6,427</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-25">99,674</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-26">95,794</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="6" id="f-27">10,609</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="6" id="f-28">9,666</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.7.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-29">8,510</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-30">8,433</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#E8EAF6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-31">3,870</ix:nonFraction>&#160;</span></td><td style="background-color:#E8EAF6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-32">3,455</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current income tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#E8EAF6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentTaxAssetsCurrent" scale="6" id="f-33">295</ix:nonFraction>&#160;</span></td><td style="background-color:#E8EAF6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentTaxAssetsCurrent" scale="6" id="f-34">391</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="2" style="background-color:#E8EAF6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-35">6,795</ix:nonFraction>&#160;</span></td><td style="background-color:#E8EAF6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-36">8,710</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" format="ixt:num-dot-decimal" scale="6" id="f-37">30,079</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" format="ixt:num-dot-decimal" scale="6" id="f-38">30,655</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Assets held for sale or exchange</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" scale="6" id="f-39">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" scale="6" id="f-40">15</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">TOTAL ASSETS</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="6" id="f-41">129,755</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="6" id="f-42">126,464</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accompanying notes on pages</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.883%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_34">10</a></span></div></td></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">to</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.490%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ef621f573d04e32b436c2b3b98c6331_286">34</a></span></div></td></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">are an integral part of the condensed half-year consolidated financial statements. </span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:2.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td></tr></table></div></div></div><div id="i3ef621f573d04e32b436c2b3b98c6331_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">CONSOLIDATED BALANCE SHEETS &#8211; EQUITY AND LIABILITIES</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:64.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Note</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity attributable to equity holders of Sanofi</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:EquityAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-43">72,690</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:EquityAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-44">74,040</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity attributable to non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncontrollingInterests" scale="6" id="f-45">307</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncontrollingInterests" scale="6" id="f-46">313</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-47">72,997</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-48">74,353</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-49">12,503</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-50">14,347</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current lease liabilities </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-51">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-52">1,755</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current liabilities related to business combinations and to non-controlling interests</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.11.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-53">527</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-54">501</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current provisions and other non-current liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.12.</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-55">8,219</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-56">7,602</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current income tax liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-57">1,949</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-58">1,842</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-59">1,800</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-60">1,857</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-61">26,731</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-62">27,904</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="6" id="f-63">7,433</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="6" id="f-64">7,328</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current liabilities related to business combinations and to non-controlling interests</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.11.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-65">201</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-66">208</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current provisions and other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:CurrentProvisionsAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-67">12,746</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:CurrentProvisionsAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-68">13,741</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current income tax liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesCurrent" scale="6" id="f-69">132</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesCurrent" scale="6" id="f-70">597</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current lease liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="f-71">279</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="f-72">275</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-73">9,236</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-74">2,045</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-75">30,027</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-76">24,194</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liabilities related to assets held for sale or exchange</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" scale="6" id="f-78">13</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">TOTAL EQUITY AND LIABILITIES</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-79">129,755</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-80">126,464</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accompanying notes on pages</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.883%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_34">10</a></span></div></td></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">to</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.186%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ef621f573d04e32b436c2b3b98c6331_286">34</a></span></div></td></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">are an integral part of the condensed half-year consolidated financial statements. </span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.251%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">3</span></div></td></tr></table></div></div></div><div id="i3ef621f573d04e32b436c2b3b98c6331_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><div><span><br/></span></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">CONSOLIDATED INCOME STATEMENTS&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:53.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.973%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Note</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31,</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2023</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(12 months)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.20.</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-81">21,209</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-82">20,187</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-83">43,070</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-84">1,289</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-85">1,358</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-86">3,374</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-87">6,849</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-88">6,347</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-89">14,236</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="f-90">15,649</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="f-91">15,198</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="f-92">32,208</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-93">3,423</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-94">3,193</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-95">6,728</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-96">5,260</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-97">5,182</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-98">10,692</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.15.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-99">617</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-100">617</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-101">1,292</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.15.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-102">2,010</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-103">1,422</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-104">3,516</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.3.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-105">1,061</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-106">1,035</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-107">2,172</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.4.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="6" id="f-108">371</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="6" id="f-109">15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="6" id="f-110">896</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.  B.11.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" scale="6" id="f-111">66</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" scale="6" id="f-112">26</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" scale="6" id="f-113">93</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.16.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" format="ixt:num-dot-decimal" scale="6" id="f-114">1,331</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" scale="6" id="f-115">547</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" format="ixt:num-dot-decimal" scale="6" id="f-116">1,490</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.17.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-117">442</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-118">73</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-119">38</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-120">3,044</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-121">4,322</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-122">7,875</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.18.</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-123">586</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-124">370</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-125">1,313</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.18.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-126">281</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-127">286</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-128">591</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-129">2,739</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-130">4,238</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-131">7,153</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.19.</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="f-132">463</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="f-133">730</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-134">1,602</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" scale="6" id="f-135">13</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" scale="6" id="f-136">52</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" scale="6" id="f-137">115</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-138">2,263</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-139">3,456</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-140">5,436</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-141">17</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-142">26</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-143">36</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-144">2,246</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-145">3,430</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-146">5,400</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding (million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.7.</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-147">1,249.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-148">1,249.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-149">1,251.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares after dilution (million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.7.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-150">1,253.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-151">1,254.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-152">1,256.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:31.59pt">Basic earnings per share (in euros)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="sny:BasicEarningsLossPerShareAttributableToOwnersOfParent" scale="0" id="f-153">1.80</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" name="sny:BasicEarningsLossPerShareAttributableToOwnersOfParent" scale="0" id="f-154">2.74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-5" decimals="2" name="sny:BasicEarningsLossPerShareAttributableToOwnersOfParent" scale="0" id="f-155">4.31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:31.59pt">Diluted earnings per share (in euros)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent" scale="0" id="f-156">1.79</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" name="sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent" scale="0" id="f-157">2.73</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-5" decimals="2" name="sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent" scale="0" id="f-158">4.30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accompanying notes on pages</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.883%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_34">10</a></span></div></td></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">to</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.186%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ef621f573d04e32b436c2b3b98c6331_286">34</a></span></div></td></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">are an integral part of the condensed half-year consolidated financial statements. </span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:2.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td></tr></table></div></div></div><div id="i3ef621f573d04e32b436c2b3b98c6331_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><div><span><br/></span></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:51.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.231%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Note</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31,</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2023</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(12 months)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-159">2,263</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-160">3,456</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-161">5,436</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Attributable to equity holders of Sanofi</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-162">2,246</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-163">3,430</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-164">5,400</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Attributable to non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-165">17</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-166">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-167">36</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.95pt">Actuarial gains/(losses)</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-168">235</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-169">141</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-170">171</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.95pt">Change in fair value of equity instruments included in financial assets and financial liabilities</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" scale="6" id="f-171">10</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" scale="6" id="f-172">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" scale="6" id="f-173">97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.95pt">Tax effects</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" scale="6" id="f-174">59</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" scale="6" id="f-175">59</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" scale="6" id="f-176">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Subtotal: items not subsequently reclassifiable to profit or loss (A)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-177">166</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-178">85</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-179">77</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.95pt">Change in fair value of debt instruments included in financial assets</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" scale="6" id="f-180">5</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" scale="6" id="f-181">6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" scale="6" id="f-182">21</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.95pt">Change in fair value of cash flow hedges</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" scale="6" id="f-183">3</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" scale="6" id="f-184">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" scale="6" id="f-185">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.95pt">Change in currency translation differences</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-186">1,040</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-187">1,057</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-188">1,540</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.95pt">Tax effects</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" scale="6" id="f-189">35</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" scale="6" id="f-190">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" scale="6" id="f-191">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Subtotal: items subsequently reclassifiable to profit or loss (B)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-192">1,067</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-193">1,058</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-194">1,526</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income for the period, net of taxes (A+B)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-195">1,233</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-196">973</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-197">1,603</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Comprehensive income</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-198">3,496</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-199">2,483</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-200">3,833</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Attributable to equity holders of Sanofi</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-201">3,471</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-202">2,465</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-203">3,810</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Attributable to non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" scale="6" id="f-204">25</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" scale="6" id="f-205">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" scale="6" id="f-206">23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accompanying notes on pages</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.883%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_34">10</a></span></div></td></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">to</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.186%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ef621f573d04e32b436c2b3b98c6331_286">34</a></span></div></td></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">are an integral part of the condensed half-year consolidated financial statements. </span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.251%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5</span></div></td></tr></table></div></div></div><div id="i3ef621f573d04e32b436c2b3b98c6331_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><div><span><br/></span></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:22.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.866%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.200%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Share capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Reserves and retained earnings</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Stock options and other share-based payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Attribut-able to equity holders of Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Attribut-able to non-controlling interests</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at January 1, 2023</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-207">2,522</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-208">125</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" sign="-" name="ifrs-full:Equity" scale="6" id="f-209">706</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-210">66,734</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-211">4,658</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-11" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-212">1,451</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-213">74,784</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-214">368</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-215">75,152</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income for the period</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-216">85</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-217">1,050</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-218">965</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-18" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-219">8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-220">973</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income for the period</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-221">3,430</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-222">3,430</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-18" decimals="-6" name="ifrs-full:ProfitLoss" scale="6" id="f-223">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-224">3,456</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Comprehensive income for the period</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-225">3,515</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-226">1,050</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-227">2,465</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-18" decimals="-6" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-228">18</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-229">2,483</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividend paid out of 2022 earnings (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="INF" name="ifrs-full:DividendsPaidOrdinarySharesPerShare" scale="0" id="f-230">3.56</ix:nonFraction> per share)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-231">4,454</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-232">4,454</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-233">4,454</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payment of dividends to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" format="ixt:fixed-zero" scale="6" id="f-234">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-18" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-235">49</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-236">49</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share repurchase program </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-19" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-237">363</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-238">363</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-239">363</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based payment plans:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.95pt">Exercise of stock options</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-20" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:fixed-zero" scale="6" id="f-240">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-21" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-241">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-242">18</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-243">18</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.95pt">Issuance of restricted shares and  vesting of existing restricted shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-20" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-244">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-21" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-245">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-19" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-246">112</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-247">112</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-248">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-249">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.95pt">Value of services obtained from employees</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-250">160</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-251">160</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-252">160</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.95pt">Tax effects of share-based payments</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-253">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-254">8</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-255">8</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other changes arising from issuance of restricted shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-256">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-257">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-258">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" scale="6" id="f-259">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" scale="6" id="f-260">9</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-18" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" scale="6" id="f-261">19</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" scale="6" id="f-262">10</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at June 30, 2023 </span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-23" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-263">2,525</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-24" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-264">140</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-25" decimals="-6" sign="-" name="ifrs-full:Equity" scale="6" id="f-265">957</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-26" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-266">65,694</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-27" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-267">4,826</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-28" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-268">401</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-29" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-269">72,629</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-30" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-270">318</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-271">72,947</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income for the period</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-32" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-272">162</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-273">463</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-274">625</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-275">5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-276">630</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income for the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-32" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-277">1,970</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-278">1,970</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:ProfitLoss" scale="6" id="f-279">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-280">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Comprehensive income for the period</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-32" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-281">1,808</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" sign="-" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-282">463</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-283">1,345</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-284">5</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-285">1,350</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payment of dividends to non-controlling interests</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-286">10</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-287">10</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share repurchase program </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-37" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-288">230</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-289">230</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-290">230</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based payment plans:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.95pt">Exercise of stock options</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-291">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-39" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-292">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-293">19</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-294">19</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.95pt">Issuance of restricted shares and  vesting of existing restricted shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-40" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-295">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-41" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-296">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-42" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-297">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-43" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-298">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-44" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-299">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.95pt">Employee share ownership plan</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-300">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-39" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-301">155</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-302">159</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-303">159</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.95pt">Value of services obtained from employees</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-45" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-304">123</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-305">123</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-306">123</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.61pt">Tax effects of share-based payments</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-45" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-307">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-308">5</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-309">5</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance&#160;at&#160;December&#160;31,&#160;</span></div><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-46" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-310">2,530</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-47" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-311">313</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-6" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-312">1,184</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-49" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-313">67,499</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-314">4,944</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-51" decimals="-6" sign="-" name="ifrs-full:Equity" scale="6" id="f-315">62</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-52" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-316">74,040</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-317">313</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-318">74,353</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;padding-left:14.2pt;text-align:justify;text-indent:-14.2pt"><span><br/></span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:2.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">6</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><div><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:-0.01pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.084%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.211%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.232%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.099%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Share capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Reserves and retained earnings</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Stock options and other share-based payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Attribut-able to equity holders of Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Attribut-able to non-controlling interests</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at January 1, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-46" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-319">2,530</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-47" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-320">313</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-6" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-321">1,184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-49" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-322">67,499</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-323">4,944</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-51" decimals="-6" sign="-" name="ifrs-full:Equity" scale="6" id="f-324">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-52" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-325">74,040</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-326">313</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-327">74,353</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income for the period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-54" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-328">166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-329">1,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-330">1,225</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-57" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-331">8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-332">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income for the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-54" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-333">2,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-334">2,246</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-57" decimals="-6" name="ifrs-full:ProfitLoss" scale="6" id="f-335">17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-336">2,263</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Comprehensive income for the period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-54" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-337">2,412</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-338">1,059</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-339">3,471</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-57" decimals="-6" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-340">25</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-341">3,496</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividend paid out of 2023 earnings (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="INF" name="ifrs-full:DividendsPaidOrdinarySharesPerShare" scale="0" id="f-342">3.76</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-54" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-343">4,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-344">4,704</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-345">4,704</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payment of dividends to non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" format="ixt:fixed-zero" scale="6" id="f-346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-57" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-347">31</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-348">31</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share repurchase program </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-58" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-349">302</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-350">302</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-351">302</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based payment plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.61pt">Exercise of stock options </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-59" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:fixed-zero" scale="6" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-60" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-353">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-354">7</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-355">7</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.61pt">Issuance of restricted shares and vesting of existing restricted shares </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-59" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-356">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-60" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-357">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-58" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-358">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-54" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-359">115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-360">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.61pt">Value of services obtained from employees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-61" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-362">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-363">173</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-364">173</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.61pt">Tax effects of share-based payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-61" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-365">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-366">4</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-367">4</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other changes arising from issuance of restricted shares </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-54" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-368">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-369">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-370">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at June 30, 2024</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-62" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-371">2,533</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-63" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-372">317</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-64" decimals="-6" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-373">1,371</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-65" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-374">65,093</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-66" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-375">5,121</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-67" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-376">997</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-68" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-377">72,690</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-69" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-378">307</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-379">72,997</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">See Note B.8.2. (for amounts relating to 2023, see Note D.1.5.4. to the consolidated financial statements for the year ended December 31, 2023).</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><ix:footnote id="fn-2" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line mainly comprises the impact on non-controlling interests arising from divestments and acquisitions.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accompanying notes on pages</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.883%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3ef621f573d04e32b436c2b3b98c6331_34">10</a></span></div></td></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">to</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.186%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ef621f573d04e32b436c2b3b98c6331_286">34</a></span></div></td></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">are an integral part of the condensed half-year consolidated financial statements. </span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.251%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">7</span></div></td></tr></table></div></div></div><div id="i3ef621f573d04e32b436c2b3b98c6331_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><div><span><br/></span></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:51.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.125%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Note</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" format="ixt:num-dot-decimal" scale="6" id="f-380">2,246</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" format="ixt:num-dot-decimal" scale="6" id="f-381">3,430</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" format="ixt:num-dot-decimal" scale="6" id="f-382">5,400</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-383">17</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-384">26</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-385">36</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of undistributed earnings from investments accounted for using the equity method</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" scale="6" id="f-386">110</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" scale="6" id="f-387">196</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" scale="6" id="f-388">295</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" format="ixt:num-dot-decimal" scale="6" id="f-389">1,445</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" format="ixt:num-dot-decimal" scale="6" id="f-390">1,838</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" format="ixt:num-dot-decimal" scale="6" id="f-391">4,792</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains and losses on disposals of non-current assets, net of tax </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="6" id="f-392">279</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="6" id="f-393">307</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="6" id="f-394">509</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in deferred taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDeferredTaxExpense" scale="6" id="f-395">780</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDeferredTaxExpense" scale="6" id="f-396">446</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDeferredTaxExpense" scale="6" id="f-397">970</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in non-current provisions and other non-current liabilities </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-398">1,087</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" scale="6" id="f-399">716</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" scale="6" id="f-400">136</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of employee benefits (stock options and other share-based payments)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="6" id="f-401">173</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="6" id="f-402">160</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="6" id="f-403">283</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of the workdown of acquired inventories remeasured at fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" scale="6" id="f-404">19</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" scale="6" id="f-405">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" scale="6" id="f-406">20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other profit or loss items with no cash effect on cash flows generated </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">by operating activities </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" scale="6" id="f-407">26</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" scale="6" id="f-408">196</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" scale="6" id="f-409">283</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Operating cash flow before changes in working capital</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="6" id="f-410">4,064</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="6" id="f-411">4,382</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="6" id="f-412">9,494</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Increase)/decrease in inventories</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="6" id="f-413">886</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="f-414">1,174</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="6" id="f-415">840</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Increase)/decrease in accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="6" id="f-416">14</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="6" id="f-417">215</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="6" id="f-418">397</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increase/(decrease) in accounts payable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="6" id="f-419">82</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="6" id="f-420">497</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="6" id="f-421">402</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in other current assets and other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-422">1,851</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" scale="6" id="f-423">73</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-424">1,599</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net cash provided by/(used in) operating activities </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-425">1,423</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-426">3,563</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-427">10,258</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment and intangible assets</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.2. - B.3.</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-428">1,886</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" scale="6" id="f-429">930</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-430">3,024</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (e)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.1.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-431">1,885</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-432">2,465</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-433">3,870</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other equity investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" scale="6" id="f-434">208</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" scale="6" id="f-435">56</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" scale="6" id="f-436">134</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" scale="6" id="f-437">607</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" scale="6" id="f-438">578</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-439">1,015</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals of consolidated undertakings and investments accounted for using the equity method </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="6" id="f-440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" scale="6" id="f-441">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" scale="6" id="f-442">42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in other non-current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:NetChangeInOtherNonCurrentAssets" scale="6" id="f-443">41</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:NetChangeInOtherNonCurrentAssets" scale="6" id="f-444">215</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="sny:NetChangeInOtherNonCurrentAssets" scale="6" id="f-445">229</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net cash provided by/(used in) investing activities</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-446">3,413</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-447">3,073</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-448">6,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Sanofi shares</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.1.</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="f-449">21</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="f-450">31</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="f-451">195</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends paid:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:14.17pt;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:12.12pt">&#160;&#160;to equity holders of Sanofi</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-452">4,704</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-453">4,454</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-454">4,454</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.95pt">to non-controlling interests</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" scale="6" id="f-455">31</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" scale="6" id="f-456">49</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" scale="6" id="f-457">61</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments received/(made) on changes of ownership interest in a subsidiary without loss of control</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries" format="ixt:fixed-zero" scale="6" id="f-458">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries" scale="6" id="f-459">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries" scale="6" id="f-460">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional long-term debt contracted</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.1.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProceedsFromNoncurrentBorrowings" format="ixt:fixed-zero" scale="6" id="f-461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProceedsFromNoncurrentBorrowings" format="ixt:fixed-zero" scale="6" id="f-462">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ProceedsFromNoncurrentBorrowings" scale="6" id="f-463">48</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.1.</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" scale="6" id="f-464">637</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-465">2,680</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-466">3,684</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repayment of lease liabilities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="6" id="f-467">144</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="6" id="f-468">127</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="6" id="f-469">265</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in short-term debt and other financial instruments </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-470">5,886</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-471">2,431</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" scale="6" id="f-472">765</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of treasury shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.2</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" scale="6" id="f-473">302</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" scale="6" id="f-474">363</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" scale="6" id="f-475">593</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net cash provided by/(used in) financing activities</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="6" id="f-476">89</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-477">5,214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-478">8,052</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Impact of exchange rates on cash and cash equivalents</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="6" id="f-479">14</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="6" id="f-480">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="6" id="f-481">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-482">1,915</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-483">4,743</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-484">4,026</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-485">8,710</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-486">12,736</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-487">12,736</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-488">6,795</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-489">7,993</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-490">8,710</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-3" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes non-current financial assets.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><ix:footnote id="fn-4" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line item includes contributions paid to pension funds (see Note B.12.).</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><ix:footnote id="fn-5" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">This line item mainly comprises unrealized foreign exchange gains and losses arising on the remeasurement of monetary items in non-functional currencies and on instruments used to hedge such items.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><ix:footnote id="fn-6" continuedAt="fn-6-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Of which:</span></ix:footnote></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:2.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">8</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:continuation id="fn-6-1"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"><tr><td style="width:1.0%"/><td style="width:59.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.989%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.989%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:14.17pt;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:12.12pt">Income tax paid</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-491">1,434</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-492">1,431</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-493">2,623</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:14.17pt;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:12.12pt">Interest paid</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="6" id="f-494">320</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="6" id="f-495">234</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="6" id="f-496">559</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:14.17pt;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:12.12pt">Interest received</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="6" id="f-497">261</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="6" id="f-498">262</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="6" id="f-499">547</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:14.17pt;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%;padding-left:12.12pt">Dividends received from non-consolidated entities</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" format="ixt:fixed-zero" scale="6" id="f-500">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" scale="6" id="f-501">8</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" scale="6" id="f-502">17</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><ix:footnote id="fn-7" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">For the six months ended June 30, 2024, this line item includes the net cash outflow arising from the acquisition of Inhibrx, Inc. (see Note B.1.1.). For the six months ended June 30, 2023, this line includes the net cash outflow arising from the acquisition of Provention Bio Inc. For the year ended December 31, 2023, it includes the net cash outflow arising from the acquisitions of Provention Bio Inc and QRIB.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)</span><ix:footnote id="fn-8" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt">This line item mainly comprises proceeds from disposals of (i) assets and businesses due to portfolio rationalization, and (ii) equity and debt instruments.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(g)</span><ix:footnote id="fn-9" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">For the six months ended June 30, 2024, this line mainly comprises a commercial paper program in the United States for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-70" decimals="-6" name="sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-503">6,060</ix:nonFraction>&#160;million, compared to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-71" decimals="-6" name="sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-504">2,630</ix:nonFraction> million in the six months ended June 30, 2023 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-72" decimals="-6" name="sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" scale="6" id="f-505">946</ix:nonFraction> million in the year ended December 31, 2023. This line also includes realized foreign exchange gains and losses on cash and cash equivalents in non-functional currencies, mainly the US dollar, and on derivatives used to manage them.</span></ix:footnote></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.251%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">9</span></div></td></tr></table></div></div></div><div id="i3ef621f573d04e32b436c2b3b98c6331_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE&#160;30, 2024 </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10.4pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-5.6pt;vertical-align:baseline">(1)</span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_31"></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="f-506" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">INTRODUCTION</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi, together with its subsidiaries (collectively &#8220;Sanofi&#8221;, &#8220;the Group&#8221; or &#8220;the Company&#8221;), is a global healthcare leader engaged in the research, development and marketing of therapeutic solutions focused on patient needs. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is listed in Paris (Euronext: SAN) and New&#160;York (Nasdaq: SNY). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The condensed consolidated financial statements for the six months ended June 30, 2024 were reviewed by the Sanofi Board of Directors at the Board meeting on July 24, 2024.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_34"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="f-507" continuedAt="f-507-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">A/ BASIS OF PREPARATION OF THE HALF-YEAR FINANCIAL STATEMENTS AND ACCOUNTING POLICIES</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:StatementOfIFRSCompliance" id="f-508" continuedAt="f-508-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.1. INTERNATIONAL FINANCIAL REPORTING STANDARDS (IFRS)</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS 34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2023. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accounting policies used in the preparation of the consolidated financial statements as of June&#160;30,&#160;2024 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2024 are available via the following web link: </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">https://www.efrag.org/Endorsement</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accounting policies applied effective January 1, 2024 are identical to those presented in the consolidated financial statements for the year ended December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On September&#160;22, 2022, the IASB issued an amendment to IFRS&#160;16 (Leases) relating to lease liabilities in a sale-and-leaseback arrangement, which is applicable from January 1, 2024 and had no impact on Sanofi's financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January&#160;23, 2020, the IASB issued &#8220;Classification of Liabilities as Current or Non-current&#8221;, an amendment to IAS&#160;1, and then on&#160;October&#160;31, 2022 issued &#8220;Non-current Liabilities with Covenants&#8221;, a further amendment to IAS&#160;1. The amendments, which are applicable from January&#160;1, 2024, had no impact on Sanofi's financial statements. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May&#160;25, 2023, the IASB issued "Supplier Finance Arrangements", an amendment to IAS&#160;7 and IFRS&#160;7, applicable from January&#160;1, 2024. The </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">amendment relates to disclosures of information about such arrangements; it had no impact on the 2024 half-year financial statements</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As a reminder, in its 2023 consolidated financial statements Sanofi applied &#8220;International Tax Reform &#8211; Pillar Two Model Rules&#8221;, an amendment to&#160;IAS&#160;12 issued by the IASB on May 23, 2023, and did not recognize any deferred tax on temporary differences related to Pillar 2 rules. </span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-508-1">In its 2024 half-year financial statements, Sanofi has used an average effective tax rate that takes into account the top-up tax applicable from January 1, 2024 (see Note B.19.).</ix:continuation> </span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" id="f-509" continuedAt="f-509-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.2. USE OF ESTIMATES</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">impairment of property, plant and equipment and intangible assets;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the valuation of goodwill and the valuation and useful life of acquired intangible assets;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the measurement of contingent consideration receivable in connection with asset divestments and of contingent consideration payable;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the measurement of financial assets and financial liabilities at amortized cost;</span></div></ix:nonNumeric></ix:nonNumeric><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> The Statutory Auditors have conducted a review of these interim financial statements according to French professional standard NEP2410</span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:2.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">10</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:continuation id="f-507-1" continuedAt="f-507-2"><ix:continuation id="f-509-1" continuedAt="f-509-2"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of post-employment benefit obligations;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences.</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actual results could differ from these estimates.</span></div></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-509-2">For half-year financial reporting purposes, and as allowed under IAS 34, Sanofi has determined income tax expense on the basis of an estimate of the effective tax rate for the full financial year. That rate is applied to business operating income plus financial income and minus financial expenses, and before (i) the share of profit/loss of investments accounted for using the equity method and (ii) net income attributable to non-controlling interests. The estimated full-year effective tax rate is based on the tax rates that will be applicable to projected pre-tax profits or losses arising in the various tax jurisdictions in which Sanofi operates.</ix:continuation> </span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" id="f-510" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.3. SEASONAL TRENDS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s activities are not subject to significant seasonal fluctuations.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfHyperinflationaryReportingExplanatory" id="f-511" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.4. CONSOLIDATION AND FOREIGN CURRENCY TRANSLATION OF THE FINANCIAL STATEMENTS OF SUBSIDIARIES IN HYPERINFLATIONARY ECONOMIES</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2024, Sanofi continues to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS&#160;10 (Consolidated Financial Statements) are still met.The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Argentina, the cumulative rate of inflation over the last three years is in excess of <ix:nonFraction unitRef="number" contextRef="c-73" decimals="2" name="sny:CumulativeConsumerPriceInflationRateOverTheLastThreeYears" scale="-2" id="f-512">100</ix:nonFraction>%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since July&#160;1, 2018 treated Argentina as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Turkey, the cumulative rate of inflation over the last three years is in excess of <ix:nonFraction unitRef="number" contextRef="c-74" decimals="2" name="sny:CumulativeConsumerPriceInflationRateOverTheLastThreeYears" scale="-2" id="f-513">100</ix:nonFraction>%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since January&#160;1, 2022 treated Turkey as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" id="f-514" continuedAt="f-514-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.5. FAIR VALUE OF FINANCIAL INSTRUMENTS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 3: valuation techniques in which not all important inputs are derived from observable market data.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.251%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">11</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" id="f-515" escape="true"><ix:continuation id="f-514-1"><ix:continuation id="f-507-2" continuedAt="f-507-3"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"><tr><td style="width:1.0%"/><td style="width:3.161%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.814%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.885%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:0.85pt;padding-right:0.85pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Type of financial</span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:0.85pt;padding-right:0.85pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%">instrument</span></div></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Measurement</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%">principle</span></div></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in fair value hierarchy</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation technique</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation model</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Volatilities</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial assets measured at fair value (quoted equity instruments)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial assets measured at fair value (quoted debt instruments)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial assets measured at fair value (unquoted equity instruments)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost/ Peer comparison (primarily)</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets at fair value (contingent consideration receivable)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2021.<br/></span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial assets measured at fair value held to meet obligations under post-employment benefit plans</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.<br/>B.12.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial Debt</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized cost </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. </span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).</span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Future lease payments are discounted using the incremental borrowing rate.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid Money Market<br/>&gt;&#160;1 year:&#160;Mid Zero Coupon</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures </span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&gt;&#160;1 year: Mid Zero Coupon</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures </span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&gt;&#160;1 year: Mid Zero Coupon</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.11.</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fair value</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div></ix:continuation></ix:continuation></ix:nonNumeric><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:2.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">12</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" id="f-516" escape="true"><ix:continuation id="f-507-3"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.6. NEW PRONOUNCEMENTS ISSUED BY THE IASB AND APPLICABLE FROM 2025</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On August&#160;15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS&#160;21 </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(The Effects of Changes in Foreign Exchange Rates), relating to</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> how to determine the exchange rate when a currency is not exchangeable. The amendment is applicable from January&#160;1, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (subject to endorsement by the European Union); it</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> will not have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027 (subject to endorsement by the European Union). An impact assessment is currently under way. Sanofi will not early adopt this new standard.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments, applicable no earlier than January 1, 2026 (subject to endorsement by the European Union). Sanofi does not expect any material impact, and will not early adopt these amendments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 18, 2024, the IASB issued Volume 11 of &#8220;Annual Improvements to IFRS&#8221;, applicable from January 1, 2026 (subject to endorsement by the European Union). Sanofi does not expect any material impact from those improvements to various standards, which are essentially in the nature of clarifications, and will not early adopt them.</span></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:12pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" xsi:nil="true" name="sny:AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock" id="f-517"/><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.251%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">13</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_37"></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">B/ SIGNIFICANT INFORMATION FOR THE FIRST HALF OF 2024</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_40"></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" id="f-518" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.1. PRINCIPAL CHANGES IN SCOPE OF CONSOLIDATION IN THE PERIOD</span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Inhibrx, Inc.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 30, 2024, Sanofi completed the acquisition of <ix:nonNumeric contextRef="c-1" name="ifrs-full:NameOfAcquiree" id="f-519">Inhibrx, Inc</ix:nonNumeric> (&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Inhibrx&#8221;), adding </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">SAR447537 (formerly INBRX-101) to Sanofi&#8217;s rare disease pipeline. SAR447537 is a human recombinant protein that holds the promise of allowing alpha-1 antitrypsin deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing. AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lungs with progressive tissue deterioration. SAR447537 may help to reduce inflammation and prevent further deterioration of lung function in affected individuals.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The transaction did not meet the criteria for a business combination under IFRS 3, and consequently was accounted for as an acquisition of a group of assets. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition price was $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-6" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="f-520">2,035</ix:nonFraction>&#160;million. Of that amount (plus acquisition-related costs), $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-6" name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-521">1,908</ix:nonFraction>&#160;million was allocated to in-process development in respect of SAR447537, and recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IAS 38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed in the transaction. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, Sanofi awarded the former shareholders of Inhibrx an unquoted, non-negotiable Contingent Value Right (CVR) certificate that entitles them to a deferred cash payment of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-75" decimals="INF" name="sny:AssetsAcquisitionPurchasePricePerShare" scale="0" id="f-522">5.00</ix:nonFraction> per Inhibrx share, subject to attainment of a regulatory milestone before June 30, 2027. The nominal value of that commitment is $<ix:nonFraction unitRef="eur" contextRef="c-75" decimals="-6" name="sny:AssetsAcquisitionNominalValue" format="ixt:num-dot-decimal" scale="6" id="f-523">300</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition, as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows, is a net cash outflow of $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-524">2,035</ix:nonFraction>&#160;million.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_43"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="f-525" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.2. PROPERTY, PLANT AND EQUIPMENT</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" id="f-526" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2024:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:72.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-527">591</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-528">1,693</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biopharma </span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-529">535</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-530">1,592</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;Of which Manufacturing &amp; Supply</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-79" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-531">366</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-80" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-532">1,188</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-533">56</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-534">101</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Of which Manufacturing &amp; Supply</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-83" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-535">41</ix:nonFraction></span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-84" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-536">90</ix:nonFraction></span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:700;line-height:100%">Of which capitalized interest</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:InterestCostsCapitalised" scale="6" id="f-537">22</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:InterestCostsCapitalised" scale="6" id="f-538">26</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Firm orders for property, plant and equipment stood at &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:FirmOrdersOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-539">659</ix:nonFraction>&#160;million as of June 30, 2024.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_46"></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:2.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">14</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory" id="f-540" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.3. GOODWILL AND OTHER INTANGIBLE ASSETS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-541">50,080</ix:nonFraction>&#160;million as of June 30, 2024, versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-542">49,404</ix:nonFraction> million as of December&#160;31, 2023. The movement during the period was mainly due to the impact of changes in exchange rates.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" id="f-543" continuedAt="f-543-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in other intangible assets during the first half of 2024 were as follows:<br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:50.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.058%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.058%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.058%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.059%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Acquired R&amp;D</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Products, trademarks and other rights</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total other intangible assets</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross value at January&#160;1, 2024</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-85" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-544">9,772</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-86" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-545">73,733</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-87" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-546">1,808</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-88" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-547">85,313</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-89" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-548">1,766</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-90" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-549">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-91" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-550">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-92" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-551">1,766</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-89" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-552">571</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-90" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-553">201</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-91" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-554">41</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-92" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-555">813</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-89" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-556">49</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-90" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-557">27</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-91" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-558">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-92" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-559">83</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-89" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-560">236</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-90" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-561">1,050</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-91" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-562">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-92" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-563">1,293</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-89" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-564">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-90" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-565">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-91" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-566">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-92" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-567">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross value at June 30, 2024</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-93" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-568">12,298</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-94" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-569">74,969</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-95" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-570">1,848</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-96" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-571">89,115</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated amortization and impairment at January&#160;1, 2024 </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-97" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-572">3,734</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-98" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-573">55,908</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-99" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-574">1,352</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-100" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-575">60,994</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-101" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-576">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-102" decimals="-6" sign="-" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-577">1,084</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-103" decimals="-6" sign="-" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="6" id="f-578">52</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-104" decimals="-6" sign="-" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-579">1,136</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-101" decimals="-6" sign="-" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="6" id="f-580">13</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-102" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="6" id="f-581">379</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-103" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-582">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-104" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="6" id="f-583">366</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-101" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-584">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-102" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-585">27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-103" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-586">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-104" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-587">82</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-101" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-588">70</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-102" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-589">701</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-103" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-590">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-104" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-591">775</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-101" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-592">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-102" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-593">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-103" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-594">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-104" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-595">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated amortization and impairment at June 30, 2024</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-105" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-596">3,768</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-106" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-597">57,291</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-107" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-598">1,403</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-108" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-599">62,462</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Carrying amount at January&#160;1, 2024</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-109" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-600">6,038</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-110" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-601">17,825</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-111" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-602">456</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-603">24,319</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Carrying amount at June 30, 2024</span></div></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-105" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-604">8,530</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-106" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-605">17,678</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-107" decimals="-6" name="ifrs-full:OtherIntangibleAssets" scale="6" id="f-606">445</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-108" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-607">26,653</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-10" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Impact of the acquisition of Inhibrx, Inc (see Note B.1.).</span></ix:footnote></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><ix:continuation id="f-543-1" continuedAt="f-543-2"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span></ix:continuation><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"><ix:continuation id="f-543-2"><ix:footnote id="fn-11" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Note B.4</ix:footnote>.</ix:continuation> </span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acquisitions of other intangible assets (excluding software) in the first half of 2024 totale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">d &#8364;<ix:nonFraction unitRef="eur" contextRef="c-112" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-608">772</ix:nonFraction> million, including &#8364;<ix:nonFraction unitRef="eur" contextRef="c-113" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-609">463</ix:nonFraction> million&#160;related to the agreements entered into between Sanofi and Novavax in May 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Products, trademarks and other products&#8221; mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">marketed products, with a carrying amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-114" decimals="-8" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="9" id="f-610">16.3</ix:nonFraction> bil</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">lion as of June 30, 2024 (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-115" decimals="-8" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="9" id="f-611">16.6</ix:nonFraction> billion as of December 31, 2023) and a weighted average amortization period of approximately <ix:nonNumeric contextRef="c-116" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-612">11</ix:nonNumeric> years; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">technological platforms brought into service, with a carrying amou</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">nt of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-117" decimals="-8" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="9" id="f-613">1.4</ix:nonFraction> billion as</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">June 30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-118" decimals="-8" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="9" id="f-614">1.2</ix:nonFraction> billion as of December 31, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and a weighted average amortization period of approximately <ix:nonNumeric contextRef="c-119" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-615">18</ix:nonNumeric> years.</span></div></ix:nonNumeric><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_49"></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" id="f-616" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.4. IMPAIRMENT OF INTANGIBLE ASSETS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The monitoring of impairment indicators for other intangible assets led to the recognition of a net reversal of impairment losses amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-120" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-617">366</ix:nonFraction>&#160;million in the first half of 2024, mainly due to an increase in the recoverable amounts of certain marketed products and other rights in the Biopharma segment.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_52"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" id="f-618" continuedAt="f-618-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.5. INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" id="f-619" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2023), and comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:58.684%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.306%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">% interest</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">EUROAPI </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-121" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="f-620">29.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-122" decimals="-6" name="ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod" scale="6" id="f-621">72</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-123" decimals="-6" name="ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod" scale="6" id="f-622">162</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Infraserv GmbH &amp; Co. H&#246;chst KG </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-124" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInJointVenture" scale="-2" id="f-623">31.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-125" decimals="-6" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-624">89</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-126" decimals="-6" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-625">90</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">MSP Vaccine Company </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-127" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInJointVenture" scale="-2" id="f-626">50.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-128" decimals="-6" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-627">90</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-129" decimals="-6" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-628">96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-130" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInJointVenture" format="ixt:fixed-zero" scale="-2" id="f-629">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-131" decimals="-6" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-630">64</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-132" decimals="-6" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-631">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-632">315</ix:nonFraction></span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-633">424</ix:nonFraction></span></td></tr></table></div><ix:footnote id="fn-12" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-133" decimals="INF" name="sny:StockPrice" scale="0" id="f-634">2.55</ix:nonFraction> as of June 30, 2024, and &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-134" decimals="INF" name="sny:StockPrice" format="ixt:num-dot-decimal" id="f-635">5.73</ix:nonFraction> as of December 31, 2023). </span></div></ix:footnote><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><ix:footnote id="fn-13" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Joint venture. </span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"><ix:footnote id="fn-14" footnoteRole="http://www.xbrl.org/2003/role/footnote">Joint venture MSP Vaccine Company owns <ix:nonFraction unitRef="number" contextRef="c-135" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-636">100</ix:nonFraction>% of MCM Vaccine BV</ix:footnote>.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.251%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">15</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:continuation id="f-618-1"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="f-637" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:58.684%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.306%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-136" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions" scale="6" id="f-638">59</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-137" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions" scale="6" id="f-639">64</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-138" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions" scale="6" id="f-640">157</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Royalties and other income</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-136" decimals="-6" name="sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions" scale="6" id="f-641">61</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-137" decimals="-6" name="sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions" scale="6" id="f-642">32</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-138" decimals="-6" name="sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions" scale="6" id="f-643">63</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable and other receivables</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="6" id="f-644">278</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-140" decimals="-6" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="6" id="f-645">213</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-141" decimals="-6" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="6" id="f-646">249</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchases of goods and services</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-136" decimals="-6" name="ifrs-full:PurchasesOfGoodsRelatedPartyTransactions" scale="6" id="f-647">345</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-137" decimals="-6" name="ifrs-full:PurchasesOfGoodsRelatedPartyTransactions" scale="6" id="f-648">302</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-138" decimals="-6" name="ifrs-full:PurchasesOfGoodsRelatedPartyTransactions" scale="6" id="f-649">642</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable and other payables</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="6" id="f-650">63</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-140" decimals="-6" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="6" id="f-651">97</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-141" decimals="-6" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="6" id="f-652">71</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subject to certain conditions, Sanofi could raise its investment in EUROAPI by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:SubordinatedLiabilities" scale="6" id="f-653">200</ix:nonFraction> million in the form of a perpetual subordinated hybrid bond.</span></div></ix:continuation><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_55"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory" id="f-654" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.6. OTHER NON-CURRENT ASSETS</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" id="f-655" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other non-current assets comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:72.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments at fair value through other comprehensive income</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-656">1,161</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-143" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-657">1,088</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments at fair value through other comprehensive income</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-144" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" scale="6" id="f-658">347</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-145" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" scale="6" id="f-659">346</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other financial assets at fair value through profit or loss</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss" scale="6" id="f-660">817</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss" scale="6" id="f-661">808</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pre-funded pension obligations</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:PreFundedPensionObligations" scale="6" id="f-662">325</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:PreFundedPensionObligations" scale="6" id="f-663">271</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term prepaid expenses </span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:LongTermPrepaidExpenses" scale="6" id="f-664">95</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:LongTermPrepaidExpenses" scale="6" id="f-665">114</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables </span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentLoansAndReceivables" scale="6" id="f-666">587</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentLoansAndReceivables" scale="6" id="f-667">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-668">3,333</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-669">3,218</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_58"></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfTradeReceivablesTextBlock" id="f-670" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.7. ACCOUNTS RECEIVABLE</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfCurrentTradeReceivablesTableTextBlock" id="f-671" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accounts receivable break down as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:72.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross value</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-96" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-672">8,602</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-88" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-673">8,528</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Allowances</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-6" name="ifrs-full:CurrentTradeReceivables" scale="6" id="f-674">92</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-147" decimals="-6" name="ifrs-full:CurrentTradeReceivables" scale="6" id="f-675">95</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Carrying amount</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-676">8,510</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-677">8,433</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of allowances against accounts receivable in the first half of 2024 was a net expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" scale="6" id="f-678">3</ix:nonFraction> million (versus a net expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" scale="6" id="f-679">2</ix:nonFraction> million for the first half of 2023).</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOverdueReceivablesGrossValueTableTextBlock" id="f-680" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the ageing profile of overdue accounts receivable, based on gross value:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:27.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.058%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.058%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.058%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.058%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.058%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Overdue accounts gross value</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Overdue by &lt;1 month</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Overdue by 1-3 months</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Overdue by 3-6 months</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Overdue by 6-12 months</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Overdue by    &gt; 12 months</span></td></tr><tr><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2024</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-681">646</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-148" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-682">264</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-149" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-683">105</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-150" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-684">137</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-685">69</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-152" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-686">71</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-687">689</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-153" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-688">269</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-154" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-689">154</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-155" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-690">123</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-156" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-691">62</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-157" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-692">81</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Some Sanofi subsidiaries have assigned receivables to factoring companies or banks without recourse. The amount of receivables that met the conditions described in Note B.8.6. to the consolidated financial statements for the year ended December 31, 2023 and hence were derecognized was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:DerecognizedReceivables" scale="6" id="f-693">503</ix:nonFraction> million as of June&#160;30, 2024 (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:DerecognizedReceivables" scale="6" id="f-694">761</ix:nonFraction> million as of December 31, 2023). The residual guarantees relating to those transfers were immaterial as of June 30, 2024.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_61"></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:2.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">16</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="f-696" continuedAt="f-696-1" escape="true"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="f-695" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.8. CONSOLIDATED SHAREHOLDERS&#8217; EQUITY</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.1. SHARE CAPITAL</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2024, the share capital was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="0" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="0" id="f-697">2,532,725,512</ix:nonFraction> and consisted of <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-698">1,266,362,756</ix:nonFraction> shares (the total number of shares outstanding) with a par value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-2" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-699">2</ix:nonFraction>.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Treasury shares held by Sanofi are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:64.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.074%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Number of shares<br/>(million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">% of share capital<br/>for the period</span></td></tr><tr><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2024</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="-4" name="sny:NumberOfSharesHeld" scale="6" id="f-700">15.33</ix:nonFraction></span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2" decimals="5" name="sny:PercentageOfShareCapitalForThePeriod" scale="-2" id="f-701">1.211</ix:nonFraction></span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-4" name="sny:NumberOfSharesHeld" scale="6" id="f-702">13.45</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-3" decimals="5" name="sny:PercentageOfShareCapitalForThePeriod" scale="-2" id="f-703">1.063</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-4" name="sny:NumberOfSharesHeld" scale="6" id="f-704">10.90</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-31" decimals="5" name="sny:PercentageOfShareCapitalForThePeriod" scale="-2" id="f-705">0.864</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-4" name="sny:NumberOfSharesHeld" scale="6" id="f-706">8.20</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="5" name="sny:PercentageOfShareCapitalForThePeriod" scale="-2" id="f-707">0.650</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A total of <ix:nonFraction unitRef="shares" contextRef="c-158" decimals="INF" name="sny:NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" format="ixt:num-dot-decimal" scale="0" id="f-708">91,355</ix:nonFraction> shares were issued in the first half of 2024 as a result of the exercise of Sanofi stock subscription options.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="sny:NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-709">2,803,637</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> shares </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">vested under Sanofi restricted share plans during the first half of 2024, of which <ix:nonFraction unitRef="shares" contextRef="c-158" decimals="INF" name="sny:NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-710">1,471,432</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;were fulfilled by issuance of new shares and </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="sny:NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-711">1,332,205</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> by allotment of existing shares free of charge</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.2. REPURCHASE OF SANOFI SHARES</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 25, 2023, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of <ix:nonNumeric contextRef="c-159" name="sny:PeriodOfShareRepurchaseProgram" format="ixt-sec:durmonth" id="f-712">18</ix:nonNumeric> months. Under that program, Sanofi repurchased <ix:nonFraction unitRef="shares" contextRef="c-160" decimals="INF" name="sny:NumberOfSharesRepurchased" format="ixt:num-dot-decimal" scale="0" id="f-713">3,215,460</ix:nonFraction> of its own shares during the first half of </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for a total amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-160" decimals="-6" name="sny:AmountOfSharesRepurchased" format="ixt:num-dot-decimal" scale="6" id="f-714">302</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 30, </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of <ix:nonNumeric contextRef="c-161" name="sny:PeriodOfShareRepurchaseProgram" format="ixt-sec:durmonth" id="f-715">18</ix:nonNumeric> months. Sanofi did n</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ot use that authorization during the first half of 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.3. REDUCTIONS IN SHARE CAPITAL</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No decision to cancel treasury shares was made by the Sanofi Board of Directors during the first half of 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.4. RESTRICTED SHARE PLANS</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" id="f-716" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2023. The principal features of the plans awarded in 2024 are set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:81.270%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.169%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Type of plan</span></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Performance share plan</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plan</span></td><td colspan="3" style="background-color:#e8eaf6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total number of shares subject to a <ix:nonNumeric contextRef="c-162" name="sny:NumberOfYearsServicePeriod" format="ixt-sec:duryear" id="f-717">3</ix:nonNumeric>-year service period</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-162" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-718">4,505,145</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with no market condition</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-163" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-719">2,888,502</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-163" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-720">81.84</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with market conditions</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-164" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-721">1,616,643</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded other than to the Chief Executive Officer (<ix:nonFraction unitRef="shares" contextRef="c-165" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-722">1,394,478</ix:nonFraction> shares in total) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-165" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-723">72.79</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fair value per share awarded other than to the Chief Executive Officer (<ix:nonFraction unitRef="shares" contextRef="c-166" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-724">139,665</ix:nonFraction> additional shares) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-166" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-725">13.50</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fair value per share awarded to the Chief Executive Officer (<ix:nonFraction unitRef="shares" contextRef="c-167" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-726">82,500</ix:nonFraction> shares) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-167" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-727">72.38</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value of plan at the date of grant (&#8364; million)</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-162" decimals="-6" name="sny:FairValueOfPlanAtDateOfGrant" scale="6" id="f-728">346</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-15" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.</span></ix:footnote></div><ix:footnote id="fn-16" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</span></div></ix:footnote><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:footnote id="fn-17" footnoteRole="http://www.xbrl.org/2003/role/footnote">(c) Additional tranche subject to a higher level of market conditions</ix:footnote>.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.251%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">17</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:continuation id="f-696-1" continuedAt="f-696-2"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" id="f-729" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:72.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.306%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total expense for restricted share plans (&#8364; million)</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-168" decimals="-6" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-730">128</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-169" decimals="-6" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-731">108</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares not yet fully vested</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-170" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-732">11,192,984</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-171" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-733">10,127,545</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2024 plans</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-172" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-734">4,498,109</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-173" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:fixed-zero" scale="0" id="f-735">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2023 plans</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-174" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-736">3,652,352</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-175" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-737">3,837,974</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2022 plans</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-176" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-738">3,031,060</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-177" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-739">3,226,321</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2021 plans</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-178" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-740">11,463</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-179" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-741">2,996,101</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2020 plans</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-180" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:fixed-zero" scale="0" id="f-742">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-181" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-743">67,149</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.5. CAPITAL INCREASES</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January 31, 2024, the Sanofi Board of Directors approved a capital increase reserved for employees, offering the opportunity for them to subscribe for new Sanofi shares at a price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-182" decimals="2" name="sny:SubscriptionPricePerShare" scale="0" id="f-744">72.87</ix:nonFraction> per share. The subscription period was open from June&#160;4 through June&#160;24, 2024. Sanofi employees subscribed for a total of <ix:nonFraction unitRef="shares" contextRef="c-183" decimals="INF" name="sny:NumberOfSharesSubscribed" format="ixt:num-dot-decimal" scale="0" id="f-745">2,124,445</ix:nonFraction> shares, and this capital increase was supplemented by the immediate issuance of a further <ix:nonFraction unitRef="shares" contextRef="c-183" decimals="INF" name="sny:IssuanceOfFurtherSharesAsAnEmployersContribution" format="ixt:num-dot-decimal" scale="0" id="f-746">119,951</ix:nonFraction> shares for the employer&#8217;s contribution. The total expense recognized for this capital increase in the first half of 2024 was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-184" decimals="-6" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-747">45</ix:nonFraction> million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February&#160;2, 2023, the Sanofi Board of Directors approved a capital increase reserved for employees, offering the opportunity for them to subscribe for new Sanofi shares at a price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-185" decimals="2" name="sny:SubscriptionPricePerShare" scale="0" id="f-748">79.58</ix:nonFraction> per share. The subscription period was open from June&#160;5 through June&#160;23, 2023. Sanofi employees subscribed for a total of <ix:nonFraction unitRef="shares" contextRef="c-186" decimals="INF" name="sny:NumberOfSharesSubscribed" format="ixt:num-dot-decimal" scale="0" id="f-749">2,009,306</ix:nonFraction> shares, and this capital increase was supplemented by the immediate issuance of a further <ix:nonFraction unitRef="shares" contextRef="c-186" decimals="INF" name="sny:IssuanceOfFurtherSharesAsAnEmployersContribution" format="ixt:num-dot-decimal" scale="0" id="f-750">119,417</ix:nonFraction> shares for the employer&#8217;s contribution. The total expense recognized for this capital increase in the first half of 2023 was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-187" decimals="-6" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-751">52</ix:nonFraction> million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.6. STOCK SUBSCRIPTION OPTION PLANS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No stock subscription option plans were awarded in the first half of 2024 or in 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No more expenses have been recognized through equity for stock option plans in either 2024 or 2023.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" id="f-752" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below provides summary information about options outstanding and exercisable as of June&#160;30, 2024:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:31.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.307%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Range of exercise prices per share</span></td><td colspan="9" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr style="height:38pt"><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted average residual life (years)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted average exercise price per share (&#8364;)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted average exercise price per share (&#8364;)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-188" decimals="INF" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-753">60.00</ix:nonFraction> to &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-189" decimals="INF" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-754">70.00</ix:nonFraction> per share</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-190" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-755">168,784</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-191" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-756">3.84</ix:nonNumeric></span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-190" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-757">65.84</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-190" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-758">168,784</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-190" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-759">65.84</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-192" decimals="INF" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-760">70.00</ix:nonFraction> to &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-193" decimals="INF" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-761">80.00</ix:nonFraction> per share</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-194" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-762">478,150</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-195" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-763">3.18</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-194" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-764">76.26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-194" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-765">478,150</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-194" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-766">76.26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-196" decimals="INF" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-767">80.00</ix:nonFraction> to &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-197" decimals="INF" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-768">90.00</ix:nonFraction> per share</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-198" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-769">594,724</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-199" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-770">1.79</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-198" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-771">89.20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-198" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-772">594,724</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-198" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-773">89.20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-200" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-774">1,241,658</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-200" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-775">1,241,658</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.7. NUMBER OF SHARES USED TO COMPUTE DILUTED EARNINGS PER SHARE</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" id="f-776" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.554%"><tr><td style="width:1.0%"/><td style="width:59.113%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-777">1,249.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-778">1,249.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-779">1,251.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustment for stock options with dilutive effect</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" scale="6" id="f-780">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" scale="6" id="f-781">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" scale="6" id="f-782">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustment for restricted shares</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" scale="6" id="f-783">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" scale="6" id="f-784">4.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" scale="6" id="f-785">4.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Average number of shares used to compute diluted earnings per share</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-786">1,253.8</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-787">1,254.5</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-788">1,256.4</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2024, December 31, 2023 and June 30, 2023 all stock options were taken into account in computing diluted earnings per share because they all had a dilutive effect. </span></div></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:2.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">18</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:continuation id="f-696-2"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.8. OTHER COMPREHENSIVE INCOME</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" id="f-789" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements within other comprehensive income are shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.554%"><tr><td style="width:1.0%"/><td style="width:56.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.857%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.857%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.857%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024 (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023 (6 months)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses):</span></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="padding-right:2.1pt;text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Actuarial gains/(losses) excluding investments accounted for using the equity method</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-6" name="sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" scale="6" id="f-790">235</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-202" decimals="-6" name="sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" scale="6" id="f-791">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-203" decimals="-6" sign="-" name="sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" scale="6" id="f-792">171</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-6" name="sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" format="ixt:fixed-zero" scale="6" id="f-793">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-202" decimals="-6" name="sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-794">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-203" decimals="-6" name="sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" format="ixt:fixed-zero" scale="6" id="f-795">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-6" name="sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" scale="6" id="f-796">57</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-202" decimals="-6" name="sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" scale="6" id="f-797">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-203" decimals="-6" sign="-" name="sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" scale="6" id="f-798">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments included in financial assets and financial liabilities:</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-204" decimals="-6" sign="-" name="sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" scale="6" id="f-799">10</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-205" decimals="-6" name="sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" scale="6" id="f-800">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-206" decimals="-6" name="sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" scale="6" id="f-801">97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-204" decimals="-6" name="sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-802">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-205" decimals="-6" name="sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-803">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-206" decimals="-6" name="sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-804">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Equity risk hedging instruments designated as fair value hedges</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-204" decimals="-6" name="sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" format="ixt:fixed-zero" scale="6" id="f-805">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-205" decimals="-6" name="sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" format="ixt:fixed-zero" scale="6" id="f-806">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-206" decimals="-6" name="sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" format="ixt:fixed-zero" scale="6" id="f-807">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-204" decimals="-6" name="sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" scale="6" id="f-808">2</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-205" decimals="-6" sign="-" name="sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" scale="6" id="f-809">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-206" decimals="-6" name="sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" scale="6" id="f-810">21</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Items not subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-811">166</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-202" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-812">85</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-203" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-813">77</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments included in financial assets:</span></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="padding-right:2.1pt;text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-207" decimals="-6" sign="-" name="sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" scale="6" id="f-814">5</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-208" decimals="-6" name="sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" scale="6" id="f-815">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-209" decimals="-6" name="sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" scale="6" id="f-816">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-207" decimals="-6" name="sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" format="ixt:fixed-zero" scale="6" id="f-817">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-208" decimals="-6" name="sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" format="ixt:fixed-zero" scale="6" id="f-818">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-209" decimals="-6" name="sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" format="ixt:fixed-zero" scale="6" id="f-819">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-207" decimals="-6" sign="-" name="sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" scale="6" id="f-820">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-208" decimals="-6" name="sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" scale="6" id="f-821">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-209" decimals="-6" name="sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" scale="6" id="f-822">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash flow hedges and fair value hedges:</span></div></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" sign="-" name="sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" scale="6" id="f-823">4</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" name="sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" scale="6" id="f-824">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-6" name="sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" scale="6" id="f-825">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" name="sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-826">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" name="sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" format="ixt:fixed-zero" scale="6" id="f-827">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-6" sign="-" name="sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-828">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" sign="-" name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" scale="6" id="f-829">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-830">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-6" name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-831">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in currency translation differences:</span></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (c)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" name="sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="f-832">1,167</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" sign="-" name="sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="f-833">1,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-6" sign="-" name="sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="f-834">1,551</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Currency translation differences (investments accounted for using the equity method) </span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" sign="-" name="sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-835">1</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" name="sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-836">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-6" name="sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-837">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Hedges of net investments in foreign operations </span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" sign="-" name="sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" scale="6" id="f-838">126</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" name="sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" scale="6" id="f-839">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-6" name="sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" scale="6" id="f-840">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" sign="-" name="sny:ChangeInCurrencyTranslationOnTaxEffects" scale="6" id="f-841">33</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" name="sny:ChangeInCurrencyTranslationOnTaxEffects" scale="6" id="f-842">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-6" name="sny:ChangeInCurrencyTranslationOnTaxEffects" scale="6" id="f-843">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Items subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-844">1,067</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-845">1,058</ix:nonFraction>)</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-846">1,526</ix:nonFraction>)</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-18" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes reclassifications to profit or loss: immaterial over all periods.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><ix:footnote id="fn-19" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes reclassifications to profit or loss: immaterial over all periods.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><ix:footnote id="fn-20" continuedAt="fn-20-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar.</span></ix:footnote></div><ix:continuation id="fn-20-1"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes a reclassification to profit or loss: immaterial in the first half of 2024 , &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-847">56</ix:nonFraction>) million in 2023 and &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-214" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-848">14</ix:nonFraction>) million in the first half of 2023.</span></div></ix:continuation></ix:nonNumeric></ix:continuation><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.251%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">19</span></div></td></tr></table></div></div></div><div id="i3ef621f573d04e32b436c2b3b98c6331_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" id="f-849" continuedAt="f-849-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.9. DEBT, CASH AND CASH EQUIVALENTS</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfChangesInFinancialPositionTableTextBlock" id="f-850" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in financial position during the period were as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:72.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.306%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-851">12,503</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-852">14,347</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-853">9,236</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-854">2,045</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-855">179</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-856">139</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-857">21,918</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-858">16,531</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-859">6,795</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-860">8,710</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-861">11</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-862">28</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net debt (a)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-863">15,112</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-864">7,793</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"><ix:footnote id="fn-21" footnoteRole="http://www.xbrl.org/2003/role/footnote">Net debt does not include lease liabilities, which amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-865">2,012</ix:nonFraction> million as of June 30, 2024 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-866">2,030</ix:nonFraction> million as of December 31, 2023</ix:footnote>.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Net debt&#8221; is a financial indicator used by management and investors to measure Sanofi&#8217;s overall net indebtedness.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.9.1. NET DEBT AT VALUE ON REDEMPTION</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" id="f-867" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2024 is shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:31.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.949%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="6" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Value on redemption</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Carrying amount at</span></div><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Adjustment to debt measured at fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-868">12,503</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-6" name="ifrs-full:LongtermBorrowings" scale="6" id="f-869">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-6" name="ifrs-full:LongtermBorrowings" scale="6" id="f-870">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-871">12,688</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-872">14,546</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-873">9,236</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:fixed-zero" scale="6" id="f-874">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" scale="6" id="f-875">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-876">9,254</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-877">2,045</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-878">179</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-879">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-880">169</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-881">10</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-882">18</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-883">21,918</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-6" name="ifrs-full:Borrowings" scale="6" id="f-884">35</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-6" sign="-" name="ifrs-full:Borrowings" scale="6" id="f-885">1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-886">21,952</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-887">16,573</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-888">6,795</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-889">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-890">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-891">6,795</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-892">8,710</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-893">11</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-894">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-895">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-896">11</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-897">28</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net debt (a)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-898">15,112</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" scale="6" id="f-899">35</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" scale="6" id="f-900">1</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-901">15,146</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-902">7,835</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"><ix:footnote id="fn-22" footnoteRole="http://www.xbrl.org/2003/role/footnote">Net debt does not include lease liabilities, which amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-903">2,012</ix:nonFraction> million as of June 30, 2024 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-904">2,030</ix:nonFraction> million as of December 31, 2023</ix:footnote>.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" id="f-905" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows an analysis of net debt by type, at value on redemption:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:35.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.082%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.231%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.626%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.082%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.082%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.086%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">non-current</span></td><td colspan="6" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">current</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #661de8;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">non-current</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">current</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-906">12,593</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-907">1,916</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-908">14,509</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#dbe5f1;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-909">14,416</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-222" decimals="-6" name="ifrs-full:BondsIssued" scale="6" id="f-910">718</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-911">15,134</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-912">95</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-913">7,118</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e8eaf6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-914">7,213</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#dbe5f1;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-915">130</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-222" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-916">1,118</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-917">1,248</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-918">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-919">5</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-920">5</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#dbe5f1;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-921">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-222" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-922">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-923">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-924">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-925">215</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-926">215</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#dbe5f1;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-927">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-222" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-928">203</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-929">203</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-930">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-931">10</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-932">10</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#dbe5f1;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-933">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-222" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-934">18</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-935">18</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-936">12,688</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-937">9,264</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-938">21,952</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-939">14,546</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-222" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-940">2,027</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-941">16,573</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-223" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-942">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-224" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-943">6,795</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-944">6,795</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-945">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-946">8,710</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-947">8,710</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-223" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-948">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-224" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-949">11</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-950">11</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-951">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-952">28</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-953">28</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-223" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-954">12,688</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-224" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-955">2,458</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-956">15,146</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-957">14,546</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-958">6,711</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-959">7,835</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><ix:footnote id="fn-23" continuedAt="fn-23-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) As of June 30, 2024, current other bank borrowings includ</span></ix:footnote><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="fn-23-1">e &#8364;<ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-960">6,955</ix:nonFraction>&#160;million related to the US Commercial Paper program and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-228" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-961">0</ix:nonFraction>&#160;million related to the Negotiable European Commercial Paper program in France</ix:continuation>.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:12pt"><span><br/></span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:2.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:continuation id="f-849-1"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Principal financing and debt reduction transactions during the period</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi did not carry out any bond issues in the first half of </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An April</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> 2016 fixed-rate bond issue of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-229" decimals="-8" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-962">600</ix:nonFraction>&#160;million, which matured on April 5, 2024, was redeemed during the first half of 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2024, Sanofi had two syndicated credit facilities linked to social and environmental criteria in place to manage its liquidity in connection with current operations:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:14.14pt">a syndicated credit facility of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-230" decimals="-9" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-963">4</ix:nonFraction>&#160;billion, drawable in euros and US dollars and expiring on December 6, 2027, for which no further extension options are available; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.27pt">a syndicated credit facility of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-230" decimals="-9" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-964">4</ix:nonFraction>&#160;billion, drawable in euros and US dollars and expiring on March 7, 2029, for which a further one-year extension option remains available. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2024, neither facility was drawn down.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi also has two short-term debt programs:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:14.14pt"> a &#8364;<ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-9" name="ifrs-full:CommercialPapersIssued" scale="9" id="f-965">6</ix:nonFraction> billion Negotiable European Commercial Paper program in France; and </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.27pt">a $<ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-9" name="ifrs-full:CommercialPapersIssued" format="ixt:num-dot-decimal" scale="9" id="f-966">10</ix:nonFraction>&#160;billion Commercial Paper program in the United States. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the first half of 2024:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:14.14pt"> the average drawdown under the US Commercial Paper program was $<ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-8" name="sny:BorrowingAverageDrawdown" scale="9" id="f-967">5.8</ix:nonFraction> billion; and </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.27pt">the average drawdown under the Negotiable European Commercial Paper program in France was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-234" decimals="-8" name="sny:BorrowingAverageDrawdown" scale="9" id="f-968">0.1</ix:nonFraction> billion.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financing in place as of June 30, 2024 at the level of the holding company (which manages most of Sanofi&#8217;s financing needs centrally) is not subject to any financial covenants, and contains no clauses linking credit spreads or fees to the credit rating.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.9.2. MARKET VALUE OF NET DEBT</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfMarketValueOfNetDebtTableTextBlock" id="f-969" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The market value of Sanofi&#8217;s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.644%"><tr><td style="width:1.0%"/><td style="width:72.130%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-235" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-970">14,214</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-236" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-971">7,086</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Value on redemption</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-237" decimals="-6" name="sny:RedemptionOfDebtInstrumentIssued" format="ixt:num-dot-decimal" scale="6" id="f-972">15,146</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-238" decimals="-6" name="sny:RedemptionOfDebtInstrumentIssued" format="ixt:num-dot-decimal" scale="6" id="f-973">7,835</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.251%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">21</span></div></td></tr></table></div></div></div><div id="i3ef621f573d04e32b436c2b3b98c6331_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory" id="f-975" continuedAt="f-975-1" escape="true"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory" id="f-974" continuedAt="f-974-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.10. DERIVATIVE FINANCIAL INSTRUMENTS</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.10.1 CURRENCY DERIVATIVES USED TO MANAGE OPERATING RISK EXPOSURES</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" id="f-976" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of June&#160;30, 2024. The notional amount is translated into euros at the relevant closing exchange rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:26.634%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.228%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Of which derivatives designated as cash flow hedges</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Of which derivatives not eligible for hedge accounting</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Of which recognized in equity</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-239" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-977">5,120</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-240" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-978">45</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-241" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-979">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-242" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-980">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-981">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-244" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-982">5,120</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-245" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-983">45</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-246" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-984">2,152</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-247" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-985">17</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-248" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-986">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-249" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-987">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-250" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-988">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-251" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-989">2,152</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-252" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-990">17</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-253" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-991">608</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-254" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-992">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-993">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-256" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-994">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-257" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-995">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-258" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-996">608</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-259" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-997">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Russian rouble</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-260" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-998">252</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-999">31</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-262" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1000">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-263" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1001">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-264" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1002">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-265" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1003">252</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-266" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1004">31</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-267" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1005">269</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-268" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1006">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-269" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1007">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-270" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1008">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-271" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1009">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-272" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1010">269</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-273" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1011">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-274" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1012">197</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-275" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1013">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-276" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1014">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1015">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-278" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1016">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-279" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1017">197</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-280" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1018">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1019">3,195</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1020">21</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1021">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-284" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1022">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1023">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-286" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1024">3,195</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-287" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1025">21</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-288" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1026">1,733</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-289" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1027">2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-290" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1028">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-291" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1029">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-292" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1030">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-293" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1031">1,733</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-294" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1032">2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-295" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1033">398</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-296" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1034">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-297" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1035">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-298" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1036">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-299" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1037">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-300" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1038">398</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-301" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1039">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Russian rouble</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-302" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1040">203</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-303" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1041">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-304" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1042">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-305" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1043">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-306" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1044">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-307" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1045">203</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-308" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1046">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Turkish lira</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-309" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1047">108</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-310" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1048">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-311" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1049">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-312" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1050">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-313" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1051">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-314" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1052">108</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-315" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1053">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Canadian dollar</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-316" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1054">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-317" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1055">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-318" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1056">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-319" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1057">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-320" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1058">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-321" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1059">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-322" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1060">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-323" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1061">8,315</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-324" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1062">24</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-325" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1063">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-326" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1064">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-327" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1065">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-328" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1066">8,315</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-329" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1067">24</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The above positions mainly hedge material foreign currency cash flows arising after the end of the reporting period in relation to transactions carried out during the six months ended June&#160;30, 2024 and recognized in the balance sheet at that date. Gains and losses on hedging in</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">struments (forward contracts) are calculated and recognized in parallel with the recognition of gains and losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange difference on those items (hedging instruments and hedged transactions) will be immaterial in the second half of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.10.2. CURRENCY AND INTEREST RATE DERIVATIVES USED TO MANAGE FINANCIAL EXPOSURE</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The cash pooling arrangements for foreign subsidiaries outside the eurozone, and some of Sanofi&#8217;s financing activities, expose certain Sanofi entities to financial foreign exchange risk (i.e.&#160;the risk of changes in the value of loans and borrowings denominated in a currency other than the functional currency of the lender or borrower).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">That foreign exchange exposure is hedged using derivative instruments (currency swaps or forward contracts) that alter the currency split of Sanofi&#8217;s debt once those instruments are taken into account.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" id="f-1068" continuedAt="f-1068-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows financial currency hedging instruments in place as of June&#160;30, 2024. The notional amount is translated into euros at the relevant closing exchange rate.</span></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:2.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">22</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:continuation id="f-975-1"><ix:continuation id="f-974-1"><ix:continuation id="f-1068-1"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:55.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.307%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Maximum expiry date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-239" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1069">7,190</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-240" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1070">30</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-330" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1071">5,797</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-331" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1072">28</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-332" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1073">301</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-333" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1074">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Canadian dollar</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-334" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1075">190</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-335" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1076">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1077">7,656</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1078">42</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-336" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1079">5,242</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b) (c)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-337" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1080">37</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-338" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1081">1,768</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-339" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1082">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Hungarian forint</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-340" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1083">182</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-341" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1084">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-323" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1085">14,846</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-324" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1086">12</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-24" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes forward sales with a notional amount of $<ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1087">3,615</ix:nonFraction> million expiring in 2024, designated as a hedge of Sanofi&#8217;s net investment in Bioverativ. As of June&#160;30, 2024, the fair value of these forward contracts represented a liability of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-342" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilities" scale="6" id="f-1088">26</ix:nonFraction> million; the opposite entry was recognized in &#8220;Other comprehensive income&#8221;, with the impact on financial income and expense being immaterial.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><ix:footnote id="fn-25" continuedAt="fn-25-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)  Includes forward purchases with a notional amount of $<ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1089">1,000</ix:nonFraction> million expiring in 2024, designated as a fair value hedge of the exposure of $<ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1090">1,000</ix:nonFraction> million of bond issues to</span></ix:footnote><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="fn-25-1"> fluctuations in the EUR/USD spot rate. As of June 30, 2024, the fair value of these contracts represented an asset of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-343" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilities" scale="6" id="f-1091">2</ix:nonFraction> million, with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-344" decimals="-6" name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" scale="6" id="f-1092">0</ix:nonFraction> million&#160;credited to &#8220;Other comprehensive income&#8221; to recognize the hedging cost</ix:continuation>.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:footnote id="fn-26" footnoteRole="http://www.xbrl.org/2003/role/footnote">(c)  Includes forward purchases with a notional amount of $<ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1093">1,080</ix:nonFraction> million expiring in 2024 , designated as a fair value hedge of $<ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1094">1,080</ix:nonFraction> million of commercial paper. As of June 30, 2024, the fair value of these contracts represented an asset of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-345" decimals="-6" name="ifrs-full:DerivativeFinancialAssets" scale="6" id="f-1095">16</ix:nonFraction> million, with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-346" decimals="-6" name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1096">0&#160;million</ix:nonFraction> credited to &#8220;Other comprehensive income&#8221; to recognize the hedging cost.</ix:footnote> .</span></div></ix:continuation><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To optimize the cost of debt or reduce the volatility of debt, Sanofi uses derivative instruments (interest rate swaps and cross currency swaps) to alter the fixed/floating rate split of its net debt.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" id="f-1097" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows instruments of this type in place as of June 30, 2024:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.279%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.279%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.279%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.834%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.255%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Of which designated as fair value hedges</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Of which designated as cash flow hedges</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2028 and beyond</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Of which recognized in equity</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD / receive <ix:nonFraction unitRef="number" contextRef="c-347" decimals="INF" name="sny:InterestRateSwapsInterestRate" scale="-2" id="f-1098">1.02</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-348" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1099"><ix:nonFraction unitRef="eur" contextRef="c-348" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1100">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-349" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1101"><ix:nonFraction unitRef="eur" contextRef="c-349" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1102">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-350" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1103"><ix:nonFraction unitRef="eur" contextRef="c-350" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1104">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-351" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1105"><ix:nonFraction unitRef="eur" contextRef="c-351" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1106">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-352" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1107"><ix:nonFraction unitRef="eur" contextRef="c-352" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1108">467</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-353" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1109"><ix:nonFraction unitRef="eur" contextRef="c-353" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1110">467</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-354" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1111"><ix:nonFraction unitRef="eur" contextRef="c-354" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1112">53</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-355" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1113"><ix:nonFraction unitRef="eur" contextRef="c-355" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1114">467</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-356" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1115"><ix:nonFraction unitRef="eur" contextRef="c-356" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1116">53</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-357" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1117"><ix:nonFraction unitRef="eur" contextRef="c-357" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1118">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-358" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1119"><ix:nonFraction unitRef="eur" contextRef="c-358" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1120">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-359" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1121"><ix:nonFraction unitRef="eur" contextRef="c-359" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1122">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">pay capitalized SOFR USD / receive  <ix:nonFraction unitRef="number" contextRef="c-360" decimals="INF" name="sny:InterestRateSwapsInterestRate" scale="-2" id="f-1123">1.32</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-361" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1124">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-362" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1125">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-363" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1126">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-364" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1127">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-365" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1128">467</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-366" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1129">467</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-367" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1130">48</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-368" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1131">467</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-369" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1132">48</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-370" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1133">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-371" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1134">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-372" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1135">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester / receive <ix:nonFraction unitRef="number" contextRef="c-373" decimals="INF" name="sny:InterestRateSwapsInterestRate" scale="-2" id="f-1136">0.69</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-374" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1137">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-375" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1138">850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-376" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1139">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-377" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1140">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-378" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1141">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-379" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1142">850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-380" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1143">24</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-381" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1144">850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-382" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1145">24</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-383" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1146">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-384" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1147">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-385" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1148">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester / receive <ix:nonFraction unitRef="number" contextRef="c-386" decimals="INF" name="sny:InterestRateSwapsInterestRate" scale="-2" id="f-1149">0.92</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-387" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1150">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-388" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1151">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-389" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1152">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-390" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1153">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-391" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1154">650</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-392" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1155">650</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-393" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1156">56</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-394" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1157">650</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-395" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1158">56</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-396" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1159">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-397" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1160">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-398" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1161">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">pay capitalized Ester / receive <ix:nonFraction unitRef="number" contextRef="c-399" decimals="INF" name="sny:InterestRateSwapsInterestRate" scale="-2" id="f-1162">3.56</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-400" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1163">997</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-401" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1164">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-402" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1165">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-403" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1166">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-404" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1167">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-405" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1168">997</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-406" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1169">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-407" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1170">997</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-408" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1171">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-409" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1172">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-410" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1173">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-411" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1174">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-412" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1175">997</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-413" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1176">850</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-414" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1177">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-415" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1178">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-416" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1179">1,584</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-323" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1180">3,431</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-324" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1181">181</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-417" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1182">3,431</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-418" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1183">181</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-325" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1184">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-326" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1185">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-327" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1186">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_70"></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.251%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">23</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" id="f-1187" continuedAt="f-1187-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.11. LIABILITIES RELATED TO BUSINESS COMBINATIONS AND TO NON-CONTROLLING INTERESTS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of the nature of the liabilities reported in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, refer to Note B.8.4. to the consolidated financial statements for the year ended December 31, 2023. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The liabilities related to business combinations and to non-controlling interests shown in the table below are level&#160;3 instruments under the IFRS 13 and IFRS 7 fair value hierarchy (see Note A.5.).</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" id="f-1188" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2024 are shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:30.055%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">MSD contingent consideration (European Vaccines business)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shire contingent consideration arising from acquisition of Translate Bio</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Contingent consideration arising from acquisition of Amunix</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"> (a)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at January 1, 2024</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-419" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1189">127</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-420" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1190">441</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-421" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1191">137</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-422" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1192">4</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1193">709</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-423" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1194">71</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-424" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-1195">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-425" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-1196">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-426" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-1197">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1198">71</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-423" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-1199">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-424" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-1200">71</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-425" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" format="ixt:fixed-zero" scale="6" id="f-1201">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-426" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" format="ixt:fixed-zero" scale="6" id="f-1202">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-1203">75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-423" decimals="-6" name="sny:OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-1204">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-424" decimals="-6" name="sny:OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-1205">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-425" decimals="-6" name="sny:OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-1206">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-426" decimals="-6" name="sny:OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1207">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1208">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-423" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" scale="6" id="f-1209">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-424" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" scale="6" id="f-1210">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-425" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" scale="6" id="f-1211">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-426" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" format="ixt:fixed-zero" scale="6" id="f-1212">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" scale="6" id="f-1213">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at June 30, 2024</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-427" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1214">61</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-428" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1215">526</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-429" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1216">140</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-430" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1217">1</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1218">728</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Of which:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt;text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt;text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt;text-align:right"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;padding-left:33.44pt">Current portion</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-1219">201</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;padding-left:33.44pt">Non-current portion</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-1220">527</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-27" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">As of January 1, 2024, this comprised a non-current portion of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-1221">501</ix:nonFraction> million and a current portion of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-1222">208</ix:nonFraction> million.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:footnote id="fn-28" footnoteRole="http://www.xbrl.org/2003/role/footnote">(b)&#160;&#160;&#160;&#160;Amounts mainly reported within the income statement line item &#8220;Fair value remeasurement of contingent consideration&#8221;</ix:footnote>.</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2024,</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">mainly comprised:</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.28pt">The MSD contingent consideration liability arising from the 2016 acquisition of the Sanofi Pasteur activities carried on within the former Sanofi Pasteur MSD joint venture, which amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-427" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1223">61</ix:nonFraction> million as of June&#160;30, 2024 versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-419" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1224">127</ix:nonFraction> million as of December 31, 2023. The fair value of this contingent consideration is determined by applying the royalty percentage stipulated in the contract to discounted projections of sales by Sanofi through December 31, 2024 of products previously commercialized by the joint venture. If the discount rate were to fall by one percentage point, the fair value of the MSD contingent consideration would increase by approximately <ix:nonFraction unitRef="number" contextRef="c-427" decimals="2" name="sny:PercentageIncreaseInFairValueLiabilities" scale="-2" id="f-1225">1</ix:nonFraction>%;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">The contingent consideration liability towards Shire Human Genetic Therapies Inc. (Shire) arising from Sanofi's acquisition of Translate Bio in September 2021. The fair value of the Shire liability is determined by applying the contractual terms to development and sales projections that are weighted to reflect the probability of success, and discounted. The liability was measured at &#8364;<ix:nonFraction unitRef="eur" contextRef="c-428" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1226">526</ix:nonFraction> million as of June&#160;30, 2024, compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-420" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1227">441</ix:nonFraction> million as of December 31, 2023. If the discount rate were to fall by one percentage point, the fair value of the Shire liability would increase by approximately <ix:nonFraction unitRef="number" contextRef="c-428" decimals="2" name="sny:PercentageIncreaseInFairValueLiabilities" scale="-2" id="f-1228">14</ix:nonFraction>%; and</span></div></ix:nonNumeric><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><ix:continuation id="f-1187-1" continuedAt="f-1187-2"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">The contingent consideration liability arising from the 2022 acquisition of Amunix. The fair value of the liability is determined on&#160;the basis of the nominal value of payments due subject to the attainment of specified</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> development milestones</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. The liability was measured at </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-429" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1229">140</ix:nonFraction> million</span></ix:continuation><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-1187-2"> as of June 30, 2024, versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-421" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1230">137</ix:nonFraction> million as of December 31, 2023.</ix:continuation> </span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:3.82pt"><span><br/></span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:2.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><div style="margin-bottom:5pt;text-align:justify;text-indent:3.82pt"><span><br/></span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_73"></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" id="f-1231" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.12. NON-CURRENT PROVISIONS AND OTHER NON-CURRENT LIABILITIES</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" id="f-1232" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current provisions and other non-current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> comprises the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:59.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1233">5,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1234">5,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1235">5,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other non-current liabilities&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1236">2,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1237">2,070</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1238">2,340</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1239">8,219</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1240">7,088</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1241">7,602</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(<ix:footnote id="fn-29" footnoteRole="http://www.xbrl.org/2003/role/footnote">a) Includes &#8364;<ix:nonFraction unitRef="eur" contextRef="c-431" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1242">1,970</ix:nonFraction> million at June 30, 2024 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States. Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#8364;<ix:nonFraction unitRef="eur" contextRef="c-432" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1243">1,147</ix:nonFraction>&#160;million; the nominal value of payments estimated to be due after more than five years is &#8364;<ix:nonFraction unitRef="eur" contextRef="c-433" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1244">2,679</ix:nonFraction> million</ix:footnote>.</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfNonCurrentProvisionsTableTextBlock" id="f-1245" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows movements in provisions:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:38.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.450%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.231%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.450%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.450%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Provisions for pensions &amp; other post-employment benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Provisions for other long-term benefits</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Restructuring provisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other provisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at January&#160;1, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-434" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1246">2,214</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-435" decimals="-6" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-1247">718</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-436" decimals="-6" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-1248">554</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-437" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1249">1,776</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1250">5,262</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increases in provisions and other liabilities</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-438" decimals="-6" sign="-" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-1251">72</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-439" decimals="-6" sign="-" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-1252">89</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-440" decimals="-6" sign="-" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-1253">581</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-441" decimals="-6" sign="-" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-1254">559</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:ChangesInOtherProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1255">1,301</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-438" decimals="-6" sign="-" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-1256">78</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-439" decimals="-6" sign="-" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-1257">65</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-440" decimals="-6" sign="-" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-1258">11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-441" decimals="-6" sign="-" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-1259">76</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-1260">230</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reversals of unutilized provisions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-438" decimals="-6" sign="-" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-1261">63</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-439" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-1262">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-440" decimals="-6" sign="-" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-1263">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-441" decimals="-6" sign="-" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-1264">53</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-1265">119</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-438" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-1266">75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-439" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-1267">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-440" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-1268">173</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-441" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-1269">24</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-1270">122</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest related to employee benefits, and unwinding of discount</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-438" decimals="-6" name="sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" scale="6" id="f-1271">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-439" decimals="-6" name="sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" scale="6" id="f-1272">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-440" decimals="-6" name="sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" scale="6" id="f-1273">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-441" decimals="-6" name="sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" scale="6" id="f-1274">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" scale="6" id="f-1275">60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-438" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-1276">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-439" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-1277">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-440" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-1278">47</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-441" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-1279">17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-1280">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains and losses on defined-benefit plans (B.12.1.)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-438" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" scale="6" id="f-1281">235</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-439" decimals="-6" name="sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-1282">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-440" decimals="-6" name="sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-1283">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-441" decimals="-6" name="sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-1284">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" scale="6" id="f-1285">235</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at June 30, 2024</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-442" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1286">2,040</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-443" decimals="-6" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-1287">759</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-444" decimals="-6" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-1288">909</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-445" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1289">2,210</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1290">5,918</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><ix:footnote id="fn-30" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the case of &#8220;Provisions for pensions and other post-employment benefits&#8221;, the &#8220;Increases in provisions&#8221; line corresponds to rights vesting in employees during the period, and past service cost; the &#8220;Provisions utilized&#8221; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#8220;Reversals of unutilized provisions&#8221; line corresponds to plan curtailments, settlements and amendments.</span></div></ix:footnote><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:footnote id="fn-31" footnoteRole="http://www.xbrl.org/2003/role/footnote">(b) Mainly transfers to the line &#8220;Current provisions and other current liabilities</ix:footnote>&#8221;.</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Provisions for pensions and other post-employment benefits</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For an analysis of the sensitivity of obligations in respect of pensions and other employee benefits as of December 31, 2023, and of the assumptions used as of that date, see Note D.19.1. to the consolidated financial statements for the year ended December 31, 2023. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal assumptions used (in particular, changes in discount and inflation rates and in the market value of plan assets) for the eurozone, the United States and the United Kingdom were reviewed as of June 30, 2024 to take into account changes during the first half of the year.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" id="f-1291" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:54.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.231%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.231%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.973%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024 (6 months)</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) on plan assets</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-446" decimals="-6" name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" scale="6" id="f-1292">138</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-447" decimals="-6" sign="-" name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" scale="6" id="f-1293">34</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-448" decimals="-6" name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" scale="6" id="f-1294">208</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) on benefit obligations</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-449" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-1295">373</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-450" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-1296">99</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-451" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-1297">379</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-32" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes the effects of (i) the change in discount rates (in a range between +<ix:nonFraction unitRef="number" contextRef="c-452" decimals="4" sign="-" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" scale="-2" id="f-1298">0.40</ix:nonFraction>% and +<ix:nonFraction unitRef="number" contextRef="c-453" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="f-1299">0.65</ix:nonFraction>%) and (ii) the change in the inflation rate in the United Kingdom (+<ix:nonFraction unitRef="number" contextRef="c-454" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="f-1300">0.10</ix:nonFraction>%) in the first half of 2024.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><ix:footnote id="fn-33" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes the effects of (i) the change in discount rates (in a range between -<ix:nonFraction unitRef="number" contextRef="c-455" decimals="4" sign="-" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="f-1301">0.15</ix:nonFraction>% and +<ix:nonFraction unitRef="number" contextRef="c-456" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="f-1302">0.40</ix:nonFraction>%) and (ii) the change in the inflation rate in the eurozone (-<ix:nonFraction unitRef="number" contextRef="c-457" decimals="4" sign="-" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="f-1303">0.10</ix:nonFraction>%) in the first half of 2023.</span></ix:footnote></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.251%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">25</span></div></td></tr></table></div></div></div><div id="i3ef621f573d04e32b436c2b3b98c6331_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" id="f-1304" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.13. OFF BALANCE SHEET COMMITMENTS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Off balance sheet commitments to third parties as of December&#160;31, 2023 are presented in Note D.21.1. to the consolidated financial statements for the year ended December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal commitments entered into, amended or discontinued during the period are described below: </span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.28pt">On May, 2024, Sanofi entered into a co-exclusive licensing agreement with Novavax. The terms of the agreement include (i)&#160;a co-exclusive license to co-commercialize Novavax&#8217;s current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements and in India, Japan, and South Korea, where Novavax has existing partnership agreements); (ii) a sole license to Novavax&#8217;s adjuvanted COVID-19 vaccine for use in combination with Sanofi&#8217;s flu vaccines; and (iii) a non-exclusive license to use the Matrix-M adjuvant in vaccine products. Novavax received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-458" decimals="-6" name="sny:UpfrontPayments" scale="6" id="f-1305">500</ix:nonFraction> million and up to $<ix:nonFraction unitRef="usd" contextRef="c-458" decimals="-6" name="sny:DevelopmentRegulatoryAndLaunchMilestonePayments" scale="6" id="f-1306">700</ix:nonFraction> million in development, regulatory and launch milestones, representing up to $<ix:nonFraction unitRef="usd" contextRef="c-458" decimals="-8" name="sny:TotalMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="f-1307">1.2</ix:nonFraction>&#160;billion in total. Starting in 2025, Sanofi will book sales of Novavax&#8217;s adjuvanted COVID-19 vaccine and will support certain R&amp;D, regulatory, and commercial expenses. Novavax will receive double-digit tiered royalties on sales of COVID-19 vaccines and combined influenza/COVID-19 vaccines made by Sanofi. Novavax is also entitled to additional launch and sales milestones opportunities of up to $<ix:nonFraction unitRef="usd" contextRef="c-458" decimals="-6" name="sny:AdditionalLaunchAndSalesMilestonePayments" scale="6" id="f-1308">200</ix:nonFraction> million, plus single-digit royalties for each additional Sanofi vaccine product developed under a non-exclusive license with Novavax&#8217;s Matrix-M adjuvant technology. In addition, Sanofi took a minority (&lt;5%) equity investment in Novavax. This agreement will provide patients with broader access from 2025 onwards to a protein-based non-mRNA adjuvanted COVID-19 vaccine. Outside of the collaboration, each party may develop and commercialize their own flu and COVID-19 vaccines and their own adjuvanted products at their own cost.</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.69pt">On May, 2024, Sanofi entered into a collaboration and license agreement with Fulcrum Therapeutics for the development and commercialization of losmapimod, an investigational oral therapy for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The agreement combines Fulcrum&#8217;s FSHD expertise with Sanofi&#8217;s global reach and commitment to treating people with rare diseases. Under the terms of the agreement, Sanofi obtained exclusive commercialization rights outside of the United States, while Fulcrum retained the US rights. Fulcrum will receive an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-6" name="sny:UpfrontPayments" scale="6" id="f-1309">80</ix:nonFraction> million, and could receive up to $<ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-6" name="sny:ContingentMilestonePayments" scale="6" id="f-1310">975</ix:nonFraction> million contingent on the attainment of specified milestones, plus royalties on non-US sales. The two parties will share worldwide development costs equally. Losmapimod, currently in worldwide Phase 3 clinical trials, has demonstrated promising results in slowing the progression of FSHD; data from the Phase 3 trial are expected by end 2024. If the results are positive, Fulcrum and Sanofi intend to file for marketing approval in the United States, Europe, Japan, and other regions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has also entered into power purchase agreements in furtherance of its ESG strategy. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The characteristics of the principal power purchase agreements in place as of June 30, 2024 are summarized below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.190%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Country</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Type of Energy</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Annual Volume</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Start Date</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Type of Contract</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accounting Treatment</span></div></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Solar</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8 GWh</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 years</span></div></td><td colspan="3" rowspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PPA </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" rowspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Own use</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">procurement contracts </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Wind</span></div></td><td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46 GWh</span></div></td><td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Wind</span></div></td><td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29 GWh</span></div></td><td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 years</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Power Purchase Agreement (PPA): long-term renewable energy contract resulting in physical supply of electricity.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) At the current stage of analysis, with reference to the own use exception permitted by paragraph 2.4 of IFRS 9.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These contracts help secure the objective of 100% green electricity supply across all operations of the Group by 2030.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_79"></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:2.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfLegalAndArbitralProceedingsTextBlock" id="f-1311" continuedAt="f-1311-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.14. LITIGATION AND ARBITRATION PROCEEDINGS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and its affiliates are involved in litigation, arbitration and other legal proceedings. These proceedings typically are related to product liability claims, intellectual property rights (particularly claims against generic companies seeking to limit the patent protection of Sanofi products), competition law and trade practices, commercial claims, employment and wrongful discharge claims, tax assessment claims, waste disposal and pollution claims, and claims under warranties or indemnification arrangements relating to business divestitures.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The matters discussed below constitute the most significant developments since publication of the financial statements for the year ended December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.14.1. PRODUCTS</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TAXOTERE PRODUCT LITIGATION IN THE US</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2024, there were approximately <ix:nonFraction unitRef="proceeding" contextRef="c-460" decimals="INF" name="sny:NumberOfPlaintiffs" format="ixt:num-dot-decimal" id="f-1312">6,770</ix:nonFraction> ingesting plaintiffs cases remaining in courts across the country. Throughout the first half of 2024, Sanofi entered into a number of settlement agreements or agreements in principle with many plaintiffs&#8217; firms encompassing nearly all the remaining cases. These agreements require the consent of the individual plaintiffs and will take some time to conclude, in order to ensure that certain threshold participation requirements are met. </span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ZANTAC PRODUCT LITIGATION IN THE US</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In March 2024, Sanofi reached agreement in principle with a number of plaintiffs&#8217; lawyers to resolve Zantac personal injury cases pending against it in all US state courts outside of Delaware. This agreement would resolve approximately 75% of nearly <ix:nonFraction unitRef="proceeding" contextRef="c-461" decimals="INF" name="sny:NumberOfCases" format="ixt:num-dot-decimal" id="f-1313">4,400</ix:nonFraction> cases. The agreement requires the consent of individual plaintiffs and will take some time to conclude.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the State court cases pending in Delaware, the State of Delaware court decided in May 2024 not to exclude plaintiffs&#8217; experts from the cases. Sanofi is appealing this decision.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOLD BOND PRODUCT LITIGATION IN THE US</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2024, Sanofi is named as a defendant in approximately <ix:nonFraction unitRef="proceeding" contextRef="c-462" decimals="INF" name="sny:NumberOfClassActionLawsuits" id="f-1314">600</ix:nonFraction> product liability ongoing actions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DEPAKINE PRODUCT LITIGATION IN FRANCE</span></td></tr></table><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Civil Proceedings </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Several questions on the Product Liability Directive have been referred to the European Court of Justice (ECJ), which will have an impact on the pending Depakine cases. A ruling from the ECJ is expected between September and December 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As a result, several stays in the proceedings have been requested including in the class action, the anxiety damage claim, and several individual proceedings. Similar requests will be made in the remaining proceedings (in particular, on appeal), depending on the timescales determined by the Courts. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the class action, a hearing is scheduled for September 2024 for this question to be tried. As regards the anxiety damage cases, the ruling is expected on August 2, 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DENGVAXIA PRODUCT LITIGATION IN THE PHILIPPINES</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 16, 2024, the Court dismissed the first eight criminal cases, ruling the prosecution failed to establish the elements of &#8220;reckless imprudence&#8221; resulting in homicide. Remaining cases are still pending at various stages.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.14.2. PATENTS</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRALUENT (alirocumab)-RELATED AMGEN PATENT LITIGATION IN EUROPE</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the revocation action filed by Sanofi against Amgen before the Munich Central Division of the Unified Patent Court, a decision on the Amgen patent&#8217;s validity was issued on July 16, 2024. This decision revokes Amgen&#8217;s patent, hence supporting Sanofi/Regeneron&#8217;s position. The decision can be appealed.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and Regeneron have also attacked the validity of the same EP 3 666 797 patent at the European Patent Office. These proceedings are ongoing.</span></div></ix:nonNumeric><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.251%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">27</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:continuation id="f-1311-1" continuedAt="f-1311-2"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.14.3. OTHER LITIGATION</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PLAVIX (clopidogrel) - ATTORNEY GENERAL ACTION IN HAWAII</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 21, 2024, the Court issued a new decision against Sanofi and BMS, imposing penalties in the total amount of $<ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-6" name="sny:GlobalPenaltyFeeIncurredByDefendantsAmountVacated" scale="6" id="f-1315">916</ix:nonFraction> million, with $<ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-6" name="sny:PenaltyFeeIncurred" scale="6" id="f-1316">458</ix:nonFraction> million attributed to Sanofi. Sanofi and BMS will appeal the decision.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PLAVIX (clopidogrel)-RELATED LITIGATION IN FRANCE</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the claim filed by the CNAM, the final expert report was issued in March 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">340B DRUG PRICING PROGRAM IN THE UNITED STATES</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In May 2024, Sanofi filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and Services Administration (HRSA) under the Freedom of Information Act (FOIA) seeking an order declaring that Sanofi is entitled to covered entities&#8217; pharmacy contracts, requiring HRSA to produce the contracts and enjoining HRSA from withholding pharmacy contracts from Sanofi pursuant to its FOIA request. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">Mosaic Health in the United States </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In February 2024, plaintiffs filed a notice of appeal of the dismissal of the complaint by the Court.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">Adventist Health System/West in the United States </span></div></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-1311-2">In March 2024, the Court dismissed the action in its entirety, without granting the plaintiff leave to amend its complaint. The plaintiff filed its appeal in April 2024. A decision on the appeal could be delivered during 2025.</ix:continuation> </span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_82"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory" id="f-1317" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.15. OTHER OPERATING INCOME AND EXPENSES</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1318">617</ix:nonFraction> million in the first half of 2024 (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1319">617</ix:nonFraction> million in the first half of 2023), and</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1320">2,010</ix:nonFraction> million (versus &#8364; <ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1321">1,422</ix:nonFraction> million in the first half of 2023).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main items included in</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> were: in the first half of 2024, (i) income from pharmaceutical partners of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-464" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1322">118</ix:nonFraction>&#160;million (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-465" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1323">160</ix:nonFraction> million in the first half of 2023), of which &#8364;<ix:nonFraction unitRef="eur" contextRef="c-466" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1324">96</ix:nonFraction> million came from Regeneron (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-467" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1325">102</ix:nonFraction> million in the first half of 2023, see table below) and (ii) gains on disposals of assets and operations of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-464" decimals="-6" name="sny:GainsOnDivestmentOfProducts" scale="6" id="f-1326">389</ix:nonFraction> million, primarily on divestments of non strategic products (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-465" decimals="-6" name="sny:GainsOnDivestmentOfProducts" scale="6" id="f-1327">413</ix:nonFraction> million in the first half of 2023). </span></div><ix:nonNumeric contextRef="c-1" name="sny:OtherOperatingExpensesTableTextBlock" id="f-1328" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">for the first half of 2024 included &#8364;<ix:nonFraction unitRef="eur" contextRef="c-468" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1329">1,841</ix:nonFraction> million of expenses related to Regeneron (compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1330">1,423</ix:nonFraction> million in the first half of 2023), as shown in the table below.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:59.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(12 months)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income &amp; expense related to profit/loss sharing under the Monoclonal Antibody Alliance</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-470" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1331">1,934</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-471" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1332">1,449</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-472" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1333">3,321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional share of profit paid by Regeneron towards development costs</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-473" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1334">389</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-474" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1335">291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-475" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1336">668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reimbursement to Regeneron of selling expenses incurred</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-476" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-1337">292</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-477" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-1338">260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-478" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-1339">543</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total: Monoclonal Antibody Alliance</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-479" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1340">1,837</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-480" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1341">1,418</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-481" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1342">3,196</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other (mainly Zaltrap and Libtayo)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-482" decimals="-6" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-1343">92</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-483" decimals="-6" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-1344">97</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-484" decimals="-6" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-1345">217</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other operating income/(expenses), net related to Regeneron </span></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1346">1,745</ix:nonFraction>)</span></td><td style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1347">1,321</ix:nonFraction>)</span></td><td style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1348">2,979</ix:nonFraction>)</span></td><td style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">of which amount presented in &#8220;Other operating income&#8221; </span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-466" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1349">96</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-467" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1350">102</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-485" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1351">227</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_85"></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:2.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">28</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" id="f-1353" escape="true"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" id="f-1352" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.16. RESTRUCTURING COSTS AND SIMILAR ITEMS</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfRestructuringCostsDetailsTableTextBlock" id="f-1354" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:59.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(12 months)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee-related expenses</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" scale="6" id="f-1355">849</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" scale="6" id="f-1356">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" scale="6" id="f-1357">489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Charges, gains or losses on assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" scale="6" id="f-1358">31</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" scale="6" id="f-1359">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" scale="6" id="f-1360">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Costs of transformation programs</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts" scale="6" id="f-1361">347</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts" scale="6" id="f-1362">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts" scale="6" id="f-1363">676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other restructuring costs</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:OtherRestructuringCosts" scale="6" id="f-1364">166</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:OtherRestructuringCosts" scale="6" id="f-1365">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:OtherRestructuringCosts" scale="6" id="f-1366">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" format="ixt:num-dot-decimal" scale="6" id="f-1367">1,331</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" scale="6" id="f-1368">547</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" format="ixt:num-dot-decimal" scale="6" id="f-1369">1,490</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:footnote id="fn-34" footnoteRole="http://www.xbrl.org/2003/role/footnote">(a) This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi</ix:footnote>.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring and similar costs increased by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-486" decimals="-6" sign="-" name="sny:IncreaseDecreaseInTotalExpenseOfRestructuringActivities" scale="6" id="f-1370">784</ix:nonFraction> million between June 30, 2023 and June 30, 2024. They mainly comprise costs relating to severance plans announced in the first half of 2024. For the six months ended June 30, 2023 and the year ended December 31, 2023, they included the impact of pension reform in France on future annuities under the rules of each severance plan. Restructuring costs also include Sanofi's ongoing transformation projects, mainly those relating to the separation of the Opella business.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_88"></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" id="f-1371" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.17. OTHER GAINS AND LOSSES, AND LITIGATION</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the first half of 2024, </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a charge of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-1372">442</ix:nonFraction> million, mainly comprising a </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">provision recognized in respect of the litigation related to Plavix (clopidogrel) in the US state of Hawaii (see note B.14.)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. That compares with a charge of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-1373">73</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> million in the first half of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2023, which comprised costs related to the settlement of a dispute with shareholders of Bioverativ.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_91"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" id="f-1374" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.18. FINANCIAL EXPENSES AND INCOME</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" id="f-1375" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of financial expenses and income is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:59.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(12 months)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of debt </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:InterestExpenseOnBorrowings" scale="6" id="f-1376">309</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:InterestExpenseOnBorrowings" scale="6" id="f-1377">232</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:InterestExpenseOnBorrowings" scale="6" id="f-1378">555</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:InterestIncome" scale="6" id="f-1379">243</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:InterestIncome" scale="6" id="f-1380">257</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:InterestIncome" scale="6" id="f-1381">533</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Cost of net debt</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:CostOfDebtNet" scale="6" id="f-1382">66</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:CostOfDebtNet" scale="6" id="f-1383">25</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:CostOfDebtNet" scale="6" id="f-1384">22</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-operating foreign exchange gains/(losses)</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:NonOperatingForeignExchangeGainsLosses" scale="6" id="f-1385">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:NonOperatingForeignExchangeGainsLosses" scale="6" id="f-1386">3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="sny:NonOperatingForeignExchangeGainsLosses" scale="6" id="f-1387">2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unwinding of discounting of provisions </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions" scale="6" id="f-1388">17</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions" scale="6" id="f-1389">22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions" scale="6" id="f-1390">59</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost related to employee benefits</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:NetInterestCostRelatedToEmployeeBenefits" scale="6" id="f-1391">40</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:NetInterestCostRelatedToEmployeeBenefits" scale="6" id="f-1392">41</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:NetInterestCostRelatedToEmployeeBenefits" scale="6" id="f-1393">73</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains/(losses) on disposals of financial assets</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1394">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1395">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets" scale="6" id="f-1396">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="6" id="f-1397">22</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="6" id="f-1398">21</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="6" id="f-1399">39</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (d)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:OtherFinanceIncomeCost" scale="6" id="f-1400">161</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:OtherFinanceIncomeCost" scale="6" id="f-1401">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:OtherFinanceIncomeCost" scale="6" id="f-1402">526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net financial income/(expenses)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:FinanceIncomeCost" scale="6" id="f-1403">305</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:FinanceIncomeCost" scale="6" id="f-1404">84</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:FinanceIncomeCost" scale="6" id="f-1405">722</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">comprising: Financial expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-1406">586</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-1407">370</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-1408">1,313</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income</span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-1409">281</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-1410">286</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-1411">591</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-35" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-487" decimals="-6" sign="-" name="sny:GainLossOnDerivativesUsedToManageDebt" scale="6" id="f-1412">24</ix:nonFraction>) million in the first half of 2024, &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-488" decimals="-6" sign="-" name="sny:GainLossOnDerivativesUsedToManageDebt" scale="6" id="f-1413">25</ix:nonFraction>) million in the first half of 2023, and &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-489" decimals="-6" sign="-" name="sny:GainLossOnDerivativesUsedToManageDebt" scale="6" id="f-1414">67</ix:nonFraction>) million over the whole of 2023.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><ix:footnote id="fn-36" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-487" decimals="-6" sign="-" name="sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents" scale="6" id="f-1415">18</ix:nonFraction>) million in the first half of 2024, &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-488" decimals="-6" sign="-" name="sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents" scale="6" id="f-1416">4</ix:nonFraction>)&#160;million in the first half of 2023, and &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-489" decimals="-6" sign="-" name="sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents" scale="6" id="f-1417">13</ix:nonFraction>) million over the whole of 2023.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><ix:footnote id="fn-37" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><ix:footnote id="fn-38" continuedAt="fn-38-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes a financial expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:LiabilityRecognisedForEstimatedFutureRoyalties" scale="6" id="f-1418">176</ix:nonFraction></span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span></ix:footnote><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="fn-38-1">million for the six months ended June 30, 2024 (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="sny:LiabilityRecognisedForEstimatedFutureRoyalties" scale="6" id="f-1419">541</ix:nonFraction> million for the year ended December 31, 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:LiabilityRecognisedForEstimatedFutureRoyalties" scale="6" id="f-1420">35</ix:nonFraction> million for the six months ended June 30, 2023) for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the US</ix:continuation>.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The impact of the ineffective portion of hedging relationships was not material in either 2024 or 2023.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.251%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">29</span></div></td></tr></table></div></div></div><div id="i3ef621f573d04e32b436c2b3b98c6331_94"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="f-1421" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.19. INCOME TAX EXPENSE</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has elected for tax consolidations in a number of countries, principally France, Germany, the United Kingdom and the United States.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" id="f-1422" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the allocation of income tax expense between current and deferred taxes:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:59.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(12 months)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current taxes</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CurrentTaxExpenseIncome" format="ixt:num-dot-decimal" scale="6" id="f-1423">1,243</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CurrentTaxExpenseIncome" format="ixt:num-dot-decimal" scale="6" id="f-1424">1,171</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CurrentTaxExpenseIncome" format="ixt:num-dot-decimal" scale="6" id="f-1425">2,560</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:DeferredTaxExpenseIncome" scale="6" id="f-1426">780</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:DeferredTaxExpenseIncome" scale="6" id="f-1427">441</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:DeferredTaxExpenseIncome" scale="6" id="f-1428">958</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="f-1429">463</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="f-1430">730</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-1431">1,602</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1432">2,739</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1433">4,238</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1434">7,153</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" id="f-1435" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:59.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(as a percentage)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(12 months)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Standard tax rate applicable in France</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-1436">25.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-1437">25.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-1438">25.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Difference between the standard French tax rate and the rates applicable to Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (b)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="ifrs-full:TaxRateEffectOfForeignTaxRates" scale="-2" id="f-1439">14.3</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" sign="-" name="ifrs-full:TaxRateEffectOfForeignTaxRates" scale="-2" id="f-1440">8.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" sign="-" name="ifrs-full:TaxRateEffectOfForeignTaxRates" scale="-2" id="f-1441">13.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Probable reversal of temporary differences on investments in Opella subsidiaries </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="sny:TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" format="ixt:fixed-zero" scale="-2" id="f-1442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="sny:TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" format="ixt:fixed-zero" scale="-2" id="f-1443">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="sny:TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" scale="-2" id="f-1444">5.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revisions to tax exposures and settlements of tax disputes</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" scale="-2" id="f-1445">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" scale="-2" id="f-1446">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" scale="-2" id="f-1447">2.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration liabilities</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="sny:TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" format="ixt:fixed-zero" scale="-2" id="f-1448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="sny:TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" format="ixt:fixed-zero" scale="-2" id="f-1449">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="sny:TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" scale="-2" id="f-1450">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (d)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="-2" id="f-1451">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" sign="-" name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="-2" id="f-1452">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="-2" id="f-1453">2.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-1454">16.9</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-1455">17.3</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-1456">22.4</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-39" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.).</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><ix:footnote id="fn-40" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><ix:footnote id="fn-41" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">In accordance with IAS12, a deferred tax liability was recognised in 2023 on the temporary differences arising on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Opella business, as announced in October 2023.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><ix:footnote id="fn-42" continuedAt="fn-42-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span></ix:footnote><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"><ix:continuation id="fn-42-1">For the six months ended June 30, 2024, this line includes a tax expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:CurrentTaxExpenseRelatedToPillarTwo" scale="6" id="f-1457">52</ix:nonFraction> million, representing the estimated impact of Pillar 2 based on Sanofi&#8217;s current understanding of Pillar Two rules</ix:continuation>.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_97"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" id="f-1458" continuedAt="f-1458-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.20. SEGMENT INFORMATION</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi reports <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="sny:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-1459">two</ix:nonFraction> operating segments: Biopharma and Opella (formerly Consumer Healthcare &#8211; CHC).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises, for all geographical territories. The segment&#8217;s results include the costs of global support functions that are not within the managerial responsibility of the Opella GBU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Opella operating segment comprises commercial operations relating to consumer healthcare products, and research, development and production activities and global support functions (as listed above) dedicated to the segment, for all geographical territories. The Opella GBU segment&#8217;s results reflect all incurred costs of global support functions attributable to its business.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Other&#8221; category comprises reconciling items, primarily but not limited to (i)&#160;gains and losses on centralized foreign exchange risk hedging transactions that cannot be allocated to the operating segments and (ii)&#160;gains and losses on retained commitments in respect of previously divested operations.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:2.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">30</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:continuation id="f-1458-1" continuedAt="f-1458-2"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.20.1. SEGMENT RESULTS</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.20.1.1. Analysis of net sales</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" id="f-1460" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth net sales for the six months ended June 30, 2024 and June 30, 2023:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.785%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.396%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="6" style="background-color:#d9c6f9;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Biopharma</span></div></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-490" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1461">4,074</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-491" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1462">8,294</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-492" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1463">6,010</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1464">18,378</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-493" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1465">4,194</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-494" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1466">7,366</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-495" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1467">5,907</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-496" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1468">17,467</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Pharma</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-497" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1469">3,692</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-498" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1470">7,550</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-499" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1471">4,817</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-500" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1472">16,059</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-501" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1473">3,624</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-502" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1474">6,709</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-503" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1475">4,744</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-504" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1476">15,077</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #deb3ff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Dupixent</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-505" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1477">770</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-506" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1478">4,437</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-507" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1479">931</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-508" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1480">6,138</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-509" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1481">587</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-510" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1482">3,682</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-511" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1483">609</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-512" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1484">4,878</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Pharma launches</span></div></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-513" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1485">249</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-514" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1486">868</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-515" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1487">178</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-516" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1488">1,295</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-517" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1489">168</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-518" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1490">460</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-519" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1491">87</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-520" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1492">715</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nexviazyme</span></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-521" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1493">95</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-522" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1494">174</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-523" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1495">51</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-524" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1496">320</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-525" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1497">42</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-526" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1498">123</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-527" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1499">19</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-528" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1500">184</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sarclisa</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-529" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1501">64</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-530" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1502">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-531" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1503">63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-532" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1504">227</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-533" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1505">56</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-534" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1506">76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-535" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1507">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-536" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1508">181</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ALTUVIIIO</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-537" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1509">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-538" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1510">259</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-539" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1511">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-540" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1512">280</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-541" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1513">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-542" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1514">17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-543" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1515">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-544" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1516">19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rezurock</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-545" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1517">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-546" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1518">188</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-547" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1519">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-548" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1520">207</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-549" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1521">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-550" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1522">140</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-551" decimals="-6" sign="-" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1523">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-552" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1524">141</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cablivi</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-553" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1525">43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-554" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1526">60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-555" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1527">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-556" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1528">113</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-557" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1529">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-558" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1530">58</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-559" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1531">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-560" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1532">113</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Xenpozyme</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-561" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1533">24</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-562" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1534">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-563" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1535">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-564" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1536">72</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-565" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1537">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-566" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1538">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-567" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1539">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-568" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1540">38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Enjaymo</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-569" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1541">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-570" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1542">30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-571" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1543">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-572" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1544">55</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-573" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1545">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-574" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1546">19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-575" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1547">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-576" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1548">33</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tzield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-577" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1549">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-578" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1550">20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-579" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1551">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-580" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1552">21</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-581" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1553">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-582" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1554">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-579" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1555">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-583" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1556">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total other products</span></div></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-584" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1557">2,673</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-585" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1558">2,245</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-586" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1559">3,708</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-587" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1560">8,626</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-588" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1561">2,869</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-589" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1562">2,567</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-590" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1563">4,048</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-591" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1564">9,484</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Industrial sales</span></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-592" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1565">274</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-593" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1566">3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-594" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1567">1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-595" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1568">278</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-596" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1569">264</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-597" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1570">3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-598" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1571">13</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-599" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1572">280</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Vaccines</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-600" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1573">382</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-601" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1574">744</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-602" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1575">1,193</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-603" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1576">2,319</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-604" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1577">570</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-605" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1578">657</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-606" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1579">1,163</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-607" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1580">2,390</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Influenza Vaccines</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-608" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1581">30</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-609" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1582">16</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-610" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1583">142</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-611" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1584">188</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-612" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1585">37</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-613" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1586">19</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-614" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1587">106</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-615" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1588">162</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Polio/Pertussis/<br/>Hib Vaccines</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-616" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1589">248</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-617" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1590">311</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-618" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1591">789</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-619" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1592">1,348</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-620" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1593">231</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-621" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1594">347</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-622" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1595">850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-623" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1596">1,428</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV vaccines (Beyfortus)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-624" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1597">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-625" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1598">116</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-626" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1599">77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-627" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1600">200</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-628" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1601">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-629" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1602">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-630" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1603">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-631" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1604">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Meningitis, travel and endemics vaccines</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-632" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1605">97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-633" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1606">301</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-634" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1607">184</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-635" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1608">582</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-636" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1609">72</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-637" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1610">291</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-638" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1611">206</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-639" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1612">569</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Opella</span></div></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-640" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1613">808</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-641" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1614">773</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-642" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1615">1,250</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1616">2,831</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-643" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1617">840</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-644" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1618">622</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-645" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1619">1,258</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-646" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1620">2,720</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Seasonal symptoms &amp; pain relief</span></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-647" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1621">1,216</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-648" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1622">1,261</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Wellness brands</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-649" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1623">1,258</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-650" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1624">1,112</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Others</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-651" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1625">357</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-652" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1626">347</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total net sales</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-653" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1627">4,882</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-654" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1628">9,067</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-655" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1629">7,260</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1630">21,209</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-656" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1631">5,034</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-657" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1632">7,988</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-658" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1633">7,165</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1634">20,187</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.20.1.2. Business operating income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi reports segment results on the basis of &#8220;Business operating income&#8221;, a non-IFRS financial measure used internally by the chief operating decision maker to measure the performance of each operating segment and to allocate resources.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Business operating income&#8221; is derived from</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, adjusted as follows: </span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amounts reported in the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items, Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> relating to business combinations (IFRS 3) or divestments and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">expenses arising from the remeasurement of inventories following a business combination (IFRS 3) are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature) are eliminated; </span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the share of profits/losses from investments accounted for using the equity method is added for joint ventures and associates with which Sanofi has entered into a strategic partnership agreement; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">net income attributable to non-controlling interests is deducted.</span></div></ix:continuation><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.251%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">31</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory" id="f-1635" escape="true"><ix:continuation id="f-1458-2" continuedAt="f-1458-3"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Segment results are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.340%"><tr><td style="width:1.0%"/><td style="width:34.702%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.951%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024 (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Opella</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1636">18,378</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1637">2,831</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-659" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1638">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-660" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1639">21,209</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1640">1,257</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-6" name="ifrs-full:OtherRevenue" scale="6" id="f-1641">32</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-659" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:fixed-zero" scale="6" id="f-1642">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-660" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1643">1,289</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-1644">5,756</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-1645">1,077</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-659" decimals="-6" sign="-" name="ifrs-full:CostOfSales" scale="6" id="f-1646">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-660" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-1647">6,830</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1648">3,331</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-1649">92</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-659" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="6" id="f-1650">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-660" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1651">3,423</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1652">4,260</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1653">1,002</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-659" decimals="-6" sign="-" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1654">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-660" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1655">5,260</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1656">1,417</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-6" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-1657">43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-659" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-1658">19</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-660" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1659">1,393</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1660">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1661">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-659" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" format="ixt:fixed-zero" scale="6" id="f-1662">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-660" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1663">75</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1664">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1665">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-659" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" format="ixt:fixed-zero" scale="6" id="f-1666">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-660" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1667">11</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1668">4,931</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-6" name="sny:BusinessOperatingIncome" scale="6" id="f-1669">739</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-659" decimals="-6" sign="-" name="sny:BusinessOperatingIncome" scale="6" id="f-1670">14</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-660" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1671">5,656</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><ix:footnote id="fn-43" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;The &#8220;Other&#8221; column reconciles segmental results to the total per the consolidated financial statements.</span></div></ix:footnote><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.403%"><tr><td style="width:1.0%"/><td style="width:34.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.235%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023 (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Opella</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-496" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1672">17,467</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-646" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1673">2,720</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-661" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1674">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-662" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1675">20,187</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-496" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1676">1,331</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-646" decimals="-6" name="ifrs-full:OtherRevenue" scale="6" id="f-1677">27</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-661" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:fixed-zero" scale="6" id="f-1678">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-662" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1679">1,358</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-496" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-1680">5,388</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-646" decimals="-6" name="ifrs-full:CostOfSales" scale="6" id="f-1681">949</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-661" decimals="-6" name="ifrs-full:CostOfSales" scale="6" id="f-1682">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-662" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-1683">6,342</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-496" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1684">3,082</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-646" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-1685">111</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-661" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="6" id="f-1686">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-662" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1687">3,193</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-496" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1688">4,248</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-646" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1689">936</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-661" decimals="-6" sign="-" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1690">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-662" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1691">5,182</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-496" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-1692">897</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-646" decimals="-6" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-1693">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-661" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-1694">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-662" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-1695">805</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-496" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1696">48</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-646" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1697">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-661" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" format="ixt:fixed-zero" scale="6" id="f-1698">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-662" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1699">55</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-496" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1700">11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-646" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1701">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-661" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" format="ixt:fixed-zero" scale="6" id="f-1702">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-662" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1703">19</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-496" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1704">5,220</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-646" decimals="-6" name="sny:BusinessOperatingIncome" scale="6" id="f-1705">850</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-661" decimals="-6" sign="-" name="sny:BusinessOperatingIncome" scale="6" id="f-1706">11</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-662" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1707">6,059</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><ix:footnote id="fn-44" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The &#8220;Other&#8221; column reconciles segmental results to the total per the consolidated financial statements.</span></div></ix:footnote><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.554%"><tr><td style="width:1.0%"/><td style="width:34.265%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.210%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Opella</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1708">37,890</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1709">5,180</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-663" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1710">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-664" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1711">43,070</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1712">3,322</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-6" name="ifrs-full:OtherRevenue" scale="6" id="f-1713">52</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-663" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:fixed-zero" scale="6" id="f-1714">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-664" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1715">3,374</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-1716">12,282</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-1717">1,933</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-663" decimals="-6" name="ifrs-full:CostOfSales" scale="6" id="f-1718">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-664" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-1719">14,216</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1720">6,509</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-1721">219</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-663" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="6" id="f-1722">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-664" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1723">6,728</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1724">8,868</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1725">1,828</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-663" decimals="-6" sign="-" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1726">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-664" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1727">10,692</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1728">2,387</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-6" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-1729">181</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-663" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-1730">18</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-664" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1731">2,224</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1732">101</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1733">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-663" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" format="ixt:fixed-zero" scale="6" id="f-1734">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-664" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1735">122</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1736">20</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1737">16</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-663" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" format="ixt:fixed-zero" scale="6" id="f-1738">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-664" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1739">36</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1740">11,247</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1741">1,438</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-663" decimals="-6" sign="-" name="sny:BusinessOperatingIncome" scale="6" id="f-1742">15</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-664" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1743">12,670</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><ix:footnote id="fn-45" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The &#8220;Other&#8221; column reconciles segmental results to the total per the consolidated financial statements.</span></div></ix:footnote></ix:continuation></ix:nonNumeric><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:2.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">32</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-1458-3" continuedAt="f-1458-4"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" id="f-1744" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below, presented in compliance with IFRS 8, shows a reconciliation between &#8220;Business operating income&#8221; and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:59.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024 ( 6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023 ( 6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-665" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1745">5,656</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-666" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1746">6,059</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-667" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1747">12,670</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-668" decimals="-6" sign="-" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1748">75</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-669" decimals="-6" sign="-" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1749">55</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-670" decimals="-6" sign="-" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1750">122</ix:nonFraction>)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net income attributable to non-controlling interests </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-668" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1751">11</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-669" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1752">19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-670" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1753">36</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization and impairment of intangible assets </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-668" decimals="-6" name="sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1754">690</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-669" decimals="-6" name="sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1755">1,050</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-670" decimals="-6" name="sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1756">3,068</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-668" decimals="-6" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" scale="6" id="f-1757">66</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-669" decimals="-6" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" scale="6" id="f-1758">26</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-670" decimals="-6" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" scale="6" id="f-1759">93</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expense arising from the impact of acquisitions on inventories </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-668" decimals="-6" name="sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" scale="6" id="f-1760">19</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-669" decimals="-6" name="sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" scale="6" id="f-1761">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-670" decimals="-6" name="sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" scale="6" id="f-1762">20</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-668" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" format="ixt:num-dot-decimal" scale="6" id="f-1763">1,331</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-669" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" scale="6" id="f-1764">547</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-670" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" format="ixt:num-dot-decimal" scale="6" id="f-1765">1,490</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-668" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-1766">442</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-669" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-1767">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-670" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-1768">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1769">3,044</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1770">4,322</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1771">7,875</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-1772">586</ix:nonFraction>)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-1773">370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-1774">1,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-1775">281</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-1776">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-1777">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1778">2,739</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1779">4,238</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1780">7,153</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-46" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Joint ventures and associates with which Sanofi has entered into a strategic alliance.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><ix:footnote id="fn-47" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><ix:footnote id="fn-48" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">As of June 30, 2024, this line includes a net reversal of impairment losses amounting to of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:NetReversalOfImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-1781">371</ix:nonFraction>&#160;million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights in the Biopharma segment. For 2023, this amount mainly comprises an impairment loss of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:NetReversalOfImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-1782">833</ix:nonFraction>&#160;million, reflecting the impact of the strategic decision to de-prioritize certain R&amp;D programs, in particular those related to the NK Cell and PRO-XTEN technology platforms. </span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><ix:footnote id="fn-49" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><ix:footnote id="fn-50" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">See note B.16.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt"><ix:footnote id="fn-51" footnoteRole="http://www.xbrl.org/2003/role/footnote">See note B.17</ix:footnote>.</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.20.2. OTHER SEGMENT INFORMATION</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The tables below show the split by operating segment of (i)&#160;the carrying amount of investments accounted for using the equity method for which Sanofi has entered into a strategic partnership agreement, (ii)&#160;acquisitions of property, plant and equipment, and (iii)&#160;acquisitions of intangible assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Investments accounted for using the equity method in the Biopharma segment mainly comprise MSP Vaccine Company and Infraserv GmbH &amp; Co. H&#246;chst&#160;KG (see Note B.5.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" id="f-1783" continuedAt="f-1783-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"><tr><td style="width:1.0%"/><td style="width:43.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024 (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Opella</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-671" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-1784">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-672" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-1785">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-673" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-1786">243</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-1787">882</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-1788">68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-660" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-1789">950</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="6" id="f-1790">922</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="6" id="f-1791">14</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-660" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="6" id="f-1792">936</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><ix:footnote id="fn-52" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Carrying amount at the end of the reporting period.</span></div></ix:footnote><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"><tr><td style="width:1.0%"/><td style="width:43.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023 (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Opella</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-674" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-1793">231</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-675" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-1794">10</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-676" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-1795">241</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-496" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-1796">751</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-677" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-1797">31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-662" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-1798">782</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets </span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-496" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="6" id="f-1799">132</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-677" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="6" id="f-1800">16</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-662" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="6" id="f-1801">148</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><ix:footnote id="fn-53" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Carrying amount at the end of the reporting period.</span></div></ix:footnote></ix:nonNumeric></ix:continuation><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.251%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">33</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:continuation id="f-1458-4"><ix:continuation id="f-1783-1"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"><tr><td style="width:1.0%"/><td style="width:43.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Opella</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-678" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-1802">234</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-679" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-1803">28</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-680" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-1804">262</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1805">1,619</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-1806">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-664" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1807">1,719</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1808">1,287</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="6" id="f-1809">18</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-664" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1810">1,305</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:footnote id="fn-54" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Carrying amount at the end of the reporting period.</span></div></ix:footnote><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.20.3. INFORMATION BY GEOGRAPHICAL REGION</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The geographical information on net sales provided below is based on the geographical location of the customer.</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGeographicalAreasExplanatory" id="f-1811" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.188%"><tr><td style="width:1.0%"/><td style="width:37.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">of which France</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">United States</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other countries</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-681" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1812">21,209</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-653" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1813">4,882</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-682" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1814">1,082</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-654" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1815">9,067</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-683" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1816">7,260</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">property, plant and equipment</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-684" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1817">10,264</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-685" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1818">5,611</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-686" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1819">3,079</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-687" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1820">2,377</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-688" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1821">2,276</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">goodwill</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-684" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1822">50,080</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-685" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1823">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-686" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1824">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-687" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1825">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-688" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1826">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">other intangible assets</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-684" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1827">26,653</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-685" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1828">5,156</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-686" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1829">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-687" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1830">20,726</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-688" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1831">771</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:37.266%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">of which France</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;United States</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other countries</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-689" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1832">20,187</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-656" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1833">5,034</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-690" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1834">1,174</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-657" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1835">7,988</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-691" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1836">7,165</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">property, plant and equipment</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-692" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1837">9,804</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-693" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1838">5,462</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-694" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1839">2,921</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-695" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1840">2,364</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-696" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1841">1,978</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">goodwill</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-692" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1842">49,243</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-693" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1843">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-694" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1844">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-695" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1845">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-696" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1846">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">other intangible assets</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-692" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1847">24,590</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-693" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1848">5,961</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-694" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1849">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-695" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1850">17,595</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-696" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1851">1,034</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:37.266%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023  (12 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">of which France</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">United States</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other countries</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1852">43,070</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-698" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1853">10,392</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-699" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1854">2,379</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-700" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1855">18,512</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-701" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1856">14,166</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">property, plant and equipment</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-702" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1857">10,160</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-703" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1858">5,659</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-704" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1859">3,085</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-705" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1860">2,322</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-706" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1861">2,179</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">goodwill</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-702" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1862">49,404</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-703" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1863">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-704" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1864">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-705" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1865">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-706" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1866">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">other intangible assets</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-702" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1867">24,319</ix:nonFraction>&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-703" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1868">5,566</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-704" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1869">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-705" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1870">17,850</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-706" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1871">903</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As stated in Note D.5. to the consolidated financial statements for the year ended December 31, 2023, goodwill is not allocated by geographical region.</span></div></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div id="i3ef621f573d04e32b436c2b3b98c6331_286"></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.20.4. PRINCIPAL CUSTOMERS AND CREDIT RISK</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales generated by Sanofi with its biggest customers, in particular certain wholesalers in the United States, represented <ix:nonFraction unitRef="number" contextRef="c-707" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1872">29</ix:nonFraction>% of net sales in the first half of 2024. Sanofi&#8217;s three largest customers respectively accounted for approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-708" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1873">13</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-709" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1874">9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-710" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1875">7</ix:nonFraction>%</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> of consolidated net sales in the first half of 2024, mostly in the Biopharma segment (versus approximately <ix:nonFraction unitRef="number" contextRef="c-711" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1876">11</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-712" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1877">9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-713" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1878">7</ix:nonFraction>% in the first half of 2023).</span></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:2.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">34</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td></tr></table></div></div></div><div id="i3ef621f573d04e32b436c2b3b98c6331_100"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  </span></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="f-1879" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">C/ EVENTS SUBSEQUENT TO JUNE 30, 2024</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No significant events occurred between the end of the reporting period and the date on which the condensed consolidated financial statements were signed off by the Board of Directors.</span></div></ix:nonNumeric><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.251%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">35</span></div></td></tr></table></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>exhibit992-2024halfyearman.htm
<DESCRIPTION>EX-99.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i0cf07956a9104271aa41947fae4e5162_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.403%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TABLE OF CONTENTS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">2</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">HALF-YEAR MANAGEMENT REPORT</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a href="#i0cf07956a9104271aa41947fae4e5162_4" style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">37</a></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#i0cf07956a9104271aa41947fae4e5162_7" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">A&#47; Significant events of the first half of </a>2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i0cf07956a9104271aa41947fae4e5162_7" style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">37</a></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#i0cf07956a9104271aa41947fae4e5162_304" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">B&#47; Progress on implementation of the Corporate Social Responsibility strategy</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i0cf07956a9104271aa41947fae4e5162_304" style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">40</a></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#i0cf07956a9104271aa41947fae4e5162_22" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">C&#47; Events subsequent to June 30</a>, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i0cf07956a9104271aa41947fae4e5162_22" style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">43</a></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#i0cf07956a9104271aa41947fae4e5162_25" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">D&#47; Consolidated financial statements for the first half of</a> 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i0cf07956a9104271aa41947fae4e5162_25" style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">44</a></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#i0cf07956a9104271aa41947fae4e5162_49" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">E&#47; Risk factors and related party transactions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i0cf07956a9104271aa41947fae4e5162_49" style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">57</a></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#i0cf07956a9104271aa41947fae4e5162_52" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">F&#47; Outlook</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i0cf07956a9104271aa41947fae4e5162_52" style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">58</a></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a href="#i0cf07956a9104271aa41947fae4e5162_58" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none">G&#47; Appendix &#8211; Research and Development Pipeline</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i0cf07956a9104271aa41947fae4e5162_58" style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">60</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">3</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a href="#i0cf07956a9104271aa41947fae4e5162_61" style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">STATUTORY AUDITORS&#8217; REPORT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a href="#i0cf07956a9104271aa41947fae4e5162_61" style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">63</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">4</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a href="#i0cf07956a9104271aa41947fae4e5162_64" style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">RESPONSIBILITY STATEMENT OF THE CERTIFYING OFFICER &#8211; HALF-YEAR FINANCIAL REPORT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a href="#i0cf07956a9104271aa41947fae4e5162_64" style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">64</a></font></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.560%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i0cf07956a9104271aa41947fae4e5162_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:23pt;font-weight:400;line-height:120%"> </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Serif',serif;font-size:26pt;font-style:italic;font-weight:400;line-height:120%">2. HALF-YEAR MANAGEMENT REPORT</font></td></tr></table></div><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:23pt;font-weight:400;line-height:120%">   </font></div><div id="i0cf07956a9104271aa41947fae4e5162_7"></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:9pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">A&#47; SIGNIFICANT EVENTS OF THE FIRST HALF OF 2024</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.1. FIRST-HALF OVERVIEW</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the first half of 2024, Sanofi continued to implement its &#8220;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Play to Win</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8221; strategy, initiating the second phase which aims to launch major innovations, redeploy resources and develop leading innovative R&#38;D. Significant events connected with the implementation of that strategy are described below (for additional information on developments related to Research and Development see also section &#8220;A.2. Research and Development&#8221;).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January 9 2024, </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Brian Foard</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a healthcare industry veteran and Sanofi leader in the United States, was named head of the Specialty Care Global Business Unit (GBU). With this appointment, Brian became a member of Sanofi&#8217;s Executive Committee.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February&#160;1, 2024, Sanofi announced that</font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> Fran&#231;ois-Xavier Roger </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">would be appointed Chief Financial Officer and a member of Sanofi&#8217;s Executive Committee effective April&#160;1, 2024. Based in Paris, he succeeds Jean-Baptiste Chasseloup de Chatillon, who has stepped down from his role to become Head of Apprentis d&#8217;Auteuil.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 10, 2024, as part of its commitment to developing a diverse portfolio of best-in-class vaccines, Sanofi announced that it had entered into a co-exclusive licensing agreement with </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Novavax</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a biotechnology company headquartered in Maryland, US. The terms of the agreement include (i) a co-exclusive license to co-commercialize Novavax&#8217;s current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements and in India, Japan, and South Korea, where Novavax has existing partnership agreements)&#59; (ii) a sole license to Novavax&#8217;s adjuvanted COVID-19 vaccine for use in combination with Sanofi&#8217;s flu vaccines&#59; and (iii) a non-exclusive license to use the Matrix-M adjuvant in vaccine products. In addition, Sanofi took a minority (&#60;5%) equity investment in Novavax.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 13, 2024, as the largest private contributor to the security and independence of France's health ecosystem, Sanofi announced that it was increasing its</font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> investment in major industrial projects by &#8364;1.1 billion</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, by creating new bioproduction capacity at its sites in Vitry-sur-Seine (Val de Marne), Le Trait (Seine-Maritime) and Lyon Gerland (Rh&#244;ne). This new investment will create more than 500 jobs and significantly strengthen France's ability to control the production of essential medicines from start to finish, for the present day and into the future. This plan brings to more than &#8364;3.5 billion the amount committed by Sanofi since the COVID-19 pandemic to major projects to keep production of medicines and vaccines in France for patients around the world.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 21, 2024, Sanofi announced a collaboration with</font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> Formation Bio and OpenAI </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This is the first collaboration of its kind within the pharma and life sciences industries. Sanofi will leverage this partnership to provide access to proprietary data to develop AI models as it continues on its path to becoming the first biopharma company powered by AI at scale.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 30, 2024, Sanofi announced that it had completed the acquisition of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Inhibrx, Inc </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(Inhibrx), a publicly-traded, clinical-stage biopharmaceutical company focused on developing a pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. The acquisition added SAR447537 (formerly INBRX-101) to Sanofi&#8217;s rare disease development portfolio, and underscores the company&#8217;s commitment to developing differentiated, potentially best-in-class therapeutics, leveraging its existing strengths and capabilities. This transaction followed on from Sanofi's January 23, 2024 announcement of a merger agreement under which Sanofi planned to acquire Inhibrx following the spin-off of its non-INBRX-101 assets and liabilities into a new publicly-traded company (&#34;New Inhibrx&#34;). Under the terms of the merger agreement, Sanofi agreed to (i) pay Inhibrx stockholders $30 per share of Inhibrx common stock on closing of the merger (approximately $1.7 billion) and issue one contingent value right (CVR) per share of Inhibrx common stock, entitling its holder to receive a deferred cash payment of $5, contingent upon the achievement of certain regulatory milestones (approximately $0.3 billion, if those milestones are achieved)&#59; (ii) pay off Inhibrx&#8217;s outstanding third-party debt (approximately $0.2 billion)&#59; and (iii) contribute capital to &#34;New Inhibrx&#34; (at least $0.2 billion). Since the closing of the merger, Sanofi has held 100% of the equity interests in Inhibrx, which has become a wholly owned subsidiary of Sanofi. Additionally, Inhibrx retained a minority stake (approximately 8%) in &#34;New Inhibrx&#34;.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On June 20, 2024, Sanofi and </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Biovac</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a biopharmaceutical company based in Cape Town, South Africa, announced a local manufacturing partnership to produce inactivated polio vaccines (IPV) in Africa. This agreement is designed to enable regional manufacturing of IPV to serve the potential needs of over 40 African countries. This partnership with Sanofi makes Biovac the first African producer of IPV on and for the African continent, and supports the Africa Centers for Disease Control and Prevention&#8217;s ambition to have 60% of local vaccines produced in Africa by 2040.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On June 21 2024, </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Audrey Duval Derveloy</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a seasoned healthcare industry leader and Sanofi France&#8217;s President, was named Executive Vice President, Global Head of Corporate Affairs. Audrey became a member of Sanofi&#8217;s Executive Committee, reporting to CEO Paul Hudson, and is based in Paris. Her appointment was effective July 1, 2024.</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:95.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> HALF-YEAR FINANCIAL REPORT</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">37</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net sales for the first half of 2024 amounted to &#8364;21,209&#160;million, 5.1% higher than in the first half of 2023. At constant exchange rates (CER)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, net sales rose by 8.4%, driven mainly by strong performances for Dupixent, increased sales of Nexviazyme, ALTUVIIIO, and Beyfortus.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;2,246&#160;million in the first half of 2024, versus &#8364;3,430 million in the first half of 2023. Earnings per share was &#8364;1.80, versus &#8364;2.74 for the first half of 2023. Business net income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">was &#8364;4,380 million, down 10.2% on the first half of 2023, while business earnings per share (business EPS</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) was &#8364;3.51, 10.0% lower than in the first half of 2023.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div id="i0cf07956a9104271aa41947fae4e5162_10"></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.2. RESEARCH AND DEVELOPMENT</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the first half of 2024, Sanofi maintained its R&#38;D efforts with the aim of improving quality of life for people around the globe by developing innovative vaccines and medicines.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immunology</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Dupixent</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (dupilumab) was approved by the US Food and Drug Administration (FDA) in January for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE). This approval expands the initial FDA approval for EoE in May 2022 for patients aged 12 years and older, weighing at least 40 kg. The FDA evaluated Dupixent for this expanded indication under Priority Review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in treating serious conditions. Dupixent is now the first and only medicine approved in the US specifically indicated to treat these patients, and regulatory submission is currently under review by the European Medicines Agency for this age group. The New England Journal of Medicine has published results from the positive Phase 3 study that was the basis for the FDA approval and regulatory submission in Europe. The study showed a greater proportion of those receiving weight-tiered higher dose Dupixent experienced significant improvements in many key disease measures of EoE, compared to placebo at week 16.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The FDA updated the label for </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Dupixent</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in atopic dermatitis, adding efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and&#47;or foot involvement. These Phase 3 data are from the first and only trial evaluating a biologic specifically for this difficult-to-treat population and have also been added to the Dupixent label in the European Union, with regulatory submissions underway in additional countries.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In July, the European Medicines Agency (EMA) approved </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Dupixent</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils. This approval represents the sixth approved indication for Dupixent in the EU and seventh approved indication globally. The approval was based on results from the landmark Phase 3 BOREAS and NOTUS studies, which were separately published in The New England Journal of Medicine and evaluated the efficacy and safety of Dupixent in adults with uncontrolled COPD with evidence of type 2 inflammation. Earlier in February, the US FDA accepted for Priority Review the supplemental Biologics License Application (sBLA) for </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Dupixent</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in this indication. In May, the agency extended by three months the target action date of its priority review of the sBLA&#59; the revised target action date is September 27, 2024. The FDA did not raise any concerns regarding the approvability of Dupixent for this indication. The FDA had requested additional efficacy analyses on the efficacy of Dupixent in the BOREAS and NOTUS pivotal trials.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The FDA has accepted for Priority Review the sBLA for </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Dupixent</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> as an add-on maintenance treatment for adolescents aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP). The target action date for the FDA decision is September 15, 2024. The sBLA in adolescents is supported by an extrapolation of efficacy data from two positive pivotal studies (SINUS-24 and SINUS-52) in adults with CRSwNP. These studies demonstrated that Dupixent significantly improved nasal congestion&#47;obstruction severity, nasal polyp size and sense of smell, while also reducing the need for systemic corticosteroids or surgery, at 24 weeks compared to placebo. The sBLA was also supported by the safety data of Dupixent in its currently approved indications for adolescents.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Dupixent</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. Japan is the first country to approve Dupixent for CSU, emphasizing the value of Dupixent as a novel treatment option to manage this disease in patients with unmet needs. Regulatory submissions are also under review in the European Union and China.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June, the FDA approved the sBLA for the expanded use of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Kevzara</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients who weigh 63 kg or greater.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rare diseases</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Regulatory submissions for </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">fitusiran</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the treatment of hemophilia A or B in adults and adolescents with or without inhibitors have been completed in China, Brazil, and the US, with a target action date for the FDA decision of March 28, 2025. The FDA granted fitusiran Breakthrough Therapy Designation for hemophilia B with inhibitors in December 2023. New ATLAS Phase 3 study data reinforcing the potential of fitusiran to provide prophylaxis for people with hemophilia A or B, with or without inhibitors were presented in June at the 32</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> Congress of the International Society on Thrombosis and Haemostasis (ISTH).</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Non-IFRS financial measure&#58; see definition in D.3., &#8220;Net sales&#8221;.</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Non-IFRS financial measure&#58; see definition in D.2., &#8220;Business net income&#8221;.</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"></td><td style="width:2.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">38</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2021</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June, the European Commission granted marketing authorization for </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ALTUVOCT</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(</font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ALTUVIIIO</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the US, Japan, and Taiwan) for the treatment and prevention of bleeds and perioperative prophylaxis in hemophilia A to Sanofi&#8217;s partner in the EU, Sobi. The EU also endorsed the retention of orphan designation, granting a ten-year market exclusivity period. The FDA updated the label for </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ALTUVIIIO</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to include full results from the XTEND-Kids phase 3 study showing that once-weekly dosing with ALTUVIIIO delivers highly effective bleed protection in children with hemophilia A. ALTUVIIIO was first approved in February 2023 for adults and children with hemophilia A for routine prophylaxis and on-demand treatment to control bleeding episodes as well as for perioperative management (surgery), and this label update builds on the interim XTEND-Kids data from 2023 to include full results. Interim results on the efficacy and safety of ALTUVIIIO from the XTEND-Kids phase 3 study were presented in June at the 32</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> Congress of the ISTH. Full results from the XTEND-Kids study were published in July in The New England Journal of Medicine (NEJM), highlighting the efficacy, safety, and pharmacokinetic profile of ALTUVIIIO.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Positive results from the LUNA 3 phase 3 study demonstrated that </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">rilzabrutinib</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia (ITP). The safety profile of rilzabrutinib was consistent with that reported in previous studies. Regulatory submission is planned for the second half of 2024. Previously, rilzabrutinib was granted Fast Track Designation and Orphan Drug Designation by the FDA. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The AMETHIST Phase 3 study of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">venglustat</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the treatment of GM2 gangliosidosis was discontinued based on the absence of positive trends on clinical endpoints. The data reinforced the favorable safety profile and did not impact the other indications currently being tested in Phase 3 studies (Fabry disease and Gaucher disease type 3).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and Fulcrum Therapeutics entered into a collaboration and license agreement for the development and commercialization of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">losmapimod</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> a selective p38&#945;&#47;&#946; mitogen-activated protein kinase (MAPK) small molecule inhibitor being investigated in phase 3 for the treatment of facioscapulohumeral muscular dystrophy. Losmapimod has orphan drug designation in US, orphan designation in the EU, FDA fast track designation and FSHD is included on the list of rare diseases in China.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurology</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Supported by encouraging efficacy and safety Phase 2 data, two Phase 3 studies, evaluating </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">rilibrubart</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in standard-of-care (SOC)-refractory chronic inflammatory demyelinating polyneuropathy (CIDP) and intravenous immunoglobulin (IVIg)-treated CIDP, have been initiated and are currently recruiting patients.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncology</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The FDA accepted for Priority Review the sBLA for the investigational use of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Sarclisa</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (isatuximab) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM). If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care VRd in newly diagnosed patients not eligible for transplant, which would be the third indication for Sarclisa in multiple myeloma. The target action date for the FDA decision is September 27, 2024. Other regulatory submissions are currently under review in the EU, Japan, and China. Data from the IMROZ Phase 3 study demonstrated </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Sarclisa </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in combination with standard-of-care (VRd) followed by Sarclisa-Rd (the IMROZ regimen) significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with NDMM not eligible for transplant. IMROZ is the first global Phase 3 study of an anti-CD38 monoclonal antibody in combination with standard-of-care VRd to significantly improve PFS and show deep responses in this patient population who often have poor prognoses.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaccines</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In March, </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Beyfortus</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(nirsevimab)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">was approved in Japan for the prophylaxis of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in all neonates, infants and children entering their first RSV season, and the prevention of RSV LRTD in neonates, infants and children at risk of serious RSV infection entering their first or second RSV season.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">New </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Beyfortus</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">real-world evidence data were published in The Lancet, showing Beyfortus substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention. Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the outcomes from HARMONIE, a Phase 3b clinical study conducted in close to real-life conditions.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Phase 3 study of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">MenQuadfi</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">to protect infants from six weeks of age against invasive meningococcal disease caused by serogroups ACWY read out positively on safety and immunogenicity, supporting regulatory submission in the US in the second half of 2024 to extend the indication down to six weeks of age.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Phase 3 study evaluating </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">SP0125</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a live attenuated RSV vaccine for toddlers, for the prevention of respiratory syncytial virus (RSV) in toddlers was initiated.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Novavax</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> announced, in May, co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">flu-COVID-19</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">combination vaccines.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For an update on our research and development pipeline, refer to Section G&#47; of this half-year management report.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:94.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SANOFI 2023 HALF-YEAR FINANCIAL REPORT</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#</font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.3. OTHER SIGNIFICANT EVENTS</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.3.1 CORPORATE GOVERNANCE</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Combined General Shareholders&#8217; Meeting of Sanofi was held on April 30, 2024 at the </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Palais des Congr&#232;s </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in Paris, and was chaired by Fr&#233;d&#233;ric Oud&#233;a. All resolutions submitted to the vote were adopted by the shareholders. Decisions taken by the General Meeting included approving the individual company and consolidated financial statements for the year ended December 31, 2023 and distributing an ordinary annual dividend of &#8364;3.76 per share. The meeting also approved the reappointment of Rachel Duan and Lise Kingo as directors, and the appointment of Clotilde Debos, Anne-Fran&#231;oise Nesmes and John Sundy as independent directors. On a proposal from the Appointments, Governance and CSR Committee, the Board of Directors appointed Clotilde Delbos as a member of the Audit and Compensation Committees&#59; Anne-Fran&#231;oise Nesmes as a member of the Audit Committee&#59; and John Sundy as member of the Scientific Committee. Carole Ferrand was appointed as Chair of the Audit Committee&#59; she succeeds Fabienne Lecorvaisier, who will remain as a member of the Committee for the final year of her term of office. Antoine Yver was appointed as Chair of the Scientific Committee and a member of the Strategy Review Committee. The Board of Directors temporarily comprises 17 members, of whom seven are women and two are directors representing employees. The Board of Directors retains a large majority of independent directors.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div id="i0cf07956a9104271aa41947fae4e5162_13"></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.3.2. LEGAL AND ARBITRATION PROCEEDINGS</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of the most significant developments in legal and arbitration proceedings since publication of the financial statements for the year ended December 31, 2023, refer to Note B.14. to the condensed half-year consolidated financial statements.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To the Company's knowledge, with the exception of the significant developments described in Note B.14. to the condensed half-year consolidated financial statements, there are no other governmental, judicial or arbitral proceedings, including any pending or threatened proceedings of which the Company is aware, that are likely to have, or have had over the last six months, material effects on the financial position or profitability of the Company and&#47;or the Group.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div id="i0cf07956a9104271aa41947fae4e5162_16"></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.3.3. OTHER EVENTS</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 31, 2024. Sanofi launched Action 2024, a global employee share ownership plan open to around 80,000 employees in 56 countries. Now in its tenth year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to ensuring that employees benefit from the company&#8217;s growth and success.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The shares were offered at a subscription price of &#8364;72.87, representing a 20% discount to the average of the 20 opening prices of Sanofi shares from May 2 to May 29, 2024. For every five shares subscribed, employees were entitled to receive one free share (up to a maximum of four free shares per employee). Every eligible employee was able to purchase up to 1,500 Sanofi shares, subject to the maximum legal limit set at 25% of their gross annual salary, minus any voluntary deductions already made under employee savings schemes (such as the Group Savings Plan or Group Retirement Savings Plan) during 2024.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div id="i0cf07956a9104271aa41947fae4e5162_304"></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.216%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">40</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">B&#47; PROGRESS ON IMPLEMENTATION OF THE CORPORATE SOCIAL RESPONSIBILITY STRATEGY</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Sanofi continues its progress to improve access to medicines </font></div><div style="margin-bottom:3pt;margin-top:9pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sanofi Global Health Unit&#58; making a difference for our patients in low- and middle-income countries</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s Global Health Unit (GHU) works to address today&#8217;s many growing healthcare challenges &#8211; with a focus on countries with the highest unmet medical needs &#8211; through a self-sustained not-for-profit social business model.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s GHU aims to provide access to a broad portfolio of medicines in 40 countries with the highest unmet medical needs. To that end the GHU created Impact, a unique not-for-profit brand with 30 standard-of-care medicines produced by Sanofi, some of which are considered essential by the World Health Organization (WHO). The Impact medicines cover a wide range of therapeutic areas including diabetes, cardiovascular disease, tuberculosis, malaria and cancer.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi's GHU aims to reach two million people with non-communicable disease (NCD) care in its 40 countries in scope by 2030. Since its creation in 2021, the GHU has made significant progress towards its objective, having already treated 506,130 NCD patients in 31 countries as of the end of March 2024.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To support the set up and development of sustainable healthcare systems, the GHU is also working closely with local communities, authorities and non-governmental organizations to develop disease awareness programs and establish partnerships to drive better care through&#58;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">strengthening supply chains&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">conducting medical training&#59; and</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">providing services to patients.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi's GHU has engaged with Ministries of Health and other partners in several countries, including Rwanda, Uganda, Tanzania and Cambodia. As of March 2024, the GHU pilots 44 active partnerships in 21 countries. Selected examples of projects supported are described below&#58;</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><br></font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:9.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Therapeutic Area</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Country(s)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Activity pillar(s)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Overview and progress in numbers</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">PharmAccess</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Cardio<br>Diabetes</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Zanzibar</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Patient Care model</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">The project is an integrated patient-centered model of care aiming at improving diagnosis and disease management for patients with cardio-metabolic diseases through a care bundle consisting of access to patient group meetings, digital self-management support, remote care and medications.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">CHAZ FBO Zambia</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Cardio<br>Diabetes</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Zambia</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Scaling Patient Care services with<br>faith-based organizations</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">The primary goal is to institutionalize NCD Prevention WHO Best Buys as a standard of care within the church health institutions participating in the project. It includes building the capacity of health workers and community educators in church health institutions in diabetes and hypertension prevention and management, raising awareness of common NCD risk factors, and providing diabetes and hypertension diagnostic and treatment services in the selected church health institutions.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">WCEA</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Cardio<br>Diabetes</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Malawi Tanzania</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Sierre Leone</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Zimbabwe Uganda</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Online HCP Training</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Online NCD training of healthcare professionals across multiple countries.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">CNSS</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Cardio<br>Diabetes</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Djibouti</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Empowering HCPs and supply chain actors</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">The specific objectives of this partnership are focused on strengthening advocacy and knowledge about NCDs, increasing the capacity of healthcare professionals for better management of NCDs and of supply chain actors, while building a sustainable procurement mechanism for affordable access to treatment.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Touch Foundation</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Cardio<br>Diabetes</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Tanzania</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Strengthen Supply Chain</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">The primary goal is to improve supply chain management for NCD medicines and patient tracking at each facility to ensure patients are adhering to treatment.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Action 4 Diabetes (A4D)</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Diabetes</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">(type 1)</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Cambodia</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Laos</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Myanmar</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Care for Type 1 Diabetes Patients</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Action 4 Diabetes focuses on type 1 diabetes patients and includes healthcare professional training, patient services, support in monitoring blood glucose levels and access to insulins, to increase efficiency in the management of type 1 diabetes patients. A4D also holds diabetes camps for patients and their families to build awareness and understanding.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">City Cancer Challenge</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Oncology</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Cambodia<br>Rwanda</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Health System Strengthening</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Working with City Cancer, the objectives are to create city-wide oncology stakeholder leadership groups and complete situational analysis and needs assessments of oncology services (including digital oncology services), forming the basis for a successful approach to empower and strengthen the health system.</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:94.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">41</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cancer and work&#58; Sanofi supporting health and wellbeing in the workplace</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has launched &#8216;Cancer &#38; Work&#58; Acting Together&#8217;, a program which covers all Sanofi employees in the world if they are diagnosed with cancer or critical illnesses</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. It provides social, emotional and financial support and secures the job, salary and benefits of any employee for up to twelve months, no matter the role or geographical location.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It will allow employees to incorporate further flexible work arrangements to better navigate cancer and work and will have access to a network of volunteer colleagues trained to help them navigate from initial diagnosis through the treatment journey and return to work. The program is also designed to better equip managers to support members of their team who are affected by cancer. Throughout 2024, Sanofi also intends to implement coverage of miscellaneous non-medical expenses. Moreover, Sanofi permanent employees will become eligible for an unpaid caregiver leave which allows them to carry out caregiving duties for their close family member suffering from a critical illness</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2017, several volunteer employees in France, with complementary expert skills and experience as patients, caregivers or managers, started the initiative. The program has since grown to a network of 27 partner teams with one team at each Sanofi site in France, with 150 members who share feedback and best practice. More than 350 employees have benefited (42% sick employees, 30% caregivers, 28% managers).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The program &#8220;Cancer &#38; Work&#8221; has started to roll out globally in early 2024 and is part of our programs supporting health and wellbeing in the workplace. This complements other initiatives already launched for employees such as the gender-neutral parental leave, allowing all new parents 14 weeks of paid leave to welcome a new child into their lives.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Sanofi continues its progress to limit its impact on the environment </font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sanofi&#8217;s Planet Care strategy&#58; concrete actions towards net zero emissions</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For several years, Sanofi has been implementing its Planet Care strategy, aiming for net zero greenhouse gas emissions across all scopes by 2045, with an intermediate carbon neutrality milestone in 2030. The company has already achieved a 43% decrease in scopes 1 and 2 emissions, targeting 55% by 2030, and a 10% reduction in scope 3 emissions, aiming for 30% by 2030.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For scopes 1 and 2, Sanofi is focusing on the following key decarbonization levers to reach its 2030 targets&#58;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Energy decarbonization&#58; increasing renewable electricity share from 11% in 2019 to 85% in Q2 2024 through solar panels, power purchase agreements (PPA), and guarantees of origin. In France, three PPAs have been signed with the Compagnie Nationale du Rh&#244;ne, for an annual volume of 83 GWh&#47;year over a twenty-year period, covering 19% of Sanofi&#8217;s annual electricity needs in France. Sanofi also has a renewable electricity PPA in Mexico to supply energy to its three Mexican sites and is exploring PPAs opportunities in other European countries and the US. Sanofi is also incorporating biomethane and biomass to reduce reliance on fossil fuels &#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Energy reduction and efficiency&#58; aiming to reduce energy consumption by 15% in existing facilities by 2025 compared to 2021.</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Eco-fleet&#58; converting Sanofi&#8217;s car fleet to an 80% eco-fleet (biofuel, hybrid and electric vehicles) by 2030 &#59; and</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Refrigerant gas&#58; replacing existing refrigerant gases with lower global warming potential alternatives and improving leak prevention.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For scope 3, the majority of greenhouse gas (GHG) emissions come from raw materials and subcontracting, thus representing the primary target for the decarbonization efforts. Sanofi's eco-design program aims to integrate environmental criteria from product design. The company is seeking less carbon-intensive suppliers and considering the country of manufacture in supplier selection. For example, sourcing of a highly carbon-intensive raw material from China has been reduced from over 50% of the volume in 2019 to just 5% in 2024, with a shift to European suppliers. Additionally, Sanofi is implementing comprehensive measures to reduce emissions across multiple areas&#58; addressing business travel and employee commuting through remote work and low-carbon travel options, shifting from air to sea freight for product transport, setting ambitious waste management goals, and focusing on energy use. </font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Community-centric carbon offsetting</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">By 2045, the residual emissions will remain under 10% of the 2019 total emissions, in line with the Science Base Targets Initiative net zero commitment. Understanding that not all emissions can be immediately abated, we also created a community-focused carbon offsetting program. These initiatives not only compensate for residual emissions but also generate substantial environmental, social, and economic benefits in local communities.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi's carbon offsetting program has invested around &#8364;60 million in four strategic projects since 2019. These include the Sundari Mangrove Restoration project in India, which has restored 380 hectares of mangroves since 2022 with plans to rehabilitate an additional 3,750 hectares. In Kenya, 18,250 energy-saving biomass cookstoves have been distributed. A new project in Mozambique aims to rehabilitate 1,040 water handpumps, reducing the need to burn biomass for boiling water and providing clean water access to 312,000 people.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Specific criteria identifying the conditions and circumstances that are eligible for coverage under this program might be governed by the terms and conditions of country-specific policies or legal requirements.</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.796%"><tr><td style="width:1.0%"></td><td style="width:2.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SANOFI 2023 HALF-YEAR FINANCIAL REPORT</font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business resilience to environmental changes</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is also actively working to strengthen its business resilience to environmental challenges which could impact its ability to support patients across the world. For instance, Sanofi has undertaken an end-to-end internal study, in order to better identify the associations between environmental change impacts and pipeline of products. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Among its conclusions, the study reported that 70% of Sanofi&#8217;s portfolio indications and 78% of the R&#38;D pipeline indications are already targeting diseases impacted by at least one environmental hazard (air pollution, shift in seasonal patterns, chemical pollution, extreme temperatures, water pollution).</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">CSR dashboard as of Q2 2024 </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Please refer to the Q2 2024 results press release ESG appendix for Sanofi CSR reporting. </font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div id="i0cf07956a9104271aa41947fae4e5162_22"></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:9pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">C&#47; EVENTS SUBSEQUENT TO JUNE 30, 2024</font></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main events related to research and development that occurred between the end of the reporting period and the date on which the condensed consolidated financial statements were signed off by the Board of Directors are described in section 'A.2. Research and Development'. No other significant events occurred during this period.</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:94.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">43</font></div></td></tr></table></div></div></div><div id="i0cf07956a9104271aa41947fae4e5162_25"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:9pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">D&#47; CONSOLIDATED FINANCIAL STATEMENTS FOR THE FIRST HALF OF 2024</font></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Unless otherwise indicated, all financial data in this report are presented in accordance with international financial reporting standards (IFRS), including international accounting standards and interpretations (see Note A.1. to the condensed half-year consolidated financial statements). </font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Consolidated income statements for the six months ended June 30, 2023 and June 30, 2024</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:52.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.906%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024 (6 months)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">as % of net sales</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023 (6 months)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">as % of net sales</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,209</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">100.0</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20,187</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">100.0</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,289&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.1&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,358&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.7&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,849)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(32.3)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,347)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(31.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross profit</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">15,649</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">73.8</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">15,198</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">75.3</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,423)</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16.1)</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,193)</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15.8)</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,260)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(24.8)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,182)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">617&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">617&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating expenses</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,010)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,422)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,061)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,035)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment of intangible assets</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,331)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(547)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(442)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(73)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Operating income</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,044</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">14.4</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,322</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21.4</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(586)</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(370)</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">281&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">286&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,739</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12.9</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,238</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21.0</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(463)</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(730)</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit&#47;(loss) from investments accounted for using the equity method</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(52)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net income</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,263</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">10.7</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,456</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">17.1</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,246</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">10.6</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,430</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">17.0</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding (million)</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,249.4&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,249.9&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares after dilution (million)</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,253.8&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,254.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.95pt">Basic earnings per share (in euros)</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.80&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.74&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.95pt">Diluted earnings per share (in euros)</font></div></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.79&#160;</font></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.73&#160;</font></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.796%"><tr><td style="width:1.0%"></td><td style="width:2.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">44</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div id="i0cf07956a9104271aa41947fae4e5162_28"></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.1. SEGMENT INFORMATION</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.1.1. OPERATING SEGMENTS</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;8 (Operating Segments), the segment information reported by Sanofi is prepared on the basis of internal management data provided to our Chief Executive Officer, who is the chief operating decision maker of Sanofi. The performance of those segments is monitored individually using internal reports and common indicators. The operating segment disclosures required under IFRS 8 are provided in Note B.20. to the condensed half-year consolidated financial statements. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi reports two operating segments&#58; Biopharma and Opella (formerly Consumer Healthcare &#8211; CHC).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Speciality Care, General Medicines and Vaccines franchises, for all geographical territories. The segment&#8217;s results include the costs of global support functions that are not within the managerial responsibility of the Opella GBU.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Opella operating segment comprises commercial operations relating to consumer healthcare products, and research, development and production activities and global support functions (as listed above) dedicated to the segment, for all geographical territories. The Opella GBU segment&#8217;s results reflect all incurred costs of global support functions attributable to its business.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Other&#8221; category comprises reconciling items, primarily but not limited to (i) gains and losses on centralized foreign exchange risk hedging transactions that cannot be allocated to the operating segments and (ii) gains and losses on retained commitments in respect of previously divested operations.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.1.2. BUSINESS OPERATING INCOME</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We report segment results on the basis of &#8220;Business operating income&#8221;. This indicator is used internally by Sanofi&#8217;s chief operating decision maker to measure the performance of each operating segment and to allocate resources. For a definition of &#8220;Business operating income&#8221;, and a reconciliation between that indicator and </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, refer to Note B.20.1.2. to our condensed half-year consolidated financial statements.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2024, &#8220;Business operating income&#8221; amounted to &#8364;5,656 million (versus &#8364;6,059 million for the first half of 2023), while &#8220;Business operating income margin&#8221; was 26.7% (versus 30.0% for the first half of 2023). &#8220;Business operating income margin&#8221; is a non-IFRS financial measure that we define as the ratio of &#8220;Business net income&#8221; to our consolidated net sales.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because our &#8220;Business operating income&#8221; and &#8220;Business operating income margin&#8221; are not standardized measures, they may not be directly comparable with the non-IFRS financial measures of other companies using the same or similar non-IFRS financial measures. Despite the use of non-IFRS measures by management in setting goals and measuring performance, these are non-IFRS measures that have no standardized meaning prescribed by IFRS.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div id="i0cf07956a9104271aa41947fae4e5162_31"></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.2. BUSINESS NET INCOME</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We believe that understanding of our operational performance by our management and our investors is enhanced by reporting &#8220;Business net income&#8221;. This non-IFRS financial measure represents &#8220;Business operating income&#8221;, less net financial expenses and the relevant income tax effects. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Business net income&#8221; for the first half of 2024 amounted to &#8364;4,380 million, 10.2% less than in the first half of 2023 (&#8364;4,876 million). That represents 20.7% of net sales, versus 24.2% for the first half of 2023.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We also report &#8220;Business earnings per share&#8221; (business EPS), a non-IFRS financial measure which we define as business net income divided by the weighted average number of shares outstanding. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Business EPS was &#8364;3.51 for the first half of 2024, 10.0% lower than the 2023 first-half figure of &#8364;3.90, based on an average number of shares outstanding of 1,249.4 million for the first half of 2024 and 1,249.9&#160;million for the first half of 2023. </font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below reconciles our &#8220;Business operating income&#8221; to our &#8220;Business net income&#8221;&#58; </font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:55.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months) </font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Business operating income</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,656</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">6,059</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12,670</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income and expenses (except those related to financial liabilities accounted for at amortized cost and subject to periodic remeasurement in accordance with paragraph&#160;B5.4.6 of IFRS&#160;9)</font></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(129)</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(181)</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,147)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,134)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,334)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Business net income</font></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,380</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,876</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">10,155</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:94.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SANOFI 2023 HALF-YEAR FINANCIAL REPORT</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We define &#8220;Business net income&#8221; as </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">determined under IFRS, excluding the following items&#58; </font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.85pt">amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature)&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.85pt">fair value remeasurements of contingent consideration relating to business combinations (IFRS&#160;3), or to business divestments&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.85pt">expenses arising from the remeasurement of inventories following business combinations (IFRS&#160;3) or acquisitions of groups of assets that do not constitute a business within the meaning of paragraph&#160;2b of IFRS&#160;3&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.85pt">restructuring costs and similar items (presented within the line item </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.85pt">other gains and losses (including gains and losses on major divestments, presented within the line item </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">)&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.85pt">other costs and provisions related to litigation (presented within the line item </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">)&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.85pt">(income)&#47;expenses related to financial liabilities accounted for at amortized cost and subject to periodic remeasurement in accordance with paragraph&#160;B5.4.6 of IFRS&#160;9 (Financial Instruments)&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.85pt">the tax effects of the items listed above, the effects of major tax disputes, and the effects of the deferred tax liability arising on investments in consolidated entities following the announcement on October&#160;27, 2023 of Sanofi&#8217;s intention to proceed with the separation of its Opella business&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.85pt">the share of profits&#47;losses from investments accounted for using the equity method, except for joint ventures and associates with which Sanofi has a strategic alliance&#59; and</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.85pt">the portion attributable to non-controlling interests of the items listed above.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below reconciles our &#8220;Business net income&#8221; to</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Net income attributable to equity holders of Sanofi</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#58; </font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:56.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,246</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,430</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,400</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:133%">Amortization of intangible assets </font></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,061&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,035&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,172&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:133%">Impairment of intangible assets </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:133%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(371)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">896&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expenses arising from the impact of acquisitions on inventories</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,331&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">547&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,490&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:133%">Other gains and losses, and litigation </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:133%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">442&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial (income)&#47;expenses relating to financial liabilities accounted for at amortized cost and subject to periodic remeasurement&#160;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">176&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">541&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax effects of the items listed above&#58;</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(691)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(415)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,097)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#9642;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:15.95pt">amortization and impairment of intangible assets</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(96)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(226)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(567)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#9642;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:15.95pt">fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(17)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(13)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#9642;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:15.95pt">tax effects of restructuring costs and similar items </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(408)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(157)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(397)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#9642;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:15.95pt">other items</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(170)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(26)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(120)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other tax effects&#160;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">365&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other items&#160;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">107&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">237&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Business net income</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,380</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,876</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">10,155</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding (million)</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,249.4&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,249.9&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,251.7&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Basic earnings per share (in euros)</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.80&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.74&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.31&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reconciling items per share (in euros)</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.71&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.16&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.80&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Business earnings per share (in euros)</font></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.51&#160;</font></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.90&#160;</font></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8.11&#160;</font></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;For the six months ended June 30, 2024, this line corresponds to a net reversal of impairment losses amounting to &#8364;371 million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights in the Biopharma segment.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">      For the year ended December 31, 2023, this line mainly comprised an impairment loss of &#8364;833&#160;million, reflecting the impact of the strategic decision to de-prioritize certain R&#38;D programs, in particular those related to the NK Cell and PRO-XTEN technology platforms.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) For the six months ended December 31, 2024, &#8220;Other gains and losses, and litigation&#8221; is a charge of &#8364;442 million, mainly comprising a provision recognized in respect of the litigation related to Plavix (clopidogrel) in the US state of Hawaii (see note B.14.). That compares with a charge of &#8364;73 million in the first half of 2023, which comprised costs related to the settlement of a dispute with shareholders of Bioverativ.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) &#160;&#160;&#160;&#160;This line corresponds to the financial expense arising from remeasurement of the financial liability recognized in the balance sheet to reflect estimated future royalties on sales of Beyfortus in the United States.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) This line mainly comprise costs relating to severance plans announced by Sanofi. Restructuring costs also include Sanofi's ongoing transformation projects, mainly those relating to the separation of the Opella business.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e) &#160;&#160;&#160;&#160;For the year ended December 31, 2023, this amount corresponds to the deferred tax liability recognized in respect of investments in consolidated entities in light of the proposed separation of the Opella business in the fourth quarter of 2024 at the earliest.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f) &#160;&#160;&#160;&#160;This line includes the share of profits&#47;losses arising from the equity-accounted investment in EUROAPI, including an impairment loss taken against the equity interests based on the quoted market price&#58; &#8364;2.55 euros as of June 30, 2024, &#8364;10.50 as of June 30, 2023, and &#8364;5.73 as of December 31, 2023.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The most significant reconciling items between &#8220;Business net income&#8221; and </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> relate to (i) the purchase accounting effects of our acquisitions and business combinations, particularly the amortization and impairment of intangible assets (other than software and other rights of an industrial or operational nature) and (ii) the impacts of </font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.796%"><tr><td style="width:1.0%"></td><td style="width:2.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">46</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">restructurings or transactions regarded as non-recurring, where the amounts involved are particularly significant. We believe that excluding those impacts enhances an investor&#8217;s understanding of our underlying economic performance, because it gives a better representation of our recurring operating performance. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We believe that eliminating charges related to the purchase accounting effect of our acquisitions and business combinations (particularly amortization and impairment of some intangible assets) enhances comparability of our ongoing operating performance relative to our peers.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We also believe that eliminating the other effects of business combinations (such as the incremental cost of sales arising from the workdown of acquired inventories remeasured at fair value in business combinations) gives a better understanding of our recurring operating performance.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Eliminating restructuring costs and similar items enhances comparability with our peers because those costs are incurred in connection with reorganization and transformation processes intended to optimize our operations.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, we believe that eliminating the effects of transactions that we regard as non-recurring and that involve particularly significant amounts (such as major gains and losses on disposals, and costs and provisions associated with major litigation and other major non-recurring items) improves comparability from one period to the next.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We remind investors, however, that &#8220;Business net income&#8221; should not be considered in isolation from, or as a substitute for, </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reported in accordance with IFRS. In addition, we strongly encourage investors and potential investors not to rely on any single financial measure but to review our financial statements, including the notes thereto, carefully and in their entirety. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We compensate for the material limitations described above by using &#8220;Business net income&#8221; only to supplement our IFRS financial reporting and by ensuring that our disclosures provide sufficient information for a full understanding of all adjustments included in &#8220;Business net income&#8221;. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because our &#8220;Business net income&#8221; and &#8220;Business EPS&#8221; are not standardized measures, they may not be directly comparable with the non-IFRS financial measures of other companies using the same or similar non-IFRS financial measures.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div id="i0cf07956a9104271aa41947fae4e5162_34"></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.3. NET SALES</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net sales for the first half of 2024 amounted to &#8364;21,209&#160;million, 5.1% higher than in the first half of 2023. Exchange rate fluctuations had a negative effect of 3.3 percentage points overall, due mainly to adverse trends in the euro exchange rate against the Argentinean peso, Turkish lira and Japanese yen. At constant exchange rates (CER, see definition below), net sales rose by 8.4%, driven mainly by strong performances for Dupixent, increased sales of Nexviazyme, ALTUVIIIO, and Beyfortus.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of net sales to net sales at constant exchange&#160;rates</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:59.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024 (6 months)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023 (6 months)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,209</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20,187</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+5.1</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of exchange rates</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">682&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales at constant exchange rates</font></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,891</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20,187</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+8.4</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When we refer to changes in our net sales at constant exchange rates (CER), that means we have excluded the effect of exchange rates by recalculating net sales for the relevant period using the exchange rates that were used for the previous period. </font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.1. NET SALES BY SEGMENT</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our net sales comprise the net sales generated by our Biopharma and Opella segments.</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"><tr><td style="width:1.0%"></td><td style="width:47.910%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.080%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024 (6 months)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023 (6 months)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change on<br>a reported<br>basis</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change at<br>constant<br>exchange rates</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Biopharma segment</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">18,378</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">17,467</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+5.2</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+8.3</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Opella segment</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,831</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,720</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+4.1</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+9.2</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total net sales</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,209</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20,187</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+5.1</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+8.4</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:94.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">47</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.2. NET SALES BY GEOGRAPHICAL REGION AND PRODUCT</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net sales by main product and geographical region break down as follows&#58;</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:26.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.961%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total sales</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change (CER)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">United States</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change (CER)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Europe</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change (CER)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Rest of the world</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change (CER)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Dupixent</font></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">6,138</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+27.1</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+25.8</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,437</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+20.4</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">770</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+31.2</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">931</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+63.9</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nexviazyme</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+79.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+73.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">174&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+41.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+126.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+221.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sarclisa</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+32.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+25.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+31.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+14.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+55.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ALTUVIIIO</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1378.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1373.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1423.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1000.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rezurock</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+46.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+46.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+34.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+500.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-800.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cablivi</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0,0%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-12.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+83.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Xenpozyme</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+92.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+89.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+76.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+60.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+500.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Enjaymo</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+72.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+66.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+57.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+150.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+70.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tzield</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+250.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+250.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+233.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Pharma launches</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,295</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+85.0</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+81.1</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">868</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+88.7</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">249</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+48.2</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">178</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+136.8</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Toujeo</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">634&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+14.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+9.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">117&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-0.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+9.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+27.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lantus</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">758&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-5.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+50.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">175&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-8.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">313&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-16.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lovenox</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-9.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-14.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+20.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">305&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-7.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-12.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plavix</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-0.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-25.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-4.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">424&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fabrazyme</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">526&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+6.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">261&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+26.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Myozyme&#47; Lumizyme</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-12.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-14.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-9.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">145&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-20.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">104&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-4.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alprolix</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">271&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">225&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+6.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cerezyme</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">407&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+21.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+8.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">126&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+44.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aubagio</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-66.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-67.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-72.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-61.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-36.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Praluent</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+31.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+30.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-100.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">170&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+19.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+64.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thymoglobulin</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">246&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+6.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aprovel</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">213&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-0.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-33.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-7.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">174&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Kevzara</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+17.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+14.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">105&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+19.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+9.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+25.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Eloctate</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-21.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-23.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-30.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Multaq</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-1.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-1.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">145&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-1.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-14.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Jevtana</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-18.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-19.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-21.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-50.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cerdelga</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">165&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+11.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+8.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+50.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aldurazyme</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">161&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+14.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+7.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+7.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+21.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Soliqua &#47; iGlarLixi</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+11.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+7.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-15.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+35.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+29.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fasturtec</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-3.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-4.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-3.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-11.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mozobil</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-65.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-66.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-94.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-22.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-12.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,220&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-7.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-11.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-13.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">658&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-6.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,377&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-6.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Industrial sales</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">278</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-0.7</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-0.7</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-33.3</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">274</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+3.8</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-84.6</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total other medicines</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,626</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-5.1</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-9.0</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,245</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-12.6</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,673</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-7.0</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,708</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+1.0</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Pharma</font></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">16,059</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+9.6</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+6.5</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,550</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+12.5</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,692</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+1.7</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,817</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+11.6</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Influenza Vaccines</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+27.2&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+16.0&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-15.8&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-18.9&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+50.9&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Polio &#47; Pertussis &#47; Hib vaccines including Boosters</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,348&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-2.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-5.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">311&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-10.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+7.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">789&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-2.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV vaccines (Beyfortus)</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Meningitis, travel and endemics vaccines</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">582&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">301&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+34.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-5.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Vaccines</font></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,319</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+0.3</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-3.0</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">744</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+13.1</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">382</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-33.0</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,193</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+9.3</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Biopharma</font></div></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">18,378</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+8.3</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+5.2</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,294</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+12.5</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,074</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-3.0</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">6,010</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+11.1</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d9c6f9;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Opella</font></div></td><td colspan="2" style="background-color:#d9c6f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,831</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#d9c6f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#d9c6f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+9.2</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#d9c6f9;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#d9c6f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+4.1</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#d9c6f9;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#d9c6f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">773</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#d9c6f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#d9c6f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+24.4</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#d9c6f9;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#d9c6f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">808</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#d9c6f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#d9c6f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-4.0</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#d9c6f9;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#d9c6f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,250</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#d9c6f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#d9c6f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+10.6</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#d9c6f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Sanofi</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,209</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+8.4</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+5.1</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,067</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+13.4</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,882</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-3.2</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,260</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+11.0</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.796%"><tr><td style="width:1.0%"></td><td style="width:2.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">48</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.367%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.3. BIOPHARMA SEGMENT </font></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma segment includes Pharma and Vaccines. Net sales increased by 8.3% CER and by 5.2% on a reported basis to &#8364;18,378 million, driven by Dupixent and new Pharma launches. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Comments on the performances of our major Biopharma segment products are provided below.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PHARMA</font></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Immunology</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Dupixent</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (collaboration with Regeneron) generated net sales of &#8364;6,138 million in the first half of 2024, up 25.8% on a reported basis and 27.1% at constant exchange rates. In the United States, sales of Dupixent reached &#8364;4,437 million in the first half of 2024, driven by continuing strong demand in the product&#8217;s approved indications&#58; atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis, and prurigo nodularis. In Europe, the product&#8217;s net sales for the first half of 2024 totaled &#8364;770 million, up 31.2% CER, driven by continuing growth in AD, asthma and CRSwNP. In the Rest of the World region, Dupixent posted net sales of &#8364;931 million (+63.9% CER), driven mainly by Japan and China.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Pharma launches</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Nexviazyme&#47;Nexviadyme </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(Pompe disease)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> sales were &#8364;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">320</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> million (including &#8364;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">174</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> million in the United States), up </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">73.9% year-on-year,</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> driven by switches from Myozyme&#47;Lumizyme in the eligible late-onset Pompe disease population and by an increase in new patients. Total sales for the Pompe franchise (Nexviazyme&#47;Nexviadyme + Myozyme&#47;Lumizyme) reached &#8364;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">691</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> million. Nexviazyme&#47;Nexviadyme now account for </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">46%</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> of total Pompe franchise sales.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ALTUVIIIO</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> (hemophilia A) generated sales of &#8364;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">280</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> million in the first half of </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">, predominantly in the United States where growth was driven by patient switches from factor-based treatments other than Eloctate. Sales also benefited from supplies to Sanofi&#8217;s partner in Europe, where the medicine obtained regulatory approval. Total hemophilia A franchise sales (ALTUVIIIO + Eloctate) amounted to &#8364;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">471 </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">million (+</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">76% versus the first half of 2023) </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">representing an increase in Sanofi&#8217;s market share of factor-based treatments as well as of the overall hemophilia A market.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Sarclisa</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> (multiple myeloma) reported sales of &#8364;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">227</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> million in the first half of 2024, up </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">32.6% CER</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">, driven by strong growth in all three regions. </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales reached &#8364;100 million in the United States (+31.6% CER), &#8364;64 million in Europe (+14.3% CER), and &#8364;63 million in the Rest of the World region (+55.1% CER).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Rezurock</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (chronic graft-versus-host disease) were &#8364;207 million in the first half of 2024, an increase of 46.8%, driven by improved patient adherence and new patients (primarily in the United States), and by new launches in China and the UK.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Cablivi</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (acquired thrombotic thrombocytopenic purpura) reported 2024 first-half sales of &#8364;113 million (+0.9% CER), including &#8364;60 million (+3.4% CER) in the United States and &#8364;43&#160;million (-12.2% CER) in Europe.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Xenpozyme</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (acid sphingomyelinase deficiency) achieved sales of &#8364;72 million in the first half of 2024, mainly in the United States.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Enjaymo</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (cold agglutinin disease) posted sales of &#8364;55 million, mainly from the United States and Japan.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Tzield</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (delayed onset of type 1 diabetes) amounted to &#8364;21 million. As expected, sales are on a gradual uptrend, driven by a higher number of infusions supported by increased awareness and screening. Efforts to increase knowledge and updates to disease guidelines will support long-term growth.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;OTHER MAIN MEDICINES</font></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Lantus</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales remained steady at &#8364;758 million (+0.6% CER) in the first half of 2024. In the United States, sales were up 50.0% CER, as volumes rose following the withdrawal of a competing medicine from the market. In the Rest of the World region, sales were down by 16.1% CER, mainly due to the strategy of switching to Toujeo in China.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Toujeo</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales increased by 14.5% CER to &#8364;634 million, driven by China, where the product&#8217;s market share now exceeds that of Lantus. Sales were stable in the United States, mainly due to the withdrawal of a competing medicine.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Lovenox</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales decreased by 9.6% CER to &#8364;518 million, reflecting an impact from VBP (volume-based procurement) in China as well as biosimilar competition in Europe.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of the Fabry disease treatment </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Fabrazyme</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reached &#8364;526 million in the first half of 2024 (+10.1% CER), propelled by the Rest of World region.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Plavix</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were up 4.4% CER at &#8364;473 million, underpinned by use in the Rest of the World.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Cerezyme</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales rose by 21.2% CER to &#8364;407 million, reflecting growth in high-inflation countries (Argentina and Turkey) included in the Rest of the World region. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Myozyme&#47;Lumizyme</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (Pompe disease) decreased by 12.6% CER in the first half of 2024 to &#8364;371 million, reflecting switches to Nexviazyme&#47;Nexviadyme as mentioned above.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in the first half of 2024, sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Alprolix</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (indicated for the treatment of hemophilia B) amounted to &#8364;271 million, an increase of 5.0% CER, driven by the United States.</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:94.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">49</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">First-half net sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Praluent</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reached &#8364;247 million CER, an increase of 31.7%, thanks largely to Europe and China.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Thymoglobulin</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales rose by 5.3% in the first half year of 2024 to &#8364;246 million, driven by the United States.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Aubagio</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> were down 66.1% CER at &#8364;209 million, reflecting the loss of exclusivity in the United States in March 2023 and competition from generics across all regions, including Europe where generics entered the market at end September 2023. The negative impact is anticipated to lessen during the rest of 2024 as the effects of loss of exclusivity annualize.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Eloctate</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, indicated in the treatment of hemophilia A, posted sales of &#8364;191 million in the first half of 2024, down 21.4% CER, reflecting the conversion to ALTUVIIIO.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Cerdelga</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;165 million, up 11.3%, underpinned by continued growth in the United States and Europe.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VACCINES</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2024, Vaccines sales were down 3.0% on a reported basis but up 0.3% CER, at &#8364;2,319 million. Sales reflected a strong start for Beyfortus, which offset the absence of COVID-19 vaccine sales in the period (versus &#8364;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">226</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> million in first half of 2023).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Polio&#47;Pertussis&#47;Hib</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (PPH) Vaccines, including Boosters, decreased by 2.9% to &#8364;1,348 million. Growth in Europe, sustained by better sales performance and favorable phasing, was partly offset by declining sales in the United States, where Vaxelis became market leader in the three-dose primary series market for infants at the end of 2023. Vaxelis sales in the United States are not consolidated by Sanofi, but profits are shared equally between Sanofi and Merck &#38; Co.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Meningitis, Travel and Endemics Vaccines</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales increased by 3.9% CER to &#8364;582 million, reflecting increased penetration of MenQuadfi in Europe.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Beyfortus</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales reached &#8364;200 million in the first half of 2024, reflecting late deliveries in the United States and implementation of &#8220;All Infant Protection&#8221; programs in some Australian states and Chile.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Influenza</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Vaccines</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reached &#8364;188 million, up 27.2% CER, benefiting from higher public tender sales in Latin America.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.4. OPELLA SEGMENT</font></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:72.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">30 June 2024          (6 months)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change at constant exchange rates</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Seasonal symptoms &#38; pain relief </font></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,216</font></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-0.2%</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Wellness brands</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,258</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21.5%</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</font></div></td><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">357</font></div></td><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.3%</font></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Opella sales increased by 9.2% CER to &#8364;2,831 million, supported by growth in the United States (including the acquisition of Qunol) and the Rest of the World region. Divestments of non-core products had a negative impact of </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">1.7 </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">percentage points, mainly reflected in the &#8220;Other&#8221; category. Excluding divestments, third-party industrial sales and the Qunol acquisition, Opella sales growth was </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">3.8%</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the first half of 2024.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.5. NET SALES BY GEOGRAPHICAL REGION</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:43.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change on a reported basis</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change at constant exchange rates </font></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,067&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,988&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+13.5&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+13.4&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:133%">Europe</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,882&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,034&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-3.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-3.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:133%">Rest of the World</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,260&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,165&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+11.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which China</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,522&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,540&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-1.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+2,8%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total net sales</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,209</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20,187</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+5.1</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">+8.4</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2024, net sales in the</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">United States</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reached &#8364;9,067 million, up 13.5% on a reported basis and 13.4% at constant exchange rates. The impacts of strong growth for Dupixent, plus Pharma launches and additional Beyfortus deliveries, were partially offset by the impact of generic competition on Aubagio.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Europe</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, 2024 first-half net sales decreased by 3.0% on a reported basis and 3.2% at constant exchange rates, to &#8364;4,882&#160;million&#59; the impact of generic competition on Aubagio and a high comparative base for Vaccines (due to COVID-19 vaccine sales recorded in the first half of 2023) more than offset a strong performance from Dupixent.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Rest of the World region</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, first-half net sales were up 1.3% on a reported basis and 11.0% at constant exchange rates at &#8364;7,260 million, driven mainly by Dupixent, the launch of Beyfortus in two Southern Hemisphere countries, and Opella. Sales in China increased by 2.8% CER to &#8364;1,522 million driven by Dupixent, Toujeo and Plavix.</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.796%"><tr><td style="width:1.0%"></td><td style="width:2.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">50</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td></tr></table></div></div></div><div id="i0cf07956a9104271aa41947fae4e5162_37"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.4. OTHER INCOME STATEMENT ITEMS</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.1. OTHER REVENUES</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">decreased by 5.1% to &#8364;1,289&#160;million in the first half of 2024 (versus &#8364;1,358&#160;million in the first half of 2023). This decline is explained in particular by the absence of COVID-19 sales in 2024, which represented &#8364;94 million in the first half of 2023.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This line item also includes VaxServe sales of non-Sanofi products, amounting to &#8364;854 million (versus &#8364;835 million in the first half of 2023).</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.2. GROSS PROFIT</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Gross profit </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">for the first half of 2024 was &#8364;15,649 million, versus &#8364;15,198 million for the first half of 2023, a rise of 3.0%.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The gross margin ratio decreased by 1.4 percentage points to 73.9% compared with the first half of 2023. The main factors were a fall in the Opella gross margin ratio from 66.1% to 63.1% due to product and country mix, and unfavorable trends in exchange rates.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma gross margin ratio decreased from 76.8% to 75.5% due to changes in product mix (lower sales of Aubagio, and COVID-19 sales booked in 2023), and unfavorable trends in exchange rates. </font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.3. RESEARCH AND DEVELOPMENT EXPENSES</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (R&#38;D expenses) in the first half of 2024 totaled &#8364;3,423&#160;million (versus &#8364;3,193&#160;million in the first half of 2023). That represents 16.1% of net sales, compared with 15.8% in the first half of 2023. R&#38;D expenses rose by 7.2%, reflecting increased expenses in Vaccines (mRNA) and Pharma (pipeline acceleration).</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.4. SELLING AND GENERAL EXPENSES</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Selling and general expenses</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;5,260 million in the first half of 2024 (24.8%&#160;of net sales), versus &#8364;5,182&#160;million in the first half of 2023 (25.7% of net sales)&#59; this 1.5% year-on-year increase reflected higher commercial spend and launch costs in the Biopharma segment, and increased selling expenses in the Opella segment.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The ratio of selling and general expenses to net sales was 0.9 of a percentage point lower than in the first half of 2023, at 24.8%.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.5. OTHER OPERATING INCOME AND EXPENSES</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2024, </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;617 million, stable versus the first half of 2023), and </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">to &#8364;2,010 million (versus &#8364;1,422&#160;million in the first half of 2023).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Overall,</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> other operating income and expenses</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> represented a net expense of &#8364;1,393 million in the first half of 2024, compared with a net expense of &#8364;805 million in the first half of 2023.</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:59.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">617&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">617&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating expenses</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,010)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,422)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(588)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other operating income&#47;(expenses), net</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,393)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(805)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(588)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the first half of 2024, this item included &#8364;1,745 million of net expenses related to Regeneron (versus &#8364;1,321 million in the first half of 2023), as shown in the table below.</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:94.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">51</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:59.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</font></div><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(12 months)</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income &#38; expense related to (profit)&#47;loss sharing under the Monoclonal Antibody Alliance</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,934)</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,449)</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,321)</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional share of profit paid by Regeneron towards development costs</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">389&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">291&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">668&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reimbursement to Regeneron of selling expenses incurred</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(292)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(260)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(543)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total&#58; Monoclonal Antibody Alliance</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,837)</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,418)</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(3,196)</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other (mainly Zaltrap and Libtayo)</font></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">92</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">97</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">217</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other operating income&#47;(expenses), net related to Regeneron Alliance</font></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,745)</font></td><td style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,321)</font></td><td style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,979)</font></td><td style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">of which amount presented in &#8220;Other operating income&#8221;</font></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">96</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">102</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">227</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income and expenses</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (net) also includes gains on divestments of assets and operations totaling &#8364;389&#160;million, mainly related to portfolio rationalization (versus &#8364;413 million for the first half of 2023).</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.6. AMORTIZATION OF INTANGIBLE ASSETS</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization charged against intangible assets in the first half of 2024 amounted to &#8364;1,061 million, versus &#8364;1,035 million in the first half of 2023. This rise was mainly driven by amortization of the intangible assets acquired through acquisitions and alliances during 2023, with the impact partly offset by some intangible assets reaching the end of their amortization periods.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.7. IMPAIRMENT OF INTANGIBLE ASSETS</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The results of impairment tests on other intangible assets led to the recognition of a net reversal of impairment losses amounting to &#8364;371 million in the first half of 2024, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights in the Biopharma segment.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The comparative for the first half of 2023 was a net impairment loss of &#8364;15 million.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.8. FAIR VALUE REMEASUREMENT OF CONTINGENT CONSIDERATION</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Fair value remeasurements of contingent consideration assets and liabilities relating to business combinations (recognized in accordance with IFRS 3) represented a net expense of &#8364;66 million in the first half of 2024, versus a net expense of &#8364;26 million in the first half of 2023. </font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.9. RESTRUCTURING COSTS AND SIMILAR ITEMS</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to a charge of &#8364;1,331&#160;million in the first half of 2024, compared with a charge of &#8364;547&#160;million in the first half of 2023.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring and similar costs increased by &#8364;784 million between June 30, 2023 and June 30, 2024. They mainly comprise costs relating to severance plans announced in the first half of 2024. For the six months ended June 30, 2023 and the year ended December 31, 2023, they included the impact of pension reform in France on future annuities under the rules of each severance plan. Restructuring costs also include Sanofi's ongoing transformation projects, mainly those relating to the separation of the Opella business.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.10. OTHER GAINS AND LOSSES, AND LITIGATION</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the first half of 2024, </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a charge of &#8364;442 million, mainly comprising a </font><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">provision recognized in respect of the litigation related to Plavix (clopidogrel) in the US state of Hawaii (see note B.14.)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. That compares with a charge of &#8364;73</font><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> million in the first half of </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2023, which comprised costs related to the settlement of a dispute with shareholders of Bioverativ.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.11. OPERATING INCOME</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;3,044 million in the first half of 2024, versus &#8364;4,322 million in the first half of 2023. The year-on-year change was mainly due to increases in </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.796%"><tr><td style="width:1.0%"></td><td style="width:2.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">52</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.12. FINANCIAL INCOME AND EXPENSES</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net financial expenses were &#8364;305 million for the first half of 2024, &#8364;221 million higher than the 2023 first-half figure of &#8364;84 million. The 2024 first-half amount includes a financial expense of &#8364;176 million (&#8364;35 million for the first half of 2023) in respect of the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the US.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our cost of net debt (see&#160;the definition in Section D.7., &#8220;Consolidated balance sheet&#8221; below) was &#8364;66 million in the first half of 2024&#59; that compares with net interest income of &#8364;25 million in the first half of 2023.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.13. INCOME BEFORE TAX AND INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the first half of 2024 was &#8364;2,739&#160;million, versus &#8364;4,238&#160;million for the first half of 2023. </font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.14. INCOME TAX EXPENSE</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income tax expense</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> totaled &#8364;463 million in the first half of 2024, versus &#8364;730 million in the first half of 2023, giving an effective tax rate (based on consolidated net income) of 16.9%, versus 17.3% in the first half of 2023. The reduction in income tax expense was mainly due to a year-on-year increase in restructuring costs relating to severance plans announced in the first half of 2024 and to Sanofi&#8217;s ongoing transformation projects (&#8364;408 million in the first half of 2024, versus &#8364;157 million in the first half of 2023). It also reflects the tax effects of amortization and impairment of intangible assets (&#8364;96 million in the first half of 2024, versus &#8364;226 million in the first half of 2023) and tax effects relating to contingencies arising from business divestitures.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The effective tax rate on our &#8220;Business net income&#8221;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a non-IFRS financial measure. It is calculated on the basis of business operating income, minus net financial expenses and before (i) the share of profit&#47;loss from investments accounted for using the equity method and (ii) net income attributable to non-controlling interests. We believe the presentation of this measure, used by our management, is also useful for investors as it provides a mean of analyzing the effective tax cost of our current business activities. It should not be seen as a substitute for the effective tax rate based on consolidated net income. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When calculated on business net income, our effective tax rate was 21.0% in the first half of 2024, compared with 19.0% in the first half of 2023 and 18.8% for 2023 as a whole. The main factor in this year-on-year change was the impact of the OECD Pillar Two model rules, which aim to ensure that large multinationals pay a minimum level of tax on the income arising in each jurisdiction where they operate.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.15. SHARE OF PROFIT&#47;(LOSS) FROM INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit&#47;(loss) from investments accounted for using the equity method</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to a net loss of &#8364;13&#160;million in the first half of 2024, versus a net loss of &#8364;52&#160;million in the comparable period of 2023. This line item includes the share of profits generated by Vaxelis.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.16. NET INCOME</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;2,263&#160;million in the first half of 2024, versus &#8364;3,456&#160;million in the first half of 2023. </font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.17. NET INCOME ATTRIBUTABLE TO NON-CONTROLLING INTERESTS</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to non-controlling interests</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the first half of 2024 was &#8364;17&#160;million, against &#8364;26 million for the first half of 2023. </font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.18. NET INCOME ATTRIBUTABLE TO EQUITY HOLDERS OF SANOFI</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;2,246&#160;million in the first half of 2024, versus &#8364;3,430&#160;million in the first half of 2023. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Basic earnings per share (EPS) was &#8364;1.80, compared with &#8364;2.74 for the first half of 2023, based on an average number of shares outstanding of 1,249.4&#160;million for the first half of 2024 and 1,249.9&#160;million for the first half of 2023. Diluted earnings per share was &#8364;1.79, versus &#8364;2.73 for the first half of 2023, based on an average number of shares after dilution of 1,253.8&#160;million for the first half of 2024 and 1,254.5&#160;million for the first half of 2023.</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> See definition in section D.2., &#8220;Business net income&#8221;.</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:94.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">53</font></div></td></tr></table></div></div></div><div id="i0cf07956a9104271aa41947fae4e5162_40"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.5. SEGMENT RESULTS</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2024, our &#8220;Business operating income&#8221; (see Note B.20.1. to our condensed half-year consolidated financial statements for a definition and further details) was &#8364;5,656 million, versus &#8364;6,059 million for the first half of 2023), a decrease of 6.7%. Our &#8220;Business operating income margin&#8221; was 26.7% (versus 30.0% for the first half of 2023).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows our &#8220;Business operating income&#8221; by segment&#58;</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"></td><td style="width:57.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024 (6 months)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023 (6 months)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biopharma segment</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,931&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,220&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-5.5&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella segment</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">739&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-13.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Business operating income</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,656</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">6,059</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-6.7</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div id="i0cf07956a9104271aa41947fae4e5162_43"></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.6. CONSOLIDATED STATEMENTS OF CASH FLOWS</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Summarized consolidated statements of cash flows </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.251%"><tr><td style="width:1.0%"></td><td style="width:58.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024 (6 months)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023 (6 months)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</font></div><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(12 months)</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) operating activities</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,423&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,563&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,258&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) investing activities</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,413)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,073)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,200)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) financing activities</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,214)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,052)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of exchange rates on cash and cash equivalents</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(32)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,915)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(4,743)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(4,026)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by&#47;(used in) operating activities</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> represented a net cash inflow of &#8364;1,423&#160;million in the first half of 2024, against &#8364;3,563&#160;million in the first half of 2023.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Operating cash flow before changes in working capital for the first half of 2024 was &#8364;4,064&#160;million, versus &#8364;4,382&#160;million in the first half of 2023.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Working capital requirements decreased by &#8364;2,641&#160;million in the first half of 2024 (versus a decrease of &#8364;819&#160;million in the first half of 2023), due mainly to the reduction in provisions for rebates in the US, a consequence of the reduction in the list price of Lantus from January 1, 2024.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by&#47;(used in) investing activities</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> represented a net cash outflow of &#8364;3,413&#160;million in the first half of 2024, due mainly to the acquisition of Inhibrx, Inc. for &#8364;1,884 million (see Note B.1. to our condensed half-year consolidated financial statements). That compares with a net cash outflow of &#8364;3,073&#160;million in the first half of 2023, resulting mainly from the acquisition of Provention Bio, Inc. for &#8364;2,465 million.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acquisitions of property, plant and equipment and intangible assets totaled &#8364;1,886 million, versus &#8364;930 million in the first half of 2023. There were &#8364;950 million of acquisitions of property, plant and equipment (versus &#8364;782&#160;million in the first half of 2023), most of which (&#8364;882 million) were in the Biopharma segment, primarily in industrial facilities. Acquisitions of intangible assets (&#8364;936&#160;million, versus &#8364;148&#160;million in the first half of 2023) mainly comprised contractual payments for intangible rights, primarily under license and collaboration agreements (in particular Novavax, for &#8364;463 million).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After-tax proceeds from disposals (excluding disposals of consolidated entities and investments in joint ventures and associates) amounted to &#8364;607&#160;million in the first half of 2024, compared with &#8364;578 million for the first half of 2023, and related mainly to divestments of assets and operations relating to portfolio streamlining and disposals of equity and debt instruments.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by&#47;(used in) financing activities</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> represented a net cash inflow of &#8364;89 million in the first half of 2024, compared with a net outflow of &#8364;5,214&#160;million in the first half of 2023. The 2024 first-half figure includes (i) the dividend payout to our shareholders of &#8364;4,704&#160;million (versus &#8364;4,454&#160;million in the first half of&#160;2023)&#59; (ii) &#8364;5,105 million of net external debt contracted (versus net external debt reimbursed of &#8364;376 million in the first half of&#160;2023)&#59; and (iii) movements in Sanofi&#8217;s share capital (purchases and disposals of treasury shares, net of capital increases) representing a net outflow of &#8364;281 million (compared with a net outflow of &#8364;332 million in the first half of 2023).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">net change in cash and cash equivalents</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the first half of 2024 was a decrease of &#8364;1,915&#160;million, compared with a decrease of &#8364;4,743&#160;million in the first half of 2023.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Free cash flow&#8221; is a non-IFRS financial measure which is reviewed by our management, and which we believe provides useful information to measure the net cash generated from the Company&#8217;s operations that is available for strategic investments</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (net of divestmen</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Above a cap of &#8364;500 million per transaction.</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.796%"><tr><td style="width:1.0%"></td><td style="width:2.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">54</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ts</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), for debt repayment, and for payments to shareholders. &#8220;Free cash flow&#8221; is determined from business net income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> after adding back (in the case of expenses and losses) or deducting (in the case of income and gains) the following items&#58; depreciation, amortization and impairment, share of undistributed earnings from investments accounted for using the equity method, gains &#38; losses on disposals of non-current assets, net change in provisions (including pensions and other post-employment benefits), deferred taxes, share-based payment expense and other non-cash items. It also includes net changes in working capital, capital expenditures and other asset acquisitions</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> net of disposal proceeds</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and payments related to restructuring and similar items. &#8220;Free cash flow&#8221; is not defined by IFRS, and is not a substitute for</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Net cash provided by&#47;(used in) operating activities </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">as reported under IFRS. Management recognizes that the term &#8220;Free cash flow&#8221; may be interpreted differently by other companies and under different circumstances. </font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth a reconciliation between</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Net cash provided by&#47;(used in) operating activities </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and &#8220;Free cash flow&#8221;&#58;</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:72.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</font></div><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(6 months)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023</font></div><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(6 months)</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net cash provided by&#47;(used in) operating activities </font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,423</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,563</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment and software</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(980)</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(796)</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of intangible assets, equity interests and other non-current financial assets </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(545)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(396)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">568&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">556&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repayment of lease liabilities</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(144)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(127)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other items</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Free cash flow </font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</font></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">545</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,129</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Most directly comparable IFRS measure to free cash flow.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Not exceeding a cap of &#8364;500 million per transaction.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) Non-IFRS financial measure (see&#160;definition in section D.2. above).</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div id="i0cf07956a9104271aa41947fae4e5162_46"></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2) </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Non-IFRS financial measure, as defined in &#8220;Business net income&#8221; above.</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Not exceeding a cap of &#8364;500 million per transaction.</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:94.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">55</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.7. CONSOLIDATED BALANCE SHEET</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total assets were &#8364;129,755&#160;million as of June&#160;30, 2024, versus &#8364;126,464 million as of December 31, 2023, representing an increase of &#8364;3,291 million. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net debt</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> was &#8364;15,112 million as of June&#160;30, 2024, versus &#8364;7,793 million as of December&#160;31, 2023. We believe the presentation of this non-IFRS financial measure, which is reviewed by our management, provides useful information to measure our overall liquidity and capital resources. We define &#8220;net debt&#8221; as (i) the sum total of short-term debt, long-term debt, and interest rate derivatives and currency derivatives used to manage debt, minus (ii) the sum total of cash and cash equivalents and interest rate derivatives and currency derivatives used to manage cash and cash equivalents.</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:72.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 </font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,503&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,347&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,236&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,045&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total debt</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,918</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">16,531</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,795)</font></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</font></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net debt </font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">15,112</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,793</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total equity</font></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72,997&#160;</font></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74,353&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gearing ratio</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20.7</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">10.5</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Net debt does not include lease liabilities, which amounted to &#8364;2,012 million as of June 30, 2024 and &#8364;2,030 million as of December 31, 2023.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To assess our financing risk, we use the &#8220;gearing ratio&#8221;, another non-IFRS financial measure. This ratio (which we define as the ratio of net debt to total equity) rose from 10.5% as of December&#160;31, 2023 to 20.7% as of June 30, 2024. Analyses of our debt as of June&#160;30, 2024 and December&#160;31,&#160;2023 are provided in Note B.9. to the condensed half-year consolidated financial statements.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because our &#8220;net debt&#8221; and &#8220;gearing ratio&#8221; are not standardized measures, they may not be directly comparable with the non-IFRS financial measures of other companies using the same or similar non-IFRS financial measures. Despite the use of non-GAAP measures by management in setting goals and measuring performance, these measures have no standardized meaning prescribed by IFRS.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We expect that the future cash flows generated by our operating activities will be sufficient to repay our debt. The financing arrangements in place as of June&#160;30, 2024 at the Sanofi parent company level are not subject to covenants regarding financial ratios and do not contain any clauses linking credit spreads or fees to Sanofi&#8217;s credit rating.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other key movements in the balance sheet are described below.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Total equity</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> was &#8364;72,997&#160;million as of June&#160;30, 2024, versus &#8364;74,353 million as of December&#160;31,&#160;2023. The net change reflects the following principal factors&#58; </font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">an increase representing our net income for the first half of 2024 (&#8364;2,263 million)&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">an increase of &#8364;1,040 million due to currency translation differences arising on the financial statements of foreign subsidiaries, mainly due to movements in the US dollar&#59; and</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">a decrease representing the dividend payout to our shareholders of &#8364;4,704 million.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2024 we held 15.33&#160;million of our own shares, recorded as a deduction from equity and representing 1.211% of our share&#160;capital.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other intangible assets</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (&#8364;76,733&#160;million in total) increased by &#8364;3,010 million, the main factors being our acquisition of Inhibrx, Inc. (impact&#58; &#8364;1,766 million) and our May 2024 agreement with Novavax (impact&#58; &#8364;463 million).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Investments accounted for using the equity method</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (&#8364;315 million) decreased by &#8364;109 million, including the recognition of an &#8364;11&#160;million impairment loss on the investment in EUROAPI based on that entity&#8217;s quoted market price as of June 30, 2024 (&#8364;2.55).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other non-current assets</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (&#8364;3,333&#160;million) decreased by &#8364;115&#160;million.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net deferred tax assets </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">were &#8364;5,484 million as of June 30, 2024, compared with &#8364;4,477 million as of December 31, 2023, an increase of &#8364;1,007 million. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current provisions and other non-current liabilities</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (&#8364;8,219&#160;million) increased by &#8364;617&#160;million relative to December 31, 2023. This variation is explained mainly by the recognition of provisions for restructuring programs and for litigation.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (&#8364;728&#160;million) increased by &#8364;19 million.</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.796%"><tr><td style="width:1.0%"></td><td style="width:2.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">56</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td></tr></table></div></div></div><div id="i0cf07956a9104271aa41947fae4e5162_49"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">E&#47; RISK FACTORS AND RELATED PARTY TRANSACTIONS</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">E.1. RISK FACTORS</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main risk factors to which Sanofi is exposed are described in our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the US Securities and Exchange Commission on February 23, 2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Any of those risks, and others that we may not yet have identified, could materialize during the second half of 2024 or during subsequent periods, and could cause actual results to differ materially from those described elsewhere in this report.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">E.2. RELATED PARTY TRANSACTIONS</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our principal related parties are defined in Note D.33. to the consolidated financial statements included in our 2023 Annual Report on Form 20-F (page F-91) </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Note B.5. to the condensed half-year consolidated financial statements provides a description of the main transactions and balances for the six months ended June 30, 2024 with equity-accounted entities that qualify as related parties. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi did not enter into any transactions with key management personnel during the first half of 2024. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Financial relations with the Group&#8217;s principal shareholders fall within the ordinary course of business and were immaterial in the first half of 2024.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">  Available on our corporate website&#58; www.sanofi.com.</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:94.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">57</font></div></td></tr></table></div></div></div><div id="i0cf07956a9104271aa41947fae4e5162_52"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">F&#47; OUTLOOK</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At constant exchange rates, we expect full-year 2024 business earnings per share</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (business EPS) to be stable, an upgrade from the low single-digit percentage decrease previously expected, underpinned by accelerated delivery of Sanofi&#8217;s pipeline-driven transformation. Applying average July 2024 exchange rates, the currency impact on 2024 business EPS is c.-5.5% to -6.5%.</font></div><div style="margin-bottom:5pt;padding-right:2.15pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Full-year business net income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1) </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">for 2023 was &#8364;10,155 million, giving business earnings per share of &#8364;8.11.</font></div><div style="margin-bottom:5pt;padding-right:2.15pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This guidance was prepared on a basis comparable with that used to prepare our historical financial information, and in accordance with Sanofi accounting policies. It was also prepared on the basis of assumptions established by Sanofi and its subsidiaries, including but not limited to&#58;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">trends in the competitive environment, in terms of innovative products and launches of generics&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">respect for our intellectual property rights&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">progress on our research and development programs&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the impact of, and progress on, our operating cost containment policy&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">trends in exchange rates and interest rates&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">integration of the contribution from acquisitions&#59; and</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the average number of shares outstanding.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Some of the above information, estimates and assumptions are derived from or rely on, in full or in part, judgments and decisions made by Sanofi management which may change or be amended in future.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Non-IFRS financial measure. For a definition, see Section D.2., &#8220;Business net income&#8221; above.</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.796%"><tr><td style="width:1.0%"></td><td style="width:2.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">58</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td></tr></table></div></div></div><div id="i0cf07956a9104271aa41947fae4e5162_55"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This document contains forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Words such as &#8220;believe&#8221;, &#8220;anticipate&#8221;, &#8220;can&#8221;, &#8220;contemplate&#8221;, &#8220;could&#8221;, &#8220;plan&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;is designed to&#8221;, &#8220;may&#8221;, &#8220;might&#8221;, &#8220;plan&#8221;, &#8220;potential&#8221;, &#8220;objective&#8221; &#8220;target&#8221;, &#8220;estimate&#8221;, &#8220;project&#8221;, &#8220;predict&#8221;, &#8220;forecast&#8221;, &#8220;ambition&#8221;, &#8220;guideline&#8221;, &#8220;should&#8221;, &#8220;will&#8221;, or the negative of these and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements.Forward-looking statements are generally identified by the words &#8220;expects&#8221;, &#8220;anticipates&#8221;, &#8220;may&#8221;, &#8220;is considering&#8221;, &#8220;believes&#8221;, &#8220;intends&#8221;, &#8220;envisages&#8221;, &#8220;aims&#8221;, &#8220;plans&#8221;, &#8220;is designed to&#8221;, &#8220;could&#8221;, &#8220;forecasts&#8221;, &#8220;predicts&#8221;, &#8220;potential&#8221;, &#8220;objective&#8221;, &#8220;estimates&#8221;, &#8220;projects&#8221;, &#8220;is programming&#8221;, &#8220;is likely to&#8221; and &#8220;wants&#8221; or the negative thereof, and similar expressions. Although Sanofi management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any marketing application or filing in respect of any drug, device or biological product for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi&#8217;s ability to benefit from external growth opportunities, to complete related transactions and&#47;or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and interest rates, cost containment initiatives and subsequent changes thereto, the average number of shares outstanding, the impact that pandemics of any other global crisis may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the Securities and Exchange Commission (SEC) and the </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Autorit&#233; des march&#233;s financiers</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (AMF) made by Sanofi, including those listed under &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; in Sanofi&#8217;s Annual Report on Form 20-F for the year ended December 31, 2023. For an update on litigation, refer to Note B.14. &#8220;Legal and arbitration proceedings&#8221; to our condensed half-year consolidated financial statements for the six months ended June 30, 2024, and to section &#8220;A.3.2. Legal and arbitration proceedings&#8221;, and section &#8220;E&#47; Risk factors and related party transactions&#8221;, of this half-year management report. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All trademarks mentioned in this document are protected and are either trademarks owned by Sanofi and&#47;or its subsidiaries, or trademarks licensed to Sanofi and&#47;or its subsidiaries, or trademarks owned by third parties (including Regeneron and Sobi).</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:94.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">59</font></div></td></tr></table></div></div></div><div id="i0cf07956a9104271aa41947fae4e5162_58"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.987%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">G&#47; APPENDIX - RESEARCH AND DEVELOPMENT PIPELINE</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:9pt"><img alt="a1a.gif" src="a1a.gif" style="height:554px;margin-bottom:5pt;vertical-align:text-bottom;width:988px"></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.882%"><tr><td style="width:1.0%"></td><td style="width:2.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">60</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><img alt="a2a.gif" src="a2a.gif" style="height:552px;margin-bottom:5pt;vertical-align:text-bottom;width:988px"></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.591%"><tr><td style="width:1.0%"></td><td style="width:94.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">61</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><img alt="a3a.gif" src="a3a.gif" style="height:472px;margin-bottom:5pt;vertical-align:text-bottom;width:988px"></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.882%"><tr><td style="width:1.0%"></td><td style="width:2.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">62</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td></tr></table></div></div></div><div id="i0cf07956a9104271aa41947fae4e5162_61"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Serif',serif;font-size:26pt;font-style:italic;font-weight:400;line-height:120%">3. STATUTORY AUDITORS&#8217; REVIEW REPORT ON THE HALF-YEARLY FINANCIAL INFORMATION</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Period from January 1 to June 30, 2024</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To the Shareholders,</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In compliance with the assignment entrusted to us by your Annual General Meetings and in accordance with the requirements of article L. 451-1-2 III of the French Monetary and Financial Code (</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Code mon&#233;taire et financier</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), we hereby report to you on&#58;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the review of the accompanying (condensed) half-yearly consolidated financial statements of Sanofi, for the period from January 1, 2024 to June 30, 2024&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the verification of the information presented in the half-yearly management report.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These condensed half-yearly consolidated financial statements are the responsibility of the Board of Directors. Our role is to express a conclusion on these financial statements based on our review.</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-21.26pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:16.62pt">Conclusion on the financial statements</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We conducted our review in accordance with professional standards applicable in France. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with professional standards applicable in France and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed half-yearly consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34 &#8211; standard of the IFRSs as adopted by the European Union applicable to interim financial information.</font></div><div style="margin-bottom:5pt;padding-left:35.43pt;text-align:justify;text-indent:-21.26pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2. &#160;&#160;&#160;&#160;Specific verification</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have also verified the information presented in the half-yearly management report on the condensed half-yearly consolidated financial statements subject to our review.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have no matters to report as to its fair presentation and consistency with the condensed half-yearly consolidated financial statements.</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Neuilly-sur-Seine and Courbevoie, July 25 2024.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 6.67pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">The statutory auditors<br>French original signed by</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 6.67pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">PricewaterhouseCoopers Audit </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">Forvis Mazars SA</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">Anne-Claire Ferri&#233;                C&#233;dric Mazille</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">Lo&#239;c Wallaert               Ariane Mignon</font></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">* This is a free translation into English of the statutory auditors&#8217; review report on the half-yearly financial information issued in French and is provided solely for the convenience of English-speaking users. This report includes information relating to the specific verification of information given in the Group&#8217;s half-yearly management report. This report should be read in conjunction with, and construed in accordance with, French law and professional standards applicable in France. </font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:94.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">63</font></div></td></tr></table></div></div></div><div id="i0cf07956a9104271aa41947fae4e5162_64"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Serif',serif;font-size:26pt;font-style:italic;font-weight:400;line-height:120%">4. RESPONSIBILITY STATEMENT OF THE CERTIFYING OFFICER &#8211; HALF-YEAR FINANCIAL REPORT</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;I hereby certify that, to the best of my knowledge, the condensed half-year consolidated financial statements have been prepared in accordance with the applicable accounting standards and present fairly the assets and liabilities, the financial position and the income of the Company and the entities included in the scope of consolidation, and that the half-year management report starting on page <a href="#i0cf07956a9104271aa41947fae4e5162_4" style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none">37</a> provides an accurate overview of the significant events of the first six months of the financial year with their impact on the half-year consolidated financial statements, together with the major transactions with related parties and a description of the main risks and uncertainties for the remaining six months of the financial year.&#8221;</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Paris, July 25, 2024</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Paul Hudson</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.796%"><tr><td style="width:1.0%"></td><td style="width:2.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">64</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">HALF-YEAR FINANCIAL REPORT</font></div></td></tr></table></div></div></div><div id="i0cf07956a9104271aa41947fae4e5162_67"></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><img alt="cvhy3a.jpg" src="cvhy3a.jpg" style="height:1121px;margin-bottom:5pt;vertical-align:text-bottom;width:794px"></div><div style="height:0pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>sny-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a012fc2d-d3ff-4c6a-950e-09cafe0bb60f,g:e711d38b-47f1-4329-bc58-181a62b743af-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sny="http://www.sanofi.com/20240630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sanofi.com/20240630">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sny-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sny-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sny-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sny-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Coverpage" roleURI="http://www.sanofi.com/role/Coverpage">
        <link:definition>0000001 - Document - Cover page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.sanofi.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedIncomeStatements" roleURI="http://www.sanofi.com/role/ConsolidatedIncomeStatements">
        <link:definition>0000003 - Statement - Consolidated Income Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedIncomeStatements_1" roleURI="http://www.sanofi.com/role/ConsolidatedIncomeStatements_1">
        <link:definition>0000003 - Statement - Consolidated Income Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>0000004 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome_1" roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome_1">
        <link:definition>0000004 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinEquity" roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity">
        <link:definition>0000005 - Statement - Consolidated Statements of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinEquityParenthetical" roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical">
        <link:definition>0000006 - Statement - Consolidated Statements of Changes in Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsParenthetical" roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical">
        <link:definition>0000008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Introduction" roleURI="http://www.sanofi.com/role/Introduction">
        <link:definition>0000009 - Disclosure - Introduction</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPolicies" roleURI="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPolicies">
        <link:definition>0000010 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreements" roleURI="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreements">
        <link:definition>0000011 - Disclosure - Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.sanofi.com/role/PropertyPlantandEquipment">
        <link:definition>0000012 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssets" roleURI="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssets">
        <link:definition>0000013 - Disclosure - Goodwill and Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpairmentofIntangibleAssets" roleURI="http://www.sanofi.com/role/ImpairmentofIntangibleAssets">
        <link:definition>0000014 - Disclosure - Impairment of Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAccountedforUsingtheEquityMethod" roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethod">
        <link:definition>0000015 - Disclosure - Investments Accounted for Using the Equity Method</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNonCurrentAssets" roleURI="http://www.sanofi.com/role/OtherNonCurrentAssets">
        <link:definition>0000016 - Disclosure - Other Non-Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivable" roleURI="http://www.sanofi.com/role/AccountsReceivable">
        <link:definition>0000017 - Disclosure - Accounts Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedShareholdersEquity" roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquity">
        <link:definition>0000018 - Disclosure - Consolidated Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtCashandCashEquivalents" roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalents">
        <link:definition>0000019 - Disclosure - Debt, Cash and Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstruments" roleURI="http://www.sanofi.com/role/DerivativeFinancialInstruments">
        <link:definition>0000020 - Disclosure - Derivative Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterests" roleURI="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterests">
        <link:definition>0000021 - Disclosure - Liabilities Related to Business Combinations and to Non-Controlling Interests</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonCurrentProvisionsAndOtherNonCurrentLiabilities" roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilities">
        <link:definition>0000022 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OffBalanceSheetCommitments" roleURI="http://www.sanofi.com/role/OffBalanceSheetCommitments">
        <link:definition>0000023 - Disclosure - Off Balance Sheet Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationandArbitrationProceedings" roleURI="http://www.sanofi.com/role/LitigationandArbitrationProceedings">
        <link:definition>0000024 - Disclosure - Litigation and Arbitration Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherOperatingIncomeAndExpenses" roleURI="http://www.sanofi.com/role/OtherOperatingIncomeAndExpenses">
        <link:definition>0000025 - Disclosure - Other Operating Income And Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringCostsandSimilarItems" roleURI="http://www.sanofi.com/role/RestructuringCostsandSimilarItems">
        <link:definition>0000026 - Disclosure - Restructuring Costs and Similar Items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherGainsandLossesandLitigation" roleURI="http://www.sanofi.com/role/OtherGainsandLossesandLitigation">
        <link:definition>0000027 - Disclosure - Other Gains and Losses, and Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialExpensesandIncome" roleURI="http://www.sanofi.com/role/FinancialExpensesandIncome">
        <link:definition>0000028 - Disclosure - Financial Expenses and Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxExpense" roleURI="http://www.sanofi.com/role/IncomeTaxExpense">
        <link:definition>0000029 - Disclosure - Income Tax Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.sanofi.com/role/SegmentInformation">
        <link:definition>0000030 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EventsSubsequenttoJune302023" roleURI="http://www.sanofi.com/role/EventsSubsequenttoJune302023">
        <link:definition>0000031 - Disclosure - Events Subsequent to June 30, 2023</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies" roleURI="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesTables" roleURI="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentTables" roleURI="http://www.sanofi.com/role/PropertyPlantandEquipmentTables">
        <link:definition>9954473 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsTables" roleURI="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsTables">
        <link:definition>9954474 - Disclosure - Goodwill and Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAccountedforUsingtheEquityMethodTables" roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodTables">
        <link:definition>9954475 - Disclosure - Investments Accounted for Using the Equity Method (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNonCurrentAssetsTables" roleURI="http://www.sanofi.com/role/OtherNonCurrentAssetsTables">
        <link:definition>9954476 - Disclosure - Other Non-Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableTables" roleURI="http://www.sanofi.com/role/AccountsReceivableTables">
        <link:definition>9954477 - Disclosure - Accounts Receivable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedShareholdersEquityTables" roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables">
        <link:definition>9954478 - Disclosure - Consolidated Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtCashandCashEquivalentsTables" roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsTables">
        <link:definition>9954479 - Disclosure - Debt, Cash and Cash Equivalents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsTables" roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsTables">
        <link:definition>9954480 - Disclosure - Derivative Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsTables" roleURI="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsTables">
        <link:definition>9954481 - Disclosure - Liabilities Related to Business Combinations and to Non-Controlling Interests (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonCurrentProvisionsAndOtherNonCurrentLiabilitiesTables" roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesTables">
        <link:definition>9954482 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherOperatingIncomeAndExpensesTables" roleURI="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesTables">
        <link:definition>9954483 - Disclosure - Other Operating Income And Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringCostsandSimilarItemsTables" roleURI="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsTables">
        <link:definition>9954484 - Disclosure - Restructuring Costs and Similar Items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialExpensesandIncomeTables" roleURI="http://www.sanofi.com/role/FinancialExpensesandIncomeTables">
        <link:definition>9954485 - Disclosure - Financial Expenses and Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxExpenseTables" roleURI="http://www.sanofi.com/role/IncomeTaxExpenseTables">
        <link:definition>9954486 - Disclosure - Income Tax Expense (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.sanofi.com/role/SegmentInformationTables">
        <link:definition>9954487 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails" roleURI="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails">
        <link:definition>9954488 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails" roleURI="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails">
        <link:definition>9954489 - Disclosure - Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Principal Changes in Scope of Consolidation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails" roleURI="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails">
        <link:definition>9954490 - Disclosure - Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Amendments to Principal Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails" roleURI="http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails">
        <link:definition>9954491 - Disclosure - Property, Plant and Equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/PropertyPlantandEquipmentAdditionalInformationDetails">
        <link:definition>9954492 - Disclosure - Property, Plant and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails">
        <link:definition>9954493 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails" roleURI="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails">
        <link:definition>9954494 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Movements in Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpairmentofIntangibleAssetsDetails" roleURI="http://www.sanofi.com/role/ImpairmentofIntangibleAssetsDetails">
        <link:definition>9954495 - Disclosure - Impairment of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails">
        <link:definition>9954496 - Disclosure - Investments Accounted for Using the Equity Method - Summary of Investments in Associates and Joint Ventures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails" roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails">
        <link:definition>9954497 - Disclosure - Investments Accounted for Using the Equity Method - Summary of Principal Transactions and Balances with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNonCurrentAssetsDetails" roleURI="http://www.sanofi.com/role/OtherNonCurrentAssetsDetails">
        <link:definition>9954498 - Disclosure - Other Non-Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableSummaryofAccountsReceivableDetails" roleURI="http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails">
        <link:definition>9954499 - Disclosure - Accounts Receivable - Summary of Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/AccountsReceivableAdditionalInformationDetails">
        <link:definition>9954500 - Disclosure - Accounts Receivable - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails" roleURI="http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails">
        <link:definition>9954501 - Disclosure - Accounts Receivable - Summary of Gross Value of Overdue Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedShareholdersEquityAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails">
        <link:definition>9954502 - Disclosure - Consolidated Shareholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedShareholdersEquitySummaryofTreasurySharesHeldDetails" roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofTreasurySharesHeldDetails">
        <link:definition>9954503 - Disclosure - Consolidated Shareholders' Equity - Summary of Treasury Shares Held (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails" roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails">
        <link:definition>9954504 - Disclosure - Consolidated Shareholders' Equity - Summary of Principal Characteristics of Restricted Share Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails" roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails">
        <link:definition>9954505 - Disclosure - Consolidated Shareholders' Equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails" roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails">
        <link:definition>9954506 - Disclosure - Consolidated Shareholders' Equity - Summary of Options Outstanding and Exercisable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails" roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails">
        <link:definition>9954507 - Disclosure - Consolidated Shareholders' Equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails" roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails">
        <link:definition>9954508 - Disclosure - Consolidated Shareholders' Equity - Summary of Movements within Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails" roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails">
        <link:definition>9954509 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Changes in Financial Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails" roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails">
        <link:definition>9954510 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails">
        <link:definition>9954511 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Net Debt by Type Valuation of Redemption (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtCashandCashEquivalentsAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails">
        <link:definition>9954512 - Disclosure - Debt, Cash and Cash Equivalents - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails" roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails">
        <link:definition>9954513 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Market Value of Net Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails" roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails">
        <link:definition>9954514 - Disclosure - Derivative Financial Instruments - Summary of Operating Currency Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails" roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails">
        <link:definition>9954515 - Disclosure - Derivative Financial Instruments - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails" roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails">
        <link:definition>9954516 - Disclosure - Derivative Financial Instruments - Disclosure of Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" roleURI="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails">
        <link:definition>9954517 - Disclosure - Liabilities Related to Business Combinations and to Non-Controlling Interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails">
        <link:definition>9954518 - Disclosure - Liabilities Related to Business Combinations and to Non-Controlling Interests - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails">
        <link:definition>9954519 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities - Summary of Non-Current Provisions and Other Non-Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails" roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails">
        <link:definition>9954520 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities - Summary of Movements in Non-Current Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails" roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails">
        <link:definition>9954521 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities - Disclosure of Remeasurement of Net Defined Benefit Liability Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OffBalanceSheetCommitmentsDetails" roleURI="http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails">
        <link:definition>9954522 - Disclosure - Off Balance Sheet Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationandArbitrationProceedingsDetails" roleURI="http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails">
        <link:definition>9954523 - Disclosure - Litigation and Arbitration Proceedings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherOperatingIncomeAndExpensesAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails">
        <link:definition>9954524 - Disclosure - Other Operating Income And Expenses - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails" roleURI="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails">
        <link:definition>9954525 - Disclosure - Other Operating Income And Expenses - Schedule of Other Operating Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails" roleURI="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails">
        <link:definition>9954526 - Disclosure - Restructuring Costs and Similar Items - Summary of Restructuring Costs and Similar Items (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringCostsandSimilarItemsAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsAdditionalInformationDetails">
        <link:definition>9954527 - Disclosure - Restructuring Costs and Similar Items - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherGainsandLossesandLitigationDetails" roleURI="http://www.sanofi.com/role/OtherGainsandLossesandLitigationDetails">
        <link:definition>9954528 - Disclosure - Other Gains and Losses, and Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialExpensesandIncomeDetails" roleURI="http://www.sanofi.com/role/FinancialExpensesandIncomeDetails">
        <link:definition>9954529 - Disclosure - Financial Expenses and Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialExpensesandIncomeDetails_1" roleURI="http://www.sanofi.com/role/FinancialExpensesandIncomeDetails_1">
        <link:definition>9954529 - Disclosure - Financial Expenses and Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails" roleURI="http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails">
        <link:definition>9954530 - Disclosure - Income Tax Expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails" roleURI="http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails">
        <link:definition>9954531 - Disclosure - Income Tax Expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical" roleURI="http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical">
        <link:definition>9954532 - Disclosure - Income Tax Expense (Details) - Summary of Effective Tax Rate and Standard Corporate Income Tax Rate (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/SegmentInformationAdditionalInformationDetails">
        <link:definition>9954533 - Disclosure - Segment Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails" roleURI="http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails">
        <link:definition>9954534 - Disclosure - Segment Information - Summary of Net Sales by Segment and Geographical Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleofSegmentResultsDetails" roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails">
        <link:definition>9954535 - Disclosure - Segment Information - Schedule of Segment Results (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails">
        <link:definition>9954536 - Disclosure - Segment Information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails" roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails">
        <link:definition>9954537 - Disclosure - Segment Information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails" roleURI="http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails">
        <link:definition>9954538 - Disclosure - Segment Information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationPrincipalCustomersandCreditRiskDetails" roleURI="http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails">
        <link:definition>9954539 - Disclosure - Segment Information - Principal Customers and Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EventsSubsequenttoJune302023Details" roleURI="http://www.sanofi.com/role/EventsSubsequenttoJune302023Details">
        <link:definition>9954540 - Disclosure - Events Subsequent to June 30, 2023 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" abstract="false" name="EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DebtNetOfCashAndCashEquivalents" abstract="false" name="DebtNetOfCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InfluenzaVaccinesMember" abstract="true" name="InfluenzaVaccinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" abstract="false" name="RoyaltiesAndOtherIncomeRelatedPartyTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_MarketConditionAxis" abstract="true" name="MarketConditionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_PeriodOfShareRepurchaseProgram" abstract="false" name="PeriodOfShareRepurchaseProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInChineseYuanRenminbiMember" abstract="true" name="ForwardCurrencySalesInChineseYuanRenminbiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInCanadianDollarMember" abstract="true" name="ForwardCurrencyPurchasesInCanadianDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" abstract="false" name="ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" abstract="true" name="OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" abstract="false" name="TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sny_CustomerTwoMember" abstract="true" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" abstract="false" name="DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_InhibrxIncMember" abstract="true" name="InhibrxIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" abstract="false" name="AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" abstract="false" name="CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" abstract="false" name="AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SarclisaMember" abstract="true" name="SarclisaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_FairValueOfPlanAtDateOfGrant" abstract="false" name="FairValueOfPlanAtDateOfGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_FairValuePerShareAwardedForThreeYearServicePeriod" abstract="false" name="FairValuePerShareAwardedForThreeYearServicePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_AcquiredResearchAndDevelopmentMember" abstract="true" name="AcquiredResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PaymentToSaleOfBusinessPeriod" abstract="false" name="PaymentToSaleOfBusinessPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_FixedRateBondMaturingApril2024Redeemed2024Member" abstract="true" name="FixedRateBondMaturingApril2024Redeemed2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_PrincipalAlliancesAxis" abstract="true" name="PrincipalAlliancesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_CerezymeMember" abstract="true" name="CerezymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_LeaseTerm" abstract="false" name="LeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" abstract="true" name="InterestRateSwapsPayCapitalizedEsterReceive092Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" abstract="false" name="DilutedEarningsLossPerShareAttributableToOwnersOfParent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_CabliviMember" abstract="true" name="CabliviMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_TypesOfAgreementAxis" abstract="true" name="TypesOfAgreementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_CreditFacilitiesExtensionOptionNumber" abstract="false" name="CreditFacilitiesExtensionOptionNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_NumberOfClassActionLawsuits" abstract="false" name="NumberOfClassActionLawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_VaccinesCoExclusiveLicensingAgreementMember" abstract="true" name="VaccinesCoExclusiveLicensingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_RegeneronPharmaceuticalsIncMember" abstract="true" name="RegeneronPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherLiabilities1Member" abstract="true" name="OtherLiabilities1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" abstract="false" name="CumulativeConsumerPriceInflationRateOverTheLastThreeYears" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" abstract="false" name="GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_PreFundedPensionObligations" abstract="false" name="PreFundedPensionObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInSingaporeDollarMember" abstract="true" name="ForwardCurrencySalesInSingaporeDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfYearsServicePeriod" abstract="false" name="NumberOfYearsServicePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" abstract="false" name="DisclosureOfMarketValueOfNetDebtTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" abstract="false" name="IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfPrincipalAgreementsTable" abstract="true" name="DisclosureOfPrincipalAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" abstract="false" name="ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_BusinessCombinationPurchasePrice" abstract="false" name="BusinessCombinationPurchasePrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" abstract="true" name="OtherCountriesExcludingEuropeAndNorthAmericaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MyozymeLumizymeMember" abstract="true" name="MyozymeLumizymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_EuroapiMember" abstract="true" name="EuroapiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" abstract="true" name="DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_FutureRoyaltiesReceivableValue" abstract="false" name="FutureRoyaltiesReceivableValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DupixentMember" abstract="true" name="DupixentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CollaborationAgreementsDevelopmentMilestonePayment" abstract="false" name="CollaborationAgreementsDevelopmentMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" abstract="true" name="DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" abstract="true" name="InterestRateSwapsPayCapitalizedEsterReceive343Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" abstract="false" name="RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_SwedishOrphanBiovitrumABMember" abstract="true" name="SwedishOrphanBiovitrumABMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NetReversalOfImpairmentLoss" abstract="false" name="NetReversalOfImpairmentLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfOtherOperatingIncomeExpensesTable" abstract="true" name="DisclosureOfOtherOperatingIncomeExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_NumberOfSharesSubscribed" abstract="false" name="NumberOfSharesSubscribed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_VaccinesMember" abstract="true" name="VaccinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SeasonalSymptomsAndPainReliefMember" abstract="true" name="SeasonalSymptomsAndPainReliefMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" abstract="false" name="ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ScribeTherapeuticsMember" abstract="true" name="ScribeTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherNonCoreAssetsMember" abstract="true" name="OtherNonCoreAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PensionsAndOtherPostEmploymentBenefitsMember" abstract="true" name="PensionsAndOtherPostEmploymentBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PercentageOfNetSalesArisingFromCommercialOperations" abstract="false" name="PercentageOfNetSalesArisingFromCommercialOperations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_LovenoxMember" abstract="true" name="LovenoxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" abstract="false" name="ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DerecognizedReceivables" abstract="false" name="DerecognizedReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_BiopharmaSegmentMember" abstract="true" name="BiopharmaSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfRestrictedSharesNotYetFullyVested" abstract="false" name="NumberOfRestrictedSharesNotYetFullyVested" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_RestrictedSharePlan2021Member" abstract="true" name="RestrictedSharePlan2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" abstract="false" name="ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DefendantAxis" abstract="true" name="DefendantAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_ValueOnRedemptionMember" abstract="true" name="ValueOnRedemptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OthersCounterpartyMember" abstract="true" name="OthersCounterpartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PolioPertussisHibVaccinesMember" abstract="true" name="PolioPertussisHibVaccinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" abstract="false" name="DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" abstract="false" name="DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" abstract="false" name="DisclosureOfCurrentTradeReceivablesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfNonCurrentProvisionsTable" abstract="true" name="DisclosureOfNonCurrentProvisionsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" abstract="false" name="NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SyndicatedCreditFacilityCanceledMember" abstract="true" name="SyndicatedCreditFacilityCanceledMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" abstract="true" name="MSDContingentConsiderationEuropeanVaccinesBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" abstract="false" name="NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_PlavixAttorneyGeneralActionInHawaiiMember" abstract="true" name="PlavixAttorneyGeneralActionInHawaiiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" abstract="false" name="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" abstract="false" name="DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember" abstract="true" name="ForwardCurrencyPurchasesInUSDollarCommercialPaperMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShareBasedPaymentPlansAbstract" abstract="true" name="ShareBasedPaymentPlansAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_NumberOfBondIssuesRedeemed" abstract="false" name="NumberOfBondIssuesRedeemed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" abstract="false" name="DisclosureOfRestructuringCostsDetailsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_EloctateMember" abstract="true" name="EloctateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" abstract="true" name="DisclosureOfOtherOperatingIncomeExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_AmountOfSharesRepurchased" abstract="false" name="AmountOfSharesRepurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OffBalanceSheetCommitmentsAbstract" abstract="true" name="OffBalanceSheetCommitmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_MajorFinancialLiabilityMember" abstract="true" name="MajorFinancialLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" abstract="false" name="DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DerivativeFinancialInstruments" abstract="false" name="DerivativeFinancialInstruments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CommercializationRelatedExpensesMember" abstract="true" name="CommercializationRelatedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" abstract="false" name="ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_AntibodiesAllianceMember" abstract="true" name="AntibodiesAllianceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_WithMarketConditionMember" abstract="true" name="WithMarketConditionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MarketConditionDomain" abstract="true" name="MarketConditionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MarketedProductsTrademarksAndOtherRightsMember" abstract="true" name="MarketedProductsTrademarksAndOtherRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_PercentageOfShareCapitalForThePeriod" abstract="false" name="PercentageOfShareCapitalForThePeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_NonCoreAssetsMember" abstract="true" name="NonCoreAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RegeneronMember" abstract="true" name="RegeneronMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShareRepurchase2022ProgramMember" abstract="true" name="ShareRepurchase2022ProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" abstract="false" name="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_MiscellaneousOtherOperatingIncomeExpenses" abstract="false" name="MiscellaneousOtherOperatingIncomeExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" abstract="false" name="DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ContingentMilestonePayments" abstract="false" name="ContingentMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" abstract="false" name="DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" abstract="false" name="CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" abstract="false" name="DisclosureOfLegalAndArbitralProceedingsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" abstract="false" name="SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_JevtanaMember" abstract="true" name="JevtanaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MarketedProductsMember" abstract="true" name="MarketedProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TaxotereProductLitigationInTheUSMember" abstract="true" name="TaxotereProductLitigationInTheUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_AubagioMember" abstract="true" name="AubagioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_WithoutMarketConditionMember" abstract="true" name="WithoutMarketConditionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInJapaneseYenMember" abstract="true" name="ForwardCurrencyPurchasesInJapaneseYenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" abstract="false" name="NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncomeResultingFromOutLicensing" abstract="false" name="IncomeResultingFromOutLicensing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" abstract="true" name="DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_AntibodiesCollaborationAgreementMember" abstract="true" name="AntibodiesCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AdditionalLaunchAndSalesMilestonePayments" abstract="false" name="AdditionalLaunchAndSalesMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ShareRepurchase2024ProgramMember" abstract="true" name="ShareRepurchase2024ProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_CurrentProvisionsAndOtherCurrentLiabilities" abstract="false" name="CurrentProvisionsAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_LeaseExtensionOptionsNumber" abstract="false" name="LeaseExtensionOptionsNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_TechnologicalPlatformsMember" abstract="true" name="TechnologicalPlatformsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" abstract="false" name="ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PenaltyFeeIncurred" abstract="false" name="PenaltyFeeIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_FinancialInstrumentsAbstract" abstract="true" name="FinancialInstrumentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_GeneralInformationAboutFinancialStatementsAbstract" abstract="true" name="GeneralInformationAboutFinancialStatementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_NovavaxMember" abstract="true" name="NovavaxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_GeneralMedicinesMember" abstract="true" name="GeneralMedicinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherBankBorrowings" abstract="false" name="OtherBankBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfOtherNonCurrentAssetsTable" abstract="true" name="DisclosureOfOtherNonCurrentAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" abstract="false" name="DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" abstract="false" name="ExpenseOfRestructuringActivitiesTransformationProgramsCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" abstract="false" name="ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PercentageIncreaseInFairValueLiabilities" abstract="false" name="PercentageIncreaseInFairValueLiabilities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" abstract="false" name="DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_FirmOrdersOfPropertyPlantAndEquipment" abstract="false" name="FirmOrdersOfPropertyPlantAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AssetsAcquisitionNominalValue" abstract="false" name="AssetsAcquisitionNominalValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InterestRateAndCurrencyDerivativesMember" abstract="true" name="InterestRateAndCurrencyDerivativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PercentageOfProfitsArisingFromCommercialOperations" abstract="false" name="PercentageOfProfitsArisingFromCommercialOperations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" abstract="false" name="IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_FulcrumTherapeuticsMember" abstract="true" name="FulcrumTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_AcquiredRDMember" abstract="true" name="AcquiredRDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" abstract="false" name="GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" abstract="false" name="OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfOffBalanceSheetCommitmentsTable" abstract="true" name="DisclosureOfOffBalanceSheetCommitmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_EUROZONEMember" abstract="true" name="EUROZONEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" abstract="false" name="DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DevelopmentRegulatoryAndLaunchMilestonePayments" abstract="false" name="DevelopmentRegulatoryAndLaunchMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AlprolixMember" abstract="true" name="AlprolixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInJapaneseYenMember" abstract="true" name="ForwardCurrencySalesInJapaneseYenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiMember" abstract="true" name="SanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AltuviiioMember" abstract="true" name="AltuviiioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestIncome" abstract="false" name="InterestIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CreditFacilitiesExtensionOptionPeriod" abstract="false" name="CreditFacilitiesExtensionOptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_CashFlowAndFairValueHedgeMember" abstract="true" name="CashFlowAndFairValueHedgeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" abstract="false" name="DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" abstract="false" name="CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" abstract="false" name="DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_CurrentTaxExpenseRelatedToPillarTwo" abstract="false" name="CurrentTaxExpenseRelatedToPillarTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InterestRateSwapsInterestRate" abstract="false" name="InterestRateSwapsInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" abstract="true" name="ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" abstract="false" name="NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInSingaporeDollarMember" abstract="true" name="ForwardCurrencyPurchasesInSingaporeDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" abstract="true" name="DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfNonCurrentProvisionsLineItems" abstract="true" name="DisclosureOfNonCurrentProvisionsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_InfraservGmbhAndCoHochstKGMember" abstract="true" name="InfraservGmbhAndCoHochstKGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" abstract="false" name="ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AllergyMember" abstract="true" name="AllergyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_LegalAndArbitralProceedingsDomain" abstract="true" name="LegalAndArbitralProceedingsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" abstract="false" name="DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" abstract="false" name="IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ImmunoOncologyAllianceMember" abstract="true" name="ImmunoOncologyAllianceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SpecialtyCareMember" abstract="true" name="SpecialtyCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_LongTermPrepaidExpenses" abstract="false" name="LongTermPrepaidExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_BusinessCombinationNominalValue" abstract="false" name="BusinessCombinationNominalValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NonCurrentLiabilitiesMember" abstract="true" name="NonCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AdjustmentToDebtMeasuredAtFairValueMember" abstract="true" name="AdjustmentToDebtMeasuredAtFairValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" abstract="false" name="DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" abstract="false" name="DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" abstract="false" name="IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PrincipalAlliancesDomain" abstract="true" name="PrincipalAlliancesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DividendsPaidAbstract" abstract="true" name="DividendsPaidAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" abstract="false" name="ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_MajorTerritoriesMember" abstract="true" name="MajorTerritoriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_LeaseExtensionOptionsTerm" abstract="false" name="LeaseExtensionOptionsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" abstract="false" name="ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" abstract="false" name="DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_RestrictedSharePlan2024Member" abstract="true" name="RestrictedSharePlan2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_CollaborationAgreementsRegulatoryMilestonePayment" abstract="false" name="CollaborationAgreementsRegulatoryMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" abstract="false" name="InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" abstract="false" name="NonCurrentProvisionsAndOtherNonCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" abstract="false" name="ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" abstract="true" name="ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PharmaSegmentMember" abstract="true" name="PharmaSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" abstract="true" name="DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_RecludixPharmaMember" abstract="true" name="RecludixPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" abstract="false" name="NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_ValueOfHedgeRecognizedInEquityMember" abstract="true" name="ValueOfHedgeRecognizedInEquityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PharmaLaunchesMember" abstract="true" name="PharmaLaunchesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_OpellaMember" abstract="true" name="OpellaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_SyndicatedCreditFacilityOneMember" abstract="true" name="SyndicatedCreditFacilityOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ManufacturingAndSupplyMember" abstract="true" name="ManufacturingAndSupplyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfLegalAndArbitralProceedingsTable" abstract="true" name="DisclosureOfLegalAndArbitralProceedingsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_SubscriptionPricePerShare" abstract="false" name="SubscriptionPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_CommercialPaperProgramInUSAMember" abstract="true" name="CommercialPaperProgramInUSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInHungarianFlorintMember" abstract="true" name="ForwardCurrencyPurchasesInHungarianFlorintMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_TzieldMember" abstract="true" name="TzieldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_CostOfDebtNet" abstract="false" name="CostOfDebtNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" abstract="false" name="IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" abstract="true" name="ForwardCurrencyPurchasesInChineseYuanRenminbiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" abstract="false" name="DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember" abstract="true" name="BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" abstract="true" name="ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DebtInstrumentAxis" abstract="true" name="DebtInstrumentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_UpfrontPayments" abstract="false" name="UpfrontPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member" abstract="true" name="InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CommercialPaperProgramInFranceMember" abstract="true" name="CommercialPaperProgramInFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MajorCollaborationAgreementMember" abstract="true" name="MajorCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfAccountsReceivableLineItems" abstract="true" name="DisclosureOfAccountsReceivableLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInUSDollarMember" abstract="true" name="ForwardCurrencyPurchasesInUSDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInMexicanPesoMember" abstract="true" name="ForwardCurrencySalesInMexicanPesoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ZantacProductLitigationInTheUSMember" abstract="true" name="ZantacProductLitigationInTheUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_ProventionBioIncMember" abstract="true" name="ProventionBioIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ProductsTrademarksAndOtherRightsMember" abstract="true" name="ProductsTrademarksAndOtherRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesMember" abstract="true" name="ForwardCurrencySalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PainCareMember" abstract="true" name="PainCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ExcludingChiefExecutiveOfficerMember" abstract="true" name="ExcludingChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AtNotionalAmountMember" abstract="true" name="AtNotionalAmountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherIntangibleAssetsExcludingSoftwareMember" abstract="true" name="OtherIntangibleAssetsExcludingSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" abstract="false" name="IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ImmunoOncologyCollaborationAgreementMember" abstract="true" name="ImmunoOncologyCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TotalMilestonePayments" abstract="false" name="TotalMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InterestsInOtherEntitiesAbstract" abstract="true" name="InterestsInOtherEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_MeningitisTravelAndEndemicVaccinesMember" abstract="true" name="MeningitisTravelAndEndemicVaccinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" abstract="false" name="PercentageOfDevelopmentCostsArisingFromCommercialOperations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_AssetsAcquisitionDomain" abstract="true" name="AssetsAcquisitionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" abstract="false" name="TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" abstract="false" name="DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" abstract="false" name="GainLossOnDerivativesUsedToManageCashAndCashEquivalents" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" abstract="false" name="InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherProductsSegmentMember" abstract="true" name="OtherProductsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" abstract="false" name="IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" abstract="false" name="DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_GoldBondProductLitigationInTheUSMember" abstract="true" name="GoldBondProductLitigationInTheUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_NetChangeInOtherNonCurrentAssets" abstract="false" name="NetChangeInOtherNonCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInUSDollarMember" abstract="true" name="ForwardCurrencySalesInUSDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated" abstract="false" name="GlobalPenaltyFeeIncurredByDefendantsAmountVacated" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CurrentAssetsMember" abstract="true" name="CurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherTerritoriesMember" abstract="true" name="OtherTerritoriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" abstract="false" name="InterestRateAndCurrencyDerivativesUsedToManageDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_BusinessCombinationPurchasePricePerShare" abstract="false" name="BusinessCombinationPurchasePricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInRussianRoubleMember" abstract="true" name="ForwardCurrencySalesInRussianRoubleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInKoreanWonMember" abstract="true" name="ForwardCurrencyPurchasesInKoreanWonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" abstract="false" name="NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_RestrictedSharesMember" abstract="true" name="RestrictedSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" abstract="false" name="OtherFinancialAssetsAtFairValueThroughProfitOrLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member" abstract="true" name="InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_UKZONEMember" abstract="true" name="UKZONEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" abstract="true" name="ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TypesOfAgreementDomain" abstract="true" name="TypesOfAgreementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" abstract="true" name="InterestRateSwapsPayCapitalizedEsterReceive069Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member" abstract="true" name="InterestRateSwapsPayCapitalizedEsterReceive3.56Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_NumberOfCases" abstract="false" name="NumberOfCases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" abstract="false" name="CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" abstract="false" name="DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member" abstract="true" name="InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_EnjaymoMember" abstract="true" name="EnjaymoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesMember" abstract="true" name="ForwardCurrencyPurchasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RezurockMember" abstract="true" name="RezurockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" abstract="true" name="ForwardCurrencyPurchasesInUSDollarUSBondMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IndustrialSalesMember" abstract="true" name="IndustrialSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IssuanceOfFurtherSharesAsAnEmployersContribution" abstract="false" name="IssuanceOfFurtherSharesAsAnEmployersContribution" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_PlavixMember" abstract="true" name="PlavixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" abstract="false" name="DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_NonOperatingForeignExchangeGainsLosses" abstract="false" name="NonOperatingForeignExchangeGainsLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" abstract="false" name="AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities" abstract="false" name="IncreaseDecreaseInTotalExpenseOfRestructuringActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" abstract="true" name="DisclosureOfOffBalanceSheetCommitmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember" abstract="true" name="ContingentConsiderationArisingFromAcquisitionOfAmunixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NotEligibleForHedgeAccountingMember" abstract="true" name="NotEligibleForHedgeAccountingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RedemptionOfDebtInstrumentIssued" abstract="false" name="RedemptionOfDebtInstrumentIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfSharesHeld" abstract="false" name="NumberOfSharesHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_CurrentLiabilitiesMember" abstract="true" name="CurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherGainsLossesAndLitigation" abstract="false" name="OtherGainsLossesAndLitigation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CollaborationAgreementWithGSKMember" abstract="true" name="CollaborationAgreementWithGSKMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_LiabilityRecognisedForEstimatedFutureRoyalties" abstract="false" name="LiabilityRecognisedForEstimatedFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_RestrictedSharePlan2020Member" abstract="true" name="RestrictedSharePlan2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfTradeReceivablesTextBlock" abstract="false" name="DisclosureOfTradeReceivablesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_StockPrice" abstract="false" name="StockPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_NumberOfOperatingSegments" abstract="false" name="NumberOfOperatingSegments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_OneBillionBondsMaturingJune2023Member" abstract="true" name="OneBillionBondsMaturingJune2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_XenpozymeMember" abstract="true" name="XenpozymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_NexviazymeMember" abstract="true" name="NexviazymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_BusinessOperatingIncome" abstract="false" name="BusinessOperatingIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ShareRepurchase2023ProgramMember" abstract="true" name="ShareRepurchase2023ProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NonCurrentRestructuringProvisionMember" abstract="true" name="NonCurrentRestructuringProvisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ReportableGeographicalZonesMember" abstract="true" name="ReportableGeographicalZonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_QRIBIntermediateHoldingsLLCMember" abstract="true" name="QRIBIntermediateHoldingsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" abstract="false" name="DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" abstract="false" name="DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ActionForWhichWeAreDefendantMember" abstract="true" name="ActionForWhichWeAreDefendantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CollaborationAgreementsUpfrontPayment" abstract="false" name="CollaborationAgreementsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInRussianRoubleMember" abstract="true" name="ForwardCurrencyPurchasesInRussianRoubleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_DisclosureOfLegalAndArbitralProceedingsLineItems" abstract="true" name="DisclosureOfLegalAndArbitralProceedingsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" abstract="false" name="ExceptionalSupplementaryDividendPercentageOfShareCapital" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_RSVVaccinesMember" abstract="true" name="RSVVaccinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_MSPVaccineCompanyMember" abstract="true" name="MSPVaccineCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DebtInstrumentsMember" abstract="true" name="DebtInstrumentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DerivativeFinancialInstrumentsToManageFinancialExposure" abstract="false" name="DerivativeFinancialInstrumentsToManageFinancialExposure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" abstract="false" name="UpfrontPaymentsForProjectsUnderCollaborationAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts" abstract="false" name="ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AssociatesAndJointVenturesMember" abstract="true" name="AssociatesAndJointVenturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_GainLossOnDerivativesUsedToManageDebt" abstract="false" name="GainLossOnDerivativesUsedToManageDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" abstract="false" name="IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" abstract="false" name="IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" abstract="true" name="ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated" abstract="false" name="PenaltyFeeIncurredByDefendantsInterestsAmountVacated" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AstraZenecaMember" abstract="true" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_EquityInstrumentsIncludedInFinancialAssetsMember" abstract="true" name="EquityInstrumentsIncludedInFinancialAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AssetsAcquisitionPurchasePricePerShare" abstract="false" name="AssetsAcquisitionPurchasePricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sny_AmortizedCostNettingMember" abstract="true" name="AmortizedCostNettingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RestrictedSharePlan2024AdditionalSharesMember" abstract="true" name="RestrictedSharePlan2024AdditionalSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_LegalAndArbitralProceedingsAxis" abstract="true" name="LegalAndArbitralProceedingsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" abstract="false" name="IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_MazeTherapeuticsMember" abstract="true" name="MazeTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MCMVaccineBVMember" abstract="true" name="MCMVaccineBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" abstract="false" name="DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_FabrazymeMember" abstract="true" name="FabrazymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfPlaintiffs" abstract="false" name="NumberOfPlaintiffs" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" abstract="true" name="DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_AtMarketValueMember" abstract="true" name="AtMarketValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" abstract="true" name="ItemsSubsequentlyReclassifiableToProfitOrLossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" abstract="false" name="ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" abstract="false" name="RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfAccountsReceivableTable" abstract="true" name="DisclosureOfAccountsReceivableTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" abstract="true" name="OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CoreAssetsMember" abstract="true" name="CoreAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DebtInstrumentDomain" abstract="true" name="DebtInstrumentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" abstract="true" name="ShareOfProfitOrLossFromCommercializationOfZaltrapMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_WellnessBrandsMember" abstract="true" name="WellnessBrandsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_OtherRestructuringCosts" abstract="false" name="OtherRestructuringCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" abstract="false" name="DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" abstract="false" name="IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NonCurrentAssetsMember" abstract="true" name="NonCurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" abstract="false" name="DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" abstract="false" name="ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NetInterestCostRelatedToEmployeeBenefits" abstract="false" name="NetInterestCostRelatedToEmployeeBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInPoundSterlingMember" abstract="true" name="ForwardCurrencySalesInPoundSterlingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" abstract="false" name="ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherOperatingIncomeExpenseMember" abstract="true" name="OtherOperatingIncomeExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" abstract="false" name="IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" abstract="true" name="DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_ConsumerHealthcareSegmentMember" abstract="true" name="ConsumerHealthcareSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfOtherNonCurrentAssetsLineItems" abstract="true" name="DisclosureOfOtherNonCurrentAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_ForeignCurrencyTranslationMember" abstract="true" name="ForeignCurrencyTranslationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill" abstract="false" name="ImpairmentLossOnIntangibleAssetOtherThanGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" abstract="false" name="IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfRestrictedSharesAlloted" abstract="false" name="NumberOfRestrictedSharesAlloted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_ProductLiabilitiesMember" abstract="true" name="ProductLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" abstract="false" name="DisclosureOfOverdueReceivablesGrossValueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_RestrictedSharePlan2022Member" abstract="true" name="RestrictedSharePlan2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RestrictedSharePlan2023Member" abstract="true" name="RestrictedSharePlan2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" abstract="false" name="DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_USGovernmentMember" abstract="true" name="USGovernmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ToujeoMember" abstract="true" name="ToujeoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" abstract="false" name="IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SAR44425Member" abstract="true" name="SAR44425Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" abstract="false" name="DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_EmployeeShareOwnershipPlanMember" abstract="true" name="EmployeeShareOwnershipPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherOperatingExpensesTableTextBlock" abstract="false" name="OtherOperatingExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_PotentialPaymentsRelatedToPercentageOfSales" abstract="false" name="PotentialPaymentsRelatedToPercentageOfSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_GainsOnDivestmentOfProducts" abstract="false" name="GainsOnDivestmentOfProducts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost" abstract="false" name="UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_BorrowingAverageDrawdown" abstract="false" name="BorrowingAverageDrawdown" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OthersMember" abstract="true" name="OthersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_RestrictedSharePlan2023AdditionalSharesMember" abstract="true" name="RestrictedSharePlan2023AdditionalSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfDismissals" abstract="false" name="NumberOfDismissals" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" abstract="false" name="DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_CustomerThreeMember" abstract="true" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShareProgramDomain" abstract="true" name="ShareProgramDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AssetsAcquisitionAxis" abstract="true" name="AssetsAcquisitionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DefendantDomain" abstract="true" name="DefendantDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock" abstract="false" name="AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_SanofiEuroMediumTermNotesMember" abstract="true" name="SanofiEuroMediumTermNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AssetsAcquisitionMember" abstract="true" name="AssetsAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_OverdueReceivablesGrossValue" abstract="false" name="OverdueReceivablesGrossValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInCurrencyTranslationOnTaxEffects" abstract="false" name="ChangeInCurrencyTranslationOnTaxEffects" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfPrincipalAgreementsLineItems" abstract="true" name="DisclosureOfPrincipalAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfNonCurrentProvisionsTableTextBlock" abstract="false" name="DisclosureOfNonCurrentProvisionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfChangesInFinancialPositionTableTextBlock" abstract="false" name="DisclosureOfChangesInFinancialPositionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DigestiveWellnessMember" abstract="true" name="DigestiveWellnessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShareProgramAxis" abstract="true" name="ShareProgramAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_LantusMember" abstract="true" name="LantusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfSharesRepurchased" abstract="false" name="NumberOfSharesRepurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_LeaseCost" abstract="false" name="LeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ProvisionsForOtherLongTermBenefitsMember" abstract="true" name="ProvisionsForOtherLongTermBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInTurkishLiraMember" abstract="true" name="ForwardCurrencyPurchasesInTurkishLiraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_StockOptionPlanMember" abstract="true" name="StockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SyndicatedCreditFacilityTwoMember" abstract="true" name="SyndicatedCreditFacilityTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CertainWholesalersInTheUnitedStatesMember" abstract="true" name="CertainWholesalersInTheUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShareCapitalReservesAndOtherEquityInterestAbstract" abstract="true" name="ShareCapitalReservesAndOtherEquityInterestAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInCanadianDollarMember" abstract="true" name="ForwardCurrencySalesInCanadianDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" abstract="false" name="BasicEarningsLossPerShareAttributableToOwnersOfParent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>sny-20240630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a012fc2d-d3ff-4c6a-950e-09cafe0bb60f,g:e711d38b-47f1-4329-bc58-181a62b743af-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_1c539df6-4dd9-4aa6-b6d3-310e65bff971" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_de6db309-7cb1-4874-9a29-df00b060dd17" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_1c539df6-4dd9-4aa6-b6d3-310e65bff971" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_de6db309-7cb1-4874-9a29-df00b060dd17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_bd779790-37c9-41ee-9e36-44a89feffcb9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_1c539df6-4dd9-4aa6-b6d3-310e65bff971" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_bd779790-37c9-41ee-9e36-44a89feffcb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_682411c7-f1ce-4ca2-983b-6defecbd4c41" xlink:href="sny-20240630.xsd#sny_CurrentProvisionsAndOtherCurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_1c539df6-4dd9-4aa6-b6d3-310e65bff971" xlink:to="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_682411c7-f1ce-4ca2-983b-6defecbd4c41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_704ced1d-6c77-4151-9a5f-e50649cd8a14" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_1c539df6-4dd9-4aa6-b6d3-310e65bff971" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_704ced1d-6c77-4151-9a5f-e50649cd8a14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_f2191bdf-de6a-4024-be49-949e05039e12" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_1c539df6-4dd9-4aa6-b6d3-310e65bff971" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_f2191bdf-de6a-4024-be49-949e05039e12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_c938685f-0553-4c48-83f6-6220f1a63da3" xlink:href="sny-20240630.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_1c539df6-4dd9-4aa6-b6d3-310e65bff971" xlink:to="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_c938685f-0553-4c48-83f6-6220f1a63da3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_111666df-63a1-456d-a6b4-1001277df2b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_c85d8959-aa88-4544-8e67-96f62109c981" xlink:href="sny-20240630.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_111666df-63a1-456d-a6b4-1001277df2b9" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_c85d8959-aa88-4544-8e67-96f62109c981" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_55415d82-fb7f-4916-9b91-0913d9b7cf71" xlink:href="sny-20240630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_111666df-63a1-456d-a6b4-1001277df2b9" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_55415d82-fb7f-4916-9b91-0913d9b7cf71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_ed5e5500-17cb-4b41-adb2-6cdf5e42ef5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_111666df-63a1-456d-a6b4-1001277df2b9" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_ed5e5500-17cb-4b41-adb2-6cdf5e42ef5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_963d8541-a03c-49e2-b99d-0bf0df30214a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_111666df-63a1-456d-a6b4-1001277df2b9" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_963d8541-a03c-49e2-b99d-0bf0df30214a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_9a17d705-0fa6-498a-b2ff-de8169b7ad1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_111666df-63a1-456d-a6b4-1001277df2b9" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_9a17d705-0fa6-498a-b2ff-de8169b7ad1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_daf0dd6e-dc64-4cd7-98b7-ce163ef0be96" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_111666df-63a1-456d-a6b4-1001277df2b9" xlink:to="loc_ifrs-full_LongtermBorrowings_daf0dd6e-dc64-4cd7-98b7-ce163ef0be96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_6c929bce-b75d-4b50-8d4e-8f18f5bda1f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_5d9cebb2-459c-4b3c-a117-a54557cd118c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_6c929bce-b75d-4b50-8d4e-8f18f5bda1f1" xlink:to="loc_ifrs-full_CashAndCashEquivalents_5d9cebb2-459c-4b3c-a117-a54557cd118c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_2db7588e-778a-401b-b7c2-3240b5465884" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_6c929bce-b75d-4b50-8d4e-8f18f5bda1f1" xlink:to="loc_ifrs-full_Inventories_2db7588e-778a-401b-b7c2-3240b5465884" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsCurrent_2dd505eb-474b-41b8-bf8c-4ee813e86d9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_6c929bce-b75d-4b50-8d4e-8f18f5bda1f1" xlink:to="loc_ifrs-full_CurrentTaxAssetsCurrent_2dd505eb-474b-41b8-bf8c-4ee813e86d9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_1efc98ba-e8c2-4505-86be-525fa5f4aa4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_6c929bce-b75d-4b50-8d4e-8f18f5bda1f1" xlink:to="loc_ifrs-full_OtherCurrentAssets_1efc98ba-e8c2-4505-86be-525fa5f4aa4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_3099fd2f-d253-4b7d-8eb5-b50da53a71df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_6c929bce-b75d-4b50-8d4e-8f18f5bda1f1" xlink:to="loc_ifrs-full_CurrentTradeReceivables_3099fd2f-d253-4b7d-8eb5-b50da53a71df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_b410568b-a081-4ce2-a62e-2c61fea79757" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_8aa916bf-d378-4c1b-8bf0-30b114d03828" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_b410568b-a081-4ce2-a62e-2c61fea79757" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_8aa916bf-d378-4c1b-8bf0-30b114d03828" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_7b959dac-b7ab-4b2a-b658-dd2ed709df9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_b410568b-a081-4ce2-a62e-2c61fea79757" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_7b959dac-b7ab-4b2a-b658-dd2ed709df9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_99b36f8f-cfa8-4b76-ae68-7d0394447c56" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_b410568b-a081-4ce2-a62e-2c61fea79757" xlink:to="loc_ifrs-full_DeferredTaxAssets_99b36f8f-cfa8-4b76-ae68-7d0394447c56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_358c7e50-ba17-44ce-a4c6-e6164520ae8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_b410568b-a081-4ce2-a62e-2c61fea79757" xlink:to="loc_ifrs-full_RightofuseAssets_358c7e50-ba17-44ce-a4c6-e6164520ae8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_2c0431b8-2fab-48dc-8ceb-9a57d92320d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_b410568b-a081-4ce2-a62e-2c61fea79757" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_2c0431b8-2fab-48dc-8ceb-9a57d92320d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsNoncurrent_e64eafe1-8bd3-467b-bd6d-bb571ac80f15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_b410568b-a081-4ce2-a62e-2c61fea79757" xlink:to="loc_ifrs-full_CurrentTaxAssetsNoncurrent_e64eafe1-8bd3-467b-bd6d-bb571ac80f15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_f2fb70f7-3a65-4ec1-a183-05f922277495" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_b410568b-a081-4ce2-a62e-2c61fea79757" xlink:to="loc_ifrs-full_Goodwill_f2fb70f7-3a65-4ec1-a183-05f922277495" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_8d44adc7-8018-4f43-8629-f5e2a45572b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_b410568b-a081-4ce2-a62e-2c61fea79757" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_8d44adc7-8018-4f43-8629-f5e2a45572b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_d8b2eb24-0be0-4c00-837d-28914a0d0a6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_a64ce213-cff1-4051-9cba-be02ccdd690a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_d8b2eb24-0be0-4c00-837d-28914a0d0a6c" xlink:to="loc_ifrs-full_NoncurrentAssets_a64ce213-cff1-4051-9cba-be02ccdd690a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_a0de2a8f-25f8-48a2-91f8-35caeffc26a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_d8b2eb24-0be0-4c00-837d-28914a0d0a6c" xlink:to="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_a0de2a8f-25f8-48a2-91f8-35caeffc26a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_daf2c57e-8273-467c-a12e-aa32b2c18f72" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_d8b2eb24-0be0-4c00-837d-28914a0d0a6c" xlink:to="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_daf2c57e-8273-467c-a12e-aa32b2c18f72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_b5c4ba67-9529-4e80-8dfd-056a0ccddfd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_b35d2c5e-415f-4381-987f-6e079d38fc80" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_b5c4ba67-9529-4e80-8dfd-056a0ccddfd3" xlink:to="loc_ifrs-full_Equity_b35d2c5e-415f-4381-987f-6e079d38fc80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_71dd95df-cbeb-4ffc-9ccc-be761662925e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_b5c4ba67-9529-4e80-8dfd-056a0ccddfd3" xlink:to="loc_ifrs-full_NoncurrentLiabilities_71dd95df-cbeb-4ffc-9ccc-be761662925e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_dec0890c-0e74-463f-a03c-159a038e587d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_b5c4ba67-9529-4e80-8dfd-056a0ccddfd3" xlink:to="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_dec0890c-0e74-463f-a03c-159a038e587d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_4035a673-2810-4d01-9046-cba8ae43ed76" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_b5c4ba67-9529-4e80-8dfd-056a0ccddfd3" xlink:to="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_4035a673-2810-4d01-9046-cba8ae43ed76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_abd34d18-69a2-4863-8d59-81baf9427a2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterests_1450cbc5-5685-42dc-a0e4-669c9cccb7dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_abd34d18-69a2-4863-8d59-81baf9427a2c" xlink:to="loc_ifrs-full_NoncontrollingInterests_1450cbc5-5685-42dc-a0e4-669c9cccb7dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent_a908581b-6150-448c-816b-14ce64fa72e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_abd34d18-69a2-4863-8d59-81baf9427a2c" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParent_a908581b-6150-448c-816b-14ce64fa72e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedIncomeStatements" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedIncomeStatements"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ConsolidatedIncomeStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_a1a1bda2-bd2e-4f94-95b2-b5990409a41e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_a376cbfa-3c44-4190-bab5-5e428c5fb592" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_a1a1bda2-bd2e-4f94-95b2-b5990409a41e" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_a376cbfa-3c44-4190-bab5-5e428c5fb592" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_a4cba4ed-6833-4b75-8cd2-413b1424aefd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_a1a1bda2-bd2e-4f94-95b2-b5990409a41e" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_a4cba4ed-6833-4b75-8cd2-413b1424aefd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_48a10ff1-7129-4bf3-bd68-d8a7409dfce8" xlink:href="sny-20240630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_e8c7706f-cb52-46de-8880-045e00caa7d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_48a10ff1-7129-4bf3-bd68-d8a7409dfce8" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_e8c7706f-cb52-46de-8880-045e00caa7d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_c900fb8b-211b-407f-a6e2-5e80b0b3c8a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_48a10ff1-7129-4bf3-bd68-d8a7409dfce8" xlink:to="loc_ifrs-full_FinanceCosts_c900fb8b-211b-407f-a6e2-5e80b0b3c8a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_0bac9145-7322-4009-9d28-b9ed97f92f66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_48a10ff1-7129-4bf3-bd68-d8a7409dfce8" xlink:to="loc_ifrs-full_FinanceIncome_0bac9145-7322-4009-9d28-b9ed97f92f66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossProfit_d7338250-fac5-4bff-9f89-9bd0026d9983" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_7a3b944a-4dea-4436-9039-4391980d0a9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GrossProfit_d7338250-fac5-4bff-9f89-9bd0026d9983" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_7a3b944a-4dea-4436-9039-4391980d0a9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_5cc3417e-b166-47dd-9bc8-8a76daddb920" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GrossProfit_d7338250-fac5-4bff-9f89-9bd0026d9983" xlink:to="loc_ifrs-full_OtherRevenue_5cc3417e-b166-47dd-9bc8-8a76daddb920" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_1909c228-5120-4a1b-b050-b8296d51cda5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GrossProfit_d7338250-fac5-4bff-9f89-9bd0026d9983" xlink:to="loc_ifrs-full_CostOfSales_1909c228-5120-4a1b-b050-b8296d51cda5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_0db96b7a-1b2d-43b7-90b1-a82b56ef792e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_d399d8da-8099-4c04-8d33-d2ba1a803e60" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_0db96b7a-1b2d-43b7-90b1-a82b56ef792e" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_d399d8da-8099-4c04-8d33-d2ba1a803e60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_e392f642-483d-4adb-99b5-e730d6541d44" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_0db96b7a-1b2d-43b7-90b1-a82b56ef792e" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_e392f642-483d-4adb-99b5-e730d6541d44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_a326f248-fffa-4a02-aa6f-ee0d5191b867" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_0db96b7a-1b2d-43b7-90b1-a82b56ef792e" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_a326f248-fffa-4a02-aa6f-ee0d5191b867" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_88ed606b-efd7-4dd5-bf64-18cb1e747210" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_0db96b7a-1b2d-43b7-90b1-a82b56ef792e" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_88ed606b-efd7-4dd5-bf64-18cb1e747210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_a6b5dc31-2f4b-4c40-bbdd-9029e52d5b1f" xlink:href="sny-20240630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_0db96b7a-1b2d-43b7-90b1-a82b56ef792e" xlink:to="loc_sny_OtherGainsLossesAndLitigation_a6b5dc31-2f4b-4c40-bbdd-9029e52d5b1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_91f682b8-eb4c-4d40-bc56-4a7094d8a40a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_0db96b7a-1b2d-43b7-90b1-a82b56ef792e" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_91f682b8-eb4c-4d40-bc56-4a7094d8a40a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_17a9a12f-0a85-44aa-a23f-e3d51be4c6f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_0db96b7a-1b2d-43b7-90b1-a82b56ef792e" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_17a9a12f-0a85-44aa-a23f-e3d51be4c6f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossProfit_fbfe0bf0-4da2-4787-bb29-b4cac5a2f967" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_0db96b7a-1b2d-43b7-90b1-a82b56ef792e" xlink:to="loc_ifrs-full_GrossProfit_fbfe0bf0-4da2-4787-bb29-b4cac5a2f967" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_db04c0f2-e789-4585-8384-552e59e968bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_0db96b7a-1b2d-43b7-90b1-a82b56ef792e" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_db04c0f2-e789-4585-8384-552e59e968bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_5bf02347-e8ed-4392-a127-ac3c3eb64aa0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_0db96b7a-1b2d-43b7-90b1-a82b56ef792e" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_5bf02347-e8ed-4392-a127-ac3c3eb64aa0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedIncomeStatements_1" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedIncomeStatements_1"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ConsolidatedIncomeStatements_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_a06b7cf9-74e3-4182-9b87-2639ebabe42e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_75f31b8c-6446-452c-bfb7-a0475ed4f812" xlink:href="sny-20240630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_a06b7cf9-74e3-4182-9b87-2639ebabe42e" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_75f31b8c-6446-452c-bfb7-a0475ed4f812" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_ffbeb632-0549-4e02-bc8a-6ed5688fc549" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_a06b7cf9-74e3-4182-9b87-2639ebabe42e" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_ffbeb632-0549-4e02-bc8a-6ed5688fc549" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_cdbac347-9c92-449c-91a8-cdd0bc17833f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_a06b7cf9-74e3-4182-9b87-2639ebabe42e" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_cdbac347-9c92-449c-91a8-cdd0bc17833f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_c64caec9-2b1c-40af-ab66-81f5f6b862eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_76dbb62b-062c-4b16-97a7-4a3ec07c93ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_c64caec9-2b1c-40af-ab66-81f5f6b862eb" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_76dbb62b-062c-4b16-97a7-4a3ec07c93ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_5f1e3a13-047b-41f9-bab6-8eb4004d437d" xlink:href="sny-20240630.xsd#sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_c64caec9-2b1c-40af-ab66-81f5f6b862eb" xlink:to="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_5f1e3a13-047b-41f9-bab6-8eb4004d437d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_e208c08d-31fb-4f2d-8f6e-ed347487be81" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_c64caec9-2b1c-40af-ab66-81f5f6b862eb" xlink:to="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_e208c08d-31fb-4f2d-8f6e-ed347487be81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_76dc5abf-3922-40aa-b9b8-7444150b5c1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_c64caec9-2b1c-40af-ab66-81f5f6b862eb" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_76dc5abf-3922-40aa-b9b8-7444150b5c1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_2e684fba-5b73-4a13-bfb1-1f0f49f553e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_0967f1ff-6c07-4740-9268-8857873edeb8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_2e684fba-5b73-4a13-bfb1-1f0f49f553e7" xlink:to="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_0967f1ff-6c07-4740-9268-8857873edeb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_a92ca958-b6e3-41b8-aa34-412a201bb857" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_2e684fba-5b73-4a13-bfb1-1f0f49f553e7" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_a92ca958-b6e3-41b8-aa34-412a201bb857" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_2fb3d656-9891-4413-aadd-734ed9280268" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_2e684fba-5b73-4a13-bfb1-1f0f49f553e7" xlink:to="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_2fb3d656-9891-4413-aadd-734ed9280268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_74b2c7b0-a53a-4673-b6ef-17218a587873" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_b522aeef-419a-48f3-80bb-960b7f59abf3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_74b2c7b0-a53a-4673-b6ef-17218a587873" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_b522aeef-419a-48f3-80bb-960b7f59abf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_14c88d8c-8f9b-4ea4-b392-1f39d792d925" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_74b2c7b0-a53a-4673-b6ef-17218a587873" xlink:to="loc_ifrs-full_ProfitLoss_14c88d8c-8f9b-4ea4-b392-1f39d792d925" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_9c4be3c0-41f5-4e7f-bcb4-f1167ac1dd1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_da2da62a-3d98-4b63-9054-14bcb481ab05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome_9c4be3c0-41f5-4e7f-bcb4-f1167ac1dd1b" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_da2da62a-3d98-4b63-9054-14bcb481ab05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_11ad12f5-88c7-4395-810d-914cc93671c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome_9c4be3c0-41f5-4e7f-bcb4-f1167ac1dd1b" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_11ad12f5-88c7-4395-810d-914cc93671c1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome_1" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedStatementsofComprehensiveIncome_1"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_8e48da39-19f8-40b2-9227-d33da6a71634" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_ffd38471-7803-4bf0-a0b5-040ea4be606a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_8e48da39-19f8-40b2-9227-d33da6a71634" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_ffd38471-7803-4bf0-a0b5-040ea4be606a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_b47298c1-0d4c-484d-9fab-3951f9f7897f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_8e48da39-19f8-40b2-9227-d33da6a71634" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_b47298c1-0d4c-484d-9fab-3951f9f7897f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_252e6831-aa5c-4e42-a426-e901eceba2cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_30dc0367-b8a9-49a3-b830-938c9225b354" xlink:href="sny-20240630.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_252e6831-aa5c-4e42-a426-e901eceba2cc" xlink:to="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_30dc0367-b8a9-49a3-b830-938c9225b354" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_3f16b24b-e7d5-4794-8177-6d6799e03e33" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_252e6831-aa5c-4e42-a426-e901eceba2cc" xlink:to="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_3f16b24b-e7d5-4794-8177-6d6799e03e33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_210ba0cb-def6-4272-8cd5-895d32837817" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_252e6831-aa5c-4e42-a426-e901eceba2cc" xlink:to="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_210ba0cb-def6-4272-8cd5-895d32837817" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_4aa151ce-67a4-4dc4-999c-659a798d3b35" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_252e6831-aa5c-4e42-a426-e901eceba2cc" xlink:to="loc_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_4aa151ce-67a4-4dc4-999c-659a798d3b35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_aacb1e10-9cb2-4a78-a61f-dc461301b607" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_252e6831-aa5c-4e42-a426-e901eceba2cc" xlink:to="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_aacb1e10-9cb2-4a78-a61f-dc461301b607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_b805dac3-bbaf-4486-91d9-0961ba053213" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_252e6831-aa5c-4e42-a426-e901eceba2cc" xlink:to="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_b805dac3-bbaf-4486-91d9-0961ba053213" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_1760cefd-9608-4bbe-8d9c-1d21c255ea6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_252e6831-aa5c-4e42-a426-e901eceba2cc" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_1760cefd-9608-4bbe-8d9c-1d21c255ea6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_740d292c-83c5-43ee-94b5-a2d89d15dbaa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_252e6831-aa5c-4e42-a426-e901eceba2cc" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_740d292c-83c5-43ee-94b5-a2d89d15dbaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_103e936f-bc4c-4bfe-9282-a3a682819ed8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_252e6831-aa5c-4e42-a426-e901eceba2cc" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_103e936f-bc4c-4bfe-9282-a3a682819ed8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_0ff27af8-65b2-45a4-8f66-82f948570ada" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_4c74261e-b7a1-4569-891f-8a8f86af664f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_0ff27af8-65b2-45a4-8f66-82f948570ada" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_4c74261e-b7a1-4569-891f-8a8f86af664f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_eaab436d-6b26-4112-ad3d-c8d61ed1f9cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_0ff27af8-65b2-45a4-8f66-82f948570ada" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_eaab436d-6b26-4112-ad3d-c8d61ed1f9cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_b97032a6-d09f-4a47-a4fb-658aca1116ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_0ff27af8-65b2-45a4-8f66-82f948570ada" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_b97032a6-d09f-4a47-a4fb-658aca1116ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_837136a9-d2d7-4c76-9163-82ac6f246f91" xlink:href="sny-20240630.xsd#sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_0ff27af8-65b2-45a4-8f66-82f948570ada" xlink:to="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_837136a9-d2d7-4c76-9163-82ac6f246f91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_b3731b25-69aa-4a60-afaf-e0c7d35e6d78" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_0ff27af8-65b2-45a4-8f66-82f948570ada" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_b3731b25-69aa-4a60-afaf-e0c7d35e6d78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_712ff0fd-dce8-4b74-83f0-2544ab159e05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherNonCurrentAssets_e2f669db-f68b-4684-8cc5-e24cec2b7301" xlink:href="sny-20240630.xsd#sny_NetChangeInOtherNonCurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_712ff0fd-dce8-4b74-83f0-2544ab159e05" xlink:to="loc_sny_NetChangeInOtherNonCurrentAssets_e2f669db-f68b-4684-8cc5-e24cec2b7301" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_08df7bef-76df-4748-ac4c-ef819f8aa29a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_712ff0fd-dce8-4b74-83f0-2544ab159e05" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_08df7bef-76df-4748-ac4c-ef819f8aa29a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_64858ea1-a66d-46ce-8abe-01d75582aa04" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_712ff0fd-dce8-4b74-83f0-2544ab159e05" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_64858ea1-a66d-46ce-8abe-01d75582aa04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_1e41a1c8-fa3c-4bb5-bb99-f26e96f2119f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_712ff0fd-dce8-4b74-83f0-2544ab159e05" xlink:to="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_1e41a1c8-fa3c-4bb5-bb99-f26e96f2119f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_389a4a60-da93-40fb-8c69-2d2d1c26e5e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_712ff0fd-dce8-4b74-83f0-2544ab159e05" xlink:to="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_389a4a60-da93-40fb-8c69-2d2d1c26e5e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_26fabc57-3db3-4010-9d7c-877242abd8a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_712ff0fd-dce8-4b74-83f0-2544ab159e05" xlink:to="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_26fabc57-3db3-4010-9d7c-877242abd8a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9edeb9ba-87fe-4073-b048-8e9d0e8ce1fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDeferredTaxExpense_99c0ba23-511c-4f33-8a4e-2f06499f8ab7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9edeb9ba-87fe-4073-b048-8e9d0e8ce1fb" xlink:to="loc_ifrs-full_AdjustmentsForDeferredTaxExpense_99c0ba23-511c-4f33-8a4e-2f06499f8ab7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_cf6a68af-fa0b-4426-b83e-b6863af00aa6" xlink:href="sny-20240630.xsd#sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9edeb9ba-87fe-4073-b048-8e9d0e8ce1fb" xlink:to="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_cf6a68af-fa0b-4426-b83e-b6863af00aa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_bfb70b95-39af-4794-a698-792c15e2c470" xlink:href="sny-20240630.xsd#sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9edeb9ba-87fe-4073-b048-8e9d0e8ce1fb" xlink:to="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_bfb70b95-39af-4794-a698-792c15e2c470" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_2bbebebf-8580-44b9-b3c7-68acfe3d1953" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9edeb9ba-87fe-4073-b048-8e9d0e8ce1fb" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_2bbebebf-8580-44b9-b3c7-68acfe3d1953" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_3ae59930-423d-451c-a8cb-4a1ffdeca9cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9edeb9ba-87fe-4073-b048-8e9d0e8ce1fb" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_3ae59930-423d-451c-a8cb-4a1ffdeca9cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_20b7c346-e4f5-44cd-97ba-0f777f7b6324" xlink:href="sny-20240630.xsd#sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9edeb9ba-87fe-4073-b048-8e9d0e8ce1fb" xlink:to="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_20b7c346-e4f5-44cd-97ba-0f777f7b6324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_8a034cfe-96eb-4551-ba35-9207932663f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9edeb9ba-87fe-4073-b048-8e9d0e8ce1fb" xlink:to="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_8a034cfe-96eb-4551-ba35-9207932663f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_a207b95d-761c-4863-8b14-d16732a68c35" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9edeb9ba-87fe-4073-b048-8e9d0e8ce1fb" xlink:to="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_a207b95d-761c-4863-8b14-d16732a68c35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_a19228de-ddd7-42c1-ba41-5e7e042ebd88" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9edeb9ba-87fe-4073-b048-8e9d0e8ce1fb" xlink:to="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_a19228de-ddd7-42c1-ba41-5e7e042ebd88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_a0246d36-78c8-492b-bf10-70c9ec2c0916" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9edeb9ba-87fe-4073-b048-8e9d0e8ce1fb" xlink:to="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_a0246d36-78c8-492b-bf10-70c9ec2c0916" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_ce0191ee-f43b-4108-acaa-c1f9554a8bb1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_dd275a02-e530-4daa-b54c-6309eb482308" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_ce0191ee-f43b-4108-acaa-c1f9554a8bb1" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_dd275a02-e530-4daa-b54c-6309eb482308" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_795f1ca6-4c50-474e-86ad-01118556ce8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_ce0191ee-f43b-4108-acaa-c1f9554a8bb1" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_795f1ca6-4c50-474e-86ad-01118556ce8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_37e75f55-5c28-4964-8027-de13ede762fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_ce0191ee-f43b-4108-acaa-c1f9554a8bb1" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_37e75f55-5c28-4964-8027-de13ede762fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_c22d7e58-4133-4e06-b09f-d362a94f77d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_ce0191ee-f43b-4108-acaa-c1f9554a8bb1" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_c22d7e58-4133-4e06-b09f-d362a94f77d7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_7261728c-d744-4732-b60e-0c5e4380f888" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_1ca70da9-e9dd-4607-9a4c-2c5e5f937974" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_7261728c-d744-4732-b60e-0c5e4380f888" xlink:to="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_1ca70da9-e9dd-4607-9a4c-2c5e5f937974" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod_3636a1c5-09c2-4151-8944-efb1f2b8a3a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_7261728c-d744-4732-b60e-0c5e4380f888" xlink:to="loc_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod_3636a1c5-09c2-4151-8944-efb1f2b8a3a3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherNonCurrentAssetsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#OtherNonCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/OtherNonCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_aa967657-3d24-432c-bd63-ac08a22a1452" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LongTermPrepaidExpenses_cd5c7812-8010-4252-8065-889131ae760f" xlink:href="sny-20240630.xsd#sny_LongTermPrepaidExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets_aa967657-3d24-432c-bd63-ac08a22a1452" xlink:to="loc_sny_LongTermPrepaidExpenses_cd5c7812-8010-4252-8065-889131ae760f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_98cd2da7-3ece-4042-b564-9cde4b601305" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets_aa967657-3d24-432c-bd63-ac08a22a1452" xlink:to="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_98cd2da7-3ece-4042-b564-9cde4b601305" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PreFundedPensionObligations_a3e9b9b5-03f8-461f-b81d-5b7ed043ecbf" xlink:href="sny-20240630.xsd#sny_PreFundedPensionObligations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets_aa967657-3d24-432c-bd63-ac08a22a1452" xlink:to="loc_sny_PreFundedPensionObligations_a3e9b9b5-03f8-461f-b81d-5b7ed043ecbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLoansAndReceivables_17e349b5-c939-4a26-b8ca-ed1d6ad726b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLoansAndReceivables"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets_aa967657-3d24-432c-bd63-ac08a22a1452" xlink:to="loc_ifrs-full_NoncurrentLoansAndReceivables_17e349b5-c939-4a26-b8ca-ed1d6ad726b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_716edfe0-bd31-40e1-bc58-076e8dd1637d" xlink:href="sny-20240630.xsd#sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets_aa967657-3d24-432c-bd63-ac08a22a1452" xlink:to="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_716edfe0-bd31-40e1-bc58-076e8dd1637d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_d790778a-ed95-46b8-8f7f-5ce0435e04e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_e4902a16-fc70-4fe3-8404-f577f8ec5f14" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares_d790778a-ed95-46b8-8f7f-5ce0435e04e6" xlink:to="loc_ifrs-full_WeightedAverageShares_e4902a16-fc70-4fe3-8404-f577f8ec5f14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_53435be2-307d-4236-bada-91914a2ded91" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares_d790778a-ed95-46b8-8f7f-5ce0435e04e6" xlink:to="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_53435be2-307d-4236-bada-91914a2ded91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_32bcf694-f40f-4112-98d0-1a0c5144cc9f" xlink:href="sny-20240630.xsd#sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares_d790778a-ed95-46b8-8f7f-5ce0435e04e6" xlink:to="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_32bcf694-f40f-4112-98d0-1a0c5144cc9f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_123eaea6-1621-44eb-834b-7fad01b09cbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_8b59c359-e67c-4e78-9d8f-4b9906681b91" xlink:href="sny-20240630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_123eaea6-1621-44eb-834b-7fad01b09cbf" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_8b59c359-e67c-4e78-9d8f-4b9906681b91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_1f55d289-ec87-4dfc-8560-c9e7d146ab19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_123eaea6-1621-44eb-834b-7fad01b09cbf" xlink:to="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_1f55d289-ec87-4dfc-8560-c9e7d146ab19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_0eb45d5c-7889-499c-9f19-3289a79d60f3" xlink:href="sny-20240630.xsd#sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_123eaea6-1621-44eb-834b-7fad01b09cbf" xlink:to="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_0eb45d5c-7889-499c-9f19-3289a79d60f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_18caec67-964c-4b30-a9d2-8b886cec20e7" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_123eaea6-1621-44eb-834b-7fad01b09cbf" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_18caec67-964c-4b30-a9d2-8b886cec20e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_cc84092f-c07a-4a3c-8ebd-80d523a52923" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_123eaea6-1621-44eb-834b-7fad01b09cbf" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_cc84092f-c07a-4a3c-8ebd-80d523a52923" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_94b3220a-0737-4b9b-bd32-2566de259a1b" xlink:href="sny-20240630.xsd#sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_123eaea6-1621-44eb-834b-7fad01b09cbf" xlink:to="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_94b3220a-0737-4b9b-bd32-2566de259a1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_dc4943e6-ee2e-40f3-9806-ed20152955bb" xlink:href="sny-20240630.xsd#sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_123eaea6-1621-44eb-834b-7fad01b09cbf" xlink:to="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_dc4943e6-ee2e-40f3-9806-ed20152955bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_f0cc49a4-1cb2-41f8-85cc-388fa5010f9c" xlink:href="sny-20240630.xsd#sny_ChangeInCurrencyTranslationOnTaxEffects"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_123eaea6-1621-44eb-834b-7fad01b09cbf" xlink:to="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_f0cc49a4-1cb2-41f8-85cc-388fa5010f9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_20d6aa44-e065-4bcf-b705-d5eaa41cfbaf" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_123eaea6-1621-44eb-834b-7fad01b09cbf" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_20d6aa44-e065-4bcf-b705-d5eaa41cfbaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_6d738cc3-eedb-4dbc-8ada-c42cc0a5f002" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_123eaea6-1621-44eb-834b-7fad01b09cbf" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_6d738cc3-eedb-4dbc-8ada-c42cc0a5f002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_1a46a447-3bc8-4221-85c8-f6bf467934fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_35aa42ec-1eee-40e0-8db1-3a61ae300fe4" xlink:href="sny-20240630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_1a46a447-3bc8-4221-85c8-f6bf467934fe" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_35aa42ec-1eee-40e0-8db1-3a61ae300fe4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_0d3e2a51-aa80-44ad-820a-bc8c3b91c422" xlink:href="sny-20240630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_1a46a447-3bc8-4221-85c8-f6bf467934fe" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_0d3e2a51-aa80-44ad-820a-bc8c3b91c422" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_3cf3aef2-e8fb-4e30-8a4b-c1e079d43622" xlink:href="sny-20240630.xsd#sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_1a46a447-3bc8-4221-85c8-f6bf467934fe" xlink:to="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_3cf3aef2-e8fb-4e30-8a4b-c1e079d43622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_7b7fbb85-5e48-4ca4-a1d1-c01573c83d55" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_1a46a447-3bc8-4221-85c8-f6bf467934fe" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_7b7fbb85-5e48-4ca4-a1d1-c01573c83d55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_e16c133c-21c3-4b95-896d-e4ffd20a0541" xlink:href="sny-20240630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_1a46a447-3bc8-4221-85c8-f6bf467934fe" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_e16c133c-21c3-4b95-896d-e4ffd20a0541" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_c0295a5a-cd7b-47c6-bb97-41b6f5b5b589" xlink:href="sny-20240630.xsd#sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_1a46a447-3bc8-4221-85c8-f6bf467934fe" xlink:to="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_c0295a5a-cd7b-47c6-bb97-41b6f5b5b589" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_062789eb-2774-4f45-80d0-a750e9a2cffb" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_1a46a447-3bc8-4221-85c8-f6bf467934fe" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_062789eb-2774-4f45-80d0-a750e9a2cffb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_4e24f848-7200-4c03-ae16-a44a88e0f990" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_3c9bd9e5-c71b-4107-9276-790a55ceda0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_4e24f848-7200-4c03-ae16-a44a88e0f990" xlink:to="loc_ifrs-full_LongtermBorrowings_3c9bd9e5-c71b-4107-9276-790a55ceda0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_5740e503-f7ef-4809-b12b-2242c455ddd7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_4e24f848-7200-4c03-ae16-a44a88e0f990" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_5740e503-f7ef-4809-b12b-2242c455ddd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_da060d79-1c7d-4909-9801-2df80e6d87b3" xlink:href="sny-20240630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_4e24f848-7200-4c03-ae16-a44a88e0f990" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_da060d79-1c7d-4909-9801-2df80e6d87b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_102d770d-c1ca-4bf2-9134-734088261b97" xlink:href="sny-20240630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_68465551-f5c6-4902-87d3-696a6138ac16" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_DebtNetOfCashAndCashEquivalents_102d770d-c1ca-4bf2-9134-734088261b97" xlink:to="loc_ifrs-full_Borrowings_68465551-f5c6-4902-87d3-696a6138ac16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_8be605dd-56a9-4f43-9521-935a67384dbd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_DebtNetOfCashAndCashEquivalents_102d770d-c1ca-4bf2-9134-734088261b97" xlink:to="loc_ifrs-full_CashAndCashEquivalents_8be605dd-56a9-4f43-9521-935a67384dbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_c906c992-ed78-4b92-872b-01374d8547fb" xlink:href="sny-20240630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_DebtNetOfCashAndCashEquivalents_102d770d-c1ca-4bf2-9134-734088261b97" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_c906c992-ed78-4b92-872b-01374d8547fb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_4c9f5af8-5b63-4104-b64c-2924e73ab05a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_7e3944da-8911-4519-93fc-a8045d99e507" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BondsIssued"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_4c9f5af8-5b63-4104-b64c-2924e73ab05a" xlink:to="loc_ifrs-full_BondsIssued_7e3944da-8911-4519-93fc-a8045d99e507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherBankBorrowings_60aa3759-20ba-4582-bce8-a0430c4b016d" xlink:href="sny-20240630.xsd#sny_OtherBankBorrowings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_4c9f5af8-5b63-4104-b64c-2924e73ab05a" xlink:to="loc_sny_OtherBankBorrowings_60aa3759-20ba-4582-bce8-a0430c4b016d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings_22027138-9482-4c26-8f49-663bcebf2674" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherBorrowings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_4c9f5af8-5b63-4104-b64c-2924e73ab05a" xlink:to="loc_ifrs-full_OtherBorrowings_22027138-9482-4c26-8f49-663bcebf2674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_bb5fb009-334b-4f98-be5d-c7e68b707c15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_4c9f5af8-5b63-4104-b64c-2924e73ab05a" xlink:to="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_bb5fb009-334b-4f98-be5d-c7e68b707c15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_2a6b06ae-a906-4137-b120-a9a2002d4650" xlink:href="sny-20240630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_4c9f5af8-5b63-4104-b64c-2924e73ab05a" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_2a6b06ae-a906-4137-b120-a9a2002d4650" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_bb228679-5a3e-44df-bf9d-8be5cca0dda9" xlink:href="sny-20240630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_ffc339cc-8e82-4ea5-b7e0-77b4abaf1c48" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_bb228679-5a3e-44df-bf9d-8be5cca0dda9" xlink:to="loc_ifrs-full_NoncurrentProvisions_ffc339cc-8e82-4ea5-b7e0-77b4abaf1c48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_c8858ba4-5fe9-4539-baf5-7def56107a91" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_bb228679-5a3e-44df-bf9d-8be5cca0dda9" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_c8858ba4-5fe9-4539-baf5-7def56107a91" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_ea24867c-0211-4a9c-aab9-6447a680c66e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_6322d61d-8256-45da-801e-4d810f399a9b" xlink:href="sny-20240630.xsd#sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities_ea24867c-0211-4a9c-aab9-6447a680c66e" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_6322d61d-8256-45da-801e-4d810f399a9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts_a418f5af-2080-4d49-9655-ac12afcde348" xlink:href="sny-20240630.xsd#sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities_ea24867c-0211-4a9c-aab9-6447a680c66e" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts_a418f5af-2080-4d49-9655-ac12afcde348" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherRestructuringCosts_e58e100d-1113-4c2f-aa59-b0e6edc64dee" xlink:href="sny-20240630.xsd#sny_OtherRestructuringCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities_ea24867c-0211-4a9c-aab9-6447a680c66e" xlink:to="loc_sny_OtherRestructuringCosts_e58e100d-1113-4c2f-aa59-b0e6edc64dee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_9f83677e-38ee-4aa8-b3b1-644c34b25e1c" xlink:href="sny-20240630.xsd#sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities_ea24867c-0211-4a9c-aab9-6447a680c66e" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_9f83677e-38ee-4aa8-b3b1-644c34b25e1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_d0b9f172-8455-4e97-b370-25a49d3a07f0" xlink:href="sny-20240630.xsd#sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities_ea24867c-0211-4a9c-aab9-6447a680c66e" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_d0b9f172-8455-4e97-b370-25a49d3a07f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialExpensesandIncomeDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#FinancialExpensesandIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/FinancialExpensesandIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_ec562f98-6540-4756-9fd8-a5d895952b6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_8148dda5-9bb4-4ecf-8e38-b13501224471" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_ec562f98-6540-4756-9fd8-a5d895952b6b" xlink:to="loc_ifrs-full_FinanceCosts_8148dda5-9bb4-4ecf-8e38-b13501224471" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_b88da99a-56f1-42d8-8230-8531822f2054" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_ec562f98-6540-4756-9fd8-a5d895952b6b" xlink:to="loc_ifrs-full_FinanceIncome_b88da99a-56f1-42d8-8230-8531822f2054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CostOfDebtNet_9de054d7-519e-4d00-b04a-53752bb92015" xlink:href="sny-20240630.xsd#sny_CostOfDebtNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_b8ecedcc-d83f-49d4-b283-fc40a5bde0b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_CostOfDebtNet_9de054d7-519e-4d00-b04a-53752bb92015" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_b8ecedcc-d83f-49d4-b283-fc40a5bde0b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestIncome_2dd78c5c-8b34-42f6-9c84-62727f8b0f16" xlink:href="sny-20240630.xsd#sny_InterestIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_CostOfDebtNet_9de054d7-519e-4d00-b04a-53752bb92015" xlink:to="loc_sny_InterestIncome_2dd78c5c-8b34-42f6-9c84-62727f8b0f16" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialExpensesandIncomeDetails_1" xlink:type="simple" xlink:href="sny-20240630.xsd#FinancialExpensesandIncomeDetails_1"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/FinancialExpensesandIncomeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_d571c100-4818-4bd3-91bc-86964c167b40" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInterestCostRelatedToEmployeeBenefits_a2aeff44-0bb2-46fd-a757-7e3353341682" xlink:href="sny-20240630.xsd#sny_NetInterestCostRelatedToEmployeeBenefits"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_d571c100-4818-4bd3-91bc-86964c167b40" xlink:to="loc_sny_NetInterestCostRelatedToEmployeeBenefits_a2aeff44-0bb2-46fd-a757-7e3353341682" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CostOfDebtNet_05e5dc68-9bbf-45b8-9582-07654c546b87" xlink:href="sny-20240630.xsd#sny_CostOfDebtNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_d571c100-4818-4bd3-91bc-86964c167b40" xlink:to="loc_sny_CostOfDebtNet_05e5dc68-9bbf-45b8-9582-07654c546b87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_98371701-e2d3-407f-81ab-6d8292812f07" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_d571c100-4818-4bd3-91bc-86964c167b40" xlink:to="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_98371701-e2d3-407f-81ab-6d8292812f07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_406d283b-d4fe-49ed-94c4-0fcbb34f67d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_d571c100-4818-4bd3-91bc-86964c167b40" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_406d283b-d4fe-49ed-94c4-0fcbb34f67d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_dc59f46b-1d37-401a-80df-824c391cb7c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_d571c100-4818-4bd3-91bc-86964c167b40" xlink:to="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_dc59f46b-1d37-401a-80df-824c391cb7c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonOperatingForeignExchangeGainsLosses_a753c596-852b-4617-93ea-cc7a7b2af903" xlink:href="sny-20240630.xsd#sny_NonOperatingForeignExchangeGainsLosses"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_d571c100-4818-4bd3-91bc-86964c167b40" xlink:to="loc_sny_NonOperatingForeignExchangeGainsLosses_a753c596-852b-4617-93ea-cc7a7b2af903" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncomeCost_36a51bdb-d155-4ca8-b1c3-0847fe1ec11f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_d571c100-4818-4bd3-91bc-86964c167b40" xlink:to="loc_ifrs-full_OtherFinanceIncomeCost_36a51bdb-d155-4ca8-b1c3-0847fe1ec11f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_778a3c62-4913-4918-b395-3fdf35b87bcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_4b5cfadc-10a6-4132-bf2c-126fddd080be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_778a3c62-4913-4918-b395-3fdf35b87bcf" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_4b5cfadc-10a6-4132-bf2c-126fddd080be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome_54832c8e-1cfa-4695-ad43-201b9460b5e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_778a3c62-4913-4918-b395-3fdf35b87bcf" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncome_54832c8e-1cfa-4695-ad43-201b9460b5e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate_0f87a0e9-d480-4152-92e4-622f094a444a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_046fb279-eee1-4530-a795-1a69e9c547e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_0f87a0e9-d480-4152-92e4-622f094a444a" xlink:to="loc_ifrs-full_ApplicableTaxRate_046fb279-eee1-4530-a795-1a69e9c547e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_d2cceab4-ad57-4780-a854-4c53767009fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_0f87a0e9-d480-4152-92e4-622f094a444a" xlink:to="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_d2cceab4-ad57-4780-a854-4c53767009fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_cbdb17fb-b3b7-4704-bd35-97f391242263" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_0f87a0e9-d480-4152-92e4-622f094a444a" xlink:to="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_cbdb17fb-b3b7-4704-bd35-97f391242263" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_92679a6c-9179-44b1-bf40-df14543f5e84" xlink:href="sny-20240630.xsd#sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_0f87a0e9-d480-4152-92e4-622f094a444a" xlink:to="loc_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_92679a6c-9179-44b1-bf40-df14543f5e84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_f99f5fca-f929-405c-9740-83f754bb4ae0" xlink:href="sny-20240630.xsd#sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_0f87a0e9-d480-4152-92e4-622f094a444a" xlink:to="loc_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_f99f5fca-f929-405c-9740-83f754bb4ae0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#SegmentInformationScheduleofSegmentResultsDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_9f695a24-6de7-4502-a055-a14ae0206873" xlink:href="sny-20240630.xsd#sny_BusinessOperatingIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_c344d879-7bba-4899-a8dd-0c9f26ff3e56" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_9f695a24-6de7-4502-a055-a14ae0206873" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_c344d879-7bba-4899-a8dd-0c9f26ff3e56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_7eded279-89fa-41f4-8920-d75ec4d3f877" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_9f695a24-6de7-4502-a055-a14ae0206873" xlink:to="loc_ifrs-full_OtherRevenue_7eded279-89fa-41f4-8920-d75ec4d3f877" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_78dfee47-1e83-4ba9-99ee-f86386f13098" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_9f695a24-6de7-4502-a055-a14ae0206873" xlink:to="loc_ifrs-full_CostOfSales_78dfee47-1e83-4ba9-99ee-f86386f13098" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_86e5c1cb-d05e-446a-be94-53dc96d5357e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_9f695a24-6de7-4502-a055-a14ae0206873" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_86e5c1cb-d05e-446a-be94-53dc96d5357e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_9e9cf385-ad9a-4244-90cc-d176fcaa34dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_9f695a24-6de7-4502-a055-a14ae0206873" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_9e9cf385-ad9a-4244-90cc-d176fcaa34dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_cc748f50-07c1-476e-9e71-9a62844f7a95" xlink:href="sny-20240630.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_9f695a24-6de7-4502-a055-a14ae0206873" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_cc748f50-07c1-476e-9e71-9a62844f7a95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_b2fb9b2d-dfbb-45f7-99b6-e7eaea1efe98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_9f695a24-6de7-4502-a055-a14ae0206873" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_b2fb9b2d-dfbb-45f7-99b6-e7eaea1efe98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_c0badf99-c937-4e3d-bb34-66eb6859c065" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_9f695a24-6de7-4502-a055-a14ae0206873" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_c0badf99-c937-4e3d-bb34-66eb6859c065" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_206ee94c-8ddf-49bc-868a-c9e43d96a350" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_6cfdaea1-e9be-4fd6-883e-6bd315548f5f" xlink:href="sny-20240630.xsd#sny_BusinessOperatingIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_206ee94c-8ddf-49bc-868a-c9e43d96a350" xlink:to="loc_sny_BusinessOperatingIncome_6cfdaea1-e9be-4fd6-883e-6bd315548f5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_10d17140-e073-4c23-bff0-52b8a372b051" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_206ee94c-8ddf-49bc-868a-c9e43d96a350" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_10d17140-e073-4c23-bff0-52b8a372b051" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_e55f4b3d-03eb-4e70-b244-a67dfe97f2ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_206ee94c-8ddf-49bc-868a-c9e43d96a350" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_e55f4b3d-03eb-4e70-b244-a67dfe97f2ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_25d42509-4aa0-4a97-8cb1-9aa1befca6c7" xlink:href="sny-20240630.xsd#sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_206ee94c-8ddf-49bc-868a-c9e43d96a350" xlink:to="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_25d42509-4aa0-4a97-8cb1-9aa1befca6c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_65fa8f84-7853-4f95-b643-7e87450ae879" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_206ee94c-8ddf-49bc-868a-c9e43d96a350" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_65fa8f84-7853-4f95-b643-7e87450ae879" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_591b33e8-5943-493f-a629-d2903e135607" xlink:href="sny-20240630.xsd#sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_206ee94c-8ddf-49bc-868a-c9e43d96a350" xlink:to="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_591b33e8-5943-493f-a629-d2903e135607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_fc6208f8-8f8a-4a3e-9314-ccdc9ea8cba6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_206ee94c-8ddf-49bc-868a-c9e43d96a350" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_fc6208f8-8f8a-4a3e-9314-ccdc9ea8cba6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_56d095f7-4ad3-47aa-8bcd-5f99da4b3a27" xlink:href="sny-20240630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_206ee94c-8ddf-49bc-868a-c9e43d96a350" xlink:to="loc_sny_OtherGainsLossesAndLitigation_56d095f7-4ad3-47aa-8bcd-5f99da4b3a27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeResultingFromOutLicensing_140877f0-c930-4e50-8824-695fe5028d99" xlink:href="sny-20240630.xsd#sny_IncomeResultingFromOutLicensing"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_206ee94c-8ddf-49bc-868a-c9e43d96a350" xlink:to="loc_sny_IncomeResultingFromOutLicensing_140877f0-c930-4e50-8824-695fe5028d99" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>sny-20240630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a012fc2d-d3ff-4c6a-950e-09cafe0bb60f,g:e711d38b-47f1-4329-bc58-181a62b743af-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sanofi.com/role/Coverpage" xlink:type="simple" xlink:href="sny-20240630.xsd#Coverpage"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/Coverpage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_5c3a9435-e83d-4dd2-b5ab-f1e1fa62b2f1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_50dc30ef-cef7-49c8-9c7d-f2c5577b53cb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_5c3a9435-e83d-4dd2-b5ab-f1e1fa62b2f1" xlink:to="loc_dei_EntitiesTable_50dc30ef-cef7-49c8-9c7d-f2c5577b53cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1d225ceb-7426-4283-b9c9-3beb2dfe0b2f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5c3a9435-e83d-4dd2-b5ab-f1e1fa62b2f1" xlink:to="loc_dei_DocumentType_1d225ceb-7426-4283-b9c9-3beb2dfe0b2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2894031c-d27e-4323-9415-79736f5eedae" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5c3a9435-e83d-4dd2-b5ab-f1e1fa62b2f1" xlink:to="loc_dei_EntityRegistrantName_2894031c-d27e-4323-9415-79736f5eedae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_65432f32-33ec-4aef-a903-d4e65450624c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5c3a9435-e83d-4dd2-b5ab-f1e1fa62b2f1" xlink:to="loc_dei_AmendmentFlag_65432f32-33ec-4aef-a903-d4e65450624c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4114c560-df52-4dcb-a2b7-9f4a9ad1e633" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5c3a9435-e83d-4dd2-b5ab-f1e1fa62b2f1" xlink:to="loc_dei_EntityCentralIndexKey_4114c560-df52-4dcb-a2b7-9f4a9ad1e633" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_cdb5e838-f198-4f3f-b2c5-60ac4f0a0e20" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5c3a9435-e83d-4dd2-b5ab-f1e1fa62b2f1" xlink:to="loc_dei_CurrentFiscalYearEndDate_cdb5e838-f198-4f3f-b2c5-60ac4f0a0e20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_553ae06c-45bb-47c4-9976-faae9d210575" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5c3a9435-e83d-4dd2-b5ab-f1e1fa62b2f1" xlink:to="loc_dei_DocumentPeriodEndDate_553ae06c-45bb-47c4-9976-faae9d210575" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_489d0450-25a1-447e-919d-6ed0c665ea7c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5c3a9435-e83d-4dd2-b5ab-f1e1fa62b2f1" xlink:to="loc_dei_DocumentFiscalYearFocus_489d0450-25a1-447e-919d-6ed0c665ea7c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_4165623a-f47a-48bb-b64c-aa0d305b1de1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_5c3a9435-e83d-4dd2-b5ab-f1e1fa62b2f1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_4165623a-f47a-48bb-b64c-aa0d305b1de1" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedStatementsofChangesinEquity"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_af0b644d-96db-48f4-a638-46b903228075" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_af0b644d-96db-48f4-a638-46b903228075" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_9af334d4-ad78-4200-b33f-1c78ef8e5469" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_af0b644d-96db-48f4-a638-46b903228075" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_9af334d4-ad78-4200-b33f-1c78ef8e5469" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_9af334d4-ad78-4200-b33f-1c78ef8e5469_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_9af334d4-ad78-4200-b33f-1c78ef8e5469" xlink:to="loc_ifrs-full_EquityMember_9af334d4-ad78-4200-b33f-1c78ef8e5469_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_0a9732fc-2301-4cdc-a6aa-4d4d31e97701" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_9af334d4-ad78-4200-b33f-1c78ef8e5469" xlink:to="loc_ifrs-full_EquityMember_0a9732fc-2301-4cdc-a6aa-4d4d31e97701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_3c5334fb-4ed7-4f70-9adc-eefa986f1e5f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_0a9732fc-2301-4cdc-a6aa-4d4d31e97701" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_3c5334fb-4ed7-4f70-9adc-eefa986f1e5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_a8ecd3de-1911-470e-8edc-0d110e64c4de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_3c5334fb-4ed7-4f70-9adc-eefa986f1e5f" xlink:to="loc_ifrs-full_IssuedCapitalMember_a8ecd3de-1911-470e-8edc-0d110e64c4de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember_57447157-d408-4d3f-8607-40f6108e1620" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_3c5334fb-4ed7-4f70-9adc-eefa986f1e5f" xlink:to="loc_ifrs-full_AdditionalPaidinCapitalMember_57447157-d408-4d3f-8607-40f6108e1620" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_c05f48a4-2acb-447f-b674-eec30af16183" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasurySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_3c5334fb-4ed7-4f70-9adc-eefa986f1e5f" xlink:to="loc_ifrs-full_TreasurySharesMember_c05f48a4-2acb-447f-b674-eec30af16183" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_20fd9508-4d34-4073-b5c9-0f48df38037c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_3c5334fb-4ed7-4f70-9adc-eefa986f1e5f" xlink:to="loc_ifrs-full_RetainedEarningsMember_20fd9508-4d34-4073-b5c9-0f48df38037c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_e4394af8-7c74-4165-b663-afcd5a7895da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_3c5334fb-4ed7-4f70-9adc-eefa986f1e5f" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_e4394af8-7c74-4165-b663-afcd5a7895da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_a4256a0b-b972-4e73-ad75-56c7db8bd125" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_3c5334fb-4ed7-4f70-9adc-eefa986f1e5f" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_a4256a0b-b972-4e73-ad75-56c7db8bd125" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_5f0bff62-2a55-4e4d-8026-9541de1e7f0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_0a9732fc-2301-4cdc-a6aa-4d4d31e97701" xlink:to="loc_ifrs-full_NoncontrollingInterestsMember_5f0bff62-2a55-4e4d-8026-9541de1e7f0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_d816a96e-4617-4efd-986c-725937539b04" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_ifrs-full_Equity_d816a96e-4617-4efd-986c-725937539b04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_6243117b-376f-4ac5-8f87-48ee47495cfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_6243117b-376f-4ac5-8f87-48ee47495cfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_09639a6a-2d3f-42de-975f-81969ced8427" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_ifrs-full_ProfitLoss_09639a6a-2d3f-42de-975f-81969ced8427" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_d854fae9-8192-4956-9534-7a0d9763c533" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_ifrs-full_ComprehensiveIncome_d854fae9-8192-4956-9534-7a0d9763c533" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_a2fa56fa-bce4-4f33-99c9-64dad4fcaa4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_a2fa56fa-bce4-4f33-99c9-64dad4fcaa4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_fb727bf7-193e-449f-bea7-37619db52934" xlink:href="sny-20240630.xsd#sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_fb727bf7-193e-449f-bea7-37619db52934" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_7f1a001b-b7e2-4859-9969-e56b521fe618" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_7f1a001b-b7e2-4859-9969-e56b521fe618" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfTreasuryShares_225d2b42-76f5-4546-86e6-ce2b02b73460" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfTreasuryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_ifrs-full_PurchaseOfTreasuryShares_225d2b42-76f5-4546-86e6-ce2b02b73460" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReductionOfIssuedCapital_760c10e7-1e23-4fef-9914-58d263f78b2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReductionOfIssuedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_ifrs-full_ReductionOfIssuedCapital_760c10e7-1e23-4fef-9914-58d263f78b2e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareBasedPaymentPlansAbstract_4b400844-bb15-4d94-b403-745dc781b68c" xlink:href="sny-20240630.xsd#sny_ShareBasedPaymentPlansAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_sny_ShareBasedPaymentPlansAbstract_4b400844-bb15-4d94-b403-745dc781b68c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_cbf3ab2f-602c-4950-8cfe-7d00143e6dd2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_4b400844-bb15-4d94-b403-745dc781b68c" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_cbf3ab2f-602c-4950-8cfe-7d00143e6dd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_1f57557e-f10f-448f-a4c3-f1237704eba2" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_4b400844-bb15-4d94-b403-745dc781b68c" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_1f57557e-f10f-448f-a4c3-f1237704eba2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_bffef20d-ec97-47bc-b236-0ca02ac6fccd" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_4b400844-bb15-4d94-b403-745dc781b68c" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_bffef20d-ec97-47bc-b236-0ca02ac6fccd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_2a75560f-45b5-4c57-a4b6-13a57fd478c6" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_4b400844-bb15-4d94-b403-745dc781b68c" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_2a75560f-45b5-4c57-a4b6-13a57fd478c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_5153bf12-8fde-4ef9-b981-5803df451c7c" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_4b400844-bb15-4d94-b403-745dc781b68c" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_5153bf12-8fde-4ef9-b981-5803df451c7c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_1224cde5-a3a5-4f55-8421-0e38db24d408" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_1224cde5-a3a5-4f55-8421-0e38db24d408" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_73f53d52-d69a-46c8-b78f-223aa520f39f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_73f53d52-d69a-46c8-b78f-223aa520f39f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_0d53699c-1703-45f1-b844-133253d43499" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedStatementsofChangesinEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_4dd61151-f7dd-44aa-93f4-6128fecf6916" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_c456faf8-b1a2-41fc-885a-4917c5238cb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_4dd61151-f7dd-44aa-93f4-6128fecf6916" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_c456faf8-b1a2-41fc-885a-4917c5238cb6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2dc0df0f-3db2-4d37-bf70-3bda5d97084d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_c456faf8-b1a2-41fc-885a-4917c5238cb6" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2dc0df0f-3db2-4d37-bf70-3bda5d97084d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2dc0df0f-3db2-4d37-bf70-3bda5d97084d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2dc0df0f-3db2-4d37-bf70-3bda5d97084d" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2dc0df0f-3db2-4d37-bf70-3bda5d97084d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_c7d600e0-f202-4870-8042-5d53e1400322" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2dc0df0f-3db2-4d37-bf70-3bda5d97084d" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_c7d600e0-f202-4870-8042-5d53e1400322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_46594038-ada7-4df9-8e18-730572912ae8" xlink:href="sny-20240630.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_c7d600e0-f202-4870-8042-5d53e1400322" xlink:to="loc_sny_EuroapiMember_46594038-ada7-4df9-8e18-730572912ae8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_3a1f912e-85a1-42f5-966b-085e5107063d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_c456faf8-b1a2-41fc-885a-4917c5238cb6" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_3a1f912e-85a1-42f5-966b-085e5107063d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_3a1f912e-85a1-42f5-966b-085e5107063d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_3a1f912e-85a1-42f5-966b-085e5107063d" xlink:to="loc_ifrs-full_EquityMember_3a1f912e-85a1-42f5-966b-085e5107063d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_b46e6147-8220-4064-8918-c281064d7de5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_3a1f912e-85a1-42f5-966b-085e5107063d" xlink:to="loc_ifrs-full_EquityMember_b46e6147-8220-4064-8918-c281064d7de5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember_0e28b611-42b1-4bd0-869f-4a255224e2a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_b46e6147-8220-4064-8918-c281064d7de5" xlink:to="loc_ifrs-full_AdditionalPaidinCapitalMember_0e28b611-42b1-4bd0-869f-4a255224e2a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_dbe71ac8-ff17-4053-ae4b-dd82f7e67786" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_b46e6147-8220-4064-8918-c281064d7de5" xlink:to="loc_ifrs-full_IssuedCapitalMember_dbe71ac8-ff17-4053-ae4b-dd82f7e67786" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_3c1c8f0b-d5d0-422d-93e2-730d7e5370a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidOrdinarySharesPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_4dd61151-f7dd-44aa-93f4-6128fecf6916" xlink:to="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_3c1c8f0b-d5d0-422d-93e2-730d7e5370a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_75578bf6-74ae-4689-b969-d6b5ae586499" xlink:href="sny-20240630.xsd#sny_ExceptionalSupplementaryDividendPercentageOfShareCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_4dd61151-f7dd-44aa-93f4-6128fecf6916" xlink:to="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_75578bf6-74ae-4689-b969-d6b5ae586499" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_cfd53864-cbdd-4a17-8131-3411ca029cb8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_4dd61151-f7dd-44aa-93f4-6128fecf6916" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_cfd53864-cbdd-4a17-8131-3411ca029cb8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_c30c77dd-5724-4b93-8ec2-9d5cb087e608" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_9c095b3d-e730-4b6b-9876-b227534ea86f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_c30c77dd-5724-4b93-8ec2-9d5cb087e608" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_9c095b3d-e730-4b6b-9876-b227534ea86f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_a2586fee-af52-4cd8-b258-34eaf1d85731" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_9c095b3d-e730-4b6b-9876-b227534ea86f" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_a2586fee-af52-4cd8-b258-34eaf1d85731" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_a2586fee-af52-4cd8-b258-34eaf1d85731_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_a2586fee-af52-4cd8-b258-34eaf1d85731" xlink:to="loc_ifrs-full_BorrowingsByNameMember_a2586fee-af52-4cd8-b258-34eaf1d85731_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_83564ecc-2045-47ae-8cc9-e9dee7d11397" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_a2586fee-af52-4cd8-b258-34eaf1d85731" xlink:to="loc_ifrs-full_BorrowingsByNameMember_83564ecc-2045-47ae-8cc9-e9dee7d11397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_182a6f19-a497-4b5b-a025-6d3b3777d313" xlink:href="sny-20240630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_83564ecc-2045-47ae-8cc9-e9dee7d11397" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_182a6f19-a497-4b5b-a025-6d3b3777d313" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_0f32144d-cf20-42e1-90e9-fdf48022ef77" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_c30c77dd-5724-4b93-8ec2-9d5cb087e608" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_0f32144d-cf20-42e1-90e9-fdf48022ef77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_d0f81a4e-a86a-45aa-9829-23d5f736e225" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_c30c77dd-5724-4b93-8ec2-9d5cb087e608" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_d0f81a4e-a86a-45aa-9829-23d5f736e225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_241349c5-11c8-43bf-80a4-96aba543236d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_c30c77dd-5724-4b93-8ec2-9d5cb087e608" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_241349c5-11c8-43bf-80a4-96aba543236d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_c84b9f51-06c2-45eb-9424-8e9b6a8f53d4" xlink:href="sny-20240630.xsd#sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_c30c77dd-5724-4b93-8ec2-9d5cb087e608" xlink:to="loc_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_c84b9f51-06c2-45eb-9424-8e9b6a8f53d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_c95a5493-f065-4fb3-990f-c8526a0d4123" xlink:href="sny-20240630.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_c30c77dd-5724-4b93-8ec2-9d5cb087e608" xlink:to="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_c95a5493-f065-4fb3-990f-c8526a0d4123" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f8115f9a-44d5-4614-b3a3-1e284ba718e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ef060b1-3c30-4288-bf1c-ee3809313b67" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f8115f9a-44d5-4614-b3a3-1e284ba718e1" xlink:to="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ef060b1-3c30-4288-bf1c-ee3809313b67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_47f26ccc-2b28-479c-92a7-b2f84c6ecc90" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ef060b1-3c30-4288-bf1c-ee3809313b67" xlink:to="loc_ifrs-full_GeographicalAreasAxis_47f26ccc-2b28-479c-92a7-b2f84c6ecc90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_47f26ccc-2b28-479c-92a7-b2f84c6ecc90_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_47f26ccc-2b28-479c-92a7-b2f84c6ecc90" xlink:to="loc_ifrs-full_GeographicalAreasMember_47f26ccc-2b28-479c-92a7-b2f84c6ecc90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_35a58fb8-f14a-461d-9ffe-607e2a0969c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_47f26ccc-2b28-479c-92a7-b2f84c6ecc90" xlink:to="loc_ifrs-full_GeographicalAreasMember_35a58fb8-f14a-461d-9ffe-607e2a0969c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AR_aa0ae69b-b353-4df2-829e-bb06583a6977" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_35a58fb8-f14a-461d-9ffe-607e2a0969c2" xlink:to="loc_country_AR_aa0ae69b-b353-4df2-829e-bb06583a6977" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR_c316f471-bb26-4730-8c24-7b647d0bdcae" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_TR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_35a58fb8-f14a-461d-9ffe-607e2a0969c2" xlink:to="loc_country_TR_c316f471-bb26-4730-8c24-7b647d0bdcae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementAxis_573747ab-c998-4d08-89f7-b79ff9e539d3" xlink:href="sny-20240630.xsd#sny_TypesOfAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ef060b1-3c30-4288-bf1c-ee3809313b67" xlink:to="loc_sny_TypesOfAgreementAxis_573747ab-c998-4d08-89f7-b79ff9e539d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_573747ab-c998-4d08-89f7-b79ff9e539d3_default" xlink:href="sny-20240630.xsd#sny_TypesOfAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_TypesOfAgreementAxis_573747ab-c998-4d08-89f7-b79ff9e539d3" xlink:to="loc_sny_TypesOfAgreementDomain_573747ab-c998-4d08-89f7-b79ff9e539d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_38170800-bfe5-4451-82ee-eefc704a3d78" xlink:href="sny-20240630.xsd#sny_TypesOfAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_TypesOfAgreementAxis_573747ab-c998-4d08-89f7-b79ff9e539d3" xlink:to="loc_sny_TypesOfAgreementDomain_38170800-bfe5-4451-82ee-eefc704a3d78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementWithGSKMember_ba6e320e-4b42-4359-a58f-7d697776bc05" xlink:href="sny-20240630.xsd#sny_CollaborationAgreementWithGSKMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_TypesOfAgreementDomain_38170800-bfe5-4451-82ee-eefc704a3d78" xlink:to="loc_sny_CollaborationAgreementWithGSKMember_ba6e320e-4b42-4359-a58f-7d697776bc05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_cee2e799-42b2-491d-b5dd-ccd1922138b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ef060b1-3c30-4288-bf1c-ee3809313b67" xlink:to="loc_ifrs-full_CounterpartiesAxis_cee2e799-42b2-491d-b5dd-ccd1922138b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_cee2e799-42b2-491d-b5dd-ccd1922138b6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_cee2e799-42b2-491d-b5dd-ccd1922138b6" xlink:to="loc_ifrs-full_CounterpartiesMember_cee2e799-42b2-491d-b5dd-ccd1922138b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_58087bda-61c3-4011-a694-fcade5c0470f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_cee2e799-42b2-491d-b5dd-ccd1922138b6" xlink:to="loc_ifrs-full_CounterpartiesMember_58087bda-61c3-4011-a694-fcade5c0470f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_USGovernmentMember_cf614da7-5c14-4fa0-83e5-d7d3e5e492cd" xlink:href="sny-20240630.xsd#sny_USGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_58087bda-61c3-4011-a694-fcade5c0470f" xlink:to="loc_sny_USGovernmentMember_cf614da7-5c14-4fa0-83e5-d7d3e5e492cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_9a44b12a-6061-4104-a360-7fda8d6414ba" xlink:href="sny-20240630.xsd#sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f8115f9a-44d5-4614-b3a3-1e284ba718e1" xlink:to="loc_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_9a44b12a-6061-4104-a360-7fda8d6414ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_4b8ad752-cb34-42a4-8e59-16e7ad56181f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f8115f9a-44d5-4614-b3a3-1e284ba718e1" xlink:to="loc_ifrs-full_CurrentContractLiabilities_4b8ad752-cb34-42a4-8e59-16e7ad56181f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_127a0a61-463d-468f-a8ab-653faf78a9c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f8115f9a-44d5-4614-b3a3-1e284ba718e1" xlink:to="loc_ifrs-full_OtherRevenue_127a0a61-463d-468f-a8ab-653faf78a9c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_6dff4720-f081-4164-9bad-59e439ace579" xlink:href="sny-20240630.xsd#sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f8115f9a-44d5-4614-b3a3-1e284ba718e1" xlink:to="loc_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_6dff4720-f081-4164-9bad-59e439ace579" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_342d38ff-5e8c-4fa2-ba21-bd19decd54c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_342d38ff-5e8c-4fa2-ba21-bd19decd54c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_4885a643-c959-4026-87c8-ab93e092720e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_342d38ff-5e8c-4fa2-ba21-bd19decd54c2" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_4885a643-c959-4026-87c8-ab93e092720e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_4885a643-c959-4026-87c8-ab93e092720e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_4885a643-c959-4026-87c8-ab93e092720e" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_4885a643-c959-4026-87c8-ab93e092720e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_07d3b2bb-e878-4053-a0b0-655f21c25958" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_4885a643-c959-4026-87c8-ab93e092720e" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_07d3b2bb-e878-4053-a0b0-655f21c25958" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember_d35b0646-35fd-433a-a437-f39201860614" xlink:href="sny-20240630.xsd#sny_ProventionBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_07d3b2bb-e878-4053-a0b0-655f21c25958" xlink:to="loc_sny_ProventionBioIncMember_d35b0646-35fd-433a-a437-f39201860614" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InhibrxIncMember_ac09f57f-0d91-474d-a38c-d5d530162622" xlink:href="sny-20240630.xsd#sny_InhibrxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_07d3b2bb-e878-4053-a0b0-655f21c25958" xlink:to="loc_sny_InhibrxIncMember_ac09f57f-0d91-474d-a38c-d5d530162622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b17cbc18-64c9-4249-ac66-af158a4f1b75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_342d38ff-5e8c-4fa2-ba21-bd19decd54c2" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b17cbc18-64c9-4249-ac66-af158a4f1b75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b17cbc18-64c9-4249-ac66-af158a4f1b75_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b17cbc18-64c9-4249-ac66-af158a4f1b75" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b17cbc18-64c9-4249-ac66-af158a4f1b75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1d72da02-feb9-45be-8d12-0ebc4ed6b8e6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b17cbc18-64c9-4249-ac66-af158a4f1b75" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1d72da02-feb9-45be-8d12-0ebc4ed6b8e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember_07108c1c-8221-40d3-80f3-cb69df2eae0e" xlink:href="sny-20240630.xsd#sny_ProventionBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1d72da02-feb9-45be-8d12-0ebc4ed6b8e6" xlink:to="loc_sny_ProventionBioIncMember_07108c1c-8221-40d3-80f3-cb69df2eae0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionAxis_29b68102-ce99-427f-a2d6-60a21e44fb27" xlink:href="sny-20240630.xsd#sny_AssetsAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_342d38ff-5e8c-4fa2-ba21-bd19decd54c2" xlink:to="loc_sny_AssetsAcquisitionAxis_29b68102-ce99-427f-a2d6-60a21e44fb27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionDomain_29b68102-ce99-427f-a2d6-60a21e44fb27_default" xlink:href="sny-20240630.xsd#sny_AssetsAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_AssetsAcquisitionAxis_29b68102-ce99-427f-a2d6-60a21e44fb27" xlink:to="loc_sny_AssetsAcquisitionDomain_29b68102-ce99-427f-a2d6-60a21e44fb27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionDomain_c4a13b9f-4d56-4d6f-98b1-5503ef7187de" xlink:href="sny-20240630.xsd#sny_AssetsAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_AssetsAcquisitionAxis_29b68102-ce99-427f-a2d6-60a21e44fb27" xlink:to="loc_sny_AssetsAcquisitionDomain_c4a13b9f-4d56-4d6f-98b1-5503ef7187de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionMember_c3a766a6-cebc-4f8b-9496-345943e14058" xlink:href="sny-20240630.xsd#sny_AssetsAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_AssetsAcquisitionDomain_c4a13b9f-4d56-4d6f-98b1-5503ef7187de" xlink:to="loc_sny_AssetsAcquisitionMember_c3a766a6-cebc-4f8b-9496-345943e14058" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashTransferred_6bd816db-beb2-40bd-80a3-28b37ee9bbaa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_ifrs-full_CashTransferred_6bd816db-beb2-40bd-80a3-28b37ee9bbaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_2da9e191-0373-4fc1-ad92-ffcd5f86dd85" xlink:href="sny-20240630.xsd#sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_2da9e191-0373-4fc1-ad92-ffcd5f86dd85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_b5b71509-94c6-4025-8a3b-55a1aee980e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_b5b71509-94c6-4025-8a3b-55a1aee980e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePricePerShare_8bd53f3a-9bc2-48bf-9824-ff8bee939720" xlink:href="sny-20240630.xsd#sny_BusinessCombinationPurchasePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_sny_BusinessCombinationPurchasePricePerShare_8bd53f3a-9bc2-48bf-9824-ff8bee939720" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_4d228f0f-317a-4178-841b-c0f998c64a1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_4d228f0f-317a-4178-841b-c0f998c64a1d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_9ee8a296-d310-423c-9af8-f5d8141b4e75" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_9ee8a296-d310-423c-9af8-f5d8141b4e75" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FutureRoyaltiesReceivableValue_3268f867-910d-4cc5-b60c-063cf75a496b" xlink:href="sny-20240630.xsd#sny_FutureRoyaltiesReceivableValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_sny_FutureRoyaltiesReceivableValue_3268f867-910d-4cc5-b60c-063cf75a496b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_09004fb0-c329-4330-b325-66d8417ee262" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_09004fb0-c329-4330-b325-66d8417ee262" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NameOfAcquiree_e8e85971-647d-45a4-b3de-57fba8ebaf4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NameOfAcquiree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_ifrs-full_NameOfAcquiree_e8e85971-647d-45a4-b3de-57fba8ebaf4c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationNominalValue_f688d0d0-ab6b-42d0-98d2-92b059da8621" xlink:href="sny-20240630.xsd#sny_BusinessCombinationNominalValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_sny_BusinessCombinationNominalValue_f688d0d0-ab6b-42d0-98d2-92b059da8621" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionNominalValue_92f18b23-b12f-4347-9c09-18428982779d" xlink:href="sny-20240630.xsd#sny_AssetsAcquisitionNominalValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_sny_AssetsAcquisitionNominalValue_92f18b23-b12f-4347-9c09-18428982779d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionPurchasePricePerShare_e427049f-554c-46b2-a524-5b88f170698d" xlink:href="sny-20240630.xsd#sny_AssetsAcquisitionPurchasePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_sny_AssetsAcquisitionPurchasePricePerShare_e427049f-554c-46b2-a524-5b88f170698d" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:href="sny-20240630.xsd#sny_DisclosureOfPrincipalAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalAgreementsTable_ba1c6206-3c59-465a-9987-ab45e884053d" xlink:href="sny-20240630.xsd#sny_DisclosureOfPrincipalAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_sny_DisclosureOfPrincipalAgreementsTable_ba1c6206-3c59-465a-9987-ab45e884053d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_e92d9fc5-e63d-4734-a50a-9eb040031dba" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_ba1c6206-3c59-465a-9987-ab45e884053d" xlink:to="loc_sny_PrincipalAlliancesAxis_e92d9fc5-e63d-4734-a50a-9eb040031dba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_e92d9fc5-e63d-4734-a50a-9eb040031dba_default" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_PrincipalAlliancesAxis_e92d9fc5-e63d-4734-a50a-9eb040031dba" xlink:to="loc_sny_PrincipalAlliancesDomain_e92d9fc5-e63d-4734-a50a-9eb040031dba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_d5bda86c-ea14-48cd-9d91-fd66613d76a3" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_PrincipalAlliancesAxis_e92d9fc5-e63d-4734-a50a-9eb040031dba" xlink:to="loc_sny_PrincipalAlliancesDomain_d5bda86c-ea14-48cd-9d91-fd66613d76a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_45dd2ffa-698e-4742-9bb9-5aa3aa79395f" xlink:href="sny-20240630.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_d5bda86c-ea14-48cd-9d91-fd66613d76a3" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_45dd2ffa-698e-4742-9bb9-5aa3aa79395f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_16c4b12d-d90d-4fdf-aac3-475e0af1fa1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_ba1c6206-3c59-465a-9987-ab45e884053d" xlink:to="loc_ifrs-full_CounterpartiesAxis_16c4b12d-d90d-4fdf-aac3-475e0af1fa1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_16c4b12d-d90d-4fdf-aac3-475e0af1fa1a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_16c4b12d-d90d-4fdf-aac3-475e0af1fa1a" xlink:to="loc_ifrs-full_CounterpartiesMember_16c4b12d-d90d-4fdf-aac3-475e0af1fa1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_67edac21-a35e-4bdb-af31-e7a5dcdb4c23" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_16c4b12d-d90d-4fdf-aac3-475e0af1fa1a" xlink:to="loc_ifrs-full_CounterpartiesMember_67edac21-a35e-4bdb-af31-e7a5dcdb4c23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AstraZenecaMember_73126122-1bb8-421b-96e1-940fafba2f63" xlink:href="sny-20240630.xsd#sny_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_67edac21-a35e-4bdb-af31-e7a5dcdb4c23" xlink:to="loc_sny_AstraZenecaMember_73126122-1bb8-421b-96e1-940fafba2f63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SwedishOrphanBiovitrumABMember_c3c36e9f-7df0-48d8-97ae-47456850d76c" xlink:href="sny-20240630.xsd#sny_SwedishOrphanBiovitrumABMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_67edac21-a35e-4bdb-af31-e7a5dcdb4c23" xlink:to="loc_sny_SwedishOrphanBiovitrumABMember_c3c36e9f-7df0-48d8-97ae-47456850d76c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_85a9afbe-c4dd-44f2-b603-24384e0bfde0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_ba1c6206-3c59-465a-9987-ab45e884053d" xlink:to="loc_ifrs-full_GeographicalAreasAxis_85a9afbe-c4dd-44f2-b603-24384e0bfde0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_85a9afbe-c4dd-44f2-b603-24384e0bfde0_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_85a9afbe-c4dd-44f2-b603-24384e0bfde0" xlink:to="loc_ifrs-full_GeographicalAreasMember_85a9afbe-c4dd-44f2-b603-24384e0bfde0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_d776dae2-6f60-4491-87bc-514223c31f43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_85a9afbe-c4dd-44f2-b603-24384e0bfde0" xlink:to="loc_ifrs-full_GeographicalAreasMember_d776dae2-6f60-4491-87bc-514223c31f43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorTerritoriesMember_f3191f21-b349-42f7-8383-0887d3eb9ccd" xlink:href="sny-20240630.xsd#sny_MajorTerritoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_d776dae2-6f60-4491-87bc-514223c31f43" xlink:to="loc_sny_MajorTerritoriesMember_f3191f21-b349-42f7-8383-0887d3eb9ccd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherTerritoriesMember_1ff16884-2e17-4f1d-a2ad-64398ee2f570" xlink:href="sny-20240630.xsd#sny_OtherTerritoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_d776dae2-6f60-4491-87bc-514223c31f43" xlink:to="loc_sny_OtherTerritoriesMember_1ff16884-2e17-4f1d-a2ad-64398ee2f570" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_8c6ebe79-1193-4829-9457-c7625fc45712" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_d776dae2-6f60-4491-87bc-514223c31f43" xlink:to="loc_country_CN_8c6ebe79-1193-4829-9457-c7625fc45712" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_add7b4b7-de7f-46b5-8371-77c2c2cb327d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_ba1c6206-3c59-465a-9987-ab45e884053d" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_add7b4b7-de7f-46b5-8371-77c2c2cb327d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_add7b4b7-de7f-46b5-8371-77c2c2cb327d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_add7b4b7-de7f-46b5-8371-77c2c2cb327d" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_add7b4b7-de7f-46b5-8371-77c2c2cb327d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c2e5f38e-a631-4086-b01e-7157c2f740ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_add7b4b7-de7f-46b5-8371-77c2c2cb327d" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c2e5f38e-a631-4086-b01e-7157c2f740ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_51725ddf-6bf3-4e59-9a29-5417d9e03d4c" xlink:href="sny-20240630.xsd#sny_OtherIntangibleAssetsExcludingSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c2e5f38e-a631-4086-b01e-7157c2f740ed" xlink:to="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_51725ddf-6bf3-4e59-9a29-5417d9e03d4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_4f208381-41a4-43e3-823a-1b1100715621" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_ba1c6206-3c59-465a-9987-ab45e884053d" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_4f208381-41a4-43e3-823a-1b1100715621" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_4f208381-41a4-43e3-823a-1b1100715621_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_4f208381-41a4-43e3-823a-1b1100715621" xlink:to="loc_ifrs-full_NonadjustingEventsMember_4f208381-41a4-43e3-823a-1b1100715621_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_b5214f73-a26e-4c5d-bc0d-033e2aa60bfd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_4f208381-41a4-43e3-823a-1b1100715621" xlink:to="loc_ifrs-full_NonadjustingEventsMember_b5214f73-a26e-4c5d-bc0d-033e2aa60bfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorFinancialLiabilityMember_f33e95da-54e4-47a5-8941-4b828620698d" xlink:href="sny-20240630.xsd#sny_MajorFinancialLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_b5214f73-a26e-4c5d-bc0d-033e2aa60bfd" xlink:to="loc_sny_MajorFinancialLiabilityMember_f33e95da-54e4-47a5-8941-4b828620698d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsUpfrontPayment_f0822339-9618-40df-a9d6-1a4be5775de5" xlink:href="sny-20240630.xsd#sny_CollaborationAgreementsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_sny_CollaborationAgreementsUpfrontPayment_f0822339-9618-40df-a9d6-1a4be5775de5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsDevelopmentMilestonePayment_faf4ad74-eef6-4550-af09-c22c981573f9" xlink:href="sny-20240630.xsd#sny_CollaborationAgreementsDevelopmentMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_sny_CollaborationAgreementsDevelopmentMilestonePayment_faf4ad74-eef6-4550-af09-c22c981573f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsRegulatoryMilestonePayment_d09f2758-fe77-4afd-baee-32f839ef02be" xlink:href="sny-20240630.xsd#sny_CollaborationAgreementsRegulatoryMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_sny_CollaborationAgreementsRegulatoryMilestonePayment_d09f2758-fe77-4afd-baee-32f839ef02be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_9dd4bf4b-f7c4-4308-83b7-f7c8ad76edd6" xlink:href="sny-20240630.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_9dd4bf4b-f7c4-4308-83b7-f7c8ad76edd6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitsArisingFromCommercialOperations_aec22a06-6918-4973-9432-5d4bb5c015ef" xlink:href="sny-20240630.xsd#sny_PercentageOfProfitsArisingFromCommercialOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_sny_PercentageOfProfitsArisingFromCommercialOperations_aec22a06-6918-4973-9432-5d4bb5c015ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfNetSalesArisingFromCommercialOperations_8cd17899-3e1f-49b0-8139-2b79362d9b73" xlink:href="sny-20240630.xsd#sny_PercentageOfNetSalesArisingFromCommercialOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_sny_PercentageOfNetSalesArisingFromCommercialOperations_8cd17899-3e1f-49b0-8139-2b79362d9b73" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_8835f6d7-3c41-46d3-9579-4843c458406b" xlink:href="sny-20240630.xsd#sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_8835f6d7-3c41-46d3-9579-4843c458406b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_9cf964cb-fe10-470f-b3a0-00e374aac423" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_9cf964cb-fe10-470f-b3a0-00e374aac423" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_cab5f2fd-cf7c-4d7b-8074-0d4191e677a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_cab5f2fd-cf7c-4d7b-8074-0d4191e677a1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_d4ea78cc-d595-415d-b872-cb8f9b96ff3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_d4ea78cc-d595-415d-b872-cb8f9b96ff3a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_29cd2cbf-7472-422c-97d5-c0f5cf0d09d7" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_29cd2cbf-7472-422c-97d5-c0f5cf0d09d7" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0d2f3250-8ced-47a6-bd33-235b8a029b5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_d65165b4-feb8-4df0-bd84-e8b6e466b322" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0d2f3250-8ced-47a6-bd33-235b8a029b5c" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_d65165b4-feb8-4df0-bd84-e8b6e466b322" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_de6c67ad-b8a5-46dd-a413-5174e357b36a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_d65165b4-feb8-4df0-bd84-e8b6e466b322" xlink:to="loc_ifrs-full_SegmentsAxis_de6c67ad-b8a5-46dd-a413-5174e357b36a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_de6c67ad-b8a5-46dd-a413-5174e357b36a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_de6c67ad-b8a5-46dd-a413-5174e357b36a" xlink:to="loc_ifrs-full_SegmentsMember_de6c67ad-b8a5-46dd-a413-5174e357b36a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_689f28f6-f1dd-4096-9324-615d5d30471c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_de6c67ad-b8a5-46dd-a413-5174e357b36a" xlink:to="loc_ifrs-full_SegmentsMember_689f28f6-f1dd-4096-9324-615d5d30471c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_02f91a51-bf2f-41e8-a643-b9b6de8630c3" xlink:href="sny-20240630.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_689f28f6-f1dd-4096-9324-615d5d30471c" xlink:to="loc_sny_BiopharmaSegmentMember_02f91a51-bf2f-41e8-a643-b9b6de8630c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_961929a7-ee1d-400f-8ac1-c0fda0e0f435" xlink:href="sny-20240630.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_689f28f6-f1dd-4096-9324-615d5d30471c" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_961929a7-ee1d-400f-8ac1-c0fda0e0f435" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaMember_1aab4d7d-162c-4295-884f-6532bff10522" xlink:href="sny-20240630.xsd#sny_OpellaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_689f28f6-f1dd-4096-9324-615d5d30471c" xlink:to="loc_sny_OpellaMember_1aab4d7d-162c-4295-884f-6532bff10522" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_2039899f-c2d2-4448-aec3-ae77cf92c30c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_d65165b4-feb8-4df0-bd84-e8b6e466b322" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_2039899f-c2d2-4448-aec3-ae77cf92c30c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_2039899f-c2d2-4448-aec3-ae77cf92c30c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_2039899f-c2d2-4448-aec3-ae77cf92c30c" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_2039899f-c2d2-4448-aec3-ae77cf92c30c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_027b8f3a-a7cf-4762-9ea0-d3128cdbeaeb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_2039899f-c2d2-4448-aec3-ae77cf92c30c" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_027b8f3a-a7cf-4762-9ea0-d3128cdbeaeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManufacturingAndSupplyMember_495d442d-c185-49ee-8718-d502e94e6a49" xlink:href="sny-20240630.xsd#sny_ManufacturingAndSupplyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_027b8f3a-a7cf-4762-9ea0-d3128cdbeaeb" xlink:to="loc_sny_ManufacturingAndSupplyMember_495d442d-c185-49ee-8718-d502e94e6a49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_1fd7856c-9787-4400-a89b-71dc4f2435ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0d2f3250-8ced-47a6-bd33-235b8a029b5c" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_1fd7856c-9787-4400-a89b-71dc4f2435ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestCostsCapitalised_f4d3bba4-5a87-455f-802d-98eafb4c4cd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestCostsCapitalised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0d2f3250-8ced-47a6-bd33-235b8a029b5c" xlink:to="loc_ifrs-full_InterestCostsCapitalised_f4d3bba4-5a87-455f-802d-98eafb4c4cd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments_531a5cfb-936b-48db-a495-6aee6759f857" xlink:href="sny-20240630.xsd#sny_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0d2f3250-8ced-47a6-bd33-235b8a029b5c" xlink:to="loc_sny_NumberOfOperatingSegments_531a5cfb-936b-48db-a495-6aee6759f857" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#GoodwillandOtherIntangibleAssetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_34919718-fed8-4ed7-9b81-4b66739fdb82" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_302d8466-91fb-445b-a09b-4829f33e5cc0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_34919718-fed8-4ed7-9b81-4b66739fdb82" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_302d8466-91fb-445b-a09b-4829f33e5cc0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_f87bde94-aa7f-46f2-8052-0352cd5f3bca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_302d8466-91fb-445b-a09b-4829f33e5cc0" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_f87bde94-aa7f-46f2-8052-0352cd5f3bca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_f87bde94-aa7f-46f2-8052-0352cd5f3bca_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_f87bde94-aa7f-46f2-8052-0352cd5f3bca" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_f87bde94-aa7f-46f2-8052-0352cd5f3bca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c92ce512-bbed-456a-a3bb-bdff3a568bdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_f87bde94-aa7f-46f2-8052-0352cd5f3bca" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c92ce512-bbed-456a-a3bb-bdff3a568bdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_302d807f-b98e-42f7-913f-f54069b4ceda" xlink:href="sny-20240630.xsd#sny_OtherIntangibleAssetsExcludingSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c92ce512-bbed-456a-a3bb-bdff3a568bdd" xlink:to="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_302d807f-b98e-42f7-913f-f54069b4ceda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsMember_910e5c82-b73a-45e9-bfae-03fb132ee339" xlink:href="sny-20240630.xsd#sny_MarketedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c92ce512-bbed-456a-a3bb-bdff3a568bdd" xlink:to="loc_sny_MarketedProductsMember_910e5c82-b73a-45e9-bfae-03fb132ee339" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TechnologicalPlatformsMember_2227a1e1-b9b1-4d23-bba8-bf75a32107a7" xlink:href="sny-20240630.xsd#sny_TechnologicalPlatformsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c92ce512-bbed-456a-a3bb-bdff3a568bdd" xlink:to="loc_sny_TechnologicalPlatformsMember_2227a1e1-b9b1-4d23-bba8-bf75a32107a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_e2c81afe-77aa-4354-9196-49b7387605c2" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_302d8466-91fb-445b-a09b-4829f33e5cc0" xlink:to="loc_sny_PrincipalAlliancesAxis_e2c81afe-77aa-4354-9196-49b7387605c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_e2c81afe-77aa-4354-9196-49b7387605c2_default" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_PrincipalAlliancesAxis_e2c81afe-77aa-4354-9196-49b7387605c2" xlink:to="loc_sny_PrincipalAlliancesDomain_e2c81afe-77aa-4354-9196-49b7387605c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_2e1b6165-dc0c-427d-a8f6-d609d2816454" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_PrincipalAlliancesAxis_e2c81afe-77aa-4354-9196-49b7387605c2" xlink:to="loc_sny_PrincipalAlliancesDomain_2e1b6165-dc0c-427d-a8f6-d609d2816454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesCoExclusiveLicensingAgreementMember_ce3777b4-ee59-45ba-bfe8-2098fd86690a" xlink:href="sny-20240630.xsd#sny_VaccinesCoExclusiveLicensingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_2e1b6165-dc0c-427d-a8f6-d609d2816454" xlink:to="loc_sny_VaccinesCoExclusiveLicensingAgreementMember_ce3777b4-ee59-45ba-bfe8-2098fd86690a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_8b271e62-4f4d-4b7a-80a0-8e9af2ba0ea4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_302d8466-91fb-445b-a09b-4829f33e5cc0" xlink:to="loc_ifrs-full_CounterpartiesAxis_8b271e62-4f4d-4b7a-80a0-8e9af2ba0ea4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_8b271e62-4f4d-4b7a-80a0-8e9af2ba0ea4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_8b271e62-4f4d-4b7a-80a0-8e9af2ba0ea4" xlink:to="loc_ifrs-full_CounterpartiesMember_8b271e62-4f4d-4b7a-80a0-8e9af2ba0ea4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_73c9da6e-28cc-432d-8aff-78433040d838" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_8b271e62-4f4d-4b7a-80a0-8e9af2ba0ea4" xlink:to="loc_ifrs-full_CounterpartiesMember_73c9da6e-28cc-432d-8aff-78433040d838" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NovavaxMember_2f9f1130-794f-470e-9009-71eba317eeb6" xlink:href="sny-20240630.xsd#sny_NovavaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_73c9da6e-28cc-432d-8aff-78433040d838" xlink:to="loc_sny_NovavaxMember_2f9f1130-794f-470e-9009-71eba317eeb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_9d855afa-be62-46c9-ad33-8d96c91c4e2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_34919718-fed8-4ed7-9b81-4b66739fdb82" xlink:to="loc_ifrs-full_Goodwill_9d855afa-be62-46c9-ad33-8d96c91c4e2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_5b358445-83bd-4832-828f-285fd38446ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_34919718-fed8-4ed7-9b81-4b66739fdb82" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_5b358445-83bd-4832-828f-285fd38446ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_0b162398-0970-4046-ae9e-bd72c9eb5a0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_34919718-fed8-4ed7-9b81-4b66739fdb82" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_0b162398-0970-4046-ae9e-bd72c9eb5a0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_6d38017f-8c6f-46dc-96f9-e089dd10151c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_34919718-fed8-4ed7-9b81-4b66739fdb82" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_6d38017f-8c6f-46dc-96f9-e089dd10151c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_2b713579-a77a-4c66-9adf-0cf8b888e78a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_2b713579-a77a-4c66-9adf-0cf8b888e78a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7248349b-db10-4ac6-b7cd-8f264a8b7043" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_2b713579-a77a-4c66-9adf-0cf8b888e78a" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7248349b-db10-4ac6-b7cd-8f264a8b7043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_7248349b-db10-4ac6-b7cd-8f264a8b7043_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7248349b-db10-4ac6-b7cd-8f264a8b7043" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_7248349b-db10-4ac6-b7cd-8f264a8b7043_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0cdb6910-a96b-4869-8065-437e766ec159" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7248349b-db10-4ac6-b7cd-8f264a8b7043" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0cdb6910-a96b-4869-8065-437e766ec159" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquiredResearchAndDevelopmentMember_e765e098-745a-4d21-9386-daf3639e7994" xlink:href="sny-20240630.xsd#sny_AcquiredResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0cdb6910-a96b-4869-8065-437e766ec159" xlink:to="loc_sny_AcquiredResearchAndDevelopmentMember_e765e098-745a-4d21-9386-daf3639e7994" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProductsTrademarksAndOtherRightsMember_0600786b-aa5f-4f53-9057-da34d1329949" xlink:href="sny-20240630.xsd#sny_ProductsTrademarksAndOtherRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0cdb6910-a96b-4869-8065-437e766ec159" xlink:to="loc_sny_ProductsTrademarksAndOtherRightsMember_0600786b-aa5f-4f53-9057-da34d1329949" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AltuviiioMember_9f777714-026f-41e8-b36f-b391e15c2d44" xlink:href="sny-20240630.xsd#sny_AltuviiioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProductsTrademarksAndOtherRightsMember_0600786b-aa5f-4f53-9057-da34d1329949" xlink:to="loc_sny_AltuviiioMember_9f777714-026f-41e8-b36f-b391e15c2d44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_c30aab14-d062-4a7d-ba09-7019563aab55" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0cdb6910-a96b-4869-8065-437e766ec159" xlink:to="loc_ifrs-full_ComputerSoftwareMember_c30aab14-d062-4a7d-ba09-7019563aab55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_ed63d9f8-e3d0-4670-9102-8888f85a398a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0cdb6910-a96b-4869-8065-437e766ec159" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_ed63d9f8-e3d0-4670-9102-8888f85a398a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquiredRDMember_7ae6c1c2-c0c0-4a86-8d82-91a8a728292b" xlink:href="sny-20240630.xsd#sny_AcquiredRDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0cdb6910-a96b-4869-8065-437e766ec159" xlink:to="loc_sny_AcquiredRDMember_7ae6c1c2-c0c0-4a86-8d82-91a8a728292b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsTrademarksAndOtherRightsMember_ee76e093-1571-4db2-8919-0c4ea200c6af" xlink:href="sny-20240630.xsd#sny_MarketedProductsTrademarksAndOtherRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0cdb6910-a96b-4869-8065-437e766ec159" xlink:to="loc_sny_MarketedProductsTrademarksAndOtherRightsMember_ee76e093-1571-4db2-8919-0c4ea200c6af" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1669e860-9ed5-4025-854d-85b8c16888aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_2b713579-a77a-4c66-9adf-0cf8b888e78a" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1669e860-9ed5-4025-854d-85b8c16888aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_1669e860-9ed5-4025-854d-85b8c16888aa_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1669e860-9ed5-4025-854d-85b8c16888aa" xlink:to="loc_ifrs-full_CarryingAmountMember_1669e860-9ed5-4025-854d-85b8c16888aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_a18c10cf-9b33-42c2-b819-8a35213e5d5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1669e860-9ed5-4025-854d-85b8c16888aa" xlink:to="loc_ifrs-full_CarryingAmountMember_a18c10cf-9b33-42c2-b819-8a35213e5d5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_47ae2f30-01b4-4537-9375-a029578ce38a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_a18c10cf-9b33-42c2-b819-8a35213e5d5a" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_47ae2f30-01b4-4537-9375-a029578ce38a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_d8255687-f0a8-45b1-aff2-ebebd9b941d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_a18c10cf-9b33-42c2-b819-8a35213e5d5a" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_d8255687-f0a8-45b1-aff2-ebebd9b941d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_c657eced-d2c0-40cb-ab30-02da9a519162" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_2b713579-a77a-4c66-9adf-0cf8b888e78a" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_c657eced-d2c0-40cb-ab30-02da9a519162" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_c657eced-d2c0-40cb-ab30-02da9a519162_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_c657eced-d2c0-40cb-ab30-02da9a519162" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_c657eced-d2c0-40cb-ab30-02da9a519162_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_61c3dccf-40d6-48fa-9326-cd16b20ad2fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_c657eced-d2c0-40cb-ab30-02da9a519162" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_61c3dccf-40d6-48fa-9326-cd16b20ad2fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember_e0615110-e6ab-4a8e-a9d7-8da74a355d72" xlink:href="sny-20240630.xsd#sny_ProventionBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_61c3dccf-40d6-48fa-9326-cd16b20ad2fc" xlink:to="loc_sny_ProventionBioIncMember_e0615110-e6ab-4a8e-a9d7-8da74a355d72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_d8edc3b1-1ebb-4c17-ad99-63ff3e271681" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_2b713579-a77a-4c66-9adf-0cf8b888e78a" xlink:to="loc_ifrs-full_CounterpartiesAxis_d8edc3b1-1ebb-4c17-ad99-63ff3e271681" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_d8edc3b1-1ebb-4c17-ad99-63ff3e271681_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_d8edc3b1-1ebb-4c17-ad99-63ff3e271681" xlink:to="loc_ifrs-full_CounterpartiesMember_d8edc3b1-1ebb-4c17-ad99-63ff3e271681_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_90f8fe11-bd84-446e-bb5b-bd3ab4f39f8f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_d8edc3b1-1ebb-4c17-ad99-63ff3e271681" xlink:to="loc_ifrs-full_CounterpartiesMember_90f8fe11-bd84-446e-bb5b-bd3ab4f39f8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NovavaxMember_65c95fe4-ebb9-4157-9c26-7c89db60fb0c" xlink:href="sny-20240630.xsd#sny_NovavaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_90f8fe11-bd84-446e-bb5b-bd3ab4f39f8f" xlink:to="loc_sny_NovavaxMember_65c95fe4-ebb9-4157-9c26-7c89db60fb0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssets_976390cd-cac2-4635-a34a-f318082f627f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_OtherIntangibleAssets_976390cd-cac2-4635-a34a-f318082f627f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_c48e1429-ee1b-4f82-b0e0-fac8c3b4a7bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_c48e1429-ee1b-4f82-b0e0-fac8c3b4a7bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_cc8cf45d-9d0d-4a63-abd9-2d625c21a933" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_cc8cf45d-9d0d-4a63-abd9-2d625c21a933" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_f248e302-8846-4055-b0c1-b0bd3ec75eac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_f248e302-8846-4055-b0c1-b0bd3ec75eac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_139e7722-2aed-4a97-98f2-1466da0388d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_139e7722-2aed-4a97-98f2-1466da0388d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_30d10f92-c0fb-4c95-ac80-c31f236da51b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_30d10f92-c0fb-4c95-ac80-c31f236da51b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_07bb75a3-827d-4f00-9392-b402e82ae6cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_07bb75a3-827d-4f00-9392-b402e82ae6cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_bc61f9ef-2226-4857-a648-b5b48765ed4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_bc61f9ef-2226-4857-a648-b5b48765ed4e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_3b0cca90-51d3-4b25-b089-7949419d0ab1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_3b0cca90-51d3-4b25-b089-7949419d0ab1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_c0e8eed8-a29d-4cec-b443-b5d022539368" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_c0e8eed8-a29d-4cec-b443-b5d022539368" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_88a8679d-2a59-4f4b-8648-f3a1424bed7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_88a8679d-2a59-4f4b-8648-f3a1424bed7d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssets_1b69c8c6-1a92-483d-9abf-010b745f5506" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_3f100954-e6c7-44ec-be2d-e212a68b62e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_3f100954-e6c7-44ec-be2d-e212a68b62e8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_8d59dc4d-b113-4683-b835-9e64384ac1b3" xlink:href="sny-20240630.xsd#sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_8d59dc4d-b113-4683-b835-9e64384ac1b3" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_6c36fbaf-917a-4959-9e1a-ca19b4d66c5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_6c36fbaf-917a-4959-9e1a-ca19b4d66c5c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_116321bd-8cdd-4025-991e-6804d6e9465c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_6c36fbaf-917a-4959-9e1a-ca19b4d66c5c" xlink:to="loc_ifrs-full_JointVenturesAxis_116321bd-8cdd-4025-991e-6804d6e9465c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_116321bd-8cdd-4025-991e-6804d6e9465c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointVenturesAxis_116321bd-8cdd-4025-991e-6804d6e9465c" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_116321bd-8cdd-4025-991e-6804d6e9465c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_2d4c4c67-0ce2-491d-9fe1-7d14259aeb0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointVenturesAxis_116321bd-8cdd-4025-991e-6804d6e9465c" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_2d4c4c67-0ce2-491d-9fe1-7d14259aeb0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfraservGmbhAndCoHochstKGMember_b7a07347-f891-49a4-9229-ddf4c21861d3" xlink:href="sny-20240630.xsd#sny_InfraservGmbhAndCoHochstKGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2d4c4c67-0ce2-491d-9fe1-7d14259aeb0b" xlink:to="loc_sny_InfraservGmbhAndCoHochstKGMember_b7a07347-f891-49a4-9229-ddf4c21861d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember_764a3d66-7045-49b5-9110-f840950be346" xlink:href="sny-20240630.xsd#sny_MSPVaccineCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2d4c4c67-0ce2-491d-9fe1-7d14259aeb0b" xlink:to="loc_sny_MSPVaccineCompanyMember_764a3d66-7045-49b5-9110-f840950be346" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_27758e18-f568-459c-aa79-ef51e0f60e93" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2d4c4c67-0ce2-491d-9fe1-7d14259aeb0b" xlink:to="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_27758e18-f568-459c-aa79-ef51e0f60e93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_fd8187fa-f4bb-40cd-abb5-aa143b9cf1be" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_6c36fbaf-917a-4959-9e1a-ca19b4d66c5c" xlink:to="loc_dei_LegalEntityAxis_fd8187fa-f4bb-40cd-abb5-aa143b9cf1be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fd8187fa-f4bb-40cd-abb5-aa143b9cf1be_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_fd8187fa-f4bb-40cd-abb5-aa143b9cf1be" xlink:to="loc_dei_EntityDomain_fd8187fa-f4bb-40cd-abb5-aa143b9cf1be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2e730c00-1bc4-4be7-bd11-3e7390f0c48e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_fd8187fa-f4bb-40cd-abb5-aa143b9cf1be" xlink:to="loc_dei_EntityDomain_2e730c00-1bc4-4be7-bd11-3e7390f0c48e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_d59b2bb0-7cd2-4b9e-a1c8-d0d987ffd5d8" xlink:href="sny-20240630.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2e730c00-1bc4-4be7-bd11-3e7390f0c48e" xlink:to="loc_sny_EuroapiMember_d59b2bb0-7cd2-4b9e-a1c8-d0d987ffd5d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember_66574fc6-682c-4310-8dd2-08c6e54d0cd9" xlink:href="sny-20240630.xsd#sny_MSPVaccineCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2e730c00-1bc4-4be7-bd11-3e7390f0c48e" xlink:to="loc_sny_MSPVaccineCompanyMember_66574fc6-682c-4310-8dd2-08c6e54d0cd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_8090ce2c-5005-4fb5-af47-9e9f9281a504" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_6c36fbaf-917a-4959-9e1a-ca19b4d66c5c" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_8090ce2c-5005-4fb5-af47-9e9f9281a504" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_8090ce2c-5005-4fb5-af47-9e9f9281a504_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_8090ce2c-5005-4fb5-af47-9e9f9281a504" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_8090ce2c-5005-4fb5-af47-9e9f9281a504_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_ab4c4b1b-3be4-4b79-8a6c-d44163d92fb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_8090ce2c-5005-4fb5-af47-9e9f9281a504" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_ab4c4b1b-3be4-4b79-8a6c-d44163d92fb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_a193f4b8-aec2-4a27-9034-39ed1cf87214" xlink:href="sny-20240630.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_ab4c4b1b-3be4-4b79-8a6c-d44163d92fb4" xlink:to="loc_sny_EuroapiMember_a193f4b8-aec2-4a27-9034-39ed1cf87214" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_194c301d-942e-44b8-9b78-84fb2db95b78" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_6c36fbaf-917a-4959-9e1a-ca19b4d66c5c" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_194c301d-942e-44b8-9b78-84fb2db95b78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_194c301d-942e-44b8-9b78-84fb2db95b78_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_194c301d-942e-44b8-9b78-84fb2db95b78" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_194c301d-942e-44b8-9b78-84fb2db95b78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_717ad8f5-d58b-46e1-8a36-0391e0411ee4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_194c301d-942e-44b8-9b78-84fb2db95b78" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_717ad8f5-d58b-46e1-8a36-0391e0411ee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MCMVaccineBVMember_19e774ad-bc06-459e-98c8-855ce8c5ff9d" xlink:href="sny-20240630.xsd#sny_MCMVaccineBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_717ad8f5-d58b-46e1-8a36-0391e0411ee4" xlink:to="loc_sny_MCMVaccineBVMember_19e774ad-bc06-459e-98c8-855ce8c5ff9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_986d9e57-ec28-406f-bd0c-37204994a36c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_986d9e57-ec28-406f-bd0c-37204994a36c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod_24d74577-d784-4ba4-9cb9-f324b304089f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:to="loc_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod_24d74577-d784-4ba4-9cb9-f324b304089f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_23686a28-478e-47eb-98ba-eb2b302fc608" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_23686a28-478e-47eb-98ba-eb2b302fc608" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_a9e82b5e-8f11-45e5-bbed-597e24521bf2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:to="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_a9e82b5e-8f11-45e5-bbed-597e24521bf2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_646a2f5e-22a5-44ce-b904-1fb6dd7870f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_646a2f5e-22a5-44ce-b904-1fb6dd7870f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_abf0ab6c-2d3e-4f5a-bdbd-b753f4e50b4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_abf0ab6c-2d3e-4f5a-bdbd-b753f4e50b4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockPrice_a539e8e0-9720-4085-845e-cf97cae5fc6e" xlink:href="sny-20240630.xsd#sny_StockPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:to="loc_sny_StockPrice_a539e8e0-9720-4085-845e-cf97cae5fc6e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_b95f6709-5d1e-43b6-bceb-9fe254e6d7e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_b95f6709-5d1e-43b6-bceb-9fe254e6d7e2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubordinatedLiabilities_68a74783-824d-4620-9732-c064bd028c6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubordinatedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:to="loc_ifrs-full_SubordinatedLiabilities_68a74783-824d-4620-9732-c064bd028c6c" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_de9dcc29-1894-43fa-ba1a-d8602bbdf374" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_44be06e1-d8fd-4b9e-a7e5-3b0233970eea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_de9dcc29-1894-43fa-ba1a-d8602bbdf374" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_44be06e1-d8fd-4b9e-a7e5-3b0233970eea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_ace902f9-d767-4146-9c00-ed2e245b575d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_44be06e1-d8fd-4b9e-a7e5-3b0233970eea" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_ace902f9-d767-4146-9c00-ed2e245b575d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_ace902f9-d767-4146-9c00-ed2e245b575d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_ace902f9-d767-4146-9c00-ed2e245b575d" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_ace902f9-d767-4146-9c00-ed2e245b575d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2faabd03-9821-487a-b062-2a62164fc82f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_ace902f9-d767-4146-9c00-ed2e245b575d" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2faabd03-9821-487a-b062-2a62164fc82f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssociatesAndJointVenturesMember_e5771fdc-60c9-4035-93f0-04dd1296f3ef" xlink:href="sny-20240630.xsd#sny_AssociatesAndJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2faabd03-9821-487a-b062-2a62164fc82f" xlink:to="loc_sny_AssociatesAndJointVenturesMember_e5771fdc-60c9-4035-93f0-04dd1296f3ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_10e4ebfc-db0f-4c26-9882-accff1551637" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_de9dcc29-1894-43fa-ba1a-d8602bbdf374" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_10e4ebfc-db0f-4c26-9882-accff1551637" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_3b81fbe6-f9b0-4b14-949f-89d7a3d798f8" xlink:href="sny-20240630.xsd#sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_de9dcc29-1894-43fa-ba1a-d8602bbdf374" xlink:to="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_3b81fbe6-f9b0-4b14-949f-89d7a3d798f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_e440d057-75b7-4149-9827-75b36a17ee11" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_de9dcc29-1894-43fa-ba1a-d8602bbdf374" xlink:to="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_e440d057-75b7-4149-9827-75b36a17ee11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_76ebb47d-83fc-4b19-bab3-797697638484" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_de9dcc29-1894-43fa-ba1a-d8602bbdf374" xlink:to="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_76ebb47d-83fc-4b19-bab3-797697638484" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_7a5be306-11a3-47cb-b7ea-717ed979eeb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_de9dcc29-1894-43fa-ba1a-d8602bbdf374" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_7a5be306-11a3-47cb-b7ea-717ed979eeb0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubordinatedLiabilities_9f2c5043-d7ad-45af-b85a-596f556c46bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubordinatedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_de9dcc29-1894-43fa-ba1a-d8602bbdf374" xlink:to="loc_ifrs-full_SubordinatedLiabilities_9f2c5043-d7ad-45af-b85a-596f556c46bf" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherNonCurrentAssetsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#OtherNonCurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/OtherNonCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_468ab5b9-1058-48d9-a85f-b972d6f9f2f7" xlink:href="sny-20240630.xsd#sny_DisclosureOfOtherNonCurrentAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_61660987-7dd0-4046-bf97-0c036849084f" xlink:href="sny-20240630.xsd#sny_DisclosureOfOtherNonCurrentAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_468ab5b9-1058-48d9-a85f-b972d6f9f2f7" xlink:to="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_61660987-7dd0-4046-bf97-0c036849084f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_caf96089-3b52-4b15-af7c-1eb406ce1320" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_61660987-7dd0-4046-bf97-0c036849084f" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_caf96089-3b52-4b15-af7c-1eb406ce1320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_caf96089-3b52-4b15-af7c-1eb406ce1320_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_caf96089-3b52-4b15-af7c-1eb406ce1320" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_caf96089-3b52-4b15-af7c-1eb406ce1320_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_bffb44c5-0e38-475f-8206-a97cebf8e5d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_caf96089-3b52-4b15-af7c-1eb406ce1320" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_bffb44c5-0e38-475f-8206-a97cebf8e5d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradingEquitySecuritiesMember_e03a34d1-846f-4b39-9c1a-e85e240303e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradingEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bffb44c5-0e38-475f-8206-a97cebf8e5d8" xlink:to="loc_ifrs-full_TradingEquitySecuritiesMember_e03a34d1-846f-4b39-9c1a-e85e240303e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtSecuritiesMember_7c147387-df80-4fa5-8d8c-3a278b49f353" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bffb44c5-0e38-475f-8206-a97cebf8e5d8" xlink:to="loc_ifrs-full_DebtSecuritiesMember_7c147387-df80-4fa5-8d8c-3a278b49f353" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_7373ad82-e37d-4cec-8549-04eed853cc98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_468ab5b9-1058-48d9-a85f-b972d6f9f2f7" xlink:to="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_7373ad82-e37d-4cec-8549-04eed853cc98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_ca8e5af3-934a-409f-85ea-d830f2179ef2" xlink:href="sny-20240630.xsd#sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_468ab5b9-1058-48d9-a85f-b972d6f9f2f7" xlink:to="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_ca8e5af3-934a-409f-85ea-d830f2179ef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PreFundedPensionObligations_2975aefa-548a-4ff1-8061-4b5059d96cbb" xlink:href="sny-20240630.xsd#sny_PreFundedPensionObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_468ab5b9-1058-48d9-a85f-b972d6f9f2f7" xlink:to="loc_sny_PreFundedPensionObligations_2975aefa-548a-4ff1-8061-4b5059d96cbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LongTermPrepaidExpenses_0980c821-8fb3-4cb9-a1bd-c7d3efa08a63" xlink:href="sny-20240630.xsd#sny_LongTermPrepaidExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_468ab5b9-1058-48d9-a85f-b972d6f9f2f7" xlink:to="loc_sny_LongTermPrepaidExpenses_0980c821-8fb3-4cb9-a1bd-c7d3efa08a63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLoansAndReceivables_27a3a2ca-c8a7-4fa3-818c-754b1c4bfd28" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLoansAndReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_468ab5b9-1058-48d9-a85f-b972d6f9f2f7" xlink:to="loc_ifrs-full_NoncurrentLoansAndReceivables_27a3a2ca-c8a7-4fa3-818c-754b1c4bfd28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_a8ad4c18-ad8d-4852-ab0a-920339299e1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_468ab5b9-1058-48d9-a85f-b972d6f9f2f7" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_a8ad4c18-ad8d-4852-ab0a-920339299e1a" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#AccountsReceivableSummaryofAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableLineItems_fc1d2867-a4d3-41a3-a059-e0fb9bc396e7" xlink:href="sny-20240630.xsd#sny_DisclosureOfAccountsReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableTable_29d21dc9-648f-4b94-8e7b-a6f548b4a4d1" xlink:href="sny-20240630.xsd#sny_DisclosureOfAccountsReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfAccountsReceivableLineItems_fc1d2867-a4d3-41a3-a059-e0fb9bc396e7" xlink:to="loc_sny_DisclosureOfAccountsReceivableTable_29d21dc9-648f-4b94-8e7b-a6f548b4a4d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_f0fd309b-6ddd-49b5-9a23-a94e51aa6719" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfAccountsReceivableTable_29d21dc9-648f-4b94-8e7b-a6f548b4a4d1" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_f0fd309b-6ddd-49b5-9a23-a94e51aa6719" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_f0fd309b-6ddd-49b5-9a23-a94e51aa6719_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_f0fd309b-6ddd-49b5-9a23-a94e51aa6719" xlink:to="loc_ifrs-full_CarryingAmountMember_f0fd309b-6ddd-49b5-9a23-a94e51aa6719_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_8095b774-85bd-4c32-a648-60028a91be2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_f0fd309b-6ddd-49b5-9a23-a94e51aa6719" xlink:to="loc_ifrs-full_CarryingAmountMember_8095b774-85bd-4c32-a648-60028a91be2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_c0b7d2ce-a61d-465a-be28-eb62a00acfef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_8095b774-85bd-4c32-a648-60028a91be2e" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_c0b7d2ce-a61d-465a-be28-eb62a00acfef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllowanceForCreditLossesMember_0a81eeae-34da-4b7b-b484-32b7d368bf93" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllowanceForCreditLossesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_8095b774-85bd-4c32-a648-60028a91be2e" xlink:to="loc_ifrs-full_AllowanceForCreditLossesMember_0a81eeae-34da-4b7b-b484-32b7d368bf93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_ca9016cc-83bb-49f6-b808-75e7551777fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfAccountsReceivableLineItems_fc1d2867-a4d3-41a3-a059-e0fb9bc396e7" xlink:to="loc_ifrs-full_CurrentTradeReceivables_ca9016cc-83bb-49f6-b808-75e7551777fb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_4dfb2a62-c28a-4290-adbe-264c532a5a3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_727d7772-5a3b-49e2-a8dc-7df2308618cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_4dfb2a62-c28a-4290-adbe-264c532a5a3c" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_727d7772-5a3b-49e2-a8dc-7df2308618cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_aaed389c-c473-4cdf-b2bf-1caa897408fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_727d7772-5a3b-49e2-a8dc-7df2308618cc" xlink:to="loc_ifrs-full_MaturityAxis_aaed389c-c473-4cdf-b2bf-1caa897408fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_aaed389c-c473-4cdf-b2bf-1caa897408fe_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_aaed389c-c473-4cdf-b2bf-1caa897408fe" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_aaed389c-c473-4cdf-b2bf-1caa897408fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_917a27f0-a15b-426a-b2ed-dc463fae0340" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_aaed389c-c473-4cdf-b2bf-1caa897408fe" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_917a27f0-a15b-426a-b2ed-dc463fae0340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneMonthMember_4319f1b4-4104-469a-99d4-8e37078869b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneMonthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_917a27f0-a15b-426a-b2ed-dc463fae0340" xlink:to="loc_ifrs-full_NotLaterThanOneMonthMember_4319f1b4-4104-469a-99d4-8e37078869b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_6ac06465-b140-4fc7-87af-3190b94ac0df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_917a27f0-a15b-426a-b2ed-dc463fae0340" xlink:to="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_6ac06465-b140-4fc7-87af-3190b94ac0df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_ac5243e8-7479-41ff-9810-c729d90d81f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_917a27f0-a15b-426a-b2ed-dc463fae0340" xlink:to="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_ac5243e8-7479-41ff-9810-c729d90d81f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_077933f5-e123-409c-b660-66a9da5b2e6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_917a27f0-a15b-426a-b2ed-dc463fae0340" xlink:to="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_077933f5-e123-409c-b660-66a9da5b2e6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearMember_b6a4be36-6cee-466f-8cfe-73a645324a2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_917a27f0-a15b-426a-b2ed-dc463fae0340" xlink:to="loc_ifrs-full_LaterThanOneYearMember_b6a4be36-6cee-466f-8cfe-73a645324a2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OverdueReceivablesGrossValue_e895ddcc-3e5e-40ca-b4a4-8cb688ae79c9" xlink:href="sny-20240630.xsd#sny_OverdueReceivablesGrossValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_4dfb2a62-c28a-4290-adbe-264c532a5a3c" xlink:to="loc_sny_OverdueReceivablesGrossValue_e895ddcc-3e5e-40ca-b4a4-8cb688ae79c9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedShareholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_041ce466-ea1a-4557-bb0f-f67bb06c2ed3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_041ce466-ea1a-4557-bb0f-f67bb06c2ed3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_8a461d09-3dad-4abe-8d83-176d9ad1e74c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_041ce466-ea1a-4557-bb0f-f67bb06c2ed3" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_8a461d09-3dad-4abe-8d83-176d9ad1e74c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_8a461d09-3dad-4abe-8d83-176d9ad1e74c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_8a461d09-3dad-4abe-8d83-176d9ad1e74c" xlink:to="loc_ifrs-full_EquityMember_8a461d09-3dad-4abe-8d83-176d9ad1e74c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_4f575efb-487d-42b1-8425-500cdbfd9861" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_8a461d09-3dad-4abe-8d83-176d9ad1e74c" xlink:to="loc_ifrs-full_EquityMember_4f575efb-487d-42b1-8425-500cdbfd9861" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_4b7fae0e-63cb-4cf6-b18a-e76d805690d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_4f575efb-487d-42b1-8425-500cdbfd9861" xlink:to="loc_ifrs-full_IssuedCapitalMember_4b7fae0e-63cb-4cf6-b18a-e76d805690d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_db7c72c2-271c-4c40-b9bb-5e9b7b02d2f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_4f575efb-487d-42b1-8425-500cdbfd9861" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_db7c72c2-271c-4c40-b9bb-5e9b7b02d2f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_68863e36-7b3c-4e5c-bc26-e13b6df2bbd7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_041ce466-ea1a-4557-bb0f-f67bb06c2ed3" xlink:to="loc_dei_LegalEntityAxis_68863e36-7b3c-4e5c-bc26-e13b6df2bbd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_68863e36-7b3c-4e5c-bc26-e13b6df2bbd7_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_68863e36-7b3c-4e5c-bc26-e13b6df2bbd7" xlink:to="loc_dei_EntityDomain_68863e36-7b3c-4e5c-bc26-e13b6df2bbd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_814e7a68-74f0-4601-b17f-0eb457eac14e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_68863e36-7b3c-4e5c-bc26-e13b6df2bbd7" xlink:to="loc_dei_EntityDomain_814e7a68-74f0-4601-b17f-0eb457eac14e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiMember_bbabe59c-dfdc-426e-ac80-39346e5437c8" xlink:href="sny-20240630.xsd#sny_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_814e7a68-74f0-4601-b17f-0eb457eac14e" xlink:to="loc_sny_SanofiMember_bbabe59c-dfdc-426e-ac80-39346e5437c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareProgramAxis_ad6dfc5e-4652-4f05-86ca-520ebd4228d0" xlink:href="sny-20240630.xsd#sny_ShareProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_041ce466-ea1a-4557-bb0f-f67bb06c2ed3" xlink:to="loc_sny_ShareProgramAxis_ad6dfc5e-4652-4f05-86ca-520ebd4228d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareProgramDomain_ad6dfc5e-4652-4f05-86ca-520ebd4228d0_default" xlink:href="sny-20240630.xsd#sny_ShareProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_ShareProgramAxis_ad6dfc5e-4652-4f05-86ca-520ebd4228d0" xlink:to="loc_sny_ShareProgramDomain_ad6dfc5e-4652-4f05-86ca-520ebd4228d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareProgramDomain_9ee0887b-fa50-4970-9b2a-7c1ed6e6beb7" xlink:href="sny-20240630.xsd#sny_ShareProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_ShareProgramAxis_ad6dfc5e-4652-4f05-86ca-520ebd4228d0" xlink:to="loc_sny_ShareProgramDomain_9ee0887b-fa50-4970-9b2a-7c1ed6e6beb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2022ProgramMember_5a9919b7-dc6e-4f44-a2f3-6fb7e2e8bdc0" xlink:href="sny-20240630.xsd#sny_ShareRepurchase2022ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareProgramDomain_9ee0887b-fa50-4970-9b2a-7c1ed6e6beb7" xlink:to="loc_sny_ShareRepurchase2022ProgramMember_5a9919b7-dc6e-4f44-a2f3-6fb7e2e8bdc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2023ProgramMember_d1bf3d41-4ca2-4d77-94df-a78cacd62928" xlink:href="sny-20240630.xsd#sny_ShareRepurchase2023ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareProgramDomain_9ee0887b-fa50-4970-9b2a-7c1ed6e6beb7" xlink:to="loc_sny_ShareRepurchase2023ProgramMember_d1bf3d41-4ca2-4d77-94df-a78cacd62928" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2024ProgramMember_492bf782-874c-4497-905e-31a4e58b99d9" xlink:href="sny-20240630.xsd#sny_ShareRepurchase2024ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareProgramDomain_9ee0887b-fa50-4970-9b2a-7c1ed6e6beb7" xlink:to="loc_sny_ShareRepurchase2024ProgramMember_492bf782-874c-4497-905e-31a4e58b99d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c630f54b-242e-459c-8942-36942328ea09" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_041ce466-ea1a-4557-bb0f-f67bb06c2ed3" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c630f54b-242e-459c-8942-36942328ea09" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_c630f54b-242e-459c-8942-36942328ea09_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c630f54b-242e-459c-8942-36942328ea09" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_c630f54b-242e-459c-8942-36942328ea09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_b7f27544-20f8-41ae-a956-83730de90abe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c630f54b-242e-459c-8942-36942328ea09" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_b7f27544-20f8-41ae-a956-83730de90abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeeShareOwnershipPlanMember_ab4643c4-ed25-44bf-86cf-c4082e555ebf" xlink:href="sny-20240630.xsd#sny_EmployeeShareOwnershipPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_b7f27544-20f8-41ae-a956-83730de90abe" xlink:to="loc_sny_EmployeeShareOwnershipPlanMember_ab4643c4-ed25-44bf-86cf-c4082e555ebf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_90d76f75-c26a-4e2c-b7fe-67fc54cb2085" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_041ce466-ea1a-4557-bb0f-f67bb06c2ed3" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_90d76f75-c26a-4e2c-b7fe-67fc54cb2085" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_90d76f75-c26a-4e2c-b7fe-67fc54cb2085_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_90d76f75-c26a-4e2c-b7fe-67fc54cb2085" xlink:to="loc_ifrs-full_FinancialAssetsMember_90d76f75-c26a-4e2c-b7fe-67fc54cb2085_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_0e322635-37e8-4851-8066-a1a9e5f28edc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_90d76f75-c26a-4e2c-b7fe-67fc54cb2085" xlink:to="loc_ifrs-full_FinancialAssetsMember_0e322635-37e8-4851-8066-a1a9e5f28edc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentsMember_cdbff0f4-86b4-4bba-b415-ad0792fefb1d" xlink:href="sny-20240630.xsd#sny_DebtInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_0e322635-37e8-4851-8066-a1a9e5f28edc" xlink:to="loc_sny_DebtInstrumentsMember_cdbff0f4-86b4-4bba-b415-ad0792fefb1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowAndFairValueHedgeMember_f50d4a00-78a1-43f8-b434-410737c5970a" xlink:href="sny-20240630.xsd#sny_CashFlowAndFairValueHedgeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_0e322635-37e8-4851-8066-a1a9e5f28edc" xlink:to="loc_sny_CashFlowAndFairValueHedgeMember_f50d4a00-78a1-43f8-b434-410737c5970a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForeignCurrencyTranslationMember_9042c947-4fbc-404c-ae22-ad2bffd51b5d" xlink:href="sny-20240630.xsd#sny_ForeignCurrencyTranslationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_0e322635-37e8-4851-8066-a1a9e5f28edc" xlink:to="loc_sny_ForeignCurrencyTranslationMember_9042c947-4fbc-404c-ae22-ad2bffd51b5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsAxis_0c5e9dd6-0737-4c57-8004-1dc621c72bf6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_041ce466-ea1a-4557-bb0f-f67bb06c2ed3" xlink:to="loc_ifrs-full_ReclassifiedItemsAxis_0c5e9dd6-0737-4c57-8004-1dc621c72bf6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsMember_0c5e9dd6-0737-4c57-8004-1dc621c72bf6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis_0c5e9dd6-0737-4c57-8004-1dc621c72bf6" xlink:to="loc_ifrs-full_ReclassifiedItemsMember_0c5e9dd6-0737-4c57-8004-1dc621c72bf6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsMember_cdb5996e-f5ea-401a-856c-a02a11c35620" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis_0c5e9dd6-0737-4c57-8004-1dc621c72bf6" xlink:to="loc_ifrs-full_ReclassifiedItemsMember_cdb5996e-f5ea-401a-856c-a02a11c35620" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_3dbb9487-c184-4d76-b0c4-2be42477f74a" xlink:href="sny-20240630.xsd#sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReclassifiedItemsMember_cdb5996e-f5ea-401a-856c-a02a11c35620" xlink:to="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_3dbb9487-c184-4d76-b0c4-2be42477f74a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_af7d3181-5715-4790-b1ac-8122146dcbf1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_ifrs-full_IssuedCapital_af7d3181-5715-4790-b1ac-8122146dcbf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_2a7595d3-ca80-478f-bce2-5a05aa501351" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_ifrs-full_NumberOfSharesIssued_2a7595d3-ca80-478f-bce2-5a05aa501351" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_80a2ebea-c1e3-4fae-8bda-1351898dad43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_ifrs-full_ParValuePerShare_80a2ebea-c1e3-4fae-8bda-1351898dad43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_13d8794f-99fe-4324-854b-8e3d7ec315e4" xlink:href="sny-20240630.xsd#sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_13d8794f-99fe-4324-854b-8e3d7ec315e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_c8aa35d0-26b9-48ed-91f5-738f0d099d79" xlink:href="sny-20240630.xsd#sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_c8aa35d0-26b9-48ed-91f5-738f0d099d79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_2b33327b-dae7-4fd5-b4ce-3c904f780143" xlink:href="sny-20240630.xsd#sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_2b33327b-dae7-4fd5-b4ce-3c904f780143" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesAlloted_ab0038bb-cf00-4302-869e-e95084ca666b" xlink:href="sny-20240630.xsd#sny_NumberOfRestrictedSharesAlloted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_NumberOfRestrictedSharesAlloted_ab0038bb-cf00-4302-869e-e95084ca666b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PeriodOfShareRepurchaseProgram_1f85469e-1dc6-489a-8501-302d68dd667f" xlink:href="sny-20240630.xsd#sny_PeriodOfShareRepurchaseProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_PeriodOfShareRepurchaseProgram_1f85469e-1dc6-489a-8501-302d68dd667f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesRepurchased_d1963e44-2843-401c-9e29-c5e6dc11e069" xlink:href="sny-20240630.xsd#sny_NumberOfSharesRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_NumberOfSharesRepurchased_d1963e44-2843-401c-9e29-c5e6dc11e069" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmountOfSharesRepurchased_0b0046ec-e01c-470f-b1af-5c4abc2d8f17" xlink:href="sny-20240630.xsd#sny_AmountOfSharesRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_AmountOfSharesRepurchased_0b0046ec-e01c-470f-b1af-5c4abc2d8f17" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubscriptionPricePerShare_1678c516-2fcf-45f5-97c9-e54fa4787530" xlink:href="sny-20240630.xsd#sny_SubscriptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_SubscriptionPricePerShare_1678c516-2fcf-45f5-97c9-e54fa4787530" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesSubscribed_28b69414-79da-4894-979e-84aacc472469" xlink:href="sny-20240630.xsd#sny_NumberOfSharesSubscribed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_NumberOfSharesSubscribed_28b69414-79da-4894-979e-84aacc472469" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_1be6bdc3-e23c-4ee8-a99e-aa5815113ed0" xlink:href="sny-20240630.xsd#sny_IssuanceOfFurtherSharesAsAnEmployersContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_1be6bdc3-e23c-4ee8-a99e-aa5815113ed0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_b7fe06e9-b4af-43ec-9a3c-de6fb7479772" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_b7fe06e9-b4af-43ec-9a3c-de6fb7479772" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_6c50910d-61bf-4c8f-92ad-8975d5db2351" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_6c50910d-61bf-4c8f-92ad-8975d5db2351" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_ad967ae6-4171-48cd-a62f-68d1a73e2a13" xlink:href="sny-20240630.xsd#sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_ad967ae6-4171-48cd-a62f-68d1a73e2a13" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_0094c4cd-cb13-49e3-80d5-472eba3bac77" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_0094c4cd-cb13-49e3-80d5-472eba3bac77" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b13a7f1f-7796-47f1-b3c5-d4fb1fa3801b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_83994e6f-6302-42a6-8094-7740fd8b0bbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b13a7f1f-7796-47f1-b3c5-d4fb1fa3801b" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_83994e6f-6302-42a6-8094-7740fd8b0bbc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_e56d5a62-138e-424e-84df-0d99fb8d8d99" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_83994e6f-6302-42a6-8094-7740fd8b0bbc" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_e56d5a62-138e-424e-84df-0d99fb8d8d99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_e56d5a62-138e-424e-84df-0d99fb8d8d99_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_e56d5a62-138e-424e-84df-0d99fb8d8d99" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_e56d5a62-138e-424e-84df-0d99fb8d8d99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_fe5321aa-8b43-49c9-9f6a-a1a5b9c7fbd5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_e56d5a62-138e-424e-84df-0d99fb8d8d99" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_fe5321aa-8b43-49c9-9f6a-a1a5b9c7fbd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023Member_9394a5d1-202c-4069-806b-9c4ea782a4f5" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_fe5321aa-8b43-49c9-9f6a-a1a5b9c7fbd5" xlink:to="loc_sny_RestrictedSharePlan2023Member_9394a5d1-202c-4069-806b-9c4ea782a4f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023AdditionalSharesMember_c7589d21-c686-4072-b9d8-406a3c3307e4" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2023AdditionalSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_fe5321aa-8b43-49c9-9f6a-a1a5b9c7fbd5" xlink:to="loc_sny_RestrictedSharePlan2023AdditionalSharesMember_c7589d21-c686-4072-b9d8-406a3c3307e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2024Member_34d11775-3d57-4414-8f07-6b39b72b437d" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_fe5321aa-8b43-49c9-9f6a-a1a5b9c7fbd5" xlink:to="loc_sny_RestrictedSharePlan2024Member_34d11775-3d57-4414-8f07-6b39b72b437d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2024AdditionalSharesMember_47ebe186-648c-4258-9d5e-b6ddcfc1a0c2" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2024AdditionalSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_fe5321aa-8b43-49c9-9f6a-a1a5b9c7fbd5" xlink:to="loc_sny_RestrictedSharePlan2024AdditionalSharesMember_47ebe186-648c-4258-9d5e-b6ddcfc1a0c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionAxis_c6e1e155-3eec-48ab-a3d8-4151a1f00ad8" xlink:href="sny-20240630.xsd#sny_MarketConditionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_83994e6f-6302-42a6-8094-7740fd8b0bbc" xlink:to="loc_sny_MarketConditionAxis_c6e1e155-3eec-48ab-a3d8-4151a1f00ad8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionDomain_c6e1e155-3eec-48ab-a3d8-4151a1f00ad8_default" xlink:href="sny-20240630.xsd#sny_MarketConditionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_MarketConditionAxis_c6e1e155-3eec-48ab-a3d8-4151a1f00ad8" xlink:to="loc_sny_MarketConditionDomain_c6e1e155-3eec-48ab-a3d8-4151a1f00ad8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionDomain_596b4c48-aa7e-456a-adbf-fa7a700ded16" xlink:href="sny-20240630.xsd#sny_MarketConditionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_MarketConditionAxis_c6e1e155-3eec-48ab-a3d8-4151a1f00ad8" xlink:to="loc_sny_MarketConditionDomain_596b4c48-aa7e-456a-adbf-fa7a700ded16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithoutMarketConditionMember_a009b99d-c623-444a-bf8b-05f51f79b960" xlink:href="sny-20240630.xsd#sny_WithoutMarketConditionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_MarketConditionDomain_596b4c48-aa7e-456a-adbf-fa7a700ded16" xlink:to="loc_sny_WithoutMarketConditionMember_a009b99d-c623-444a-bf8b-05f51f79b960" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithMarketConditionMember_ad58f0bc-2567-4c3b-89fd-cb6822c846dd" xlink:href="sny-20240630.xsd#sny_WithMarketConditionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_MarketConditionDomain_596b4c48-aa7e-456a-adbf-fa7a700ded16" xlink:to="loc_sny_WithMarketConditionMember_ad58f0bc-2567-4c3b-89fd-cb6822c846dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_11e61ce0-c65e-4058-8758-9ca192a4064f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_83994e6f-6302-42a6-8094-7740fd8b0bbc" xlink:to="loc_srt_TitleOfIndividualAxis_11e61ce0-c65e-4058-8758-9ca192a4064f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_11e61ce0-c65e-4058-8758-9ca192a4064f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_11e61ce0-c65e-4058-8758-9ca192a4064f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_11e61ce0-c65e-4058-8758-9ca192a4064f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ceba45a6-5b91-4098-a6f5-07b605d8f37a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_11e61ce0-c65e-4058-8758-9ca192a4064f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ceba45a6-5b91-4098-a6f5-07b605d8f37a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExcludingChiefExecutiveOfficerMember_384fd928-ca7f-4efe-9bb9-a811461b1feb" xlink:href="sny-20240630.xsd#sny_ExcludingChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ceba45a6-5b91-4098-a6f5-07b605d8f37a" xlink:to="loc_sny_ExcludingChiefExecutiveOfficerMember_384fd928-ca7f-4efe-9bb9-a811461b1feb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_1330d550-3977-4747-8c88-eda4199ed5c2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ceba45a6-5b91-4098-a6f5-07b605d8f37a" xlink:to="loc_srt_ChiefExecutiveOfficerMember_1330d550-3977-4747-8c88-eda4199ed5c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_67e5feb1-4b72-40a1-ac4d-efed4446b25f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b13a7f1f-7796-47f1-b3c5-d4fb1fa3801b" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_67e5feb1-4b72-40a1-ac4d-efed4446b25f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod_8c30a6ea-c067-46d7-8453-b722baf3a8a5" xlink:href="sny-20240630.xsd#sny_FairValuePerShareAwardedForThreeYearServicePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b13a7f1f-7796-47f1-b3c5-d4fb1fa3801b" xlink:to="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod_8c30a6ea-c067-46d7-8453-b722baf3a8a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfPlanAtDateOfGrant_23c36a38-3f1c-4298-85b3-4e3812b9c8d3" xlink:href="sny-20240630.xsd#sny_FairValueOfPlanAtDateOfGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b13a7f1f-7796-47f1-b3c5-d4fb1fa3801b" xlink:to="loc_sny_FairValueOfPlanAtDateOfGrant_23c36a38-3f1c-4298-85b3-4e3812b9c8d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfYearsServicePeriod_824179c4-31b9-477a-bdf8-5618b8911aba" xlink:href="sny-20240630.xsd#sny_NumberOfYearsServicePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b13a7f1f-7796-47f1-b3c5-d4fb1fa3801b" xlink:to="loc_sny_NumberOfYearsServicePeriod_824179c4-31b9-477a-bdf8-5618b8911aba" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4a9842fa-3aa7-451a-8281-d022b573af4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_83e85f1c-0f78-44f5-b6e6-5d74a01c6b4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4a9842fa-3aa7-451a-8281-d022b573af4a" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_83e85f1c-0f78-44f5-b6e6-5d74a01c6b4e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2b4c10fb-8d64-44d9-9dd2-21f4a4783858" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_83e85f1c-0f78-44f5-b6e6-5d74a01c6b4e" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2b4c10fb-8d64-44d9-9dd2-21f4a4783858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2b4c10fb-8d64-44d9-9dd2-21f4a4783858_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2b4c10fb-8d64-44d9-9dd2-21f4a4783858" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2b4c10fb-8d64-44d9-9dd2-21f4a4783858_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_30db1d9e-db8a-4bcc-8f66-e9bc82ed40dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2b4c10fb-8d64-44d9-9dd2-21f4a4783858" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_30db1d9e-db8a-4bcc-8f66-e9bc82ed40dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharesMember_401695ec-aa11-4705-9f03-e4f122ab96e5" xlink:href="sny-20240630.xsd#sny_RestrictedSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_30db1d9e-db8a-4bcc-8f66-e9bc82ed40dd" xlink:to="loc_sny_RestrictedSharesMember_401695ec-aa11-4705-9f03-e4f122ab96e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023Member_58646a73-d30d-4f97-a342-377388be36aa" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_RestrictedSharesMember_401695ec-aa11-4705-9f03-e4f122ab96e5" xlink:to="loc_sny_RestrictedSharePlan2023Member_58646a73-d30d-4f97-a342-377388be36aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2022Member_4bc58e53-697b-4d77-bb93-7edece859391" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_RestrictedSharesMember_401695ec-aa11-4705-9f03-e4f122ab96e5" xlink:to="loc_sny_RestrictedSharePlan2022Member_4bc58e53-697b-4d77-bb93-7edece859391" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2021Member_fd147525-f37b-46f5-b0c3-de6934f0fb0b" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_RestrictedSharesMember_401695ec-aa11-4705-9f03-e4f122ab96e5" xlink:to="loc_sny_RestrictedSharePlan2021Member_fd147525-f37b-46f5-b0c3-de6934f0fb0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2020Member_487f024f-e610-4bc2-942b-81b48740701d" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_RestrictedSharesMember_401695ec-aa11-4705-9f03-e4f122ab96e5" xlink:to="loc_sny_RestrictedSharePlan2020Member_487f024f-e610-4bc2-942b-81b48740701d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2024Member_60abf380-51bb-4f0c-be08-fee119b01cf5" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_30db1d9e-db8a-4bcc-8f66-e9bc82ed40dd" xlink:to="loc_sny_RestrictedSharePlan2024Member_60abf380-51bb-4f0c-be08-fee119b01cf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_51d249fe-2144-495c-9be0-60a0b24e9e70" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4a9842fa-3aa7-451a-8281-d022b573af4a" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_51d249fe-2144-495c-9be0-60a0b24e9e70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesNotYetFullyVested_b9cf00bf-837b-42bd-9492-124a84b646c6" xlink:href="sny-20240630.xsd#sny_NumberOfRestrictedSharesNotYetFullyVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4a9842fa-3aa7-451a-8281-d022b573af4a" xlink:to="loc_sny_NumberOfRestrictedSharesNotYetFullyVested_b9cf00bf-837b-42bd-9492-124a84b646c6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aab93865-6de6-495d-af98-ecbf3ab59722" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c1991f7f-f74c-49c3-a18f-f5d959e277d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aab93865-6de6-495d-af98-ecbf3ab59722" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c1991f7f-f74c-49c3-a18f-f5d959e277d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_f3f5c27a-8949-4d66-9926-b8bbe654dd9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c1991f7f-f74c-49c3-a18f-f5d959e277d7" xlink:to="loc_ifrs-full_RangeAxis_f3f5c27a-8949-4d66-9926-b8bbe654dd9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_f3f5c27a-8949-4d66-9926-b8bbe654dd9a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_f3f5c27a-8949-4d66-9926-b8bbe654dd9a" xlink:to="loc_ifrs-full_RangesMember_f3f5c27a-8949-4d66-9926-b8bbe654dd9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_fc57be7a-40ed-4852-9495-1264c00f72e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_f3f5c27a-8949-4d66-9926-b8bbe654dd9a" xlink:to="loc_ifrs-full_RangesMember_fc57be7a-40ed-4852-9495-1264c00f72e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_73c28137-c264-4dd8-a12a-150ea8d1e70b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_fc57be7a-40ed-4852-9495-1264c00f72e0" xlink:to="loc_ifrs-full_BottomOfRangeMember_73c28137-c264-4dd8-a12a-150ea8d1e70b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_17ba7eb1-231f-43ab-9f37-88577b8fc962" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_fc57be7a-40ed-4852-9495-1264c00f72e0" xlink:to="loc_ifrs-full_TopOfRangeMember_17ba7eb1-231f-43ab-9f37-88577b8fc962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_b1e62988-52a5-4717-9806-a595e7adc0da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c1991f7f-f74c-49c3-a18f-f5d959e277d7" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_b1e62988-52a5-4717-9806-a595e7adc0da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_b1e62988-52a5-4717-9806-a595e7adc0da_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_b1e62988-52a5-4717-9806-a595e7adc0da" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_b1e62988-52a5-4717-9806-a595e7adc0da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_02f993ed-ce75-42f3-9c87-fe51d3624b93" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_b1e62988-52a5-4717-9806-a595e7adc0da" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_02f993ed-ce75-42f3-9c87-fe51d3624b93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeTwoMember_fd00d37a-c083-4789-b0aa-71a10105213f" xlink:href="sny-20240630.xsd#sny_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_02f993ed-ce75-42f3-9c87-fe51d3624b93" xlink:to="loc_sny_ExercisePriceRangeTwoMember_fd00d37a-c083-4789-b0aa-71a10105213f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeThreeMember_2a04f960-646c-4e8b-af39-a7990e5eb2c3" xlink:href="sny-20240630.xsd#sny_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_02f993ed-ce75-42f3-9c87-fe51d3624b93" xlink:to="loc_sny_ExercisePriceRangeThreeMember_2a04f960-646c-4e8b-af39-a7990e5eb2c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeFourMember_778de72e-02b0-44b8-b507-2d0372e7d628" xlink:href="sny-20240630.xsd#sny_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_02f993ed-ce75-42f3-9c87-fe51d3624b93" xlink:to="loc_sny_ExercisePriceRangeFourMember_778de72e-02b0-44b8-b507-2d0372e7d628" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_c71e329a-0df7-4bff-be19-4d9b1ffac59b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c1991f7f-f74c-49c3-a18f-f5d959e277d7" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_c71e329a-0df7-4bff-be19-4d9b1ffac59b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_c71e329a-0df7-4bff-be19-4d9b1ffac59b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_c71e329a-0df7-4bff-be19-4d9b1ffac59b" xlink:to="loc_ifrs-full_EquityMember_c71e329a-0df7-4bff-be19-4d9b1ffac59b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_32fd4081-6433-46ab-a8ef-4193ed0ed855" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_c71e329a-0df7-4bff-be19-4d9b1ffac59b" xlink:to="loc_ifrs-full_EquityMember_32fd4081-6433-46ab-a8ef-4193ed0ed855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionPlanMember_dc498eb7-b02f-4906-83c8-30a9098fe308" xlink:href="sny-20240630.xsd#sny_StockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_32fd4081-6433-46ab-a8ef-4193ed0ed855" xlink:to="loc_sny_StockOptionPlanMember_dc498eb7-b02f-4906-83c8-30a9098fe308" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_77bb8745-677d-4a1d-9d8f-189548aae611" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aab93865-6de6-495d-af98-ecbf3ab59722" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_77bb8745-677d-4a1d-9d8f-189548aae611" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_f4af6bd2-c225-4f42-91c5-c6e7604ee484" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aab93865-6de6-495d-af98-ecbf3ab59722" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_f4af6bd2-c225-4f42-91c5-c6e7604ee484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_e47acd86-c8c6-477a-853b-39f6bc9dc6fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aab93865-6de6-495d-af98-ecbf3ab59722" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_e47acd86-c8c6-477a-853b-39f6bc9dc6fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_cff7f356-6d01-44ce-ae77-bc6423d81d3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aab93865-6de6-495d-af98-ecbf3ab59722" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_cff7f356-6d01-44ce-ae77-bc6423d81d3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_b18681ac-e048-4050-bc3a-2c5c50103b05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aab93865-6de6-495d-af98-ecbf3ab59722" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_b18681ac-e048-4050-bc3a-2c5c50103b05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_e0cef4d9-1c81-4f1d-a501-e9c05a35dbaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aab93865-6de6-495d-af98-ecbf3ab59722" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_e0cef4d9-1c81-4f1d-a501-e9c05a35dbaf" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_5a1912fa-4a35-4b65-8794-7060ef324c57" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_5a1912fa-4a35-4b65-8794-7060ef324c57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_caf85cd3-21d6-4ce4-b204-d3f8b6618392" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_5a1912fa-4a35-4b65-8794-7060ef324c57" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_caf85cd3-21d6-4ce4-b204-d3f8b6618392" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_caf85cd3-21d6-4ce4-b204-d3f8b6618392_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_caf85cd3-21d6-4ce4-b204-d3f8b6618392" xlink:to="loc_ifrs-full_EquityMember_caf85cd3-21d6-4ce4-b204-d3f8b6618392_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_36260e2c-a0bc-4553-8217-4eb1780ed5d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_caf85cd3-21d6-4ce4-b204-d3f8b6618392" xlink:to="loc_ifrs-full_EquityMember_36260e2c-a0bc-4553-8217-4eb1780ed5d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_a7892027-d609-49b2-a4e7-c40e29e6afa9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_36260e2c-a0bc-4553-8217-4eb1780ed5d7" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_a7892027-d609-49b2-a4e7-c40e29e6afa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsAxis_4d452a85-bf71-4ec2-8cfa-31493286b417" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_5a1912fa-4a35-4b65-8794-7060ef324c57" xlink:to="loc_ifrs-full_ReclassifiedItemsAxis_4d452a85-bf71-4ec2-8cfa-31493286b417" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsMember_4d452a85-bf71-4ec2-8cfa-31493286b417_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis_4d452a85-bf71-4ec2-8cfa-31493286b417" xlink:to="loc_ifrs-full_ReclassifiedItemsMember_4d452a85-bf71-4ec2-8cfa-31493286b417_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsMember_7052ab7d-e3a9-4039-ad39-130646024d81" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis_4d452a85-bf71-4ec2-8cfa-31493286b417" xlink:to="loc_ifrs-full_ReclassifiedItemsMember_7052ab7d-e3a9-4039-ad39-130646024d81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_ec675317-1144-48e0-a20e-8bd39982c3f2" xlink:href="sny-20240630.xsd#sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReclassifiedItemsMember_7052ab7d-e3a9-4039-ad39-130646024d81" xlink:to="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_ec675317-1144-48e0-a20e-8bd39982c3f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_2365f6e1-4ef3-4583-821a-0eeed991960e" xlink:href="sny-20240630.xsd#sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReclassifiedItemsMember_7052ab7d-e3a9-4039-ad39-130646024d81" xlink:to="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_2365f6e1-4ef3-4583-821a-0eeed991960e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1ceac5c5-a692-4c59-a8af-7c958e5baa23" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_5a1912fa-4a35-4b65-8794-7060ef324c57" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1ceac5c5-a692-4c59-a8af-7c958e5baa23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_1ceac5c5-a692-4c59-a8af-7c958e5baa23_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1ceac5c5-a692-4c59-a8af-7c958e5baa23" xlink:to="loc_ifrs-full_FinancialAssetsMember_1ceac5c5-a692-4c59-a8af-7c958e5baa23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_427456f3-0e9c-410e-af4f-554709bfd095" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1ceac5c5-a692-4c59-a8af-7c958e5baa23" xlink:to="loc_ifrs-full_FinancialAssetsMember_427456f3-0e9c-410e-af4f-554709bfd095" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInstrumentsIncludedInFinancialAssetsMember_dc39ecae-c9d8-491d-8da6-a608e034823a" xlink:href="sny-20240630.xsd#sny_EquityInstrumentsIncludedInFinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_427456f3-0e9c-410e-af4f-554709bfd095" xlink:to="loc_sny_EquityInstrumentsIncludedInFinancialAssetsMember_dc39ecae-c9d8-491d-8da6-a608e034823a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentsMember_ba533f48-06fc-4033-b9a4-88abf6ba4d61" xlink:href="sny-20240630.xsd#sny_DebtInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_427456f3-0e9c-410e-af4f-554709bfd095" xlink:to="loc_sny_DebtInstrumentsMember_ba533f48-06fc-4033-b9a4-88abf6ba4d61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowAndFairValueHedgeMember_d52a6afb-56eb-4ecb-b265-03488843605d" xlink:href="sny-20240630.xsd#sny_CashFlowAndFairValueHedgeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_427456f3-0e9c-410e-af4f-554709bfd095" xlink:to="loc_sny_CashFlowAndFairValueHedgeMember_d52a6afb-56eb-4ecb-b265-03488843605d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForeignCurrencyTranslationMember_beaf1caa-c1d0-4bd2-9c63-2c168ace8670" xlink:href="sny-20240630.xsd#sny_ForeignCurrencyTranslationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_427456f3-0e9c-410e-af4f-554709bfd095" xlink:to="loc_sny_ForeignCurrencyTranslationMember_beaf1caa-c1d0-4bd2-9c63-2c168ace8670" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_afa242f5-93d1-4a27-9ea5-39f60b07296f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_5a1912fa-4a35-4b65-8794-7060ef324c57" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_afa242f5-93d1-4a27-9ea5-39f60b07296f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_afa242f5-93d1-4a27-9ea5-39f60b07296f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_afa242f5-93d1-4a27-9ea5-39f60b07296f" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_afa242f5-93d1-4a27-9ea5-39f60b07296f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_802f2f71-0a7c-4c0a-8b9a-e1f800e632f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_afa242f5-93d1-4a27-9ea5-39f60b07296f" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_802f2f71-0a7c-4c0a-8b9a-e1f800e632f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_71b9761c-e352-4482-a036-5fb29ace881e" xlink:href="sny-20240630.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_802f2f71-0a7c-4c0a-8b9a-e1f800e632f4" xlink:to="loc_sny_EuroapiMember_71b9761c-e352-4482-a036-5fb29ace881e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_10e24b9b-a516-4325-91ce-ba5551cb83ed" xlink:href="sny-20240630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_10e24b9b-a516-4325-91ce-ba5551cb83ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_e85e4264-804f-40fe-ac1e-adac731c8464" xlink:href="sny-20240630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_e85e4264-804f-40fe-ac1e-adac731c8464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_0e4ead48-b2fa-4b9f-ad49-6b0980176de1" xlink:href="sny-20240630.xsd#sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_0e4ead48-b2fa-4b9f-ad49-6b0980176de1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_56fc1629-7331-479b-a430-d928a380d204" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_56fc1629-7331-479b-a430-d928a380d204" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_6d51a1db-cdd7-461d-89fc-badce9db606a" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_6d51a1db-cdd7-461d-89fc-badce9db606a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_df74c72f-de09-47e0-a453-778872b30eb3" xlink:href="sny-20240630.xsd#sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_df74c72f-de09-47e0-a453-778872b30eb3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_7832f0e2-39f3-41fe-98e1-103036f2eeb1" xlink:href="sny-20240630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_7832f0e2-39f3-41fe-98e1-103036f2eeb1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_fa96befc-55da-4e9e-95c3-cb9ce4f13cb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_fa96befc-55da-4e9e-95c3-cb9ce4f13cb2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_d236f9ef-c902-4ae5-8d3e-88c7e06036a8" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_d236f9ef-c902-4ae5-8d3e-88c7e06036a8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_0631e9aa-4993-4810-af81-3e582d4480b5" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_0631e9aa-4993-4810-af81-3e582d4480b5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_79fef6d1-64a0-4a8c-bcb4-efdefcf670fd" xlink:href="sny-20240630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_79fef6d1-64a0-4a8c-bcb4-efdefcf670fd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_69e1d4ac-ba2a-4855-8b43-a89b36ad36c8" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_69e1d4ac-ba2a-4855-8b43-a89b36ad36c8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_e8d0ca9a-a4ee-4c17-8fd0-a0b3484bd462" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_e8d0ca9a-a4ee-4c17-8fd0-a0b3484bd462" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_d62bc124-2efb-480d-bdac-0fd809db0644" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_d62bc124-2efb-480d-bdac-0fd809db0644" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_956670c7-81b5-4f26-aee2-80feedfd3215" xlink:href="sny-20240630.xsd#sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_956670c7-81b5-4f26-aee2-80feedfd3215" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_318bd66f-5315-4be4-8cec-e1ef0f5794b5" xlink:href="sny-20240630.xsd#sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_318bd66f-5315-4be4-8cec-e1ef0f5794b5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_c91fd476-8357-4f42-884d-44a0a1f03e5d" xlink:href="sny-20240630.xsd#sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_c91fd476-8357-4f42-884d-44a0a1f03e5d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_95d183cf-e87a-4579-b486-8c6ce45aaac2" xlink:href="sny-20240630.xsd#sny_ChangeInCurrencyTranslationOnTaxEffects"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_95d183cf-e87a-4579-b486-8c6ce45aaac2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_54d2e5d4-1d7e-43b6-84d3-012f2fa0913f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_54d2e5d4-1d7e-43b6-84d3-012f2fa0913f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_4849bbb8-6536-4c8f-9b15-8495b71f52e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_4849bbb8-6536-4c8f-9b15-8495b71f52e5" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_9179aaca-48e5-4e7a-ab4b-66c83332474f" xlink:href="sny-20240630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_cd92c9d5-f165-4d5a-ae05-dfe33c7db25a" xlink:href="sny-20240630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_9179aaca-48e5-4e7a-ab4b-66c83332474f" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_cd92c9d5-f165-4d5a-ae05-dfe33c7db25a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_4e9a48cd-cb45-4062-a4b8-9abbc15d04ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_cd92c9d5-f165-4d5a-ae05-dfe33c7db25a" xlink:to="loc_ifrs-full_MeasurementAxis_4e9a48cd-cb45-4062-a4b8-9abbc15d04ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_4e9a48cd-cb45-4062-a4b8-9abbc15d04ee_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_4e9a48cd-cb45-4062-a4b8-9abbc15d04ee" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_4e9a48cd-cb45-4062-a4b8-9abbc15d04ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_ac627650-ccaf-4a66-9040-0252fb17e1e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_4e9a48cd-cb45-4062-a4b8-9abbc15d04ee" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_ac627650-ccaf-4a66-9040-0252fb17e1e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizedCostNettingMember_d8ca5727-ec40-49c7-b4d9-e079b74a0f63" xlink:href="sny-20240630.xsd#sny_AmortizedCostNettingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_ac627650-ccaf-4a66-9040-0252fb17e1e3" xlink:to="loc_sny_AmortizedCostNettingMember_d8ca5727-ec40-49c7-b4d9-e079b74a0f63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember_135e1ef6-da5b-4227-bba2-de256368b33e" xlink:href="sny-20240630.xsd#sny_AdjustmentToDebtMeasuredAtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_ac627650-ccaf-4a66-9040-0252fb17e1e3" xlink:to="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember_135e1ef6-da5b-4227-bba2-de256368b33e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_e4ba4839-76fc-4915-b2a9-b5b39217b47a" xlink:href="sny-20240630.xsd#sny_ValueOnRedemptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_ac627650-ccaf-4a66-9040-0252fb17e1e3" xlink:to="loc_sny_ValueOnRedemptionMember_e4ba4839-76fc-4915-b2a9-b5b39217b47a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_ee9f3f6e-1c0e-46d5-9902-33f8e44e4f1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_9179aaca-48e5-4e7a-ab4b-66c83332474f" xlink:to="loc_ifrs-full_LongtermBorrowings_ee9f3f6e-1c0e-46d5-9902-33f8e44e4f1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_733eda23-d1e3-4605-b626-ebb23517b241" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_9179aaca-48e5-4e7a-ab4b-66c83332474f" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_733eda23-d1e3-4605-b626-ebb23517b241" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_37871f20-8beb-4bef-889a-e1f300d5fb0a" xlink:href="sny-20240630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_9179aaca-48e5-4e7a-ab4b-66c83332474f" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_37871f20-8beb-4bef-889a-e1f300d5fb0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_b25a1f67-7a42-42c7-9aa5-fdcb31cae580" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_9179aaca-48e5-4e7a-ab4b-66c83332474f" xlink:to="loc_ifrs-full_Borrowings_b25a1f67-7a42-42c7-9aa5-fdcb31cae580" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_225b514c-d3a6-4fa0-af7b-f6e2ec3d257f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_9179aaca-48e5-4e7a-ab4b-66c83332474f" xlink:to="loc_ifrs-full_CashAndCashEquivalents_225b514c-d3a6-4fa0-af7b-f6e2ec3d257f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_5f14e9c7-db9f-48c8-950e-62a42d4aa975" xlink:href="sny-20240630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_9179aaca-48e5-4e7a-ab4b-66c83332474f" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_5f14e9c7-db9f-48c8-950e-62a42d4aa975" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_51156af0-87ba-4b24-a462-f922119548db" xlink:href="sny-20240630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_9179aaca-48e5-4e7a-ab4b-66c83332474f" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_51156af0-87ba-4b24-a462-f922119548db" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_c79451cf-2f96-4548-8893-fcee8a868adb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_9179aaca-48e5-4e7a-ab4b-66c83332474f" xlink:to="loc_ifrs-full_LeaseLiabilities_c79451cf-2f96-4548-8893-fcee8a868adb" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:href="sny-20240630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_8ee17277-7b5f-48af-89ac-6209bd4f5eec" xlink:href="sny-20240630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_8ee17277-7b5f-48af-89ac-6209bd4f5eec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_d349d0c1-8c50-4790-8ee1-c65f88aef71b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_8ee17277-7b5f-48af-89ac-6209bd4f5eec" xlink:to="loc_ifrs-full_MeasurementAxis_d349d0c1-8c50-4790-8ee1-c65f88aef71b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_d349d0c1-8c50-4790-8ee1-c65f88aef71b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_d349d0c1-8c50-4790-8ee1-c65f88aef71b" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_d349d0c1-8c50-4790-8ee1-c65f88aef71b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_75f6da7c-2a57-4fcc-bcf6-e6f4f49ba119" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_d349d0c1-8c50-4790-8ee1-c65f88aef71b" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_75f6da7c-2a57-4fcc-bcf6-e6f4f49ba119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_1151a0fe-645d-4488-8b8f-d16d761887ce" xlink:href="sny-20240630.xsd#sny_ValueOnRedemptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_75f6da7c-2a57-4fcc-bcf6-e6f4f49ba119" xlink:to="loc_sny_ValueOnRedemptionMember_1151a0fe-645d-4488-8b8f-d16d761887ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis_28140fb5-fcd3-45ec-8fbc-b3baae28ec44" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAndLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_8ee17277-7b5f-48af-89ac-6209bd4f5eec" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesAxis_28140fb5-fcd3-45ec-8fbc-b3baae28ec44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_28140fb5-fcd3-45ec-8fbc-b3baae28ec44_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAndLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_28140fb5-fcd3-45ec-8fbc-b3baae28ec44" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_28140fb5-fcd3-45ec-8fbc-b3baae28ec44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_582daedc-a9b5-49b3-9319-ffe440f3ceed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAndLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_28140fb5-fcd3-45ec-8fbc-b3baae28ec44" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_582daedc-a9b5-49b3-9319-ffe440f3ceed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesMember_e09bcbe0-79bc-4fdb-b48c-a9ac1000e742" xlink:href="sny-20240630.xsd#sny_NonCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_582daedc-a9b5-49b3-9319-ffe440f3ceed" xlink:to="loc_sny_NonCurrentLiabilitiesMember_e09bcbe0-79bc-4fdb-b48c-a9ac1000e742" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesMember_8dccdaff-bfd3-4517-8343-8e7309bd659c" xlink:href="sny-20240630.xsd#sny_CurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_582daedc-a9b5-49b3-9319-ffe440f3ceed" xlink:to="loc_sny_CurrentLiabilitiesMember_8dccdaff-bfd3-4517-8343-8e7309bd659c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_f4799290-32dd-4799-94f7-fbf9e69c20b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_8ee17277-7b5f-48af-89ac-6209bd4f5eec" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_f4799290-32dd-4799-94f7-fbf9e69c20b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_f4799290-32dd-4799-94f7-fbf9e69c20b3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_f4799290-32dd-4799-94f7-fbf9e69c20b3" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_f4799290-32dd-4799-94f7-fbf9e69c20b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_73cf05e3-b7e2-4728-8548-9b264d2ed9d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_f4799290-32dd-4799-94f7-fbf9e69c20b3" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_73cf05e3-b7e2-4728-8548-9b264d2ed9d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsMember_8040f6bd-8682-4935-8fd1-4c4bf6306e1b" xlink:href="sny-20240630.xsd#sny_NonCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_73cf05e3-b7e2-4728-8548-9b264d2ed9d0" xlink:to="loc_sny_NonCurrentAssetsMember_8040f6bd-8682-4935-8fd1-4c4bf6306e1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentAssetsMember_6516d4a7-8828-43a0-a09a-908ae574f8d0" xlink:href="sny-20240630.xsd#sny_CurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_73cf05e3-b7e2-4728-8548-9b264d2ed9d0" xlink:to="loc_sny_CurrentAssetsMember_6516d4a7-8828-43a0-a09a-908ae574f8d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_4e86206d-eaaa-4e65-bc61-618aea2ecb4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_8ee17277-7b5f-48af-89ac-6209bd4f5eec" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_4e86206d-eaaa-4e65-bc61-618aea2ecb4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_4e86206d-eaaa-4e65-bc61-618aea2ecb4b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_4e86206d-eaaa-4e65-bc61-618aea2ecb4b" xlink:to="loc_ifrs-full_BorrowingsByNameMember_4e86206d-eaaa-4e65-bc61-618aea2ecb4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_b7a14cb7-5ab1-411f-9f3b-bfce9b1a0c86" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_4e86206d-eaaa-4e65-bc61-618aea2ecb4b" xlink:to="loc_ifrs-full_BorrowingsByNameMember_b7a14cb7-5ab1-411f-9f3b-bfce9b1a0c86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_7a971f45-8e49-4d88-8fc9-58fba675c0eb" xlink:href="sny-20240630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_b7a14cb7-5ab1-411f-9f3b-bfce9b1a0c86" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_7a971f45-8e49-4d88-8fc9-58fba675c0eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInFranceMember_5d0bab8a-75f6-4f04-872f-7cb638c9a4ef" xlink:href="sny-20240630.xsd#sny_CommercialPaperProgramInFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_b7a14cb7-5ab1-411f-9f3b-bfce9b1a0c86" xlink:to="loc_sny_CommercialPaperProgramInFranceMember_5d0bab8a-75f6-4f04-872f-7cb638c9a4ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_a4c12ae0-6217-41b9-97c3-1f02a857c87b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BondsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:to="loc_ifrs-full_BondsIssued_a4c12ae0-6217-41b9-97c3-1f02a857c87b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherBankBorrowings_6317f69e-edd4-4ea3-9f0a-71730a4ecd2f" xlink:href="sny-20240630.xsd#sny_OtherBankBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:to="loc_sny_OtherBankBorrowings_6317f69e-edd4-4ea3-9f0a-71730a4ecd2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings_78ff410f-2e3a-48a6-991f-29be0ef897d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:to="loc_ifrs-full_OtherBorrowings_78ff410f-2e3a-48a6-991f-29be0ef897d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_8e884525-1b4e-4db0-87db-8ad2d968beb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:to="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_8e884525-1b4e-4db0-87db-8ad2d968beb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_32a95c16-2591-46f7-959a-f48dad78a7db" xlink:href="sny-20240630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_32a95c16-2591-46f7-959a-f48dad78a7db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_1d14709b-c1f5-41cf-bfa6-e86a9af31a26" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:to="loc_ifrs-full_Borrowings_1d14709b-c1f5-41cf-bfa6-e86a9af31a26" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_eafb14d1-951c-4669-9f53-034d8ea0fc0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:to="loc_ifrs-full_CashAndCashEquivalents_eafb14d1-951c-4669-9f53-034d8ea0fc0f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_b07be86e-9638-4a8e-bc7f-3857fff0d63a" xlink:href="sny-20240630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_b07be86e-9638-4a8e-bc7f-3857fff0d63a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_8b8fdd5c-bc65-4df1-aadd-e8df10452db3" xlink:href="sny-20240630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_8b8fdd5c-bc65-4df1-aadd-e8df10452db3" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#DebtCashandCashEquivalentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_dcd2c805-28aa-4007-918f-3cb2b4426bf0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_fc16b61a-cb53-4819-8e1d-6a58c3a67406" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_dcd2c805-28aa-4007-918f-3cb2b4426bf0" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_fc16b61a-cb53-4819-8e1d-6a58c3a67406" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_5458e012-7dd7-4220-97b5-dd61a9c61dc5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_fc16b61a-cb53-4819-8e1d-6a58c3a67406" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_5458e012-7dd7-4220-97b5-dd61a9c61dc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_5458e012-7dd7-4220-97b5-dd61a9c61dc5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_5458e012-7dd7-4220-97b5-dd61a9c61dc5" xlink:to="loc_ifrs-full_BorrowingsByNameMember_5458e012-7dd7-4220-97b5-dd61a9c61dc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_4a970488-f280-41a2-8543-18e038138270" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_5458e012-7dd7-4220-97b5-dd61a9c61dc5" xlink:to="loc_ifrs-full_BorrowingsByNameMember_4a970488-f280-41a2-8543-18e038138270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_72fb34aa-4742-4abb-b959-99e104d6e230" xlink:href="sny-20240630.xsd#sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4a970488-f280-41a2-8543-18e038138270" xlink:to="loc_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_72fb34aa-4742-4abb-b959-99e104d6e230" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionBondsMaturingJune2023Member_2818665f-676a-44e0-8801-d62d4173c2f2" xlink:href="sny-20240630.xsd#sny_OneBillionBondsMaturingJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4a970488-f280-41a2-8543-18e038138270" xlink:to="loc_sny_OneBillionBondsMaturingJune2023Member_2818665f-676a-44e0-8801-d62d4173c2f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityOneMember_736e5bc6-a073-4c30-b13c-a1bd35655ec3" xlink:href="sny-20240630.xsd#sny_SyndicatedCreditFacilityOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4a970488-f280-41a2-8543-18e038138270" xlink:to="loc_sny_SyndicatedCreditFacilityOneMember_736e5bc6-a073-4c30-b13c-a1bd35655ec3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityTwoMember_239c13af-2c33-4d3e-b0a0-0a640edb0a43" xlink:href="sny-20240630.xsd#sny_SyndicatedCreditFacilityTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4a970488-f280-41a2-8543-18e038138270" xlink:to="loc_sny_SyndicatedCreditFacilityTwoMember_239c13af-2c33-4d3e-b0a0-0a640edb0a43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityCanceledMember_fe32670c-390d-42e8-b289-d4f4ff5636ac" xlink:href="sny-20240630.xsd#sny_SyndicatedCreditFacilityCanceledMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4a970488-f280-41a2-8543-18e038138270" xlink:to="loc_sny_SyndicatedCreditFacilityCanceledMember_fe32670c-390d-42e8-b289-d4f4ff5636ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInFranceMember_c14a7960-2373-41c1-96df-07216d2432c5" xlink:href="sny-20240630.xsd#sny_CommercialPaperProgramInFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4a970488-f280-41a2-8543-18e038138270" xlink:to="loc_sny_CommercialPaperProgramInFranceMember_c14a7960-2373-41c1-96df-07216d2432c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_206067c1-9b97-4f56-bae7-654419a8a48b" xlink:href="sny-20240630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4a970488-f280-41a2-8543-18e038138270" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_206067c1-9b97-4f56-bae7-654419a8a48b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingApril2024Redeemed2024Member_4194aee8-6a3f-40a7-89cb-d0c88182a5c6" xlink:href="sny-20240630.xsd#sny_FixedRateBondMaturingApril2024Redeemed2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4a970488-f280-41a2-8543-18e038138270" xlink:to="loc_sny_FixedRateBondMaturingApril2024Redeemed2024Member_4194aee8-6a3f-40a7-89cb-d0c88182a5c6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentAxis_24c616a5-5997-45c3-8458-a9c56dd116bc" xlink:href="sny-20240630.xsd#sny_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_fc16b61a-cb53-4819-8e1d-6a58c3a67406" xlink:to="loc_sny_DebtInstrumentAxis_24c616a5-5997-45c3-8458-a9c56dd116bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain_24c616a5-5997-45c3-8458-a9c56dd116bc_default" xlink:href="sny-20240630.xsd#sny_DebtInstrumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_DebtInstrumentAxis_24c616a5-5997-45c3-8458-a9c56dd116bc" xlink:to="loc_sny_DebtInstrumentDomain_24c616a5-5997-45c3-8458-a9c56dd116bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain_b90a9eec-099a-46e0-858a-0dc66922276d" xlink:href="sny-20240630.xsd#sny_DebtInstrumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_DebtInstrumentAxis_24c616a5-5997-45c3-8458-a9c56dd116bc" xlink:to="loc_sny_DebtInstrumentDomain_b90a9eec-099a-46e0-858a-0dc66922276d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiEuroMediumTermNotesMember_066fcc35-294a-4b44-9887-8edf2662dd82" xlink:href="sny-20240630.xsd#sny_SanofiEuroMediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DebtInstrumentDomain_b90a9eec-099a-46e0-858a-0dc66922276d" xlink:to="loc_sny_SanofiEuroMediumTermNotesMember_066fcc35-294a-4b44-9887-8edf2662dd82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingApril2024Redeemed2024Member_6e79e1f5-e264-45e1-a302-273b7b06b988" xlink:href="sny-20240630.xsd#sny_FixedRateBondMaturingApril2024Redeemed2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DebtInstrumentDomain_b90a9eec-099a-46e0-858a-0dc66922276d" xlink:to="loc_sny_FixedRateBondMaturingApril2024Redeemed2024Member_6e79e1f5-e264-45e1-a302-273b7b06b988" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_65017fb8-21e0-4046-a84d-cfc4c811d91d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_fc16b61a-cb53-4819-8e1d-6a58c3a67406" xlink:to="loc_ifrs-full_CounterpartiesAxis_65017fb8-21e0-4046-a84d-cfc4c811d91d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_65017fb8-21e0-4046-a84d-cfc4c811d91d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_65017fb8-21e0-4046-a84d-cfc4c811d91d" xlink:to="loc_ifrs-full_CounterpartiesMember_65017fb8-21e0-4046-a84d-cfc4c811d91d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_2712e95b-b57a-446a-b2d7-ca9dd1d45154" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_65017fb8-21e0-4046-a84d-cfc4c811d91d" xlink:to="loc_ifrs-full_CounterpartiesMember_2712e95b-b57a-446a-b2d7-ca9dd1d45154" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MazeTherapeuticsMember_67c5158b-34a1-44d8-8efe-7a749e933e82" xlink:href="sny-20240630.xsd#sny_MazeTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_2712e95b-b57a-446a-b2d7-ca9dd1d45154" xlink:to="loc_sny_MazeTherapeuticsMember_67c5158b-34a1-44d8-8efe-7a749e933e82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfBondIssuesRedeemed_c3c3f4d9-513e-4547-8c7f-61500ae82e6f" xlink:href="sny-20240630.xsd#sny_NumberOfBondIssuesRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_dcd2c805-28aa-4007-918f-3cb2b4426bf0" xlink:to="loc_sny_NumberOfBondIssuesRedeemed_c3c3f4d9-513e-4547-8c7f-61500ae82e6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_6b91249a-f588-4031-9b02-88151886e3ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_dcd2c805-28aa-4007-918f-3cb2b4426bf0" xlink:to="loc_ifrs-full_NotionalAmount_6b91249a-f588-4031-9b02-88151886e3ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CreditFacilitiesExtensionOptionNumber_d1de0152-32f0-48ec-8963-d980627e61ba" xlink:href="sny-20240630.xsd#sny_CreditFacilitiesExtensionOptionNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_dcd2c805-28aa-4007-918f-3cb2b4426bf0" xlink:to="loc_sny_CreditFacilitiesExtensionOptionNumber_d1de0152-32f0-48ec-8963-d980627e61ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CreditFacilitiesExtensionOptionPeriod_a7ca89db-80b8-4472-b836-759d939a76fd" xlink:href="sny-20240630.xsd#sny_CreditFacilitiesExtensionOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_dcd2c805-28aa-4007-918f-3cb2b4426bf0" xlink:to="loc_sny_CreditFacilitiesExtensionOptionPeriod_a7ca89db-80b8-4472-b836-759d939a76fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommercialPapersIssued_171156b5-6438-4576-97d8-3eef778c307a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommercialPapersIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_dcd2c805-28aa-4007-918f-3cb2b4426bf0" xlink:to="loc_ifrs-full_CommercialPapersIssued_171156b5-6438-4576-97d8-3eef778c307a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BorrowingAverageDrawdown_7f8e8388-1253-4e05-9193-2e0dc9d44577" xlink:href="sny-20240630.xsd#sny_BorrowingAverageDrawdown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_dcd2c805-28aa-4007-918f-3cb2b4426bf0" xlink:to="loc_sny_BorrowingAverageDrawdown_7f8e8388-1253-4e05-9193-2e0dc9d44577" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPayments_21f7e995-fd55-4295-9f41-d0411e6e98d7" xlink:href="sny-20240630.xsd#sny_UpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_dcd2c805-28aa-4007-918f-3cb2b4426bf0" xlink:to="loc_sny_UpfrontPayments_21f7e995-fd55-4295-9f41-d0411e6e98d7" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_796a8624-d35a-4e6d-9e70-08e267677d31" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_99922072-14f9-4854-870f-2906d906c6fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_796a8624-d35a-4e6d-9e70-08e267677d31" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_99922072-14f9-4854-870f-2906d906c6fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_dafbfa8a-8e0e-4fca-b4db-3e576a7f8879" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_99922072-14f9-4854-870f-2906d906c6fa" xlink:to="loc_ifrs-full_MeasurementAxis_dafbfa8a-8e0e-4fca-b4db-3e576a7f8879" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_dafbfa8a-8e0e-4fca-b4db-3e576a7f8879_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_dafbfa8a-8e0e-4fca-b4db-3e576a7f8879" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_dafbfa8a-8e0e-4fca-b4db-3e576a7f8879_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_622f614d-c3c4-423d-9234-af7d04e207ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_dafbfa8a-8e0e-4fca-b4db-3e576a7f8879" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_622f614d-c3c4-423d-9234-af7d04e207ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtMarketValueMember_78eaaa13-8277-4f27-a953-d381e0b99c2b" xlink:href="sny-20240630.xsd#sny_AtMarketValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_622f614d-c3c4-423d-9234-af7d04e207ca" xlink:to="loc_sny_AtMarketValueMember_78eaaa13-8277-4f27-a953-d381e0b99c2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_eb86d9c0-1152-4f47-a64d-39930343b43a" xlink:href="sny-20240630.xsd#sny_ValueOnRedemptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_622f614d-c3c4-423d-9234-af7d04e207ca" xlink:to="loc_sny_ValueOnRedemptionMember_eb86d9c0-1152-4f47-a64d-39930343b43a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_fcd22edf-be8a-4a7f-8660-641299c31545" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_796a8624-d35a-4e6d-9e70-08e267677d31" xlink:to="loc_ifrs-full_Borrowings_fcd22edf-be8a-4a7f-8660-641299c31545" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RedemptionOfDebtInstrumentIssued_b26e7c3a-a2bf-4d1a-b295-1c5982f2f590" xlink:href="sny-20240630.xsd#sny_RedemptionOfDebtInstrumentIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_796a8624-d35a-4e6d-9e70-08e267677d31" xlink:to="loc_sny_RedemptionOfDebtInstrumentIssued_b26e7c3a-a2bf-4d1a-b295-1c5982f2f590" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_aaaff834-b1fa-4658-963f-32629c27af0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_15de73d8-9a51-4253-a42c-091f97d78f53" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_aaaff834-b1fa-4658-963f-32629c27af0f" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_15de73d8-9a51-4253-a42c-091f97d78f53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_d91649a5-157f-46bb-8b7f-383830b86a95" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_15de73d8-9a51-4253-a42c-091f97d78f53" xlink:to="loc_ifrs-full_MeasurementAxis_d91649a5-157f-46bb-8b7f-383830b86a95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_d91649a5-157f-46bb-8b7f-383830b86a95_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_d91649a5-157f-46bb-8b7f-383830b86a95" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_d91649a5-157f-46bb-8b7f-383830b86a95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_19737a9a-8ec9-442c-a0bd-31bcd54b9a35" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_d91649a5-157f-46bb-8b7f-383830b86a95" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_19737a9a-8ec9-442c-a0bd-31bcd54b9a35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_1c1a13dc-ce54-4624-a243-0b3f99de5973" xlink:href="sny-20240630.xsd#sny_AtNotionalAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_19737a9a-8ec9-442c-a0bd-31bcd54b9a35" xlink:to="loc_sny_AtNotionalAmountMember_1c1a13dc-ce54-4624-a243-0b3f99de5973" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_ae87eb9f-91a7-4859-b444-8b80a383f6a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_19737a9a-8ec9-442c-a0bd-31bcd54b9a35" xlink:to="loc_ifrs-full_AtFairValueMember_ae87eb9f-91a7-4859-b444-8b80a383f6a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfHedgeRecognizedInEquityMember_67b94591-0e1f-4005-a075-ce7e235f7346" xlink:href="sny-20240630.xsd#sny_ValueOfHedgeRecognizedInEquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AtFairValueMember_ae87eb9f-91a7-4859-b444-8b80a383f6a1" xlink:to="loc_sny_ValueOfHedgeRecognizedInEquityMember_67b94591-0e1f-4005-a075-ce7e235f7346" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_74e9a762-9a0e-4210-bf6f-bc0fd982d9ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_15de73d8-9a51-4253-a42c-091f97d78f53" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_74e9a762-9a0e-4210-bf6f-bc0fd982d9ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesMember_74e9a762-9a0e-4210-bf6f-bc0fd982d9ec_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_74e9a762-9a0e-4210-bf6f-bc0fd982d9ec" xlink:to="loc_ifrs-full_TypesOfHedgesMember_74e9a762-9a0e-4210-bf6f-bc0fd982d9ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesMember_49d9d3ff-5501-41c1-9b3a-c22099704fa2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_74e9a762-9a0e-4210-bf6f-bc0fd982d9ec" xlink:to="loc_ifrs-full_TypesOfHedgesMember_49d9d3ff-5501-41c1-9b3a-c22099704fa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowHedgesMember_d2d9ffae-a573-408c-9228-6697e94af9a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesMember_49d9d3ff-5501-41c1-9b3a-c22099704fa2" xlink:to="loc_ifrs-full_CashFlowHedgesMember_d2d9ffae-a573-408c-9228-6697e94af9a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NotEligibleForHedgeAccountingMember_64bee025-551d-4f2a-b3ff-40db2ac8673b" xlink:href="sny-20240630.xsd#sny_NotEligibleForHedgeAccountingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesMember_49d9d3ff-5501-41c1-9b3a-c22099704fa2" xlink:to="loc_sny_NotEligibleForHedgeAccountingMember_64bee025-551d-4f2a-b3ff-40db2ac8673b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_3efd7a74-2273-471f-be1a-62131232680a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_15de73d8-9a51-4253-a42c-091f97d78f53" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_3efd7a74-2273-471f-be1a-62131232680a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_3efd7a74-2273-471f-be1a-62131232680a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_3efd7a74-2273-471f-be1a-62131232680a" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_3efd7a74-2273-471f-be1a-62131232680a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_d4f66589-d70e-4c5d-b6a7-48b6107be7e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_3efd7a74-2273-471f-be1a-62131232680a" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_d4f66589-d70e-4c5d-b6a7-48b6107be7e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesMember_5cef69ea-cacc-4b3c-bf1b-325e3bfddc14" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_d4f66589-d70e-4c5d-b6a7-48b6107be7e7" xlink:to="loc_sny_ForwardCurrencySalesMember_5cef69ea-cacc-4b3c-bf1b-325e3bfddc14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarMember_5976119d-c634-4b18-9446-a04fdec461cf" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_5cef69ea-cacc-4b3c-bf1b-325e3bfddc14" xlink:to="loc_sny_ForwardCurrencySalesInUSDollarMember_5976119d-c634-4b18-9446-a04fdec461cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_dd12c69a-1fd4-4a7b-b8a4-03c9684e824c" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInChineseYuanRenminbiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_5cef69ea-cacc-4b3c-bf1b-325e3bfddc14" xlink:to="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_dd12c69a-1fd4-4a7b-b8a4-03c9684e824c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInJapaneseYenMember_6328771f-cbe1-4e7f-b72c-cf2c20d76438" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInJapaneseYenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_5cef69ea-cacc-4b3c-bf1b-325e3bfddc14" xlink:to="loc_sny_ForwardCurrencySalesInJapaneseYenMember_6328771f-cbe1-4e7f-b72c-cf2c20d76438" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInMexicanPesoMember_8c9ec318-d74a-445f-a042-f7b5f2fe1438" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInMexicanPesoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_5cef69ea-cacc-4b3c-bf1b-325e3bfddc14" xlink:to="loc_sny_ForwardCurrencySalesInMexicanPesoMember_8c9ec318-d74a-445f-a042-f7b5f2fe1438" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_aa033aef-f3fd-4c0f-8cc9-7890b35b7d0e" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInSingaporeDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_5cef69ea-cacc-4b3c-bf1b-325e3bfddc14" xlink:to="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_aa033aef-f3fd-4c0f-8cc9-7890b35b7d0e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesMember_60211734-a120-44d4-a2c9-44724dfba86c" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_d4f66589-d70e-4c5d-b6a7-48b6107be7e7" xlink:to="loc_sny_ForwardCurrencyPurchasesMember_60211734-a120-44d4-a2c9-44724dfba86c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_da7b339e-25c3-4d7c-aaad-7076e2f46e09" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_60211734-a120-44d4-a2c9-44724dfba86c" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_da7b339e-25c3-4d7c-aaad-7076e2f46e09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_38e0c56a-09ac-4d7e-b6a4-55cd6f0f29a1" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInSingaporeDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_60211734-a120-44d4-a2c9-44724dfba86c" xlink:to="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_38e0c56a-09ac-4d7e-b6a4-55cd6f0f29a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInCanadianDollarMember_e10dee8b-e46b-4ee8-a586-23a71b501517" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInCanadianDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_60211734-a120-44d4-a2c9-44724dfba86c" xlink:to="loc_sny_ForwardCurrencyPurchasesInCanadianDollarMember_e10dee8b-e46b-4ee8-a586-23a71b501517" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInKoreanWonMember_80931853-1721-418b-a458-075df72919bf" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInKoreanWonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_60211734-a120-44d4-a2c9-44724dfba86c" xlink:to="loc_sny_ForwardCurrencyPurchasesInKoreanWonMember_80931853-1721-418b-a458-075df72919bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_1a5e5378-9e4f-4128-a963-6e4e879945ed" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_60211734-a120-44d4-a2c9-44724dfba86c" xlink:to="loc_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_1a5e5378-9e4f-4128-a963-6e4e879945ed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInRussianRoubleMember_06d7ae16-113c-4c56-854e-25b3e43fcfe5" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInRussianRoubleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_d4f66589-d70e-4c5d-b6a7-48b6107be7e7" xlink:to="loc_sny_ForwardCurrencySalesInRussianRoubleMember_06d7ae16-113c-4c56-854e-25b3e43fcfe5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInTurkishLiraMember_1d06a4c3-4465-4d75-9a41-8c1d75ab5931" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInTurkishLiraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_d4f66589-d70e-4c5d-b6a7-48b6107be7e7" xlink:to="loc_sny_ForwardCurrencyPurchasesInTurkishLiraMember_1d06a4c3-4465-4d75-9a41-8c1d75ab5931" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInRussianRoubleMember_31865908-3adf-4934-85d8-89e0e42b5037" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInRussianRoubleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_d4f66589-d70e-4c5d-b6a7-48b6107be7e7" xlink:to="loc_sny_ForwardCurrencyPurchasesInRussianRoubleMember_31865908-3adf-4934-85d8-89e0e42b5037" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstruments_07fd5937-0502-4262-872e-0e2670f3ee58" xlink:href="sny-20240630.xsd#sny_DerivativeFinancialInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_aaaff834-b1fa-4658-963f-32629c27af0f" xlink:to="loc_sny_DerivativeFinancialInstruments_07fd5937-0502-4262-872e-0e2670f3ee58" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_eb743dbd-8545-4b97-8b73-71947ef51982" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_9975b939-aef3-4fb3-b4a1-deeac47e88e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_eb743dbd-8545-4b97-8b73-71947ef51982" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_9975b939-aef3-4fb3-b4a1-deeac47e88e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_34fff19a-fe63-43bd-91f3-f6e47a1c8224" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_9975b939-aef3-4fb3-b4a1-deeac47e88e8" xlink:to="loc_ifrs-full_MeasurementAxis_34fff19a-fe63-43bd-91f3-f6e47a1c8224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_34fff19a-fe63-43bd-91f3-f6e47a1c8224_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_34fff19a-fe63-43bd-91f3-f6e47a1c8224" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_34fff19a-fe63-43bd-91f3-f6e47a1c8224_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_9f51a6a3-ad3e-4a1d-9864-74d181bb81f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_34fff19a-fe63-43bd-91f3-f6e47a1c8224" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_9f51a6a3-ad3e-4a1d-9864-74d181bb81f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_92db833b-68a7-42e1-8e1c-ac06af58d594" xlink:href="sny-20240630.xsd#sny_AtNotionalAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_9f51a6a3-ad3e-4a1d-9864-74d181bb81f6" xlink:to="loc_sny_AtNotionalAmountMember_92db833b-68a7-42e1-8e1c-ac06af58d594" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_05e27170-fda0-42f4-882d-86e4313eed2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_9f51a6a3-ad3e-4a1d-9864-74d181bb81f6" xlink:to="loc_ifrs-full_AtFairValueMember_05e27170-fda0-42f4-882d-86e4313eed2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_3c11a25d-2b72-4927-a9b6-cba9141a2afb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_9975b939-aef3-4fb3-b4a1-deeac47e88e8" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_3c11a25d-2b72-4927-a9b6-cba9141a2afb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_3c11a25d-2b72-4927-a9b6-cba9141a2afb_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_3c11a25d-2b72-4927-a9b6-cba9141a2afb" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_3c11a25d-2b72-4927-a9b6-cba9141a2afb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_a0c5a091-1399-4883-aebd-8d881e23b2cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_3c11a25d-2b72-4927-a9b6-cba9141a2afb" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_a0c5a091-1399-4883-aebd-8d881e23b2cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesMember_cf4b4c2b-0ff5-4902-a544-39e23d930080" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_a0c5a091-1399-4883-aebd-8d881e23b2cd" xlink:to="loc_sny_ForwardCurrencySalesMember_cf4b4c2b-0ff5-4902-a544-39e23d930080" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarMember_496fc861-07d1-48ed-bdee-f6af3771647d" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_cf4b4c2b-0ff5-4902-a544-39e23d930080" xlink:to="loc_sny_ForwardCurrencySalesInUSDollarMember_496fc861-07d1-48ed-bdee-f6af3771647d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_08c54f82-ae62-4c49-9af5-f5306fb494d8" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInSingaporeDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_cf4b4c2b-0ff5-4902-a544-39e23d930080" xlink:to="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_08c54f82-ae62-4c49-9af5-f5306fb494d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInPoundSterlingMember_7ec1d3bf-46aa-4477-a478-516d01733ad8" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInPoundSterlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_cf4b4c2b-0ff5-4902-a544-39e23d930080" xlink:to="loc_sny_ForwardCurrencySalesInPoundSterlingMember_7ec1d3bf-46aa-4477-a478-516d01733ad8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesMember_edee1cf3-e441-4e66-9c5f-c2193284687a" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_a0c5a091-1399-4883-aebd-8d881e23b2cd" xlink:to="loc_sny_ForwardCurrencyPurchasesMember_edee1cf3-e441-4e66-9c5f-c2193284687a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_e6f2e222-69db-4e9a-99d7-93998e24eaab" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_edee1cf3-e441-4e66-9c5f-c2193284687a" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_e6f2e222-69db-4e9a-99d7-93998e24eaab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_3ea0b17c-f69e-479f-88a6-799e6bda7195" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInSingaporeDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_edee1cf3-e441-4e66-9c5f-c2193284687a" xlink:to="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_3ea0b17c-f69e-479f-88a6-799e6bda7195" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInJapaneseYenMember_37f754ec-bd61-4d80-b830-f85eb47e0925" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInJapaneseYenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_edee1cf3-e441-4e66-9c5f-c2193284687a" xlink:to="loc_sny_ForwardCurrencyPurchasesInJapaneseYenMember_37f754ec-bd61-4d80-b830-f85eb47e0925" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_e1cebaf3-42aa-448a-ae13-ce829a386a4f" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInUSDollarUSBondMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_a0c5a091-1399-4883-aebd-8d881e23b2cd" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_e1cebaf3-42aa-448a-ae13-ce829a386a4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember_71acf3f8-c7f1-4021-9513-2ac5f8b63d25" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_a0c5a091-1399-4883-aebd-8d881e23b2cd" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember_71acf3f8-c7f1-4021-9513-2ac5f8b63d25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_64241a0a-868b-4006-9cda-df992a90222c" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInChineseYuanRenminbiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_a0c5a091-1399-4883-aebd-8d881e23b2cd" xlink:to="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_64241a0a-868b-4006-9cda-df992a90222c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInCanadianDollarMember_5c341b7b-5fac-4989-a731-2877fcc67796" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInCanadianDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_a0c5a091-1399-4883-aebd-8d881e23b2cd" xlink:to="loc_sny_ForwardCurrencySalesInCanadianDollarMember_5c341b7b-5fac-4989-a731-2877fcc67796" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_ef1233bb-9350-42c4-9233-bd513b81ddbb" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInHungarianFlorintMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_a0c5a091-1399-4883-aebd-8d881e23b2cd" xlink:to="loc_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_ef1233bb-9350-42c4-9233-bd513b81ddbb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_29f80ec9-1dcc-434f-bf1f-38e893777e7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_9975b939-aef3-4fb3-b4a1-deeac47e88e8" xlink:to="loc_ifrs-full_MaturityAxis_29f80ec9-1dcc-434f-bf1f-38e893777e7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_29f80ec9-1dcc-434f-bf1f-38e893777e7a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_29f80ec9-1dcc-434f-bf1f-38e893777e7a" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_29f80ec9-1dcc-434f-bf1f-38e893777e7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_65e72af1-04ef-4d28-a8d5-7f971a79957a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_29f80ec9-1dcc-434f-bf1f-38e893777e7a" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_65e72af1-04ef-4d28-a8d5-7f971a79957a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_9cc28eaa-8316-48a2-b607-b576f19ebddb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_65e72af1-04ef-4d28-a8d5-7f971a79957a" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_9cc28eaa-8316-48a2-b607-b576f19ebddb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_c39799f7-5193-45b8-9791-766d76b928ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_65e72af1-04ef-4d28-a8d5-7f971a79957a" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_c39799f7-5193-45b8-9791-766d76b928ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_4d4406a4-099b-445c-bb68-11d4c20a6687" xlink:href="sny-20240630.xsd#sny_DerivativeFinancialInstrumentsToManageFinancialExposure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_eb743dbd-8545-4b97-8b73-71947ef51982" xlink:to="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_4d4406a4-099b-445c-bb68-11d4c20a6687" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_7eb38f5f-6ed9-4442-ab20-a2a70f4582e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_eb743dbd-8545-4b97-8b73-71947ef51982" xlink:to="loc_ifrs-full_NotionalAmount_7eb38f5f-6ed9-4442-ab20-a2a70f4582e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialAssets_b17c61ef-4115-40a2-bd7f-241e05e5d6b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_eb743dbd-8545-4b97-8b73-71947ef51982" xlink:to="loc_ifrs-full_DerivativeFinancialAssets_b17c61ef-4115-40a2-bd7f-241e05e5d6b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_e91669ab-d09b-4d81-8731-f5ffb27593c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_eb743dbd-8545-4b97-8b73-71947ef51982" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_e91669ab-d09b-4d81-8731-f5ffb27593c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_c1b86414-9ce0-4cf3-b08f-95112b8bc459" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_eb743dbd-8545-4b97-8b73-71947ef51982" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_c1b86414-9ce0-4cf3-b08f-95112b8bc459" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_65dff0b2-f28f-4fba-9d17-733598448e5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_258f5f11-db55-4c93-b188-939696500221" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_65dff0b2-f28f-4fba-9d17-733598448e5a" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_258f5f11-db55-4c93-b188-939696500221" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_47e583fc-86df-4ac8-a23a-878ccbea8f31" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_258f5f11-db55-4c93-b188-939696500221" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_47e583fc-86df-4ac8-a23a-878ccbea8f31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_47e583fc-86df-4ac8-a23a-878ccbea8f31_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_47e583fc-86df-4ac8-a23a-878ccbea8f31" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_47e583fc-86df-4ac8-a23a-878ccbea8f31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_819dfa4f-455f-4341-b425-c399e3e19250" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_47e583fc-86df-4ac8-a23a-878ccbea8f31" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_819dfa4f-455f-4341-b425-c399e3e19250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member_2013ca91-9f61-489b-a842-d24d11c12abe" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_819dfa4f-455f-4341-b425-c399e3e19250" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member_2013ca91-9f61-489b-a842-d24d11c12abe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member_fd293dab-dbac-46a3-9cf9-eae7a9779d0b" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_819dfa4f-455f-4341-b425-c399e3e19250" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member_fd293dab-dbac-46a3-9cf9-eae7a9779d0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_12eeba27-393d-424e-8029-2e368f8d9db6" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive069Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_819dfa4f-455f-4341-b425-c399e3e19250" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_12eeba27-393d-424e-8029-2e368f8d9db6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_bf1a158c-f677-490f-9cd8-268c6e490d52" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive092Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_819dfa4f-455f-4341-b425-c399e3e19250" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_bf1a158c-f677-490f-9cd8-268c6e490d52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_9359b43c-5d91-4965-996e-654b8bb0fbba" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive343Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_819dfa4f-455f-4341-b425-c399e3e19250" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_9359b43c-5d91-4965-996e-654b8bb0fbba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member_a61344e1-950f-4029-92f4-513f8b323fb8" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_819dfa4f-455f-4341-b425-c399e3e19250" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member_a61344e1-950f-4029-92f4-513f8b323fb8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member_284497a9-e46b-404a-9c27-d490afdd104c" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_819dfa4f-455f-4341-b425-c399e3e19250" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member_284497a9-e46b-404a-9c27-d490afdd104c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_4a4cc214-5848-4106-acaf-f3d4cc908168" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_258f5f11-db55-4c93-b188-939696500221" xlink:to="loc_ifrs-full_MeasurementAxis_4a4cc214-5848-4106-acaf-f3d4cc908168" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_4a4cc214-5848-4106-acaf-f3d4cc908168_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_4a4cc214-5848-4106-acaf-f3d4cc908168" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_4a4cc214-5848-4106-acaf-f3d4cc908168_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_7d2f9f64-b5d5-47e6-a825-e30a1c196906" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_4a4cc214-5848-4106-acaf-f3d4cc908168" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_7d2f9f64-b5d5-47e6-a825-e30a1c196906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_945640c0-3073-4982-8178-05145e81867f" xlink:href="sny-20240630.xsd#sny_AtNotionalAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_7d2f9f64-b5d5-47e6-a825-e30a1c196906" xlink:to="loc_sny_AtNotionalAmountMember_945640c0-3073-4982-8178-05145e81867f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_155aa1c8-1fac-4bbd-85a3-ca14102a5f7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_7d2f9f64-b5d5-47e6-a825-e30a1c196906" xlink:to="loc_ifrs-full_AtFairValueMember_155aa1c8-1fac-4bbd-85a3-ca14102a5f7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfHedgeRecognizedInEquityMember_c1b22ede-2ddf-45dd-8504-f72f055a459c" xlink:href="sny-20240630.xsd#sny_ValueOfHedgeRecognizedInEquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_7d2f9f64-b5d5-47e6-a825-e30a1c196906" xlink:to="loc_sny_ValueOfHedgeRecognizedInEquityMember_c1b22ede-2ddf-45dd-8504-f72f055a459c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_d29a7f71-cd95-48df-b0e2-d5ac67ee35f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_258f5f11-db55-4c93-b188-939696500221" xlink:to="loc_ifrs-full_MaturityAxis_d29a7f71-cd95-48df-b0e2-d5ac67ee35f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_d29a7f71-cd95-48df-b0e2-d5ac67ee35f4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_d29a7f71-cd95-48df-b0e2-d5ac67ee35f4" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_d29a7f71-cd95-48df-b0e2-d5ac67ee35f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_449b6759-4dc6-451e-b30d-9b2eb0bae1f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_d29a7f71-cd95-48df-b0e2-d5ac67ee35f4" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_449b6759-4dc6-451e-b30d-9b2eb0bae1f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_85a157cc-021d-4fda-bd08-a68fd7ee4df5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_449b6759-4dc6-451e-b30d-9b2eb0bae1f9" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_85a157cc-021d-4fda-bd08-a68fd7ee4df5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_d8d56b3b-f45d-4201-aa6b-c4789c237217" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_449b6759-4dc6-451e-b30d-9b2eb0bae1f9" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_d8d56b3b-f45d-4201-aa6b-c4789c237217" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_e6a1d23d-5b0c-4b67-99a1-baf8273587c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_449b6759-4dc6-451e-b30d-9b2eb0bae1f9" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_e6a1d23d-5b0c-4b67-99a1-baf8273587c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_de614ffc-7ff4-4305-83e9-7c6e74a929c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_449b6759-4dc6-451e-b30d-9b2eb0bae1f9" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_de614ffc-7ff4-4305-83e9-7c6e74a929c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_a24dff2f-f307-4c78-851b-9d5d7b80671c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_449b6759-4dc6-451e-b30d-9b2eb0bae1f9" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_a24dff2f-f307-4c78-851b-9d5d7b80671c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_bb591882-ab2e-4493-8209-2a54ed457f71" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_258f5f11-db55-4c93-b188-939696500221" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_bb591882-ab2e-4493-8209-2a54ed457f71" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesMember_bb591882-ab2e-4493-8209-2a54ed457f71_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_bb591882-ab2e-4493-8209-2a54ed457f71" xlink:to="loc_ifrs-full_TypesOfHedgesMember_bb591882-ab2e-4493-8209-2a54ed457f71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesMember_1ccc3c0c-9d6f-4c48-a58c-0ef896934d61" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_bb591882-ab2e-4493-8209-2a54ed457f71" xlink:to="loc_ifrs-full_TypesOfHedgesMember_1ccc3c0c-9d6f-4c48-a58c-0ef896934d61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FairValueHedgesMember_aa5a710b-cac4-459d-93ce-17db95138987" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FairValueHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesMember_1ccc3c0c-9d6f-4c48-a58c-0ef896934d61" xlink:to="loc_ifrs-full_FairValueHedgesMember_aa5a710b-cac4-459d-93ce-17db95138987" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowHedgesMember_b2166777-7cbd-4459-97ab-e782f4a09da0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesMember_1ccc3c0c-9d6f-4c48-a58c-0ef896934d61" xlink:to="loc_ifrs-full_CashFlowHedgesMember_b2166777-7cbd-4459-97ab-e782f4a09da0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsInterestRate_2601a480-4733-4cd0-9e20-c1a8547d6ce1" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_65dff0b2-f28f-4fba-9d17-733598448e5a" xlink:to="loc_sny_InterestRateSwapsInterestRate_2601a480-4733-4cd0-9e20-c1a8547d6ce1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_eb411cbf-62b4-456b-8272-ca2423623aeb" xlink:href="sny-20240630.xsd#sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_65dff0b2-f28f-4fba-9d17-733598448e5a" xlink:to="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_eb411cbf-62b4-456b-8272-ca2423623aeb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_85b6e65b-dfc4-4b26-83bb-8c2892eeb02b" xlink:href="sny-20240630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_72c89153-77eb-4440-953d-0ce461a8ff2e" xlink:href="sny-20240630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_85b6e65b-dfc4-4b26-83bb-8c2892eeb02b" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_72c89153-77eb-4440-953d-0ce461a8ff2e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_9f4caec8-0f09-47b9-8500-f5063c7a21f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_72c89153-77eb-4440-953d-0ce461a8ff2e" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_9f4caec8-0f09-47b9-8500-f5063c7a21f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_9f4caec8-0f09-47b9-8500-f5063c7a21f4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_9f4caec8-0f09-47b9-8500-f5063c7a21f4" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_9f4caec8-0f09-47b9-8500-f5063c7a21f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_4420a51c-5e57-4bd1-87e4-ebb105a7bf15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_9f4caec8-0f09-47b9-8500-f5063c7a21f4" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_4420a51c-5e57-4bd1-87e4-ebb105a7bf15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_bed0771f-b066-46a4-b845-6b4340f3cacd" xlink:href="sny-20240630.xsd#sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_4420a51c-5e57-4bd1-87e4-ebb105a7bf15" xlink:to="loc_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_bed0771f-b066-46a4-b845-6b4340f3cacd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_900e6a76-41bb-4fc8-8bec-809b91accd9f" xlink:href="sny-20240630.xsd#sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_4420a51c-5e57-4bd1-87e4-ebb105a7bf15" xlink:to="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_900e6a76-41bb-4fc8-8bec-809b91accd9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_c7aac595-2b5e-4cb5-8a86-da7262dc8a73" xlink:href="sny-20240630.xsd#sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_4420a51c-5e57-4bd1-87e4-ebb105a7bf15" xlink:to="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_c7aac595-2b5e-4cb5-8a86-da7262dc8a73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_e16c4abe-24b0-4926-aa29-131ccde2efa6" xlink:href="sny-20240630.xsd#sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_4420a51c-5e57-4bd1-87e4-ebb105a7bf15" xlink:to="loc_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_e16c4abe-24b0-4926-aa29-131ccde2efa6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherLiabilities1Member_52a6560c-566e-4bdb-98a0-997a8d583bd5" xlink:href="sny-20240630.xsd#sny_OtherLiabilities1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_4420a51c-5e57-4bd1-87e4-ebb105a7bf15" xlink:to="loc_sny_OtherLiabilities1Member_52a6560c-566e-4bdb-98a0-997a8d583bd5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_6f440e7c-e6d2-4cbb-8186-0c3279ca76ef" xlink:href="sny-20240630.xsd#sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_85b6e65b-dfc4-4b26-83bb-8c2892eeb02b" xlink:to="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_6f440e7c-e6d2-4cbb-8186-0c3279ca76ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_75dc0cc1-b3b2-4f0c-8b7f-653b2d0d2466" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_6f440e7c-e6d2-4cbb-8186-0c3279ca76ef" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_75dc0cc1-b3b2-4f0c-8b7f-653b2d0d2466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_ae0257d5-787d-44b7-a266-3bc0a04a747a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_6f440e7c-e6d2-4cbb-8186-0c3279ca76ef" xlink:to="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_ae0257d5-787d-44b7-a266-3bc0a04a747a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_0bebc019-fed9-4def-82aa-c080d23aafdc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_6f440e7c-e6d2-4cbb-8186-0c3279ca76ef" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_0bebc019-fed9-4def-82aa-c080d23aafdc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination_23ec9d6e-38a9-4dfd-8112-3b6074f19b9f" xlink:href="sny-20240630.xsd#sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_6f440e7c-e6d2-4cbb-8186-0c3279ca76ef" xlink:to="loc_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination_23ec9d6e-38a9-4dfd-8112-3b6074f19b9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_11193e13-8ced-4cea-b85c-d0ee78386d6e" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_6f440e7c-e6d2-4cbb-8186-0c3279ca76ef" xlink:to="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_11193e13-8ced-4cea-b85c-d0ee78386d6e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_337cb2ca-311e-4c8b-a242-c0bb6daa132f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_fe424aa1-559a-4830-af72-575642e80a24" xlink:href="sny-20240630.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_85b6e65b-dfc4-4b26-83bb-8c2892eeb02b" xlink:to="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_fe424aa1-559a-4830-af72-575642e80a24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_ae65d26d-93ab-46ff-b1ae-217fbefb2c5e" xlink:href="sny-20240630.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_85b6e65b-dfc4-4b26-83bb-8c2892eeb02b" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_ae65d26d-93ab-46ff-b1ae-217fbefb2c5e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_fa21397d-89e4-4dfa-a2f6-c6291398924f" xlink:href="sny-20240630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_d21332c0-80f7-436a-bac0-b2c171497704" xlink:href="sny-20240630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_fa21397d-89e4-4dfa-a2f6-c6291398924f" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_d21332c0-80f7-436a-bac0-b2c171497704" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_cc0c26e1-f1ea-475d-a4bc-6c73bbba2950" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_d21332c0-80f7-436a-bac0-b2c171497704" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_cc0c26e1-f1ea-475d-a4bc-6c73bbba2950" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_cc0c26e1-f1ea-475d-a4bc-6c73bbba2950_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_cc0c26e1-f1ea-475d-a4bc-6c73bbba2950" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_cc0c26e1-f1ea-475d-a4bc-6c73bbba2950_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2be4e95f-41b4-443e-9f82-4e4ea8f67bda" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_cc0c26e1-f1ea-475d-a4bc-6c73bbba2950" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2be4e95f-41b4-443e-9f82-4e4ea8f67bda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_dc2bece2-d02c-43ae-9f42-77a1939eeba6" xlink:href="sny-20240630.xsd#sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2be4e95f-41b4-443e-9f82-4e4ea8f67bda" xlink:to="loc_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_dc2bece2-d02c-43ae-9f42-77a1939eeba6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_9cf60abf-8cce-4d07-a3a4-28c44492c0ea" xlink:href="sny-20240630.xsd#sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2be4e95f-41b4-443e-9f82-4e4ea8f67bda" xlink:to="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_9cf60abf-8cce-4d07-a3a4-28c44492c0ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_e87e8cca-0c1d-4c34-b009-d4ee10bf0b4a" xlink:href="sny-20240630.xsd#sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2be4e95f-41b4-443e-9f82-4e4ea8f67bda" xlink:to="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_e87e8cca-0c1d-4c34-b009-d4ee10bf0b4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_9c72c97d-a171-4576-a471-d71a98248dc1" xlink:href="sny-20240630.xsd#sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2be4e95f-41b4-443e-9f82-4e4ea8f67bda" xlink:to="loc_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_9c72c97d-a171-4576-a471-d71a98248dc1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_730ea52a-ac5c-4969-ac2f-ccf0dfa91655" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_d21332c0-80f7-436a-bac0-b2c171497704" xlink:to="loc_ifrs-full_RangeAxis_730ea52a-ac5c-4969-ac2f-ccf0dfa91655" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_730ea52a-ac5c-4969-ac2f-ccf0dfa91655_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_730ea52a-ac5c-4969-ac2f-ccf0dfa91655" xlink:to="loc_ifrs-full_RangesMember_730ea52a-ac5c-4969-ac2f-ccf0dfa91655_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_268a0b48-5e0c-4694-aad6-6d46a247c6b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_730ea52a-ac5c-4969-ac2f-ccf0dfa91655" xlink:to="loc_ifrs-full_RangesMember_268a0b48-5e0c-4694-aad6-6d46a247c6b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_739ceaf1-b817-440c-a38c-2eed56528b3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_268a0b48-5e0c-4694-aad6-6d46a247c6b8" xlink:to="loc_ifrs-full_TopOfRangeMember_739ceaf1-b817-440c-a38c-2eed56528b3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PotentialPaymentsRelatedToPercentageOfSales_9e605692-62e7-46ca-9bca-bdb359973687" xlink:href="sny-20240630.xsd#sny_PotentialPaymentsRelatedToPercentageOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_fa21397d-89e4-4dfa-a2f6-c6291398924f" xlink:to="loc_sny_PotentialPaymentsRelatedToPercentageOfSales_9e605692-62e7-46ca-9bca-bdb359973687" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PaymentToSaleOfBusinessPeriod_ce610936-4fa3-4f22-a6fe-4bc3c5040f39" xlink:href="sny-20240630.xsd#sny_PaymentToSaleOfBusinessPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_fa21397d-89e4-4dfa-a2f6-c6291398924f" xlink:to="loc_sny_PaymentToSaleOfBusinessPeriod_ce610936-4fa3-4f22-a6fe-4bc3c5040f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_b75dda80-3841-4d4d-ac5d-9dab628f697f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_fa21397d-89e4-4dfa-a2f6-c6291398924f" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_b75dda80-3841-4d4d-ac5d-9dab628f697f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageIncreaseInFairValueLiabilities_ad6c2345-0c7a-4d21-ba81-7e157f23b9cd" xlink:href="sny-20240630.xsd#sny_PercentageIncreaseInFairValueLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_fa21397d-89e4-4dfa-a2f6-c6291398924f" xlink:to="loc_sny_PercentageIncreaseInFairValueLiabilities_ad6c2345-0c7a-4d21-ba81-7e157f23b9cd" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_742314bb-7fa1-4a76-850f-8a14de3063a1" xlink:href="sny-20240630.xsd#sny_DisclosureOfNonCurrentProvisionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTable_1d45b579-797e-4329-a6ff-d0b1fb9efafb" xlink:href="sny-20240630.xsd#sny_DisclosureOfNonCurrentProvisionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_742314bb-7fa1-4a76-850f-8a14de3063a1" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsTable_1d45b579-797e-4329-a6ff-d0b1fb9efafb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_c93dffbc-8e60-45d0-838b-54fdb49bd481" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_1d45b579-797e-4329-a6ff-d0b1fb9efafb" xlink:to="loc_sny_PrincipalAlliancesAxis_c93dffbc-8e60-45d0-838b-54fdb49bd481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_c93dffbc-8e60-45d0-838b-54fdb49bd481_default" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_PrincipalAlliancesAxis_c93dffbc-8e60-45d0-838b-54fdb49bd481" xlink:to="loc_sny_PrincipalAlliancesDomain_c93dffbc-8e60-45d0-838b-54fdb49bd481_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_ea348499-5502-4f4a-9b56-698d34aca544" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_PrincipalAlliancesAxis_c93dffbc-8e60-45d0-838b-54fdb49bd481" xlink:to="loc_sny_PrincipalAlliancesDomain_ea348499-5502-4f4a-9b56-698d34aca544" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_de461471-0ca6-49f5-9bad-a0796b387bf4" xlink:href="sny-20240630.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_ea348499-5502-4f4a-9b56-698d34aca544" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_de461471-0ca6-49f5-9bad-a0796b387bf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_905275e9-e390-47c5-932f-d9fb81cbd8cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_1d45b579-797e-4329-a6ff-d0b1fb9efafb" xlink:to="loc_ifrs-full_CounterpartiesAxis_905275e9-e390-47c5-932f-d9fb81cbd8cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_905275e9-e390-47c5-932f-d9fb81cbd8cb_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_905275e9-e390-47c5-932f-d9fb81cbd8cb" xlink:to="loc_ifrs-full_CounterpartiesMember_905275e9-e390-47c5-932f-d9fb81cbd8cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_d6d98085-5686-42cc-8e7e-13c48c4dc69e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_905275e9-e390-47c5-932f-d9fb81cbd8cb" xlink:to="loc_ifrs-full_CounterpartiesMember_d6d98085-5686-42cc-8e7e-13c48c4dc69e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SwedishOrphanBiovitrumABMember_eeb86ab7-73e0-4777-bb1d-b5417fcc49a1" xlink:href="sny-20240630.xsd#sny_SwedishOrphanBiovitrumABMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_d6d98085-5686-42cc-8e7e-13c48c4dc69e" xlink:to="loc_sny_SwedishOrphanBiovitrumABMember_eeb86ab7-73e0-4777-bb1d-b5417fcc49a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_a2591c08-d7d9-4b0d-a687-93852ab53221" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_1d45b579-797e-4329-a6ff-d0b1fb9efafb" xlink:to="loc_ifrs-full_MaturityAxis_a2591c08-d7d9-4b0d-a687-93852ab53221" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_a2591c08-d7d9-4b0d-a687-93852ab53221_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_a2591c08-d7d9-4b0d-a687-93852ab53221" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_a2591c08-d7d9-4b0d-a687-93852ab53221_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_af708ca2-ad46-4035-a2ac-04f59b6fb179" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_a2591c08-d7d9-4b0d-a687-93852ab53221" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_af708ca2-ad46-4035-a2ac-04f59b6fb179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_4c85141b-9472-4d2c-a9c1-21ea778c9563" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_af708ca2-ad46-4035-a2ac-04f59b6fb179" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_4c85141b-9472-4d2c-a9c1-21ea778c9563" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_1e599168-2163-4bf6-a576-7c076727837a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_af708ca2-ad46-4035-a2ac-04f59b6fb179" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_1e599168-2163-4bf6-a576-7c076727837a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_dd1743df-0766-4520-9084-0519956493a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_742314bb-7fa1-4a76-850f-8a14de3063a1" xlink:to="loc_ifrs-full_NoncurrentProvisions_dd1743df-0766-4520-9084-0519956493a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_6b80ff58-413a-442f-a65b-26ab0edd81df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_742314bb-7fa1-4a76-850f-8a14de3063a1" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_6b80ff58-413a-442f-a65b-26ab0edd81df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_85ae15ef-6a75-4a6d-839c-9e6935d7ace5" xlink:href="sny-20240630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_742314bb-7fa1-4a76-850f-8a14de3063a1" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_85ae15ef-6a75-4a6d-839c-9e6935d7ace5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_40f274b9-b80c-4062-bc84-04107070acf5" xlink:href="sny-20240630.xsd#sny_DisclosureOfNonCurrentProvisionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTable_6c6b01e9-f875-478d-881f-4b2b80c4fa7c" xlink:href="sny-20240630.xsd#sny_DisclosureOfNonCurrentProvisionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_40f274b9-b80c-4062-bc84-04107070acf5" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsTable_6c6b01e9-f875-478d-881f-4b2b80c4fa7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_6987de59-352e-46b8-8f3e-61b37f1281ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_6c6b01e9-f875-478d-881f-4b2b80c4fa7c" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_6987de59-352e-46b8-8f3e-61b37f1281ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_6987de59-352e-46b8-8f3e-61b37f1281ca_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_6987de59-352e-46b8-8f3e-61b37f1281ca" xlink:to="loc_ifrs-full_OtherProvisionsMember_6987de59-352e-46b8-8f3e-61b37f1281ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_00151050-7ba4-48a3-9706-1635c9566b9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_6987de59-352e-46b8-8f3e-61b37f1281ca" xlink:to="loc_ifrs-full_OtherProvisionsMember_00151050-7ba4-48a3-9706-1635c9566b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_18d45c18-d2b9-4943-a58d-94b2c61c4bda" xlink:href="sny-20240630.xsd#sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_00151050-7ba4-48a3-9706-1635c9566b9e" xlink:to="loc_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_18d45c18-d2b9-4943-a58d-94b2c61c4bda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForOtherLongTermBenefitsMember_8557be9a-1f0b-499b-972b-730a4f7cd84a" xlink:href="sny-20240630.xsd#sny_ProvisionsForOtherLongTermBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_00151050-7ba4-48a3-9706-1635c9566b9e" xlink:to="loc_sny_ProvisionsForOtherLongTermBenefitsMember_8557be9a-1f0b-499b-972b-730a4f7cd84a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentRestructuringProvisionMember_a566c3a9-bd16-4f98-9793-6672c4fdeb4e" xlink:href="sny-20240630.xsd#sny_NonCurrentRestructuringProvisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_00151050-7ba4-48a3-9706-1635c9566b9e" xlink:to="loc_sny_NonCurrentRestructuringProvisionMember_a566c3a9-bd16-4f98-9793-6672c4fdeb4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherProvisionsMember_4482a8fd-c7b0-45a7-abf1-c466ee5b6326" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_00151050-7ba4-48a3-9706-1635c9566b9e" xlink:to="loc_ifrs-full_MiscellaneousOtherProvisionsMember_4482a8fd-c7b0-45a7-abf1-c466ee5b6326" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_40f274b9-b80c-4062-bc84-04107070acf5" xlink:to="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_aa4a35be-3f97-45fe-99c9-901defb76bfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:to="loc_ifrs-full_NoncurrentProvisions_aa4a35be-3f97-45fe-99c9-901defb76bfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInOtherProvisions_e3ce0caf-45ea-4c36-8ffd-d00cfbab19ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:to="loc_ifrs-full_ChangesInOtherProvisions_e3ce0caf-45ea-4c36-8ffd-d00cfbab19ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_d986b76e-58c3-4e3e-8b81-8f10858fd19b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_d986b76e-58c3-4e3e-8b81-8f10858fd19b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_1f48d35b-6c75-485d-9624-b0e597e8e803" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_1f48d35b-6c75-485d-9624-b0e597e8e803" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_ac6eac8a-c137-46ac-950b-e0272b0f7a11" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:to="loc_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_ac6eac8a-c137-46ac-950b-e0272b0f7a11" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_941f87f1-d689-4883-8d7e-883a61bfa481" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:to="loc_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_941f87f1-d689-4883-8d7e-883a61bfa481" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_f23d1e60-6533-407d-a7fc-dba7f0bb58be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_f23d1e60-6533-407d-a7fc-dba7f0bb58be" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_e713b578-2345-477f-8d6f-0f1170badbb8" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:to="loc_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_e713b578-2345-477f-8d6f-0f1170badbb8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_58adef21-6cd1-4ee8-83df-65de1bd2c106" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_5b76c15b-3293-495d-86ba-79183b97e83b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_7d26eae6-513a-459c-aa45-7380cea9a9d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_5b76c15b-3293-495d-86ba-79183b97e83b" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_7d26eae6-513a-459c-aa45-7380cea9a9d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_73d7bb6d-dad3-4293-9a33-b949abae30ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_7d26eae6-513a-459c-aa45-7380cea9a9d2" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_73d7bb6d-dad3-4293-9a33-b949abae30ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_73d7bb6d-dad3-4293-9a33-b949abae30ec_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_73d7bb6d-dad3-4293-9a33-b949abae30ec" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_73d7bb6d-dad3-4293-9a33-b949abae30ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_fbbf5e27-7f3d-4f51-a2c2-9570bb1f89d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_73d7bb6d-dad3-4293-9a33-b949abae30ec" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_fbbf5e27-7f3d-4f51-a2c2-9570bb1f89d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsMember_d9c6480a-d473-4edc-84b4-011b6603237a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PlanAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_fbbf5e27-7f3d-4f51-a2c2-9570bb1f89d2" xlink:to="loc_ifrs-full_PlanAssetsMember_d9c6480a-d473-4edc-84b4-011b6603237a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_f7dc90dd-da0e-445a-97c9-d092f70a0b25" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_7d26eae6-513a-459c-aa45-7380cea9a9d2" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_f7dc90dd-da0e-445a-97c9-d092f70a0b25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_f7dc90dd-da0e-445a-97c9-d092f70a0b25_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_f7dc90dd-da0e-445a-97c9-d092f70a0b25" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_f7dc90dd-da0e-445a-97c9-d092f70a0b25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_ddb9d842-eed3-4b1b-b9cb-0bbcb5e29356" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_f7dc90dd-da0e-445a-97c9-d092f70a0b25" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_ddb9d842-eed3-4b1b-b9cb-0bbcb5e29356" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_7cd794af-b9f8-4d67-abf1-c80147d0a32e" xlink:href="sny-20240630.xsd#sny_PensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_ddb9d842-eed3-4b1b-b9cb-0bbcb5e29356" xlink:to="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_7cd794af-b9f8-4d67-abf1-c80147d0a32e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_08f618f9-fbbc-4013-b48a-6d4400bdf815" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_7d26eae6-513a-459c-aa45-7380cea9a9d2" xlink:to="loc_ifrs-full_GeographicalAreasAxis_08f618f9-fbbc-4013-b48a-6d4400bdf815" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_08f618f9-fbbc-4013-b48a-6d4400bdf815_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_08f618f9-fbbc-4013-b48a-6d4400bdf815" xlink:to="loc_ifrs-full_GeographicalAreasMember_08f618f9-fbbc-4013-b48a-6d4400bdf815_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_cf5acf10-27d0-43b7-9b6b-ef435e8d0f00" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_08f618f9-fbbc-4013-b48a-6d4400bdf815" xlink:to="loc_ifrs-full_GeographicalAreasMember_cf5acf10-27d0-43b7-9b6b-ef435e8d0f00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_6b5516b3-1997-4c19-8f6e-44057945ff45" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_cf5acf10-27d0-43b7-9b6b-ef435e8d0f00" xlink:to="loc_country_GB_6b5516b3-1997-4c19-8f6e-44057945ff45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EUROZONEMember_05594e40-aa20-465c-ab1d-868468b4d053" xlink:href="sny-20240630.xsd#sny_EUROZONEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_cf5acf10-27d0-43b7-9b6b-ef435e8d0f00" xlink:to="loc_sny_EUROZONEMember_05594e40-aa20-465c-ab1d-868468b4d053" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UKZONEMember_92546ce9-0137-4be5-a12a-5c9ccaaf5a02" xlink:href="sny-20240630.xsd#sny_UKZONEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_cf5acf10-27d0-43b7-9b6b-ef435e8d0f00" xlink:to="loc_sny_UKZONEMember_92546ce9-0137-4be5-a12a-5c9ccaaf5a02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis_67d3975b-125f-4f22-bea2-372baa1bd93c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_7d26eae6-513a-459c-aa45-7380cea9a9d2" xlink:to="loc_ifrs-full_ActuarialAssumptionsAxis_67d3975b-125f-4f22-bea2-372baa1bd93c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember_67d3975b-125f-4f22-bea2-372baa1bd93c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_67d3975b-125f-4f22-bea2-372baa1bd93c" xlink:to="loc_ifrs-full_ActuarialAssumptionsMember_67d3975b-125f-4f22-bea2-372baa1bd93c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember_51813975-9ecc-4605-9970-f0579321606e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_67d3975b-125f-4f22-bea2-372baa1bd93c" xlink:to="loc_ifrs-full_ActuarialAssumptionsMember_51813975-9ecc-4605-9970-f0579321606e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_70109a90-16ce-458e-907b-0c882b2084a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_51813975-9ecc-4605-9970-f0579321606e" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_70109a90-16ce-458e-907b-0c882b2084a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_e440d4df-998c-4fa1-99c8-f53287fc6c93" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_51813975-9ecc-4605-9970-f0579321606e" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_e440d4df-998c-4fa1-99c8-f53287fc6c93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_87a50c54-308b-4653-b32c-c2af62d99c96" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_7d26eae6-513a-459c-aa45-7380cea9a9d2" xlink:to="loc_srt_RangeAxis_87a50c54-308b-4653-b32c-c2af62d99c96" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_87a50c54-308b-4653-b32c-c2af62d99c96_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_87a50c54-308b-4653-b32c-c2af62d99c96" xlink:to="loc_srt_RangeMember_87a50c54-308b-4653-b32c-c2af62d99c96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_27e03c4a-5c70-4b70-baa1-040b013eff6a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_87a50c54-308b-4653-b32c-c2af62d99c96" xlink:to="loc_srt_RangeMember_27e03c4a-5c70-4b70-baa1-040b013eff6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e601b326-7c34-4621-b66b-e5c4ed8e77d8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_27e03c4a-5c70-4b70-baa1-040b013eff6a" xlink:to="loc_srt_MinimumMember_e601b326-7c34-4621-b66b-e5c4ed8e77d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_282992af-f2ae-4d47-92ad-fb9a2240e9c1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_27e03c4a-5c70-4b70-baa1-040b013eff6a" xlink:to="loc_srt_MaximumMember_282992af-f2ae-4d47-92ad-fb9a2240e9c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_597096e1-dbcb-493e-abe5-617eee4ad4ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_5b76c15b-3293-495d-86ba-79183b97e83b" xlink:to="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_597096e1-dbcb-493e-abe5-617eee4ad4ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_70ea7937-26f8-4e20-8dc5-c5d9d82110c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_5b76c15b-3293-495d-86ba-79183b97e83b" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_70ea7937-26f8-4e20-8dc5-c5d9d82110c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_24b1410f-214b-44c3-8910-a62ed83ff223" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_5b76c15b-3293-495d-86ba-79183b97e83b" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_24b1410f-214b-44c3-8910-a62ed83ff223" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_3ea0eae1-a40e-40eb-9ac4-ebd1f5ec8213" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_5b76c15b-3293-495d-86ba-79183b97e83b" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_3ea0eae1-a40e-40eb-9ac4-ebd1f5ec8213" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#OffBalanceSheetCommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:href="sny-20240630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_eac391c7-5414-40ef-94eb-f5b5f9f6671f" xlink:href="sny-20240630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_eac391c7-5414-40ef-94eb-f5b5f9f6671f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_83035c8a-8a7a-4ad3-8fef-9412c24c96da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_eac391c7-5414-40ef-94eb-f5b5f9f6671f" xlink:to="loc_ifrs-full_CounterpartiesAxis_83035c8a-8a7a-4ad3-8fef-9412c24c96da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_83035c8a-8a7a-4ad3-8fef-9412c24c96da_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_83035c8a-8a7a-4ad3-8fef-9412c24c96da" xlink:to="loc_ifrs-full_CounterpartiesMember_83035c8a-8a7a-4ad3-8fef-9412c24c96da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_e48309db-eac9-4ea9-8e23-6d0cedac06b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_83035c8a-8a7a-4ad3-8fef-9412c24c96da" xlink:to="loc_ifrs-full_CounterpartiesMember_e48309db-eac9-4ea9-8e23-6d0cedac06b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MazeTherapeuticsMember_1f04c4f2-049a-4185-8a8c-d796ce19d21e" xlink:href="sny-20240630.xsd#sny_MazeTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_e48309db-eac9-4ea9-8e23-6d0cedac06b0" xlink:to="loc_sny_MazeTherapeuticsMember_1f04c4f2-049a-4185-8a8c-d796ce19d21e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ScribeTherapeuticsMember_62a6a631-5d8c-49f4-a19d-36f728212ba8" xlink:href="sny-20240630.xsd#sny_ScribeTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_e48309db-eac9-4ea9-8e23-6d0cedac06b0" xlink:to="loc_sny_ScribeTherapeuticsMember_62a6a631-5d8c-49f4-a19d-36f728212ba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NovavaxMember_5978acd1-f008-479d-b820-66304c263d08" xlink:href="sny-20240630.xsd#sny_NovavaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_e48309db-eac9-4ea9-8e23-6d0cedac06b0" xlink:to="loc_sny_NovavaxMember_5978acd1-f008-479d-b820-66304c263d08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FulcrumTherapeuticsMember_d39b2eea-559d-43bc-8dde-e4de5c9d56a3" xlink:href="sny-20240630.xsd#sny_FulcrumTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_e48309db-eac9-4ea9-8e23-6d0cedac06b0" xlink:to="loc_sny_FulcrumTherapeuticsMember_d39b2eea-559d-43bc-8dde-e4de5c9d56a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_e9d06772-0e5c-4b47-8c46-9920d34d322b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_eac391c7-5414-40ef-94eb-f5b5f9f6671f" xlink:to="loc_ifrs-full_RangeAxis_e9d06772-0e5c-4b47-8c46-9920d34d322b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_e9d06772-0e5c-4b47-8c46-9920d34d322b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_e9d06772-0e5c-4b47-8c46-9920d34d322b" xlink:to="loc_ifrs-full_RangesMember_e9d06772-0e5c-4b47-8c46-9920d34d322b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_a87cee42-235e-4e5e-a0a3-6c8494858b83" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_e9d06772-0e5c-4b47-8c46-9920d34d322b" xlink:to="loc_ifrs-full_RangesMember_a87cee42-235e-4e5e-a0a3-6c8494858b83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_59f7d82c-a292-4eaa-9c4e-1597e9743f26" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_a87cee42-235e-4e5e-a0a3-6c8494858b83" xlink:to="loc_srt_MaximumMember_59f7d82c-a292-4eaa-9c4e-1597e9743f26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_69ab4135-020f-4890-ae5f-9cece6747da2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_eac391c7-5414-40ef-94eb-f5b5f9f6671f" xlink:to="loc_srt_RangeAxis_69ab4135-020f-4890-ae5f-9cece6747da2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_69ab4135-020f-4890-ae5f-9cece6747da2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_69ab4135-020f-4890-ae5f-9cece6747da2" xlink:to="loc_srt_RangeMember_69ab4135-020f-4890-ae5f-9cece6747da2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_056aac65-d3b0-43b9-a8e9-d8ccb94fbdd2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_69ab4135-020f-4890-ae5f-9cece6747da2" xlink:to="loc_srt_RangeMember_056aac65-d3b0-43b9-a8e9-d8ccb94fbdd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f709e753-668b-4ea6-99ed-6ab03e283fd3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_056aac65-d3b0-43b9-a8e9-d8ccb94fbdd2" xlink:to="loc_srt_MinimumMember_f709e753-668b-4ea6-99ed-6ab03e283fd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPayments_53ff7056-3ed3-4009-b135-c2b6017c6d17" xlink:href="sny-20240630.xsd#sny_UpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_UpfrontPayments_53ff7056-3ed3-4009-b135-c2b6017c6d17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_3926b7a0-29ec-45d7-a52f-66610b139f57" xlink:href="sny-20240630.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_3926b7a0-29ec-45d7-a52f-66610b139f57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseTerm_1d3843ac-e853-4a23-8aa7-73687897ff64" xlink:href="sny-20240630.xsd#sny_LeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_LeaseTerm_1d3843ac-e853-4a23-8aa7-73687897ff64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseCost_dc1c21d9-f078-4c73-98fe-3b21a34a5fc4" xlink:href="sny-20240630.xsd#sny_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_LeaseCost_dc1c21d9-f078-4c73-98fe-3b21a34a5fc4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseExtensionOptionsNumber_94b91573-28f2-42f4-96b2-da8177172d4d" xlink:href="sny-20240630.xsd#sny_LeaseExtensionOptionsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_LeaseExtensionOptionsNumber_94b91573-28f2-42f4-96b2-da8177172d4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseExtensionOptionsTerm_011ed612-281f-4cd1-aa2f-054dc7f5cc84" xlink:href="sny-20240630.xsd#sny_LeaseExtensionOptionsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_LeaseExtensionOptionsTerm_011ed612-281f-4cd1-aa2f-054dc7f5cc84" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalMilestonePayments_5fd4bd29-5f15-44cf-b0a3-4251375bc286" xlink:href="sny-20240630.xsd#sny_TotalMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_TotalMilestonePayments_5fd4bd29-5f15-44cf-b0a3-4251375bc286" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DevelopmentRegulatoryAndLaunchMilestonePayments_a9ed0689-8dea-4883-bd8e-36a53ae385a8" xlink:href="sny-20240630.xsd#sny_DevelopmentRegulatoryAndLaunchMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_DevelopmentRegulatoryAndLaunchMilestonePayments_a9ed0689-8dea-4883-bd8e-36a53ae385a8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdditionalLaunchAndSalesMilestonePayments_df5ed4c4-863f-4ba4-a168-79f0e43bbaee" xlink:href="sny-20240630.xsd#sny_AdditionalLaunchAndSalesMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_AdditionalLaunchAndSalesMilestonePayments_df5ed4c4-863f-4ba4-a168-79f0e43bbaee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentMilestonePayments_818b61dd-6f39-4318-9a39-59a3373b8696" xlink:href="sny-20240630.xsd#sny_ContingentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_ContingentMilestonePayments_818b61dd-6f39-4318-9a39-59a3373b8696" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#LitigationandArbitrationProceedingsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_3fa351bb-a191-4180-b12a-ccc1bd8f4eed" xlink:href="sny-20240630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_18d1c38e-f33b-45e8-94aa-e36470ca591b" xlink:href="sny-20240630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_3fa351bb-a191-4180-b12a-ccc1bd8f4eed" xlink:to="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_18d1c38e-f33b-45e8-94aa-e36470ca591b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsAxis_75dfbed1-9ff2-4283-9e5c-ada36ec12659" xlink:href="sny-20240630.xsd#sny_LegalAndArbitralProceedingsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_18d1c38e-f33b-45e8-94aa-e36470ca591b" xlink:to="loc_sny_LegalAndArbitralProceedingsAxis_75dfbed1-9ff2-4283-9e5c-ada36ec12659" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsDomain_75dfbed1-9ff2-4283-9e5c-ada36ec12659_default" xlink:href="sny-20240630.xsd#sny_LegalAndArbitralProceedingsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_LegalAndArbitralProceedingsAxis_75dfbed1-9ff2-4283-9e5c-ada36ec12659" xlink:to="loc_sny_LegalAndArbitralProceedingsDomain_75dfbed1-9ff2-4283-9e5c-ada36ec12659_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsDomain_ec4a92bc-b212-4e43-b7dc-24aee9598a53" xlink:href="sny-20240630.xsd#sny_LegalAndArbitralProceedingsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_LegalAndArbitralProceedingsAxis_75dfbed1-9ff2-4283-9e5c-ada36ec12659" xlink:to="loc_sny_LegalAndArbitralProceedingsDomain_ec4a92bc-b212-4e43-b7dc-24aee9598a53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixAttorneyGeneralActionInHawaiiMember_f03beeb8-24d3-4586-932c-70e2ebbd44a8" xlink:href="sny-20240630.xsd#sny_PlavixAttorneyGeneralActionInHawaiiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_ec4a92bc-b212-4e43-b7dc-24aee9598a53" xlink:to="loc_sny_PlavixAttorneyGeneralActionInHawaiiMember_f03beeb8-24d3-4586-932c-70e2ebbd44a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxotereProductLitigationInTheUSMember_402149f9-79af-4ce4-b7a5-83508cce6d53" xlink:href="sny-20240630.xsd#sny_TaxotereProductLitigationInTheUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_ec4a92bc-b212-4e43-b7dc-24aee9598a53" xlink:to="loc_sny_TaxotereProductLitigationInTheUSMember_402149f9-79af-4ce4-b7a5-83508cce6d53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ZantacProductLitigationInTheUSMember_5a95950e-f799-4ddc-887a-1af86e0c3161" xlink:href="sny-20240630.xsd#sny_ZantacProductLitigationInTheUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_ec4a92bc-b212-4e43-b7dc-24aee9598a53" xlink:to="loc_sny_ZantacProductLitigationInTheUSMember_5a95950e-f799-4ddc-887a-1af86e0c3161" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GoldBondProductLitigationInTheUSMember_5a0f1598-1ef0-4781-853d-69f36c6908f3" xlink:href="sny-20240630.xsd#sny_GoldBondProductLitigationInTheUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_ec4a92bc-b212-4e43-b7dc-24aee9598a53" xlink:to="loc_sny_GoldBondProductLitigationInTheUSMember_5a0f1598-1ef0-4781-853d-69f36c6908f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantAxis_1e0003ab-70b3-4d8a-b7c4-a8c3379efba9" xlink:href="sny-20240630.xsd#sny_DefendantAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_18d1c38e-f33b-45e8-94aa-e36470ca591b" xlink:to="loc_sny_DefendantAxis_1e0003ab-70b3-4d8a-b7c4-a8c3379efba9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantDomain_1e0003ab-70b3-4d8a-b7c4-a8c3379efba9_default" xlink:href="sny-20240630.xsd#sny_DefendantDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_DefendantAxis_1e0003ab-70b3-4d8a-b7c4-a8c3379efba9" xlink:to="loc_sny_DefendantDomain_1e0003ab-70b3-4d8a-b7c4-a8c3379efba9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantDomain_b3398cd9-d776-4b76-893c-d5d8adce3999" xlink:href="sny-20240630.xsd#sny_DefendantDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_DefendantAxis_1e0003ab-70b3-4d8a-b7c4-a8c3379efba9" xlink:to="loc_sny_DefendantDomain_b3398cd9-d776-4b76-893c-d5d8adce3999" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActionForWhichWeAreDefendantMember_b808088e-11c1-437c-9a75-97d648861ffa" xlink:href="sny-20240630.xsd#sny_ActionForWhichWeAreDefendantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DefendantDomain_b3398cd9-d776-4b76-893c-d5d8adce3999" xlink:to="loc_sny_ActionForWhichWeAreDefendantMember_b808088e-11c1-437c-9a75-97d648861ffa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_b0dd1863-fb1e-41f3-8426-fbc9d03b605c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_18d1c38e-f33b-45e8-94aa-e36470ca591b" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_b0dd1863-fb1e-41f3-8426-fbc9d03b605c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_b0dd1863-fb1e-41f3-8426-fbc9d03b605c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_b0dd1863-fb1e-41f3-8426-fbc9d03b605c" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_b0dd1863-fb1e-41f3-8426-fbc9d03b605c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_eed59bdb-cc31-456b-8a4e-cc46f9dfc868" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_b0dd1863-fb1e-41f3-8426-fbc9d03b605c" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_eed59bdb-cc31-456b-8a4e-cc46f9dfc868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProductLiabilitiesMember_2c7c808f-2036-42c7-98b3-d8995f81d581" xlink:href="sny-20240630.xsd#sny_ProductLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember_eed59bdb-cc31-456b-8a4e-cc46f9dfc868" xlink:to="loc_sny_ProductLiabilitiesMember_2c7c808f-2036-42c7-98b3-d8995f81d581" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated_ec198ed1-bdb6-48cd-b17c-e5b3410f20df" xlink:href="sny-20240630.xsd#sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_3fa351bb-a191-4180-b12a-ccc1bd8f4eed" xlink:to="loc_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated_ec198ed1-bdb6-48cd-b17c-e5b3410f20df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated_8d7bd783-59ec-461a-8a55-e14981db3c54" xlink:href="sny-20240630.xsd#sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_3fa351bb-a191-4180-b12a-ccc1bd8f4eed" xlink:to="loc_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated_8d7bd783-59ec-461a-8a55-e14981db3c54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPlaintiffs_6ad7d732-0f7a-4e49-b0d0-9453e65c2230" xlink:href="sny-20240630.xsd#sny_NumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_3fa351bb-a191-4180-b12a-ccc1bd8f4eed" xlink:to="loc_sny_NumberOfPlaintiffs_6ad7d732-0f7a-4e49-b0d0-9453e65c2230" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCases_6a4d7a3c-038e-49db-a3ef-c100863c5d0a" xlink:href="sny-20240630.xsd#sny_NumberOfCases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_3fa351bb-a191-4180-b12a-ccc1bd8f4eed" xlink:to="loc_sny_NumberOfCases_6a4d7a3c-038e-49db-a3ef-c100863c5d0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClassActionLawsuits_4bb606b3-6514-4dda-a803-d2e67467be89" xlink:href="sny-20240630.xsd#sny_NumberOfClassActionLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_3fa351bb-a191-4180-b12a-ccc1bd8f4eed" xlink:to="loc_sny_NumberOfClassActionLawsuits_4bb606b3-6514-4dda-a803-d2e67467be89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfDismissals_7da30259-d6d0-4314-a7c7-5572d25814cc" xlink:href="sny-20240630.xsd#sny_NumberOfDismissals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_3fa351bb-a191-4180-b12a-ccc1bd8f4eed" xlink:to="loc_sny_NumberOfDismissals_7da30259-d6d0-4314-a7c7-5572d25814cc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PenaltyFeeIncurred_43c4a03f-7571-43e9-9edc-c2b781ebad20" xlink:href="sny-20240630.xsd#sny_PenaltyFeeIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_3fa351bb-a191-4180-b12a-ccc1bd8f4eed" xlink:to="loc_sny_PenaltyFeeIncurred_43c4a03f-7571-43e9-9edc-c2b781ebad20" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#OtherOperatingIncomeAndExpensesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e56e46eb-d727-4f22-9a87-3c169f285372" xlink:href="sny-20240630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_698b18c0-595b-4bcf-b34f-e04d44a6f72f" xlink:href="sny-20240630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e56e46eb-d727-4f22-9a87-3c169f285372" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_698b18c0-595b-4bcf-b34f-e04d44a6f72f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_482d23fe-7338-4ff4-812e-369db3228a66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_698b18c0-595b-4bcf-b34f-e04d44a6f72f" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_482d23fe-7338-4ff4-812e-369db3228a66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_482d23fe-7338-4ff4-812e-369db3228a66_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_482d23fe-7338-4ff4-812e-369db3228a66" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_482d23fe-7338-4ff4-812e-369db3228a66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_4cb9f845-e291-4e05-a6f3-5b9e8575f2ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_482d23fe-7338-4ff4-812e-369db3228a66" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_4cb9f845-e291-4e05-a6f3-5b9e8575f2ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember_9dec0d0a-9a01-4b78-8c44-6db844289b96" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_4cb9f845-e291-4e05-a6f3-5b9e8575f2ca" xlink:to="loc_ifrs-full_OtherRelatedPartiesMember_9dec0d0a-9a01-4b78-8c44-6db844289b96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_9e8e8eed-ae4a-4638-9fd7-c6e1e32e51d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_698b18c0-595b-4bcf-b34f-e04d44a6f72f" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_9e8e8eed-ae4a-4638-9fd7-c6e1e32e51d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_9e8e8eed-ae4a-4638-9fd7-c6e1e32e51d2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_9e8e8eed-ae4a-4638-9fd7-c6e1e32e51d2" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_9e8e8eed-ae4a-4638-9fd7-c6e1e32e51d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_481acd68-5532-48b5-9bff-613c20066fcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_9e8e8eed-ae4a-4638-9fd7-c6e1e32e51d2" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_481acd68-5532-48b5-9bff-613c20066fcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember_59acdf4b-3edf-43de-9cee-f3e73133affd" xlink:href="sny-20240630.xsd#sny_RegeneronMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_481acd68-5532-48b5-9bff-613c20066fcf" xlink:to="loc_sny_RegeneronMember_59acdf4b-3edf-43de-9cee-f3e73133affd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_b063b2df-7e23-48c5-a147-86e1e98607cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_698b18c0-595b-4bcf-b34f-e04d44a6f72f" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_b063b2df-7e23-48c5-a147-86e1e98607cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_b063b2df-7e23-48c5-a147-86e1e98607cd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_b063b2df-7e23-48c5-a147-86e1e98607cd" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_b063b2df-7e23-48c5-a147-86e1e98607cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_bb88b1fd-f08e-4d98-9d07-ecff95b56a8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_b063b2df-7e23-48c5-a147-86e1e98607cd" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_bb88b1fd-f08e-4d98-9d07-ecff95b56a8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingIncomeExpenseMember_32ff5ee1-46f9-4847-8dfb-268750746a93" xlink:href="sny-20240630.xsd#sny_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_bb88b1fd-f08e-4d98-9d07-ecff95b56a8b" xlink:to="loc_sny_OtherOperatingIncomeExpenseMember_32ff5ee1-46f9-4847-8dfb-268750746a93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_c0bd6f3a-d5ea-4dd9-8683-09edabead5f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e56e46eb-d727-4f22-9a87-3c169f285372" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_c0bd6f3a-d5ea-4dd9-8683-09edabead5f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_7524f479-973e-443c-a949-d1eda0ed27b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e56e46eb-d727-4f22-9a87-3c169f285372" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_7524f479-973e-443c-a949-d1eda0ed27b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsOnDivestmentOfProducts_03647fac-8403-4345-b07b-241ac9541e77" xlink:href="sny-20240630.xsd#sny_GainsOnDivestmentOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e56e46eb-d727-4f22-9a87-3c169f285372" xlink:to="loc_sny_GainsOnDivestmentOfProducts_03647fac-8403-4345-b07b-241ac9541e77" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1885ea94-22be-401c-9d93-be5a7cbf35f1" xlink:href="sny-20240630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_9bb22cc1-9ed1-4946-9427-d1a031a3f913" xlink:href="sny-20240630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1885ea94-22be-401c-9d93-be5a7cbf35f1" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_9bb22cc1-9ed1-4946-9427-d1a031a3f913" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_fda6c739-6e08-4629-a20b-c24dfbd46bf7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_9bb22cc1-9ed1-4946-9427-d1a031a3f913" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_fda6c739-6e08-4629-a20b-c24dfbd46bf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_fda6c739-6e08-4629-a20b-c24dfbd46bf7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_fda6c739-6e08-4629-a20b-c24dfbd46bf7" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_fda6c739-6e08-4629-a20b-c24dfbd46bf7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_34b0e13e-75d8-4ddd-a308-121e83010321" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_fda6c739-6e08-4629-a20b-c24dfbd46bf7" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_34b0e13e-75d8-4ddd-a308-121e83010321" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember_0caaf26b-248d-4a1f-8ba0-adb95916aeec" xlink:href="sny-20240630.xsd#sny_RegeneronMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_34b0e13e-75d8-4ddd-a308-121e83010321" xlink:to="loc_sny_RegeneronMember_0caaf26b-248d-4a1f-8ba0-adb95916aeec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7a75e13d-ae32-42b8-a34c-cfd78072a105" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_9bb22cc1-9ed1-4946-9427-d1a031a3f913" xlink:to="loc_srt_CounterpartyNameAxis_7a75e13d-ae32-42b8-a34c-cfd78072a105" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a75e13d-ae32-42b8-a34c-cfd78072a105_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7a75e13d-ae32-42b8-a34c-cfd78072a105" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a75e13d-ae32-42b8-a34c-cfd78072a105_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00dac23b-3307-445d-84ef-f01d3e6c0f81" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7a75e13d-ae32-42b8-a34c-cfd78072a105" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00dac23b-3307-445d-84ef-f01d3e6c0f81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesAllianceMember_81ee5bda-1b01-4be1-aab2-9aa5488664cc" xlink:href="sny-20240630.xsd#sny_AntibodiesAllianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00dac23b-3307-445d-84ef-f01d3e6c0f81" xlink:to="loc_sny_AntibodiesAllianceMember_81ee5bda-1b01-4be1-aab2-9aa5488664cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunoOncologyAllianceMember_722800f8-2a6d-4aff-95f3-586628a0fbfc" xlink:href="sny-20240630.xsd#sny_ImmunoOncologyAllianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00dac23b-3307-445d-84ef-f01d3e6c0f81" xlink:to="loc_sny_ImmunoOncologyAllianceMember_722800f8-2a6d-4aff-95f3-586628a0fbfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OthersCounterpartyMember_d3ad6995-31af-4333-9ec5-52fd51863503" xlink:href="sny-20240630.xsd#sny_OthersCounterpartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00dac23b-3307-445d-84ef-f01d3e6c0f81" xlink:to="loc_sny_OthersCounterpartyMember_d3ad6995-31af-4333-9ec5-52fd51863503" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_d01eff86-657a-4d54-a4e3-72e032209020" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_9bb22cc1-9ed1-4946-9427-d1a031a3f913" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_d01eff86-657a-4d54-a4e3-72e032209020" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_d01eff86-657a-4d54-a4e3-72e032209020_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_d01eff86-657a-4d54-a4e3-72e032209020" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_d01eff86-657a-4d54-a4e3-72e032209020_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_0d05f1d9-1f3e-4c82-bd35-38230923e52d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_d01eff86-657a-4d54-a4e3-72e032209020" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_0d05f1d9-1f3e-4c82-bd35-38230923e52d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember_dba6ea54-68e1-416e-b685-7d0a2f6d49b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_0d05f1d9-1f3e-4c82-bd35-38230923e52d" xlink:to="loc_ifrs-full_OtherRelatedPartiesMember_dba6ea54-68e1-416e-b685-7d0a2f6d49b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_af856d7e-4751-4ebe-904a-3cde377c970a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_9bb22cc1-9ed1-4946-9427-d1a031a3f913" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_af856d7e-4751-4ebe-904a-3cde377c970a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_af856d7e-4751-4ebe-904a-3cde377c970a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_af856d7e-4751-4ebe-904a-3cde377c970a" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_af856d7e-4751-4ebe-904a-3cde377c970a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_ced5d7e4-8c96-4a7d-8e44-f381e13dd80b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_af856d7e-4751-4ebe-904a-3cde377c970a" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_ced5d7e4-8c96-4a7d-8e44-f381e13dd80b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_6711e698-c4fa-4d2b-bf78-1dabe2c2a516" xlink:href="sny-20240630.xsd#sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_ced5d7e4-8c96-4a7d-8e44-f381e13dd80b" xlink:to="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_6711e698-c4fa-4d2b-bf78-1dabe2c2a516" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_48cf593f-e5aa-4b18-895d-56bef89cc40f" xlink:href="sny-20240630.xsd#sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_ced5d7e4-8c96-4a7d-8e44-f381e13dd80b" xlink:to="loc_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_48cf593f-e5aa-4b18-895d-56bef89cc40f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercializationRelatedExpensesMember_a777825b-1525-4109-8810-7dec4862016b" xlink:href="sny-20240630.xsd#sny_CommercializationRelatedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_ced5d7e4-8c96-4a7d-8e44-f381e13dd80b" xlink:to="loc_sny_CommercializationRelatedExpensesMember_a777825b-1525-4109-8810-7dec4862016b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingIncomeExpenseMember_bcb47128-953f-47e7-881e-057cf905901a" xlink:href="sny-20240630.xsd#sny_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_ced5d7e4-8c96-4a7d-8e44-f381e13dd80b" xlink:to="loc_sny_OtherOperatingIncomeExpenseMember_bcb47128-953f-47e7-881e-057cf905901a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_aa0a8058-ec4b-44c7-a2f1-22b59cbffbbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1885ea94-22be-401c-9d93-be5a7cbf35f1" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_aa0a8058-ec4b-44c7-a2f1-22b59cbffbbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_7084d038-5521-4e0f-b82b-2aff55a4f677" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1885ea94-22be-401c-9d93-be5a7cbf35f1" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_7084d038-5521-4e0f-b82b-2aff55a4f677" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_511e507d-7b67-4cc4-aa16-10dd5e90e281" xlink:href="sny-20240630.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1885ea94-22be-401c-9d93-be5a7cbf35f1" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_511e507d-7b67-4cc4-aa16-10dd5e90e281" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_2862d203-8dcd-41b2-abef-1b27ba4a5433" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1885ea94-22be-401c-9d93-be5a7cbf35f1" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_2862d203-8dcd-41b2-abef-1b27ba4a5433" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialExpensesandIncomeDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#FinancialExpensesandIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/FinancialExpensesandIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:href="sny-20240630.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_e2a78bfc-8e75-429c-b74a-90f99c9f0e23" xlink:href="sny-20240630.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_e2a78bfc-8e75-429c-b74a-90f99c9f0e23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsAxis_b1394678-4304-48ff-ba0d-77ac125b1dc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgedItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_e2a78bfc-8e75-429c-b74a-90f99c9f0e23" xlink:to="loc_ifrs-full_HedgedItemsAxis_b1394678-4304-48ff-ba0d-77ac125b1dc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsMember_b1394678-4304-48ff-ba0d-77ac125b1dc6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgedItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgedItemsAxis_b1394678-4304-48ff-ba0d-77ac125b1dc6" xlink:to="loc_ifrs-full_HedgedItemsMember_b1394678-4304-48ff-ba0d-77ac125b1dc6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsMember_a3297c59-5170-4871-b02d-a58dae0cc13e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgedItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgedItemsAxis_b1394678-4304-48ff-ba0d-77ac125b1dc6" xlink:to="loc_ifrs-full_HedgedItemsMember_a3297c59-5170-4871-b02d-a58dae0cc13e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesMember_80064842-4133-47c2-8879-5edbe725e364" xlink:href="sny-20240630.xsd#sny_InterestRateAndCurrencyDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsMember_a3297c59-5170-4871-b02d-a58dae0cc13e" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesMember_80064842-4133-47c2-8879-5edbe725e364" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_01d056ce-1081-43d4-8bc5-4dd12f10ab43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_01d056ce-1081-43d4-8bc5-4dd12f10ab43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestIncome_0a08deb7-2140-4435-9cbc-8defee4d131c" xlink:href="sny-20240630.xsd#sny_InterestIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_sny_InterestIncome_0a08deb7-2140-4435-9cbc-8defee4d131c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CostOfDebtNet_b81b7c6d-bde3-410e-bd08-48095aa0ac88" xlink:href="sny-20240630.xsd#sny_CostOfDebtNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_sny_CostOfDebtNet_b81b7c6d-bde3-410e-bd08-48095aa0ac88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonOperatingForeignExchangeGainsLosses_0c64e147-04d5-40db-9818-6e0d50ba9de0" xlink:href="sny-20240630.xsd#sny_NonOperatingForeignExchangeGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_sny_NonOperatingForeignExchangeGainsLosses_0c64e147-04d5-40db-9818-6e0d50ba9de0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_9b06326d-eee8-44d6-9f22-32dfdfc2b29b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_9b06326d-eee8-44d6-9f22-32dfdfc2b29b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInterestCostRelatedToEmployeeBenefits_18855017-05b6-4f29-9a07-34522ce1a845" xlink:href="sny-20240630.xsd#sny_NetInterestCostRelatedToEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_sny_NetInterestCostRelatedToEmployeeBenefits_18855017-05b6-4f29-9a07-34522ce1a845" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_73dc8af0-0287-497f-93c7-ebefd37b614c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_73dc8af0-0287-497f-93c7-ebefd37b614c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_2dfb91a1-76fd-4422-bbb7-3711ffc3acaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_2dfb91a1-76fd-4422-bbb7-3711ffc3acaf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncomeCost_ed903ee6-2cee-4f54-8ed2-856c7d836735" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_ifrs-full_OtherFinanceIncomeCost_ed903ee6-2cee-4f54-8ed2-856c7d836735" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_fca9740d-e88c-4388-b8aa-27265a9c75f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_ifrs-full_FinanceIncomeCost_fca9740d-e88c-4388-b8aa-27265a9c75f3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_4c32165c-df82-4b84-a6b9-8fdf84360055" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_ifrs-full_FinanceCosts_4c32165c-df82-4b84-a6b9-8fdf84360055" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_a06c4aba-398b-419f-9883-3f0a49d940b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_ifrs-full_FinanceIncome_a06c4aba-398b-419f-9883-3f0a49d940b9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnDerivativesUsedToManageDebt_f7272e7a-67d2-42d8-ab5d-84a7ecbda35a" xlink:href="sny-20240630.xsd#sny_GainLossOnDerivativesUsedToManageDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_sny_GainLossOnDerivativesUsedToManageDebt_f7272e7a-67d2-42d8-ab5d-84a7ecbda35a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_e330bf7c-3e9e-49ce-bd43-d3c3a201e425" xlink:href="sny-20240630.xsd#sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_e330bf7c-3e9e-49ce-bd43-d3c3a201e425" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost_d137a987-f3d6-46b0-9d95-e1e577aca5fd" xlink:href="sny-20240630.xsd#sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost_d137a987-f3d6-46b0-9d95-e1e577aca5fd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties_b21d2bbb-40e1-435a-b320-762b21d20e9c" xlink:href="sny-20240630.xsd#sny_LiabilityRecognisedForEstimatedFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties_b21d2bbb-40e1-435a-b320-762b21d20e9c" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical" xlink:type="simple" xlink:href="sny-20240630.xsd#IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_ae53b97c-8845-4cd4-a83e-d46b390e55f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4ab1d385-1667-4971-a3cc-a3b07b1da19c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_ae53b97c-8845-4cd4-a83e-d46b390e55f5" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4ab1d385-1667-4971-a3cc-a3b07b1da19c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_befbd9c0-cecc-4800-bc64-0e7dc93ee112" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4ab1d385-1667-4971-a3cc-a3b07b1da19c" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_befbd9c0-cecc-4800-bc64-0e7dc93ee112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_befbd9c0-cecc-4800-bc64-0e7dc93ee112_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_befbd9c0-cecc-4800-bc64-0e7dc93ee112" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_befbd9c0-cecc-4800-bc64-0e7dc93ee112_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_7bdd2e6d-211a-40c9-bd8c-02af017a6dd6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_befbd9c0-cecc-4800-bc64-0e7dc93ee112" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_7bdd2e6d-211a-40c9-bd8c-02af017a6dd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentTaxExpenseRelatedToPillarTwo_a3f261d4-6d8b-4804-9abd-6352bd3b4cb1" xlink:href="sny-20240630.xsd#sny_CurrentTaxExpenseRelatedToPillarTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_ae53b97c-8845-4cd4-a83e-d46b390e55f5" xlink:to="loc_sny_CurrentTaxExpenseRelatedToPillarTwo_a3f261d4-6d8b-4804-9abd-6352bd3b4cb1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_a4639979-1568-451d-9cca-0ce351f93b97" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_a4639979-1568-451d-9cca-0ce351f93b97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_545d7714-f611-42df-84b5-c44ae19d45b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_a4639979-1568-451d-9cca-0ce351f93b97" xlink:to="loc_ifrs-full_GeographicalAreasAxis_545d7714-f611-42df-84b5-c44ae19d45b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_545d7714-f611-42df-84b5-c44ae19d45b5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_545d7714-f611-42df-84b5-c44ae19d45b5" xlink:to="loc_ifrs-full_GeographicalAreasMember_545d7714-f611-42df-84b5-c44ae19d45b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_1af46ae6-671a-484f-b9b4-48118d8e6352" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_545d7714-f611-42df-84b5-c44ae19d45b5" xlink:to="loc_ifrs-full_GeographicalAreasMember_1af46ae6-671a-484f-b9b4-48118d8e6352" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_1dc162ff-3f35-4ffa-b3fe-dc9a38159fa6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1af46ae6-671a-484f-b9b4-48118d8e6352" xlink:to="loc_srt_EuropeMember_1dc162ff-3f35-4ffa-b3fe-dc9a38159fa6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b8a148c3-0237-41ea-addf-aebfcf280b6f" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1af46ae6-671a-484f-b9b4-48118d8e6352" xlink:to="loc_country_US_b8a148c3-0237-41ea-addf-aebfcf280b6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember_2c6196d8-04ce-4ff5-b349-e94cc43a0f87" xlink:href="sny-20240630.xsd#sny_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_1af46ae6-671a-484f-b9b4-48118d8e6352" xlink:to="loc_sny_OtherCountriesMember_2c6196d8-04ce-4ff5-b349-e94cc43a0f87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_b9c553b3-c716-4ee1-aeab-8c8a9d4787fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_a4639979-1568-451d-9cca-0ce351f93b97" xlink:to="loc_ifrs-full_SegmentsAxis_b9c553b3-c716-4ee1-aeab-8c8a9d4787fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_b9c553b3-c716-4ee1-aeab-8c8a9d4787fc_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_b9c553b3-c716-4ee1-aeab-8c8a9d4787fc" xlink:to="loc_ifrs-full_SegmentsMember_b9c553b3-c716-4ee1-aeab-8c8a9d4787fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_d77c0fcf-39dc-4023-adcc-7d4efe2ff195" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_b9c553b3-c716-4ee1-aeab-8c8a9d4787fc" xlink:to="loc_ifrs-full_SegmentsMember_d77c0fcf-39dc-4023-adcc-7d4efe2ff195" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_e0be3bfc-004c-4911-b522-ec9f96452e3d" xlink:href="sny-20240630.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_d77c0fcf-39dc-4023-adcc-7d4efe2ff195" xlink:to="loc_sny_BiopharmaSegmentMember_e0be3bfc-004c-4911-b522-ec9f96452e3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_01ac830d-2c23-47c4-b704-e10b15cba633" xlink:href="sny-20240630.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_d77c0fcf-39dc-4023-adcc-7d4efe2ff195" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_01ac830d-2c23-47c4-b704-e10b15cba633" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaMember_5a4247de-2794-4c38-abc0-2ace32f1a35a" xlink:href="sny-20240630.xsd#sny_OpellaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_d77c0fcf-39dc-4023-adcc-7d4efe2ff195" xlink:to="loc_sny_OpellaMember_5a4247de-2794-4c38-abc0-2ace32f1a35a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllOtherSegmentsMember_f5ab685c-16a2-4e6f-8db3-24936b665d3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_d77c0fcf-39dc-4023-adcc-7d4efe2ff195" xlink:to="loc_ifrs-full_AllOtherSegmentsMember_f5ab685c-16a2-4e6f-8db3-24936b665d3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaSegmentMember_0f028122-9258-4c4d-b898-24164c5f4e8e" xlink:href="sny-20240630.xsd#sny_PharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_d77c0fcf-39dc-4023-adcc-7d4efe2ff195" xlink:to="loc_sny_PharmaSegmentMember_0f028122-9258-4c4d-b898-24164c5f4e8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProductsSegmentMember_b8bc2c88-2384-4de8-810e-e2ac1d02f2d3" xlink:href="sny-20240630.xsd#sny_OtherProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_d77c0fcf-39dc-4023-adcc-7d4efe2ff195" xlink:to="loc_sny_OtherProductsSegmentMember_b8bc2c88-2384-4de8-810e-e2ac1d02f2d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_c18c6624-3ec5-41a6-9af8-5d1280b276f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_a4639979-1568-451d-9cca-0ce351f93b97" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_c18c6624-3ec5-41a6-9af8-5d1280b276f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_c18c6624-3ec5-41a6-9af8-5d1280b276f1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_c18c6624-3ec5-41a6-9af8-5d1280b276f1" xlink:to="loc_ifrs-full_ProductsAndServicesMember_c18c6624-3ec5-41a6-9af8-5d1280b276f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_c18c6624-3ec5-41a6-9af8-5d1280b276f1" xlink:to="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SpecialtyCareMember_a3d6dd95-0102-4304-a816-390bebf372f2" xlink:href="sny-20240630.xsd#sny_SpecialtyCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_SpecialtyCareMember_a3d6dd95-0102-4304-a816-390bebf372f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DupixentMember_68c036ac-330a-4f7c-9702-80f2face9252" xlink:href="sny-20240630.xsd#sny_DupixentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_a3d6dd95-0102-4304-a816-390bebf372f2" xlink:to="loc_sny_DupixentMember_68c036ac-330a-4f7c-9702-80f2face9252" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AubagioMember_19ced847-4137-4fdd-aad1-2d78fe081f61" xlink:href="sny-20240630.xsd#sny_AubagioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_a3d6dd95-0102-4304-a816-390bebf372f2" xlink:to="loc_sny_AubagioMember_19ced847-4137-4fdd-aad1-2d78fe081f61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CerezymeMember_07a44f89-7143-4eba-b7a1-de0f415dd671" xlink:href="sny-20240630.xsd#sny_CerezymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_a3d6dd95-0102-4304-a816-390bebf372f2" xlink:to="loc_sny_CerezymeMember_07a44f89-7143-4eba-b7a1-de0f415dd671" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MyozymeLumizymeMember_6fe705f5-9421-4a36-b866-78100219806e" xlink:href="sny-20240630.xsd#sny_MyozymeLumizymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_a3d6dd95-0102-4304-a816-390bebf372f2" xlink:to="loc_sny_MyozymeLumizymeMember_6fe705f5-9421-4a36-b866-78100219806e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FabrazymeMember_f1fe59a2-097f-40aa-bf90-89d9d5dc3cab" xlink:href="sny-20240630.xsd#sny_FabrazymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_a3d6dd95-0102-4304-a816-390bebf372f2" xlink:to="loc_sny_FabrazymeMember_f1fe59a2-097f-40aa-bf90-89d9d5dc3cab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_JevtanaMember_1f67c578-ab77-4495-b572-6a6bac98c773" xlink:href="sny-20240630.xsd#sny_JevtanaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_a3d6dd95-0102-4304-a816-390bebf372f2" xlink:to="loc_sny_JevtanaMember_1f67c578-ab77-4495-b572-6a6bac98c773" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AlprolixMember_8c11c0a7-9d18-46d8-8983-e3ad177a3323" xlink:href="sny-20240630.xsd#sny_AlprolixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_a3d6dd95-0102-4304-a816-390bebf372f2" xlink:to="loc_sny_AlprolixMember_8c11c0a7-9d18-46d8-8983-e3ad177a3323" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EloctateMember_6004c491-f9f5-4d82-9716-8fcb91bcb12b" xlink:href="sny-20240630.xsd#sny_EloctateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_a3d6dd95-0102-4304-a816-390bebf372f2" xlink:to="loc_sny_EloctateMember_6004c491-f9f5-4d82-9716-8fcb91bcb12b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GeneralMedicinesMember_70b48de9-8d32-4c8a-858b-04374ec3d43d" xlink:href="sny-20240630.xsd#sny_GeneralMedicinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_GeneralMedicinesMember_70b48de9-8d32-4c8a-858b-04374ec3d43d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CoreAssetsMember_70821d68-8ef4-48a2-8219-2a4d7102a41f" xlink:href="sny-20240630.xsd#sny_CoreAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_GeneralMedicinesMember_70b48de9-8d32-4c8a-858b-04374ec3d43d" xlink:to="loc_sny_CoreAssetsMember_70821d68-8ef4-48a2-8219-2a4d7102a41f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LovenoxMember_3981daba-1feb-40cf-ad13-7550a430499a" xlink:href="sny-20240630.xsd#sny_LovenoxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_CoreAssetsMember_70821d68-8ef4-48a2-8219-2a4d7102a41f" xlink:to="loc_sny_LovenoxMember_3981daba-1feb-40cf-ad13-7550a430499a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ToujeoMember_535f1036-e127-4b6f-8b78-085b635142b7" xlink:href="sny-20240630.xsd#sny_ToujeoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_CoreAssetsMember_70821d68-8ef4-48a2-8219-2a4d7102a41f" xlink:to="loc_sny_ToujeoMember_535f1036-e127-4b6f-8b78-085b635142b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixMember_403f8d7c-075b-4941-ab9c-07a250c63334" xlink:href="sny-20240630.xsd#sny_PlavixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_CoreAssetsMember_70821d68-8ef4-48a2-8219-2a4d7102a41f" xlink:to="loc_sny_PlavixMember_403f8d7c-075b-4941-ab9c-07a250c63334" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCoreAssetsMember_1970879f-d22f-4d4e-a2f4-133281b153ee" xlink:href="sny-20240630.xsd#sny_NonCoreAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_GeneralMedicinesMember_70b48de9-8d32-4c8a-858b-04374ec3d43d" xlink:to="loc_sny_NonCoreAssetsMember_1970879f-d22f-4d4e-a2f4-133281b153ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LantusMember_767357ab-60f4-458d-90d0-63612ff1c26b" xlink:href="sny-20240630.xsd#sny_LantusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_NonCoreAssetsMember_1970879f-d22f-4d4e-a2f4-133281b153ee" xlink:to="loc_sny_LantusMember_767357ab-60f4-458d-90d0-63612ff1c26b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherNonCoreAssetsMember_acc94018-9547-46e8-970e-1051e1cbe0ef" xlink:href="sny-20240630.xsd#sny_OtherNonCoreAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_NonCoreAssetsMember_1970879f-d22f-4d4e-a2f4-133281b153ee" xlink:to="loc_sny_OtherNonCoreAssetsMember_acc94018-9547-46e8-970e-1051e1cbe0ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IndustrialSalesMember_c43bedcc-b1cf-41d6-a712-ff3eed48bb0a" xlink:href="sny-20240630.xsd#sny_IndustrialSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_GeneralMedicinesMember_70b48de9-8d32-4c8a-858b-04374ec3d43d" xlink:to="loc_sny_IndustrialSalesMember_c43bedcc-b1cf-41d6-a712-ff3eed48bb0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesMember_0bff2710-6685-479f-9b69-fce0997b03cb" xlink:href="sny-20240630.xsd#sny_VaccinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_VaccinesMember_0bff2710-6685-479f-9b69-fce0997b03cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PolioPertussisHibVaccinesMember_c79ea395-33f4-4068-a159-1e3e609499e5" xlink:href="sny-20240630.xsd#sny_PolioPertussisHibVaccinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_VaccinesMember_0bff2710-6685-479f-9b69-fce0997b03cb" xlink:to="loc_sny_PolioPertussisHibVaccinesMember_c79ea395-33f4-4068-a159-1e3e609499e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfluenzaVaccinesMember_f24341e9-f5df-48c0-bd49-801672d136d2" xlink:href="sny-20240630.xsd#sny_InfluenzaVaccinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_VaccinesMember_0bff2710-6685-479f-9b69-fce0997b03cb" xlink:to="loc_sny_InfluenzaVaccinesMember_f24341e9-f5df-48c0-bd49-801672d136d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AllergyMember_197cc7d5-14ce-410c-ba44-152a8a532a65" xlink:href="sny-20240630.xsd#sny_AllergyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_AllergyMember_197cc7d5-14ce-410c-ba44-152a8a532a65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PainCareMember_f6be1b7c-c16f-4942-82a2-f55a842bad7b" xlink:href="sny-20240630.xsd#sny_PainCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_PainCareMember_f6be1b7c-c16f-4942-82a2-f55a842bad7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DigestiveWellnessMember_588bf19e-af11-4215-9f7b-063d19f45eda" xlink:href="sny-20240630.xsd#sny_DigestiveWellnessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_DigestiveWellnessMember_588bf19e-af11-4215-9f7b-063d19f45eda" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NexviazymeMember_d0c1251f-08a1-448e-b539-482cbe1dc531" xlink:href="sny-20240630.xsd#sny_NexviazymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_NexviazymeMember_d0c1251f-08a1-448e-b539-482cbe1dc531" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SarclisaMember_bc2d5164-4526-4d21-8419-5e686a193046" xlink:href="sny-20240630.xsd#sny_SarclisaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_SarclisaMember_bc2d5164-4526-4d21-8419-5e686a193046" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AltuviiioMember_9332edca-0d7a-43a3-a6ad-8887334bea8f" xlink:href="sny-20240630.xsd#sny_AltuviiioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_AltuviiioMember_9332edca-0d7a-43a3-a6ad-8887334bea8f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RezurockMember_efe28d56-8326-4ec7-a4c4-3f8d439eb85d" xlink:href="sny-20240630.xsd#sny_RezurockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_RezurockMember_efe28d56-8326-4ec7-a4c4-3f8d439eb85d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CabliviMember_4c745fb6-eedf-4b7c-a2a7-665402f1d180" xlink:href="sny-20240630.xsd#sny_CabliviMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_CabliviMember_4c745fb6-eedf-4b7c-a2a7-665402f1d180" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_XenpozymeMember_5b8236e4-bad9-44fd-864f-5164505b776b" xlink:href="sny-20240630.xsd#sny_XenpozymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_XenpozymeMember_5b8236e4-bad9-44fd-864f-5164505b776b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EnjaymoMember_6babad9e-5765-46d2-9b47-5ee3e386c991" xlink:href="sny-20240630.xsd#sny_EnjaymoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_EnjaymoMember_6babad9e-5765-46d2-9b47-5ee3e386c991" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TzieldMember_a7776f11-7712-4986-a4f9-c8f88a16e2be" xlink:href="sny-20240630.xsd#sny_TzieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_TzieldMember_a7776f11-7712-4986-a4f9-c8f88a16e2be" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RSVVaccinesMember_8d916eab-4296-467e-b9e9-bcdf9fe18830" xlink:href="sny-20240630.xsd#sny_RSVVaccinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_RSVVaccinesMember_8d916eab-4296-467e-b9e9-bcdf9fe18830" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MeningitisTravelAndEndemicVaccinesMember_2b22059f-3527-4e3f-bf4d-88a19e18c81c" xlink:href="sny-20240630.xsd#sny_MeningitisTravelAndEndemicVaccinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_MeningitisTravelAndEndemicVaccinesMember_2b22059f-3527-4e3f-bf4d-88a19e18c81c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SeasonalSymptomsAndPainReliefMember_83d398d3-fe63-4302-bb33-613dd771cf43" xlink:href="sny-20240630.xsd#sny_SeasonalSymptomsAndPainReliefMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_SeasonalSymptomsAndPainReliefMember_83d398d3-fe63-4302-bb33-613dd771cf43" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WellnessBrandsMember_3e5cbbf6-b7b3-4496-8e8a-ea574d8dbacd" xlink:href="sny-20240630.xsd#sny_WellnessBrandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_WellnessBrandsMember_3e5cbbf6-b7b3-4496-8e8a-ea574d8dbacd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OthersMember_492c3237-a8d3-46b9-9d35-af202860e690" xlink:href="sny-20240630.xsd#sny_OthersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_OthersMember_492c3237-a8d3-46b9-9d35-af202860e690" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_442175cd-ce04-4d5d-91be-8f46439dbf6d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_a4639979-1568-451d-9cca-0ce351f93b97" xlink:to="loc_srt_ProductOrServiceAxis_442175cd-ce04-4d5d-91be-8f46439dbf6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_442175cd-ce04-4d5d-91be-8f46439dbf6d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_442175cd-ce04-4d5d-91be-8f46439dbf6d" xlink:to="loc_srt_ProductsAndServicesDomain_442175cd-ce04-4d5d-91be-8f46439dbf6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_46961d04-5378-41d2-98f1-246d18be02d9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_442175cd-ce04-4d5d-91be-8f46439dbf6d" xlink:to="loc_srt_ProductsAndServicesDomain_46961d04-5378-41d2-98f1-246d18be02d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaSegmentMember_283fd640-478d-4d7f-88dc-934f9ee89525" xlink:href="sny-20240630.xsd#sny_PharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_46961d04-5378-41d2-98f1-246d18be02d9" xlink:to="loc_sny_PharmaSegmentMember_283fd640-478d-4d7f-88dc-934f9ee89525" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaLaunchesMember_93be2ee0-81b1-4798-a0e9-ad6c8e846dc4" xlink:href="sny-20240630.xsd#sny_PharmaLaunchesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_46961d04-5378-41d2-98f1-246d18be02d9" xlink:to="loc_sny_PharmaLaunchesMember_93be2ee0-81b1-4798-a0e9-ad6c8e846dc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProductsSegmentMember_ebb09660-8522-423c-86e8-874f52f3e284" xlink:href="sny-20240630.xsd#sny_OtherProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_46961d04-5378-41d2-98f1-246d18be02d9" xlink:to="loc_sny_OtherProductsSegmentMember_ebb09660-8522-423c-86e8-874f52f3e284" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_827d64f5-5194-4924-a254-633e4e50076b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_827d64f5-5194-4924-a254-633e4e50076b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments_6e7e0907-7529-4b8a-ae18-2a014c8c0f30" xlink:href="sny-20240630.xsd#sny_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_sny_NumberOfOperatingSegments_6e7e0907-7529-4b8a-ae18-2a014c8c0f30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_fe76df81-96f4-4376-9ec2-9953cef68e71" xlink:href="sny-20240630.xsd#sny_BusinessOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_sny_BusinessOperatingIncome_fe76df81-96f4-4376-9ec2-9953cef68e71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_d81ec377-46a8-4239-9e71-4d61f34bc56c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_ifrs-full_OtherRevenue_d81ec377-46a8-4239-9e71-4d61f34bc56c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_7824b5cf-bb94-498a-8f53-ea2a7fb37433" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_ifrs-full_CostOfSales_7824b5cf-bb94-498a-8f53-ea2a7fb37433" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_7a09168f-64e4-4804-821f-e554283faabd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_7a09168f-64e4-4804-821f-e554283faabd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_d547017c-6284-4b01-a774-b002d86043d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_d547017c-6284-4b01-a774-b002d86043d4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_1b067839-ee87-42b5-aac1-60fee5f1c37d" xlink:href="sny-20240630.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_1b067839-ee87-42b5-aac1-60fee5f1c37d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_d57018a8-26a2-4ae1-aa74-1fca48ef8e57" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_d57018a8-26a2-4ae1-aa74-1fca48ef8e57" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_84d806d4-f7a3-42e0-bb4e-2d64a6c997fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_84d806d4-f7a3-42e0-bb4e-2d64a6c997fa" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#SegmentInformationScheduleofSegmentResultsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_f3d32f59-53d4-4c67-acaa-ae85b765d9a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_f3d32f59-53d4-4c67-acaa-ae85b765d9a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_5f823050-dc78-48e8-b073-2f54d4a5b00c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_f3d32f59-53d4-4c67-acaa-ae85b765d9a4" xlink:to="loc_ifrs-full_SegmentsAxis_5f823050-dc78-48e8-b073-2f54d4a5b00c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_5f823050-dc78-48e8-b073-2f54d4a5b00c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_5f823050-dc78-48e8-b073-2f54d4a5b00c" xlink:to="loc_ifrs-full_SegmentsMember_5f823050-dc78-48e8-b073-2f54d4a5b00c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_2c912e0a-670f-4dd2-a1ed-61e371ae1a19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_5f823050-dc78-48e8-b073-2f54d4a5b00c" xlink:to="loc_ifrs-full_SegmentsMember_2c912e0a-670f-4dd2-a1ed-61e371ae1a19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReportableSegmentsMember_b7fc9f50-1187-4814-8eb2-f9414ce48f5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReportableSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_2c912e0a-670f-4dd2-a1ed-61e371ae1a19" xlink:to="loc_ifrs-full_ReportableSegmentsMember_b7fc9f50-1187-4814-8eb2-f9414ce48f5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_40815b01-64cf-4401-ad42-de514e746487" xlink:href="sny-20240630.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReportableSegmentsMember_b7fc9f50-1187-4814-8eb2-f9414ce48f5a" xlink:to="loc_sny_BiopharmaSegmentMember_40815b01-64cf-4401-ad42-de514e746487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_570ba325-1a98-42c3-b38b-0e006b50f985" xlink:href="sny-20240630.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReportableSegmentsMember_b7fc9f50-1187-4814-8eb2-f9414ce48f5a" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_570ba325-1a98-42c3-b38b-0e006b50f985" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllOtherSegmentsMember_ac626560-6a74-49b2-8cc8-961710102766" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReportableSegmentsMember_b7fc9f50-1187-4814-8eb2-f9414ce48f5a" xlink:to="loc_ifrs-full_AllOtherSegmentsMember_ac626560-6a74-49b2-8cc8-961710102766" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_6f439544-e6be-414b-bb1a-5de1886998bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_6f439544-e6be-414b-bb1a-5de1886998bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_1841b8c1-b257-496f-97da-5c836149150d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_ifrs-full_OtherRevenue_1841b8c1-b257-496f-97da-5c836149150d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_e3fcf8f7-44b5-416e-8335-ed8079c82b01" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_ifrs-full_CostOfSales_e3fcf8f7-44b5-416e-8335-ed8079c82b01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_bafad0cc-9366-46fe-b460-37a477e40500" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_bafad0cc-9366-46fe-b460-37a477e40500" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_cca28ddd-5849-45a5-9e73-221399f42cd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_cca28ddd-5849-45a5-9e73-221399f42cd4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_3948fac4-9d9b-4056-9132-f523d053e5f0" xlink:href="sny-20240630.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_3948fac4-9d9b-4056-9132-f523d053e5f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_02725475-9691-48be-9a1b-8f7498f163cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_02725475-9691-48be-9a1b-8f7498f163cf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_58a08b25-052c-4726-8695-44d3981cf64f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_58a08b25-052c-4726-8695-44d3981cf64f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_89fb9117-2152-47e5-9abd-3fd144507b01" xlink:href="sny-20240630.xsd#sny_BusinessOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_sny_BusinessOperatingIncome_89fb9117-2152-47e5-9abd-3fd144507b01" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments_8055e36f-7083-405e-9418-404489caba3c" xlink:href="sny-20240630.xsd#sny_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_sny_NumberOfOperatingSegments_8055e36f-7083-405e-9418-404489caba3c" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_7cb6ad3c-a0c5-4559-a63e-52f0b366f2c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_7cb6ad3c-a0c5-4559-a63e-52f0b366f2c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsAxis_8cbc73ab-1eed-45a4-9684-e93d31ab1258" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_7cb6ad3c-a0c5-4559-a63e-52f0b366f2c6" xlink:to="loc_ifrs-full_SegmentConsolidationItemsAxis_8cbc73ab-1eed-45a4-9684-e93d31ab1258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_8cbc73ab-1eed-45a4-9684-e93d31ab1258_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentConsolidationItemsAxis_8cbc73ab-1eed-45a4-9684-e93d31ab1258" xlink:to="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_8cbc73ab-1eed-45a4-9684-e93d31ab1258_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_7b00b299-7415-4b72-8543-e65f0a5ebc34" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentConsolidationItemsAxis_8cbc73ab-1eed-45a4-9684-e93d31ab1258" xlink:to="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_7b00b299-7415-4b72-8543-e65f0a5ebc34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingSegmentsMember_0810fa54-8ffe-43ae-b007-5949529af8ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_7b00b299-7415-4b72-8543-e65f0a5ebc34" xlink:to="loc_ifrs-full_OperatingSegmentsMember_0810fa54-8ffe-43ae-b007-5949529af8ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaterialReconcilingItemsMember_f5ba54de-50d4-41a2-91aa-6fcc8c3f9f9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_7b00b299-7415-4b72-8543-e65f0a5ebc34" xlink:to="loc_ifrs-full_MaterialReconcilingItemsMember_f5ba54de-50d4-41a2-91aa-6fcc8c3f9f9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_5cf7c520-7c0a-4e60-bbf0-46ba636634f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_7cb6ad3c-a0c5-4559-a63e-52f0b366f2c6" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_5cf7c520-7c0a-4e60-bbf0-46ba636634f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_5cf7c520-7c0a-4e60-bbf0-46ba636634f9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_5cf7c520-7c0a-4e60-bbf0-46ba636634f9" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_5cf7c520-7c0a-4e60-bbf0-46ba636634f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_2c986bad-3d22-4923-aee8-75ff3728da08" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_5cf7c520-7c0a-4e60-bbf0-46ba636634f9" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_2c986bad-3d22-4923-aee8-75ff3728da08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember_bd7eb3c2-eeb5-4e55-b19a-472ebc83628f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_2c986bad-3d22-4923-aee8-75ff3728da08" xlink:to="loc_ifrs-full_OtherIntangibleAssetsMember_bd7eb3c2-eeb5-4e55-b19a-472ebc83628f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_f52e6d45-0db3-4ff5-8cbe-e5caefa2b58a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_7cb6ad3c-a0c5-4559-a63e-52f0b366f2c6" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_f52e6d45-0db3-4ff5-8cbe-e5caefa2b58a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_f52e6d45-0db3-4ff5-8cbe-e5caefa2b58a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_f52e6d45-0db3-4ff5-8cbe-e5caefa2b58a" xlink:to="loc_ifrs-full_ProductsAndServicesMember_f52e6d45-0db3-4ff5-8cbe-e5caefa2b58a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_2349ee80-d930-426f-b66c-c4296cf394ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_f52e6d45-0db3-4ff5-8cbe-e5caefa2b58a" xlink:to="loc_ifrs-full_ProductsAndServicesMember_2349ee80-d930-426f-b66c-c4296cf394ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EloctateMember_0ef7f1ce-4fed-4bce-9725-eabe40e019e5" xlink:href="sny-20240630.xsd#sny_EloctateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_2349ee80-d930-426f-b66c-c4296cf394ad" xlink:to="loc_sny_EloctateMember_0ef7f1ce-4fed-4bce-9725-eabe40e019e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SAR44425Member_c0cd51f8-d60e-49e5-8ec7-f8cec3312905" xlink:href="sny-20240630.xsd#sny_SAR44425Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_2349ee80-d930-426f-b66c-c4296cf394ad" xlink:to="loc_sny_SAR44425Member_c0cd51f8-d60e-49e5-8ec7-f8cec3312905" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_c0445a13-575e-452a-abe7-f9e027e2901d" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_7cb6ad3c-a0c5-4559-a63e-52f0b366f2c6" xlink:to="loc_sny_PrincipalAlliancesAxis_c0445a13-575e-452a-abe7-f9e027e2901d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_c0445a13-575e-452a-abe7-f9e027e2901d_default" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_PrincipalAlliancesAxis_c0445a13-575e-452a-abe7-f9e027e2901d" xlink:to="loc_sny_PrincipalAlliancesDomain_c0445a13-575e-452a-abe7-f9e027e2901d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_fe7edfda-8142-4c1f-af79-6e94a5eaccfe" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_PrincipalAlliancesAxis_c0445a13-575e-452a-abe7-f9e027e2901d" xlink:to="loc_sny_PrincipalAlliancesDomain_fe7edfda-8142-4c1f-af79-6e94a5eaccfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunoOncologyCollaborationAgreementMember_da7e39b0-dc38-4fae-a62c-dc5bc2426229" xlink:href="sny-20240630.xsd#sny_ImmunoOncologyCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_fe7edfda-8142-4c1f-af79-6e94a5eaccfe" xlink:to="loc_sny_ImmunoOncologyCollaborationAgreementMember_da7e39b0-dc38-4fae-a62c-dc5bc2426229" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_ec1bd55c-e225-42be-90a7-27de5a28fd6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_7cb6ad3c-a0c5-4559-a63e-52f0b366f2c6" xlink:to="loc_ifrs-full_CounterpartiesAxis_ec1bd55c-e225-42be-90a7-27de5a28fd6d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_ec1bd55c-e225-42be-90a7-27de5a28fd6d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_ec1bd55c-e225-42be-90a7-27de5a28fd6d" xlink:to="loc_ifrs-full_CounterpartiesMember_ec1bd55c-e225-42be-90a7-27de5a28fd6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_7f38c54b-f94b-4da6-86f2-dc952e05feaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_ec1bd55c-e225-42be-90a7-27de5a28fd6d" xlink:to="loc_ifrs-full_CounterpartiesMember_7f38c54b-f94b-4da6-86f2-dc952e05feaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember_53966a94-1045-4f98-8028-8275ac919a0d" xlink:href="sny-20240630.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_7f38c54b-f94b-4da6-86f2-dc952e05feaf" xlink:to="loc_sny_RegeneronPharmaceuticalsIncMember_53966a94-1045-4f98-8028-8275ac919a0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_84a38248-d454-4b6f-8b4b-64a3d5bdf612" xlink:href="sny-20240630.xsd#sny_BusinessOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_sny_BusinessOperatingIncome_84a38248-d454-4b6f-8b4b-64a3d5bdf612" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_a6b4f975-38e8-4700-996a-2da1672ae649" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_a6b4f975-38e8-4700-996a-2da1672ae649" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_8a8dfa6d-94c5-44da-9b54-59452536b3b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_8a8dfa6d-94c5-44da-9b54-59452536b3b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_b66aa5a6-959a-4c15-92b6-8967f07f7250" xlink:href="sny-20240630.xsd#sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_b66aa5a6-959a-4c15-92b6-8967f07f7250" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_c3923d7d-812a-4485-8749-c24f4668bb4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_c3923d7d-812a-4485-8749-c24f4668bb4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_ab88375e-8287-4922-82e5-ad108f817c5f" xlink:href="sny-20240630.xsd#sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_ab88375e-8287-4922-82e5-ad108f817c5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_ab5b0708-e62b-42dc-a68b-147489d43c02" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_ab5b0708-e62b-42dc-a68b-147489d43c02" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_5033d349-a14f-44fe-a1fe-ad00664bbddf" xlink:href="sny-20240630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_sny_OtherGainsLossesAndLitigation_5033d349-a14f-44fe-a1fe-ad00664bbddf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeResultingFromOutLicensing_8f9067d3-921a-461e-a679-a1b0f4085f7a" xlink:href="sny-20240630.xsd#sny_IncomeResultingFromOutLicensing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_sny_IncomeResultingFromOutLicensing_8f9067d3-921a-461e-a679-a1b0f4085f7a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_15b69573-cdbb-48f9-9194-5524c01fd4bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_15b69573-cdbb-48f9-9194-5524c01fd4bc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_8dfd5b45-3081-400c-8caf-ae1bdcb9cb43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_ifrs-full_FinanceCosts_8dfd5b45-3081-400c-8caf-ae1bdcb9cb43" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_84211bbf-f5b6-42b5-9661-b1460c474cf4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_ifrs-full_FinanceIncome_84211bbf-f5b6-42b5-9661-b1460c474cf4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_62709543-06e6-4e1b-8c4c-43c3c821dfbd" xlink:href="sny-20240630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_62709543-06e6-4e1b-8c4c-43c3c821dfbd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_9f930801-2f29-41f5-ad12-df7fe6e58699" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_9f930801-2f29-41f5-ad12-df7fe6e58699" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_ca2a48a0-67f9-42e1-9808-09e286ac2d70" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_ca2a48a0-67f9-42e1-9808-09e286ac2d70" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_2e3cb07c-c0d5-4afe-a967-547280427bed" xlink:href="sny-20240630.xsd#sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_2e3cb07c-c0d5-4afe-a967-547280427bed" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_547005ad-e102-4084-9818-c4d2586b0e6d" xlink:href="sny-20240630.xsd#sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_547005ad-e102-4084-9818-c4d2586b0e6d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetReversalOfImpairmentLoss_7be9058a-1e14-491b-9f46-38ee73887d6c" xlink:href="sny-20240630.xsd#sny_NetReversalOfImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_sny_NetReversalOfImpairmentLoss_7be9058a-1e14-491b-9f46-38ee73887d6c" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_04762100-c29f-4f91-827e-aa1ed95f00bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_90cf4d31-7e08-4d76-81de-78fbcafa2aac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_04762100-c29f-4f91-827e-aa1ed95f00bb" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_90cf4d31-7e08-4d76-81de-78fbcafa2aac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_86bc1bd9-a8f1-4e30-afe0-c5bb006a152f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_90cf4d31-7e08-4d76-81de-78fbcafa2aac" xlink:to="loc_ifrs-full_SegmentsAxis_86bc1bd9-a8f1-4e30-afe0-c5bb006a152f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_86bc1bd9-a8f1-4e30-afe0-c5bb006a152f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_86bc1bd9-a8f1-4e30-afe0-c5bb006a152f" xlink:to="loc_ifrs-full_SegmentsMember_86bc1bd9-a8f1-4e30-afe0-c5bb006a152f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_356af9b4-c284-44b0-9d7f-969eb886f720" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_86bc1bd9-a8f1-4e30-afe0-c5bb006a152f" xlink:to="loc_ifrs-full_SegmentsMember_356af9b4-c284-44b0-9d7f-969eb886f720" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReportableSegmentsMember_4a4e2fd2-8c49-4c25-81f4-c64e97666624" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReportableSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_356af9b4-c284-44b0-9d7f-969eb886f720" xlink:to="loc_ifrs-full_ReportableSegmentsMember_4a4e2fd2-8c49-4c25-81f4-c64e97666624" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_e0a38c7e-f12e-441b-adae-69c3d7ff91f5" xlink:href="sny-20240630.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReportableSegmentsMember_4a4e2fd2-8c49-4c25-81f4-c64e97666624" xlink:to="loc_sny_BiopharmaSegmentMember_e0a38c7e-f12e-441b-adae-69c3d7ff91f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_0980649a-4017-4e41-ac15-3b76246110de" xlink:href="sny-20240630.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReportableSegmentsMember_4a4e2fd2-8c49-4c25-81f4-c64e97666624" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_0980649a-4017-4e41-ac15-3b76246110de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaMember_79935007-2da5-430d-b779-1e65bf65d0d0" xlink:href="sny-20240630.xsd#sny_OpellaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_356af9b4-c284-44b0-9d7f-969eb886f720" xlink:to="loc_sny_OpellaMember_79935007-2da5-430d-b779-1e65bf65d0d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_068ea6a8-94e9-4edd-adf4-e9b4efc702cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_04762100-c29f-4f91-827e-aa1ed95f00bb" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_068ea6a8-94e9-4edd-adf4-e9b4efc702cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_1378cb90-de21-4175-950e-3d8d965a9425" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_04762100-c29f-4f91-827e-aa1ed95f00bb" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_1378cb90-de21-4175-950e-3d8d965a9425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_9bf7a21d-81bd-44d2-8708-e2fb4ff17d4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_04762100-c29f-4f91-827e-aa1ed95f00bb" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_9bf7a21d-81bd-44d2-8708-e2fb4ff17d4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments_5f05cf4f-f44c-4df2-b7fe-bc23eccc89f9" xlink:href="sny-20240630.xsd#sny_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_04762100-c29f-4f91-827e-aa1ed95f00bb" xlink:to="loc_sny_NumberOfOperatingSegments_5f05cf4f-f44c-4df2-b7fe-bc23eccc89f9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_9220a667-97b1-40c1-9a42-e3054c7953f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_cf8803a2-7629-41d1-83b9-9a803830c5cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_9220a667-97b1-40c1-9a42-e3054c7953f2" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_cf8803a2-7629-41d1-83b9-9a803830c5cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_efef6c4e-0acf-4f29-964d-df44448114dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_cf8803a2-7629-41d1-83b9-9a803830c5cf" xlink:to="loc_ifrs-full_GeographicalAreasAxis_efef6c4e-0acf-4f29-964d-df44448114dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_efef6c4e-0acf-4f29-964d-df44448114dc_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_efef6c4e-0acf-4f29-964d-df44448114dc" xlink:to="loc_ifrs-full_GeographicalAreasMember_efef6c4e-0acf-4f29-964d-df44448114dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_28a97414-387a-4d30-b5f6-5caa863d6560" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_efef6c4e-0acf-4f29-964d-df44448114dc" xlink:to="loc_ifrs-full_GeographicalAreasMember_28a97414-387a-4d30-b5f6-5caa863d6560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReportableGeographicalZonesMember_17bc22b7-018c-48ba-9490-b9c849bb128a" xlink:href="sny-20240630.xsd#sny_ReportableGeographicalZonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_28a97414-387a-4d30-b5f6-5caa863d6560" xlink:to="loc_sny_ReportableGeographicalZonesMember_17bc22b7-018c-48ba-9490-b9c849bb128a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_5b9802ca-6929-4739-88f6-d84d9a43fa8a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ReportableGeographicalZonesMember_17bc22b7-018c-48ba-9490-b9c849bb128a" xlink:to="loc_srt_EuropeMember_5b9802ca-6929-4739-88f6-d84d9a43fa8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_0ea7e859-f773-40f5-b2cf-3669df4af332" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EuropeMember_5b9802ca-6929-4739-88f6-d84d9a43fa8a" xlink:to="loc_country_FR_0ea7e859-f773-40f5-b2cf-3669df4af332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f6dc2711-1c96-4be6-a7aa-0a1fd73b4699" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ReportableGeographicalZonesMember_17bc22b7-018c-48ba-9490-b9c849bb128a" xlink:to="loc_country_US_f6dc2711-1c96-4be6-a7aa-0a1fd73b4699" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_e14dd2dd-b124-4548-b260-ab1ccba2040c" xlink:href="sny-20240630.xsd#sny_OtherCountriesExcludingEuropeAndNorthAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ReportableGeographicalZonesMember_17bc22b7-018c-48ba-9490-b9c849bb128a" xlink:to="loc_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_e14dd2dd-b124-4548-b260-ab1ccba2040c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_2a28e552-5442-4eef-9061-02dce2b0e430" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_9220a667-97b1-40c1-9a42-e3054c7953f2" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_2a28e552-5442-4eef-9061-02dce2b0e430" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_b45bed6f-3484-4128-8a12-a2d340c6b681" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_9220a667-97b1-40c1-9a42-e3054c7953f2" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_b45bed6f-3484-4128-8a12-a2d340c6b681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_1a412ec4-6f72-4f9c-962e-63f6073b5ede" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_b45bed6f-3484-4128-8a12-a2d340c6b681" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_1a412ec4-6f72-4f9c-962e-63f6073b5ede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_718e4201-fc2a-413c-9bae-4db9ec5cd3e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_b45bed6f-3484-4128-8a12-a2d340c6b681" xlink:to="loc_ifrs-full_Goodwill_718e4201-fc2a-413c-9bae-4db9ec5cd3e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_d0661b9b-4ba3-4a98-806e-32f47738ea4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_b45bed6f-3484-4128-8a12-a2d340c6b681" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_d0661b9b-4ba3-4a98-806e-32f47738ea4e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#SegmentInformationPrincipalCustomersandCreditRiskDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_c9638347-d0b3-41b1-8404-e1401ff72068" xlink:href="sny-20240630.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_ee3cd036-d1ac-4d00-bf5e-5224e967be3b" xlink:href="sny-20240630.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_c9638347-d0b3-41b1-8404-e1401ff72068" xlink:to="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_ee3cd036-d1ac-4d00-bf5e-5224e967be3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis_9f8b3888-14db-4755-a3b3-82f8fd44df8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_ee3cd036-d1ac-4d00-bf5e-5224e967be3b" xlink:to="loc_ifrs-full_MajorCustomersAxis_9f8b3888-14db-4755-a3b3-82f8fd44df8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember_9f8b3888-14db-4755-a3b3-82f8fd44df8a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MajorCustomersAxis_9f8b3888-14db-4755-a3b3-82f8fd44df8a" xlink:to="loc_ifrs-full_MajorCustomersMember_9f8b3888-14db-4755-a3b3-82f8fd44df8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember_0c64bee3-6b45-4fed-bfbc-377d5e5302d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MajorCustomersAxis_9f8b3888-14db-4755-a3b3-82f8fd44df8a" xlink:to="loc_ifrs-full_MajorCustomersMember_0c64bee3-6b45-4fed-bfbc-377d5e5302d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CertainWholesalersInTheUnitedStatesMember_1439fe70-fb64-417f-bd74-2acfeb963328" xlink:href="sny-20240630.xsd#sny_CertainWholesalersInTheUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_0c64bee3-6b45-4fed-bfbc-377d5e5302d8" xlink:to="loc_sny_CertainWholesalersInTheUnitedStatesMember_1439fe70-fb64-417f-bd74-2acfeb963328" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerOneMember_46a2149e-e876-45db-a115-8cb3b6ca6884" xlink:href="sny-20240630.xsd#sny_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_0c64bee3-6b45-4fed-bfbc-377d5e5302d8" xlink:to="loc_sny_CustomerOneMember_46a2149e-e876-45db-a115-8cb3b6ca6884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerTwoMember_416aa220-4ee2-4754-9a7f-b42b37895cfb" xlink:href="sny-20240630.xsd#sny_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_0c64bee3-6b45-4fed-bfbc-377d5e5302d8" xlink:to="loc_sny_CustomerTwoMember_416aa220-4ee2-4754-9a7f-b42b37895cfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerThreeMember_5fbbcedd-c541-4100-bbfe-5845273d26a7" xlink:href="sny-20240630.xsd#sny_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_0c64bee3-6b45-4fed-bfbc-377d5e5302d8" xlink:to="loc_sny_CustomerThreeMember_5fbbcedd-c541-4100-bbfe-5845273d26a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfEntitysRevenue_ce3ae105-b258-4e3b-b385-fe8083d8e569" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfEntitysRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_c9638347-d0b3-41b1-8404-e1401ff72068" xlink:to="loc_ifrs-full_PercentageOfEntitysRevenue_ce3ae105-b258-4e3b-b385-fe8083d8e569" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/EventsSubsequenttoJune302023Details" xlink:type="simple" xlink:href="sny-20240630.xsd#EventsSubsequenttoJune302023Details"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/EventsSubsequenttoJune302023Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_848b8bd4-3fda-4b81-b2ef-3646f7f10879" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_da742460-e2cf-431c-8d15-e94d502caf0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_848b8bd4-3fda-4b81-b2ef-3646f7f10879" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_da742460-e2cf-431c-8d15-e94d502caf0f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_0d3b28a9-b865-4080-bf33-508e064ab30b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_da742460-e2cf-431c-8d15-e94d502caf0f" xlink:to="loc_ifrs-full_CounterpartiesAxis_0d3b28a9-b865-4080-bf33-508e064ab30b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_0d3b28a9-b865-4080-bf33-508e064ab30b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_0d3b28a9-b865-4080-bf33-508e064ab30b" xlink:to="loc_ifrs-full_CounterpartiesMember_0d3b28a9-b865-4080-bf33-508e064ab30b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_3022df69-0a37-41c3-bb2b-05d56a22f15a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_0d3b28a9-b865-4080-bf33-508e064ab30b" xlink:to="loc_ifrs-full_CounterpartiesMember_3022df69-0a37-41c3-bb2b-05d56a22f15a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RecludixPharmaMember_95db97fc-3c00-4661-8933-0173cd765a2a" xlink:href="sny-20240630.xsd#sny_RecludixPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_3022df69-0a37-41c3-bb2b-05d56a22f15a" xlink:to="loc_sny_RecludixPharmaMember_95db97fc-3c00-4661-8933-0173cd765a2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_691ba471-8e51-4171-8c44-74a47708795f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_da742460-e2cf-431c-8d15-e94d502caf0f" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_691ba471-8e51-4171-8c44-74a47708795f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_691ba471-8e51-4171-8c44-74a47708795f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_691ba471-8e51-4171-8c44-74a47708795f" xlink:to="loc_ifrs-full_NonadjustingEventsMember_691ba471-8e51-4171-8c44-74a47708795f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_d18c7396-ac46-4a1c-b6be-b03eae090afd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_691ba471-8e51-4171-8c44-74a47708795f" xlink:to="loc_ifrs-full_NonadjustingEventsMember_d18c7396-ac46-4a1c-b6be-b03eae090afd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorCollaborationAgreementMember_0fcb2665-8c72-4f44-9489-14bff00fb27a" xlink:href="sny-20240630.xsd#sny_MajorCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_d18c7396-ac46-4a1c-b6be-b03eae090afd" xlink:to="loc_sny_MajorCollaborationAgreementMember_0fcb2665-8c72-4f44-9489-14bff00fb27a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorBusinessCombinationMember_65148179-61e0-46bd-aed5-4925230468c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorBusinessCombinationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_d18c7396-ac46-4a1c-b6be-b03eae090afd" xlink:to="loc_ifrs-full_MajorBusinessCombinationMember_65148179-61e0-46bd-aed5-4925230468c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_f1cc038b-7f83-43fe-adfb-664e4bc205bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_da742460-e2cf-431c-8d15-e94d502caf0f" xlink:to="loc_ifrs-full_RangeAxis_f1cc038b-7f83-43fe-adfb-664e4bc205bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_f1cc038b-7f83-43fe-adfb-664e4bc205bf_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_f1cc038b-7f83-43fe-adfb-664e4bc205bf" xlink:to="loc_ifrs-full_RangesMember_f1cc038b-7f83-43fe-adfb-664e4bc205bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_3e421c20-f513-4647-9c5b-1591b7f3bcc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_f1cc038b-7f83-43fe-adfb-664e4bc205bf" xlink:to="loc_ifrs-full_RangesMember_3e421c20-f513-4647-9c5b-1591b7f3bcc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c763f1ea-574a-485b-a0fe-69416c5ec598" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_3e421c20-f513-4647-9c5b-1591b7f3bcc6" xlink:to="loc_srt_MaximumMember_c763f1ea-574a-485b-a0fe-69416c5ec598" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_183114d7-d134-4aeb-8b71-e7e9f9da5075" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_da742460-e2cf-431c-8d15-e94d502caf0f" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_183114d7-d134-4aeb-8b71-e7e9f9da5075" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_183114d7-d134-4aeb-8b71-e7e9f9da5075_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_183114d7-d134-4aeb-8b71-e7e9f9da5075" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_183114d7-d134-4aeb-8b71-e7e9f9da5075_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_31aa18fa-3aef-4db6-9b64-679bdb67c0c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_183114d7-d134-4aeb-8b71-e7e9f9da5075" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_31aa18fa-3aef-4db6-9b64-679bdb67c0c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QRIBIntermediateHoldingsLLCMember_8a069296-bc48-44ac-af9d-be7ef1e3afb2" xlink:href="sny-20240630.xsd#sny_QRIBIntermediateHoldingsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_31aa18fa-3aef-4db6-9b64-679bdb67c0c9" xlink:to="loc_sny_QRIBIntermediateHoldingsLLCMember_8a069296-bc48-44ac-af9d-be7ef1e3afb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPayments_38b8c633-a42f-4510-aa1c-c7529fb0e93b" xlink:href="sny-20240630.xsd#sny_UpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_848b8bd4-3fda-4b81-b2ef-3646f7f10879" xlink:to="loc_sny_UpfrontPayments_38b8c633-a42f-4510-aa1c-c7529fb0e93b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_3a2ea788-6857-485e-881e-50544a5e94a4" xlink:href="sny-20240630.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_848b8bd4-3fda-4b81-b2ef-3646f7f10879" xlink:to="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_3a2ea788-6857-485e-881e-50544a5e94a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePrice_f5d09043-88ad-4ff9-b74b-92fc52f7bafd" xlink:href="sny-20240630.xsd#sny_BusinessCombinationPurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_848b8bd4-3fda-4b81-b2ef-3646f7f10879" xlink:to="loc_sny_BusinessCombinationPurchasePrice_f5d09043-88ad-4ff9-b74b-92fc52f7bafd" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>sny-20240630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a012fc2d-d3ff-4c6a-950e-09cafe0bb60f,g:e711d38b-47f1-4329-bc58-181a62b743af-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_e96fffc9-e25a-4118-ac02-59a9aa9b275d_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment for stock options with dilutive effect (in shares)</link:label>
    <link:label id="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_label_en-US" xlink:label="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive effect of share options on weighted average number of ordinary shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:to="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_8cb6f57b-6380-443f-894c-845114928913_terseLabel_en-US" xlink:label="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends received from non-consolidated entities</link:label>
    <link:label id="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Received From Nonconsolidated Entities Classified As Operating Activities</link:label>
    <link:label id="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_documentation_en-US" xlink:label="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dividends received from non-consolidated entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" xlink:href="sny-20240630.xsd#sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" xlink:to="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_bbc9b342-e58b-4bb1-8a2b-b7c2aae267f5_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross value</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ScribeTherapeuticsMember_e0e9ce8e-b198-4639-918b-85b17880a380_terseLabel_en-US" xlink:label="lab_sny_ScribeTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scribe Therapeutics</link:label>
    <link:label id="lab_sny_ScribeTherapeuticsMember_label_en-US" xlink:label="lab_sny_ScribeTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scribe Therapeutics [Member]</link:label>
    <link:label id="lab_sny_ScribeTherapeuticsMember_documentation_en-US" xlink:label="lab_sny_ScribeTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Scribe Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ScribeTherapeuticsMember" xlink:href="sny-20240630.xsd#sny_ScribeTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ScribeTherapeuticsMember" xlink:to="lab_sny_ScribeTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_6046ae53-39df-48e3-845b-bd21c259881d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information about credit exposures designated as measured at fair value through profit or loss [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_09c96425-6782-419c-b0e0-9d18a2ea1f29_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other changes arising from issuance of restricted shares</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Issuance Of Restricted Shares, Equity</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) through issuance of restricted shares, equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:to="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DebtInstrumentAxis_ea40b268-a746-497e-9e6d-057e627330d7_terseLabel_en-US" xlink:label="lab_sny_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_sny_DebtInstrumentAxis_label_en-US" xlink:label="lab_sny_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_sny_DebtInstrumentAxis_documentation_en-US" xlink:label="lab_sny_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentAxis" xlink:href="sny-20240630.xsd#sny_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DebtInstrumentAxis" xlink:to="lab_sny_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherIntangibleAssets_f300abaf-0c14-422e-af92-105b4776f771_periodStartLabel_en-US" xlink:label="lab_ifrs-full_OtherIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets, beginning balance</link:label>
    <link:label id="lab_ifrs-full_OtherIntangibleAssets_71d7bc79-10d4-4a3e-ba61-310d6ad78f95_periodEndLabel_en-US" xlink:label="lab_ifrs-full_OtherIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets, ending balance</link:label>
    <link:label id="lab_ifrs-full_OtherIntangibleAssets_label_en-US" xlink:label="lab_ifrs-full_OtherIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherIntangibleAssets" xlink:to="lab_ifrs-full_OtherIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_bd844164-aa08-45bb-b33c-095dc2bc1b62_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency purchases in Singapore dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Singapore Dollar [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency purchases in Singapore Dollar.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInSingaporeDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BondsIssued_82e094cf-57d8-44e1-b24b-a70d074daa36_terseLabel_en-US" xlink:label="lab_ifrs-full_BondsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bond issues</link:label>
    <link:label id="lab_ifrs-full_BondsIssued_label_en-US" xlink:label="lab_ifrs-full_BondsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bonds issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BondsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BondsIssued" xlink:to="lab_ifrs-full_BondsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForJointVenturesMember_0ba1644b-ec12-4ec0-afd0-28df93bef24b_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for joint ventures [Member]</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForJointVenturesMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for joint ventures [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember" xlink:to="lab_ifrs-full_EntitysTotalForJointVenturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TreasurySharesMember_c87b8ce7-8220-4a8d-8bc6-7f35019174aa_terseLabel_en-US" xlink:label="lab_ifrs-full_TreasurySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
    <link:label id="lab_ifrs-full_TreasurySharesMember_label_en-US" xlink:label="lab_ifrs-full_TreasurySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasurySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TreasurySharesMember" xlink:to="lab_ifrs-full_TreasurySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_987e3c2a-a02a-42f1-bda6-1b723644022e_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_8398a104-18d0-4d46-9f62-ed0cdad6d0bb_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">pay capitalized Ester / receive 0.92%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 0.92% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 0.92%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive092Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SyndicatedCreditFacilityOneMember_212116bb-2962-4c73-a580-03e4f70c9ef1_terseLabel_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Syndicated credit facility, expires in 2027</link:label>
    <link:label id="lab_sny_SyndicatedCreditFacilityOneMember_label_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Syndicated Credit Facility One [Member]</link:label>
    <link:label id="lab_sny_SyndicatedCreditFacilityOneMember_documentation_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Syndicated credit facility one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityOneMember" xlink:href="sny-20240630.xsd#sny_SyndicatedCreditFacilityOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SyndicatedCreditFacilityOneMember" xlink:to="lab_sny_SyndicatedCreditFacilityOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_40a8d6ee-66ff-45ad-a9cf-e15c2947a7db_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_6c0d73c2-d2d2-4feb-bacc-8ea1bc09bd4a_negatedLabel_en-US" xlink:label="lab_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments made</link:label>
    <link:label id="lab_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_label_en-US" xlink:label="lab_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settled liabilities, contingent liabilities recognised in business combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:to="lab_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PeriodOfShareRepurchaseProgram_15271f87-a6eb-4ff9-a916-ac25d641b585_terseLabel_en-US" xlink:label="lab_sny_PeriodOfShareRepurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of share repurchase program</link:label>
    <link:label id="lab_sny_PeriodOfShareRepurchaseProgram_label_en-US" xlink:label="lab_sny_PeriodOfShareRepurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Share Repurchase Program</link:label>
    <link:label id="lab_sny_PeriodOfShareRepurchaseProgram_documentation_en-US" xlink:label="lab_sny_PeriodOfShareRepurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of share repurchase program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PeriodOfShareRepurchaseProgram" xlink:href="sny-20240630.xsd#sny_PeriodOfShareRepurchaseProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PeriodOfShareRepurchaseProgram" xlink:to="lab_sny_PeriodOfShareRepurchaseProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CashFlowAndFairValueHedgeMember_448d7fa2-047b-4152-a5a3-646b70bb16ec_terseLabel_en-US" xlink:label="lab_sny_CashFlowAndFairValueHedgeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flow and fair value hedge</link:label>
    <link:label id="lab_sny_CashFlowAndFairValueHedgeMember_label_en-US" xlink:label="lab_sny_CashFlowAndFairValueHedgeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow And Fair Value Hedge [Member]</link:label>
    <link:label id="lab_sny_CashFlowAndFairValueHedgeMember_documentation_en-US" xlink:label="lab_sny_CashFlowAndFairValueHedgeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Flow And Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowAndFairValueHedgeMember" xlink:href="sny-20240630.xsd#sny_CashFlowAndFairValueHedgeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CashFlowAndFairValueHedgeMember" xlink:to="lab_sny_CashFlowAndFairValueHedgeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradingEquitySecuritiesMember_4aa67edb-dbde-4ac2-b776-465adc54a262_terseLabel_en-US" xlink:label="lab_ifrs-full_TradingEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading equity securities</link:label>
    <link:label id="lab_ifrs-full_TradingEquitySecuritiesMember_label_en-US" xlink:label="lab_ifrs-full_TradingEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading equity securities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradingEquitySecuritiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradingEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradingEquitySecuritiesMember" xlink:to="lab_ifrs-full_TradingEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_febb1a36-9400-4720-97d0-4b18755d5f9e_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains and losses on disposals of non-current assets, net of tax</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for losses (gains) on disposal of non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:to="lab_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetInterestCostRelatedToEmployeeBenefits_5c47a491-f33c-4dd7-a7a8-1e686b3df84c_negatedLabel_en-US" xlink:label="lab_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net interest cost related to employee benefits</link:label>
    <link:label id="lab_sny_NetInterestCostRelatedToEmployeeBenefits_label_en-US" xlink:label="lab_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Interest Cost Related To Employee Benefits</link:label>
    <link:label id="lab_sny_NetInterestCostRelatedToEmployeeBenefits_documentation_en-US" xlink:label="lab_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net interest cost related to employee benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:href="sny-20240630.xsd#sny_NetInterestCostRelatedToEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:to="lab_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_335cfee4-7988-45b8-a2df-618de551f58d_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposals of consolidated undertakings and investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from losing control of subsidiaries or other businesses, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_3bd58d42-22ec-473c-94db-e4e49eb3c373_periodStartLabel_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_d8a11bdd-e9d4-4bce-b241-88b13cbf0e0a_periodEndLabel_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_b6e9b553-df76-45fa-81a8-ad843807f4f7_terseLabel_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration payable</link:label>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_label_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent liabilities recognised in business combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:to="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BorrowingAverageDrawdown_ad3feb66-a97d-4be6-8211-3a0192c6697d_terseLabel_en-US" xlink:label="lab_sny_BorrowingAverageDrawdown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowing, average drawdown</link:label>
    <link:label id="lab_sny_BorrowingAverageDrawdown_label_en-US" xlink:label="lab_sny_BorrowingAverageDrawdown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing, Average Drawdown</link:label>
    <link:label id="lab_sny_BorrowingAverageDrawdown_documentation_en-US" xlink:label="lab_sny_BorrowingAverageDrawdown" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowing, Average Drawdown</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BorrowingAverageDrawdown" xlink:href="sny-20240630.xsd#sny_BorrowingAverageDrawdown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BorrowingAverageDrawdown" xlink:to="lab_sny_BorrowingAverageDrawdown" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock_f8dd182b-7b0f-4bab-a769-e4551b67ba25_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Analysis of Financial Income and Expenses</link:label>
    <link:label id="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Income And Expenses Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for financial income and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_4347a11d-f17c-4aa5-9092-e84b9222e7c7_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment losses, net of reversals</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in other comprehensive income, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_cda5925d-1562-4dad-b9d2-27405916ed48_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_a75e5744-7a38-47ea-8e5e-e56f45d9fbe9_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PenaltyFeeIncurred_696bb07b-6f3e-45b0-8d4b-d6cd82868639_terseLabel_en-US" xlink:label="lab_sny_PenaltyFeeIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Penalty Fee Incurred</link:label>
    <link:label id="lab_sny_PenaltyFeeIncurred_label_en-US" xlink:label="lab_sny_PenaltyFeeIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Penalty Fee Incurred</link:label>
    <link:label id="lab_sny_PenaltyFeeIncurred_documentation_en-US" xlink:label="lab_sny_PenaltyFeeIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Penalty Fee Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PenaltyFeeIncurred" xlink:href="sny-20240630.xsd#sny_PenaltyFeeIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PenaltyFeeIncurred" xlink:to="lab_sny_PenaltyFeeIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OthersMember_cba87205-fd09-4cd1-a519-2ed8f24ef824_terseLabel_en-US" xlink:label="lab_sny_OthersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Others</link:label>
    <link:label id="lab_sny_OthersMember_label_en-US" xlink:label="lab_sny_OthersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Others [Member]</link:label>
    <link:label id="lab_sny_OthersMember_documentation_en-US" xlink:label="lab_sny_OthersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Others</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OthersMember" xlink:href="sny-20240630.xsd#sny_OthersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OthersMember" xlink:to="lab_sny_OthersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments_7ccfd64b-3bb7-4876-ae2d-567acf259cec_terseLabel_en-US" xlink:label="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Rate Effect Of Reversal Of Temporary Difference On Investments</link:label>
    <link:label id="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments_label_en-US" xlink:label="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Rate Effect Of Reversal Of Temporary Difference On Investments</link:label>
    <link:label id="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments_documentation_en-US" xlink:label="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Rate Effect Of Reversal Of Temporary Difference On Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" xlink:href="sny-20240630.xsd#sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" xlink:to="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherLiabilities1Member_622a6c82-19d5-41f7-b7e9-75cea9d5345d_terseLabel_en-US" xlink:label="lab_sny_OtherLiabilities1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_sny_OtherLiabilities1Member_label_en-US" xlink:label="lab_sny_OtherLiabilities1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities1 [member]</link:label>
    <link:label id="lab_sny_OtherLiabilities1Member_documentation_en-US" xlink:label="lab_sny_OtherLiabilities1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherLiabilities1Member" xlink:href="sny-20240630.xsd#sny_OtherLiabilities1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherLiabilities1Member" xlink:to="lab_sny_OtherLiabilities1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainsOnDivestmentOfProducts_0abb2efb-3360-4009-bc15-79a59de76da3_terseLabel_en-US" xlink:label="lab_sny_GainsOnDivestmentOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains on divestment of some mature products</link:label>
    <link:label id="lab_sny_GainsOnDivestmentOfProducts_label_en-US" xlink:label="lab_sny_GainsOnDivestmentOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains On Divestment Of Products</link:label>
    <link:label id="lab_sny_GainsOnDivestmentOfProducts_documentation_en-US" xlink:label="lab_sny_GainsOnDivestmentOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gains on divestment of products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsOnDivestmentOfProducts" xlink:href="sny-20240630.xsd#sny_GainsOnDivestmentOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainsOnDivestmentOfProducts" xlink:to="lab_sny_GainsOnDivestmentOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_c8f8df21-4ec2-46a0-a816-86caca36912c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeAxis_56ea61fc-75e2-43be-8e92-56c6304f68e2_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_label_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IndustrialSalesMember_80b6f9e3-3be0-403e-9790-e4f6988ae5ee_terseLabel_en-US" xlink:label="lab_sny_IndustrialSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">of which</link:label>
    <link:label id="lab_sny_IndustrialSalesMember_label_en-US" xlink:label="lab_sny_IndustrialSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Industrial Sales [Member]</link:label>
    <link:label id="lab_sny_IndustrialSalesMember_documentation_en-US" xlink:label="lab_sny_IndustrialSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Industrial Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IndustrialSalesMember" xlink:href="sny-20240630.xsd#sny_IndustrialSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IndustrialSalesMember" xlink:to="lab_sny_IndustrialSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment_d53f3247-b2fc-4903-98bd-6bc16c3e0d5a_terseLabel_en-US" xlink:label="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreements, development milestone payment</link:label>
    <link:label id="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment_label_en-US" xlink:label="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Development Milestone Payment</link:label>
    <link:label id="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment_documentation_en-US" xlink:label="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Development Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsDevelopmentMilestonePayment" xlink:href="sny-20240630.xsd#sny_CollaborationAgreementsDevelopmentMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CollaborationAgreementsDevelopmentMilestonePayment" xlink:to="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AcquiredRDMember_468fe3ab-d7f9-4c2c-b1f5-791e51906d99_terseLabel_en-US" xlink:label="lab_sny_AcquiredRDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired R D</link:label>
    <link:label id="lab_sny_AcquiredRDMember_label_en-US" xlink:label="lab_sny_AcquiredRDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired R D [Member]</link:label>
    <link:label id="lab_sny_AcquiredRDMember_documentation_en-US" xlink:label="lab_sny_AcquiredRDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquired R D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquiredRDMember" xlink:href="sny-20240630.xsd#sny_AcquiredRDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AcquiredRDMember" xlink:to="lab_sny_AcquiredRDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock_ca81a825-3dec-4f7d-b6f8-c87408019f79_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests</link:label>
    <link:label id="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Changes In Liabilities Related To Business Combinations And To Noncontrolling Interests [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of changes in liabilities related to business combinations and to non-controlling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" xlink:to="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncome_1a403d2d-9415-4a9f-ace2-11a0d62e61a9_verboseLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_86db24dc-12d0-45d0-8aee-c832065a6017_terseLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_label_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="lab_ifrs-full_FinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_0819471a-77b9-4a5a-9f62-2754c793915b_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Hungarian florint</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Hungarian florint [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Hungarian florint</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInHungarianFlorintMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInHungarianFlorintMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInHungarianFlorintMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock_51f989d4-4aa4-452d-bcb3-2490cf7b0e5a_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Remeasurement of Net Defined Benefit Liability Asset</link:label>
    <link:label id="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Remeasurement Of Net Defined Benefit Liability Asset [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Remeasurement Of Net Defined Benefit Liability Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:to="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FairValueHedgesMember_ecefaf2a-4ebd-4c31-9224-eb7d3fcd24a5_terseLabel_en-US" xlink:label="lab_ifrs-full_FairValueHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value hedges</link:label>
    <link:label id="lab_ifrs-full_FairValueHedgesMember_label_en-US" xlink:label="lab_ifrs-full_FairValueHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value hedges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FairValueHedgesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FairValueHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FairValueHedgesMember" xlink:to="lab_ifrs-full_FairValueHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_e56166b8-55d9-4d9c-a7b9-bd3c516d6085_terseLabel_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_label_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareProgramDomain_1c0106a1-1e83-4195-b261-bd52fc688267_terseLabel_en-US" xlink:label="lab_sny_ShareProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Program [Domain]</link:label>
    <link:label id="lab_sny_ShareProgramDomain_label_en-US" xlink:label="lab_sny_ShareProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Program [Domain]</link:label>
    <link:label id="lab_sny_ShareProgramDomain_documentation_en-US" xlink:label="lab_sny_ShareProgramDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareProgramDomain" xlink:href="sny-20240630.xsd#sny_ShareProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareProgramDomain" xlink:to="lab_sny_ShareProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesMember_a936e896-eb9c-47e9-88b6-1a5be4c01e82_terseLabel_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent liabilities [member]</link:label>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember" xlink:to="lab_ifrs-full_ContingentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_8697e73a-4286-443b-b00a-297bf98a9918_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating cash flow before changes in working capital</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operations before changes in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PharmaSegmentMember_4f45b360-c726-4461-a850-22c41836cb97_terseLabel_en-US" xlink:label="lab_sny_PharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharma Segment</link:label>
    <link:label id="lab_sny_PharmaSegmentMember_label_en-US" xlink:label="lab_sny_PharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharma Segment [Member]</link:label>
    <link:label id="lab_sny_PharmaSegmentMember_documentation_en-US" xlink:label="lab_sny_PharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharma Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaSegmentMember" xlink:href="sny-20240630.xsd#sny_PharmaSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PharmaSegmentMember" xlink:to="lab_sny_PharmaSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_bf1fb8ed-e5b6-46c3-8755-6ab916d3d14b_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmountsPayableRelatedPartyTransactions_4703e12c-3e24-439c-940f-01768132a8ba_terseLabel_en-US" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and other payables</link:label>
    <link:label id="lab_ifrs-full_AmountsPayableRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts payable, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:to="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_6370d255-bf33-4b42-bd2c-ae405025f6bd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_ee4bd6cd-7474-426d-acaa-071dcf85e675_negatedLabel_en-US" xlink:label="lab_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments received/(made) on changes of ownership interest in a subsidiary without loss of control</link:label>
    <link:label id="lab_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_label_en-US" xlink:label="lab_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments from changes in ownership interests in subsidiaries that do not result in loss of control</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:to="lab_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable_0977631e-faf7-4ce9-a8e4-01beb9679814_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Other Operating Income Expenses [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable_label_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Operating Income Expenses [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of other operating income expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:href="sny-20240630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:to="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities_75825326-07ae-48fc-8fa6-b33fbf1a802f_negatedLabel_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest paid, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesMember_957faa85-fdc8-49f1-a269-cb24bdff91ba_terseLabel_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate and currency derivatives used to hedge debt</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesMember_label_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate And Currency Derivatives [Member]</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesMember_documentation_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest rate and currency derivatives used to hedge debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesMember" xlink:href="sny-20240630.xsd#sny_InterestRateAndCurrencyDerivativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateAndCurrencyDerivativesMember" xlink:to="lab_sny_InterestRateAndCurrencyDerivativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NameOfAcquiree_86186d06-e34b-4477-b910-6d0580595cf0_terseLabel_en-US" xlink:label="lab_ifrs-full_NameOfAcquiree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of acquiree</link:label>
    <link:label id="lab_ifrs-full_NameOfAcquiree_label_en-US" xlink:label="lab_ifrs-full_NameOfAcquiree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of acquiree</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NameOfAcquiree" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NameOfAcquiree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NameOfAcquiree" xlink:to="lab_ifrs-full_NameOfAcquiree" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_df758bd3-677d-4145-915f-4ba2228e08f9_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL EQUITY AND LIABILITIES</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_86444320-2b85-4891-bcfd-be2b4ebea5ce_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value (investments accounted for using the equity method, net of taxes)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Equity Instruments For Investments Accounted For Using The Equity Method Net Of Tax</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Equity Instruments For Investments Accounted For Using The Equity Method Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:to="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_cce76973-1d59-42e8-9df6-7df3c6869f51_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Results</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EmployeeShareOwnershipPlanMember_4ae63759-57ea-444b-a148-efb41a2ef079_terseLabel_en-US" xlink:label="lab_sny_EmployeeShareOwnershipPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employees share ownership plan</link:label>
    <link:label id="lab_sny_EmployeeShareOwnershipPlanMember_label_en-US" xlink:label="lab_sny_EmployeeShareOwnershipPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Share Ownership Plan [Member]</link:label>
    <link:label id="lab_sny_EmployeeShareOwnershipPlanMember_documentation_en-US" xlink:label="lab_sny_EmployeeShareOwnershipPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employees share ownership plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeeShareOwnershipPlanMember" xlink:href="sny-20240630.xsd#sny_EmployeeShareOwnershipPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EmployeeShareOwnershipPlanMember" xlink:to="lab_sny_EmployeeShareOwnershipPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_10e1fac7-aad0-400f-896d-02d61f6b5ca9_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International Financial Reporting Standards (IFRS)</link:label>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_label_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of IFRS compliance [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfIFRSCompliance" xlink:to="lab_ifrs-full_StatementOfIFRSCompliance" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProductsAndServicesMember_dacb633a-7574-4a0e-9a3a-b8c984fc3413_terseLabel_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and services [member]</link:label>
    <link:label id="lab_ifrs-full_ProductsAndServicesMember_label_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesMember" xlink:to="lab_ifrs-full_ProductsAndServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherTerritoriesMember_bec97338-3b5e-4787-b4ea-c540e3422344_terseLabel_en-US" xlink:label="lab_sny_OtherTerritoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other territories</link:label>
    <link:label id="lab_sny_OtherTerritoriesMember_label_en-US" xlink:label="lab_sny_OtherTerritoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Territories [Member]</link:label>
    <link:label id="lab_sny_OtherTerritoriesMember_documentation_en-US" xlink:label="lab_sny_OtherTerritoriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Territories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherTerritoriesMember" xlink:href="sny-20240630.xsd#sny_OtherTerritoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherTerritoriesMember" xlink:to="lab_sny_OtherTerritoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapitalMember_145189a8-9d2d-4b5c-867c-c7a39f477ff8_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapitalMember_label_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalPaidinCapitalMember" xlink:to="lab_ifrs-full_AdditionalPaidinCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_faf78da0-36ac-477a-9eda-84c1a4cf0259_negatedLabel_en-US" xlink:label="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization and impairment of intangible assets</link:label>
    <link:label id="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization And Impairment Of Intangible Assets Other Than Goodwill</link:label>
    <link:label id="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_documentation_en-US" xlink:label="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization and impairment of intangible assets other than goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" xlink:href="sny-20240630.xsd#sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" xlink:to="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems_7f36ba34-e7c9-4f58-902a-fd975b793feb_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Non Current Assets [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Non-Current Assets [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of other non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:href="sny-20240630.xsd#sny_DisclosureOfOtherNonCurrentAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:to="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_6e48d70a-d787-488e-9ac1-79a9d13c8f20_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current contract liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentContractLiabilities" xlink:to="lab_ifrs-full_CurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherProductsSegmentMember_7030f2aa-0f91-4502-ba26-d966e12894ed_terseLabel_en-US" xlink:label="lab_sny_OtherProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Products Segment</link:label>
    <link:label id="lab_sny_OtherProductsSegmentMember_label_en-US" xlink:label="lab_sny_OtherProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Products Segment [Member]</link:label>
    <link:label id="lab_sny_OtherProductsSegmentMember_documentation_en-US" xlink:label="lab_sny_OtherProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Products Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProductsSegmentMember" xlink:href="sny-20240630.xsd#sny_OtherProductsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherProductsSegmentMember" xlink:to="lab_sny_OtherProductsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncontrollingInterestsMember_2bd02b17-3f83-4138-b970-a22ef98fd68c_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to&#160;non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_NoncontrollingInterestsMember_label_en-US" xlink:label="lab_ifrs-full_NoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-controlling interests [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncontrollingInterestsMember" xlink:to="lab_ifrs-full_NoncontrollingInterestsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_57aadf70-4f05-4faa-9237-9043ce7fb128_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_09805f0f-e8d8-49a0-b91c-afa2a0d3f2a9_terseLabel_en-US" xlink:label="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_label_en-US" xlink:label="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_documentation_en-US" xlink:label="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:href="sny-20240630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:to="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_914b3fab-18ad-43d1-901c-8fb0eeb1f4b7_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase through remeasurement of financial liability</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Remeasurement, Other Current Liabilities</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Remeasurement, Other Non-Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" xlink:to="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAxis_c1c6b2d5-a292-4a23-a96d-a48bbeeaeb8e_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity [Axis]</link:label>
    <link:label id="lab_ifrs-full_MaturityAxis_label_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_7e8a324f-4ad2-4727-a5b5-78c814a0d7b3_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock_8bba86a0-033e-4fe8-a5d6-c6c44fa0435f_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation and Arbitration Proceedings</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Legal And Arbitral Proceedings [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Legal And Arbitral Proceedings [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:to="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DebtSecuritiesMember_47e5b531-34ff-48fc-ba70-67417e307a80_terseLabel_en-US" xlink:label="lab_ifrs-full_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_ifrs-full_DebtSecuritiesMember_label_en-US" xlink:label="lab_ifrs-full_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt securities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtSecuritiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DebtSecuritiesMember" xlink:to="lab_ifrs-full_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MarketConditionDomain_9a63ff48-981a-4e5e-b71c-9cd9980c413d_terseLabel_en-US" xlink:label="lab_sny_MarketConditionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market Condition [Domain]</link:label>
    <link:label id="lab_sny_MarketConditionDomain_label_en-US" xlink:label="lab_sny_MarketConditionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Condition [Domain]</link:label>
    <link:label id="lab_sny_MarketConditionDomain_documentation_en-US" xlink:label="lab_sny_MarketConditionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market Condition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionDomain" xlink:href="sny-20240630.xsd#sny_MarketConditionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MarketConditionDomain" xlink:to="lab_sny_MarketConditionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TypesOfAgreementAxis_a1326f52-4108-4e7a-9602-96b2d5ffd651_terseLabel_en-US" xlink:label="lab_sny_TypesOfAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types Of Agreement [Axis]</link:label>
    <link:label id="lab_sny_TypesOfAgreementAxis_label_en-US" xlink:label="lab_sny_TypesOfAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types Of Agreement [Axis]</link:label>
    <link:label id="lab_sny_TypesOfAgreementAxis_documentation_en-US" xlink:label="lab_sny_TypesOfAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Types Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementAxis" xlink:href="sny-20240630.xsd#sny_TypesOfAgreementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TypesOfAgreementAxis" xlink:to="lab_sny_TypesOfAgreementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_86e8993f-d9dc-4bef-9bd4-d9a133969a7a_terseLabel_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exceptional supplementary dividend, in percentage</link:label>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_label_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exceptional Supplementary Dividend, Percentage Of Share Capital</link:label>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_documentation_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exceptional Supplementary Dividend, Percentage Of Share Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" xlink:href="sny-20240630.xsd#sny_ExceptionalSupplementaryDividendPercentageOfShareCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" xlink:to="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AllergyMember_4975bf5d-3afa-436f-8e3d-8a4037e8b9bd_terseLabel_en-US" xlink:label="lab_sny_AllergyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Seasonal symptoms &amp; pain relief</link:label>
    <link:label id="lab_sny_AllergyMember_label_en-US" xlink:label="lab_sny_AllergyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allergy [Member]</link:label>
    <link:label id="lab_sny_AllergyMember_documentation_en-US" xlink:label="lab_sny_AllergyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allergy, Cough And Cold [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AllergyMember" xlink:href="sny-20240630.xsd#sny_AllergyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AllergyMember" xlink:to="lab_sny_AllergyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherBankBorrowings_0c04eeb7-1d07-4886-89dc-b9e7fc41a2c3_terseLabel_en-US" xlink:label="lab_sny_OtherBankBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other bank borrowings</link:label>
    <link:label id="lab_sny_OtherBankBorrowings_label_en-US" xlink:label="lab_sny_OtherBankBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Bank Borrowings</link:label>
    <link:label id="lab_sny_OtherBankBorrowings_documentation_en-US" xlink:label="lab_sny_OtherBankBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other bank borrowings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherBankBorrowings" xlink:href="sny-20240630.xsd#sny_OtherBankBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherBankBorrowings" xlink:to="lab_sny_OtherBankBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_12633a0f-d04a-425a-84cf-e5b985892051_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:to="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsMember_3170abd3-1767-4d44-863f-7107784de733_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets, class [Member]</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsMember" xlink:to="lab_ifrs-full_FinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MajorFinancialLiabilityMember_c342c598-05ce-4f02-9b43-24391b01a230_terseLabel_en-US" xlink:label="lab_sny_MajorFinancialLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major financial liability</link:label>
    <link:label id="lab_sny_MajorFinancialLiabilityMember_label_en-US" xlink:label="lab_sny_MajorFinancialLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Financial Liability [Member]</link:label>
    <link:label id="lab_sny_MajorFinancialLiabilityMember_documentation_en-US" xlink:label="lab_sny_MajorFinancialLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Major Financial Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorFinancialLiabilityMember" xlink:href="sny-20240630.xsd#sny_MajorFinancialLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MajorFinancialLiabilityMember" xlink:to="lab_sny_MajorFinancialLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsLineItems_45534c51-f107-49c6-9c81-a16406b87f7c_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-current Provisions [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-Current Provisions [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-current Provisions [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:href="sny-20240630.xsd#sny_DisclosureOfNonCurrentProvisionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:to="lab_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_8cfc55a5-a09c-4b84-819a-4e8f03529c0f_terseLabel_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/(losses) excluding investments accounted for using the equity method</link:label>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset excluding associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:href="sny-20240630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:to="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BiopharmaSegmentMember_43a31ca8-47a1-4e30-9ef9-af2456516915_terseLabel_en-US" xlink:label="lab_sny_BiopharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dupixent</link:label>
    <link:label id="lab_sny_BiopharmaSegmentMember_label_en-US" xlink:label="lab_sny_BiopharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biopharma Segment [Member]</link:label>
    <link:label id="lab_sny_BiopharmaSegmentMember_documentation_en-US" xlink:label="lab_sny_BiopharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharmaceuticals segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember" xlink:href="sny-20240630.xsd#sny_BiopharmaSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BiopharmaSegmentMember" xlink:to="lab_sny_BiopharmaSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestIncome_766485a2-d27e-4b58-a5b8-2348835d2beb_terseLabel_en-US" xlink:label="lab_sny_InterestIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_sny_InterestIncome_label_en-US" xlink:label="lab_sny_InterestIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income</link:label>
    <link:label id="lab_sny_InterestIncome_documentation_en-US" xlink:label="lab_sny_InterestIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestIncome" xlink:href="sny-20240630.xsd#sny_InterestIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestIncome" xlink:to="lab_sny_InterestIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_9e9d72c8-b1fb-4b48-af2e-9e3e11523423_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_b90ff832-e6a3-4973-a31d-de8bf3a6cd10_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about finance income expense [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Finance Income Expense [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line items represent detailed information about finance income expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:href="sny-20240630.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:to="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_8925792e-b16f-41ec-bef2-8b8daadd229d_negatedLabel_en-US" xlink:label="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Dividends paid to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends paid to equity holders of parent, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OneBillionBondsMaturingJune2023Member_8f6edb1a-1c5d-4b69-944b-b7c762b42797_terseLabel_en-US" xlink:label="lab_sny_OneBillionBondsMaturingJune2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">&#8364;1 billion bonds maturing June 2023</link:label>
    <link:label id="lab_sny_OneBillionBondsMaturingJune2023Member_label_en-US" xlink:label="lab_sny_OneBillionBondsMaturingJune2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One Billion Bonds Maturing June 2023 [Member]</link:label>
    <link:label id="lab_sny_OneBillionBondsMaturingJune2023Member_documentation_en-US" xlink:label="lab_sny_OneBillionBondsMaturingJune2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One Billion Bonds Maturing June 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionBondsMaturingJune2023Member" xlink:href="sny-20240630.xsd#sny_OneBillionBondsMaturingJune2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OneBillionBondsMaturingJune2023Member" xlink:to="lab_sny_OneBillionBondsMaturingJune2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_d17fc5c8-6b0b-473a-81ef-6d7bfa0905f3_terseLabel_en-US" xlink:label="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revisions to tax exposures and settlements of tax disputes</link:label>
    <link:label id="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_label_en-US" xlink:label="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revisions To Tax Exposures And Settlements Of Tax Disputes</link:label>
    <link:label id="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_documentation_en-US" xlink:label="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revisions to tax exposures and settlements of tax disputes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:href="sny-20240630.xsd#sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:to="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_4b3f69e0-1dbf-4080-bb78-77150bf3df8e_terseLabel_en-US" xlink:label="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in other current assets and other current liabilities</link:label>
    <link:label id="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Change In Other Current Assets And Other Current Liabilities</link:label>
    <link:label id="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in other current assets and increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:href="sny-20240630.xsd#sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:to="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_3d66b3b6-1da6-4092-afea-f2f23266c085_terseLabel_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average amortization period</link:label>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DupixentMember_c64b161a-dd00-42de-b1ff-748100616741_terseLabel_en-US" xlink:label="lab_sny_DupixentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dupixent</link:label>
    <link:label id="lab_sny_DupixentMember_label_en-US" xlink:label="lab_sny_DupixentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dupixent [Member]</link:label>
    <link:label id="lab_sny_DupixentMember_documentation_en-US" xlink:label="lab_sny_DupixentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dupixent [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DupixentMember" xlink:href="sny-20240630.xsd#sny_DupixentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DupixentMember" xlink:to="lab_sny_DupixentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MarketedProductsTrademarksAndOtherRightsMember_30b362ed-064f-4750-860c-d59ae1c504f5_terseLabel_en-US" xlink:label="lab_sny_MarketedProductsTrademarksAndOtherRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketed Products Trademarks And Other Rights</link:label>
    <link:label id="lab_sny_MarketedProductsTrademarksAndOtherRightsMember_label_en-US" xlink:label="lab_sny_MarketedProductsTrademarksAndOtherRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketed Products Trademarks And Other Rights [Member]</link:label>
    <link:label id="lab_sny_MarketedProductsTrademarksAndOtherRightsMember_documentation_en-US" xlink:label="lab_sny_MarketedProductsTrademarksAndOtherRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketed Products Trademarks And Other Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsTrademarksAndOtherRightsMember" xlink:href="sny-20240630.xsd#sny_MarketedProductsTrademarksAndOtherRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MarketedProductsTrademarksAndOtherRightsMember" xlink:to="lab_sny_MarketedProductsTrademarksAndOtherRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeographicalAreasAxis_8263de91-2c2e-4aed-a62f-9e8c6199d461_terseLabel_en-US" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical areas [Axis]</link:label>
    <link:label id="lab_ifrs-full_GeographicalAreasAxis_label_en-US" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasAxis" xlink:to="lab_ifrs-full_GeographicalAreasAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_27838466-b602-4d9b-96b7-f89d42e3bc73_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_333d19a9-7c91-485a-8839-5d10bff19fac_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Operating Income Expenses [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Operating Income Expenses [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of other operating income (expenses).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:href="sny-20240630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:to="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_40508c72-37d3-4529-9cf2-e93c3ea70c99_terseLabel_en-US" xlink:label="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regular milestone payments</link:label>
    <link:label id="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_label_en-US" xlink:label="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regular Milestone Payments For Projects Under Collaboration Agreements</link:label>
    <link:label id="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_documentation_en-US" xlink:label="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regular Milestone Payments For Projects Under Collaboration Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" xlink:href="sny-20240630.xsd#sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" xlink:to="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_90f27100-a1d6-41a2-b3aa-f69ddc839a43_verboseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation differences</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_f8f88764-ef0a-4cdc-8f56-5d31f97fba23_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:to="lab_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GeneralMedicinesMember_40a15332-d77f-48b4-ba8a-1d2cbd335ef4_terseLabel_en-US" xlink:label="lab_sny_GeneralMedicinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General Medicines [Member]</link:label>
    <link:label id="lab_sny_GeneralMedicinesMember_label_en-US" xlink:label="lab_sny_GeneralMedicinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General Medicines [Member]</link:label>
    <link:label id="lab_sny_GeneralMedicinesMember_documentation_en-US" xlink:label="lab_sny_GeneralMedicinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General Medicines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GeneralMedicinesMember" xlink:href="sny-20240630.xsd#sny_GeneralMedicinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GeneralMedicinesMember" xlink:to="lab_sny_GeneralMedicinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfSharesSubscribed_f8155bf8-27e1-4741-b790-1a0d003d9eff_terseLabel_en-US" xlink:label="lab_sny_NumberOfSharesSubscribed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares subscribed (in shares)</link:label>
    <link:label id="lab_sny_NumberOfSharesSubscribed_label_en-US" xlink:label="lab_sny_NumberOfSharesSubscribed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Subscribed</link:label>
    <link:label id="lab_sny_NumberOfSharesSubscribed_documentation_en-US" xlink:label="lab_sny_NumberOfSharesSubscribed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares subscribed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesSubscribed" xlink:href="sny-20240630.xsd#sny_NumberOfSharesSubscribed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfSharesSubscribed" xlink:to="lab_sny_NumberOfSharesSubscribed" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_9824086c-03d5-4b0d-b2a1-c5eb63072afb_terseLabel_en-US" xlink:label="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">&#8364;1.75 billion bonds maturing March 2023</link:label>
    <link:label id="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_label_en-US" xlink:label="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One Billion Seven Hundred Fifty Million Bonds Maturing March 2023 [Member]</link:label>
    <link:label id="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_documentation_en-US" xlink:label="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One Billion Seven Hundred Fifty Million Bonds Maturing March 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" xlink:href="sny-20240630.xsd#sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" xlink:to="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_country_AR_c2a39dd1-2cbf-4054-a556-0ebea5fab7a7_terseLabel_en-US" xlink:label="lab_country_AR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Argentina</link:label>
    <link:label id="lab_country_AR_label_en-US" xlink:label="lab_country_AR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ARGENTINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_AR" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_AR" xlink:to="lab_country_AR" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssets_bb1bab4e-59be-4a9e-bc3d-14c541a034af_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ToujeoMember_780f6578-30ad-4bfd-be6a-f33316f57a40_terseLabel_en-US" xlink:label="lab_sny_ToujeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Toujeo</link:label>
    <link:label id="lab_sny_ToujeoMember_label_en-US" xlink:label="lab_sny_ToujeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Toujeo [Member]</link:label>
    <link:label id="lab_sny_ToujeoMember_documentation_en-US" xlink:label="lab_sny_ToujeoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Toujeo.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ToujeoMember" xlink:href="sny-20240630.xsd#sny_ToujeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ToujeoMember" xlink:to="lab_sny_ToujeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_WithoutMarketConditionMember_3c900106-2d81-41eb-ac19-8aaf089b0fad_terseLabel_en-US" xlink:label="lab_sny_WithoutMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Without market condition</link:label>
    <link:label id="lab_sny_WithoutMarketConditionMember_label_en-US" xlink:label="lab_sny_WithoutMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Without Market Condition [Member]</link:label>
    <link:label id="lab_sny_WithoutMarketConditionMember_documentation_en-US" xlink:label="lab_sny_WithoutMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Without Market Condition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithoutMarketConditionMember" xlink:href="sny-20240630.xsd#sny_WithoutMarketConditionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_WithoutMarketConditionMember" xlink:to="lab_sny_WithoutMarketConditionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_f29896c3-971d-475d-8f7b-71e2ade88dc4_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_b6c0b67a-6675-4ff3-9457-481760c19755_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise&#160;price per share, options exercisable (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAttributableToOwnersOfParent_08d43389-419b-4e17-9ab1-44daa7f92c5c_verboseLabel_en-US" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_EquityAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_EquityAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxAssetsCurrent_b30e203a-91cb-443d-ba0a-a06253a906d8_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income tax assets</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxAssetsCurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax assets, current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxAssetsCurrent" xlink:to="lab_ifrs-full_CurrentTaxAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowHedgesMember_4c49186b-6a5e-4063-825d-30bd37e4c4f4_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flow hedges</link:label>
    <link:label id="lab_ifrs-full_CashFlowHedgesMember_label_en-US" xlink:label="lab_ifrs-full_CashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flow hedges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowHedgesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowHedgesMember" xlink:to="lab_ifrs-full_CashFlowHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_5c483609-9ec5-4b9c-a05c-2c2830874927_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities other than liabilities included in disposal groups classified as held for sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lab_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_f2fbc772-0751-4a89-91ee-913f3d666e07_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Pronouncements Issued by the IASB and Applicable from 2024</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_60976209-404d-46d6-91d5-5c813f5c3840_negatedLabel_en-US" xlink:label="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/(losses) on plan assets</link:label>
    <link:label id="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_JevtanaMember_c87cbcaa-84de-4355-b48e-b2ed86f05b94_terseLabel_en-US" xlink:label="lab_sny_JevtanaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Jevtana</link:label>
    <link:label id="lab_sny_JevtanaMember_label_en-US" xlink:label="lab_sny_JevtanaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jevtana [Member]</link:label>
    <link:label id="lab_sny_JevtanaMember_documentation_en-US" xlink:label="lab_sny_JevtanaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Jevtana.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_JevtanaMember" xlink:href="sny-20240630.xsd#sny_JevtanaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_JevtanaMember" xlink:to="lab_sny_JevtanaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_a1c33cd6-cecf-48a1-8764-fffaa64bea7c_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase)/decrease in inventories</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_9dd53211-89f8-431a-9b8c-389eef213efe_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_24abd8e0-0a66-4cf0-8bdf-14bfea421c96_terseLabel_en-US" xlink:label="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial assets at fair value through profit or loss</link:label>
    <link:label id="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_label_en-US" xlink:label="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Assets At Fair Value Through Profit Or Loss</link:label>
    <link:label id="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_documentation_en-US" xlink:label="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Financial Assets At Fair Value Through Profit Or Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="sny-20240630.xsd#sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromSaleOfGoods_9ad99c56-7456-445d-b09e-f6edf1dddb42_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromSaleOfGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_ifrs-full_RevenueFromSaleOfGoods_label_en-US" xlink:label="lab_ifrs-full_RevenueFromSaleOfGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromSaleOfGoods" xlink:to="lab_ifrs-full_RevenueFromSaleOfGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherNonCoreAssetsMember_25ee3b1c-f723-4ddb-91fe-240ca9512070_terseLabel_en-US" xlink:label="lab_sny_OtherNonCoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Non-Core Assets [Member]</link:label>
    <link:label id="lab_sny_OtherNonCoreAssetsMember_label_en-US" xlink:label="lab_sny_OtherNonCoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Non-Core Assets [Member]</link:label>
    <link:label id="lab_sny_OtherNonCoreAssetsMember_documentation_en-US" xlink:label="lab_sny_OtherNonCoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Non-Core Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherNonCoreAssetsMember" xlink:href="sny-20240630.xsd#sny_OtherNonCoreAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherNonCoreAssetsMember" xlink:to="lab_sny_OtherNonCoreAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_25d4e39a-dd2f-4721-acbc-1de56358f48e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of analysis of other comprehensive income by item [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of analysis of other comprehensive income by item [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems" xlink:to="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProventionBioIncMember_25b0af9f-ca34-4c2a-b392-e04e015815a7_terseLabel_en-US" xlink:label="lab_sny_ProventionBioIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provention Bio</link:label>
    <link:label id="lab_sny_ProventionBioIncMember_label_en-US" xlink:label="lab_sny_ProventionBioIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provention Bio, Inc [Member]</link:label>
    <link:label id="lab_sny_ProventionBioIncMember_documentation_en-US" xlink:label="lab_sny_ProventionBioIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provention Bio, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember" xlink:href="sny-20240630.xsd#sny_ProventionBioIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProventionBioIncMember" xlink:to="lab_sny_ProventionBioIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_a2659f14-56df-4717-bd5a-3a9a06afe528_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherReceivablesAbstract_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other receivables [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="lab_ifrs-full_TradeAndOtherReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a782880f-40f1-49c8-8268-10c860676505_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2022Member_54650b94-fd1c-4a66-b924-d5dfe11e1618_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted share plan 2022</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2022Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2022 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2022Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2022Member" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2022Member" xlink:to="lab_sny_RestrictedSharePlan2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OthersCounterpartyMember_b1b0554b-1251-4ab5-aecd-2c0e1a80fc3d_terseLabel_en-US" xlink:label="lab_sny_OthersCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (mainly Zaltrap and Libtayo)</link:label>
    <link:label id="lab_sny_OthersCounterpartyMember_label_en-US" xlink:label="lab_sny_OthersCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Others Counterparty [Member]</link:label>
    <link:label id="lab_sny_OthersCounterpartyMember_documentation_en-US" xlink:label="lab_sny_OthersCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Others Counterparty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OthersCounterpartyMember" xlink:href="sny-20240630.xsd#sny_OthersCounterpartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OthersCounterpartyMember" xlink:to="lab_sny_OthersCounterpartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_2af52d23-590c-45be-81cc-b8313f633c58_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Legal and Arbitral Proceedings [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Legal And Arbitral Proceedings [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of legal and arbitral proceedings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:href="sny-20240630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:to="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f6070d92-42fa-489c-a956-bc9d6eccdee2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossProfit_d07a17cc-1f8d-45e2-aff4-81b2cc8123d1_totalLabel_en-US" xlink:label="lab_ifrs-full_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_ifrs-full_GrossProfit_label_en-US" xlink:label="lab_ifrs-full_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossProfit" xlink:to="lab_ifrs-full_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesMember_51659576-df7f-4dd5-b6fe-711c0f4adc95_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency sales</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesMember" xlink:to="lab_sny_ForwardCurrencySalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfSharesHeld_19c61421-1bad-46e1-a084-91b2898f9837_terseLabel_en-US" xlink:label="lab_sny_NumberOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares (in shares)</link:label>
    <link:label id="lab_sny_NumberOfSharesHeld_label_en-US" xlink:label="lab_sny_NumberOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Held</link:label>
    <link:label id="lab_sny_NumberOfSharesHeld_documentation_en-US" xlink:label="lab_sny_NumberOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares held.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesHeld" xlink:href="sny-20240630.xsd#sny_NumberOfSharesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfSharesHeld" xlink:to="lab_sny_NumberOfSharesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_9c94f3e6-843d-42fc-8239-e0efc7723fa8_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other profit or loss items with no cash effect on cash flows generated by operating activities</link:label>
    <link:label id="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_label_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other adjustments to reconcile profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:to="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AtNotionalAmountMember_34ec64b3-1f4f-42df-84fc-efde6371def3_terseLabel_en-US" xlink:label="lab_sny_AtNotionalAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
    <link:label id="lab_sny_AtNotionalAmountMember_label_en-US" xlink:label="lab_sny_AtNotionalAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At Notional Amount [member]</link:label>
    <link:label id="lab_sny_AtNotionalAmountMember_documentation_en-US" xlink:label="lab_sny_AtNotionalAmountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At notional amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember" xlink:href="sny-20240630.xsd#sny_AtNotionalAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AtNotionalAmountMember" xlink:to="lab_sny_AtNotionalAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock_c29af964-f893-489f-8c6e-517a9fd608a0_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Instruments</link:label>
    <link:label id="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Interest Rates Hedging Instruments With Notional Amount By Expiry Date Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of interest rates hedging instruments with notional amount by expiry date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_5bfe89fd-195c-425d-8ad8-4b4e9e77b157_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of entity's operating segments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceCosts_49f5be8e-d1df-4782-8e5a-e529b6404e2f_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Financial expenses</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_label_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="lab_ifrs-full_FinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherOperatingIncomeExpense_54fa8599-e8de-4582-8d54-083177f62fc6_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating income/(expenses), net related to Regeneron</link:label>
    <link:label id="lab_ifrs-full_OtherOperatingIncomeExpense_label_en-US" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other operating income (expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:to="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_45c39168-6e2e-4835-9f36-a91f8b00a244_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028 and beyond</link:label>
    <link:label id="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than four years and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_d8104c27-85ef-4e9c-bc6c-e421d2f1bcee_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three years and not later than four years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:to="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_275d3b24-1449-41ee-a516-ffd3748df78e_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, number&#160;of options (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_label_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_0e588716-f457-42a7-b64d-b4ce3ca6c182_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_4176dc9a-25e9-48f0-a683-f388901def65_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_b238e4f5-1894-433c-ab74-4f8298891f2c_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_06469bc7-bc36-4269-b9e5-1ef45aa80c3e_netLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FabrazymeMember_0c0470b5-4a82-4ebd-887a-f2fb8e24271b_terseLabel_en-US" xlink:label="lab_sny_FabrazymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fabrazyme</link:label>
    <link:label id="lab_sny_FabrazymeMember_label_en-US" xlink:label="lab_sny_FabrazymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fabrazyme [Member]</link:label>
    <link:label id="lab_sny_FabrazymeMember_documentation_en-US" xlink:label="lab_sny_FabrazymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fabrazyme [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FabrazymeMember" xlink:href="sny-20240630.xsd#sny_FabrazymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FabrazymeMember" xlink:to="lab_sny_FabrazymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock_1eb6fee0-abc6-4a6d-bd78-15453382afc5_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Accounts Receivable</link:label>
    <link:label id="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Current Trade Receivables [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of current trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfCurrentTradeReceivablesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:to="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_45d983c4-1f9f-437c-88ed-d48c0b97c3b8_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value (excluding investments accounted for using the equity method)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Equity Instruments Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Equity Instruments Excluding Associates And Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_e2084721-c41d-45b0-a911-4ce8cbd3f02d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_9d2ae175-51ed-486b-819d-d0e1a8b67d89_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_a1393516-f6b9-49a8-a226-0a8c0fd49fb9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherProvisionsMember_083463aa-cc31-45e1-aac7-4776292a7d36_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other provisions</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherProvisionsMember_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous other provisions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherProvisionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherProvisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherProvisionsMember" xlink:to="lab_ifrs-full_MiscellaneousOtherProvisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SyndicatedCreditFacilityCanceledMember_027cc665-f55c-45a7-91bc-7fec3763b1ab_terseLabel_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityCanceledMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Syndicated credit facility canceled</link:label>
    <link:label id="lab_sny_SyndicatedCreditFacilityCanceledMember_label_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityCanceledMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Syndicated Credit Facility Canceled [Member]</link:label>
    <link:label id="lab_sny_SyndicatedCreditFacilityCanceledMember_documentation_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityCanceledMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Syndicated Credit Facility Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityCanceledMember" xlink:href="sny-20240630.xsd#sny_SyndicatedCreditFacilityCanceledMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SyndicatedCreditFacilityCanceledMember" xlink:to="lab_sny_SyndicatedCreditFacilityCanceledMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LeaseCost_87605957-b94e-4fbb-88b1-73f910f0e9c1_terseLabel_en-US" xlink:label="lab_sny_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, cost</link:label>
    <link:label id="lab_sny_LeaseCost_label_en-US" xlink:label="lab_sny_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_sny_LeaseCost_documentation_en-US" xlink:label="lab_sny_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseCost" xlink:href="sny-20240630.xsd#sny_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LeaseCost" xlink:to="lab_sny_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsTable_47967430-24aa-480e-a419-7fe17b61d90f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TopOfRangeMember_58ad72a9-15dc-4f2c-81d7-4b66c2f86c5e_terseLabel_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Top of range</link:label>
    <link:label id="lab_ifrs-full_TopOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_782d39b7-0b49-4a3f-9ffd-3e9b4fbc0e0f_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentAssets" xlink:to="lab_ifrs-full_OtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_a81000a4-edf4-4c0f-bc11-a4eb8e44d15a_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase/(decrease) in accounts payable</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInSingaporeDollarMember_e5784b29-127b-4151-97e6-64250fb662ed_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency sales in Singapore dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInSingaporeDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Singapore Dollar [member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInSingaporeDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency sales in Singapore Dollar.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInSingaporeDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:to="lab_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExercisePriceRangeTwoMember_00de82e0-5e67-4641-8d4a-08c94c50a991_terseLabel_en-US" xlink:label="lab_sny_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">From &#8364;60.00 to &#8364;70.00 per share</link:label>
    <link:label id="lab_sny_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_sny_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_sny_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_sny_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeTwoMember" xlink:href="sny-20240630.xsd#sny_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExercisePriceRangeTwoMember" xlink:to="lab_sny_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_da89a2d3-4511-41e2-83d7-31615b044555_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Operating Income and Expenses</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other operating income (expense) [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_57482070-58a0-4b84-b920-5d38624a99b1_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net interest expense on lease liabilities</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member_475c056f-db71-425c-9f3d-f6379f592d7c_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">pay capitalized SOFR USD / receive 1.02%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.03% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.03%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_c868e2fb-6331-4e39-acbf-62db495032b8_terseLabel_en-US" xlink:label="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other countries</link:label>
    <link:label id="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_label_en-US" xlink:label="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Countries, Excluding Europe And North America [Member]</link:label>
    <link:label id="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_documentation_en-US" xlink:label="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Countries, Excluding Europe And North America</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" xlink:href="sny-20240630.xsd#sny_OtherCountriesExcludingEuropeAndNorthAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" xlink:to="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_3327b31b-370d-48f6-87ba-44a1a287e8aa_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of intangible assets and goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MCMVaccineBVMember_0983f522-72fe-4ecf-a694-f5ef7313d3ae_terseLabel_en-US" xlink:label="lab_sny_MCMVaccineBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MCM Vaccine BV</link:label>
    <link:label id="lab_sny_MCMVaccineBVMember_label_en-US" xlink:label="lab_sny_MCMVaccineBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MCM Vaccine BV [Member]</link:label>
    <link:label id="lab_sny_MCMVaccineBVMember_documentation_en-US" xlink:label="lab_sny_MCMVaccineBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MCM Vaccine BV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MCMVaccineBVMember" xlink:href="sny-20240630.xsd#sny_MCMVaccineBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MCMVaccineBVMember" xlink:to="lab_sny_MCMVaccineBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_35d7bbb1-e71b-429b-8db2-7eeafbb06d38_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments Accounted for Using the Equity Method</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of investments accounted for using equity method [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PaymentToSaleOfBusinessPeriod_dd6c010b-d016-4342-87ef-dfc7e61e33b9_terseLabel_en-US" xlink:label="lab_sny_PaymentToSaleOfBusinessPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment to sale of business period</link:label>
    <link:label id="lab_sny_PaymentToSaleOfBusinessPeriod_label_en-US" xlink:label="lab_sny_PaymentToSaleOfBusinessPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment To Sale Of Business Period</link:label>
    <link:label id="lab_sny_PaymentToSaleOfBusinessPeriod_documentation_en-US" xlink:label="lab_sny_PaymentToSaleOfBusinessPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment to sale of business period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PaymentToSaleOfBusinessPeriod" xlink:href="sny-20240630.xsd#sny_PaymentToSaleOfBusinessPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PaymentToSaleOfBusinessPeriod" xlink:to="lab_sny_PaymentToSaleOfBusinessPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AssetsAcquisitionMember_3e46dc97-dcfa-4354-a394-4370122a6821_terseLabel_en-US" xlink:label="lab_sny_AssetsAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Acquisition</link:label>
    <link:label id="lab_sny_AssetsAcquisitionMember_label_en-US" xlink:label="lab_sny_AssetsAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Acquisition [Member]</link:label>
    <link:label id="lab_sny_AssetsAcquisitionMember_documentation_en-US" xlink:label="lab_sny_AssetsAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionMember" xlink:href="sny-20240630.xsd#sny_AssetsAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AssetsAcquisitionMember" xlink:to="lab_sny_AssetsAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_bfca2ca2-a33e-4aa1-9b31-575332f3e0f5_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than two years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_1ae8a0ce-23f2-4290-8346-01420e551297_terseLabel_en-US" xlink:label="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of debt instruments included in financial assets</link:label>
    <link:label id="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_label_en-US" xlink:label="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (Losses) On Remeasuring Debt Instruments, Before Tax</link:label>
    <link:label id="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_documentation_en-US" xlink:label="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gains (Losses) On Remeasuring Debt Instruments, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:href="sny-20240630.xsd#sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:to="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_8af6a879-2a3a-483a-8721-aaff74fae6d6_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_bd41b74b-b7dc-44d6-b52f-6a10e5f7c1d1_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_99b4d375-3ed5-422f-ae3a-8401442dfc61_negatedTerseLabel_en-US" xlink:label="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_label_en-US" xlink:label="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Relating To Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Equity Investments</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_documentation_en-US" xlink:label="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Relating To Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" xlink:href="sny-20240630.xsd#sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" xlink:to="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessOperatingIncome_cb83eb3f-e9d4-47f9-af3a-6c0f2a3ecd87_terseLabel_en-US" xlink:label="lab_sny_BusinessOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business operating income</link:label>
    <link:label id="lab_sny_BusinessOperatingIncome_de59b71f-5581-4810-991e-24523b4dbde2_totalLabel_en-US" xlink:label="lab_sny_BusinessOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Business operating income</link:label>
    <link:label id="lab_sny_BusinessOperatingIncome_label_en-US" xlink:label="lab_sny_BusinessOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Operating Income</link:label>
    <link:label id="lab_sny_BusinessOperatingIncome_documentation_en-US" xlink:label="lab_sny_BusinessOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business operating income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome" xlink:href="sny-20240630.xsd#sny_BusinessOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessOperatingIncome" xlink:to="lab_sny_BusinessOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory_395f96dc-1cb7-4202-8c16-bac23339dbfc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation and Foreign Currency Translation of the Financial Statements of Subsidiaries in Hyperinflationary Economies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information about hyperinflationary reporting [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory" xlink:to="lab_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_9a11ad82-d47b-4403-89b0-61949025582e_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_ed9a29d3-666f-4ec6-ac13-5aa4d73c0e37_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_bf604fb3-c437-4862-b2e8-d7f78ebe8f79_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net interest related to employee benefits, and unwinding of discount</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Net Interest Related To Employees Benefits And Unwinding Of Discount, Other Provisions</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net interest related to employees benefits and unwinding of discount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" xlink:to="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2021Member_0dbfd3ae-6271-401c-8a71-3716a1401ca5_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted share plan 2021</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2021Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2021 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2021Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2021Member" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2021Member" xlink:to="lab_sny_RestrictedSharePlan2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_f88c847c-d7f2-497f-93c4-7ca56a8fb5b7_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains and losses on defined-benefit plans (B.12.1.)</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Actuarial Gains And Losses On Defined Benefit Plans, Other Provisions</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Actuarial gains and losses on defined-benefit plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" xlink:to="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInCanadianDollarMember_98862290-21ac-4dcf-b9ad-8df10114c65e_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInCanadianDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Canadian Dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInCanadianDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInCanadianDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Canadian Dollar [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInCanadianDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInCanadianDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Canadian Dollar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInCanadianDollarMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInCanadianDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInCanadianDollarMember" xlink:to="lab_sny_ForwardCurrencySalesInCanadianDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NotEligibleForHedgeAccountingMember_aa64529e-977d-4b3f-9548-213a6e968222_terseLabel_en-US" xlink:label="lab_sny_NotEligibleForHedgeAccountingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not eligible for hedge accounting</link:label>
    <link:label id="lab_sny_NotEligibleForHedgeAccountingMember_label_en-US" xlink:label="lab_sny_NotEligibleForHedgeAccountingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Eligible For Hedge Accounting [Member]</link:label>
    <link:label id="lab_sny_NotEligibleForHedgeAccountingMember_documentation_en-US" xlink:label="lab_sny_NotEligibleForHedgeAccountingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Not eligible for hedge accounting.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NotEligibleForHedgeAccountingMember" xlink:href="sny-20240630.xsd#sny_NotEligibleForHedgeAccountingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NotEligibleForHedgeAccountingMember" xlink:to="lab_sny_NotEligibleForHedgeAccountingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareProgramAxis_24304fd9-27ab-42c7-b9b8-05b3691e734b_terseLabel_en-US" xlink:label="lab_sny_ShareProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Program [Axis]</link:label>
    <link:label id="lab_sny_ShareProgramAxis_label_en-US" xlink:label="lab_sny_ShareProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Program [Axis]</link:label>
    <link:label id="lab_sny_ShareProgramAxis_documentation_en-US" xlink:label="lab_sny_ShareProgramAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareProgramAxis" xlink:href="sny-20240630.xsd#sny_ShareProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareProgramAxis" xlink:to="lab_sny_ShareProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_b77666fc-5982-467f-a8ee-148c10865aab_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_label_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer software [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerSoftwareMember" xlink:to="lab_ifrs-full_ComputerSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable_0b2df500-4ec6-426d-b263-503ccef53453_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Legal and Arbitral Proceedings [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable_label_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Legal And Arbitral Proceedings [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of legal and arbitral proceedings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:href="sny-20240630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:to="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ContingentMilestonePayments_6e5ef123-9053-40ea-908e-f20f582610c3_terseLabel_en-US" xlink:label="lab_sny_ContingentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Milestone Payments</link:label>
    <link:label id="lab_sny_ContingentMilestonePayments_label_en-US" xlink:label="lab_sny_ContingentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Milestone Payments</link:label>
    <link:label id="lab_sny_ContingentMilestonePayments_documentation_en-US" xlink:label="lab_sny_ContingentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentMilestonePayments" xlink:href="sny-20240630.xsd#sny_ContingentMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ContingentMilestonePayments" xlink:to="lab_sny_ContingentMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxRateEffectOfForeignTaxRates_39a3b38d-fe9e-48a5-b28c-e28728dd94c6_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Difference between the standard French tax rate and the rates applicable to Sanofi</link:label>
    <link:label id="lab_ifrs-full_TaxRateEffectOfForeignTaxRates_label_en-US" xlink:label="lab_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate effect of foreign tax rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:to="lab_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_c2139de9-bc30-4479-9770-4a8b3d1ebe40_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_fc329e5a-587e-4368-b96d-94a5e2b56cb5_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [Member]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsMember" xlink:to="lab_ifrs-full_NonadjustingEventsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExcludingChiefExecutiveOfficerMember_67a13baa-8f0e-4961-968c-7ef5e342a176_terseLabel_en-US" xlink:label="lab_sny_ExcludingChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excluding General Director</link:label>
    <link:label id="lab_sny_ExcludingChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_sny_ExcludingChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Excluding Chief Executive Officer [Member]</link:label>
    <link:label id="lab_sny_ExcludingChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_sny_ExcludingChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Excluding Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExcludingChiefExecutiveOfficerMember" xlink:href="sny-20240630.xsd#sny_ExcludingChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExcludingChiefExecutiveOfficerMember" xlink:to="lab_sny_ExcludingChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RegeneronMember_5cae6766-8893-41f3-abff-620aba71641d_terseLabel_en-US" xlink:label="lab_sny_RegeneronMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regeneron</link:label>
    <link:label id="lab_sny_RegeneronMember_label_en-US" xlink:label="lab_sny_RegeneronMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regeneron [Member]</link:label>
    <link:label id="lab_sny_RegeneronMember_documentation_en-US" xlink:label="lab_sny_RegeneronMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regeneron</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember" xlink:href="sny-20240630.xsd#sny_RegeneronMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RegeneronMember" xlink:to="lab_sny_RegeneronMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AllOtherSegmentsMember_a3ff98bc-4d41-444f-8813-a1a0abcc3de4_terseLabel_en-US" xlink:label="lab_ifrs-full_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other segment</link:label>
    <link:label id="lab_ifrs-full_AllOtherSegmentsMember_3bd96d5c-13ea-42f2-b65c-9e83c64a9db4_verboseLabel_en-US" xlink:label="lab_ifrs-full_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_AllOtherSegmentsMember_label_en-US" xlink:label="lab_ifrs-full_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All other segments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllOtherSegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllOtherSegmentsMember" xlink:to="lab_ifrs-full_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock_1d0d7b96-7f77-4166-83c0-5519f2beae56_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes</link:label>
    <link:label id="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Allocation Of Income Tax Between Current And Deferred Taxes [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of allocation of income tax between current and deferred taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:to="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LegalAndArbitralProceedingsDomain_a29ca376-915b-41b5-af83-855ab9cb343e_terseLabel_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal And Arbitral Proceedings [Domain]</link:label>
    <link:label id="lab_sny_LegalAndArbitralProceedingsDomain_label_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal And Arbitral Proceedings [Domain]</link:label>
    <link:label id="lab_sny_LegalAndArbitralProceedingsDomain_documentation_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Legal And Arbitral Proceedings [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsDomain" xlink:href="sny-20240630.xsd#sny_LegalAndArbitralProceedingsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain" xlink:to="lab_sny_LegalAndArbitralProceedingsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommercialPaperProgramInUSAMember_fbf044b2-3466-48d8-943c-f88714b24135_terseLabel_en-US" xlink:label="lab_sny_CommercialPaperProgramInUSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper program in USA</link:label>
    <link:label id="lab_sny_CommercialPaperProgramInUSAMember_label_en-US" xlink:label="lab_sny_CommercialPaperProgramInUSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper Program In USA [Member]</link:label>
    <link:label id="lab_sny_CommercialPaperProgramInUSAMember_documentation_en-US" xlink:label="lab_sny_CommercialPaperProgramInUSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial paper program in USA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember" xlink:href="sny-20240630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommercialPaperProgramInUSAMember" xlink:to="lab_sny_CommercialPaperProgramInUSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReclassifiedItemsMember_bde198de-5215-4149-97fb-ac4318ae6d6e_terseLabel_en-US" xlink:label="lab_ifrs-full_ReclassifiedItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassified items [Member]</link:label>
    <link:label id="lab_ifrs-full_ReclassifiedItemsMember_label_en-US" xlink:label="lab_ifrs-full_ReclassifiedItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassified items [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReclassifiedItemsMember" xlink:to="lab_ifrs-full_ReclassifiedItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock_6f89425e-5da4-42d7-aedc-c37e8c6ca848_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities Related to Business Combinations and to Non-Controlling Interests</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for liabilities related to business combination and to non-controlling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SwedishOrphanBiovitrumABMember_0d91fe6f-6104-4b3a-8dfd-66c46a948dfc_terseLabel_en-US" xlink:label="lab_sny_SwedishOrphanBiovitrumABMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swedish Orphan Biovitrum AB</link:label>
    <link:label id="lab_sny_SwedishOrphanBiovitrumABMember_label_en-US" xlink:label="lab_sny_SwedishOrphanBiovitrumABMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Swedish Orphan Biovitrum AB [Member]</link:label>
    <link:label id="lab_sny_SwedishOrphanBiovitrumABMember_documentation_en-US" xlink:label="lab_sny_SwedishOrphanBiovitrumABMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Swedish Orphan Biovitrum AB</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SwedishOrphanBiovitrumABMember" xlink:href="sny-20240630.xsd#sny_SwedishOrphanBiovitrumABMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SwedishOrphanBiovitrumABMember" xlink:to="lab_sny_SwedishOrphanBiovitrumABMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock_2c3871fe-53da-4446-b935-7f545e1dd6c2_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Current Provisions And Other Non-Current Liabilities</link:label>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Provisions And Other Non-Current Liabilities [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Provisions And Other Non-Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" xlink:to="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AdditionalLaunchAndSalesMilestonePayments_7637c04b-0fd0-403f-b333-ae9e4d57f92d_terseLabel_en-US" xlink:label="lab_sny_AdditionalLaunchAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Launch And Sales Milestone Payments</link:label>
    <link:label id="lab_sny_AdditionalLaunchAndSalesMilestonePayments_label_en-US" xlink:label="lab_sny_AdditionalLaunchAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Launch And Sales Milestone Payments</link:label>
    <link:label id="lab_sny_AdditionalLaunchAndSalesMilestonePayments_documentation_en-US" xlink:label="lab_sny_AdditionalLaunchAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Launch And Sales Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdditionalLaunchAndSalesMilestonePayments" xlink:href="sny-20240630.xsd#sny_AdditionalLaunchAndSalesMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AdditionalLaunchAndSalesMilestonePayments" xlink:to="lab_sny_AdditionalLaunchAndSalesMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_09053620-4b55-4268-a10e-edb8dd6cd1f7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_3b6ecf81-5d68-4a18-b836-efdd0723ab08_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of restricted shares and vesting of existing restricted shares</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Share-Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) through share-based payment plans issuance of restricted shares and vesting of existing restricted shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:to="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CerezymeMember_b0d47ddc-f109-4035-a6e7-9f10cdce2029_terseLabel_en-US" xlink:label="lab_sny_CerezymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cerezyme</link:label>
    <link:label id="lab_sny_CerezymeMember_label_en-US" xlink:label="lab_sny_CerezymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cerezyme [Member]</link:label>
    <link:label id="lab_sny_CerezymeMember_documentation_en-US" xlink:label="lab_sny_CerezymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cerezyme.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CerezymeMember" xlink:href="sny-20240630.xsd#sny_CerezymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CerezymeMember" xlink:to="lab_sny_CerezymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FinancialInstrumentsAbstract_e1bc92f9-4d65-4f6d-9e49-5dd6065f99ef_terseLabel_en-US" xlink:label="lab_sny_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_sny_FinancialInstrumentsAbstract_label_en-US" xlink:label="lab_sny_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_sny_FinancialInstrumentsAbstract_documentation_en-US" xlink:label="lab_sny_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract" xlink:href="sny-20240630.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FinancialInstrumentsAbstract" xlink:to="lab_sny_FinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_1be58528-c251-4e3a-8b90-27c1607b06b8_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_ifrs-full_Equity_8362621c-5551-43d6-897b-3b3d676a653d_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_Equity_adf930be-98e4-4db5-8e7b-ffd971a6776c_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfPrincipalAgreementsLineItems_2171b10a-0fe5-4347-8d03-34946cac461a_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfPrincipalAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Principal Agreements [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfPrincipalAgreementsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfPrincipalAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Principal Agreements [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfPrincipalAgreementsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfPrincipalAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Principal Agreements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalAgreementsLineItems" xlink:href="sny-20240630.xsd#sny_DisclosureOfPrincipalAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems" xlink:to="lab_sny_DisclosureOfPrincipalAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock_eba32ea7-00ae-4d05-b791-1a8b9978806e_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method</link:label>
    <link:label id="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Operating Segments Reconciling Items [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of operating segments reconciling items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:to="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DerivativeFinancialAssets_db7b571e-a6b6-4e6b-bbe1-26bba6a27108_terseLabel_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial assets</link:label>
    <link:label id="lab_ifrs-full_DerivativeFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativeFinancialAssets" xlink:to="lab_ifrs-full_DerivativeFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CostOfDebtNet_e89c354a-f49a-4eee-a117-188ee5a410a9_negatedTotalLabel_en-US" xlink:label="lab_sny_CostOfDebtNet" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Cost of net debt</link:label>
    <link:label id="lab_sny_CostOfDebtNet_label_en-US" xlink:label="lab_sny_CostOfDebtNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost Of Debt Net</link:label>
    <link:label id="lab_sny_CostOfDebtNet_documentation_en-US" xlink:label="lab_sny_CostOfDebtNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cost of debt net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CostOfDebtNet" xlink:href="sny-20240630.xsd#sny_CostOfDebtNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CostOfDebtNet" xlink:to="lab_sny_CostOfDebtNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_78bcba7e-8f5e-410f-b2f0-37e359a01fc8_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock_1e1d6048-afa6-4220-8acc-efc7ded4f55b_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment</link:label>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Acquisitions Of Property Plant And Equipment And Other Intangible Assets And Carrying Amount Of Investments In Associates And Joint Ventures By Operating Segment [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of acquisitions of property plant and equipment and other intangible assets and carrying amount of investments in associates and joint ventures by operating segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:to="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_55038afd-9151-4741-8287-99525bd8320c_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of cash flow hedges</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on cash flow hedges, before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:to="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CollaborationAgreementWithGSKMember_b9543389-2579-4d08-9079-e49291cd9c07_terseLabel_en-US" xlink:label="lab_sny_CollaborationAgreementWithGSKMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement with GSK</link:label>
    <link:label id="lab_sny_CollaborationAgreementWithGSKMember_label_en-US" xlink:label="lab_sny_CollaborationAgreementWithGSKMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement With GSK [Member]</link:label>
    <link:label id="lab_sny_CollaborationAgreementWithGSKMember_documentation_en-US" xlink:label="lab_sny_CollaborationAgreementWithGSKMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement With GSK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementWithGSKMember" xlink:href="sny-20240630.xsd#sny_CollaborationAgreementWithGSKMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CollaborationAgreementWithGSKMember" xlink:to="lab_sny_CollaborationAgreementWithGSKMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RedemptionOfDebtInstrumentIssued_1f891f53-c8aa-4641-9c4b-74b1f06a6381_terseLabel_en-US" xlink:label="lab_sny_RedemptionOfDebtInstrumentIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value on redemption</link:label>
    <link:label id="lab_sny_RedemptionOfDebtInstrumentIssued_label_en-US" xlink:label="lab_sny_RedemptionOfDebtInstrumentIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redemption Of Debt Instrument Issued</link:label>
    <link:label id="lab_sny_RedemptionOfDebtInstrumentIssued_documentation_en-US" xlink:label="lab_sny_RedemptionOfDebtInstrumentIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redemption of debt instrument issued.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RedemptionOfDebtInstrumentIssued" xlink:href="sny-20240630.xsd#sny_RedemptionOfDebtInstrumentIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RedemptionOfDebtInstrumentIssued" xlink:to="lab_sny_RedemptionOfDebtInstrumentIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_933b3b6d-0f61-4f9e-880d-e5d9852c2a56_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PlavixMember_31bfbbf9-3e37-4faa-8644-2ec4a38de3c8_terseLabel_en-US" xlink:label="lab_sny_PlavixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plavix</link:label>
    <link:label id="lab_sny_PlavixMember_label_en-US" xlink:label="lab_sny_PlavixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plavix [Member]</link:label>
    <link:label id="lab_sny_PlavixMember_documentation_en-US" xlink:label="lab_sny_PlavixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plavix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixMember" xlink:href="sny-20240630.xsd#sny_PlavixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PlavixMember" xlink:to="lab_sny_PlavixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LegalAndArbitralProceedingsAxis_5e101d4d-ca53-4932-ac39-43c2983b456f_terseLabel_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal And Arbitral Proceedings [Axis]</link:label>
    <link:label id="lab_sny_LegalAndArbitralProceedingsAxis_label_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal And Arbitral Proceedings [Axis]</link:label>
    <link:label id="lab_sny_LegalAndArbitralProceedingsAxis_documentation_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Legal And Arbitral Proceedings [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsAxis" xlink:href="sny-20240630.xsd#sny_LegalAndArbitralProceedingsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LegalAndArbitralProceedingsAxis" xlink:to="lab_sny_LegalAndArbitralProceedingsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities_ac1969e8-b9bb-4811-806f-51e9e806b8cb_terseLabel_en-US" xlink:label="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current provisions and other current liabilities</link:label>
    <link:label id="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions And Other Current Liabilities</link:label>
    <link:label id="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of current provisions and current other liabilities that the entity does not separately disclose in the same statement or note.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:href="sny-20240630.xsd#sny_CurrentProvisionsAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:to="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ZantacProductLitigationInTheUSMember_555824d4-7b4c-4e8f-9718-4b354f077978_terseLabel_en-US" xlink:label="lab_sny_ZantacProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zantac Product Litigation in the US</link:label>
    <link:label id="lab_sny_ZantacProductLitigationInTheUSMember_label_en-US" xlink:label="lab_sny_ZantacProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zantac Product Litigation in the US [Member]</link:label>
    <link:label id="lab_sny_ZantacProductLitigationInTheUSMember_documentation_en-US" xlink:label="lab_sny_ZantacProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zantac Product Litigation in the US</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ZantacProductLitigationInTheUSMember" xlink:href="sny-20240630.xsd#sny_ZantacProductLitigationInTheUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ZantacProductLitigationInTheUSMember" xlink:to="lab_sny_ZantacProductLitigationInTheUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessCombinationPurchasePrice_89baaf54-0d18-497b-b32c-3e23cd8daf82_terseLabel_en-US" xlink:label="lab_sny_BusinessCombinationPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combination, purchase price</link:label>
    <link:label id="lab_sny_BusinessCombinationPurchasePrice_label_en-US" xlink:label="lab_sny_BusinessCombinationPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Purchase Price</link:label>
    <link:label id="lab_sny_BusinessCombinationPurchasePrice_documentation_en-US" xlink:label="lab_sny_BusinessCombinationPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Purchase Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePrice" xlink:href="sny-20240630.xsd#sny_BusinessCombinationPurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessCombinationPurchasePrice" xlink:to="lab_sny_BusinessCombinationPurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInRussianRoubleMember_b2fd8288-c866-4af7-ac24-805db33fd74f_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInRussianRoubleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Russian rouble</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInRussianRoubleMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInRussianRoubleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Russian rouble [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInRussianRoubleMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInRussianRoubleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Russian rouble</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInRussianRoubleMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInRussianRoubleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInRussianRoubleMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInRussianRoubleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_b10ce546-0b32-4326-a893-a5ba819058bf_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Items subsequently reclassifiable to profit or loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_dc5b1a24-e244-4460-9c99-344a825af170_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will be reclassified to profit or loss, net of tax</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will be reclassified to profit or loss, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod_ffcc32f0-3590-4910-a438-a64ec858826a_terseLabel_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value per share awarded (in euros per share)</link:label>
    <link:label id="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod_label_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Per Share Awarded For Three Year Service Period</link:label>
    <link:label id="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod_documentation_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value per share awarded to a three year service period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:href="sny-20240630.xsd#sny_FairValuePerShareAwardedForThreeYearServicePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:to="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_2a220602-4f1a-4dab-8dfa-d81fc97e7b81_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Off Balance Sheet Commitments [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Off-Balance Sheet Commitments [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Disclosure Of Off Balance Sheet Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:href="sny-20240630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:to="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CostOfSales_f3691d7b-0bde-46c8-99a5-f3055c72e6ba_negatedLabel_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_ifrs-full_CostOfSales_c1634d59-a4ea-41ef-9f8d-53b8fc1054eb_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_ifrs-full_CostOfSales_label_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfSales" xlink:to="lab_ifrs-full_CostOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_1ee5963a-c984-4780-962b-9b0fd8218e51_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Later than one year and not later than five years [member]</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiEuroMediumTermNotesMember_946b339a-f34a-49f2-97d3-958b12a1fcb6_terseLabel_en-US" xlink:label="lab_sny_SanofiEuroMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi Euro Medium Term Notes</link:label>
    <link:label id="lab_sny_SanofiEuroMediumTermNotesMember_label_en-US" xlink:label="lab_sny_SanofiEuroMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi Euro Medium Term Notes [Member]</link:label>
    <link:label id="lab_sny_SanofiEuroMediumTermNotesMember_documentation_en-US" xlink:label="lab_sny_SanofiEuroMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sanofi Euro Medium Term Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiEuroMediumTermNotesMember" xlink:href="sny-20240630.xsd#sny_SanofiEuroMediumTermNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiEuroMediumTermNotesMember" xlink:to="lab_sny_SanofiEuroMediumTermNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_4a559e71-88c0-4e61-869b-5dc19759fc74_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GoldBondProductLitigationInTheUSMember_d43740b5-53b1-4429-95fe-7a50120b83b0_terseLabel_en-US" xlink:label="lab_sny_GoldBondProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gold Bond Product Litigation In The US</link:label>
    <link:label id="lab_sny_GoldBondProductLitigationInTheUSMember_label_en-US" xlink:label="lab_sny_GoldBondProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gold Bond Product Litigation In The US [Member]</link:label>
    <link:label id="lab_sny_GoldBondProductLitigationInTheUSMember_documentation_en-US" xlink:label="lab_sny_GoldBondProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gold Bond Product Litigation In The US</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GoldBondProductLitigationInTheUSMember" xlink:href="sny-20240630.xsd#sny_GoldBondProductLitigationInTheUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GoldBondProductLitigationInTheUSMember" xlink:to="lab_sny_GoldBondProductLitigationInTheUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AggregatedMeasurementMember_083a43aa-5dee-4b14-bebc-8b57a50c63cd_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedMeasurementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregated measurement [Member]</link:label>
    <link:label id="lab_ifrs-full_AggregatedMeasurementMember_label_en-US" xlink:label="lab_ifrs-full_AggregatedMeasurementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated measurement [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedMeasurementMember" xlink:to="lab_ifrs-full_AggregatedMeasurementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_4ecf6946-1e35-4d70-b4a9-31463e99fb2e_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency purchases in Chinese yuan renminbi</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Chinese Yuan Renminbi [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Chinese Yuan Renminbi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations_b9898203-ebf4-4179-9404-538d96cd2b51_terseLabel_en-US" xlink:label="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of net sales arising from commercial operations</link:label>
    <link:label id="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations_label_en-US" xlink:label="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Net Sales Arising From Commercial Operations</link:label>
    <link:label id="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations_documentation_en-US" xlink:label="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Net Sales Arising From Commercial Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfNetSalesArisingFromCommercialOperations" xlink:href="sny-20240630.xsd#sny_PercentageOfNetSalesArisingFromCommercialOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfNetSalesArisingFromCommercialOperations" xlink:to="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetMember_539dad53-b5e3-48be-a65c-00101f31f850_terseLabel_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset) [Member]</link:label>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetMember_label_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset) [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:to="lab_ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FixedRateBondMaturingApril2024Redeemed2024Member_23370e64-ecf7-40d6-ac47-ead29bb6dab6_terseLabel_en-US" xlink:label="lab_sny_FixedRateBondMaturingApril2024Redeemed2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing April2024 Redeemed2024</link:label>
    <link:label id="lab_sny_FixedRateBondMaturingApril2024Redeemed2024Member_label_en-US" xlink:label="lab_sny_FixedRateBondMaturingApril2024Redeemed2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing April2024 Redeemed2024 [Member]</link:label>
    <link:label id="lab_sny_FixedRateBondMaturingApril2024Redeemed2024Member_documentation_en-US" xlink:label="lab_sny_FixedRateBondMaturingApril2024Redeemed2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing April2024 Redeemed2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingApril2024Redeemed2024Member" xlink:href="sny-20240630.xsd#sny_FixedRateBondMaturingApril2024Redeemed2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FixedRateBondMaturingApril2024Redeemed2024Member" xlink:to="lab_sny_FixedRateBondMaturingApril2024Redeemed2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock_e28460fe-3a90-4b11-babb-db17efa3271a_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Principal Characteristics of Restricted Share Plans</link:label>
    <link:label id="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Employee Stock Ownership Plan Awarded In Capital Increase Reserved Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of employee stock ownership plan awarded in capital increase reserved explanatory [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SegmentsMember_42d84f42-edf7-4f0e-8115-aacb1a6a62b1_terseLabel_en-US" xlink:label="lab_ifrs-full_SegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Member]</link:label>
    <link:label id="lab_ifrs-full_SegmentsMember_label_en-US" xlink:label="lab_ifrs-full_SegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SegmentsMember" xlink:to="lab_ifrs-full_SegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_dda6992a-06a1-41e9-86a1-a19ab30a7ade_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfPrincipalAgreementsTable_67480686-0a17-4131-99c6-ce2a444eda04_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfPrincipalAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Principal Agreements [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfPrincipalAgreementsTable_label_en-US" xlink:label="lab_sny_DisclosureOfPrincipalAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Principal Agreements [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfPrincipalAgreementsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfPrincipalAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Principal Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalAgreementsTable" xlink:href="sny-20240630.xsd#sny_DisclosureOfPrincipalAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable" xlink:to="lab_sny_DisclosureOfPrincipalAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_7e8ac20f-8486-4a0d-a5b5-cb382f50f5f7_terseLabel_en-US" xlink:label="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, ownership percentage</link:label>
    <link:label id="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_label_en-US" xlink:label="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income, Ownership Percentage</link:label>
    <link:label id="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_documentation_en-US" xlink:label="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" xlink:href="sny-20240630.xsd#sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" xlink:to="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ValueOnRedemptionMember_b6bcbc7c-8667-4043-8146-430bf2cd5689_terseLabel_en-US" xlink:label="lab_sny_ValueOnRedemptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value on redemption</link:label>
    <link:label id="lab_sny_ValueOnRedemptionMember_label_en-US" xlink:label="lab_sny_ValueOnRedemptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value On Redemption [Member]</link:label>
    <link:label id="lab_sny_ValueOnRedemptionMember_documentation_en-US" xlink:label="lab_sny_ValueOnRedemptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value on redemption.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember" xlink:href="sny-20240630.xsd#sny_ValueOnRedemptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ValueOnRedemptionMember" xlink:to="lab_sny_ValueOnRedemptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_372dac1b-2f06-4699-b943-4c4b37be0241_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProductLiabilitiesMember_625e6061-c78a-4c0a-aeec-96c5f652b856_terseLabel_en-US" xlink:label="lab_sny_ProductLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Liabilities</link:label>
    <link:label id="lab_sny_ProductLiabilitiesMember_label_en-US" xlink:label="lab_sny_ProductLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Liabilities [Member]</link:label>
    <link:label id="lab_sny_ProductLiabilitiesMember_documentation_en-US" xlink:label="lab_sny_ProductLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProductLiabilitiesMember" xlink:href="sny-20240630.xsd#sny_ProductLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProductLiabilitiesMember" xlink:to="lab_sny_ProductLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_4e9d36b6-d5bc-4e5b-a859-ee3e02e4f059_negatedLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cost of debt</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:to="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OffBalanceSheetCommitmentsAbstract_label_en-US" xlink:label="lab_sny_OffBalanceSheetCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Off-Balance Sheet Commitments [Abstract]</link:label>
    <link:label id="lab_sny_OffBalanceSheetCommitmentsAbstract_documentation_en-US" xlink:label="lab_sny_OffBalanceSheetCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Off-Balance Sheet Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OffBalanceSheetCommitmentsAbstract" xlink:href="sny-20240630.xsd#sny_OffBalanceSheetCommitmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OffBalanceSheetCommitmentsAbstract" xlink:to="lab_sny_OffBalanceSheetCommitmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_31674166-6a29-4aa0-954f-ccd63cdb3c01_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of other equity investments</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of financial instruments, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock_cebb0893-630b-48f1-8d33-786b3c526630_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Off Balance Sheet Commitments</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Off-Balance Sheet Commitments Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of off-balance sheet commitments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DefinedBenefitPlansMember_83443dba-53cb-4002-bc0a-9aaf49118397_terseLabel_en-US" xlink:label="lab_ifrs-full_DefinedBenefitPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit plans [Member]</link:label>
    <link:label id="lab_ifrs-full_DefinedBenefitPlansMember_label_en-US" xlink:label="lab_ifrs-full_DefinedBenefitPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plans [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember" xlink:to="lab_ifrs-full_DefinedBenefitPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_f8699c63-dd82-4361-80b4-04ccdbba1b88_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_acaae731-94e2-4caf-8d8f-258715cee757_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of profit/(loss) from investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of profit (loss) of associates and joint ventures accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember_142fb42a-e511-418a-a108-838f637cf3f9_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency purchases in US dollar, commercial paper</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In US Dollar, Commercial Paper [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In US Dollar, Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_33508778-a103-4ab7-84d6-1704ff8e1fff_negatedLabel_en-US" xlink:label="lab_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Dividend paid out of earnings</link:label>
    <link:label id="lab_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends recognised as distributions to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:to="lab_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_0069c80f-fa61-421b-8aa7-2cc81a1c039a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Shareholders' Equity</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LongtermBorrowings_e6234548-a898-455d-94a0-6e54d359e8d5_terseLabel_en-US" xlink:label="lab_ifrs-full_LongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_ifrs-full_LongtermBorrowings_label_en-US" xlink:label="lab_ifrs-full_LongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current portion of non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LongtermBorrowings" xlink:to="lab_ifrs-full_LongtermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_48cf3550-71b9-445b-97e0-3dbc1c8a7997_negatedLabel_en-US" xlink:label="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of dividends to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_label_en-US" xlink:label="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends recognised as distributions to non-controlling interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:to="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TechnologicalPlatformsMember_922ce7fe-7742-474f-b885-3e532ac4b528_terseLabel_en-US" xlink:label="lab_sny_TechnologicalPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technological platforms</link:label>
    <link:label id="lab_sny_TechnologicalPlatformsMember_label_en-US" xlink:label="lab_sny_TechnologicalPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technological Platforms [Member]</link:label>
    <link:label id="lab_sny_TechnologicalPlatformsMember_documentation_en-US" xlink:label="lab_sny_TechnologicalPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Technological Platforms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TechnologicalPlatformsMember" xlink:href="sny-20240630.xsd#sny_TechnologicalPlatformsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TechnologicalPlatformsMember" xlink:to="lab_sny_TechnologicalPlatformsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentAssetsMember_ef6889b4-66a7-4fdf-8cb5-eb3feee2c068_terseLabel_en-US" xlink:label="lab_sny_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">current</link:label>
    <link:label id="lab_sny_CurrentAssetsMember_label_en-US" xlink:label="lab_sny_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Assets [Member]</link:label>
    <link:label id="lab_sny_CurrentAssetsMember_documentation_en-US" xlink:label="lab_sny_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentAssetsMember" xlink:href="sny-20240630.xsd#sny_CurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentAssetsMember" xlink:to="lab_sny_CurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_c19e51be-2632-4204-ae9b-a9257420baa2_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_9757d34e-a330-4253-91a7-08cd8ab62742_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets that are either past due or impaired [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_15f088b3-755f-43cd-b6c2-c121d9f155b0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Financial Assets that are Either Past Due or Impaired [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets that are either past due or impaired [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_240a92d3-a5f4-4298-a29d-e768de6c9e61_terseLabel_en-US" xlink:label="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Items not subsequently reclassifiable to profit or loss</link:label>
    <link:label id="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_label_en-US" xlink:label="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Items Not Subsequently Reclassifiable To Profit Or Loss [Member]</link:label>
    <link:label id="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_documentation_en-US" xlink:label="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Items not subsequently reclassifiable to profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:href="sny-20240630.xsd#sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:to="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_09f237ed-0513-459e-b37f-a21eee73378d_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest received</link:label>
    <link:label id="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest received, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetReversalOfImpairmentLoss_b93fb8f4-5b7d-42c6-8618-fbdccc7ce1ff_terseLabel_en-US" xlink:label="lab_sny_NetReversalOfImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Reversal of Impairment Loss</link:label>
    <link:label id="lab_sny_NetReversalOfImpairmentLoss_label_en-US" xlink:label="lab_sny_NetReversalOfImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Reversal of Impairment Loss</link:label>
    <link:label id="lab_sny_NetReversalOfImpairmentLoss_documentation_en-US" xlink:label="lab_sny_NetReversalOfImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Reversal of Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetReversalOfImpairmentLoss" xlink:href="sny-20240630.xsd#sny_NetReversalOfImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetReversalOfImpairmentLoss" xlink:to="lab_sny_NetReversalOfImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_5a9ea36d-c20e-463c-be1f-4a91f8805af3_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense recognized</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_b6ea5649-7ebe-4a0d-9f4d-3a92aee506be_netLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Total expense for restricted share plans</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from equity-settled share-based payment transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockOptionPlanMember_1fea1b38-321d-41c0-89b2-46ada733ecf0_terseLabel_en-US" xlink:label="lab_sny_StockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Plan</link:label>
    <link:label id="lab_sny_StockOptionPlanMember_label_en-US" xlink:label="lab_sny_StockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Plan [member]</link:label>
    <link:label id="lab_sny_StockOptionPlanMember_documentation_en-US" xlink:label="lab_sny_StockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Option Plan [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionPlanMember" xlink:href="sny-20240630.xsd#sny_StockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockOptionPlanMember" xlink:to="lab_sny_StockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_FR_51dff15c-5aa8-4fa5-8838-f77abdfc65c9_terseLabel_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">France</link:label>
    <link:label id="lab_country_FR_label_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FRANCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_FR" xlink:to="lab_country_FR" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_3b7f5a1b-a70f-48aa-a399-cb11078ce1c6_terseLabel_en-US" xlink:label="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of the workdown of acquired inventories remeasured at fair value</link:label>
    <link:label id="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_label_en-US" xlink:label="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact Of The Workdown Of Acquired Inventories Remeasured At Fair Value</link:label>
    <link:label id="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_documentation_en-US" xlink:label="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Impact of the workdown of acquired inventories remeasured at fair value arising from business combination in accordance with IFRS 3.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:href="sny-20240630.xsd#sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:to="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_cd9fae18-a53b-482b-87d9-6a40f8273e9d_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in actuarial assumption</link:label>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_label_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of reasonably possible decrease in actuarial assumption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:to="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_UKZONEMember_61f5e4d7-29d4-420c-991a-e9cf208b6792_terseLabel_en-US" xlink:label="lab_sny_UKZONEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UKZONE</link:label>
    <link:label id="lab_sny_UKZONEMember_label_en-US" xlink:label="lab_sny_UKZONEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UKZONE [Member]</link:label>
    <link:label id="lab_sny_UKZONEMember_documentation_en-US" xlink:label="lab_sny_UKZONEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UKZONE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UKZONEMember" xlink:href="sny-20240630.xsd#sny_UKZONEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_UKZONEMember" xlink:to="lab_sny_UKZONEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_684a844b-e5b2-4f62-88a4-fc603b94eb99_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income for the period, net of taxes</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_a0ef7104-3698-44b8-904f-51337869b052_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income for the period</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="lab_ifrs-full_OtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_fdcf27fd-3d09-4c91-b4dd-b6f1899ea1d9_terseLabel_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities related to business combinations and to non-controlling interests</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_3449dccd-51ff-4bd7-acfb-82894fc76516_verboseLabel_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_label_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Liabilities Related To Business Combinations And To Non-Controlling Interests</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_documentation_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This account includes non-current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes non-current portion of liabilities related to non-controlling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:href="sny-20240630.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:to="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_d36d5fb2-d95d-4b47-b43f-e7db01ad3c4b_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation differences</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Net Exchange Differences Business Combinations And Noncontrolling Interests</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease through net exchange differences business combinations and noncontrolling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" xlink:to="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_913f2831-bb72-4bf2-b752-9a885418273b_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">pay capitalized Ester / receive 0.69%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive069Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherRevenue_c38e72d9-a690-414c-a67d-4100966131bb_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_ifrs-full_OtherRevenue_label_en-US" xlink:label="lab_ifrs-full_OtherRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherRevenue" xlink:to="lab_ifrs-full_OtherRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_7e6bd080-f922-4f27-9f73-c089757a3a50_negatedLabel_en-US" xlink:label="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Dividends paid to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends paid to non-controlling interests, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_4a611e66-679b-4997-918b-a20dd13ed3a1_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_973c8ad9-7fe2-4419-a978-e411ef595010_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_XenpozymeMember_eb135a25-74ad-4f01-97fb-db4b80a35e11_terseLabel_en-US" xlink:label="lab_sny_XenpozymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Xenpozyme</link:label>
    <link:label id="lab_sny_XenpozymeMember_label_en-US" xlink:label="lab_sny_XenpozymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xenpozyme [Member]</link:label>
    <link:label id="lab_sny_XenpozymeMember_documentation_en-US" xlink:label="lab_sny_XenpozymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Xenpozyme</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_XenpozymeMember" xlink:href="sny-20240630.xsd#sny_XenpozymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_XenpozymeMember" xlink:to="lab_sny_XenpozymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_df7c145a-5254-45d7-90cb-0eaeaf374c1f_terseLabel_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedges of net investments in foreign operations</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_label_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Currency Translation On Hedges Of Net Investments In Foreign Operations</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_documentation_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in currency translation on hedges of net investments in foreign operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:href="sny-20240630.xsd#sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:to="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock_403bfba3-0de4-4ef6-b084-729e48b4dc80_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Market Value of Net Debt</link:label>
    <link:label id="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Market Value Of Net Debt [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of market value of net debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfMarketValueOfNetDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:to="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent_3f1c2cf9-3553-4fb8-a6ad-c446fbc7bfa9_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current income tax liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax liabilities, non-current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:to="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member_34395af7-f505-4e1b-aa7a-fd67d4aa56c4_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">pay capitalized SOFR USD / receive 1.32%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.32% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.32%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RezurockMember_a73832fd-8a47-4672-a13d-b50c421647b8_terseLabel_en-US" xlink:label="lab_sny_RezurockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rezurock</link:label>
    <link:label id="lab_sny_RezurockMember_label_en-US" xlink:label="lab_sny_RezurockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rezurock [Member]</link:label>
    <link:label id="lab_sny_RezurockMember_documentation_en-US" xlink:label="lab_sny_RezurockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rezurock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RezurockMember" xlink:href="sny-20240630.xsd#sny_RezurockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RezurockMember" xlink:to="lab_sny_RezurockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated_012e3de9-d013-4ccc-85b3-490d3e1dbb90_terseLabel_en-US" xlink:label="lab_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Penalty fee incurred by defendants, interests, amount vacated</link:label>
    <link:label id="lab_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated_label_en-US" xlink:label="lab_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Penalty Fee Incurred By Defendants, Interests, Amount Vacated</link:label>
    <link:label id="lab_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated_documentation_en-US" xlink:label="lab_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Penalty Fee Incurred By Defendants, Interests, Amount Vacated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated" xlink:href="sny-20240630.xsd#sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated" xlink:to="lab_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_7f90cca2-c541-4356-b12c-a035fd583995_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax relating to cash flow hedges included in other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:to="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_fe09d124-e7c6-45d6-97e4-a7e9d3328e8f_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PolioPertussisHibVaccinesMember_9bcf8187-6950-4de9-a301-197411ff2364_terseLabel_en-US" xlink:label="lab_sny_PolioPertussisHibVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Polio/Pertussis/ Hib Vaccines</link:label>
    <link:label id="lab_sny_PolioPertussisHibVaccinesMember_label_en-US" xlink:label="lab_sny_PolioPertussisHibVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Polio Pertussis Hib Vaccines [Member]</link:label>
    <link:label id="lab_sny_PolioPertussisHibVaccinesMember_documentation_en-US" xlink:label="lab_sny_PolioPertussisHibVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Polio Pertussis Hib Vaccines.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PolioPertussisHibVaccinesMember" xlink:href="sny-20240630.xsd#sny_PolioPertussisHibVaccinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PolioPertussisHibVaccinesMember" xlink:to="lab_sny_PolioPertussisHibVaccinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LovenoxMember_e49a867e-ff64-4c1b-b5cf-82a692118e60_terseLabel_en-US" xlink:label="lab_sny_LovenoxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lovenox</link:label>
    <link:label id="lab_sny_LovenoxMember_label_en-US" xlink:label="lab_sny_LovenoxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lovenox [Member]</link:label>
    <link:label id="lab_sny_LovenoxMember_documentation_en-US" xlink:label="lab_sny_LovenoxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lovenox.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LovenoxMember" xlink:href="sny-20240630.xsd#sny_LovenoxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LovenoxMember" xlink:to="lab_sny_LovenoxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SyndicatedCreditFacilityTwoMember_5d946e71-b609-4a04-9755-afc440540cbd_terseLabel_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Syndicated credit facility, expires in 2028</link:label>
    <link:label id="lab_sny_SyndicatedCreditFacilityTwoMember_label_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Syndicated Credit Facility Two [Member]</link:label>
    <link:label id="lab_sny_SyndicatedCreditFacilityTwoMember_documentation_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Syndicated credit facility two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityTwoMember" xlink:href="sny-20240630.xsd#sny_SyndicatedCreditFacilityTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SyndicatedCreditFacilityTwoMember" xlink:to="lab_sny_SyndicatedCreditFacilityTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherGainsLossesAndLitigation_dbca354b-f4c2-464b-819b-564295022221_verboseLabel_en-US" xlink:label="lab_sny_OtherGainsLossesAndLitigation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other gains and losses, and litigation</link:label>
    <link:label id="lab_sny_OtherGainsLossesAndLitigation_ea29ce84-1caf-426f-ab68-517177fc8491_negatedNetLabel_en-US" xlink:label="lab_sny_OtherGainsLossesAndLitigation" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xml:lang="en-US">Other gains and litigation</link:label>
    <link:label id="lab_sny_OtherGainsLossesAndLitigation_label_en-US" xlink:label="lab_sny_OtherGainsLossesAndLitigation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Gains, (Losses) And Litigation</link:label>
    <link:label id="lab_sny_OtherGainsLossesAndLitigation_documentation_en-US" xlink:label="lab_sny_OtherGainsLossesAndLitigation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation" xlink:href="sny-20240630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherGainsLossesAndLitigation" xlink:to="lab_sny_OtherGainsLossesAndLitigation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDeferredTaxExpense_7deffe68-7815-4e9f-8d2d-57852d6c531a_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in deferred taxes</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDeferredTaxExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for deferred tax expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:to="lab_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AlprolixMember_2d8b892e-ee89-4605-ac03-3eb632e6c10b_terseLabel_en-US" xlink:label="lab_sny_AlprolixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alprolix</link:label>
    <link:label id="lab_sny_AlprolixMember_label_en-US" xlink:label="lab_sny_AlprolixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alprolix [Member]</link:label>
    <link:label id="lab_sny_AlprolixMember_documentation_en-US" xlink:label="lab_sny_AlprolixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alprolix</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AlprolixMember" xlink:href="sny-20240630.xsd#sny_AlprolixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AlprolixMember" xlink:to="lab_sny_AlprolixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory_c2571336-e357-4e3c-b11f-effabd69ef15_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Geographical Information on Net Sales and Non-Current Assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncomeCost_b72804af-a1e8-4933-83fd-f4e263612136_totalLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net financial income/(expenses)</link:label>
    <link:label id="lab_ifrs-full_FinanceIncomeCost_label_en-US" xlink:label="lab_ifrs-full_FinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income (cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncomeCost" xlink:to="lab_ifrs-full_FinanceIncomeCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LineItemsByFunctionMember_ae3a699b-4742-4b5d-8c4a-7e16c7b1465e_terseLabel_en-US" xlink:label="lab_ifrs-full_LineItemsByFunctionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line items by function [member]</link:label>
    <link:label id="lab_ifrs-full_LineItemsByFunctionMember_label_en-US" xlink:label="lab_ifrs-full_LineItemsByFunctionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line items by function [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LineItemsByFunctionMember" xlink:to="lab_ifrs-full_LineItemsByFunctionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Inventories_7e689acc-186e-46c7-a248-f7e47790b591_terseLabel_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_ifrs-full_Inventories_label_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Inventories" xlink:to="lab_ifrs-full_Inventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions_e7e1a834-ce64-4a74-ae45-d46db0bc5c70_terseLabel_en-US" xlink:label="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable and other receivables</link:label>
    <link:label id="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts receivable, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:to="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesMember_4a3558fa-5a2f-4f7a-a28a-9793b0b24a35_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges [Member]</link:label>
    <link:label id="lab_ifrs-full_RangesMember_label_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesMember" xlink:to="lab_ifrs-full_RangesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_7dca7425-7606-4599-b922-7e745da156b2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_f3c82332-c482-4d25-baf0-0e6b23e1abaa_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity interest in acquiree held before acquisition date</link:label>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:to="lab_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_57f742c0-48ed-4cb6-a9d1-a0ac09e0882e_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings by name [Axis]</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameAxis" xlink:to="lab_ifrs-full_BorrowingsByNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_8bbc6ad4-ea95-43d2-a579-de626760d479_terseLabel_en-US" xlink:label="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets</link:label>
    <link:label id="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_label_en-US" xlink:label="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Depreciation And Amortisation Expense And Impairment Loss Reversal Of Impairment Loss Of Property Plant And Equipment Right-Of Use Assets And Intangible Asset</link:label>
    <link:label id="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_documentation_en-US" xlink:label="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and impairment of property, plant and equipment, right-of use assets and intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:href="sny-20240630.xsd#sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:to="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_06918702-1ef3-44c6-8e25-eafbaec16689_terseLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to non-controlling interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingIncome_9bb4c250-646b-4392-be2d-f0538b674520_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingIncome_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous other operating income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:to="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_35bccb64-9008-45cc-a7cb-e9bea7d5786a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_4be19d96-ce0e-4b23-b6f6-2cbeaf27613b_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregated time bands [Member]</link:label>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_label_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember" xlink:to="lab_ifrs-full_AggregatedTimeBandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HedgingInstrumentsAxis_9e8df6b6-3b4b-44a8-a687-fa6041b87144_terseLabel_en-US" xlink:label="lab_ifrs-full_HedgingInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Instruments [Axis]</link:label>
    <link:label id="lab_ifrs-full_HedgingInstrumentsAxis_label_en-US" xlink:label="lab_ifrs-full_HedgingInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging instruments [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis" xlink:to="lab_ifrs-full_HedgingInstrumentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwillAbstract_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="lab_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_f0253b81-72ea-4ad1-b8d7-02fd8614c9ad_terseLabel_en-US" xlink:label="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment for restricted shares (in shares)</link:label>
    <link:label id="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_label_en-US" xlink:label="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Effect Of Share Options On Number Of Restricted Shares</link:label>
    <link:label id="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_documentation_en-US" xlink:label="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dilutive effect of share options on number of restricted shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:href="sny-20240630.xsd#sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:to="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_965178e2-2146-4d53-ba07-fabd41e8d890_terseLabel_en-US" xlink:label="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency and interest rate derivatives</link:label>
    <link:label id="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_label_en-US" xlink:label="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency And Interest Rate Derivatives Used To Manage Debt Net Of Cash And Cash Equivalents</link:label>
    <link:label id="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_documentation_en-US" xlink:label="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Currency and interest rate derivatives used to manage debt, net of cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:href="sny-20240630.xsd#sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:to="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_8657f707-8388-4c6f-9ea6-66d0bb568d1e_terseLabel_en-US" xlink:label="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of development costs arising from commercial operations</link:label>
    <link:label id="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_label_en-US" xlink:label="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Development Costs Arising From Commercial Operations</link:label>
    <link:label id="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_documentation_en-US" xlink:label="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Development Costs Arising From Commercial Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" xlink:href="sny-20240630.xsd#sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" xlink:to="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_882b17cc-2cbd-4f7d-85d3-f1e04227d6d5_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held for sale or exchange</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets or disposal groups classified as held for sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:to="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessCombinationPurchasePricePerShare_62976429-79aa-44d5-b3c5-ba05d6560062_terseLabel_en-US" xlink:label="lab_sny_BusinessCombinationPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price per share (in USD per share)</link:label>
    <link:label id="lab_sny_BusinessCombinationPurchasePricePerShare_label_en-US" xlink:label="lab_sny_BusinessCombinationPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Purchase Price Per Share</link:label>
    <link:label id="lab_sny_BusinessCombinationPurchasePricePerShare_documentation_en-US" xlink:label="lab_sny_BusinessCombinationPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Purchase Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePricePerShare" xlink:href="sny-20240630.xsd#sny_BusinessCombinationPurchasePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessCombinationPurchasePricePerShare" xlink:to="lab_sny_BusinessCombinationPurchasePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_ecd90ffe-6250-4c55-9f28-0245fcc0614a_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization and impairment</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation, amortisation and impairment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_e5471d25-e116-4e88-9c65-668082e0bdf8_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instruments at fair value through other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets at fair value through other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:to="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MazeTherapeuticsMember_44c0dd5d-9aaa-42b9-b9ad-6694a24e9fb4_terseLabel_en-US" xlink:label="lab_sny_MazeTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maze Therapeutics</link:label>
    <link:label id="lab_sny_MazeTherapeuticsMember_label_en-US" xlink:label="lab_sny_MazeTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maze Therapeutics [Member]</link:label>
    <link:label id="lab_sny_MazeTherapeuticsMember_documentation_en-US" xlink:label="lab_sny_MazeTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maze Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MazeTherapeuticsMember" xlink:href="sny-20240630.xsd#sny_MazeTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MazeTherapeuticsMember" xlink:to="lab_sny_MazeTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_b0c42904-27e3-4e7e-8c34-acac6f93b89a_terseLabel_en-US" xlink:label="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets other than goodwill, reversal amount</link:label>
    <link:label id="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_eae1a2ce-1fd4-4306-a42b-38e24f2bd76b_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers, intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DevelopmentRegulatoryAndLaunchMilestonePayments_ffdd9cb6-3e6c-42ac-a5a3-b936ec8743af_terseLabel_en-US" xlink:label="lab_sny_DevelopmentRegulatoryAndLaunchMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development Regulatory And Launch Milestone Payments</link:label>
    <link:label id="lab_sny_DevelopmentRegulatoryAndLaunchMilestonePayments_label_en-US" xlink:label="lab_sny_DevelopmentRegulatoryAndLaunchMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Regulatory And Launch Milestone Payments</link:label>
    <link:label id="lab_sny_DevelopmentRegulatoryAndLaunchMilestonePayments_documentation_en-US" xlink:label="lab_sny_DevelopmentRegulatoryAndLaunchMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development Regulatory And Launch Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DevelopmentRegulatoryAndLaunchMilestonePayments" xlink:href="sny-20240630.xsd#sny_DevelopmentRegulatoryAndLaunchMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DevelopmentRegulatoryAndLaunchMilestonePayments" xlink:to="lab_sny_DevelopmentRegulatoryAndLaunchMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_97e7fa79-b759-46c1-aca7-4227404a3887_negatedLabel_en-US" xlink:label="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unwinding of discounting of provisions</link:label>
    <link:label id="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_label_en-US" xlink:label="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense arising from passage of time on other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:to="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ConsumerHealthcareSegmentMember_d8ec2431-5e8d-4471-88b2-f9884f02f0f8_terseLabel_en-US" xlink:label="lab_sny_ConsumerHealthcareSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Opella</link:label>
    <link:label id="lab_sny_ConsumerHealthcareSegmentMember_label_en-US" xlink:label="lab_sny_ConsumerHealthcareSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumer Healthcare Segment [Member]</link:label>
    <link:label id="lab_sny_ConsumerHealthcareSegmentMember_documentation_en-US" xlink:label="lab_sny_ConsumerHealthcareSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consumer Healthcare segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember" xlink:href="sny-20240630.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ConsumerHealthcareSegmentMember" xlink:to="lab_sny_ConsumerHealthcareSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_c7ff0e59-497d-4912-b91d-599011217f18_terseLabel_en-US" xlink:label="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Items subsequently reclassifiable to profit or loss</link:label>
    <link:label id="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_label_en-US" xlink:label="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Items Subsequently Reclassifiable To Profit Or Loss [Member]</link:label>
    <link:label id="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_documentation_en-US" xlink:label="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Items subsequently reclassifiable to profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:href="sny-20240630.xsd#sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:to="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_d96397bc-3a91-455f-b884-7df529a45b93_terseLabel_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options and other share-based payment [Member]</link:label>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_label_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_1884bb8d-c44a-4141-8e48-8b793cc58486_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overdue by 1-3 months</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one month and not later than three months [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:to="lab_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_99f18285-d423-4321-bbe1-94a701e84a52_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">pay capitalized Ester / receive 3.56%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 3.43% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 3.43%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive343Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CreditFacilitiesExtensionOptionNumber_55b46c75-61bc-451e-93c0-6d1d61c88e39_terseLabel_en-US" xlink:label="lab_sny_CreditFacilitiesExtensionOptionNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit facilities, number of extension options</link:label>
    <link:label id="lab_sny_CreditFacilitiesExtensionOptionNumber_label_en-US" xlink:label="lab_sny_CreditFacilitiesExtensionOptionNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facilities, Extension Option, Number</link:label>
    <link:label id="lab_sny_CreditFacilitiesExtensionOptionNumber_documentation_en-US" xlink:label="lab_sny_CreditFacilitiesExtensionOptionNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Facilities, Extension Option, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CreditFacilitiesExtensionOptionNumber" xlink:href="sny-20240630.xsd#sny_CreditFacilitiesExtensionOptionNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CreditFacilitiesExtensionOptionNumber" xlink:to="lab_sny_CreditFacilitiesExtensionOptionNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_1bd5b4d6-fa77-40c8-94b0-f37cb22a1fa9_negatedLabel_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest rate and currency derivatives used to manage cash and cash equivalents</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_label_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate And Currency Derivatives Used To Manage Cash And Cash Equivalent</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_documentation_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest rate and currency derivatives used to manage cash and cash equivalent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:href="sny-20240630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:to="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherCountriesMember_0b3b12e0-aea2-404f-8a3d-d4cdba0a7b51_terseLabel_en-US" xlink:label="lab_sny_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other countries</link:label>
    <link:label id="lab_sny_OtherCountriesMember_label_en-US" xlink:label="lab_sny_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Countries [member]</link:label>
    <link:label id="lab_sny_OtherCountriesMember_documentation_en-US" xlink:label="lab_sny_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other countries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember" xlink:href="sny-20240630.xsd#sny_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherCountriesMember" xlink:to="lab_sny_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems_41ad921b-4267-49e3-9f56-f1c42cbe5a52_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_7db8a5d6-a9ae-411d-abe9-1c05a46c428a_terseLabel_en-US" xlink:label="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change In Scope Of Consolidation Through Business Combination, Intangible Assets</link:label>
    <link:label id="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_label_en-US" xlink:label="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Scope Of Consolidation Through Business Combination, Intangible Assets</link:label>
    <link:label id="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_documentation_en-US" xlink:label="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Scope Of Consolidation Through Business Combination, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" xlink:href="sny-20240630.xsd#sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" xlink:to="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_f04eb9ee-0d51-41ad-a6a9-71d3642655f7_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [Member]</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_fa93e411-e82a-4048-9a0e-563937b89f8c_netLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Total number of shares awarded (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLoansAndReceivables_1bdd6ec6-8623-469d-8623-753731086ca8_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLoansAndReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term loans and advances and other non-current receivables</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLoansAndReceivables_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLoansAndReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current loans and receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLoansAndReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLoansAndReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLoansAndReceivables" xlink:to="lab_ifrs-full_NoncurrentLoansAndReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForRelatedPartiesMember_d783c319-cb47-4b6c-9e67-aaf8157bb9b6_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for related parties [Member]</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForRelatedPartiesMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for related parties [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of impairment loss and reversal of impairment loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract" xlink:to="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_488cc711-4f60-4baf-aaae-dd038ff30b47_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_431bfb07-af5d-412c-8d04-d5ae87f2be53_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_55fe26af-f693-424b-9473-50c9506ee1cc_negatedLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Current taxes</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_1241001c-59dd-4f27-b93e-5e24a1016989_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current tax expense (income)</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfHedgesAxis_241400e6-59eb-4754-a541-651068858140_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfHedgesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of Hedges [Axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfHedgesAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfHedgesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of hedges [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfHedgesAxis" xlink:to="lab_ifrs-full_TypesOfHedgesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CoreAssetsMember_91a16ff8-9d1e-4951-9b07-d34aac53b536_terseLabel_en-US" xlink:label="lab_sny_CoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Core Assets [Member]</link:label>
    <link:label id="lab_sny_CoreAssetsMember_label_en-US" xlink:label="lab_sny_CoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Core Assets [Member]</link:label>
    <link:label id="lab_sny_CoreAssetsMember_documentation_en-US" xlink:label="lab_sny_CoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Core Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CoreAssetsMember" xlink:href="sny-20240630.xsd#sny_CoreAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CoreAssetsMember" xlink:to="lab_sny_CoreAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SAR44425Member_ff7822c7-8e81-479c-8914-a689e0aa07ff_terseLabel_en-US" xlink:label="lab_sny_SAR44425Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SAR44425</link:label>
    <link:label id="lab_sny_SAR44425Member_label_en-US" xlink:label="lab_sny_SAR44425Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SAR44425 [Member]</link:label>
    <link:label id="lab_sny_SAR44425Member_documentation_en-US" xlink:label="lab_sny_SAR44425Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SAR44425</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SAR44425Member" xlink:href="sny-20240630.xsd#sny_SAR44425Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SAR44425Member" xlink:to="lab_sny_SAR44425Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LeaseExtensionOptionsTerm_f1513763-a749-45f6-a91f-f9420fd5fbcd_terseLabel_en-US" xlink:label="lab_sny_LeaseExtensionOptionsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, extension options, term</link:label>
    <link:label id="lab_sny_LeaseExtensionOptionsTerm_label_en-US" xlink:label="lab_sny_LeaseExtensionOptionsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Extension Options, Term</link:label>
    <link:label id="lab_sny_LeaseExtensionOptionsTerm_documentation_en-US" xlink:label="lab_sny_LeaseExtensionOptionsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Extension Options, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseExtensionOptionsTerm" xlink:href="sny-20240630.xsd#sny_LeaseExtensionOptionsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LeaseExtensionOptionsTerm" xlink:to="lab_sny_LeaseExtensionOptionsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_940325f6-5a69-49a8-a55c-bc82752302cb_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_label_en-US" xlink:label="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated individually immaterial associates [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:to="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_f6f2035b-f5af-4209-8971-0997594436ef_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Information About Major Customers and Credit Risk [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_label_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Information About Major Customers And Credit Risk [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of information about major customers and credit risk.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:href="sny-20240630.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:to="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RSVVaccinesMember_9e222338-b643-44ae-a45c-1ce67812a7e8_terseLabel_en-US" xlink:label="lab_sny_RSVVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSV Vaccines</link:label>
    <link:label id="lab_sny_RSVVaccinesMember_label_en-US" xlink:label="lab_sny_RSVVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RSV Vaccines [Member]</link:label>
    <link:label id="lab_sny_RSVVaccinesMember_documentation_en-US" xlink:label="lab_sny_RSVVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RSV Vaccines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RSVVaccinesMember" xlink:href="sny-20240630.xsd#sny_RSVVaccinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RSVVaccinesMember" xlink:to="lab_sny_RSVVaccinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis_f7b81c57-4af0-4050-9578-ad1f7ab8e440_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of Contingent Liabilities [Axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of contingent liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NexviazymeMember_6a77d88e-478e-47fe-8e03-e46c832e98b9_terseLabel_en-US" xlink:label="lab_sny_NexviazymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nexviazyme</link:label>
    <link:label id="lab_sny_NexviazymeMember_label_en-US" xlink:label="lab_sny_NexviazymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nexviazyme [Member]</link:label>
    <link:label id="lab_sny_NexviazymeMember_documentation_en-US" xlink:label="lab_sny_NexviazymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nexviazyme</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NexviazymeMember" xlink:href="sny-20240630.xsd#sny_NexviazymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NexviazymeMember" xlink:to="lab_sny_NexviazymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_fd9a51ba-4d3e-48e4-a22d-0660ba0440bd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SpecialtyCareMember_fddd664f-17e9-463d-ad7a-c360e260d63e_terseLabel_en-US" xlink:label="lab_sny_SpecialtyCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Pharma launches</link:label>
    <link:label id="lab_sny_SpecialtyCareMember_label_en-US" xlink:label="lab_sny_SpecialtyCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Specialty Care [Member]</link:label>
    <link:label id="lab_sny_SpecialtyCareMember_documentation_en-US" xlink:label="lab_sny_SpecialtyCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Specialty Care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SpecialtyCareMember" xlink:href="sny-20240630.xsd#sny_SpecialtyCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SpecialtyCareMember" xlink:to="lab_sny_SpecialtyCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_32f4291e-05f1-42d6-a866-a7bf1b3ade8b_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation differences</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_820c63c1-d6ec-484d-8501-95875a92a0e0_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in scope of consolidation</link:label>
    <link:label id="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_2a3ddbda-27e2-4930-bae0-daa359247600_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_c8c15448-464b-4bbe-81d4-85cc97bf238b_negatedLabel_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/(losses)</link:label>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_c8277ecd-e567-49ec-ab61-698e18bb87fb_terseLabel_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional share of profit paid by Regeneron towards development costs</link:label>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_label_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Profit Or Loss From Commercialization Of Zaltrap [Member]</link:label>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_documentation_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of profit or loss from commercialization of Zaltrap.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" xlink:href="sny-20240630.xsd#sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" xlink:to="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LongTermPrepaidExpenses_fd132d2c-5021-4386-8365-78d471d384f5_terseLabel_en-US" xlink:label="lab_sny_LongTermPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term prepaid expenses</link:label>
    <link:label id="lab_sny_LongTermPrepaidExpenses_label_en-US" xlink:label="lab_sny_LongTermPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Prepaid Expenses</link:label>
    <link:label id="lab_sny_LongTermPrepaidExpenses_documentation_en-US" xlink:label="lab_sny_LongTermPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long term prepaid expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LongTermPrepaidExpenses" xlink:href="sny-20240630.xsd#sny_LongTermPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LongTermPrepaidExpenses" xlink:to="lab_sny_LongTermPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock_05a90219-833a-4248-846e-2bcabd34991f_terseLabel_en-US" xlink:label="lab_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreements Relating to the Recombinant COVID-19 Vaccine Candidate Developed by Sanofi in Collaboration with GSK</link:label>
    <link:label id="lab_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock_label_en-US" xlink:label="lab_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreements Relating To The Recombinant COVID-19 Vaccine Candidate, Policy [Policy Text Block]</link:label>
    <link:label id="lab_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreements Relating To The Recombinant COVID-19 Vaccine Candidate, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock" xlink:href="sny-20240630.xsd#sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock" xlink:to="lab_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MiscellaneousOtherOperatingIncomeExpenses_1785e614-13d4-4a66-9827-5715869c23f5_terseLabel_en-US" xlink:label="lab_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating income and expenses</link:label>
    <link:label id="lab_sny_MiscellaneousOtherOperatingIncomeExpenses_label_en-US" xlink:label="lab_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous Other Operating Income (Expenses)</link:label>
    <link:label id="lab_sny_MiscellaneousOtherOperatingIncomeExpenses_documentation_en-US" xlink:label="lab_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other operating income and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:href="sny-20240630.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:to="lab_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockPrice_fe0457b2-c975-430b-9a97-c4b7dda65c98_terseLabel_en-US" xlink:label="lab_sny_StockPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock price (in euro per share)</link:label>
    <link:label id="lab_sny_StockPrice_label_en-US" xlink:label="lab_sny_StockPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price</link:label>
    <link:label id="lab_sny_StockPrice_documentation_en-US" xlink:label="lab_sny_StockPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockPrice" xlink:href="sny-20240630.xsd#sny_StockPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockPrice" xlink:to="lab_sny_StockPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsTable_615c7b7c-f894-4f59-b3d9-c3f5db2692b5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentLiabilities_a5c623e2-3796-4006-8957-b79c21098de4_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentLiabilities" xlink:to="lab_ifrs-full_OtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EloctateMember_20ef1dfb-edbe-4baa-ad4c-e9d7977151d8_terseLabel_en-US" xlink:label="lab_sny_EloctateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eloctate</link:label>
    <link:label id="lab_sny_EloctateMember_label_en-US" xlink:label="lab_sny_EloctateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eloctate [Member]</link:label>
    <link:label id="lab_sny_EloctateMember_documentation_en-US" xlink:label="lab_sny_EloctateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eloctate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EloctateMember" xlink:href="sny-20240630.xsd#sny_EloctateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EloctateMember" xlink:to="lab_sny_EloctateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture_2438b0ae-5b6b-45ae-882a-da83f43a9538_terseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in joint venture</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture_label_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in joint venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorCustomersMember_708f00a2-cbfd-45d2-98d8-b91b72e353d9_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customers [Member]</link:label>
    <link:label id="lab_ifrs-full_MajorCustomersMember_label_en-US" xlink:label="lab_ifrs-full_MajorCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customers [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorCustomersMember" xlink:to="lab_ifrs-full_MajorCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_3cf9b5a7-e9c5-4036-90b6-51f7af556523_terseLabel_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities related to business combinations and to non-controlling interests</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_f8358aa1-3ca8-483a-a57b-85b59b676d25_verboseLabel_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_label_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Liabilities Related To Business Combinations And To Non-Controlling Interests</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_documentation_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This account includes current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes current portion of liabilities related to non-controlling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:href="sny-20240630.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:to="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAndLiabilitiesAxis_864667d2-5729-4f34-9d17-cb8530dec6f7_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities [Axis]</link:label>
    <link:label id="lab_ifrs-full_AssetsAndLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAndLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis" xlink:to="lab_ifrs-full_AssetsAndLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_7a7334ac-55c8-459a-ab22-b3e1a79ba312_terseLabel_en-US" xlink:label="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in joint ventures</link:label>
    <link:label id="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in joint ventures accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SegmentsAxis_86928cb0-53c2-4eb2-86dd-116e1e007c14_terseLabel_en-US" xlink:label="lab_ifrs-full_SegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_ifrs-full_SegmentsAxis_label_en-US" xlink:label="lab_ifrs-full_SegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SegmentsAxis" xlink:to="lab_ifrs-full_SegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate_caff57f6-c31f-4bc0-94d7-0e1840d0d7fb_terseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in associate</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate_label_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in associate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_bc23bd0d-94ee-4e39-8f2c-256717a3c6d2_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfRestrictedSharesAlloted_bf62fe62-774b-47c6-8c0a-f5fb06bf711f_terseLabel_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesAlloted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of restricted shares alloted (in shares)</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesAlloted_label_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesAlloted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Restricted Shares Alloted</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesAlloted_documentation_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesAlloted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Restricted Shares Alloted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesAlloted" xlink:href="sny-20240630.xsd#sny_NumberOfRestrictedSharesAlloted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfRestrictedSharesAlloted" xlink:to="lab_sny_NumberOfRestrictedSharesAlloted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_d637951c-989a-4f29-b15d-82ba3e1d17e1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Principal Transactions and Balances with Related Parties</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1834e8b8-b4f8-40b5-8fe8-0a1178423184_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average residual life (years)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment_3b5c405f-41d5-4949-9c21-e402d5ac76ac_terseLabel_en-US" xlink:label="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreements, regulatory milestone payment</link:label>
    <link:label id="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment_label_en-US" xlink:label="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Regulatory Milestone Payment</link:label>
    <link:label id="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment_documentation_en-US" xlink:label="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Regulatory Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsRegulatoryMilestonePayment" xlink:href="sny-20240630.xsd#sny_CollaborationAgreementsRegulatoryMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CollaborationAgreementsRegulatoryMilestonePayment" xlink:to="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_17442f7d-741c-478d-b6cd-ba3565c13dde_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfEntitysRevenue_054c72ee-d426-4d84-8b5e-8582e4c5b86b_terseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfEntitysRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of entity's revenue</link:label>
    <link:label id="lab_ifrs-full_PercentageOfEntitysRevenue_label_en-US" xlink:label="lab_ifrs-full_PercentageOfEntitysRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of entity's revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfEntitysRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfEntitysRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfEntitysRevenue" xlink:to="lab_ifrs-full_PercentageOfEntitysRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AllowanceForCreditLossesMember_407682e1-dc3f-4aa3-ad78-30a1209b86d3_terseLabel_en-US" xlink:label="lab_ifrs-full_AllowanceForCreditLossesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowances</link:label>
    <link:label id="lab_ifrs-full_AllowanceForCreditLossesMember_label_en-US" xlink:label="lab_ifrs-full_AllowanceForCreditLossesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for credit losses [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllowanceForCreditLossesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllowanceForCreditLossesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllowanceForCreditLossesMember" xlink:to="lab_ifrs-full_AllowanceForCreditLossesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BusinessCombinationsAxis_8d3da86e-b07c-48fb-8978-1f664598eda5_terseLabel_en-US" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations [Axis]</link:label>
    <link:label id="lab_ifrs-full_BusinessCombinationsAxis_label_en-US" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business combinations [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BusinessCombinationsAxis" xlink:to="lab_ifrs-full_BusinessCombinationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_e8c82325-e9d3-4495-a37c-92eec620673e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Expenses and Income</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of finance income (cost) [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasTable_e075fe63-8242-4737-b22b-8fa46427d400_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_ce9bd134-4fe1-4f0e-b98e-2a59ed2e9a12_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of carrying amount to value on redemption [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_label_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of carrying amount to value on redemption [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:href="sny-20240630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:to="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod_5a6efeca-6366-4fb7-a6be-d0032c126325_terseLabel_en-US" xlink:label="lab_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in associates</link:label>
    <link:label id="lab_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in associates accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_4aace6bb-5109-4809-aa8b-40ddb0f90b3e_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee share ownership plan</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Share-Based Payment Plans Employee Share Ownership Plans</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee share ownership plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:to="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_50087f54-23ed-4e1e-9dc3-139aace2d1d1_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment owned</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_68e4aa50-3de9-4e05-a5e7-181649b4cb76_verboseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeResultingFromOutLicensing_d9d0da4d-1db5-487c-8207-40073b508657_terseLabel_en-US" xlink:label="lab_sny_IncomeResultingFromOutLicensing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from out-licensing</link:label>
    <link:label id="lab_sny_IncomeResultingFromOutLicensing_label_en-US" xlink:label="lab_sny_IncomeResultingFromOutLicensing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Resulting From Out-Licensing</link:label>
    <link:label id="lab_sny_IncomeResultingFromOutLicensing_documentation_en-US" xlink:label="lab_sny_IncomeResultingFromOutLicensing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Resulting From Out-Licensing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeResultingFromOutLicensing" xlink:href="sny-20240630.xsd#sny_IncomeResultingFromOutLicensing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeResultingFromOutLicensing" xlink:to="lab_sny_IncomeResultingFromOutLicensing" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_99022d74-dc55-42f7-a26f-72b42b1235e2_totalLabel_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before tax and investments accounted for using the equity method</link:label>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_c2403f93-4e0c-4c1b-82c7-2bb3caa70e1f_terseLabel_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before tax and investments accounted for using the equity method</link:label>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_label_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Before Tax And Investments Accounted For Equity Method Investments</link:label>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_documentation_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income before tax and investments accounted for equity method investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:href="sny-20240630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:to="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GeneralInformationAboutFinancialStatementsAbstract_7ed3d531-9565-4b00-85ee-0303ab88260d_terseLabel_en-US" xlink:label="lab_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General Information About Financial Statements [Abstract]</link:label>
    <link:label id="lab_sny_GeneralInformationAboutFinancialStatementsAbstract_label_en-US" xlink:label="lab_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General Information About Financial Statements [Abstract]</link:label>
    <link:label id="lab_sny_GeneralInformationAboutFinancialStatementsAbstract_documentation_en-US" xlink:label="lab_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General Information About Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:href="sny-20240630.xsd#sny_GeneralInformationAboutFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:to="lab_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForSubsidiariesMember_dd2e2f39-75e7-41e4-b1af-6aaccfc5ded9_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for subsidiaries [member]</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForSubsidiariesMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for subsidiaries [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="lab_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_39bfe59d-8026-4b37-b24c-2fe4f1292a0d_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (d)</link:label>
    <link:label id="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other tax rate effects for reconciliation between accounting profit and tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis_c6999372-d0d6-41ae-b80f-68a8c58abc99_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associates [Axis]</link:label>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis_label_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associates [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_13e84820-3bb8-4939-b397-3435bd1eb5d8_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxAssets" xlink:to="lab_ifrs-full_DeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_85b65f45-1696-499d-bcea-3da759b3c07d_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value (investments accounted for using the equity method, net of taxes)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Cash Flow Hedges Net Of Tax On Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in fair value on cash flow hedges net of tax on associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EUROZONEMember_53c25f19-9e39-4518-b2e6-763c76d1800b_terseLabel_en-US" xlink:label="lab_sny_EUROZONEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eurozone</link:label>
    <link:label id="lab_sny_EUROZONEMember_label_en-US" xlink:label="lab_sny_EUROZONEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EUROZONE [Member]</link:label>
    <link:label id="lab_sny_EUROZONEMember_documentation_en-US" xlink:label="lab_sny_EUROZONEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">EUROZONE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EUROZONEMember" xlink:href="sny-20240630.xsd#sny_EUROZONEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EUROZONEMember" xlink:to="lab_sny_EUROZONEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestCostsCapitalised_144e8a94-1732-491c-9924-0b72bf0aef1c_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestCostsCapitalised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest costs capitalised</link:label>
    <link:label id="lab_ifrs-full_InterestCostsCapitalised_label_en-US" xlink:label="lab_ifrs-full_InterestCostsCapitalised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest costs capitalised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestCostsCapitalised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestCostsCapitalised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestCostsCapitalised" xlink:to="lab_ifrs-full_InterestCostsCapitalised" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock_d44ff32c-3447-4373-9b14-c57e0af2a85c_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Investments in Associates and Joint Ventures</link:label>
    <link:label id="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Investments In Associates And Joint Ventures [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure of investments in associates and joint ventures explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:to="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e040550e-07fe-4c03-8e8d-0dc18c9dd780_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_a58c20cc-49c7-4c8e-a364-b485028440d6_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_0381997a-67bd-4ce0-8794-4176d5cc03c4_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_5184b27d-18e1-40ab-9e44-d139c0069a4a_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_8398dca3-57f9-4198-b4ce-cf29cd22d6b2_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_ca68a028-bca4-4832-a79f-2284c618628c_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_3bd77ec1-50db-4ebe-9df9-9485ccf94a71_negatedLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AssetsAcquisitionNominalValue_54d8e034-8363-4898-85e9-c3b8fce1b5a3_terseLabel_en-US" xlink:label="lab_sny_AssetsAcquisitionNominalValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Acquisition Nominal Value</link:label>
    <link:label id="lab_sny_AssetsAcquisitionNominalValue_label_en-US" xlink:label="lab_sny_AssetsAcquisitionNominalValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Acquisition Nominal Value</link:label>
    <link:label id="lab_sny_AssetsAcquisitionNominalValue_documentation_en-US" xlink:label="lab_sny_AssetsAcquisitionNominalValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets Acquisition Nominal Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionNominalValue" xlink:href="sny-20240630.xsd#sny_AssetsAcquisitionNominalValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AssetsAcquisitionNominalValue" xlink:to="lab_sny_AssetsAcquisitionNominalValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_7603b2af-66f6-4a63-b067-fc65a925a7f3_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lab_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_da1ed068-4f80-48b7-ad02-3df25e268078_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase)/decrease in accounts receivable</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_9ac3e77c-a855-46ee-b955-db9602ddd501_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="lab_ifrs-full_NoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_acc26e01-be19-40eb-831b-85080c81e535_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaterialReconcilingItemsMember_4d491d1e-8e1e-4aa3-9a00-ed7cdf9a487f_terseLabel_en-US" xlink:label="lab_ifrs-full_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material reconciling items</link:label>
    <link:label id="lab_ifrs-full_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_ifrs-full_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material reconciling items [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaterialReconcilingItemsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaterialReconcilingItemsMember" xlink:to="lab_ifrs-full_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_fe5037de-6df3-4c49-b8bf-b51a72e4ad36_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Options Outstanding and Exercisable</link:label>
    <link:label id="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of share based compensation shares authorized under stock option plans by exercise price range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:to="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_598a9624-70a1-42a6-aa1a-3da9d043b666_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_e0f6fac6-48c7-4c23-8449-5ce853034758_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_80725365-f5f0-48aa-8389-6c6fdba93164_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock_942b4048-3ed9-4c45-9231-845632e3672d_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Movements in Non-Current Provisions</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-Current Provisions [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of noncurrent provisions explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfNonCurrentProvisionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:to="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock_b5d0a0ef-b266-42e1-bc09-178796061009_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Gross Value of Overdue Receivables</link:label>
    <link:label id="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Overdue Receivables Gross Value [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of overdue receivables gross value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:to="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_144c7a72-e70b-4c39-9c4f-bd5f8ccf354f_negatedLabel_en-US" xlink:label="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expense arising from the impact of acquisitions on inventories</link:label>
    <link:label id="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_label_en-US" xlink:label="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Arising From The Impact Of Acquisitions On Inventories</link:label>
    <link:label id="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_documentation_en-US" xlink:label="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expenses arising from the impact of acquisitions on inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:href="sny-20240630.xsd#sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:to="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotionalAmount_699c7759-0d07-446d-8ccf-8cc7a8d6667a_terseLabel_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
    <link:label id="lab_ifrs-full_NotionalAmount_label_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotionalAmount" xlink:to="lab_ifrs-full_NotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables_40b0ad3b-fba0-40f5-a68f-01592a732c46_negatedLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:to="lab_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_12b8106c-fe45-48bf-ac3f-6245510939ce_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred, acquisition-date fair value</link:label>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_label_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration transferred, acquisition-date fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b5728966-ac3c-4d87-be2e-62e5e899974c_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_ce4c0cd6-cfac-4921-859b-91cd79f762ee_terseLabel_en-US" xlink:label="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital&#160;increase&#160;by&#160;exercise&#160;of stock subscription options (in shares)</link:label>
    <link:label id="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_label_en-US" xlink:label="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Issued In Regards Of Capital Increase By Exercise Of Stock Subscription Options</link:label>
    <link:label id="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_documentation_en-US" xlink:label="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued in regards of capital increase by exercise of stock subscription options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:href="sny-20240630.xsd#sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:to="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_c1e13039-9a55-46e7-8a9e-b2f9add2ec33_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_TR_4166f566-3c3d-4e57-b88a-8fecbc951b7c_terseLabel_en-US" xlink:label="lab_country_TR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Turkey</link:label>
    <link:label id="lab_country_TR_label_en-US" xlink:label="lab_country_TR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">T&#220;RKIYE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_TR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_TR" xlink:to="lab_country_TR" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_c3041ff3-d3db-4615-822a-43c83296c7b3_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than two years and not later than three years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:to="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_00e8ef7f-e529-47b9-aae5-140128728c9c_terseLabel_en-US" xlink:label="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</link:label>
    <link:label id="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_label_en-US" xlink:label="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</link:label>
    <link:label id="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_documentation_en-US" xlink:label="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" xlink:href="sny-20240630.xsd#sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" xlink:to="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock_2c761d73-5a87-4a6c-8107-ec31529827cd_terseLabel_en-US" xlink:label="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Seasonal Trends</link:label>
    <link:label id="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock_label_en-US" xlink:label="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seasonality Or Cyclicality Of Interim Operations [Policy Text Block]</link:label>
    <link:label id="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock_documentation_en-US" xlink:label="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Seasonality Or Cyclicality Of Interim Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" xlink:href="sny-20240630.xsd#sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" xlink:to="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TzieldMember_f2846532-7b5b-4c39-b84d-2142f025a945_terseLabel_en-US" xlink:label="lab_sny_TzieldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tzield</link:label>
    <link:label id="lab_sny_TzieldMember_label_en-US" xlink:label="lab_sny_TzieldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tzield [Member]</link:label>
    <link:label id="lab_sny_TzieldMember_documentation_en-US" xlink:label="lab_sny_TzieldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tzield</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TzieldMember" xlink:href="sny-20240630.xsd#sny_TzieldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TzieldMember" xlink:to="lab_sny_TzieldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_862f1e04-b378-4c66-a700-669c336fff55_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentLiabilities" xlink:to="lab_ifrs-full_OtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_44898f40-3666-44f8-acfa-400a61b9747a_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average number of shares outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_326ee79a-3a89-4773-ac5e-348be2de1e27_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average number of shares outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CabliviMember_66c0c6aa-39e0-4203-a06d-89ef6849c589_terseLabel_en-US" xlink:label="lab_sny_CabliviMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cablivi</link:label>
    <link:label id="lab_sny_CabliviMember_label_en-US" xlink:label="lab_sny_CabliviMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cablivi [Member]</link:label>
    <link:label id="lab_sny_CabliviMember_documentation_en-US" xlink:label="lab_sny_CabliviMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cablivi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CabliviMember" xlink:href="sny-20240630.xsd#sny_CabliviMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CabliviMember" xlink:to="lab_sny_CabliviMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2024AdditionalSharesMember_c75b1f4e-b629-45ba-9c09-dfe8f36dc06a_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2024AdditionalSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2024, Additional Shares</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2024AdditionalSharesMember_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2024AdditionalSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2024, Additional Shares [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2024AdditionalSharesMember_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2024AdditionalSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2024, Additional Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2024AdditionalSharesMember" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2024AdditionalSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2024AdditionalSharesMember" xlink:to="lab_sny_RestrictedSharePlan2024AdditionalSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EnjaymoMember_b5db330f-187e-45a2-bb74-ff15e77290ba_terseLabel_en-US" xlink:label="lab_sny_EnjaymoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Enjaymo</link:label>
    <link:label id="lab_sny_EnjaymoMember_label_en-US" xlink:label="lab_sny_EnjaymoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enjaymo [Member]</link:label>
    <link:label id="lab_sny_EnjaymoMember_documentation_en-US" xlink:label="lab_sny_EnjaymoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Enjaymo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EnjaymoMember" xlink:href="sny-20240630.xsd#sny_EnjaymoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EnjaymoMember" xlink:to="lab_sny_EnjaymoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AssetsAcquisitionPurchasePricePerShare_1eb0f59a-cb66-45fc-a962-8734fc2deae8_terseLabel_en-US" xlink:label="lab_sny_AssetsAcquisitionPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Acquisition, Purchase Price Per Share</link:label>
    <link:label id="lab_sny_AssetsAcquisitionPurchasePricePerShare_label_en-US" xlink:label="lab_sny_AssetsAcquisitionPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Acquisition, Purchase Price Per Share</link:label>
    <link:label id="lab_sny_AssetsAcquisitionPurchasePricePerShare_documentation_en-US" xlink:label="lab_sny_AssetsAcquisitionPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets Acquisition, Purchase Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionPurchasePricePerShare" xlink:href="sny-20240630.xsd#sny_AssetsAcquisitionPurchasePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AssetsAcquisitionPurchasePricePerShare" xlink:to="lab_sny_AssetsAcquisitionPurchasePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e4381d32-0ea0-4f00-9706-441717674226_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfOperatingSegments_08025aaf-a8df-401b-b3f0-992b7dc23862_terseLabel_en-US" xlink:label="lab_sny_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_sny_NumberOfOperatingSegments_label_en-US" xlink:label="lab_sny_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Operating Segments</link:label>
    <link:label id="lab_sny_NumberOfOperatingSegments_documentation_en-US" xlink:label="lab_sny_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of operating segments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments" xlink:href="sny-20240630.xsd#sny_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfOperatingSegments" xlink:to="lab_sny_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RecludixPharmaMember_e36501d3-9eb3-47b4-9a1f-5300e3bbe3df_terseLabel_en-US" xlink:label="lab_sny_RecludixPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recludix Pharma</link:label>
    <link:label id="lab_sny_RecludixPharmaMember_label_en-US" xlink:label="lab_sny_RecludixPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recludix Pharma [Member]</link:label>
    <link:label id="lab_sny_RecludixPharmaMember_documentation_en-US" xlink:label="lab_sny_RecludixPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recludix Pharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RecludixPharmaMember" xlink:href="sny-20240630.xsd#sny_RecludixPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RecludixPharmaMember" xlink:to="lab_sny_RecludixPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HedgedItemsAxis_bd8fc79a-e907-4aed-ad3e-83df6c0940f3_terseLabel_en-US" xlink:label="lab_ifrs-full_HedgedItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedged items [Axis]</link:label>
    <link:label id="lab_ifrs-full_HedgedItemsAxis_label_en-US" xlink:label="lab_ifrs-full_HedgedItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged items [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgedItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgedItemsAxis" xlink:to="lab_ifrs-full_HedgedItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiMember_10d26455-9965-4fc5-812f-c305e51eedf5_terseLabel_en-US" xlink:label="lab_sny_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_sny_SanofiMember_label_en-US" xlink:label="lab_sny_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi [member]</link:label>
    <link:label id="lab_sny_SanofiMember_documentation_en-US" xlink:label="lab_sny_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sanofi.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiMember" xlink:href="sny-20240630.xsd#sny_SanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiMember" xlink:to="lab_sny_SanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherOperatingExpensesTableTextBlock_f5c420b3-15a7-4317-a86c-755c89a42f97_terseLabel_en-US" xlink:label="lab_sny_OtherOperatingExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Operating Expenses</link:label>
    <link:label id="lab_sny_OtherOperatingExpensesTableTextBlock_label_en-US" xlink:label="lab_sny_OtherOperatingExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Expenses [Table Text Block]</link:label>
    <link:label id="lab_sny_OtherOperatingExpensesTableTextBlock_documentation_en-US" xlink:label="lab_sny_OtherOperatingExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Operating Expenses [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingExpensesTableTextBlock" xlink:href="sny-20240630.xsd#sny_OtherOperatingExpensesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherOperatingExpensesTableTextBlock" xlink:to="lab_sny_OtherOperatingExpensesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_29784c54-9376-4a19-951b-770a68e9d85a_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherRestructuringCosts_ef911c81-a862-49af-b998-2139f050f86c_terseLabel_en-US" xlink:label="lab_sny_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other restructuring costs</link:label>
    <link:label id="lab_sny_OtherRestructuringCosts_label_en-US" xlink:label="lab_sny_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Restructuring Costs</link:label>
    <link:label id="lab_sny_OtherRestructuringCosts_documentation_en-US" xlink:label="lab_sny_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other restructuring costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherRestructuringCosts" xlink:href="sny-20240630.xsd#sny_OtherRestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherRestructuringCosts" xlink:to="lab_sny_OtherRestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_e1d2fc2a-a6ea-4e6d-85da-ba3e44eb2ff8_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax paid</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund), classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember_ae24dfa7-05c9-4bfb-a699-481ce38464bd_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Turkish lira</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Turkish lira [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Turkish lira</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInTurkishLiraMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInTurkishLiraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInTurkishLiraMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_64b255d2-032b-4219-aea3-afe05e0e689f_terseLabel_en-US" xlink:label="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for pensions &amp; other post-employment benefits</link:label>
    <link:label id="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_label_en-US" xlink:label="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions For Pensions And Other Postemployment Benefits [member]</link:label>
    <link:label id="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_documentation_en-US" xlink:label="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provisions for pensions and other post-employment benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" xlink:href="sny-20240630.xsd#sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" xlink:to="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInUSDollarMember_677732d9-0171-40da-a70a-0dee83868117_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency sales in US dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInUSDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In US Dollar [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInUSDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency sales in USD.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInUSDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInUSDollarMember" xlink:to="lab_sny_ForwardCurrencySalesInUSDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_27c13b98-0de2-4e48-8d09-162295b7b8c5_terseLabel_en-US" xlink:label="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value remeasurement of contingent consideration liabilities</link:label>
    <link:label id="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_label_en-US" xlink:label="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Rate Effect Of Fair Value Remeasurement Of Contingent Considerations</link:label>
    <link:label id="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_documentation_en-US" xlink:label="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Rate Effect Of Fair Value Remeasurement Of Contingent Considerations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" xlink:href="sny-20240630.xsd#sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" xlink:to="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfYearsServicePeriod_3c0f239e-2b6c-4067-8bd6-1fbac693acaa_terseLabel_en-US" xlink:label="lab_sny_NumberOfYearsServicePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service period</link:label>
    <link:label id="lab_sny_NumberOfYearsServicePeriod_label_en-US" xlink:label="lab_sny_NumberOfYearsServicePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Years, Service Period</link:label>
    <link:label id="lab_sny_NumberOfYearsServicePeriod_documentation_en-US" xlink:label="lab_sny_NumberOfYearsServicePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Years, Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfYearsServicePeriod" xlink:href="sny-20240630.xsd#sny_NumberOfYearsServicePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfYearsServicePeriod" xlink:to="lab_sny_NumberOfYearsServicePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_c19fcb9f-45d1-4e72-8a45-2d17213157ba_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ChangesInOtherProvisions_2e29b6fc-8abe-43da-b0c9-3bf222656cbb_terseLabel_en-US" xlink:label="lab_ifrs-full_ChangesInOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases in provisions and other liabilities</link:label>
    <link:label id="lab_ifrs-full_ChangesInOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_ChangesInOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangesInOtherProvisions" xlink:to="lab_ifrs-full_ChangesInOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember_e840eda3-6524-4850-9368-7678eb637ad7_terseLabel_en-US" xlink:label="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity instruments included in financial assets</link:label>
    <link:label id="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember_label_en-US" xlink:label="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Instruments Included In Financial Assets [Member]</link:label>
    <link:label id="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember_documentation_en-US" xlink:label="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Instruments Included In Financial Assets[member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInstrumentsIncludedInFinancialAssetsMember" xlink:href="sny-20240630.xsd#sny_EquityInstrumentsIncludedInFinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityInstrumentsIncludedInFinancialAssetsMember" xlink:to="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfRestrictedSharesNotYetFullyVested_af9a788a-1419-40db-a0fa-85fcec9bc7d1_terseLabel_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares not yet fully vested (in shares)</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesNotYetFullyVested_label_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Restricted Shares Not Yet Fully Vested</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesNotYetFullyVested_documentation_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of restricted shares not yet fully vested.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:href="sny-20240630.xsd#sny_NumberOfRestrictedSharesNotYetFullyVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:to="lab_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_f322aaf9-70ae-47ae-99fa-7881bb987a1e_negatedLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share of undistributed earnings from investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for undistributed profits of investments accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AntibodiesAllianceMember_78bbc4f2-d4cb-4468-b8f4-a8336da55e4c_terseLabel_en-US" xlink:label="lab_sny_AntibodiesAllianceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monoclonal Antibodies Alliance</link:label>
    <link:label id="lab_sny_AntibodiesAllianceMember_label_en-US" xlink:label="lab_sny_AntibodiesAllianceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antibodies Alliance [Member]</link:label>
    <link:label id="lab_sny_AntibodiesAllianceMember_documentation_en-US" xlink:label="lab_sny_AntibodiesAllianceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Antibodies Alliance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesAllianceMember" xlink:href="sny-20240630.xsd#sny_AntibodiesAllianceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AntibodiesAllianceMember" xlink:to="lab_sny_AntibodiesAllianceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_87faf20c-d955-43e3-9383-0426642eb82b_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_f4317c35-9aa6-463d-9629-375a36431243_negatedLabel_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_629a7cfc-2141-494e-a99e-1faf93daf6db_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortisation, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_c199baea-7a27-42df-b3d6-46926cd415e6_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of information about major customers and credit risk [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Information About Major Customers And Credit Risk [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of information about major customers and credit risk.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:href="sny-20240630.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:to="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PainCareMember_c59c54f2-81b4-4686-a385-e99fbb5c79b1_terseLabel_en-US" xlink:label="lab_sny_PainCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wellness brands</link:label>
    <link:label id="lab_sny_PainCareMember_label_en-US" xlink:label="lab_sny_PainCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pain Care [Member]</link:label>
    <link:label id="lab_sny_PainCareMember_documentation_en-US" xlink:label="lab_sny_PainCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pain [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PainCareMember" xlink:href="sny-20240630.xsd#sny_PainCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PainCareMember" xlink:to="lab_sny_PainCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5bd22dc8-856d-47e6-921e-efbdf0f3e039_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MyozymeLumizymeMember_25d0879a-c68c-46b6-a8ec-81c214f35f47_terseLabel_en-US" xlink:label="lab_sny_MyozymeLumizymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Myozyme/Lumizyme</link:label>
    <link:label id="lab_sny_MyozymeLumizymeMember_label_en-US" xlink:label="lab_sny_MyozymeLumizymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Myozyme/Lumizyme [Member]</link:label>
    <link:label id="lab_sny_MyozymeLumizymeMember_documentation_en-US" xlink:label="lab_sny_MyozymeLumizymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Myozyme/Lumizyme</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MyozymeLumizymeMember" xlink:href="sny-20240630.xsd#sny_MyozymeLumizymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MyozymeLumizymeMember" xlink:to="lab_sny_MyozymeLumizymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ValueOfHedgeRecognizedInEquityMember_864ffa88-9858-4a93-9bbb-127342e57ba2_terseLabel_en-US" xlink:label="lab_sny_ValueOfHedgeRecognizedInEquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of hedge recognized in equity</link:label>
    <link:label id="lab_sny_ValueOfHedgeRecognizedInEquityMember_label_en-US" xlink:label="lab_sny_ValueOfHedgeRecognizedInEquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value Of Hedge Recognized In Equity [Member]</link:label>
    <link:label id="lab_sny_ValueOfHedgeRecognizedInEquityMember_documentation_en-US" xlink:label="lab_sny_ValueOfHedgeRecognizedInEquityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value Of Hedge Recognized In Equity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfHedgeRecognizedInEquityMember" xlink:href="sny-20240630.xsd#sny_ValueOfHedgeRecognizedInEquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ValueOfHedgeRecognizedInEquityMember" xlink:to="lab_sny_ValueOfHedgeRecognizedInEquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_6aa49c93-2906-403e-b9a6-6ab2dd229dc0_terseLabel_en-US" xlink:label="lab_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration arising from acquisition of Amunix</link:label>
    <link:label id="lab_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_label_en-US" xlink:label="lab_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Arising From Acquisition Of Amunix [Member]</link:label>
    <link:label id="lab_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_documentation_en-US" xlink:label="lab_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Consideration Arising From Acquisition Of Amunix</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember" xlink:href="sny-20240630.xsd#sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember" xlink:to="lab_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_1b9e5d4a-896b-47b2-ae1b-cda7e086d386_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_7d477560-fe9c-48e0-9f62-7d9cdc3253e1_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_996611d2-862d-4361-afba-200f72e6bd77_negatedLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other operating expenses</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_175f71e4-5c28-4925-8fdf-6061745c844f_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating expense</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous other operating expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:to="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_3f8c8dc8-c7b5-4457-a290-17f321430c19_terseLabel_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Currency Translation Before Tax Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in currency translation before tax excluding associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:href="sny-20240630.xsd#sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_54f975f6-562a-4c62-a239-0c5be6bfbb2b_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InhibrxIncMember_33ab46f4-f996-4ae5-8ac2-688c74127569_terseLabel_en-US" xlink:label="lab_sny_InhibrxIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inhibrx, Inc</link:label>
    <link:label id="lab_sny_InhibrxIncMember_label_en-US" xlink:label="lab_sny_InhibrxIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inhibrx, Inc [Member]</link:label>
    <link:label id="lab_sny_InhibrxIncMember_documentation_en-US" xlink:label="lab_sny_InhibrxIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inhibrx, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InhibrxIncMember" xlink:href="sny-20240630.xsd#sny_InhibrxIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InhibrxIncMember" xlink:to="lab_sny_InhibrxIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock_30ce3911-6f1d-4129-9770-093639a12b28_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets</link:label>
    <link:label id="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Impairment Of Intangible Assets And Property Plant And Equipment Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for impairment of intangible assets and property, plant and equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesMember_d48f9faa-460d-4e23-a9da-3a5fac3377cf_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency purchases</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency purchases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesMember" xlink:to="lab_sny_ForwardCurrencyPurchasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LeaseExtensionOptionsNumber_264d3116-2de4-44f4-b5bd-bdc84e89ccf9_terseLabel_en-US" xlink:label="lab_sny_LeaseExtensionOptionsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, extension options, number</link:label>
    <link:label id="lab_sny_LeaseExtensionOptionsNumber_label_en-US" xlink:label="lab_sny_LeaseExtensionOptionsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Extension Options, Number</link:label>
    <link:label id="lab_sny_LeaseExtensionOptionsNumber_documentation_en-US" xlink:label="lab_sny_LeaseExtensionOptionsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Extension Options, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseExtensionOptionsNumber" xlink:href="sny-20240630.xsd#sny_LeaseExtensionOptionsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LeaseExtensionOptionsNumber" xlink:to="lab_sny_LeaseExtensionOptionsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember_3c09a9f9-32d8-41d9-89fb-5551a3355787_terseLabel_en-US" xlink:label="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets excluding software</link:label>
    <link:label id="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember_label_en-US" xlink:label="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Intangible Assets Excluding Software [Member]</link:label>
    <link:label id="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember_documentation_en-US" xlink:label="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets excluding software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember" xlink:href="sny-20240630.xsd#sny_OtherIntangibleAssetsExcludingSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember" xlink:to="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExercisePriceRangeFourMember_9a7a4436-8345-4f42-9970-a4c2a0338dc5_terseLabel_en-US" xlink:label="lab_sny_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">From &#8364;80.00 to &#8364;90.00 per share</link:label>
    <link:label id="lab_sny_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_sny_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_sny_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_sny_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeFourMember" xlink:href="sny-20240630.xsd#sny_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExercisePriceRangeFourMember" xlink:to="lab_sny_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_7536a7bf-7883-4ea3-a05e-d4ed246a7134_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_58b3ab83-12cf-48fd-8726-50cde1e14864_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_a4f65982-0e8b-4c62-a04e-ef93d65b9e0f_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_label_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentProvisions" xlink:to="lab_ifrs-full_NoncurrentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MarketedProductsMember_551a9c3c-a0ce-4add-a43c-01b72171adc4_terseLabel_en-US" xlink:label="lab_sny_MarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketed products</link:label>
    <link:label id="lab_sny_MarketedProductsMember_label_en-US" xlink:label="lab_sny_MarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketed Products [Member]</link:label>
    <link:label id="lab_sny_MarketedProductsMember_documentation_en-US" xlink:label="lab_sny_MarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketed products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsMember" xlink:href="sny-20240630.xsd#sny_MarketedProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MarketedProductsMember" xlink:to="lab_sny_MarketedProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AverageEffectiveTaxRate_364660e5-4091-43aa-a207-74110f3961dc_totalLabel_en-US" xlink:label="lab_ifrs-full_AverageEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_ifrs-full_AverageEffectiveTaxRate_label_en-US" xlink:label="lab_ifrs-full_AverageEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average effective tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate" xlink:to="lab_ifrs-full_AverageEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_bfe3e0eb-d054-4724-b75c-7900d9ed6266_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember_5830ec0b-9ff0-496d-b4aa-5a710b2d17b5_terseLabel_en-US" xlink:label="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to debt measured at fair value</link:label>
    <link:label id="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember_label_en-US" xlink:label="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To Debt Measured At Fair Value [Member]</link:label>
    <link:label id="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember_documentation_en-US" xlink:label="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustment to debt measured at fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:href="sny-20240630.xsd#sny_AdjustmentToDebtMeasuredAtFairValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:to="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LantusMember_970325a2-2f86-476f-8454-06e5e5b8abdb_terseLabel_en-US" xlink:label="lab_sny_LantusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lantus</link:label>
    <link:label id="lab_sny_LantusMember_label_en-US" xlink:label="lab_sny_LantusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lantus [Member]</link:label>
    <link:label id="lab_sny_LantusMember_documentation_en-US" xlink:label="lab_sny_LantusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lantus.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LantusMember" xlink:href="sny-20240630.xsd#sny_LantusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LantusMember" xlink:to="lab_sny_LantusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock_4f5b8851-5e16-4c4f-bf15-e8207a1eb967_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Costs and Similar Items</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Restructuring Costs And Similar Items [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure of restructuring costs and similar items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:to="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent_a59915fd-ea38-4a3a-89f9-607624a0a31b_verboseLabel_en-US" xlink:label="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share (in euros per share)</link:label>
    <link:label id="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent_label_en-US" xlink:label="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic Earnings (Loss) Per Share, Attributable To Owners Of Parent</link:label>
    <link:label id="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent_documentation_en-US" xlink:label="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic Earnings (Loss) Per Share, Attributable To Owners Of Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:href="sny-20240630.xsd#sny_BasicEarningsLossPerShareAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:to="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_c5107c39-78a1-41ce-9f30-f6df026c797c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_9efda325-bfd2-47a4-8ba8-24b542aae452_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through exercise of options, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInMexicanPesoMember_fc8db955-abdb-468b-b32f-b4e5d987b115_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInMexicanPesoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency sales in Mexican peso</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInMexicanPesoMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInMexicanPesoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Mexican Peso [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInMexicanPesoMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInMexicanPesoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Mexican Peso</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInMexicanPesoMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInMexicanPesoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInMexicanPesoMember" xlink:to="lab_sny_ForwardCurrencySalesInMexicanPesoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2024Member_065047ea-f425-4e8b-a902-75ba2e1aea0f_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2024</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2024Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2024 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2024Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2024Member" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2024Member" xlink:to="lab_sny_RestrictedSharePlan2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_ea19b69c-9332-43de-b16a-d5aa61895ec5_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of other provisions [Axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:to="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RegeneronPharmaceuticalsIncMember_b9ce8d61-4606-4107-be1f-c83ba5258593_terseLabel_en-US" xlink:label="lab_sny_RegeneronPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regeneron Pharmaceuticals, Inc</link:label>
    <link:label id="lab_sny_RegeneronPharmaceuticalsIncMember_label_en-US" xlink:label="lab_sny_RegeneronPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regeneron Pharmaceuticals, Inc [Member]</link:label>
    <link:label id="lab_sny_RegeneronPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_sny_RegeneronPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regeneron Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember" xlink:href="sny-20240630.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RegeneronPharmaceuticalsIncMember" xlink:to="lab_sny_RegeneronPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_841a0a3c-df76-40e6-9eed-98b43f8eb85a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:to="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfDismissals_24043dd9-2b82-4bff-a19e-974e363a73a6_terseLabel_en-US" xlink:label="lab_sny_NumberOfDismissals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Of Dismissals</link:label>
    <link:label id="lab_sny_NumberOfDismissals_label_en-US" xlink:label="lab_sny_NumberOfDismissals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Dismissals</link:label>
    <link:label id="lab_sny_NumberOfDismissals_documentation_en-US" xlink:label="lab_sny_NumberOfDismissals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Dismissals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfDismissals" xlink:href="sny-20240630.xsd#sny_NumberOfDismissals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfDismissals" xlink:to="lab_sny_NumberOfDismissals" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_8499827e-c8b4-47a4-a735-98b25c075aa7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock_75d8c2d8-e142-4867-80af-a3d6a3fe13f4_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated</link:label>
    <link:label id="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Currency Hedging Instruments With Notional Amount Translated In To Euros At Closing Exchange Rate Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of financial currency hedging instruments with notional amount translated in to euros at closing exchange rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DividendsPaidAbstract_8874fb51-0ea6-4850-aeb0-c2182ab5e2f2_terseLabel_en-US" xlink:label="lab_sny_DividendsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends paid:</link:label>
    <link:label id="lab_sny_DividendsPaidAbstract_label_en-US" xlink:label="lab_sny_DividendsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Paid [Abstract]</link:label>
    <link:label id="lab_sny_DividendsPaidAbstract_documentation_en-US" xlink:label="lab_sny_DividendsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dividends Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DividendsPaidAbstract" xlink:href="sny-20240630.xsd#sny_DividendsPaidAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DividendsPaidAbstract" xlink:to="lab_sny_DividendsPaidAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AtFairValueMember_4940c267-d725-4313-9787-5fcbaf0268ae_terseLabel_en-US" xlink:label="lab_ifrs-full_AtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_ifrs-full_AtFairValueMember_label_en-US" xlink:label="lab_ifrs-full_AtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At fair value [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AtFairValueMember" xlink:to="lab_ifrs-full_AtFairValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareRepurchase2023ProgramMember_a56461aa-02e6-43cf-ac8f-9896e964b8f6_terseLabel_en-US" xlink:label="lab_sny_ShareRepurchase2023ProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase 2023 program</link:label>
    <link:label id="lab_sny_ShareRepurchase2023ProgramMember_label_en-US" xlink:label="lab_sny_ShareRepurchase2023ProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase 2023 Program [Member]</link:label>
    <link:label id="lab_sny_ShareRepurchase2023ProgramMember_documentation_en-US" xlink:label="lab_sny_ShareRepurchase2023ProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase 2023 Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2023ProgramMember" xlink:href="sny-20240630.xsd#sny_ShareRepurchase2023ProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareRepurchase2023ProgramMember" xlink:to="lab_sny_ShareRepurchase2023ProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AcquiredResearchAndDevelopmentMember_22e2179d-4dbc-4366-bb01-e59474185f3b_terseLabel_en-US" xlink:label="lab_sny_AcquiredResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired R&amp;D</link:label>
    <link:label id="lab_sny_AcquiredResearchAndDevelopmentMember_label_en-US" xlink:label="lab_sny_AcquiredResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Research And Development [Member]</link:label>
    <link:label id="lab_sny_AcquiredResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_sny_AcquiredResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquired Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquiredResearchAndDevelopmentMember" xlink:href="sny-20240630.xsd#sny_AcquiredResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AcquiredResearchAndDevelopmentMember" xlink:to="lab_sny_AcquiredResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProvisionUsedOtherProvisions_514efac0-e3d5-4938-bf66-40275b120575_negatedLabel_en-US" xlink:label="lab_ifrs-full_ProvisionUsedOtherProvisions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Provisions utilized</link:label>
    <link:label id="lab_ifrs-full_ProvisionUsedOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_ProvisionUsedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision used, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProvisionUsedOtherProvisions" xlink:to="lab_ifrs-full_ProvisionUsedOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_5dba662b-055d-4be2-af58-d4865e53a470_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Treasury Shares Held</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_VaccinesMember_ded27720-7588-4892-a871-007ea773f0f0_terseLabel_en-US" xlink:label="lab_sny_VaccinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Vaccines</link:label>
    <link:label id="lab_sny_VaccinesMember_label_en-US" xlink:label="lab_sny_VaccinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vaccines [Member]</link:label>
    <link:label id="lab_sny_VaccinesMember_documentation_en-US" xlink:label="lab_sny_VaccinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vaccines.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesMember" xlink:href="sny-20240630.xsd#sny_VaccinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_VaccinesMember" xlink:to="lab_sny_VaccinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_85c647b4-2b56-4433-8ac2-414ef6a6e011_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of property, plant and equipment and intangible assets</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentAssets_0aedc766-7fc4-4a2b-81d0-ac515b80ed06_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentAssets_7fc1854e-0c5c-4d5d-85cf-564717b59b96_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentAssets" xlink:to="lab_ifrs-full_OtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_f40060d1-42bd-487f-82f4-8a0225d1e10c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromNoncurrentBorrowings_f6bd5ada-8244-4b96-8522-e1262e5de0c3_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional long-term debt contracted</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromNoncurrentBorrowings_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:to="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalAlliancesAxis_6d1e0963-bcc3-422e-91f8-dbb2286688cd_terseLabel_en-US" xlink:label="lab_sny_PrincipalAlliancesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Alliances [Axis]</link:label>
    <link:label id="lab_sny_PrincipalAlliancesAxis_label_en-US" xlink:label="lab_sny_PrincipalAlliancesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal Alliances [Axis]</link:label>
    <link:label id="lab_sny_PrincipalAlliancesAxis_documentation_en-US" xlink:label="lab_sny_PrincipalAlliancesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Principal Alliances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalAlliancesAxis" xlink:to="lab_sny_PrincipalAlliancesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ActionForWhichWeAreDefendantMember_db5fd1f4-b4f7-4912-9f08-bf4e4961f0b7_terseLabel_en-US" xlink:label="lab_sny_ActionForWhichWeAreDefendantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Action for which we are defendant</link:label>
    <link:label id="lab_sny_ActionForWhichWeAreDefendantMember_label_en-US" xlink:label="lab_sny_ActionForWhichWeAreDefendantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Action For Which We Are Defendant [member]</link:label>
    <link:label id="lab_sny_ActionForWhichWeAreDefendantMember_documentation_en-US" xlink:label="lab_sny_ActionForWhichWeAreDefendantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Action for which we are defendant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActionForWhichWeAreDefendantMember" xlink:href="sny-20240630.xsd#sny_ActionForWhichWeAreDefendantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ActionForWhichWeAreDefendantMember" xlink:to="lab_sny_ActionForWhichWeAreDefendantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_e9f272f3-7077-4fc5-80dd-a5daac227d34_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overdue by 6-12 months</link:label>
    <link:label id="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than six months and not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:to="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilities_0b7548f8-94b4-443e-bebb-e07812c0fa51_terseLabel_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaMember_af07b790-f34a-44d3-bb66-8f0b41b7d9cf_terseLabel_en-US" xlink:label="lab_sny_OpellaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Opella</link:label>
    <link:label id="lab_sny_OpellaMember_label_en-US" xlink:label="lab_sny_OpellaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Opella [Member]</link:label>
    <link:label id="lab_sny_OpellaMember_documentation_en-US" xlink:label="lab_sny_OpellaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Opella</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaMember" xlink:href="sny-20240630.xsd#sny_OpellaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaMember" xlink:to="lab_sny_OpellaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_4e66577e-1518-4c7c-99ed-dbec59a33acf_terseLabel_en-US" xlink:label="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in short-term debt and other financial instruments</link:label>
    <link:label id="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_label_en-US" xlink:label="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments</link:label>
    <link:label id="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_documentation_en-US" xlink:label="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:href="sny-20240630.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:to="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_7597c63b-9893-4692-accc-6a00298db217_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Finance Income Expense [table]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_label_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Finance Income Expense [table]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to details of finance income (expense).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:href="sny-20240630.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:to="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_f968053b-69fc-4ace-842d-d91b4cbcd31e_terseLabel_en-US" xlink:label="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on derivatives used to manage cash and cash equivalents</link:label>
    <link:label id="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_label_en-US" xlink:label="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Derivatives Used To Manage Cash And Cash Equivalents</link:label>
    <link:label id="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_documentation_en-US" xlink:label="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (loss) on derivatives used to manage cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" xlink:href="sny-20240630.xsd#sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" xlink:to="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_dcd54dd9-d759-442f-a016-a55b591c88e2_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of employee benefits (stock options and other share-based payments)</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_6e673cf8-3a18-49aa-8341-005fd6f1f820_terseLabel_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</link:label>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_label_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CustomerTwoMember_79ad22e5-dbd4-42d1-ab15-9c28cde394cf_terseLabel_en-US" xlink:label="lab_sny_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer two</link:label>
    <link:label id="lab_sny_CustomerTwoMember_label_en-US" xlink:label="lab_sny_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Two [member]</link:label>
    <link:label id="lab_sny_CustomerTwoMember_documentation_en-US" xlink:label="lab_sny_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerTwoMember" xlink:href="sny-20240630.xsd#sny_CustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CustomerTwoMember" xlink:to="lab_sny_CustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MajorTerritoriesMember_33647cf4-43be-4572-9947-976980a05335_terseLabel_en-US" xlink:label="lab_sny_MajorTerritoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major territories</link:label>
    <link:label id="lab_sny_MajorTerritoriesMember_label_en-US" xlink:label="lab_sny_MajorTerritoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Territories [Member]</link:label>
    <link:label id="lab_sny_MajorTerritoriesMember_documentation_en-US" xlink:label="lab_sny_MajorTerritoriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Major Territories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorTerritoriesMember" xlink:href="sny-20240630.xsd#sny_MajorTerritoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MajorTerritoriesMember" xlink:to="lab_sny_MajorTerritoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_551d72dd-24df-4099-8e23-d4d3bf2e6d3a_terseLabel_en-US" xlink:label="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity risk hedging instruments designated as fair value hedges</link:label>
    <link:label id="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_label_en-US" xlink:label="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Risk Hedging Instruments Designated At Fair Value Hedges</link:label>
    <link:label id="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_documentation_en-US" xlink:label="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Risk Hedging Instruments Designated At Fair Value Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:href="sny-20240630.xsd#sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:to="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_WithMarketConditionMember_0983b552-9ce6-4831-82ad-2637fe917121_terseLabel_en-US" xlink:label="lab_sny_WithMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">With market condition</link:label>
    <link:label id="lab_sny_WithMarketConditionMember_label_en-US" xlink:label="lab_sny_WithMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">With Market Condition [Member]</link:label>
    <link:label id="lab_sny_WithMarketConditionMember_documentation_en-US" xlink:label="lab_sny_WithMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">With Market Condition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithMarketConditionMember" xlink:href="sny-20240630.xsd#sny_WithMarketConditionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_WithMarketConditionMember" xlink:to="lab_sny_WithMarketConditionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentTaxExpenseRelatedToPillarTwo_4871a851-9c5b-4503-be96-d10c972f5048_terseLabel_en-US" xlink:label="lab_sny_CurrentTaxExpenseRelatedToPillarTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Tax Expense Related to Pillar Two</link:label>
    <link:label id="lab_sny_CurrentTaxExpenseRelatedToPillarTwo_label_en-US" xlink:label="lab_sny_CurrentTaxExpenseRelatedToPillarTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Tax Expense Related to Pillar Two</link:label>
    <link:label id="lab_sny_CurrentTaxExpenseRelatedToPillarTwo_documentation_en-US" xlink:label="lab_sny_CurrentTaxExpenseRelatedToPillarTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Tax Expense Related to Pillar Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentTaxExpenseRelatedToPillarTwo" xlink:href="sny-20240630.xsd#sny_CurrentTaxExpenseRelatedToPillarTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentTaxExpenseRelatedToPillarTwo" xlink:to="lab_sny_CurrentTaxExpenseRelatedToPillarTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent_c00947fc-65df-4a43-a709-9c5f269b6115_terseLabel_en-US" xlink:label="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share (in euros per share)</link:label>
    <link:label id="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent_label_en-US" xlink:label="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted Earnings (Loss) Per Share, Attributable To Owners Of Parent</link:label>
    <link:label id="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent_documentation_en-US" xlink:label="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Diluted Earnings (Loss) Per Share, Attributable To Owners Of Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:href="sny-20240630.xsd#sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:to="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock_8a9b7184-2eab-4b02-aa0d-0462a6d8c96f_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Changes in Financial Position</link:label>
    <link:label id="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Changes In Financial Position [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of changes in financial position [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfChangesInFinancialPositionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:to="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsMember_ce1b0ab3-d722-425a-891f-ea3aefc12df8_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial assumptions [member]</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsMember_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumptions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember" xlink:to="lab_ifrs-full_ActuarialAssumptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_70eab24d-098f-47dc-92d0-fab9760e9d3c_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_e349210e-943d-4368-8436-06bef911412a_terseLabel_en-US" xlink:label="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties and other income</link:label>
    <link:label id="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalties And Other Income, Related Party Transactions</link:label>
    <link:label id="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalties and other income, related party transactions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:href="sny-20240630.xsd#sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:to="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_5a00b1b5-d64c-4507-9ed4-d56907e94698_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherBorrowings_cd4812dd-db2e-4ba4-aca0-468b6904a424_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other borrowings</link:label>
    <link:label id="lab_ifrs-full_OtherBorrowings_label_en-US" xlink:label="lab_ifrs-full_OtherBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherBorrowings" xlink:to="lab_ifrs-full_OtherBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfShareCapitalForThePeriod_563a5f8b-d138-4cf0-a728-9e2c88b53222_terseLabel_en-US" xlink:label="lab_sny_PercentageOfShareCapitalForThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">% of share capital for the period</link:label>
    <link:label id="lab_sny_PercentageOfShareCapitalForThePeriod_label_en-US" xlink:label="lab_sny_PercentageOfShareCapitalForThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Share Capital For The Period</link:label>
    <link:label id="lab_sny_PercentageOfShareCapitalForThePeriod_documentation_en-US" xlink:label="lab_sny_PercentageOfShareCapitalForThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of share capital for the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfShareCapitalForThePeriod" xlink:href="sny-20240630.xsd#sny_PercentageOfShareCapitalForThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfShareCapitalForThePeriod" xlink:to="lab_sny_PercentageOfShareCapitalForThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_4075ed92-3acf-4a61-b9b6-6995a0e216e4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AssetsAcquisitionAxis_b024ab0a-89c2-4e67-9b59-405f502aade7_terseLabel_en-US" xlink:label="lab_sny_AssetsAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Acquisition [Axis]</link:label>
    <link:label id="lab_sny_AssetsAcquisitionAxis_label_en-US" xlink:label="lab_sny_AssetsAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Acquisition [Axis]</link:label>
    <link:label id="lab_sny_AssetsAcquisitionAxis_documentation_en-US" xlink:label="lab_sny_AssetsAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionAxis" xlink:href="sny-20240630.xsd#sny_AssetsAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AssetsAcquisitionAxis" xlink:to="lab_sny_AssetsAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InfluenzaVaccinesMember_6026e610-0f67-415b-8012-fe7c14dd06fc_terseLabel_en-US" xlink:label="lab_sny_InfluenzaVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Influenza Vaccines</link:label>
    <link:label id="lab_sny_InfluenzaVaccinesMember_label_en-US" xlink:label="lab_sny_InfluenzaVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Influenza Vaccines [Member]</link:label>
    <link:label id="lab_sny_InfluenzaVaccinesMember_documentation_en-US" xlink:label="lab_sny_InfluenzaVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Influenza Vaccines.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfluenzaVaccinesMember" xlink:href="sny-20240630.xsd#sny_InfluenzaVaccinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InfluenzaVaccinesMember" xlink:to="lab_sny_InfluenzaVaccinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_f5d8df56-f5c6-4f00-957a-36e962940ed5_terseLabel_en-US" xlink:label="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in non-current provisions and other non-current liabilities</link:label>
    <link:label id="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_label_en-US" xlink:label="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Non-Current Provisions And Other Non-Current Liabilities</link:label>
    <link:label id="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_documentation_en-US" xlink:label="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for noncurrent provisions and other noncurrent liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:href="sny-20240630.xsd#sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:to="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_12157f0c-b05a-47e9-b375-8a4b74deb9fc_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_9fffdd9a-38f1-46c2-99b6-3f86caba0ed2_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of related parties [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of related parties [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DigestiveWellnessMember_d4ec1069-8f6e-4270-be2c-275126e0b436_terseLabel_en-US" xlink:label="lab_sny_DigestiveWellnessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Others</link:label>
    <link:label id="lab_sny_DigestiveWellnessMember_label_en-US" xlink:label="lab_sny_DigestiveWellnessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Digestive Wellness [Member]</link:label>
    <link:label id="lab_sny_DigestiveWellnessMember_documentation_en-US" xlink:label="lab_sny_DigestiveWellnessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Digestive Wellness [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DigestiveWellnessMember" xlink:href="sny-20240630.xsd#sny_DigestiveWellnessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DigestiveWellnessMember" xlink:to="lab_sny_DigestiveWellnessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_03943ee2-f9a6-4177-96c4-9e0221e51172_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_33614da3-0c91-4246-be5c-9e8fae302288_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax relating to components of other comprehensive income that will be reclassified to profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" xlink:to="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForAssociatesMember_01197025-d487-49f3-80e1-b982dad1e21b_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForAssociatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for associates [Member]</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForAssociatesMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForAssociatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for associates [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember" xlink:to="lab_ifrs-full_EntitysTotalForAssociatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_08fe4c21-4aa2-4b51-b0e9-79dbaf5e3716_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial assets [Axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAbstract_68da505d-3b30-4ad1-9aad-fd741c7a40d8_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit (loss) [abstract]</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAbstract_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAbstract" xlink:to="lab_ifrs-full_ProfitLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAbstract_eeada7fb-7e80-4e0d-94f6-2355764ef74a_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_fef53e43-e487-4379-8e51-84494dabaccc_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax relating to components of other comprehensive income that will not be reclassified to profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" xlink:to="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_202cf1b4-5dd9-402f-ae09-3c6c0502fc32_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency purchases in US dollar, US bond</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In US Dollar, US Bond [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In US Dollar, US Bond</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInUSDollarUSBondMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentLiabilitiesMember_62d46454-1a51-442b-a8a1-d602b242b204_terseLabel_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">non-current</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesMember_label_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Liabilities [Member]</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesMember" xlink:href="sny-20240630.xsd#sny_NonCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentLiabilitiesMember" xlink:to="lab_sny_NonCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentLiabilitiesMember_d2fd542a-e073-45eb-9efe-a65ccf4b5826_terseLabel_en-US" xlink:label="lab_sny_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">current</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesMember_label_en-US" xlink:label="lab_sny_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Liabilities [Member]</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_sny_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesMember" xlink:href="sny-20240630.xsd#sny_CurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentLiabilitiesMember" xlink:to="lab_sny_CurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_f5117a39-80f4-4a60-a4b9-faccaa68d46c_terseLabel_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of restricted shares vested (in shares)</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_label_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Restricted Shares Vested In Regards Of Capital Increase</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_documentation_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Restricted Shares Vested In Regards Of Capital Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" xlink:href="sny-20240630.xsd#sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" xlink:to="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DerecognizedReceivables_a31004c6-480e-4275-9007-01205cbb811d_terseLabel_en-US" xlink:label="lab_sny_DerecognizedReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derecognized receivables</link:label>
    <link:label id="lab_sny_DerecognizedReceivables_label_en-US" xlink:label="lab_sny_DerecognizedReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derecognized Receivables</link:label>
    <link:label id="lab_sny_DerecognizedReceivables_documentation_en-US" xlink:label="lab_sny_DerecognizedReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derecognized receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerecognizedReceivables" xlink:href="sny-20240630.xsd#sny_DerecognizedReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DerecognizedReceivables" xlink:to="lab_sny_DerecognizedReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_23924ac9-24f5-4c90-9e02-8aec760d6f3a_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareRepurchase2024ProgramMember_8852c66d-7c95-4cd2-ac3f-6aa7291c6ece_terseLabel_en-US" xlink:label="lab_sny_ShareRepurchase2024ProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase 2024 Program</link:label>
    <link:label id="lab_sny_ShareRepurchase2024ProgramMember_label_en-US" xlink:label="lab_sny_ShareRepurchase2024ProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase 2024 Program [Member]</link:label>
    <link:label id="lab_sny_ShareRepurchase2024ProgramMember_documentation_en-US" xlink:label="lab_sny_ShareRepurchase2024ProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase 2024 Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2024ProgramMember" xlink:href="sny-20240630.xsd#sny_ShareRepurchase2024ProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareRepurchase2024ProgramMember" xlink:to="lab_sny_ShareRepurchase2024ProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock_649486eb-db0c-41ed-9431-2bc3156f6aa2_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Number of Restricted Shares Not Yet Fully Vested</link:label>
    <link:label id="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Number Of Restricted Share Plans Not Yet Fully Vested [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of number of restricted share plans Not yet fully vested.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:to="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_a639d9f3-4917-41a5-88ef-bdd11afaa623_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_9a0dd98d-b822-4f4e-afe7-d82e538c0bba_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income for the period</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCoreAssetsMember_55eb8c3c-9767-43ef-938f-dbd001d1f8d6_terseLabel_en-US" xlink:label="lab_sny_NonCoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Core Assets [Member]</link:label>
    <link:label id="lab_sny_NonCoreAssetsMember_label_en-US" xlink:label="lab_sny_NonCoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Core Assets [Member]</link:label>
    <link:label id="lab_sny_NonCoreAssetsMember_documentation_en-US" xlink:label="lab_sny_NonCoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Core Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCoreAssetsMember" xlink:href="sny-20240630.xsd#sny_NonCoreAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCoreAssetsMember" xlink:to="lab_sny_NonCoreAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ParValuePerShare_9a914b5f-c507-47b9-b0a6-079eaae8c582_terseLabel_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Par value per share (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_ParValuePerShare_label_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Par value per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ParValuePerShare" xlink:to="lab_ifrs-full_ParValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_UpfrontPayments_61cc7f5e-71ec-491a-b62d-de0e9619eb42_terseLabel_en-US" xlink:label="lab_sny_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_sny_UpfrontPayments_label_en-US" xlink:label="lab_sny_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payments</link:label>
    <link:label id="lab_sny_UpfrontPayments_documentation_en-US" xlink:label="lab_sny_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPayments" xlink:href="sny-20240630.xsd#sny_UpfrontPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_UpfrontPayments" xlink:to="lab_sny_UpfrontPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock_b1eed554-f9b0-4d3f-b28a-4298c74a5888_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Movements within Other Comprehensive Income</link:label>
    <link:label id="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Accumulated Other Comprehensive Income Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information of accumulated other comprehensive income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_7e1a1d64-45f8-47bd-a123-1c92ffeeaee7_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers, intangible assets other than goodwill</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_859a03ab-288e-4249-ba97-47e70328db01_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Measurement Principles Applied to Financial Instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_b4589b09-988a-4539-8cd8-af6f35bbebfa_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities related to assets held for sale or exchange</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities included in disposal groups classified as held for sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lab_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalAlliancesDomain_d74608f0-cb9d-4b76-aa31-a4d278841abe_terseLabel_en-US" xlink:label="lab_sny_PrincipalAlliancesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Alliances [Domain]</link:label>
    <link:label id="lab_sny_PrincipalAlliancesDomain_label_en-US" xlink:label="lab_sny_PrincipalAlliancesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal Alliances [Domain]</link:label>
    <link:label id="lab_sny_PrincipalAlliancesDomain_documentation_en-US" xlink:label="lab_sny_PrincipalAlliancesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Principal Alliances [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalAlliancesDomain" xlink:to="lab_sny_PrincipalAlliancesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsInterestRate_0be8bffd-b329-4a98-9e01-c8282195f285_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_sny_InterestRateSwapsInterestRate_label_en-US" xlink:label="lab_sny_InterestRateSwapsInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps, Interest Rate</link:label>
    <link:label id="lab_sny_InterestRateSwapsInterestRate_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsInterestRate" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsInterestRate" xlink:to="lab_sny_InterestRateSwapsInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommercialPaperProgramInFranceMember_9f4f6d5f-6f19-4059-821b-9f6aaa9cd72f_terseLabel_en-US" xlink:label="lab_sny_CommercialPaperProgramInFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper program in France</link:label>
    <link:label id="lab_sny_CommercialPaperProgramInFranceMember_label_en-US" xlink:label="lab_sny_CommercialPaperProgramInFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper Program In France [Member]</link:label>
    <link:label id="lab_sny_CommercialPaperProgramInFranceMember_documentation_en-US" xlink:label="lab_sny_CommercialPaperProgramInFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial paper program In France.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInFranceMember" xlink:href="sny-20240630.xsd#sny_CommercialPaperProgramInFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommercialPaperProgramInFranceMember" xlink:to="lab_sny_CommercialPaperProgramInFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FairValueOfPlanAtDateOfGrant_41ff89ae-d154-496c-9e66-468642927a70_terseLabel_en-US" xlink:label="lab_sny_FairValueOfPlanAtDateOfGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan at the date of grant</link:label>
    <link:label id="lab_sny_FairValueOfPlanAtDateOfGrant_label_en-US" xlink:label="lab_sny_FairValueOfPlanAtDateOfGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Plan At Date Of Grant</link:label>
    <link:label id="lab_sny_FairValueOfPlanAtDateOfGrant_documentation_en-US" xlink:label="lab_sny_FairValueOfPlanAtDateOfGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of plan at the date of grant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfPlanAtDateOfGrant" xlink:href="sny-20240630.xsd#sny_FairValueOfPlanAtDateOfGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FairValueOfPlanAtDateOfGrant" xlink:to="lab_sny_FairValueOfPlanAtDateOfGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_2dcd37f4-2d0e-4966-a117-e3de63f293df_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CustomerThreeMember_d299556b-bcdd-4c71-82c0-6ad2481a544f_terseLabel_en-US" xlink:label="lab_sny_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer three</link:label>
    <link:label id="lab_sny_CustomerThreeMember_label_en-US" xlink:label="lab_sny_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Three [member]</link:label>
    <link:label id="lab_sny_CustomerThreeMember_documentation_en-US" xlink:label="lab_sny_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerThreeMember" xlink:href="sny-20240630.xsd#sny_CustomerThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CustomerThreeMember" xlink:to="lab_sny_CustomerThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_c769ed8f-dd5a-4326-9a29-e85d0deebccd_terseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in actuarial assumption</link:label>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_label_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of reasonably possible increase in actuarial assumption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:to="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneMonthMember_19d9b976-741d-4d0e-af5c-18ba9e9a003e_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneMonthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overdue by less than 1 month</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneMonthMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneMonthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one month [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneMonthMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneMonthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneMonthMember" xlink:to="lab_ifrs-full_NotLaterThanOneMonthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_65981554-2f7e-4fd6-a8db-124f24813a01_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparties [Axis]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesAxis" xlink:to="lab_ifrs-full_CounterpartiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_1ccbe1d3-9503-4a6c-93b6-c4e1f47aed37_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial assumption of discount rates</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of discount rates [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:to="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorBusinessCombinationMember_9ea29bb4-70ac-4102-9d57-28fc4f0bd067_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorBusinessCombinationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major business combination</link:label>
    <link:label id="lab_ifrs-full_MajorBusinessCombinationMember_label_en-US" xlink:label="lab_ifrs-full_MajorBusinessCombinationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major business combination [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorBusinessCombinationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorBusinessCombinationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorBusinessCombinationMember" xlink:to="lab_ifrs-full_MajorBusinessCombinationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill_31b5e0c1-16d2-445b-825e-3b18ac6047f0_terseLabel_en-US" xlink:label="lab_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment Loss on Intangible Asset Other Than Goodwill</link:label>
    <link:label id="lab_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill_label_en-US" xlink:label="lab_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment Loss on Intangible Asset Other Than Goodwill</link:label>
    <link:label id="lab_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill_documentation_en-US" xlink:label="lab_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Impairment Loss on Intangible Asset Other Than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill" xlink:href="sny-20240630.xsd#sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill" xlink:to="lab_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_b0ab12ae-0f55-40bc-863a-97e63ea272d9_terseLabel_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standard tax rate applicable in France</link:label>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate" xlink:to="lab_ifrs-full_ApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_3c9b34ab-274b-41c5-9c10-65d4f877caf2_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains/(losses) on disposals of financial assets</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on available-for-sale financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:to="lab_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_ce676337-a732-4a86-964b-95965e50fb4c_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overdue by 3-6 months</link:label>
    <link:label id="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three months and not later than six months [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:to="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock_fd7b8d67-a8ca-4ae0-94b3-0d03c7e65326_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Other Non-Current Assets</link:label>
    <link:label id="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Components Of Other Non-Current Assets [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of components of other noncurrent assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:to="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_4936eb8f-0c50-432a-9e8d-02347c05cd02_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Preparation of the Half-Year Financial Statements and Accounting Policies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TaxotereProductLitigationInTheUSMember_a0063210-0a5d-44c7-8f2a-c129f3ab8567_terseLabel_en-US" xlink:label="lab_sny_TaxotereProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxotere Product Litigation In The US</link:label>
    <link:label id="lab_sny_TaxotereProductLitigationInTheUSMember_label_en-US" xlink:label="lab_sny_TaxotereProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxotere Product Litigation In The US [Member]</link:label>
    <link:label id="lab_sny_TaxotereProductLitigationInTheUSMember_documentation_en-US" xlink:label="lab_sny_TaxotereProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Taxotere Product Litigation In The US</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxotereProductLitigationInTheUSMember" xlink:href="sny-20240630.xsd#sny_TaxotereProductLitigationInTheUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TaxotereProductLitigationInTheUSMember" xlink:to="lab_sny_TaxotereProductLitigationInTheUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfBondIssuesRedeemed_2065dbee-21eb-4450-b8e8-28a86cb8a19c_terseLabel_en-US" xlink:label="lab_sny_NumberOfBondIssuesRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of bond issues redeemed</link:label>
    <link:label id="lab_sny_NumberOfBondIssuesRedeemed_label_en-US" xlink:label="lab_sny_NumberOfBondIssuesRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Bond Issues Redeemed</link:label>
    <link:label id="lab_sny_NumberOfBondIssuesRedeemed_documentation_en-US" xlink:label="lab_sny_NumberOfBondIssuesRedeemed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Bond Issues Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfBondIssuesRedeemed" xlink:href="sny-20240630.xsd#sny_NumberOfBondIssuesRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfBondIssuesRedeemed" xlink:to="lab_sny_NumberOfBondIssuesRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CertainWholesalersInTheUnitedStatesMember_9d5000c0-7de7-4fcd-b1a3-1eae536b9d58_terseLabel_en-US" xlink:label="lab_sny_CertainWholesalersInTheUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain wholesalers in the United States</link:label>
    <link:label id="lab_sny_CertainWholesalersInTheUnitedStatesMember_label_en-US" xlink:label="lab_sny_CertainWholesalersInTheUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certain Wholesalers, In The United States [Member]</link:label>
    <link:label id="lab_sny_CertainWholesalersInTheUnitedStatesMember_documentation_en-US" xlink:label="lab_sny_CertainWholesalersInTheUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Certain Wholesalers, In The United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CertainWholesalersInTheUnitedStatesMember" xlink:href="sny-20240630.xsd#sny_CertainWholesalersInTheUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CertainWholesalersInTheUnitedStatesMember" xlink:to="lab_sny_CertainWholesalersInTheUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_e7e56318-3c36-46f8-9067-0ea0a14f7f50_negatedLabel_en-US" xlink:label="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of treasury shares</link:label>
    <link:label id="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_label_en-US" xlink:label="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to acquire or redeem entity's shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:to="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_7fd1f0c4-4f84-40f2-a805-c44761ac24a2_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of equity instruments included in financial assets and financial liabilities</link:label>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_label_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) recognised in other comprehensive income including exchange differences, fair value measurement, entity's own equity instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" xlink:to="lab_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProvisionsForOtherLongTermBenefitsMember_543707c9-9af3-4371-bace-3022a3948a6c_terseLabel_en-US" xlink:label="lab_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for other long-term benefits</link:label>
    <link:label id="lab_sny_ProvisionsForOtherLongTermBenefitsMember_label_en-US" xlink:label="lab_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions For Other Long Term Benefits [member]</link:label>
    <link:label id="lab_sny_ProvisionsForOtherLongTermBenefitsMember_documentation_en-US" xlink:label="lab_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provisions for other long term benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:href="sny-20240630.xsd#sny_ProvisionsForOtherLongTermBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:to="lab_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsMember_7fba2244-e45c-4280-a9e4-14da6a70eb6b_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets [Member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsMember" xlink:to="lab_ifrs-full_ClassesOfAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommercializationRelatedExpensesMember_5ba5d7bd-12d1-4b2f-96a7-c1b76cf96e9f_terseLabel_en-US" xlink:label="lab_sny_CommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement to Regeneron of selling expenses incurred</link:label>
    <link:label id="lab_sny_CommercializationRelatedExpensesMember_label_en-US" xlink:label="lab_sny_CommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercialization Related Expenses [Member]</link:label>
    <link:label id="lab_sny_CommercializationRelatedExpensesMember_documentation_en-US" xlink:label="lab_sny_CommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercialization related expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercializationRelatedExpensesMember" xlink:href="sny-20240630.xsd#sny_CommercializationRelatedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommercializationRelatedExpensesMember" xlink:to="lab_sny_CommercializationRelatedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2023Member_ac9eaf37-80d2-4b5e-9a13-8ca3d2408c16_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted share plan 2023</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2023Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2023 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2023Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023Member" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2023Member" xlink:to="lab_sny_RestrictedSharePlan2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_30d72b30-39ca-4cbe-a338-9c3bec98ee86_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Non-Current Assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other non-current assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_58178836-483e-47ce-9454-11a1ea72fc41_verboseLabel_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current provisions and other non-current liabilities</link:label>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_d71b8f64-455f-4c46-829b-098c4193f099_totalLabel_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Non-current provisions</link:label>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_label_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Provisions And Other Non-Current Liabilities</link:label>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_documentation_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of non-current provisions and non-current other liabilities that the entity does not separately disclose in the same statement or note.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:href="sny-20240630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:to="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination_8228ba62-6cf4-4b20-98e7-2ed176b5f20a_negatedTerseLabel_en-US" xlink:label="lab_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other movements</link:label>
    <link:label id="lab_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination_label_en-US" xlink:label="lab_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Movements, Contingent Liabilities Recognised In Business Combination</link:label>
    <link:label id="lab_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination_documentation_en-US" xlink:label="lab_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other movements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" xlink:href="sny-20240630.xsd#sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" xlink:to="lab_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_52c7f463-da83-4a20-92db-2871d872b888_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_2fb5a474-eb99-47c4-8853-a86c2929e3b9_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current lease liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_13adf75c-d7a0-44f5-9dcc-626cc4391a0c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfSharesRepurchased_b876156c-5896-44cd-9ce8-58713ddfa041_terseLabel_en-US" xlink:label="lab_sny_NumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares repurchased (in shares)</link:label>
    <link:label id="lab_sny_NumberOfSharesRepurchased_label_en-US" xlink:label="lab_sny_NumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Repurchased</link:label>
    <link:label id="lab_sny_NumberOfSharesRepurchased_documentation_en-US" xlink:label="lab_sny_NumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares repurchased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesRepurchased" xlink:href="sny-20240630.xsd#sny_NumberOfSharesRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfSharesRepurchased" xlink:to="lab_sny_NumberOfSharesRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_f63e7d6e-4142-438c-88df-cc113a28bbd6_terseLabel_en-US" xlink:label="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government grant recognised as deduction from development expenses</link:label>
    <link:label id="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_label_en-US" xlink:label="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Grant Recognised As Deduction From Development Expenses</link:label>
    <link:label id="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_documentation_en-US" xlink:label="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Grant Recognised As Deduction From Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" xlink:href="sny-20240630.xsd#sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" xlink:to="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DebtInstrumentsMember_487288b5-ff44-4e97-861c-27e0b455f03b_terseLabel_en-US" xlink:label="lab_sny_DebtInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instruments included in financial assets</link:label>
    <link:label id="lab_sny_DebtInstrumentsMember_label_en-US" xlink:label="lab_sny_DebtInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instruments [Member]</link:label>
    <link:label id="lab_sny_DebtInstrumentsMember_documentation_en-US" xlink:label="lab_sny_DebtInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentsMember" xlink:href="sny-20240630.xsd#sny_DebtInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DebtInstrumentsMember" xlink:to="lab_sny_DebtInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AssociatesAndJointVenturesMember_52b0d06c-3d0c-4569-8394-b607612942c6_terseLabel_en-US" xlink:label="lab_sny_AssociatesAndJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associates and joint ventures</link:label>
    <link:label id="lab_sny_AssociatesAndJointVenturesMember_label_en-US" xlink:label="lab_sny_AssociatesAndJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associates And Joint Ventures [Member]</link:label>
    <link:label id="lab_sny_AssociatesAndJointVenturesMember_documentation_en-US" xlink:label="lab_sny_AssociatesAndJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Associates and Joint Ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssociatesAndJointVenturesMember" xlink:href="sny-20240630.xsd#sny_AssociatesAndJointVenturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AssociatesAndJointVenturesMember" xlink:to="lab_sny_AssociatesAndJointVenturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ImmunoOncologyAllianceMember_bddcd5de-695e-46db-a226-1a198dd154b2_terseLabel_en-US" xlink:label="lab_sny_ImmunoOncologyAllianceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Immuno-Oncology Alliance</link:label>
    <link:label id="lab_sny_ImmunoOncologyAllianceMember_label_en-US" xlink:label="lab_sny_ImmunoOncologyAllianceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Immuno-Oncology Alliance [Member]</link:label>
    <link:label id="lab_sny_ImmunoOncologyAllianceMember_documentation_en-US" xlink:label="lab_sny_ImmunoOncologyAllianceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Immuno-oncology Alliance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunoOncologyAllianceMember" xlink:href="sny-20240630.xsd#sny_ImmunoOncologyAllianceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ImmunoOncologyAllianceMember" xlink:to="lab_sny_ImmunoOncologyAllianceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfPlaintiffs_cfb3ad8f-d305-405e-8218-fc9b8e746600_terseLabel_en-US" xlink:label="lab_sny_NumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Of Plaintiffs</link:label>
    <link:label id="lab_sny_NumberOfPlaintiffs_label_en-US" xlink:label="lab_sny_NumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Plaintiffs</link:label>
    <link:label id="lab_sny_NumberOfPlaintiffs_documentation_en-US" xlink:label="lab_sny_NumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPlaintiffs" xlink:href="sny-20240630.xsd#sny_NumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfPlaintiffs" xlink:to="lab_sny_NumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_497dea79-2e76-45bc-a471-eae1a96cefe9_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements</link:label>
    <link:label id="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Impact Of Changes In The Scope Of Consolidation Due To Acquisitions And Divestments Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for impact of changes in the scope of consolidation due to acquisitions and divestments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentRestructuringProvisionMember_559b0f6b-ba51-43e6-8270-9af82538ef28_terseLabel_en-US" xlink:label="lab_sny_NonCurrentRestructuringProvisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring provisions</link:label>
    <link:label id="lab_sny_NonCurrentRestructuringProvisionMember_label_en-US" xlink:label="lab_sny_NonCurrentRestructuringProvisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Restructuring Provision [Member]</link:label>
    <link:label id="lab_sny_NonCurrentRestructuringProvisionMember_documentation_en-US" xlink:label="lab_sny_NonCurrentRestructuringProvisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring provisions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentRestructuringProvisionMember" xlink:href="sny-20240630.xsd#sny_NonCurrentRestructuringProvisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentRestructuringProvisionMember" xlink:to="lab_sny_NonCurrentRestructuringProvisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_fff3d616-73c1-4067-90b3-fe08d880f1bf_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_cb9083e1-0371-4737-a245-8a7b4500b2c8_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock_f76d20ba-52fe-441d-95ea-6f5021eafc3c_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Operating Currency Hedging Instruments</link:label>
    <link:label id="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Operating Currency Hedging Instruments With Notional Amount Translated In To Euros At Closing Exchange Rate [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of operating currency hedging instruments with notional amount translated in to euros at closing exchange rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:to="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearMember_8755a67f-9bf8-46ac-8dec-ed1b47aea95c_verboseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overdue by &gt; 12 months</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearMember" xlink:to="lab_ifrs-full_LaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_98767bea-d2f8-4978-acf2-a891f9f094ab_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information about credit exposures designated as measured at fair value through profit or loss [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_4f7dde29-706d-4523-9b93-16f0faceab17_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of inflation</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of inflation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember" xlink:to="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_9cb498b6-ef56-4c44-a6d0-93535d0e66af_terseLabel_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset) [Axis]</link:label>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_label_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset) [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:to="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock_827fdafa-9126-4964-8472-bf3a22af134d_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Number of Shares Used to Compute Diluted Earnings Per Share</link:label>
    <link:label id="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Shares Used To Compute Diluted Earnings Per Share [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of shares used to compute diluted earnings per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" xlink:to="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_QRIBIntermediateHoldingsLLCMember_0c364f23-ab4b-43c5-a3e3-1874a119275e_terseLabel_en-US" xlink:label="lab_sny_QRIBIntermediateHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">QRIB intermediate Holdings, LLC</link:label>
    <link:label id="lab_sny_QRIBIntermediateHoldingsLLCMember_label_en-US" xlink:label="lab_sny_QRIBIntermediateHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">QRIB intermediate Holdings, LLC [Member]</link:label>
    <link:label id="lab_sny_QRIBIntermediateHoldingsLLCMember_documentation_en-US" xlink:label="lab_sny_QRIBIntermediateHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">QRIB intermediate Holdings, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QRIBIntermediateHoldingsLLCMember" xlink:href="sny-20240630.xsd#sny_QRIBIntermediateHoldingsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_QRIBIntermediateHoldingsLLCMember" xlink:to="lab_sny_QRIBIntermediateHoldingsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost_32f35d07-6c84-4aa9-8deb-647d4ba6ec80_terseLabel_en-US" xlink:label="lab_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unwinding of discount and gains (losses) arising from revisions of expected cash flows</link:label>
    <link:label id="lab_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost_label_en-US" xlink:label="lab_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unwinding Of Discount And Gains (Losses) Arising From Revisions Of Expected Cash Flows On Financial Income (Expense) Related To Liabilities At Amortized Cost</link:label>
    <link:label id="lab_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost_documentation_en-US" xlink:label="lab_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unwinding Of Discount And Gains (Losses) Arising From Revisions Of Expected Cash Flows On Financial Income (Expense) Related To Liabilities At Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost" xlink:href="sny-20240630.xsd#sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost" xlink:to="lab_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherRelatedPartiesMember_6f00512c-b817-4231-be0a-daa117a2d14a_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other related parties</link:label>
    <link:label id="lab_ifrs-full_OtherRelatedPartiesMember_label_en-US" xlink:label="lab_ifrs-full_OtherRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other related parties [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherRelatedPartiesMember" xlink:to="lab_ifrs-full_OtherRelatedPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AssetsAcquisitionDomain_8c948fa2-b963-41bf-a9aa-b556c617a6d9_terseLabel_en-US" xlink:label="lab_sny_AssetsAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Acquisition [Domain]</link:label>
    <link:label id="lab_sny_AssetsAcquisitionDomain_label_en-US" xlink:label="lab_sny_AssetsAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Acquisition [Domain]</link:label>
    <link:label id="lab_sny_AssetsAcquisitionDomain_documentation_en-US" xlink:label="lab_sny_AssetsAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionDomain" xlink:href="sny-20240630.xsd#sny_AssetsAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AssetsAcquisitionDomain" xlink:to="lab_sny_AssetsAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_26bc6aec-9999-4b7f-b120-db1f855688b9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherOperatingIncomeExpenseMember_3798047d-dc51-4375-a026-a70008d3fbc5_terseLabel_en-US" xlink:label="lab_sny_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating income (expense)</link:label>
    <link:label id="lab_sny_OtherOperatingIncomeExpenseMember_label_en-US" xlink:label="lab_sny_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense) [Member]</link:label>
    <link:label id="lab_sny_OtherOperatingIncomeExpenseMember_documentation_en-US" xlink:label="lab_sny_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingIncomeExpenseMember" xlink:href="sny-20240630.xsd#sny_OtherOperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherOperatingIncomeExpenseMember" xlink:to="lab_sny_OtherOperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_fc1c2f64-073c-4a9d-b4ef-23d4627f8c03_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherProvisionsMember_6859d26f-5372-4a8c-bcdd-a9368a3b7fcd_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other provisions [Member]</link:label>
    <link:label id="lab_ifrs-full_OtherProvisionsMember_label_en-US" xlink:label="lab_ifrs-full_OtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other provisions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherProvisionsMember" xlink:to="lab_ifrs-full_OtherProvisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InfraservGmbhAndCoHochstKGMember_dc421ebe-652f-436e-8726-d05c734d8a36_terseLabel_en-US" xlink:label="lab_sny_InfraservGmbhAndCoHochstKGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Infraserv GmbH &amp; Co. H&#246;chst KG</link:label>
    <link:label id="lab_sny_InfraservGmbhAndCoHochstKGMember_label_en-US" xlink:label="lab_sny_InfraservGmbhAndCoHochstKGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Infraserv Gmbh And Co Hochst KG [member]</link:label>
    <link:label id="lab_sny_InfraservGmbhAndCoHochstKGMember_documentation_en-US" xlink:label="lab_sny_InfraservGmbhAndCoHochstKGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Infraserv GmbH and Co. Hochst KG.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfraservGmbhAndCoHochstKGMember" xlink:href="sny-20240630.xsd#sny_InfraservGmbhAndCoHochstKGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InfraservGmbhAndCoHochstKGMember" xlink:to="lab_sny_InfraservGmbhAndCoHochstKGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_JointVenturesAxis_d59b7518-0d04-4066-8172-f62079ff670a_terseLabel_en-US" xlink:label="lab_ifrs-full_JointVenturesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Joint ventures [Axis]</link:label>
    <link:label id="lab_ifrs-full_JointVenturesAxis_label_en-US" xlink:label="lab_ifrs-full_JointVenturesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Joint ventures [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_JointVenturesAxis" xlink:to="lab_ifrs-full_JointVenturesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SubordinatedLiabilities_0d29bb5c-c402-4e02-9112-8d39f43460d2_terseLabel_en-US" xlink:label="lab_ifrs-full_SubordinatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subordinated liabilities</link:label>
    <link:label id="lab_ifrs-full_SubordinatedLiabilities_label_en-US" xlink:label="lab_ifrs-full_SubordinatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subordinated liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubordinatedLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubordinatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SubordinatedLiabilities" xlink:to="lab_ifrs-full_SubordinatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashTransferred_f2007b0f-9b8f-4411-aaa4-c5da6247494c_terseLabel_en-US" xlink:label="lab_ifrs-full_CashTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash transferred</link:label>
    <link:label id="lab_ifrs-full_CashTransferred_label_en-US" xlink:label="lab_ifrs-full_CashTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashTransferred" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashTransferred" xlink:to="lab_ifrs-full_CashTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CollaborationAgreementsUpfrontPayment_8d7d36db-83fa-4f0b-8cae-ce61392d940b_terseLabel_en-US" xlink:label="lab_sny_CollaborationAgreementsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreements, upfront payment</link:label>
    <link:label id="lab_sny_CollaborationAgreementsUpfrontPayment_label_en-US" xlink:label="lab_sny_CollaborationAgreementsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Upfront Payment</link:label>
    <link:label id="lab_sny_CollaborationAgreementsUpfrontPayment_documentation_en-US" xlink:label="lab_sny_CollaborationAgreementsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsUpfrontPayment" xlink:href="sny-20240630.xsd#sny_CollaborationAgreementsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CollaborationAgreementsUpfrontPayment" xlink:to="lab_sny_CollaborationAgreementsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentAssetsMember_6f995c85-63a5-4fd2-b52b-e9e9d610950a_terseLabel_en-US" xlink:label="lab_sny_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">non-current</link:label>
    <link:label id="lab_sny_NonCurrentAssetsMember_label_en-US" xlink:label="lab_sny_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Assets [Member]</link:label>
    <link:label id="lab_sny_NonCurrentAssetsMember_documentation_en-US" xlink:label="lab_sny_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsMember" xlink:href="sny-20240630.xsd#sny_NonCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentAssetsMember" xlink:to="lab_sny_NonCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DefendantDomain_a53d2928-622b-45e2-81de-f406ed8175ef_terseLabel_en-US" xlink:label="lab_sny_DefendantDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defendant [Domain]</link:label>
    <link:label id="lab_sny_DefendantDomain_label_en-US" xlink:label="lab_sny_DefendantDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defendant [Domain]</link:label>
    <link:label id="lab_sny_DefendantDomain_documentation_en-US" xlink:label="lab_sny_DefendantDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defendant [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantDomain" xlink:href="sny-20240630.xsd#sny_DefendantDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DefendantDomain" xlink:to="lab_sny_DefendantDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SarclisaMember_bf3f561d-0069-4c45-8e50-8a8c543497f3_terseLabel_en-US" xlink:label="lab_sny_SarclisaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sarclisa</link:label>
    <link:label id="lab_sny_SarclisaMember_label_en-US" xlink:label="lab_sny_SarclisaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sarclisa [Member]</link:label>
    <link:label id="lab_sny_SarclisaMember_documentation_en-US" xlink:label="lab_sny_SarclisaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sarclisa</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SarclisaMember" xlink:href="sny-20240630.xsd#sny_SarclisaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SarclisaMember" xlink:to="lab_sny_SarclisaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessCombinationNominalValue_9cad9f59-9e8e-479a-9890-4b4325c3fa16_terseLabel_en-US" xlink:label="lab_sny_BusinessCombinationNominalValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination Nominal Value</link:label>
    <link:label id="lab_sny_BusinessCombinationNominalValue_label_en-US" xlink:label="lab_sny_BusinessCombinationNominalValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Nominal Value</link:label>
    <link:label id="lab_sny_BusinessCombinationNominalValue_documentation_en-US" xlink:label="lab_sny_BusinessCombinationNominalValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination Nominal Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationNominalValue" xlink:href="sny-20240630.xsd#sny_BusinessCombinationNominalValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessCombinationNominalValue" xlink:to="lab_sny_BusinessCombinationNominalValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_3626aa25-943a-42d6-97be-c2d22d2e340c_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in currency translation differences</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on exchange differences on translation of foreign operations, before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharesMember_dc84d053-b76c-4aa5-90bd-a748cddeaff8_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted shares</link:label>
    <link:label id="lab_sny_RestrictedSharesMember_label_en-US" xlink:label="lab_sny_RestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Shares [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharesMember_documentation_en-US" xlink:label="lab_sny_RestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharesMember" xlink:href="sny-20240630.xsd#sny_RestrictedSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharesMember" xlink:to="lab_sny_RestrictedSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfHedgesMember_237e2665-f795-47cb-8044-894fc188461e_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedges [Member]</link:label>
    <link:label id="lab_ifrs-full_TypesOfHedgesMember_label_en-US" xlink:label="lab_ifrs-full_TypesOfHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfHedgesMember" xlink:to="lab_ifrs-full_TypesOfHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_af4d28ad-098e-4bf0-80ee-4b7268e68aac_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in contingent consideration asset (liability)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:to="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2020Member_1df1ff56-db6d-4c20-8e4d-0d6d5a27b495_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted share plan 2020</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2020Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2020 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2020Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2020Member" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2020Member" xlink:to="lab_sny_RestrictedSharePlan2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_4d8b972f-3735-4442-aa14-906db8c6937a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FirmOrdersOfPropertyPlantAndEquipment_276d0636-1fb9-4aec-85ff-4742ce7ebf4c_terseLabel_en-US" xlink:label="lab_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Firm orders of property, plant and equipment</link:label>
    <link:label id="lab_sny_FirmOrdersOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Firm Orders Of Property Plant And Equipment</link:label>
    <link:label id="lab_sny_FirmOrdersOfPropertyPlantAndEquipment_documentation_en-US" xlink:label="lab_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Firm orders of property plant and equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:href="sny-20240630.xsd#sny_FirmOrdersOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:to="lab_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FulcrumTherapeuticsMember_9fcf86a4-d3e5-4595-bade-e0d218274de0_terseLabel_en-US" xlink:label="lab_sny_FulcrumTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fulcrum Therapeutics</link:label>
    <link:label id="lab_sny_FulcrumTherapeuticsMember_label_en-US" xlink:label="lab_sny_FulcrumTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fulcrum Therapeutics [Member]</link:label>
    <link:label id="lab_sny_FulcrumTherapeuticsMember_documentation_en-US" xlink:label="lab_sny_FulcrumTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fulcrum Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FulcrumTherapeuticsMember" xlink:href="sny-20240630.xsd#sny_FulcrumTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FulcrumTherapeuticsMember" xlink:to="lab_sny_FulcrumTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_7febb88d-7330-4a56-aef2-e87a3dd11c89_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Items not subsequently reclassifiable to profit or loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will not be reclassified to profit or loss, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_0ec467a4-4699-4dd2-b39d-8422a133ef59_terseLabel_en-US" xlink:label="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bank credit balances</link:label>
    <link:label id="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bank overdrafts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:to="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_2b759d66-5859-4330-baf5-86f2a04f54d4_terseLabel_en-US" xlink:label="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Identifiable intangible assets recognised as of acquisition date</link:label>
    <link:label id="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Identifiable intangible assets recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableTable_bc6a98ba-9dcd-41b8-b9c7-e4aedae476db_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Accounts Receivable [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableTable_label_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounts Receivable [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of Accounts receivable Table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableTable" xlink:href="sny-20240630.xsd#sny_DisclosureOfAccountsReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAccountsReceivableTable" xlink:to="lab_sny_DisclosureOfAccountsReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_58bec989-1c27-4375-b74e-edfd764452f4_terseLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAndLiabilitiesMember_0e8341c0-98a8-4bb1-812d-70976ab213d8_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities [Member]</link:label>
    <link:label id="lab_ifrs-full_AssetsAndLiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_AssetsAndLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAndLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember" xlink:to="lab_ifrs-full_AssetsAndLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_8ed648d9-c022-47e4-aed6-3c5d1f541649_terseLabel_en-US" xlink:label="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</link:label>
    <link:label id="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_label_en-US" xlink:label="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</link:label>
    <link:label id="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_documentation_en-US" xlink:label="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:href="sny-20240630.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:to="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_aad2171c-8a16-4b94-ae5a-8aa7f7545890_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Average Effective Tax Rate And Applicable Tax Rate Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of average effective tax rate and applicable tax rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_79cd5c9c-ae28-408a-801a-f6cc859a7073_terseLabel_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</link:label>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Net Of Tax On Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset net of tax on associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:href="sny-20240630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:to="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CreditFacilitiesExtensionOptionPeriod_e92444fb-ef66-4335-9161-f6809db3fb8b_terseLabel_en-US" xlink:label="lab_sny_CreditFacilitiesExtensionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit facilities, extension option period</link:label>
    <link:label id="lab_sny_CreditFacilitiesExtensionOptionPeriod_label_en-US" xlink:label="lab_sny_CreditFacilitiesExtensionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facilities, Extension Option, Period</link:label>
    <link:label id="lab_sny_CreditFacilitiesExtensionOptionPeriod_documentation_en-US" xlink:label="lab_sny_CreditFacilitiesExtensionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Facilities, Extension Option, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CreditFacilitiesExtensionOptionPeriod" xlink:href="sny-20240630.xsd#sny_CreditFacilitiesExtensionOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CreditFacilitiesExtensionOptionPeriod" xlink:to="lab_sny_CreditFacilitiesExtensionOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncome_a1c5003b-30e4-49fe-86d0-78440734e4c4_negatedLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncome" xlink:to="lab_ifrs-full_DeferredTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MeasurementAxis_cf9b5496-998a-4d53-936d-0b8c2980f255_terseLabel_en-US" xlink:label="lab_ifrs-full_MeasurementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement [Axis]</link:label>
    <link:label id="lab_ifrs-full_MeasurementAxis_label_en-US" xlink:label="lab_ifrs-full_MeasurementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MeasurementAxis" xlink:to="lab_ifrs-full_MeasurementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_6f7c8dc8-6b9d-4af5-8795-3fe364795339_negatedTerseLabel_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of the distribution of an exceptional supplementary dividend of 58% of the shares of EUROAPI to the equity holders of Sanofi</link:label>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_label_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exceptional Supplementary Dividends Recognised As Distributions To Owners Of Parent</link:label>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_documentation_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exceptional Supplementary Dividends Recognised As Distributions To Owners Of Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" xlink:href="sny-20240630.xsd#sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" xlink:to="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonOperatingForeignExchangeGainsLosses_10cabba8-6d54-4df0-8d61-234970d8f7e7_terseLabel_en-US" xlink:label="lab_sny_NonOperatingForeignExchangeGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-operating foreign exchange gains/(losses)</link:label>
    <link:label id="lab_sny_NonOperatingForeignExchangeGainsLosses_label_en-US" xlink:label="lab_sny_NonOperatingForeignExchangeGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Operating Foreign Exchange Gains/(Losses)</link:label>
    <link:label id="lab_sny_NonOperatingForeignExchangeGainsLosses_documentation_en-US" xlink:label="lab_sny_NonOperatingForeignExchangeGainsLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-operating foreign exchange gains/(losses).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonOperatingForeignExchangeGainsLosses" xlink:href="sny-20240630.xsd#sny_NonOperatingForeignExchangeGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonOperatingForeignExchangeGainsLosses" xlink:to="lab_sny_NonOperatingForeignExchangeGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock_ed6b458b-71f5-453a-a67f-95b2f2b901d8_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Acquisitions and Capitalized Interest by Operating Segment</link:label>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Acquisitions Of Property Plant And Equipment By Operating Segments Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of acquisitions of property plant and equipment by operating segments explanatory [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilities_32feaab1-aa15-4f3b-8ab7-391083a91fc6_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilities_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilities" xlink:to="lab_ifrs-full_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_65f91e0b-09ea-41a3-805a-91d8c399b6eb_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value (excluding investments accounted for using the equity method)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Cash Flow Hedges Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in fair value on cash flow hedges excluding associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities_61ad091c-190d-4812-9fd7-d90cbfe691d1_negatedLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decrease in total expense of restructuring activities</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities_label_en-US" xlink:label="lab_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Total Expense Of Restructuring Activities</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Total Expense Of Restructuring Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities" xlink:to="lab_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LeaseTerm_388b0ee7-c7ef-4374-864c-53071051a1a9_terseLabel_en-US" xlink:label="lab_sny_LeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, term</link:label>
    <link:label id="lab_sny_LeaseTerm_label_en-US" xlink:label="lab_sny_LeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Term</link:label>
    <link:label id="lab_sny_LeaseTerm_documentation_en-US" xlink:label="lab_sny_LeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseTerm" xlink:href="sny-20240630.xsd#sny_LeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LeaseTerm" xlink:to="lab_sny_LeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_fdd1ab09-3a8d-4934-8dd6-40b43456abc2_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value (excluding investments accounted for using the equity method)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Debt Instrument Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Debt Instrument Excluding Associates And Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareRepurchase2022ProgramMember_ba55262d-03a5-4eaf-a352-8d75b3245d3e_terseLabel_en-US" xlink:label="lab_sny_ShareRepurchase2022ProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase 2022 program</link:label>
    <link:label id="lab_sny_ShareRepurchase2022ProgramMember_label_en-US" xlink:label="lab_sny_ShareRepurchase2022ProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase 2022 Program [Member]</link:label>
    <link:label id="lab_sny_ShareRepurchase2022ProgramMember_documentation_en-US" xlink:label="lab_sny_ShareRepurchase2022ProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase 2022 Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2022ProgramMember" xlink:href="sny-20240630.xsd#sny_ShareRepurchase2022ProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareRepurchase2022ProgramMember" xlink:to="lab_sny_ShareRepurchase2022ProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_c390263b-f060-4836-8e22-8765c7cbde04_negatedLabel_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Selling and general expenses</link:label>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_f5b10f1c-bf0a-413b-98e8-a05688d8815a_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_293f9297-f685-4349-9e94-d824d792dc66_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [Axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PlanAssetsMember_82cc3838-2aea-4b03-83bf-22de10f1ee57_terseLabel_en-US" xlink:label="lab_ifrs-full_PlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan assets</link:label>
    <link:label id="lab_ifrs-full_PlanAssetsMember_label_en-US" xlink:label="lab_ifrs-full_PlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PlanAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PlanAssetsMember" xlink:to="lab_ifrs-full_PlanAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_75a7adbd-414d-4806-b7e9-c2dcb0b4c6d1_terseLabel_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bottom of range</link:label>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bottom of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_c91b18df-62a7-4c1d-8d71-33867dee1a2b_negatedLabel_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of lease liabilities</link:label>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_b3712384-6c91-46cc-9bd8-1ead0e6b6a5e_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" xlink:href="sny-20240630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" xlink:to="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareBasedPaymentPlansAbstract_712a4b11-68ec-4cc4-abff-40571c8a1ffd_terseLabel_en-US" xlink:label="lab_sny_ShareBasedPaymentPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment plans:</link:label>
    <link:label id="lab_sny_ShareBasedPaymentPlansAbstract_label_en-US" xlink:label="lab_sny_ShareBasedPaymentPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Payment Plans [abstract]</link:label>
    <link:label id="lab_sny_ShareBasedPaymentPlansAbstract_documentation_en-US" xlink:label="lab_sny_ShareBasedPaymentPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based payment plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareBasedPaymentPlansAbstract" xlink:href="sny-20240630.xsd#sny_ShareBasedPaymentPlansAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract" xlink:to="lab_sny_ShareBasedPaymentPlansAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_3d7e4366-f0bd-4668-b8e3-cc5577cef48e_terseLabel_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation differences (investments accounted for using the equity method)</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Currency Translation Net Of Tax On Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in currency translation net of tax on associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:href="sny-20240630.xsd#sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member_bdb17e22-615b-48d8-bb07-89a186142465_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock_478d73e8-0e7e-4219-a35d-013c152dc229_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Movements in Other Intangible Assets</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Changes In Other Intangible Assets [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in other intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:to="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock_2fd266e3-aad5-4482-a688-83ff92905e78_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Net Debt by Type Valuation of Redemption</link:label>
    <link:label id="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Debt Net Of Cash And Cash Equivalents By Type At Value On Redemption Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of debt net of cash and cash equivalents by type at value on redemption.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_0b547666-37ae-47b2-b827-7aef0d0bcb19_terseLabel_en-US" xlink:label="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued immediately for employer's contribution (in shares)</link:label>
    <link:label id="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_label_en-US" xlink:label="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Further Shares As An Employers Contribution</link:label>
    <link:label id="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_documentation_en-US" xlink:label="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Further shares as an employers contribution.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:href="sny-20240630.xsd#sny_IssuanceOfFurtherSharesAsAnEmployersContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:to="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings_a3990b39-cf37-414e-980b-7850dd225fe5_negatedLabel_en-US" xlink:label="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings_label_en-US" xlink:label="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:to="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_8058619b-b029-440c-8dc3-ef9be8fbcb4a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CommercialPapersIssued_2aa10b08-e75d-4c21-bae1-0203156d09c5_terseLabel_en-US" xlink:label="lab_ifrs-full_CommercialPapersIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper programs</link:label>
    <link:label id="lab_ifrs-full_CommercialPapersIssued_label_en-US" xlink:label="lab_ifrs-full_CommercialPapersIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial papers issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommercialPapersIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommercialPapersIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CommercialPapersIssued" xlink:to="lab_ifrs-full_CommercialPapersIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_67c2ae2c-d5e0-40c0-97d4-07a650fbe820_terseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposals and retirements, intangible assets other than goodwill</link:label>
    <link:label id="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals and retirements, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_0c2d9cf2-d4cf-42f9-83aa-3749a210f83a_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserves and retained earnings</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember" xlink:to="lab_ifrs-full_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProductsAndServicesAxis_731a0f14-ecf0-449e-91ba-0fd5f9997101_terseLabel_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and services [axis]</link:label>
    <link:label id="lab_ifrs-full_ProductsAndServicesAxis_label_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesAxis" xlink:to="lab_ifrs-full_ProductsAndServicesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_125ab605-73e2-4d07-b117-fcc68edbe82b_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [Axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_3bc79998-27b1-4747-b9e1-6193f461f537_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInPoundSterlingMember_fdb80f30-67b2-4695-a34e-440a1e9c5f8d_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInPoundSterlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency sales in Pound sterling</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInPoundSterlingMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInPoundSterlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Pound Sterling [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInPoundSterlingMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInPoundSterlingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Pound Sterling</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInPoundSterlingMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInPoundSterlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInPoundSterlingMember" xlink:to="lab_sny_ForwardCurrencySalesInPoundSterlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts_a0bfde71-3a6f-46dc-a2b6-92384c116657_terseLabel_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation for early termination of contracts (other than contracts of employment)</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts_label_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Of Restructuring Activities Compensation For Early Termination Of Contracts</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts_documentation_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compensation for early termination of contracts (other than contracts of employment).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts" xlink:href="sny-20240630.xsd#sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts" xlink:to="lab_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DebtNetOfCashAndCashEquivalents_4ddc8bd1-3081-44a6-a0cd-87c91b27aa00_totalLabel_en-US" xlink:label="lab_sny_DebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net debt</link:label>
    <link:label id="lab_sny_DebtNetOfCashAndCashEquivalents_label_en-US" xlink:label="lab_sny_DebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Net Of Cash And Cash Equivalents</link:label>
    <link:label id="lab_sny_DebtNetOfCashAndCashEquivalents_documentation_en-US" xlink:label="lab_sny_DebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt net of cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents" xlink:href="sny-20240630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DebtNetOfCashAndCashEquivalents" xlink:to="lab_sny_DebtNetOfCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SubscriptionPricePerShare_88819019-764e-4747-92c1-c25728f8cb0c_terseLabel_en-US" xlink:label="lab_sny_SubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subscription price (in euros per share)</link:label>
    <link:label id="lab_sny_SubscriptionPricePerShare_label_en-US" xlink:label="lab_sny_SubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subscription Price Per Share</link:label>
    <link:label id="lab_sny_SubscriptionPricePerShare_documentation_en-US" xlink:label="lab_sny_SubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subscription price per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubscriptionPricePerShare" xlink:href="sny-20240630.xsd#sny_SubscriptionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SubscriptionPricePerShare" xlink:to="lab_sny_SubscriptionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_8a74b9d7-c2f3-4ce4-8828-f16b839343b0_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_4a2c34f3-28dc-48b9-aa66-7b626bd50668_verboseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfProfitsArisingFromCommercialOperations_d7cffd87-6611-41bf-9c28-b38e35ddc5da_terseLabel_en-US" xlink:label="lab_sny_PercentageOfProfitsArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of profits arising from commercial operations</link:label>
    <link:label id="lab_sny_PercentageOfProfitsArisingFromCommercialOperations_label_en-US" xlink:label="lab_sny_PercentageOfProfitsArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Profits Arising From Commercial Operations</link:label>
    <link:label id="lab_sny_PercentageOfProfitsArisingFromCommercialOperations_documentation_en-US" xlink:label="lab_sny_PercentageOfProfitsArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Profits Arising From Commercial Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitsArisingFromCommercialOperations" xlink:href="sny-20240630.xsd#sny_PercentageOfProfitsArisingFromCommercialOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfProfitsArisingFromCommercialOperations" xlink:to="lab_sny_PercentageOfProfitsArisingFromCommercialOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_bc434e73-ec74-4272-a99e-e9c2f665ad91_negatedLabel_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest rate and currency derivatives used to manage debt</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_label_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate And Currency Derivatives Used To Manage Debt</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_documentation_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest rate and currency derivatives used to manage debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:href="sny-20240630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:to="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FutureRoyaltiesReceivableValue_5955a505-ba21-4380-acd1-0be2946b86d0_terseLabel_en-US" xlink:label="lab_sny_FutureRoyaltiesReceivableValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future royalties receivable, value</link:label>
    <link:label id="lab_sny_FutureRoyaltiesReceivableValue_label_en-US" xlink:label="lab_sny_FutureRoyaltiesReceivableValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Royalties Receivable, Value</link:label>
    <link:label id="lab_sny_FutureRoyaltiesReceivableValue_documentation_en-US" xlink:label="lab_sny_FutureRoyaltiesReceivableValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Royalties Receivable, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FutureRoyaltiesReceivableValue" xlink:href="sny-20240630.xsd#sny_FutureRoyaltiesReceivableValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FutureRoyaltiesReceivableValue" xlink:to="lab_sny_FutureRoyaltiesReceivableValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PreFundedPensionObligations_82784228-3b7e-4698-8e3f-f8977b2f5828_terseLabel_en-US" xlink:label="lab_sny_PreFundedPensionObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-funded pension obligations</link:label>
    <link:label id="lab_sny_PreFundedPensionObligations_label_en-US" xlink:label="lab_sny_PreFundedPensionObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Pension Obligations</link:label>
    <link:label id="lab_sny_PreFundedPensionObligations_documentation_en-US" xlink:label="lab_sny_PreFundedPensionObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-funded pension obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PreFundedPensionObligations" xlink:href="sny-20240630.xsd#sny_PreFundedPensionObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PreFundedPensionObligations" xlink:to="lab_sny_PreFundedPensionObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AltuviiioMember_bb1f8b0e-6d7d-4f4c-826e-f780517d89a8_terseLabel_en-US" xlink:label="lab_sny_AltuviiioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Altuviiio</link:label>
    <link:label id="lab_sny_AltuviiioMember_label_en-US" xlink:label="lab_sny_AltuviiioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Altuviiio [Member]</link:label>
    <link:label id="lab_sny_AltuviiioMember_documentation_en-US" xlink:label="lab_sny_AltuviiioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Altuviiio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AltuviiioMember" xlink:href="sny-20240630.xsd#sny_AltuviiioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AltuviiioMember" xlink:to="lab_sny_AltuviiioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_81a9ae85-145d-494b-9953-bd47a1c0dcba_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and other increases</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_3b26af17-b18c-4538-9ae2-690b2aa17b05_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net interest related to employee benefits, and unwinding of discount</link:label>
    <link:label id="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_label_en-US" xlink:label="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease Of Unused Provision Reversed, Other Provisions</link:label>
    <link:label id="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase Decrease Of Unused Provision Reversed, Other Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" xlink:to="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TypesOfAgreementDomain_17849fc6-8ebc-4b8f-bd72-5d32ab51797c_terseLabel_en-US" xlink:label="lab_sny_TypesOfAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types Of Agreement [Domain]</link:label>
    <link:label id="lab_sny_TypesOfAgreementDomain_label_en-US" xlink:label="lab_sny_TypesOfAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types Of Agreement [Domain]</link:label>
    <link:label id="lab_sny_TypesOfAgreementDomain_documentation_en-US" xlink:label="lab_sny_TypesOfAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Types Of Agreement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain" xlink:href="sny-20240630.xsd#sny_TypesOfAgreementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TypesOfAgreementDomain" xlink:to="lab_sny_TypesOfAgreementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableLineItems_2e6ab760-6a8f-4e55-8963-224209aa3187_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Accounts Receivable [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounts Receivable [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounts Receivable [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableLineItems" xlink:href="sny-20240630.xsd#sny_DisclosureOfAccountsReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAccountsReceivableLineItems" xlink:to="lab_sny_DisclosureOfAccountsReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxAssetsNoncurrent_0a3303c7-c58c-40d7-9355-067f61725d25_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current income tax assets</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxAssetsNoncurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax assets, non-current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsNoncurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxAssetsNoncurrent" xlink:to="lab_ifrs-full_CurrentTaxAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod_13094a23-a47e-4e56-8cd1-f89993da0303_terseLabel_en-US" xlink:label="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod_d0469044-8a4e-4eff-9e6d-bc21f15d4ee3_totalLabel_en-US" xlink:label="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2023AdditionalSharesMember_ca5aadb9-f1ab-4689-9edd-0cade5f5a9f1_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2023AdditionalSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted share plan 2023, additional shares</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2023AdditionalSharesMember_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2023AdditionalSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2023, Additional Shares [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2023AdditionalSharesMember_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2023AdditionalSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2023, Additional Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023AdditionalSharesMember" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2023AdditionalSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2023AdditionalSharesMember" xlink:to="lab_sny_RestrictedSharePlan2023AdditionalSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CustomerOneMember_1b75a7cb-942e-4b04-a8cc-00f357459342_terseLabel_en-US" xlink:label="lab_sny_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer one</link:label>
    <link:label id="lab_sny_CustomerOneMember_label_en-US" xlink:label="lab_sny_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer One [member]</link:label>
    <link:label id="lab_sny_CustomerOneMember_documentation_en-US" xlink:label="lab_sny_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerOneMember" xlink:href="sny-20240630.xsd#sny_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CustomerOneMember" xlink:to="lab_sny_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems_8023450b-fe94-4c57-a241-96988ef23627_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProductsTrademarksAndOtherRightsMember_260723b1-d060-4b77-8d88-ca7041307110_terseLabel_en-US" xlink:label="lab_sny_ProductsTrademarksAndOtherRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products, trademarks and other rights</link:label>
    <link:label id="lab_sny_ProductsTrademarksAndOtherRightsMember_label_en-US" xlink:label="lab_sny_ProductsTrademarksAndOtherRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products, Trademarks And Other Rights [Member]</link:label>
    <link:label id="lab_sny_ProductsTrademarksAndOtherRightsMember_documentation_en-US" xlink:label="lab_sny_ProductsTrademarksAndOtherRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Products, trademarks and other rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProductsTrademarksAndOtherRightsMember" xlink:href="sny-20240630.xsd#sny_ProductsTrademarksAndOtherRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProductsTrademarksAndOtherRightsMember" xlink:to="lab_sny_ProductsTrademarksAndOtherRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_b2c85b71-21d7-400c-85b4-751657b0070e_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock_4c7db957-c95e-429d-bb31-6f872a9f9093_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Restructuring Costs and Similar Items</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Restructuring Costs Details [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of restructuring costs details.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfRestructuringCostsDetailsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:to="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock_a36ee57c-87eb-4a66-8dc9-3cfcf01380bd_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, Cash and Cash Equivalents</link:label>
    <link:label id="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Debt Instruments Issued Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of debt instruments issued explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_WellnessBrandsMember_93b928b5-44fa-4e48-bafa-7d670570cb8f_terseLabel_en-US" xlink:label="lab_sny_WellnessBrandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wellness Brands</link:label>
    <link:label id="lab_sny_WellnessBrandsMember_label_en-US" xlink:label="lab_sny_WellnessBrandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wellness Brands [Member]</link:label>
    <link:label id="lab_sny_WellnessBrandsMember_documentation_en-US" xlink:label="lab_sny_WellnessBrandsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Wellness Brands</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WellnessBrandsMember" xlink:href="sny-20240630.xsd#sny_WellnessBrandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_WellnessBrandsMember" xlink:to="lab_sny_WellnessBrandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_ff5e17ce-12e0-4a99-9b0e-1d15c9a6bd65_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers and other changes, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TotalMilestonePayments_31b4c6a7-98e4-4835-868d-1bfd2da539e9_terseLabel_en-US" xlink:label="lab_sny_TotalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Milestone Payments</link:label>
    <link:label id="lab_sny_TotalMilestonePayments_label_en-US" xlink:label="lab_sny_TotalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Milestone Payments</link:label>
    <link:label id="lab_sny_TotalMilestonePayments_documentation_en-US" xlink:label="lab_sny_TotalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalMilestonePayments" xlink:href="sny-20240630.xsd#sny_TotalMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TotalMilestonePayments" xlink:to="lab_sny_TotalMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnTaxEffects_e4d0f4fe-bed4-468c-a1a0-a32d45a34e04_negatedTerseLabel_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnTaxEffects_label_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Currency Translation On Tax Effects</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnTaxEffects_documentation_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in currency translation on tax effects.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:href="sny-20240630.xsd#sny_ChangeInCurrencyTranslationOnTaxEffects"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:to="lab_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_d8107d6e-0d59-4877-a851-5a06d45a06cb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTable_51ff1867-0316-4d4e-b066-41a5e48927cc_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Noncurrent Provisions [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTable_label_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-Current Provisions [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Noncurrent Provisions [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTable" xlink:href="sny-20240630.xsd#sny_DisclosureOfNonCurrentProvisionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable" xlink:to="lab_sny_DisclosureOfNonCurrentProvisionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsTable_87713903-dfe9-4d07-9fb3-a4c1ce64dc24_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Non-current Assets [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsTable_label_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Non-Current Assets [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to other non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:href="sny-20240630.xsd#sny_DisclosureOfOtherNonCurrentAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:to="lab_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_a5468697-f3f0-4ad7-aecd-559da22c02e2_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncontrollingInterests_3f69f782-900b-4a30-b83c-ada3a471a294_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity attributable to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_NoncontrollingInterests_label_en-US" xlink:label="lab_ifrs-full_NoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncontrollingInterests" xlink:to="lab_ifrs-full_NoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_7b480b97-e081-4396-9cdd-8903beab433a_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Sanofi shares</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DerivativeFinancialInstruments_43c86f35-ec81-4dad-9ea9-79b2e7700596_terseLabel_en-US" xlink:label="lab_sny_DerivativeFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating currency hedging instruments in place</link:label>
    <link:label id="lab_sny_DerivativeFinancialInstruments_label_en-US" xlink:label="lab_sny_DerivativeFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_sny_DerivativeFinancialInstruments_documentation_en-US" xlink:label="lab_sny_DerivativeFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative financial instrument</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstruments" xlink:href="sny-20240630.xsd#sny_DerivativeFinancialInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DerivativeFinancialInstruments" xlink:to="lab_sny_DerivativeFinancialInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_e36c989c-a8e3-431b-89ea-36b44fab6362_negatedLabel_en-US" xlink:label="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Disposals and other decreases</link:label>
    <link:label id="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals and retirements, intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_USGovernmentMember_5a3e3440-fec1-439f-a953-c7efbdaa597e_terseLabel_en-US" xlink:label="lab_sny_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Government</link:label>
    <link:label id="lab_sny_USGovernmentMember_label_en-US" xlink:label="lab_sny_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government [Member]</link:label>
    <link:label id="lab_sny_USGovernmentMember_documentation_en-US" xlink:label="lab_sny_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">US Government</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_USGovernmentMember" xlink:href="sny-20240630.xsd#sny_USGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_USGovernmentMember" xlink:to="lab_sny_USGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_0008bf0c-9165-4c92-903a-d0310e45c3ae_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c137b14b-fdeb-432d-a992-d396b3de56f0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_dbd14977-57c1-44d3-a154-bec1445ce2f0_terseLabel_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of restricted shares alloted in regards of capital increase</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_label_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of restricted shares alloted in regards of capital increase</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_documentation_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of restricted shares alloted in regards of capital increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" xlink:href="sny-20240630.xsd#sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" xlink:to="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AntibodiesCollaborationAgreementMember_d49d84b7-9ec7-46e0-b4fd-8f903a1e2f8b_terseLabel_en-US" xlink:label="lab_sny_AntibodiesCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antibodies Collaboration Agreement</link:label>
    <link:label id="lab_sny_AntibodiesCollaborationAgreementMember_label_en-US" xlink:label="lab_sny_AntibodiesCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antibodies Collaboration Agreement [Member]</link:label>
    <link:label id="lab_sny_AntibodiesCollaborationAgreementMember_documentation_en-US" xlink:label="lab_sny_AntibodiesCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Antibodies Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember" xlink:href="sny-20240630.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AntibodiesCollaborationAgreementMember" xlink:to="lab_sny_AntibodiesCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_07ef11cc-14e5-4bca-a122-b82ecf383936_terseLabel_en-US" xlink:label="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial currency hedging instruments in place</link:label>
    <link:label id="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_label_en-US" xlink:label="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Financial Instruments To Manage Financial Exposure</link:label>
    <link:label id="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_documentation_en-US" xlink:label="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative financial instruments to manage financial exposure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:href="sny-20240630.xsd#sny_DerivativeFinancialInstrumentsToManageFinancialExposure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:to="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_975df4c4-36ec-4b89-8795-0b05ff49c811_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in other provisions [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in other provisions [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract" xlink:to="lab_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfCases_01692f6f-9715-4c07-a9e2-1b71bebd81f4_terseLabel_en-US" xlink:label="lab_sny_NumberOfCases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Of Cases</link:label>
    <link:label id="lab_sny_NumberOfCases_label_en-US" xlink:label="lab_sny_NumberOfCases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Cases</link:label>
    <link:label id="lab_sny_NumberOfCases_documentation_en-US" xlink:label="lab_sny_NumberOfCases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Cases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCases" xlink:href="sny-20240630.xsd#sny_NumberOfCases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfCases" xlink:to="lab_sny_NumberOfCases" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MajorCollaborationAgreementMember_3d80df53-94b9-45f5-bbfa-dab375cf9a42_terseLabel_en-US" xlink:label="lab_sny_MajorCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major collaboration agreement</link:label>
    <link:label id="lab_sny_MajorCollaborationAgreementMember_label_en-US" xlink:label="lab_sny_MajorCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Collaboration Agreement [Member]</link:label>
    <link:label id="lab_sny_MajorCollaborationAgreementMember_documentation_en-US" xlink:label="lab_sny_MajorCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Major Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorCollaborationAgreementMember" xlink:href="sny-20240630.xsd#sny_MajorCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MajorCollaborationAgreementMember" xlink:to="lab_sny_MajorCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReclassifiedItemsAxis_e242e9f9-89b3-4136-8b66-7ea3b049085b_terseLabel_en-US" xlink:label="lab_ifrs-full_ReclassifiedItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassified items [Axis]</link:label>
    <link:label id="lab_ifrs-full_ReclassifiedItemsAxis_label_en-US" xlink:label="lab_ifrs-full_ReclassifiedItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassified items [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis" xlink:to="lab_ifrs-full_ReclassifiedItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_cd60d7ee-7747-4dc5-8afc-0539070a8273_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c95483de-2805-4fce-b678-8075987fc0d0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetChangeInOtherNonCurrentAssets_f9b1a084-1dc0-4ab5-8faf-ac58a86dcaa5_terseLabel_en-US" xlink:label="lab_sny_NetChangeInOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in other non-current assets</link:label>
    <link:label id="lab_sny_NetChangeInOtherNonCurrentAssets_label_en-US" xlink:label="lab_sny_NetChangeInOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Change In Other Non-Current Assets</link:label>
    <link:label id="lab_sny_NetChangeInOtherNonCurrentAssets_documentation_en-US" xlink:label="lab_sny_NetChangeInOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net change in other non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherNonCurrentAssets" xlink:href="sny-20240630.xsd#sny_NetChangeInOtherNonCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetChangeInOtherNonCurrentAssets" xlink:to="lab_sny_NetChangeInOtherNonCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInKoreanWonMember_3158b75a-1e1c-4469-8141-47029db15584_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInKoreanWonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency purchases in Korean won</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInKoreanWonMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInKoreanWonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Korean Won [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInKoreanWonMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInKoreanWonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Korean Won</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInKoreanWonMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInKoreanWonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInKoreanWonMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInKoreanWonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_da255762-7a1b-42b7-a8ff-ccf13e71cc41_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other movements (b)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through other changes, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PharmaLaunchesMember_e8bd69b2-8051-4d47-8d1a-0b2cf5115735_terseLabel_en-US" xlink:label="lab_sny_PharmaLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharma Launches</link:label>
    <link:label id="lab_sny_PharmaLaunchesMember_label_en-US" xlink:label="lab_sny_PharmaLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharma Launches [Member]</link:label>
    <link:label id="lab_sny_PharmaLaunchesMember_documentation_en-US" xlink:label="lab_sny_PharmaLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharma Launches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaLaunchesMember" xlink:href="sny-20240630.xsd#sny_PharmaLaunchesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PharmaLaunchesMember" xlink:to="lab_sny_PharmaLaunchesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OperatingSegmentsMember_8a319a80-77aa-434b-b59e-c70962202546_terseLabel_en-US" xlink:label="lab_ifrs-full_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating segments</link:label>
    <link:label id="lab_ifrs-full_OperatingSegmentsMember_label_en-US" xlink:label="lab_ifrs-full_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating segments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingSegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OperatingSegmentsMember" xlink:to="lab_ifrs-full_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_f3aefeb2-33e3-418c-87ad-98ac74bab364_terseLabel_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee-related expenses</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_label_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Of Restructuring Activities Employee Related Expenses</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_documentation_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee related expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:href="sny-20240630.xsd#sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:to="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ImmunoOncologyCollaborationAgreementMember_77d6cb5b-3974-45f5-92d7-a98c0b54ecf5_terseLabel_en-US" xlink:label="lab_sny_ImmunoOncologyCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Immuno Oncology Collaboration Agreement</link:label>
    <link:label id="lab_sny_ImmunoOncologyCollaborationAgreementMember_label_en-US" xlink:label="lab_sny_ImmunoOncologyCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Immuno Oncology Collaboration Agreement [Member]</link:label>
    <link:label id="lab_sny_ImmunoOncologyCollaborationAgreementMember_documentation_en-US" xlink:label="lab_sny_ImmunoOncologyCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Immuno oncology collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunoOncologyCollaborationAgreementMember" xlink:href="sny-20240630.xsd#sny_ImmunoOncologyCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ImmunoOncologyCollaborationAgreementMember" xlink:to="lab_sny_ImmunoOncologyCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReportableSegmentsMember_d80552c7-1dc0-4ea5-be3d-61513f70fc7f_verboseLabel_en-US" xlink:label="lab_ifrs-full_ReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_ReportableSegmentsMember_label_en-US" xlink:label="lab_ifrs-full_ReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable segments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReportableSegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReportableSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReportableSegmentsMember" xlink:to="lab_ifrs-full_ReportableSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_af8ac66c-445f-40fd-8cc8-72be2c6d080c_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInJapaneseYenMember_e706a518-dabb-412a-bac6-60ad2ab29593_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency sales in Japanese yen</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInJapaneseYenMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Japanese Yen [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInJapaneseYenMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency sales in Japanese Yen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInJapaneseYenMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInJapaneseYenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInJapaneseYenMember" xlink:to="lab_sny_ForwardCurrencySalesInJapaneseYenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_036c6ac8-fef4-492d-854d-4806e998b5ac_negatedLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_8b206dd9-0e71-444d-be84-b1210dd22071_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseOfRestructuringActivities_5e622964-dd91-44f1-8514-dfa3d485e3ce_negatedLabel_en-US" xlink:label="lab_ifrs-full_ExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Restructuring costs and similar items</link:label>
    <link:label id="lab_ifrs-full_ExpenseOfRestructuringActivities_0178f73c-ad81-4f77-970d-9ab80ee6df32_totalLabel_en-US" xlink:label="lab_ifrs-full_ExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_ExpenseOfRestructuringActivities_label_en-US" xlink:label="lab_ifrs-full_ExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense of restructuring activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities" xlink:to="lab_ifrs-full_ExpenseOfRestructuringActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_ea82bac0-ba4a-438c-a3b4-c0cc721bc09d_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt and current portion of long-term debt</link:label>
    <link:label id="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_label_en-US" xlink:label="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current borrowings and current portion of non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:to="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameMember_173d8ea7-9e91-4027-9dde-c4b37efd2821_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings by name [Member]</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameMember_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameMember" xlink:to="lab_ifrs-full_BorrowingsByNameMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated_5677b431-a534-4896-9def-b50b4d6f4e8f_terseLabel_en-US" xlink:label="lab_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global penalty fee incurred by defendants, amount vacated</link:label>
    <link:label id="lab_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated_label_en-US" xlink:label="lab_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global Penalty Fee Incurred By Defendants, Amount Vacated</link:label>
    <link:label id="lab_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated_documentation_en-US" xlink:label="lab_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global Penalty Fee Incurred By Defendants, Amount Vacated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated" xlink:href="sny-20240630.xsd#sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated" xlink:to="lab_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_84cd367d-c915-4bff-97ca-fc3abc99f1fd_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options and other share-based payments</link:label>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve of share-based payments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_d862fc10-648f-4593-ac60-561a9bd3a099_terseLabel_en-US" xlink:label="lab_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of goods and services</link:label>
    <link:label id="lab_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchases of goods, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:to="lab_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsAxis_cacd07fa-1a64-4f91-bf0b-f3c58c03093b_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial assumptions [axis]</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsAxis_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumptions [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis" xlink:to="lab_ifrs-full_ActuarialAssumptionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_496cddc5-cb03-442a-93ab-63c291347d54_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of consolidated undertakings and investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_36015ee2-ee80-40c4-a140-7e6a471a517b_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flow on acquisition</link:label>
    <link:label id="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_6d684d2f-3e13-492e-9c74-5b86b561e2d1_terseLabel_en-US" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/(losses) on benefit obligations</link:label>
    <link:label id="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_209a2713-2f81-4788-ab56-8306170c80a2_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [Axis]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RightofuseAssets_9e23f6af-0b0b-4de5-a2d4-6e989c1b1b45_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets" xlink:to="lab_ifrs-full_RightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilities_9c66b294-9c14-491c-b64a-b078f105a483_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="lab_ifrs-full_LeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesCurrent_dfb22540-d8d9-4a9c-ba25-9141d07dc33a_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income tax liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesCurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax liabilities, current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:to="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AmortizedCostNettingMember_6da63e27-8dfa-4d51-b926-8397ebaebf57_terseLabel_en-US" xlink:label="lab_sny_AmortizedCostNettingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_sny_AmortizedCostNettingMember_label_en-US" xlink:label="lab_sny_AmortizedCostNettingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortized Cost, Netting [Member]</link:label>
    <link:label id="lab_sny_AmortizedCostNettingMember_documentation_en-US" xlink:label="lab_sny_AmortizedCostNettingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortized cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizedCostNettingMember" xlink:href="sny-20240630.xsd#sny_AmortizedCostNettingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AmortizedCostNettingMember" xlink:to="lab_sny_AmortizedCostNettingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInJapaneseYenMember_d70d23b0-e27e-4ee0-bd07-cca4174315dc_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency purchases in Japanese Yen</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInJapaneseYenMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Japanese Yen [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInJapaneseYenMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchased In Japanese yen [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInJapaneseYenMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInJapaneseYenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInJapaneseYenMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInJapaneseYenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_8cb59eb7-1e2c-4a54-9e1b-b3d860064d94_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_label_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests Table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" xlink:href="sny-20240630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" xlink:to="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member_87c1dc5b-c9ee-46cc-8431-c86de2214651_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 3.56%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 3.56%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember_50cd094b-fe46-42bc-ab17-036f6da6c059_terseLabel_en-US" xlink:label="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plavix Attorney General action in Hawaii</link:label>
    <link:label id="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember_label_en-US" xlink:label="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plavix Attorney General Action In Hawaii [Member]</link:label>
    <link:label id="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember_documentation_en-US" xlink:label="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plavix Attorney General Action In Hawaii</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixAttorneyGeneralActionInHawaiiMember" xlink:href="sny-20240630.xsd#sny_PlavixAttorneyGeneralActionInHawaiiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PlavixAttorneyGeneralActionInHawaiiMember" xlink:to="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_c77bf076-96cf-42a6-8885-1d2ba38c8cf3_terseLabel_en-US" xlink:label="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shire contingent consideration arising from acquisition of Translate Bio</link:label>
    <link:label id="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_label_en-US" xlink:label="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shire Contingent Consideration Arising From Acquisition Of Translate Bio [Member]</link:label>
    <link:label id="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_documentation_en-US" xlink:label="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shire Contingent Consideration Arising From Acquisition Of Translate Bio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" xlink:href="sny-20240630.xsd#sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" xlink:to="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_07db7e0b-008a-4549-ae70-f3c98e280017_terseLabel_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital increase by issuance of restricted shares (in shares)</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_label_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Restricted Shares Issued In Regards Of Capital Increase</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_documentation_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of restricted shares issued in regards of capital increase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:href="sny-20240630.xsd#sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:to="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_ecde1a61-3953-46ef-9660-7beacdab9299_verboseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAttributableToOwnersOfParentMember_5f27775e-5189-4e9c-9a43-d899f19fa3df_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_EquityAttributableToOwnersOfParentMember_label_en-US" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity attributable to owners of parent [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:to="lab_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestsInOtherEntitiesAbstract_2ae9ca39-9b96-4b50-9e78-e5e2f6217e4f_terseLabel_en-US" xlink:label="lab_sny_InterestsInOtherEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interests In Other Entities [Abstract]</link:label>
    <link:label id="lab_sny_InterestsInOtherEntitiesAbstract_label_en-US" xlink:label="lab_sny_InterestsInOtherEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interests In Other Entities [Abstract]</link:label>
    <link:label id="lab_sny_InterestsInOtherEntitiesAbstract_documentation_en-US" xlink:label="lab_sny_InterestsInOtherEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interests In Other Entities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract" xlink:href="sny-20240630.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract" xlink:to="lab_sny_InterestsInOtherEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainLossOnDerivativesUsedToManageDebt_3b73d022-6bb0-4a0f-bf3b-a9474f76da75_terseLabel_en-US" xlink:label="lab_sny_GainLossOnDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on derivatives used to manage debt</link:label>
    <link:label id="lab_sny_GainLossOnDerivativesUsedToManageDebt_label_en-US" xlink:label="lab_sny_GainLossOnDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Derivatives Used To Manage Debt</link:label>
    <link:label id="lab_sny_GainLossOnDerivativesUsedToManageDebt_documentation_en-US" xlink:label="lab_sny_GainLossOnDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (loss) on derivatives used to manage debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnDerivativesUsedToManageDebt" xlink:href="sny-20240630.xsd#sny_GainLossOnDerivativesUsedToManageDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainLossOnDerivativesUsedToManageDebt" xlink:to="lab_sny_GainLossOnDerivativesUsedToManageDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EuroapiMember_e7a82635-37ce-451e-a73c-6cfc681775e9_terseLabel_en-US" xlink:label="lab_sny_EuroapiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Euroapi</link:label>
    <link:label id="lab_sny_EuroapiMember_a96d7c1a-334b-4a9a-9e1d-260228f210fa_verboseLabel_en-US" xlink:label="lab_sny_EuroapiMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">EUROAPI</link:label>
    <link:label id="lab_sny_EuroapiMember_label_en-US" xlink:label="lab_sny_EuroapiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euroapi [Member]</link:label>
    <link:label id="lab_sny_EuroapiMember_documentation_en-US" xlink:label="lab_sny_EuroapiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Euroapi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember" xlink:href="sny-20240630.xsd#sny_EuroapiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EuroapiMember" xlink:to="lab_sny_EuroapiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock_a1058821-eaa8-4f96-b703-380179045bc6_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Net Sales by Segment and Geographical Area</link:label>
    <link:label id="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Net Sales By Segment And Geographical Area [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of net sales by segment and geographical area.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" xlink:to="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_748aeb0f-9da8-4f8d-991d-0862becf04bc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Introduction</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of general information about financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_c9c1c3fb-c749-417d-a0c7-36c504dbd363_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_9f6cc24f-57f1-4986-ab0e-72f2ad430fe7_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SegmentConsolidationItemsAxis_10ef5860-4cea-4d50-8230-c5fa7329b7ee_terseLabel_en-US" xlink:label="lab_ifrs-full_SegmentConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment consolidation items [Axis]</link:label>
    <link:label id="lab_ifrs-full_SegmentConsolidationItemsAxis_label_en-US" xlink:label="lab_ifrs-full_SegmentConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment consolidation items [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SegmentConsolidationItemsAxis" xlink:to="lab_ifrs-full_SegmentConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_f00c8080-46de-4e02-80eb-c18cee383386_terseLabel_en-US" xlink:label="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subclassifications of assets, liabilities and equities [abstract]</link:label>
    <link:label id="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subclassifications of assets, liabilities and equities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_fff1aaa6-384b-42fa-a55d-7c629d3d6bb4_terseLabel_en-US" xlink:label="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:label id="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_label_en-US" xlink:label="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate information and statement of IFRS compliance [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:to="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInRussianRoubleMember_2902873c-8841-4c3e-80cc-a99846459950_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInRussianRoubleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Russian rouble</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInRussianRoubleMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInRussianRoubleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Russian rouble [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInRussianRoubleMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInRussianRoubleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Russian rouble</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInRussianRoubleMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInRussianRoubleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInRussianRoubleMember" xlink:to="lab_sny_ForwardCurrencySalesInRussianRoubleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_e4c6723e-76db-45ad-b2b6-c2fc4f142d56_negatedLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_cd70edd1-a091-4a9e-9539-063cc74d69fe_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss on other intangible assets</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_e25dac23-c315-4d3b-9c7c-da4c279224b0_terseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in subsidiary</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_label_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities in business combination [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReductionOfIssuedCapital_bb8086fa-4598-4b07-8534-8c77c4f21f5b_negatedLabel_en-US" xlink:label="lab_ifrs-full_ReductionOfIssuedCapital" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reductions in share capital</link:label>
    <link:label id="lab_ifrs-full_ReductionOfIssuedCapital_label_en-US" xlink:label="lab_ifrs-full_ReductionOfIssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction of issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReductionOfIssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReductionOfIssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReductionOfIssuedCapital" xlink:to="lab_ifrs-full_ReductionOfIssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AtMarketValueMember_b9f573d5-d141-48d2-81da-b01e00339221_terseLabel_en-US" xlink:label="lab_sny_AtMarketValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market value</link:label>
    <link:label id="lab_sny_AtMarketValueMember_label_en-US" xlink:label="lab_sny_AtMarketValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At Market Value [member]</link:label>
    <link:label id="lab_sny_AtMarketValueMember_documentation_en-US" xlink:label="lab_sny_AtMarketValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At market value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtMarketValueMember" xlink:href="sny-20240630.xsd#sny_AtMarketValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AtMarketValueMember" xlink:to="lab_sny_AtMarketValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_d785a5dd-9b08-45cc-87f8-e4ce4ee0124a_terseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_09a22474-0395-418d-a0f4-852ec124b8af_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, number of options (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Goodwill_0e357ef1-c9cd-4269-9d70-41f43ffe28ce_terseLabel_en-US" xlink:label="lab_ifrs-full_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_ifrs-full_Goodwill_label_en-US" xlink:label="lab_ifrs-full_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Goodwill" xlink:to="lab_ifrs-full_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e380bfe4-5042-4e0b-88aa-9daa46e8d0a4_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiaries [axis]</link:label>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_label_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_44a6a54b-c3fd-4141-b0c2-e07c4efdd294_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_215c2ab2-e63e-43a6-9ea5-dd99f1850fda_terseLabel_en-US" xlink:label="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative consumer price inflation rate</link:label>
    <link:label id="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_label_en-US" xlink:label="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Consumer Price Inflation Rate Over The Last Three Years</link:label>
    <link:label id="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_documentation_en-US" xlink:label="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumulative Consumer Price Inflation Rate Over The Last Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" xlink:href="sny-20240630.xsd#sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" xlink:to="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember_e0244866-1f53-47ef-aa50-4e5a05edd4a0_terseLabel_en-US" xlink:label="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pensions and other post-employment benefits</link:label>
    <link:label id="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember_label_en-US" xlink:label="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pensions And Other Post-Employment Benefits [Member]</link:label>
    <link:label id="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember_documentation_en-US" xlink:label="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pensions and other post-employment benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:href="sny-20240630.xsd#sny_PensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:to="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock_46b5ada7-96d7-4159-b120-e70f57b78267_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Non-Current Provisions and Other Non-Current Liabilities</link:label>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Provisions And Other Non Current Liabilities Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Provisions And Other Non Current Liabilities Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_73af864b-8c74-4630-a568-0b1247d81203_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_e542491c-b683-4eb6-aa3d-982e5101a092_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of analysis of other comprehensive income by item [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of analysis of other comprehensive income by item [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable" xlink:to="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageIncreaseInFairValueLiabilities_5a3965fc-0e77-4f32-b38f-91172f2b7ce5_terseLabel_en-US" xlink:label="lab_sny_PercentageIncreaseInFairValueLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in fair value of liability</link:label>
    <link:label id="lab_sny_PercentageIncreaseInFairValueLiabilities_label_en-US" xlink:label="lab_sny_PercentageIncreaseInFairValueLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Increase In Fair Value Liabilities</link:label>
    <link:label id="lab_sny_PercentageIncreaseInFairValueLiabilities_documentation_en-US" xlink:label="lab_sny_PercentageIncreaseInFairValueLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage increase in fair value liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageIncreaseInFairValueLiabilities" xlink:href="sny-20240630.xsd#sny_PercentageIncreaseInFairValueLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageIncreaseInFairValueLiabilities" xlink:to="lab_sny_PercentageIncreaseInFairValueLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_95864c1e-1a57-4915-94fd-c43f1748b48d_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency sales in Chinese yuan renminbi</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Chinese Yuan Renminbi [member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency sales in Chinese Yuan Renminbi.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInChineseYuanRenminbiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:to="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_794e625a-c084-4a87-b8ee-4a4a62927aa5_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for segment consolidation items [Member]</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for segment consolidation items [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lab_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesMember_260c5411-5fa7-4de1-a11f-69dcf3eafc5f_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparties [Member]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesMember_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparties [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesMember" xlink:to="lab_ifrs-full_CounterpartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AstraZenecaMember_0b6f1338-935a-4b87-bcf0-5d66fd205a8d_terseLabel_en-US" xlink:label="lab_sny_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_sny_AstraZenecaMember_label_en-US" xlink:label="lab_sny_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_sny_AstraZenecaMember_documentation_en-US" xlink:label="lab_sny_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AstraZeneca</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AstraZenecaMember" xlink:href="sny-20240630.xsd#sny_AstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AstraZenecaMember" xlink:to="lab_sny_AstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_87ee0ccf-613f-4319-93c5-a432126cae89_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_e9cb0a9f-f4c4-43a2-a649-f041d09ae1c8_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AubagioMember_dbb31da8-7c28-44da-9204-967203d98611_terseLabel_en-US" xlink:label="lab_sny_AubagioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aubagio</link:label>
    <link:label id="lab_sny_AubagioMember_label_en-US" xlink:label="lab_sny_AubagioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aubagio [Member]</link:label>
    <link:label id="lab_sny_AubagioMember_documentation_en-US" xlink:label="lab_sny_AubagioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aubagio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AubagioMember" xlink:href="sny-20240630.xsd#sny_AubagioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AubagioMember" xlink:to="lab_sny_AubagioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_f3ae78e6-419a-49b5-afa6-b14d34231866_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DefendantAxis_0bc10586-78f7-4013-9d7e-906f8ecf15b3_terseLabel_en-US" xlink:label="lab_sny_DefendantAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defendant [Axis]</link:label>
    <link:label id="lab_sny_DefendantAxis_label_en-US" xlink:label="lab_sny_DefendantAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defendant [Axis]</link:label>
    <link:label id="lab_sny_DefendantAxis_documentation_en-US" xlink:label="lab_sny_DefendantAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defendant [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantAxis" xlink:href="sny-20240630.xsd#sny_DefendantAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DefendantAxis" xlink:to="lab_sny_DefendantAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AmountOfSharesRepurchased_bf322f5b-ac02-46b4-842a-1680cfdb36f2_terseLabel_en-US" xlink:label="lab_sny_AmountOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of shares repurchased</link:label>
    <link:label id="lab_sny_AmountOfSharesRepurchased_label_en-US" xlink:label="lab_sny_AmountOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount Of Shares Repurchased</link:label>
    <link:label id="lab_sny_AmountOfSharesRepurchased_documentation_en-US" xlink:label="lab_sny_AmountOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of shares repurchased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmountOfSharesRepurchased" xlink:href="sny-20240630.xsd#sny_AmountOfSharesRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AmountOfSharesRepurchased" xlink:to="lab_sny_AmountOfSharesRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_7b708520-df9f-4e16-b58b-a4c01e190e82_terseLabel_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of outstanding options (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_a0e1b804-7aae-41a7-89ff-cf73af82b156_negatedTerseLabel_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_label_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Relating To Change In Fair Value Of Debt Instrument Excluding Equity Investments</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_documentation_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Relating To Change In Fair Value Of Debt Instrument Excluding Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" xlink:href="sny-20240630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" xlink:to="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems_4e20bdab-89a7-4958-9200-12dc113c6a99_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NovavaxMember_6a543299-c1e2-49c3-b308-8f11341d57a9_terseLabel_en-US" xlink:label="lab_sny_NovavaxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novavax</link:label>
    <link:label id="lab_sny_NovavaxMember_label_en-US" xlink:label="lab_sny_NovavaxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novavax [Member]</link:label>
    <link:label id="lab_sny_NovavaxMember_documentation_en-US" xlink:label="lab_sny_NovavaxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Novavax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NovavaxMember" xlink:href="sny-20240630.xsd#sny_NovavaxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NovavaxMember" xlink:to="lab_sny_NovavaxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MSPVaccineCompanyMember_80d8da37-761f-4680-8be9-0b2e6414ffdf_terseLabel_en-US" xlink:label="lab_sny_MSPVaccineCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MSP Vaccine Company</link:label>
    <link:label id="lab_sny_MSPVaccineCompanyMember_label_en-US" xlink:label="lab_sny_MSPVaccineCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MSP Vaccine Company [Member]</link:label>
    <link:label id="lab_sny_MSPVaccineCompanyMember_documentation_en-US" xlink:label="lab_sny_MSPVaccineCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MSP Vaccine Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember" xlink:href="sny-20240630.xsd#sny_MSPVaccineCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MSPVaccineCompanyMember" xlink:to="lab_sny_MSPVaccineCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeographicalAreasMember_c3959e5e-faa8-4574-9277-7d8c8f2f1a1d_terseLabel_en-US" xlink:label="lab_ifrs-full_GeographicalAreasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical areas [Member]</link:label>
    <link:label id="lab_ifrs-full_GeographicalAreasMember_label_en-US" xlink:label="lab_ifrs-full_GeographicalAreasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasMember" xlink:to="lab_ifrs-full_GeographicalAreasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_7f435277-e548-489f-a661-3c57d3d647ad_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_1db8f124-bfce-4170-9ba0-4aab9584c6e1_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_label_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTradeReceivables" xlink:to="lab_ifrs-full_CurrentTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HedgingInstrumentsMember_82651708-6012-4a98-8257-0beecfb65171_terseLabel_en-US" xlink:label="lab_ifrs-full_HedgingInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging instruments [Member]</link:label>
    <link:label id="lab_ifrs-full_HedgingInstrumentsMember_label_en-US" xlink:label="lab_ifrs-full_HedgingInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging instruments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgingInstrumentsMember" xlink:to="lab_ifrs-full_HedgingInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_def71513-4310-4f82-82c0-9973f2f7d9d3_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued" xlink:to="lab_ifrs-full_NumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityMember_0be8a9ac-63e1-4db6-b18d-718bb6f85606_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [member]</link:label>
    <link:label id="lab_ifrs-full_EquityMember_label_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityMember" xlink:to="lab_ifrs-full_EquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a123c1bb-c21d-4d04-92d3-ce77a6feb74e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfTreasuryShares_01dbddbc-68e5-42ce-882d-bc5b261f1940_negatedLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfTreasuryShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfTreasuryShares_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfTreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfTreasuryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfTreasuryShares" xlink:to="lab_ifrs-full_PurchaseOfTreasuryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_9a3566b0-990a-4b1b-8c15-f9767514da31_terseLabel_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges, gains or losses on assets</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_label_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Of Restructuring Activities Related To Property Plant And Equipment And To Inventories</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_documentation_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense of restructuring activities related to property plant and equipment to inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:href="sny-20240630.xsd#sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:to="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_daca230b-df31-412b-88d0-80f12b98116f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of accounting judgements and estimates [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_7ae87607-b5e4-4315-8e97-16d42bac59b2_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherFinanceIncomeCost_9ea22c35-be20-408d-98e3-ee6a6f8f5bc5_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherFinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_OtherFinanceIncomeCost_label_en-US" xlink:label="lab_ifrs-full_OtherFinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other finance income (cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherFinanceIncomeCost" xlink:to="lab_ifrs-full_OtherFinanceIncomeCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInCanadianDollarMember_88884e9c-bf7b-4289-94aa-196f00da3eca_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInCanadianDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency purchases in Canadian dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInCanadianDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInCanadianDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Canadian Dollar [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInCanadianDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInCanadianDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Canadian Dollar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInCanadianDollarMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInCanadianDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInCanadianDollarMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInCanadianDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ManufacturingAndSupplyMember_868768c7-22d0-4b13-9374-1aa0690f7353_terseLabel_en-US" xlink:label="lab_sny_ManufacturingAndSupplyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing &amp; Supply</link:label>
    <link:label id="lab_sny_ManufacturingAndSupplyMember_label_en-US" xlink:label="lab_sny_ManufacturingAndSupplyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing And Supply [Member]</link:label>
    <link:label id="lab_sny_ManufacturingAndSupplyMember_documentation_en-US" xlink:label="lab_sny_ManufacturingAndSupplyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing and supply</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManufacturingAndSupplyMember" xlink:href="sny-20240630.xsd#sny_ManufacturingAndSupplyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ManufacturingAndSupplyMember" xlink:to="lab_sny_ManufacturingAndSupplyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_f662b812-92f4-4c5f-a9ef-48360a8451bb_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value (investments accounted for using the equity method, net of taxes)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Debt Instrument Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Debt Instrument Associates And Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_da70f633-535d-463f-919f-78be0668aa80_terseLabel_en-US" xlink:label="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments related to potential milestone payments for projects under collaboration agreements</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_label_en-US" xlink:label="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments Related To Milestone Payments For Projects Under Collaboration Agreement</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments Related To Milestone Payments For Projects Under Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" xlink:href="sny-20240630.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" xlink:to="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfTradeReceivablesTextBlock_fdbbd83a-0782-49f3-a188-9d2ebfa86b76_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfTradeReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_sny_DisclosureOfTradeReceivablesTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfTradeReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Trade Receivables [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfTradeReceivablesTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfTradeReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfTradeReceivablesTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfTradeReceivablesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfTradeReceivablesTextBlock" xlink:to="lab_sny_DisclosureOfTradeReceivablesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SeasonalSymptomsAndPainReliefMember_f0ac148a-1b13-4976-9324-4939e9cf231b_terseLabel_en-US" xlink:label="lab_sny_SeasonalSymptomsAndPainReliefMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Seasonal Symptoms And Pain Relief</link:label>
    <link:label id="lab_sny_SeasonalSymptomsAndPainReliefMember_label_en-US" xlink:label="lab_sny_SeasonalSymptomsAndPainReliefMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seasonal Symptoms And Pain Relief [Member]</link:label>
    <link:label id="lab_sny_SeasonalSymptomsAndPainReliefMember_documentation_en-US" xlink:label="lab_sny_SeasonalSymptomsAndPainReliefMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Seasonal Symptoms And Pain Relief</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SeasonalSymptomsAndPainReliefMember" xlink:href="sny-20240630.xsd#sny_SeasonalSymptomsAndPainReliefMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SeasonalSymptomsAndPainReliefMember" xlink:to="lab_sny_SeasonalSymptomsAndPainReliefMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_12374c57-51c9-4ac8-b3da-cfd7b622828c_terseLabel_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs of transformation programs</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_label_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Of Restructuring Activities, Transformation Programs Costs</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_documentation_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense Of Restructuring Activities, Transformation Programs Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:href="sny-20240630.xsd#sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:to="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HedgedItemsMember_71feaef0-d5ce-46b3-a0d9-97c70edb43f3_terseLabel_en-US" xlink:label="lab_ifrs-full_HedgedItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedged items [Member]</link:label>
    <link:label id="lab_ifrs-full_HedgedItemsMember_label_en-US" xlink:label="lab_ifrs-full_HedgedItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged items [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgedItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgedItemsMember" xlink:to="lab_ifrs-full_HedgedItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_fa211c7a-9918-4c78-b209-ae1271efcef1_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</link:label>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_label_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:to="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_67267ee2-157b-485d-9605-9690caad2308_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of services obtained from employees</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Share-Based Payment Plans Value Of Services Obtained From Employees</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of services obtained from employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:to="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountMember_3a29cc67-493a-45ec-b08c-31411827b8d8_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount [Member]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DebtInstrumentDomain_d59cd54c-eecc-40b5-8c60-1ad77916afd7_terseLabel_en-US" xlink:label="lab_sny_DebtInstrumentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Domain]</link:label>
    <link:label id="lab_sny_DebtInstrumentDomain_label_en-US" xlink:label="lab_sny_DebtInstrumentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Domain]</link:label>
    <link:label id="lab_sny_DebtInstrumentDomain_documentation_en-US" xlink:label="lab_sny_DebtInstrumentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain" xlink:href="sny-20240630.xsd#sny_DebtInstrumentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DebtInstrumentDomain" xlink:to="lab_sny_DebtInstrumentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_5816e140-965a-493f-8237-4ac0fa514e7b_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of profit/(loss) from investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of profit (loss) of associates accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Borrowings_3153c60d-91b4-4121-9b77-6efcb95f6f41_totalLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_ifrs-full_Borrowings_7a282f35-dc0a-4790-98b3-6fa05af9f416_verboseLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market value</link:label>
    <link:label id="lab_ifrs-full_Borrowings_label_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Borrowings" xlink:to="lab_ifrs-full_Borrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_0b862e2f-df97-4b9a-aa60-ae79f7c575d1_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax effects of share-based payments</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Share-Based Payment Plans Tax Effects Of The Exercise Of Stock Options</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax effects of the exercise of stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" xlink:to="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfClassActionLawsuits_a5572412-cfb2-4127-9485-b8bcc707ba30_terseLabel_en-US" xlink:label="lab_sny_NumberOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Of Class Action Lawsuits</link:label>
    <link:label id="lab_sny_NumberOfClassActionLawsuits_label_en-US" xlink:label="lab_sny_NumberOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Class Action Lawsuits</link:label>
    <link:label id="lab_sny_NumberOfClassActionLawsuits_documentation_en-US" xlink:label="lab_sny_NumberOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Class Action Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClassActionLawsuits" xlink:href="sny-20240630.xsd#sny_NumberOfClassActionLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfClassActionLawsuits" xlink:to="lab_sny_NumberOfClassActionLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExercisePriceRangeThreeMember_3759b094-cbc9-4064-b7ea-b538f2df9e2b_terseLabel_en-US" xlink:label="lab_sny_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">From &#8364;70.00 to &#8364;80.00 per share</link:label>
    <link:label id="lab_sny_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_sny_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_sny_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_sny_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeThreeMember" xlink:href="sny-20240630.xsd#sny_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExercisePriceRangeThreeMember" xlink:to="lab_sny_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_0b28cde1-b161-4465-8ba4-568768ef9834_terseLabel_en-US" xlink:label="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payments</link:label>
    <link:label id="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_label_en-US" xlink:label="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payments For Projects Under Collaboration Agreements</link:label>
    <link:label id="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_documentation_en-US" xlink:label="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payments For Projects Under Collaboration Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" xlink:href="sny-20240630.xsd#sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" xlink:to="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MeningitisTravelAndEndemicVaccinesMember_5197cc72-e037-4434-b584-76c4e63024dc_terseLabel_en-US" xlink:label="lab_sny_MeningitisTravelAndEndemicVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Meningitis Travel And Endemic Vaccines</link:label>
    <link:label id="lab_sny_MeningitisTravelAndEndemicVaccinesMember_label_en-US" xlink:label="lab_sny_MeningitisTravelAndEndemicVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Meningitis Travel And Endemic Vaccines [Member]</link:label>
    <link:label id="lab_sny_MeningitisTravelAndEndemicVaccinesMember_documentation_en-US" xlink:label="lab_sny_MeningitisTravelAndEndemicVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Meningitis Travel And Endemic Vaccines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MeningitisTravelAndEndemicVaccinesMember" xlink:href="sny-20240630.xsd#sny_MeningitisTravelAndEndemicVaccinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MeningitisTravelAndEndemicVaccinesMember" xlink:to="lab_sny_MeningitisTravelAndEndemicVaccinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_36e73cfa-06c8-4051-a6de-2958d6af993e_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of carrying amount to value on redemption [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of carrying amount to value on redemption.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:href="sny-20240630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:to="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable_b3eea8ae-7d1f-40e9-9473-248a9d2aad0c_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Off Balance Sheet Commitments [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable_label_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Off-Balance Sheet Commitments [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Off Balance Sheet Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:href="sny-20240630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:to="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_8bff8736-db06-4256-9f4e-da71f0cb07ef_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_6c4af394-2fb6-4ea9-8b8b-08faf1e9dc54_negatedTerseLabel_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_label_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Relating To Change In Fair Value Of Equity Instruments Excluding Equity Method</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_documentation_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Relating To Change In Fair Value Of Equity Instruments Excluding Equity Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:href="sny-20240630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:to="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ReportableGeographicalZonesMember_9d3446d1-7425-4905-851a-8236e6097ee0_terseLabel_en-US" xlink:label="lab_sny_ReportableGeographicalZonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_sny_ReportableGeographicalZonesMember_label_en-US" xlink:label="lab_sny_ReportableGeographicalZonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Geographical Zones [Member]</link:label>
    <link:label id="lab_sny_ReportableGeographicalZonesMember_documentation_en-US" xlink:label="lab_sny_ReportableGeographicalZonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable geographical zones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReportableGeographicalZonesMember" xlink:href="sny-20240630.xsd#sny_ReportableGeographicalZonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ReportableGeographicalZonesMember" xlink:to="lab_sny_ReportableGeographicalZonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_befae6bf-c3ae-4df9-9859-85001dc37de7_terseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of other intangible assets</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_664bde11-a179-46bd-b805-a176e6097ef4_terseLabel_en-US" xlink:label="lab_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bayer contingent consideration arising from acquisition of Genzyme</link:label>
    <link:label id="lab_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_label_en-US" xlink:label="lab_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bayer Contingent Purchase Consideration Arising From Acquisition Of Genzyme [Member]</link:label>
    <link:label id="lab_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_documentation_en-US" xlink:label="lab_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bayer contingent purchase consideration arising from the acquisition of Genzyme.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember" xlink:href="sny-20240630.xsd#sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember" xlink:to="lab_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_50fd97cb-e893-451f-9c16-861349bdac7e_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of assets [Axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_c0215fb1-b1b9-4f8a-bb89-d6cdfec0c97b_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from disposals of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:to="lab_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherIntangibleAssetsMember_ce023d67-8a3d-493b-8fbf-1e6ab79b8b15_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_ifrs-full_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_ifrs-full_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherIntangibleAssetsMember" xlink:to="lab_ifrs-full_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PotentialPaymentsRelatedToPercentageOfSales_0a7b3fcf-1df1-44a0-be82-1d398ba294d9_terseLabel_en-US" xlink:label="lab_sny_PotentialPaymentsRelatedToPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentiel payments related to percentage of sales of alemtuzumab</link:label>
    <link:label id="lab_sny_PotentialPaymentsRelatedToPercentageOfSales_label_en-US" xlink:label="lab_sny_PotentialPaymentsRelatedToPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Payments Related To Percentage Of Sales</link:label>
    <link:label id="lab_sny_PotentialPaymentsRelatedToPercentageOfSales_documentation_en-US" xlink:label="lab_sny_PotentialPaymentsRelatedToPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential payments related to percentage of sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PotentialPaymentsRelatedToPercentageOfSales" xlink:href="sny-20240630.xsd#sny_PotentialPaymentsRelatedToPercentageOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PotentialPaymentsRelatedToPercentageOfSales" xlink:to="lab_sny_PotentialPaymentsRelatedToPercentageOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_97d7320c-8b5f-4714-87bd-bdc5c090211e_terseLabel_en-US" xlink:label="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MSD contingent consideration (European Vaccines business)</link:label>
    <link:label id="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_label_en-US" xlink:label="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MSD Contingent Consideration European Vaccines Business [Member]</link:label>
    <link:label id="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_documentation_en-US" xlink:label="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MSD contingent consideration European vaccines business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" xlink:href="sny-20240630.xsd#sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" xlink:to="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarMember_436d0609-9616-4a05-873a-df9dc92ec16c_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency purchases in US dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In US Dollar [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency purchases in USD.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarMember" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInUSDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInUSDollarMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInUSDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DefinedBenefitPlansAxis_4b18edad-b48d-435a-8466-05e09bfbdb3d_terseLabel_en-US" xlink:label="lab_ifrs-full_DefinedBenefitPlansAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit plans [Axis]</link:label>
    <link:label id="lab_ifrs-full_DefinedBenefitPlansAxis_label_en-US" xlink:label="lab_ifrs-full_DefinedBenefitPlansAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plans [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis" xlink:to="lab_ifrs-full_DefinedBenefitPlansAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties_7739f976-42bf-431f-81d4-8b8a6ebcd1f9_terseLabel_en-US" xlink:label="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Recognised For Estimated Future Royalties</link:label>
    <link:label id="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties_label_en-US" xlink:label="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Recognised For Estimated Future Royalties</link:label>
    <link:label id="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties_documentation_en-US" xlink:label="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Recognised For Estimated Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:href="sny-20240630.xsd#sny_LiabilityRecognisedForEstimatedFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:to="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_VaccinesCoExclusiveLicensingAgreementMember_c68e837e-b40b-440e-95df-d19c171798a4_terseLabel_en-US" xlink:label="lab_sny_VaccinesCoExclusiveLicensingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vaccines Co-exclusive licensing agreement</link:label>
    <link:label id="lab_sny_VaccinesCoExclusiveLicensingAgreementMember_label_en-US" xlink:label="lab_sny_VaccinesCoExclusiveLicensingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vaccines Co-exclusive licensing agreement [Member]</link:label>
    <link:label id="lab_sny_VaccinesCoExclusiveLicensingAgreementMember_documentation_en-US" xlink:label="lab_sny_VaccinesCoExclusiveLicensingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vaccines Co-exclusive licensing agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesCoExclusiveLicensingAgreementMember" xlink:href="sny-20240630.xsd#sny_VaccinesCoExclusiveLicensingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_VaccinesCoExclusiveLicensingAgreementMember" xlink:to="lab_sny_VaccinesCoExclusiveLicensingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentAbstract_05bad9b6-8903-4723-8ddd-a8dd9a24cba7_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_c341fd63-52e7-4122-a669-0a4efdb68f0e_terseLabel_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income &amp; expense related to profit/loss sharing under the Monoclonal Antibody Alliance</link:label>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_label_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Profit Or Loss From Commercialization Of Monoclonal Antibodies [Member]</link:label>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_documentation_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of profit or loss from commercialization of monoclonal antibodies member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:href="sny-20240630.xsd#sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:to="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_1f84f855-8164-4e91-a22c-11b1947568fe_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_9c534277-ab13-40e2-92ac-77b1fe674b86_verboseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_dfad476d-1598-4cbf-b12e-363c2655aa79_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount of intangible assets</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare_29a015a3-7608-4c65-8aad-867fb4a6e5d1_terseLabel_en-US" xlink:label="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend paid per share (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare_label_en-US" xlink:label="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends paid, ordinary shares per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidOrdinarySharesPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:to="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_3221f010-a69a-40bb-8583-6057973c50b9_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets other than goodwill</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember_cfbe838d-acaa-42a1-95fb-85eca9b4c154_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for business combinations [Member]</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for business combinations [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock_20e4783b-3004-4d1c-a6a4-02ad4ad8dfef_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Reconciliation of Carrying Amount to Value on Redemption</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of carrying amount to value on redemption [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:to="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract_6303c36d-3b61-4ba9-a80a-7b04b1dea528_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of comprehensive income [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MarketConditionAxis_fcfcb7ed-9b12-46f0-b884-e8fe61294535_terseLabel_en-US" xlink:label="lab_sny_MarketConditionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market Condition [Axis]</link:label>
    <link:label id="lab_sny_MarketConditionAxis_label_en-US" xlink:label="lab_sny_MarketConditionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Condition [Axis]</link:label>
    <link:label id="lab_sny_MarketConditionAxis_documentation_en-US" xlink:label="lab_sny_MarketConditionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market Condition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionAxis" xlink:href="sny-20240630.xsd#sny_MarketConditionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MarketConditionAxis" xlink:to="lab_sny_MarketConditionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OverdueReceivablesGrossValue_a07b5742-9b6a-4b42-a63a-1aeb0cfc5e91_verboseLabel_en-US" xlink:label="lab_sny_OverdueReceivablesGrossValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overdue receivables gross value</link:label>
    <link:label id="lab_sny_OverdueReceivablesGrossValue_label_en-US" xlink:label="lab_sny_OverdueReceivablesGrossValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Overdue Receivables Gross Value</link:label>
    <link:label id="lab_sny_OverdueReceivablesGrossValue_documentation_en-US" xlink:label="lab_sny_OverdueReceivablesGrossValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Overdue receivables gross value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OverdueReceivablesGrossValue" xlink:href="sny-20240630.xsd#sny_OverdueReceivablesGrossValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OverdueReceivablesGrossValue" xlink:to="lab_sny_OverdueReceivablesGrossValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bf6f21e0-d81e-4f01-8366-d822abe7e96d_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [Axis]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_3285dadb-4430-43ca-b3a6-a8466dc6e5eb_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Gains and Losses, and Litigation</link:label>
    <link:label id="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Gains And Losses, And Litigation [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure of other gains and losses, and litigation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:href="sny-20240630.xsd#sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:to="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorCustomersAxis_e27835a4-8c6f-497f-ae1a-06051464c885_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major customers [Axis]</link:label>
    <link:label id="lab_ifrs-full_MajorCustomersAxis_label_en-US" xlink:label="lab_ifrs-full_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major customers [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorCustomersAxis" xlink:to="lab_ifrs-full_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_aebfc61d-4315-4703-9504-e30854c54966_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Events Subsequent to June 30, 2023</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of events after reporting period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForeignCurrencyTranslationMember_70b64a20-6dbf-44af-b62f-faf0f4d16d58_terseLabel_en-US" xlink:label="lab_sny_ForeignCurrencyTranslationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_sny_ForeignCurrencyTranslationMember_label_en-US" xlink:label="lab_sny_ForeignCurrencyTranslationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation [Member]</link:label>
    <link:label id="lab_sny_ForeignCurrencyTranslationMember_documentation_en-US" xlink:label="lab_sny_ForeignCurrencyTranslationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForeignCurrencyTranslationMember" xlink:href="sny-20240630.xsd#sny_ForeignCurrencyTranslationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForeignCurrencyTranslationMember" xlink:to="lab_sny_ForeignCurrencyTranslationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_d9583724-9a18-4f15-8b5c-4c2bdc1b9da5_verboseLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average number of shares after dilution (in shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_ee245b2e-110a-4c58-b5d0-1df15ddb711e_totalLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Average number of shares used to compute diluted earnings per share (in shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>sny-20240630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a012fc2d-d3ff-4c6a-950e-09cafe0bb60f,g:e711d38b-47f1-4329-bc58-181a62b743af-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sanofi.com/role/Coverpage" xlink:type="simple" xlink:href="sny-20240630.xsd#Coverpage"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Coverpage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_776cf2a5-4e7a-4995-9224-1c3f10e0ef21" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_50dc30ef-cef7-49c8-9c7d-f2c5577b53cb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_776cf2a5-4e7a-4995-9224-1c3f10e0ef21" xlink:to="loc_dei_EntitiesTable_50dc30ef-cef7-49c8-9c7d-f2c5577b53cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_5c3a9435-e83d-4dd2-b5ab-f1e1fa62b2f1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_50dc30ef-cef7-49c8-9c7d-f2c5577b53cb" xlink:to="loc_dei_EntityInformationLineItems_5c3a9435-e83d-4dd2-b5ab-f1e1fa62b2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1d225ceb-7426-4283-b9c9-3beb2dfe0b2f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5c3a9435-e83d-4dd2-b5ab-f1e1fa62b2f1" xlink:to="loc_dei_DocumentType_1d225ceb-7426-4283-b9c9-3beb2dfe0b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2894031c-d27e-4323-9415-79736f5eedae" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5c3a9435-e83d-4dd2-b5ab-f1e1fa62b2f1" xlink:to="loc_dei_EntityRegistrantName_2894031c-d27e-4323-9415-79736f5eedae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_65432f32-33ec-4aef-a903-d4e65450624c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5c3a9435-e83d-4dd2-b5ab-f1e1fa62b2f1" xlink:to="loc_dei_AmendmentFlag_65432f32-33ec-4aef-a903-d4e65450624c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4114c560-df52-4dcb-a2b7-9f4a9ad1e633" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5c3a9435-e83d-4dd2-b5ab-f1e1fa62b2f1" xlink:to="loc_dei_EntityCentralIndexKey_4114c560-df52-4dcb-a2b7-9f4a9ad1e633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_cdb5e838-f198-4f3f-b2c5-60ac4f0a0e20" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5c3a9435-e83d-4dd2-b5ab-f1e1fa62b2f1" xlink:to="loc_dei_CurrentFiscalYearEndDate_cdb5e838-f198-4f3f-b2c5-60ac4f0a0e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_553ae06c-45bb-47c4-9976-faae9d210575" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5c3a9435-e83d-4dd2-b5ab-f1e1fa62b2f1" xlink:to="loc_dei_DocumentPeriodEndDate_553ae06c-45bb-47c4-9976-faae9d210575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_489d0450-25a1-447e-919d-6ed0c665ea7c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5c3a9435-e83d-4dd2-b5ab-f1e1fa62b2f1" xlink:to="loc_dei_DocumentFiscalYearFocus_489d0450-25a1-447e-919d-6ed0c665ea7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_4165623a-f47a-48bb-b64c-aa0d305b1de1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_5c3a9435-e83d-4dd2-b5ab-f1e1fa62b2f1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_4165623a-f47a-48bb-b64c-aa0d305b1de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_4bbb2b1b-a0e1-463e-b6d5-9c3a88fc0e90" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract_a0b1fb4f-6fa7-4c35-b332-18f4be1e517c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_4bbb2b1b-a0e1-463e-b6d5-9c3a88fc0e90" xlink:to="loc_ifrs-full_AssetsAbstract_a0b1fb4f-6fa7-4c35-b332-18f4be1e517c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_24d452ca-9426-4537-aac1-b864b6ca663d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_a0b1fb4f-6fa7-4c35-b332-18f4be1e517c" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_24d452ca-9426-4537-aac1-b864b6ca663d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_3f868e9f-2502-4b12-8994-d8481cc1eef8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_a0b1fb4f-6fa7-4c35-b332-18f4be1e517c" xlink:to="loc_ifrs-full_RightofuseAssets_3f868e9f-2502-4b12-8994-d8481cc1eef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_9e7d2f12-a66b-45dc-8029-0c997a179500" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_a0b1fb4f-6fa7-4c35-b332-18f4be1e517c" xlink:to="loc_ifrs-full_Goodwill_9e7d2f12-a66b-45dc-8029-0c997a179500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_ea2d1296-7a38-4c20-84f5-3a5ea0d312ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_a0b1fb4f-6fa7-4c35-b332-18f4be1e517c" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_ea2d1296-7a38-4c20-84f5-3a5ea0d312ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_36b3dcd1-0ef4-41bc-b644-4dcaaed6824e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_a0b1fb4f-6fa7-4c35-b332-18f4be1e517c" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_36b3dcd1-0ef4-41bc-b644-4dcaaed6824e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_d7c97304-6ff0-4889-8d26-e5432d755ebc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_a0b1fb4f-6fa7-4c35-b332-18f4be1e517c" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_d7c97304-6ff0-4889-8d26-e5432d755ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsNoncurrent_11f7d65c-4bf7-45dd-9f03-90f756899a6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_a0b1fb4f-6fa7-4c35-b332-18f4be1e517c" xlink:to="loc_ifrs-full_CurrentTaxAssetsNoncurrent_11f7d65c-4bf7-45dd-9f03-90f756899a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_a1dd4a27-00e6-42c5-ac86-2851ad96f1cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_a0b1fb4f-6fa7-4c35-b332-18f4be1e517c" xlink:to="loc_ifrs-full_DeferredTaxAssets_a1dd4a27-00e6-42c5-ac86-2851ad96f1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_5a86e47d-0d41-4b01-bb38-44dd9743712c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_a0b1fb4f-6fa7-4c35-b332-18f4be1e517c" xlink:to="loc_ifrs-full_NoncurrentAssets_5a86e47d-0d41-4b01-bb38-44dd9743712c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_3138010b-c712-4291-9e1b-5c6cac9583aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_a0b1fb4f-6fa7-4c35-b332-18f4be1e517c" xlink:to="loc_ifrs-full_Inventories_3138010b-c712-4291-9e1b-5c6cac9583aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_3f81a41e-2749-4093-85a4-7436909d8592" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_a0b1fb4f-6fa7-4c35-b332-18f4be1e517c" xlink:to="loc_ifrs-full_CurrentTradeReceivables_3f81a41e-2749-4093-85a4-7436909d8592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_f5d1b440-a21c-47ba-bd9e-32ae75768ffe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_a0b1fb4f-6fa7-4c35-b332-18f4be1e517c" xlink:to="loc_ifrs-full_OtherCurrentAssets_f5d1b440-a21c-47ba-bd9e-32ae75768ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsCurrent_e4908dc0-2901-4537-ac1c-c7ddc7d4d43a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_a0b1fb4f-6fa7-4c35-b332-18f4be1e517c" xlink:to="loc_ifrs-full_CurrentTaxAssetsCurrent_e4908dc0-2901-4537-ac1c-c7ddc7d4d43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_f087d43c-3944-4d60-9c0d-dc57e06eb528" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_a0b1fb4f-6fa7-4c35-b332-18f4be1e517c" xlink:to="loc_ifrs-full_CashAndCashEquivalents_f087d43c-3944-4d60-9c0d-dc57e06eb528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_5f9415fb-7bb6-409b-b257-ac2c84217ef9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_a0b1fb4f-6fa7-4c35-b332-18f4be1e517c" xlink:to="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_5f9415fb-7bb6-409b-b257-ac2c84217ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_10a680a8-ae02-4351-85c6-47c318c4bebc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_a0b1fb4f-6fa7-4c35-b332-18f4be1e517c" xlink:to="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_10a680a8-ae02-4351-85c6-47c318c4bebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_59b47995-4f37-464c-b3d6-9a5659ea5655" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_a0b1fb4f-6fa7-4c35-b332-18f4be1e517c" xlink:to="loc_ifrs-full_Assets_59b47995-4f37-464c-b3d6-9a5659ea5655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_4bbb2b1b-a0e1-463e-b6d5-9c3a88fc0e90" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent_0163b131-30c5-4f88-b471-60ec2aaf1b22" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParent_0163b131-30c5-4f88-b471-60ec2aaf1b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterests_6aba71af-027f-4c87-81a9-6df16e2d9b6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:to="loc_ifrs-full_NoncontrollingInterests_6aba71af-027f-4c87-81a9-6df16e2d9b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_a9b05e0b-261f-46f0-bdd7-e2a0c8d7251c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:to="loc_ifrs-full_Equity_a9b05e0b-261f-46f0-bdd7-e2a0c8d7251c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_848af8cb-bec1-4436-951a-5e0b7d251c8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:to="loc_ifrs-full_LongtermBorrowings_848af8cb-bec1-4436-951a-5e0b7d251c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_f65a7b4c-0867-4d50-b458-78e00e743dc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_f65a7b4c-0867-4d50-b458-78e00e743dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_ede1dbd6-64c6-4fff-922f-0efe032174ce" xlink:href="sny-20240630.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_ede1dbd6-64c6-4fff-922f-0efe032174ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_442e69ee-cdb5-460a-89fc-c65e1e0113be" xlink:href="sny-20240630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_442e69ee-cdb5-460a-89fc-c65e1e0113be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_bfd4e477-bd00-46f9-89ea-743084d7897a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_bfd4e477-bd00-46f9-89ea-743084d7897a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_5d50a191-0c27-48e9-9150-9eea74cda549" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_5d50a191-0c27-48e9-9150-9eea74cda549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_08af9fcf-eb62-4e12-9249-de9e6d9f90ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:to="loc_ifrs-full_NoncurrentLiabilities_08af9fcf-eb62-4e12-9249-de9e6d9f90ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_2de4622e-39c0-4ec4-b4c0-019f376576e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_2de4622e-39c0-4ec4-b4c0-019f376576e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_bf444f87-969b-4477-93ef-a68352d3f8a0" xlink:href="sny-20240630.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:to="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_bf444f87-969b-4477-93ef-a68352d3f8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_8056f6ad-e3a5-46b4-a42c-c5f101ef04f2" xlink:href="sny-20240630.xsd#sny_CurrentProvisionsAndOtherCurrentLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:to="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_8056f6ad-e3a5-46b4-a42c-c5f101ef04f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_6c058239-4f4f-487c-8553-416285e3b6fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_6c058239-4f4f-487c-8553-416285e3b6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_1ee38a1b-956d-4bb1-aee2-88f5bb898edf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_1ee38a1b-956d-4bb1-aee2-88f5bb898edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_49e8f65d-642e-4467-b52b-3885d2657ac8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_49e8f65d-642e-4467-b52b-3885d2657ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_1ba59367-448e-424a-a30c-2bc15dd6b7f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:to="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_1ba59367-448e-424a-a30c-2bc15dd6b7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_dec0a779-0aec-4fb7-9743-31b3e914db11" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:to="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_dec0a779-0aec-4fb7-9743-31b3e914db11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_5c93c01c-b97c-4e85-826c-9bd2dcbe2fee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_0c87e2b7-d0c7-49d1-8cc9-ad451e27edd7" xlink:to="loc_ifrs-full_EquityAndLiabilities_5c93c01c-b97c-4e85-826c-9bd2dcbe2fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedIncomeStatements" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedIncomeStatements"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedIncomeStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_172faf55-c2b3-4933-ab24-f2acd89439d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_172faf55-c2b3-4933-ab24-f2acd89439d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_83026807-f12e-479f-bf51-9bb075c8ae61" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_OtherRevenue_83026807-f12e-479f-bf51-9bb075c8ae61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_dcb4388d-05e5-48fe-a3e6-95bc28db4641" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_CostOfSales_dcb4388d-05e5-48fe-a3e6-95bc28db4641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossProfit_3cdf5928-b764-49d0-b241-16667bbb0ad8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_GrossProfit_3cdf5928-b764-49d0-b241-16667bbb0ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_610f295c-4cf6-4b9c-8a07-9df92091d5d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_610f295c-4cf6-4b9c-8a07-9df92091d5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_57583375-04e0-4788-9dee-f17c5fe9d764" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_57583375-04e0-4788-9dee-f17c5fe9d764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_e5741b45-1662-4cd3-b577-275ceae3f828" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_e5741b45-1662-4cd3-b577-275ceae3f828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_dd593268-9abf-4e71-b6a4-b5f20b51956d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_dd593268-9abf-4e71-b6a4-b5f20b51956d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_34cbd720-c89c-4892-945c-a4a1ccd5da29" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_34cbd720-c89c-4892-945c-a4a1ccd5da29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_b20cc6a8-e2a1-4aa0-888a-cda8843cbb5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_b20cc6a8-e2a1-4aa0-888a-cda8843cbb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_31888931-fef6-4f87-b0c2-99120922b157" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_31888931-fef6-4f87-b0c2-99120922b157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_7b36c1d3-03ae-46c1-b1a1-64267fa6988e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_7b36c1d3-03ae-46c1-b1a1-64267fa6988e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_12dae5ef-f566-4a64-b1a6-8b18cbf64324" xlink:href="sny-20240630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_sny_OtherGainsLossesAndLitigation_12dae5ef-f566-4a64-b1a6-8b18cbf64324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_7f088829-8606-4079-84f6-bb9df6b69125" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_7f088829-8606-4079-84f6-bb9df6b69125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_2b283e1c-9162-4fc5-b8de-43d7e64f78d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_FinanceCosts_2b283e1c-9162-4fc5-b8de-43d7e64f78d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_3521e69a-2102-419d-92b9-e4868da55a05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_FinanceIncome_3521e69a-2102-419d-92b9-e4868da55a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_5feadd45-7310-4de6-bba9-0028c00426f7" xlink:href="sny-20240630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_5feadd45-7310-4de6-bba9-0028c00426f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_800ab3c5-0a5b-4e11-8a48-58723d3fd37d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_800ab3c5-0a5b-4e11-8a48-58723d3fd37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_ba6faeda-bc2c-4dc9-986d-a31ce175211a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_ba6faeda-bc2c-4dc9-986d-a31ce175211a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_4703eba7-b3b9-442a-89d3-9c10234fd85c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_ProfitLoss_4703eba7-b3b9-442a-89d3-9c10234fd85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_36d4fd1b-9259-49de-8e11-6140d39cc1e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_36d4fd1b-9259-49de-8e11-6140d39cc1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_570356b0-7aa4-492b-a373-cf9871c4a2f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_570356b0-7aa4-492b-a373-cf9871c4a2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_327cb971-bc2b-44ab-b816-c463537ec822" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_WeightedAverageShares_327cb971-bc2b-44ab-b816-c463537ec822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_14cf7255-17f1-4504-8d13-f9638619c53d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_14cf7255-17f1-4504-8d13-f9638619c53d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent_a1f6db32-c40c-46c6-ac7e-7a4b9a66eac0" xlink:href="sny-20240630.xsd#sny_BasicEarningsLossPerShareAttributableToOwnersOfParent"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent_a1f6db32-c40c-46c6-ac7e-7a4b9a66eac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent_86ab477e-b605-4710-b22b-28ef3606f8c9" xlink:href="sny-20240630.xsd#sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_7f9289a9-8602-4385-82a3-4189739f4db5" xlink:to="loc_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent_86ab477e-b605-4710-b22b-28ef3606f8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_f8afa56f-9e34-4a38-942c-db73b3fd833d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_5f9a49f6-e8d7-4deb-ad93-053ab5ed3a02" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_f8afa56f-9e34-4a38-942c-db73b3fd833d" xlink:to="loc_ifrs-full_ProfitLoss_5f9a49f6-e8d7-4deb-ad93-053ab5ed3a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_3caad9ac-5364-4729-94ea-9e30ec294354" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_f8afa56f-9e34-4a38-942c-db73b3fd833d" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_3caad9ac-5364-4729-94ea-9e30ec294354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_5ac8ad74-5a99-483c-9c56-fa8cea83904b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_f8afa56f-9e34-4a38-942c-db73b3fd833d" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_5ac8ad74-5a99-483c-9c56-fa8cea83904b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_231b3a19-102b-41ea-9130-a2e42a153c6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_f8afa56f-9e34-4a38-942c-db73b3fd833d" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_231b3a19-102b-41ea-9130-a2e42a153c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_ebb4de24-ab06-40c8-b7d1-edad2826ef6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_231b3a19-102b-41ea-9130-a2e42a153c6a" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_ebb4de24-ab06-40c8-b7d1-edad2826ef6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_a812c2dc-e5fa-4ec3-b42b-641c8b878782" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_231b3a19-102b-41ea-9130-a2e42a153c6a" xlink:to="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_a812c2dc-e5fa-4ec3-b42b-641c8b878782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_6aa82a05-6a2f-4650-9466-d16cdabe377c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_231b3a19-102b-41ea-9130-a2e42a153c6a" xlink:to="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_6aa82a05-6a2f-4650-9466-d16cdabe377c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_1b7ad51f-39d5-4746-957a-0bb2c4d8d898" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_231b3a19-102b-41ea-9130-a2e42a153c6a" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_1b7ad51f-39d5-4746-957a-0bb2c4d8d898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_36cd50d0-7813-42b2-b8cb-36c529c83640" xlink:href="sny-20240630.xsd#sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_231b3a19-102b-41ea-9130-a2e42a153c6a" xlink:to="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_36cd50d0-7813-42b2-b8cb-36c529c83640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_2150d610-bfea-4121-b0d6-612000eb2fe2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_231b3a19-102b-41ea-9130-a2e42a153c6a" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_2150d610-bfea-4121-b0d6-612000eb2fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_3da3871a-5952-49af-b461-324b88cd44b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_231b3a19-102b-41ea-9130-a2e42a153c6a" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_3da3871a-5952-49af-b461-324b88cd44b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_77e6e35b-5a98-4f4c-aa18-5f3640fb25d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_231b3a19-102b-41ea-9130-a2e42a153c6a" xlink:to="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_77e6e35b-5a98-4f4c-aa18-5f3640fb25d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_b4e17801-5853-451e-9b43-ee58609805b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_231b3a19-102b-41ea-9130-a2e42a153c6a" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_b4e17801-5853-451e-9b43-ee58609805b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_2be3cbb1-d189-4663-80d4-29ed277d81b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_231b3a19-102b-41ea-9130-a2e42a153c6a" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_2be3cbb1-d189-4663-80d4-29ed277d81b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_3cda7a9d-be24-4934-8248-300df6276521" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_f8afa56f-9e34-4a38-942c-db73b3fd833d" xlink:to="loc_ifrs-full_ComprehensiveIncome_3cda7a9d-be24-4934-8248-300df6276521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_0b116f32-f608-42bf-a1b6-4cf57e64301e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_f8afa56f-9e34-4a38-942c-db73b3fd833d" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_0b116f32-f608-42bf-a1b6-4cf57e64301e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_1d66866c-0591-44da-92b7-b79cf203e81d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_f8afa56f-9e34-4a38-942c-db73b3fd833d" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_1d66866c-0591-44da-92b7-b79cf203e81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedStatementsofChangesinEquity"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_5e99e983-7c5a-4ca5-b533-449e4a5384d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_af0b644d-96db-48f4-a638-46b903228075" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_5e99e983-7c5a-4ca5-b533-449e4a5384d8" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_af0b644d-96db-48f4-a638-46b903228075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_9af334d4-ad78-4200-b33f-1c78ef8e5469" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_af0b644d-96db-48f4-a638-46b903228075" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_9af334d4-ad78-4200-b33f-1c78ef8e5469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_0a9732fc-2301-4cdc-a6aa-4d4d31e97701" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_9af334d4-ad78-4200-b33f-1c78ef8e5469" xlink:to="loc_ifrs-full_EquityMember_0a9732fc-2301-4cdc-a6aa-4d4d31e97701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_3c5334fb-4ed7-4f70-9adc-eefa986f1e5f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_0a9732fc-2301-4cdc-a6aa-4d4d31e97701" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_3c5334fb-4ed7-4f70-9adc-eefa986f1e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_a8ecd3de-1911-470e-8edc-0d110e64c4de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_3c5334fb-4ed7-4f70-9adc-eefa986f1e5f" xlink:to="loc_ifrs-full_IssuedCapitalMember_a8ecd3de-1911-470e-8edc-0d110e64c4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember_57447157-d408-4d3f-8607-40f6108e1620" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_3c5334fb-4ed7-4f70-9adc-eefa986f1e5f" xlink:to="loc_ifrs-full_AdditionalPaidinCapitalMember_57447157-d408-4d3f-8607-40f6108e1620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_c05f48a4-2acb-447f-b674-eec30af16183" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasurySharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_3c5334fb-4ed7-4f70-9adc-eefa986f1e5f" xlink:to="loc_ifrs-full_TreasurySharesMember_c05f48a4-2acb-447f-b674-eec30af16183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_20fd9508-4d34-4073-b5c9-0f48df38037c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_3c5334fb-4ed7-4f70-9adc-eefa986f1e5f" xlink:to="loc_ifrs-full_RetainedEarningsMember_20fd9508-4d34-4073-b5c9-0f48df38037c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_e4394af8-7c74-4165-b663-afcd5a7895da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_3c5334fb-4ed7-4f70-9adc-eefa986f1e5f" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_e4394af8-7c74-4165-b663-afcd5a7895da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_a4256a0b-b972-4e73-ad75-56c7db8bd125" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_3c5334fb-4ed7-4f70-9adc-eefa986f1e5f" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_a4256a0b-b972-4e73-ad75-56c7db8bd125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_5f0bff62-2a55-4e4d-8026-9541de1e7f0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_0a9732fc-2301-4cdc-a6aa-4d4d31e97701" xlink:to="loc_ifrs-full_NoncontrollingInterestsMember_5f0bff62-2a55-4e4d-8026-9541de1e7f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_af0b644d-96db-48f4-a638-46b903228075" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_d816a96e-4617-4efd-986c-725937539b04" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_ifrs-full_Equity_d816a96e-4617-4efd-986c-725937539b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_6243117b-376f-4ac5-8f87-48ee47495cfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_6243117b-376f-4ac5-8f87-48ee47495cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_09639a6a-2d3f-42de-975f-81969ced8427" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_ifrs-full_ProfitLoss_09639a6a-2d3f-42de-975f-81969ced8427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_d854fae9-8192-4956-9534-7a0d9763c533" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_ifrs-full_ComprehensiveIncome_d854fae9-8192-4956-9534-7a0d9763c533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_a2fa56fa-bce4-4f33-99c9-64dad4fcaa4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_a2fa56fa-bce4-4f33-99c9-64dad4fcaa4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_fb727bf7-193e-449f-bea7-37619db52934" xlink:href="sny-20240630.xsd#sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_fb727bf7-193e-449f-bea7-37619db52934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_7f1a001b-b7e2-4859-9969-e56b521fe618" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_7f1a001b-b7e2-4859-9969-e56b521fe618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfTreasuryShares_225d2b42-76f5-4546-86e6-ce2b02b73460" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfTreasuryShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_ifrs-full_PurchaseOfTreasuryShares_225d2b42-76f5-4546-86e6-ce2b02b73460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReductionOfIssuedCapital_760c10e7-1e23-4fef-9914-58d263f78b2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReductionOfIssuedCapital"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_ifrs-full_ReductionOfIssuedCapital_760c10e7-1e23-4fef-9914-58d263f78b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareBasedPaymentPlansAbstract_4b400844-bb15-4d94-b403-745dc781b68c" xlink:href="sny-20240630.xsd#sny_ShareBasedPaymentPlansAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_sny_ShareBasedPaymentPlansAbstract_4b400844-bb15-4d94-b403-745dc781b68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_cbf3ab2f-602c-4950-8cfe-7d00143e6dd2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_4b400844-bb15-4d94-b403-745dc781b68c" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_cbf3ab2f-602c-4950-8cfe-7d00143e6dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_1f57557e-f10f-448f-a4c3-f1237704eba2" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_4b400844-bb15-4d94-b403-745dc781b68c" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_1f57557e-f10f-448f-a4c3-f1237704eba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_bffef20d-ec97-47bc-b236-0ca02ac6fccd" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_4b400844-bb15-4d94-b403-745dc781b68c" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_bffef20d-ec97-47bc-b236-0ca02ac6fccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_2a75560f-45b5-4c57-a4b6-13a57fd478c6" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_4b400844-bb15-4d94-b403-745dc781b68c" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_2a75560f-45b5-4c57-a4b6-13a57fd478c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_5153bf12-8fde-4ef9-b981-5803df451c7c" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_4b400844-bb15-4d94-b403-745dc781b68c" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_5153bf12-8fde-4ef9-b981-5803df451c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_1224cde5-a3a5-4f55-8421-0e38db24d408" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_1224cde5-a3a5-4f55-8421-0e38db24d408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_73f53d52-d69a-46c8-b78f-223aa520f39f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_73f53d52-d69a-46c8-b78f-223aa520f39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_0d53699c-1703-45f1-b844-133253d43499" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_c7e4bfb7-210d-431e-891d-a28aaa2bd84d" xlink:to="loc_ifrs-full_Equity_0d53699c-1703-45f1-b844-133253d43499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedStatementsofChangesinEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_30b2f3b8-b78f-41a2-aead-3f3d230b3e67" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_c456faf8-b1a2-41fc-885a-4917c5238cb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_30b2f3b8-b78f-41a2-aead-3f3d230b3e67" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_c456faf8-b1a2-41fc-885a-4917c5238cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2dc0df0f-3db2-4d37-bf70-3bda5d97084d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_c456faf8-b1a2-41fc-885a-4917c5238cb6" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2dc0df0f-3db2-4d37-bf70-3bda5d97084d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_c7d600e0-f202-4870-8042-5d53e1400322" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2dc0df0f-3db2-4d37-bf70-3bda5d97084d" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_c7d600e0-f202-4870-8042-5d53e1400322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_46594038-ada7-4df9-8e18-730572912ae8" xlink:href="sny-20240630.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_c7d600e0-f202-4870-8042-5d53e1400322" xlink:to="loc_sny_EuroapiMember_46594038-ada7-4df9-8e18-730572912ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_3a1f912e-85a1-42f5-966b-085e5107063d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_c456faf8-b1a2-41fc-885a-4917c5238cb6" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_3a1f912e-85a1-42f5-966b-085e5107063d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_b46e6147-8220-4064-8918-c281064d7de5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_3a1f912e-85a1-42f5-966b-085e5107063d" xlink:to="loc_ifrs-full_EquityMember_b46e6147-8220-4064-8918-c281064d7de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember_0e28b611-42b1-4bd0-869f-4a255224e2a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_b46e6147-8220-4064-8918-c281064d7de5" xlink:to="loc_ifrs-full_AdditionalPaidinCapitalMember_0e28b611-42b1-4bd0-869f-4a255224e2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_dbe71ac8-ff17-4053-ae4b-dd82f7e67786" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_b46e6147-8220-4064-8918-c281064d7de5" xlink:to="loc_ifrs-full_IssuedCapitalMember_dbe71ac8-ff17-4053-ae4b-dd82f7e67786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_4dd61151-f7dd-44aa-93f4-6128fecf6916" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_c456faf8-b1a2-41fc-885a-4917c5238cb6" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_4dd61151-f7dd-44aa-93f4-6128fecf6916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_3c1c8f0b-d5d0-422d-93e2-730d7e5370a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidOrdinarySharesPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_4dd61151-f7dd-44aa-93f4-6128fecf6916" xlink:to="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_3c1c8f0b-d5d0-422d-93e2-730d7e5370a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_75578bf6-74ae-4689-b969-d6b5ae586499" xlink:href="sny-20240630.xsd#sny_ExceptionalSupplementaryDividendPercentageOfShareCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_4dd61151-f7dd-44aa-93f4-6128fecf6916" xlink:to="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_75578bf6-74ae-4689-b969-d6b5ae586499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_cfd53864-cbdd-4a17-8131-3411ca029cb8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_4dd61151-f7dd-44aa-93f4-6128fecf6916" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_cfd53864-cbdd-4a17-8131-3411ca029cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_b7c96dbe-5cd3-4387-a495-806d2f7866c5" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_30b2f3b8-b78f-41a2-aead-3f3d230b3e67" xlink:to="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_b7c96dbe-5cd3-4387-a495-806d2f7866c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_feb28453-5901-4452-9505-3b68ecb00933" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_30b2f3b8-b78f-41a2-aead-3f3d230b3e67" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_feb28453-5901-4452-9505-3b68ecb00933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_f1039bc2-4220-4e53-b0b7-78cb87d95543" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_30b2f3b8-b78f-41a2-aead-3f3d230b3e67" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_f1039bc2-4220-4e53-b0b7-78cb87d95543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_7bf17716-4e85-4c5e-8366-54145fca25bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_44bf26b7-3b84-4db1-a107-d615e8d69d2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_7bf17716-4e85-4c5e-8366-54145fca25bc" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_44bf26b7-3b84-4db1-a107-d615e8d69d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_1e909ec1-da47-4529-938c-92910c2a0a4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_44bf26b7-3b84-4db1-a107-d615e8d69d2d" xlink:to="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_1e909ec1-da47-4529-938c-92910c2a0a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_bce78558-e73e-46fd-ab3b-a0d13519e177" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_44bf26b7-3b84-4db1-a107-d615e8d69d2d" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_bce78558-e73e-46fd-ab3b-a0d13519e177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_48ce4e35-d84f-4534-87d7-67a37f0d9c33" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_44bf26b7-3b84-4db1-a107-d615e8d69d2d" xlink:to="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_48ce4e35-d84f-4534-87d7-67a37f0d9c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_3e40f5f9-c7c1-4fa9-bdfd-df33ea8ff0f3" xlink:href="sny-20240630.xsd#sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_44bf26b7-3b84-4db1-a107-d615e8d69d2d" xlink:to="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_3e40f5f9-c7c1-4fa9-bdfd-df33ea8ff0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_e2405b52-8b3d-408c-bb69-9f549ef20a57" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_44bf26b7-3b84-4db1-a107-d615e8d69d2d" xlink:to="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_e2405b52-8b3d-408c-bb69-9f549ef20a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDeferredTaxExpense_ccc9251a-f7bc-4b37-8762-fce8e2c3010a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_44bf26b7-3b84-4db1-a107-d615e8d69d2d" xlink:to="loc_ifrs-full_AdjustmentsForDeferredTaxExpense_ccc9251a-f7bc-4b37-8762-fce8e2c3010a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_1f3fe99a-11d2-4c13-b050-ee0398c44a75" xlink:href="sny-20240630.xsd#sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_44bf26b7-3b84-4db1-a107-d615e8d69d2d" xlink:to="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_1f3fe99a-11d2-4c13-b050-ee0398c44a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_0a42ce7a-9466-4ef5-bb32-52466d5cca4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_44bf26b7-3b84-4db1-a107-d615e8d69d2d" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_0a42ce7a-9466-4ef5-bb32-52466d5cca4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_300b39e2-d510-4de9-994f-749ff3442507" xlink:href="sny-20240630.xsd#sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_44bf26b7-3b84-4db1-a107-d615e8d69d2d" xlink:to="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_300b39e2-d510-4de9-994f-749ff3442507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_84717a12-b630-4647-9ea1-d61e92b62cc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_44bf26b7-3b84-4db1-a107-d615e8d69d2d" xlink:to="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_84717a12-b630-4647-9ea1-d61e92b62cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_aa1ebca9-7cb1-4959-97dc-29c0553126c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_44bf26b7-3b84-4db1-a107-d615e8d69d2d" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_aa1ebca9-7cb1-4959-97dc-29c0553126c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_05817da0-dd19-4f5f-962f-8882d5c26b51" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_44bf26b7-3b84-4db1-a107-d615e8d69d2d" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_05817da0-dd19-4f5f-962f-8882d5c26b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_04a600ef-86b1-4528-ad45-8ab8c017b25d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_05817da0-dd19-4f5f-962f-8882d5c26b51" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_04a600ef-86b1-4528-ad45-8ab8c017b25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_3ac43e7f-484f-47fe-8e99-84c1fb294bdf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_05817da0-dd19-4f5f-962f-8882d5c26b51" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_3ac43e7f-484f-47fe-8e99-84c1fb294bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_7da17fcd-7ab2-4af8-97f3-9a04f2ee56fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_05817da0-dd19-4f5f-962f-8882d5c26b51" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_7da17fcd-7ab2-4af8-97f3-9a04f2ee56fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_d113ffd7-03c0-4651-b68a-ce53c6c4861c" xlink:href="sny-20240630.xsd#sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_05817da0-dd19-4f5f-962f-8882d5c26b51" xlink:to="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_d113ffd7-03c0-4651-b68a-ce53c6c4861c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_c467b03d-c42a-4bac-82cd-ea992bb87ebf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_44bf26b7-3b84-4db1-a107-d615e8d69d2d" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_c467b03d-c42a-4bac-82cd-ea992bb87ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_bdf924af-1b03-4f47-b646-d9305bc38c13" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_7bf17716-4e85-4c5e-8366-54145fca25bc" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_bdf924af-1b03-4f47-b646-d9305bc38c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_f1acf1a6-2dba-4622-a0d7-4ea7c073eb1f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_bdf924af-1b03-4f47-b646-d9305bc38c13" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_f1acf1a6-2dba-4622-a0d7-4ea7c073eb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_f8d2967b-ef08-4352-b2c8-5580ad4891b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_bdf924af-1b03-4f47-b646-d9305bc38c13" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_f8d2967b-ef08-4352-b2c8-5580ad4891b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_d1580e08-f3b1-4ce0-a1c1-d5a0b358eccf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_bdf924af-1b03-4f47-b646-d9305bc38c13" xlink:to="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_d1580e08-f3b1-4ce0-a1c1-d5a0b358eccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_1c912954-2536-41ff-a878-f0b35e9647a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_bdf924af-1b03-4f47-b646-d9305bc38c13" xlink:to="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_1c912954-2536-41ff-a878-f0b35e9647a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_e26d66b2-bac0-4fbe-be43-3e0072fb4650" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_bdf924af-1b03-4f47-b646-d9305bc38c13" xlink:to="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_e26d66b2-bac0-4fbe-be43-3e0072fb4650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherNonCurrentAssets_d21361eb-cc90-4936-a5ff-4c6e0f2c46df" xlink:href="sny-20240630.xsd#sny_NetChangeInOtherNonCurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_bdf924af-1b03-4f47-b646-d9305bc38c13" xlink:to="loc_sny_NetChangeInOtherNonCurrentAssets_d21361eb-cc90-4936-a5ff-4c6e0f2c46df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_a5d7ab1b-da86-4ea6-b766-e8c1d2e0b73f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_bdf924af-1b03-4f47-b646-d9305bc38c13" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_a5d7ab1b-da86-4ea6-b766-e8c1d2e0b73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2b83e81e-0b81-447a-8168-6618420664a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_7bf17716-4e85-4c5e-8366-54145fca25bc" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2b83e81e-0b81-447a-8168-6618420664a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_a46ec7e8-c22c-4e32-9507-c0915abbc298" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2b83e81e-0b81-447a-8168-6618420664a7" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_a46ec7e8-c22c-4e32-9507-c0915abbc298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DividendsPaidAbstract_85452705-4a8d-4bc0-90cd-21ad82553950" xlink:href="sny-20240630.xsd#sny_DividendsPaidAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2b83e81e-0b81-447a-8168-6618420664a7" xlink:to="loc_sny_DividendsPaidAbstract_85452705-4a8d-4bc0-90cd-21ad82553950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_f3fc8826-6f9e-4c54-973a-5658022b9186" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DividendsPaidAbstract_85452705-4a8d-4bc0-90cd-21ad82553950" xlink:to="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_f3fc8826-6f9e-4c54-973a-5658022b9186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_74d01de9-bbf2-4d20-9a7f-208d1f029110" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DividendsPaidAbstract_85452705-4a8d-4bc0-90cd-21ad82553950" xlink:to="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_74d01de9-bbf2-4d20-9a7f-208d1f029110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_79c23990-990e-4ba0-9fca-7e2008bb12c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2b83e81e-0b81-447a-8168-6618420664a7" xlink:to="loc_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_79c23990-990e-4ba0-9fca-7e2008bb12c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_d4369d8a-0760-4568-9d4f-2a7b722e3325" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2b83e81e-0b81-447a-8168-6618420664a7" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_d4369d8a-0760-4568-9d4f-2a7b722e3325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_2eee02df-203c-4de8-9865-a7704180a265" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2b83e81e-0b81-447a-8168-6618420664a7" xlink:to="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_2eee02df-203c-4de8-9865-a7704180a265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_9d1cde9e-d2c2-4b56-a0d5-b80ca2269b89" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2b83e81e-0b81-447a-8168-6618420664a7" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_9d1cde9e-d2c2-4b56-a0d5-b80ca2269b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_32c8e8f5-afe3-4c3f-b3ea-50e1a05dec2f" xlink:href="sny-20240630.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2b83e81e-0b81-447a-8168-6618420664a7" xlink:to="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_32c8e8f5-afe3-4c3f-b3ea-50e1a05dec2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_830ba854-6ccd-4bba-88eb-60fa862b961b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2b83e81e-0b81-447a-8168-6618420664a7" xlink:to="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_830ba854-6ccd-4bba-88eb-60fa862b961b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_7cda940e-8f39-42f8-9a0a-fa80c18b75d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_7bf17716-4e85-4c5e-8366-54145fca25bc" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_7cda940e-8f39-42f8-9a0a-fa80c18b75d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_12838e96-36d4-453a-b9f6-86e5e586f338" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_7bf17716-4e85-4c5e-8366-54145fca25bc" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_12838e96-36d4-453a-b9f6-86e5e586f338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_376d1a49-390f-4fb8-9e47-65cd6776ffb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_7bf17716-4e85-4c5e-8366-54145fca25bc" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_376d1a49-390f-4fb8-9e47-65cd6776ffb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_6c727e2f-d83d-446f-88bd-5161f47582e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_7bf17716-4e85-4c5e-8366-54145fca25bc" xlink:to="loc_ifrs-full_CashAndCashEquivalents_6c727e2f-d83d-446f-88bd-5161f47582e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_14314891-4767-4a29-9883-0fdfdbb0bf5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_7bf17716-4e85-4c5e-8366-54145fca25bc" xlink:to="loc_ifrs-full_CashAndCashEquivalents_14314891-4767-4a29-9883-0fdfdbb0bf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_b92e951f-9094-400a-9eae-870ccbe6860b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_9c095b3d-e730-4b6b-9876-b227534ea86f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_b92e951f-9094-400a-9eae-870ccbe6860b" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_9c095b3d-e730-4b6b-9876-b227534ea86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_a2586fee-af52-4cd8-b258-34eaf1d85731" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_9c095b3d-e730-4b6b-9876-b227534ea86f" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_a2586fee-af52-4cd8-b258-34eaf1d85731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_83564ecc-2045-47ae-8cc9-e9dee7d11397" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_a2586fee-af52-4cd8-b258-34eaf1d85731" xlink:to="loc_ifrs-full_BorrowingsByNameMember_83564ecc-2045-47ae-8cc9-e9dee7d11397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_182a6f19-a497-4b5b-a025-6d3b3777d313" xlink:href="sny-20240630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_83564ecc-2045-47ae-8cc9-e9dee7d11397" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_182a6f19-a497-4b5b-a025-6d3b3777d313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_c30c77dd-5724-4b93-8ec2-9d5cb087e608" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_9c095b3d-e730-4b6b-9876-b227534ea86f" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_c30c77dd-5724-4b93-8ec2-9d5cb087e608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_0f32144d-cf20-42e1-90e9-fdf48022ef77" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_c30c77dd-5724-4b93-8ec2-9d5cb087e608" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_0f32144d-cf20-42e1-90e9-fdf48022ef77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_d0f81a4e-a86a-45aa-9829-23d5f736e225" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_c30c77dd-5724-4b93-8ec2-9d5cb087e608" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_d0f81a4e-a86a-45aa-9829-23d5f736e225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_241349c5-11c8-43bf-80a4-96aba543236d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_c30c77dd-5724-4b93-8ec2-9d5cb087e608" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_241349c5-11c8-43bf-80a4-96aba543236d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_c84b9f51-06c2-45eb-9424-8e9b6a8f53d4" xlink:href="sny-20240630.xsd#sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_c30c77dd-5724-4b93-8ec2-9d5cb087e608" xlink:to="loc_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_c84b9f51-06c2-45eb-9424-8e9b6a8f53d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_c95a5493-f065-4fb3-990f-c8526a0d4123" xlink:href="sny-20240630.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_c30c77dd-5724-4b93-8ec2-9d5cb087e608" xlink:to="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_c95a5493-f065-4fb3-990f-c8526a0d4123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Introduction" xlink:type="simple" xlink:href="sny-20240630.xsd#Introduction"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Introduction" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_GeneralInformationAboutFinancialStatementsAbstract_048f9cb9-31a3-4a93-a2db-865a06915c29" xlink:href="sny-20240630.xsd#sny_GeneralInformationAboutFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_539b071f-897c-4b68-af94-9224b0a11397" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_GeneralInformationAboutFinancialStatementsAbstract_048f9cb9-31a3-4a93-a2db-865a06915c29" xlink:to="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_539b071f-897c-4b68-af94-9224b0a11397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPolicies" xlink:type="simple" xlink:href="sny-20240630.xsd#BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_4c026fa2-fc2c-4f5b-bb06-a1ccc03a034e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_9c9cd2c8-aa3b-4cce-88f8-edb6f936e1e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_4c026fa2-fc2c-4f5b-bb06-a1ccc03a034e" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_9c9cd2c8-aa3b-4cce-88f8-edb6f936e1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreements" xlink:type="simple" xlink:href="sny-20240630.xsd#PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreements"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_cbe21fa3-f927-4004-bad5-6b0576a99e49" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_c537505b-21be-4f06-b519-42086785c9cf" xlink:href="sny-20240630.xsd#sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_cbe21fa3-f927-4004-bad5-6b0576a99e49" xlink:to="loc_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_c537505b-21be-4f06-b519-42086785c9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_e74a8d18-866d-4f73-92f1-81fb34c03953" xlink:href="sny-20240630.xsd#sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="sny-20240630.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_5b461b01-7bb9-4732-bc69-bccd2f99a356" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_c26d5cf9-e189-4d6e-8b0f-cfcc7c3e9624" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_5b461b01-7bb9-4732-bc69-bccd2f99a356" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_c26d5cf9-e189-4d6e-8b0f-cfcc7c3e9624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="sny-20240630.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_35f418e6-c25c-4270-b9a2-e45f36312a99" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_c6e2c87c-045e-4623-9b7b-b0c90b2ea502" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_35f418e6-c25c-4270-b9a2-e45f36312a99" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_c6e2c87c-045e-4623-9b7b-b0c90b2ea502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ImpairmentofIntangibleAssets" xlink:type="simple" xlink:href="sny-20240630.xsd#ImpairmentofIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ImpairmentofIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract_a1cf572b-ca2f-44f5-9ad8-269ee956eb18" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock_586a51f7-c1fe-449f-8559-dbb2d4052d66" xlink:href="sny-20240630.xsd#sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract_a1cf572b-ca2f-44f5-9ad8-269ee956eb18" xlink:to="loc_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock_586a51f7-c1fe-449f-8559-dbb2d4052d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethod" xlink:type="simple" xlink:href="sny-20240630.xsd#InvestmentsAccountedforUsingtheEquityMethod"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethod" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_7e273125-54f7-4a3c-8ef8-cb30b2c99eb5" xlink:href="sny-20240630.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_73ec440b-4b94-4e67-b961-0069af42ef89" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_7e273125-54f7-4a3c-8ef8-cb30b2c99eb5" xlink:to="loc_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_73ec440b-4b94-4e67-b961-0069af42ef89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherNonCurrentAssets" xlink:type="simple" xlink:href="sny-20240630.xsd#OtherNonCurrentAssets"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtherNonCurrentAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_d7fbe2e4-ad0a-42ab-b588-852c0cfdef5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_6f7f3610-b04c-46d0-b55a-0f18e8eab9b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_d7fbe2e4-ad0a-42ab-b588-852c0cfdef5e" xlink:to="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_6f7f3610-b04c-46d0-b55a-0f18e8eab9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsReceivable" xlink:type="simple" xlink:href="sny-20240630.xsd#AccountsReceivable"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AccountsReceivable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_1a95b668-2da9-4e13-b25a-2ee7758b8863" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfTradeReceivablesTextBlock_720515dc-a074-4ae3-95a7-412f5c9779a0" xlink:href="sny-20240630.xsd#sny_DisclosureOfTradeReceivablesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_1a95b668-2da9-4e13-b25a-2ee7758b8863" xlink:to="loc_sny_DisclosureOfTradeReceivablesTextBlock_720515dc-a074-4ae3-95a7-412f5c9779a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquity" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_dd0b55b8-b6c4-486e-8349-73b3bb0e8489" xlink:href="sny-20240630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_e5984d2d-67ba-4819-90c9-a6f187d5f023" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_dd0b55b8-b6c4-486e-8349-73b3bb0e8489" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_e5984d2d-67ba-4819-90c9-a6f187d5f023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_366ec650-2b43-4ef4-a379-0b5e9975155d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_dd0b55b8-b6c4-486e-8349-73b3bb0e8489" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_366ec650-2b43-4ef4-a379-0b5e9975155d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalents" xlink:type="simple" xlink:href="sny-20240630.xsd#DebtCashandCashEquivalents"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_c30d8fb7-6fb2-4969-93b4-d9078237cea7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock_3a74dc1d-87d0-446c-a503-aa857e8ee5f3" xlink:href="sny-20240630.xsd#sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_c30d8fb7-6fb2-4969-93b4-d9078237cea7" xlink:to="loc_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock_3a74dc1d-87d0-446c-a503-aa857e8ee5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativeFinancialInstruments" xlink:type="simple" xlink:href="sny-20240630.xsd#DerivativeFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DerivativeFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_f516bb83-f1f0-4242-ba9f-69683ced35d1" xlink:href="sny-20240630.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_f6dcf13f-e21b-495f-83af-270e0559b179" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_f516bb83-f1f0-4242-ba9f-69683ced35d1" xlink:to="loc_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_f6dcf13f-e21b-495f-83af-270e0559b179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterests" xlink:type="simple" xlink:href="sny-20240630.xsd#LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterests"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterests" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_8c9b224c-89c1-4651-a139-27423d19c38b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:type="simple" xlink:href="sny-20240630.xsd#NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_62db8067-5ef2-4733-9393-e7d11b90be59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock_a324b588-25fa-48a8-aff3-a9adccec49f6" xlink:href="sny-20240630.xsd#sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_62db8067-5ef2-4733-9393-e7d11b90be59" xlink:to="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock_a324b588-25fa-48a8-aff3-a9adccec49f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OffBalanceSheetCommitments" xlink:type="simple" xlink:href="sny-20240630.xsd#OffBalanceSheetCommitments"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OffBalanceSheetCommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OffBalanceSheetCommitmentsAbstract_158ebc8c-4ef1-4cc8-83d1-e2636913c9f4" xlink:href="sny-20240630.xsd#sny_OffBalanceSheetCommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock_3368aadc-6668-460e-9a88-b3205d686973" xlink:href="sny-20240630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OffBalanceSheetCommitmentsAbstract_158ebc8c-4ef1-4cc8-83d1-e2636913c9f4" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock_3368aadc-6668-460e-9a88-b3205d686973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LitigationandArbitrationProceedings" xlink:type="simple" xlink:href="sny-20240630.xsd#LitigationandArbitrationProceedings"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LitigationandArbitrationProceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_9917ee87-8460-4997-ba21-ec1614e927ac" xlink:href="sny-20240630.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock_711e6c6a-31ab-4f75-ac1e-b6ad7b10920c" xlink:href="sny-20240630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_9917ee87-8460-4997-ba21-ec1614e927ac" xlink:to="loc_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock_711e6c6a-31ab-4f75-ac1e-b6ad7b10920c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherOperatingIncomeAndExpenses" xlink:type="simple" xlink:href="sny-20240630.xsd#OtherOperatingIncomeAndExpenses"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtherOperatingIncomeAndExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b356b55a-39bc-4b56-8c17-f15ab1e90d7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_b7a482b7-bc3e-4bc9-a0e5-e56fef97e5fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b356b55a-39bc-4b56-8c17-f15ab1e90d7a" xlink:to="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_b7a482b7-bc3e-4bc9-a0e5-e56fef97e5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RestructuringCostsandSimilarItems" xlink:type="simple" xlink:href="sny-20240630.xsd#RestructuringCostsandSimilarItems"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RestructuringCostsandSimilarItems" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_314db569-f451-4822-8365-50c9ab6f7a75" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock_1ae87fe0-af08-41f7-b7b2-b5438a79edeb" xlink:href="sny-20240630.xsd#sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_314db569-f451-4822-8365-50c9ab6f7a75" xlink:to="loc_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock_1ae87fe0-af08-41f7-b7b2-b5438a79edeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherGainsandLossesandLitigation" xlink:type="simple" xlink:href="sny-20240630.xsd#OtherGainsandLossesandLitigation"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtherGainsandLossesandLitigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_3ed63bdf-87e0-4a3b-899d-b8f1926b8e07" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_dddf510e-980b-4827-9f90-1373ba0da039" xlink:href="sny-20240630.xsd#sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_3ed63bdf-87e0-4a3b-899d-b8f1926b8e07" xlink:to="loc_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_dddf510e-980b-4827-9f90-1373ba0da039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialExpensesandIncome" xlink:type="simple" xlink:href="sny-20240630.xsd#FinancialExpensesandIncome"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/FinancialExpensesandIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b93bf859-a55e-4dfd-8fc2-b1d856ac16a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_c884cdc4-da8f-4491-90f0-500d2c20eed4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b93bf859-a55e-4dfd-8fc2-b1d856ac16a6" xlink:to="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_c884cdc4-da8f-4491-90f0-500d2c20eed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncomeTaxExpense" xlink:type="simple" xlink:href="sny-20240630.xsd#IncomeTaxExpense"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/IncomeTaxExpense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_11444f6c-9210-4056-87b7-4886af659539" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_693c2390-d929-4a9a-8356-481262bbefab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_11444f6c-9210-4056-87b7-4886af659539" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_693c2390-d929-4a9a-8356-481262bbefab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformation" xlink:type="simple" xlink:href="sny-20240630.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_47bd51a9-596e-4488-9333-7cb0c6973446" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_e25616b0-c392-474e-ba32-7de24cb211bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_47bd51a9-596e-4488-9333-7cb0c6973446" xlink:to="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_e25616b0-c392-474e-ba32-7de24cb211bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/EventsSubsequenttoJune302023" xlink:type="simple" xlink:href="sny-20240630.xsd#EventsSubsequenttoJune302023"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/EventsSubsequenttoJune302023" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_666dd543-7ee2-4c10-9353-ce8c93bb0d65" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_bc88525f-e90a-47a9-bd0c-96bb4ef28a9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_666dd543-7ee2-4c10-9353-ce8c93bb0d65" xlink:to="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_bc88525f-e90a-47a9-bd0c-96bb4ef28a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sny-20240630.xsd#BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_a8154047-5996-4a20-8a8f-d72a9ad5e404" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance_f4aa4021-3da3-466f-a0df-358aa13582f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_a8154047-5996-4a20-8a8f-d72a9ad5e404" xlink:to="loc_ifrs-full_StatementOfIFRSCompliance_f4aa4021-3da3-466f-a0df-358aa13582f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_530c4ce9-5003-47d6-8d8e-7d1ca203ffd2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_a8154047-5996-4a20-8a8f-d72a9ad5e404" xlink:to="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_530c4ce9-5003-47d6-8d8e-7d1ca203ffd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock_f3f81a15-c6cc-427c-93a3-4e7271d9c036" xlink:href="sny-20240630.xsd#sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_a8154047-5996-4a20-8a8f-d72a9ad5e404" xlink:to="loc_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock_f3f81a15-c6cc-427c-93a3-4e7271d9c036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory_2f8bb6cd-3111-4077-9c31-6bbaa5ae48a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_a8154047-5996-4a20-8a8f-d72a9ad5e404" xlink:to="loc_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory_2f8bb6cd-3111-4077-9c31-6bbaa5ae48a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_79cb0261-d4d2-4097-9388-fbb149f81700" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_a8154047-5996-4a20-8a8f-d72a9ad5e404" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_79cb0261-d4d2-4097-9388-fbb149f81700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_cf681d00-8caa-4604-8c01-82eefea93242" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_a8154047-5996-4a20-8a8f-d72a9ad5e404" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_cf681d00-8caa-4604-8c01-82eefea93242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock_26ad91a6-fa57-4d33-a712-1e0380d3ac7a" xlink:href="sny-20240630.xsd#sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_a8154047-5996-4a20-8a8f-d72a9ad5e404" xlink:to="loc_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock_26ad91a6-fa57-4d33-a712-1e0380d3ac7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesTables" xlink:type="simple" xlink:href="sny-20240630.xsd#BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_5428259f-53d3-45bb-bd56-7470e699fd3f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_4b83a194-8ddb-44b1-b311-0283449c3e38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_5428259f-53d3-45bb-bd56-7470e699fd3f" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_4b83a194-8ddb-44b1-b311-0283449c3e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="sny-20240630.xsd#PropertyPlantandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PropertyPlantandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_714b37c8-26a3-4f03-ae16-6a42814c0772" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock_fa11b950-cd14-4422-8a53-2298c783e3cd" xlink:href="sny-20240630.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_714b37c8-26a3-4f03-ae16-6a42814c0772" xlink:to="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock_fa11b950-cd14-4422-8a53-2298c783e3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="sny-20240630.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_ba752a7a-62d1-46db-a4e3-03213ee6c968" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock_ab68c069-0e50-4a3d-a8ed-b885cee8a83a" xlink:href="sny-20240630.xsd#sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_ba752a7a-62d1-46db-a4e3-03213ee6c968" xlink:to="loc_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock_ab68c069-0e50-4a3d-a8ed-b885cee8a83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodTables" xlink:type="simple" xlink:href="sny-20240630.xsd#InvestmentsAccountedforUsingtheEquityMethodTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_ec71aff3-f601-484d-a6d7-2a7ae721c712" xlink:href="sny-20240630.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock_a852874c-9122-423e-93de-b72956714019" xlink:href="sny-20240630.xsd#sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_ec71aff3-f601-484d-a6d7-2a7ae721c712" xlink:to="loc_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock_a852874c-9122-423e-93de-b72956714019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_7c2ade1d-1645-4dc1-a2e0-df71cacba15f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_ec71aff3-f601-484d-a6d7-2a7ae721c712" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_7c2ade1d-1645-4dc1-a2e0-df71cacba15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherNonCurrentAssetsTables" xlink:type="simple" xlink:href="sny-20240630.xsd#OtherNonCurrentAssetsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtherNonCurrentAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_dfcdacfb-aa12-4ac9-a34a-d1b9b30fb607" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock_f2668531-b730-40c0-94c9-d94bd959e1a2" xlink:href="sny-20240630.xsd#sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_dfcdacfb-aa12-4ac9-a34a-d1b9b30fb607" xlink:to="loc_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock_f2668531-b730-40c0-94c9-d94bd959e1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsReceivableTables" xlink:type="simple" xlink:href="sny-20240630.xsd#AccountsReceivableTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AccountsReceivableTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_b35665c3-45bd-4ade-b296-71f777b4af6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock_31364b43-bc9b-4be6-9df1-a1fad26afa1a" xlink:href="sny-20240630.xsd#sny_DisclosureOfCurrentTradeReceivablesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_b35665c3-45bd-4ade-b296-71f777b4af6d" xlink:to="loc_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock_31364b43-bc9b-4be6-9df1-a1fad26afa1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock_695a709d-dbba-40c7-aaee-617e98995279" xlink:href="sny-20240630.xsd#sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_b35665c3-45bd-4ade-b296-71f777b4af6d" xlink:to="loc_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock_695a709d-dbba-40c7-aaee-617e98995279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_d65a53b6-d304-45f0-b2a2-ea1aad930026" xlink:href="sny-20240630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_2a86cc4e-5028-4c63-b624-1f8a54c0f218" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_d65a53b6-d304-45f0-b2a2-ea1aad930026" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_2a86cc4e-5028-4c63-b624-1f8a54c0f218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock_494428c5-32c0-4967-b490-f24aa630a765" xlink:href="sny-20240630.xsd#sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_d65a53b6-d304-45f0-b2a2-ea1aad930026" xlink:to="loc_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock_494428c5-32c0-4967-b490-f24aa630a765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock_5ad7f931-761d-4495-a714-7009b9d27f3e" xlink:href="sny-20240630.xsd#sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_d65a53b6-d304-45f0-b2a2-ea1aad930026" xlink:to="loc_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock_5ad7f931-761d-4495-a714-7009b9d27f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_aa2e5707-86e3-484f-9cf6-a07beba0b641" xlink:href="sny-20240630.xsd#sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_d65a53b6-d304-45f0-b2a2-ea1aad930026" xlink:to="loc_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_aa2e5707-86e3-484f-9cf6-a07beba0b641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock_03ac43e6-1934-427c-bd24-7494d4c86a23" xlink:href="sny-20240630.xsd#sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_d65a53b6-d304-45f0-b2a2-ea1aad930026" xlink:to="loc_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock_03ac43e6-1934-427c-bd24-7494d4c86a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock_de22105b-2970-4a63-9f7f-7f294ce6a1e5" xlink:href="sny-20240630.xsd#sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_d65a53b6-d304-45f0-b2a2-ea1aad930026" xlink:to="loc_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock_de22105b-2970-4a63-9f7f-7f294ce6a1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsTables" xlink:type="simple" xlink:href="sny-20240630.xsd#DebtCashandCashEquivalentsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_427f1ebf-be96-4eeb-ba05-c11f6897fd75" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfChangesInFinancialPositionTableTextBlock_a55ef003-0bc3-45f1-94d1-7a2e864bc144" xlink:href="sny-20240630.xsd#sny_DisclosureOfChangesInFinancialPositionTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_427f1ebf-be96-4eeb-ba05-c11f6897fd75" xlink:to="loc_sny_DisclosureOfChangesInFinancialPositionTableTextBlock_a55ef003-0bc3-45f1-94d1-7a2e864bc144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock_8bfc804a-4dbc-4985-907b-c36ec150eead" xlink:href="sny-20240630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_427f1ebf-be96-4eeb-ba05-c11f6897fd75" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock_8bfc804a-4dbc-4985-907b-c36ec150eead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock_8e90e804-463a-4e6e-b782-1616a087aa3b" xlink:href="sny-20240630.xsd#sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_427f1ebf-be96-4eeb-ba05-c11f6897fd75" xlink:to="loc_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock_8e90e804-463a-4e6e-b782-1616a087aa3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock_b57161d4-574e-4070-8a42-ec65a6923020" xlink:href="sny-20240630.xsd#sny_DisclosureOfMarketValueOfNetDebtTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_427f1ebf-be96-4eeb-ba05-c11f6897fd75" xlink:to="loc_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock_b57161d4-574e-4070-8a42-ec65a6923020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsTables" xlink:type="simple" xlink:href="sny-20240630.xsd#DerivativeFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_ff99831b-9749-497c-b3a9-d66c73f7904a" xlink:href="sny-20240630.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock_6c338569-c8b3-4093-b21b-b000851d643d" xlink:href="sny-20240630.xsd#sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_ff99831b-9749-497c-b3a9-d66c73f7904a" xlink:to="loc_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock_6c338569-c8b3-4093-b21b-b000851d643d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock_b24329c5-5974-4a43-bb22-029de6232940" xlink:href="sny-20240630.xsd#sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_ff99831b-9749-497c-b3a9-d66c73f7904a" xlink:to="loc_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock_b24329c5-5974-4a43-bb22-029de6232940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock_e2ce29e1-2709-4ae9-bacd-bd98ba69b53c" xlink:href="sny-20240630.xsd#sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_ff99831b-9749-497c-b3a9-d66c73f7904a" xlink:to="loc_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock_e2ce29e1-2709-4ae9-bacd-bd98ba69b53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsTables" xlink:type="simple" xlink:href="sny-20240630.xsd#LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_b6f14fa8-135d-4e39-b6f3-330b35415745" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock_1446c0ab-1b82-4c09-8559-9a39b481dcb7" xlink:href="sny-20240630.xsd#sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_b6f14fa8-135d-4e39-b6f3-330b35415745" xlink:to="loc_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock_1446c0ab-1b82-4c09-8559-9a39b481dcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesTables" xlink:type="simple" xlink:href="sny-20240630.xsd#NonCurrentProvisionsAndOtherNonCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b1534957-5c81-4611-bc1a-690da0f6d7d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock_97aace23-e471-4522-b5f7-24f0c922f09d" xlink:href="sny-20240630.xsd#sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b1534957-5c81-4611-bc1a-690da0f6d7d6" xlink:to="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock_97aace23-e471-4522-b5f7-24f0c922f09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTableTextBlock_2aee7c79-d0f6-42da-938d-b3f8f387237b" xlink:href="sny-20240630.xsd#sny_DisclosureOfNonCurrentProvisionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b1534957-5c81-4611-bc1a-690da0f6d7d6" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsTableTextBlock_2aee7c79-d0f6-42da-938d-b3f8f387237b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock_8e5ac0ac-e949-4615-afe6-f1e28092c76e" xlink:href="sny-20240630.xsd#sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b1534957-5c81-4611-bc1a-690da0f6d7d6" xlink:to="loc_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock_8e5ac0ac-e949-4615-afe6-f1e28092c76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesTables" xlink:type="simple" xlink:href="sny-20240630.xsd#OtherOperatingIncomeAndExpensesTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_26e935d6-ddfd-4a9c-9c71-a0ba42edadc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingExpensesTableTextBlock_57e032cd-9db9-4027-ab44-c694dbc29aa9" xlink:href="sny-20240630.xsd#sny_OtherOperatingExpensesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_26e935d6-ddfd-4a9c-9c71-a0ba42edadc2" xlink:to="loc_sny_OtherOperatingExpensesTableTextBlock_57e032cd-9db9-4027-ab44-c694dbc29aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsTables" xlink:type="simple" xlink:href="sny-20240630.xsd#RestructuringCostsandSimilarItemsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_700e7cde-dfc1-4892-860c-ed2006ab1b43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock_5bd499b2-03cc-4fb2-a0a9-aa45ceca72f0" xlink:href="sny-20240630.xsd#sny_DisclosureOfRestructuringCostsDetailsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_700e7cde-dfc1-4892-860c-ed2006ab1b43" xlink:to="loc_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock_5bd499b2-03cc-4fb2-a0a9-aa45ceca72f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialExpensesandIncomeTables" xlink:type="simple" xlink:href="sny-20240630.xsd#FinancialExpensesandIncomeTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/FinancialExpensesandIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_c7bf7b4f-a270-4c1d-9001-b8eaec5999a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock_f39afb2c-c0a8-4431-85d0-cb7f17bcc779" xlink:href="sny-20240630.xsd#sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_c7bf7b4f-a270-4c1d-9001-b8eaec5999a3" xlink:to="loc_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock_f39afb2c-c0a8-4431-85d0-cb7f17bcc779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncomeTaxExpenseTables" xlink:type="simple" xlink:href="sny-20240630.xsd#IncomeTaxExpenseTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/IncomeTaxExpenseTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_f87250f5-9935-4cf3-b26e-50e6beafc3d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock_96d68b28-567e-4043-bf0e-10632f87cbc4" xlink:href="sny-20240630.xsd#sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_f87250f5-9935-4cf3-b26e-50e6beafc3d9" xlink:to="loc_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock_96d68b28-567e-4043-bf0e-10632f87cbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_95f08dd6-44b5-481a-be2e-4b95b9e40299" xlink:href="sny-20240630.xsd#sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_f87250f5-9935-4cf3-b26e-50e6beafc3d9" xlink:to="loc_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_95f08dd6-44b5-481a-be2e-4b95b9e40299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_3f494c9d-4db2-4261-ae94-fbe4b949d2e6" xlink:href="sny-20240630.xsd#sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="sny-20240630.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_78b6e22b-e63f-4faf-91f0-8ca49d6ff35e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock_56695bfa-0533-4891-b05f-025c502d0536" xlink:href="sny-20240630.xsd#sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_78b6e22b-e63f-4faf-91f0-8ca49d6ff35e" xlink:to="loc_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock_56695bfa-0533-4891-b05f-025c502d0536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_f6a82fbe-dd04-49a3-aecd-d6514ce40a62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_78b6e22b-e63f-4faf-91f0-8ca49d6ff35e" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_f6a82fbe-dd04-49a3-aecd-d6514ce40a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock_69cdbd48-5ae0-4599-9a9b-b9dd30f65a66" xlink:href="sny-20240630.xsd#sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_78b6e22b-e63f-4faf-91f0-8ca49d6ff35e" xlink:to="loc_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock_69cdbd48-5ae0-4599-9a9b-b9dd30f65a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock_40473bc1-6ac0-42c3-8ebc-4eae1a9ecbbf" xlink:href="sny-20240630.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_78b6e22b-e63f-4faf-91f0-8ca49d6ff35e" xlink:to="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock_40473bc1-6ac0-42c3-8ebc-4eae1a9ecbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_b331b806-22ff-493a-bc89-fccbe4142d66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_78b6e22b-e63f-4faf-91f0-8ca49d6ff35e" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_b331b806-22ff-493a-bc89-fccbe4142d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_63a5090b-deb8-4df2-b580-d6d65346217c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ef060b1-3c30-4288-bf1c-ee3809313b67" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_63a5090b-deb8-4df2-b580-d6d65346217c" xlink:to="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ef060b1-3c30-4288-bf1c-ee3809313b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_47f26ccc-2b28-479c-92a7-b2f84c6ecc90" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ef060b1-3c30-4288-bf1c-ee3809313b67" xlink:to="loc_ifrs-full_GeographicalAreasAxis_47f26ccc-2b28-479c-92a7-b2f84c6ecc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_35a58fb8-f14a-461d-9ffe-607e2a0969c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_47f26ccc-2b28-479c-92a7-b2f84c6ecc90" xlink:to="loc_ifrs-full_GeographicalAreasMember_35a58fb8-f14a-461d-9ffe-607e2a0969c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AR_aa0ae69b-b353-4df2-829e-bb06583a6977" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_35a58fb8-f14a-461d-9ffe-607e2a0969c2" xlink:to="loc_country_AR_aa0ae69b-b353-4df2-829e-bb06583a6977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR_c316f471-bb26-4730-8c24-7b647d0bdcae" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_TR"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_35a58fb8-f14a-461d-9ffe-607e2a0969c2" xlink:to="loc_country_TR_c316f471-bb26-4730-8c24-7b647d0bdcae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementAxis_573747ab-c998-4d08-89f7-b79ff9e539d3" xlink:href="sny-20240630.xsd#sny_TypesOfAgreementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ef060b1-3c30-4288-bf1c-ee3809313b67" xlink:to="loc_sny_TypesOfAgreementAxis_573747ab-c998-4d08-89f7-b79ff9e539d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_38170800-bfe5-4451-82ee-eefc704a3d78" xlink:href="sny-20240630.xsd#sny_TypesOfAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementAxis_573747ab-c998-4d08-89f7-b79ff9e539d3" xlink:to="loc_sny_TypesOfAgreementDomain_38170800-bfe5-4451-82ee-eefc704a3d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementWithGSKMember_ba6e320e-4b42-4359-a58f-7d697776bc05" xlink:href="sny-20240630.xsd#sny_CollaborationAgreementWithGSKMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementDomain_38170800-bfe5-4451-82ee-eefc704a3d78" xlink:to="loc_sny_CollaborationAgreementWithGSKMember_ba6e320e-4b42-4359-a58f-7d697776bc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_cee2e799-42b2-491d-b5dd-ccd1922138b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ef060b1-3c30-4288-bf1c-ee3809313b67" xlink:to="loc_ifrs-full_CounterpartiesAxis_cee2e799-42b2-491d-b5dd-ccd1922138b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_58087bda-61c3-4011-a694-fcade5c0470f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_cee2e799-42b2-491d-b5dd-ccd1922138b6" xlink:to="loc_ifrs-full_CounterpartiesMember_58087bda-61c3-4011-a694-fcade5c0470f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_USGovernmentMember_cf614da7-5c14-4fa0-83e5-d7d3e5e492cd" xlink:href="sny-20240630.xsd#sny_USGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_58087bda-61c3-4011-a694-fcade5c0470f" xlink:to="loc_sny_USGovernmentMember_cf614da7-5c14-4fa0-83e5-d7d3e5e492cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f8115f9a-44d5-4614-b3a3-1e284ba718e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_5ef060b1-3c30-4288-bf1c-ee3809313b67" xlink:to="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f8115f9a-44d5-4614-b3a3-1e284ba718e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_9a44b12a-6061-4104-a360-7fda8d6414ba" xlink:href="sny-20240630.xsd#sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f8115f9a-44d5-4614-b3a3-1e284ba718e1" xlink:to="loc_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_9a44b12a-6061-4104-a360-7fda8d6414ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_4b8ad752-cb34-42a4-8e59-16e7ad56181f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f8115f9a-44d5-4614-b3a3-1e284ba718e1" xlink:to="loc_ifrs-full_CurrentContractLiabilities_4b8ad752-cb34-42a4-8e59-16e7ad56181f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_127a0a61-463d-468f-a8ab-653faf78a9c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f8115f9a-44d5-4614-b3a3-1e284ba718e1" xlink:to="loc_ifrs-full_OtherRevenue_127a0a61-463d-468f-a8ab-653faf78a9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_6dff4720-f081-4164-9bad-59e439ace579" xlink:href="sny-20240630.xsd#sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f8115f9a-44d5-4614-b3a3-1e284ba718e1" xlink:to="loc_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_6dff4720-f081-4164-9bad-59e439ace579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_3a110ff7-3996-418d-a335-803af6587e6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_342d38ff-5e8c-4fa2-ba21-bd19decd54c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_3a110ff7-3996-418d-a335-803af6587e6c" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_342d38ff-5e8c-4fa2-ba21-bd19decd54c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_4885a643-c959-4026-87c8-ab93e092720e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_342d38ff-5e8c-4fa2-ba21-bd19decd54c2" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_4885a643-c959-4026-87c8-ab93e092720e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_07d3b2bb-e878-4053-a0b0-655f21c25958" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_4885a643-c959-4026-87c8-ab93e092720e" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_07d3b2bb-e878-4053-a0b0-655f21c25958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember_d35b0646-35fd-433a-a437-f39201860614" xlink:href="sny-20240630.xsd#sny_ProventionBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_07d3b2bb-e878-4053-a0b0-655f21c25958" xlink:to="loc_sny_ProventionBioIncMember_d35b0646-35fd-433a-a437-f39201860614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InhibrxIncMember_ac09f57f-0d91-474d-a38c-d5d530162622" xlink:href="sny-20240630.xsd#sny_InhibrxIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_07d3b2bb-e878-4053-a0b0-655f21c25958" xlink:to="loc_sny_InhibrxIncMember_ac09f57f-0d91-474d-a38c-d5d530162622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b17cbc18-64c9-4249-ac66-af158a4f1b75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_342d38ff-5e8c-4fa2-ba21-bd19decd54c2" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b17cbc18-64c9-4249-ac66-af158a4f1b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1d72da02-feb9-45be-8d12-0ebc4ed6b8e6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b17cbc18-64c9-4249-ac66-af158a4f1b75" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1d72da02-feb9-45be-8d12-0ebc4ed6b8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember_07108c1c-8221-40d3-80f3-cb69df2eae0e" xlink:href="sny-20240630.xsd#sny_ProventionBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1d72da02-feb9-45be-8d12-0ebc4ed6b8e6" xlink:to="loc_sny_ProventionBioIncMember_07108c1c-8221-40d3-80f3-cb69df2eae0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionAxis_29b68102-ce99-427f-a2d6-60a21e44fb27" xlink:href="sny-20240630.xsd#sny_AssetsAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_342d38ff-5e8c-4fa2-ba21-bd19decd54c2" xlink:to="loc_sny_AssetsAcquisitionAxis_29b68102-ce99-427f-a2d6-60a21e44fb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionDomain_c4a13b9f-4d56-4d6f-98b1-5503ef7187de" xlink:href="sny-20240630.xsd#sny_AssetsAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AssetsAcquisitionAxis_29b68102-ce99-427f-a2d6-60a21e44fb27" xlink:to="loc_sny_AssetsAcquisitionDomain_c4a13b9f-4d56-4d6f-98b1-5503ef7187de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionMember_c3a766a6-cebc-4f8b-9496-345943e14058" xlink:href="sny-20240630.xsd#sny_AssetsAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AssetsAcquisitionDomain_c4a13b9f-4d56-4d6f-98b1-5503ef7187de" xlink:to="loc_sny_AssetsAcquisitionMember_c3a766a6-cebc-4f8b-9496-345943e14058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_342d38ff-5e8c-4fa2-ba21-bd19decd54c2" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashTransferred_6bd816db-beb2-40bd-80a3-28b37ee9bbaa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashTransferred"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_ifrs-full_CashTransferred_6bd816db-beb2-40bd-80a3-28b37ee9bbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_2da9e191-0373-4fc1-ad92-ffcd5f86dd85" xlink:href="sny-20240630.xsd#sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_2da9e191-0373-4fc1-ad92-ffcd5f86dd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_b5b71509-94c6-4025-8a3b-55a1aee980e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_b5b71509-94c6-4025-8a3b-55a1aee980e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePricePerShare_8bd53f3a-9bc2-48bf-9824-ff8bee939720" xlink:href="sny-20240630.xsd#sny_BusinessCombinationPurchasePricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_sny_BusinessCombinationPurchasePricePerShare_8bd53f3a-9bc2-48bf-9824-ff8bee939720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_4d228f0f-317a-4178-841b-c0f998c64a1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_4d228f0f-317a-4178-841b-c0f998c64a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_9ee8a296-d310-423c-9af8-f5d8141b4e75" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_9ee8a296-d310-423c-9af8-f5d8141b4e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FutureRoyaltiesReceivableValue_3268f867-910d-4cc5-b60c-063cf75a496b" xlink:href="sny-20240630.xsd#sny_FutureRoyaltiesReceivableValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_sny_FutureRoyaltiesReceivableValue_3268f867-910d-4cc5-b60c-063cf75a496b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_09004fb0-c329-4330-b325-66d8417ee262" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_09004fb0-c329-4330-b325-66d8417ee262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NameOfAcquiree_e8e85971-647d-45a4-b3de-57fba8ebaf4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NameOfAcquiree"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_ifrs-full_NameOfAcquiree_e8e85971-647d-45a4-b3de-57fba8ebaf4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationNominalValue_f688d0d0-ab6b-42d0-98d2-92b059da8621" xlink:href="sny-20240630.xsd#sny_BusinessCombinationNominalValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_sny_BusinessCombinationNominalValue_f688d0d0-ab6b-42d0-98d2-92b059da8621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionNominalValue_92f18b23-b12f-4347-9c09-18428982779d" xlink:href="sny-20240630.xsd#sny_AssetsAcquisitionNominalValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_sny_AssetsAcquisitionNominalValue_92f18b23-b12f-4347-9c09-18428982779d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsAcquisitionPurchasePricePerShare_e427049f-554c-46b2-a524-5b88f170698d" xlink:href="sny-20240630.xsd#sny_AssetsAcquisitionPurchasePricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5078a6f4-a362-4c5a-ae0d-3c2d70204572" xlink:to="loc_sny_AssetsAcquisitionPurchasePricePerShare_e427049f-554c-46b2-a524-5b88f170698d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_0af063bf-2147-44a8-bf6c-62575ed4650f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalAgreementsTable_ba1c6206-3c59-465a-9987-ab45e884053d" xlink:href="sny-20240630.xsd#sny_DisclosureOfPrincipalAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_0af063bf-2147-44a8-bf6c-62575ed4650f" xlink:to="loc_sny_DisclosureOfPrincipalAgreementsTable_ba1c6206-3c59-465a-9987-ab45e884053d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_e92d9fc5-e63d-4734-a50a-9eb040031dba" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_ba1c6206-3c59-465a-9987-ab45e884053d" xlink:to="loc_sny_PrincipalAlliancesAxis_e92d9fc5-e63d-4734-a50a-9eb040031dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_d5bda86c-ea14-48cd-9d91-fd66613d76a3" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesAxis_e92d9fc5-e63d-4734-a50a-9eb040031dba" xlink:to="loc_sny_PrincipalAlliancesDomain_d5bda86c-ea14-48cd-9d91-fd66613d76a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_45dd2ffa-698e-4742-9bb9-5aa3aa79395f" xlink:href="sny-20240630.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_d5bda86c-ea14-48cd-9d91-fd66613d76a3" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_45dd2ffa-698e-4742-9bb9-5aa3aa79395f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_16c4b12d-d90d-4fdf-aac3-475e0af1fa1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_ba1c6206-3c59-465a-9987-ab45e884053d" xlink:to="loc_ifrs-full_CounterpartiesAxis_16c4b12d-d90d-4fdf-aac3-475e0af1fa1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_67edac21-a35e-4bdb-af31-e7a5dcdb4c23" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_16c4b12d-d90d-4fdf-aac3-475e0af1fa1a" xlink:to="loc_ifrs-full_CounterpartiesMember_67edac21-a35e-4bdb-af31-e7a5dcdb4c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AstraZenecaMember_73126122-1bb8-421b-96e1-940fafba2f63" xlink:href="sny-20240630.xsd#sny_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_67edac21-a35e-4bdb-af31-e7a5dcdb4c23" xlink:to="loc_sny_AstraZenecaMember_73126122-1bb8-421b-96e1-940fafba2f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SwedishOrphanBiovitrumABMember_c3c36e9f-7df0-48d8-97ae-47456850d76c" xlink:href="sny-20240630.xsd#sny_SwedishOrphanBiovitrumABMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_67edac21-a35e-4bdb-af31-e7a5dcdb4c23" xlink:to="loc_sny_SwedishOrphanBiovitrumABMember_c3c36e9f-7df0-48d8-97ae-47456850d76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_85a9afbe-c4dd-44f2-b603-24384e0bfde0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_ba1c6206-3c59-465a-9987-ab45e884053d" xlink:to="loc_ifrs-full_GeographicalAreasAxis_85a9afbe-c4dd-44f2-b603-24384e0bfde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_d776dae2-6f60-4491-87bc-514223c31f43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_85a9afbe-c4dd-44f2-b603-24384e0bfde0" xlink:to="loc_ifrs-full_GeographicalAreasMember_d776dae2-6f60-4491-87bc-514223c31f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorTerritoriesMember_f3191f21-b349-42f7-8383-0887d3eb9ccd" xlink:href="sny-20240630.xsd#sny_MajorTerritoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_d776dae2-6f60-4491-87bc-514223c31f43" xlink:to="loc_sny_MajorTerritoriesMember_f3191f21-b349-42f7-8383-0887d3eb9ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherTerritoriesMember_1ff16884-2e17-4f1d-a2ad-64398ee2f570" xlink:href="sny-20240630.xsd#sny_OtherTerritoriesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_d776dae2-6f60-4491-87bc-514223c31f43" xlink:to="loc_sny_OtherTerritoriesMember_1ff16884-2e17-4f1d-a2ad-64398ee2f570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_8c6ebe79-1193-4829-9457-c7625fc45712" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_d776dae2-6f60-4491-87bc-514223c31f43" xlink:to="loc_country_CN_8c6ebe79-1193-4829-9457-c7625fc45712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_add7b4b7-de7f-46b5-8371-77c2c2cb327d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_ba1c6206-3c59-465a-9987-ab45e884053d" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_add7b4b7-de7f-46b5-8371-77c2c2cb327d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c2e5f38e-a631-4086-b01e-7157c2f740ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_add7b4b7-de7f-46b5-8371-77c2c2cb327d" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c2e5f38e-a631-4086-b01e-7157c2f740ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_51725ddf-6bf3-4e59-9a29-5417d9e03d4c" xlink:href="sny-20240630.xsd#sny_OtherIntangibleAssetsExcludingSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c2e5f38e-a631-4086-b01e-7157c2f740ed" xlink:to="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_51725ddf-6bf3-4e59-9a29-5417d9e03d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_4f208381-41a4-43e3-823a-1b1100715621" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_ba1c6206-3c59-465a-9987-ab45e884053d" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_4f208381-41a4-43e3-823a-1b1100715621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_b5214f73-a26e-4c5d-bc0d-033e2aa60bfd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_4f208381-41a4-43e3-823a-1b1100715621" xlink:to="loc_ifrs-full_NonadjustingEventsMember_b5214f73-a26e-4c5d-bc0d-033e2aa60bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorFinancialLiabilityMember_f33e95da-54e4-47a5-8941-4b828620698d" xlink:href="sny-20240630.xsd#sny_MajorFinancialLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_b5214f73-a26e-4c5d-bc0d-033e2aa60bfd" xlink:to="loc_sny_MajorFinancialLiabilityMember_f33e95da-54e4-47a5-8941-4b828620698d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:href="sny-20240630.xsd#sny_DisclosureOfPrincipalAgreementsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsTable_ba1c6206-3c59-465a-9987-ab45e884053d" xlink:to="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsUpfrontPayment_f0822339-9618-40df-a9d6-1a4be5775de5" xlink:href="sny-20240630.xsd#sny_CollaborationAgreementsUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_sny_CollaborationAgreementsUpfrontPayment_f0822339-9618-40df-a9d6-1a4be5775de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsDevelopmentMilestonePayment_faf4ad74-eef6-4550-af09-c22c981573f9" xlink:href="sny-20240630.xsd#sny_CollaborationAgreementsDevelopmentMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_sny_CollaborationAgreementsDevelopmentMilestonePayment_faf4ad74-eef6-4550-af09-c22c981573f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsRegulatoryMilestonePayment_d09f2758-fe77-4afd-baee-32f839ef02be" xlink:href="sny-20240630.xsd#sny_CollaborationAgreementsRegulatoryMilestonePayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_sny_CollaborationAgreementsRegulatoryMilestonePayment_d09f2758-fe77-4afd-baee-32f839ef02be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_9dd4bf4b-f7c4-4308-83b7-f7c8ad76edd6" xlink:href="sny-20240630.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_9dd4bf4b-f7c4-4308-83b7-f7c8ad76edd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitsArisingFromCommercialOperations_aec22a06-6918-4973-9432-5d4bb5c015ef" xlink:href="sny-20240630.xsd#sny_PercentageOfProfitsArisingFromCommercialOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_sny_PercentageOfProfitsArisingFromCommercialOperations_aec22a06-6918-4973-9432-5d4bb5c015ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfNetSalesArisingFromCommercialOperations_8cd17899-3e1f-49b0-8139-2b79362d9b73" xlink:href="sny-20240630.xsd#sny_PercentageOfNetSalesArisingFromCommercialOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_sny_PercentageOfNetSalesArisingFromCommercialOperations_8cd17899-3e1f-49b0-8139-2b79362d9b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_8835f6d7-3c41-46d3-9579-4843c458406b" xlink:href="sny-20240630.xsd#sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_8835f6d7-3c41-46d3-9579-4843c458406b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_9cf964cb-fe10-470f-b3a0-00e374aac423" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_9cf964cb-fe10-470f-b3a0-00e374aac423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_cab5f2fd-cf7c-4d7b-8074-0d4191e677a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_cab5f2fd-cf7c-4d7b-8074-0d4191e677a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_d4ea78cc-d595-415d-b872-cb8f9b96ff3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_d4ea78cc-d595-415d-b872-cb8f9b96ff3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_29cd2cbf-7472-422c-97d5-c0f5cf0d09d7" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAgreementsLineItems_e92326cf-cf4a-4c50-9b48-c8fb81236a4c" xlink:to="loc_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_29cd2cbf-7472-422c-97d5-c0f5cf0d09d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_989b7827-31c4-4e5f-8f33-e384e967f3b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_d65165b4-feb8-4df0-bd84-e8b6e466b322" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_989b7827-31c4-4e5f-8f33-e384e967f3b3" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_d65165b4-feb8-4df0-bd84-e8b6e466b322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_de6c67ad-b8a5-46dd-a413-5174e357b36a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_d65165b4-feb8-4df0-bd84-e8b6e466b322" xlink:to="loc_ifrs-full_SegmentsAxis_de6c67ad-b8a5-46dd-a413-5174e357b36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_689f28f6-f1dd-4096-9324-615d5d30471c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_de6c67ad-b8a5-46dd-a413-5174e357b36a" xlink:to="loc_ifrs-full_SegmentsMember_689f28f6-f1dd-4096-9324-615d5d30471c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_02f91a51-bf2f-41e8-a643-b9b6de8630c3" xlink:href="sny-20240630.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_689f28f6-f1dd-4096-9324-615d5d30471c" xlink:to="loc_sny_BiopharmaSegmentMember_02f91a51-bf2f-41e8-a643-b9b6de8630c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_961929a7-ee1d-400f-8ac1-c0fda0e0f435" xlink:href="sny-20240630.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_689f28f6-f1dd-4096-9324-615d5d30471c" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_961929a7-ee1d-400f-8ac1-c0fda0e0f435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaMember_1aab4d7d-162c-4295-884f-6532bff10522" xlink:href="sny-20240630.xsd#sny_OpellaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_689f28f6-f1dd-4096-9324-615d5d30471c" xlink:to="loc_sny_OpellaMember_1aab4d7d-162c-4295-884f-6532bff10522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_2039899f-c2d2-4448-aec3-ae77cf92c30c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_d65165b4-feb8-4df0-bd84-e8b6e466b322" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_2039899f-c2d2-4448-aec3-ae77cf92c30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_027b8f3a-a7cf-4762-9ea0-d3128cdbeaeb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_2039899f-c2d2-4448-aec3-ae77cf92c30c" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_027b8f3a-a7cf-4762-9ea0-d3128cdbeaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManufacturingAndSupplyMember_495d442d-c185-49ee-8718-d502e94e6a49" xlink:href="sny-20240630.xsd#sny_ManufacturingAndSupplyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_027b8f3a-a7cf-4762-9ea0-d3128cdbeaeb" xlink:to="loc_sny_ManufacturingAndSupplyMember_495d442d-c185-49ee-8718-d502e94e6a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0d2f3250-8ced-47a6-bd33-235b8a029b5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_d65165b4-feb8-4df0-bd84-e8b6e466b322" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0d2f3250-8ced-47a6-bd33-235b8a029b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_1fd7856c-9787-4400-a89b-71dc4f2435ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0d2f3250-8ced-47a6-bd33-235b8a029b5c" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_1fd7856c-9787-4400-a89b-71dc4f2435ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestCostsCapitalised_f4d3bba4-5a87-455f-802d-98eafb4c4cd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestCostsCapitalised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0d2f3250-8ced-47a6-bd33-235b8a029b5c" xlink:to="loc_ifrs-full_InterestCostsCapitalised_f4d3bba4-5a87-455f-802d-98eafb4c4cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments_531a5cfb-936b-48db-a495-6aee6759f857" xlink:href="sny-20240630.xsd#sny_NumberOfOperatingSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0d2f3250-8ced-47a6-bd33-235b8a029b5c" xlink:to="loc_sny_NumberOfOperatingSegments_531a5cfb-936b-48db-a495-6aee6759f857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#PropertyPlantandEquipmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_a82f7645-54d7-42c5-bb65-141f44c99f1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FirmOrdersOfPropertyPlantAndEquipment_8883232a-755a-4ea0-be58-9cf3ac99bb5a" xlink:href="sny-20240630.xsd#sny_FirmOrdersOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_a82f7645-54d7-42c5-bb65-141f44c99f1b" xlink:to="loc_sny_FirmOrdersOfPropertyPlantAndEquipment_8883232a-755a-4ea0-be58-9cf3ac99bb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#GoodwillandOtherIntangibleAssetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_f47903bb-0726-4787-a6ab-569136a791f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_302d8466-91fb-445b-a09b-4829f33e5cc0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_f47903bb-0726-4787-a6ab-569136a791f6" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_302d8466-91fb-445b-a09b-4829f33e5cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_f87bde94-aa7f-46f2-8052-0352cd5f3bca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_302d8466-91fb-445b-a09b-4829f33e5cc0" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_f87bde94-aa7f-46f2-8052-0352cd5f3bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c92ce512-bbed-456a-a3bb-bdff3a568bdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_f87bde94-aa7f-46f2-8052-0352cd5f3bca" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c92ce512-bbed-456a-a3bb-bdff3a568bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_302d807f-b98e-42f7-913f-f54069b4ceda" xlink:href="sny-20240630.xsd#sny_OtherIntangibleAssetsExcludingSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c92ce512-bbed-456a-a3bb-bdff3a568bdd" xlink:to="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_302d807f-b98e-42f7-913f-f54069b4ceda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsMember_910e5c82-b73a-45e9-bfae-03fb132ee339" xlink:href="sny-20240630.xsd#sny_MarketedProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c92ce512-bbed-456a-a3bb-bdff3a568bdd" xlink:to="loc_sny_MarketedProductsMember_910e5c82-b73a-45e9-bfae-03fb132ee339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TechnologicalPlatformsMember_2227a1e1-b9b1-4d23-bba8-bf75a32107a7" xlink:href="sny-20240630.xsd#sny_TechnologicalPlatformsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_c92ce512-bbed-456a-a3bb-bdff3a568bdd" xlink:to="loc_sny_TechnologicalPlatformsMember_2227a1e1-b9b1-4d23-bba8-bf75a32107a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_e2c81afe-77aa-4354-9196-49b7387605c2" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_302d8466-91fb-445b-a09b-4829f33e5cc0" xlink:to="loc_sny_PrincipalAlliancesAxis_e2c81afe-77aa-4354-9196-49b7387605c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_2e1b6165-dc0c-427d-a8f6-d609d2816454" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesAxis_e2c81afe-77aa-4354-9196-49b7387605c2" xlink:to="loc_sny_PrincipalAlliancesDomain_2e1b6165-dc0c-427d-a8f6-d609d2816454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesCoExclusiveLicensingAgreementMember_ce3777b4-ee59-45ba-bfe8-2098fd86690a" xlink:href="sny-20240630.xsd#sny_VaccinesCoExclusiveLicensingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_2e1b6165-dc0c-427d-a8f6-d609d2816454" xlink:to="loc_sny_VaccinesCoExclusiveLicensingAgreementMember_ce3777b4-ee59-45ba-bfe8-2098fd86690a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_8b271e62-4f4d-4b7a-80a0-8e9af2ba0ea4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_302d8466-91fb-445b-a09b-4829f33e5cc0" xlink:to="loc_ifrs-full_CounterpartiesAxis_8b271e62-4f4d-4b7a-80a0-8e9af2ba0ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_73c9da6e-28cc-432d-8aff-78433040d838" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_8b271e62-4f4d-4b7a-80a0-8e9af2ba0ea4" xlink:to="loc_ifrs-full_CounterpartiesMember_73c9da6e-28cc-432d-8aff-78433040d838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NovavaxMember_2f9f1130-794f-470e-9009-71eba317eeb6" xlink:href="sny-20240630.xsd#sny_NovavaxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_73c9da6e-28cc-432d-8aff-78433040d838" xlink:to="loc_sny_NovavaxMember_2f9f1130-794f-470e-9009-71eba317eeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_34919718-fed8-4ed7-9b81-4b66739fdb82" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_302d8466-91fb-445b-a09b-4829f33e5cc0" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_34919718-fed8-4ed7-9b81-4b66739fdb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_9d855afa-be62-46c9-ad33-8d96c91c4e2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_34919718-fed8-4ed7-9b81-4b66739fdb82" xlink:to="loc_ifrs-full_Goodwill_9d855afa-be62-46c9-ad33-8d96c91c4e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_5b358445-83bd-4832-828f-285fd38446ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_34919718-fed8-4ed7-9b81-4b66739fdb82" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_5b358445-83bd-4832-828f-285fd38446ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_0b162398-0970-4046-ae9e-bd72c9eb5a0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_34919718-fed8-4ed7-9b81-4b66739fdb82" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_0b162398-0970-4046-ae9e-bd72c9eb5a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_6d38017f-8c6f-46dc-96f9-e089dd10151c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_34919718-fed8-4ed7-9b81-4b66739fdb82" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_6d38017f-8c6f-46dc-96f9-e089dd10151c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_db22681a-813d-4d6e-bdb9-be89773e82d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_2b713579-a77a-4c66-9adf-0cf8b888e78a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_db22681a-813d-4d6e-bdb9-be89773e82d2" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_2b713579-a77a-4c66-9adf-0cf8b888e78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7248349b-db10-4ac6-b7cd-8f264a8b7043" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_2b713579-a77a-4c66-9adf-0cf8b888e78a" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7248349b-db10-4ac6-b7cd-8f264a8b7043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0cdb6910-a96b-4869-8065-437e766ec159" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_7248349b-db10-4ac6-b7cd-8f264a8b7043" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0cdb6910-a96b-4869-8065-437e766ec159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquiredResearchAndDevelopmentMember_e765e098-745a-4d21-9386-daf3639e7994" xlink:href="sny-20240630.xsd#sny_AcquiredResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0cdb6910-a96b-4869-8065-437e766ec159" xlink:to="loc_sny_AcquiredResearchAndDevelopmentMember_e765e098-745a-4d21-9386-daf3639e7994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProductsTrademarksAndOtherRightsMember_0600786b-aa5f-4f53-9057-da34d1329949" xlink:href="sny-20240630.xsd#sny_ProductsTrademarksAndOtherRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0cdb6910-a96b-4869-8065-437e766ec159" xlink:to="loc_sny_ProductsTrademarksAndOtherRightsMember_0600786b-aa5f-4f53-9057-da34d1329949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AltuviiioMember_9f777714-026f-41e8-b36f-b391e15c2d44" xlink:href="sny-20240630.xsd#sny_AltuviiioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProductsTrademarksAndOtherRightsMember_0600786b-aa5f-4f53-9057-da34d1329949" xlink:to="loc_sny_AltuviiioMember_9f777714-026f-41e8-b36f-b391e15c2d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_c30aab14-d062-4a7d-ba09-7019563aab55" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0cdb6910-a96b-4869-8065-437e766ec159" xlink:to="loc_ifrs-full_ComputerSoftwareMember_c30aab14-d062-4a7d-ba09-7019563aab55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_ed63d9f8-e3d0-4670-9102-8888f85a398a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0cdb6910-a96b-4869-8065-437e766ec159" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_ed63d9f8-e3d0-4670-9102-8888f85a398a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquiredRDMember_7ae6c1c2-c0c0-4a86-8d82-91a8a728292b" xlink:href="sny-20240630.xsd#sny_AcquiredRDMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0cdb6910-a96b-4869-8065-437e766ec159" xlink:to="loc_sny_AcquiredRDMember_7ae6c1c2-c0c0-4a86-8d82-91a8a728292b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsTrademarksAndOtherRightsMember_ee76e093-1571-4db2-8919-0c4ea200c6af" xlink:href="sny-20240630.xsd#sny_MarketedProductsTrademarksAndOtherRightsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0cdb6910-a96b-4869-8065-437e766ec159" xlink:to="loc_sny_MarketedProductsTrademarksAndOtherRightsMember_ee76e093-1571-4db2-8919-0c4ea200c6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1669e860-9ed5-4025-854d-85b8c16888aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_2b713579-a77a-4c66-9adf-0cf8b888e78a" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1669e860-9ed5-4025-854d-85b8c16888aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_a18c10cf-9b33-42c2-b819-8a35213e5d5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1669e860-9ed5-4025-854d-85b8c16888aa" xlink:to="loc_ifrs-full_CarryingAmountMember_a18c10cf-9b33-42c2-b819-8a35213e5d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_47ae2f30-01b4-4537-9375-a029578ce38a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_a18c10cf-9b33-42c2-b819-8a35213e5d5a" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_47ae2f30-01b4-4537-9375-a029578ce38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_d8255687-f0a8-45b1-aff2-ebebd9b941d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_a18c10cf-9b33-42c2-b819-8a35213e5d5a" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_d8255687-f0a8-45b1-aff2-ebebd9b941d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_c657eced-d2c0-40cb-ab30-02da9a519162" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_2b713579-a77a-4c66-9adf-0cf8b888e78a" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_c657eced-d2c0-40cb-ab30-02da9a519162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_61c3dccf-40d6-48fa-9326-cd16b20ad2fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_c657eced-d2c0-40cb-ab30-02da9a519162" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_61c3dccf-40d6-48fa-9326-cd16b20ad2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember_e0615110-e6ab-4a8e-a9d7-8da74a355d72" xlink:href="sny-20240630.xsd#sny_ProventionBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_61c3dccf-40d6-48fa-9326-cd16b20ad2fc" xlink:to="loc_sny_ProventionBioIncMember_e0615110-e6ab-4a8e-a9d7-8da74a355d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_d8edc3b1-1ebb-4c17-ad99-63ff3e271681" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_2b713579-a77a-4c66-9adf-0cf8b888e78a" xlink:to="loc_ifrs-full_CounterpartiesAxis_d8edc3b1-1ebb-4c17-ad99-63ff3e271681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_90f8fe11-bd84-446e-bb5b-bd3ab4f39f8f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_d8edc3b1-1ebb-4c17-ad99-63ff3e271681" xlink:to="loc_ifrs-full_CounterpartiesMember_90f8fe11-bd84-446e-bb5b-bd3ab4f39f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NovavaxMember_65c95fe4-ebb9-4157-9c26-7c89db60fb0c" xlink:href="sny-20240630.xsd#sny_NovavaxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_90f8fe11-bd84-446e-bb5b-bd3ab4f39f8f" xlink:to="loc_sny_NovavaxMember_65c95fe4-ebb9-4157-9c26-7c89db60fb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_2b713579-a77a-4c66-9adf-0cf8b888e78a" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssets_976390cd-cac2-4635-a34a-f318082f627f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_OtherIntangibleAssets_976390cd-cac2-4635-a34a-f318082f627f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_c48e1429-ee1b-4f82-b0e0-fac8c3b4a7bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_c48e1429-ee1b-4f82-b0e0-fac8c3b4a7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_cc8cf45d-9d0d-4a63-abd9-2d625c21a933" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_cc8cf45d-9d0d-4a63-abd9-2d625c21a933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_f248e302-8846-4055-b0c1-b0bd3ec75eac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_f248e302-8846-4055-b0c1-b0bd3ec75eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_139e7722-2aed-4a97-98f2-1466da0388d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_139e7722-2aed-4a97-98f2-1466da0388d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_30d10f92-c0fb-4c95-ac80-c31f236da51b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_30d10f92-c0fb-4c95-ac80-c31f236da51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_07bb75a3-827d-4f00-9392-b402e82ae6cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_07bb75a3-827d-4f00-9392-b402e82ae6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_bc61f9ef-2226-4857-a648-b5b48765ed4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_bc61f9ef-2226-4857-a648-b5b48765ed4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_3b0cca90-51d3-4b25-b089-7949419d0ab1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_3b0cca90-51d3-4b25-b089-7949419d0ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_c0e8eed8-a29d-4cec-b443-b5d022539368" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_c0e8eed8-a29d-4cec-b443-b5d022539368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_88a8679d-2a59-4f4b-8648-f3a1424bed7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_88a8679d-2a59-4f4b-8648-f3a1424bed7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssets_1b69c8c6-1a92-483d-9abf-010b745f5506" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIntangibleAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_OtherIntangibleAssets_1b69c8c6-1a92-483d-9abf-010b745f5506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_3f100954-e6c7-44ec-be2d-e212a68b62e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_3f100954-e6c7-44ec-be2d-e212a68b62e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_8d59dc4d-b113-4683-b835-9e64384ac1b3" xlink:href="sny-20240630.xsd#sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a7596e24-2ffd-4de0-89f0-8a0e805913cc" xlink:to="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_8d59dc4d-b113-4683-b835-9e64384ac1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ImpairmentofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#ImpairmentofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ImpairmentofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract_e37d461b-4bf1-4202-9df9-9701833ee3da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_ea4ba333-b15a-4ad5-a2ca-593f2e42b2cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract_e37d461b-4bf1-4202-9df9-9701833ee3da" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_ea4ba333-b15a-4ad5-a2ca-593f2e42b2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill_2cf56226-441b-484f-8938-1b1be2f31c12" xlink:href="sny-20240630.xsd#sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract_e37d461b-4bf1-4202-9df9-9701833ee3da" xlink:to="loc_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill_2cf56226-441b-484f-8938-1b1be2f31c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_4994d7c2-3264-403c-8740-424b4aff1d7c" xlink:href="sny-20240630.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_6c36fbaf-917a-4959-9e1a-ca19b4d66c5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_4994d7c2-3264-403c-8740-424b4aff1d7c" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_6c36fbaf-917a-4959-9e1a-ca19b4d66c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_116321bd-8cdd-4025-991e-6804d6e9465c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_6c36fbaf-917a-4959-9e1a-ca19b4d66c5c" xlink:to="loc_ifrs-full_JointVenturesAxis_116321bd-8cdd-4025-991e-6804d6e9465c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_2d4c4c67-0ce2-491d-9fe1-7d14259aeb0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesAxis_116321bd-8cdd-4025-991e-6804d6e9465c" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_2d4c4c67-0ce2-491d-9fe1-7d14259aeb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfraservGmbhAndCoHochstKGMember_b7a07347-f891-49a4-9229-ddf4c21861d3" xlink:href="sny-20240630.xsd#sny_InfraservGmbhAndCoHochstKGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2d4c4c67-0ce2-491d-9fe1-7d14259aeb0b" xlink:to="loc_sny_InfraservGmbhAndCoHochstKGMember_b7a07347-f891-49a4-9229-ddf4c21861d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember_764a3d66-7045-49b5-9110-f840950be346" xlink:href="sny-20240630.xsd#sny_MSPVaccineCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2d4c4c67-0ce2-491d-9fe1-7d14259aeb0b" xlink:to="loc_sny_MSPVaccineCompanyMember_764a3d66-7045-49b5-9110-f840950be346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_27758e18-f568-459c-aa79-ef51e0f60e93" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_2d4c4c67-0ce2-491d-9fe1-7d14259aeb0b" xlink:to="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_27758e18-f568-459c-aa79-ef51e0f60e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_fd8187fa-f4bb-40cd-abb5-aa143b9cf1be" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_6c36fbaf-917a-4959-9e1a-ca19b4d66c5c" xlink:to="loc_dei_LegalEntityAxis_fd8187fa-f4bb-40cd-abb5-aa143b9cf1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2e730c00-1bc4-4be7-bd11-3e7390f0c48e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_fd8187fa-f4bb-40cd-abb5-aa143b9cf1be" xlink:to="loc_dei_EntityDomain_2e730c00-1bc4-4be7-bd11-3e7390f0c48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_d59b2bb0-7cd2-4b9e-a1c8-d0d987ffd5d8" xlink:href="sny-20240630.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2e730c00-1bc4-4be7-bd11-3e7390f0c48e" xlink:to="loc_sny_EuroapiMember_d59b2bb0-7cd2-4b9e-a1c8-d0d987ffd5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember_66574fc6-682c-4310-8dd2-08c6e54d0cd9" xlink:href="sny-20240630.xsd#sny_MSPVaccineCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2e730c00-1bc4-4be7-bd11-3e7390f0c48e" xlink:to="loc_sny_MSPVaccineCompanyMember_66574fc6-682c-4310-8dd2-08c6e54d0cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_8090ce2c-5005-4fb5-af47-9e9f9281a504" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_6c36fbaf-917a-4959-9e1a-ca19b4d66c5c" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_8090ce2c-5005-4fb5-af47-9e9f9281a504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_ab4c4b1b-3be4-4b79-8a6c-d44163d92fb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_8090ce2c-5005-4fb5-af47-9e9f9281a504" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_ab4c4b1b-3be4-4b79-8a6c-d44163d92fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_a193f4b8-aec2-4a27-9034-39ed1cf87214" xlink:href="sny-20240630.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_ab4c4b1b-3be4-4b79-8a6c-d44163d92fb4" xlink:to="loc_sny_EuroapiMember_a193f4b8-aec2-4a27-9034-39ed1cf87214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_194c301d-942e-44b8-9b78-84fb2db95b78" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_6c36fbaf-917a-4959-9e1a-ca19b4d66c5c" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_194c301d-942e-44b8-9b78-84fb2db95b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_717ad8f5-d58b-46e1-8a36-0391e0411ee4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_194c301d-942e-44b8-9b78-84fb2db95b78" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_717ad8f5-d58b-46e1-8a36-0391e0411ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MCMVaccineBVMember_19e774ad-bc06-459e-98c8-855ce8c5ff9d" xlink:href="sny-20240630.xsd#sny_MCMVaccineBVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_717ad8f5-d58b-46e1-8a36-0391e0411ee4" xlink:to="loc_sny_MCMVaccineBVMember_19e774ad-bc06-459e-98c8-855ce8c5ff9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_6c36fbaf-917a-4959-9e1a-ca19b4d66c5c" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_986d9e57-ec28-406f-bd0c-37204994a36c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_986d9e57-ec28-406f-bd0c-37204994a36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod_24d74577-d784-4ba4-9cb9-f324b304089f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:to="loc_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod_24d74577-d784-4ba4-9cb9-f324b304089f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_23686a28-478e-47eb-98ba-eb2b302fc608" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInJointVenture"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_23686a28-478e-47eb-98ba-eb2b302fc608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_a9e82b5e-8f11-45e5-bbed-597e24521bf2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:to="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_a9e82b5e-8f11-45e5-bbed-597e24521bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_646a2f5e-22a5-44ce-b904-1fb6dd7870f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_646a2f5e-22a5-44ce-b904-1fb6dd7870f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_abf0ab6c-2d3e-4f5a-bdbd-b753f4e50b4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_abf0ab6c-2d3e-4f5a-bdbd-b753f4e50b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockPrice_a539e8e0-9720-4085-845e-cf97cae5fc6e" xlink:href="sny-20240630.xsd#sny_StockPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:to="loc_sny_StockPrice_a539e8e0-9720-4085-845e-cf97cae5fc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_b95f6709-5d1e-43b6-bceb-9fe254e6d7e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_b95f6709-5d1e-43b6-bceb-9fe254e6d7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubordinatedLiabilities_68a74783-824d-4620-9732-c064bd028c6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubordinatedLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_825a93d4-538a-4303-a44f-71e744ee8d7b" xlink:to="loc_ifrs-full_SubordinatedLiabilities_68a74783-824d-4620-9732-c064bd028c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_30863ed9-9aa3-44bd-b61e-08867074f22d" xlink:href="sny-20240630.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_44be06e1-d8fd-4b9e-a7e5-3b0233970eea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_30863ed9-9aa3-44bd-b61e-08867074f22d" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_44be06e1-d8fd-4b9e-a7e5-3b0233970eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_ace902f9-d767-4146-9c00-ed2e245b575d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_44be06e1-d8fd-4b9e-a7e5-3b0233970eea" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_ace902f9-d767-4146-9c00-ed2e245b575d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2faabd03-9821-487a-b062-2a62164fc82f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_ace902f9-d767-4146-9c00-ed2e245b575d" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2faabd03-9821-487a-b062-2a62164fc82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssociatesAndJointVenturesMember_e5771fdc-60c9-4035-93f0-04dd1296f3ef" xlink:href="sny-20240630.xsd#sny_AssociatesAndJointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2faabd03-9821-487a-b062-2a62164fc82f" xlink:to="loc_sny_AssociatesAndJointVenturesMember_e5771fdc-60c9-4035-93f0-04dd1296f3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_de9dcc29-1894-43fa-ba1a-d8602bbdf374" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_44be06e1-d8fd-4b9e-a7e5-3b0233970eea" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_de9dcc29-1894-43fa-ba1a-d8602bbdf374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_10e4ebfc-db0f-4c26-9882-accff1551637" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_de9dcc29-1894-43fa-ba1a-d8602bbdf374" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_10e4ebfc-db0f-4c26-9882-accff1551637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_3b81fbe6-f9b0-4b14-949f-89d7a3d798f8" xlink:href="sny-20240630.xsd#sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_de9dcc29-1894-43fa-ba1a-d8602bbdf374" xlink:to="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_3b81fbe6-f9b0-4b14-949f-89d7a3d798f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_e440d057-75b7-4149-9827-75b36a17ee11" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_de9dcc29-1894-43fa-ba1a-d8602bbdf374" xlink:to="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_e440d057-75b7-4149-9827-75b36a17ee11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_76ebb47d-83fc-4b19-bab3-797697638484" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_de9dcc29-1894-43fa-ba1a-d8602bbdf374" xlink:to="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_76ebb47d-83fc-4b19-bab3-797697638484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_7a5be306-11a3-47cb-b7ea-717ed979eeb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_de9dcc29-1894-43fa-ba1a-d8602bbdf374" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_7a5be306-11a3-47cb-b7ea-717ed979eeb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubordinatedLiabilities_9f2c5043-d7ad-45af-b85a-596f556c46bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubordinatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_de9dcc29-1894-43fa-ba1a-d8602bbdf374" xlink:to="loc_ifrs-full_SubordinatedLiabilities_9f2c5043-d7ad-45af-b85a-596f556c46bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherNonCurrentAssetsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#OtherNonCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtherNonCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_3bb30160-1b79-4a7f-a77f-fcb4937376b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_61660987-7dd0-4046-bf97-0c036849084f" xlink:href="sny-20240630.xsd#sny_DisclosureOfOtherNonCurrentAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_3bb30160-1b79-4a7f-a77f-fcb4937376b2" xlink:to="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_61660987-7dd0-4046-bf97-0c036849084f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_caf96089-3b52-4b15-af7c-1eb406ce1320" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_61660987-7dd0-4046-bf97-0c036849084f" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_caf96089-3b52-4b15-af7c-1eb406ce1320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_bffb44c5-0e38-475f-8206-a97cebf8e5d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_caf96089-3b52-4b15-af7c-1eb406ce1320" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_bffb44c5-0e38-475f-8206-a97cebf8e5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradingEquitySecuritiesMember_e03a34d1-846f-4b39-9c1a-e85e240303e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradingEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bffb44c5-0e38-475f-8206-a97cebf8e5d8" xlink:to="loc_ifrs-full_TradingEquitySecuritiesMember_e03a34d1-846f-4b39-9c1a-e85e240303e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtSecuritiesMember_7c147387-df80-4fa5-8d8c-3a278b49f353" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bffb44c5-0e38-475f-8206-a97cebf8e5d8" xlink:to="loc_ifrs-full_DebtSecuritiesMember_7c147387-df80-4fa5-8d8c-3a278b49f353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_468ab5b9-1058-48d9-a85f-b972d6f9f2f7" xlink:href="sny-20240630.xsd#sny_DisclosureOfOtherNonCurrentAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_61660987-7dd0-4046-bf97-0c036849084f" xlink:to="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_468ab5b9-1058-48d9-a85f-b972d6f9f2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_7373ad82-e37d-4cec-8549-04eed853cc98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_468ab5b9-1058-48d9-a85f-b972d6f9f2f7" xlink:to="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_7373ad82-e37d-4cec-8549-04eed853cc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_ca8e5af3-934a-409f-85ea-d830f2179ef2" xlink:href="sny-20240630.xsd#sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_468ab5b9-1058-48d9-a85f-b972d6f9f2f7" xlink:to="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_ca8e5af3-934a-409f-85ea-d830f2179ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PreFundedPensionObligations_2975aefa-548a-4ff1-8061-4b5059d96cbb" xlink:href="sny-20240630.xsd#sny_PreFundedPensionObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_468ab5b9-1058-48d9-a85f-b972d6f9f2f7" xlink:to="loc_sny_PreFundedPensionObligations_2975aefa-548a-4ff1-8061-4b5059d96cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LongTermPrepaidExpenses_0980c821-8fb3-4cb9-a1bd-c7d3efa08a63" xlink:href="sny-20240630.xsd#sny_LongTermPrepaidExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_468ab5b9-1058-48d9-a85f-b972d6f9f2f7" xlink:to="loc_sny_LongTermPrepaidExpenses_0980c821-8fb3-4cb9-a1bd-c7d3efa08a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLoansAndReceivables_27a3a2ca-c8a7-4fa3-818c-754b1c4bfd28" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLoansAndReceivables"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_468ab5b9-1058-48d9-a85f-b972d6f9f2f7" xlink:to="loc_ifrs-full_NoncurrentLoansAndReceivables_27a3a2ca-c8a7-4fa3-818c-754b1c4bfd28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_a8ad4c18-ad8d-4852-ab0a-920339299e1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_468ab5b9-1058-48d9-a85f-b972d6f9f2f7" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_a8ad4c18-ad8d-4852-ab0a-920339299e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#AccountsReceivableSummaryofAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_14314f41-3780-421a-93b6-17beb202c9a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableTable_29d21dc9-648f-4b94-8e7b-a6f548b4a4d1" xlink:href="sny-20240630.xsd#sny_DisclosureOfAccountsReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_14314f41-3780-421a-93b6-17beb202c9a2" xlink:to="loc_sny_DisclosureOfAccountsReceivableTable_29d21dc9-648f-4b94-8e7b-a6f548b4a4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_f0fd309b-6ddd-49b5-9a23-a94e51aa6719" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAccountsReceivableTable_29d21dc9-648f-4b94-8e7b-a6f548b4a4d1" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_f0fd309b-6ddd-49b5-9a23-a94e51aa6719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_8095b774-85bd-4c32-a648-60028a91be2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_f0fd309b-6ddd-49b5-9a23-a94e51aa6719" xlink:to="loc_ifrs-full_CarryingAmountMember_8095b774-85bd-4c32-a648-60028a91be2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_c0b7d2ce-a61d-465a-be28-eb62a00acfef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_8095b774-85bd-4c32-a648-60028a91be2e" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_c0b7d2ce-a61d-465a-be28-eb62a00acfef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllowanceForCreditLossesMember_0a81eeae-34da-4b7b-b484-32b7d368bf93" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllowanceForCreditLossesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_8095b774-85bd-4c32-a648-60028a91be2e" xlink:to="loc_ifrs-full_AllowanceForCreditLossesMember_0a81eeae-34da-4b7b-b484-32b7d368bf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableLineItems_fc1d2867-a4d3-41a3-a059-e0fb9bc396e7" xlink:href="sny-20240630.xsd#sny_DisclosureOfAccountsReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAccountsReceivableTable_29d21dc9-648f-4b94-8e7b-a6f548b4a4d1" xlink:to="loc_sny_DisclosureOfAccountsReceivableLineItems_fc1d2867-a4d3-41a3-a059-e0fb9bc396e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_ca9016cc-83bb-49f6-b808-75e7551777fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAccountsReceivableLineItems_fc1d2867-a4d3-41a3-a059-e0fb9bc396e7" xlink:to="loc_ifrs-full_CurrentTradeReceivables_ca9016cc-83bb-49f6-b808-75e7551777fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsReceivableAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#AccountsReceivableAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AccountsReceivableAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_f60e098d-352a-4985-a401-c8dd2afbfc9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables_cb374b1d-1738-4e46-81b5-88dbce79a472" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_f60e098d-352a-4985-a401-c8dd2afbfc9e" xlink:to="loc_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables_cb374b1d-1738-4e46-81b5-88dbce79a472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerecognizedReceivables_34027bfc-4de7-45c8-8169-a6818110389e" xlink:href="sny-20240630.xsd#sny_DerecognizedReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_f60e098d-352a-4985-a401-c8dd2afbfc9e" xlink:to="loc_sny_DerecognizedReceivables_34027bfc-4de7-45c8-8169-a6818110389e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_c7079556-4bd0-425f-a227-30f458707ce9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_727d7772-5a3b-49e2-a8dc-7df2308618cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_c7079556-4bd0-425f-a227-30f458707ce9" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_727d7772-5a3b-49e2-a8dc-7df2308618cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_aaed389c-c473-4cdf-b2bf-1caa897408fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_727d7772-5a3b-49e2-a8dc-7df2308618cc" xlink:to="loc_ifrs-full_MaturityAxis_aaed389c-c473-4cdf-b2bf-1caa897408fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_917a27f0-a15b-426a-b2ed-dc463fae0340" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_aaed389c-c473-4cdf-b2bf-1caa897408fe" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_917a27f0-a15b-426a-b2ed-dc463fae0340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneMonthMember_4319f1b4-4104-469a-99d4-8e37078869b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneMonthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_917a27f0-a15b-426a-b2ed-dc463fae0340" xlink:to="loc_ifrs-full_NotLaterThanOneMonthMember_4319f1b4-4104-469a-99d4-8e37078869b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_6ac06465-b140-4fc7-87af-3190b94ac0df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_917a27f0-a15b-426a-b2ed-dc463fae0340" xlink:to="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_6ac06465-b140-4fc7-87af-3190b94ac0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_ac5243e8-7479-41ff-9810-c729d90d81f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_917a27f0-a15b-426a-b2ed-dc463fae0340" xlink:to="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_ac5243e8-7479-41ff-9810-c729d90d81f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_077933f5-e123-409c-b660-66a9da5b2e6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_917a27f0-a15b-426a-b2ed-dc463fae0340" xlink:to="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_077933f5-e123-409c-b660-66a9da5b2e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearMember_b6a4be36-6cee-466f-8cfe-73a645324a2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_917a27f0-a15b-426a-b2ed-dc463fae0340" xlink:to="loc_ifrs-full_LaterThanOneYearMember_b6a4be36-6cee-466f-8cfe-73a645324a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_4dfb2a62-c28a-4290-adbe-264c532a5a3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_727d7772-5a3b-49e2-a8dc-7df2308618cc" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_4dfb2a62-c28a-4290-adbe-264c532a5a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OverdueReceivablesGrossValue_e895ddcc-3e5e-40ca-b4a4-8cb688ae79c9" xlink:href="sny-20240630.xsd#sny_OverdueReceivablesGrossValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_4dfb2a62-c28a-4290-adbe-264c532a5a3c" xlink:to="loc_sny_OverdueReceivablesGrossValue_e895ddcc-3e5e-40ca-b4a4-8cb688ae79c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedShareholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_3b78d470-9b37-4826-887a-3505ebf92ae4" xlink:href="sny-20240630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_041ce466-ea1a-4557-bb0f-f67bb06c2ed3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_3b78d470-9b37-4826-887a-3505ebf92ae4" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_041ce466-ea1a-4557-bb0f-f67bb06c2ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_8a461d09-3dad-4abe-8d83-176d9ad1e74c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_041ce466-ea1a-4557-bb0f-f67bb06c2ed3" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_8a461d09-3dad-4abe-8d83-176d9ad1e74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_4f575efb-487d-42b1-8425-500cdbfd9861" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_8a461d09-3dad-4abe-8d83-176d9ad1e74c" xlink:to="loc_ifrs-full_EquityMember_4f575efb-487d-42b1-8425-500cdbfd9861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_4b7fae0e-63cb-4cf6-b18a-e76d805690d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_4f575efb-487d-42b1-8425-500cdbfd9861" xlink:to="loc_ifrs-full_IssuedCapitalMember_4b7fae0e-63cb-4cf6-b18a-e76d805690d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_db7c72c2-271c-4c40-b9bb-5e9b7b02d2f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_4f575efb-487d-42b1-8425-500cdbfd9861" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_db7c72c2-271c-4c40-b9bb-5e9b7b02d2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_68863e36-7b3c-4e5c-bc26-e13b6df2bbd7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_041ce466-ea1a-4557-bb0f-f67bb06c2ed3" xlink:to="loc_dei_LegalEntityAxis_68863e36-7b3c-4e5c-bc26-e13b6df2bbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_814e7a68-74f0-4601-b17f-0eb457eac14e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_68863e36-7b3c-4e5c-bc26-e13b6df2bbd7" xlink:to="loc_dei_EntityDomain_814e7a68-74f0-4601-b17f-0eb457eac14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiMember_bbabe59c-dfdc-426e-ac80-39346e5437c8" xlink:href="sny-20240630.xsd#sny_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_814e7a68-74f0-4601-b17f-0eb457eac14e" xlink:to="loc_sny_SanofiMember_bbabe59c-dfdc-426e-ac80-39346e5437c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareProgramAxis_ad6dfc5e-4652-4f05-86ca-520ebd4228d0" xlink:href="sny-20240630.xsd#sny_ShareProgramAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_041ce466-ea1a-4557-bb0f-f67bb06c2ed3" xlink:to="loc_sny_ShareProgramAxis_ad6dfc5e-4652-4f05-86ca-520ebd4228d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareProgramDomain_9ee0887b-fa50-4970-9b2a-7c1ed6e6beb7" xlink:href="sny-20240630.xsd#sny_ShareProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareProgramAxis_ad6dfc5e-4652-4f05-86ca-520ebd4228d0" xlink:to="loc_sny_ShareProgramDomain_9ee0887b-fa50-4970-9b2a-7c1ed6e6beb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2022ProgramMember_5a9919b7-dc6e-4f44-a2f3-6fb7e2e8bdc0" xlink:href="sny-20240630.xsd#sny_ShareRepurchase2022ProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareProgramDomain_9ee0887b-fa50-4970-9b2a-7c1ed6e6beb7" xlink:to="loc_sny_ShareRepurchase2022ProgramMember_5a9919b7-dc6e-4f44-a2f3-6fb7e2e8bdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2023ProgramMember_d1bf3d41-4ca2-4d77-94df-a78cacd62928" xlink:href="sny-20240630.xsd#sny_ShareRepurchase2023ProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareProgramDomain_9ee0887b-fa50-4970-9b2a-7c1ed6e6beb7" xlink:to="loc_sny_ShareRepurchase2023ProgramMember_d1bf3d41-4ca2-4d77-94df-a78cacd62928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2024ProgramMember_492bf782-874c-4497-905e-31a4e58b99d9" xlink:href="sny-20240630.xsd#sny_ShareRepurchase2024ProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareProgramDomain_9ee0887b-fa50-4970-9b2a-7c1ed6e6beb7" xlink:to="loc_sny_ShareRepurchase2024ProgramMember_492bf782-874c-4497-905e-31a4e58b99d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c630f54b-242e-459c-8942-36942328ea09" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_041ce466-ea1a-4557-bb0f-f67bb06c2ed3" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c630f54b-242e-459c-8942-36942328ea09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_b7f27544-20f8-41ae-a956-83730de90abe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c630f54b-242e-459c-8942-36942328ea09" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_b7f27544-20f8-41ae-a956-83730de90abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeeShareOwnershipPlanMember_ab4643c4-ed25-44bf-86cf-c4082e555ebf" xlink:href="sny-20240630.xsd#sny_EmployeeShareOwnershipPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_b7f27544-20f8-41ae-a956-83730de90abe" xlink:to="loc_sny_EmployeeShareOwnershipPlanMember_ab4643c4-ed25-44bf-86cf-c4082e555ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_90d76f75-c26a-4e2c-b7fe-67fc54cb2085" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_041ce466-ea1a-4557-bb0f-f67bb06c2ed3" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_90d76f75-c26a-4e2c-b7fe-67fc54cb2085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_0e322635-37e8-4851-8066-a1a9e5f28edc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_90d76f75-c26a-4e2c-b7fe-67fc54cb2085" xlink:to="loc_ifrs-full_FinancialAssetsMember_0e322635-37e8-4851-8066-a1a9e5f28edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentsMember_cdbff0f4-86b4-4bba-b415-ad0792fefb1d" xlink:href="sny-20240630.xsd#sny_DebtInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_0e322635-37e8-4851-8066-a1a9e5f28edc" xlink:to="loc_sny_DebtInstrumentsMember_cdbff0f4-86b4-4bba-b415-ad0792fefb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowAndFairValueHedgeMember_f50d4a00-78a1-43f8-b434-410737c5970a" xlink:href="sny-20240630.xsd#sny_CashFlowAndFairValueHedgeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_0e322635-37e8-4851-8066-a1a9e5f28edc" xlink:to="loc_sny_CashFlowAndFairValueHedgeMember_f50d4a00-78a1-43f8-b434-410737c5970a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForeignCurrencyTranslationMember_9042c947-4fbc-404c-ae22-ad2bffd51b5d" xlink:href="sny-20240630.xsd#sny_ForeignCurrencyTranslationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_0e322635-37e8-4851-8066-a1a9e5f28edc" xlink:to="loc_sny_ForeignCurrencyTranslationMember_9042c947-4fbc-404c-ae22-ad2bffd51b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsAxis_0c5e9dd6-0737-4c57-8004-1dc621c72bf6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_041ce466-ea1a-4557-bb0f-f67bb06c2ed3" xlink:to="loc_ifrs-full_ReclassifiedItemsAxis_0c5e9dd6-0737-4c57-8004-1dc621c72bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsMember_cdb5996e-f5ea-401a-856c-a02a11c35620" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis_0c5e9dd6-0737-4c57-8004-1dc621c72bf6" xlink:to="loc_ifrs-full_ReclassifiedItemsMember_cdb5996e-f5ea-401a-856c-a02a11c35620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_3dbb9487-c184-4d76-b0c4-2be42477f74a" xlink:href="sny-20240630.xsd#sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReclassifiedItemsMember_cdb5996e-f5ea-401a-856c-a02a11c35620" xlink:to="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_3dbb9487-c184-4d76-b0c4-2be42477f74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_041ce466-ea1a-4557-bb0f-f67bb06c2ed3" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_af7d3181-5715-4790-b1ac-8122146dcbf1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_ifrs-full_IssuedCapital_af7d3181-5715-4790-b1ac-8122146dcbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_2a7595d3-ca80-478f-bce2-5a05aa501351" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_ifrs-full_NumberOfSharesIssued_2a7595d3-ca80-478f-bce2-5a05aa501351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_80a2ebea-c1e3-4fae-8bda-1351898dad43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_ifrs-full_ParValuePerShare_80a2ebea-c1e3-4fae-8bda-1351898dad43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_13d8794f-99fe-4324-854b-8e3d7ec315e4" xlink:href="sny-20240630.xsd#sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_13d8794f-99fe-4324-854b-8e3d7ec315e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_c8aa35d0-26b9-48ed-91f5-738f0d099d79" xlink:href="sny-20240630.xsd#sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_c8aa35d0-26b9-48ed-91f5-738f0d099d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_2b33327b-dae7-4fd5-b4ce-3c904f780143" xlink:href="sny-20240630.xsd#sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_2b33327b-dae7-4fd5-b4ce-3c904f780143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesAlloted_ab0038bb-cf00-4302-869e-e95084ca666b" xlink:href="sny-20240630.xsd#sny_NumberOfRestrictedSharesAlloted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_NumberOfRestrictedSharesAlloted_ab0038bb-cf00-4302-869e-e95084ca666b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PeriodOfShareRepurchaseProgram_1f85469e-1dc6-489a-8501-302d68dd667f" xlink:href="sny-20240630.xsd#sny_PeriodOfShareRepurchaseProgram"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_PeriodOfShareRepurchaseProgram_1f85469e-1dc6-489a-8501-302d68dd667f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesRepurchased_d1963e44-2843-401c-9e29-c5e6dc11e069" xlink:href="sny-20240630.xsd#sny_NumberOfSharesRepurchased"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_NumberOfSharesRepurchased_d1963e44-2843-401c-9e29-c5e6dc11e069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmountOfSharesRepurchased_0b0046ec-e01c-470f-b1af-5c4abc2d8f17" xlink:href="sny-20240630.xsd#sny_AmountOfSharesRepurchased"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_AmountOfSharesRepurchased_0b0046ec-e01c-470f-b1af-5c4abc2d8f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubscriptionPricePerShare_1678c516-2fcf-45f5-97c9-e54fa4787530" xlink:href="sny-20240630.xsd#sny_SubscriptionPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_SubscriptionPricePerShare_1678c516-2fcf-45f5-97c9-e54fa4787530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesSubscribed_28b69414-79da-4894-979e-84aacc472469" xlink:href="sny-20240630.xsd#sny_NumberOfSharesSubscribed"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_NumberOfSharesSubscribed_28b69414-79da-4894-979e-84aacc472469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_1be6bdc3-e23c-4ee8-a99e-aa5815113ed0" xlink:href="sny-20240630.xsd#sny_IssuanceOfFurtherSharesAsAnEmployersContribution"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_1be6bdc3-e23c-4ee8-a99e-aa5815113ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_b7fe06e9-b4af-43ec-9a3c-de6fb7479772" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_b7fe06e9-b4af-43ec-9a3c-de6fb7479772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_6c50910d-61bf-4c8f-92ad-8975d5db2351" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_6c50910d-61bf-4c8f-92ad-8975d5db2351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_ad967ae6-4171-48cd-a62f-68d1a73e2a13" xlink:href="sny-20240630.xsd#sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_ad967ae6-4171-48cd-a62f-68d1a73e2a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_0094c4cd-cb13-49e3-80d5-472eba3bac77" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c489fe3b-6398-4733-b8aa-3efcaa3400b2" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_0094c4cd-cb13-49e3-80d5-472eba3bac77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofTreasurySharesHeldDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedShareholdersEquitySummaryofTreasurySharesHeldDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofTreasurySharesHeldDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_162cbdb6-9f3d-44f1-955c-8272a7a0496a" xlink:href="sny-20240630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesHeld_f6567c77-c7ce-4f53-b831-98c5742a8c17" xlink:href="sny-20240630.xsd#sny_NumberOfSharesHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_162cbdb6-9f3d-44f1-955c-8272a7a0496a" xlink:to="loc_sny_NumberOfSharesHeld_f6567c77-c7ce-4f53-b831-98c5742a8c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfShareCapitalForThePeriod_e53c5dc5-740e-428b-80d7-e64c77476ccc" xlink:href="sny-20240630.xsd#sny_PercentageOfShareCapitalForThePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_162cbdb6-9f3d-44f1-955c-8272a7a0496a" xlink:to="loc_sny_PercentageOfShareCapitalForThePeriod_e53c5dc5-740e-428b-80d7-e64c77476ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_efbfc9e2-87ca-4129-8f56-fe3bb8bee0a7" xlink:href="sny-20240630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_83994e6f-6302-42a6-8094-7740fd8b0bbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_efbfc9e2-87ca-4129-8f56-fe3bb8bee0a7" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_83994e6f-6302-42a6-8094-7740fd8b0bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_e56d5a62-138e-424e-84df-0d99fb8d8d99" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_83994e6f-6302-42a6-8094-7740fd8b0bbc" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_e56d5a62-138e-424e-84df-0d99fb8d8d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_fe5321aa-8b43-49c9-9f6a-a1a5b9c7fbd5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_e56d5a62-138e-424e-84df-0d99fb8d8d99" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_fe5321aa-8b43-49c9-9f6a-a1a5b9c7fbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023Member_9394a5d1-202c-4069-806b-9c4ea782a4f5" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_fe5321aa-8b43-49c9-9f6a-a1a5b9c7fbd5" xlink:to="loc_sny_RestrictedSharePlan2023Member_9394a5d1-202c-4069-806b-9c4ea782a4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023AdditionalSharesMember_c7589d21-c686-4072-b9d8-406a3c3307e4" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2023AdditionalSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_fe5321aa-8b43-49c9-9f6a-a1a5b9c7fbd5" xlink:to="loc_sny_RestrictedSharePlan2023AdditionalSharesMember_c7589d21-c686-4072-b9d8-406a3c3307e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2024Member_34d11775-3d57-4414-8f07-6b39b72b437d" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_fe5321aa-8b43-49c9-9f6a-a1a5b9c7fbd5" xlink:to="loc_sny_RestrictedSharePlan2024Member_34d11775-3d57-4414-8f07-6b39b72b437d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2024AdditionalSharesMember_47ebe186-648c-4258-9d5e-b6ddcfc1a0c2" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2024AdditionalSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_fe5321aa-8b43-49c9-9f6a-a1a5b9c7fbd5" xlink:to="loc_sny_RestrictedSharePlan2024AdditionalSharesMember_47ebe186-648c-4258-9d5e-b6ddcfc1a0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionAxis_c6e1e155-3eec-48ab-a3d8-4151a1f00ad8" xlink:href="sny-20240630.xsd#sny_MarketConditionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_83994e6f-6302-42a6-8094-7740fd8b0bbc" xlink:to="loc_sny_MarketConditionAxis_c6e1e155-3eec-48ab-a3d8-4151a1f00ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionDomain_596b4c48-aa7e-456a-adbf-fa7a700ded16" xlink:href="sny-20240630.xsd#sny_MarketConditionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_MarketConditionAxis_c6e1e155-3eec-48ab-a3d8-4151a1f00ad8" xlink:to="loc_sny_MarketConditionDomain_596b4c48-aa7e-456a-adbf-fa7a700ded16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithoutMarketConditionMember_a009b99d-c623-444a-bf8b-05f51f79b960" xlink:href="sny-20240630.xsd#sny_WithoutMarketConditionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_MarketConditionDomain_596b4c48-aa7e-456a-adbf-fa7a700ded16" xlink:to="loc_sny_WithoutMarketConditionMember_a009b99d-c623-444a-bf8b-05f51f79b960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithMarketConditionMember_ad58f0bc-2567-4c3b-89fd-cb6822c846dd" xlink:href="sny-20240630.xsd#sny_WithMarketConditionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_MarketConditionDomain_596b4c48-aa7e-456a-adbf-fa7a700ded16" xlink:to="loc_sny_WithMarketConditionMember_ad58f0bc-2567-4c3b-89fd-cb6822c846dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_11e61ce0-c65e-4058-8758-9ca192a4064f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_83994e6f-6302-42a6-8094-7740fd8b0bbc" xlink:to="loc_srt_TitleOfIndividualAxis_11e61ce0-c65e-4058-8758-9ca192a4064f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ceba45a6-5b91-4098-a6f5-07b605d8f37a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_11e61ce0-c65e-4058-8758-9ca192a4064f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ceba45a6-5b91-4098-a6f5-07b605d8f37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExcludingChiefExecutiveOfficerMember_384fd928-ca7f-4efe-9bb9-a811461b1feb" xlink:href="sny-20240630.xsd#sny_ExcludingChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ceba45a6-5b91-4098-a6f5-07b605d8f37a" xlink:to="loc_sny_ExcludingChiefExecutiveOfficerMember_384fd928-ca7f-4efe-9bb9-a811461b1feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_1330d550-3977-4747-8c88-eda4199ed5c2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ceba45a6-5b91-4098-a6f5-07b605d8f37a" xlink:to="loc_srt_ChiefExecutiveOfficerMember_1330d550-3977-4747-8c88-eda4199ed5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b13a7f1f-7796-47f1-b3c5-d4fb1fa3801b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_83994e6f-6302-42a6-8094-7740fd8b0bbc" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b13a7f1f-7796-47f1-b3c5-d4fb1fa3801b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_67e5feb1-4b72-40a1-ac4d-efed4446b25f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b13a7f1f-7796-47f1-b3c5-d4fb1fa3801b" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_67e5feb1-4b72-40a1-ac4d-efed4446b25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod_8c30a6ea-c067-46d7-8453-b722baf3a8a5" xlink:href="sny-20240630.xsd#sny_FairValuePerShareAwardedForThreeYearServicePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b13a7f1f-7796-47f1-b3c5-d4fb1fa3801b" xlink:to="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod_8c30a6ea-c067-46d7-8453-b722baf3a8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfPlanAtDateOfGrant_23c36a38-3f1c-4298-85b3-4e3812b9c8d3" xlink:href="sny-20240630.xsd#sny_FairValueOfPlanAtDateOfGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b13a7f1f-7796-47f1-b3c5-d4fb1fa3801b" xlink:to="loc_sny_FairValueOfPlanAtDateOfGrant_23c36a38-3f1c-4298-85b3-4e3812b9c8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfYearsServicePeriod_824179c4-31b9-477a-bdf8-5618b8911aba" xlink:href="sny-20240630.xsd#sny_NumberOfYearsServicePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b13a7f1f-7796-47f1-b3c5-d4fb1fa3801b" xlink:to="loc_sny_NumberOfYearsServicePeriod_824179c4-31b9-477a-bdf8-5618b8911aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_02e40c4c-8fe4-493b-bddf-fe131532a57e" xlink:href="sny-20240630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_83e85f1c-0f78-44f5-b6e6-5d74a01c6b4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_02e40c4c-8fe4-493b-bddf-fe131532a57e" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_83e85f1c-0f78-44f5-b6e6-5d74a01c6b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2b4c10fb-8d64-44d9-9dd2-21f4a4783858" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_83e85f1c-0f78-44f5-b6e6-5d74a01c6b4e" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2b4c10fb-8d64-44d9-9dd2-21f4a4783858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_30db1d9e-db8a-4bcc-8f66-e9bc82ed40dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_2b4c10fb-8d64-44d9-9dd2-21f4a4783858" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_30db1d9e-db8a-4bcc-8f66-e9bc82ed40dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharesMember_401695ec-aa11-4705-9f03-e4f122ab96e5" xlink:href="sny-20240630.xsd#sny_RestrictedSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_30db1d9e-db8a-4bcc-8f66-e9bc82ed40dd" xlink:to="loc_sny_RestrictedSharesMember_401695ec-aa11-4705-9f03-e4f122ab96e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023Member_58646a73-d30d-4f97-a342-377388be36aa" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RestrictedSharesMember_401695ec-aa11-4705-9f03-e4f122ab96e5" xlink:to="loc_sny_RestrictedSharePlan2023Member_58646a73-d30d-4f97-a342-377388be36aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2022Member_4bc58e53-697b-4d77-bb93-7edece859391" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RestrictedSharesMember_401695ec-aa11-4705-9f03-e4f122ab96e5" xlink:to="loc_sny_RestrictedSharePlan2022Member_4bc58e53-697b-4d77-bb93-7edece859391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2021Member_fd147525-f37b-46f5-b0c3-de6934f0fb0b" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RestrictedSharesMember_401695ec-aa11-4705-9f03-e4f122ab96e5" xlink:to="loc_sny_RestrictedSharePlan2021Member_fd147525-f37b-46f5-b0c3-de6934f0fb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2020Member_487f024f-e610-4bc2-942b-81b48740701d" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2020Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RestrictedSharesMember_401695ec-aa11-4705-9f03-e4f122ab96e5" xlink:to="loc_sny_RestrictedSharePlan2020Member_487f024f-e610-4bc2-942b-81b48740701d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2024Member_60abf380-51bb-4f0c-be08-fee119b01cf5" xlink:href="sny-20240630.xsd#sny_RestrictedSharePlan2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_30db1d9e-db8a-4bcc-8f66-e9bc82ed40dd" xlink:to="loc_sny_RestrictedSharePlan2024Member_60abf380-51bb-4f0c-be08-fee119b01cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4a9842fa-3aa7-451a-8281-d022b573af4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_83e85f1c-0f78-44f5-b6e6-5d74a01c6b4e" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4a9842fa-3aa7-451a-8281-d022b573af4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_51d249fe-2144-495c-9be0-60a0b24e9e70" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4a9842fa-3aa7-451a-8281-d022b573af4a" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_51d249fe-2144-495c-9be0-60a0b24e9e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesNotYetFullyVested_b9cf00bf-837b-42bd-9492-124a84b646c6" xlink:href="sny-20240630.xsd#sny_NumberOfRestrictedSharesNotYetFullyVested"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4a9842fa-3aa7-451a-8281-d022b573af4a" xlink:to="loc_sny_NumberOfRestrictedSharesNotYetFullyVested_b9cf00bf-837b-42bd-9492-124a84b646c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_8e342b23-534f-447a-9599-539896734ebe" xlink:href="sny-20240630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c1991f7f-f74c-49c3-a18f-f5d959e277d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_8e342b23-534f-447a-9599-539896734ebe" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c1991f7f-f74c-49c3-a18f-f5d959e277d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_f3f5c27a-8949-4d66-9926-b8bbe654dd9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c1991f7f-f74c-49c3-a18f-f5d959e277d7" xlink:to="loc_ifrs-full_RangeAxis_f3f5c27a-8949-4d66-9926-b8bbe654dd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_fc57be7a-40ed-4852-9495-1264c00f72e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_f3f5c27a-8949-4d66-9926-b8bbe654dd9a" xlink:to="loc_ifrs-full_RangesMember_fc57be7a-40ed-4852-9495-1264c00f72e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_73c28137-c264-4dd8-a12a-150ea8d1e70b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_fc57be7a-40ed-4852-9495-1264c00f72e0" xlink:to="loc_ifrs-full_BottomOfRangeMember_73c28137-c264-4dd8-a12a-150ea8d1e70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_17ba7eb1-231f-43ab-9f37-88577b8fc962" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_fc57be7a-40ed-4852-9495-1264c00f72e0" xlink:to="loc_ifrs-full_TopOfRangeMember_17ba7eb1-231f-43ab-9f37-88577b8fc962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_b1e62988-52a5-4717-9806-a595e7adc0da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c1991f7f-f74c-49c3-a18f-f5d959e277d7" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_b1e62988-52a5-4717-9806-a595e7adc0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_02f993ed-ce75-42f3-9c87-fe51d3624b93" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_b1e62988-52a5-4717-9806-a595e7adc0da" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_02f993ed-ce75-42f3-9c87-fe51d3624b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeTwoMember_fd00d37a-c083-4789-b0aa-71a10105213f" xlink:href="sny-20240630.xsd#sny_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_02f993ed-ce75-42f3-9c87-fe51d3624b93" xlink:to="loc_sny_ExercisePriceRangeTwoMember_fd00d37a-c083-4789-b0aa-71a10105213f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeThreeMember_2a04f960-646c-4e8b-af39-a7990e5eb2c3" xlink:href="sny-20240630.xsd#sny_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_02f993ed-ce75-42f3-9c87-fe51d3624b93" xlink:to="loc_sny_ExercisePriceRangeThreeMember_2a04f960-646c-4e8b-af39-a7990e5eb2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeFourMember_778de72e-02b0-44b8-b507-2d0372e7d628" xlink:href="sny-20240630.xsd#sny_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_02f993ed-ce75-42f3-9c87-fe51d3624b93" xlink:to="loc_sny_ExercisePriceRangeFourMember_778de72e-02b0-44b8-b507-2d0372e7d628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_c71e329a-0df7-4bff-be19-4d9b1ffac59b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c1991f7f-f74c-49c3-a18f-f5d959e277d7" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_c71e329a-0df7-4bff-be19-4d9b1ffac59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_32fd4081-6433-46ab-a8ef-4193ed0ed855" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_c71e329a-0df7-4bff-be19-4d9b1ffac59b" xlink:to="loc_ifrs-full_EquityMember_32fd4081-6433-46ab-a8ef-4193ed0ed855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionPlanMember_dc498eb7-b02f-4906-83c8-30a9098fe308" xlink:href="sny-20240630.xsd#sny_StockOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_32fd4081-6433-46ab-a8ef-4193ed0ed855" xlink:to="loc_sny_StockOptionPlanMember_dc498eb7-b02f-4906-83c8-30a9098fe308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aab93865-6de6-495d-af98-ecbf3ab59722" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c1991f7f-f74c-49c3-a18f-f5d959e277d7" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aab93865-6de6-495d-af98-ecbf3ab59722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_77bb8745-677d-4a1d-9d8f-189548aae611" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aab93865-6de6-495d-af98-ecbf3ab59722" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_77bb8745-677d-4a1d-9d8f-189548aae611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_f4af6bd2-c225-4f42-91c5-c6e7604ee484" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aab93865-6de6-495d-af98-ecbf3ab59722" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_f4af6bd2-c225-4f42-91c5-c6e7604ee484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_e47acd86-c8c6-477a-853b-39f6bc9dc6fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aab93865-6de6-495d-af98-ecbf3ab59722" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_e47acd86-c8c6-477a-853b-39f6bc9dc6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_cff7f356-6d01-44ce-ae77-bc6423d81d3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aab93865-6de6-495d-af98-ecbf3ab59722" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_cff7f356-6d01-44ce-ae77-bc6423d81d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_b18681ac-e048-4050-bc3a-2c5c50103b05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aab93865-6de6-495d-af98-ecbf3ab59722" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_b18681ac-e048-4050-bc3a-2c5c50103b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_e0cef4d9-1c81-4f1d-a501-e9c05a35dbaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aab93865-6de6-495d-af98-ecbf3ab59722" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_e0cef4d9-1c81-4f1d-a501-e9c05a35dbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_a1b77268-56f7-4d17-a495-0a674956e019" xlink:href="sny-20240630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_9f9c7c57-238f-4c68-aef9-05c599d9313d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_a1b77268-56f7-4d17-a495-0a674956e019" xlink:to="loc_ifrs-full_WeightedAverageShares_9f9c7c57-238f-4c68-aef9-05c599d9313d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_e766f29c-3cbf-4653-85c2-9fc34d23a1ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_a1b77268-56f7-4d17-a495-0a674956e019" xlink:to="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_e766f29c-3cbf-4653-85c2-9fc34d23a1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_42a52f0c-d6f8-440b-8348-07c10c00408c" xlink:href="sny-20240630.xsd#sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_a1b77268-56f7-4d17-a495-0a674956e019" xlink:to="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_42a52f0c-d6f8-440b-8348-07c10c00408c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_544108d2-4d56-42da-a389-9ec8c8a9808d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_a1b77268-56f7-4d17-a495-0a674956e019" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_544108d2-4d56-42da-a389-9ec8c8a9808d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_cc523085-cd00-4b42-8468-70aca6c65f32" xlink:href="sny-20240630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_5a1912fa-4a35-4b65-8794-7060ef324c57" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_cc523085-cd00-4b42-8468-70aca6c65f32" xlink:to="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_5a1912fa-4a35-4b65-8794-7060ef324c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_caf85cd3-21d6-4ce4-b204-d3f8b6618392" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_5a1912fa-4a35-4b65-8794-7060ef324c57" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_caf85cd3-21d6-4ce4-b204-d3f8b6618392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_36260e2c-a0bc-4553-8217-4eb1780ed5d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_caf85cd3-21d6-4ce4-b204-d3f8b6618392" xlink:to="loc_ifrs-full_EquityMember_36260e2c-a0bc-4553-8217-4eb1780ed5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_a7892027-d609-49b2-a4e7-c40e29e6afa9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_36260e2c-a0bc-4553-8217-4eb1780ed5d7" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_a7892027-d609-49b2-a4e7-c40e29e6afa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsAxis_4d452a85-bf71-4ec2-8cfa-31493286b417" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_5a1912fa-4a35-4b65-8794-7060ef324c57" xlink:to="loc_ifrs-full_ReclassifiedItemsAxis_4d452a85-bf71-4ec2-8cfa-31493286b417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsMember_7052ab7d-e3a9-4039-ad39-130646024d81" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis_4d452a85-bf71-4ec2-8cfa-31493286b417" xlink:to="loc_ifrs-full_ReclassifiedItemsMember_7052ab7d-e3a9-4039-ad39-130646024d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_ec675317-1144-48e0-a20e-8bd39982c3f2" xlink:href="sny-20240630.xsd#sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReclassifiedItemsMember_7052ab7d-e3a9-4039-ad39-130646024d81" xlink:to="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_ec675317-1144-48e0-a20e-8bd39982c3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_2365f6e1-4ef3-4583-821a-0eeed991960e" xlink:href="sny-20240630.xsd#sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReclassifiedItemsMember_7052ab7d-e3a9-4039-ad39-130646024d81" xlink:to="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_2365f6e1-4ef3-4583-821a-0eeed991960e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1ceac5c5-a692-4c59-a8af-7c958e5baa23" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_5a1912fa-4a35-4b65-8794-7060ef324c57" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1ceac5c5-a692-4c59-a8af-7c958e5baa23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_427456f3-0e9c-410e-af4f-554709bfd095" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1ceac5c5-a692-4c59-a8af-7c958e5baa23" xlink:to="loc_ifrs-full_FinancialAssetsMember_427456f3-0e9c-410e-af4f-554709bfd095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInstrumentsIncludedInFinancialAssetsMember_dc39ecae-c9d8-491d-8da6-a608e034823a" xlink:href="sny-20240630.xsd#sny_EquityInstrumentsIncludedInFinancialAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_427456f3-0e9c-410e-af4f-554709bfd095" xlink:to="loc_sny_EquityInstrumentsIncludedInFinancialAssetsMember_dc39ecae-c9d8-491d-8da6-a608e034823a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentsMember_ba533f48-06fc-4033-b9a4-88abf6ba4d61" xlink:href="sny-20240630.xsd#sny_DebtInstrumentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_427456f3-0e9c-410e-af4f-554709bfd095" xlink:to="loc_sny_DebtInstrumentsMember_ba533f48-06fc-4033-b9a4-88abf6ba4d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowAndFairValueHedgeMember_d52a6afb-56eb-4ecb-b265-03488843605d" xlink:href="sny-20240630.xsd#sny_CashFlowAndFairValueHedgeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_427456f3-0e9c-410e-af4f-554709bfd095" xlink:to="loc_sny_CashFlowAndFairValueHedgeMember_d52a6afb-56eb-4ecb-b265-03488843605d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForeignCurrencyTranslationMember_beaf1caa-c1d0-4bd2-9c63-2c168ace8670" xlink:href="sny-20240630.xsd#sny_ForeignCurrencyTranslationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_427456f3-0e9c-410e-af4f-554709bfd095" xlink:to="loc_sny_ForeignCurrencyTranslationMember_beaf1caa-c1d0-4bd2-9c63-2c168ace8670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_afa242f5-93d1-4a27-9ea5-39f60b07296f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_5a1912fa-4a35-4b65-8794-7060ef324c57" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_afa242f5-93d1-4a27-9ea5-39f60b07296f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_802f2f71-0a7c-4c0a-8b9a-e1f800e632f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_afa242f5-93d1-4a27-9ea5-39f60b07296f" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_802f2f71-0a7c-4c0a-8b9a-e1f800e632f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_71b9761c-e352-4482-a036-5fb29ace881e" xlink:href="sny-20240630.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_802f2f71-0a7c-4c0a-8b9a-e1f800e632f4" xlink:to="loc_sny_EuroapiMember_71b9761c-e352-4482-a036-5fb29ace881e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_5a1912fa-4a35-4b65-8794-7060ef324c57" xlink:to="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_10e24b9b-a516-4325-91ce-ba5551cb83ed" xlink:href="sny-20240630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_10e24b9b-a516-4325-91ce-ba5551cb83ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_e85e4264-804f-40fe-ac1e-adac731c8464" xlink:href="sny-20240630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_e85e4264-804f-40fe-ac1e-adac731c8464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_0e4ead48-b2fa-4b9f-ad49-6b0980176de1" xlink:href="sny-20240630.xsd#sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_0e4ead48-b2fa-4b9f-ad49-6b0980176de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_56fc1629-7331-479b-a430-d928a380d204" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_56fc1629-7331-479b-a430-d928a380d204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_6d51a1db-cdd7-461d-89fc-badce9db606a" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_6d51a1db-cdd7-461d-89fc-badce9db606a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_df74c72f-de09-47e0-a453-778872b30eb3" xlink:href="sny-20240630.xsd#sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_df74c72f-de09-47e0-a453-778872b30eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_7832f0e2-39f3-41fe-98e1-103036f2eeb1" xlink:href="sny-20240630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_7832f0e2-39f3-41fe-98e1-103036f2eeb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_fa96befc-55da-4e9e-95c3-cb9ce4f13cb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_fa96befc-55da-4e9e-95c3-cb9ce4f13cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_d236f9ef-c902-4ae5-8d3e-88c7e06036a8" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_d236f9ef-c902-4ae5-8d3e-88c7e06036a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_0631e9aa-4993-4810-af81-3e582d4480b5" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_0631e9aa-4993-4810-af81-3e582d4480b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_79fef6d1-64a0-4a8c-bcb4-efdefcf670fd" xlink:href="sny-20240630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_79fef6d1-64a0-4a8c-bcb4-efdefcf670fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_69e1d4ac-ba2a-4855-8b43-a89b36ad36c8" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_69e1d4ac-ba2a-4855-8b43-a89b36ad36c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_e8d0ca9a-a4ee-4c17-8fd0-a0b3484bd462" xlink:href="sny-20240630.xsd#sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_e8d0ca9a-a4ee-4c17-8fd0-a0b3484bd462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_d62bc124-2efb-480d-bdac-0fd809db0644" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_d62bc124-2efb-480d-bdac-0fd809db0644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_956670c7-81b5-4f26-aee2-80feedfd3215" xlink:href="sny-20240630.xsd#sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_956670c7-81b5-4f26-aee2-80feedfd3215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_318bd66f-5315-4be4-8cec-e1ef0f5794b5" xlink:href="sny-20240630.xsd#sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_318bd66f-5315-4be4-8cec-e1ef0f5794b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_c91fd476-8357-4f42-884d-44a0a1f03e5d" xlink:href="sny-20240630.xsd#sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_c91fd476-8357-4f42-884d-44a0a1f03e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_95d183cf-e87a-4579-b486-8c6ce45aaac2" xlink:href="sny-20240630.xsd#sny_ChangeInCurrencyTranslationOnTaxEffects"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_95d183cf-e87a-4579-b486-8c6ce45aaac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_54d2e5d4-1d7e-43b6-84d3-012f2fa0913f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_54d2e5d4-1d7e-43b6-84d3-012f2fa0913f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_4849bbb8-6536-4c8f-9b15-8495b71f52e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_d2ed14c8-1e42-4c04-a33a-47c98eb9adb6" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_4849bbb8-6536-4c8f-9b15-8495b71f52e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_a3e2eb14-a2ba-49fc-90df-a67f85071759" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_5d4e948c-db68-4fc5-8fa2-ac07eb6c93fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_a3e2eb14-a2ba-49fc-90df-a67f85071759" xlink:to="loc_ifrs-full_LongtermBorrowings_5d4e948c-db68-4fc5-8fa2-ac07eb6c93fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_4e7f5a0f-7b25-44bc-9f99-999e4a06b042" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_a3e2eb14-a2ba-49fc-90df-a67f85071759" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_4e7f5a0f-7b25-44bc-9f99-999e4a06b042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_eae45399-b020-4be8-9bca-d4885e6e32b3" xlink:href="sny-20240630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_a3e2eb14-a2ba-49fc-90df-a67f85071759" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_eae45399-b020-4be8-9bca-d4885e6e32b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_abd1e894-9221-408a-9617-ce9c7db4bff0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_a3e2eb14-a2ba-49fc-90df-a67f85071759" xlink:to="loc_ifrs-full_Borrowings_abd1e894-9221-408a-9617-ce9c7db4bff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_84ae7aaf-54b1-4a78-a95a-e6ca11ef750e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_a3e2eb14-a2ba-49fc-90df-a67f85071759" xlink:to="loc_ifrs-full_CashAndCashEquivalents_84ae7aaf-54b1-4a78-a95a-e6ca11ef750e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_aa250c8c-5c2f-4d64-afbc-a9f0cced37d9" xlink:href="sny-20240630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_a3e2eb14-a2ba-49fc-90df-a67f85071759" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_aa250c8c-5c2f-4d64-afbc-a9f0cced37d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_f37991be-1992-41a4-8859-824c3128550f" xlink:href="sny-20240630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_a3e2eb14-a2ba-49fc-90df-a67f85071759" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_f37991be-1992-41a4-8859-824c3128550f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_43bc227a-7031-4df6-b48b-15a2d88fcc19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_a3e2eb14-a2ba-49fc-90df-a67f85071759" xlink:to="loc_ifrs-full_LeaseLiabilities_43bc227a-7031-4df6-b48b-15a2d88fcc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_afddff65-e8bb-4424-991c-050e35de576b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_cd92c9d5-f165-4d5a-ae05-dfe33c7db25a" xlink:href="sny-20240630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_afddff65-e8bb-4424-991c-050e35de576b" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_cd92c9d5-f165-4d5a-ae05-dfe33c7db25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_4e9a48cd-cb45-4062-a4b8-9abbc15d04ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_cd92c9d5-f165-4d5a-ae05-dfe33c7db25a" xlink:to="loc_ifrs-full_MeasurementAxis_4e9a48cd-cb45-4062-a4b8-9abbc15d04ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_ac627650-ccaf-4a66-9040-0252fb17e1e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_4e9a48cd-cb45-4062-a4b8-9abbc15d04ee" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_ac627650-ccaf-4a66-9040-0252fb17e1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizedCostNettingMember_d8ca5727-ec40-49c7-b4d9-e079b74a0f63" xlink:href="sny-20240630.xsd#sny_AmortizedCostNettingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_ac627650-ccaf-4a66-9040-0252fb17e1e3" xlink:to="loc_sny_AmortizedCostNettingMember_d8ca5727-ec40-49c7-b4d9-e079b74a0f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember_135e1ef6-da5b-4227-bba2-de256368b33e" xlink:href="sny-20240630.xsd#sny_AdjustmentToDebtMeasuredAtFairValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_ac627650-ccaf-4a66-9040-0252fb17e1e3" xlink:to="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember_135e1ef6-da5b-4227-bba2-de256368b33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_e4ba4839-76fc-4915-b2a9-b5b39217b47a" xlink:href="sny-20240630.xsd#sny_ValueOnRedemptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_ac627650-ccaf-4a66-9040-0252fb17e1e3" xlink:to="loc_sny_ValueOnRedemptionMember_e4ba4839-76fc-4915-b2a9-b5b39217b47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_9179aaca-48e5-4e7a-ab4b-66c83332474f" xlink:href="sny-20240630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_cd92c9d5-f165-4d5a-ae05-dfe33c7db25a" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_9179aaca-48e5-4e7a-ab4b-66c83332474f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_ee9f3f6e-1c0e-46d5-9902-33f8e44e4f1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_9179aaca-48e5-4e7a-ab4b-66c83332474f" xlink:to="loc_ifrs-full_LongtermBorrowings_ee9f3f6e-1c0e-46d5-9902-33f8e44e4f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_733eda23-d1e3-4605-b626-ebb23517b241" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_9179aaca-48e5-4e7a-ab4b-66c83332474f" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_733eda23-d1e3-4605-b626-ebb23517b241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_37871f20-8beb-4bef-889a-e1f300d5fb0a" xlink:href="sny-20240630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_9179aaca-48e5-4e7a-ab4b-66c83332474f" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_37871f20-8beb-4bef-889a-e1f300d5fb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_b25a1f67-7a42-42c7-9aa5-fdcb31cae580" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_9179aaca-48e5-4e7a-ab4b-66c83332474f" xlink:to="loc_ifrs-full_Borrowings_b25a1f67-7a42-42c7-9aa5-fdcb31cae580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_225b514c-d3a6-4fa0-af7b-f6e2ec3d257f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_9179aaca-48e5-4e7a-ab4b-66c83332474f" xlink:to="loc_ifrs-full_CashAndCashEquivalents_225b514c-d3a6-4fa0-af7b-f6e2ec3d257f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_5f14e9c7-db9f-48c8-950e-62a42d4aa975" xlink:href="sny-20240630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_9179aaca-48e5-4e7a-ab4b-66c83332474f" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_5f14e9c7-db9f-48c8-950e-62a42d4aa975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_51156af0-87ba-4b24-a462-f922119548db" xlink:href="sny-20240630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_9179aaca-48e5-4e7a-ab4b-66c83332474f" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_51156af0-87ba-4b24-a462-f922119548db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_c79451cf-2f96-4548-8893-fcee8a868adb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_9179aaca-48e5-4e7a-ab4b-66c83332474f" xlink:to="loc_ifrs-full_LeaseLiabilities_c79451cf-2f96-4548-8893-fcee8a868adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_8c3c490a-a3a8-4457-b845-49b21afe1e1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_8ee17277-7b5f-48af-89ac-6209bd4f5eec" xlink:href="sny-20240630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_8c3c490a-a3a8-4457-b845-49b21afe1e1c" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_8ee17277-7b5f-48af-89ac-6209bd4f5eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_d349d0c1-8c50-4790-8ee1-c65f88aef71b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_8ee17277-7b5f-48af-89ac-6209bd4f5eec" xlink:to="loc_ifrs-full_MeasurementAxis_d349d0c1-8c50-4790-8ee1-c65f88aef71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_75f6da7c-2a57-4fcc-bcf6-e6f4f49ba119" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_d349d0c1-8c50-4790-8ee1-c65f88aef71b" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_75f6da7c-2a57-4fcc-bcf6-e6f4f49ba119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_1151a0fe-645d-4488-8b8f-d16d761887ce" xlink:href="sny-20240630.xsd#sny_ValueOnRedemptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_75f6da7c-2a57-4fcc-bcf6-e6f4f49ba119" xlink:to="loc_sny_ValueOnRedemptionMember_1151a0fe-645d-4488-8b8f-d16d761887ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesAxis_28140fb5-fcd3-45ec-8fbc-b3baae28ec44" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAndLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_8ee17277-7b5f-48af-89ac-6209bd4f5eec" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesAxis_28140fb5-fcd3-45ec-8fbc-b3baae28ec44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAndLiabilitiesMember_582daedc-a9b5-49b3-9319-ffe440f3ceed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAndLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesAxis_28140fb5-fcd3-45ec-8fbc-b3baae28ec44" xlink:to="loc_ifrs-full_AssetsAndLiabilitiesMember_582daedc-a9b5-49b3-9319-ffe440f3ceed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesMember_e09bcbe0-79bc-4fdb-b48c-a9ac1000e742" xlink:href="sny-20240630.xsd#sny_NonCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_582daedc-a9b5-49b3-9319-ffe440f3ceed" xlink:to="loc_sny_NonCurrentLiabilitiesMember_e09bcbe0-79bc-4fdb-b48c-a9ac1000e742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesMember_8dccdaff-bfd3-4517-8343-8e7309bd659c" xlink:href="sny-20240630.xsd#sny_CurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAndLiabilitiesMember_582daedc-a9b5-49b3-9319-ffe440f3ceed" xlink:to="loc_sny_CurrentLiabilitiesMember_8dccdaff-bfd3-4517-8343-8e7309bd659c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_f4799290-32dd-4799-94f7-fbf9e69c20b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_8ee17277-7b5f-48af-89ac-6209bd4f5eec" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_f4799290-32dd-4799-94f7-fbf9e69c20b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_73cf05e3-b7e2-4728-8548-9b264d2ed9d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_f4799290-32dd-4799-94f7-fbf9e69c20b3" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_73cf05e3-b7e2-4728-8548-9b264d2ed9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsMember_8040f6bd-8682-4935-8fd1-4c4bf6306e1b" xlink:href="sny-20240630.xsd#sny_NonCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_73cf05e3-b7e2-4728-8548-9b264d2ed9d0" xlink:to="loc_sny_NonCurrentAssetsMember_8040f6bd-8682-4935-8fd1-4c4bf6306e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentAssetsMember_6516d4a7-8828-43a0-a09a-908ae574f8d0" xlink:href="sny-20240630.xsd#sny_CurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_73cf05e3-b7e2-4728-8548-9b264d2ed9d0" xlink:to="loc_sny_CurrentAssetsMember_6516d4a7-8828-43a0-a09a-908ae574f8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_4e86206d-eaaa-4e65-bc61-618aea2ecb4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_8ee17277-7b5f-48af-89ac-6209bd4f5eec" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_4e86206d-eaaa-4e65-bc61-618aea2ecb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_b7a14cb7-5ab1-411f-9f3b-bfce9b1a0c86" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_4e86206d-eaaa-4e65-bc61-618aea2ecb4b" xlink:to="loc_ifrs-full_BorrowingsByNameMember_b7a14cb7-5ab1-411f-9f3b-bfce9b1a0c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_7a971f45-8e49-4d88-8fc9-58fba675c0eb" xlink:href="sny-20240630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_b7a14cb7-5ab1-411f-9f3b-bfce9b1a0c86" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_7a971f45-8e49-4d88-8fc9-58fba675c0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInFranceMember_5d0bab8a-75f6-4f04-872f-7cb638c9a4ef" xlink:href="sny-20240630.xsd#sny_CommercialPaperProgramInFranceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_b7a14cb7-5ab1-411f-9f3b-bfce9b1a0c86" xlink:to="loc_sny_CommercialPaperProgramInFranceMember_5d0bab8a-75f6-4f04-872f-7cb638c9a4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:href="sny-20240630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_8ee17277-7b5f-48af-89ac-6209bd4f5eec" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_a4c12ae0-6217-41b9-97c3-1f02a857c87b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BondsIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:to="loc_ifrs-full_BondsIssued_a4c12ae0-6217-41b9-97c3-1f02a857c87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherBankBorrowings_6317f69e-edd4-4ea3-9f0a-71730a4ecd2f" xlink:href="sny-20240630.xsd#sny_OtherBankBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:to="loc_sny_OtherBankBorrowings_6317f69e-edd4-4ea3-9f0a-71730a4ecd2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings_78ff410f-2e3a-48a6-991f-29be0ef897d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:to="loc_ifrs-full_OtherBorrowings_78ff410f-2e3a-48a6-991f-29be0ef897d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_8e884525-1b4e-4db0-87db-8ad2d968beb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:to="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_8e884525-1b4e-4db0-87db-8ad2d968beb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_32a95c16-2591-46f7-959a-f48dad78a7db" xlink:href="sny-20240630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_32a95c16-2591-46f7-959a-f48dad78a7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_1d14709b-c1f5-41cf-bfa6-e86a9af31a26" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:to="loc_ifrs-full_Borrowings_1d14709b-c1f5-41cf-bfa6-e86a9af31a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_eafb14d1-951c-4669-9f53-034d8ea0fc0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:to="loc_ifrs-full_CashAndCashEquivalents_eafb14d1-951c-4669-9f53-034d8ea0fc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_b07be86e-9638-4a8e-bc7f-3857fff0d63a" xlink:href="sny-20240630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_b07be86e-9638-4a8e-bc7f-3857fff0d63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_8b8fdd5c-bc65-4df1-aadd-e8df10452db3" xlink:href="sny-20240630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_bcd08df4-c357-4670-ad14-d5ca6c92d5e0" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_8b8fdd5c-bc65-4df1-aadd-e8df10452db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#DebtCashandCashEquivalentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_1b53fa43-864f-4c17-837f-adf5bef966cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_fc16b61a-cb53-4819-8e1d-6a58c3a67406" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_1b53fa43-864f-4c17-837f-adf5bef966cb" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_fc16b61a-cb53-4819-8e1d-6a58c3a67406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_5458e012-7dd7-4220-97b5-dd61a9c61dc5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_fc16b61a-cb53-4819-8e1d-6a58c3a67406" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_5458e012-7dd7-4220-97b5-dd61a9c61dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_4a970488-f280-41a2-8543-18e038138270" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_5458e012-7dd7-4220-97b5-dd61a9c61dc5" xlink:to="loc_ifrs-full_BorrowingsByNameMember_4a970488-f280-41a2-8543-18e038138270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_72fb34aa-4742-4abb-b959-99e104d6e230" xlink:href="sny-20240630.xsd#sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4a970488-f280-41a2-8543-18e038138270" xlink:to="loc_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_72fb34aa-4742-4abb-b959-99e104d6e230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionBondsMaturingJune2023Member_2818665f-676a-44e0-8801-d62d4173c2f2" xlink:href="sny-20240630.xsd#sny_OneBillionBondsMaturingJune2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4a970488-f280-41a2-8543-18e038138270" xlink:to="loc_sny_OneBillionBondsMaturingJune2023Member_2818665f-676a-44e0-8801-d62d4173c2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityOneMember_736e5bc6-a073-4c30-b13c-a1bd35655ec3" xlink:href="sny-20240630.xsd#sny_SyndicatedCreditFacilityOneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4a970488-f280-41a2-8543-18e038138270" xlink:to="loc_sny_SyndicatedCreditFacilityOneMember_736e5bc6-a073-4c30-b13c-a1bd35655ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityTwoMember_239c13af-2c33-4d3e-b0a0-0a640edb0a43" xlink:href="sny-20240630.xsd#sny_SyndicatedCreditFacilityTwoMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4a970488-f280-41a2-8543-18e038138270" xlink:to="loc_sny_SyndicatedCreditFacilityTwoMember_239c13af-2c33-4d3e-b0a0-0a640edb0a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityCanceledMember_fe32670c-390d-42e8-b289-d4f4ff5636ac" xlink:href="sny-20240630.xsd#sny_SyndicatedCreditFacilityCanceledMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4a970488-f280-41a2-8543-18e038138270" xlink:to="loc_sny_SyndicatedCreditFacilityCanceledMember_fe32670c-390d-42e8-b289-d4f4ff5636ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInFranceMember_c14a7960-2373-41c1-96df-07216d2432c5" xlink:href="sny-20240630.xsd#sny_CommercialPaperProgramInFranceMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4a970488-f280-41a2-8543-18e038138270" xlink:to="loc_sny_CommercialPaperProgramInFranceMember_c14a7960-2373-41c1-96df-07216d2432c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_206067c1-9b97-4f56-bae7-654419a8a48b" xlink:href="sny-20240630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4a970488-f280-41a2-8543-18e038138270" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_206067c1-9b97-4f56-bae7-654419a8a48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingApril2024Redeemed2024Member_4194aee8-6a3f-40a7-89cb-d0c88182a5c6" xlink:href="sny-20240630.xsd#sny_FixedRateBondMaturingApril2024Redeemed2024Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4a970488-f280-41a2-8543-18e038138270" xlink:to="loc_sny_FixedRateBondMaturingApril2024Redeemed2024Member_4194aee8-6a3f-40a7-89cb-d0c88182a5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentAxis_24c616a5-5997-45c3-8458-a9c56dd116bc" xlink:href="sny-20240630.xsd#sny_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_fc16b61a-cb53-4819-8e1d-6a58c3a67406" xlink:to="loc_sny_DebtInstrumentAxis_24c616a5-5997-45c3-8458-a9c56dd116bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain_b90a9eec-099a-46e0-858a-0dc66922276d" xlink:href="sny-20240630.xsd#sny_DebtInstrumentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DebtInstrumentAxis_24c616a5-5997-45c3-8458-a9c56dd116bc" xlink:to="loc_sny_DebtInstrumentDomain_b90a9eec-099a-46e0-858a-0dc66922276d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiEuroMediumTermNotesMember_066fcc35-294a-4b44-9887-8edf2662dd82" xlink:href="sny-20240630.xsd#sny_SanofiEuroMediumTermNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DebtInstrumentDomain_b90a9eec-099a-46e0-858a-0dc66922276d" xlink:to="loc_sny_SanofiEuroMediumTermNotesMember_066fcc35-294a-4b44-9887-8edf2662dd82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingApril2024Redeemed2024Member_6e79e1f5-e264-45e1-a302-273b7b06b988" xlink:href="sny-20240630.xsd#sny_FixedRateBondMaturingApril2024Redeemed2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DebtInstrumentDomain_b90a9eec-099a-46e0-858a-0dc66922276d" xlink:to="loc_sny_FixedRateBondMaturingApril2024Redeemed2024Member_6e79e1f5-e264-45e1-a302-273b7b06b988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_65017fb8-21e0-4046-a84d-cfc4c811d91d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_fc16b61a-cb53-4819-8e1d-6a58c3a67406" xlink:to="loc_ifrs-full_CounterpartiesAxis_65017fb8-21e0-4046-a84d-cfc4c811d91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_2712e95b-b57a-446a-b2d7-ca9dd1d45154" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_65017fb8-21e0-4046-a84d-cfc4c811d91d" xlink:to="loc_ifrs-full_CounterpartiesMember_2712e95b-b57a-446a-b2d7-ca9dd1d45154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MazeTherapeuticsMember_67c5158b-34a1-44d8-8efe-7a749e933e82" xlink:href="sny-20240630.xsd#sny_MazeTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_2712e95b-b57a-446a-b2d7-ca9dd1d45154" xlink:to="loc_sny_MazeTherapeuticsMember_67c5158b-34a1-44d8-8efe-7a749e933e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_dcd2c805-28aa-4007-918f-3cb2b4426bf0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_fc16b61a-cb53-4819-8e1d-6a58c3a67406" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_dcd2c805-28aa-4007-918f-3cb2b4426bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfBondIssuesRedeemed_c3c3f4d9-513e-4547-8c7f-61500ae82e6f" xlink:href="sny-20240630.xsd#sny_NumberOfBondIssuesRedeemed"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_dcd2c805-28aa-4007-918f-3cb2b4426bf0" xlink:to="loc_sny_NumberOfBondIssuesRedeemed_c3c3f4d9-513e-4547-8c7f-61500ae82e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_6b91249a-f588-4031-9b02-88151886e3ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_dcd2c805-28aa-4007-918f-3cb2b4426bf0" xlink:to="loc_ifrs-full_NotionalAmount_6b91249a-f588-4031-9b02-88151886e3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CreditFacilitiesExtensionOptionNumber_d1de0152-32f0-48ec-8963-d980627e61ba" xlink:href="sny-20240630.xsd#sny_CreditFacilitiesExtensionOptionNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_dcd2c805-28aa-4007-918f-3cb2b4426bf0" xlink:to="loc_sny_CreditFacilitiesExtensionOptionNumber_d1de0152-32f0-48ec-8963-d980627e61ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CreditFacilitiesExtensionOptionPeriod_a7ca89db-80b8-4472-b836-759d939a76fd" xlink:href="sny-20240630.xsd#sny_CreditFacilitiesExtensionOptionPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_dcd2c805-28aa-4007-918f-3cb2b4426bf0" xlink:to="loc_sny_CreditFacilitiesExtensionOptionPeriod_a7ca89db-80b8-4472-b836-759d939a76fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommercialPapersIssued_171156b5-6438-4576-97d8-3eef778c307a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommercialPapersIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_dcd2c805-28aa-4007-918f-3cb2b4426bf0" xlink:to="loc_ifrs-full_CommercialPapersIssued_171156b5-6438-4576-97d8-3eef778c307a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BorrowingAverageDrawdown_7f8e8388-1253-4e05-9193-2e0dc9d44577" xlink:href="sny-20240630.xsd#sny_BorrowingAverageDrawdown"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_dcd2c805-28aa-4007-918f-3cb2b4426bf0" xlink:to="loc_sny_BorrowingAverageDrawdown_7f8e8388-1253-4e05-9193-2e0dc9d44577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPayments_21f7e995-fd55-4295-9f41-d0411e6e98d7" xlink:href="sny-20240630.xsd#sny_UpfrontPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_dcd2c805-28aa-4007-918f-3cb2b4426bf0" xlink:to="loc_sny_UpfrontPayments_21f7e995-fd55-4295-9f41-d0411e6e98d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_493aa075-0cf1-4597-8f9f-0933d9a2afd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_99922072-14f9-4854-870f-2906d906c6fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_493aa075-0cf1-4597-8f9f-0933d9a2afd9" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_99922072-14f9-4854-870f-2906d906c6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_dafbfa8a-8e0e-4fca-b4db-3e576a7f8879" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_99922072-14f9-4854-870f-2906d906c6fa" xlink:to="loc_ifrs-full_MeasurementAxis_dafbfa8a-8e0e-4fca-b4db-3e576a7f8879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_622f614d-c3c4-423d-9234-af7d04e207ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_dafbfa8a-8e0e-4fca-b4db-3e576a7f8879" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_622f614d-c3c4-423d-9234-af7d04e207ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtMarketValueMember_78eaaa13-8277-4f27-a953-d381e0b99c2b" xlink:href="sny-20240630.xsd#sny_AtMarketValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_622f614d-c3c4-423d-9234-af7d04e207ca" xlink:to="loc_sny_AtMarketValueMember_78eaaa13-8277-4f27-a953-d381e0b99c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_eb86d9c0-1152-4f47-a64d-39930343b43a" xlink:href="sny-20240630.xsd#sny_ValueOnRedemptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_622f614d-c3c4-423d-9234-af7d04e207ca" xlink:to="loc_sny_ValueOnRedemptionMember_eb86d9c0-1152-4f47-a64d-39930343b43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_796a8624-d35a-4e6d-9e70-08e267677d31" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_99922072-14f9-4854-870f-2906d906c6fa" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_796a8624-d35a-4e6d-9e70-08e267677d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_fcd22edf-be8a-4a7f-8660-641299c31545" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_796a8624-d35a-4e6d-9e70-08e267677d31" xlink:to="loc_ifrs-full_Borrowings_fcd22edf-be8a-4a7f-8660-641299c31545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RedemptionOfDebtInstrumentIssued_b26e7c3a-a2bf-4d1a-b295-1c5982f2f590" xlink:href="sny-20240630.xsd#sny_RedemptionOfDebtInstrumentIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_796a8624-d35a-4e6d-9e70-08e267677d31" xlink:to="loc_sny_RedemptionOfDebtInstrumentIssued_b26e7c3a-a2bf-4d1a-b295-1c5982f2f590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_569b5c4e-c9cf-4115-b94b-fc402f4727d5" xlink:href="sny-20240630.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_15de73d8-9a51-4253-a42c-091f97d78f53" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_569b5c4e-c9cf-4115-b94b-fc402f4727d5" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_15de73d8-9a51-4253-a42c-091f97d78f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_d91649a5-157f-46bb-8b7f-383830b86a95" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_15de73d8-9a51-4253-a42c-091f97d78f53" xlink:to="loc_ifrs-full_MeasurementAxis_d91649a5-157f-46bb-8b7f-383830b86a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_19737a9a-8ec9-442c-a0bd-31bcd54b9a35" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_d91649a5-157f-46bb-8b7f-383830b86a95" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_19737a9a-8ec9-442c-a0bd-31bcd54b9a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_1c1a13dc-ce54-4624-a243-0b3f99de5973" xlink:href="sny-20240630.xsd#sny_AtNotionalAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_19737a9a-8ec9-442c-a0bd-31bcd54b9a35" xlink:to="loc_sny_AtNotionalAmountMember_1c1a13dc-ce54-4624-a243-0b3f99de5973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_ae87eb9f-91a7-4859-b444-8b80a383f6a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_19737a9a-8ec9-442c-a0bd-31bcd54b9a35" xlink:to="loc_ifrs-full_AtFairValueMember_ae87eb9f-91a7-4859-b444-8b80a383f6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfHedgeRecognizedInEquityMember_67b94591-0e1f-4005-a075-ce7e235f7346" xlink:href="sny-20240630.xsd#sny_ValueOfHedgeRecognizedInEquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AtFairValueMember_ae87eb9f-91a7-4859-b444-8b80a383f6a1" xlink:to="loc_sny_ValueOfHedgeRecognizedInEquityMember_67b94591-0e1f-4005-a075-ce7e235f7346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_74e9a762-9a0e-4210-bf6f-bc0fd982d9ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_15de73d8-9a51-4253-a42c-091f97d78f53" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_74e9a762-9a0e-4210-bf6f-bc0fd982d9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesMember_49d9d3ff-5501-41c1-9b3a-c22099704fa2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_74e9a762-9a0e-4210-bf6f-bc0fd982d9ec" xlink:to="loc_ifrs-full_TypesOfHedgesMember_49d9d3ff-5501-41c1-9b3a-c22099704fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowHedgesMember_d2d9ffae-a573-408c-9228-6697e94af9a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowHedgesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesMember_49d9d3ff-5501-41c1-9b3a-c22099704fa2" xlink:to="loc_ifrs-full_CashFlowHedgesMember_d2d9ffae-a573-408c-9228-6697e94af9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NotEligibleForHedgeAccountingMember_64bee025-551d-4f2a-b3ff-40db2ac8673b" xlink:href="sny-20240630.xsd#sny_NotEligibleForHedgeAccountingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesMember_49d9d3ff-5501-41c1-9b3a-c22099704fa2" xlink:to="loc_sny_NotEligibleForHedgeAccountingMember_64bee025-551d-4f2a-b3ff-40db2ac8673b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_3efd7a74-2273-471f-be1a-62131232680a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_15de73d8-9a51-4253-a42c-091f97d78f53" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_3efd7a74-2273-471f-be1a-62131232680a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_d4f66589-d70e-4c5d-b6a7-48b6107be7e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_3efd7a74-2273-471f-be1a-62131232680a" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_d4f66589-d70e-4c5d-b6a7-48b6107be7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesMember_5cef69ea-cacc-4b3c-bf1b-325e3bfddc14" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_d4f66589-d70e-4c5d-b6a7-48b6107be7e7" xlink:to="loc_sny_ForwardCurrencySalesMember_5cef69ea-cacc-4b3c-bf1b-325e3bfddc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarMember_5976119d-c634-4b18-9446-a04fdec461cf" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInUSDollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_5cef69ea-cacc-4b3c-bf1b-325e3bfddc14" xlink:to="loc_sny_ForwardCurrencySalesInUSDollarMember_5976119d-c634-4b18-9446-a04fdec461cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_dd12c69a-1fd4-4a7b-b8a4-03c9684e824c" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInChineseYuanRenminbiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_5cef69ea-cacc-4b3c-bf1b-325e3bfddc14" xlink:to="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_dd12c69a-1fd4-4a7b-b8a4-03c9684e824c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInJapaneseYenMember_6328771f-cbe1-4e7f-b72c-cf2c20d76438" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInJapaneseYenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_5cef69ea-cacc-4b3c-bf1b-325e3bfddc14" xlink:to="loc_sny_ForwardCurrencySalesInJapaneseYenMember_6328771f-cbe1-4e7f-b72c-cf2c20d76438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInMexicanPesoMember_8c9ec318-d74a-445f-a042-f7b5f2fe1438" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInMexicanPesoMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_5cef69ea-cacc-4b3c-bf1b-325e3bfddc14" xlink:to="loc_sny_ForwardCurrencySalesInMexicanPesoMember_8c9ec318-d74a-445f-a042-f7b5f2fe1438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_aa033aef-f3fd-4c0f-8cc9-7890b35b7d0e" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInSingaporeDollarMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_5cef69ea-cacc-4b3c-bf1b-325e3bfddc14" xlink:to="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_aa033aef-f3fd-4c0f-8cc9-7890b35b7d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesMember_60211734-a120-44d4-a2c9-44724dfba86c" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_d4f66589-d70e-4c5d-b6a7-48b6107be7e7" xlink:to="loc_sny_ForwardCurrencyPurchasesMember_60211734-a120-44d4-a2c9-44724dfba86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_da7b339e-25c3-4d7c-aaad-7076e2f46e09" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInUSDollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_60211734-a120-44d4-a2c9-44724dfba86c" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_da7b339e-25c3-4d7c-aaad-7076e2f46e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_38e0c56a-09ac-4d7e-b6a4-55cd6f0f29a1" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInSingaporeDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_60211734-a120-44d4-a2c9-44724dfba86c" xlink:to="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_38e0c56a-09ac-4d7e-b6a4-55cd6f0f29a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInCanadianDollarMember_e10dee8b-e46b-4ee8-a586-23a71b501517" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInCanadianDollarMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_60211734-a120-44d4-a2c9-44724dfba86c" xlink:to="loc_sny_ForwardCurrencyPurchasesInCanadianDollarMember_e10dee8b-e46b-4ee8-a586-23a71b501517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInKoreanWonMember_80931853-1721-418b-a458-075df72919bf" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInKoreanWonMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_60211734-a120-44d4-a2c9-44724dfba86c" xlink:to="loc_sny_ForwardCurrencyPurchasesInKoreanWonMember_80931853-1721-418b-a458-075df72919bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_1a5e5378-9e4f-4128-a963-6e4e879945ed" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_60211734-a120-44d4-a2c9-44724dfba86c" xlink:to="loc_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_1a5e5378-9e4f-4128-a963-6e4e879945ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInRussianRoubleMember_06d7ae16-113c-4c56-854e-25b3e43fcfe5" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInRussianRoubleMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_d4f66589-d70e-4c5d-b6a7-48b6107be7e7" xlink:to="loc_sny_ForwardCurrencySalesInRussianRoubleMember_06d7ae16-113c-4c56-854e-25b3e43fcfe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInTurkishLiraMember_1d06a4c3-4465-4d75-9a41-8c1d75ab5931" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInTurkishLiraMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_d4f66589-d70e-4c5d-b6a7-48b6107be7e7" xlink:to="loc_sny_ForwardCurrencyPurchasesInTurkishLiraMember_1d06a4c3-4465-4d75-9a41-8c1d75ab5931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInRussianRoubleMember_31865908-3adf-4934-85d8-89e0e42b5037" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInRussianRoubleMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_d4f66589-d70e-4c5d-b6a7-48b6107be7e7" xlink:to="loc_sny_ForwardCurrencyPurchasesInRussianRoubleMember_31865908-3adf-4934-85d8-89e0e42b5037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_aaaff834-b1fa-4658-963f-32629c27af0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_15de73d8-9a51-4253-a42c-091f97d78f53" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_aaaff834-b1fa-4658-963f-32629c27af0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstruments_07fd5937-0502-4262-872e-0e2670f3ee58" xlink:href="sny-20240630.xsd#sny_DerivativeFinancialInstruments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_aaaff834-b1fa-4658-963f-32629c27af0f" xlink:to="loc_sny_DerivativeFinancialInstruments_07fd5937-0502-4262-872e-0e2670f3ee58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_e701585f-9374-447a-b0a0-f4686422aa6d" xlink:href="sny-20240630.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_9975b939-aef3-4fb3-b4a1-deeac47e88e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_e701585f-9374-447a-b0a0-f4686422aa6d" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_9975b939-aef3-4fb3-b4a1-deeac47e88e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_34fff19a-fe63-43bd-91f3-f6e47a1c8224" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_9975b939-aef3-4fb3-b4a1-deeac47e88e8" xlink:to="loc_ifrs-full_MeasurementAxis_34fff19a-fe63-43bd-91f3-f6e47a1c8224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_9f51a6a3-ad3e-4a1d-9864-74d181bb81f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_34fff19a-fe63-43bd-91f3-f6e47a1c8224" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_9f51a6a3-ad3e-4a1d-9864-74d181bb81f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_92db833b-68a7-42e1-8e1c-ac06af58d594" xlink:href="sny-20240630.xsd#sny_AtNotionalAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_9f51a6a3-ad3e-4a1d-9864-74d181bb81f6" xlink:to="loc_sny_AtNotionalAmountMember_92db833b-68a7-42e1-8e1c-ac06af58d594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_05e27170-fda0-42f4-882d-86e4313eed2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_9f51a6a3-ad3e-4a1d-9864-74d181bb81f6" xlink:to="loc_ifrs-full_AtFairValueMember_05e27170-fda0-42f4-882d-86e4313eed2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_3c11a25d-2b72-4927-a9b6-cba9141a2afb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_9975b939-aef3-4fb3-b4a1-deeac47e88e8" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_3c11a25d-2b72-4927-a9b6-cba9141a2afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_a0c5a091-1399-4883-aebd-8d881e23b2cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_3c11a25d-2b72-4927-a9b6-cba9141a2afb" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_a0c5a091-1399-4883-aebd-8d881e23b2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesMember_cf4b4c2b-0ff5-4902-a544-39e23d930080" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_a0c5a091-1399-4883-aebd-8d881e23b2cd" xlink:to="loc_sny_ForwardCurrencySalesMember_cf4b4c2b-0ff5-4902-a544-39e23d930080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarMember_496fc861-07d1-48ed-bdee-f6af3771647d" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInUSDollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_cf4b4c2b-0ff5-4902-a544-39e23d930080" xlink:to="loc_sny_ForwardCurrencySalesInUSDollarMember_496fc861-07d1-48ed-bdee-f6af3771647d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_08c54f82-ae62-4c49-9af5-f5306fb494d8" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInSingaporeDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_cf4b4c2b-0ff5-4902-a544-39e23d930080" xlink:to="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_08c54f82-ae62-4c49-9af5-f5306fb494d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInPoundSterlingMember_7ec1d3bf-46aa-4477-a478-516d01733ad8" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInPoundSterlingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_cf4b4c2b-0ff5-4902-a544-39e23d930080" xlink:to="loc_sny_ForwardCurrencySalesInPoundSterlingMember_7ec1d3bf-46aa-4477-a478-516d01733ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesMember_edee1cf3-e441-4e66-9c5f-c2193284687a" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_a0c5a091-1399-4883-aebd-8d881e23b2cd" xlink:to="loc_sny_ForwardCurrencyPurchasesMember_edee1cf3-e441-4e66-9c5f-c2193284687a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_e6f2e222-69db-4e9a-99d7-93998e24eaab" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInUSDollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_edee1cf3-e441-4e66-9c5f-c2193284687a" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_e6f2e222-69db-4e9a-99d7-93998e24eaab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_3ea0b17c-f69e-479f-88a6-799e6bda7195" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInSingaporeDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_edee1cf3-e441-4e66-9c5f-c2193284687a" xlink:to="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_3ea0b17c-f69e-479f-88a6-799e6bda7195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInJapaneseYenMember_37f754ec-bd61-4d80-b830-f85eb47e0925" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInJapaneseYenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_edee1cf3-e441-4e66-9c5f-c2193284687a" xlink:to="loc_sny_ForwardCurrencyPurchasesInJapaneseYenMember_37f754ec-bd61-4d80-b830-f85eb47e0925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_e1cebaf3-42aa-448a-ae13-ce829a386a4f" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInUSDollarUSBondMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_a0c5a091-1399-4883-aebd-8d881e23b2cd" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_e1cebaf3-42aa-448a-ae13-ce829a386a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember_71acf3f8-c7f1-4021-9513-2ac5f8b63d25" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_a0c5a091-1399-4883-aebd-8d881e23b2cd" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember_71acf3f8-c7f1-4021-9513-2ac5f8b63d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_64241a0a-868b-4006-9cda-df992a90222c" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInChineseYuanRenminbiMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_a0c5a091-1399-4883-aebd-8d881e23b2cd" xlink:to="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_64241a0a-868b-4006-9cda-df992a90222c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInCanadianDollarMember_5c341b7b-5fac-4989-a731-2877fcc67796" xlink:href="sny-20240630.xsd#sny_ForwardCurrencySalesInCanadianDollarMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_a0c5a091-1399-4883-aebd-8d881e23b2cd" xlink:to="loc_sny_ForwardCurrencySalesInCanadianDollarMember_5c341b7b-5fac-4989-a731-2877fcc67796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_ef1233bb-9350-42c4-9233-bd513b81ddbb" xlink:href="sny-20240630.xsd#sny_ForwardCurrencyPurchasesInHungarianFlorintMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_a0c5a091-1399-4883-aebd-8d881e23b2cd" xlink:to="loc_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_ef1233bb-9350-42c4-9233-bd513b81ddbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_29f80ec9-1dcc-434f-bf1f-38e893777e7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_9975b939-aef3-4fb3-b4a1-deeac47e88e8" xlink:to="loc_ifrs-full_MaturityAxis_29f80ec9-1dcc-434f-bf1f-38e893777e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_65e72af1-04ef-4d28-a8d5-7f971a79957a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_29f80ec9-1dcc-434f-bf1f-38e893777e7a" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_65e72af1-04ef-4d28-a8d5-7f971a79957a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_9cc28eaa-8316-48a2-b607-b576f19ebddb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_65e72af1-04ef-4d28-a8d5-7f971a79957a" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_9cc28eaa-8316-48a2-b607-b576f19ebddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_c39799f7-5193-45b8-9791-766d76b928ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_65e72af1-04ef-4d28-a8d5-7f971a79957a" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_c39799f7-5193-45b8-9791-766d76b928ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_eb743dbd-8545-4b97-8b73-71947ef51982" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_9975b939-aef3-4fb3-b4a1-deeac47e88e8" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_eb743dbd-8545-4b97-8b73-71947ef51982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_4d4406a4-099b-445c-bb68-11d4c20a6687" xlink:href="sny-20240630.xsd#sny_DerivativeFinancialInstrumentsToManageFinancialExposure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_eb743dbd-8545-4b97-8b73-71947ef51982" xlink:to="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_4d4406a4-099b-445c-bb68-11d4c20a6687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_7eb38f5f-6ed9-4442-ab20-a2a70f4582e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_eb743dbd-8545-4b97-8b73-71947ef51982" xlink:to="loc_ifrs-full_NotionalAmount_7eb38f5f-6ed9-4442-ab20-a2a70f4582e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialAssets_b17c61ef-4115-40a2-bd7f-241e05e5d6b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_eb743dbd-8545-4b97-8b73-71947ef51982" xlink:to="loc_ifrs-full_DerivativeFinancialAssets_b17c61ef-4115-40a2-bd7f-241e05e5d6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_e91669ab-d09b-4d81-8731-f5ffb27593c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_eb743dbd-8545-4b97-8b73-71947ef51982" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_e91669ab-d09b-4d81-8731-f5ffb27593c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_c1b86414-9ce0-4cf3-b08f-95112b8bc459" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_eb743dbd-8545-4b97-8b73-71947ef51982" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_c1b86414-9ce0-4cf3-b08f-95112b8bc459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_2e955b26-f783-4bc8-9d5e-921bcf82097b" xlink:href="sny-20240630.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_258f5f11-db55-4c93-b188-939696500221" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_2e955b26-f783-4bc8-9d5e-921bcf82097b" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_258f5f11-db55-4c93-b188-939696500221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_47e583fc-86df-4ac8-a23a-878ccbea8f31" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_258f5f11-db55-4c93-b188-939696500221" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_47e583fc-86df-4ac8-a23a-878ccbea8f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_819dfa4f-455f-4341-b425-c399e3e19250" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_47e583fc-86df-4ac8-a23a-878ccbea8f31" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_819dfa4f-455f-4341-b425-c399e3e19250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member_2013ca91-9f61-489b-a842-d24d11c12abe" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_819dfa4f-455f-4341-b425-c399e3e19250" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member_2013ca91-9f61-489b-a842-d24d11c12abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member_fd293dab-dbac-46a3-9cf9-eae7a9779d0b" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_819dfa4f-455f-4341-b425-c399e3e19250" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member_fd293dab-dbac-46a3-9cf9-eae7a9779d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_12eeba27-393d-424e-8029-2e368f8d9db6" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive069Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_819dfa4f-455f-4341-b425-c399e3e19250" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_12eeba27-393d-424e-8029-2e368f8d9db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_bf1a158c-f677-490f-9cd8-268c6e490d52" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive092Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_819dfa4f-455f-4341-b425-c399e3e19250" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_bf1a158c-f677-490f-9cd8-268c6e490d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_9359b43c-5d91-4965-996e-654b8bb0fbba" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive343Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_819dfa4f-455f-4341-b425-c399e3e19250" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_9359b43c-5d91-4965-996e-654b8bb0fbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member_a61344e1-950f-4029-92f4-513f8b323fb8" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_819dfa4f-455f-4341-b425-c399e3e19250" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member_a61344e1-950f-4029-92f4-513f8b323fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member_284497a9-e46b-404a-9c27-d490afdd104c" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_819dfa4f-455f-4341-b425-c399e3e19250" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member_284497a9-e46b-404a-9c27-d490afdd104c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_4a4cc214-5848-4106-acaf-f3d4cc908168" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_258f5f11-db55-4c93-b188-939696500221" xlink:to="loc_ifrs-full_MeasurementAxis_4a4cc214-5848-4106-acaf-f3d4cc908168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_7d2f9f64-b5d5-47e6-a825-e30a1c196906" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_4a4cc214-5848-4106-acaf-f3d4cc908168" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_7d2f9f64-b5d5-47e6-a825-e30a1c196906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_945640c0-3073-4982-8178-05145e81867f" xlink:href="sny-20240630.xsd#sny_AtNotionalAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_7d2f9f64-b5d5-47e6-a825-e30a1c196906" xlink:to="loc_sny_AtNotionalAmountMember_945640c0-3073-4982-8178-05145e81867f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_155aa1c8-1fac-4bbd-85a3-ca14102a5f7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_7d2f9f64-b5d5-47e6-a825-e30a1c196906" xlink:to="loc_ifrs-full_AtFairValueMember_155aa1c8-1fac-4bbd-85a3-ca14102a5f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfHedgeRecognizedInEquityMember_c1b22ede-2ddf-45dd-8504-f72f055a459c" xlink:href="sny-20240630.xsd#sny_ValueOfHedgeRecognizedInEquityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_7d2f9f64-b5d5-47e6-a825-e30a1c196906" xlink:to="loc_sny_ValueOfHedgeRecognizedInEquityMember_c1b22ede-2ddf-45dd-8504-f72f055a459c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_d29a7f71-cd95-48df-b0e2-d5ac67ee35f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_258f5f11-db55-4c93-b188-939696500221" xlink:to="loc_ifrs-full_MaturityAxis_d29a7f71-cd95-48df-b0e2-d5ac67ee35f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_449b6759-4dc6-451e-b30d-9b2eb0bae1f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_d29a7f71-cd95-48df-b0e2-d5ac67ee35f4" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_449b6759-4dc6-451e-b30d-9b2eb0bae1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_85a157cc-021d-4fda-bd08-a68fd7ee4df5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_449b6759-4dc6-451e-b30d-9b2eb0bae1f9" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_85a157cc-021d-4fda-bd08-a68fd7ee4df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_d8d56b3b-f45d-4201-aa6b-c4789c237217" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_449b6759-4dc6-451e-b30d-9b2eb0bae1f9" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_d8d56b3b-f45d-4201-aa6b-c4789c237217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_e6a1d23d-5b0c-4b67-99a1-baf8273587c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_449b6759-4dc6-451e-b30d-9b2eb0bae1f9" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_e6a1d23d-5b0c-4b67-99a1-baf8273587c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_de614ffc-7ff4-4305-83e9-7c6e74a929c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_449b6759-4dc6-451e-b30d-9b2eb0bae1f9" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_de614ffc-7ff4-4305-83e9-7c6e74a929c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_a24dff2f-f307-4c78-851b-9d5d7b80671c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_449b6759-4dc6-451e-b30d-9b2eb0bae1f9" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_a24dff2f-f307-4c78-851b-9d5d7b80671c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_bb591882-ab2e-4493-8209-2a54ed457f71" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_258f5f11-db55-4c93-b188-939696500221" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_bb591882-ab2e-4493-8209-2a54ed457f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesMember_1ccc3c0c-9d6f-4c48-a58c-0ef896934d61" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_bb591882-ab2e-4493-8209-2a54ed457f71" xlink:to="loc_ifrs-full_TypesOfHedgesMember_1ccc3c0c-9d6f-4c48-a58c-0ef896934d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FairValueHedgesMember_aa5a710b-cac4-459d-93ce-17db95138987" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FairValueHedgesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesMember_1ccc3c0c-9d6f-4c48-a58c-0ef896934d61" xlink:to="loc_ifrs-full_FairValueHedgesMember_aa5a710b-cac4-459d-93ce-17db95138987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowHedgesMember_b2166777-7cbd-4459-97ab-e782f4a09da0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowHedgesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesMember_1ccc3c0c-9d6f-4c48-a58c-0ef896934d61" xlink:to="loc_ifrs-full_CashFlowHedgesMember_b2166777-7cbd-4459-97ab-e782f4a09da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_65dff0b2-f28f-4fba-9d17-733598448e5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_258f5f11-db55-4c93-b188-939696500221" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_65dff0b2-f28f-4fba-9d17-733598448e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsInterestRate_2601a480-4733-4cd0-9e20-c1a8547d6ce1" xlink:href="sny-20240630.xsd#sny_InterestRateSwapsInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_65dff0b2-f28f-4fba-9d17-733598448e5a" xlink:to="loc_sny_InterestRateSwapsInterestRate_2601a480-4733-4cd0-9e20-c1a8547d6ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_eb411cbf-62b4-456b-8272-ca2423623aeb" xlink:href="sny-20240630.xsd#sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_65dff0b2-f28f-4fba-9d17-733598448e5a" xlink:to="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_eb411cbf-62b4-456b-8272-ca2423623aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_d93ab4c7-762e-462a-ac26-71320d093f11" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock_f74ef85d-c2a3-43fa-8f2e-2fc8cb6b01ae" xlink:href="sny-20240630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_d93ab4c7-762e-462a-ac26-71320d093f11" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock_f74ef85d-c2a3-43fa-8f2e-2fc8cb6b01ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_72c89153-77eb-4440-953d-0ce461a8ff2e" xlink:href="sny-20240630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_d93ab4c7-762e-462a-ac26-71320d093f11" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_72c89153-77eb-4440-953d-0ce461a8ff2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_9f4caec8-0f09-47b9-8500-f5063c7a21f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_72c89153-77eb-4440-953d-0ce461a8ff2e" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_9f4caec8-0f09-47b9-8500-f5063c7a21f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_4420a51c-5e57-4bd1-87e4-ebb105a7bf15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_9f4caec8-0f09-47b9-8500-f5063c7a21f4" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_4420a51c-5e57-4bd1-87e4-ebb105a7bf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_bed0771f-b066-46a4-b845-6b4340f3cacd" xlink:href="sny-20240630.xsd#sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_4420a51c-5e57-4bd1-87e4-ebb105a7bf15" xlink:to="loc_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_bed0771f-b066-46a4-b845-6b4340f3cacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_900e6a76-41bb-4fc8-8bec-809b91accd9f" xlink:href="sny-20240630.xsd#sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_4420a51c-5e57-4bd1-87e4-ebb105a7bf15" xlink:to="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_900e6a76-41bb-4fc8-8bec-809b91accd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_c7aac595-2b5e-4cb5-8a86-da7262dc8a73" xlink:href="sny-20240630.xsd#sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_4420a51c-5e57-4bd1-87e4-ebb105a7bf15" xlink:to="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_c7aac595-2b5e-4cb5-8a86-da7262dc8a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_e16c4abe-24b0-4926-aa29-131ccde2efa6" xlink:href="sny-20240630.xsd#sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_4420a51c-5e57-4bd1-87e4-ebb105a7bf15" xlink:to="loc_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_e16c4abe-24b0-4926-aa29-131ccde2efa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherLiabilities1Member_52a6560c-566e-4bdb-98a0-997a8d583bd5" xlink:href="sny-20240630.xsd#sny_OtherLiabilities1Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_4420a51c-5e57-4bd1-87e4-ebb105a7bf15" xlink:to="loc_sny_OtherLiabilities1Member_52a6560c-566e-4bdb-98a0-997a8d583bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_85b6e65b-dfc4-4b26-83bb-8c2892eeb02b" xlink:href="sny-20240630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_72c89153-77eb-4440-953d-0ce461a8ff2e" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_85b6e65b-dfc4-4b26-83bb-8c2892eeb02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_6f440e7c-e6d2-4cbb-8186-0c3279ca76ef" xlink:href="sny-20240630.xsd#sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_85b6e65b-dfc4-4b26-83bb-8c2892eeb02b" xlink:to="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_6f440e7c-e6d2-4cbb-8186-0c3279ca76ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_75dc0cc1-b3b2-4f0c-8b7f-653b2d0d2466" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_6f440e7c-e6d2-4cbb-8186-0c3279ca76ef" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_75dc0cc1-b3b2-4f0c-8b7f-653b2d0d2466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_ae0257d5-787d-44b7-a266-3bc0a04a747a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_6f440e7c-e6d2-4cbb-8186-0c3279ca76ef" xlink:to="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_ae0257d5-787d-44b7-a266-3bc0a04a747a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_0bebc019-fed9-4def-82aa-c080d23aafdc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_6f440e7c-e6d2-4cbb-8186-0c3279ca76ef" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_0bebc019-fed9-4def-82aa-c080d23aafdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination_23ec9d6e-38a9-4dfd-8112-3b6074f19b9f" xlink:href="sny-20240630.xsd#sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_6f440e7c-e6d2-4cbb-8186-0c3279ca76ef" xlink:to="loc_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination_23ec9d6e-38a9-4dfd-8112-3b6074f19b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_11193e13-8ced-4cea-b85c-d0ee78386d6e" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_6f440e7c-e6d2-4cbb-8186-0c3279ca76ef" xlink:to="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_11193e13-8ced-4cea-b85c-d0ee78386d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_337cb2ca-311e-4c8b-a242-c0bb6daa132f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_6f440e7c-e6d2-4cbb-8186-0c3279ca76ef" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_337cb2ca-311e-4c8b-a242-c0bb6daa132f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_fe424aa1-559a-4830-af72-575642e80a24" xlink:href="sny-20240630.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_85b6e65b-dfc4-4b26-83bb-8c2892eeb02b" xlink:to="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_fe424aa1-559a-4830-af72-575642e80a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_ae65d26d-93ab-46ff-b1ae-217fbefb2c5e" xlink:href="sny-20240630.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_85b6e65b-dfc4-4b26-83bb-8c2892eeb02b" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_ae65d26d-93ab-46ff-b1ae-217fbefb2c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_fe5a0b23-c99b-460f-ab55-8f17a9991865" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_d21332c0-80f7-436a-bac0-b2c171497704" xlink:href="sny-20240630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_fe5a0b23-c99b-460f-ab55-8f17a9991865" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_d21332c0-80f7-436a-bac0-b2c171497704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_cc0c26e1-f1ea-475d-a4bc-6c73bbba2950" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_d21332c0-80f7-436a-bac0-b2c171497704" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_cc0c26e1-f1ea-475d-a4bc-6c73bbba2950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2be4e95f-41b4-443e-9f82-4e4ea8f67bda" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_cc0c26e1-f1ea-475d-a4bc-6c73bbba2950" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2be4e95f-41b4-443e-9f82-4e4ea8f67bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_dc2bece2-d02c-43ae-9f42-77a1939eeba6" xlink:href="sny-20240630.xsd#sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2be4e95f-41b4-443e-9f82-4e4ea8f67bda" xlink:to="loc_sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember_dc2bece2-d02c-43ae-9f42-77a1939eeba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_9cf60abf-8cce-4d07-a3a4-28c44492c0ea" xlink:href="sny-20240630.xsd#sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2be4e95f-41b4-443e-9f82-4e4ea8f67bda" xlink:to="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_9cf60abf-8cce-4d07-a3a4-28c44492c0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_e87e8cca-0c1d-4c34-b009-d4ee10bf0b4a" xlink:href="sny-20240630.xsd#sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2be4e95f-41b4-443e-9f82-4e4ea8f67bda" xlink:to="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_e87e8cca-0c1d-4c34-b009-d4ee10bf0b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_9c72c97d-a171-4576-a471-d71a98248dc1" xlink:href="sny-20240630.xsd#sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2be4e95f-41b4-443e-9f82-4e4ea8f67bda" xlink:to="loc_sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember_9c72c97d-a171-4576-a471-d71a98248dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_730ea52a-ac5c-4969-ac2f-ccf0dfa91655" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_d21332c0-80f7-436a-bac0-b2c171497704" xlink:to="loc_ifrs-full_RangeAxis_730ea52a-ac5c-4969-ac2f-ccf0dfa91655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_268a0b48-5e0c-4694-aad6-6d46a247c6b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_730ea52a-ac5c-4969-ac2f-ccf0dfa91655" xlink:to="loc_ifrs-full_RangesMember_268a0b48-5e0c-4694-aad6-6d46a247c6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_739ceaf1-b817-440c-a38c-2eed56528b3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_268a0b48-5e0c-4694-aad6-6d46a247c6b8" xlink:to="loc_ifrs-full_TopOfRangeMember_739ceaf1-b817-440c-a38c-2eed56528b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_fa21397d-89e4-4dfa-a2f6-c6291398924f" xlink:href="sny-20240630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_d21332c0-80f7-436a-bac0-b2c171497704" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_fa21397d-89e4-4dfa-a2f6-c6291398924f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PotentialPaymentsRelatedToPercentageOfSales_9e605692-62e7-46ca-9bca-bdb359973687" xlink:href="sny-20240630.xsd#sny_PotentialPaymentsRelatedToPercentageOfSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_fa21397d-89e4-4dfa-a2f6-c6291398924f" xlink:to="loc_sny_PotentialPaymentsRelatedToPercentageOfSales_9e605692-62e7-46ca-9bca-bdb359973687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PaymentToSaleOfBusinessPeriod_ce610936-4fa3-4f22-a6fe-4bc3c5040f39" xlink:href="sny-20240630.xsd#sny_PaymentToSaleOfBusinessPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_fa21397d-89e4-4dfa-a2f6-c6291398924f" xlink:to="loc_sny_PaymentToSaleOfBusinessPeriod_ce610936-4fa3-4f22-a6fe-4bc3c5040f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_b75dda80-3841-4d4d-ac5d-9dab628f697f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_fa21397d-89e4-4dfa-a2f6-c6291398924f" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_b75dda80-3841-4d4d-ac5d-9dab628f697f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageIncreaseInFairValueLiabilities_ad6c2345-0c7a-4d21-ba81-7e157f23b9cd" xlink:href="sny-20240630.xsd#sny_PercentageIncreaseInFairValueLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_fa21397d-89e4-4dfa-a2f6-c6291398924f" xlink:to="loc_sny_PercentageIncreaseInFairValueLiabilities_ad6c2345-0c7a-4d21-ba81-7e157f23b9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_6585d767-d29f-484f-965b-ebc5d6603894" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTable_1d45b579-797e-4329-a6ff-d0b1fb9efafb" xlink:href="sny-20240630.xsd#sny_DisclosureOfNonCurrentProvisionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_6585d767-d29f-484f-965b-ebc5d6603894" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsTable_1d45b579-797e-4329-a6ff-d0b1fb9efafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_c93dffbc-8e60-45d0-838b-54fdb49bd481" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_1d45b579-797e-4329-a6ff-d0b1fb9efafb" xlink:to="loc_sny_PrincipalAlliancesAxis_c93dffbc-8e60-45d0-838b-54fdb49bd481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_ea348499-5502-4f4a-9b56-698d34aca544" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesAxis_c93dffbc-8e60-45d0-838b-54fdb49bd481" xlink:to="loc_sny_PrincipalAlliancesDomain_ea348499-5502-4f4a-9b56-698d34aca544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_de461471-0ca6-49f5-9bad-a0796b387bf4" xlink:href="sny-20240630.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_ea348499-5502-4f4a-9b56-698d34aca544" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_de461471-0ca6-49f5-9bad-a0796b387bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_905275e9-e390-47c5-932f-d9fb81cbd8cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_1d45b579-797e-4329-a6ff-d0b1fb9efafb" xlink:to="loc_ifrs-full_CounterpartiesAxis_905275e9-e390-47c5-932f-d9fb81cbd8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_d6d98085-5686-42cc-8e7e-13c48c4dc69e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_905275e9-e390-47c5-932f-d9fb81cbd8cb" xlink:to="loc_ifrs-full_CounterpartiesMember_d6d98085-5686-42cc-8e7e-13c48c4dc69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SwedishOrphanBiovitrumABMember_eeb86ab7-73e0-4777-bb1d-b5417fcc49a1" xlink:href="sny-20240630.xsd#sny_SwedishOrphanBiovitrumABMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_d6d98085-5686-42cc-8e7e-13c48c4dc69e" xlink:to="loc_sny_SwedishOrphanBiovitrumABMember_eeb86ab7-73e0-4777-bb1d-b5417fcc49a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_a2591c08-d7d9-4b0d-a687-93852ab53221" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_1d45b579-797e-4329-a6ff-d0b1fb9efafb" xlink:to="loc_ifrs-full_MaturityAxis_a2591c08-d7d9-4b0d-a687-93852ab53221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_af708ca2-ad46-4035-a2ac-04f59b6fb179" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_a2591c08-d7d9-4b0d-a687-93852ab53221" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_af708ca2-ad46-4035-a2ac-04f59b6fb179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_4c85141b-9472-4d2c-a9c1-21ea778c9563" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_af708ca2-ad46-4035-a2ac-04f59b6fb179" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_4c85141b-9472-4d2c-a9c1-21ea778c9563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_1e599168-2163-4bf6-a576-7c076727837a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_af708ca2-ad46-4035-a2ac-04f59b6fb179" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_1e599168-2163-4bf6-a576-7c076727837a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_742314bb-7fa1-4a76-850f-8a14de3063a1" xlink:href="sny-20240630.xsd#sny_DisclosureOfNonCurrentProvisionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_1d45b579-797e-4329-a6ff-d0b1fb9efafb" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_742314bb-7fa1-4a76-850f-8a14de3063a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_dd1743df-0766-4520-9084-0519956493a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_742314bb-7fa1-4a76-850f-8a14de3063a1" xlink:to="loc_ifrs-full_NoncurrentProvisions_dd1743df-0766-4520-9084-0519956493a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_6b80ff58-413a-442f-a65b-26ab0edd81df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_742314bb-7fa1-4a76-850f-8a14de3063a1" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_6b80ff58-413a-442f-a65b-26ab0edd81df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_85ae15ef-6a75-4a6d-839c-9e6935d7ace5" xlink:href="sny-20240630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_742314bb-7fa1-4a76-850f-8a14de3063a1" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_85ae15ef-6a75-4a6d-839c-9e6935d7ace5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_acb49330-eca0-4066-a039-352e072395c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTable_6c6b01e9-f875-478d-881f-4b2b80c4fa7c" xlink:href="sny-20240630.xsd#sny_DisclosureOfNonCurrentProvisionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_acb49330-eca0-4066-a039-352e072395c6" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsTable_6c6b01e9-f875-478d-881f-4b2b80c4fa7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_6987de59-352e-46b8-8f3e-61b37f1281ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_6c6b01e9-f875-478d-881f-4b2b80c4fa7c" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_6987de59-352e-46b8-8f3e-61b37f1281ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_00151050-7ba4-48a3-9706-1635c9566b9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_6987de59-352e-46b8-8f3e-61b37f1281ca" xlink:to="loc_ifrs-full_OtherProvisionsMember_00151050-7ba4-48a3-9706-1635c9566b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_18d45c18-d2b9-4943-a58d-94b2c61c4bda" xlink:href="sny-20240630.xsd#sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_00151050-7ba4-48a3-9706-1635c9566b9e" xlink:to="loc_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_18d45c18-d2b9-4943-a58d-94b2c61c4bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForOtherLongTermBenefitsMember_8557be9a-1f0b-499b-972b-730a4f7cd84a" xlink:href="sny-20240630.xsd#sny_ProvisionsForOtherLongTermBenefitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_00151050-7ba4-48a3-9706-1635c9566b9e" xlink:to="loc_sny_ProvisionsForOtherLongTermBenefitsMember_8557be9a-1f0b-499b-972b-730a4f7cd84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentRestructuringProvisionMember_a566c3a9-bd16-4f98-9793-6672c4fdeb4e" xlink:href="sny-20240630.xsd#sny_NonCurrentRestructuringProvisionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_00151050-7ba4-48a3-9706-1635c9566b9e" xlink:to="loc_sny_NonCurrentRestructuringProvisionMember_a566c3a9-bd16-4f98-9793-6672c4fdeb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherProvisionsMember_4482a8fd-c7b0-45a7-abf1-c466ee5b6326" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherProvisionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_00151050-7ba4-48a3-9706-1635c9566b9e" xlink:to="loc_ifrs-full_MiscellaneousOtherProvisionsMember_4482a8fd-c7b0-45a7-abf1-c466ee5b6326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_40f274b9-b80c-4062-bc84-04107070acf5" xlink:href="sny-20240630.xsd#sny_DisclosureOfNonCurrentProvisionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_6c6b01e9-f875-478d-881f-4b2b80c4fa7c" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_40f274b9-b80c-4062-bc84-04107070acf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_40f274b9-b80c-4062-bc84-04107070acf5" xlink:to="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_aa4a35be-3f97-45fe-99c9-901defb76bfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:to="loc_ifrs-full_NoncurrentProvisions_aa4a35be-3f97-45fe-99c9-901defb76bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInOtherProvisions_e3ce0caf-45ea-4c36-8ffd-d00cfbab19ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInOtherProvisions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:to="loc_ifrs-full_ChangesInOtherProvisions_e3ce0caf-45ea-4c36-8ffd-d00cfbab19ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_d986b76e-58c3-4e3e-8b81-8f10858fd19b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_d986b76e-58c3-4e3e-8b81-8f10858fd19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_1f48d35b-6c75-485d-9624-b0e597e8e803" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_1f48d35b-6c75-485d-9624-b0e597e8e803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_ac6eac8a-c137-46ac-950b-e0272b0f7a11" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:to="loc_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_ac6eac8a-c137-46ac-950b-e0272b0f7a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_941f87f1-d689-4883-8d7e-883a61bfa481" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:to="loc_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_941f87f1-d689-4883-8d7e-883a61bfa481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_f23d1e60-6533-407d-a7fc-dba7f0bb58be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_f23d1e60-6533-407d-a7fc-dba7f0bb58be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_e713b578-2345-477f-8d6f-0f1170badbb8" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:to="loc_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_e713b578-2345-477f-8d6f-0f1170badbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_58adef21-6cd1-4ee8-83df-65de1bd2c106" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_bdb47abb-2bfd-4327-8a95-5b0e78676e8e" xlink:to="loc_ifrs-full_NoncurrentProvisions_58adef21-6cd1-4ee8-83df-65de1bd2c106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_3ed5a2c5-3526-46c3-a887-e4888c43fe89" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_7d26eae6-513a-459c-aa45-7380cea9a9d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_3ed5a2c5-3526-46c3-a887-e4888c43fe89" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_7d26eae6-513a-459c-aa45-7380cea9a9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_73d7bb6d-dad3-4293-9a33-b949abae30ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_7d26eae6-513a-459c-aa45-7380cea9a9d2" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_73d7bb6d-dad3-4293-9a33-b949abae30ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_fbbf5e27-7f3d-4f51-a2c2-9570bb1f89d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_73d7bb6d-dad3-4293-9a33-b949abae30ec" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_fbbf5e27-7f3d-4f51-a2c2-9570bb1f89d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsMember_d9c6480a-d473-4edc-84b4-011b6603237a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PlanAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_fbbf5e27-7f3d-4f51-a2c2-9570bb1f89d2" xlink:to="loc_ifrs-full_PlanAssetsMember_d9c6480a-d473-4edc-84b4-011b6603237a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_f7dc90dd-da0e-445a-97c9-d092f70a0b25" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_7d26eae6-513a-459c-aa45-7380cea9a9d2" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_f7dc90dd-da0e-445a-97c9-d092f70a0b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_ddb9d842-eed3-4b1b-b9cb-0bbcb5e29356" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_f7dc90dd-da0e-445a-97c9-d092f70a0b25" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_ddb9d842-eed3-4b1b-b9cb-0bbcb5e29356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_7cd794af-b9f8-4d67-abf1-c80147d0a32e" xlink:href="sny-20240630.xsd#sny_PensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_ddb9d842-eed3-4b1b-b9cb-0bbcb5e29356" xlink:to="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_7cd794af-b9f8-4d67-abf1-c80147d0a32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_08f618f9-fbbc-4013-b48a-6d4400bdf815" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_7d26eae6-513a-459c-aa45-7380cea9a9d2" xlink:to="loc_ifrs-full_GeographicalAreasAxis_08f618f9-fbbc-4013-b48a-6d4400bdf815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_cf5acf10-27d0-43b7-9b6b-ef435e8d0f00" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_08f618f9-fbbc-4013-b48a-6d4400bdf815" xlink:to="loc_ifrs-full_GeographicalAreasMember_cf5acf10-27d0-43b7-9b6b-ef435e8d0f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_6b5516b3-1997-4c19-8f6e-44057945ff45" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_cf5acf10-27d0-43b7-9b6b-ef435e8d0f00" xlink:to="loc_country_GB_6b5516b3-1997-4c19-8f6e-44057945ff45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EUROZONEMember_05594e40-aa20-465c-ab1d-868468b4d053" xlink:href="sny-20240630.xsd#sny_EUROZONEMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_cf5acf10-27d0-43b7-9b6b-ef435e8d0f00" xlink:to="loc_sny_EUROZONEMember_05594e40-aa20-465c-ab1d-868468b4d053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UKZONEMember_92546ce9-0137-4be5-a12a-5c9ccaaf5a02" xlink:href="sny-20240630.xsd#sny_UKZONEMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_cf5acf10-27d0-43b7-9b6b-ef435e8d0f00" xlink:to="loc_sny_UKZONEMember_92546ce9-0137-4be5-a12a-5c9ccaaf5a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis_67d3975b-125f-4f22-bea2-372baa1bd93c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_7d26eae6-513a-459c-aa45-7380cea9a9d2" xlink:to="loc_ifrs-full_ActuarialAssumptionsAxis_67d3975b-125f-4f22-bea2-372baa1bd93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember_51813975-9ecc-4605-9970-f0579321606e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_67d3975b-125f-4f22-bea2-372baa1bd93c" xlink:to="loc_ifrs-full_ActuarialAssumptionsMember_51813975-9ecc-4605-9970-f0579321606e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_70109a90-16ce-458e-907b-0c882b2084a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_51813975-9ecc-4605-9970-f0579321606e" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_70109a90-16ce-458e-907b-0c882b2084a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_e440d4df-998c-4fa1-99c8-f53287fc6c93" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_51813975-9ecc-4605-9970-f0579321606e" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_e440d4df-998c-4fa1-99c8-f53287fc6c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_87a50c54-308b-4653-b32c-c2af62d99c96" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_7d26eae6-513a-459c-aa45-7380cea9a9d2" xlink:to="loc_srt_RangeAxis_87a50c54-308b-4653-b32c-c2af62d99c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_27e03c4a-5c70-4b70-baa1-040b013eff6a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_87a50c54-308b-4653-b32c-c2af62d99c96" xlink:to="loc_srt_RangeMember_27e03c4a-5c70-4b70-baa1-040b013eff6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e601b326-7c34-4621-b66b-e5c4ed8e77d8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_27e03c4a-5c70-4b70-baa1-040b013eff6a" xlink:to="loc_srt_MinimumMember_e601b326-7c34-4621-b66b-e5c4ed8e77d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_282992af-f2ae-4d47-92ad-fb9a2240e9c1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_27e03c4a-5c70-4b70-baa1-040b013eff6a" xlink:to="loc_srt_MaximumMember_282992af-f2ae-4d47-92ad-fb9a2240e9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_5b76c15b-3293-495d-86ba-79183b97e83b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_7d26eae6-513a-459c-aa45-7380cea9a9d2" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_5b76c15b-3293-495d-86ba-79183b97e83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_597096e1-dbcb-493e-abe5-617eee4ad4ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_5b76c15b-3293-495d-86ba-79183b97e83b" xlink:to="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_597096e1-dbcb-493e-abe5-617eee4ad4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_70ea7937-26f8-4e20-8dc5-c5d9d82110c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_5b76c15b-3293-495d-86ba-79183b97e83b" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_70ea7937-26f8-4e20-8dc5-c5d9d82110c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_24b1410f-214b-44c3-8910-a62ed83ff223" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_5b76c15b-3293-495d-86ba-79183b97e83b" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_24b1410f-214b-44c3-8910-a62ed83ff223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_3ea0eae1-a40e-40eb-9ac4-ebd1f5ec8213" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_5b76c15b-3293-495d-86ba-79183b97e83b" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_3ea0eae1-a40e-40eb-9ac4-ebd1f5ec8213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#OffBalanceSheetCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OffBalanceSheetCommitmentsAbstract_8ea9eed4-d738-40b8-bb74-43437594cbd1" xlink:href="sny-20240630.xsd#sny_OffBalanceSheetCommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_eac391c7-5414-40ef-94eb-f5b5f9f6671f" xlink:href="sny-20240630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OffBalanceSheetCommitmentsAbstract_8ea9eed4-d738-40b8-bb74-43437594cbd1" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_eac391c7-5414-40ef-94eb-f5b5f9f6671f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_83035c8a-8a7a-4ad3-8fef-9412c24c96da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_eac391c7-5414-40ef-94eb-f5b5f9f6671f" xlink:to="loc_ifrs-full_CounterpartiesAxis_83035c8a-8a7a-4ad3-8fef-9412c24c96da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_e48309db-eac9-4ea9-8e23-6d0cedac06b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_83035c8a-8a7a-4ad3-8fef-9412c24c96da" xlink:to="loc_ifrs-full_CounterpartiesMember_e48309db-eac9-4ea9-8e23-6d0cedac06b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MazeTherapeuticsMember_1f04c4f2-049a-4185-8a8c-d796ce19d21e" xlink:href="sny-20240630.xsd#sny_MazeTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_e48309db-eac9-4ea9-8e23-6d0cedac06b0" xlink:to="loc_sny_MazeTherapeuticsMember_1f04c4f2-049a-4185-8a8c-d796ce19d21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ScribeTherapeuticsMember_62a6a631-5d8c-49f4-a19d-36f728212ba8" xlink:href="sny-20240630.xsd#sny_ScribeTherapeuticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_e48309db-eac9-4ea9-8e23-6d0cedac06b0" xlink:to="loc_sny_ScribeTherapeuticsMember_62a6a631-5d8c-49f4-a19d-36f728212ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NovavaxMember_5978acd1-f008-479d-b820-66304c263d08" xlink:href="sny-20240630.xsd#sny_NovavaxMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_e48309db-eac9-4ea9-8e23-6d0cedac06b0" xlink:to="loc_sny_NovavaxMember_5978acd1-f008-479d-b820-66304c263d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FulcrumTherapeuticsMember_d39b2eea-559d-43bc-8dde-e4de5c9d56a3" xlink:href="sny-20240630.xsd#sny_FulcrumTherapeuticsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_e48309db-eac9-4ea9-8e23-6d0cedac06b0" xlink:to="loc_sny_FulcrumTherapeuticsMember_d39b2eea-559d-43bc-8dde-e4de5c9d56a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_e9d06772-0e5c-4b47-8c46-9920d34d322b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_eac391c7-5414-40ef-94eb-f5b5f9f6671f" xlink:to="loc_ifrs-full_RangeAxis_e9d06772-0e5c-4b47-8c46-9920d34d322b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_a87cee42-235e-4e5e-a0a3-6c8494858b83" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_e9d06772-0e5c-4b47-8c46-9920d34d322b" xlink:to="loc_ifrs-full_RangesMember_a87cee42-235e-4e5e-a0a3-6c8494858b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_59f7d82c-a292-4eaa-9c4e-1597e9743f26" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_a87cee42-235e-4e5e-a0a3-6c8494858b83" xlink:to="loc_srt_MaximumMember_59f7d82c-a292-4eaa-9c4e-1597e9743f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_69ab4135-020f-4890-ae5f-9cece6747da2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_eac391c7-5414-40ef-94eb-f5b5f9f6671f" xlink:to="loc_srt_RangeAxis_69ab4135-020f-4890-ae5f-9cece6747da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_056aac65-d3b0-43b9-a8e9-d8ccb94fbdd2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_69ab4135-020f-4890-ae5f-9cece6747da2" xlink:to="loc_srt_RangeMember_056aac65-d3b0-43b9-a8e9-d8ccb94fbdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f709e753-668b-4ea6-99ed-6ab03e283fd3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_056aac65-d3b0-43b9-a8e9-d8ccb94fbdd2" xlink:to="loc_srt_MinimumMember_f709e753-668b-4ea6-99ed-6ab03e283fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:href="sny-20240630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_eac391c7-5414-40ef-94eb-f5b5f9f6671f" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPayments_53ff7056-3ed3-4009-b135-c2b6017c6d17" xlink:href="sny-20240630.xsd#sny_UpfrontPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_UpfrontPayments_53ff7056-3ed3-4009-b135-c2b6017c6d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_3926b7a0-29ec-45d7-a52f-66610b139f57" xlink:href="sny-20240630.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_3926b7a0-29ec-45d7-a52f-66610b139f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseTerm_1d3843ac-e853-4a23-8aa7-73687897ff64" xlink:href="sny-20240630.xsd#sny_LeaseTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_LeaseTerm_1d3843ac-e853-4a23-8aa7-73687897ff64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseCost_dc1c21d9-f078-4c73-98fe-3b21a34a5fc4" xlink:href="sny-20240630.xsd#sny_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_LeaseCost_dc1c21d9-f078-4c73-98fe-3b21a34a5fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseExtensionOptionsNumber_94b91573-28f2-42f4-96b2-da8177172d4d" xlink:href="sny-20240630.xsd#sny_LeaseExtensionOptionsNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_LeaseExtensionOptionsNumber_94b91573-28f2-42f4-96b2-da8177172d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseExtensionOptionsTerm_011ed612-281f-4cd1-aa2f-054dc7f5cc84" xlink:href="sny-20240630.xsd#sny_LeaseExtensionOptionsTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_LeaseExtensionOptionsTerm_011ed612-281f-4cd1-aa2f-054dc7f5cc84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalMilestonePayments_5fd4bd29-5f15-44cf-b0a3-4251375bc286" xlink:href="sny-20240630.xsd#sny_TotalMilestonePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_TotalMilestonePayments_5fd4bd29-5f15-44cf-b0a3-4251375bc286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DevelopmentRegulatoryAndLaunchMilestonePayments_a9ed0689-8dea-4883-bd8e-36a53ae385a8" xlink:href="sny-20240630.xsd#sny_DevelopmentRegulatoryAndLaunchMilestonePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_DevelopmentRegulatoryAndLaunchMilestonePayments_a9ed0689-8dea-4883-bd8e-36a53ae385a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdditionalLaunchAndSalesMilestonePayments_df5ed4c4-863f-4ba4-a168-79f0e43bbaee" xlink:href="sny-20240630.xsd#sny_AdditionalLaunchAndSalesMilestonePayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_AdditionalLaunchAndSalesMilestonePayments_df5ed4c4-863f-4ba4-a168-79f0e43bbaee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentMilestonePayments_818b61dd-6f39-4318-9a39-59a3373b8696" xlink:href="sny-20240630.xsd#sny_ContingentMilestonePayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_d56227b1-f6e4-4648-91a6-c7ffa38f6fe8" xlink:to="loc_sny_ContingentMilestonePayments_818b61dd-6f39-4318-9a39-59a3373b8696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#LitigationandArbitrationProceedingsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_fe69de08-b1e1-4b82-a774-053a2bccbb65" xlink:href="sny-20240630.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_18d1c38e-f33b-45e8-94aa-e36470ca591b" xlink:href="sny-20240630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_fe69de08-b1e1-4b82-a774-053a2bccbb65" xlink:to="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_18d1c38e-f33b-45e8-94aa-e36470ca591b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsAxis_75dfbed1-9ff2-4283-9e5c-ada36ec12659" xlink:href="sny-20240630.xsd#sny_LegalAndArbitralProceedingsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_18d1c38e-f33b-45e8-94aa-e36470ca591b" xlink:to="loc_sny_LegalAndArbitralProceedingsAxis_75dfbed1-9ff2-4283-9e5c-ada36ec12659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsDomain_ec4a92bc-b212-4e43-b7dc-24aee9598a53" xlink:href="sny-20240630.xsd#sny_LegalAndArbitralProceedingsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsAxis_75dfbed1-9ff2-4283-9e5c-ada36ec12659" xlink:to="loc_sny_LegalAndArbitralProceedingsDomain_ec4a92bc-b212-4e43-b7dc-24aee9598a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixAttorneyGeneralActionInHawaiiMember_f03beeb8-24d3-4586-932c-70e2ebbd44a8" xlink:href="sny-20240630.xsd#sny_PlavixAttorneyGeneralActionInHawaiiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_ec4a92bc-b212-4e43-b7dc-24aee9598a53" xlink:to="loc_sny_PlavixAttorneyGeneralActionInHawaiiMember_f03beeb8-24d3-4586-932c-70e2ebbd44a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxotereProductLitigationInTheUSMember_402149f9-79af-4ce4-b7a5-83508cce6d53" xlink:href="sny-20240630.xsd#sny_TaxotereProductLitigationInTheUSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_ec4a92bc-b212-4e43-b7dc-24aee9598a53" xlink:to="loc_sny_TaxotereProductLitigationInTheUSMember_402149f9-79af-4ce4-b7a5-83508cce6d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ZantacProductLitigationInTheUSMember_5a95950e-f799-4ddc-887a-1af86e0c3161" xlink:href="sny-20240630.xsd#sny_ZantacProductLitigationInTheUSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_ec4a92bc-b212-4e43-b7dc-24aee9598a53" xlink:to="loc_sny_ZantacProductLitigationInTheUSMember_5a95950e-f799-4ddc-887a-1af86e0c3161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GoldBondProductLitigationInTheUSMember_5a0f1598-1ef0-4781-853d-69f36c6908f3" xlink:href="sny-20240630.xsd#sny_GoldBondProductLitigationInTheUSMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_ec4a92bc-b212-4e43-b7dc-24aee9598a53" xlink:to="loc_sny_GoldBondProductLitigationInTheUSMember_5a0f1598-1ef0-4781-853d-69f36c6908f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantAxis_1e0003ab-70b3-4d8a-b7c4-a8c3379efba9" xlink:href="sny-20240630.xsd#sny_DefendantAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_18d1c38e-f33b-45e8-94aa-e36470ca591b" xlink:to="loc_sny_DefendantAxis_1e0003ab-70b3-4d8a-b7c4-a8c3379efba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantDomain_b3398cd9-d776-4b76-893c-d5d8adce3999" xlink:href="sny-20240630.xsd#sny_DefendantDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DefendantAxis_1e0003ab-70b3-4d8a-b7c4-a8c3379efba9" xlink:to="loc_sny_DefendantDomain_b3398cd9-d776-4b76-893c-d5d8adce3999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActionForWhichWeAreDefendantMember_b808088e-11c1-437c-9a75-97d648861ffa" xlink:href="sny-20240630.xsd#sny_ActionForWhichWeAreDefendantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DefendantDomain_b3398cd9-d776-4b76-893c-d5d8adce3999" xlink:to="loc_sny_ActionForWhichWeAreDefendantMember_b808088e-11c1-437c-9a75-97d648861ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_b0dd1863-fb1e-41f3-8426-fbc9d03b605c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_18d1c38e-f33b-45e8-94aa-e36470ca591b" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_b0dd1863-fb1e-41f3-8426-fbc9d03b605c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_eed59bdb-cc31-456b-8a4e-cc46f9dfc868" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_b0dd1863-fb1e-41f3-8426-fbc9d03b605c" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_eed59bdb-cc31-456b-8a4e-cc46f9dfc868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProductLiabilitiesMember_2c7c808f-2036-42c7-98b3-d8995f81d581" xlink:href="sny-20240630.xsd#sny_ProductLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember_eed59bdb-cc31-456b-8a4e-cc46f9dfc868" xlink:to="loc_sny_ProductLiabilitiesMember_2c7c808f-2036-42c7-98b3-d8995f81d581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_3fa351bb-a191-4180-b12a-ccc1bd8f4eed" xlink:href="sny-20240630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_18d1c38e-f33b-45e8-94aa-e36470ca591b" xlink:to="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_3fa351bb-a191-4180-b12a-ccc1bd8f4eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated_ec198ed1-bdb6-48cd-b17c-e5b3410f20df" xlink:href="sny-20240630.xsd#sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_3fa351bb-a191-4180-b12a-ccc1bd8f4eed" xlink:to="loc_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated_ec198ed1-bdb6-48cd-b17c-e5b3410f20df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated_8d7bd783-59ec-461a-8a55-e14981db3c54" xlink:href="sny-20240630.xsd#sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_3fa351bb-a191-4180-b12a-ccc1bd8f4eed" xlink:to="loc_sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated_8d7bd783-59ec-461a-8a55-e14981db3c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPlaintiffs_6ad7d732-0f7a-4e49-b0d0-9453e65c2230" xlink:href="sny-20240630.xsd#sny_NumberOfPlaintiffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_3fa351bb-a191-4180-b12a-ccc1bd8f4eed" xlink:to="loc_sny_NumberOfPlaintiffs_6ad7d732-0f7a-4e49-b0d0-9453e65c2230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCases_6a4d7a3c-038e-49db-a3ef-c100863c5d0a" xlink:href="sny-20240630.xsd#sny_NumberOfCases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_3fa351bb-a191-4180-b12a-ccc1bd8f4eed" xlink:to="loc_sny_NumberOfCases_6a4d7a3c-038e-49db-a3ef-c100863c5d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClassActionLawsuits_4bb606b3-6514-4dda-a803-d2e67467be89" xlink:href="sny-20240630.xsd#sny_NumberOfClassActionLawsuits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_3fa351bb-a191-4180-b12a-ccc1bd8f4eed" xlink:to="loc_sny_NumberOfClassActionLawsuits_4bb606b3-6514-4dda-a803-d2e67467be89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfDismissals_7da30259-d6d0-4314-a7c7-5572d25814cc" xlink:href="sny-20240630.xsd#sny_NumberOfDismissals"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_3fa351bb-a191-4180-b12a-ccc1bd8f4eed" xlink:to="loc_sny_NumberOfDismissals_7da30259-d6d0-4314-a7c7-5572d25814cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PenaltyFeeIncurred_43c4a03f-7571-43e9-9edc-c2b781ebad20" xlink:href="sny-20240630.xsd#sny_PenaltyFeeIncurred"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_3fa351bb-a191-4180-b12a-ccc1bd8f4eed" xlink:to="loc_sny_PenaltyFeeIncurred_43c4a03f-7571-43e9-9edc-c2b781ebad20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#OtherOperatingIncomeAndExpensesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_461a4af5-afdd-42a0-8ec3-ae365e2a0109" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_698b18c0-595b-4bcf-b34f-e04d44a6f72f" xlink:href="sny-20240630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_461a4af5-afdd-42a0-8ec3-ae365e2a0109" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_698b18c0-595b-4bcf-b34f-e04d44a6f72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_482d23fe-7338-4ff4-812e-369db3228a66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_698b18c0-595b-4bcf-b34f-e04d44a6f72f" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_482d23fe-7338-4ff4-812e-369db3228a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_4cb9f845-e291-4e05-a6f3-5b9e8575f2ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_482d23fe-7338-4ff4-812e-369db3228a66" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_4cb9f845-e291-4e05-a6f3-5b9e8575f2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember_9dec0d0a-9a01-4b78-8c44-6db844289b96" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_4cb9f845-e291-4e05-a6f3-5b9e8575f2ca" xlink:to="loc_ifrs-full_OtherRelatedPartiesMember_9dec0d0a-9a01-4b78-8c44-6db844289b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_9e8e8eed-ae4a-4638-9fd7-c6e1e32e51d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_698b18c0-595b-4bcf-b34f-e04d44a6f72f" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_9e8e8eed-ae4a-4638-9fd7-c6e1e32e51d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_481acd68-5532-48b5-9bff-613c20066fcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_9e8e8eed-ae4a-4638-9fd7-c6e1e32e51d2" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_481acd68-5532-48b5-9bff-613c20066fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember_59acdf4b-3edf-43de-9cee-f3e73133affd" xlink:href="sny-20240630.xsd#sny_RegeneronMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_481acd68-5532-48b5-9bff-613c20066fcf" xlink:to="loc_sny_RegeneronMember_59acdf4b-3edf-43de-9cee-f3e73133affd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_b063b2df-7e23-48c5-a147-86e1e98607cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_698b18c0-595b-4bcf-b34f-e04d44a6f72f" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_b063b2df-7e23-48c5-a147-86e1e98607cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_bb88b1fd-f08e-4d98-9d07-ecff95b56a8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_b063b2df-7e23-48c5-a147-86e1e98607cd" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_bb88b1fd-f08e-4d98-9d07-ecff95b56a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingIncomeExpenseMember_32ff5ee1-46f9-4847-8dfb-268750746a93" xlink:href="sny-20240630.xsd#sny_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_bb88b1fd-f08e-4d98-9d07-ecff95b56a8b" xlink:to="loc_sny_OtherOperatingIncomeExpenseMember_32ff5ee1-46f9-4847-8dfb-268750746a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e56e46eb-d727-4f22-9a87-3c169f285372" xlink:href="sny-20240630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_698b18c0-595b-4bcf-b34f-e04d44a6f72f" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e56e46eb-d727-4f22-9a87-3c169f285372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_c0bd6f3a-d5ea-4dd9-8683-09edabead5f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e56e46eb-d727-4f22-9a87-3c169f285372" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_c0bd6f3a-d5ea-4dd9-8683-09edabead5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_7524f479-973e-443c-a949-d1eda0ed27b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e56e46eb-d727-4f22-9a87-3c169f285372" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_7524f479-973e-443c-a949-d1eda0ed27b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsOnDivestmentOfProducts_03647fac-8403-4345-b07b-241ac9541e77" xlink:href="sny-20240630.xsd#sny_GainsOnDivestmentOfProducts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e56e46eb-d727-4f22-9a87-3c169f285372" xlink:to="loc_sny_GainsOnDivestmentOfProducts_03647fac-8403-4345-b07b-241ac9541e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_3be82106-e1dc-43d8-821a-51e190041322" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_9bb22cc1-9ed1-4946-9427-d1a031a3f913" xlink:href="sny-20240630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_3be82106-e1dc-43d8-821a-51e190041322" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_9bb22cc1-9ed1-4946-9427-d1a031a3f913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_fda6c739-6e08-4629-a20b-c24dfbd46bf7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_9bb22cc1-9ed1-4946-9427-d1a031a3f913" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_fda6c739-6e08-4629-a20b-c24dfbd46bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_34b0e13e-75d8-4ddd-a308-121e83010321" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_fda6c739-6e08-4629-a20b-c24dfbd46bf7" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_34b0e13e-75d8-4ddd-a308-121e83010321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember_0caaf26b-248d-4a1f-8ba0-adb95916aeec" xlink:href="sny-20240630.xsd#sny_RegeneronMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_34b0e13e-75d8-4ddd-a308-121e83010321" xlink:to="loc_sny_RegeneronMember_0caaf26b-248d-4a1f-8ba0-adb95916aeec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7a75e13d-ae32-42b8-a34c-cfd78072a105" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_9bb22cc1-9ed1-4946-9427-d1a031a3f913" xlink:to="loc_srt_CounterpartyNameAxis_7a75e13d-ae32-42b8-a34c-cfd78072a105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00dac23b-3307-445d-84ef-f01d3e6c0f81" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7a75e13d-ae32-42b8-a34c-cfd78072a105" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00dac23b-3307-445d-84ef-f01d3e6c0f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesAllianceMember_81ee5bda-1b01-4be1-aab2-9aa5488664cc" xlink:href="sny-20240630.xsd#sny_AntibodiesAllianceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00dac23b-3307-445d-84ef-f01d3e6c0f81" xlink:to="loc_sny_AntibodiesAllianceMember_81ee5bda-1b01-4be1-aab2-9aa5488664cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunoOncologyAllianceMember_722800f8-2a6d-4aff-95f3-586628a0fbfc" xlink:href="sny-20240630.xsd#sny_ImmunoOncologyAllianceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00dac23b-3307-445d-84ef-f01d3e6c0f81" xlink:to="loc_sny_ImmunoOncologyAllianceMember_722800f8-2a6d-4aff-95f3-586628a0fbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OthersCounterpartyMember_d3ad6995-31af-4333-9ec5-52fd51863503" xlink:href="sny-20240630.xsd#sny_OthersCounterpartyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00dac23b-3307-445d-84ef-f01d3e6c0f81" xlink:to="loc_sny_OthersCounterpartyMember_d3ad6995-31af-4333-9ec5-52fd51863503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_d01eff86-657a-4d54-a4e3-72e032209020" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_9bb22cc1-9ed1-4946-9427-d1a031a3f913" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_d01eff86-657a-4d54-a4e3-72e032209020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_0d05f1d9-1f3e-4c82-bd35-38230923e52d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_d01eff86-657a-4d54-a4e3-72e032209020" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_0d05f1d9-1f3e-4c82-bd35-38230923e52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember_dba6ea54-68e1-416e-b685-7d0a2f6d49b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_0d05f1d9-1f3e-4c82-bd35-38230923e52d" xlink:to="loc_ifrs-full_OtherRelatedPartiesMember_dba6ea54-68e1-416e-b685-7d0a2f6d49b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_af856d7e-4751-4ebe-904a-3cde377c970a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_9bb22cc1-9ed1-4946-9427-d1a031a3f913" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_af856d7e-4751-4ebe-904a-3cde377c970a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_ced5d7e4-8c96-4a7d-8e44-f381e13dd80b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_af856d7e-4751-4ebe-904a-3cde377c970a" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_ced5d7e4-8c96-4a7d-8e44-f381e13dd80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_6711e698-c4fa-4d2b-bf78-1dabe2c2a516" xlink:href="sny-20240630.xsd#sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_ced5d7e4-8c96-4a7d-8e44-f381e13dd80b" xlink:to="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_6711e698-c4fa-4d2b-bf78-1dabe2c2a516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_48cf593f-e5aa-4b18-895d-56bef89cc40f" xlink:href="sny-20240630.xsd#sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_ced5d7e4-8c96-4a7d-8e44-f381e13dd80b" xlink:to="loc_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_48cf593f-e5aa-4b18-895d-56bef89cc40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercializationRelatedExpensesMember_a777825b-1525-4109-8810-7dec4862016b" xlink:href="sny-20240630.xsd#sny_CommercializationRelatedExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_ced5d7e4-8c96-4a7d-8e44-f381e13dd80b" xlink:to="loc_sny_CommercializationRelatedExpensesMember_a777825b-1525-4109-8810-7dec4862016b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingIncomeExpenseMember_bcb47128-953f-47e7-881e-057cf905901a" xlink:href="sny-20240630.xsd#sny_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_ced5d7e4-8c96-4a7d-8e44-f381e13dd80b" xlink:to="loc_sny_OtherOperatingIncomeExpenseMember_bcb47128-953f-47e7-881e-057cf905901a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1885ea94-22be-401c-9d93-be5a7cbf35f1" xlink:href="sny-20240630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_9bb22cc1-9ed1-4946-9427-d1a031a3f913" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1885ea94-22be-401c-9d93-be5a7cbf35f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_aa0a8058-ec4b-44c7-a2f1-22b59cbffbbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1885ea94-22be-401c-9d93-be5a7cbf35f1" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_aa0a8058-ec4b-44c7-a2f1-22b59cbffbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_7084d038-5521-4e0f-b82b-2aff55a4f677" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1885ea94-22be-401c-9d93-be5a7cbf35f1" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_7084d038-5521-4e0f-b82b-2aff55a4f677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_511e507d-7b67-4cc4-aa16-10dd5e90e281" xlink:href="sny-20240630.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1885ea94-22be-401c-9d93-be5a7cbf35f1" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_511e507d-7b67-4cc4-aa16-10dd5e90e281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_2862d203-8dcd-41b2-abef-1b27ba4a5433" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_1885ea94-22be-401c-9d93-be5a7cbf35f1" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_2862d203-8dcd-41b2-abef-1b27ba4a5433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_d6898977-33bf-4440-a258-bc330ac23bd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_e34855a0-1569-4c6f-ba84-cee4857884c6" xlink:href="sny-20240630.xsd#sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_d6898977-33bf-4440-a258-bc330ac23bd3" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_e34855a0-1569-4c6f-ba84-cee4857884c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_8a4986a1-3d6c-4754-89a8-b9fc60b69c29" xlink:href="sny-20240630.xsd#sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_d6898977-33bf-4440-a258-bc330ac23bd3" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_8a4986a1-3d6c-4754-89a8-b9fc60b69c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts_04576688-008b-4dda-872e-281133c194b2" xlink:href="sny-20240630.xsd#sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_d6898977-33bf-4440-a258-bc330ac23bd3" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts_04576688-008b-4dda-872e-281133c194b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_1e3c70b2-9d13-419a-82a6-7232793c8c8b" xlink:href="sny-20240630.xsd#sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_d6898977-33bf-4440-a258-bc330ac23bd3" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_1e3c70b2-9d13-419a-82a6-7232793c8c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherRestructuringCosts_28f5eb48-7fa8-4df1-9e73-f34ab7345560" xlink:href="sny-20240630.xsd#sny_OtherRestructuringCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_d6898977-33bf-4440-a258-bc330ac23bd3" xlink:to="loc_sny_OtherRestructuringCosts_28f5eb48-7fa8-4df1-9e73-f34ab7345560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_71a65d9b-6aa4-42f9-a4cf-beed0292cd78" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_d6898977-33bf-4440-a258-bc330ac23bd3" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_71a65d9b-6aa4-42f9-a4cf-beed0292cd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#RestructuringCostsandSimilarItemsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RestructuringCostsandSimilarItemsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_e21d5bb2-309a-427e-935d-f01c6dec33b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities_39260605-5020-4461-8dd7-fa09e4743752" xlink:href="sny-20240630.xsd#sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_e21d5bb2-309a-427e-935d-f01c6dec33b1" xlink:to="loc_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities_39260605-5020-4461-8dd7-fa09e4743752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtherGainsandLossesandLitigationDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#OtherGainsandLossesandLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtherGainsandLossesandLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_cfbf8e44-7c3d-42c7-8e52-91ae6b2a3098" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_c61e8d3f-ea6b-49f5-871b-eb40936171f8" xlink:href="sny-20240630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_cfbf8e44-7c3d-42c7-8e52-91ae6b2a3098" xlink:to="loc_sny_OtherGainsLossesAndLitigation_c61e8d3f-ea6b-49f5-871b-eb40936171f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialExpensesandIncomeDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#FinancialExpensesandIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/FinancialExpensesandIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_0a101d77-bdea-409a-923f-e7e3e2044db6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_e2a78bfc-8e75-429c-b74a-90f99c9f0e23" xlink:href="sny-20240630.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_0a101d77-bdea-409a-923f-e7e3e2044db6" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_e2a78bfc-8e75-429c-b74a-90f99c9f0e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsAxis_b1394678-4304-48ff-ba0d-77ac125b1dc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgedItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_e2a78bfc-8e75-429c-b74a-90f99c9f0e23" xlink:to="loc_ifrs-full_HedgedItemsAxis_b1394678-4304-48ff-ba0d-77ac125b1dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsMember_a3297c59-5170-4871-b02d-a58dae0cc13e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgedItemsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsAxis_b1394678-4304-48ff-ba0d-77ac125b1dc6" xlink:to="loc_ifrs-full_HedgedItemsMember_a3297c59-5170-4871-b02d-a58dae0cc13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesMember_80064842-4133-47c2-8879-5edbe725e364" xlink:href="sny-20240630.xsd#sny_InterestRateAndCurrencyDerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsMember_a3297c59-5170-4871-b02d-a58dae0cc13e" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesMember_80064842-4133-47c2-8879-5edbe725e364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:href="sny-20240630.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_e2a78bfc-8e75-429c-b74a-90f99c9f0e23" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_01d056ce-1081-43d4-8bc5-4dd12f10ab43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_01d056ce-1081-43d4-8bc5-4dd12f10ab43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestIncome_0a08deb7-2140-4435-9cbc-8defee4d131c" xlink:href="sny-20240630.xsd#sny_InterestIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_sny_InterestIncome_0a08deb7-2140-4435-9cbc-8defee4d131c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CostOfDebtNet_b81b7c6d-bde3-410e-bd08-48095aa0ac88" xlink:href="sny-20240630.xsd#sny_CostOfDebtNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_sny_CostOfDebtNet_b81b7c6d-bde3-410e-bd08-48095aa0ac88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonOperatingForeignExchangeGainsLosses_0c64e147-04d5-40db-9818-6e0d50ba9de0" xlink:href="sny-20240630.xsd#sny_NonOperatingForeignExchangeGainsLosses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_sny_NonOperatingForeignExchangeGainsLosses_0c64e147-04d5-40db-9818-6e0d50ba9de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_9b06326d-eee8-44d6-9f22-32dfdfc2b29b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_9b06326d-eee8-44d6-9f22-32dfdfc2b29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInterestCostRelatedToEmployeeBenefits_18855017-05b6-4f29-9a07-34522ce1a845" xlink:href="sny-20240630.xsd#sny_NetInterestCostRelatedToEmployeeBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_sny_NetInterestCostRelatedToEmployeeBenefits_18855017-05b6-4f29-9a07-34522ce1a845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_73dc8af0-0287-497f-93c7-ebefd37b614c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_73dc8af0-0287-497f-93c7-ebefd37b614c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_2dfb91a1-76fd-4422-bbb7-3711ffc3acaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_2dfb91a1-76fd-4422-bbb7-3711ffc3acaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncomeCost_ed903ee6-2cee-4f54-8ed2-856c7d836735" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_ifrs-full_OtherFinanceIncomeCost_ed903ee6-2cee-4f54-8ed2-856c7d836735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_fca9740d-e88c-4388-b8aa-27265a9c75f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_ifrs-full_FinanceIncomeCost_fca9740d-e88c-4388-b8aa-27265a9c75f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_4c32165c-df82-4b84-a6b9-8fdf84360055" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_ifrs-full_FinanceCosts_4c32165c-df82-4b84-a6b9-8fdf84360055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_a06c4aba-398b-419f-9883-3f0a49d940b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_ifrs-full_FinanceIncome_a06c4aba-398b-419f-9883-3f0a49d940b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnDerivativesUsedToManageDebt_f7272e7a-67d2-42d8-ab5d-84a7ecbda35a" xlink:href="sny-20240630.xsd#sny_GainLossOnDerivativesUsedToManageDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_sny_GainLossOnDerivativesUsedToManageDebt_f7272e7a-67d2-42d8-ab5d-84a7ecbda35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_e330bf7c-3e9e-49ce-bd43-d3c3a201e425" xlink:href="sny-20240630.xsd#sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_e330bf7c-3e9e-49ce-bd43-d3c3a201e425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost_d137a987-f3d6-46b0-9d95-e1e577aca5fd" xlink:href="sny-20240630.xsd#sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost_d137a987-f3d6-46b0-9d95-e1e577aca5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties_b21d2bbb-40e1-435a-b320-762b21d20e9c" xlink:href="sny-20240630.xsd#sny_LiabilityRecognisedForEstimatedFutureRoyalties"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_51e1e123-1359-4706-b06f-cd326d55d8f8" xlink:to="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties_b21d2bbb-40e1-435a-b320-762b21d20e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_33884bc1-406d-4264-9c61-922d7fc618d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_401dfe1f-eca1-4d56-9899-e51e15e37a5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_33884bc1-406d-4264-9c61-922d7fc618d3" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_401dfe1f-eca1-4d56-9899-e51e15e37a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome_fd968636-5458-44b0-8e38-46949f6c420c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_33884bc1-406d-4264-9c61-922d7fc618d3" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncome_fd968636-5458-44b0-8e38-46949f6c420c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_7bd2081d-6964-4732-b395-49141d3b457f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_33884bc1-406d-4264-9c61-922d7fc618d3" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_7bd2081d-6964-4732-b395-49141d3b457f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_7493a3f3-b9d9-4669-aa89-cee13fec05e6" xlink:href="sny-20240630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_33884bc1-406d-4264-9c61-922d7fc618d3" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_7493a3f3-b9d9-4669-aa89-cee13fec05e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_9920706e-c9e4-43ef-93d4-8a0791a59085" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_b4784577-3cb0-4fbd-a27c-ac640ab04aa3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_9920706e-c9e4-43ef-93d4-8a0791a59085" xlink:to="loc_ifrs-full_ApplicableTaxRate_b4784577-3cb0-4fbd-a27c-ac640ab04aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_c20dbe6d-142f-4904-bd2d-e40c160f0b88" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_9920706e-c9e4-43ef-93d4-8a0791a59085" xlink:to="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_c20dbe6d-142f-4904-bd2d-e40c160f0b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_abec3318-5558-4ef7-9695-7f193d026192" xlink:href="sny-20240630.xsd#sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_9920706e-c9e4-43ef-93d4-8a0791a59085" xlink:to="loc_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_abec3318-5558-4ef7-9695-7f193d026192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments_db6a8836-2b7b-48fe-bb6f-93b46e919dc2" xlink:href="sny-20240630.xsd#sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_9920706e-c9e4-43ef-93d4-8a0791a59085" xlink:to="loc_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments_db6a8836-2b7b-48fe-bb6f-93b46e919dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_37626f52-69d1-4150-880f-9e162de28eaa" xlink:href="sny-20240630.xsd#sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_9920706e-c9e4-43ef-93d4-8a0791a59085" xlink:to="loc_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_37626f52-69d1-4150-880f-9e162de28eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_dd9339f2-1aa3-4167-a524-863446f7d8fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_9920706e-c9e4-43ef-93d4-8a0791a59085" xlink:to="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_dd9339f2-1aa3-4167-a524-863446f7d8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate_c3e719dd-b075-48f0-903b-43b14eaddf9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_9920706e-c9e4-43ef-93d4-8a0791a59085" xlink:to="loc_ifrs-full_AverageEffectiveTaxRate_c3e719dd-b075-48f0-903b-43b14eaddf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_5be5e910-73b7-4e24-8f32-a01bc9be5ecf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_9920706e-c9e4-43ef-93d4-8a0791a59085" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_5be5e910-73b7-4e24-8f32-a01bc9be5ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentTaxExpenseRelatedToPillarTwo_169df63b-b150-460f-82c5-49f676d5b1a6" xlink:href="sny-20240630.xsd#sny_CurrentTaxExpenseRelatedToPillarTwo"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_9920706e-c9e4-43ef-93d4-8a0791a59085" xlink:to="loc_sny_CurrentTaxExpenseRelatedToPillarTwo_169df63b-b150-460f-82c5-49f676d5b1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical" xlink:type="simple" xlink:href="sny-20240630.xsd#IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4ab1d385-1667-4971-a3cc-a3b07b1da19c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_befbd9c0-cecc-4800-bc64-0e7dc93ee112" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4ab1d385-1667-4971-a3cc-a3b07b1da19c" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_befbd9c0-cecc-4800-bc64-0e7dc93ee112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_7bdd2e6d-211a-40c9-bd8c-02af017a6dd6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_befbd9c0-cecc-4800-bc64-0e7dc93ee112" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_7bdd2e6d-211a-40c9-bd8c-02af017a6dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_ae53b97c-8845-4cd4-a83e-d46b390e55f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4ab1d385-1667-4971-a3cc-a3b07b1da19c" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_ae53b97c-8845-4cd4-a83e-d46b390e55f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentTaxExpenseRelatedToPillarTwo_a3f261d4-6d8b-4804-9abd-6352bd3b4cb1" xlink:href="sny-20240630.xsd#sny_CurrentTaxExpenseRelatedToPillarTwo"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_ae53b97c-8845-4cd4-a83e-d46b390e55f5" xlink:to="loc_sny_CurrentTaxExpenseRelatedToPillarTwo_a3f261d4-6d8b-4804-9abd-6352bd3b4cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#SegmentInformationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentInformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_ab3a45e1-1c91-457e-bfdc-af75a34a7d5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments_04c19d8c-3d1f-40e5-b428-ee4d7761dea4" xlink:href="sny-20240630.xsd#sny_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_ab3a45e1-1c91-457e-bfdc-af75a34a7d5c" xlink:to="loc_sny_NumberOfOperatingSegments_04c19d8c-3d1f-40e5-b428-ee4d7761dea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_0e0c1fef-3d17-42d1-9d64-81fedbf50bdf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_a4639979-1568-451d-9cca-0ce351f93b97" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_0e0c1fef-3d17-42d1-9d64-81fedbf50bdf" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_a4639979-1568-451d-9cca-0ce351f93b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_545d7714-f611-42df-84b5-c44ae19d45b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_a4639979-1568-451d-9cca-0ce351f93b97" xlink:to="loc_ifrs-full_GeographicalAreasAxis_545d7714-f611-42df-84b5-c44ae19d45b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_1af46ae6-671a-484f-b9b4-48118d8e6352" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_545d7714-f611-42df-84b5-c44ae19d45b5" xlink:to="loc_ifrs-full_GeographicalAreasMember_1af46ae6-671a-484f-b9b4-48118d8e6352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_1dc162ff-3f35-4ffa-b3fe-dc9a38159fa6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1af46ae6-671a-484f-b9b4-48118d8e6352" xlink:to="loc_srt_EuropeMember_1dc162ff-3f35-4ffa-b3fe-dc9a38159fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b8a148c3-0237-41ea-addf-aebfcf280b6f" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1af46ae6-671a-484f-b9b4-48118d8e6352" xlink:to="loc_country_US_b8a148c3-0237-41ea-addf-aebfcf280b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember_2c6196d8-04ce-4ff5-b349-e94cc43a0f87" xlink:href="sny-20240630.xsd#sny_OtherCountriesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_1af46ae6-671a-484f-b9b4-48118d8e6352" xlink:to="loc_sny_OtherCountriesMember_2c6196d8-04ce-4ff5-b349-e94cc43a0f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_b9c553b3-c716-4ee1-aeab-8c8a9d4787fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_a4639979-1568-451d-9cca-0ce351f93b97" xlink:to="loc_ifrs-full_SegmentsAxis_b9c553b3-c716-4ee1-aeab-8c8a9d4787fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_d77c0fcf-39dc-4023-adcc-7d4efe2ff195" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_b9c553b3-c716-4ee1-aeab-8c8a9d4787fc" xlink:to="loc_ifrs-full_SegmentsMember_d77c0fcf-39dc-4023-adcc-7d4efe2ff195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_e0be3bfc-004c-4911-b522-ec9f96452e3d" xlink:href="sny-20240630.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_d77c0fcf-39dc-4023-adcc-7d4efe2ff195" xlink:to="loc_sny_BiopharmaSegmentMember_e0be3bfc-004c-4911-b522-ec9f96452e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_01ac830d-2c23-47c4-b704-e10b15cba633" xlink:href="sny-20240630.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_d77c0fcf-39dc-4023-adcc-7d4efe2ff195" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_01ac830d-2c23-47c4-b704-e10b15cba633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaMember_5a4247de-2794-4c38-abc0-2ace32f1a35a" xlink:href="sny-20240630.xsd#sny_OpellaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_d77c0fcf-39dc-4023-adcc-7d4efe2ff195" xlink:to="loc_sny_OpellaMember_5a4247de-2794-4c38-abc0-2ace32f1a35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllOtherSegmentsMember_f5ab685c-16a2-4e6f-8db3-24936b665d3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllOtherSegmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_d77c0fcf-39dc-4023-adcc-7d4efe2ff195" xlink:to="loc_ifrs-full_AllOtherSegmentsMember_f5ab685c-16a2-4e6f-8db3-24936b665d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaSegmentMember_0f028122-9258-4c4d-b898-24164c5f4e8e" xlink:href="sny-20240630.xsd#sny_PharmaSegmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_d77c0fcf-39dc-4023-adcc-7d4efe2ff195" xlink:to="loc_sny_PharmaSegmentMember_0f028122-9258-4c4d-b898-24164c5f4e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProductsSegmentMember_b8bc2c88-2384-4de8-810e-e2ac1d02f2d3" xlink:href="sny-20240630.xsd#sny_OtherProductsSegmentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_d77c0fcf-39dc-4023-adcc-7d4efe2ff195" xlink:to="loc_sny_OtherProductsSegmentMember_b8bc2c88-2384-4de8-810e-e2ac1d02f2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_c18c6624-3ec5-41a6-9af8-5d1280b276f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_a4639979-1568-451d-9cca-0ce351f93b97" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_c18c6624-3ec5-41a6-9af8-5d1280b276f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_c18c6624-3ec5-41a6-9af8-5d1280b276f1" xlink:to="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SpecialtyCareMember_a3d6dd95-0102-4304-a816-390bebf372f2" xlink:href="sny-20240630.xsd#sny_SpecialtyCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_SpecialtyCareMember_a3d6dd95-0102-4304-a816-390bebf372f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DupixentMember_68c036ac-330a-4f7c-9702-80f2face9252" xlink:href="sny-20240630.xsd#sny_DupixentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_a3d6dd95-0102-4304-a816-390bebf372f2" xlink:to="loc_sny_DupixentMember_68c036ac-330a-4f7c-9702-80f2face9252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AubagioMember_19ced847-4137-4fdd-aad1-2d78fe081f61" xlink:href="sny-20240630.xsd#sny_AubagioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_a3d6dd95-0102-4304-a816-390bebf372f2" xlink:to="loc_sny_AubagioMember_19ced847-4137-4fdd-aad1-2d78fe081f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CerezymeMember_07a44f89-7143-4eba-b7a1-de0f415dd671" xlink:href="sny-20240630.xsd#sny_CerezymeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_a3d6dd95-0102-4304-a816-390bebf372f2" xlink:to="loc_sny_CerezymeMember_07a44f89-7143-4eba-b7a1-de0f415dd671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MyozymeLumizymeMember_6fe705f5-9421-4a36-b866-78100219806e" xlink:href="sny-20240630.xsd#sny_MyozymeLumizymeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_a3d6dd95-0102-4304-a816-390bebf372f2" xlink:to="loc_sny_MyozymeLumizymeMember_6fe705f5-9421-4a36-b866-78100219806e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FabrazymeMember_f1fe59a2-097f-40aa-bf90-89d9d5dc3cab" xlink:href="sny-20240630.xsd#sny_FabrazymeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_a3d6dd95-0102-4304-a816-390bebf372f2" xlink:to="loc_sny_FabrazymeMember_f1fe59a2-097f-40aa-bf90-89d9d5dc3cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_JevtanaMember_1f67c578-ab77-4495-b572-6a6bac98c773" xlink:href="sny-20240630.xsd#sny_JevtanaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_a3d6dd95-0102-4304-a816-390bebf372f2" xlink:to="loc_sny_JevtanaMember_1f67c578-ab77-4495-b572-6a6bac98c773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AlprolixMember_8c11c0a7-9d18-46d8-8983-e3ad177a3323" xlink:href="sny-20240630.xsd#sny_AlprolixMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_a3d6dd95-0102-4304-a816-390bebf372f2" xlink:to="loc_sny_AlprolixMember_8c11c0a7-9d18-46d8-8983-e3ad177a3323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EloctateMember_6004c491-f9f5-4d82-9716-8fcb91bcb12b" xlink:href="sny-20240630.xsd#sny_EloctateMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_a3d6dd95-0102-4304-a816-390bebf372f2" xlink:to="loc_sny_EloctateMember_6004c491-f9f5-4d82-9716-8fcb91bcb12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GeneralMedicinesMember_70b48de9-8d32-4c8a-858b-04374ec3d43d" xlink:href="sny-20240630.xsd#sny_GeneralMedicinesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_GeneralMedicinesMember_70b48de9-8d32-4c8a-858b-04374ec3d43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CoreAssetsMember_70821d68-8ef4-48a2-8219-2a4d7102a41f" xlink:href="sny-20240630.xsd#sny_CoreAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_GeneralMedicinesMember_70b48de9-8d32-4c8a-858b-04374ec3d43d" xlink:to="loc_sny_CoreAssetsMember_70821d68-8ef4-48a2-8219-2a4d7102a41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LovenoxMember_3981daba-1feb-40cf-ad13-7550a430499a" xlink:href="sny-20240630.xsd#sny_LovenoxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_CoreAssetsMember_70821d68-8ef4-48a2-8219-2a4d7102a41f" xlink:to="loc_sny_LovenoxMember_3981daba-1feb-40cf-ad13-7550a430499a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ToujeoMember_535f1036-e127-4b6f-8b78-085b635142b7" xlink:href="sny-20240630.xsd#sny_ToujeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_CoreAssetsMember_70821d68-8ef4-48a2-8219-2a4d7102a41f" xlink:to="loc_sny_ToujeoMember_535f1036-e127-4b6f-8b78-085b635142b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixMember_403f8d7c-075b-4941-ab9c-07a250c63334" xlink:href="sny-20240630.xsd#sny_PlavixMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_CoreAssetsMember_70821d68-8ef4-48a2-8219-2a4d7102a41f" xlink:to="loc_sny_PlavixMember_403f8d7c-075b-4941-ab9c-07a250c63334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCoreAssetsMember_1970879f-d22f-4d4e-a2f4-133281b153ee" xlink:href="sny-20240630.xsd#sny_NonCoreAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_GeneralMedicinesMember_70b48de9-8d32-4c8a-858b-04374ec3d43d" xlink:to="loc_sny_NonCoreAssetsMember_1970879f-d22f-4d4e-a2f4-133281b153ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LantusMember_767357ab-60f4-458d-90d0-63612ff1c26b" xlink:href="sny-20240630.xsd#sny_LantusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_NonCoreAssetsMember_1970879f-d22f-4d4e-a2f4-133281b153ee" xlink:to="loc_sny_LantusMember_767357ab-60f4-458d-90d0-63612ff1c26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherNonCoreAssetsMember_acc94018-9547-46e8-970e-1051e1cbe0ef" xlink:href="sny-20240630.xsd#sny_OtherNonCoreAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_NonCoreAssetsMember_1970879f-d22f-4d4e-a2f4-133281b153ee" xlink:to="loc_sny_OtherNonCoreAssetsMember_acc94018-9547-46e8-970e-1051e1cbe0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IndustrialSalesMember_c43bedcc-b1cf-41d6-a712-ff3eed48bb0a" xlink:href="sny-20240630.xsd#sny_IndustrialSalesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_GeneralMedicinesMember_70b48de9-8d32-4c8a-858b-04374ec3d43d" xlink:to="loc_sny_IndustrialSalesMember_c43bedcc-b1cf-41d6-a712-ff3eed48bb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesMember_0bff2710-6685-479f-9b69-fce0997b03cb" xlink:href="sny-20240630.xsd#sny_VaccinesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_VaccinesMember_0bff2710-6685-479f-9b69-fce0997b03cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PolioPertussisHibVaccinesMember_c79ea395-33f4-4068-a159-1e3e609499e5" xlink:href="sny-20240630.xsd#sny_PolioPertussisHibVaccinesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_VaccinesMember_0bff2710-6685-479f-9b69-fce0997b03cb" xlink:to="loc_sny_PolioPertussisHibVaccinesMember_c79ea395-33f4-4068-a159-1e3e609499e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfluenzaVaccinesMember_f24341e9-f5df-48c0-bd49-801672d136d2" xlink:href="sny-20240630.xsd#sny_InfluenzaVaccinesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_VaccinesMember_0bff2710-6685-479f-9b69-fce0997b03cb" xlink:to="loc_sny_InfluenzaVaccinesMember_f24341e9-f5df-48c0-bd49-801672d136d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AllergyMember_197cc7d5-14ce-410c-ba44-152a8a532a65" xlink:href="sny-20240630.xsd#sny_AllergyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_AllergyMember_197cc7d5-14ce-410c-ba44-152a8a532a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PainCareMember_f6be1b7c-c16f-4942-82a2-f55a842bad7b" xlink:href="sny-20240630.xsd#sny_PainCareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_PainCareMember_f6be1b7c-c16f-4942-82a2-f55a842bad7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DigestiveWellnessMember_588bf19e-af11-4215-9f7b-063d19f45eda" xlink:href="sny-20240630.xsd#sny_DigestiveWellnessMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_DigestiveWellnessMember_588bf19e-af11-4215-9f7b-063d19f45eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NexviazymeMember_d0c1251f-08a1-448e-b539-482cbe1dc531" xlink:href="sny-20240630.xsd#sny_NexviazymeMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_NexviazymeMember_d0c1251f-08a1-448e-b539-482cbe1dc531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SarclisaMember_bc2d5164-4526-4d21-8419-5e686a193046" xlink:href="sny-20240630.xsd#sny_SarclisaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_SarclisaMember_bc2d5164-4526-4d21-8419-5e686a193046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AltuviiioMember_9332edca-0d7a-43a3-a6ad-8887334bea8f" xlink:href="sny-20240630.xsd#sny_AltuviiioMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_AltuviiioMember_9332edca-0d7a-43a3-a6ad-8887334bea8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RezurockMember_efe28d56-8326-4ec7-a4c4-3f8d439eb85d" xlink:href="sny-20240630.xsd#sny_RezurockMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_RezurockMember_efe28d56-8326-4ec7-a4c4-3f8d439eb85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CabliviMember_4c745fb6-eedf-4b7c-a2a7-665402f1d180" xlink:href="sny-20240630.xsd#sny_CabliviMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_CabliviMember_4c745fb6-eedf-4b7c-a2a7-665402f1d180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_XenpozymeMember_5b8236e4-bad9-44fd-864f-5164505b776b" xlink:href="sny-20240630.xsd#sny_XenpozymeMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_XenpozymeMember_5b8236e4-bad9-44fd-864f-5164505b776b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EnjaymoMember_6babad9e-5765-46d2-9b47-5ee3e386c991" xlink:href="sny-20240630.xsd#sny_EnjaymoMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_EnjaymoMember_6babad9e-5765-46d2-9b47-5ee3e386c991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TzieldMember_a7776f11-7712-4986-a4f9-c8f88a16e2be" xlink:href="sny-20240630.xsd#sny_TzieldMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_TzieldMember_a7776f11-7712-4986-a4f9-c8f88a16e2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RSVVaccinesMember_8d916eab-4296-467e-b9e9-bcdf9fe18830" xlink:href="sny-20240630.xsd#sny_RSVVaccinesMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_RSVVaccinesMember_8d916eab-4296-467e-b9e9-bcdf9fe18830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MeningitisTravelAndEndemicVaccinesMember_2b22059f-3527-4e3f-bf4d-88a19e18c81c" xlink:href="sny-20240630.xsd#sny_MeningitisTravelAndEndemicVaccinesMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_MeningitisTravelAndEndemicVaccinesMember_2b22059f-3527-4e3f-bf4d-88a19e18c81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SeasonalSymptomsAndPainReliefMember_83d398d3-fe63-4302-bb33-613dd771cf43" xlink:href="sny-20240630.xsd#sny_SeasonalSymptomsAndPainReliefMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_SeasonalSymptomsAndPainReliefMember_83d398d3-fe63-4302-bb33-613dd771cf43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WellnessBrandsMember_3e5cbbf6-b7b3-4496-8e8a-ea574d8dbacd" xlink:href="sny-20240630.xsd#sny_WellnessBrandsMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_WellnessBrandsMember_3e5cbbf6-b7b3-4496-8e8a-ea574d8dbacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OthersMember_492c3237-a8d3-46b9-9d35-af202860e690" xlink:href="sny-20240630.xsd#sny_OthersMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_9a7b3b99-c592-41d1-b981-0ad4427fd6e3" xlink:to="loc_sny_OthersMember_492c3237-a8d3-46b9-9d35-af202860e690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_442175cd-ce04-4d5d-91be-8f46439dbf6d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_a4639979-1568-451d-9cca-0ce351f93b97" xlink:to="loc_srt_ProductOrServiceAxis_442175cd-ce04-4d5d-91be-8f46439dbf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_46961d04-5378-41d2-98f1-246d18be02d9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_442175cd-ce04-4d5d-91be-8f46439dbf6d" xlink:to="loc_srt_ProductsAndServicesDomain_46961d04-5378-41d2-98f1-246d18be02d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaSegmentMember_283fd640-478d-4d7f-88dc-934f9ee89525" xlink:href="sny-20240630.xsd#sny_PharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_46961d04-5378-41d2-98f1-246d18be02d9" xlink:to="loc_sny_PharmaSegmentMember_283fd640-478d-4d7f-88dc-934f9ee89525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaLaunchesMember_93be2ee0-81b1-4798-a0e9-ad6c8e846dc4" xlink:href="sny-20240630.xsd#sny_PharmaLaunchesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_46961d04-5378-41d2-98f1-246d18be02d9" xlink:to="loc_sny_PharmaLaunchesMember_93be2ee0-81b1-4798-a0e9-ad6c8e846dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProductsSegmentMember_ebb09660-8522-423c-86e8-874f52f3e284" xlink:href="sny-20240630.xsd#sny_OtherProductsSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_46961d04-5378-41d2-98f1-246d18be02d9" xlink:to="loc_sny_OtherProductsSegmentMember_ebb09660-8522-423c-86e8-874f52f3e284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_a4639979-1568-451d-9cca-0ce351f93b97" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_827d64f5-5194-4924-a254-633e4e50076b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_827d64f5-5194-4924-a254-633e4e50076b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments_6e7e0907-7529-4b8a-ae18-2a014c8c0f30" xlink:href="sny-20240630.xsd#sny_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_sny_NumberOfOperatingSegments_6e7e0907-7529-4b8a-ae18-2a014c8c0f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_fe76df81-96f4-4376-9ec2-9953cef68e71" xlink:href="sny-20240630.xsd#sny_BusinessOperatingIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_sny_BusinessOperatingIncome_fe76df81-96f4-4376-9ec2-9953cef68e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_d81ec377-46a8-4239-9e71-4d61f34bc56c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_ifrs-full_OtherRevenue_d81ec377-46a8-4239-9e71-4d61f34bc56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_7824b5cf-bb94-498a-8f53-ea2a7fb37433" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_ifrs-full_CostOfSales_7824b5cf-bb94-498a-8f53-ea2a7fb37433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_7a09168f-64e4-4804-821f-e554283faabd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_7a09168f-64e4-4804-821f-e554283faabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_d547017c-6284-4b01-a774-b002d86043d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_d547017c-6284-4b01-a774-b002d86043d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_1b067839-ee87-42b5-aac1-60fee5f1c37d" xlink:href="sny-20240630.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_1b067839-ee87-42b5-aac1-60fee5f1c37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_d57018a8-26a2-4ae1-aa74-1fca48ef8e57" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_d57018a8-26a2-4ae1-aa74-1fca48ef8e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_84d806d4-f7a3-42e0-bb4e-2d64a6c997fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_162c0cac-84e0-400d-b5a7-ed3cbbf23de7" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_84d806d4-f7a3-42e0-bb4e-2d64a6c997fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#SegmentInformationScheduleofSegmentResultsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_cbb8bf7d-41a2-4664-be37-2c8ce11e2394" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_f3d32f59-53d4-4c67-acaa-ae85b765d9a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_cbb8bf7d-41a2-4664-be37-2c8ce11e2394" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_f3d32f59-53d4-4c67-acaa-ae85b765d9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_5f823050-dc78-48e8-b073-2f54d4a5b00c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_f3d32f59-53d4-4c67-acaa-ae85b765d9a4" xlink:to="loc_ifrs-full_SegmentsAxis_5f823050-dc78-48e8-b073-2f54d4a5b00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_2c912e0a-670f-4dd2-a1ed-61e371ae1a19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_5f823050-dc78-48e8-b073-2f54d4a5b00c" xlink:to="loc_ifrs-full_SegmentsMember_2c912e0a-670f-4dd2-a1ed-61e371ae1a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReportableSegmentsMember_b7fc9f50-1187-4814-8eb2-f9414ce48f5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReportableSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_2c912e0a-670f-4dd2-a1ed-61e371ae1a19" xlink:to="loc_ifrs-full_ReportableSegmentsMember_b7fc9f50-1187-4814-8eb2-f9414ce48f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_40815b01-64cf-4401-ad42-de514e746487" xlink:href="sny-20240630.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReportableSegmentsMember_b7fc9f50-1187-4814-8eb2-f9414ce48f5a" xlink:to="loc_sny_BiopharmaSegmentMember_40815b01-64cf-4401-ad42-de514e746487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_570ba325-1a98-42c3-b38b-0e006b50f985" xlink:href="sny-20240630.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReportableSegmentsMember_b7fc9f50-1187-4814-8eb2-f9414ce48f5a" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_570ba325-1a98-42c3-b38b-0e006b50f985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllOtherSegmentsMember_ac626560-6a74-49b2-8cc8-961710102766" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReportableSegmentsMember_b7fc9f50-1187-4814-8eb2-f9414ce48f5a" xlink:to="loc_ifrs-full_AllOtherSegmentsMember_ac626560-6a74-49b2-8cc8-961710102766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_f3d32f59-53d4-4c67-acaa-ae85b765d9a4" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_6f439544-e6be-414b-bb1a-5de1886998bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_6f439544-e6be-414b-bb1a-5de1886998bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_1841b8c1-b257-496f-97da-5c836149150d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_ifrs-full_OtherRevenue_1841b8c1-b257-496f-97da-5c836149150d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_e3fcf8f7-44b5-416e-8335-ed8079c82b01" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_ifrs-full_CostOfSales_e3fcf8f7-44b5-416e-8335-ed8079c82b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_bafad0cc-9366-46fe-b460-37a477e40500" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_bafad0cc-9366-46fe-b460-37a477e40500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_cca28ddd-5849-45a5-9e73-221399f42cd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_cca28ddd-5849-45a5-9e73-221399f42cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_3948fac4-9d9b-4056-9132-f523d053e5f0" xlink:href="sny-20240630.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_3948fac4-9d9b-4056-9132-f523d053e5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_02725475-9691-48be-9a1b-8f7498f163cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_02725475-9691-48be-9a1b-8f7498f163cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_58a08b25-052c-4726-8695-44d3981cf64f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_58a08b25-052c-4726-8695-44d3981cf64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_89fb9117-2152-47e5-9abd-3fd144507b01" xlink:href="sny-20240630.xsd#sny_BusinessOperatingIncome"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_sny_BusinessOperatingIncome_89fb9117-2152-47e5-9abd-3fd144507b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments_8055e36f-7083-405e-9418-404489caba3c" xlink:href="sny-20240630.xsd#sny_NumberOfOperatingSegments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_d40b35d9-2d24-45db-a812-873b62efd0be" xlink:to="loc_sny_NumberOfOperatingSegments_8055e36f-7083-405e-9418-404489caba3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_079589e4-80ea-4ee5-8e10-f9fab027d33b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_7cb6ad3c-a0c5-4559-a63e-52f0b366f2c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_079589e4-80ea-4ee5-8e10-f9fab027d33b" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_7cb6ad3c-a0c5-4559-a63e-52f0b366f2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsAxis_8cbc73ab-1eed-45a4-9684-e93d31ab1258" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_7cb6ad3c-a0c5-4559-a63e-52f0b366f2c6" xlink:to="loc_ifrs-full_SegmentConsolidationItemsAxis_8cbc73ab-1eed-45a4-9684-e93d31ab1258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_7b00b299-7415-4b72-8543-e65f0a5ebc34" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentConsolidationItemsAxis_8cbc73ab-1eed-45a4-9684-e93d31ab1258" xlink:to="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_7b00b299-7415-4b72-8543-e65f0a5ebc34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingSegmentsMember_0810fa54-8ffe-43ae-b007-5949529af8ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_7b00b299-7415-4b72-8543-e65f0a5ebc34" xlink:to="loc_ifrs-full_OperatingSegmentsMember_0810fa54-8ffe-43ae-b007-5949529af8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaterialReconcilingItemsMember_f5ba54de-50d4-41a2-91aa-6fcc8c3f9f9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_7b00b299-7415-4b72-8543-e65f0a5ebc34" xlink:to="loc_ifrs-full_MaterialReconcilingItemsMember_f5ba54de-50d4-41a2-91aa-6fcc8c3f9f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_5cf7c520-7c0a-4e60-bbf0-46ba636634f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_7cb6ad3c-a0c5-4559-a63e-52f0b366f2c6" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_5cf7c520-7c0a-4e60-bbf0-46ba636634f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_2c986bad-3d22-4923-aee8-75ff3728da08" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_5cf7c520-7c0a-4e60-bbf0-46ba636634f9" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_2c986bad-3d22-4923-aee8-75ff3728da08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember_bd7eb3c2-eeb5-4e55-b19a-472ebc83628f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_2c986bad-3d22-4923-aee8-75ff3728da08" xlink:to="loc_ifrs-full_OtherIntangibleAssetsMember_bd7eb3c2-eeb5-4e55-b19a-472ebc83628f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_f52e6d45-0db3-4ff5-8cbe-e5caefa2b58a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_7cb6ad3c-a0c5-4559-a63e-52f0b366f2c6" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_f52e6d45-0db3-4ff5-8cbe-e5caefa2b58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_2349ee80-d930-426f-b66c-c4296cf394ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_f52e6d45-0db3-4ff5-8cbe-e5caefa2b58a" xlink:to="loc_ifrs-full_ProductsAndServicesMember_2349ee80-d930-426f-b66c-c4296cf394ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EloctateMember_0ef7f1ce-4fed-4bce-9725-eabe40e019e5" xlink:href="sny-20240630.xsd#sny_EloctateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_2349ee80-d930-426f-b66c-c4296cf394ad" xlink:to="loc_sny_EloctateMember_0ef7f1ce-4fed-4bce-9725-eabe40e019e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SAR44425Member_c0cd51f8-d60e-49e5-8ec7-f8cec3312905" xlink:href="sny-20240630.xsd#sny_SAR44425Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_2349ee80-d930-426f-b66c-c4296cf394ad" xlink:to="loc_sny_SAR44425Member_c0cd51f8-d60e-49e5-8ec7-f8cec3312905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_c0445a13-575e-452a-abe7-f9e027e2901d" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_7cb6ad3c-a0c5-4559-a63e-52f0b366f2c6" xlink:to="loc_sny_PrincipalAlliancesAxis_c0445a13-575e-452a-abe7-f9e027e2901d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_fe7edfda-8142-4c1f-af79-6e94a5eaccfe" xlink:href="sny-20240630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesAxis_c0445a13-575e-452a-abe7-f9e027e2901d" xlink:to="loc_sny_PrincipalAlliancesDomain_fe7edfda-8142-4c1f-af79-6e94a5eaccfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunoOncologyCollaborationAgreementMember_da7e39b0-dc38-4fae-a62c-dc5bc2426229" xlink:href="sny-20240630.xsd#sny_ImmunoOncologyCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_fe7edfda-8142-4c1f-af79-6e94a5eaccfe" xlink:to="loc_sny_ImmunoOncologyCollaborationAgreementMember_da7e39b0-dc38-4fae-a62c-dc5bc2426229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_ec1bd55c-e225-42be-90a7-27de5a28fd6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_7cb6ad3c-a0c5-4559-a63e-52f0b366f2c6" xlink:to="loc_ifrs-full_CounterpartiesAxis_ec1bd55c-e225-42be-90a7-27de5a28fd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_7f38c54b-f94b-4da6-86f2-dc952e05feaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_ec1bd55c-e225-42be-90a7-27de5a28fd6d" xlink:to="loc_ifrs-full_CounterpartiesMember_7f38c54b-f94b-4da6-86f2-dc952e05feaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember_53966a94-1045-4f98-8028-8275ac919a0d" xlink:href="sny-20240630.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_7f38c54b-f94b-4da6-86f2-dc952e05feaf" xlink:to="loc_sny_RegeneronPharmaceuticalsIncMember_53966a94-1045-4f98-8028-8275ac919a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_7cb6ad3c-a0c5-4559-a63e-52f0b366f2c6" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_84a38248-d454-4b6f-8b4b-64a3d5bdf612" xlink:href="sny-20240630.xsd#sny_BusinessOperatingIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_sny_BusinessOperatingIncome_84a38248-d454-4b6f-8b4b-64a3d5bdf612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_a6b4f975-38e8-4700-996a-2da1672ae649" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_a6b4f975-38e8-4700-996a-2da1672ae649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_8a8dfa6d-94c5-44da-9b54-59452536b3b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_8a8dfa6d-94c5-44da-9b54-59452536b3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_b66aa5a6-959a-4c15-92b6-8967f07f7250" xlink:href="sny-20240630.xsd#sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_b66aa5a6-959a-4c15-92b6-8967f07f7250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_c3923d7d-812a-4485-8749-c24f4668bb4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_c3923d7d-812a-4485-8749-c24f4668bb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_ab88375e-8287-4922-82e5-ad108f817c5f" xlink:href="sny-20240630.xsd#sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_ab88375e-8287-4922-82e5-ad108f817c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_ab5b0708-e62b-42dc-a68b-147489d43c02" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_ab5b0708-e62b-42dc-a68b-147489d43c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_5033d349-a14f-44fe-a1fe-ad00664bbddf" xlink:href="sny-20240630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_sny_OtherGainsLossesAndLitigation_5033d349-a14f-44fe-a1fe-ad00664bbddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeResultingFromOutLicensing_8f9067d3-921a-461e-a679-a1b0f4085f7a" xlink:href="sny-20240630.xsd#sny_IncomeResultingFromOutLicensing"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_sny_IncomeResultingFromOutLicensing_8f9067d3-921a-461e-a679-a1b0f4085f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_15b69573-cdbb-48f9-9194-5524c01fd4bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_15b69573-cdbb-48f9-9194-5524c01fd4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_8dfd5b45-3081-400c-8caf-ae1bdcb9cb43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_ifrs-full_FinanceCosts_8dfd5b45-3081-400c-8caf-ae1bdcb9cb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_84211bbf-f5b6-42b5-9661-b1460c474cf4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_ifrs-full_FinanceIncome_84211bbf-f5b6-42b5-9661-b1460c474cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_62709543-06e6-4e1b-8c4c-43c3c821dfbd" xlink:href="sny-20240630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_62709543-06e6-4e1b-8c4c-43c3c821dfbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_9f930801-2f29-41f5-ad12-df7fe6e58699" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_9f930801-2f29-41f5-ad12-df7fe6e58699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_ca2a48a0-67f9-42e1-9808-09e286ac2d70" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_ca2a48a0-67f9-42e1-9808-09e286ac2d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_2e3cb07c-c0d5-4afe-a967-547280427bed" xlink:href="sny-20240630.xsd#sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_2e3cb07c-c0d5-4afe-a967-547280427bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_547005ad-e102-4084-9818-c4d2586b0e6d" xlink:href="sny-20240630.xsd#sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_547005ad-e102-4084-9818-c4d2586b0e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetReversalOfImpairmentLoss_7be9058a-1e14-491b-9f46-38ee73887d6c" xlink:href="sny-20240630.xsd#sny_NetReversalOfImpairmentLoss"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_b24a8670-5301-4809-a932-d94ff997bf81" xlink:to="loc_sny_NetReversalOfImpairmentLoss_7be9058a-1e14-491b-9f46-38ee73887d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_b9e18517-9593-4695-a6bf-61b68d9aa5b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_90cf4d31-7e08-4d76-81de-78fbcafa2aac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_b9e18517-9593-4695-a6bf-61b68d9aa5b7" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_90cf4d31-7e08-4d76-81de-78fbcafa2aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_86bc1bd9-a8f1-4e30-afe0-c5bb006a152f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_90cf4d31-7e08-4d76-81de-78fbcafa2aac" xlink:to="loc_ifrs-full_SegmentsAxis_86bc1bd9-a8f1-4e30-afe0-c5bb006a152f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_356af9b4-c284-44b0-9d7f-969eb886f720" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_86bc1bd9-a8f1-4e30-afe0-c5bb006a152f" xlink:to="loc_ifrs-full_SegmentsMember_356af9b4-c284-44b0-9d7f-969eb886f720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReportableSegmentsMember_4a4e2fd2-8c49-4c25-81f4-c64e97666624" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReportableSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_356af9b4-c284-44b0-9d7f-969eb886f720" xlink:to="loc_ifrs-full_ReportableSegmentsMember_4a4e2fd2-8c49-4c25-81f4-c64e97666624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_e0a38c7e-f12e-441b-adae-69c3d7ff91f5" xlink:href="sny-20240630.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReportableSegmentsMember_4a4e2fd2-8c49-4c25-81f4-c64e97666624" xlink:to="loc_sny_BiopharmaSegmentMember_e0a38c7e-f12e-441b-adae-69c3d7ff91f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_0980649a-4017-4e41-ac15-3b76246110de" xlink:href="sny-20240630.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReportableSegmentsMember_4a4e2fd2-8c49-4c25-81f4-c64e97666624" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_0980649a-4017-4e41-ac15-3b76246110de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaMember_79935007-2da5-430d-b779-1e65bf65d0d0" xlink:href="sny-20240630.xsd#sny_OpellaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_356af9b4-c284-44b0-9d7f-969eb886f720" xlink:to="loc_sny_OpellaMember_79935007-2da5-430d-b779-1e65bf65d0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_04762100-c29f-4f91-827e-aa1ed95f00bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_90cf4d31-7e08-4d76-81de-78fbcafa2aac" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_04762100-c29f-4f91-827e-aa1ed95f00bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_068ea6a8-94e9-4edd-adf4-e9b4efc702cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_04762100-c29f-4f91-827e-aa1ed95f00bb" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_068ea6a8-94e9-4edd-adf4-e9b4efc702cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_1378cb90-de21-4175-950e-3d8d965a9425" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_04762100-c29f-4f91-827e-aa1ed95f00bb" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_1378cb90-de21-4175-950e-3d8d965a9425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_9bf7a21d-81bd-44d2-8708-e2fb4ff17d4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_04762100-c29f-4f91-827e-aa1ed95f00bb" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_9bf7a21d-81bd-44d2-8708-e2fb4ff17d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments_5f05cf4f-f44c-4df2-b7fe-bc23eccc89f9" xlink:href="sny-20240630.xsd#sny_NumberOfOperatingSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_04762100-c29f-4f91-827e-aa1ed95f00bb" xlink:to="loc_sny_NumberOfOperatingSegments_5f05cf4f-f44c-4df2-b7fe-bc23eccc89f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_6f399d27-e05d-4296-80e7-61692756d739" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_cf8803a2-7629-41d1-83b9-9a803830c5cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_6f399d27-e05d-4296-80e7-61692756d739" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_cf8803a2-7629-41d1-83b9-9a803830c5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_efef6c4e-0acf-4f29-964d-df44448114dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_cf8803a2-7629-41d1-83b9-9a803830c5cf" xlink:to="loc_ifrs-full_GeographicalAreasAxis_efef6c4e-0acf-4f29-964d-df44448114dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_28a97414-387a-4d30-b5f6-5caa863d6560" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_efef6c4e-0acf-4f29-964d-df44448114dc" xlink:to="loc_ifrs-full_GeographicalAreasMember_28a97414-387a-4d30-b5f6-5caa863d6560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReportableGeographicalZonesMember_17bc22b7-018c-48ba-9490-b9c849bb128a" xlink:href="sny-20240630.xsd#sny_ReportableGeographicalZonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_28a97414-387a-4d30-b5f6-5caa863d6560" xlink:to="loc_sny_ReportableGeographicalZonesMember_17bc22b7-018c-48ba-9490-b9c849bb128a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_5b9802ca-6929-4739-88f6-d84d9a43fa8a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ReportableGeographicalZonesMember_17bc22b7-018c-48ba-9490-b9c849bb128a" xlink:to="loc_srt_EuropeMember_5b9802ca-6929-4739-88f6-d84d9a43fa8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_0ea7e859-f773-40f5-b2cf-3669df4af332" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EuropeMember_5b9802ca-6929-4739-88f6-d84d9a43fa8a" xlink:to="loc_country_FR_0ea7e859-f773-40f5-b2cf-3669df4af332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f6dc2711-1c96-4be6-a7aa-0a1fd73b4699" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ReportableGeographicalZonesMember_17bc22b7-018c-48ba-9490-b9c849bb128a" xlink:to="loc_country_US_f6dc2711-1c96-4be6-a7aa-0a1fd73b4699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_e14dd2dd-b124-4548-b260-ab1ccba2040c" xlink:href="sny-20240630.xsd#sny_OtherCountriesExcludingEuropeAndNorthAmericaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ReportableGeographicalZonesMember_17bc22b7-018c-48ba-9490-b9c849bb128a" xlink:to="loc_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_e14dd2dd-b124-4548-b260-ab1ccba2040c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_9220a667-97b1-40c1-9a42-e3054c7953f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_cf8803a2-7629-41d1-83b9-9a803830c5cf" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_9220a667-97b1-40c1-9a42-e3054c7953f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_2a28e552-5442-4eef-9061-02dce2b0e430" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_9220a667-97b1-40c1-9a42-e3054c7953f2" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_2a28e552-5442-4eef-9061-02dce2b0e430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_b45bed6f-3484-4128-8a12-a2d340c6b681" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_9220a667-97b1-40c1-9a42-e3054c7953f2" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_b45bed6f-3484-4128-8a12-a2d340c6b681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_1a412ec4-6f72-4f9c-962e-63f6073b5ede" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_b45bed6f-3484-4128-8a12-a2d340c6b681" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_1a412ec4-6f72-4f9c-962e-63f6073b5ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_718e4201-fc2a-413c-9bae-4db9ec5cd3e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_b45bed6f-3484-4128-8a12-a2d340c6b681" xlink:to="loc_ifrs-full_Goodwill_718e4201-fc2a-413c-9bae-4db9ec5cd3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_d0661b9b-4ba3-4a98-806e-32f47738ea4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_b45bed6f-3484-4128-8a12-a2d340c6b681" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_d0661b9b-4ba3-4a98-806e-32f47738ea4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails" xlink:type="simple" xlink:href="sny-20240630.xsd#SegmentInformationPrincipalCustomersandCreditRiskDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_99004adc-f0dc-4f3d-b005-bc13f7db4618" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_ee3cd036-d1ac-4d00-bf5e-5224e967be3b" xlink:href="sny-20240630.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_99004adc-f0dc-4f3d-b005-bc13f7db4618" xlink:to="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_ee3cd036-d1ac-4d00-bf5e-5224e967be3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis_9f8b3888-14db-4755-a3b3-82f8fd44df8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_ee3cd036-d1ac-4d00-bf5e-5224e967be3b" xlink:to="loc_ifrs-full_MajorCustomersAxis_9f8b3888-14db-4755-a3b3-82f8fd44df8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember_0c64bee3-6b45-4fed-bfbc-377d5e5302d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersAxis_9f8b3888-14db-4755-a3b3-82f8fd44df8a" xlink:to="loc_ifrs-full_MajorCustomersMember_0c64bee3-6b45-4fed-bfbc-377d5e5302d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CertainWholesalersInTheUnitedStatesMember_1439fe70-fb64-417f-bd74-2acfeb963328" xlink:href="sny-20240630.xsd#sny_CertainWholesalersInTheUnitedStatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_0c64bee3-6b45-4fed-bfbc-377d5e5302d8" xlink:to="loc_sny_CertainWholesalersInTheUnitedStatesMember_1439fe70-fb64-417f-bd74-2acfeb963328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerOneMember_46a2149e-e876-45db-a115-8cb3b6ca6884" xlink:href="sny-20240630.xsd#sny_CustomerOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_0c64bee3-6b45-4fed-bfbc-377d5e5302d8" xlink:to="loc_sny_CustomerOneMember_46a2149e-e876-45db-a115-8cb3b6ca6884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerTwoMember_416aa220-4ee2-4754-9a7f-b42b37895cfb" xlink:href="sny-20240630.xsd#sny_CustomerTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_0c64bee3-6b45-4fed-bfbc-377d5e5302d8" xlink:to="loc_sny_CustomerTwoMember_416aa220-4ee2-4754-9a7f-b42b37895cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerThreeMember_5fbbcedd-c541-4100-bbfe-5845273d26a7" xlink:href="sny-20240630.xsd#sny_CustomerThreeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_0c64bee3-6b45-4fed-bfbc-377d5e5302d8" xlink:to="loc_sny_CustomerThreeMember_5fbbcedd-c541-4100-bbfe-5845273d26a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_c9638347-d0b3-41b1-8404-e1401ff72068" xlink:href="sny-20240630.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_ee3cd036-d1ac-4d00-bf5e-5224e967be3b" xlink:to="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_c9638347-d0b3-41b1-8404-e1401ff72068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfEntitysRevenue_ce3ae105-b258-4e3b-b385-fe8083d8e569" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfEntitysRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_c9638347-d0b3-41b1-8404-e1401ff72068" xlink:to="loc_ifrs-full_PercentageOfEntitysRevenue_ce3ae105-b258-4e3b-b385-fe8083d8e569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/EventsSubsequenttoJune302023Details" xlink:type="simple" xlink:href="sny-20240630.xsd#EventsSubsequenttoJune302023Details"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/EventsSubsequenttoJune302023Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_000306ae-6fc2-440e-af97-4f38ec5ec270" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_da742460-e2cf-431c-8d15-e94d502caf0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_000306ae-6fc2-440e-af97-4f38ec5ec270" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_da742460-e2cf-431c-8d15-e94d502caf0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_0d3b28a9-b865-4080-bf33-508e064ab30b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_da742460-e2cf-431c-8d15-e94d502caf0f" xlink:to="loc_ifrs-full_CounterpartiesAxis_0d3b28a9-b865-4080-bf33-508e064ab30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_3022df69-0a37-41c3-bb2b-05d56a22f15a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_0d3b28a9-b865-4080-bf33-508e064ab30b" xlink:to="loc_ifrs-full_CounterpartiesMember_3022df69-0a37-41c3-bb2b-05d56a22f15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RecludixPharmaMember_95db97fc-3c00-4661-8933-0173cd765a2a" xlink:href="sny-20240630.xsd#sny_RecludixPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_3022df69-0a37-41c3-bb2b-05d56a22f15a" xlink:to="loc_sny_RecludixPharmaMember_95db97fc-3c00-4661-8933-0173cd765a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_691ba471-8e51-4171-8c44-74a47708795f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_da742460-e2cf-431c-8d15-e94d502caf0f" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_691ba471-8e51-4171-8c44-74a47708795f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_d18c7396-ac46-4a1c-b6be-b03eae090afd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_691ba471-8e51-4171-8c44-74a47708795f" xlink:to="loc_ifrs-full_NonadjustingEventsMember_d18c7396-ac46-4a1c-b6be-b03eae090afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorCollaborationAgreementMember_0fcb2665-8c72-4f44-9489-14bff00fb27a" xlink:href="sny-20240630.xsd#sny_MajorCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_d18c7396-ac46-4a1c-b6be-b03eae090afd" xlink:to="loc_sny_MajorCollaborationAgreementMember_0fcb2665-8c72-4f44-9489-14bff00fb27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorBusinessCombinationMember_65148179-61e0-46bd-aed5-4925230468c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorBusinessCombinationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_d18c7396-ac46-4a1c-b6be-b03eae090afd" xlink:to="loc_ifrs-full_MajorBusinessCombinationMember_65148179-61e0-46bd-aed5-4925230468c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_f1cc038b-7f83-43fe-adfb-664e4bc205bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_da742460-e2cf-431c-8d15-e94d502caf0f" xlink:to="loc_ifrs-full_RangeAxis_f1cc038b-7f83-43fe-adfb-664e4bc205bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_3e421c20-f513-4647-9c5b-1591b7f3bcc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_f1cc038b-7f83-43fe-adfb-664e4bc205bf" xlink:to="loc_ifrs-full_RangesMember_3e421c20-f513-4647-9c5b-1591b7f3bcc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c763f1ea-574a-485b-a0fe-69416c5ec598" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_3e421c20-f513-4647-9c5b-1591b7f3bcc6" xlink:to="loc_srt_MaximumMember_c763f1ea-574a-485b-a0fe-69416c5ec598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_183114d7-d134-4aeb-8b71-e7e9f9da5075" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_da742460-e2cf-431c-8d15-e94d502caf0f" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_183114d7-d134-4aeb-8b71-e7e9f9da5075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_31aa18fa-3aef-4db6-9b64-679bdb67c0c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_183114d7-d134-4aeb-8b71-e7e9f9da5075" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_31aa18fa-3aef-4db6-9b64-679bdb67c0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QRIBIntermediateHoldingsLLCMember_8a069296-bc48-44ac-af9d-be7ef1e3afb2" xlink:href="sny-20240630.xsd#sny_QRIBIntermediateHoldingsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_31aa18fa-3aef-4db6-9b64-679bdb67c0c9" xlink:to="loc_sny_QRIBIntermediateHoldingsLLCMember_8a069296-bc48-44ac-af9d-be7ef1e3afb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_848b8bd4-3fda-4b81-b2ef-3646f7f10879" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_da742460-e2cf-431c-8d15-e94d502caf0f" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_848b8bd4-3fda-4b81-b2ef-3646f7f10879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPayments_38b8c633-a42f-4510-aa1c-c7529fb0e93b" xlink:href="sny-20240630.xsd#sny_UpfrontPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_848b8bd4-3fda-4b81-b2ef-3646f7f10879" xlink:to="loc_sny_UpfrontPayments_38b8c633-a42f-4510-aa1c-c7529fb0e93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_3a2ea788-6857-485e-881e-50544a5e94a4" xlink:href="sny-20240630.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_848b8bd4-3fda-4b81-b2ef-3646f7f10879" xlink:to="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_3a2ea788-6857-485e-881e-50544a5e94a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePrice_f5d09043-88ad-4ff9-b74b-92fc52f7bafd" xlink:href="sny-20240630.xsd#sny_BusinessCombinationPurchasePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_848b8bd4-3fda-4b81-b2ef-3646f7f10879" xlink:to="loc_sny_BusinessCombinationPurchasePrice_f5d09043-88ad-4ff9-b74b-92fc52f7bafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>a1a.gif
<TEXT>
begin 644 a1a.gif
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MZ/KZ^O+R\DA(2/_!$8EH"=VG#\.4#:=^"VE0!R,; D<V!;!8_N[:__3G_\.
M_MZX_^_;I>_+9_GS_]*@_N?,_]FN_]RT_^W9_^_<_^3&__'Q\8^/CW5U==S<
MW,C(R+BXN(*"@IV=G965E9Z>GL+"P@
M
M
M
M
M
M                                              BE  $('$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7
M,&/*G$FSILV;.'/JW,FSI\^?0(,*'4JTJ-&C2),J7<JTJ=.G4*-*G4JUJM6K
M6+-JW<JUJ]>O8,.*'4NVK-FS:-.J7<NVK=NW<./*G4NWKMV[>//JW<NWK]^_
M@ ,+'DRXL.'#B!,K7LRXL>/'D"-+_YZ\,8#E  (HUQQ0H("!2G,K(>B<0+.
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M%OB;0%:(/.V],"$G<%[VH"<U1C#@> M9H=,:8  @,42!SS/  "E2!6XI+TL
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MY'8(8"KMD;,*5N .93F2N. .A#P4Z!%!<O:S@Q1*N0N1;4$8, #S@6"1\&-
M63.PR'<6I'X&: Y_-[B (2ID<@0X[4"F6@#R)M(Y2@; (BE<WNZH5R#<#$JK
M0Z:Z68%P!XJP#?_SB0AJ5[X"H',JGNUE%+:0&: & P<)W<<4L@6)6A3&PD5N
M' >[6]0@Q(,?:(B#(%!=<FV$>.W$4EOC6^$:1AD  8QR:ITS@1M*V;0)8?1
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MCAF)/JI6*:BB461/M395#6&?8@6FH%:6TO>NNJ:?H"A)8RF=!&&B^OH0+Q8
ML_DY&LJ7WIH0L!@PJ-%B"P&E$M%5)0!K'BBDDYBCENF$_BH0P<D022 !7XI
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M#)%)#@$&UIG($:R]$^RVG=%MYA2V,[E9PZR\T=RD^Z80,_!%%8F>\HO" "#
M@P-Y%2!-Z(@0'$N/-_:1H5J\A[N]3G.*72MK-/4T(5C/W5*[_RR<9_H1CD@
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M7A_9V+!;]$/(O.7M#AJ\LT9T)RPL RWGX+I[MC"/;\#A+>OV!M=E\I8Y@6T
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ML^ @EE?=6N%('C,^3O!_?<(+)OE"[SUYYS5ZOR^;Q/$<1<H^0UH*#&9_WSR
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M4/N!P #Z(F@!!S8" ]F+P IQ2(K:8<!\%<P]\;X_/_I;3OS8BV %I0< YDE
M@A,D8?'3-SWF88""*I  \151^P( @-Y=WT!PP.+!0"54P0$B1?\17NNM7?I%
MH 22W/")@ D 0!68P-REP/M5X 52GPA,WP!^X$"$WD ;+$#W_5_F#03P[1X
MN)[YY<3>;805M-\$WB ._VZ<X-'=")" Z V$X*V ]H7@Z!7?0,1!%:P=P[P@
M >9$$&Y$_B'%W)$@ *B=$>8@%F8AQ*F= R)%^+$?W@' #J+ 1CPA$")>"=C$
MW(4A -0@!WX?4ZA "+Z?%M:A'1[<W%WA42P>%:Y=  )  ]I$#>HA]XW "PS$
MZ9V "FS?"K@ '#1%!JY "SPB'-ZA)5[BME7"VK%A3B2A")Q 1: @Z@' W+G@
M0& >%8JA]5W@#H:@#SH%[JT \F$B+=:BH,FA"*0A4I@A"%[AVKF 3:P=*.8$
M"MA?&T(@5>R@+MHB,S9C8KD ,C*@",0@ "S@*8H )\JA$ [$XJ$ ',HAW^W@
M,&0J7A54HE+TWS8ZHSJN(QUMH%+P8>6)P!\"(A&JX/2M'R(2H =N1 MPXE*X
MWBBRHT .).]4 4". !DBQ=HM(P!L8D6<7AJ6  EPX?O)GC>6P APX$#TGP@<
MX@GT(U348$ 2)$F6>R3KU%WPY00NV@1'IL '8N3DH0 *S)TDGH!!0E\*D  =
MOB#F7=\A'@7HK4 ;V 07FJ11'F5-F2-7X-XX D %_B!21J54>IO:L4!%(&$>
M3J56;B6A@9Y+ N$:<J58CJ5WH8!(NF)3DJ5:KB4V*25;OB5<QJ5<SB5=UJ5=
MWB<E7N:E7NXE7_:E7_XE8 :F8 XF81:F81XF8B:F8BXF8S:F8SXF9$;_IF1.
M)F5Z7@%<)F9FIF9N)F=VIF=^)FB&IFB.)FF6IFF>)FJFIFJN)FNVIFN^)FS&
MIFS.)FW6IFW>)FZ2YE=<P1+PIF_V)G#^IG &)W$.IW$6)W(>IW(F)W,NIW,V
M)W0^IW1&)W5.IW56)W9>IW9F)W=NIW=V)WA^IWB&)WF.IWF6)WJ>IWJF9WAV
M16Z^)WS&IWS.)WW6IWW>)W[FIW[N)W]^Q1+\)X &J( .*($6J($>*((FJ((N
M*(,VJ(,^*(1&J(1.*(56J(5>*(9FJ(9N*(=VJ(=^*(@RJ'OR)XF6J(F>*(JF
MJ(JN*(NV:'SZ9XC&J(S.*(W6J(W>*([FJ([N@"B/]FB/CJB+!JF0#BF1%JF1
M'BF2KBB,^BB3-JF3/BF41JF43BF55JF, FF29JF6;BF7=JF7?NF)+JF5CBF9
MEJF9GBF:IJF:2BF6@JF;OBF<QJF<SBF7BNF:WBF>YJF>[BF?]JF3MBF=!JJ@
M#BJA%JJAMJ:=^JFB+BJC-JJC/FJ>_P+JH4XJI5:JI5ZJEB8JI&XJIW:JIWXJ
MJ$[H%4@JII:JJ9XJJJ8J;NYFJ+:JJ[XJK,9JGY*JBP( &)B JN:JKNXJK]:G
MIN(H$UR$K XKL1:KL8)JFS: 392 BH(! $A KT:KM$XKM9ZFLW;%@#X!1@"H
M)44!B :K#!RKN(XKN9;KF4IJ&H(!B]HJKE:KN[XKO$9KHFKK14C!?Q:*MWXH
MN)HKO_:KO_YKC4KJ'V+F4(+ 4 I@ 2QANQ;LP8) P@+A90XE!URFLS*K"8#!
MK3HK&#@ P59$&V#F0$!K 3B QHHA9EYLR7YLZ3%K 0R LW)LO,:LS,YLD<YK
MO<H ;W8K@/^B2+Z"*V]*@; NP46 *Q/T)HH4[1+LZW]& 8H$J"4=+;WRYA(
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MV!9 "%.O^Y(P\YJP^OJM"E^F]A8 UP+ 98HMM(IOZ1WOXGXP[.EP")<O\X&
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M9FR^3CW^DSP [3 X ;N2!;H21DFG9PN?-$R-#]Q2ILD4QZ<TB5J BXT<,Z&
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M<A>*/3A=%[;5CBXG$\=A4VJ.UZR TH5796Y[CDU/+BV4"HG5QJ3D?C.4X:B
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M&XX926G<!U8Z1A&'4%WZYF21!#RAN&.HJ'76=U"PUWVC^[P78XOY,B6JM"4
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M@BI@$I?*&NNLMM:*JZRWZIHKK;S^ZFNPNPK;Z[#&]BKGG,HFRRRO08D'%WN
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MW&;][M[;V_=OX,&%#R=>W'C<W6P-?JXB\#, JU EG^8,0(&:QY4):DZ-%3&
MYM59$WR:=2IJ\@!8)RZH6N 6 )FEYZ9?W_Y]_/GU[T^8O.]Q  ,4<$ ""S3P
M0./\8\HI .)0K+7.& , O:GBD.HO@53+2D/L&NS.PX'<4\,TZ 0**:K$LAJH
M,><FE!" Q?B3<48::[3Q1AL57 M!'GOT\4<@@Q1R.!W_E3+(P20NV^PI"PN#
M44(*1VK/L _EVV(ZD+X3:0W56'LJ--5 >Q$D%$,:#T<TTU1S33;;C*C(I8:4
M<TXZZ[3SSB'AE+(@YM1X3D7O2#PL,/0N4ZC+*M5PS<+TXDLL1H$,A9*@,"7<
MS*#$+G5S4TX[]?13VO1L"T]22S7U5%13!4K4D R"#S4'K5/#P<@>G50T%=?0
MU-)$'V,T1(^N\P@]Z-B;U46"7(-.M<780&^Z9T&5=EIJJ[76(59%4G5;;KOU
M]ML\L\6PQ2L_C"_,6 _[+-K)//J5()'DLS!,*EO,<DP'0WO.H_!,I"[68:\5
M>&"""W937)# 57AAAAMV>"Z$D4LT>&***[;X8OLB]HBN#SSJX&&00Q9Y9 ,C
MQOADE%-6>66,- : )0] >B.HC@'P@62<<]9Y9[I,9OEGH(,6VF*-XUBI!P!F
M,(F3C7^2PZ,\>)9Z:JJKMLGGH;/6>FNNTW19I0X\^N DUWH((&P 8O;X)#U
M\L"D?6<.H.8Y3$)[;9/:ECD C]X.0&VK Q=\\%/_L>[Z<,035SRVKU.:*@F4
M[( J !\\4AIIR -P3>D @'B[[P"05OH!C^H&G.^T.V_Z*;-%-PEIN0F7?7;:
M>31\<=QSUWWWBAI':7.45 L@#[$#$![MJ$]B^N6SQ28=@+I9?SWI *H P.P
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MA*D<??#5D.@@J4DK*UC1F(FONK3_C12-Z2,Y@=:^J%4D-ABJ&G-@U)'P(*1
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MW: EGDP,+4U*-,\/ZH\G0L:$/!P$G=H9%8;@8<2V._9'/%J20?"C3\"21M2
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MS+R.R&W<3[[R&3E1#<K.@/9$#&396R(QUB%YJ]=<5O5RU=Z(J8<@5N26J%F
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M((A"X >6326[L]KD!-9.LDC78T=<$D91Y&DT*BDI#"1%((504XG@LLG*= U
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MWG6QP6WO57=Z$=JV>)%%_N\RD[N@<"[HFJ'K[83?'.>.;OC.>>Y?Y(3JNJ#
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MC7&,CLE8CFF,C=^8B_L8CN\8C<G8C4_,C]VXD /9PP!YD!&9D6O_[(H?>21
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MD,.KLM8BR\L3PPV'$O8R,.L3>$?+>VIBKLWE3,#_H[&XO=_\73$4O*EV&I;
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MZ,&\*6<)J5N",RM*\[ :<6>VKUHLU]IR3QE3T3)R-,YR<X;_)N_V@A8OIT[
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MPE6?F#DB:J>?@Z[7UT4N,=384CD(^F=&=2':E_^?_6U:$']?(?HCH7PE)M5
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MJ5",%31A_!#X0S6NB(][TJ,=K?>G]032>@_[&'(VY:A!7H@G99/CGK+HO<_
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MEG]=BG D2.BIR<FI759DH/?=4WLZ*&D$UA&Q3:'EHR3&* K12XC\%N*PVZ4
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MK8/O*I0AC952;VAM#)%J^MQ"W8YT+%1OQ!_&;QH_S$EMZ8,U:R.KI>@(+-#
M Q%,4,$%&6S0P0<AC%#""2FLT,(+,<Q00P*-NVBU#4$,$<3Q-)R)P/00[%#$
M%5ELT447YWN1!K1>W)#$&K$S$53''7GLT<<?@0Q2R"&)+-)((:N3;#(=CVSR
MP=XTO*G & ^LS\DKL322RA"I"BI+!*'L,<DOR2S3S#/13%/--=ELT\TWX8Q3
0SCGIK-/.._',4T\- P( .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>a2a.gif
<TEXT>
begin 644 a2a.gif
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M]K^ ]W5U=8*"@H^/CYV=G=S<W+BXN,C(R,+"P@
M
M
M
M
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MC34P' &Z$8#CD4@FJ21W.B940FDE/.7B<+?EMN256&:I_R5A32:D8I <U:#
MEP'HT8 0$G42(9D!H)9$0QAJ9(&89)J)9D1J,D#F:0Q$.56'$7RXY:"$%FJH
M6ETBU,"4&9*FW$&,5K" ?B\ZU$D%^C&FAY\)D=8*0GHTI@="&BIW::;H+71J
MIILZI&$ E>ZD&V]N>? "H(&^0,JAO/;J:WV)'H1I8Y\VVMBC!L560H^9!L!
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M/$  ?6P,IW@W465BK*5U!( AF6DQE-HQA3E:8=VZNI"/$M,@8W6565V"Q(3
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M&[,;$G<!#_EF"L>0IXB*$J"%%!AJ%/!J"-%J(2EZ)?F58&D84]()#< !),<
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M!P R(+ZZU7P'M452A&#KV\,^_,,A*[$+;!"@ZZ6KFR'V^[Y>"L'U^RAB:K,
M#  )S+KTVP)@2K\ZB\51/! L$ )WTKOP*\5AW,725,08?,9HG,9T.KQV<GO#
M.G=0HT#";HP;<"S'T(O"HKE /B4#Q(L;)Y-*-9-83#19PG58APL !>)3$7 R
MH0G$COS(D'P^F'L"?M+%82R_]+L"27RZ-&FUK0L O=NV#>REE14"3%P0-,#$
MFEP>74R_ ^&V>):VW07&:ES+MGS+8/]:MP# P6\, "D<PKW\RY:(/]91,R"\
M0"L,OCYT,EL4PX UPS7<P3(< ?UAO9%\S=@<R>]Z BV@!$D, )I,P* < O0+
MNA/\I3EKIE LSOL[P%\J327 Q&8<NA$, );LI:Z<OTH\IGY"P;C\SP!MP6R\
MRX=,Q[YLQQV,Q^!KB>0;O7D< 7L< 5(DO8)R&V%+S9)KS>"[0-#KQN^4S2 =
MTNK;OO;LI2U0P/K<Q:J\R6!ZTO?LP%\JNE$\Q3!-S@(!NOUQ E_: C6PMB'@
MTF$:)58LSVI[SZ0LQ@&=U$H]M_@ZM'/LT O]U K=PA)=$+^LQP*AA&_6(8KK
MP@/1<P<H.<NP)=)D7=9CZQ%6'*9*  !I[<HKX,HG#<[VVP(Z#:;WZ\ZY++NC
M?,H"$<XX&]<"H;/AU!]=?-=IO<4"T<4)9-1+W=B.[;,JBZV&G!OE45AF?=F8
M_;(T*Z8S\-B>_=F@W:F1?:TO#'TTG-FHG=H;N]FAW=JN_=I1&[3H^FU%A4E'
MJ]JXG=OZRMJPW=N^_=MP.MJZ/=S$7=SDB-; G=S*O=R!*MO&_=S0'=U-RQ',
M7=W6;=W_PBW=VKW=9<W;U_W=X+W4V<W=Y%W>CXS<X9W>ZNW8XVW>[OW>ENO=
MZSW?] V\&R$!+R !,B !^HW?_=W?^;W? /[?^QW@_%W@!.[? H[@"Z[@!^[@
M ][@!A[A#S[A$" !%X[A&J[A&7[A'3Z-',[?'B[B&S[B(7[B)I[B);[B'<[B
M)-[B,/[B,H[B+D[C,6[C,Z[B-Z[C.5[C/([C0/[C0N[C1+[C+NX" C[D1K[D
M/<[D05[D31[E3^[D2B[E53[E5@[E6+[E5Y[B\HVR/5 #8C[F9%[F9G[F:)[F
M:K[F;-[F;O[F<![G<C[G=%[G=B[G#W#G>K[G?-[G?O[G@![H;6L>$L@) (5>
MZ )QZ .!Z(:^Z(Y.$(J>Z 41Z8T.Z8]>Z9<NI IRTIS.UIX>UX!-%ITPZJ1>
MZJ9^ZJB>ZJJ^ZJS>ZJ[^ZK >Z[(^Z[1>Z[9^Z[B>Z[J^Z[S>Z[[^Z\ .[)H^
M[,1>[,9^[,B>[,K_ONS,WNPX&@<[L ,@$0<\T -(X0IH,!.N(.V'$@='\!%R
M\.T@<00Z  #A;A#G3C58$.T   OL_A!&L -$D!'KSNT($>WE?@0[4.Y @079
MCA#Q+KL[  L $ ?_/A !OXI8,.\R<01 \!'DWA [X HLL?!(P0/1GO%T,!$Z
M\.X8$>VR8.A*0 1$P ,RT?'L+@0[$/(&(0L33Q! @ 0 D/%Q  ! (.X% 01R
M,! J'^T''Q$NO_,"@03VOB0O+Q Z\.VM8/(:<?1 P/0?P0/E_O0"X?10+S4H
M#P!)X/$-0?0_0!$=+^Y9GQ#X#@ 87_,E@?$93_'ZGO'13NX,#P#;3O #_Z$#
M7X\01"_P;V+W!9'W ( &:"\U*B^7.A#W/( %*[$#1I 0?"\3/"#T'<$#@5\0
MVSX0.R#S*]'X1J'O_/X#^_X2("\0VQ[O:QT32/#O*L_R!.'R/X#Y57\GK2\0
M5$\0T+X##R_ZF#_[$2$''3\0E8\EEU_W)J\#5W\1P4\21P"$QR]![E[T#+'M
M=R\1ZU[\#H'Q_([\M^_W L$#MP\ C>_N$:']!J'Y!O$#UR\U/(#Y^GXG.V""
M(['\.\']47_^!"'^=V']4AOM0M#S&W_V  $ R X>.PS" H!D!QH !N, $.(0
M@ ^#.XX  *##XL =/@"@J;C#29$CL':TPIA2Y?]*EBU=OF2)Y ?&B+)61@3P
MPU5*)#Q2HD&"$<A%ECR M$3"<"4:CCLB+E2)QHE.C HY/H295>M6KEV]?@4;
M5NS8'3LQZO#9BFA#B1_;[M"X0U;3G04-ZD K4$[*(U@KFEUYQ"!1D#NP\M"1
MT:==N'D%5D0X5O)DRI4M7\9LLN,.( J) $AB\'%(5YH-?DZXD",6C 9=[2#R
M5 @ P7$45NP,5?/K'44P@@Q:,.Z.))B+'H7H-*71E*T81IR]$@EJN*>K5C?<
M&J&.'W9WRMHQ>L=>T\4CQBUN7/UZ]NW=K]2!G//.)$H9(SQOT*K!(G%9WZP(
MM:$P>@T QA[B+;R$E"+_HJFG4-,!#<%V0&)"_':(C(B'Y.#!PI2(,.@_E8PJ
M++VG, 3 )([Z"_'#MA#[R B:* Q)"*H 2# ]OB!++JZUXD*-0Q#E&G*VI,ZJ
M2,3W+A,NI1\HE(TVN!Z;2:$J=YB)+2$&"DJCH[P$@!7]8A&-+?,LXN&'M9;,
MRH=%9K0II=!F^R$HC(ZP,R<[@?#IN)9XZ%.E1;)\$J,?$@- %I\<4RBH.=F$
M-%))V:,P)1TN<@P-1(]BKJ:&LLP(R=;LS N\&7]+[%&5^!1*H#XKA=&Q2A7#
M4:DD )LT5UUWI<PTSJQ,L<SK0+WNJ-N0B#*D'Z)L4J,^@0V-,S-S@E4T9]UC
M_X[6Y9#+:";E8LH22T.#>BU5!8G+"%V%0%/PT)0J73>B0'FEMUY[7X*%H21X
M0.)+Y#:=25Z,3#+W*%53@B6]*5E-;=09B]/A,YD,);3=Q#2"N%+NDDO/W8$@
M[K-3N58JR *!Y MJW= *9G<VAF%-;.(P?5KWMZ# F^U6^(0*F*#6;#)"0>8&
M<N*QXEB5&5&%HKMWJR8Q$H[9A:75$EAV%Z'Z29NB3=>G9%$,NI/4=*2W!J4\
M?3<]H-Y5J4ZAYMUVI8'>9$E3J!&%4:"@<&K84%R;!CQPXV:E-:_05(+N[H;R
M3"GQ63/MTF %<_H;W;3/6NSB5TFE>7+!/P=]2:Z'9?]W\BA+M\[J@H(RR$2#
M9FO6Y]1FTLS0LJ@-;LJGL UIWFR[[<XEF6>%L6;'MT.MH21,,E1I4(%".W3I
MI[?,*1WBZ.0S?E<Z/*+('DT\<9> .(KAFA\/E#B9W340[XM1D_E([YMWM:K/
MQ,\[;EIE5MZDV<)7CN7RDK>1K:UF>CJ95KIGN;7E[4@,<TQ>IL,2%%%O1%.R
M';)>9Z"IR8<X00-57-X5$FOY[&MD$YP/LA01'8&'A#'C%@+KQY(CQ+ Y2FD;
M2@R$G&Q-;GL'S)\%A3C$M6&.5JX@5K1PL[B4N'"#Z#,B&HH3M) @:D9,$U^$
MVJ<M*')06$,$8QA94CO2D9&5@Z02#;!4-Z6#S$@YL7N6N$;WI*#0D8.).=UZ
M?L>P'5J*. U""G7LQ!SCH0M=&\,($9!PN)P@RC&-9*$8)3E) _6D.&BP0&RN
M4Q&.#4PYD8S>C@Q2OC@Z+(&C0B+]^MA'1-8L7@Q,C/G"H\11!N9?GQF.?OS7
M219F47N.!$(2X#<YMP51.B%)3F3<]21D0A!"$EMA2%#_2+VGR49JL926;*QF
M RS)SHXJN=;7(@,ZF<VO)6ZKI$H4^;8_V1 CC&P;WGAH+!)VSDE_HV0^=X7.
M!!K.<^)[EYTBLK< <NYAJ(%G2RJH'2/&:G-&')$[]3G1IHTN-9\9W;6@-B4U
MB@MWTTK.&Z>D46"1T8YV;))%]<@M_OTN8@!P N%X$JY!TG-&"$$1(ONG("(@
MJ@9TTY,Y*3K4P,5'0(@$#T(6^+U/HDBH/!/*ETK)1&TU1!8R6X0\H?:E++GR
M7,J,92D!ZJ=N)818+4MF6BLX0$1%! A*F]PZR><2DVPM/)%LY!97U2=$;FQX
MB%JH$)_VS=;=\3%?\IG51#.0_XMY-"=="RF=9)I"U."5)6[CFY/V!+>MI@0(
MT0%"\GZBU3Z^M7%.\2I150LIC<RH2WWJ::NRE83$S"IQ2\MK59\&@-@FA'$S
M)*7#'(HJ(^H@%HI;;7)U9<:2BL:,ATW7E68RNC:V!EU-LAJTRG32:F%3HI>I
MH?Y6659VQ6FFIB2D@B)Y2 A-5VC<@M==+:=<^DK*)'%$S@,4U%J\[A*4\XVJ
MH8R%FH*H<GY^1<T/=)@MYK12035SFW[#>IW.)LJ*%4;DXQ+6U#,=[:'Y*[ G
MH^.V7<*"<8SD;P7=!<09]K5*X2J.2:8Y/<9L<),5P69%NHJEI^#Q+JG1,62C
M=)MO%?^5DR?Z\8<BIQ(<BZ>$%3%2D"]+6J-8MGU$'EE]M6R9IA@4 )UH,K6>
MF">.%"3*C0D4;D?X12<9I$_,=)^V;H,7GSAQ35O&LW$LJMWPU)B-!GG2E6ID
M71UA&8/,S WMMELIE/;N/37V';=TVBB5#*^F?9M?3@?-O-));H-/S7.H+X/!
M@2['S?)EZO^<&MB0$@0YB'[PCXE<E2SUEL%<I7#?;I.F"?=-S$7&<#0!'2Q5
M7TB92<Y??"[H%'0.AVD;)8A\.^;()D,P2PA&4K3'2=^!?%?48.'!MK\];G*7
MV]SG1G>ZU;UN=D_R!S-N]Z2Z'6^MQ.*L],9WOO6];W[WV]___P9X>RX5<((7
MW. '1WC"%;YPAC?<X0^'>,0E/G&*5]SB%\=XQI?4B4X(P>-"8 +(F3!RDI?<
MY"='><I5CG*1@]SE'X=YS&4^<YK7G.9.\#@E1$YR(>@\Y#YW.="%'G2B_]SE
M(4?ZT8^>])"_O.E,1[K1A8!SJD_=ZE7'^M6UGG6N;]WK70?[U\4>=K*/W>QE
M1_O9U9YUH"<=YDQO^<B5'O6>$[WN=3=ZWN_.]IWK?>AR__O>;3YXPA?>\(='
M?.(5OWC$/\$X'9<YW*&^<LK'G>X^ISS+Y;YYN#.^\!P'?>A%#WHA<-P)G3A]
MZE'/\=*SGO2CASWL6S][CEN $JX_;WWI==]QWN_>][T'_N^%'WSB#]_XQ4?^
M\96??.8OW_G-A_[S51_[V-.>]J[GO1-80(GILX#ZWP=_^+]_^]N??O6=V#['
M;U_ZW'?B]DQ0O_CE#WO;BY_VIT\_]GG/<?C/__NIUSXG$, !), "-, #+/^:
MRWB"!00 QTL)L?DRC(# "93 "HS "Z1 #+3 #(1  + $C'"\$&S !ES $C3!
M$T3!%%3!%63 %O1 C/C $11!$I1!& 3!$7S!&L1!E9C!&!P%'KS!'73 (23!
M!52")SC")$3")53")F3")W3"*(3"*93"*J3"*[3"+,3"+=3"+N3"+6Q!(MQ!
M&\1!,1Q#'50"C$A# $C#$"1"-RQ"!Q0;$9S!-J1!.J1!-@1!%N3#/O3#/P3$
M0!3$023$/[Q XX!#!\S!1=S 1M3 0XS!19Q!#G3$#HQ$1L3#0E3!"A2;3HQ
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M&:;"XHCER50-KHB4AM-:LNW+R$QI H !E9/6L=?;B"&C]J,LB9:!):'HX,M
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M*O4QUP!:D;5=WS5>Y_4\_YLU>,P2]FB=]QJD46LUNWC3^,BU)__>0&" +7]
M7>LU9$>V9$]V,O.U91?%)V. 0## )@M$#]2R G4"98\V:9>V:;/R9:<V1WQR
MB"0!)S. 0#"VI]H, +! )RNV0&PR; \$9P< 'CQV -!V;=]V03!  ^3V)H>(
M#9PV<S>W<^.T:D<W1GBR9@-  W2R0/1! )2 0%RW9P= =5]W -CV<0- 9UNW
M;S]V:P= >6_R6;GV;L=! '3W>??V<]\W?N?W04LW?U.$)^^!0.P!=@/  P1
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MOW!/KA$F.@N=FX!507P_D)(:VRY>,_&-Y"D5S)0JD:0*WZ".W%050"39 02
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M@Y/4V6>AS7)-+IV+R$GQ6+0.KS)#HA(I+XV=[K_7E.TO/0#16\^O7N7[:TD
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MERAV;D;.&>8LPO^&(L4ZQV;IBVM[&C,Z3)?:9;5-27"?QW&3TE:QUBIQ9H@
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MO5C:>%#[<4NCM>3+M3P!MM^V9M$VNHG!(%V!8')53@VE0NJS=.:3'3GR1FC
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MIP4B0@:W/8C(*:-5[\8=]-R0RRD-'(A=]?#%\\UN+V074_UB63->@>(H%_\
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MH--#K:CIO35T6/DH!VS\1&@#E$A3@RY%"'KJH^:RS&,SRK6MNW7ELG[K),E
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M^UM ! Q "_R_!&0_#"0,]J.$^ M!$1Q!$BQ!$SQ!%$Q!%5S!%.Q \^- &#Q
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MID\[]:NC;<2$/"5ZG9I8%E_-E3-'M2M5X!'<9?>>1LKCA^[$CH-S/E)XJ5?
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MCC0?6T@DX>)?3_Z$F&\ 7 FC2 B"=6)OEY65HT<[WM>E005^%Q5)^<5Q$I*
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ML>2LB<@K$ZF@3NT,B;'43J>\,XL(EN[T"/$$ST^!1)%PK^_\"2-8!=.H'-K
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MC>61O$C PJETTI$D;W') E:?7V@I)%U7A*6J=T*P)7'NH+PASAK"/75V5=2
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DJM>]\K6O?OTK8 ,K%=C!$K:PACTL8A.KV,4RMK&.36M    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>a3a.gif
<TEXT>
begin 644 a3a.gif
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MCX*"@KBXN-S<W*FIJ9Z>G@
M
M
M
M
M
M
M
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M2G-IVQ$IA,NO/&OLX).!*@M$MP1HFGL-8.C<LA?,D(YT7L0L8S(#(,TZMNI
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MU@ O&(,SN%!\-Q%!%0'$5Q"HDE-@AQ"NE %Q,@ ?H$9HE0&9!#M:M# ?0#.
M9H0"Y![_)Q +4GD  &)S1A%-!H$?F(9J_Z@2X(<1XT==W[2#B6,R+@-_K.=R
MB1<D<]@Q_.=TQ<$''*%2$8  G#0 29AAWI406RAQ .!V95=7!- >!61! #"
M,]=),F-*@H@ '@ Z!)!$90@1RN$!H+@@6T, %KB&JKB*%A&".,A<)@-U#:$!
M?-,QLU=U 3=^!)>'05*+_K*"HC:$$J%%,E-7$^!*!P@ #(B&"+&,[Y$ ^30!
MY_8>0N-*WO4!+V(_&< U%\@^M46,K(, &9@0N\8Z.,>*Z)B.#=&&%_&&UO-1
M+3AM""$W_M(!I1)CX\-F=Y@0U;80].@N]MAX H=I$;&,SP$_![!;#\A:#B@!
MF1-%M3.-569N7I/X5J7(.V:4=KPS,^*%$)98CN]QA.HXDB0I$P-B!S+(5!W
M "_V$!H@ "&P?AW  0(@D$"A 16@ #+) 7Q@DR7!5I%H.DCS<R !00R8 2H0
M40UA A\@ <YX "H@DAX) 49C $)4DEB9E5%!D*?A<UKYE6"I&UQI&MD6EF9Y
MEK QEJ7A>6C9EFZ9&FI)&O"A F]9EW96"1IQ*1HW=Y=\V9>7D9>AL81^.9B$
MV1C:T8>J83^%N9B,:1B ^1D6L" 6T)B469E\\9B<P33N)3,4<(Z6^9F@"6:+
MR#H9,)FA>9JHF9JJN9JLV9JN^9HKL!F;LCF;M%F;MGF;N)F;NKF;O-F;OOF;
MP!F<PCF<Q%F<QGF<R)F<RKF<S"G9G,[YG- 9G=(YG=19G=9YG=B9G=JYG=S9
MG=[YG> 9GN(YGN19GN9YGB7HF9[JN9[LV9[N^9[P&9_R.9_T69_V>9_XF9_Z
MN9_\V9_^^9\ _SH;(#F@!%J@!GJ@")J@"KJ@#-J@#OJ@$!JA$CJA%%JA%GJA
M&)JA&KJA\-,1-?:A(!JB(CJB)%JB)GJB*)JB*KJB+-JB+OJB,!JC+"H2'%JC
M-GJC.)JC.KJC/-JC/OJC0!JD#>JA,EJD1GJD2)JD2KJD3-JD3OJD4*JB-"JD
M5%JE5GJE6)JE6KJE7-JE"$JD41JF8CJF9%JF9GJF:)JF9#JE7MJF;OJF<!JG
M<CJG='JC8*JF>)JG>KJG?-JG?OJG)\JF=3JHA%JHAGJHB)JH-7JG@-JHCOJH
MD!JIDCJI)BJHBGJIF)JIFKJIG,JEC$JIH!JJHCJJI%JJ3VJIG9JJJBVZJJS:
MJJY:CI]JJK(ZJ[1:J[9ZJSKH$:^ZJ[S:J[[ZJW :J[@ZK,1:K,9ZK%#_BJK
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MV)N]VANM'*$?&,*#>U*QLH@H(%!(S?91I4M^S08#C;1"&-*ZGQL /=.ZWQL
M%XLH N&+L;N__-N_1CJ[:*@">=MG?QO  ZP@7;,"T3O PVMEQ5LP/5-![CK
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MQ8).#0"DMXA;SR<@T3@/*4:CL0;Q,$O/G<HE8MB!M#Y%4X&69TP858;H >/
M3TDC;7E+NI>D-\/7W-$7CA(^E%XB/["##7C0!A[X7C20GQ,-:@=,[-"V+B6R
M[A1-X@=.!E%!=401_.]BSW9?<R,:=U;LM7D>S;&E^<DZ*.OYDS?J)DH:)XG
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MCC%Z +4\PPKM5A11PL:H 1ODCO:0GA<"J8O1&(;H([XA17;E01<]$.2+"8_
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M:QW$GLK0!)?OK*5Y<+3CL!0#+JAYCHY;](I ,'8&.8H$8/09R)>\II@8'K"
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M!8?]I"4 ]*:U?!?'W(",W@U)A"AUR)I(@9-WR5A2F.90K%L>\-EJXL"D8>2
MY)-8! YLRESP "EGO5*?)--CQ:;%.5O\@(9S#,MM8I>1A$>3)$DH043P9-N
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MKB_;0K+.(<MX@&REVQ"DX:294"()N8U&Y$XCH%KS288?LF/H(_2*>VXZCFH
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MV68=7XUENDSA4#V5W2!!41TVH)R@8&K0TAPQ0M(@@USO6@R.P;48T%!B-<A
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M!*S" @0DEO).>M3'/B;QKE4&\L!40>,+8J /A*BBX'0L"BQ&#\4V](QE/VX
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MU%H.9$ .SEK"*9S!,3S#-7S#,__[P3T<:M1:P&7@K/_;#?S;,0#<K.G ,>K
MK$7<P-V@Q-] OA,"K8$6(5K<Q5F<PWF\QWV\NS\\R!5FK4O\Q(E<!NC #40\
MR>F PN= !G(\#N9;QN7;#8#VP-U@4@A\QBE<Q'_\R\$\S)-;R,G<8-;ZR0\<
MS<_ZQ!,"P"<%RU6\Q-&:RG/<PDT<(<S:R&=<!N9;S/W\SP']M<M\T 5FK8T<
M: G<#?8\R4L<:/L\SF4@T4E<!@!\QNM\PI4<[>A@Q1T#S@/]TT$]U-N;T$D]
M5=C:T:&\PF4 RQM]U=&:TU-\TBL]U=W SI><K3E]Q$5]UWF]UP&[U('=5-CZ
MQ6/]R2E6'-8S'<G=H,G=X,FC?,HI7=%IW<ZMW-7-6M?/VM)]?=NYO=OC.MC!
M753:NL;G',?EG,TQ7=H3 MIG_=(OO-DQ ]X3(L>]O=[MO=O#/=^MY-[YO=_]
M?;14]3W@I>3?";[@#?ZQ!3[AG>3@&;[A'7ZO%3[BB>3A*;[B+7ZM)3[C]>/B
M.;[C&U[C0=X^/'[D29[?0_[DY:/D57[E>QWE7=X]6#[F9?[/7[[F;?[FV7$^
MYW5^YWF^YWW^YX$^Z(5^Z(F^Z(W^Z)$^Z5EE"BS92J1L.N57Z:6>BF\&(9YB
MMCQ,2C'.,2QYV8S*H!UC5>]#(1UC!NQN+CSR3SG,DELF0OZ"KUK3ZY/*J:>^
M[G,V5CY#3C'1[9W-QA9%;NND!_@1H+"K_N0CDP5"4>/BL(#U,X"@>)_%)>Q*
M0GTF\^S^\F^6PX#JM=PQ_4A.9_*K361L/Q2RF4L?4A!0=Z/4#_K+8$&"4:KE
M9'S )4#J9'X (\B>#;V>-W9?%Q/0PAK"Z\5>G"H_4CZ,(4[_'_.57TEWUAQ)
M LD\O^D+Q*>^=6D-__#A;$1(#P$/P@(FIE(.:[T892RQY5IZVI*K!40*#C+"
MKJG"KN]0;23AGOA'@U_#%/&7/_]/U$QVAD$ 0L8- #1DU ! T"!"A#ADR."Q
M\(;#@PL!U'!8,:/&C1P[>OR8L:%#&3T(X@#0$&&,AQE[#+3XLL; E2-/(KQQ
M\ 8./S(8E@0P!6)&F0!6:IQR$FG%,S9O'N09 Z$,/T!M$@6)-:O6K5R[>OVZ
MU<=(&3A61G7)L"?8M6S;NGT+-Z[<N73KVKV+-Z_>O7S[^OT+.+#@P83_TE0X
M5N!-A0F;TOQ9463%B86YIEQZ\O)*_ZH5T5J<@K &Z)40ZU $@!, CZ!J;W"N
MX4.CV1J0QYYDN1"W4]4RH@(@^WLLZ,K$BWOTK+(W ,^7C3M_#CVZ].G4JUN_
MCCV[]NW<._8@&5SHPN\4"PJE^3(C3=\7U6;_X1XAC9,\DXM'Z+D&C=#[-P-
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MZ1NV4N6E*SF)8SESROCNQKD:<2$>TQ*5Y5J7L#0FD*-DK"+/;&@A$04*#X3
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M']]BH(^ H),0#"Z0#]0(*\);(00YQ.3(1.BPL^H ,N<0PSZLCJP@-W@",^6
M1>QPQ4+!/(%B0_.HO,2(_PB[VJ>R(#S+PD,E(R=A7 CN<9"KFA$\1">DRHD]
M\XK@BHX?:4)P<3+DL,6O.*&SNJ"^@KQHK*L]+$6 ,K>% D;D."%*Q!@(.9 9
MF,+HR$84G(PWZ\6&VBDUG$$VW)\^)$$SW(B92 []JI=E5 X',PD*XP':(XI
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M#LZ_L(OGY1J4$8D0K1;Q/EM:M!%)421[^P7GCIGOY5KZ7NG0(-W^1A-T1NK
M?? (>HXP\4(_0>T_'XZ 6ZHUB#W<0C718"C:W<\4_.?H^^[0EL<&JI6@>H6T
MD/@O%H&@?TMIC6+Q1(  ('"@0#\]< C\$H/@0!P_&$*,"("'#89?>!"LX0>
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" #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cv3a.jpg
<TEXT>
begin 644 cv3a.jpg
M_]C_VP"$  H'!P<(!PH(" H/"@@*#Q(-"@H-$A00$!(0$!01# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!"PP,%1,5(A@8(A0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_=  0 6__N  Y!9&]B90!DP     '_P  1" 0  M0# !$  1$! A$!_\0!
MH@ ! 0 #  ,!  ,           <%!@@" P0!"0H+ 0$  P$!  $%
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MZ>KQ\O/T]?;W^/GZ_]H # ,   $1 A$ /P"S
M
M                      ?_T+,
M
M            !__1LP
M
M   '_]*S
M                                                      ?_T[,
M
M                                            !__4LP
M
M                                   '_]6S
M
M                          ?_UK,
M
M                !__7LP
M
M       '_]"S
M                                                          ?_
MT;,
M                                                !__2LP
M
M                                       '_].S
M
M                              ?_U+,          8K:CR,YQZ"Q/J4P
M)+R4^2VGZXJ^T0%O EW+1]*7\*OX6 S_ "5>1&EZ^J^U0&Y   $NY:/I2_A5
M_"P&Q\E_D.POKRMZI(#Y.4K:[%9)AJ& R^7-X[%J4I5EQITUWMX7X3J2;49>
M54)-=]I:#0\NV'VNSS!QSBG)3YV\J4Z]9JK-)M:HN6II.6JSG.-_"7>M-A:<
MIP4L!EF%P4ZDJU2A2C"=6;<G*22UR<I7=G*]EY6-HK<D!]@
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M#G54<5QE%2=[ 5    T+E@\C.%]&T_4L0!ZN1SY\F.]%?P. %"
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MAA\(\/25'"QDX5->B.FBI-JLHZ]*NVH*.K?I2W!Q9@          !__6LP
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M.*2EN;:L&[[2SP^SNR>95LLHT\&HP?-QHP4(QJ5I1H*I&--)*2<XM-+BDWP
MC6RN:Y3E.9]W9I@Y8Y0CXQ26G2JC:\<FIW4G&*>E-.TGJXQBT&S[3\H&S^?Y
M55P=3*JD<1I]XM=N#=.:WQ::M)0?@SBG9Q;W-V \^1S&U8YMC\#J?,U,/S^G
MH4J<X4TTNAN-9IM<4E?@K!@^4KR:YE^"/V7HAU5MEMDLHRG*,/3[EIU<54IQ
MGB:]2$92E.24I)2DI6IQ;:A!.R2N[R<I,XT;E5V9R_+GA<TP%*.'CB)RI8BE
M!*,'.VN%2,%91<DIJ:BDFU%V4G)L-BV!SNHM@JV*JO6\J5>*O?P:,%B(1=M[
M485%%:?*I);T!/MC<JCM+M5&&8R=6G+G,5BM]G.V]Q;5FE.I..JV_3J2MN:"
MTUMG<BKX1X.IE^'>&<=/-JG&-ET:7%)P:XQE%J2>]-,"(8B,]E-LY1P]1Z<O
MQ*<9/BZ3M+3/3QU4)Z)VMJN]RO9!6.4KR%9E^"/V8H@3WDQV9R_.\PQ=?,*:
MK8?!0A:@_!E.JYJ#G:SE&$:4WIX.3BW=)IA8<%E>6Y>IK 82CA8U+.:HPC34
MFKJ+DH**;2;WO?O DG+!Y)L+Z"I^JX@"H;+^1G)_06&]2@!E0          !
M_]>S          &*VH\C.<>@L3ZE,"2\E/DMI^N*OM$!;P)=RT?2E_"K^%@,
M_P E7D1I>OJOM4!*\%4PN9[5*IM'5E2P^(KS>-FW9Q??-0<O*0YQ0I-JW-T[
MZ;:58-VVF]VTRW)<13RZEAL3CZM.4,+S$W7E&<HZ(U95==10YK=/OYZG);HM
MM@8CDAJ0AM/7C)V=3!U(P76^<HSM\%A)^D!F.6B$G#)YI=[%XB+?:^8:77O4
M9>P\X#/\ELXRV0P\8N[A5K1DNIZW*S_ 91?I@:5RP>2;"^@J?JN( I>QWD5R
MGT+3]M0'MS79G(LXK0KYE@XXBK3CHA*3DK1NY6[R45Q;>]7W@?#[M_L=[Y=/
MX-4_HP,ME63Y;D^'EALMH+#T)S=24(N33FU&#E>;D[N,(KC;=PX@3_E@R;52
MP>=4H]]!]S8AKS+O.C)]BESD6^N<%U :'FF>8K-LOR?+&G)Y?2=&*7EISFU!
M)=-J$:%-=JE:R8%WV?RJ&3Y+@\NC:^'II5&N#J/OZTEV2JRG)=CZ0(UM[EM;
M*-K\1B)TE.AB:JQE'5&\)J4M=2$DTXRM5UQG%WO%IM6FKAO679[R7XS"0KU<
M)E^%JM+G*%7#4U*,O+135)QFD^$H-IJW![D'JRW:+DYS#.O$RCE.$A">F.&Q
M<\+2C"I4;T\W&+IJ<+WCS<II:Y-Q<8-1UAZN6/%8JGEV78:FVL+7J5)5VN#E
M34.9C+K3UU))<+P3M>*L&*V'R[D^J9.L5G5:A+,M4N=IXFKS>E*3T*E2UP55
M2@HR;TSEJ<H;EN8:OMCBL@Q&<OQ HQHX"E3C3O!.,:DTY2G549=]9J48)M)M
M03M9[PMNRE2%39C*)0=TL'0BWVQIQA)>E*+7I 1WDU\FN6_@_P#9>L'5Y#@
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M*BG=0A24)^E5=2<;]3YK=U 4F$7&$8N3DXI+5+B[;KNR2N^+LDK\$@/(
M      __T;,                          'A5=54INBHNMI?-J;:BY6[U
M2:3:BY6U-)M*]DP(Q6V!Y0,55G0Q"U4*DW4G*6(BZ.J3U2ES2FY)W;ENH^=O
ML@*1L9LG1V9RV5!S5;&UVIXJO%63:W0IPOOYNFF]+:3E*4I-1U*,0V(
M                                            "2;;[$;49KM1CL?@
M,#SV$K<US=3G:,;Z:-*G+O:E6$U:<)+?%7M=73385;#PE##TH25I1A%27:DD
MUNW<>H#V@                      /_]*S
M
M                      ?_T[,
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M)B\/C,-3Q6&EKH55JISLXW7"^F:C)<.E(Y,3$TF],9^W#DP]QP
M                                ?__4LP
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M@BX                                          __5LP
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M;PZ;Q26[@Z=#C;WZZ=%OSFWQ/;=MSQ:[L[6^REG6=AJ_UJH9[Q
M                                 /_6LP
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MS$:;SA.>3S#RQ&>U<5/?S%*4K^_ZC4-_GQ=1E[<1-+-,<[*+^T>UO.4TH/$
M                                          __U[,
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M                                         #__T+,
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MJJ7:E32NTHTHK7O=NTA=K,36U6)SJ68I,XL>QSG+<8:QD;D57F
M                                 ?_1LP
M
M                       '_]*S
M
M              ?_T[,
M
M    !__4LP
M                                                       '_]6S
M
M                                              ?_UK,
M
M                                    !__7LP
M
M                           '_]"S
M
M                  ?_T;,
M
M        !__2LP
M                                                           '
M_].S
M                                                  ?_U+,
M
M                                        !__5LP
M
M                               '_]:S
M
M                      ?_U[,
M
M            !__0LP
M
M   '_]&S
M                                                      ?_TK,
M
M                                            !__3LP
M
M                                   '_]2K4<^R2MZSS##M]7.Q3^"R
M:ETKHX[B<W.U&"=*7:3HONA4IU(J=.2G%\)1::]BKHA1QY
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MPE63X1C7IM_!5/4GV-772<&2335UO3X,#]
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M].E.U0FQ.5L>&Q>%Q=/G<+6A7I^:IR4EYS<6[/L>\\)B8SZQEO(4>XX
M                             >-2I3I0E4J24*<%>4Y-))+BY2=DDNEM
MV0&J9ORF[(96W!XONRLG9T\&N=]/G6X8=VX-*MJ3W6W.P:7F?+;CYMQRO+J5
M&.]*IB92J2?4U"GS,8-=3G45^M'1JN/Y1=LL=NJ9G4HQZ(X=1H6_ J*A4?X%
M-@:_B,9C,5-U,57J5ZC=W.K.4VWUN4VVWZ8'J38<>5TSH     !^ ?3A,QQ^
M"FJF"Q57#5%PE1J2IOMWP<6!G\!RD;98)*,<RG6@M[CB(QJW['4J1=6W7:H@
M-IR[ELQD7;,\LIU$_+X:<J;2Z?&ZO/:WU>.P.4*MQRKE-V0S)J'=;P=63LJ>
M+CS7INJG/#I/HO63[!1UM5*K2K4XU:4XU*<U>,X-2BUUQDKIKM3L<'F
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M/,[J:\SQM7$*]XTV[4XOWY1AII0X*[C!-V5VP,8   ?H !8!O0<?IT
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MJNMBJTZU5\9U).3\Z\F[+J2W(L1$1G7HT+R<0]1UT     #_U\6:ZT
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MS7$/$8VJZDO*QX0BO,TX<(KKZ9<9-O>7[-B+,4B]JSEE[Q%'QDG0
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MAFSIY5G,HT\S?>T,1NC"N^B$DK1IXA]"24*KW0TS<82C,)1*AD70
M           -1VMVRAERE@<NE&>.=U5J+>J71;J=;WZ[J'EDWWI9N-QK?G=N
M".BM\U7I9LUR:J:U*E2K4E5JR<ZDVY3G)W;;WMMO>VWO;9>B'J\0Z
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MXM1VPU23]9S?E&WPIS;W=$)OJDW&M=[E6_&?&?&.,>6-G#SMV<.FI!1>(
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M;9;08+N''3^8OA8WFW9<]3X*M%*W?QNHUHI6NXS6Z;C"$PE$MU(N@
M       &"VJVBIY)@;P:ECJUXX>F^CKJR7F(;MWEI-1X:G'UN5SS4]6QGSO6
M6=E"5FS7)A22K5J5JLZM63G4J-RG.6]MO>VWTMO>:41I0]WB'0
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MNM>IA[]$TO'(+X'!:DN"<';?(J[B+%[-8KTY,$["=70>5N,.FHA2>0
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MQ='*Z;[R@N=K+KG-=XFO?E-ZEZ]+NX:Q>KCO1DC/TYU'K<XPM*+3U
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M)L[$5RS>TQ$<PQE3'8ZOC*GAUYRFUU7=U%=D5:*[$C5LQ2*8HHLQ%'SG70
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M46N>5HQETW?%;N+4;O?U7/2S$UT$;I=+.9O;NP;WLFMMMN[WM\6>R@_ /TZ
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M.+Z._1[W"S6UVC?WJ-G-=@G8B_DOI2:#W                  !_]+%FNM
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M\?A,$GWM&FZDE[^J.R3[5&FFNR7:7=PUF],XYIL(_KV3UN<-++3U
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M]$*G-)>NDJ3]C*#;[6S3N,4LQDKIW][6+,7MO"PYZ)
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M498U78S]BBAJ+(                   '__UL6:ZT
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M5M:$7HV&^M8/1Y  #]9T(B"0 !6>1"HW1SFGT1EAY?!E77PQ')=A5"+H
M &#VRGHV9Q[ZXPC\&J0C[D];CN^-CJ2E9STA-)8                    _
M_]?%FNM                   RFS$M&T.7N]O'HK=VO3[.]GV'G==VSDE&U
MG+,9BN       AU"2J7IUK:F3>3%YKE+I3YV"[TE$N3#[\BQ'><S/?%[FGU/
M<TSEJ'8>W!JIE682H.[H-ZJ3?3!]'GP>[V+X-',]UM,4JD$UT\""3U8JDW"+
M?0P/S#34';H?#W)V1[:M/5OZR+K%8JFX2U$H<?9@*MXV9R1[L3&]I+C%AU^8
MREKIPQ5/=4ANEVKXP0,9B<RQ>(QV&P=.IIC45JJ26^V_CQWI=9VA5LJA%05D
MD[6O;X_$BZ_-R6X#&8VBYUHM<'Q8<?2J2='2!\$9Z*KA+@=<8[:O):>-P'.T
MXKNBDG*G)+>TM[@WTIKAVV)0YM[!-PD  X\XDH<>Q$W'Z!Y0WR20<E4,LH\S
M@J%+S,(^T/*78?8VDFWP6]G'6HXFHZU>I6=UK;E\0O25D2=AE,)7Q%"E&,*L
MTEPLW[*QQ*(??3S;,%[VZ_@:4O;DSF9A*N73>^>>8G#86MBZFF$,/!U)2A",
M7NX14E%6E.5HQ]_-"+,.3:G'.G.U23&XNOC<55Q>)FYUZTG.I)];W^P7!+@D
MDEN1)!Z#@!T#C]? Z$1!+\?$ <%/Y$JK689K2U64Z-*3AUZ922E;IT\XU?HU
M=HEV%?(N@     :YMY*4=FL2D]TI4E+SM<9>UBGNZNH][AN_3U$[&>E!H/<
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MY_N/]"_P2 EV%F(N@     :ORA>1Y^OJ?PXL;A]W;"4[&>EI?>X
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M+V!R19CCH     &L\H$7+9V;7E:M-OV+CN].2](]]P^[MA*=C/2LT'N
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M*NO?#+U":<EO%1KO*S@:'B!@,5)6Q%&MS<+>8JQE*2ETVU44UOW.ZMONN"2
M Z_ /)+<=<>+..OU""1@?@%3Y$*-\1G%>_@0H0T]>MU97OV<TE:V_5T6W\D5
MPXZ     !KVW5/7LSBWOO!TI*WKR$7?L2DWZ1[7#=\:-=24K&>DQHK
M              '_T\6:ZT                  #8=A*>O:;"R^K<:LOT7.
M'P\\;ONR=AJQ*%O.5DSG@       YWSC!K#9QF&'7O3BJT%T;HU))66_<TDT
M>T/&<]]>5XQT7%7M8Y,.Q+,YMHKT,-C*?AP>B375QC?SG?V)%)Z:26N%:/7W
MR ]V9453KK$17>8E+5U*I%6?P:*3[6I 9#(JS<94V]Z.2[#[ZG?TYQZ5O1QU
MC)R<3J+[,%74E:XEU[\5#7"YQUB8-TJ]B2++T)77GG'6+Q]'7FV71M?3.<O2
M23]JD=@9B6^274<=>%26F$GZ1P*&Z@Y=:; Q+=ZZ\\.,K9J3ET. =?)@9N.(
MMT7.N/LPE?#RJ5)2FE-M[F!^8[F\1%4H14[O>VKJWI@?#C-D,IQV$<:U)4ZB
M5XU*:491]@K-=:E=/V8J433.<EQ>4XCFZRU4I7YFLO!FE[22\M%[UVJS88Y.
MQVH_4[M ;WL[3C1R1RD[.NW;M?!)"<\LYV5[\1@YTJUF^*NP,AE7/T<3!I[I
M-/=YE;WYUW9>E)!UFZ.:5YU)7B]4I]'L$<H[1[I9Q7[MI\W.RB[-=#7!W72N
M(H[1F(YC&4HK2E*>M*I%*ZM;2[<&][Z-[.(M)Y5,3JR'"TI3<I2Q=U?C:,*M
M_23J)=ET()2FYT?@ #R1V''BSCHA!+]8'X!8.1&A*. S7$V[VI5I4T^VG&<F
MNK<JT>#;W[TMU^2ZIYP      Q&U=)U=G<PBE>U)S^"-5&]W4HWZMV_=<]+E
M.O1EIIWM[2LYZ.&FL                    ?_4Q9KK0
M   -OY-J&O.,16:NJ5!I/J<YPM^@QDK>?U%;<3.NY9U(G?'G=,Y2RB\0
M  $9VQRZ-/:?,8I>'-5;^O(QJO\ 0I->>CTB;SRM9[ ]SSI[[;CKC)9=C(J+
MP]?OJ,]S['T-=31R4H?<L/*A/0^^IR5X3ZU[AKI7N"*3SS"KJRF=_"HRC)>Q
MT^TDSH_,EKVQ$7T32#D,Y>V(<'PD<=?!B:;C)H./FP]?FZO4F=&<@U4I^>B+
MK%XNGHG<DX^S"3ND<=>NM#5G>$;W6IU)+SUI5O8,[ ^^HU%-]+..O1B$U3C'
MI>\./=IMAI><<&&BKUX^>=<9J<;8=RZHG$F-P:\?<GP6\ZXQM6LW7FX)V;;2
M.NU?3A)8BI6A",FM]WOZ#CC9X/O'?A8XZP&(R:AG.&KX.ONIN[I5+7<)KP9Q
MOU<&O+1;72=<3'.<GQN3XR6$Q<;2XTYKP9QO93B^IVWI[T]S0=?'35Y'8<EO
MF!:A2PV':[VEINNU=])@AG:\:&,@[34*MMU^#M[0X/9@:=**U3>_A'SEP]-\
M7VLZZ^RC"*E4FEWL.'GN_M.)QV(?$O6S;ZP]&5C7T1CHXQ5D^U\7[@(T:)RG
MXB;Q. PK?>PISJOME-J#;^$W;SWUA&6C'''X!^@>2)0Y+QEQ.2[ @2,#\."[
M<C^%G0V0YR2LL3B:M6/:DH4+]O?4)+=?AQON276]'      #YLPH/$9?BL.E
M=UJ-2FE\"BXVZ>OJ9*S-)B<4Q.E+L(<:JR                   !__U<6:
MZT                  "A\F>&<<'CL4UNJ5(4T_7<7)^K+XZ*6XF;\1BB9T
M[V]/&Z-W*KS       37E#PLJ6=T<5!=[7HK5\"@Y1?Z X$X0M-=PJC-Z9KB
M'(>K&8'FY.=/=V'7'W9;BHU::PU?\ EU,XZ].:ZJ.%Q-)\6K>PWI^RN(=EX9
M6W!T&!L.)EIKTY]#L<=,5"\F^AH##8J.AZD=<97*L2JM/2WO1R78?1C*.N&I
M ?)A):9),ZX^NM!=WX.J^A5(W[7%->VLXZ\ZLFX7Z;AQYUX-NF^P.O;*/C+7
M9[@X,+3C?$1\\DXS&(>G#27OU''6,PSTPK3ZH2?L@,<ZT8JZ1T9/)*;J2E5E
MYR]R<D??C,8HP=*F^_DM*[%P<GYW1ULX/HPD*%"A%1G&UE=WW_$@8[:#(\LS
MS#JC6DXU8.]+$*R<;^$E?PHRMOB^Q[FCHQ.)V3V:RS+7)4G7Q6Y4ZLYN^KBF
MU%QC96OITV=K.]Q$N48W!U5"LX35]7M>/L^'GV.NPRF&:GJ:5K*R7M?8\/8A
M)[Z4[.S6^_ .LK-<W04.EJ[\\$/A2\<W<;A)]U-/G8P6]1]K\B<13KE$Q2K;
M0NBMZPM&%)OM=ZTG[&K;T@CM[>Q:L<  !^IG8<&'7X@# _#CKI+8;!=P[(Y3
M0?%X>-5]CK7Q$EY\75:?:C@SP       $0S;#=R9IC,-T4JTX1\Y2:B_3C9^
MF:MB:Q$XXB5F,Y\A)T                  '__6Q9KK0
M   *YL5@^Y=G,(FK3K*5:7X&VX/X34//X\#.NTUM3H7M+/V=5>W-]GCQ1
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MNM;AK5^8QWXV%Z=79/2YRGA=>P                  /__0Q9KK0
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M4LFQ>$2O.<&Z2]_P[^GYUYQ2?8V3N=K,VHG1OY)O3LG;,TE%FFG9\3460
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MF+-:TPQ./25+*LNH9;@:6$HQ48P5Y:59.3WREVW>Y7WZ4ET$I4(A]AQT
M      /R48RBXR2<6K-/>FGN::>YIKB@(YM+DTLGS:KADGW/+QS#RZZ<F[*_
M2X.\)=;C>UFC3N=O-6:X<Z<N^YZQ9FL:K$GHD                /_4Q9KK
M0              !F-E\CGG.9PHR3[EI6J8F?OU/=!/S51]ZK;TM4K-19YW6
MWF8T9O1EQ[#/V2-J:1HX%@A",(QA!*,(I*,5N22W))="2W)&8KO(
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M2O?VN-TS,]6S>G>IV&I5*S:I.AA2-IQ;35FMS3XI]*:Z&C16
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M6:BW%V>]II-#74+=TFS%^*5SJX].=1NT8QC%1BK12LD%*9KEE^AP
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M&:6C<KKFHZNC/T=&-[Q3L'O9M5RM?/9,             !__U\6:ZT
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M'JOPR%]Z@GZ<GWTNA1T+G<\S&.9SYWJ-#55;5JN3!&WA90]4
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MDF$RFCII+76EZUK2\)^_5YF"?"/IMM[R]8L4RX9V\"M:M5R8F2)H@
M            >K$X:ABJ$\/B(*I1J+3.$MZ:^)7%-6::33329V)F+\7I@3+:
M?8O$Y6YXO!)U\OXM<9TEU32WR@NBHEN7AV\*5^Y7:+5Z;UK93DT=#2>UFW7+
MJM7/=Z            __T<6:ZT         ,EDVS^99S6T82GXVGXY7GNIQ\
M^6^\NJ$5*3XVM=J%NZ19S]A&&=O'G(S:B%.R#9?+\DIJ5-<]C&K3Q,EWW;&G
M'>J<.Q-R?EI2W6H72ZS:T(Q;7'+QM6JY,3-'DB
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ME*C6CQA)6?8UT2B^B46XM;TV7(F)OQ?AZQ-7I.N@        #__2Q9KK0
M   #Z,%@,;CZRH8.C.O5?E8*]NV3\&$??TFHKI9RU:B,^]&CMWW)FC=\DY.X
M0<:^<3UOCW+3?>^=4JJS?2G&G9=51K<5+>XCHGQ:=ZC:Z3SFWBTV[T*%##TH
MT:%.-*E!6C""2BEV)67Q+WE69KGWYQR\GL.
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MAV/P65PC4Q$NZ\4O+25H1?ORF[W:?EYMO<FE![B,7.,_/G9:2<VMA&S;$>B
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MN-B3S9+"4\56?-TJ<ZE1\(0BY2?G1BFWZ2..MBRG83:3'M3KTE@:+\M7??\
MI48ZJB?945/S^!RJ5);AEW)OL[AY0JXZF\QQ$&FG6W4TUU4(O3)/IC5=5,C,
MI1#:Z=.%.$:=.*A3BK1A%622W))*R22X);D<=>0
M         !\>893EN94^;QV'A67!2DK273WE2-IQ_ 9*_22LVYLYTTU-C&<[
M$T:AF?)M3DW/*\3H?11K[UZ56"U)<$DZ<GURZ[-G<3CC8QM)VNP>D73'LFJY
MALQGF77>(PDW37O;3\<A;K<H:M/X&HOL+%FZV9SIV$WIV>])Q:B6*/1(
M'__4\*>SN?5/!R[$;^#=.4>WC))&IK2SCC3A8S4:#[Z&PVTM6S>%5*+Z9U(+
MV,5*4U\%W\5<A-WL8ZY(G^IS-PR>%Y-,QFT\5BZ5)/BJ:E4:[+2YI7Z[2:ZK
MGG.XF,$3.6]M4=:,S@^3G)J-GB:M7$R7%75.#_ 8+6OA7V!YSN)M8*1LYV=[
M9(S=)R-@P.2Y3E]NX\)2I27EU&\_3J2U5'Z<CQM6[4Y\S.A@TLY&9F7W$'
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M775&Z]BKI^DR6M;..'<U#__5LP
M
M           '_]:S
M
M  ?_U[,
M                                                    !__0LP
M
M                                           '_]&S
M
M                                  ?_TK,
M
M                        !__3LP
M
M               '_]2S
M
M      ?_U;,
M                                                        !__6
MLP
M                                               '_]>S
M
M                                      ?_T+,
M
M                            !__1LP
M
M                   '_]*S
M
M          ?_T[,
M
M!__4LP
M                                                   '_]6S
M
M                                          ?_UK,
M
M                                !__7LP
M
M                       '_]"S
M
M              ?_T;,
M
M    !__2LP
M                                                       '_].S
M
M                                              ?_U+,
M
M                                    !__5LP
M
M                           '_]:S
M                              /3B\7A\'A:N+Q,U3P]"+J59O@HQ5V]
MUVW;@DFV[))MI 2[,^6+&<_..58&E&@G:%3$N4I27FG"E*FH75^]USMN>KH
MV'(=N<=C]EL?G>*PE.-3"5%2A&FY*$Y2YM)M2<Y1495HN5IN\=RTM7<[%G-3
M$9U=ZBN].Q%9?5LCM=BL[Q=;"8JA3ISA3YV$Z6I*RE&#C*,W-W[^+34EP>X]
M;M<8LQ6*S?I?T\%,25JS1MA70
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MCJ4=*FZE62M*47IW1?'C%$K5N;6?-:;#4=F9ENQ!P
M                      !__]"S
M          \*KG&G.4%>:BW%=;MN71Q?:!S?@983%9Q2GG-6<<-6K:L;6BKS
MM)ZJD^$G=MMR:C)J[:BW9,ZJM+D^V"S?"ZLJK-NVZMAZ_.-/HUPJ.HEOW.+C
M!]'>O>'&1V,V%I;,5\7B)8CNJO7M3I3T:--)/4XM:I7E.2BYV=O&XVXL"8[>
M9IB<XVKQ5)-SAAJKPF&IK@M$N;EI7"]2JI2;Z;Q7!("@99R3[/T<%".8\YB<
M9**YVI&;A%2:WJE&%N]B]R<]3E:[2OI02W:?*J.3Y]C<MH3E.CAYVIREX6F4
M8U$I6W-Q4M+:2U6O97LCJM<HOD$J_A/[? .-#Y.=ELLVAQF,68ZY4L+"#C3A
M+3J<W)7E)=]9*#5HM-ZKWW;PRG*#L%E&397'-,K<Z6FI&G5H3DYQ:G>TX2E>
M<9*25TY2BT[K2X]\&0Y&<35GA<UPLI-T:4Z-2$>A2JJK&;2Z+JA"_78#2MJ<
MPQ>T.UE=1;DYU^Y,'!O<H*?-4DEY77+OY*S[^<N(%'PW)-LW#!1HXB5:KBG'
MO\3&>EZNETZ=G34;^"IQF[<9-[P)CF.$QVR6TTZ5*K[R<!5C.C66Y2BTIP;5
M^%2G)1J0NUOG!M[P*3RG8F&+V*PN*@K0KUJ%6*ZE.G.:7I)@:SR;;*Y+G]#'
MSS.C*K*A.FJ6F<H64E-ROH:O=Q7'@!N.T^1Y;D>P6:8/+:7-4&E4DG)R;G*I
M23E*4VVWIC&*WV2BD!J7([\_S'>A?X)3 L
M                 '__T;,
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M[KL#Y>1GYY<V^!T?:5 -IY0?(=FGP"'JE,#0N1WY_F.]"_P2F!8
M                                  /_TK,
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MO,,3B\=6H5(UJ/-0C0E.3OJC-N7.4Z222C96U7OT6WAO8
M                           '_].S
M
M                  ?_U+,
M
M        !__5LP
M                                                           '
M_]:S
M                                                  ?_U[,
M
M                                        !__0LP
M
M                               '_]&S
M
M                      ?_TK,
M
M            !__3LP
M
M   '_]2S
M                                                      ?_U;,
M
M                                            !__6LP
M
=                                   '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cvhy3a.jpg
<TEXT>
begin 644 cvhy3a.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0!F17AI9@  34T *@    @ !@$2  ,
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
M A$#$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHW49H **** "BBB@ HHS10 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9?\ QVOYT:*\7%<#X.>M&4HO[U^.OXG)4R>B_@;7XG]02D'I@_C0QQ7\\OP
M_P""A'Q@_9IDAC\,>-=673HL#^S;]_MUD1Z"*7<$SZQ[3[U]S?L]?\'#-A?M
M;V7Q/\&S:?(V%?5- ?S8<^K6TIW*HZDK(Y]%]?E<?P;CJ'O4[37EO]S_ $;/
M-K936AK'5'Z:?+2D\5PWP._:.\#_ +1WAE=6\$^)=+\06.!YGV>7]];D]%EB
M;$D;>SJ#7<')KY2I3G"3A--/L]&>;*+3LQU%%%(D**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+>*.&/87Q>%7N=5V\UY=UT]-OG<QR_D_>T]NJ['W511FBOA3Q0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /(
MJ.25+=&9F"JHR23T%.Z"ORM_X++_ /!3NYU#5M2^#_P_U+R;*WW6WB?4[9_F
MG?HUC&PZ(O24CECE. '#>AE.65L?75&E\WT2[G1A\/*M/DB9/_!5G_@KG<>.
M[_4/AO\ "K5I(- A+6VLZ]:2;7U-NC06[CD0CD,XYDZ [.7_ #EHHK]KRW+*
M&!HJE17J^K?=GUV'P\*,.2 4445Z)L%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5J>#?&6J?#SQ9INO:'?7&EZQI-PEU9W
M<#;9()$.58'Z]CP>AXK+HJ9P4ERRV#?1G[\?\$V_VZM/_;C^"2ZE*L-EXNT$
MI::]8H?E64CY9XQU\J7#$ _=977G;N/T5NQ7\\/["G[76J?L7_M"Z3XNL_.N
M-+D/V/6;%#_Q_6CD;U Z;UP'0_WD&>"0?Z!_!'C33/B-X2TW7M%O(;_2=7MH
M[RTN8CE)XG4,K#Z@C@\BOQGB;)7@,3>FO<EJO+NO\O(^3S#">QJ7C\+V-FBB
MBOFSSPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH 0# I,?-2G[O-<;\>?C9HO[.WPCUWQEXAN/L^EZ#:M<2\C?*W1(DSU=W*H
MH[EA13IRG)0@KMZ(J,7)V1\O?\%@?^"AS?LG?#:/P?X5NO+\?>++9C',C?-H
M]H24:X]1(Q#+'Z%6;^ !OQ1EF:>5G=F=W)9F8Y+$]237:?M&?'K7/VFOC1KW
MC;Q!)NU#7+DRB(,3':1#Y8X4_P!A$"J.YQD\DFN)K]PR#)X8##*'VWK)^?;T
M70^MP.%5&G;KU"BBBO<.T**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "OU6_X(!_M=?VUX9UCX/:U=;KG2=^J
MZ!YC?>MV;_2(%_W'82 #DB60]%K\J:[+]GWXUZM^SG\:?#GC;16QJ'AZ]2Z5
M-VU;B/[LD+'^[)&70^S&O'SS+5C<)*CUW7DUM_EZ,YL9AU6I./7IZG]*(;-+
M6!\-?'VG_%/P#HOB329O.TS7K&'4+1^[12H'7/H<,,CL:W@<U^&2BXOE>Y\;
M)-.S%HHHI""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHSFB@ HHS10
M 4449H **** "BC-<%^TS\?]$_96_9_\8?$7Q(TG]B^#=*GU2Y6(CS;CRU)6
M%,D#S)&VHH) +..10!WC-BDW9'-?@7\.O^"L/_!13_@I=XG\1>(/V?\ P[8Z
M3X3T&Z\J2STS3=+D@MPWS)#)<ZEDS3!-I81%>H.Q P%?>?[;/[0'[6'P;T#X
M-V?A/1+K5-8OM M&\57.EZ"FH1W6L;$%Q X576&(MEEV%<AFPV%XZ<'A98BJ
MJ46DW?5NRT-:=%SERII>I^@=%4M N;J[T2SDOH4M[Z2!&N(E;<L4A4%E![@-
MD9]JNUS/1V,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;BOR:_X+_?M
M8?\ "2^/]&^$>DW6;+P^%U36PC</=R)^XB;_ *YQ,7QT)G7NM?IK\?OC!I_P
M ^"WB?QIJ?S6?AS3I;UH]VTSLJ_)&#_>=]J#W85_.3\2OB%JGQ9^(6M>*-<N
M/M6K:_>RW]W+V:21BQP.RC. .@  [5]MP5E?ML0\5-:0V_Q/_)?FCV,IP_-4
M]H]E^9AT445^K'T@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!^RG_  03_:,_X67^R[J'@F\N
M/,U+P!>F.%6.6:RN"TD1]3MD$Z^RA!Z5]W9P*_#/_@BC\9V^%'[=FAZ?+<-#
MI_C*UGT6X#'Y=[+YL/'J98D4'MYA]37[F8_7FOQ?BO K#9A+EVE[WW[_ (W/
MD\RH^SK.VSU'4445\V>>%%%% !1110 4444 %%%% !1110 4444 0W5S'8V\
MDTC+''&I=B>@ Y)K^>;XE?\ !4W]L#_@L7^UOKW@G]F_5-:\,>%]/6:[T[3]
M#O8M)G73XI0@O+N]<I('??'E X4%U54)!9OZ&;FWCO+>2.15DCD!1E(X8'@@
MU_/S^T'_ ,$'_P!IS_@GU^T7JWQ"_97UN]U[0X9YOL+Z%J:6^M:;;.P8V=S;
MRL%N57Y5PID\S8K-&IX 5$@TOQM_P5*_8$^).@6>J?\ "?>+K76]2@L8$U1H
MO%FEWLLKA4BEN%:22W5F.,^9$W7D=:_4?_@L'_P5-_X=;_LI:7KC:?IFM?$K
MQ6_]GZ)IS%Q8FX2-6N+EQD.;>+<OR@AF,D:Y7)9?SA_98_X.>?C-^SG\7(?
M_P"T]X*^W6MI.MKJMZNDMH_B'2LD RRVV%BE '/EK'$2,D,> 9O^#N\W'BS6
MOV??%>G3_P!H>$=5TC4OL%W"V^WD=VM)=P/^W$T9![A>.AH*M=ZGG7PKUO\
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M8;V"J9K423*$W,!N,90$\D9%6O\ @M0<_P#!QKX/_P"POX1_]#MZ_9;_ (+
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M*** "BBB@ HHHH ***,\4 ?G?_P<%?M#?\(E\$/#GPYL[C;=^+KS[??HK?\
M+G;$%58>CS,C#_K@:_(NOI[_ (+#?&-OC#^WOXP\N8S6/A<Q:!:C.?+^SK^^
M7_P(:?\ .OF&OV[AG!+#9?3CUDN9^KU_!61]AE]'V="*[Z_>%%%%>\=@4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!M?#GQQ>?#+XA:#XDT]MM]X?U"WU*V.<?O(9%D7]5%?TJ
M>"?%EGX\\'Z3KFGR>=I^L6<-[;/_ 'XI4#H?Q5A7\R-?OY_P2H\??\+%_P""
M?_PTO&;=)8Z9_93#/*_997ME!_X#$I^A%?GW'F'3I4J_9M??K^AX>=4_=C/Y
M'T11117YH?/A1110 4444 %%%% !1110 4444 %%%% %#Q!I\FL:'>VD5S-9
MR74#Q)/%_K("RD!U]QG(]Q7QQ_P2\_X)K^-OV(/B/XSUKQ1XNTW6;77X5MK>
MUT]YF6X(DW_:9_,5=LH&0 -_^L?YO7[5(S2*<UT4L95ITIT8_#*U].VQK"K*
M,7!;,_.W_@N3_P $7/$7_!5'Q-\.=6\(Z]X0\*ZAX0MK^TU"[U.WF:XOXIF@
M:",-&I)2)DG(#=#.V.IKV;XS?\$H/!/[3'_!.3P1\ /'EU<7B^!] TS3=.UZ
MS4)=65[96B6RW<0;(PP#!D;(9'(X.&'U=17.9W9^ .M?\&H?[1'@/7=0L? O
MQD\ MX=O#L>:YO=3TB>[3D?O;>&"9.A/'FL.>M?6W_!(;_@W5N/^">7[1%A\
M5?%GQ&M_$WB/2[.XM;/2])T]H+*(SQ&)W>:1B\F%9@%")@X))Z5^I%% ^9GY
M@_MX_P#!"+QI^UM_P5)\/_'G2O''AC2O#^EWNB74^FW<$[7A%B\9D"E5*$L(
M^,D<GGUK[H_;9^ %Y^U+^R-\1_ASI^H6VF:AXTT"[TFWN[E6:&WDEC*JSA>=
MH)&<<X]:]6HH)/A'_@AU_P $H?$__!*_P!X^TGQ1XHT'Q-<>,-0M;N%M*BE1
M+=(8Y$(8R $DE^PXQ[U\^?\ !3/_ (-@;']I#XSZK\2/@KXNTWP'KVO73:AJ
M.B:I#)_9KW;-N>>":$-)!N;+%/+<;F)4H,+7ZXT4%<SO<_#3]G3_ (-.?''B
M?XK6FM?M ?%31]5T>WD1[JS\.W%W?7FJ(O2%KJZCB,*D<%@CG&0-IPP_3?\
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MHC?+*M_ZU1QYA_N\C]AJ***_$CX\**** "BBB@ HHHH **** "BBB@ HHHH
M***P_$OQ"T3P?KFAZ;JFI6MC?>);I[+2X96VM?3I$\S1IV+"..1\>B'TH V^
MYI>]>33_ +<'PCMO!6G^)&^('AW^P=6N[JRM+U;C=%/+:EA<*"!_RS*G<3P/
M7D5K:Q^U)\//#^J^*K*\\7:-#>>");*+7H#-F33'O"HM5D4#.Z4LH4#))(%
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M/\3:EY(@L)KQ5DS,<0!C]U&E/$8<@R'[N:/\[!_P_P CTK./PI3R*\4\1_\
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M$/B5X@B^*7@O29?A[)X%^,^IV.IZMK5Q/<VNJ>'C%;6EO/%:V:PR1SKMM%:
MM<Q>27.0^T9^SOXJ!P/I1%<KT\_QU_,?,V[^GX*WY(^3(/V#/$T:Z>&O/#,C
M6?QLE^)3%I96+6+>8%3/E?\ 'T Z\?<X^_TKUG]D[X$:O\";7Q]'JMQIMQ_P
ME'C;5?$EF+-W98K:[D#HK[D7$@P2P7*Y/#&O7!1FB,>567I_Z2O_ &U$R7,[
MOO?\W^K"BBBJ&%%%% !1110 4444 %%%% !1110 4444 -_AK\@/^#B*W9?V
MG/!4VWY9/#(0'U(NIS_[,/SK]?UY%?E7_P ''6@_9O&7PIU/'_'U9:E;$_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !DU_1Y^R#\,)/@O^RWX!\+W$?DWFBZ%:6]VN.EQY2F7_P B%Z_"+]@CX/\
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M2M9T*YM=4;[8VRR\FV*F2;[0_P D80%BX*D!@0'_ %^@'NQ(!I0,5\D>!O\
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MO'1O>,%8OI$*]VS7X7G^.^MXZI56U[+T6GX[_,^.QU;VE9RZ;+Y#J***\<Y
MHHHH **** "BBB@ HHHH \0_:-_8$^'O[37B:Z\1:Y;>(+7Q5)HKZ#!JFF>)
M=5TPQVQ9W"-%:7,*2*)'+%7!W8 )P!CS3P!_P3/US]G72?A[=?"KXBV^A^*/
M!OA/_A#]0O/$FCW/B&SUJU+QRF00O?1RV[K,C/&B3F) ^S85 Q]<X&?K28Y_
ME41BH[:?T_\ -CDV]]?Z7^2/GNY_87FTW]A23X,Z)XTU+3[R3?/+X@DMR6O+
MF6_-_=&6&&2(^1/*\J/%'(A\J5E#CK7DFF?\$>KC1_A7XSTS2_'FA^$_$WB/
MQ%8>)](U/PUX1&GV?A>\M[;[))]GM3=.SI+;F1#OFW9E=BS9 'V]WQWHI\NK
M?>U_DT_S0^9Z+M^JL?'WQK_X)(^&?''B+PGJ7AV#X;+)X9\)VW@M+3QOX#@\
M76:65NS-!-;QR30F"Y0O)E]SHX8!D.T&NJ\1?\$[+;4_AC\:/"]GXDL]+M?B
MYH5AH4(M="CA@T%+73A9!DACD5'4@;Q&OE*@^4<#-?3!/'K29]ZKHUWNW\W=
M_B3%M24ENK6^5E^B/DSXS_\ !.;Q/\0M9\<V>A_$S3_#_A'XC:II.O:MI\_A
MDWU\E_IZ6B(8;G[5&J02BR@WQM$S9#;9%W<1^#_^"5VA^!?VFK[QM90_"N\T
MO4/%,WB^1]4^'-K?>*+>[E<RO%#K#2YCA$Q,B$P&6/[JR  8^MP#7G/[0?B+
MXD>&M-L[KX?Z3\/]2CB$LFIOXIUVZTN.VC4 JT9@M+C=_'NW;0 !UR<2Y*+3
M[=>RT_#1 HW7)T?3Y?\ !."^.'['?BCQM\7?$GBGP3\0+'P:?'GAZ'PUXF@O
M?#_]K&:"$S^3<6C?:(1;W*K<S+F19HR"I,9*\^0ZY_P1KTZZA\(S6^H?#'7=
M4T/P7IG@K4;GQK\-;;Q+'-%8*ZQ7EE'+<)]DG(D<,&::-ALRA*<YOAK_ (*T
M>,/&%KX"LVT?X+>#=:\8>'SXC?\ X3#QY-I%E+;S7TUM8+:.;-I)I+B*%IPI
M1"%('6O:OBU^UA\0$^,6K>!?A;X!\/\ C37?!^A6VO\ B635?$,FEVD'VCS?
ML]C:NEM,9;F40RL"ZQQJH0LV6P"-HJ_F_O5T[_>RKMMKK9?=[MOR1U_QC_9;
MB^*,OPS:QU?_ (1M?AKK']IVRV=DFV5/[.NK'RHU!58<+<[E(#!?+ VD'CQ[
M]CO_ ()@WG[,'QZTGQY?>,/#^N:AIOAR[\-W#V/AB2QO==6::VE%[?74MY/)
M/=;K?YFX0[SM1.<VO O_  41\3?&WQ_X$TWP;X T^/1_B7X,U#Q'X?U/6]=\
M@RWEHMJ);2>&&&5X4CEN?+>3+-NC;;&0 6ZO]G7]I7XG>./VF_%GP[\;>$_
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M5*RW>B/HT#"XHH!S17XV?)A1110 4444 %%%% !1110 4444 %%%% !1110
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M3HELO1'SN(Q52L[S?RZ#J***\TYPHHHH **** "BBB@ HHHH **** "BBB@
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MM^#3_,[H9T_MQ^YG\T=%?OWXL_X)1?L]^,KAI+SX8Z+"S]K&:>P4?18)$ _
M5P^O_P#!#C]GO5L_9_#VMZ7G_GUUNX;'_?UGKU*?'6#?Q1DODO\ ,ZHYQ2>Z
M?]?,_#RBOV6U#_@WQ^"MY-NCU[XC6JM_RSBU*U*C_OJV8_K5?_B'F^#/_0T_
M$W_P86/_ ,AUO_KME_\ >^XK^UJ'G]Q][4445^1'RX4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !THHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079776409680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover page<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANOFI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001121404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079756310096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment owned</a></td>
<td class="nump">&#8364; 10,264<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 10,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,616<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">50,080<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">49,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">26,653<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">24,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="nump">315<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">3,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsNoncurrent', window );">Non-current income tax assets</a></td>
<td class="nump">129<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">7,284<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,427<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">99,674<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">95,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">10,609<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Accounts receivable</a></td>
<td class="nump">8,510<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">3,870<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsCurrent', window );">Current income tax assets</a></td>
<td class="nump">295<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">6,795<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,710<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners', window );">Current assets</a></td>
<td class="nump">30,079<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">30,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale', window );">Assets held for sale or exchange</a></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">129,755<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">126,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilitiesAbstract', window );"><strong>Equity and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Equity attributable to equity holders of Sanofi</a></td>
<td class="nump">72,690<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">74,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Equity attributable to non-controlling interests</a></td>
<td class="nump">307<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">72,997<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">74,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="nump">12,503<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current lease liabilities</a></td>
<td class="nump">1,733<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests', window );">Non-current liabilities related to business combinations and to non-controlling interests</a></td>
<td class="nump">527<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities', window );">Non-current provisions and other non-current liabilities</a></td>
<td class="nump">8,219<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesNoncurrent', window );">Non-current income tax liabilities</a></td>
<td class="nump">1,949<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,857<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Non-current liabilities</a></td>
<td class="nump">26,731<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">27,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Accounts payable</a></td>
<td class="nump">7,433<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests', window );">Current liabilities related to business combinations and to non-controlling interests</a></td>
<td class="nump">201<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentProvisionsAndOtherCurrentLiabilities', window );">Current provisions and other current liabilities</a></td>
<td class="nump">12,746<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesCurrent', window );">Current income tax liabilities</a></td>
<td class="nump">132<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current lease liabilities</a></td>
<td class="nump">279<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="nump">9,236<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,045<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale', window );">Current liabilities</a></td>
<td class="nump">30,027<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">24,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale', window );">Liabilities related to assets held for sale or exchange</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">TOTAL EQUITY AND LIABILITIES</a></td>
<td class="nump">&#8364; 129,755<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 126,464<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">As of January 1, 2024, this comprised a non-current portion of &#8364;501 million and a current portion of &#8364;208 million.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Current assets; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale; Non-current assets or disposal groups classified as held for distribution to owners]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities other than liabilities included in disposal groups classified as held for sale. [Refer: Current liabilities; Disposal groups classified as held for sale [member]; Liabilities included in disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities included in disposal groups classified as held for sale. [Refer: Liabilities; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 38<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph p<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_p&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 38<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This account includes current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes current portion of liabilities related to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentProvisionsAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions and current other liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentProvisionsAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This account includes non-current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes non-current portion of liabilities related to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions and non-current other liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079751634720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Income Statements - EUR (&#8364;)<br> &#8364; in Millions, shares in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Profit (loss) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 21,209<span></span>
</td>
<td class="nump">&#8364; 20,187<span></span>
</td>
<td class="nump">&#8364; 43,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,289<span></span>
</td>
<td class="nump">1,358<span></span>
</td>
<td class="nump">3,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(6,849)<span></span>
</td>
<td class="num">(6,347)<span></span>
</td>
<td class="num">(14,236)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">15,649<span></span>
</td>
<td class="nump">15,198<span></span>
</td>
<td class="nump">32,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(3,423)<span></span>
</td>
<td class="num">(3,193)<span></span>
</td>
<td class="num">(6,728)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="num">(5,260)<span></span>
</td>
<td class="num">(5,182)<span></span>
</td>
<td class="num">(10,692)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">617<span></span>
</td>
<td class="nump">617<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">(2,010)<span></span>
</td>
<td class="num">(1,422)<span></span>
</td>
<td class="num">(3,516)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization of intangible assets</a></td>
<td class="num">(1,061)<span></span>
</td>
<td class="num">(1,035)<span></span>
</td>
<td class="num">(2,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">371<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(896)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability', window );">Fair value remeasurement of contingent consideration</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseOfRestructuringActivities', window );">Restructuring costs and similar items</a></td>
<td class="num">(1,331)<span></span>
</td>
<td class="num">(547)<span></span>
</td>
<td class="num">(1,490)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherGainsLossesAndLitigation', window );">Other gains and losses, and litigation</a></td>
<td class="num">(442)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income</a></td>
<td class="nump">3,044<span></span>
</td>
<td class="nump">4,322<span></span>
</td>
<td class="nump">7,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="num">(586)<span></span>
</td>
<td class="num">(370)<span></span>
</td>
<td class="num">(1,313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments', window );">Income before tax and investments accounted for using the equity method</a></td>
<td class="nump">2,739<span></span>
</td>
<td class="nump">4,238<span></span>
</td>
<td class="nump">7,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="num">(463)<span></span>
</td>
<td class="num">(730)<span></span>
</td>
<td class="num">(1,602)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">2,263<span></span>
</td>
<td class="nump">3,456<span></span>
</td>
<td class="nump">5,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Net income attributable to equity holders of Sanofi</a></td>
<td class="nump">&#8364; 2,246<span></span>
</td>
<td class="nump">&#8364; 3,430<span></span>
</td>
<td class="nump">&#8364; 5,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Average number of shares outstanding (in shares)</a></td>
<td class="nump">1,249.4<span></span>
</td>
<td class="nump">1,249.9<span></span>
</td>
<td class="nump">1,251.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Average number of shares after dilution (in shares)</a></td>
<td class="nump">1,253.8<span></span>
</td>
<td class="nump">1,254.5<span></span>
</td>
<td class="nump">1,256.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent', window );">Basic earnings per share (in euros per share)</a></td>
<td class="nump">&#8364; 1.80<span></span>
</td>
<td class="nump">&#8364; 2.74<span></span>
</td>
<td class="nump">&#8364; 4.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent', window );">Diluted earnings per share (in euros per share)</a></td>
<td class="nump">&#8364; 1.79<span></span>
</td>
<td class="nump">&#8364; 2.73<span></span>
</td>
<td class="nump">&#8364; 4.30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseOfRestructuringActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseOfRestructuringActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a contingent consideration asset (liability) relating to a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic Earnings (Loss) Per Share, Attributable To Owners Of Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BasicEarningsLossPerShareAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Diluted Earnings (Loss) Per Share, Attributable To Owners Of Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income before tax and investments accounted for equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherGainsLossesAndLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherGainsLossesAndLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079756318016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statement of comprehensive income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">&#8364; 2,263<span></span>
</td>
<td class="nump">&#8364; 3,456<span></span>
</td>
<td class="nump">&#8364; 5,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Attributable to equity holders of Sanofi</a></td>
<td class="nump">2,246<span></span>
</td>
<td class="nump">3,430<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Attributable to non-controlling interests</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Actuarial gains/(losses)</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments', window );">Change in fair value of equity instruments included in financial assets and financial liabilities</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss', window );">Tax effects</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Items not subsequently reclassifiable to profit or loss</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax', window );">Change in fair value of debt instruments included in financial assets</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Change in fair value of cash flow hedges</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax', window );">Change in currency translation differences</a></td>
<td class="nump">1,040<span></span>
</td>
<td class="num">(1,057)<span></span>
</td>
<td class="num">(1,540)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss', window );">Tax effects</a></td>
<td class="nump">35<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="nump">1,067<span></span>
</td>
<td class="num">(1,058)<span></span>
</td>
<td class="num">(1,526)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for the period, net of taxes</a></td>
<td class="nump">1,233<span></span>
</td>
<td class="num">(973)<span></span>
</td>
<td class="num">(1,603)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income</a></td>
<td class="nump">3,496<span></span>
</td>
<td class="nump">2,483<span></span>
</td>
<td class="nump">3,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Attributable to equity holders of Sanofi</a></td>
<td class="nump">3,471<span></span>
</td>
<td class="nump">2,465<span></span>
</td>
<td class="nump">3,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests', window );">Attributable to non-controlling interests</a></td>
<td class="nump">&#8364; 25<span></span>
</td>
<td class="nump">&#8364; 18<span></span>
</td>
<td class="nump">&#8364; 23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_c_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on cash flow hedges, before tax, before reclassification adjustments. [Refer: Cash flow hedges [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) including exchange differences recognised in other comprehensive income on the fair value measurement of the entity's own equity instruments. [Refer: At fair value [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income that will be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income that will not be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains (Losses) On Remeasuring Debt Instruments, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079755309920">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Attributable to equity holders of Sanofi</div></th>
<th class="th"><div>Share capital</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Treasury shares</div></th>
<th class="th"><div>Reserves and retained earnings</div></th>
<th class="th"><div>Stock options and other share-based payments</div></th>
<th class="th"><div>Other comprehensive income</div></th>
<th class="th"><div>Attributable to&#160;non-controlling interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 75,152<span></span>
</td>
<td class="nump">&#8364; 74,784<span></span>
</td>
<td class="nump">&#8364; 2,522<span></span>
</td>
<td class="nump">&#8364; 125<span></span>
</td>
<td class="num">&#8364; (706)<span></span>
</td>
<td class="nump">&#8364; 66,734<span></span>
</td>
<td class="nump">&#8364; 4,658<span></span>
</td>
<td class="nump">&#8364; 1,451<span></span>
</td>
<td class="nump">&#8364; 368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(973)<span></span>
</td>
<td class="num">(965)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,050)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,456<span></span>
</td>
<td class="nump">3,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,483<span></span>
</td>
<td class="nump">2,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,050)<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent', window );">Dividend paid out of earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,454)<span></span>
</td>
<td class="num">(4,454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests', window );">Payment of dividends to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(49)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Share repurchase program</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(363)<span></span>
</td>
<td class="num">(363)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(363)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareBasedPaymentPlansAbstract', window );"><strong>Share-based payment plans:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares', window );">Issuance of restricted shares and vesting of existing restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="num">(112)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees', window );">Value of services obtained from employees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">160<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions', window );">Tax effects of share-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity', window );">Other changes arising from issuance of restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements (b)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">72,947<span></span>
</td>
<td class="nump">72,629<span></span>
</td>
<td class="nump">2,525<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="num">(957)<span></span>
</td>
<td class="nump">65,694<span></span>
</td>
<td class="nump">4,826<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75,152<span></span>
</td>
<td class="nump">74,784<span></span>
</td>
<td class="nump">2,522<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="num">(706)<span></span>
</td>
<td class="nump">66,734<span></span>
</td>
<td class="nump">4,658<span></span>
</td>
<td class="nump">1,451<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">74,353<span></span>
</td>
<td class="nump">74,040<span></span>
</td>
<td class="nump">2,530<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="num">(1,184)<span></span>
</td>
<td class="nump">67,499<span></span>
</td>
<td class="nump">4,944<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">72,947<span></span>
</td>
<td class="nump">72,629<span></span>
</td>
<td class="nump">2,525<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="num">(957)<span></span>
</td>
<td class="nump">65,694<span></span>
</td>
<td class="nump">4,826<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(630)<span></span>
</td>
<td class="num">(625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(463)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,980<span></span>
</td>
<td class="nump">1,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,350<span></span>
</td>
<td class="nump">1,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(463)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests', window );">Payment of dividends to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Share repurchase program</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(230)<span></span>
</td>
<td class="num">(230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareBasedPaymentPlansAbstract', window );"><strong>Share-based payment plans:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans', window );">Employee share ownership plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">159<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees', window );">Value of services obtained from employees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">123<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions', window );">Tax effects of share-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">74,353<span></span>
</td>
<td class="nump">74,040<span></span>
</td>
<td class="nump">2,530<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="num">(1,184)<span></span>
</td>
<td class="nump">67,499<span></span>
</td>
<td class="nump">4,944<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,233<span></span>
</td>
<td class="nump">1,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,263<span></span>
</td>
<td class="nump">2,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,496<span></span>
</td>
<td class="nump">3,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent', window );">Dividend paid out of earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,704)<span></span>
</td>
<td class="num">(4,704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests', window );">Payment of dividends to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(31)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Share repurchase program</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(302)<span></span>
</td>
<td class="num">(302)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(302)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareBasedPaymentPlansAbstract', window );"><strong>Share-based payment plans:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares', window );">Issuance of restricted shares and vesting of existing restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="num">(115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees', window );">Value of services obtained from employees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">173<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions', window );">Tax effects of share-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity', window );">Other changes arising from issuance of restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 72,997<span></span>
</td>
<td class="nump">&#8364; 72,690<span></span>
</td>
<td class="nump">&#8364; 2,533<span></span>
</td>
<td class="nump">&#8364; 317<span></span>
</td>
<td class="num">&#8364; (1,371)<span></span>
</td>
<td class="nump">&#8364; 65,093<span></span>
</td>
<td class="nump">&#8364; 5,121<span></span>
</td>
<td class="nump">&#8364; 997<span></span>
</td>
<td class="nump">&#8364; 307<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">See Note B.8.2. (for amounts relating to 2023, see Note D.1.5.4. to the consolidated financial statements for the year ended December 31, 2023).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line mainly comprises the impact on non-controlling interests arising from divestments and acquisitions.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as distributions to non-controlling interests. [Refer: Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as distributions to owners of the parent. [Refer: Parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through issuance of restricted shares, equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee share ownership plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through share-based payment plans issuance of restricted shares and vesting of existing restricted shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax effects of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of services obtained from employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareBasedPaymentPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based payment plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareBasedPaymentPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079754080368">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity (Parenthetical) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidOrdinarySharesPerShare', window );">Dividend paid per share (in euros per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 3.76<span></span>
</td>
<td class="nump">&#8364; 3.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 7<span></span>
</td>
<td class="nump">&#8364; 18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity', window );">Other changes arising from issuance of restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements (b)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AdditionalPaidinCapitalMember', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line mainly comprises the impact on non-controlling interests arising from divestments and acquisitions.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidOrdinarySharesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends paid per ordinary share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 34<br> -IssueDate 2023-01-01<br> -Paragraph 16A<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=34&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16A_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidOrdinarySharesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through issuance of restricted shares, equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AdditionalPaidinCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_AdditionalPaidinCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079755979232">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from (used in) operating activities [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity', window );">Net income attributable to equity holders of Sanofi</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 2,246<span></span>
</td>
<td class="nump">&#8364; 3,430<span></span>
</td>
<td class="nump">&#8364; 5,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod', window );">Share of undistributed earnings from investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">110<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset', window );">Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,445<span></span>
</td>
<td class="nump">1,838<span></span>
</td>
<td class="nump">4,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets', window );">Gains and losses on disposals of non-current assets, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(279)<span></span>
</td>
<td class="num">(307)<span></span>
</td>
<td class="num">(509)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDeferredTaxExpense', window );">Net change in deferred taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(780)<span></span>
</td>
<td class="num">(446)<span></span>
</td>
<td class="num">(970)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities', window );">Net change in non-current provisions and other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,087<span></span>
</td>
<td class="num">(716)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of employee benefits (stock options and other share-based payments)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">173<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue', window );">Impact of the workdown of acquired inventories remeasured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsToReconcileProfitLoss', window );">Other profit or loss items with no cash effect on cash flows generated by operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">26<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Operating cash flow before changes in working capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,064<span></span>
</td>
<td class="nump">4,382<span></span>
</td>
<td class="nump">9,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments to reconcile profit (loss) [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">(Increase)/decrease in inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(886)<span></span>
</td>
<td class="num">(1,174)<span></span>
</td>
<td class="num">(840)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">(Increase)/decrease in accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14<span></span>
</td>
<td class="num">(215)<span></span>
</td>
<td class="num">(397)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Increase/(decrease) in accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">82<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities', window );">Net change in other current assets and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,851)<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">1,599<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash provided by/(used in) operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">1,423<span></span>
</td>
<td class="nump">3,563<span></span>
</td>
<td class="nump">10,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from (used in) investing activities [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets', window );">Acquisitions of property, plant and equipment and intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,886)<span></span>
</td>
<td class="num">(930)<span></span>
</td>
<td class="num">(3,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Acquisitions of consolidated undertakings and investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(1,885)<span></span>
</td>
<td class="num">(2,465)<span></span>
</td>
<td class="num">(3,870)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Acquisitions of other equity investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(208)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets', window );">Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">607<span></span>
</td>
<td class="nump">578<span></span>
</td>
<td class="nump">1,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Disposals of consolidated undertakings and investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetChangeInOtherNonCurrentAssets', window );">Net change in other non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(215)<span></span>
</td>
<td class="num">(229)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,413)<span></span>
</td>
<td class="num">(3,073)<span></span>
</td>
<td class="num">(6,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from (used in) financing activities [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Issuance of Sanofi shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DividendsPaidAbstract', window );"><strong>Dividends paid:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities', window );">Dividends paid to equity holders of Sanofi</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,704)<span></span>
</td>
<td class="num">(4,454)<span></span>
</td>
<td class="num">(4,454)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities', window );">Dividends paid to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries', window );">Payments received/(made) on changes of ownership interest in a subsidiary without loss of control</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Additional long-term debt contracted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfNoncurrentBorrowings', window );">Repayments of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(637)<span></span>
</td>
<td class="num">(2,680)<span></span>
</td>
<td class="num">(3,684)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(144)<span></span>
</td>
<td class="num">(127)<span></span>
</td>
<td class="num">(265)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments', window );">Net change in short-term debt and other financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">5,886<span></span>
</td>
<td class="nump">2,431<span></span>
</td>
<td class="nump">765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares', window );">Acquisitions of treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(302)<span></span>
</td>
<td class="num">(363)<span></span>
</td>
<td class="num">(593)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by/(used in) financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">89<span></span>
</td>
<td class="num">(5,214)<span></span>
</td>
<td class="num">(8,052)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Impact of exchange rates on cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net change in cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,915)<span></span>
</td>
<td class="num">(4,743)<span></span>
</td>
<td class="num">(4,026)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,710<span></span>
</td>
<td class="nump">12,736<span></span>
</td>
<td class="nump">12,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 6,795<span></span>
</td>
<td class="nump">&#8364; 7,993<span></span>
</td>
<td class="nump">&#8364; 8,710<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes non-current financial assets.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line item includes contributions paid to pension funds (see Note B.12.).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">This line item mainly comprises unrealized foreign exchange gains and losses arising on the remeasurement of monetary items in non-functional currencies and on instruments used to hedge such items.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Of which:</span><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"><tr><td style="width:1.0%"></td><td style="width:59.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:14.17pt;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:12.12pt">Income tax paid</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,434)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,431)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,623)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:14.17pt;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:12.12pt">Interest paid</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(234)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(559)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:14.17pt;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:12.12pt">Interest received</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:14.17pt;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%;padding-left:12.12pt">Dividends received from non-consolidated entities</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">For the six months ended June 30, 2024, this line item includes the net cash outflow arising from the acquisition of Inhibrx, Inc. (see Note B.1.1.). For the six months ended June 30, 2023, this line includes the net cash outflow arising from the acquisition of Provention Bio Inc. For the year ended December 31, 2023, it includes the net cash outflow arising from the acquisitions of Provention Bio Inc and QRIB.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt">This line item mainly comprises proceeds from disposals of (i) assets and businesses due to portfolio rationalization, and (ii) equity and debt instruments.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">For the six months ended June 30, 2024, this line mainly comprises a commercial paper program in the United States for &#8364;6,060&#160;million, compared to &#8364;2,630 million in the six months ended June 30, 2023 and &#8364;946 million in the year ended December 31, 2023. This line also includes realized foreign exchange gains and losses on cash and cash equivalents in non-functional currencies, mainly the US dollar, and on derivatives used to manage them.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDeferredTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDeferredTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_14&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for undistributed profits of investments accounted for using the equity method to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Investments accounted for using equity method; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows arising from losing control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) from the entity's operations before changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for dividends paid to equity holders of the parent, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for dividends paid to non-controlling interests, classified as financing activities. [Refer: Non-controlling interests; Dividends paid to non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsToReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Adjustments to reconcile profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsToReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for changes in ownership interests in subsidiaries that do not result in a loss of control. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 42A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_42A&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 42B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_42B&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire or redeem entity's shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsToAcquireOrRedeemEntitysShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the disposal of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-current borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) attributable to ordinary equity holders of the parent entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation, amortization and impairment of property, plant and equipment, right-of use assets and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for noncurrent provisions and other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DividendsPaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DividendsPaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impact of the workdown of acquired inventories remeasured at fair value arising from business combination in accordance with IFRS 3.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other current assets and increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetChangeInOtherNonCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net change in other non-current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetChangeInOtherNonCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079757049856">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Income tax paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (1,434)<span></span>
</td>
<td class="num">&#8364; (1,431)<span></span>
</td>
<td class="num">&#8364; (2,623)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(320)<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="num">(559)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">261<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="nump">547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities', window );">Dividends received from non-consolidated entities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments', window );">Net change in short-term debt and other financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,886<span></span>
</td>
<td class="nump">2,431<span></span>
</td>
<td class="nump">765<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember', window );">Commercial paper program in USA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments', window );">Net change in short-term debt and other financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 6,060<span></span>
</td>
<td class="nump">&#8364; 2,630<span></span>
</td>
<td class="nump">&#8364; 946<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">For the six months ended June 30, 2024, this line mainly comprises a commercial paper program in the United States for &#8364;6,060&#160;million, compared to &#8364;2,630 million in the six months ended June 30, 2023 and &#8364;946 million in the year ended December 31, 2023. This line also includes realized foreign exchange gains and losses on cash and cash equivalents in non-functional currencies, mainly the US dollar, and on derivatives used to manage them.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends received from non-consolidated entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079756951104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Introduction<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GeneralInformationAboutFinancialStatementsAbstract', window );"><strong>General Information About Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">Introduction</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">INTRODUCTION</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi, together with its subsidiaries (collectively &#8220;Sanofi&#8221;, &#8220;the Group&#8221; or &#8220;the Company&#8221;), is a global healthcare leader engaged in the research, development and marketing of therapeutic solutions focused on patient needs. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is listed in Paris (Euronext: SAN) and New&#160;York (Nasdaq: SNY). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The condensed consolidated financial statements for the six months ended June 30, 2024 were reviewed by the Sanofi Board of Directors at the Board meeting on July 24, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GeneralInformationAboutFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General Information About Financial Statements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GeneralInformationAboutFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079753625040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Preparation of the Half-Year Financial Statements and Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of Preparation of the Half-Year Financial Statements and Accounting Policies</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">A/ BASIS OF PREPARATION OF THE HALF-YEAR FINANCIAL STATEMENTS AND ACCOUNTING POLICIES</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.1. INTERNATIONAL FINANCIAL REPORTING STANDARDS (IFRS)</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS 34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2023. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accounting policies used in the preparation of the consolidated financial statements as of June&#160;30,&#160;2024 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2024 are available via the following web link: </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">https://www.efrag.org/Endorsement</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accounting policies applied effective January 1, 2024 are identical to those presented in the consolidated financial statements for the year ended December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On September&#160;22, 2022, the IASB issued an amendment to IFRS&#160;16 (Leases) relating to lease liabilities in a sale-and-leaseback arrangement, which is applicable from January 1, 2024 and had no impact on Sanofi's financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January&#160;23, 2020, the IASB issued &#8220;Classification of Liabilities as Current or Non-current&#8221;, an amendment to IAS&#160;1, and then on&#160;October&#160;31, 2022 issued &#8220;Non-current Liabilities with Covenants&#8221;, a further amendment to IAS&#160;1. The amendments, which are applicable from January&#160;1, 2024, had no impact on Sanofi's financial statements. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May&#160;25, 2023, the IASB issued "Supplier Finance Arrangements", an amendment to IAS&#160;7 and IFRS&#160;7, applicable from January&#160;1, 2024. The </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">amendment relates to disclosures of information about such arrangements; it had no impact on the 2024 half-year financial statements</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As a reminder, in its 2023 consolidated financial statements Sanofi applied &#8220;International Tax Reform &#8211; Pillar Two Model Rules&#8221;, an amendment to&#160;IAS&#160;12 issued by the IASB on May 23, 2023, and did not recognize any deferred tax on temporary differences related to Pillar 2 rules. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In its 2024 half-year financial statements, Sanofi has used an average effective tax rate that takes into account the top-up tax applicable from January 1, 2024 (see Note B.19.). </span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.2. USE OF ESTIMATES</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">impairment of property, plant and equipment and intangible assets;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the valuation of goodwill and the valuation and useful life of acquired intangible assets;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the measurement of contingent consideration receivable in connection with asset divestments and of contingent consideration payable;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the measurement of financial assets and financial liabilities at amortized cost;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of post-employment benefit obligations;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences.</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actual results could differ from these estimates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For half-year financial reporting purposes, and as allowed under IAS 34, Sanofi has determined income tax expense on the basis of an estimate of the effective tax rate for the full financial year. That rate is applied to business operating income plus financial income and minus financial expenses, and before (i) the share of profit/loss of investments accounted for using the equity method and (ii) net income attributable to non-controlling interests. The estimated full-year effective tax rate is based on the tax rates that will be applicable to projected pre-tax profits or losses arising in the various tax jurisdictions in which Sanofi operates. </span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.3. SEASONAL TRENDS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s activities are not subject to significant seasonal fluctuations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.4. CONSOLIDATION AND FOREIGN CURRENCY TRANSLATION OF THE FINANCIAL STATEMENTS OF SUBSIDIARIES IN HYPERINFLATIONARY ECONOMIES</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2024, Sanofi continues to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS&#160;10 (Consolidated Financial Statements) are still met.The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since July&#160;1, 2018 treated Argentina as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Turkey, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since January&#160;1, 2022 treated Turkey as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.5. FAIR VALUE OF FINANCIAL INSTRUMENTS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 3: valuation techniques in which not all important inputs are derived from observable market data.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"><tr><td style="width:1.0%"></td><td style="width:3.161%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.885%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:0.85pt;padding-right:0.85pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Type of financial</span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:0.85pt;padding-right:0.85pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%">instrument</span></div></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Measurement</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%">principle</span></div></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in fair value hierarchy</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation technique</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation model</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Volatilities</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial assets measured at fair value (quoted equity instruments)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial assets measured at fair value (quoted debt instruments)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial assets measured at fair value (unquoted equity instruments)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost/ Peer comparison (primarily)</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets at fair value (contingent consideration receivable)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2021.<br/></span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial assets measured at fair value held to meet obligations under post-employment benefit plans</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.<br/>B.12.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial Debt</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized cost </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. </span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).</span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Future lease payments are discounted using the incremental borrowing rate.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid Money Market<br/>&gt;&#160;1 year:&#160;Mid Zero Coupon</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures </span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&gt;&#160;1 year: Mid Zero Coupon</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures </span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&gt;&#160;1 year: Mid Zero Coupon</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.11.</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fair value</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.6. NEW PRONOUNCEMENTS ISSUED BY THE IASB AND APPLICABLE FROM 2025</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On August&#160;15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS&#160;21 </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(The Effects of Changes in Foreign Exchange Rates), relating to</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> how to determine the exchange rate when a currency is not exchangeable. The amendment is applicable from January&#160;1, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (subject to endorsement by the European Union); it</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> will not have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027 (subject to endorsement by the European Union). An impact assessment is currently under way. Sanofi will not early adopt this new standard.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments, applicable no earlier than January 1, 2026 (subject to endorsement by the European Union). Sanofi does not expect any material impact, and will not early adopt these amendments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 18, 2024, the IASB issued Volume 11 of &#8220;Annual Improvements to IFRS&#8221;, applicable from January 1, 2026 (subject to endorsement by the European Union). Sanofi does not expect any material impact from those improvements to various standards, which are essentially in the nature of clarifications, and will not early adopt them.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079753850928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract', window );"><strong>Disclosure of detailed information about business combination [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock', window );">Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.1. PRINCIPAL CHANGES IN SCOPE OF CONSOLIDATION IN THE PERIOD</span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Inhibrx, Inc.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 30, 2024, Sanofi completed the acquisition of Inhibrx, Inc (&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Inhibrx&#8221;), adding </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">SAR447537 (formerly INBRX-101) to Sanofi&#8217;s rare disease pipeline. SAR447537 is a human recombinant protein that holds the promise of allowing alpha-1 antitrypsin deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing. AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lungs with progressive tissue deterioration. SAR447537 may help to reduce inflammation and prevent further deterioration of lung function in affected individuals.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The transaction did not meet the criteria for a business combination under IFRS 3, and consequently was accounted for as an acquisition of a group of assets. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition price was $2,035&#160;million. Of that amount (plus acquisition-related costs), $1,908&#160;million was allocated to in-process development in respect of SAR447537, and recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IAS 38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed in the transaction. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, Sanofi awarded the former shareholders of Inhibrx an unquoted, non-negotiable Contingent Value Right (CVR) certificate that entitles them to a deferred cash payment of $5.00 per Inhibrx share, subject to attainment of a regulatory milestone before June 30, 2027. The nominal value of that commitment is $300&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition, as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows, is a net cash outflow of $2,035&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for impact of changes in the scope of consolidation due to acquisitions and divestments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079751585792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.2. PROPERTY, PLANT AND EQUIPMENT</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2024:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:72.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">591</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,693</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biopharma </span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;Of which Manufacturing &amp; Supply</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">366&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Of which Manufacturing &amp; Supply</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:700;line-height:100%">Of which capitalized interest</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:700;line-height:100%">22</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:700;line-height:100%">26</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Firm orders for property, plant and equipment stood at &#8364;659&#160;million as of June 30, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079780652528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract', window );"><strong>Intangible assets and goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.3. GOODWILL AND OTHER INTANGIBLE ASSETS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill amounted to &#8364;50,080&#160;million as of June 30, 2024, versus &#8364;49,404 million as of December&#160;31, 2023. The movement during the period was mainly due to the impact of changes in exchange rates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in other intangible assets during the first half of 2024 were as follows:<br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:50.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Acquired R&amp;D</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Products, trademarks and other rights</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total other intangible assets</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross value at January&#160;1, 2024</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,772</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">73,733</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,808</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">85,313</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(27)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(83)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,293&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross value at June 30, 2024</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12,298</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">74,969</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,848</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">89,115</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated amortization and impairment at January&#160;1, 2024 </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(3,734)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(55,908)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,352)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(60,994)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,084)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(52)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,136)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(70)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(701)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(775)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated amortization and impairment at June 30, 2024</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(3,768)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(57,291)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,403)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(62,462)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Carrying amount at January&#160;1, 2024</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">6,038</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">17,825</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">456</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">24,319</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Carrying amount at June 30, 2024</span></div></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,530</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">17,678</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">445</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">26,653</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Impact of the acquisition of Inhibrx, Inc (see Note B.1.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">See Note B.4. </span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acquisitions of other intangible assets (excluding software) in the first half of 2024 totale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">d &#8364;772 million, including &#8364;463 million&#160;related to the agreements entered into between Sanofi and Novavax in May 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Products, trademarks and other products&#8221; mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">marketed products, with a carrying amount of &#8364;16.3 bil</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">lion as of June 30, 2024 (versus &#8364;16.6 billion as of December 31, 2023) and a weighted average amortization period of approximately 11 years; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">technological platforms brought into service, with a carrying amou</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">nt of &#8364;1.4 billion as</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">June 30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (versus &#8364;1.2 billion as of December 31, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and a weighted average amortization period of approximately 18 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079754170528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock', window );">Impairment of Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.4. IMPAIRMENT OF INTANGIBLE ASSETS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The monitoring of impairment indicators for other intangible assets led to the recognition of a net reversal of impairment losses amounting to &#8364;366&#160;million in the first half of 2024, mainly due to an increase in the recoverable amounts of certain marketed products and other rights in the Biopharma segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for impairment of intangible assets and property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079755071376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments Accounted for Using the Equity Method<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestsInOtherEntitiesAbstract', window );"><strong>Interests In Other Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory', window );">Investments Accounted for Using the Equity Method</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.5. INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2023), and comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:58.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">% interest</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">EUROAPI </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Infraserv GmbH &amp; Co. H&#246;chst KG </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">MSP Vaccine Company </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">315</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">424</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (&#8364;2.55 as of June 30, 2024, and &#8364;5.73 as of December 31, 2023). </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Joint venture. </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Joint venture MSP Vaccine Company owns 100% of MCM Vaccine BV.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:58.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Royalties and other income</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable and other receivables</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">213</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">249</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchases of goods and services</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">302</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">642</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable and other payables</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97</span></td><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subject to certain conditions, Sanofi could raise its investment in EUROAPI by &#8364;200 million in the form of a perpetual subordinated hybrid bond.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestsInOtherEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interests In Other Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestsInOtherEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079750582880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Non-Current Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory', window );">Other Non-Current Assets</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.6. OTHER NON-CURRENT ASSETS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other non-current assets comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:72.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments at fair value through other comprehensive income</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,161&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments at fair value through other comprehensive income</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other financial assets at fair value through profit or loss</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pre-funded pension obligations</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term prepaid expenses </span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables </span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,333</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,218</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other non-current assets. [Refer: Other non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079753829040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Trade and other receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfTradeReceivablesTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.7. ACCOUNTS RECEIVABLE</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accounts receivable break down as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:72.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross value</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,602&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,528&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Allowances</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(95)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Carrying amount</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,510</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,433</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of allowances against accounts receivable in the first half of 2024 was a net expense of &#8364;3 million (versus a net expense of &#8364;2 million for the first half of 2023).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the ageing profile of overdue accounts receivable, based on gross value:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:27.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Overdue accounts gross value</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Overdue by &lt;1 month</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Overdue by 1-3 months</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Overdue by 3-6 months</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Overdue by 6-12 months</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Overdue by    &gt; 12 months</span></td></tr><tr><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2024</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Some Sanofi subsidiaries have assigned receivables to factoring companies or banks without recourse. The amount of receivables that met the conditions described in Note B.8.6. to the consolidated financial statements for the year ended December 31, 2023 and hence were derecognized was &#8364;503 million as of June&#160;30, 2024 (versus &#8364;761 million as of December 31, 2023). The residual guarantees relating to those transfers were immaterial as of June 30, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfTradeReceivablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfTradeReceivablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079780065120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Consolidated Shareholders' Equity</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.8. CONSOLIDATED SHAREHOLDERS&#8217; EQUITY</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.1. SHARE CAPITAL</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2024, the share capital was &#8364;2,532,725,512 and consisted of 1,266,362,756 shares (the total number of shares outstanding) with a par value of &#8364;2.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Treasury shares held by Sanofi are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:64.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Number of shares<br/>(million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">% of share capital<br/>for the period</span></td></tr><tr><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2024</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15.33</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.211</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10.90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.864&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8.20&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.650&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A total of 91,355 shares were issued in the first half of 2024 as a result of the exercise of Sanofi stock subscription options.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2,803,637</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> shares </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">vested under Sanofi restricted share plans during the first half of 2024, of which 1,471,432</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;were fulfilled by issuance of new shares and </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1,332,205</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> by allotment of existing shares free of charge</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.2. REPURCHASE OF SANOFI SHARES</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 25, 2023, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of 18 months. Under that program, Sanofi repurchased 3,215,460 of its own shares during the first half of </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for a total amount of &#8364;302&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 30, </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of 18 months. Sanofi did n</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ot use that authorization during the first half of 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.3. REDUCTIONS IN SHARE CAPITAL</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No decision to cancel treasury shares was made by the Sanofi Board of Directors during the first half of 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.4. RESTRICTED SHARE PLANS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2023. The principal features of the plans awarded in 2024 are set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:81.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.169%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Type of plan</span></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Performance share plan</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plan</span></td><td colspan="3" style="background-color:#e8eaf6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total number of shares subject to a 3-year service period</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,505,145&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with no market condition</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,888,502&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;81.84&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with market conditions</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,616,643&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded other than to the Chief Executive Officer (1,394,478 shares in total) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;72.79&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fair value per share awarded other than to the Chief Executive Officer (139,665 additional shares) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;13.50&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fair value per share awarded to the Chief Executive Officer (82,500 shares) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;72.38&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value of plan at the date of grant (&#8364; million)</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">346</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) Additional tranche subject to a higher level of market conditions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:72.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total expense for restricted share plans (&#8364; million)</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares not yet fully vested</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,192,984&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,127,545&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2024 plans</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4,498,109&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2023 plans</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,652,352&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,837,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2022 plans</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,031,060&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,226,321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2021 plans</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">11,463&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,996,101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2020 plans</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">67,149&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.5. CAPITAL INCREASES</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January 31, 2024, the Sanofi Board of Directors approved a capital increase reserved for employees, offering the opportunity for them to subscribe for new Sanofi shares at a price of &#8364;72.87 per share. The subscription period was open from June&#160;4 through June&#160;24, 2024. Sanofi employees subscribed for a total of 2,124,445 shares, and this capital increase was supplemented by the immediate issuance of a further 119,951 shares for the employer&#8217;s contribution. The total expense recognized for this capital increase in the first half of 2024 was &#8364;45 million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February&#160;2, 2023, the Sanofi Board of Directors approved a capital increase reserved for employees, offering the opportunity for them to subscribe for new Sanofi shares at a price of &#8364;79.58 per share. The subscription period was open from June&#160;5 through June&#160;23, 2023. Sanofi employees subscribed for a total of 2,009,306 shares, and this capital increase was supplemented by the immediate issuance of a further 119,417 shares for the employer&#8217;s contribution. The total expense recognized for this capital increase in the first half of 2023 was &#8364;52 million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.6. STOCK SUBSCRIPTION OPTION PLANS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No stock subscription option plans were awarded in the first half of 2024 or in 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No more expenses have been recognized through equity for stock option plans in either 2024 or 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below provides summary information about options outstanding and exercisable as of June&#160;30, 2024:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:31.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.307%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Range of exercise prices per share</span></td><td colspan="9" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr style="height:38pt"><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted average residual life (years)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted average exercise price per share (&#8364;)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted average exercise price per share (&#8364;)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;60.00 to &#8364;70.00 per share</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.84</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;70.00 to &#8364;80.00 per share</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">478,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.18</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76.26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">478,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76.26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;80.00 to &#8364;90.00 per share</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594,724&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.79</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594,724&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,241,658</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,241,658</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.7. NUMBER OF SHARES USED TO COMPUTE DILUTED EARNINGS PER SHARE</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.554%"><tr><td style="width:1.0%"></td><td style="width:59.113%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,249.4&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,249.9&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,251.7&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustment for stock options with dilutive effect</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustment for restricted shares</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Average number of shares used to compute diluted earnings per share</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,253.8</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,254.5</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,256.4</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2024, December 31, 2023 and June 30, 2023 all stock options were taken into account in computing diluted earnings per share because they all had a dilutive effect. </span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.8. OTHER COMPREHENSIVE INCOME</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements within other comprehensive income are shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.554%"><tr><td style="width:1.0%"></td><td style="width:56.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.857%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024 (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023 (6 months)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses):</span></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="padding-right:2.1pt;text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Actuarial gains/(losses) excluding investments accounted for using the equity method</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(171)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments included in financial assets and financial liabilities:</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Equity risk hedging instruments designated as fair value hedges</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Items not subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">166</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">85</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(77)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments included in financial assets:</span></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="padding-right:2.1pt;text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash flow hedges and fair value hedges:</span></div></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in currency translation differences:</span></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (c)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,167&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,551)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Currency translation differences (investments accounted for using the equity method) </span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Hedges of net investments in foreign operations </span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Items subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,067</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,058)</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,526)</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes reclassifications to profit or loss: immaterial over all periods.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes reclassifications to profit or loss: immaterial over all periods.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes a reclassification to profit or loss: immaterial in the first half of 2024 , &#8364;(56) million in 2023 and &#8364;(14) million in the first half of 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Summary of Treasury Shares Held</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.8. CONSOLIDATED SHAREHOLDERS&#8217; EQUITY</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.1. SHARE CAPITAL</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2024, the share capital was &#8364;2,532,725,512 and consisted of 1,266,362,756 shares (the total number of shares outstanding) with a par value of &#8364;2.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Treasury shares held by Sanofi are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:64.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Number of shares<br/>(million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">% of share capital<br/>for the period</span></td></tr><tr><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2024</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15.33</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.211</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10.90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.864&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8.20&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.650&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A total of 91,355 shares were issued in the first half of 2024 as a result of the exercise of Sanofi stock subscription options.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2,803,637</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> shares </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">vested under Sanofi restricted share plans during the first half of 2024, of which 1,471,432</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;were fulfilled by issuance of new shares and </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1,332,205</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> by allotment of existing shares free of charge</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079751129008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt, Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock', window );">Debt, Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.9. DEBT, CASH AND CASH EQUIVALENTS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in financial position during the period were as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:72.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,503&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,347&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,236&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,045&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,918</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">16,531</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,795)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net debt (a)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">15,112</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,793</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Net debt does not include lease liabilities, which amounted to &#8364;2,012 million as of June 30, 2024 and &#8364;2,030 million as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Net debt&#8221; is a financial indicator used by management and investors to measure Sanofi&#8217;s overall net indebtedness.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.9.1. NET DEBT AT VALUE ON REDEMPTION</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2024 is shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:31.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.949%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="6" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Value on redemption</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Carrying amount at</span></div><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Adjustment to debt measured at fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,503&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,688&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,546&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,236&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,254&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,045&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,918</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">35</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,952</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">16,573</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,795)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,795)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net debt (a)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">15,112</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">35</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">15,146</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,835</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Net debt does not include lease liabilities, which amounted to &#8364;2,012 million as of June 30, 2024 and &#8364;2,030 million as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows an analysis of net debt by type, at value on redemption:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:35.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.626%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.086%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">non-current</span></td><td colspan="6" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">current</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #661de8;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">non-current</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">current</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,593&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,916&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,509&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbe5f1;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,416&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,134&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,118&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,213&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbe5f1;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbe5f1;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbe5f1;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbe5f1;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12,688</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,264</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,952</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">14,546</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,027</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">16,573</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,795)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,795)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12,688</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,458</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">15,146</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">14,546</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(6,711)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,835</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) As of June 30, 2024, current other bank borrowings includ</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">e &#8364;6,955&#160;million related to the US Commercial Paper program and &#8364;0&#160;million related to the Negotiable European Commercial Paper program in France.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Principal financing and debt reduction transactions during the period</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi did not carry out any bond issues in the first half of </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An April</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> 2016 fixed-rate bond issue of &#8364;600&#160;million, which matured on April 5, 2024, was redeemed during the first half of 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2024, Sanofi had two syndicated credit facilities linked to social and environmental criteria in place to manage its liquidity in connection with current operations:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:14.14pt">a syndicated credit facility of &#8364;4&#160;billion, drawable in euros and US dollars and expiring on December 6, 2027, for which no further extension options are available; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.27pt">a syndicated credit facility of &#8364;4&#160;billion, drawable in euros and US dollars and expiring on March 7, 2029, for which a further one-year extension option remains available. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2024, neither facility was drawn down.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi also has two short-term debt programs:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:14.14pt"> a &#8364;6 billion Negotiable European Commercial Paper program in France; and </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.27pt">a $10&#160;billion Commercial Paper program in the United States. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the first half of 2024:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:14.14pt"> the average drawdown under the US Commercial Paper program was $5.8 billion; and </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.27pt">the average drawdown under the Negotiable European Commercial Paper program in France was &#8364;0.1 billion.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financing in place as of June 30, 2024 at the level of the holding company (which manages most of Sanofi&#8217;s financing needs centrally) is not subject to any financial covenants, and contains no clauses linking credit spreads or fees to the credit rating.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.9.2. MARKET VALUE OF NET DEBT</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The market value of Sanofi&#8217;s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.644%"><tr><td style="width:1.0%"></td><td style="width:72.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,214&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,086&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Value on redemption</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,146&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,835&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of debt instruments issued explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079753789600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory', window );">Derivative Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.10. DERIVATIVE FINANCIAL INSTRUMENTS</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.10.1 CURRENCY DERIVATIVES USED TO MANAGE OPERATING RISK EXPOSURES</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of June&#160;30, 2024. The notional amount is translated into euros at the relevant closing exchange rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:26.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Of which derivatives designated as cash flow hedges</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Of which derivatives not eligible for hedge accounting</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Of which recognized in equity</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,120</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(45)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,120</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(45)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,152&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(17)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,152&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(17)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">608&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">608&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Russian rouble</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">197&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">197&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,195</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,195</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">398&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">398&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Russian rouble</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Turkish lira</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Canadian dollar</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,315</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,315</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The above positions mainly hedge material foreign currency cash flows arising after the end of the reporting period in relation to transactions carried out during the six months ended June&#160;30, 2024 and recognized in the balance sheet at that date. Gains and losses on hedging in</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">struments (forward contracts) are calculated and recognized in parallel with the recognition of gains and losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange difference on those items (hedging instruments and hedged transactions) will be immaterial in the second half of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.10.2. CURRENCY AND INTEREST RATE DERIVATIVES USED TO MANAGE FINANCIAL EXPOSURE</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The cash pooling arrangements for foreign subsidiaries outside the eurozone, and some of Sanofi&#8217;s financing activities, expose certain Sanofi entities to financial foreign exchange risk (i.e.&#160;the risk of changes in the value of loans and borrowings denominated in a currency other than the functional currency of the lender or borrower).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">That foreign exchange exposure is hedged using derivative instruments (currency swaps or forward contracts) that alter the currency split of Sanofi&#8217;s debt once those instruments are taken into account.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows financial currency hedging instruments in place as of June&#160;30, 2024. The notional amount is translated into euros at the relevant closing exchange rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:55.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.307%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Maximum expiry date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,190</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(30)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5,797&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(28)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Canadian dollar</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">190&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,656</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">42</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5,242&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b) (c)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">37&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,768&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Hungarian forint</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">182&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">14,846</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes forward sales with a notional amount of $3,615 million expiring in 2024, designated as a hedge of Sanofi&#8217;s net investment in Bioverativ. As of June&#160;30, 2024, the fair value of these forward contracts represented a liability of &#8364;26 million; the opposite entry was recognized in &#8220;Other comprehensive income&#8221;, with the impact on financial income and expense being immaterial.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)  Includes forward purchases with a notional amount of $1,000 million expiring in 2024, designated as a fair value hedge of the exposure of $1,000 million of bond issues to</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> fluctuations in the EUR/USD spot rate. As of June 30, 2024, the fair value of these contracts represented an asset of &#8364;2 million, with &#8364;0 million&#160;credited to &#8220;Other comprehensive income&#8221; to recognize the hedging cost.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)  Includes forward purchases with a notional amount of $1,080 million expiring in 2024 , designated as a fair value hedge of $1,080 million of commercial paper. As of June 30, 2024, the fair value of these contracts represented an asset of &#8364;16 million, with &#8364;0&#160;million credited to &#8220;Other comprehensive income&#8221; to recognize the hedging cost. .</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To optimize the cost of debt or reduce the volatility of debt, Sanofi uses derivative instruments (interest rate swaps and cross currency swaps) to alter the fixed/floating rate split of its net debt.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows instruments of this type in place as of June 30, 2024:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.834%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.255%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Of which designated as fair value hedges</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Of which designated as cash flow hedges</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2028 and beyond</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Of which recognized in equity</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD / receive 1.02%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(53)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(53)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">pay capitalized SOFR USD / receive  1.32%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester / receive 0.69%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester / receive 0.92%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">pay capitalized Ester / receive 3.56%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">997</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">850</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,584</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,431</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(181)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,431</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(181)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of derivative financial instruments. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079756942864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Current Provisions And Other Non-Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock', window );">Non-Current Provisions And Other Non-Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.12. NON-CURRENT PROVISIONS AND OTHER NON-CURRENT LIABILITIES</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current provisions and other non-current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> comprises the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:59.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,918&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,018&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,262&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other non-current liabilities&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,340&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,219</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,088</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,602</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Includes &#8364;1,970 million at June 30, 2024 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States. Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#8364;1,147&#160;million; the nominal value of payments estimated to be due after more than five years is &#8364;2,679 million.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows movements in provisions:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:38.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.450%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.450%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Provisions for pensions &amp; other post-employment benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Provisions for other long-term benefits</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Restructuring provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at January&#160;1, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,214</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">718</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">554</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,776</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,262</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increases in provisions and other liabilities</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(78)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(65)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(76)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(230)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reversals of unutilized provisions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(63)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(53)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(119)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(173)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(122)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest related to employee benefits, and unwinding of discount</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains and losses on defined-benefit plans (B.12.1.)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(235)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(235)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at June 30, 2024</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,040</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">759</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">909</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,210</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,918</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the case of &#8220;Provisions for pensions and other post-employment benefits&#8221;, the &#8220;Increases in provisions&#8221; line corresponds to rights vesting in employees during the period, and past service cost; the &#8220;Provisions utilized&#8221; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#8220;Reversals of unutilized provisions&#8221; line corresponds to plan curtailments, settlements and amendments.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Mainly transfers to the line &#8220;Current provisions and other current liabilities&#8221;.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Provisions for pensions and other post-employment benefits</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For an analysis of the sensitivity of obligations in respect of pensions and other employee benefits as of December 31, 2023, and of the assumptions used as of that date, see Note D.19.1. to the consolidated financial statements for the year ended December 31, 2023. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal assumptions used (in particular, changes in discount and inflation rates and in the market value of plan assets) for the eurozone, the United States and the United Kingdom were reviewed as of June 30, 2024 to take into account changes during the first half of the year.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:54.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.973%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024 (6 months)</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) on plan assets</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(208)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) on benefit obligations</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes the effects of (i) the change in discount rates (in a range between +0.40% and +0.65%) and (ii) the change in the inflation rate in the United Kingdom (+0.10%) in the first half of 2024.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes the effects of (i) the change in discount rates (in a range between -0.15% and +0.40%) and (ii) the change in the inflation rate in the eurozone (-0.10%) in the first half of 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Provisions And Other Non-Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079779202272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Off Balance Sheet Commitments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OffBalanceSheetCommitmentsAbstract', window );"><strong>Off-Balance Sheet Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock', window );">Off Balance Sheet Commitments</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.13. OFF BALANCE SHEET COMMITMENTS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Off balance sheet commitments to third parties as of December&#160;31, 2023 are presented in Note D.21.1. to the consolidated financial statements for the year ended December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal commitments entered into, amended or discontinued during the period are described below: </span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.28pt">On May, 2024, Sanofi entered into a co-exclusive licensing agreement with Novavax. The terms of the agreement include (i)&#160;a co-exclusive license to co-commercialize Novavax&#8217;s current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements and in India, Japan, and South Korea, where Novavax has existing partnership agreements); (ii) a sole license to Novavax&#8217;s adjuvanted COVID-19 vaccine for use in combination with Sanofi&#8217;s flu vaccines; and (iii) a non-exclusive license to use the Matrix-M adjuvant in vaccine products. Novavax received an upfront payment of $500 million and up to $700 million in development, regulatory and launch milestones, representing up to $1.2&#160;billion in total. Starting in 2025, Sanofi will book sales of Novavax&#8217;s adjuvanted COVID-19 vaccine and will support certain R&amp;D, regulatory, and commercial expenses. Novavax will receive double-digit tiered royalties on sales of COVID-19 vaccines and combined influenza/COVID-19 vaccines made by Sanofi. Novavax is also entitled to additional launch and sales milestones opportunities of up to $200 million, plus single-digit royalties for each additional Sanofi vaccine product developed under a non-exclusive license with Novavax&#8217;s Matrix-M adjuvant technology. In addition, Sanofi took a minority (&lt;5%) equity investment in Novavax. This agreement will provide patients with broader access from 2025 onwards to a protein-based non-mRNA adjuvanted COVID-19 vaccine. Outside of the collaboration, each party may develop and commercialize their own flu and COVID-19 vaccines and their own adjuvanted products at their own cost.</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.69pt">On May, 2024, Sanofi entered into a collaboration and license agreement with Fulcrum Therapeutics for the development and commercialization of losmapimod, an investigational oral therapy for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The agreement combines Fulcrum&#8217;s FSHD expertise with Sanofi&#8217;s global reach and commitment to treating people with rare diseases. Under the terms of the agreement, Sanofi obtained exclusive commercialization rights outside of the United States, while Fulcrum retained the US rights. Fulcrum will receive an upfront payment of $80 million, and could receive up to $975 million contingent on the attainment of specified milestones, plus royalties on non-US sales. The two parties will share worldwide development costs equally. Losmapimod, currently in worldwide Phase 3 clinical trials, has demonstrated promising results in slowing the progression of FSHD; data from the Phase 3 trial are expected by end 2024. If the results are positive, Fulcrum and Sanofi intend to file for marketing approval in the United States, Europe, Japan, and other regions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has also entered into power purchase agreements in furtherance of its ESG strategy. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The characteristics of the principal power purchase agreements in place as of June 30, 2024 are summarized below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Country</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Type of Energy</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Annual Volume</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Start Date</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Type of Contract</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accounting Treatment</span></div></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Solar</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8 GWh</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 years</span></div></td><td colspan="3" rowspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PPA </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" rowspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Own use</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">procurement contracts </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Wind</span></div></td><td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46 GWh</span></div></td><td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Wind</span></div></td><td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29 GWh</span></div></td><td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 years</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Power Purchase Agreement (PPA): long-term renewable energy contract resulting in physical supply of electricity.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) At the current stage of analysis, with reference to the own use exception permitted by paragraph 2.4 of IFRS 9.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These contracts help secure the objective of 100% green electricity supply across all operations of the Group by 2030.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of off-balance sheet commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OffBalanceSheetCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Off-Balance Sheet Commitments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OffBalanceSheetCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079780830944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation and Arbitration Proceedings<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract', window );"><strong>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock', window );">Litigation and Arbitration Proceedings</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.14. LITIGATION AND ARBITRATION PROCEEDINGS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and its affiliates are involved in litigation, arbitration and other legal proceedings. These proceedings typically are related to product liability claims, intellectual property rights (particularly claims against generic companies seeking to limit the patent protection of Sanofi products), competition law and trade practices, commercial claims, employment and wrongful discharge claims, tax assessment claims, waste disposal and pollution claims, and claims under warranties or indemnification arrangements relating to business divestitures.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The matters discussed below constitute the most significant developments since publication of the financial statements for the year ended December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.14.1. PRODUCTS</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TAXOTERE PRODUCT LITIGATION IN THE US</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2024, there were approximately 6,770 ingesting plaintiffs cases remaining in courts across the country. Throughout the first half of 2024, Sanofi entered into a number of settlement agreements or agreements in principle with many plaintiffs&#8217; firms encompassing nearly all the remaining cases. These agreements require the consent of the individual plaintiffs and will take some time to conclude, in order to ensure that certain threshold participation requirements are met. </span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ZANTAC PRODUCT LITIGATION IN THE US</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In March 2024, Sanofi reached agreement in principle with a number of plaintiffs&#8217; lawyers to resolve Zantac personal injury cases pending against it in all US state courts outside of Delaware. This agreement would resolve approximately 75% of nearly 4,400 cases. The agreement requires the consent of individual plaintiffs and will take some time to conclude.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the State court cases pending in Delaware, the State of Delaware court decided in May 2024 not to exclude plaintiffs&#8217; experts from the cases. Sanofi is appealing this decision.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOLD BOND PRODUCT LITIGATION IN THE US</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2024, Sanofi is named as a defendant in approximately 600 product liability ongoing actions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DEPAKINE PRODUCT LITIGATION IN FRANCE</span></td></tr></table><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Civil Proceedings </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Several questions on the Product Liability Directive have been referred to the European Court of Justice (ECJ), which will have an impact on the pending Depakine cases. A ruling from the ECJ is expected between September and December 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As a result, several stays in the proceedings have been requested including in the class action, the anxiety damage claim, and several individual proceedings. Similar requests will be made in the remaining proceedings (in particular, on appeal), depending on the timescales determined by the Courts. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the class action, a hearing is scheduled for September 2024 for this question to be tried. As regards the anxiety damage cases, the ruling is expected on August 2, 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DENGVAXIA PRODUCT LITIGATION IN THE PHILIPPINES</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 16, 2024, the Court dismissed the first eight criminal cases, ruling the prosecution failed to establish the elements of &#8220;reckless imprudence&#8221; resulting in homicide. Remaining cases are still pending at various stages.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.14.2. PATENTS</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRALUENT (alirocumab)-RELATED AMGEN PATENT LITIGATION IN EUROPE</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the revocation action filed by Sanofi against Amgen before the Munich Central Division of the Unified Patent Court, a decision on the Amgen patent&#8217;s validity was issued on July 16, 2024. This decision revokes Amgen&#8217;s patent, hence supporting Sanofi/Regeneron&#8217;s position. The decision can be appealed.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and Regeneron have also attacked the validity of the same EP 3 666 797 patent at the European Patent Office. These proceedings are ongoing.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.14.3. OTHER LITIGATION</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PLAVIX (clopidogrel) - ATTORNEY GENERAL ACTION IN HAWAII</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 21, 2024, the Court issued a new decision against Sanofi and BMS, imposing penalties in the total amount of $916 million, with $458 million attributed to Sanofi. Sanofi and BMS will appeal the decision.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PLAVIX (clopidogrel)-RELATED LITIGATION IN FRANCE</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the claim filed by the CNAM, the final expert report was issued in March 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">340B DRUG PRICING PROGRAM IN THE UNITED STATES</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In May 2024, Sanofi filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and Services Administration (HRSA) under the Freedom of Information Act (FOIA) seeking an order declaring that Sanofi is entitled to covered entities&#8217; pharmacy contracts, requiring HRSA to produce the contracts and enjoining HRSA from withholding pharmacy contracts from Sanofi pursuant to its FOIA request. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">Mosaic Health in the United States </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In February 2024, plaintiffs filed a notice of appeal of the dismissal of the complaint by the Court.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">Adventist Health System/West in the United States </span></div>In March 2024, the Court dismissed the action in its entirety, without granting the plaintiff leave to amend its complaint. The plaintiff filed its appeal in April 2024. A decision on the appeal could be delivered during 2025.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Legal And Arbitral Proceedings [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfLegalAndArbitralProceedingsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079779238112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Operating Income And Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory', window );">Other Operating Income and Expenses</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.15. OTHER OPERATING INCOME AND EXPENSES</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;617 million in the first half of 2024 (versus &#8364;617 million in the first half of 2023), and</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to &#8364;2,010 million (versus &#8364; 1,422 million in the first half of 2023).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main items included in</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> were: in the first half of 2024, (i) income from pharmaceutical partners of &#8364;118&#160;million (versus &#8364;160 million in the first half of 2023), of which &#8364;96 million came from Regeneron (versus &#8364;102 million in the first half of 2023, see table below) and (ii) gains on disposals of assets and operations of &#8364;389 million, primarily on divestments of non strategic products (versus &#8364;413 million in the first half of 2023). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">for the first half of 2024 included &#8364;1,841 million of expenses related to Regeneron (compared with &#8364;1,423 million in the first half of 2023), as shown in the table below.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:59.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(12 months)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income &amp; expense related to profit/loss sharing under the Monoclonal Antibody Alliance</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,934)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,449)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,321)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional share of profit paid by Regeneron towards development costs</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reimbursement to Regeneron of selling expenses incurred</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(543)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total: Monoclonal Antibody Alliance</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,837)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,418)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(3,196)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other (mainly Zaltrap and Libtayo)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">92</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">97</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">217</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other operating income/(expenses), net related to Regeneron </span></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,745)</span></td><td style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,321)</span></td><td style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,979)</span></td><td style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">of which amount presented in &#8220;Other operating income&#8221; </span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">96</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">102</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">227</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating income or expense. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079780831696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Costs and Similar Items<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock', window );">Restructuring Costs and Similar Items</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.16. RESTRUCTURING COSTS AND SIMILAR ITEMS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:59.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(12 months)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee-related expenses</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Charges, gains or losses on assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Costs of transformation programs</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other restructuring costs</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,331</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">547</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,490</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring and similar costs increased by &#8364;784 million between June 30, 2023 and June 30, 2024. They mainly comprise costs relating to severance plans announced in the first half of 2024. For the six months ended June 30, 2023 and the year ended December 31, 2023, they included the impact of pension reform in France on future annuities under the rules of each severance plan. Restructuring costs also include Sanofi's ongoing transformation projects, mainly those relating to the separation of the Opella business.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of restructuring costs and similar items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079813109360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Gains and Losses, and Litigation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock', window );">Other Gains and Losses, and Litigation</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.17. OTHER GAINS AND LOSSES, AND LITIGATION</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the first half of 2024, </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a charge of &#8364;442 million, mainly comprising a </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">provision recognized in respect of the litigation related to Plavix (clopidogrel) in the US state of Hawaii (see note B.14.)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. That compares with a charge of &#8364;73</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> million in the first half of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2023, which comprised costs related to the settlement of a dispute with shareholders of Bioverativ.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of other gains and losses, and litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079812516144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Expenses and Income<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Financial Expenses and Income</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.18. FINANCIAL EXPENSES AND INCOME</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of financial expenses and income is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:59.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(12 months)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of debt </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(232)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(555)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Cost of net debt</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(66)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">25</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(22)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-operating foreign exchange gains/(losses)</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unwinding of discounting of provisions </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(59)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost related to employee benefits</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(41)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(73)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains/(losses) on disposals of financial assets</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (d)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net financial income/(expenses)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(305)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(84)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(722)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">comprising: Financial expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(586)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(370)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,313)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income</span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">281</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">286</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">591</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: &#8364;(24) million in the first half of 2024, &#8364;(25) million in the first half of 2023, and &#8364;(67) million over the whole of 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: &#8364;(18) million in the first half of 2024, &#8364;(4)&#160;million in the first half of 2023, and &#8364;(13) million over the whole of 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes a financial expense of &#8364;176</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">million for the six months ended June 30, 2024 (&#8364;541 million for the year ended December 31, 2023, &#8364;35 million for the six months ended June 30, 2023) for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the US.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The impact of the ineffective portion of hedging relationships was not material in either 2024 or 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079781866736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax Expense<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Income taxes paid (refund) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income Tax Expense</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.19. INCOME TAX EXPENSE</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has elected for tax consolidations in a number of countries, principally France, Germany, the United Kingdom and the United States.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the allocation of income tax expense between current and deferred taxes:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:59.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(12 months)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current taxes</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,243)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,171)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,560)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(463)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(730)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,602)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,739</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,238</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,153</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:59.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(as a percentage)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(12 months)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Standard tax rate applicable in France</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Difference between the standard French tax rate and the rates applicable to Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (b)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Probable reversal of temporary differences on investments in Opella subsidiaries </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revisions to tax exposures and settlements of tax disputes</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration liabilities</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (d)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">16.9</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">17.3</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">22.4</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">In accordance with IAS12, a deferred tax liability was recognised in 2023 on the temporary differences arising on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Opella business, as announced in October 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">For the six months ended June 30, 2024, this line includes a tax expense of &#8364;52 million, representing the estimated impact of Pillar 2 based on Sanofi&#8217;s current understanding of Pillar Two rules.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079756943904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.20. SEGMENT INFORMATION</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi reports two operating segments: Biopharma and Opella (formerly Consumer Healthcare &#8211; CHC).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises, for all geographical territories. The segment&#8217;s results include the costs of global support functions that are not within the managerial responsibility of the Opella GBU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Opella operating segment comprises commercial operations relating to consumer healthcare products, and research, development and production activities and global support functions (as listed above) dedicated to the segment, for all geographical territories. The Opella GBU segment&#8217;s results reflect all incurred costs of global support functions attributable to its business.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Other&#8221; category comprises reconciling items, primarily but not limited to (i)&#160;gains and losses on centralized foreign exchange risk hedging transactions that cannot be allocated to the operating segments and (ii)&#160;gains and losses on retained commitments in respect of previously divested operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.20.1. SEGMENT RESULTS</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.20.1.1. Analysis of net sales</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth net sales for the six months ended June 30, 2024 and June 30, 2023:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="6" style="background-color:#d9c6f9;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Biopharma</span></div></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,074</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,294</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">6,010</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">18,378</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,194</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,366</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,907</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">17,467</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Pharma</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,692</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,550</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,817</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">16,059</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,624</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">6,709</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,744</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">15,077</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #deb3ff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Dupixent</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">770</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,437</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">931</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">6,138</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">587</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,682</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">609</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,878</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Pharma launches</span></div></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">249</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">868</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">178</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,295</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">168</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">460</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">87</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">715</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nexviazyme</span></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sarclisa</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ALTUVIIIO</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rezurock</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cablivi</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Xenpozyme</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Enjaymo</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tzield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total other products</span></div></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,673</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,245</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,708</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,626</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,869</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,567</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,048</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,484</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Industrial sales</span></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Vaccines</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">382</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">744</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,193</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,319</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">570</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">657</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,163</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,390</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Influenza Vaccines</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Polio/Pertussis/<br/>Hib Vaccines</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,428&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV vaccines (Beyfortus)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Meningitis, travel and endemics vaccines</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Opella</span></div></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">808</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">773</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,250</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,831</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">840</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">622</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,258</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,720</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Seasonal symptoms &amp; pain relief</span></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,216&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,261&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Wellness brands</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,258&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Others</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total net sales</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,882</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,067</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,260</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,209</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,034</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,988</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,165</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20,187</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.20.1.2. Business operating income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi reports segment results on the basis of &#8220;Business operating income&#8221;, a non-IFRS financial measure used internally by the chief operating decision maker to measure the performance of each operating segment and to allocate resources.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Business operating income&#8221; is derived from</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, adjusted as follows: </span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amounts reported in the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items, Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> relating to business combinations (IFRS 3) or divestments and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">expenses arising from the remeasurement of inventories following a business combination (IFRS 3) are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature) are eliminated; </span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the share of profits/losses from investments accounted for using the equity method is added for joint ventures and associates with which Sanofi has entered into a strategic partnership agreement; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">net income attributable to non-controlling interests is deducted.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Segment results are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.340%"><tr><td style="width:1.0%"></td><td style="width:34.702%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.951%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024 (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Opella</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">18,378</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,831</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,209</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,756)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,077)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,830)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,331)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(92)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,423)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,260)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,002)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,260)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,417)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,393)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,931</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">739</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,656</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;The &#8220;Other&#8221; column reconciles segmental results to the total per the consolidated financial statements.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.403%"><tr><td style="width:1.0%"></td><td style="width:34.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.781%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023 (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Opella</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">17,467</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,720</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20,187</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,388)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(949)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,342)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,082)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(111)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,193)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,248)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(936)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,182)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(897)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(805)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,220</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">850</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">6,059</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The &#8220;Other&#8221; column reconciles segmental results to the total per the consolidated financial statements.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.554%"><tr><td style="width:1.0%"></td><td style="width:34.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Opella</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">37,890</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,180</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">43,070</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,322&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,374&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,282)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,933)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14,216)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,509)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(219)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,728)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,868)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,692)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,387)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,224)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">11,247</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,438</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12,670</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The &#8220;Other&#8221; column reconciles segmental results to the total per the consolidated financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below, presented in compliance with IFRS 8, shows a reconciliation between &#8220;Business operating income&#8221; and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:59.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024 ( 6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023 ( 6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,656</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">6,059</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12,670</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(55)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(122)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net income attributable to non-controlling interests </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization and impairment of intangible assets </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(690)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,050)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,068)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(93)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expense arising from the impact of acquisitions on inventories </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,331)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(547)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,490)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(442)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,044</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,322</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,875</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(586)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(370)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,313)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,739</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,238</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,153</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Joint ventures and associates with which Sanofi has entered into a strategic alliance.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">As of June 30, 2024, this line includes a net reversal of impairment losses amounting to of &#8364;371&#160;million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights in the Biopharma segment. For 2023, this amount mainly comprises an impairment loss of &#8364;833&#160;million, reflecting the impact of the strategic decision to de-prioritize certain R&amp;D programs, in particular those related to the NK Cell and PRO-XTEN technology platforms. </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">See note B.16.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt">See note B.17.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.20.2. OTHER SEGMENT INFORMATION</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The tables below show the split by operating segment of (i)&#160;the carrying amount of investments accounted for using the equity method for which Sanofi has entered into a strategic partnership agreement, (ii)&#160;acquisitions of property, plant and equipment, and (iii)&#160;acquisitions of intangible assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Investments accounted for using the equity method in the Biopharma segment mainly comprise MSP Vaccine Company and Infraserv GmbH &amp; Co. H&#246;chst&#160;KG (see Note B.5.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"><tr><td style="width:1.0%"></td><td style="width:43.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024 (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Opella</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Carrying amount at the end of the reporting period.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"><tr><td style="width:1.0%"></td><td style="width:43.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023 (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Opella</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets </span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Carrying amount at the end of the reporting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"><tr><td style="width:1.0%"></td><td style="width:43.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Opella</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,619&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,305&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Carrying amount at the end of the reporting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.20.3. INFORMATION BY GEOGRAPHICAL REGION</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The geographical information on net sales provided below is based on the geographical location of the customer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.188%"><tr><td style="width:1.0%"></td><td style="width:37.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">of which France</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">United States</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other countries</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,209</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,882</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,082</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,067</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,260</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">property, plant and equipment</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,264&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,611&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,079&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,276&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">goodwill</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50,080&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">other intangible assets</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26,653&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,156&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,726&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:37.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.230%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">of which France</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;United States</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other countries</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20,187</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,034</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,174</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,988</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,165</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">property, plant and equipment</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,804&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,462&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,921&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,364&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,978&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">goodwill</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49,243&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">other intangible assets</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,590&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,961&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,595&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,034&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:37.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.230%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023  (12 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">of which France</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">United States</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other countries</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">43,070</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">10,392</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,379</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">18,512</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">14,166</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">property, plant and equipment</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,160&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,659&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,085&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,322&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">goodwill</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49,404&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">other intangible assets</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,319&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,566&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,850&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As stated in Note D.5. to the consolidated financial statements for the year ended December 31, 2023, goodwill is not allocated by geographical region.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079779212720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events Subsequent to June 30, 2023<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Disclosure of non-adjusting events after reporting period [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Events Subsequent to June 30, 2023</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">C/ EVENTS SUBSEQUENT TO JUNE 30, 2024</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No significant events occurred between the end of the reporting period and the date on which the condensed consolidated financial statements were signed off by the Board of Directors.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079754163600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfIFRSCompliance', window );">International Financial Reporting Standards (IFRS)</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.1. INTERNATIONAL FINANCIAL REPORTING STANDARDS (IFRS)</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS 34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2023. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accounting policies used in the preparation of the consolidated financial statements as of June&#160;30,&#160;2024 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2024 are available via the following web link: </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">https://www.efrag.org/Endorsement</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accounting policies applied effective January 1, 2024 are identical to those presented in the consolidated financial statements for the year ended December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On September&#160;22, 2022, the IASB issued an amendment to IFRS&#160;16 (Leases) relating to lease liabilities in a sale-and-leaseback arrangement, which is applicable from January 1, 2024 and had no impact on Sanofi's financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January&#160;23, 2020, the IASB issued &#8220;Classification of Liabilities as Current or Non-current&#8221;, an amendment to IAS&#160;1, and then on&#160;October&#160;31, 2022 issued &#8220;Non-current Liabilities with Covenants&#8221;, a further amendment to IAS&#160;1. The amendments, which are applicable from January&#160;1, 2024, had no impact on Sanofi's financial statements. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May&#160;25, 2023, the IASB issued "Supplier Finance Arrangements", an amendment to IAS&#160;7 and IFRS&#160;7, applicable from January&#160;1, 2024. The </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">amendment relates to disclosures of information about such arrangements; it had no impact on the 2024 half-year financial statements</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As a reminder, in its 2023 consolidated financial statements Sanofi applied &#8220;International Tax Reform &#8211; Pillar Two Model Rules&#8221;, an amendment to&#160;IAS&#160;12 issued by the IASB on May 23, 2023, and did not recognize any deferred tax on temporary differences related to Pillar 2 rules. </span></div>In its 2024 half-year financial statements, Sanofi has used an average effective tax rate that takes into account the top-up tax applicable from January 1, 2024 (see Note B.19.).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.2. USE OF ESTIMATES</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">impairment of property, plant and equipment and intangible assets;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the valuation of goodwill and the valuation and useful life of acquired intangible assets;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the measurement of contingent consideration receivable in connection with asset divestments and of contingent consideration payable;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the measurement of financial assets and financial liabilities at amortized cost;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of post-employment benefit obligations;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences.</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actual results could differ from these estimates.</span></div>For half-year financial reporting purposes, and as allowed under IAS 34, Sanofi has determined income tax expense on the basis of an estimate of the effective tax rate for the full financial year. That rate is applied to business operating income plus financial income and minus financial expenses, and before (i) the share of profit/loss of investments accounted for using the equity method and (ii) net income attributable to non-controlling interests. The estimated full-year effective tax rate is based on the tax rates that will be applicable to projected pre-tax profits or losses arising in the various tax jurisdictions in which Sanofi operates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock', window );">Seasonal Trends</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.3. SEASONAL TRENDS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s activities are not subject to significant seasonal fluctuations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory', window );">Consolidation and Foreign Currency Translation of the Financial Statements of Subsidiaries in Hyperinflationary Economies</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.4. CONSOLIDATION AND FOREIGN CURRENCY TRANSLATION OF THE FINANCIAL STATEMENTS OF SUBSIDIARIES IN HYPERINFLATIONARY ECONOMIES</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2024, Sanofi continues to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS&#160;10 (Consolidated Financial Statements) are still met.The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since July&#160;1, 2018 treated Argentina as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Turkey, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since January&#160;1, 2022 treated Turkey as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.5. FAIR VALUE OF FINANCIAL INSTRUMENTS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 3: valuation techniques in which not all important inputs are derived from observable market data.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"><tr><td style="width:1.0%"></td><td style="width:3.161%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.885%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:0.85pt;padding-right:0.85pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Type of financial</span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:0.85pt;padding-right:0.85pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%">instrument</span></div></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Measurement</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%">principle</span></div></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in fair value hierarchy</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation technique</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation model</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Volatilities</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial assets measured at fair value (quoted equity instruments)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial assets measured at fair value (quoted debt instruments)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial assets measured at fair value (unquoted equity instruments)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost/ Peer comparison (primarily)</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets at fair value (contingent consideration receivable)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2021.<br/></span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial assets measured at fair value held to meet obligations under post-employment benefit plans</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.<br/>B.12.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial Debt</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized cost </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. </span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).</span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Future lease payments are discounted using the incremental borrowing rate.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid Money Market<br/>&gt;&#160;1 year:&#160;Mid Zero Coupon</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures </span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&gt;&#160;1 year: Mid Zero Coupon</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures </span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&gt;&#160;1 year: Mid Zero Coupon</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.11.</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fair value</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">New Pronouncements Issued by the IASB and Applicable from 2024</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.6. NEW PRONOUNCEMENTS ISSUED BY THE IASB AND APPLICABLE FROM 2025</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On August&#160;15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS&#160;21 </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(The Effects of Changes in Foreign Exchange Rates), relating to</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> how to determine the exchange rate when a currency is not exchangeable. The amendment is applicable from January&#160;1, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (subject to endorsement by the European Union); it</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> will not have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027 (subject to endorsement by the European Union). An impact assessment is currently under way. Sanofi will not early adopt this new standard.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments, applicable no earlier than January 1, 2026 (subject to endorsement by the European Union). Sanofi does not expect any material impact, and will not early adopt these amendments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 18, 2024, the IASB issued Volume 11 of &#8220;Annual Improvements to IFRS&#8221;, applicable from January 1, 2026 (subject to endorsement by the European Union). Sanofi does not expect any material impact from those improvements to various standards, which are essentially in the nature of clarifications, and will not early adopt them.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock', window );">Agreements Relating to the Recombinant COVID-19 Vaccine Candidate Developed by Sanofi in Collaboration with GSK</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 30<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about financial reporting in hyperinflationary economies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 29<br> -IssueDate 2023-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=29&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS29_g39-40_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfIFRSCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An explicit and unreserved statement of compliance with all the requirements of IFRSs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfIFRSCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreements Relating To The Recombinant COVID-19 Vaccine Candidate, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Seasonality Or Cyclicality Of Interim Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079811931840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">Disclosure of Measurement Principles Applied to Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"><tr><td style="width:1.0%"></td><td style="width:3.161%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.885%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:0.85pt;padding-right:0.85pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Type of financial</span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:0.85pt;padding-right:0.85pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%">instrument</span></div></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Measurement</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%">principle</span></div></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in fair value hierarchy</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation technique</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation model</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Volatilities</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial assets measured at fair value (quoted equity instruments)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial assets measured at fair value (quoted debt instruments)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial assets measured at fair value (unquoted equity instruments)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost/ Peer comparison (primarily)</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets at fair value (contingent consideration receivable)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2021.<br/></span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial assets measured at fair value held to meet obligations under post-employment benefit plans</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.<br/>B.12.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial Debt</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized cost </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. </span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).</span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Future lease payments are discounted using the incremental borrowing rate.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid Money Market<br/>&gt;&#160;1 year:&#160;Mid Zero Coupon</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures </span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&gt;&#160;1 year: Mid Zero Coupon</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures </span></div><div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&gt;&#160;1 year: Mid Zero Coupon</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.11.</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fair value</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35K<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079812564544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock', window );">Summary of Acquisitions and Capitalized Interest by Operating Segment</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2024:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:72.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">591</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,693</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biopharma </span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;Of which Manufacturing &amp; Supply</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">366&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Of which Manufacturing &amp; Supply</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:700;line-height:100%">Of which capitalized interest</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:700;line-height:100%">22</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:700;line-height:100%">26</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of acquisitions of property plant and equipment by operating segments explanatory [text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079795284144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract', window );"><strong>Intangible assets and goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock', window );">Schedule of Movements in Other Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in other intangible assets during the first half of 2024 were as follows:<br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:50.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Acquired R&amp;D</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Products, trademarks and other rights</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total other intangible assets</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross value at January&#160;1, 2024</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,772</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">73,733</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,808</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">85,313</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(27)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(83)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,293&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross value at June 30, 2024</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12,298</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">74,969</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,848</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">89,115</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated amortization and impairment at January&#160;1, 2024 </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(3,734)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(55,908)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,352)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(60,994)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,084)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(52)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,136)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(70)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(701)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(775)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated amortization and impairment at June 30, 2024</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(3,768)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(57,291)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,403)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(62,462)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Carrying amount at January&#160;1, 2024</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">6,038</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">17,825</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">456</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">24,319</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Carrying amount at June 30, 2024</span></div></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,530</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">17,678</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">445</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">26,653</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Impact of the acquisition of Inhibrx, Inc (see Note B.1.).</span></div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span>See Note B.4.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of changes in other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079779213504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments Accounted for Using the Equity Method (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestsInOtherEntitiesAbstract', window );"><strong>Interests In Other Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock', window );">Summary of Investments in Associates and Joint Ventures</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2023), and comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:58.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">% interest</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">EUROAPI </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Infraserv GmbH &amp; Co. H&#246;chst KG </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">MSP Vaccine Company </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">315</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">424</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (&#8364;2.55 as of June 30, 2024, and &#8364;5.73 as of December 31, 2023). </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Joint venture. </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Joint venture MSP Vaccine Company owns 100% of MCM Vaccine BV.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Summary of Principal Transactions and Balances with Related Parties</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:58.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Royalties and other income</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable and other receivables</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">213</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">249</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchases of goods and services</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">302</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">642</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable and other payables</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97</span></td><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of investments in associates and joint ventures explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestsInOtherEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interests In Other Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestsInOtherEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079756887744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Non-Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock', window );">Summary of Other Non-Current Assets</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other non-current assets comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:72.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments at fair value through other comprehensive income</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,161&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments at fair value through other comprehensive income</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other financial assets at fair value through profit or loss</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pre-funded pension obligations</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term prepaid expenses </span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables </span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,333</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,218</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of components of other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079753786224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Trade and other receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock', window );">Summary of Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accounts receivable break down as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:72.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross value</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,602&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,528&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Allowances</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(95)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Carrying amount</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,510</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,433</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock', window );">Summary of Gross Value of Overdue Receivables</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the ageing profile of overdue accounts receivable, based on gross value:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:27.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Overdue accounts gross value</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Overdue by &lt;1 month</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Overdue by 1-3 months</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Overdue by 3-6 months</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Overdue by 6-12 months</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Overdue by    &gt; 12 months</span></td></tr><tr><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2024</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of current trade receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfCurrentTradeReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of overdue receivables gross value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079756960752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Summary of Treasury Shares Held</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.8. CONSOLIDATED SHAREHOLDERS&#8217; EQUITY</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.1. SHARE CAPITAL</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2024, the share capital was &#8364;2,532,725,512 and consisted of 1,266,362,756 shares (the total number of shares outstanding) with a par value of &#8364;2.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Treasury shares held by Sanofi are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:64.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Number of shares<br/>(million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">% of share capital<br/>for the period</span></td></tr><tr><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2024</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15.33</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.211</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10.90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.864&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8.20&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.650&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A total of 91,355 shares were issued in the first half of 2024 as a result of the exercise of Sanofi stock subscription options.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2,803,637</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> shares </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">vested under Sanofi restricted share plans during the first half of 2024, of which 1,471,432</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;were fulfilled by issuance of new shares and </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1,332,205</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> by allotment of existing shares free of charge</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock', window );">Summary of Principal Characteristics of Restricted Share Plans</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2023. The principal features of the plans awarded in 2024 are set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:81.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.169%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Type of plan</span></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Performance share plan</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plan</span></td><td colspan="3" style="background-color:#e8eaf6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total number of shares subject to a 3-year service period</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,505,145&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with no market condition</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,888,502&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;81.84&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with market conditions</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,616,643&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded other than to the Chief Executive Officer (1,394,478 shares in total) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;72.79&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fair value per share awarded other than to the Chief Executive Officer (139,665 additional shares) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;13.50&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fair value per share awarded to the Chief Executive Officer (82,500 shares) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;72.38&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value of plan at the date of grant (&#8364; million)</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">346</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) Additional tranche subject to a higher level of market conditions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock', window );">Summary of Number of Restricted Shares Not Yet Fully Vested</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:72.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total expense for restricted share plans (&#8364; million)</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares not yet fully vested</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,192,984&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,127,545&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2024 plans</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4,498,109&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2023 plans</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,652,352&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,837,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2022 plans</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,031,060&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,226,321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2021 plans</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">11,463&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,996,101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2020 plans</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">67,149&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock', window );">Summary of Options Outstanding and Exercisable</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below provides summary information about options outstanding and exercisable as of June&#160;30, 2024:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:31.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.307%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Range of exercise prices per share</span></td><td colspan="9" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr style="height:38pt"><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted average residual life (years)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted average exercise price per share (&#8364;)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted average exercise price per share (&#8364;)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;60.00 to &#8364;70.00 per share</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.84</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;70.00 to &#8364;80.00 per share</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">478,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.18</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76.26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">478,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76.26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;80.00 to &#8364;90.00 per share</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594,724&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.79</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594,724&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,241,658</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,241,658</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock', window );">Summary of Number of Shares Used to Compute Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.554%"><tr><td style="width:1.0%"></td><td style="width:59.113%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,249.4&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,249.9&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,251.7&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustment for stock options with dilutive effect</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustment for restricted shares</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Average number of shares used to compute diluted earnings per share</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,253.8</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,254.5</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,256.4</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock', window );">Summary of Movements within Other Comprehensive Income</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements within other comprehensive income are shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.554%"><tr><td style="width:1.0%"></td><td style="width:56.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.857%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024 (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023 (6 months)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses):</span></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="padding-right:2.1pt;text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Actuarial gains/(losses) excluding investments accounted for using the equity method</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(171)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments included in financial assets and financial liabilities:</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Equity risk hedging instruments designated as fair value hedges</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Items not subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">166</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">85</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(77)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments included in financial assets:</span></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="padding-right:2.1pt;text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash flow hedges and fair value hedges:</span></div></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in currency translation differences:</span></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (c)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,167&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,551)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Currency translation differences (investments accounted for using the equity method) </span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Hedges of net investments in foreign operations </span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Items subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,067</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,058)</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,526)</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes reclassifications to profit or loss: immaterial over all periods.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes reclassifications to profit or loss: immaterial over all periods.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes a reclassification to profit or loss: immaterial in the first half of 2024 , &#8364;(56) million in 2023 and &#8364;(14) million in the first half of 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information of accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of employee stock ownership plan awarded in capital increase reserved explanatory [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of number of restricted share plans Not yet fully vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of share based compensation shares authorized under stock option plans by exercise price range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of shares used to compute diluted earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079780074208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt, Cash and Cash Equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfChangesInFinancialPositionTableTextBlock', window );">Summary of Changes in Financial Position</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in financial position during the period were as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:72.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,503&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,347&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,236&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,045&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,918</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">16,531</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,795)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net debt (a)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">15,112</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,793</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Net debt does not include lease liabilities, which amounted to &#8364;2,012 million as of June 30, 2024 and &#8364;2,030 million as of December 31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock', window );">Summary of Reconciliation of Carrying Amount to Value on Redemption</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2024 is shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:31.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.949%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="6" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Value on redemption</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Carrying amount at</span></div><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Adjustment to debt measured at fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,503&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,688&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,546&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,236&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,254&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,045&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,918</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">35</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,952</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">16,573</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,795)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,795)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net debt (a)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">15,112</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">35</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">15,146</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,835</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Net debt does not include lease liabilities, which amounted to &#8364;2,012 million as of June 30, 2024 and &#8364;2,030 million as of December 31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock', window );">Summary of Net Debt by Type Valuation of Redemption</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows an analysis of net debt by type, at value on redemption:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:35.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.626%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.086%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">non-current</span></td><td colspan="6" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">current</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #661de8;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">non-current</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">current</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,593&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,916&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,509&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbe5f1;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,416&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,134&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,118&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,213&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbe5f1;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbe5f1;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbe5f1;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbe5f1;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12,688</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,264</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,952</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">14,546</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,027</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">16,573</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,795)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,795)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12,688</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,458</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">15,146</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">14,546</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(6,711)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,835</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) As of June 30, 2024, current other bank borrowings includ</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">e &#8364;6,955&#160;million related to the US Commercial Paper program and &#8364;0&#160;million related to the Negotiable European Commercial Paper program in France.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock', window );">Summary of Market Value of Net Debt</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The market value of Sanofi&#8217;s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.644%"><tr><td style="width:1.0%"></td><td style="width:72.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,214&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,086&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Value on redemption</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,146&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,835&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfChangesInFinancialPositionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of changes in financial position [text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfChangesInFinancialPositionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of debt net of cash and cash equivalents by type at value on redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of market value of net debt [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfMarketValueOfNetDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of carrying amount to value on redemption [text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079753822064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock', window );">Summary of Operating Currency Hedging Instruments</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of June&#160;30, 2024. The notional amount is translated into euros at the relevant closing exchange rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:26.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Of which derivatives designated as cash flow hedges</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Of which derivatives not eligible for hedge accounting</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Of which recognized in equity</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,120</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(45)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,120</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(45)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,152&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(17)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,152&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(17)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">608&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">608&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Russian rouble</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">197&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">197&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,195</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,195</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">398&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">398&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Russian rouble</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Turkish lira</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Canadian dollar</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,315</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,315</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The above positions mainly hedge material foreign currency cash flows arising after the end of the reporting period in relation to transactions carried out during the six months ended June&#160;30, 2024 and recognized in the balance sheet at that date. Gains and losses on hedging in</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">struments (forward contracts) are calculated and recognized in parallel with the recognition of gains and losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange difference on those items (hedging instruments and hedged transactions) will be immaterial in the second half of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock', window );">Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows financial currency hedging instruments in place as of June&#160;30, 2024. The notional amount is translated into euros at the relevant closing exchange rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:55.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.307%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Maximum expiry date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,190</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(30)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5,797&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(28)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Canadian dollar</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">190&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,656</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">42</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5,242&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b) (c)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">37&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,768&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Hungarian forint</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">182&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">14,846</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes forward sales with a notional amount of $3,615 million expiring in 2024, designated as a hedge of Sanofi&#8217;s net investment in Bioverativ. As of June&#160;30, 2024, the fair value of these forward contracts represented a liability of &#8364;26 million; the opposite entry was recognized in &#8220;Other comprehensive income&#8221;, with the impact on financial income and expense being immaterial.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)  Includes forward purchases with a notional amount of $1,000 million expiring in 2024, designated as a fair value hedge of the exposure of $1,000 million of bond issues to</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> fluctuations in the EUR/USD spot rate. As of June 30, 2024, the fair value of these contracts represented an asset of &#8364;2 million, with &#8364;0 million&#160;credited to &#8220;Other comprehensive income&#8221; to recognize the hedging cost.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)  Includes forward purchases with a notional amount of $1,080 million expiring in 2024 , designated as a fair value hedge of $1,080 million of commercial paper. As of June 30, 2024, the fair value of these contracts represented an asset of &#8364;16 million, with &#8364;0&#160;million credited to &#8220;Other comprehensive income&#8221; to recognize the hedging cost. .</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock', window );">Disclosure of Instruments</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows instruments of this type in place as of June 30, 2024:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.834%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.255%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Of which designated as fair value hedges</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Of which designated as cash flow hedges</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2028 and beyond</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Of which recognized in equity</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD / receive 1.02%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(53)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(53)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">pay capitalized SOFR USD / receive  1.32%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester / receive 0.69%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester / receive 0.92%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">pay capitalized Ester / receive 3.56%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">997</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">850</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,584</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,431</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(181)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,431</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(181)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial currency hedging instruments with notional amount translated in to euros at closing exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of interest rates hedging instruments with notional amount by expiry date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating currency hedging instruments with notional amount translated in to euros at closing exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079756917152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to Business Combinations and to Non-Controlling Interests (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract', window );"><strong>Disclosure of contingent liabilities in business combination [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock', window );">Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2024 are shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:30.055%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">MSD contingent consideration (European Vaccines business)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shire contingent consideration arising from acquisition of Translate Bio</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Contingent consideration arising from acquisition of Amunix</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"> (a)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at January 1, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">127</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">441</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">137</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">709</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(71)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(71)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at June 30, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">61</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">526</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">140</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">728</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Of which:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt;text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt;text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt;text-align:right"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;padding-left:33.44pt">Current portion</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">201</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;padding-left:33.44pt">Non-current portion</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">527</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">As of January 1, 2024, this comprised a non-current portion of &#8364;501 million and a current portion of &#8364;208 million.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Amounts mainly reported within the income statement line item &#8220;Fair value remeasurement of contingent consideration&#8221;.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of changes in liabilities related to business combinations and to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079779223872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Current Provisions And Other Non-Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock', window );">Summary of Non-Current Provisions and Other Non-Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current provisions and other non-current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> comprises the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:59.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,918&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,018&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,262&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other non-current liabilities&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,340&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,219</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,088</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,602</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Includes &#8364;1,970 million at June 30, 2024 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States. Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#8364;1,147&#160;million; the nominal value of payments estimated to be due after more than five years is &#8364;2,679 million.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNonCurrentProvisionsTableTextBlock', window );">Summary of Movements in Non-Current Provisions</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows movements in provisions:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:38.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.450%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.450%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Provisions for pensions &amp; other post-employment benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Provisions for other long-term benefits</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Restructuring provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at January&#160;1, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,214</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">718</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">554</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,776</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,262</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increases in provisions and other liabilities</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(78)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(65)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(76)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(230)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reversals of unutilized provisions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(63)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(53)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(119)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(173)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(122)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest related to employee benefits, and unwinding of discount</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains and losses on defined-benefit plans (B.12.1.)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(235)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(235)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at June 30, 2024</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,040</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">759</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">909</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,210</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,918</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the case of &#8220;Provisions for pensions and other post-employment benefits&#8221;, the &#8220;Increases in provisions&#8221; line corresponds to rights vesting in employees during the period, and past service cost; the &#8220;Provisions utilized&#8221; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#8220;Reversals of unutilized provisions&#8221; line corresponds to plan curtailments, settlements and amendments.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Mainly transfers to the line &#8220;Current provisions and other current liabilities&#8221;.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock', window );">Disclosure of Remeasurement of Net Defined Benefit Liability Asset</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:54.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.973%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024 (6 months)</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) on plan assets</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(208)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) on benefit obligations</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes the effects of (i) the change in discount rates (in a range between +0.40% and +0.65%) and (ii) the change in the inflation rate in the United Kingdom (+0.10%) in the first half of 2024.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes the effects of (i) the change in discount rates (in a range between -0.15% and +0.40%) and (ii) the change in the inflation rate in the eurozone (-0.10%) in the first half of 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfNonCurrentProvisionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of noncurrent provisions explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfNonCurrentProvisionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Provisions And Other Non Current Liabilities Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Remeasurement Of Net Defined Benefit Liability Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079780896144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Operating Income And Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherOperatingExpensesTableTextBlock', window );">Schedule of Other Operating Expenses</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">for the first half of 2024 included &#8364;1,841 million of expenses related to Regeneron (compared with &#8364;1,423 million in the first half of 2023), as shown in the table below.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:59.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(12 months)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income &amp; expense related to profit/loss sharing under the Monoclonal Antibody Alliance</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,934)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,449)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,321)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional share of profit paid by Regeneron towards development costs</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reimbursement to Regeneron of selling expenses incurred</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(543)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total: Monoclonal Antibody Alliance</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,837)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,418)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(3,196)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other (mainly Zaltrap and Libtayo)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">92</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">97</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">217</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other operating income/(expenses), net related to Regeneron </span></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,745)</span></td><td style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,321)</span></td><td style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,979)</span></td><td style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">of which amount presented in &#8220;Other operating income&#8221; </span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">96</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">102</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">227</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherOperatingExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Operating Expenses [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherOperatingExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079780951024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Costs and Similar Items (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock', window );">Summary of Restructuring Costs and Similar Items</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:59.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(12 months)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee-related expenses</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Charges, gains or losses on assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Costs of transformation programs</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other restructuring costs</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,331</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">547</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,490</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of restructuring costs details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfRestructuringCostsDetailsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079779024528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Expenses and Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock', window );">Summary of Analysis of Financial Income and Expenses</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of financial expenses and income is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:59.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(12 months)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of debt </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(232)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(555)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Cost of net debt</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(66)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">25</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(22)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-operating foreign exchange gains/(losses)</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unwinding of discounting of provisions </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(59)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost related to employee benefits</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(41)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(73)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains/(losses) on disposals of financial assets</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (d)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net financial income/(expenses)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(305)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(84)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(722)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">comprising: Financial expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(586)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(370)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,313)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income</span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">281</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">286</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">591</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: &#8364;(24) million in the first half of 2024, &#8364;(25) million in the first half of 2023, and &#8364;(67) million over the whole of 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: &#8364;(18) million in the first half of 2024, &#8364;(4)&#160;million in the first half of 2023, and &#8364;(13) million over the whole of 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes a financial expense of &#8364;176</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">million for the six months ended June 30, 2024 (&#8364;541 million for the year ended December 31, 2023, &#8364;35 million for the six months ended June 30, 2023) for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the US.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial income and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079753825440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Income taxes paid (refund) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock', window );">Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the allocation of income tax expense between current and deferred taxes:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:59.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(12 months)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current taxes</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,243)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,171)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,560)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(463)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(730)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,602)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,739</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,238</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,153</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock', window );">Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:59.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(as a percentage)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(12 months)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Standard tax rate applicable in France</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Difference between the standard French tax rate and the rates applicable to Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (b)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Probable reversal of temporary differences on investments in Opella subsidiaries </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revisions to tax exposures and settlements of tax disputes</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration liabilities</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (d)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">16.9</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">17.3</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">22.4</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">In accordance with IAS12, a deferred tax liability was recognised in 2023 on the temporary differences arising on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Opella business, as announced in October 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">For the six months ended June 30, 2024, this line includes a tax expense of &#8364;52 million, representing the estimated impact of Pillar 2 based on Sanofi&#8217;s current understanding of Pillar Two rules.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of allocation of income tax between current and deferred taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of average effective tax rate and applicable tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079780721168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock', window );">Summary of Net Sales by Segment and Geographical Area</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth net sales for the six months ended June 30, 2024 and June 30, 2023:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="6" style="background-color:#d9c6f9;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Biopharma</span></div></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,074</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,294</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">6,010</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">18,378</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,194</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,366</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,907</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">17,467</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Pharma</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,692</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,550</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,817</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">16,059</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,624</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">6,709</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,744</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">15,077</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #deb3ff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Dupixent</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">770</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,437</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">931</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">6,138</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">587</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,682</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">609</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,878</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Pharma launches</span></div></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">249</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">868</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">178</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,295</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">168</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">460</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">87</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">715</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nexviazyme</span></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sarclisa</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ALTUVIIIO</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rezurock</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cablivi</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Xenpozyme</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Enjaymo</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tzield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total other products</span></div></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,673</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,245</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,708</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,626</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,869</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,567</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,048</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,484</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Industrial sales</span></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Vaccines</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">382</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">744</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,193</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,319</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">570</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">657</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,163</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,390</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Influenza Vaccines</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Polio/Pertussis/<br/>Hib Vaccines</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,428&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV vaccines (Beyfortus)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Meningitis, travel and endemics vaccines</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Opella</span></div></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">808</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">773</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,250</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,831</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">840</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">622</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,258</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,720</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Seasonal symptoms &amp; pain relief</span></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,216&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,261&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Wellness brands</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,258&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Others</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total net sales</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,882</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,067</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,260</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,209</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,034</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,988</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,165</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20,187</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Schedule of Segment Results</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Segment results are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.340%"><tr><td style="width:1.0%"></td><td style="width:34.702%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.951%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024 (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Opella</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">18,378</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,831</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,209</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,756)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,077)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,830)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,331)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(92)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,423)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,260)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,002)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,260)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,417)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,393)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,931</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">739</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,656</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;The &#8220;Other&#8221; column reconciles segmental results to the total per the consolidated financial statements.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.403%"><tr><td style="width:1.0%"></td><td style="width:34.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.781%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023 (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Opella</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">17,467</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,720</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20,187</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,388)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(949)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,342)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,082)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(111)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,193)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,248)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(936)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,182)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(897)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(805)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,220</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">850</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">6,059</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The &#8220;Other&#8221; column reconciles segmental results to the total per the consolidated financial statements.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.554%"><tr><td style="width:1.0%"></td><td style="width:34.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Opella</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">37,890</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,180</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">43,070</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,322&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,374&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,282)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,933)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14,216)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,509)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(219)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,728)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,868)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,692)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,387)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,224)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">11,247</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,438</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12,670</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The &#8220;Other&#8221; column reconciles segmental results to the total per the consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock', window );">Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below, presented in compliance with IFRS 8, shows a reconciliation between &#8220;Business operating income&#8221; and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:59.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024 ( 6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023 ( 6 months)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,656</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">6,059</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12,670</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(55)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(122)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net income attributable to non-controlling interests </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization and impairment of intangible assets </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(690)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,050)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,068)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(93)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expense arising from the impact of acquisitions on inventories </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,331)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(547)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,490)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(442)</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,044</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,322</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,875</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(586)</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(370)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,313)</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</span></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,739</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,238</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,153</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Joint ventures and associates with which Sanofi has entered into a strategic alliance.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">As of June 30, 2024, this line includes a net reversal of impairment losses amounting to of &#8364;371&#160;million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights in the Biopharma segment. For 2023, this amount mainly comprises an impairment loss of &#8364;833&#160;million, reflecting the impact of the strategic decision to de-prioritize certain R&amp;D programs, in particular those related to the NK Cell and PRO-XTEN technology platforms. </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">See note B.16.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt">See note B.17.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock', window );">Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"><tr><td style="width:1.0%"></td><td style="width:43.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024 (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Opella</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Carrying amount at the end of the reporting period.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"><tr><td style="width:1.0%"></td><td style="width:43.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023 (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Opella</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets </span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Carrying amount at the end of the reporting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"><tr><td style="width:1.0%"></td><td style="width:43.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023 (12 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Opella</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,619&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,305&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory', window );">Summary of Geographical Information on Net Sales and Non-Current Assets</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.188%"><tr><td style="width:1.0%"></td><td style="width:37.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2024  (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">of which France</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">United States</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other countries</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,209</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,882</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,082</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,067</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,260</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">property, plant and equipment</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,264&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,611&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,079&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,276&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">goodwill</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50,080&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">other intangible assets</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26,653&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,156&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,726&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:37.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.230%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2023  (6 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">of which France</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;United States</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other countries</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20,187</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,034</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,174</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,988</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">7,165</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">property, plant and equipment</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,804&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,462&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,921&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,364&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,978&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">goodwill</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49,243&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">other intangible assets</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,590&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,961&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,595&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,034&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:37.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.230%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2023  (12 months)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">of which France</span></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">United States</span></div></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other countries</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">43,070</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">10,392</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,379</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">18,512</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">14,166</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">property, plant and equipment</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,160&#160;</span></td><td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,659&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,085&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,322&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">goodwill</span></div></td><td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49,404&#160;</span></td><td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt">other intangible assets</span></div></td><td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,319&#160;</span></td><td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,566&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,850&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of geographical information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of acquisitions of property plant and equipment and other intangible assets and carrying amount of investments in associates and joint ventures by operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of net sales by segment and geographical area.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments reconciling items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079757084880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">&#8364; 1,289<span></span>
</td>
<td class="nump">&#8364; 1,358<span></span>
</td>
<td class="nump">&#8364; 3,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_AR', window );">Argentina</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears', window );">Cumulative consumer price inflation rate</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_TR', window );">Turkey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears', window );">Cumulative consumer price inflation rate</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative Consumer Price Inflation Rate Over The Last Three Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_AR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_AR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_TR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_TR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079752371904">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Principal Changes in Scope of Consolidation (Details)<br> $ / shares in Units, &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Net cash flow on acquisition | &#8364;</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 1,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,465<span></span>
</td>
<td class="nump">&#8364; 3,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfAcquiree', window );">Name of acquiree</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Inhibrx, Inc<span></span>
</td>
<td class="text">Inhibrx, Inc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AssetsAcquisitionAxis=sny_AssetsAcquisitionMember', window );">Assets Acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Identifiable intangible assets recognised as of acquisition date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Net cash flow on acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AssetsAcquisitionNominalValue', window );">Assets Acquisition Nominal Value | &#8364;</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AssetsAcquisitionPurchasePricePerShare', window );">Assets Acquisition, Purchase Price Per Share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">For the six months ended June 30, 2024, this line item includes the net cash outflow arising from the acquisition of Inhibrx, Inc. (see Note B.1.1.). For the six months ended June 30, 2023, this line includes the net cash outflow arising from the acquisition of Provention Bio Inc. For the year ended December 31, 2023, it includes the net cash outflow arising from the acquisitions of Provention Bio Inc and QRIB.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NameOfAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The name of the business or businesses that the acquirer obtains control of in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NameOfAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AssetsAcquisitionNominalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets Acquisition Nominal Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AssetsAcquisitionNominalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AssetsAcquisitionPurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets Acquisition, Purchase Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AssetsAcquisitionPurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AssetsAcquisitionAxis=sny_AssetsAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AssetsAcquisitionAxis=sny_AssetsAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079756063152">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Amendments to Principal Agreements (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfPrincipalAgreementsLineItems', window );"><strong>Disclosure Of Principal Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 2,301<span></span>
</td>
<td class="nump">&#8364; 2,340<span></span>
</td>
<td class="nump">&#8364; 2,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_OtherIntangibleAssetsExcludingSoftwareMember', window );">Other intangible assets excluding software</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfPrincipalAgreementsLineItems', window );"><strong>Disclosure Of Principal Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration Agreement | Swedish Orphan Biovitrum AB</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfPrincipalAgreementsLineItems', window );"><strong>Disclosure Of Principal Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 1,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">a) Includes &#8364;1,970 million at June 30, 2024 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States. Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#8364;1,147&#160;million; the nominal value of payments estimated to be due after more than five years is &#8364;2,679 million</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfPrincipalAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Principal Agreements [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfPrincipalAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_OtherIntangibleAssetsExcludingSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_OtherIntangibleAssetsExcludingSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_SwedishOrphanBiovitrumABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_SwedishOrphanBiovitrumABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079753970176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions other than through business combinations, property, plant and equipment</a></td>
<td class="nump">&#8364; 591<span></span>
</td>
<td class="nump">&#8364; 1,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestCostsCapitalised', window );">Interest costs capitalised</a></td>
<td class="nump">&#8364; 22<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions other than through business combinations, property, plant and equipment</a></td>
<td class="nump">&#8364; 535<span></span>
</td>
<td class="nump">1,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent | Manufacturing &amp; Supply</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions other than through business combinations, property, plant and equipment</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">1,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember', window );">Opella | Manufacturing &amp; Supply</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions other than through business combinations, property, plant and equipment</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_OpellaMember', window );">Opella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions other than through business combinations, property, plant and equipment</a></td>
<td class="nump">&#8364; 56<span></span>
</td>
<td class="nump">&#8364; 101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestCostsCapitalised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestCostsCapitalised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_ManufacturingAndSupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_ManufacturingAndSupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_OpellaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_OpellaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079779241824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Additional Information (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FirmOrdersOfPropertyPlantAndEquipment', window );">Firm orders of property, plant and equipment</a></td>
<td class="nump">&#8364; 659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FirmOrdersOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Firm orders of property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FirmOrdersOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079755780304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 10, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 50,080<span></span>
</td>
<td class="nump">&#8364; 49,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,653<span></span>
</td>
<td class="nump">24,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_OtherIntangibleAssetsExcludingSoftwareMember', window );">Other intangible assets excluding software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_OtherIntangibleAssetsExcludingSoftwareMember', window );">Other intangible assets excluding software | Vaccines Co-exclusive licensing agreement | Novavax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="nump">&#8364; 463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsMember', window );">Marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16,300<span></span>
</td>
<td class="nump">16,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Weighted average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_TechnologicalPlatformsMember', window );">Technological platforms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,400<span></span>
</td>
<td class="nump">&#8364; 1,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Weighted average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_OtherIntangibleAssetsExcludingSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_OtherIntangibleAssetsExcludingSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PrincipalAlliancesAxis=sny_VaccinesCoExclusiveLicensingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PrincipalAlliancesAxis=sny_VaccinesCoExclusiveLicensingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_NovavaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_NovavaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_TechnologicalPlatformsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_TechnologicalPlatformsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079754912816">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Schedule of Movements in Other Intangible Assets (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (1,061)<span></span>
</td>
<td class="num">&#8364; (1,035)<span></span>
</td>
<td class="num">&#8364; (2,172)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,319<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and retirements, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(83)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through transfers, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">89,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,313<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets', window );">Change In Scope Of Consolidation Through Business Combination, Intangible Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization and impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and retirements, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(775)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through transfers, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill', window );">Impairment losses, net of reversals</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(366)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(62,462)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,994)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredResearchAndDevelopmentMember', window );">Acquired R&amp;D</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,038<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredResearchAndDevelopmentMember', window );">Acquired R&amp;D | Gross value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and retirements, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through transfers, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,772<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets', window );">Change In Scope Of Consolidation Through Business Combination, Intangible Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredResearchAndDevelopmentMember', window );">Acquired R&amp;D | Accumulated amortization and impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and retirements, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through transfers, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill', window );">Impairment losses, net of reversals</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,768)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,734)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ProductsTrademarksAndOtherRightsMember', window );">Products, trademarks and other rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,825<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ProductsTrademarksAndOtherRightsMember', window );">Products, trademarks and other rights | Gross value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and retirements, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through transfers, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">74,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,733<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets', window );">Change In Scope Of Consolidation Through Business Combination, Intangible Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ProductsTrademarksAndOtherRightsMember', window );">Products, trademarks and other rights | Accumulated amortization and impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and retirements, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(701)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through transfers, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill', window );">Impairment losses, net of reversals</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(379)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(57,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,908)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">456<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software | Gross value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and retirements, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through transfers, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,808<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets', window );">Change In Scope Of Consolidation Through Business Combination, Intangible Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software | Accumulated amortization and impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and retirements, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through transfers, intangible assets other than goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill', window );">Impairment losses, net of reversals</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (1,403)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (1,352)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Impact of the acquisition of Inhibrx, Inc (see Note B.1.).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">See Note B.4</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in intangible assets other than goodwill resulting from disposals and retirements. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in other comprehensive income for intangible assets other than goodwill. [Refer: Impairment loss recognised in other comprehensive income; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 119<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_119&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Scope Of Consolidation Through Business Combination, Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ProductsTrademarksAndOtherRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ProductsTrademarksAndOtherRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079780021552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of Intangible Assets (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment loss on other intangible assets</a></td>
<td class="num">&#8364; (371)<span></span>
</td>
<td class="nump">&#8364; 15<span></span>
</td>
<td class="nump">&#8364; 896<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079754775696">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Investments Accounted for Using the Equity Method - Summary of Investments in Associates and Joint Ventures (Details) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 315<span></span>
</td>
<td class="nump">&#8364; 424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubordinatedLiabilities', window );">Subordinated liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember', window );">EUROAPI</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Proportion of ownership interest in associate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">29.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod', window );">Investments in associates</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 72<span></span>
</td>
<td class="nump">&#8364; 162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sny_EuroapiMember', window );">EUROAPI</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_StockPrice', window );">Stock price (in euro per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 2.55<span></span>
</td>
<td class="nump">&#8364; 5.73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sny_MSPVaccineCompanyMember', window );">MSP Vaccine Company | MCM Vaccine BV</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=sny_InfraservGmbhAndCoHochstKGMember', window );">Infraserv GmbH &amp; Co. H&#246;chst KG</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointVenture', window );">Proportion of ownership interest in joint venture</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">31.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod', window );">Investments in joint ventures</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">&#8364; 89<span></span>
</td>
<td class="nump">&#8364; 90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=sny_MSPVaccineCompanyMember', window );">MSP Vaccine Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointVenture', window );">Proportion of ownership interest in joint venture</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod', window );">Investments in joint ventures</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">&#8364; 90<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember', window );">Other investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointVenture', window );">Proportion of ownership interest in joint venture</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod', window );">Investments in joint ventures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 64<span></span>
</td>
<td class="nump">&#8364; 76<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (&#8364;2.55 as of June 30, 2024, and &#8364;5.73 as of December 31, 2023). </span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Joint venture. </span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Joint venture MSP Vaccine Company owns 100% of MCM Vaccine BV</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in joint ventures accounted for using the equity method. [Refer: Joint ventures [member]; Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a joint venture attributable to the entity. [Refer: Joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubordinatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are subordinate to other liabilities with respect to claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubordinatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_StockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_StockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sny_EuroapiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sny_EuroapiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sny_MSPVaccineCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sny_MSPVaccineCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_MCMVaccineBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_MCMVaccineBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=sny_InfraservGmbhAndCoHochstKGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=sny_InfraservGmbhAndCoHochstKGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=sny_MSPVaccineCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=sny_MSPVaccineCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079755960848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments Accounted for Using the Equity Method - Summary of Principal Transactions and Balances with Related Parties (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubordinatedLiabilities', window );">Subordinated liabilities</a></td>
<td class="nump">&#8364; 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember', window );">Associates and joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions', window );">Sales</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">&#8364; 64<span></span>
</td>
<td class="nump">&#8364; 157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions', window );">Royalties and other income</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Accounts receivable and other receivables</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions', window );">Purchases of goods and services</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="nump">642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Accounts payable and other payables</a></td>
<td class="nump">&#8364; 63<span></span>
</td>
<td class="nump">&#8364; 97<span></span>
</td>
<td class="nump">&#8364; 71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsPayableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts payable resulting from related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsPayableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsReceivableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts receivable resulting from related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsReceivableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goods purchased by the entity in related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchasesOfGoodsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods in related party transactions. [Refer: Revenue; Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubordinatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are subordinate to other liabilities with respect to claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubordinatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties and other income, related party transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079751786320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Non-Current Assets (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss', window );">Other financial assets at fair value through profit or loss</a></td>
<td class="nump">&#8364; 817<span></span>
</td>
<td class="nump">&#8364; 808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PreFundedPensionObligations', window );">Pre-funded pension obligations</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LongTermPrepaidExpenses', window );">Long-term prepaid expenses</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLoansAndReceivables', window );">Long-term loans and advances and other non-current receivables</a></td>
<td class="nump">587<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Total</a></td>
<td class="nump">3,333<span></span>
</td>
<td class="nump">3,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradingEquitySecuritiesMember', window );">Trading equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome', window );">Instruments at fair value through other comprehensive income</a></td>
<td class="nump">1,161<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome', window );">Instruments at fair value through other comprehensive income</a></td>
<td class="nump">&#8364; 347<span></span>
</td>
<td class="nump">&#8364; 346<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets at fair value through other comprehensive income. [Refer: Financial assets at fair value through other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLoansAndReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current loans and receivables. [Refer: Loans and receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_8_c&amp;doctype=Standard&amp;book=b<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLoansAndReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other non-current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOtherNonCurrentAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LongTermPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LongTermPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Assets At Fair Value Through Profit Or Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PreFundedPensionObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-funded pension obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PreFundedPensionObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradingEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradingEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079751246224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable - Summary of Accounts Receivable (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAccountsReceivableLineItems', window );"><strong>Disclosure of Accounts Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Accounts receivable</a></td>
<td class="nump">&#8364; 8,510<span></span>
</td>
<td class="nump">&#8364; 8,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAccountsReceivableLineItems', window );"><strong>Disclosure of Accounts Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Accounts receivable</a></td>
<td class="nump">8,602<span></span>
</td>
<td class="nump">8,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AllowanceForCreditLossesMember', window );">Allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAccountsReceivableLineItems', window );"><strong>Disclosure of Accounts Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Accounts receivable</a></td>
<td class="nump">&#8364; 92<span></span>
</td>
<td class="nump">&#8364; 95<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAccountsReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Accounts Receivable [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAccountsReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AllowanceForCreditLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AllowanceForCreditLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079753823648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Trade and other receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables</a></td>
<td class="nump">&#8364; 3<span></span>
</td>
<td class="nump">&#8364; 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerecognizedReceivables', window );">Derecognized receivables</a></td>
<td class="nump">&#8364; 503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 761<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss or reversal of impairment loss recognised in profit or loss for trade receivables. [Refer: Impairment loss recognised in profit or loss; Reversal of impairment loss recognised in profit or loss; Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DerecognizedReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derecognized receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DerecognizedReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079757026384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable - Summary of Gross Value of Overdue Receivables (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">&#8364; 646<span></span>
</td>
<td class="nump">&#8364; 689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Overdue by less than 1 month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Overdue by 1-3 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember', window );">Overdue by 3-6 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember', window );">Overdue by 6-12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember', window );">Overdue by &gt; 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">&#8364; 71<span></span>
</td>
<td class="nump">&#8364; 81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OverdueReceivablesGrossValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Overdue receivables gross value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OverdueReceivablesGrossValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079750845696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Shareholders' Equity - Additional Information (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>May 25, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 24, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jun. 23, 2023</div></th>
<th class="th"><div>Feb. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,532,725,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,266,362,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease', window );">Number of restricted shares vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,803,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease', window );">Number of restricted shares alloted in regards of capital increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,332,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income that will be reclassified to profit or loss, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,067,000,000<span></span>
</td>
<td class="num">&#8364; (1,058,000,000)<span></span>
</td>
<td class="num">&#8364; (1,526,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_EmployeeShareOwnershipPlanMember', window );">Employees share ownership plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_SubscriptionPricePerShare', window );">Subscription price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 72.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 79.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesSubscribed', window );">Number of shares subscribed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,124,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,009,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IssuanceOfFurtherSharesAsAnEmployersContribution', window );">Number of shares issued immediately for employer's contribution (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 45,000,000<span></span>
</td>
<td class="nump">52,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareProgramAxis=sny_ShareRepurchase2023ProgramMember', window );">Share Repurchase 2023 program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PeriodOfShareRepurchaseProgram', window );">Period of share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesRepurchased', window );">Number of shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,215,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AmountOfSharesRepurchased', window );">Amount of shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 302,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareProgramAxis=sny_ShareRepurchase2024ProgramMember', window );">Share Repurchase 2024 Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PeriodOfShareRepurchaseProgram', window );">Period of share repurchase program</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions', window );">Capital&#160;increase&#160;by&#160;exercise&#160;of stock subscription options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease', window );">Capital increase by issuance of restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,471,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Other comprehensive income | Items subsequently reclassifiable to profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income that will be reclassified to profit or loss, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,067,000,000<span></span>
</td>
<td class="num">(1,058,000,000)<span></span>
</td>
<td class="num">(1,526,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Other comprehensive income | Foreign Currency Translation | Items subsequently reclassifiable to profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income that will be reclassified to profit or loss, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (14,000,000)<span></span>
</td>
<td class="num">&#8364; (56,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AmountOfSharesRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AmountOfSharesRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IssuanceOfFurtherSharesAsAnEmployersContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Further shares as an employers contribution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IssuanceOfFurtherSharesAsAnEmployersContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of restricted shares alloted in regards of capital increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of restricted shares issued in regards of capital increase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Restricted Shares Vested In Regards Of Capital Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in regards of capital increase by exercise of stock subscription options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfSharesRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfSharesRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfSharesSubscribed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares subscribed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfSharesSubscribed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PeriodOfShareRepurchaseProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of share repurchase program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PeriodOfShareRepurchaseProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_SubscriptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subscription price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_SubscriptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_EmployeeShareOwnershipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_EmployeeShareOwnershipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareProgramAxis=sny_ShareRepurchase2023ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareProgramAxis=sny_ShareRepurchase2023ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareProgramAxis=sny_ShareRepurchase2024ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareProgramAxis=sny_ShareRepurchase2024ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sny_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sny_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassifiedItemsAxis=sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassifiedItemsAxis=sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=sny_ForeignCurrencyTranslationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=sny_ForeignCurrencyTranslationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079779537920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Shareholders' Equity - Summary of Treasury Shares Held (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesHeld', window );">Number of shares (in shares)</a></td>
<td class="nump">15,330<span></span>
</td>
<td class="nump">13,450<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
<td class="nump">8,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfShareCapitalForThePeriod', window );">% of share capital for the period</a></td>
<td class="nump">1.211%<span></span>
</td>
<td class="nump">1.063%<span></span>
</td>
<td class="nump">0.864%<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfSharesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfSharesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfShareCapitalForThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of share capital for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfShareCapitalForThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079755780944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Shareholders' Equity - Summary of Principal Characteristics of Restricted Share Plans (Details)<br> &#8364; / shares in Units, &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024Member', window );">Restricted Share Plan 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of shares awarded (in shares)</a></td>
<td class="nump">4,505,145<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValueOfPlanAtDateOfGrant', window );">Fair value of plan at the date of grant | &#8364;</a></td>
<td class="nump">&#8364; 346<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfYearsServicePeriod', window );">Service period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024Member', window );">Restricted Share Plan 2024 | Without market condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of shares awarded (in shares)</a></td>
<td class="nump">2,888,502<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 81.84<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024Member', window );">Restricted Share Plan 2024 | With market condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of shares awarded (in shares)</a></td>
<td class="nump">1,616,643<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024Member', window );">Restricted Share Plan 2024 | With market condition | Excluding General Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of shares awarded (in shares)</a></td>
<td class="nump">1,394,478<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 72.79<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024Member', window );">Restricted Share Plan 2024 | With market condition | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of shares awarded (in shares)</a></td>
<td class="nump">82,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 72.38<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024AdditionalSharesMember', window );">Restricted Share Plan 2024, Additional Shares | With market condition | Excluding General Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of shares awarded (in shares)</a></td>
<td class="nump">139,665<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 13.50<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">(c) Additional tranche subject to a higher level of market conditions</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FairValueOfPlanAtDateOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of plan at the date of grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FairValueOfPlanAtDateOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value per share awarded to a three year service period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FairValuePerShareAwardedForThreeYearServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfYearsServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Years, Service Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfYearsServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MarketConditionAxis=sny_WithoutMarketConditionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MarketConditionAxis=sny_WithoutMarketConditionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MarketConditionAxis=sny_WithMarketConditionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MarketConditionAxis=sny_WithMarketConditionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=sny_ExcludingChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=sny_ExcludingChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024AdditionalSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024AdditionalSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079757087120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Shareholders' Equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharesMember', window );">Restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Total expense for restricted share plans</a></td>
<td class="nump">&#8364; 128<span></span>
</td>
<td class="nump">&#8364; 108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="nump">11,192,984<span></span>
</td>
<td class="nump">10,127,545<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member', window );">Restricted share plan 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="nump">3,652,352<span></span>
</td>
<td class="nump">3,837,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member', window );">Restricted share plan 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="nump">3,031,060<span></span>
</td>
<td class="nump">3,226,321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2021Member', window );">Restricted share plan 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="nump">11,463<span></span>
</td>
<td class="nump">2,996,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2020Member', window );">Restricted share plan 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">67,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024Member', window );">Restricted Share Plan 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="nump">4,498,109<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfRestrictedSharesNotYetFullyVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of restricted shares not yet fully vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfRestrictedSharesNotYetFullyVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079756360896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Shareholders' Equity - Summary of Options Outstanding and Exercisable (Details) - Stock Option Plan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, number&#160;of options (in shares) | shares</a></td>
<td class="nump">1,241,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Exercisable, number of options (in shares) | shares</a></td>
<td class="nump">1,241,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeTwoMember', window );">From &#8364;60.00 to &#8364;70.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, number&#160;of options (in shares) | shares</a></td>
<td class="nump">168,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average residual life (years)</a></td>
<td class="text">3 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)</a></td>
<td class="nump">&#8364; 65.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Exercisable, number of options (in shares) | shares</a></td>
<td class="nump">168,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise&#160;price per share, options exercisable (in euros per share)</a></td>
<td class="nump">&#8364; 65.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeThreeMember', window );">From &#8364;70.00 to &#8364;80.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, number&#160;of options (in shares) | shares</a></td>
<td class="nump">478,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average residual life (years)</a></td>
<td class="text">3 years 2 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)</a></td>
<td class="nump">&#8364; 76.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Exercisable, number of options (in shares) | shares</a></td>
<td class="nump">478,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise&#160;price per share, options exercisable (in euros per share)</a></td>
<td class="nump">&#8364; 76.26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeFourMember', window );">From &#8364;80.00 to &#8364;90.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, number&#160;of options (in shares) | shares</a></td>
<td class="nump">594,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average residual life (years)</a></td>
<td class="text">1 year 9 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)</a></td>
<td class="nump">&#8364; 89.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Exercisable, number of options (in shares) | shares</a></td>
<td class="nump">594,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise&#160;price per share, options exercisable (in euros per share)</a></td>
<td class="nump">&#8364; 89.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range | From &#8364;60.00 to &#8364;70.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">60.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range | From &#8364;70.00 to &#8364;80.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">70.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range | From &#8364;80.00 to &#8364;90.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">80.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range | From &#8364;60.00 to &#8364;70.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">70.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range | From &#8364;70.00 to &#8364;80.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">80.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range | From &#8364;80.00 to &#8364;90.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">&#8364; 90.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sny_StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sny_StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079813077760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Shareholders' Equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Average number of shares outstanding (in shares)</a></td>
<td class="nump">1,249.4<span></span>
</td>
<td class="nump">1,249.9<span></span>
</td>
<td class="nump">1,251.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares', window );">Adjustment for stock options with dilutive effect (in shares)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares', window );">Adjustment for restricted shares (in shares)</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Average number of shares used to compute diluted earnings per share (in shares)</a></td>
<td class="nump">1,253.8<span></span>
</td>
<td class="nump">1,254.5<span></span>
</td>
<td class="nump">1,256.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed exercise of the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dilutive effect of share options on number of restricted shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079750546528">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Shareholders' Equity - Summary of Movements within Other Comprehensive Income (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Items not subsequently reclassifiable to profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 166<span></span>
</td>
<td class="nump">&#8364; 85<span></span>
</td>
<td class="num">&#8364; (77)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,067<span></span>
</td>
<td class="num">(1,058)<span></span>
</td>
<td class="num">(1,526)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items not subsequently reclassifiable to profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures', window );">Actuarial gains/(losses) excluding investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">235<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures', window );">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments', window );">Tax effects</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Items not subsequently reclassifiable to profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">166<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items not subsequently reclassifiable to profit or loss | Equity instruments included in financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures', window );">Change in fair value (excluding investments accounted for using the equity method)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax', window );">Change in fair value (investments accounted for using the equity method, net of taxes)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges', window );">Equity risk hedging instruments designated as fair value hedges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod', window );">Tax effects</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures', window );">Change in fair value (excluding investments accounted for using the equity method)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures', window );">Change in fair value (investments accounted for using the equity method, net of taxes)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome', window );">Tax effects</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures', window );">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,167<span></span>
</td>
<td class="num">(1,089)<span></span>
</td>
<td class="num">(1,551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures', window );">Currency translation differences (investments accounted for using the equity method)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations', window );">Hedges of net investments in foreign operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(126)<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInCurrencyTranslationOnTaxEffects', window );">Tax effects</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,067<span></span>
</td>
<td class="num">(1,058)<span></span>
</td>
<td class="num">(1,526)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss | Debt instruments included in financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures', window );">Change in fair value (excluding investments accounted for using the equity method)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures', window );">Change in fair value (investments accounted for using the equity method, net of taxes)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments', window );">Tax effects</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss | Foreign Currency Translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (14)<span></span>
</td>
<td class="num">&#8364; (56)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes reclassifications to profit or loss: immaterial over all periods.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar.</span><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes a reclassification to profit or loss: immaterial in the first half of 2024 , &#8364;(56) million in 2023 and &#8364;(14) million in the first half of 2023.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes reclassifications to profit or loss: immaterial over all periods.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income in relation to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph ab<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_ab&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 90<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_90&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset excluding associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset net of tax on associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in currency translation before tax excluding associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in currency translation net of tax on associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in currency translation on hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInCurrencyTranslationOnTaxEffects">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in currency translation on tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInCurrencyTranslationOnTaxEffects</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value on cash flow hedges excluding associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value on cash flow hedges net of tax on associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value On Debt Instrument Associates And Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value On Debt Instrument Excluding Associates And Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value On Equity Instruments Excluding Associates And Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value On Equity Instruments For Investments Accounted For Using The Equity Method Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Risk Hedging Instruments Designated At Fair Value Hedges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Relating To Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Equity Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Relating To Change In Fair Value Of Debt Instrument Excluding Equity Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Relating To Change In Fair Value Of Equity Instruments Excluding Equity Method</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassifiedItemsAxis=sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassifiedItemsAxis=sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=sny_EquityInstrumentsIncludedInFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=sny_EquityInstrumentsIncludedInFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassifiedItemsAxis=sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassifiedItemsAxis=sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=sny_DebtInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=sny_DebtInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=sny_ForeignCurrencyTranslationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=sny_ForeignCurrencyTranslationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079756078672">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Debt, Cash and Cash Equivalents - Summary of Changes in Financial Position (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 12,503<span></span>
</td>
<td class="nump">&#8364; 14,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,236<span></span>
</td>
<td class="nump">2,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">179<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,918<span></span>
</td>
<td class="nump">16,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,795)<span></span>
</td>
<td class="num">(8,710)<span></span>
</td>
<td class="num">&#8364; (7,993)<span></span>
</td>
<td class="num">&#8364; (12,736)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">15,112<span></span>
</td>
<td class="nump">7,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 2,012<span></span>
</td>
<td class="nump">&#8364; 2,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Net debt does not include lease liabilities, which amounted to &#8364;2,012 million as of June 30, 2024 and &#8364;2,030 million as of December 31, 2023</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtNetOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtNetOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage cash and cash equivalent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079757009072">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Debt, Cash and Cash Equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 12,503<span></span>
</td>
<td class="nump">&#8364; 14,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,236<span></span>
</td>
<td class="nump">2,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">179<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,918<span></span>
</td>
<td class="nump">16,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,795)<span></span>
</td>
<td class="num">(8,710)<span></span>
</td>
<td class="num">&#8364; (7,993)<span></span>
</td>
<td class="num">&#8364; (12,736)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">15,112<span></span>
</td>
<td class="nump">7,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,012<span></span>
</td>
<td class="nump">2,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AmortizedCostNettingMember', window );">Amortized cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AdjustmentToDebtMeasuredAtFairValueMember', window );">Adjustment to debt measured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,688<span></span>
</td>
<td class="nump">14,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,254<span></span>
</td>
<td class="nump">2,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,952<span></span>
</td>
<td class="nump">16,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,795)<span></span>
</td>
<td class="num">(8,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">&#8364; 15,146<span></span>
</td>
<td class="nump">&#8364; 7,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Net debt does not include lease liabilities, which amounted to &#8364;2,012 million as of June 30, 2024 and &#8364;2,030 million as of December 31, 2023</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Net debt does not include lease liabilities, which amounted to &#8364;2,012 million as of June 30, 2024 and &#8364;2,030 million as of December 31, 2023</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtNetOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtNetOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of carrying amount to value on redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage cash and cash equivalent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AmortizedCostNettingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AmortizedCostNettingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AdjustmentToDebtMeasuredAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AdjustmentToDebtMeasuredAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079750636864">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Debt, Cash and Cash Equivalents - Summary of Net Debt by Type Valuation of Redemption (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 179<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,918<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,795)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,710)<span></span>
</td>
<td class="num">&#8364; (7,993)<span></span>
</td>
<td class="num">&#8364; (12,736)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">15,112<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,509<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,213<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">215<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,952<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,795)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">15,146<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,688<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,795)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,458<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,711)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,593<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">95<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,688<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,916<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,118<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">1,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">215<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,264<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 2,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | current | Commercial paper program in USA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,955<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | current | Commercial paper program in France</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Net debt does not include lease liabilities, which amounted to &#8364;2,012 million as of June 30, 2024 and &#8364;2,030 million as of December 31, 2023</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Net debt does not include lease liabilities, which amounted to &#8364;2,012 million as of June 30, 2024 and &#8364;2,030 million as of December 31, 2023</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) As of June 30, 2024, current other bank borrowings includ</span>e &#8364;6,955&#160;million related to the US Commercial Paper program and &#8364;0&#160;million related to the Negotiable European Commercial Paper program in France</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that has been withdrawn from an account in excess of existing cash balances. This is considered a short-term extension of credit by the bank. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BankOverdraftsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BondsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of bonds issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BondsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtNetOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtNetOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of carrying amount to value on redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage cash and cash equivalent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherBankBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other bank borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherBankBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_NonCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_NonCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_CurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_CurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=sny_NonCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=sny_NonCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=sny_CurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=sny_CurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079754727952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt, Cash and Cash Equivalents - Additional Information (Details) - 6 months ended Jun. 30, 2024<br> &#8364; in Billions, $ in Billions</strong></div></th>
<th class="th"><div>EUR (&#8364;)</div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>USD ($)</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_SyndicatedCreditFacilityOneMember', window );">Syndicated credit facility, expires in 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">&#8364; 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInFranceMember', window );">Commercial paper program in France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommercialPapersIssued', window );">Commercial paper programs</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInFranceMember', window );">Commercial paper program in France | Sanofi Euro Medium Term Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BorrowingAverageDrawdown', window );">Borrowing, average drawdown</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember', window );">Commercial paper program in USA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommercialPapersIssued', window );">Commercial paper programs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember', window );">Commercial paper program in USA | Sanofi Euro Medium Term Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BorrowingAverageDrawdown', window );">Borrowing, average drawdown | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingApril2024Redeemed2024Member', window );">Fixed Rate Bond Maturing April2024 Redeemed2024 | Sanofi Euro Medium Term Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">&#8364; 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommercialPapersIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of commercial paper issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommercialPapersIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BorrowingAverageDrawdown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Average Drawdown</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BorrowingAverageDrawdown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_SyndicatedCreditFacilityOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_SyndicatedCreditFacilityOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtInstrumentAxis=sny_SanofiEuroMediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtInstrumentAxis=sny_SanofiEuroMediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingApril2024Redeemed2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingApril2024Redeemed2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079755378480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt, Cash and Cash Equivalents - Summary of Market Value of Net Debt (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Market value</a></td>
<td class="nump">&#8364; 21,918<span></span>
</td>
<td class="nump">&#8364; 16,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtMarketValueMember', window );">Market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Market value</a></td>
<td class="nump">14,214<span></span>
</td>
<td class="nump">7,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Market value</a></td>
<td class="nump">21,952<span></span>
</td>
<td class="nump">16,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RedemptionOfDebtInstrumentIssued', window );">Value on redemption</a></td>
<td class="nump">&#8364; 15,146<span></span>
</td>
<td class="nump">&#8364; 7,835<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RedemptionOfDebtInstrumentIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption of debt instrument issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RedemptionOfDebtInstrumentIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AtMarketValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AtMarketValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079753374976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Financial Instruments - Summary of Operating Currency Hedging Instruments (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">&#8364; 8,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">5,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">2,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales in Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales in Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">3,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">1,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases in Canadian dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward Currency Sales In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward Currency Purchases In Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward Currency Purchases In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency sales in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency sales in Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency sales in Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency sales in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency purchases in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency purchases in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency purchases in Canadian dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward Currency Sales In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward Currency Purchases In Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward Currency Purchases In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">8,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">5,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency sales in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">2,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency sales in Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency sales in Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency sales in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">3,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency purchases in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">1,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency purchases in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency purchases in Canadian dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward Currency Sales In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward Currency Purchases In Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward Currency Purchases In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales in Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales in Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases in Canadian dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward Currency Sales In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward Currency Purchases In Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward Currency Purchases In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency sales in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency sales in Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency sales in Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency sales in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency purchases in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency purchases in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency purchases in Canadian dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward Currency Sales In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward Currency Purchases In Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward Currency Purchases In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency sales in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency sales in Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency sales in Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency sales in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency purchases in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency purchases in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency purchases in Canadian dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward Currency Sales In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward Currency Purchases In Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward Currency Purchases In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward currency sales in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward currency sales in Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward currency sales in Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward currency sales in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward currency purchases in US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward currency purchases in Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward currency purchases in Canadian dollar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward Currency Sales In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward Currency Purchases In Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward Currency Purchases In Russian rouble</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DerivativeFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative financial instrument</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DerivativeFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInChineseYuanRenminbiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInChineseYuanRenminbiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInJapaneseYenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInJapaneseYenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInSingaporeDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInSingaporeDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInSingaporeDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInSingaporeDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInCanadianDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInCanadianDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInRussianRoubleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInRussianRoubleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInTurkishLiraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInTurkishLiraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInRussianRoubleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInRussianRoubleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=sny_NotEligibleForHedgeAccountingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=sny_NotEligibleForHedgeAccountingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079775871696">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Change in fair value of cash flow hedges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (3)<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="num">&#8364; (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarMember', window );">Forward currency sales in US dollar</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarUSBondMember', window );">Forward currency purchases in US dollar, US bond</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Change in fair value of cash flow hedges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember', window );">Forward currency purchases in US dollar, commercial paper</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialAssets', window );">Derivative financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Change in fair value of cash flow hedges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales in US dollar | 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases in US dollar | 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">5,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases in Singapore dollar | 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales in Chinese yuan renminbi | 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward Currency Sales In Canadian Dollar | 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward Currency Purchases In Hungarian florint | 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales in US dollar | 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases in US dollar | 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases in Singapore dollar | 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales in Chinese yuan renminbi | 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward Currency Sales In Canadian Dollar | 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward Currency Purchases In Hungarian florint | 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes forward sales with a notional amount of $3,615 million expiring in 2024, designated as a hedge of Sanofi&#8217;s net investment in Bioverativ. As of June&#160;30, 2024, the fair value of these forward contracts represented a liability of &#8364;26 million; the opposite entry was recognized in &#8220;Other comprehensive income&#8221;, with the impact on financial income and expense being immaterial.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">(c)  Includes forward purchases with a notional amount of $1,080 million expiring in 2024 , designated as a fair value hedge of $1,080 million of commercial paper. As of June 30, 2024, the fair value of these contracts represented an asset of &#8364;16 million, with &#8364;0&#160;million credited to &#8220;Other comprehensive income&#8221; to recognize the hedging cost.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)  Includes forward purchases with a notional amount of $1,000 million expiring in 2024, designated as a fair value hedge of the exposure of $1,000 million of bond issues to</span> fluctuations in the EUR/USD spot rate. As of June 30, 2024, the fair value of these contracts represented an asset of &#8364;2 million, with &#8364;0 million&#160;credited to &#8220;Other comprehensive income&#8221; to recognize the hedging cost</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on cash flow hedges, before tax, before reclassification adjustments. [Refer: Cash flow hedges [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative financial instruments to manage financial exposure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DerivativeFinancialInstrumentsToManageFinancialExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarUSBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarUSBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInSingaporeDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInSingaporeDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInChineseYuanRenminbiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInChineseYuanRenminbiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInCanadianDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInCanadianDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInHungarianFlorintMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInHungarianFlorintMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079752850848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Financial Instruments - Disclosure of Instruments (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 3,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">3,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | 2028 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">1,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(181)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(181)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member', window );">pay capitalized SOFR USD / receive 1.32%</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateSwapsInterestRate', window );">Interest rate</a></td>
<td class="nump">1.32%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member', window );">pay capitalized SOFR USD / receive 1.32% | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member', window );">pay capitalized SOFR USD / receive 1.32% | Notional amount | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member', window );">pay capitalized SOFR USD / receive 1.32% | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member', window );">pay capitalized SOFR USD / receive 1.32% | Notional amount | 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member', window );">pay capitalized SOFR USD / receive 1.32% | Notional amount | 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member', window );">pay capitalized SOFR USD / receive 1.32% | Notional amount | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member', window );">pay capitalized SOFR USD / receive 1.32% | Notional amount | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member', window );">pay capitalized SOFR USD / receive 1.32% | Notional amount | 2028 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member', window );">pay capitalized SOFR USD / receive 1.32% | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member', window );">pay capitalized SOFR USD / receive 1.32% | Fair value | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member', window );">pay capitalized SOFR USD / receive 1.32% | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member', window );">pay capitalized SOFR USD / receive 1.32% | Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay capitalized Ester / receive 0.69%</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateSwapsInterestRate', window );">Interest rate</a></td>
<td class="nump">0.69%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay capitalized Ester / receive 0.69% | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay capitalized Ester / receive 0.69% | Notional amount | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay capitalized Ester / receive 0.69% | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay capitalized Ester / receive 0.69% | Notional amount | 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay capitalized Ester / receive 0.69% | Notional amount | 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay capitalized Ester / receive 0.69% | Notional amount | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay capitalized Ester / receive 0.69% | Notional amount | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay capitalized Ester / receive 0.69% | Notional amount | 2028 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay capitalized Ester / receive 0.69% | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay capitalized Ester / receive 0.69% | Fair value | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay capitalized Ester / receive 0.69% | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">pay capitalized Ester / receive 0.69% | Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92%</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateSwapsInterestRate', window );">Interest rate</a></td>
<td class="nump">0.92%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Notional amount | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Notional amount | 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Notional amount | 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Notional amount | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Notional amount | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Notional amount | 2028 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Fair value | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester / receive 0.92% | Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02%</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateSwapsInterestRate', window );">Interest rate</a></td>
<td class="nump">1.02%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Notional amount | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Notional amount | 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Notional amount | 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Notional amount | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Notional amount | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Notional amount | 2028 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Fair value | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member', window );">Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% | Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 3.56%</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateSwapsInterestRate', window );">Interest rate</a></td>
<td class="nump">3.56%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% | Notional amount | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% | Notional amount | 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% | Notional amount | 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% | Notional amount | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% | Notional amount | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% | Notional amount | 2028 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% | Fair value | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% | Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Currency and interest rate derivatives used to manage debt, net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateSwapsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Rate Swaps, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateSwapsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_FairValueHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=ifrs-full_FairValueHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079750618688">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to Business Combinations and to Non-Controlling Interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract', window );"><strong>Disclosure of contingent liabilities in business combination [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock', window );">Liabilities Related to Business Combinations and to Non-Controlling Interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.11. LIABILITIES RELATED TO BUSINESS COMBINATIONS AND TO NON-CONTROLLING INTERESTS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of the nature of the liabilities reported in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, refer to Note B.8.4. to the consolidated financial statements for the year ended December 31, 2023. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The liabilities related to business combinations and to non-controlling interests shown in the table below are level&#160;3 instruments under the IFRS 13 and IFRS 7 fair value hierarchy (see Note A.5.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2024 are shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:30.055%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">MSD contingent consideration (European Vaccines business)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shire contingent consideration arising from acquisition of Translate Bio</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Contingent consideration arising from acquisition of Amunix</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"> (a)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at January 1, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">127</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">441</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">137</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">709</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(71)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(71)</span></td><td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at June 30, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">61</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">526</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">140</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">728</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Of which:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt;text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt;text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt;text-align:right"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;padding-left:33.44pt">Current portion</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">201</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;padding-left:33.44pt">Non-current portion</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">527</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">As of January 1, 2024, this comprised a non-current portion of &#8364;501 million and a current portion of &#8364;208 million.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Amounts mainly reported within the income statement line item &#8220;Fair value remeasurement of contingent consideration&#8221;.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2024,</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">mainly comprised:</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.28pt">The MSD contingent consideration liability arising from the 2016 acquisition of the Sanofi Pasteur activities carried on within the former Sanofi Pasteur MSD joint venture, which amounted to &#8364;61 million as of June&#160;30, 2024 versus &#8364;127 million as of December 31, 2023. The fair value of this contingent consideration is determined by applying the royalty percentage stipulated in the contract to discounted projections of sales by Sanofi through December 31, 2024 of products previously commercialized by the joint venture. If the discount rate were to fall by one percentage point, the fair value of the MSD contingent consideration would increase by approximately 1%;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">The contingent consideration liability towards Shire Human Genetic Therapies Inc. (Shire) arising from Sanofi's acquisition of Translate Bio in September 2021. The fair value of the Shire liability is determined by applying the contractual terms to development and sales projections that are weighted to reflect the probability of success, and discounted. The liability was measured at &#8364;526 million as of June&#160;30, 2024, compared with &#8364;441 million as of December 31, 2023. If the discount rate were to fall by one percentage point, the fair value of the Shire liability would increase by approximately 14%; and</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">The contingent consideration liability arising from the 2022 acquisition of Amunix. The fair value of the liability is determined on&#160;the basis of the nominal value of payments due subject to the attainment of specified</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> development milestones</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. The liability was measured at </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8364;140 million</span> as of June 30, 2024, versus &#8364;137 million as of December 31, 2023.<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward', window );"><strong>Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 709<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Payments made</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(71)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">75<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination', window );">Other movements</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests', window );">Currency translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">728<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests', window );">Current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">201<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests', window );">Non-current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">527<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember', window );">MSD contingent consideration (European Vaccines business)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward', window );"><strong>Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">127<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Payments made</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(71)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination', window );">Other movements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests', window );">Currency translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember', window );">Shire contingent consideration arising from acquisition of Translate Bio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward', window );"><strong>Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">441<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Payments made</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">71<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination', window );">Other movements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests', window );">Currency translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">526<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember', window );">Contingent consideration arising from acquisition of Amunix</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward', window );"><strong>Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">137<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Payments made</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination', window );">Other movements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests', window );">Currency translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">140<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_OtherLiabilities1Member', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward', window );"><strong>Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Payments made</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination', window );">Other movements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests', window );">Currency translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">As of January 1, 2024, this comprised a non-current portion of &#8364;501 million and a current portion of &#8364;208 million.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">(b)&#160;&#160;&#160;&#160;Amounts mainly reported within the income statement line item &#8220;Fair value remeasurement of contingent consideration&#8221;</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised in a business combination that were settled. [Refer: Contingent liabilities recognised in business combination]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This account includes current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes current portion of liabilities related to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liabilities related to business combination and to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through net exchange differences business combinations and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This account includes non-current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes non-current portion of liabilities related to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other movements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_OtherLiabilities1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_OtherLiabilities1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079757115376">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Liabilities Related to Business Combinations and to Non-Controlling Interests - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Fair value of contingent consideration payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 728<span></span>
</td>
<td class="nump">&#8364; 709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember', window );">MSD contingent consideration (European Vaccines business)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Fair value of contingent consideration payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 61<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageIncreaseInFairValueLiabilities', window );">Increase in fair value of liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember', window );">Shire contingent consideration arising from acquisition of Translate Bio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Fair value of contingent consideration payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 526<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageIncreaseInFairValueLiabilities', window );">Increase in fair value of liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember', window );">Contingent consideration arising from acquisition of Amunix</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Fair value of contingent consideration payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 140<span></span>
</td>
<td class="nump">&#8364; 137<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">As of January 1, 2024, this comprised a non-current portion of &#8364;501 million and a current portion of &#8364;208 million.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageIncreaseInFairValueLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage increase in fair value liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageIncreaseInFairValueLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079751024752">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Non-Current Provisions And Other Non-Current Liabilities - Summary of Non-Current Provisions and Other Non-Current Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNonCurrentProvisionsLineItems', window );"><strong>Disclosure Of Non-current Provisions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Provisions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 5,918<span></span>
</td>
<td class="nump">&#8364; 5,262<span></span>
</td>
<td class="nump">&#8364; 5,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,301<span></span>
</td>
<td class="nump">2,340<span></span>
</td>
<td class="nump">2,070<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities', window );">Non-current provisions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,219<span></span>
</td>
<td class="nump">&#8364; 7,602<span></span>
</td>
<td class="nump">&#8364; 7,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration Agreement | Swedish Orphan Biovitrum AB</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNonCurrentProvisionsLineItems', window );"><strong>Disclosure Of Non-current Provisions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration Agreement | Swedish Orphan Biovitrum AB | Later than one year and not later than five years [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNonCurrentProvisionsLineItems', window );"><strong>Disclosure Of Non-current Provisions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration Agreement | Swedish Orphan Biovitrum AB | Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNonCurrentProvisionsLineItems', window );"><strong>Disclosure Of Non-current Provisions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 2,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">a) Includes &#8364;1,970 million at June 30, 2024 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States. Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#8364;1,147&#160;million; the nominal value of payments estimated to be due after more than five years is &#8364;2,679 million</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfNonCurrentProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Non-current Provisions [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfNonCurrentProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions and non-current other liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_SwedishOrphanBiovitrumABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_SwedishOrphanBiovitrumABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079756365504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Current Provisions And Other Non-Current Liabilities - Summary of Movements in Non-Current Provisions (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">&#8364; 5,262<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInOtherProvisions', window );">Increases in provisions and other liabilities</a></td>
<td class="num">(1,301)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="nump">230<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="num">(122)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">60<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="num">(119)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions', window );">Actuarial gains and losses on defined-benefit plans (B.12.1.)</a></td>
<td class="num">(235)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Ending balance</a></td>
<td class="nump">5,918<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember', window );">Provisions for pensions &amp; other post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">2,214<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInOtherProvisions', window );">Increases in provisions and other liabilities</a></td>
<td class="num">(72)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="nump">78<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="nump">75<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">37<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="num">(63)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="nump">18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions', window );">Actuarial gains and losses on defined-benefit plans (B.12.1.)</a></td>
<td class="num">(235)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Ending balance</a></td>
<td class="nump">2,040<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForOtherLongTermBenefitsMember', window );">Provisions for other long-term benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">718<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInOtherProvisions', window );">Increases in provisions and other liabilities</a></td>
<td class="num">(89)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="nump">65<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="nump">13<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions', window );">Actuarial gains and losses on defined-benefit plans (B.12.1.)</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Ending balance</a></td>
<td class="nump">759<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_NonCurrentRestructuringProvisionMember', window );">Restructuring provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">554<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInOtherProvisions', window );">Increases in provisions and other liabilities</a></td>
<td class="num">(581)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="nump">11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="num">(173)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="num">(4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="num">(47)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions', window );">Actuarial gains and losses on defined-benefit plans (B.12.1.)</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Ending balance</a></td>
<td class="nump">909<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_MiscellaneousOtherProvisionsMember', window );">Other provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">1,776<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInOtherProvisions', window );">Increases in provisions and other liabilities</a></td>
<td class="num">(559)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="nump">76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="num">(24)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="num">(53)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="nump">17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions', window );">Actuarial gains and losses on defined-benefit plans (B.12.1.)</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Ending balance</a></td>
<td class="nump">&#8364; 2,210<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(b) Mainly transfers to the line &#8220;Current provisions and other current liabilities</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the case of &#8220;Provisions for pensions and other post-employment benefits&#8221;, the &#8220;Increases in provisions&#8221; line corresponds to rights vesting in employees during the period, and past service cost; the &#8220;Provisions utilized&#8221; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#8220;Reversals of unutilized provisions&#8221; line corresponds to plan curtailments, settlements and amendments.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionUsedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionUsedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease Of Unused Provision Reversed, Other Provisions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial gains and losses on defined-benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net interest related to employees benefits and unwinding of discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForOtherLongTermBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForOtherLongTermBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_NonCurrentRestructuringProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_NonCurrentRestructuringProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_MiscellaneousOtherProvisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=ifrs-full_MiscellaneousOtherProvisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079757854672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Current Provisions And Other Non-Current Liabilities - Disclosure of Remeasurement of Net Defined Benefit Liability Asset (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="4">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember', window );">Actuarial assumption of discount rates | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption', window );">Decrease in actuarial assumption</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase in actuarial assumption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(0.15%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember', window );">Actuarial assumption of discount rates | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase in actuarial assumption</a></td>
<td class="nump">0.65%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.40%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_EUROZONEMember', window );">Eurozone | Actuarial assumption of expected rates of inflation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase in actuarial assumption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_UKZONEMember', window );">UKZONE | Actuarial assumption of expected rates of inflation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase in actuarial assumption</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember', window );">Pensions and other post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Actuarial gains/(losses) on benefit obligations</a></td>
<td class="nump">&#8364; 373<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 99<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">&#8364; 379<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember', window );">Plan assets | Pensions and other post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset', window );">Actuarial gains/(losses) on plan assets</a></td>
<td class="num">&#8364; (138)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 34<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">&#8364; (208)<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes the effects of (i) the change in discount rates (in a range between +0.40% and +0.65%) and (ii) the change in the inflation rate in the United Kingdom (+0.10%) in the first half of 2024.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes the effects of (i) the change in discount rates (in a range between -0.15% and +0.40%) and (ii) the change in the inflation rate in the eurozone (-0.10%) in the first half of 2023.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reasonably possible percentage of the decrease in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 145<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 145<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [member]; Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_EUROZONEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_EUROZONEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_UKZONEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_UKZONEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079756867424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Off Balance Sheet Commitments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>May 13, 2024</div></th>
<th class="th"><div>May 10, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_NovavaxMember', window );">Novavax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_UpfrontPayments', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalMilestonePayments', window );">Total Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DevelopmentRegulatoryAndLaunchMilestonePayments', window );">Development Regulatory And Launch Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AdditionalLaunchAndSalesMilestonePayments', window );">Additional Launch And Sales Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_FulcrumTherapeuticsMember', window );">Fulcrum Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_UpfrontPayments', window );">Upfront payment</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ContingentMilestonePayments', window );">Contingent Milestone Payments</a></td>
<td class="nump">$ 975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AdditionalLaunchAndSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Launch And Sales Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AdditionalLaunchAndSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ContingentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ContingentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DevelopmentRegulatoryAndLaunchMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development Regulatory And Launch Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DevelopmentRegulatoryAndLaunchMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Disclosure Of Off Balance Sheet Commitments [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOffBalanceSheetCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TotalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TotalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_NovavaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_NovavaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_FulcrumTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_FulcrumTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079779081920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation and Arbitration Proceedings (Details) - Action for which we are defendant<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 21, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>proceeding</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_PlavixAttorneyGeneralActionInHawaiiMember', window );">Plavix Attorney General action in Hawaii</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated', window );">Global penalty fee incurred by defendants, amount vacated | $</a></td>
<td class="nump">$ 916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PenaltyFeeIncurred', window );">Penalty Fee Incurred | $</a></td>
<td class="nump">$ 458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_TaxotereProductLitigationInTheUSMember', window );">Taxotere Product Litigation In The US | Product Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfPlaintiffs', window );">Number Of Plaintiffs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_ZantacProductLitigationInTheUSMember', window );">Zantac Product Litigation in the US | Product Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfCases', window );">Number Of Cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_GoldBondProductLitigationInTheUSMember', window );">Gold Bond Product Litigation In The US | Product Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfClassActionLawsuits', window );">Number Of Class Action Lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of legal and arbitral proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfLegalAndArbitralProceedingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Global Penalty Fee Incurred By Defendants, Amount Vacated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfCases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Cases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfCases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfClassActionLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Class Action Lawsuits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfClassActionLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Plaintiffs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PenaltyFeeIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Penalty Fee Incurred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PenaltyFeeIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_PlavixAttorneyGeneralActionInHawaiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_PlavixAttorneyGeneralActionInHawaiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DefendantAxis=sny_ActionForWhichWeAreDefendantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DefendantAxis=sny_ActionForWhichWeAreDefendantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_TaxotereProductLitigationInTheUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_TaxotereProductLitigationInTheUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_ProductLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_ProductLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_ZantacProductLitigationInTheUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_ZantacProductLitigationInTheUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_GoldBondProductLitigationInTheUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_GoldBondProductLitigationInTheUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079756442800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Operating Income And Expenses - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">&#8364; 617<span></span>
</td>
<td class="nump">&#8364; 617<span></span>
</td>
<td class="nump">&#8364; 1,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expense</a></td>
<td class="nump">2,010<span></span>
</td>
<td class="nump">1,422<span></span>
</td>
<td class="nump">3,516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember', window );">Regeneron | Other operating income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">&#8364; 227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember', window );">Other related parties | Other operating income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainsOnDivestmentOfProducts', window );">Gains on divestment of some mature products</a></td>
<td class="nump">&#8364; 389<span></span>
</td>
<td class="nump">&#8364; 413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other operating income (expenses).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOtherOperatingIncomeExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainsOnDivestmentOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains on divestment of products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainsOnDivestmentOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079754837344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Operating Income And Expenses - Schedule of Other Operating Expenses (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">&#8364; (2,010)<span></span>
</td>
<td class="num">&#8364; (1,422)<span></span>
</td>
<td class="num">&#8364; (3,516)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">617<span></span>
</td>
<td class="nump">617<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other operating income/(expenses), net related to Regeneron</a></td>
<td class="num">(1,745)<span></span>
</td>
<td class="num">(1,321)<span></span>
</td>
<td class="num">(2,979)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember', window );">Other related parties | Other operating income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember', window );">Monoclonal Antibodies Alliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">(1,837)<span></span>
</td>
<td class="num">(1,418)<span></span>
</td>
<td class="num">(3,196)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember', window );">Monoclonal Antibodies Alliance | Income &amp; expense related to profit/loss sharing under the Monoclonal Antibody Alliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">(1,934)<span></span>
</td>
<td class="num">(1,449)<span></span>
</td>
<td class="num">(3,321)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember', window );">Monoclonal Antibodies Alliance | Additional share of profit paid by Regeneron towards development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">389<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember', window );">Monoclonal Antibodies Alliance | Reimbursement to Regeneron of selling expenses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">(292)<span></span>
</td>
<td class="num">(260)<span></span>
</td>
<td class="num">(543)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sny_OthersCounterpartyMember', window );">Other (mainly Zaltrap and Libtayo)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Other operating income and expenses</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember', window );">Regeneron | Other operating income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">&#8364; 227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember', window );">Regeneron | Other related parties | Reimbursement to Regeneron of selling expenses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">&#8364; (1,841)<span></span>
</td>
<td class="num">&#8364; (1,423)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income (expense) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other operating income (expenses).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOtherOperatingIncomeExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MiscellaneousOtherOperatingIncomeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other operating income and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MiscellaneousOtherOperatingIncomeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_CommercializationRelatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_CommercializationRelatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sny_OthersCounterpartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sny_OthersCounterpartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079825095408">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Restructuring Costs and Similar Items - Summary of Restructuring Costs and Similar Items (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses', window );">Employee-related expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 849<span></span>
</td>
<td class="nump">&#8364; 185<span></span>
</td>
<td class="nump">&#8364; 489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories', window );">Charges, gains or losses on assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(31)<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts', window );">Costs of transformation programs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">347<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="nump">676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherRestructuringCosts', window );">Other restructuring costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">166<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseOfRestructuringActivities', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 1,331<span></span>
</td>
<td class="nump">&#8364; 547<span></span>
</td>
<td class="nump">&#8364; 1,490<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(a) This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseOfRestructuringActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseOfRestructuringActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee related expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense of restructuring activities related to property plant and equipment to inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense Of Restructuring Activities, Transformation Programs Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other restructuring costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079780075200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Costs and Similar Items - Additional Information (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities', window );">Decrease in total expense of restructuring activities</a></td>
<td class="nump">&#8364; 784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Total Expense Of Restructuring Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079779214304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Gains and Losses, and Litigation (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherGainsLossesAndLitigation', window );">Other gains and litigation</a></td>
<td class="nump">&#8364; 442<span></span>
</td>
<td class="nump">&#8364; 73<span></span>
</td>
<td class="nump">&#8364; 38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherGainsLossesAndLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherGainsLossesAndLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079754341488">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Expenses and Income (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems', window );"><strong>Disclosure of detailed information about finance income expense [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Cost of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">&#8364; (309)<span></span>
</td>
<td class="num">&#8364; (232)<span></span>
</td>
<td class="num">&#8364; (555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestIncome', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">243<span></span>
</td>
<td class="nump">257<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CostOfDebtNet', window );">Cost of net debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(66)<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonOperatingForeignExchangeGainsLosses', window );">Non-operating foreign exchange gains/(losses)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions', window );">Unwinding of discounting of provisions</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetInterestCostRelatedToEmployeeBenefits', window );">Net interest cost related to employee benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets', window );">Gains/(losses) on disposals of financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Net interest expense on lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">(161)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(526)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Net financial income/(expenses)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(305)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="num">(722)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(586)<span></span>
</td>
<td class="num">(370)<span></span>
</td>
<td class="num">(1,313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">281<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LiabilityRecognisedForEstimatedFutureRoyalties', window );">Liability Recognised For Estimated Future Royalties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(176)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(541)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgedItemsAxis=sny_InterestRateAndCurrencyDerivativesMember', window );">Interest rate and currency derivatives used to hedge debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems', window );"><strong>Disclosure of detailed information about finance income expense [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainLossOnDerivativesUsedToManageDebt', window );">Gain on derivatives used to manage debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents', window );">Gain on derivatives used to manage cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (18)<span></span>
</td>
<td class="num">&#8364; (4)<span></span>
</td>
<td class="num">&#8364; (13)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: &#8364;(24) million in the first half of 2024, &#8364;(25) million in the first half of 2023, and &#8364;(67) million over the whole of 2023.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: &#8364;(18) million in the first half of 2024, &#8364;(4)&#160;million in the first half of 2023, and &#8364;(13) million over the whole of 2023.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes a financial expense of &#8364;176</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span>million for the six months ended June 30, 2024 (&#8364;541 million for the year ended December 31, 2023, &#8364;35 million for the six months ended June 30, 2023) for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the US</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised due to the unwinding of the discount on provisions other than provisions for employee benefits, resulting from the effect of the passage of time. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on available-for-sale financial assets. [Refer: Financial assets available-for-sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_20_a_ii&amp;doctype=Standard&amp;book=b<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CostOfDebtNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of debt net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CostOfDebtNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent detailed information about finance income expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on derivatives used to manage cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainLossOnDerivativesUsedToManageDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on derivatives used to manage debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainLossOnDerivativesUsedToManageDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LiabilityRecognisedForEstimatedFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Recognised For Estimated Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LiabilityRecognisedForEstimatedFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetInterestCostRelatedToEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net interest cost related to employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetInterestCostRelatedToEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonOperatingForeignExchangeGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-operating foreign exchange gains/(losses).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonOperatingForeignExchangeGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgedItemsAxis=sny_InterestRateAndCurrencyDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgedItemsAxis=sny_InterestRateAndCurrencyDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079807562128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax Expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Income taxes paid (refund) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current taxes</a></td>
<td class="num">&#8364; (1,243)<span></span>
</td>
<td class="num">&#8364; (1,171)<span></span>
</td>
<td class="num">&#8364; (2,560)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred taxes</a></td>
<td class="nump">780<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="nump">958<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Total</a></td>
<td class="num">(463)<span></span>
</td>
<td class="num">(730)<span></span>
</td>
<td class="num">(1,602)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments', window );">Income before tax and investments accounted for using the equity method</a></td>
<td class="nump">&#8364; 2,739<span></span>
</td>
<td class="nump">&#8364; 4,238<span></span>
</td>
<td class="nump">&#8364; 7,153<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income before tax and investments accounted for equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079757844496">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Income Tax Expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="4">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Income taxes paid (refund) [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Standard tax rate applicable in France</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25.80%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">25.80%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">25.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfForeignTaxRates', window );">Difference between the standard French tax rate and the rates applicable to Sanofi</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(14.30%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(8.20%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(13.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes', window );">Revisions to tax exposures and settlements of tax disputes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.20%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.50%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments', window );">Tax Rate Effect Of Reversal Of Temporary Difference On Investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations', window );">Fair value remeasurement of contingent consideration liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Other (d)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">2.20%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">Effective tax rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16.90%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">17.30%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">22.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense (income)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 1,243<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 1,171<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 2,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentTaxExpenseRelatedToPillarTwo', window );">Current Tax Expense Related to Pillar Two</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">In accordance with IAS12, a deferred tax liability was recognised in 2023 on the temporary differences arising on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Opella business, as announced in October 2023.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span>For the six months ended June 30, 2024, this line includes a tax expense of &#8364;52 million, representing the estimated impact of Pillar 2 based on Sanofi&#8217;s current understanding of Pillar Two rules</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax rate effects, in aggregate, on the reconciliation between the average effective tax rate and the applicable tax rate that the entity does not separately disclose in the reconciliation. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the application of foreign tax rates. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentTaxExpenseRelatedToPillarTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Tax Expense Related to Pillar Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentTaxExpenseRelatedToPillarTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revisions to tax exposures and settlements of tax disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Rate Effect Of Fair Value Remeasurement Of Contingent Considerations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Rate Effect Of Reversal Of Temporary Difference On Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079753844176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax Expense (Details) - Summary of Effective Tax Rate and Standard Corporate Income Tax Rate (Parenthetical)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentTaxExpenseRelatedToPillarTwo', window );">Current Tax Expense Related to Pillar Two</a></td>
<td class="nump">&#8364; 52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentTaxExpenseRelatedToPillarTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Tax Expense Related to Pillar Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentTaxExpenseRelatedToPillarTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079780975168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079777327600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Summary of Net Sales by Segment and Geographical Area (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="4">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>segment</div>
</th>
<th class="th" colspan="2">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 21,209<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 20,187<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 43,070<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">&#8364; 1,289<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,358<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,374<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(6,849)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,347)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(14,236)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="num">(3,423)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,193)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,728)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="num">(5,260)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,182)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(10,692)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Attributable to non-controlling interests</a></td>
<td class="nump">17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">36<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">18,378<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,467<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">37,890<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="nump">4,931<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,220<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,247<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,257<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,331<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,322<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(5,756)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,388)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(12,282)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="num">(3,331)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,082)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,509)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="num">(4,260)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,248)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,868)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Other operating income and expenses</a></td>
<td class="num">(1,417)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(897)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,387)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="nump">66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">48<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">101<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Attributable to non-controlling interests</a></td>
<td class="num">(6)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(20)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent | Pharma Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">16,059<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,077<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent | Pharma Launches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,295<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">715<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent | Dupixent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">6,138<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,878<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent | Total Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">2,319<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,390<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent | Polio/Pertussis/ Hib Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,348<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,428<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent | Influenza Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">188<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">162<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent | Nexviazyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">320<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">184<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent | Sarclisa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">227<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">181<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent | Altuviiio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">280<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent | Rezurock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">207<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">141<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent | Cablivi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">113<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">113<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent | Xenpozyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">72<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">38<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent | Enjaymo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">55<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">33<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent | Tzield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent | RSV Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent | Meningitis Travel And Endemic Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">582<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">569<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_OpellaMember', window );">Opella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">2,831<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,720<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,180<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="nump">739<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">850<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,438<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">32<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">27<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(1,077)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(949)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,933)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="num">(92)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(111)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(219)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="num">(1,002)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(936)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,828)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Other operating income and expenses</a></td>
<td class="nump">43<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">181<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="nump">9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Attributable to non-controlling interests</a></td>
<td class="num">(5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(16)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_OpellaMember', window );">Opella | Seasonal Symptoms And Pain Relief</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,216<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,261<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_OpellaMember', window );">Opella | Wellness Brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,258<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,112<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_OpellaMember', window );">Opella | Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">357<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">347<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember', window );">Other segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="num">(14)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(11)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(15)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Other operating income and expenses</a></td>
<td class="num">(19)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(18)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Attributable to non-controlling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_OtherProductsSegmentMember', window );">Other Products Segment | Other Products Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">8,626<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_OtherProductsSegmentMember', window );">Other Products Segment | of which</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">278<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">280<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">4,882<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,034<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,392<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Dupixent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">4,074<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,194<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Dupixent | Pharma Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">3,692<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,624<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Dupixent | Pharma Launches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">249<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">168<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Dupixent | Dupixent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">770<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">587<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Dupixent | Total Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">382<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">570<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Dupixent | Polio/Pertussis/ Hib Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">248<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">231<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Dupixent | Influenza Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">30<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">37<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Dupixent | Nexviazyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">95<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">42<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Dupixent | Sarclisa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">64<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Dupixent | Altuviiio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Dupixent | Rezurock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">12<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Dupixent | Cablivi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">43<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">49<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Dupixent | Xenpozyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">24<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Dupixent | Enjaymo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Dupixent | Tzield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Dupixent | RSV Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Dupixent | Meningitis Travel And Endemic Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">97<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">72<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Opella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">808<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">840<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Other Products Segment | Other Products Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">2,673<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,869<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Other Products Segment | of which</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">274<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">264<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">9,067<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,988<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 18,512<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Dupixent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">8,294<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,366<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Dupixent | Pharma Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">7,550<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,709<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Dupixent | Pharma Launches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">868<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">460<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Dupixent | Dupixent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">4,437<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,682<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Dupixent | Total Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">744<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">657<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Dupixent | Polio/Pertussis/ Hib Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">311<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">347<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Dupixent | Influenza Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Dupixent | Nexviazyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">174<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">123<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Dupixent | Sarclisa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Dupixent | Altuviiio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">259<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Dupixent | Rezurock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">188<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">140<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Dupixent | Cablivi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">60<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">58<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Dupixent | Xenpozyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">37<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Dupixent | Enjaymo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">30<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Dupixent | Tzield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Dupixent | RSV Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">116<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Dupixent | Meningitis Travel And Endemic Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">301<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">291<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Opella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">773<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">622<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Other Products Segment | Other Products Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">2,245<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,567<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Other Products Segment | of which</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">7,260<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,165<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries | Dupixent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">6,010<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,907<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries | Dupixent | Pharma Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">4,817<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,744<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries | Dupixent | Pharma Launches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">178<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">87<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries | Dupixent | Dupixent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">931<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">609<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries | Dupixent | Total Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,193<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,163<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries | Dupixent | Polio/Pertussis/ Hib Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">789<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">850<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries | Dupixent | Influenza Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">142<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">106<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries | Dupixent | Nexviazyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">51<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries | Dupixent | Sarclisa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">63<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">49<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries | Dupixent | Altuviiio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries | Dupixent | Rezurock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries | Dupixent | Cablivi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries | Dupixent | Xenpozyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries | Dupixent | Enjaymo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries | Dupixent | Tzield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries | Dupixent | RSV Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">77<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries | Dupixent | Meningitis Travel And Endemic Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">184<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">206<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries | Opella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,258<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries | Other Products Segment | Other Products Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">3,708<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,048<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries | Other Products Segment | of which</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 13<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;The &#8220;Other&#8221; column reconciles segmental results to the total per the consolidated financial statements.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The &#8220;Other&#8221; column reconciles segmental results to the total per the consolidated financial statements.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The &#8220;Other&#8221; column reconciles segmental results to the total per the consolidated financial statements.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MiscellaneousOtherOperatingIncomeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other operating income and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MiscellaneousOtherOperatingIncomeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sny_PharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sny_PharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sny_PharmaLaunchesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sny_PharmaLaunchesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_DupixentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_DupixentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_VaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_VaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_PolioPertussisHibVaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_PolioPertussisHibVaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_InfluenzaVaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_InfluenzaVaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_NexviazymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_NexviazymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_SarclisaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_SarclisaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_AltuviiioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_AltuviiioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_RezurockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_RezurockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_CabliviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_CabliviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_XenpozymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_XenpozymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_EnjaymoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_EnjaymoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_TzieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_TzieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_RSVVaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_RSVVaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_MeningitisTravelAndEndemicVaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_MeningitisTravelAndEndemicVaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_OpellaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_OpellaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_SeasonalSymptomsAndPainReliefMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_SeasonalSymptomsAndPainReliefMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_WellnessBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_WellnessBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_OthersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_OthersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_OtherProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_OtherProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sny_OtherProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sny_OtherProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_IndustrialSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_IndustrialSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079756803856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Segment Results (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="4">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>segment</div>
</th>
<th class="th" colspan="2">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 21,209<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 20,187<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 43,070<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,289<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,358<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,374<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(6,849)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,347)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(14,236)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(3,423)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,193)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,728)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="num">(5,260)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,182)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(10,692)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="nump">&#8364; 17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">36<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=ifrs-full_ReportableSegmentsMember', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 21,209<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20,187<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">43,070<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,289<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,358<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,374<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(6,830)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,342)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(14,216)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(3,423)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,193)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,728)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="num">(5,260)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,182)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(10,692)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Other operating income and expenses</a></td>
<td class="num">(1,393)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(805)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,224)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="nump">75<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">55<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">122<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="num">(11)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(19)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(36)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="nump">5,656<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,059<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,670<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">18,378<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,467<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">37,890<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,257<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,331<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,322<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(5,756)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,388)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(12,282)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(3,331)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,082)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,509)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="num">(4,260)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,248)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,868)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Other operating income and expenses</a></td>
<td class="num">(1,417)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(897)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,387)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="nump">66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">48<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">101<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="num">(6)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(20)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="nump">4,931<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,220<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,247<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Other operating income and expenses</a></td>
<td class="num">(19)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(18)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="num">&#8364; (14)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">&#8364; (11)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">&#8364; (15)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;The &#8220;Other&#8221; column reconciles segmental results to the total per the consolidated financial statements.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The &#8220;Other&#8221; column reconciles segmental results to the total per the consolidated financial statements.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The &#8220;Other&#8221; column reconciles segmental results to the total per the consolidated financial statements.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MiscellaneousOtherOperatingIncomeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other operating income and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MiscellaneousOtherOperatingIncomeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=ifrs-full_ReportableSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=ifrs-full_ReportableSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079779514064">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 17<span></span>
</td>
<td class="nump">&#8364; 26<span></span>
</td>
<td class="nump">&#8364; 36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability', window );">Fair value remeasurement of contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseOfRestructuringActivities', window );">Restructuring costs and similar items</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,331)<span></span>
</td>
<td class="num">(547)<span></span>
</td>
<td class="num">(1,490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherGainsLossesAndLitigation', window );">Other gains and losses, and litigation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(442)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,044<span></span>
</td>
<td class="nump">4,322<span></span>
</td>
<td class="nump">7,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(586)<span></span>
</td>
<td class="num">(370)<span></span>
</td>
<td class="num">(1,313)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">281<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments', window );">Income before tax and investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,739<span></span>
</td>
<td class="nump">4,238<span></span>
</td>
<td class="nump">7,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment loss on other intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(371)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetReversalOfImpairmentLoss', window );">Net Reversal of Impairment Loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">371<span></span>
</td>
<td class="nump">833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,656<span></span>
</td>
<td class="nump">6,059<span></span>
</td>
<td class="nump">12,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_MaterialReconcilingItemsMember', window );">Material reconciling items</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(75)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="num">(122)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">11<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill', window );">Amortization and impairment of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(690)<span></span>
</td>
<td class="num">(1,050)<span></span>
</td>
<td class="num">(3,068)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability', window );">Fair value remeasurement of contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories', window );">Expense arising from the impact of acquisitions on inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseOfRestructuringActivities', window );">Restructuring costs and similar items</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(1,331)<span></span>
</td>
<td class="num">(547)<span></span>
</td>
<td class="num">(1,490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherGainsLossesAndLitigation', window );">Other gains and losses, and litigation</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="num">&#8364; (442)<span></span>
</td>
<td class="num">&#8364; (73)<span></span>
</td>
<td class="num">&#8364; (38)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Joint ventures and associates with which Sanofi has entered into a strategic alliance.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">As of June 30, 2024, this line includes a net reversal of impairment losses amounting to of &#8364;371&#160;million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights in the Biopharma segment. For 2023, this amount mainly comprises an impairment loss of &#8364;833&#160;million, reflecting the impact of the strategic decision to de-prioritize certain R&amp;D programs, in particular those related to the NK Cell and PRO-XTEN technology platforms. </span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">See note B.16.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">See note B.17</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseOfRestructuringActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseOfRestructuringActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a contingent consideration asset (liability) relating to a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization and impairment of intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses arising from the impact of acquisitions on inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income before tax and investments accounted for equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetReversalOfImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Reversal of Impairment Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetReversalOfImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherGainsLossesAndLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherGainsLossesAndLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079754768064">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="4">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>segment</div>
</th>
<th class="th" colspan="2">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 315<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 424<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=ifrs-full_ReportableSegmentsMember', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 243<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 241<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">262<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisitions of property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">950<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">782<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,719<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Acquisitions of other intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">936<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">148<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,305<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Dupixent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">229<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">231<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">234<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisitions of property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">882<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">751<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,619<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Acquisitions of other intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">132<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,287<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember', window );">Opella</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisitions of property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">31<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Acquisitions of other intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_OpellaMember', window );">Opella</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">28<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisitions of property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">68<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Acquisitions of other intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Carrying amount at the end of the reporting period.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Carrying amount at the end of the reporting period.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Carrying amount at the end of the reporting period.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=ifrs-full_ReportableSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=ifrs-full_ReportableSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_OpellaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_OpellaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079754805744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 21,209<span></span>
</td>
<td class="nump">&#8364; 20,187<span></span>
</td>
<td class="nump">&#8364; 43,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">property, plant and equipment</a></td>
<td class="nump">10,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">50,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">26,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_ReportableGeographicalZonesMember', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">21,209<span></span>
</td>
<td class="nump">20,187<span></span>
</td>
<td class="nump">43,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">property, plant and equipment</a></td>
<td class="nump">10,264<span></span>
</td>
<td class="nump">9,804<span></span>
</td>
<td class="nump">10,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">50,080<span></span>
</td>
<td class="nump">49,243<span></span>
</td>
<td class="nump">49,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">26,653<span></span>
</td>
<td class="nump">24,590<span></span>
</td>
<td class="nump">24,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">4,882<span></span>
</td>
<td class="nump">5,034<span></span>
</td>
<td class="nump">10,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">property, plant and equipment</a></td>
<td class="nump">5,611<span></span>
</td>
<td class="nump">5,462<span></span>
</td>
<td class="nump">5,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">5,156<span></span>
</td>
<td class="nump">5,961<span></span>
</td>
<td class="nump">5,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,082<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
<td class="nump">2,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">property, plant and equipment</a></td>
<td class="nump">3,079<span></span>
</td>
<td class="nump">2,921<span></span>
</td>
<td class="nump">3,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">9,067<span></span>
</td>
<td class="nump">7,988<span></span>
</td>
<td class="nump">18,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">property, plant and equipment</a></td>
<td class="nump">2,377<span></span>
</td>
<td class="nump">2,364<span></span>
</td>
<td class="nump">2,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">20,726<span></span>
</td>
<td class="nump">17,595<span></span>
</td>
<td class="nump">17,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesExcludingEuropeAndNorthAmericaMember', window );">Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">7,260<span></span>
</td>
<td class="nump">7,165<span></span>
</td>
<td class="nump">14,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">property, plant and equipment</a></td>
<td class="nump">2,276<span></span>
</td>
<td class="nump">1,978<span></span>
</td>
<td class="nump">2,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 771<span></span>
</td>
<td class="nump">&#8364; 1,034<span></span>
</td>
<td class="nump">&#8364; 903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_ReportableGeographicalZonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_ReportableGeographicalZonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesExcludingEuropeAndNorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_OtherCountriesExcludingEuropeAndNorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079752348096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Principal Customers and Credit Risk (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=sny_CertainWholesalersInTheUnitedStatesMember', window );">Certain wholesalers in the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems', window );"><strong>Disclosure of information about major customers and credit risk [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=sny_CustomerOneMember', window );">Customer one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems', window );"><strong>Disclosure of information about major customers and credit risk [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=sny_CustomerTwoMember', window );">Customer two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems', window );"><strong>Disclosure of information about major customers and credit risk [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=sny_CustomerThreeMember', window );">Customer three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems', window );"><strong>Disclosure of information about major customers and credit risk [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfEntitysRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of the entity's revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfEntitysRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of information about major customers and credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=sny_CertainWholesalersInTheUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=sny_CertainWholesalersInTheUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=sny_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=sny_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=sny_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=sny_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=sny_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=sny_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140079752396128">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares', window );">Increase (Decrease) Through Share-Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares</a></td>
<td class="th" style="border-bottom: 0px;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_TreasurySharesMember', window );">Treasury shares [member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares', window );">Increase (Decrease) Through Share-Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares</a></td>
<td class="th" style="border-bottom: 0px;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Issued capital [member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares', window );">Increase (Decrease) Through Share-Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares</a></td>
<td class="th" style="border-bottom: 0px;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_RetainedEarningsMember', window );">Retained earnings [member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares', window );">Increase (Decrease) Through Share-Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares</a></td>
<td class="th" style="border-bottom: 0px;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares</td>
<td class="num">(3,000,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AdditionalPaidinCapitalMember', window );">Additional paid-in capital [member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares', window );">Increase (Decrease) Through Share-Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares</a></td>
<td class="th" style="border-bottom: 0px;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets [member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill', window );">Impairment Loss on Intangible Asset Other Than Goodwill</a></td>
<td class="th" style="border-bottom: 0px;">sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill</td>
<td class="nump">&#8364; 366,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment Loss on Intangible Asset Other Than Goodwill</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through share-based payment plans issuance of restricted shares and vesting of existing restricted shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_TreasurySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_TreasurySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AdditionalPaidinCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_AdditionalPaidinCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>116
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M5FIG:U/;;-BSJ;"A$!6U: 1946(HL6F+3FI'Y_C_BD141R=Q.LLP/B'6$(G
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MX5?6$8JMOUP4JOF+'EIL:L!YK;0H.V,30<FK]C]][ ;BR,#X@0U(9T!<@VC
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M]_LS'(9>#@%8[+5>T%DT'U _N)</>%P_M&5D8S;"+2NK@YG9NS377//-<-X
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M*%:U 3T!BHCBE4'2A3FJ98'*YJ*R>:AL/BI;@,H6#FBC*]O6B3#43L04_WF
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MWF",KI1EVU\.M"AL(_PL-+;5]C/%JQ)((X#K2R'T^\!L4%^^YO\!4$L#!!0
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MU;M.U9<BW>F7>99I4:1;_7$C.%A  >#W50JYIOZB;G!XX^SZ?U!+ P04
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MDPT@OW1]&/[>R 5'M+*SK@*B2ZZK1K'9;>;ISW:*;.W/PNO;T+%_$T;PPH6
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ME/7G,B6'HW*:CRNHQ-4*'($>]++:&Z@ H@F3*QVJ75Y_1.&%/M]V"%;&<DX
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MLBVIQ*UVNLY8W5S"7=LTX@'2+"/O>#R&FX;F!,')CN(_P@YCF$0_/!_-2))
MDL%+KFM0ND#M\PG-R2M)$T 5P"SLDY.-)H?\ #,N>3\E:?#870N/YD.->NNG
MH(%<M=)VHZ+?[0?MHILO/]R[*7W-])93L@66!(T&ST<!Z&[R=895C9\V&V5I
M=OEE13\+U,Z!OI=*V8/A#NA_/_/_ 5!+ P04    " !54_E8UJ" RZP%   ]
M#0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6RE5]MNVS@0_96!"Q0V
M(,BZ2\X-<"[;NFB3(,YN'Q;[0$MCFZ@DNB05)_OU.Z1DQ6D3%[O[8$LB9P[G
MS R/J).MD-_4&E'#8U76ZG2PUGIS-!ZK?(T54Z[88$TS2R$KINE1KL9J(Y$5
MUJDJQX'G)>.*\7IP=F+';N79B6ATR6N\E:":JF+RZ1Q+L3T=^(/=P!U?K;49
M&)^=;-@*YZA_W]Q*>AKW* 6OL%9<U"!Q>3J8^D?GD;&W!G]PW*J]>S!,%D)\
M,P^SXG3@F8"PQ%P;!$:7![S LC1 %,;W#G/0+VD<]^]WZ+]9[L1EP11>B/(K
M+_3Z=) -H, E:TI])[8?L>,3&[Q<E,K^P[:UC8(!Y(W2HNJ<*8**U^V5/79Y
MV'/(O#<<@LXAL'&W"]DH+YEF9R=2;$$::T(S-Y:J]:;@>&V*,M>29CGYZ;,/
M0A1;7I; Z@)N]!HES&K-ZA5?E A3I5"KD[&FE8S]..]0SUO4X W4!+Z(6J\5
M7-4%%B_]QQ1A'V:P"_,\. CXJ:E="#T' B^(#N"%/>W0XH5OX.UQ9):CY;_:
M)>-/ME!:4L?\]1KW%CIZ'=KLHB.U83F>#FB;*)0/.#A[_\Y/O.,#@4=]X-$A
M]/]<K\.HYV[HPH>;F\NOL\^?87I]"3?W'Z_N8'9]/[W^,#O_? 73^?SJ?@[/
MZU>BJ346H 6\?Y>%270<>XZ7>=2E96DWG *Q!*H<]I5SX &E:M3.(YHXD1?]
MX'&).58+(A;ZUHM"NU\C5.(!20TT%(WD]0J(.VQ0<E' EAR- )5/-(DF(C/)
M*ZJ"-HCYFA*$"G@-^-@^@&0:E4M]VJ+:26'SR7_JC;T5EUPJ#6M6+@VPX01;
ME,82EJ(DB5-',.S8[7B-8)I_;[BD9-V]9]7F^!)NI2B:7"L'J,T*TEG28%O2
M-@1IM$3!7"SUEA'ZO="L?#.\#U(H!0^L).Y,PR=6-Z2OT&8O@HF3I@&DH9.&
M(0UF7@99[(1^"!?/>5$YZ;S-E:B5*'G!K&@.V8A<TB0Q%0O\X+B_MJ.6F.+&
M=C]^7N?TAE $':<^1>%#Y$-&*UYRM1&*E?O&!>Z,A]%D!,,@I3_SR\(17#12
M8IT_F3S5JFRC*OARB6:8?((PH5B\V(.4KL$DA'MC2?,T!WX 0Y\HA#\E:;\M
MR8P\,T@C9Y),3(XBRM'$\?V8&.9-U=#"5#WJ>:GYWVT0AH!I,2YM5[Z2>).\
MH4E[1-<X=B9>1C>^$\8!71//F4QH9KH/BH_TME789YFLO<RZ!];5#Y,1S)Y7
M+8D44A?5:!M=HME?)KW#A;&G!(;II$<+J6*'*Q!-($@A@2SX=>:'J6<*Y5%^
MAR;$-(U'>\GO*9@Y8Q./_E4R7Q3(I#$QV8M3JI1O<Q%YH4ECX$0))>>"2?ED
M=FDK3*_5(W&\, ,_=;(@ABA.@ 0I]">ONKY8/7/BT#..29I!%,40)$X2A[;
MLUYEC#RPY_U@AF;UFB_DHT,W.0P5(EP+C7#N^N[(M36:/X]%[LOM1/YO[?@A
MR5C9%"9FU6G$R.SB-Q1*&_E *':R:_2@TR;'[-4.:B?*2=@KLL2V6)VDLI7$
M3B[I#XVB47 "%JBWB#7,62V6W%;S6CRP!_9HHOK"GFP<KNV)P#O^A?IMNFEK
M[1_OI#T7U49RA4<M3&(FY#<TX6UZP"W7:V"0_U!2RD3'SD_<$!:\A+?>43!\
M^8XBA\0X''I#C6STC%X%1KA-<Q,&G6E?-GGWMB( MJ&('SD=*I&(^3X\(9/J
MV*+LR&G,U[4HQ8KGI/T;JH,Y@BM82-'0(FWBS?&"Y_@Z;WA)W(U^H'&8MAO\
MBC7\3]I92]M][5@TWCO25BA7]N"NJ >HFNWIMA_MOPVF[9'XV;S]L/C"Y(K3
M?BIQ2:Z>F\:#]@6[>]!B8P_("Z'IN&UOU_1]@](8T/Q2T ;M'LP"_1?3V3]0
M2P,$%     @ 55/Y6$W=,?'0 @  ,@8  !D   !X;"]W;W)K<VAE971S+W-H
M965T,30N>&ULG55-<]HP$/TK.\Y,3AGL&$(R"3 #"6GIA)0)M#UT>A#VVM9$
MEEQ)#LF_[TH&AW8(AUZP/O:]?2MI'X.-TL^F0+3P6@IIAD%A;74=AB8IL&2F
MHRJ4M),I73)+4YV'IM+(4@\J11A'43\L&9?!:.#7%GHT4+457.)"@ZG+DNFW
M"0JU&0;GP6[AB>>%=0OA:%"Q')=HOU4+3;.P94EYB=)P)4%C-@S&Y]>3GHOW
M =\Y;LS>&%PE:Z6>W626#H/("4*!B74,C#XO>(M"."*2\7O+&;0I'7!_O&._
M][53+6MF\%:)'SRUQ3"X"B#%C-7"/JG-9]S6<^'X$B6,_X5-$WO9#2"IC57E
M%DP*2BZ;+WO=GL,>X"KZ !!O ;'7W23R*N^89:.!5AO0+IK8W,"7ZM$DCDMW
M*4NK:9<3SHYF9<6XIE.VH#*82<MDSM<"86P,6C,(+25QH6&R)9PTA/$'A'V8
M*VD+ U.98OHW/B1QK<)XIW 2'R7\4LL.=*,SB*.X=X2OVU;<]7S=#_CNN$F$
M,K5&5S%_KY\6#3"9TEM[06V8.+3_DZV-U?26?ATZFB9S[W!FUU_7IF()#@-J
M((/Z!8/1Z<EY/[HY4E>OK:MWC/U_;O(XX:33Z\!LOAC/GN;3QQ5\O8?9XVK\
M^&DV>9C">+F<KI:P*A!*);E5FLO\GQ/C,N4)HRT#9!^@;(&:%EMES"L#@2E8
M!;1+1Y^HG-A<PQ(7 TF^=.0^D&ZL5+6T+CEQG)Y<=?N]FVZ_3\TBA*/ATC-G
M7!L+!1.9HW%OZ0R<:8DW2&MT6.9B$W(V@SN0DT.YF1?K\QB'3E!;@A)>/Z,E
M]956:9W8YODT96IG!V9'-.&J*ABY"!C,G?K.H1L/]_JX1)U[MS*0N,1-2[>K
MK2&.&Q]X#V_<=,YTSJ4[VXR@4>?R(F@D[2965=X5ULJ2Q_AA0::.V@70?J:4
MW4U<@O9O8O0'4$L#!!0    ( %53^5@C\R+$Q@0  $,*   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;*U6VV[;.!#]E8&*!@G0E67)ES@7 W'B)N["
M239VLE@L]H&2QA9;B51)*J[WZW=(R8Z3NGG:%ULDYW)XYI"<LY54WW2&:.!'
MD0M][F7&E">MEDXR+)CV98F"5A92%<S04"U;NE3(4N=4Y*TP"'JM@G'A#<_<
MW+T:GLG*Y%S@O0)=%053ZQ'F<G7NM;W-Q -?9L9.M(9G)5OB#,UC>:]HU-I&
M27F!0G,I0.'BW+MHGXPZUMX9/'%<Z9UOL#N)I?QF!Y/TW LL(,PQ,38"H[]G
MO,0\MX$(QO<FIK=-:1UWOS?1/[N]TUYBIO%2YG_RU&3GWK$'*2Y8E9L'N;K!
M9C]=&R^1N7:_L*IMNX$'2:6-+!IG0E!P4?^S'PT/.P['OW((&X?0X:X3.917
MS+#AF9(K4-::HMD/MU7G3>"XL$69&46KG/S,<"*>41MBV6BX2!)9"8,I4+'A
M47.Q!),AC+]7W*QABB:3Z5G+4%KKW$J:%*,Z1?B+%#V82F$R#6.1XAO_%L'=
M8@XWF$?ANP&_5,*'*/@$81!VWHD7;3F(7+SHEQP85,2"AHF .]JQ(JB&&XX:
M_KZ(M5&DG7_V;;R.V]D?UYZG$UVR!,\].C :U3-ZPX,/[5YP^@[JSA9UY[WH
M_T_EWD\Q\KL^3&Z?QK/Y='P[G\'%Y>7=X^U\? 6?[Q[@<3:YO8;YS1C&?SQ.
MYG_!=#R_N;N"763L%;)JBPQK9(5#!HFD4ZX-R 4PK67"F2'NF4CAJ^3"P#/%
MJHA".-2(<"L-PLAO^V"D"V;=9<Y3YO)PP01%R$$;FJAAV.36<HU, 5H=PA4F
M6,14ZZCME!0=?7(9$UF4BFL\@<.##\=1KW-*YR[/Z0HY@H_ &ZT B1"W(OPY
M&(P?'^XN[B=PR(X@'/C'T ^AW0N)G(5B5@MP7<0W<,"*\A0NI0\W!Q_"3N\T
MR2CX[]=P&!]1,#^$XP$, IC.[N&)R*0*D751,K&&P^0(NH$?V/5!KU$NWR&?
M\(?M\!1Z'>CW8"X-D1*UN] AQ!;7G!AYL:?/+6HNDKQ*70V 4S:NG$4NM:8[
MCRB@JX@XC-?V8B9"1(*;8GROI"T#7?'?Z$TA*FEIPV3H=[M485OG5_S5S#=&
M7;\?-48_U\AWQ'S9587OB'@UM9<NN1(:VD'PT4:>7DZW!J,GWU&Q5SD-$U86
M!2JW2O>!T,R]*AIB-"M$ 3,FY(*[?6A9; 3^VXO^=PMC,F: $<XD)[WS!:=U
MVK'"W$FX9,I>/C4J8I! E6_SVD0QRPDP56G%3?;6V\6OWUK^KZV5?8#WB?JU
MDG='T1Y=SUA.L;L#*ZIVMP\/<LWR.A\ADHT&$TM!KPU1"+UH<SW9#2;(GUF<
MXX[URZ2&L'\,83N"L#. ^THE&1T5IX2EE&F=PIX=;C<==;H$E!)TPI<,)5N_
M"=_,: MDT(=^&V95_)6: BO8!)6ASL7>("EWQ'[:5)("YBDH1E<!<">$?0>%
M3L!&VT&PX=0:V*-@>R9WIT&)JD1366E5L50I*<V6*EO'BE-I*+N_[TEH[3SL
MI+ZE:U\TN+W6;_QV=MLA7=2-P8MYW5Y-F5IRTDV."W(-_'[7 U6W+/7 R-*U
M";$TU'2XSXRZ/%36@-87DLYU,[ )MGWC\#]02P,$%     @ 55/Y6.-R4_4<
M P  QP8  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&ULI55M;]LX#/XK
MA <,&]#&;XGC=4F ILMA=[BU1=)M'P[W0;;I6)@L>9*<=/_^*-O),EP:X' ?
M+(LR^9 /2=&SO=+?3(5HX;D6TLR]RMKFQO=-7F'-S$@U*.E+J73-+(EZZYM&
M(RLZHUKX41 D?LVX]!:S[NQ1+V:JM8)+?-1@VKIF^L<2A=K/O= ['*SYMK+N
MP%_,&K;%#=K/S:,FR3^B%+Q&:;B2H+&<>[?AS7+L]#N%+QSWYF0/CDFFU#<G
M_%[,O< %A )SZQ 8O79XAT(X( KC^X#I'5TZP]/] ?VWCCMQR9C!.R6^\L)6
M<R_UH,"2M<*NU?XC#GPF#B]7PG0K['O=)/$@;XU5]6!,$=1<]F_V/.3AQ" -
M7C"(!H.HB[MWU$7Y@5FVF&FU!^VT"<UM.JJ=-07'I2O*QFKZRLG.+AYLA1KN
ME;R^:[5&:>'6&+1FYEM"=SI^/B M>Z3H!:0$/BEI*P,K66#QJ[U/41U#BPZA
M+:.+@'^T<@1Q< 51$(TOX,5'JG&'%[^ MVFS7#!C>,ESYEK"@"J!=72O0'"6
M<<$M1P-,%H#?VU[XBV7&:NJ>O\_EI'<Y/N_2W:@;T[ <YQY=&8-ZA][B]:LP
M"=Y?(#0^$AI?0O]/M;N(=#[.Y2@9P</3Q]4:[A_NK^\^K]>K^R>XW6Q63QOH
MG4MRG@_.^TQ"KNI&<X,W\.;UJS1.QN^I;X6@?+\%*BD>2PH?,,<Z(Y0X[$YB
M6+FD_P N*>,M77V"8Q9*QC7LF&@1;*55NZU ==X[5UBY$;%#LB(9(;P*DY#6
M($W)0V;_'UH\GM*3#'1++IG,.1,'LN?Q&JU*;D%I$,H82,,II$$*CQJOR];=
M#FB&L:8RP;=#,\;1!*)I"'\JN;VVJ&O"P89QZL5GIT^]^&X"83@^T1"*R;Y?
M6;&CT(;F5?\JCJ9<\QW+!&E,TBE,WH7PI"PQB:_B.*8U"E,XUY3^R7"I46^[
M$>K*W$K;SYGCZ7%*W_;#Z:=Z/^(_,;VE:H# DDR#T73B@>['9B]8U72C*E.6
M!E^WK>A/@]HIT/=2*7L0G(/COVOQ#U!+ P04    " !54_E8S]$G-AP$   U
M"0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6R-5FUOVS80_BL'%0@2
M(+'U8BM.8ANPW6SKL+9!DG8?AGV@I9-$A"(]DK*3_?H=)5EV6B78%TD\WCV\
MEX=WFNZ4?C(%HH7G4D@S\PIK-]?#H4D*+)D9J U*VLF4+IFEI<Z'9J.1I;51
M*8:A[\?#DG'IS:>U[$[/IZJR@DN\TV"JLF3Z98E"[69>X.T%]SPOK!,,Y],-
MR_$![;?-G:;5L$-)>8G2<"5!8S;S%L'U<N3T:X7O''?FZ!M<)&NEGMSB4SKS
M?.<0"DRL0V#TVN(*A7! Y,8_+:;7'>D,C[_WZ+_4L5,L:V9PI<2?/+7%S)MX
MD&+&*F'OU>XW;.,9.[Q$"5,_8=?H1E<>))6QJFR-R8.2R^;-GML\'!E,_#<,
MPM8@K/UN#JJ]_,@LFT^UVH%VVH3F/NI0:VMRCDM7E >K:9>3G9TODD15TAJX
MQP3YEJT%3H>6@-WV,&E!E@U(^ 9(#)^5M(6!6YEB^MI^2 YU7H5[KY;ANX"_
M5W( D7\.H1^.WL&+NBBC&B]Z ^]1LQ2!R124+5 3F_;!&OB+K8W5Q(Z_^P)O
M<$?]N.[&7)L-2W#FT94PJ+?HS4\^!+%_\X[7H\[KT7OH_[<V[X,L!Y<#6*Q6
M7[]]>7R ^]O5[:?OB^4?M]"A'Y(!:[K73Y"J'5T7 YD2=&?--9R>?)A$\>B&
M""@$W:4SH )A5R#X2 CEFO(:!;4D@E^U,@:V3%0(D_/8#^DY#B>P<(A,)I3W
MTZOPC![C,U@QK5^XS(&5SB.G&OCT'$41/!8(O*046U 9L(,YRZGC&$O7^N<P
MN 0J,V1<DT+!1.9L:T]W%!8#2<T.GZFO&70[;731/CPXW:(VU=N:8:=)7;'_
MJ.AL4/MNF[RZY@>FH&S6ZM3N7+P;K3(N:F1%1Z:4K)YPSNNV0]25D!_2VE>5
MKS^"'.EWF^L7.!'V)H#2W=EC<7 1-4)S+(TNXAYI?!&$/>*3W-[ 8><U3>)1
M#&$\@L ?0Q!=0GP%ET$/>>+)%>E=03 F7;<F]@3PH$J$!R8I931"UH:GG&E.
M3"C8ED(VAN>2LG1\M:V"C)BCM$MVHHA&TADHU\CEDZ%6:PL:5,Y&5=I@4[*6
MA5245U@%LU 2'5S]$B53[J:*H0E@$LW7=#*Q[HNR",O!9! /W.&MJE&"I\R2
M2L8EL9<S <:2@(:;-1V'7I!I0-=!>W+B>E>!Q'S8H48ZU?F<2_XO:3M2MUP8
M^P<6DY1B>%V"/;-;]<LX^$']IY-;'E-WXVE%CN<5TTQ:1$=1P:Q+;1VJHBM"
M?52:C(YHO.0TZ"UJ%V^/,X.^%CD\&F4EZKP>V 9J/C=3K9-V_P2+9A0>U)L?
MBL],Y]0B0&!&IO[@<NR!;H9TL[!J4P_&M;(T9NO/@OYK4#L%VL\4E;-=N .Z
M/Z7Y?U!+ P04    " !54_E8^NE4"BL-  "?*@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6SM6FMSXD86_2M=3FT6JA2L!Q+"\ZC"F(G9G;$=L)/:
MVMH/C=28S@B)J"5[O+]^S^V6D,#8GDDR-;55^6"#I.[[?IS;Z/5]EG]4*R$*
M]FF=I.K-T:HH-B?'QRI:B357O6PC4CQ99OF:%[C,;X_5)A<\UIO6R;%KV\'Q
MFLOTZ.UK?>\J?_LZ*XM$IN(J9ZI<KWG^<"J2[/[-D7-4WYC)VU5!-X[?OM[P
M6S$7Q<WF*L?5\99*+-<B53)+62Z6;XY&SLFI3^OU@I^EN%>M[XPT66391[J8
MQF^.;!)()"(JB +'QYT8BR0A0A#CMXKFT98E;6Q_KZF_T[I#EP578IPEO\BX
M6+TY"H]8+):\3(I9=G\N*GVT@%&6*/V?W9NU 3A&I2JR=;49UVN9FD_^J;)#
M:T-H/['!K3:X6F[#2$MYQ@O^]G6>W;.<5H,:?=&JZMT03J;DE'F1XZG$ON+M
M.$M5ELB8%R)F\Q7/Q2I+8I&KO[/);Z4L'EX?%V!#BX^CBN2I(>D^03)@'[*T
M6"DV26,1[^X_AGA;&=U:QE/W68+_*-,>\VR+N;;;?X:>M]79T_2\)^AI-=F8
M;V3!$XO-A!+YG5!LE,;LLEB)O%*=3=-"Y$(5[-^CA2IR1-!_#IG#<.L?YD99
M=:(V/!)OCI VFM71V^^_<P+[U3.Z]+>Z])^C_OO\]SS)TU[88^/+B_GE^^G9
MZ'IRQN;GH]GD_/+]V60V__Z[T'4&K]CDIYOI];\8+79Z9@4;CZZFUZ/W;*18
MMF1PF]BZS6(P+%/:\I&Q/+OGBH&<%_1?N9;ON=; ]2W?<1F'(R(H)A5I!5*.
MY0:!Y058X@>&BF(=HEAD1"DMUPNX#2NK9R@_J@ 9F=YVD5'%BG&VX3F[XTDI
M:%W-M\>N4<M4F3_46U<BB=GB@<UYFBTE(X$AYS)+4+_4";O89_6W[?>M8CN:
M,\?O>1YS>J[C8/&9B(2FX#GZ.9YXO;Z/YW;@X7E[+Y[9O:'-[%X8].D93TM4
M3E;O#'LN/0Q\&P]'E2T@S="Q/-^O!;Q'##.I5 E;RE3[82ES1/6*)TM:KJ6$
MCAQ55J&:T3U:)3Z)/))*VZNR!NI1]!$5?*&B7&YT7<WTA^HA6QB/8TE7D,\*
M;<\*O$$M!1*,G%FB)N0U-<JM7$9TWQAPD_!4L;C,X;<G!+7HR_U*1BN8H3_
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MTE0#L0%.4QWG$J-=3C]Z_$%+1E#1<H(!'8W;X9#*B>7[K5K]HF!?;N.NCJ4
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M([8&5K<[&K3@T<M\^K 76J3F<\-2:"UB<[IE%)H@$L#Z6@A=7*""\OO3Q7\
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M7WU@U_>_?+Q] O#I\OSB\M/E_>7'.W:_%8Q(,FE%[J1*:JG*O=AD=.7$+CH
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M/U\,''1_-L4C#/&8S_"(XF  Y1Z$1@"[S*F*%JLC0G\6>P(AZT^PFL:.S'+
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MVU] Y_[/QQ[<_S_ZS/6&DBH3:Z &H_FTYWMM\V%5Z?Z#K)2U*G?++>X20A,
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MA-:^A].N84D=FN<8T"@PSGU#S9$=#?N_HXWN-A+YY;CAI&"I1.&!HJ"W"OY
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M^@#>GQNNZWKB$[2?H=%O4$L#!!0    ( %53^5A%(@('!P4  ,\+   9
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MSN0L*N&Q &\ JXTR.T2*L,:5](0P'I'B.*:_*=E^]S4AFGMD?&.<4(]R*$B
MU"E#29R\Z:Y1_(C!OC,(22&-/U!2+*627E+^&]8)&T^)^@=?4J*B@GV:Q)U3
MR:3!?##>I&(8[0LIY(UR%<W&[ >KD<#&4I3T^ABNGE9>E,TFK#5E[^.C-";?
MKQ[A0S*+Z3>!['4<BH.:1=4%:7.N.75-H$*8.H<IU<U,R&MK4><[J@HK[P1_
M/1S4KDE$19U!^>>".8:VS*.$V+>E3GA T2"?+6&60JTX_%SU1P_BV8_%TZ/
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M+!.R/.1>+'BKHG8.?)X3V:WB$O1[>O8;4$L#!!0    ( %53^5@>I>J>\!
M '4U   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;-5;;7/;N!'^*QAW
MFMHSLBS)B9W8269H6;[H:LNN)/LF[?0#1$(2$I)@ -**[M=W=P&^R93BRZ77
MZX?$$E^P[[O/+J"W*Z4_FZ40*?L:A;%YM[=,T^3LZ,CX2Q%QTU:)B.'.7.F(
MI_!5+XY,H@4/Z*4H/.IU.B='$9?QWONW=.U.OW^KLC24L;C3S&11Q/7Z0H1J
M]6ZONY=?&,O%,L4+1^_?)GPA)B*]3^XT?#LJ5@ED)&(C5<RTF+_;\[IG%]T.
MOD!//$BQ,I7/#$69*?49OPR#=WL=Y$B$PD]Q"0Y_'D5?A"&N!'Q\<8ON%33Q
MQ>KG?/4K$AZ$F7$C^BK\10;I\MW>ZST6B#G/PG2L5A^$$^@5KN>KT-#_;.6>
M[>PQ/S.IBMS+P$$D8_N7?W6*>,X+/?="C_BVA(C+2Y[R]V^U6C&-3\-J^(%$
MI;>!.1FC52:IAKL2WDO?7W C#5-S=J=%PC4G5<'7="G8!Q[.#S\*KMF5C'GL
M2QZR2<I3 59)#>-QP#S?5UF<RGC![E0H?2D,V\\_';P]2H%%)'3D.W8N+#N]
M+>R<L!L5ITO#!G$@@OK[1R!:(5\OE^^BMW/!G[.XS8X[+=;K]%[N6.^XT-<Q
MK7>\9;V^THD"-0DF8QL3Y%N@"I-K!M4WO!I/F*^B))2@.,'^Q6<FU>""_V[2
MB27YLIDDQN692;@OWNU!X!FA'\7>^Q=_Z9YTSG<(]+(0Z.6NU=\/XU3HF,0
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M\$N<_-.D(^]0>.JF=. 4NO )LUO)T:X2TNV4OP#I[$[J"RT<Z^,-%QT+AR%
M8_W;A^'E8?<->X#&$#-D'WBCT@AMZZ,(08]4=IP&0;(^0!X^4PX,4"OWT^3O
MC3\*V<EA\^\'&D_S'55^"1,)O:#?^QB[46A_%%-<+7Y3Y-E?TI2/VQ\D 7H$
ML&"@HYC#JYWVZ:L]*-WT&Q_[)54)_:YFIM)41?1Q*3BD%WP [L\5H!?W!0D4
MO[1Z_Q]02P,$%     @ 55/Y6#PI'E,X!P  P14  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&ULS5AM;]LV$/XKA <4*9#8CI.F6Y<$R$N#9FB*K.DZ
M;,,^4-+)XBJ)"DG9\7[]GB,E6?;L+.N*;1_:6!)Y]]S=<R_D\5R;3S8C<N*A
MR$M[,LB<JUZ-1C;.J)!VJ"LJ\275II .CV8ZLI4AF?A-13Z:C,='HT*J<G!Z
M[-_=FM-C7;M<E71KA*V+0IK%.>5Z?C+8'[0OWJMIYOC%Z/2XDE.Z(_=#=6OP
M-.JD)*J@TBI="D/IR>!L_]7Y(:_W"SXJFMO>;\&61%I_XH?KY&0P9D"44^Q8
M@L2?&5U0GK,@P+AO9 XZE;RQ_[N5?N5MARV1M'2A\Q]5XK*3P=<#D5 JZ]R]
MU_,WU-CS@N7%.K?^?S%OUHX'(JZMTT6S&0@*58:_\J'QPU,V3)H-$X\[*/(H
M+Z63I\=&SX7AU9#&/[RI?C? J9*#<N<,OBKL<Z?GTBHK="IN#5722.\J/+J,
MQ!N9IWL_D33B2I6RC)7,Q9V3CA 49X4L$W$6Q[HNG2JGXE;G*E9DQ<X'&>5D
MGQ^/' "RFE'<@#D/8"9;P!R)&UVZS(K794+)ZOX1#.NLF[36G4\>%?A=70[%
MP7A73,:3PT?D'73>.O#R#K;(N]"FTG 2"56&A/#,@B-LZQ=VWO75^SL1ZZ+*
M%=Q&XA<966= P%\W^22H/-RLDI/RE:UD3"<#9)TE,Z/!Z;.O]H_&WSYBT&%G
MT.%CTD\OE8US;6M#C/N&)/_T9MP:A8A7"*0XJV ()<+I'A&N2YA4>R9L,NIQ
MM1_ +L<L$1&7!6$S/;>><TD'R"+G[VMEH+@&'4SPZDN\S:4G'.#PCJ('NEJ"
MEDO0:0=:+4$/Q3N-.'Y85-[T36M6_-&)%F]I1KQ,I%(9,9-Y32)39*2)LX7X
MB.= "T=Q5JI[?+TAEVF880.>A!P9Y#+U)=Q(\PDU.$$2]V04.H&NUP]Q)LLI
M"4^]ZQ+;R;KP]%&S.W+E./7.AT?#7HRDM81$;3R4".GZ&G?N:W@@$>QEM^C[
MYKFX6B[;;Z&%Q^_#IB*\@U? [W>CL\]3G5#D_EW%=?DTJP_$6:&-4[]C::RM
M&XE; @<YJ:51%J'9 02 4?GBN;A._2(10RO"@!A')"2HZE.V1&U ZVDQ>;IU
MFG91/H "(2V!?M9%GEM-(CH= J^J-00HW$RIX187K%D>:U^GF<OX:152*F@R
M%).:<3:N>> ]B%[6M!>@(*&,EG$F.'E[@C7;_I>B&6S'^T1$"R&3W]#>?")#
MX%81L(*_$VILTY;@58X,-E9DE,^K5DH1$BTA&QL500^RU*?YY?#E\&#8E@S6
M@&Z%7,.29>;;96]#<?<K%]S]B+N1N(0M180('.S[?K+?^/VM+J=[;)C(M2Q#
M6Y3)C M_>- 09$2IR[VX-H8M7+K%KM',,YK_L9/EZB>8G_\S74_P)<)4:H<L
M@Q;X!,1+5)J2%Y4:7? NA'X9_VWLVY* &>6^!A8\<.HH5U,?9MO4^ J&[A$:
MIU[XJAM12:E"NN=L[I<J#N"'FI8^^G\+':8],L;'H\!4; -#/Q_;-T,4\QE*
M>2 =R%K4K@;.%/H>$_D.O[PM[7,K[AU-M5,^X=9KZRZC+LAX1U02\=[UGR7<
M+&,0B/T"_ZMFM/,TZ]YLH>DYQ1(UB%EAJ:]-9'+&)1!$J@T76F8OZW#H9*@M
MA1_T=M<YKKCK3Z7AA).,PT.KPJS@*]"#*KHAM1<Y+&Y&AY#U3&X0.13C)^7\
M,'AP299+=N":W3OR>6?[== 2HSJN3A"8^J*V(\^5R_Y=-X24_GPOX+#S=%L
MF]9M^9)PUMH&*5_?T#T,^:*$5(*H^S]GV).*73N&K P!VLMG,K4G&]Z;(C&-
M#W8FTIRGU= 5.0(13^4^-$5OB'N*_FX:Z2-X+ 2=TAEF *^RDHO@*5NC-[/#
M]4+FO'@E$JM^U"$647OX:ZUE_K46PH_ZMW!V;G/C+8\W*WBVE(6KX*W<K^\0
M2D-]3<NVC<DZ3-FP-M(&9QC^PN,M*]X?>X_,D0XB=+5XX><%/E&M5,D)GV)Y
MWEJ.)G^.VXU*VF)Z5Z'5/<O=MZBOW.E?A8^ZI$6[)%16AK Z=MNYK-9T;QF7
MOC@D+LZO:X-7#RY,CAVJ(-J*9],U 3^3T>)"UQ4BOS3IPFAK]SJ?;K#I_PH>
MP]?;'@W]F3 <KB*F%5=8=+L(.13ZMV]H.@Q&S!R=YTRQ%H!]TN#[0SB&GMV)
M@\GN]HD5? \3+ZKV1CB<C')#@B^&&V9KG];]E/MO!^G@>VZ#:^W/CQO]P8IM
MS"B9\F94\^".E5DKF?HT]^=Y0,U4M=N(-&;!G] 542K:SK'2+"*9^ZN5<'.)
M I+74"[".=FNG<ZE<["B#NVS:3T--)RD/NV@YFZZ2QGUKM4P.$W]Y2%'$J#"
M#5OWMKN?/ O7<LOEX7(3[(>Q%A4QQ=;Q\.6+ 53["\/PX'3E+^DB[9PN_,^,
M)(+'"_ ]U?!^\\ *NEO;TS\ 4$L#!!0    ( %53^5ASJ!^&U@(  $\&   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;(U5[T_;,!#]5TZ9A$!"Y%=;
MVM)6HL T)B$JRK8/TSZXR:6Q<.Q@.Y3NK]\Y:4.92K<OC<^^]_R>[;N.5DH_
MF1S1PFLAI!E[N;7ET/=-DF/!S)DJ4=)*IG3!+(5ZZ9M2(TMK4"'\* AZ?L&X
M]":C>FZF)R-56<$ESC28JBB87D]1J-78"[WMQ -?YM9-^)-1R98X1_NMG&F*
M_)8EY05*PY4$C=G8NPR'TX[+KQ.^<UR9G3$X)PNEGEQPFXZ]P E"@8EU#(P^
M+WB%0C@BDO&\X?3:+1UP=[QE_UQ[)R\+9O!*B1\\M?G8ZWN08L8J81_4Z@MN
M_'0=7Z*$J7]AU>2>!QXDE;&JV(!)0<%E\V6OFW/8 ?0_ D0;0%3K;C:J55XS
MRR8CK5:@73:QN4%MM4:3."[=I<RMIE5..#N9:;I?;=>G,!-,6F RA9OGBI=T
M\!:.']E"H#D9^9;V<@@_V?!.&][H ]X>W"EI<P,W,L7T/=XGC:W0:"MT&ATD
M_%K),XB#4XB"J'. +VZ-QS5?_$_C96L<6^,_V<)834_FUS[K#7-G/[,KHZ$I
M68)CC^K$H'Y!;W+T*>P%%P=T=UK=G4/LDWE3/: RN$Q(K^'N=9M:_Q4KN66"
M_\84;J5%VMW"8@WWY)19+I<PQZ7SM\_4P6WWFWK,$:Q[(;!PU0T&K0%J%#:G
M:OM+6[*CC>]H4ZTVTVAS!&").>.:4G(F,F?67?L0CH\^]>->YX)*00CB/@%Z
M%]B^"[C&!(L%:HC#>B9^?TC=00CA:6\0PY2K,F=4UM"-NS37'41PG\$JYTD.
M=TQ6&5U^I9VN(U:4%S"ORE*L(>[U*#OL]]VA"D%PBH/PO["=$ ;!6^;>$XDB
MB'JP[YWX.T5>H%[6K<Q HBIIFWIO9]MN>=DTB;?TIM7>,;WD=!P",X(&9^==
M#W33OIK JK)N&0MEJ0'5PYPZ/FJ70.N94G8;N W:_Y#)'U!+ P04    " !5
M4_E8IQ"_ID $  !3"0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6R5
M5MMNXS80_96!%@AL0+!UOR2.@5S:;1;8-DC2]J'H RW1-K$4Z26I..G7=T:R
M%0?KN.B#S=O,X9DS'%*SK3;?[)IS!R^-5/;26SNW.9].;;7F#;,3O>$*5Y;:
M-,SAT*RF=F,XJSNG1DZC(,BF#1/*F\^ZN7LSG^G62:'XO0';-@TSK]=<ZNVE
M%WK[B0>Q6CN:F,YG&[;BC]S]OKDW.)H.*+5HN+)"*S!\>>E=A>?7"=EW!G\(
MOK4'?:!(%EI_H\%=?>D%1(A+7CE"8-@\\QLN)0$AC>\[3&_8DAP/^WOTG[O8
M,98%L_Q&RS]%[=:77N%!S9>LE>Y!;W_ANWA2PJNTM-T_;'O;I/2@:JW3S<X9
M&31"]2U[V>EPX% $'SA$.X>HX]UOU+&\98[-9T9OP9 UHE&G"[7S1G)"45(>
MG<%5@7YN_EGK>BND!*9J^,VMN8$[Y9A:B87D<&4M=Q9&3PQ'=CR;.MR2'*?5
M#OZZAX\^@,_@JU9N;>$G5?/ZO?\4J0Y\HSW?Z^@DX)=632 .?(B"*#F!%P_Q
MQQU>_ '>0;"L#Y:$6.U5^8LMK#-X=/X^%GL/G1R'IG(ZMQM6\4L/Z\5R\\R]
M^=FG, LN3A!/!N+)*?3Y(Y9GW2)MO42-GSD6"I(7ZJ,D'N-_>H=WJ+I#%3^H
M5;=&J!7@*BR%L0[63"Z)$^4'MMR0)2RUQ.JWYS Z^U3$67*!1UE*K,HQ7%7?
M6V%X#0]GK-E<W,*]T75;.>L#"E_C%8374Y>4GH*A,K/PJ)=NRQ#]23LF/Z3W
MV6AKX9G)%J<<?&&JQ:L'PO[\0.GG>01Y[.=QC)-%4$"1^G$8P\T:D7@7NJWP
M"J20*JVLEJ)FW7TR8F-TR;,,,*8HC"Z&MI_M K."; _Y"U7AY6D1.LU#9!%"
M$D*!.]X*N]&6R4/CFN^-1TDYAE&4XQ_]BG@,-ZTQ7%6OI).RLF=5B^62TS3Z
M1'&&7((T@!S;J(SAB2QQ'=<@C& 48@CQ#R*UB@\EAF;H64">^&56DD8):E3Z
M89ABA%7;M+@Q9H\UVCCQ3T^" A#-A@E#Y^>8\"3>B&1/L$U3OPP*[(1^G$;8
M9H%?EKAR=0C*7_ ALGQ0&:V#HG./.M<PSL9P][:KQ* XGB*%+QLFS_!GC)OD
M'2W('@6,\W) BS%CIS.0E!#ED$$1_;?RHSR@1 6H[X@HYGDZ/A!_"('6R"8=
M_R\QWR6(9,Q(O33'3(6=%DD0DXR1GV0HS@TSYI6J%'';X_G(_" N(,S](DHA
M23.($BR#\JCKN]T+/XT#<LSR I(DA2CSLS3N$DS)J#KQZ7I@;_5 4W=J+1;F
MQ<=.!2/+.?RJ'8?K23@93RA'Q^[(Z<%#UW"SZIYSBX6)W/HW;Y@=OABN^H?R
MS;S_W/C*S$I@94J^1-=@DJ=>?[?L!TYONF=SH1T^PEUWC5\]W) !KB\U\MT-
M:(/A.VK^+U!+ P04    " !54_E874X6)(0$   ["@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6R-5MMRXC@0_94NIB9%JF:-+UP30E7(9";)%CM4
M2+(/6_L@[ 9K8TN.),*P7[\MV3B0(=2^@"WUY?3ITY:&:ZF>=8IHX&>>"7W1
M2(TISEHM':>8,^W) @7M+*3*F:%7M6SI0B%+G%.>M4+?[[9RQD5C-'1K4S4:
MRI7)N,"I KW*<Z8V8\SD^J(1-+8+]WR9&KO0&@T+ML09FL=BJNBM54=)>(Y"
M<RE X>*B<1F<C3O6WAD\<5SKG6>PE<RE?+8OM\E%P[> ,,/8V B,_E[Q"K/,
M!B(8+U7,1IW2.NX^;Z-_<[53+7.F\4IF?_+$I!>-?@,27+!59N[E^@:K>AS
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M&>[O=^BO/7?BDC.#UTI\XZ6MET$60(D5ZX2]5=LW./"9.KQ"">-7V/:ZLUD
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M"'J]^D7%OMW'0YU+(9I6(^2#R21]!EUNV"$[LW/@!6X0#"9;.&2 T-'.D-#
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M/<J[RP4R6CT[@.[/I#1=PT[0OXV9_ 502P,$%     @ 55/Y6/.)E&6(!P
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MY1F'%KU#BW/2X9#O./+BE7SSK^7[E$OGE7[>"T9[3#I1>[%Y)[9YKE=[O6I
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MP ?](()Y",)I3#C5\>?E4Q:<K[8M7?;,[O7!PLN!JJ?6/]7 @X:C*F["W8^
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MSXW#*Y0T_A?VO6YZ$T#1&:OJHS$QJ$73K_SY&(<S@WGTB@$[&C#/N[_(L_S
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M[JPL2<U,2+5"&JF2=[S*+D4XUL%IZI$C2')NB1F,:+)%6WEJ DG#JF"WXTG
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MZBM/C_\B:W/^>XMQV')A[PA>%-@5=;5:RV%-H 6_<81FJ4:/#P-]+N^$KXN
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M<'E<>"/O?N":[?;&#OC+>4%W< /F<[%1V/,;EHSE(#23@BC8+KS+T44R"BS
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M.:B=@=RYL!Z$33_H>>M#3:LFM?SC29.*27YW/^E(@W:I0?L-&G!I:7?A,X'
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MW3VG.X_74CWK L"0EY(+/?$*8ZJ1[^NL@)+J4UF!P)N%5"4UN%5+7U<*:.Y
M)??#P6#HEY0)+QF[LWN5C&5M.!-PKXBNRY*JOU/@<CWQ F]S\,"6A;$'?C*N
MZ!(>P3Q5]PIW?L>2LQ*$9E(0!8N)=Q6,TMC:.X,?#-9Z:TUL)G,IG^WF-I]X
M QL0<,B,9:#X6\$,.+=$&,:?EM/K7%K@]GK#_LWECKG,J8:9Y#]9;HJ)=^&1
M'!:TYN9!KF^@S>?,\F62:_<EZ\;V//)(5FLCRQ:,$91,-'_ZTNJP!4">?D#8
M L+W@'@'(&H!T7O < <@;@%.:K])Q>F04D.3L9)KHJPULMF%$].A,7TF;-D?
MC<);ACB3W)8590KK:(A<D%MAJ%BR.0=RI34838Y2,)1Q?4Q.R/73 SDZ/+B(
MAO'E,6D7A ERQSC'(NJQ;S D2^QGK?MIXS[<X7Y([J0PA2;7(H>\!Y_NQP?A
M'@(?M>@$"3>"3,.]C-]K<4JBP1<2#L*X)Z#9_\.COGSVPU/($![TP=]D$W7E
MC1Q?M(N/Z8Q+72NPY66OQ<9#3:C(L757H#3E??>_Z%P;A:WYNZ^RC>>XW[,=
M5R-=T0PF'LXC#6H%7G)X$ P'EWVJ?B99^DED;Q2/.\7C?>S;#>4TQ-DF30$*
M^Z3K+>IZJT_3AOO,<=N)O4I.HO-@[*^VM?IH%)R]-4D_FEQ\'78V36+^UM0H
M02W=]-4DD[4P3;]TI]V OW)S[=WY-!C-FCG]2M.\&G=4+9G0A,,"*0>GYQB1
M:B9QLS&R<K-I+@U..K<L\/$"90WP?B&EV6RL@^XY3/X!4$L#!!0    ( %53
M^5@W.VTGTP4  $$>   9    >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;+U9
MVV[;.!#]%<(%@@1H+8GR-7$,)$ZW31=&@V:3?0CZ0$MTQ(TDJB1E-\!^_)*2
MK(M-,W56S4NB"^>0<S@S/-9,UI0]\0!C 7Y&8<S/.X$0R:EE<2_ $>)=FN!8
MOEE2%B$A;]FCQ1.&D9\91:$%;7M@18C$G>DD>W;#IA.:BI#$^(8!GD818L^7
M.*3K\X[3V3SX1AX#H1Y8TTF"'O$M%G?)#9-W5HGBDPC'G- 8,+P\[UPXIU=P
MK RR$?<$KWGM&BA7%I0^J9MK_[QCJQ7A$'M"02#Y;X5G. P5DES'CP*T4\ZI
M#.O7&_0_,N>E,PO$\8R&?Q-?!.>=40?X>(G24'RCZ\^X<*BO\#P:\NPO6!=C
M[0[P4BYH5!C+%40DSO^CGP41-0/'W6, "P.X;=#?8^ 6!NZV06^/0:\PZ&7,
MY*YD/%PA@:831M> J=$235UD9&;6TGT2JWV_%4R^)=).3*_C%>9";J3@X,+S
M:!H+[ ,93^".D_@1B "#CS]2(I[!'(N ^N #N,UC!- EJ)N3&%QP3CV"!.8
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MS,USC=(&F/V%$'H[L0<T?P#BWU!+ P04    " !54_E8T/:)ZJX#  "/$P
M&0   'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6S%6%UOVS@0_"N$"@0MT$2B
M),M*8@M(D[:7PQ47)&COX7 /M+RVB$JB2])V^N^/E!1].+)@!P3\8I/2SFAW
M=FRL.-DR_E,D !(]9VDNIE8BY>K*MD6<0$;$!5M!KNXL&,^(5%N^M,6* YD7
MH"RU7<<)[(S0W(HFQ;4''DW86J8TAP>.Q#K+"/_]"5*VG5K8>KGP2)>)U!?L
M:+(B2W@"^7WUP-7.KEGF-(-<4)8C#HNI=8.O;G&H 47$#PI;T5HC7<J,L9]Z
M<S^?6H[."%*(I:8@ZFL#MY"FFDGE\:LBM>IG:F![_<+^I2A>%3,C FY9^@^=
MRV1JA1::PX*L4_G(MG] 5=!(\\4L%<4GVE:QCH7BM9 LJ\ J@XSFY3=YKH1H
M ;"_!^!6 /=0@%<!O*+0,K.BK#LB233A;(NXCE9L>E%H4Z!5-337;7R27-VE
M"B>CFSAFZUP*] @QT V9I8#.T5/95,06Z"MG0J ?)%V#WOZ] 3Y7RR9<H/=W
M( E-Q0>%_/S]$;T_>Q=Z@7_] 54+1'/TC::IZIN8V%*EK1]NQU6*G\H4W3TI
M_KG.+Y#G?$2NX_H]\-MA^!W$"HX+N->%VTJL6C&W5LPM^+Q]?%3$*1-K7NCQ
MA>8DCRE)T8T0H'24"9&(J)N?J4R HP<B)+K3XG%TGZT(Y3!'__ZE2-&]A$S\
MUR=(F8'?GX'^95^)%8EA:JF?K@"^ 2LZ>X<#Y[I/'D-D';&\6BQOB#UZL0MO
MV659.&JC'=57>TDX*@CUG] F"OQ@8F_:)?7$A)=U3"=3O\[4/RC3V6^DDBSZ
MF".,,I;+I"_-0;9C6V2(K%/XJ"Y\='(_CTR*98BL(U90BQ68]G-)&+2\Z@;^
MCI_[8O;X>5QG.C[4S_C<*WW<^^<[2'-L;PR1=2H.ZXK#DQLY-"F6(;*.6)>U
M6)>FC7SYRJ38&>T8N2=FY/<;&3O-B.(<:F7O/!BP\C#/L>TQQ=:MNC68X9/;
MN4K!E&"&V+J"-7,9'IQDWF+IBK'C5V^\X^F^(#U)]IJZ&8SP89.1,G5PCMTA
M5P\2'=TD0VS=LILI"_NG=[71V<P46U>P9CK#@_/,FUP]>F78UC115=43X^[Q
M=#,<X<.F(^7ILZ6\1L.V'N0ZNDN&V+J5-\,6'I_>UD8G-5-L7<&:60T/3C=O
MLG7XZJUOC'=M_3HFQ#NVMENG)?JHZAOA2YH+]=JW4"#G8JS0O#S]*3>2K8H#
ME!F3DF7%,@$R!ZX#U/T%8_)EH\]DZC.XZ']02P,$%     @ 55/Y6&4R +9G
M"0  \&8  !D   !X;"]W;W)K<VAE971S+W-H965T-C(N>&ULO9U;;^,V&H;_
M"N$"[13HQ!(E^3!- F2B,W9V@TG;O5CLA6S3L3"2Z*'H'(K^^-4IEF7+C%V\
MF[D86XJ^AY3]O3+)5Z0NG[CXEJ\8D^0Y3;+\:K"2<OUI.,SG*Y9&^05?LZSX
MRY*+-)+%IG@8YFO!HD45E"9#JFFC81K%V>#ZLMIW)ZXO^48F<<;N!,DW:1J)
ME\\LX4]7 WWPNN-K_+"2Y8[A]>4Z>F#W3/Z^OA/%UG!+6<0IR_*89T2PY=7@
M1O\4&D894!WQ1\R>\IWWI#R5&>??RHU@<370RAJQA,UEB8B*ET=VRY*D)!7U
M^-Y !]LRR\#=]Z]TMSKYXF1F4<YN>?+O>"%75X/)@"S8,MHD\BM_\EES0E;)
MF_,DK_XG3\VQVH#,-[GD:1-<U""-L_HU>FX^B)T W3P20)L NA]@' DPF@!C
M/\ Z$F V >:I 5838.T'C(X$C)J T:DG/6X"QJ<&3)J R:D!TR9@>FJ KKU^
M<UJ50?577N6+'<GH^E+P)R+*XPM>^:9*NBJ^2),X*_5Q+T7QU[B(D]>W/,MY
M$B\BR1;D?A4)MN+)@HG\)^)\W\3RA7PD-XM%7"9SE) @JR59IO8'F\DH3O*?
MBT.<W[^2#S_^,#%&YJ\_7PYE4;.2/YPWM;#K6M CM1B1+SR3JYPXV8(M>N)=
M=;Q.%8!A\9%L/Q?Z^KE\IDKBS5I<$$/[A5"-FCT5NE6'?XE>"+6J:*/OXU!'
MAYM,6;AS>GA?Z:XZW&;S(EP_&NZ=4#HUCU;>?R,\RK:E]X4'IY1N'*U\J YW
MV>R":+0OO)-&QE9>1L4SCGV6<3Y/>+X1C/ EF2=1GK.\?)N74B/S:!W+0E;_
M^4<11P+)TOR_/97^7!=B]A=2_H1^RM?1G%T-BM_(G(E'-KC^\0=]I/W:E[E(
MF(V$.4B8BX1Y2)B/A 5(6 B"=:1B;J5BJNC7][N*Z!.!,OQ<$2!A=@VS*EC9
M('V\II9!Q]2R='HY?-Q-<62Y+A+F(6$^$A8@82$(UDEQ:YOBEC+%_[E)9TQL
M+_\Y^1!GS=N^1M-G)>W<C$?"[!HVVLEXG8Y&QHB.K=%>QB/+=9$P#PGSD;
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M!5!:B*)U$[ZUX VU!:]L>;E<L/@A([<;(5@V?R&_B2C+DWJ!9%C#3%W#L]4
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M'*0!X/>E$'J[,*V\_6\0_P-02P,$%     @ 55/Y6-.S;H!%!0  !!@  !D
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M@"W YS)_(KP:/1 A>9:T;@)\9A+\I83WL:3T!7Q5\VKNW0V1.*/B0N'<?GD
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MOAV\[BW6#Y*M=7ONB4G)<CU<$9P27AFH^05C\O6A6J#M\,[^!5!+ P04
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MDZ?:UTG;,;)V]7HE#59_URSQ00?* O#_M91FW[$3]$_$^7=02P,$%     @
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M-=<?5!=CHGBL1TVGZEWF6\\_U&0@,<ED[/0\XM@'/4QP(A+CU4LQ:.4Q,^.
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M900  (X;   9    >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;+V976_B.!1
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M;!_^;!N*I_GCD#E7BB?YX0I)A,*<H+]?<)W91<,\82D?P4W^!5!+ P04
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MNG93&8(TH'PAE? 3J?(3J7B^D$[S!8UG2\EV@:7IPO_K:E%6SX_FVF3E!]*
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M$MXH&GBC C(U[M7@2W*>#F)BTI#B'A$<*A(<*O*$42_JS*QOP$%")D4#F51
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M*(U":0Q%T_53=LOHT%;VC*!6#91&H32&HNG2*ZMF].PK>ZH:3#MR3LRMZ*T
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MXC(/TQ$%##08, YQS7>-Z878UAX!QB#S&ZRS4,8 8<: )GVYB"LS?U(<D<%
M@P;C$)?B,UE9[LD1=@PRO\D["V(,$&,,:,R7D[B,V=N L&"@X8)QB&N^QTPO
MQ+KV^+.)_<;P+&PR0' RH/E@3N(RQJ  XHF!*5#LB.+2MI[I-5E_LC2Z&,C]
MYO,L@#- A#.@(6,N.LNG^;SZ-A)AR4##)7-4FJ8C34]N77%T"9#[#>-9.&>
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M@S B:-98K"2'R?WUMR7;^"U8#]3,A]W@1[?Z'+6ZCSSVY8;QO\22$(F^K?Q
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MM37P10.5*%/)X2H%.WE]3_&,^E12(M 3\;$D<R09N@T%W"@$&K'5C 983:I
M.- 7'UCP;L0"R9D/[E[0))"$$R$%>H>F4<(AMD ?V2N!E(+3-$"''>?DCDA,
M?=&&$<>?G]#)K[^<.0/WHHWB'VK(CQ3,P-UE5P)1"F[7BTD91:38-:0,(/9
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MK+(Q;O9BY"J=4\ZD,3)*'Y>TV:CL I+/I30O+]9 ,4R?_ M02P,$%     @
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M&=(L/P//;P1=ZC/;"16"9OIR@6""F.H@G\\H%9L;-4#YGPC#?P%02P,$%
M  @ 55/Y6/V,HWL5 P  8PP  !D   !X;"]W;W)K<VAE971S+W-H965T.#(N
M>&ULO9==3]LP%(;_BI6AB4D;^>H'96TD:(6&!*.BL%U,NS#)26/AQ)GMM/3?
MSW9":$<:M5NUF]9.\K[V<X[MG R7C#^)!$"BYY1F8F0E4N9GMBW"!%(L3E@.
MF;H3,YYBJ;I\;HN< XZ,**6VYS@].\4DLX*AN3;EP9 5DI(,IAR)(DTQ7UT
M9<N1Y5HO%^[(/)'Z@AT,<SR'&<B'?,I5SZY=(I)")@C+$(=X9)V[9V/7",P3
MWP@LQ5H;:91'QIYTYRH:68Z>$5 (I;; ZF\!8Z!4.ZEY_*I,K7I,+5QOO[A?
M&G@%\X@%C!G]3B*9C*Q3"T40XX+*.[;\ A505_N%C KSBY;EL[V.A<)"2)96
M8C6#E&3E/WZN K$F</TM J\2>+L*_$K@&]!R9@9K@B4.AIPM$==/*S?=,+$Q
M:D5#,IW&F>3J+E$Z&=S&,;K %&<AH)E9-V.6ID2J3$F!CB<@,:'B _J$'F83
M='ST 1TADJ$;0JG*@AC:4DU"6]EA->!%.:"W9< ;O$*N_Q%YCM=I4(]W4#M-
M:EN!U_1>3>\9N\X6NZ]L@1?XN8FB5:@WUYG(<0@C2^T> 7P!5O#^G=MS/C=!
M'<AL@]&O&7WC[F]AG! 14B8*#N@V1NWY_G&MQ.A*0BI^-@7%/V10#F2V$91.
M'91.:^(?\IBS3*(<KS1Y$VNKP;ZLI9GK&#=]M"Z"KN,,[44#0[=FZ+8RW#.)
MJ=Z)H$X)E;9IR=*X)UN=]H4IS7IK+*ZW#:97P_1:82:P4*^47 .@.Y@7%$O&
M5^@\B] U+K(PV1&T=91]07MO0/O;./LU9[^5\SR*B'Y_J<Q57!IQAA7;CH2M
M_OL2]M^NRZVI/*T13UL1+PL:\B)%]PEPG$,A2=@(TNJR+\B!S#: !S7PX+^=
ML(-#!N5 9AM!<9W7RL+YUS.V<MA8?Z>ORZ^J"%J'^5N,M0+);<48*P:2S?7!
MM-L&K?PVH ;][I]4K:/N2V6O58"Z_+[!?$XR@2C$RMXYZ:LSFY<5;=F1+#=%
MX2.3JL0TS41]!0#7#ZC[,6/RI:/KS/J[(O@-4$L#!!0    ( %53^5CC;>;9
MZ@,   D1   9    >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;+U8:V_;-A3]
M*X06#"W010\_D]D&'&=-,R2;T;0;L&$?:.G*(DJ1'DE9,; ?OZN'9:N1A;G0
M\L46)=YS[SDZI"\]2:7ZHB, 0YYC+O34BHS97-NV]B.(J;Z4&Q#X))0JI@:'
M:FWKC0(:Y$$QMSW'&=HQ9<*:3?)[2S6;R,1P)F"IB$[BF*K=#7"93BW7VM_X
MR-:1R6[8L\F&KN$)S.?-4N'(KE "%H/03 JB()Q:<_=ZX0ZR@'S&;PQ2?71-
M,BHK*;]D@_M@:CE91<#!-QD$Q:\M+(#S# GK^+L$M:J<6>#Q]1[]?4X>R:RH
MAH7DO[/ 1%-K;)$ 0IIP\U&F'Z DE!?H2Z[S3Y*6<QV+^(DV,BZ#L8*8B>*;
M/I="' 5X[HD KPSPO@X8G CHE0&]G&A164[KEAHZFRB9$I7-1K3L(M<FCT8V
M3&2O\<DH?,HPSLP>F&%K6B@J C)7*V94,5XJZ0,$3*PU>7,+AC*NWY(?R+QX
M 6@ADD;,CT@*A"K(Q ,14&'(!6&"/#+.<9Z>V ;KS++9?EG335&3=Z(FESQ*
M82)-?A(!!/5X&_E5)+T]R1NO%?"1[HCGOB.>X_7)YZ=;\N;B;4-9BW:4GQ-Q
M27I.";.IU&DIL%>]A5X.W3\!O>1TRY[)W!BI!.S('0A0E.<F1ZE1S0\TI8PU
M:=F*G.T"UWI#?9A:N,PUJ"U8L^^_<X?.CTT*= 16$Z%?B=#/T7LG1+AEVN=2
M)V@E&9('6&<"'#S):X;\\P&CR;V!6/_5I$J_2U4Z JNI,JA4&;1:XX[+%7+'
M;9MRLR,A -K!3Y2"@*QVAT6GWQ$:RP17WY;ZU.#3?\A%DS)%.M?)\V6[_'9V
MY0XG]O:8<6M-W\AX6#$>MB^&DNI[I'J_IWJ"S/ EF?Y@_!69UG3?2&94D1FU
MDOE$GZ4!M#2:-TA\0XXVW'M!/D6 &Q*R.SRF*\9Q#C1NG*W)SK5U1V U7<:5
M+N/76^SC+E7I"*RFRE6ERE6K6WY)XA4H\FM(\!>!"</"L-$&K2CG$B[ AD=+
M:#@:.=4:JA%QG4-?X;12^0/W).HWV1Y_S<R9MF_/=2[AKM#JRAQU7.[K6;_,
MU94R':'5E?$.RGC_T?X+[,R;G="*<#9?[X7W^WWGE/</W9S;WL[=21Z0&XGO
MM)M=OSW=V:3_CR;//71Y[BNV>6ZG?5Y7:'5E#IV>V][J'=F?4ZWW!ZT'FNJ$
MF69G=-2HE?P'+W\*7JP&^^BP&8-:YV=P3?RL]RS.G=7=ZIP_ST^W]F%Z\2?!
M(U5K)C3A$&*H<SG"_*HX=Q<#(S?YT74E\604YY<1T !4-@&?AS)KKHI!EJ#Z
M]V/V+U!+ P04    " !54_E82N)F2:@#   D$   &0   'AL+W=O<FMS:&5E
M=',O<VAE970X-"YX;6R]6-%NVS84_15"!8H$V"*1DF4[M0TD4=9E6) @1;>'
M80^,=&T3I4B-I.,,V,>/E!3%EF4A*82^V"1USR'/(2^MZ]E6JF]Z#6#0<\Z%
MGGMK8XISW]?I&G*JSV0!PCY92I538[MJY>M" <U*4,Y]$@2QGU,FO,6L'+M7
MBYG<&,X$W"ND-WE.U;^7P.5V[F'O9>"!K=;&#?B+64%7\ 7,U^)>V9[?L&0L
M!Z&9%$C!<NY=X/,$$P<H(_Y@L-4[;>2D/$KYS75NLKD7N!4!A]0X"FJ_GN *
M.'=,=AW_U*1>,Z<#[K9?V'\IQ5LQCU3#E>1_LLRLY][$0QDLZ8:;![G]%6I!
M(\>72J[+3[2M8P,/I1MM9%Z#[0IR)JIO^EP;L0.P/-T 4@-(&Q = 80U(&P#
MXB. J 9$I3.5E-*'A!JZF"FY1<I%6S;7*,TLT58^$V[?OQAEGS*+,XL[LP:%
M[@I0U#"Q0C<BE3F@"Y&AZV=[N#1H]#.ZR#+FMHER&U =-K=I)PD8RK@^M2'7
M7Q_0R<</DS"./IVBNH&80+>,<QNL9[ZQZW6S^FF]MLMJ;>3(VF)T*X59:W0M
M,L@Z\$D_'I,> M\:U;A%7MRZ)+V,OVW$&0J#GQ )2-2QH*NWP\,N/?WP!%(+
MQUWP/35AL_=AR1<>XV,ZY5)O%*"[)3IR$II3\-?O%HYN#.3Z[ZZ]K.:*NN=R
MU]>Y+F@*<\_>3QK4$WB+CQ]P''SJ\G%(LF0@LCV/H\;CJ(^]SB_9N,I*5[O\
MJWA&)8^[K9\6,1[/_*==6]X0DQS&8#(E3=">BE&C8O0N%5 =BBX9%5&\,ST)
M<-#2<1B$(T):0@Z#PA&.NX7$C9"X5\@#K$" LG?7?ZA[:]!)+>ZT2UTO^WL/
M^9!DR4!D>ZZ.&U?'/_ B&0_I\9!DR4!D>QY/&H\G UTDDX.\F<:M_#L,P4$[
M_28']P@AX^[LFS8:IF_0H(!3 QDJJ#+,GH?OR\3>F=Y[2H8D2P8BVW,8!Z_O
M<\$/S,5ZLH%L'I0M&8IMW^B=%V<\4$+61'OIAB>ME.P*BEN_FTG_DKY7,GF5
M3'HE?[9UI$;VQS.SM9HVMOPS2"Z1=D?*E@3NS!5*9IO4=+_MDX,K)9Q,VSX<
M!D4X;/O0N\[W^N#OE$\YJ%59AFJ4RHTP56W0C#:E[D59X+7&+_'Y556POM)4
M]?,M52OG'8>EI0S.QE:?JDK2JF-D419IC]+8DJ]LKFT9#\H%V.=+*<U+QTW0
M_#&P^!]02P,$%     @ 55/Y6(,&S@+G!0  DR8  !D   !X;"]W;W)K<VAE
M971S+W-H965T.#4N>&ULO5I=;]LV%/TKA L4"=!4(B7+=NH82*(.S="B18IN
MP(8]T!9M"Y5$C:3C!MB/'RG+^J39J"#\DDCRO4>\ASS4O23G>\J^\RTA OQ(
MDXS?C+9"Y->.PU=;DF+^EN8DD[^L*4NQD+=LX_"<$1P53FGB(-<-G!3'V6@Q
M+YY]88LYW8DDSL@7!O@N33%[OB,)W=^,X.CXX#'>;(5ZX"SF.=Z0KT1\R[\P
M>>=4*%&<DHS'- .,K&]&M_ Z]%SE4%C\$9,];UP#%<J2TN_JYB&Z&;FJ120A
M*Z$@L/SW1.Y)DB@DV8Y_2]!1]4[EV+P^HO]6!"^#66).[FGR9QR)[<UH.@(1
M6>-=(A[I_@,I QHKO!5->/$7[$M;=P16.RYH6CK+%J1Q=OB/?Y1$-!PDCMX!
ME0ZHZ^"?</!*!Z_K$)QP\$L'OV#F$$K!0X@%7LP9W0.FK"6:NBC(++QE^'&F
M^OVK8/+76/J)Q6>Q)0Q\S@G#(LXVX"%;T92 VRP"[W_(P<4)!U?@JQQNT2XA
M@*Y!UZ,RNPB)P''"+Z7#^V^/X.+UJZD7^.\N07D!X@Q\BI-$]C>?.T*V7K7!
M694MO3NT%)UH:0 ^T4QL.7B?1232^(=F?X@, (ZDK>(.';F[0T;$WW?96^"Y
M;P!RD:]IT/W+W3U=/&;WD*RD.]2YMZ+QJI'@%7C>*;R8KQ+*=XR S_U>+L=%
MU=E_?Y3NX$&0E/^CZ\O#NWS]N]1D=LUSO"(W(SE;<<*>R&CQ^A4,W'<Z'FV"
MA9; 6AS[%<>^";U4&ZU8)26=.@8/2.,"2<W>3XLKY$)W[CPUJ=%801^AME6H
ML?+&,*BL6L&,JV#&@X*)BR&B"^6 $S1>'\!))Y 7V(1]&XAF2!]%4$41_$(4
MSL6Q:R[?@$Q^?AE)L" 1$!0\D@W)"*.9+M2@U\0K./''G6!U5AZ"G7 U5F@V
MF>GCG53Q3EX0[S&<'#,12SG_!_0\@",/E[I@C6\:*G*;8*$EL!;#TXKAZ1DG
MTJE-CFV"A9; 6AS/*HYGEN:>67_.@-..'#4V06>B#8WM^<5HH5MG::XQ7IFY
M4#FH,IS(U$S$2QHIU=[*7 IG*VW<9L"A \<J6F@+K4UF(^6%9Q1H^3);1-M$
M"VVAM8E&-='(6KI30K6_B5.OFR9HS?RNHD.=F0=G)S(>6.?(T)@>_D2'\C-:
MCI[7.,W?'>-M)@\YH^M8.'+X<<"WF"E:=K(>84!R!?KPSV:16TVSK:*%MM#:
M/55GVM _I\B->?U@HFVBA;;0VD3750 <5@881=[/X*_@S/.[(M>9^?ZL*W*-
MF==,H]L1U14!-)<$/Q7Y;13%:M5*&B@-%\LB!V'+A#J.P/*Y+A*DZ/>811Q$
MY(DD-$]))L"*<J$GR-BRP>/,)EIH"ZW=*W7= B?G%+35VL4J6F@+K4UT7;Y
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M'B\VT4);:&UJZXH#!><4IM4BPBI:: NM371=1*"7['Z\)+<M@5HZ"[I:[-M
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M'LEV2HNB!J,'!2NK7_I2!^(($,8G %$-B-J W@E 7 /B-B Y 4AJ0-(&I"<
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M=ECI*PF$"=#[2\[5=F(^T%URZ5]02P,$%     @ 55/Y6'IFXKLN!@  LAD
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MC'7Q T%Q8]4B_P+^J*Q567XY%QRRR@'@_51!D,H;-T#U,\WH7U!+ P04
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M)N :H+ZO&9.'CIZ@?X:E?P!02P,$%     @ 55/Y6.F,9?4.!@  )A8  !D
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MBNG=[),K?T0?N<SV=.:SJR#WL,MM?/OT*L@RO6T24N'WRBNUCN*-\JE]C*O
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M@-G(#U50!,R$UM@TJB1CD>\]LB+0F56@;K(A*TJQ&@5T:F6<TR5@D>\\MR(
M_@0C?8*#S&BDXBYD)E:FR!2'I"GR H=7!#J7TE(_ \T\#:D@LS XV]YT0Y-$
M1?H]P2( _?@Z*,)FOM9B$'%%H0%_B60I8F>I;^1$HI.-V&EH!U>063369@;
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M ;Q?"J!=W)@&RG]VF/T#4$L#!!0    ( %53^5CDPH\^R 4  %DC   9
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M:X(#DLH)XOD#I?SU1CHHOZ:9_@]02P,$%     @ 55/Y6&Y_KGZM!@  X"T
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MQE\WC2<CC??0QSP3VQ*]S=9\;8B/X'A, (*YK&173O)0SFL",OY^R%XAZKQ
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M-LXD5T^)BI/A#)9J4R2ZH;DEM+2?T)03&I$53M'$I !<($QC-.$0$XGNB'A
M[Z]!8I**#T-;JD0TG!T5BX[S1;T3BW;1+:,R$>@+C2&NQMN*0,G"V[$8>XV
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MY^^\JGV+Y5O2JBVTJE@'-R6W90L7@%5[.L<']?]F5=/U]NEZS[1QPJ$^O4:
MLW>G);0JW?V5R_5?U\JM7LS:0JN*M;^:N8T7FI=8.:@S:<^I?-QC9Y\7E).Q
M#XH9M5-+4^,)%+$UE7E%4(Z6=>25J9Z.QL>ZOC1%TAXF+TYO,5\2*E *"P7I
M='KJKL3S>B_O2+8R)=.<2647TTQ4C0Q<3U#/%XS)74<O4%;=X3]02P,$%
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M466#5DZ,+%RS,I$&.R8WS+"I!64WX/NIE&8YL6U3W29W_P%02P,$%     @
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MK 39Y8.<!+GE@[P$^>6#@@2%Y8.B!,7E@Y($I>6#L@3EY8.*!)7E@TRC,C:
MI!G6 *V-<FT 7AL%VP#$-DJV 9AM%&T#4-LHVP;@ME&X#4!NHW0;@-U&\38
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MUU,LY.;0GG_%U\18^N+W<Z=I-Z[YR^QXO3_&^;#,PV?+X_([_G7&K_7?V8>
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M2P$"% ,4    " !54_E8)S78Z^\    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !54_E8F5R<(Q &  "<)P
M$P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( %53^5AB,J,$O0(  )<(   8              " @0X(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !54_E8AGG5<A$'  #6'P
M&               @($!"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ 55/Y6#:Y+YBM!@  !AP  !@              ("!2!(  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( %53^5CUVR"[)04
M "05   8              " @2L9  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " !54_E8]U^+YC@-  !]>0  &               @(&&
M'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 55/Y6'ND
M>Y+- P  B T  !@              ("!]"L  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( %53^5@^^;L;0PP  'TV   8
M  " @?<O  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !5
M4_E8._=:;LP$  "]$   &               @(%P/   >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ 55/Y6/VJ#\DL P  I 8  !@
M         ("!<D$  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( %53^5A]$$OB(1$  - T   9              " @=1$  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 55/Y6-SW4'3S!0  IPP
M !D              ("!+%8  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " !54_E8T#5JU/P"  "*!@  &0              @(%67
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( %53^5C6H(#+
MK 4  #T-   9              " @8E?  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ 55/Y6$W=,?'0 @  ,@8  !D
M ("!;&4  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !5
M4_E8(_,BQ,8$  !#"@  &0              @(%S:   >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( %53^5CC<E/U' ,  ,<&   9
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M970R,"YX;6Q02P$"% ,4    " !54_E8?[@@A),'   D$P  &0
M    @(&HDP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M %53^5B* ))4C@@   44   9              " @7*;  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ 55/Y6+AHF'E1"@  >!<  !D
M             ("!-Z0  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " !54_E8:<=6PY4$   R"P  &0              @(&_K@  >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( %53^5@\: 5+0 0
M $$)   9              " @8NS  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ 55/Y6.>__:,+ P  D@8  !D              ("!
M K@  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !54_E8
M12("!P<%  #/"P  &0              @(%$NP  >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( %53^5AC(XXYJ@4  /D,   9
M      " @8+   !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ 55/Y6&P<3G9*$   MB\  !D              ("!8\8  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !54_E80Z%H49L"  "S!0
M&0              @('DU@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( %53^5@>I>J>\!   '4U   9              " @;;9  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ 55/Y6#PI'E,X
M!P  P14  !D              ("!W>H  'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " !54_E8<Z@?AM8"  !/!@  &0
M@(%,\@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( %53
M^5BG$+^F0 0  %,)   9              " @5GU  !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ 55/Y6%U.%B2$!   .PH  !D
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M=#,Y+GAM;%!+ 0(4 Q0    ( %53^5CSB91EB <  %88   9
M  " @0 6 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
M55/Y6#Z;TT\(!   :PD  !D              ("!OQT! 'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    " !54_E8SC%%YND&  #O$0  &0
M            @('^(0$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( %53^5CM%AY/M0,  "@(   9              " @1XI 0!X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ 55/Y6"_Y-051 P
M&P<  !D              ("!"BT! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    " !54_E8B"13EL4$  !C"P  &0              @(&2
M, $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( %53^5@L
MKBW9E@4  'L-   9              " @8XU 0!X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ 55/Y6.!LS.H;#0  <"8  !D
M     ("!6SL! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %53^5@]CQ6&20(  /8$   9              "
M@6-; 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ 55/Y
M6 (??+"0!   S!D  !D              ("!XUT! 'AL+W=O<FMS:&5E=',O
M<VAE970U,RYX;6Q02P$"% ,4    " !54_E8 !XP&P4+  #,;0  &0
M        @(&J8@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0
M   ( %53^5@AHK_ H0(  !H'   9              " @>9M 0!X;"]W;W)K
M<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ 55/Y6#<[;2?3!0  01X
M !D              ("!OG ! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q0
M2P$"% ,4    " !54_E8PBK[;]@#  !1#@  &0              @('(=@$
M>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( %53^5AWJ^A^
MD ,  )0-   9              " @==Z 0!X;"]W;W)K<VAE971S+W-H965T
M-3@N>&UL4$L! A0#%     @ 55/Y6*>]]D&P @  6PH  !D
M ("!GGX! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " !5
M4_E8*.N0]-$"   ,"   &0              @(&%@0$ >&PO=V]R:W-H965T
M<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( %53^5C0]HGJK@,  (\3   9
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M970V-2YX;6Q02P$"% ,4    " !54_E8NV83-'L%  #*(P  &0
M    @(']G@$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    (
M %53^5ALY^.B9@,  "X*   9              " @:^D 0!X;"]W;W)K<VAE
M971S+W-H965T-C<N>&UL4$L! A0#%     @ 55/Y6#>0@1%[!P  C2T  !D
M             ("!3*@! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"
M% ,4    " !54_E8+J[X(T@$  #D$0  &0              @('^KP$ >&PO
M=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( %53^5B_N!'/9 <
M $4[   9              " @7VT 0!X;"]W;W)K<VAE971S+W-H965T-S N
M>&UL4$L! A0#%     @ 55/Y6(NJ^;3V"   24T  !D              ("!
M&+P! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " !54_E8
MG/\^/F4$  ".&P  &0              @(%%Q0$ >&PO=V]R:W-H965T<R]S
M:&5E=#<R+GAM;%!+ 0(4 Q0    ( %53^5BT0^LI+0,  !<,   9
M      " @>') 0!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%
M  @ 55/Y6.S.]Y O$0  E^@  !D              ("!1<T! 'AL+W=O<FMS
M:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " !54_E8"08EDY$+   :@
M&0              @(&KW@$ >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+
M 0(4 Q0    ( %53^5@1-;#:B0X  %*R   9              " @7/J 0!X
M;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ 55/Y6$QEDK 5
M"P  SSP  !D              ("!,_D! 'AL+W=O<FMS:&5E=',O<VAE970W
M-RYX;6Q02P$"% ,4    " !54_E8,G#I\#L$  !Z$@  &0
M@(%_! ( >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( %53
M^5A3,30^& 4  %@7   9              " @?$( @!X;"]W;W)K<VAE971S
M+W-H965T-SDN>&UL4$L! A0#%     @ 55/Y6$[';4A?!P  >B@  !D
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M=#@T+GAM;%!+ 0(4 Q0    ( %53^5B#!LX"YP4  ),F   9
M  " @>LF @!X;"]W;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @
M55/Y6&2^ZJCZ P  %0P  !D              ("!"2T" 'AL+W=O<FMS:&5E
M=',O<VAE970X-BYX;6Q02P$"% ,4    " !54_E817C&(&4"   )!0  &0
M            @($Z,0( >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4
M Q0    ( %53^5C6R"26D@(  / &   9              " @=8S @!X;"]W
M;W)K<VAE971S+W-H965T.#@N>&UL4$L! A0#%     @ 55/Y6'IFXKLN!@
MLAD  !D              ("!GS8" 'AL+W=O<FMS:&5E=',O<VAE970X.2YX
M;6Q02P$"% ,4    " !54_E8EZ.8CSD#  "2"0  &0              @($$
M/0( >&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;%!+ 0(4 Q0    ( %53^5CI
MC&7U#@8  "86   9              " @71  @!X;"]W;W)K<VAE971S+W-H
M965T.3$N>&UL4$L! A0#%     @ 55/Y6+=2>4&* @  5@4  !D
M     ("!N48" 'AL+W=O<FMS:&5E=',O<VAE970Y,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %53^5CDPH\^R 4  %DC   9              "
M@<YZ @!X;"]W;W)K<VAE971S+W-H965T.3<N>&UL4$L! A0#%     @ 55/Y
M6&Y_KGZM!@  X"T  !D              ("!S8 " 'AL+W=O<FMS:&5E=',O
M<VAE970Y."YX;6Q02P$"% ,4    " !54_E8]/3T$E8#  "!#P  &0
M        @(&QAP( >&PO=V]R:W-H965T<R]S:&5E=#DY+GAM;%!+ 0(4 Q0
M   ( %53^5C1]5YX20,  #(/   :              " @3Z+ @!X;"]W;W)K
M<VAE971S+W-H965T,3 P+GAM;%!+ 0(4 Q0    ( %53^5AD>BGY:0,   P6
M   -              "  ;^. @!X;"]S='EL97,N>&UL4$L! A0#%     @
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !L &P K!T  ,2? @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>713</ContextCount>
  <ElementCount>369</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>185</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Coverpage</Role>
      <ShortName>Cover page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Income Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedIncomeStatements</Role>
      <ShortName>Consolidated Income Statements</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Changes in Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Introduction</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Introduction</Role>
      <ShortName>Introduction</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPolicies</Role>
      <ShortName>Basis of Preparation of the Half-Year Financial Statements and Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreements</Role>
      <ShortName>Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Goodwill and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/GoodwillandOtherIntangibleAssets</Role>
      <ShortName>Goodwill and Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Impairment of Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ImpairmentofIntangibleAssets</Role>
      <ShortName>Impairment of Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Investments Accounted for Using the Equity Method</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethod</Role>
      <ShortName>Investments Accounted for Using the Equity Method</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Other Non-Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtherNonCurrentAssets</Role>
      <ShortName>Other Non-Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AccountsReceivable</Role>
      <ShortName>Accounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Consolidated Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedShareholdersEquity</Role>
      <ShortName>Consolidated Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Debt, Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtCashandCashEquivalents</Role>
      <ShortName>Debt, Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Derivative Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DerivativeFinancialInstruments</Role>
      <ShortName>Derivative Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilities</Role>
      <ShortName>Non-Current Provisions And Other Non-Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Off Balance Sheet Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OffBalanceSheetCommitments</Role>
      <ShortName>Off Balance Sheet Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Litigation and Arbitration Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/LitigationandArbitrationProceedings</Role>
      <ShortName>Litigation and Arbitration Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Other Operating Income And Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtherOperatingIncomeAndExpenses</Role>
      <ShortName>Other Operating Income And Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Restructuring Costs and Similar Items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RestructuringCostsandSimilarItems</Role>
      <ShortName>Restructuring Costs and Similar Items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Other Gains and Losses, and Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtherGainsandLossesandLitigation</Role>
      <ShortName>Other Gains and Losses, and Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Financial Expenses and Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/FinancialExpensesandIncome</Role>
      <ShortName>Financial Expenses and Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Income Tax Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/IncomeTaxExpense</Role>
      <ShortName>Income Tax Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Events Subsequent to June 30, 2023</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/EventsSubsequenttoJune302023</Role>
      <ShortName>Events Subsequent to June 30, 2023</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesTables</Role>
      <ShortName>Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Goodwill and Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/GoodwillandOtherIntangibleAssets</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Investments Accounted for Using the Equity Method (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodTables</Role>
      <ShortName>Investments Accounted for Using the Equity Method (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethod</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Other Non-Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtherNonCurrentAssetsTables</Role>
      <ShortName>Other Non-Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/OtherNonCurrentAssets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Accounts Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AccountsReceivableTables</Role>
      <ShortName>Accounts Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/AccountsReceivable</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Consolidated Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables</Role>
      <ShortName>Consolidated Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/ConsolidatedShareholdersEquity</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Debt, Cash and Cash Equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtCashandCashEquivalentsTables</Role>
      <ShortName>Debt, Cash and Cash Equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/DebtCashandCashEquivalents</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Derivative Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DerivativeFinancialInstrumentsTables</Role>
      <ShortName>Derivative Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/DerivativeFinancialInstruments</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Liabilities Related to Business Combinations and to Non-Controlling Interests (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsTables</Role>
      <ShortName>Liabilities Related to Business Combinations and to Non-Controlling Interests (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesTables</Role>
      <ShortName>Non-Current Provisions And Other Non-Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilities</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Other Operating Income And Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesTables</Role>
      <ShortName>Other Operating Income And Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/OtherOperatingIncomeAndExpenses</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Restructuring Costs and Similar Items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RestructuringCostsandSimilarItemsTables</Role>
      <ShortName>Restructuring Costs and Similar Items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/RestructuringCostsandSimilarItems</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Financial Expenses and Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/FinancialExpensesandIncomeTables</Role>
      <ShortName>Financial Expenses and Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/FinancialExpensesandIncome</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Income Tax Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/IncomeTaxExpenseTables</Role>
      <ShortName>Income Tax Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/IncomeTaxExpense</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/SegmentInformation</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails</Role>
      <ShortName>Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Principal Changes in Scope of Consolidation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails</Role>
      <ShortName>Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Principal Changes in Scope of Consolidation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Amendments to Principal Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails</Role>
      <ShortName>Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Amendments to Principal Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Property, Plant and Equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails</Role>
      <ShortName>Property, Plant and Equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Property, Plant and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PropertyPlantandEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property, Plant and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Movements in Other Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Schedule of Movements in Other Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Impairment of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ImpairmentofIntangibleAssetsDetails</Role>
      <ShortName>Impairment of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/ImpairmentofIntangibleAssets</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Investments Accounted for Using the Equity Method - Summary of Investments in Associates and Joint Ventures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails</Role>
      <ShortName>Investments Accounted for Using the Equity Method - Summary of Investments in Associates and Joint Ventures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Investments Accounted for Using the Equity Method - Summary of Principal Transactions and Balances with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails</Role>
      <ShortName>Investments Accounted for Using the Equity Method - Summary of Principal Transactions and Balances with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Other Non-Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtherNonCurrentAssetsDetails</Role>
      <ShortName>Other Non-Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/OtherNonCurrentAssetsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Accounts Receivable - Summary of Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails</Role>
      <ShortName>Accounts Receivable - Summary of Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Accounts Receivable - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AccountsReceivableAdditionalInformationDetails</Role>
      <ShortName>Accounts Receivable - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Accounts Receivable - Summary of Gross Value of Overdue Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails</Role>
      <ShortName>Accounts Receivable - Summary of Gross Value of Overdue Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Consolidated Shareholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Consolidated Shareholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Consolidated Shareholders' Equity - Summary of Treasury Shares Held (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofTreasurySharesHeldDetails</Role>
      <ShortName>Consolidated Shareholders' Equity - Summary of Treasury Shares Held (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Consolidated Shareholders' Equity - Summary of Principal Characteristics of Restricted Share Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails</Role>
      <ShortName>Consolidated Shareholders' Equity - Summary of Principal Characteristics of Restricted Share Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Consolidated Shareholders' Equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails</Role>
      <ShortName>Consolidated Shareholders' Equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Consolidated Shareholders' Equity - Summary of Options Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails</Role>
      <ShortName>Consolidated Shareholders' Equity - Summary of Options Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Consolidated Shareholders' Equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails</Role>
      <ShortName>Consolidated Shareholders' Equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Consolidated Shareholders' Equity - Summary of Movements within Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails</Role>
      <ShortName>Consolidated Shareholders' Equity - Summary of Movements within Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Changes in Financial Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails</Role>
      <ShortName>Debt, Cash and Cash Equivalents - Summary of Changes in Financial Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails</Role>
      <ShortName>Debt, Cash and Cash Equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Net Debt by Type Valuation of Redemption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails</Role>
      <ShortName>Debt, Cash and Cash Equivalents - Summary of Net Debt by Type Valuation of Redemption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Debt, Cash and Cash Equivalents - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails</Role>
      <ShortName>Debt, Cash and Cash Equivalents - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Market Value of Net Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails</Role>
      <ShortName>Debt, Cash and Cash Equivalents - Summary of Market Value of Net Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Derivative Financial Instruments - Summary of Operating Currency Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails</Role>
      <ShortName>Derivative Financial Instruments - Summary of Operating Currency Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Derivative Financial Instruments - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails</Role>
      <ShortName>Derivative Financial Instruments - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Derivative Financial Instruments - Disclosure of Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails</Role>
      <ShortName>Derivative Financial Instruments - Disclosure of Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Liabilities Related to Business Combinations and to Non-Controlling Interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails</Role>
      <ShortName>Liabilities Related to Business Combinations and to Non-Controlling Interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Liabilities Related to Business Combinations and to Non-Controlling Interests - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails</Role>
      <ShortName>Liabilities Related to Business Combinations and to Non-Controlling Interests - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities - Summary of Non-Current Provisions and Other Non-Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails</Role>
      <ShortName>Non-Current Provisions And Other Non-Current Liabilities - Summary of Non-Current Provisions and Other Non-Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities - Summary of Movements in Non-Current Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails</Role>
      <ShortName>Non-Current Provisions And Other Non-Current Liabilities - Summary of Movements in Non-Current Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities - Disclosure of Remeasurement of Net Defined Benefit Liability Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails</Role>
      <ShortName>Non-Current Provisions And Other Non-Current Liabilities - Disclosure of Remeasurement of Net Defined Benefit Liability Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Off Balance Sheet Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails</Role>
      <ShortName>Off Balance Sheet Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/OffBalanceSheetCommitments</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Litigation and Arbitration Proceedings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails</Role>
      <ShortName>Litigation and Arbitration Proceedings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/LitigationandArbitrationProceedings</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Other Operating Income And Expenses - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails</Role>
      <ShortName>Other Operating Income And Expenses - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Other Operating Income And Expenses - Schedule of Other Operating Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails</Role>
      <ShortName>Other Operating Income And Expenses - Schedule of Other Operating Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Restructuring Costs and Similar Items - Summary of Restructuring Costs and Similar Items (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails</Role>
      <ShortName>Restructuring Costs and Similar Items - Summary of Restructuring Costs and Similar Items (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - Restructuring Costs and Similar Items - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RestructuringCostsandSimilarItemsAdditionalInformationDetails</Role>
      <ShortName>Restructuring Costs and Similar Items - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9954528 - Disclosure - Other Gains and Losses, and Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtherGainsandLossesandLitigationDetails</Role>
      <ShortName>Other Gains and Losses, and Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/OtherGainsandLossesandLitigation</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9954529 - Disclosure - Financial Expenses and Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/FinancialExpensesandIncomeDetails</Role>
      <ShortName>Financial Expenses and Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/FinancialExpensesandIncomeTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9954530 - Disclosure - Income Tax Expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails</Role>
      <ShortName>Income Tax Expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9954531 - Disclosure - Income Tax Expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails</Role>
      <ShortName>Income Tax Expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9954532 - Disclosure - Income Tax Expense (Details) - Summary of Effective Tax Rate and Standard Corporate Income Tax Rate (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical</Role>
      <ShortName>Income Tax Expense (Details) - Summary of Effective Tax Rate and Standard Corporate Income Tax Rate (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/IncomeTaxExpenseTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9954533 - Disclosure - Segment Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentInformationAdditionalInformationDetails</Role>
      <ShortName>Segment Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9954534 - Disclosure - Segment Information - Summary of Net Sales by Segment and Geographical Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails</Role>
      <ShortName>Segment Information - Summary of Net Sales by Segment and Geographical Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9954535 - Disclosure - Segment Information - Schedule of Segment Results (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails</Role>
      <ShortName>Segment Information - Schedule of Segment Results (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9954536 - Disclosure - Segment Information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails</Role>
      <ShortName>Segment Information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9954537 - Disclosure - Segment Information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails</Role>
      <ShortName>Segment Information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9954538 - Disclosure - Segment Information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails</Role>
      <ShortName>Segment Information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9954539 - Disclosure - Segment Information - Principal Customers and Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails</Role>
      <ShortName>Segment Information - Principal Customers and Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="sny-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - _IXDS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - _IXDS</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="sny-20240630.htm">sny-20240630.htm</File>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="sny-20240630_d2.htm">sny-20240630_d2.htm</File>
    <File>sny-20240630.xsd</File>
    <File>sny-20240630_cal.xml</File>
    <File>sny-20240630_def.xml</File>
    <File>sny-20240630_lab.xml</File>
    <File>sny-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="1220">https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>123
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sny-20240630.htm sny-20240630_d2.htm": {
   "nsprefix": "sny",
   "nsuri": "http://www.sanofi.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "sny-20240630.htm",
      "sny-20240630_d2.htm"
     ]
    },
    "schema": {
     "local": [
      "sny-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sny-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sny-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sny-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sny-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 211,
   "keyCustom": 158,
   "axisStandard": 39,
   "axisCustom": 7,
   "memberStandard": 50,
   "memberCustom": 132,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2023": 6
   },
   "contextCount": 713,
   "entityCount": 1,
   "segmentCount": 185,
   "elementCount": 854,
   "unitCount": 8,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 1220,
    "http://xbrl.sec.gov/dei/2023": 8
   },
   "report": {
    "R1": {
     "role": "http://www.sanofi.com/role/Coverpage",
     "longName": "0000001 - Document - Cover page",
     "shortName": "Cover page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
     "longName": "0000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
     "longName": "0000003 - Statement - Consolidated Income Statements",
     "shortName": "Consolidated Income Statements",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:GrossProfit",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "longName": "0000004 - Statement - Consolidated Statements of Comprehensive Income",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
     "longName": "0000005 - Statement - Consolidated Statements of Changes in Equity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:Equity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-17",
      "name": "ifrs-full:OtherComprehensiveIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical",
     "longName": "0000006 - Statement - Consolidated Statements of Changes in Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Changes in Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DividendsPaidOrdinarySharesPerShare",
      "unitRef": "eurPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DividendsPaidOrdinarySharesPerShare",
      "unitRef": "eurPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000007 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
     "longName": "0000008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.sanofi.com/role/Introduction",
     "longName": "0000009 - Disclosure - Introduction",
     "shortName": "Introduction",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPolicies",
     "longName": "0000010 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies",
     "shortName": "Basis of Preparation of the Half-Year Financial Statements and Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreements",
     "longName": "0000011 - Disclosure - Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements",
     "shortName": "Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.sanofi.com/role/PropertyPlantandEquipment",
     "longName": "0000012 - Disclosure - Property, Plant and Equipment",
     "shortName": "Property, Plant and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssets",
     "longName": "0000013 - Disclosure - Goodwill and Other Intangible Assets",
     "shortName": "Goodwill and Other Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.sanofi.com/role/ImpairmentofIntangibleAssets",
     "longName": "0000014 - Disclosure - Impairment of Intangible Assets",
     "shortName": "Impairment of Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethod",
     "longName": "0000015 - Disclosure - Investments Accounted for Using the Equity Method",
     "shortName": "Investments Accounted for Using the Equity Method",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.sanofi.com/role/OtherNonCurrentAssets",
     "longName": "0000016 - Disclosure - Other Non-Current Assets",
     "shortName": "Other Non-Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.sanofi.com/role/AccountsReceivable",
     "longName": "0000017 - Disclosure - Accounts Receivable",
     "shortName": "Accounts Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfTradeReceivablesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfTradeReceivablesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.sanofi.com/role/ConsolidatedShareholdersEquity",
     "longName": "0000018 - Disclosure - Consolidated Shareholders' Equity",
     "shortName": "Consolidated Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.sanofi.com/role/DebtCashandCashEquivalents",
     "longName": "0000019 - Disclosure - Debt, Cash and Cash Equivalents",
     "shortName": "Debt, Cash and Cash Equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.sanofi.com/role/DerivativeFinancialInstruments",
     "longName": "0000020 - Disclosure - Derivative Financial Instruments",
     "shortName": "Derivative Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilities",
     "longName": "0000022 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities",
     "shortName": "Non-Current Provisions And Other Non-Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.sanofi.com/role/OffBalanceSheetCommitments",
     "longName": "0000023 - Disclosure - Off Balance Sheet Commitments",
     "shortName": "Off Balance Sheet Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.sanofi.com/role/LitigationandArbitrationProceedings",
     "longName": "0000024 - Disclosure - Litigation and Arbitration Proceedings",
     "shortName": "Litigation and Arbitration Proceedings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfLegalAndArbitralProceedingsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfLegalAndArbitralProceedingsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.sanofi.com/role/OtherOperatingIncomeAndExpenses",
     "longName": "0000025 - Disclosure - Other Operating Income And Expenses",
     "shortName": "Other Operating Income And Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.sanofi.com/role/RestructuringCostsandSimilarItems",
     "longName": "0000026 - Disclosure - Restructuring Costs and Similar Items",
     "shortName": "Restructuring Costs and Similar Items",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.sanofi.com/role/OtherGainsandLossesandLitigation",
     "longName": "0000027 - Disclosure - Other Gains and Losses, and Litigation",
     "shortName": "Other Gains and Losses, and Litigation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.sanofi.com/role/FinancialExpensesandIncome",
     "longName": "0000028 - Disclosure - Financial Expenses and Income",
     "shortName": "Financial Expenses and Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.sanofi.com/role/IncomeTaxExpense",
     "longName": "0000029 - Disclosure - Income Tax Expense",
     "shortName": "Income Tax Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.sanofi.com/role/SegmentInformation",
     "longName": "0000030 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.sanofi.com/role/EventsSubsequenttoJune302023",
     "longName": "0000031 - Disclosure - Events Subsequent to June 30, 2023",
     "shortName": "Events Subsequent to June 30, 2023",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Policies)",
     "shortName": "Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Tables)",
     "shortName": "Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.sanofi.com/role/PropertyPlantandEquipmentTables",
     "longName": "9954473 - Disclosure - Property, Plant and Equipment (Tables)",
     "shortName": "Property, Plant and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsTables",
     "longName": "9954474 - Disclosure - Goodwill and Other Intangible Assets (Tables)",
     "shortName": "Goodwill and Other Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodTables",
     "longName": "9954475 - Disclosure - Investments Accounted for Using the Equity Method (Tables)",
     "shortName": "Investments Accounted for Using the Equity Method (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.sanofi.com/role/OtherNonCurrentAssetsTables",
     "longName": "9954476 - Disclosure - Other Non-Current Assets (Tables)",
     "shortName": "Other Non-Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.sanofi.com/role/AccountsReceivableTables",
     "longName": "9954477 - Disclosure - Accounts Receivable (Tables)",
     "shortName": "Accounts Receivable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfCurrentTradeReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfCurrentTradeReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables",
     "longName": "9954478 - Disclosure - Consolidated Shareholders' Equity (Tables)",
     "shortName": "Consolidated Shareholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.sanofi.com/role/DebtCashandCashEquivalentsTables",
     "longName": "9954479 - Disclosure - Debt, Cash and Cash Equivalents (Tables)",
     "shortName": "Debt, Cash and Cash Equivalents (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfChangesInFinancialPositionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfChangesInFinancialPositionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.sanofi.com/role/DerivativeFinancialInstrumentsTables",
     "longName": "9954480 - Disclosure - Derivative Financial Instruments (Tables)",
     "shortName": "Derivative Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsTables",
     "longName": "9954481 - Disclosure - Liabilities Related to Business Combinations and to Non-Controlling Interests (Tables)",
     "shortName": "Liabilities Related to Business Combinations and to Non-Controlling Interests (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesTables",
     "longName": "9954482 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities (Tables)",
     "shortName": "Non-Current Provisions And Other Non-Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesTables",
     "longName": "9954483 - Disclosure - Other Operating Income And Expenses (Tables)",
     "shortName": "Other Operating Income And Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:OtherOperatingExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:OtherOperatingExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsTables",
     "longName": "9954484 - Disclosure - Restructuring Costs and Similar Items (Tables)",
     "shortName": "Restructuring Costs and Similar Items (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfRestructuringCostsDetailsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfRestructuringCostsDetailsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.sanofi.com/role/FinancialExpensesandIncomeTables",
     "longName": "9954485 - Disclosure - Financial Expenses and Income (Tables)",
     "shortName": "Financial Expenses and Income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.sanofi.com/role/IncomeTaxExpenseTables",
     "longName": "9954486 - Disclosure - Income Tax Expense (Tables)",
     "shortName": "Income Tax Expense (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.sanofi.com/role/SegmentInformationTables",
     "longName": "9954487 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails",
     "longName": "9954488 - Disclosure - Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Details)",
     "shortName": "Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OtherRevenue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-73",
      "name": "sny:CumulativeConsumerPriceInflationRateOverTheLastThreeYears",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfHyperinflationaryReportingExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails",
     "longName": "9954489 - Disclosure - Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Principal Changes in Scope of Consolidation (Details)",
     "shortName": "Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Principal Changes in Scope of Consolidation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-75",
      "name": "ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
     "longName": "9954490 - Disclosure - Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Amendments to Principal Agreements (Details)",
     "shortName": "Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Amendments to Principal Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:OtherNoncurrentLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R51": {
     "role": "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
     "longName": "9954491 - Disclosure - Property, Plant and Equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)",
     "shortName": "Property, Plant and Equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.sanofi.com/role/PropertyPlantandEquipmentAdditionalInformationDetails",
     "longName": "9954492 - Disclosure - Property, Plant and Equipment - Additional Information (Details)",
     "shortName": "Property, Plant and Equipment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:FirmOrdersOfPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:FirmOrdersOfPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
     "longName": "9954493 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:Goodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-113",
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
     "longName": "9954494 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Movements in Other Intangible Assets (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Schedule of Movements in Other Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-92",
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock",
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.sanofi.com/role/ImpairmentofIntangibleAssetsDetails",
     "longName": "9954495 - Disclosure - Impairment of Intangible Assets (Details)",
     "shortName": "Impairment of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
     "longName": "9954496 - Disclosure - Investments Accounted for Using the Equity Method - Summary of Investments in Associates and Joint Ventures (Details)",
     "shortName": "Investments Accounted for Using the Equity Method - Summary of Investments in Associates and Joint Ventures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-121",
      "name": "ifrs-full:ProportionOfOwnershipInterestInAssociate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails",
     "longName": "9954497 - Disclosure - Investments Accounted for Using the Equity Method - Summary of Principal Transactions and Balances with Related Parties (Details)",
     "shortName": "Investments Accounted for Using the Equity Method - Summary of Principal Transactions and Balances with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:SubordinatedLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-136",
      "name": "ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails",
     "longName": "9954498 - Disclosure - Other Non-Current Assets (Details)",
     "shortName": "Other Non-Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
       "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
       "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails",
     "longName": "9954499 - Disclosure - Accounts Receivable - Summary of Accounts Receivable (Details)",
     "shortName": "Accounts Receivable - Summary of Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CurrentTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfCurrentTradeReceivablesTableTextBlock",
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-96",
      "name": "ifrs-full:CurrentTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfCurrentTradeReceivablesTableTextBlock",
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.sanofi.com/role/AccountsReceivableAdditionalInformationDetails",
     "longName": "9954500 - Disclosure - Accounts Receivable - Additional Information (Details)",
     "shortName": "Accounts Receivable - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails",
     "longName": "9954501 - Disclosure - Accounts Receivable - Summary of Gross Value of Overdue Receivables (Details)",
     "shortName": "Accounts Receivable - Summary of Gross Value of Overdue Receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "sny:OverdueReceivablesGrossValue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOverdueReceivablesGrossValueTableTextBlock",
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "sny:OverdueReceivablesGrossValue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOverdueReceivablesGrossValueTableTextBlock",
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
     "longName": "9954502 - Disclosure - Consolidated Shareholders' Equity - Additional Information (Details)",
     "shortName": "Consolidated Shareholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:IssuedCapital",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:IssuedCapital",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofTreasurySharesHeldDetails",
     "longName": "9954503 - Disclosure - Consolidated Shareholders' Equity - Summary of Treasury Shares Held (Details)",
     "shortName": "Consolidated Shareholders' Equity - Summary of Treasury Shares Held (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "sny:NumberOfSharesHeld",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "sny:NumberOfSharesHeld",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails",
     "longName": "9954504 - Disclosure - Consolidated Shareholders' Equity - Summary of Principal Characteristics of Restricted Share Plans (Details)",
     "shortName": "Consolidated Shareholders' Equity - Summary of Principal Characteristics of Restricted Share Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-162",
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-162",
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
     "longName": "9954505 - Disclosure - Consolidated Shareholders' Equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)",
     "shortName": "Consolidated Shareholders' Equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-168",
      "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-168",
      "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails",
     "longName": "9954506 - Disclosure - Consolidated Shareholders' Equity - Summary of Options Outstanding and Exercisable (Details)",
     "shortName": "Consolidated Shareholders' Equity - Summary of Options Outstanding and Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-200",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-200",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails",
     "longName": "9954507 - Disclosure - Consolidated Shareholders' Equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details)",
     "shortName": "Consolidated Shareholders' Equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
     "longName": "9954508 - Disclosure - Consolidated Shareholders' Equity - Summary of Movements within Other Comprehensive Income (Details)",
     "shortName": "Consolidated Shareholders' Equity - Summary of Movements within Other Comprehensive Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-201",
      "name": "sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails",
     "longName": "9954509 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Changes in Financial Position (Details)",
     "shortName": "Debt, Cash and Cash Equivalents - Summary of Changes in Financial Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:LongtermBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R70": {
     "role": "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails",
     "longName": "9954510 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details)",
     "shortName": "Debt, Cash and Cash Equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:LongtermBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-215",
      "name": "ifrs-full:LongtermBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock",
       "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
     "longName": "9954511 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Net Debt by Type Valuation of Redemption (Details)",
     "shortName": "Debt, Cash and Cash Equivalents - Summary of Net Debt by Type Valuation of Redemption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "sny:InterestRateAndCurrencyDerivativesUsedToManageDebt",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock",
       "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-217",
      "name": "ifrs-full:BondsIssued",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock",
       "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
     "longName": "9954512 - Disclosure - Debt, Cash and Cash Equivalents - Additional Information (Details)",
     "shortName": "Debt, Cash and Cash Equivalents - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-230",
      "name": "ifrs-full:NotionalAmount",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-9",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-230",
      "name": "ifrs-full:NotionalAmount",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-9",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails",
     "longName": "9954513 - Disclosure - Debt, Cash and Cash Equivalents - Summary of Market Value of Net Debt (Details)",
     "shortName": "Debt, Cash and Cash Equivalents - Summary of Market Value of Net Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:Borrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock",
       "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-235",
      "name": "ifrs-full:Borrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfMarketValueOfNetDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails",
     "longName": "9954514 - Disclosure - Derivative Financial Instruments - Summary of Operating Currency Hedging Instruments (Details)",
     "shortName": "Derivative Financial Instruments - Summary of Operating Currency Hedging Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-323",
      "name": "sny:DerivativeFinancialInstruments",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-323",
      "name": "sny:DerivativeFinancialInstruments",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
     "longName": "9954515 - Disclosure - Derivative Financial Instruments - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)",
     "shortName": "Derivative Financial Instruments - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-342",
      "name": "ifrs-full:NotionalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
     "longName": "9954516 - Disclosure - Derivative Financial Instruments - Disclosure of Instruments (Details)",
     "shortName": "Derivative Financial Instruments - Disclosure of Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-323",
      "name": "sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-323",
      "name": "sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails",
     "longName": "9954517 - Disclosure - Liabilities Related to Business Combinations and to Non-Controlling Interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)",
     "shortName": "Liabilities Related to Business Combinations and to Non-Controlling Interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
     "longName": "9954518 - Disclosure - Liabilities Related to Business Combinations and to Non-Controlling Interests - Additional Information (Details)",
     "shortName": "Liabilities Related to Business Combinations and to Non-Controlling Interests - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock",
       "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-427",
      "name": "sny:PercentageIncreaseInFairValueLiabilities",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
     "longName": "9954519 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities - Summary of Non-Current Provisions and Other Non-Current Liabilities (Details)",
     "shortName": "Non-Current Provisions And Other Non-Current Liabilities - Summary of Non-Current Provisions and Other Non-Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:NoncurrentProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfNonCurrentProvisionsTableTextBlock",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "ifrs-full:NoncurrentProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails",
     "longName": "9954520 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities - Summary of Movements in Non-Current Provisions (Details)",
     "shortName": "Non-Current Provisions And Other Non-Current Liabilities - Summary of Movements in Non-Current Provisions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:NoncurrentProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfNonCurrentProvisionsTableTextBlock",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ChangesInOtherProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfNonCurrentProvisionsTableTextBlock",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
     "longName": "9954521 - Disclosure - Non-Current Provisions And Other Non-Current Liabilities - Disclosure of Remeasurement of Net Defined Benefit Liability Asset (Details)",
     "shortName": "Non-Current Provisions And Other Non-Current Liabilities - Disclosure of Remeasurement of Net Defined Benefit Liability Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-452",
      "name": "ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "sny:DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-452",
      "name": "ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "sny:DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails",
     "longName": "9954522 - Disclosure - Off Balance Sheet Commitments (Details)",
     "shortName": "Off Balance Sheet Commitments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-458",
      "name": "sny:UpfrontPayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-458",
      "name": "sny:UpfrontPayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails",
     "longName": "9954523 - Disclosure - Litigation and Arbitration Proceedings (Details)",
     "shortName": "Litigation and Arbitration Proceedings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-463",
      "name": "sny:GlobalPenaltyFeeIncurredByDefendantsAmountVacated",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-463",
      "name": "sny:GlobalPenaltyFeeIncurredByDefendantsAmountVacated",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
     "longName": "9954524 - Disclosure - Other Operating Income And Expenses - Additional Information (Details)",
     "shortName": "Other Operating Income And Expenses - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:MiscellaneousOtherOperatingIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-464",
      "name": "sny:GainsOnDivestmentOfProducts",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails",
     "longName": "9954525 - Disclosure - Other Operating Income And Expenses - Schedule of Other Operating Expenses (Details)",
     "shortName": "Other Operating Income And Expenses - Schedule of Other Operating Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:MiscellaneousOtherOperatingExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OtherOperatingIncomeExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:OtherOperatingExpensesTableTextBlock",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails",
     "longName": "9954526 - Disclosure - Restructuring Costs and Similar Items - Summary of Restructuring Costs and Similar Items (Details)",
     "shortName": "Restructuring Costs and Similar Items - Summary of Restructuring Costs and Similar Items (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfRestructuringCostsDetailsTableTextBlock",
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfRestructuringCostsDetailsTableTextBlock",
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsAdditionalInformationDetails",
     "longName": "9954527 - Disclosure - Restructuring Costs and Similar Items - Additional Information (Details)",
     "shortName": "Restructuring Costs and Similar Items - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-486",
      "name": "sny:IncreaseDecreaseInTotalExpenseOfRestructuringActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-486",
      "name": "sny:IncreaseDecreaseInTotalExpenseOfRestructuringActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.sanofi.com/role/OtherGainsandLossesandLitigationDetails",
     "longName": "9954528 - Disclosure - Other Gains and Losses, and Litigation (Details)",
     "shortName": "Other Gains and Losses, and Litigation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:OtherGainsLossesAndLitigation",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R89": {
     "role": "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails",
     "longName": "9954529 - Disclosure - Financial Expenses and Income (Details)",
     "shortName": "Financial Expenses and Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InterestExpenseOnBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InterestExpenseOnBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails",
     "longName": "9954530 - Disclosure - Income Tax Expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details)",
     "shortName": "Income Tax Expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DeferredTaxExpenseIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails",
     "longName": "9954531 - Disclosure - Income Tax Expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)",
     "shortName": "Income Tax Expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical",
     "longName": "9954532 - Disclosure - Income Tax Expense (Details) - Summary of Effective Tax Rate and Standard Corporate Income Tax Rate (Parenthetical)",
     "shortName": "Income Tax Expense (Details) - Summary of Effective Tax Rate and Standard Corporate Income Tax Rate (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:CurrentTaxExpenseRelatedToPillarTwo",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R93": {
     "role": "http://www.sanofi.com/role/SegmentInformationAdditionalInformationDetails",
     "longName": "9954533 - Disclosure - Segment Information - Additional Information (Details)",
     "shortName": "Segment Information - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R94": {
     "role": "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails",
     "longName": "9954534 - Disclosure - Segment Information - Summary of Net Sales by Segment and Geographical Area (Details)",
     "shortName": "Segment Information - Summary of Net Sales by Segment and Geographical Area (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-500",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
     "longName": "9954535 - Disclosure - Segment Information - Schedule of Segment Results (Details)",
     "shortName": "Segment Information - Schedule of Segment Results (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-660",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
     "longName": "9954536 - Disclosure - Segment Information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)",
     "shortName": "Segment Information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossAttributableToNoncontrollingInterests",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:NetReversalOfImpairmentLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "sny:DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
     "longName": "9954537 - Disclosure - Segment Information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)",
     "shortName": "Segment Information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-673",
      "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
     "longName": "9954538 - Disclosure - Segment Information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details)",
     "shortName": "Segment Information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-681",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfGeographicalAreasExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails",
     "longName": "9954539 - Disclosure - Segment Information - Principal Customers and Credit Risk (Details)",
     "shortName": "Segment Information - Principal Customers and Credit Risk (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-707",
      "name": "ifrs-full:PercentageOfEntitysRevenue",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-707",
      "name": "ifrs-full:PercentageOfEntitysRevenue",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R9999": {
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "longName": "Uncategorized Items - _IXDS",
     "shortName": "Uncategorized Items - _IXDS",
     "isDefault": "false",
     "groupType": "",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-44",
      "name": "sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "country_AR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "AR",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Argentina",
        "label": "ARGENTINA"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated amortization and impairment",
        "label": "Accumulated depreciation, amortisation and impairment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r60",
      "r64",
      "r101",
      "r115",
      "r118"
     ]
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income",
        "verboseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated other comprehensive income [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "sny_AcquiredRDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AcquiredRDMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired R D",
        "label": "Acquired R D [Member]",
        "documentation": "Acquired R D"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AcquiredResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AcquiredResearchAndDevelopmentMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired R&amp;D",
        "label": "Acquired Research And Development [Member]",
        "documentation": "Acquired Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest in acquiree held before acquisition date",
        "label": "Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The acquisition-date fair value of equity interest in the acquiree held by the acquirer immediately before the acquisition date in a business combination achieved in stages. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration transferred, acquisition-date fair value",
        "label": "Consideration transferred, acquisition-date fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in scope of consolidation",
        "label": "Acquisitions through business combinations, intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in intangible assets and goodwill resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "sny_ActionForWhichWeAreDefendantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ActionForWhichWeAreDefendantMember",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Action for which we are defendant",
        "label": "Action For Which We Are Defendant [member]",
        "documentation": "Action for which we are defendant."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ActuarialAssumptionOfDiscountRatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ActuarialAssumptionOfDiscountRatesMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial assumption of discount rates",
        "label": "Actuarial assumption of discount rates [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the discount rates used as actuarial assumptions. [Refer: Actuarial assumptions [member]]"
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ActuarialAssumptionOfExpectedRatesOfInflationMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial assumption of expected rates of inflation",
        "label": "Actuarial assumption of expected rates of inflation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the expected rates of inflation used as actuarial assumptions. [Refer: Actuarial assumptions [member]]"
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "ifrs-full_ActuarialAssumptionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ActuarialAssumptionsAxis",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial assumptions [axis]",
        "label": "Actuarial assumptions [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ifrs-full_ActuarialAssumptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ActuarialAssumptionsMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial assumptions [member]",
        "label": "Actuarial assumptions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all actuarial assumptions. Actuarial assumptions are the entity\u2019s unbiased and mutually compatible best estimates of the demographic and financial variables that will determine the ultimate cost of providing post-employment benefits. It also represents the standard value for the 'Actuarial assumptions' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Actuarial gains/(losses)",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial gains/(losses) excluding investments accounted for using the equity method",
        "label": "Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Associates And Joint Ventures",
        "documentation": "Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset excluding associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes",
        "label": "Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Net Of Tax On Associates And Joint Ventures",
        "documentation": "Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset net of tax on associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AdditionalLaunchAndSalesMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AdditionalLaunchAndSalesMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Launch And Sales Milestone Payments",
        "label": "Additional Launch And Sales Milestone Payments",
        "documentation": "Additional Launch And Sales Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionalPaidinCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionalPaidinCapitalMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional paid-in capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for amounts received from issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions and other increases",
        "label": "Additions other than through business combinations, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additions other than through business combinations, property, plant and equipment",
        "label": "Additions other than through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Average number of shares after dilution (in shares)",
        "totalLabel": "Average number of shares used to compute diluted earnings per share (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "sny_AdjustmentToDebtMeasuredAtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AdjustmentToDebtMeasuredAtFairValueMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to debt measured at fair value",
        "label": "Adjustment To Debt Measured At Fair Value [Member]",
        "documentation": "Adjustment to debt measured at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Increase)/decrease in inventories",
        "label": "Adjustments for decrease (increase) in inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Increase)/decrease in accounts receivable",
        "label": "Adjustments for decrease (increase) in trade accounts receivable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "ifrs-full_AdjustmentsForDeferredTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDeferredTaxExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in deferred taxes",
        "label": "Adjustments for deferred tax expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets",
        "label": "Adjustments For Depreciation And Amortisation Expense And Impairment Loss Reversal Of Impairment Loss Of Property Plant And Equipment Right-Of Use Assets And Intangible Asset",
        "documentation": "Depreciation, amortization and impairment of property, plant and equipment, right-of use assets and intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase/(decrease) in accounts payable",
        "label": "Adjustments for increase (decrease) in trade accounts payable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains and losses on disposals of non-current assets, net of tax",
        "label": "Adjustments for losses (gains) on disposal of non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in non-current provisions and other non-current liabilities",
        "label": "Adjustments For Non-Current Provisions And Other Non-Current Liabilities",
        "documentation": "Adjustments for noncurrent provisions and other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile profit (loss) [abstract]",
        "label": "Adjustments to reconcile profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of employee benefits (stock options and other share-based payments)",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share of undistributed earnings from investments accounted for using the equity method",
        "label": "Adjustments for undistributed profits of investments accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for undistributed profits of investments accounted for using the equity method to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Investments accounted for using equity method; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedIndividuallyImmaterialAssociatesMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other investments",
        "label": "Aggregated individually immaterial associates [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the aggregation of associates that are individually immaterial. [Refer: Associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ifrs-full_AggregatedMeasurementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedMeasurementMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregated measurement [Member]",
        "label": "Aggregated measurement [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r117",
      "r153"
     ]
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedTimeBandsMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregated time bands [Member]",
        "label": "Aggregated time bands [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r162",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r193",
      "r239",
      "r267",
      "r273"
     ]
    },
    "sny_AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreements Relating to the Recombinant COVID-19 Vaccine Candidate Developed by Sanofi in Collaboration with GSK",
        "label": "Agreements Relating To The Recombinant COVID-19 Vaccine Candidate, Policy [Policy Text Block]",
        "documentation": "Agreements Relating To The Recombinant COVID-19 Vaccine Candidate, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment",
        "verboseLabel": "Other",
        "label": "All other segments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for business activities and operating segments that are not reportable."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r209"
     ]
    },
    "sny_AllergyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AllergyMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Seasonal symptoms &amp; pain relief",
        "label": "Allergy [Member]",
        "documentation": "Allergy, Cough And Cold [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AllowanceForCreditLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AllowanceForCreditLossesMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowances",
        "label": "Allowance for credit losses [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an allowance account used to record impairments to financial assets due to credit losses."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "sny_AlprolixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AlprolixMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alprolix",
        "label": "Alprolix [Member]",
        "documentation": "Alprolix"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AltuviiioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AltuviiioMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Altuviiio",
        "label": "Altuviiio [Member]",
        "documentation": "Altuviiio"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of intangible assets",
        "negatedTerseLabel": "Amortization expense",
        "label": "Amortisation, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization and impairment of intangible assets",
        "label": "Amortization And Impairment Of Intangible Assets Other Than Goodwill",
        "documentation": "Amortization and impairment of intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AmortizedCostNettingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AmortizedCostNettingMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized cost",
        "label": "Amortized Cost, Netting [Member]",
        "documentation": "Amortized cost."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AmountOfSharesRepurchased": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AmountOfSharesRepurchased",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of shares repurchased",
        "label": "Amount Of Shares Repurchased",
        "documentation": "Amount of shares repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmountsPayableRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmountsPayableRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and other payables",
        "label": "Amounts payable, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts payable resulting from related party transactions. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r76",
      "r80"
     ]
    },
    "ifrs-full_AmountsReceivableRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmountsReceivableRelatedPartyTransactions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable and other receivables",
        "label": "Amounts receivable, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts receivable resulting from related party transactions. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r76",
      "r80"
     ]
    },
    "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AnalysisOfIncomeAndExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Analysis of income and expense [abstract]",
        "label": "Analysis of income and expense [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AntibodiesAllianceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AntibodiesAllianceMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monoclonal Antibodies Alliance",
        "label": "Antibodies Alliance [Member]",
        "documentation": "Antibodies Alliance [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AntibodiesCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AntibodiesCollaborationAgreementMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antibodies Collaboration Agreement",
        "label": "Antibodies Collaboration Agreement [Member]",
        "documentation": "Antibodies Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ApplicableTaxRate",
     "calculation": {
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standard tax rate applicable in France",
        "label": "Applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r153",
      "r154",
      "r157",
      "r212",
      "r215"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AssetsAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AssetsAcquisitionAxis",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets Acquisition [Axis]",
        "label": "Assets Acquisition [Axis]",
        "documentation": "Assets Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AssetsAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AssetsAcquisitionDomain",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets Acquisition [Domain]",
        "label": "Assets Acquisition [Domain]",
        "documentation": "Assets Acquisition [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AssetsAcquisitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AssetsAcquisitionMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets Acquisition",
        "label": "Assets Acquisition [Member]",
        "documentation": "Assets Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AssetsAcquisitionNominalValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AssetsAcquisitionNominalValue",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets Acquisition Nominal Value",
        "label": "Assets Acquisition Nominal Value",
        "documentation": "Assets Acquisition Nominal Value"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AssetsAcquisitionPurchasePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AssetsAcquisitionPurchasePricePerShare",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets Acquisition, Purchase Price Per Share",
        "label": "Assets Acquisition, Purchase Price Per Share",
        "documentation": "Assets Acquisition, Purchase Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AssetsAndLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AssetsAndLiabilitiesAxis",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets and liabilities [Axis]",
        "label": "Assets and liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ifrs-full_AssetsAndLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AssetsAndLiabilitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets and liabilities [Member]",
        "label": "Assets and liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for assets and liabilities. It also represents the standard value for the 'Assets and liabilities' axis if no other member is used. [Refer: Assets; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "sny_AssociatesAndJointVenturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AssociatesAndJointVenturesMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Associates and joint ventures",
        "label": "Associates And Joint Ventures [Member]",
        "documentation": "Associates and Joint Ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AstraZenecaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AstraZenecaMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AstraZeneca",
        "label": "AstraZeneca [Member]",
        "documentation": "AstraZeneca"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AtFairValueMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value",
        "label": "At fair value [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r117",
      "r153"
     ]
    },
    "sny_AtMarketValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AtMarketValueMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market value",
        "label": "At Market Value [member]",
        "documentation": "At market value."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AtNotionalAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AtNotionalAmountMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional amount",
        "label": "At Notional Amount [member]",
        "documentation": "At notional amount."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attribution of expenses by nature to their function [axis]",
        "label": "Attribution of expenses by nature to their function [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r280"
     ]
    },
    "sny_AubagioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "AubagioMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aubagio",
        "label": "Aubagio [Member]",
        "documentation": "Aubagio."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AverageEffectiveTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AverageEffectiveTaxRate",
     "calculation": {
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Average effective tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ifrs-full_BankOverdraftsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BankOverdraftsClassifiedAsCashEquivalents",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank credit balances",
        "label": "Bank overdrafts"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that has been withdrawn from an account in excess of existing cash balances. This is considered a short-term extension of credit by the bank. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "sny_BasicEarningsLossPerShareAttributableToOwnersOfParent": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "BasicEarningsLossPerShareAttributableToOwnersOfParent",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic earnings per share (in euros per share)",
        "label": "Basic Earnings (Loss) Per Share, Attributable To Owners Of Parent",
        "documentation": "Basic Earnings (Loss) Per Share, Attributable To Owners Of Parent"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bayer contingent consideration arising from acquisition of Genzyme",
        "label": "Bayer Contingent Purchase Consideration Arising From Acquisition Of Genzyme [Member]",
        "documentation": "Bayer contingent purchase consideration arising from the acquisition of Genzyme."
       }
      }
     },
     "auth_ref": []
    },
    "sny_BiopharmaSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "BiopharmaSegmentMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dupixent",
        "label": "Biopharma Segment [Member]",
        "documentation": "Pharmaceuticals segment."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BondsIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BondsIssued",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bond issues",
        "label": "Bonds issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of bonds issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "sny_BorrowingAverageDrawdown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "BorrowingAverageDrawdown",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing, average drawdown",
        "label": "Borrowing, Average Drawdown",
        "documentation": "Borrowing, Average Drawdown"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Borrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Borrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "sny_DebtNetOfCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total debt",
        "verboseLabel": "Market value",
        "label": "Borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsByNameAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings by name [Axis]",
        "label": "Borrowings by name [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "ifrs-full_BorrowingsByNameMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsByNameMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings by name [Member]",
        "label": "Borrowings by name [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bottom of range",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r172",
      "r178",
      "r252",
      "r254",
      "r301"
     ]
    },
    "sny_BusinessCombinationNominalValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "BusinessCombinationNominalValue",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination Nominal Value",
        "label": "Business Combination Nominal Value",
        "documentation": "Business Combination Nominal Value"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BusinessCombinationPurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "BusinessCombinationPurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination, purchase price",
        "label": "Business Combination, Purchase Price",
        "documentation": "Business Combination, Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BusinessCombinationPurchasePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "BusinessCombinationPurchasePricePerShare",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share (in USD per share)",
        "label": "Business Combination, Purchase Price Per Share",
        "documentation": "Business Combination, Purchase Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BusinessCombinationsAxis",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations [Axis]",
        "label": "Business combinations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "sny_BusinessOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "BusinessOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business operating income",
        "totalLabel": "Business operating income",
        "label": "Business Operating Income",
        "documentation": "Business operating income."
       }
      }
     },
     "auth_ref": []
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CN",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China",
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CabliviMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CabliviMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cablivi",
        "label": "Cablivi [Member]",
        "documentation": "Cablivi"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [Axis]",
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62",
      "r101",
      "r108",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r189",
      "r199",
      "r200"
     ]
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount [Member]",
        "label": "Carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r62",
      "r108",
      "r114",
      "r116",
      "r117",
      "r189",
      "r199",
      "r200"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "sny_DebtNetOfCashAndCashEquivalents",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "negatedLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r129",
      "r147"
     ]
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CashFlowAndFairValueHedgeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CashFlowAndFairValueHedgeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow and fair value hedge",
        "label": "Cash Flow And Fair Value Hedge [Member]",
        "documentation": "Cash Flow And Fair Value Hedge"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowHedgesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowHedgesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow hedges",
        "label": "Cash flow hedges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedges of the exposure to variability in cash flows that (a) are attributable to a particular risk associated with a recognised asset or liability (such as all or some future interest payments on variable rate debt) or a highly probable forecast transaction; and (b) could affect profit or loss. [Refer: Hedges [member]]"
       }
      }
     },
     "auth_ref": [
      "r112",
      "r194",
      "r195",
      "r196"
     ]
    },
    "ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposals of consolidated undertakings and investments accounted for using the equity method",
        "label": "Cash flows from losing control of subsidiaries or other businesses, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate cash flows arising from losing control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by/(used in) financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r130"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from (used in) financing activities [abstract]",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in short-term debt and other financial instruments",
        "label": "Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments",
        "documentation": "Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by/(used in) investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r130"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from (used in) investing activities [abstract]",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by/(used in) operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r119",
      "r130"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from (used in) operating activities [abstract]",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating cash flow before changes in working capital",
        "label": "Cash flows from (used in) operations before changes in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r298"
     ]
    },
    "ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisitions of consolidated undertakings and investments accounted for using the equity method",
        "terseLabel": "Net cash flow on acquisition",
        "label": "Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "ifrs-full_CashTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash transferred",
        "label": "Cash transferred"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of related parties [axis]",
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "sny_CerezymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CerezymeMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cerezyme",
        "label": "Cerezyme [Member]",
        "documentation": "Cerezyme."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CertainWholesalersInTheUnitedStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CertainWholesalersInTheUnitedStatesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certain wholesalers in the United States",
        "label": "Certain Wholesalers, In The United States [Member]",
        "documentation": "Certain Wholesalers, In The United States"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)",
        "label": "Change In Currency Translation Before Tax Excluding Associates And Joint Ventures",
        "documentation": "Change in currency translation before tax excluding associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences (investments accounted for using the equity method)",
        "label": "Change In Currency Translation Net Of Tax On Associates And Joint Ventures",
        "documentation": "Change in currency translation net of tax on associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedges of net investments in foreign operations",
        "label": "Change In Currency Translation On Hedges Of Net Investments In Foreign Operations",
        "documentation": "Change in currency translation on hedges of net investments in foreign operations."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInCurrencyTranslationOnTaxEffects": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ChangeInCurrencyTranslationOnTaxEffects",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax effects",
        "label": "Change In Currency Translation On Tax Effects",
        "documentation": "Change in currency translation on tax effects."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (excluding investments accounted for using the equity method)",
        "label": "Change In Fair Value On Cash Flow Hedges Excluding Associates And Joint Ventures",
        "documentation": "Change in fair value on cash flow hedges excluding associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (investments accounted for using the equity method, net of taxes)",
        "label": "Change In Fair Value On Cash Flow Hedges Net Of Tax On Associates And Joint Ventures",
        "documentation": "Change in fair value on cash flow hedges net of tax on associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (investments accounted for using the equity method, net of taxes)",
        "label": "Change In Fair Value On Debt Instrument Associates And Joint Ventures",
        "documentation": "Change In Fair Value On Debt Instrument Associates And Joint Ventures"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (excluding investments accounted for using the equity method)",
        "label": "Change In Fair Value On Debt Instrument Excluding Associates And Joint Ventures",
        "documentation": "Change In Fair Value On Debt Instrument Excluding Associates And Joint Ventures"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (excluding investments accounted for using the equity method)",
        "label": "Change In Fair Value On Equity Instruments Excluding Associates And Joint Ventures",
        "documentation": "Change In Fair Value On Equity Instruments Excluding Associates And Joint Ventures"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (investments accounted for using the equity method, net of taxes)",
        "label": "Change In Fair Value On Equity Instruments For Investments Accounted For Using The Equity Method Net Of Tax",
        "documentation": "Change In Fair Value On Equity Instruments For Investments Accounted For Using The Equity Method Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change In Scope Of Consolidation Through Business Combination, Intangible Assets",
        "label": "Change In Scope Of Consolidation Through Business Combination, Intangible Assets",
        "documentation": "Change In Scope Of Consolidation Through Business Combination, Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]",
        "label": "Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]",
        "documentation": "Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ChangesInOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ChangesInOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases in provisions and other liabilities",
        "label": "Increase (decrease) in other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer",
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of assets [Axis]",
        "label": "Classes of assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r93",
      "r158",
      "r167"
     ]
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets [Member]",
        "label": "Assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r158",
      "r167"
     ]
    },
    "ifrs-full_ClassesOfContingentLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfContingentLiabilitiesAxis",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of Contingent Liabilities [Axis]",
        "label": "Classes of contingent liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r188"
     ]
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialAssetsAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial assets [Axis]",
        "label": "Classes of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r204",
      "r205",
      "r222",
      "r223"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets other than goodwill [axis]",
        "label": "Classes of intangible assets other than goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [Axis]",
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfProvisionsAxis",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of other provisions [Axis]",
        "label": "Classes of other provisions [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "sny_CollaborationAgreementWithGSKMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CollaborationAgreementWithGSKMember",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Agreement with GSK",
        "label": "Collaboration Agreement With GSK [Member]",
        "documentation": "Collaboration Agreement With GSK"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CollaborationAgreementsDevelopmentMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CollaborationAgreementsDevelopmentMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreements, development milestone payment",
        "label": "Collaboration Agreements, Development Milestone Payment",
        "documentation": "Collaboration Agreements, Development Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CollaborationAgreementsRegulatoryMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CollaborationAgreementsRegulatoryMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreements, regulatory milestone payment",
        "label": "Collaboration Agreements, Regulatory Milestone Payment",
        "documentation": "Collaboration Agreements, Regulatory Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CollaborationAgreementsUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CollaborationAgreementsUpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreements, upfront payment",
        "label": "Collaboration Agreements, Upfront Payment",
        "documentation": "Collaboration Agreements, Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommercialPaperProgramInFranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CommercialPaperProgramInFranceMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper program in France",
        "label": "Commercial Paper Program In France [Member]",
        "documentation": "Commercial paper program In France."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommercialPaperProgramInUSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CommercialPaperProgramInUSAMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper program in USA",
        "label": "Commercial Paper Program In USA [Member]",
        "documentation": "Commercial paper program in USA."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CommercialPapersIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CommercialPapersIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper programs",
        "label": "Commercial papers issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of commercial paper issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "sny_CommercializationRelatedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CommercializationRelatedExpensesMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement to Regeneron of selling expenses incurred",
        "label": "Commercialization Related Expenses [Member]",
        "documentation": "Commercialization related expenses."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments related to potential milestone payments for projects under collaboration agreements",
        "label": "Commitments Related To Milestone Payments For Projects Under Collaboration Agreement",
        "documentation": "Commitments Related To Milestone Payments For Projects Under Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [axis]",
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r36",
      "r134",
      "r136",
      "r145",
      "r250"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome_1": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributable to non-controlling interests",
        "label": "Comprehensive income, attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r39"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome_1": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributable to equity holders of Sanofi",
        "label": "Comprehensive income, attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r40"
     ]
    },
    "ifrs-full_ComputerSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComputerSoftwareMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Computer software [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "sny_ConsumerHealthcareSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ConsumerHealthcareSegmentMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella",
        "label": "Consumer Healthcare Segment [Member]",
        "documentation": "Consumer Healthcare segment."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ContingentConsiderationArisingFromAcquisitionOfAmunixMember",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration arising from acquisition of Amunix",
        "label": "Contingent Consideration Arising From Acquisition Of Amunix [Member]",
        "documentation": "Contingent Consideration Arising From Acquisition Of Amunix"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContingentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContingentLiabilitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent liabilities [member]",
        "label": "Contingent liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for possible obligations that arise from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity; or, present obligations that arise from past events but are not recognised because (a) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligations; or (b) the amount of the obligations cannot be measured with sufficient reliability. It also represents the standard value for the 'Classes of contingent liabilities' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r188"
     ]
    },
    "ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContingentLiabilitiesRecognisedInBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "terseLabel": "Fair value of contingent consideration payable",
        "label": "Contingent liabilities recognised in business combination"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "sny_ContingentMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ContingentMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Milestone Payments",
        "label": "Contingent Milestone Payments",
        "documentation": "Contingent Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CoreAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CoreAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Core Assets [Member]",
        "label": "Core Assets [Member]",
        "documentation": "Core Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CorporateInformationAndStatementOfIFRSComplianceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Information And Statement Of IFRS Compliance [Abstract]",
        "label": "Corporate information and statement of IFRS compliance [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CostOfDebtNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CostOfDebtNet",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Cost of net debt",
        "label": "Cost Of Debt Net",
        "documentation": "Cost of debt net."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of sales",
        "negatedTerseLabel": "Cost of sales",
        "label": "Cost of sales"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r49"
     ]
    },
    "ifrs-full_CounterpartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CounterpartiesAxis",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparties [Axis]",
        "label": "Counterparties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_CounterpartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CounterpartiesMember",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparties [Member]",
        "label": "Counterparties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CreditFacilitiesExtensionOptionNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CreditFacilitiesExtensionOptionNumber",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facilities, number of extension options",
        "label": "Credit Facilities, Extension Option, Number",
        "documentation": "Credit Facilities, Extension Option, Number"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CreditFacilitiesExtensionOptionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CreditFacilitiesExtensionOptionPeriod",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facilities, extension option period",
        "label": "Credit Facilities, Extension Option, Period",
        "documentation": "Credit Facilities, Extension Option, Period"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CumulativeConsumerPriceInflationRateOverTheLastThreeYears",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative consumer price inflation rate",
        "label": "Cumulative Consumer Price Inflation Rate Over The Last Three Years",
        "documentation": "Cumulative Consumer Price Inflation Rate Over The Last Three Years"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency and interest rate derivatives",
        "label": "Currency And Interest Rate Derivatives Used To Manage Debt Net Of Cash And Cash Equivalents",
        "documentation": "Currency and interest rate derivatives used to manage debt, net of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CurrentAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "current",
        "label": "Current Assets [Member]",
        "documentation": "Current assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current assets",
        "label": "Current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Current assets; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale; Non-current assets or disposal groups classified as held for distribution to owners]"
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term debt and current portion of long-term debt",
        "label": "Current borrowings and current portion of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ifrs-full_CurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current contract liabilities",
        "label": "Current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current lease liabilities",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "sny_CurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CurrentLiabilitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "current",
        "label": "Current Liabilities [Member]",
        "documentation": "Current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current liabilities",
        "label": "Current liabilities other than liabilities included in disposal groups classified as held for sale"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities other than liabilities included in disposal groups classified as held for sale. [Refer: Current liabilities; Disposal groups classified as held for sale [member]; Liabilities included in disposal groups classified as held for sale]"
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities related to business combinations and to non-controlling interests",
        "verboseLabel": "Current portion",
        "label": "Current Liabilities Related To Business Combinations And To Non-Controlling Interests",
        "documentation": "This account includes current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes current portion of liabilities related to non-controlling interests."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrentProvisionsAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CurrentProvisionsAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current provisions and other current liabilities",
        "label": "Current Provisions And Other Current Liabilities",
        "documentation": "The amount of current provisions and current other liabilities that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentTaxAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current income tax assets",
        "label": "Current tax assets, current"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax assets. [Refer: Current tax assets]"
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "ifrs-full_CurrentTaxAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current income tax assets",
        "label": "Current tax assets, non-current"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current amount of current tax assets. [Refer: Current tax assets]"
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails",
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Current taxes",
        "terseLabel": "Current tax expense (income)",
        "label": "Current tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "sny_CurrentTaxExpenseRelatedToPillarTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CurrentTaxExpenseRelatedToPillarTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical",
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Tax Expense Related to Pillar Two",
        "label": "Current Tax Expense Related to Pillar Two",
        "documentation": "Current Tax Expense Related to Pillar Two"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentTaxLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current income tax liabilities",
        "label": "Current tax liabilities, current"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "ifrs-full_CurrentTaxLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current income tax liabilities",
        "label": "Current tax liabilities, non-current"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails",
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Current trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r229",
      "r231"
     ]
    },
    "sny_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer one",
        "label": "Customer One [member]",
        "documentation": "Customer one."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CustomerThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CustomerThreeMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer three",
        "label": "Customer Three [member]",
        "documentation": "Customer three."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer two",
        "label": "Customer Two [member]",
        "documentation": "Customer two."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Debt Instrument"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DebtInstrumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DebtInstrumentDomain",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Domain]",
        "label": "Debt Instrument [Domain]",
        "documentation": "Debt Instrument [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DebtInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DebtInstrumentsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instruments included in financial assets",
        "label": "Debt Instruments [Member]",
        "documentation": "Debt Instruments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DebtNetOfCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DebtNetOfCashAndCashEquivalents",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net debt",
        "label": "Debt Net Of Cash And Cash Equivalents",
        "documentation": "Debt net of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DebtSecuritiesMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities",
        "label": "Debt securities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for instruments held by the entity that represent indebtedness."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r253"
     ]
    },
    "sny_DefendantAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DefendantAxis",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defendant [Axis]",
        "label": "Defendant [Axis]",
        "documentation": "Defendant [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DefendantDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DefendantDomain",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defendant [Domain]",
        "label": "Defendant [Domain]",
        "documentation": "Defendant [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r19",
      "r24",
      "r56"
     ]
    },
    "ifrs-full_DeferredTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred taxes",
        "label": "Deferred tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred tax liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r19",
      "r24",
      "r56"
     ]
    },
    "ifrs-full_DefinedBenefitPlansAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DefinedBenefitPlansAxis",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined benefit plans [Axis]",
        "label": "Defined benefit plans [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ifrs-full_DefinedBenefitPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DefinedBenefitPlansMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined benefit plans [Member]",
        "label": "Defined benefit plans [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "sny_DerecognizedReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DerecognizedReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derecognized receivables",
        "label": "Derecognized Receivables",
        "documentation": "Derecognized receivables."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DerivativeFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DerivativeFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative financial assets",
        "label": "Derivative financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "sny_DerivativeFinancialInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DerivativeFinancialInstruments",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating currency hedging instruments in place",
        "label": "Derivative Financial Instruments",
        "documentation": "Derivative financial instrument"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DerivativeFinancialInstrumentsToManageFinancialExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DerivativeFinancialInstrumentsToManageFinancialExposure",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial currency hedging instruments in place",
        "label": "Derivative Financial Instruments To Manage Financial Exposure",
        "documentation": "Derivative financial instruments to manage financial exposure."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DerivativeFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative financial liabilities",
        "label": "Derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Description of accounting policy for financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Pronouncements Issued by the IASB and Applicable from 2024",
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "sny_DevelopmentRegulatoryAndLaunchMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DevelopmentRegulatoryAndLaunchMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development Regulatory And Launch Milestone Payments",
        "label": "Development Regulatory And Launch Milestone Payments",
        "documentation": "Development Regulatory And Launch Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DigestiveWellnessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DigestiveWellnessMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Digestive Wellness [Member]",
        "documentation": "Digestive Wellness [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DilutedEarningsLossPerShareAttributableToOwnersOfParent",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted earnings per share (in euros per share)",
        "label": "Diluted Earnings (Loss) Per Share, Attributable To Owners Of Parent",
        "documentation": "Diluted Earnings (Loss) Per Share, Attributable To Owners Of Parent"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails": {
       "parentTag": "ifrs-full_AdjustedWeightedAverageShares",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment for stock options with dilutive effect (in shares)",
        "label": "Dilutive effect of share options on weighted average number of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed exercise of the entity's share options."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails": {
       "parentTag": "ifrs-full_AdjustedWeightedAverageShares",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment for restricted shares (in shares)",
        "label": "Dilutive Effect Of Share Options On Number Of Restricted Shares",
        "documentation": "Dilutive effect of share options on number of restricted shares."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Disclosure of accounting judgements and estimates [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "sny_DisclosureOfAccountsReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfAccountsReceivableLineItems",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Accounts Receivable [Line Items]",
        "label": "Disclosure Of Accounts Receivable [line items]",
        "documentation": "Disclosure Of Accounts Receivable [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAccountsReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfAccountsReceivableTable",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Accounts Receivable [Table]",
        "label": "Disclosure Of Accounts Receivable [Table]",
        "documentation": "Disclosure of Accounts receivable Table."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Movements within Other Comprehensive Income",
        "label": "Disclosure Of Accumulated Other Comprehensive Income Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information of accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment",
        "label": "Disclosure Of Acquisitions Of Property Plant And Equipment And Other Intangible Assets And Carrying Amount Of Investments In Associates And Joint Ventures By Operating Segment [Table Text Block]",
        "documentation": "The disclosure of acquisitions of property plant and equipment and other intangible assets and carrying amount of investments in associates and joint ventures by operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Acquisitions and Capitalized Interest by Operating Segment",
        "label": "Disclosure Of Acquisitions Of Property Plant And Equipment By Operating Segments Explanatory [Table Text Block]",
        "documentation": "Disclosure of acquisitions of property plant and equipment by operating segments explanatory [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes",
        "label": "Disclosure Of Allocation Of Income Tax Between Current And Deferred Taxes [Table Text Block]",
        "documentation": "The disclosure of allocation of income tax between current and deferred taxes."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of analysis of other comprehensive income by item [Line Items]",
        "label": "Disclosure of analysis of other comprehensive income by item [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of analysis of other comprehensive income by item [Table]",
        "label": "Disclosure of analysis of other comprehensive income by item [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the analysis of other comprehensive income by item."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Preparation of the Half-Year Financial Statements and Accounting Policies",
        "label": "Disclosure of basis of preparation of financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "ifrs-full_DisclosureOfBusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBusinessCombinationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about business combination [line items]",
        "label": "Disclosure of detailed information about business combination [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBusinessCombinationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsTable",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about business combination [table]",
        "label": "Disclosure of detailed information about business combination [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of business combinations."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "sny_DisclosureOfChangesInFinancialPositionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfChangesInFinancialPositionTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Changes in Financial Position",
        "label": "Disclosure Of Changes In Financial Position [Table Text Block]",
        "documentation": "Disclosure of changes in financial position [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests",
        "label": "Disclosure Of Changes In Liabilities Related To Business Combinations And To Noncontrolling Interests [Table Text Block]",
        "documentation": "The disclosure of changes in liabilities related to business combinations and to non-controlling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquity",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Treasury Shares Held",
        "label": "Disclosure of classes of share capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]"
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [Line Items]",
        "label": "Disclosure of classes of share capital [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [table]",
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Other Non-Current Assets",
        "label": "Disclosure Of Components Of Other Non-Current Assets [Table Text Block]",
        "documentation": "The disclosure of components of other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities in business combination [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfCurrentTradeReceivablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfCurrentTradeReceivablesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Accounts Receivable",
        "label": "Disclosure Of Current Trade Receivables [Table Text Block]",
        "documentation": "The disclosure of current trade receivables."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt, Cash and Cash Equivalents",
        "label": "Disclosure Of Debt Instruments Issued Explanatory [Text Block]",
        "documentation": "Disclosure of debt instruments issued explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Net Debt by Type Valuation of Redemption",
        "label": "Disclosure Of Debt Net Of Cash And Cash Equivalents By Type At Value On Redemption Explanatory [Table Text Block]",
        "documentation": "The disclosure of debt net of cash and cash equivalents by type at value on redemption."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDerivativeFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Financial Instruments",
        "label": "Disclosure of derivative financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of derivative financial instruments. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about borrowings [Line Items]",
        "label": "Disclosure of detailed information about borrowings [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about borrowings [Table]",
        "label": "Disclosure of detailed information about borrowings [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about finance income expense [Line Items]",
        "label": "Disclosure Of Detailed Information About Finance Income Expense [Line Items]",
        "documentation": "Line items represent detailed information about finance income expense."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Finance Income Expense [table]",
        "label": "Disclosure Of Detailed Information About Finance Income Expense [table]",
        "documentation": "Schedule disclosing information related to details of finance income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Measurement Principles Applied to Financial Instruments",
        "label": "Disclosure of detailed information about financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r201",
      "r206"
     ]
    },
    "sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Principal Characteristics of Restricted Share Plans",
        "label": "Disclosure Of Employee Stock Ownership Plan Awarded In Capital Increase Reserved Explanatory [Table Text Block]",
        "documentation": "Disclosure of employee stock ownership plan awarded in capital increase reserved explanatory [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Disclosure of entity's operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Events Subsequent to June 30, 2023",
        "label": "Disclosure of events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Expenses and Income",
        "label": "Disclosure of finance income (cost) [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]",
        "label": "Disclosure of financial assets that are either past due or impaired [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Financial Assets that are Either Past Due or Impaired [Table]",
        "label": "Disclosure of financial assets that are either past due or impaired [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial assets that are either past due or impaired."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated",
        "label": "Disclosure Of Financial Currency Hedging Instruments With Notional Amount Translated In To Euros At Closing Exchange Rate Explanatory [Table Text Block]",
        "documentation": "The disclosure of financial currency hedging instruments with notional amount translated in to euros at closing exchange rate."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Analysis of Financial Income and Expenses",
        "label": "Disclosure Of Financial Income And Expenses Explanatory [Table Text Block]",
        "documentation": "The entire disclosure for financial income and expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [line items]",
        "label": "Disclosure of detailed information about financial instruments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [table]",
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r201",
      "r206"
     ]
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Introduction"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Introduction",
        "label": "Disclosure of general information about financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_DisclosureOfGeographicalAreasExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Geographical Information on Net Sales and Non-Current Assets",
        "label": "Disclosure of geographical areas [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of geographical information."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_DisclosureOfGeographicalAreasLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasLineItems",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of geographical areas [line items]",
        "label": "Disclosure of geographical areas [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeographicalAreasTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasTable",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of geographical areas [table]",
        "label": "Disclosure of geographical areas [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to geographical areas."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfHyperinflationaryReportingExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation and Foreign Currency Translation of the Financial Statements of Subsidiaries in Hyperinflationary Economies",
        "label": "Disclosure of information about hyperinflationary reporting [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about financial reporting in hyperinflationary economies."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements",
        "label": "Disclosure Of Impact Of Changes In The Scope Of Consolidation Due To Acquisitions And Divestments Explanatory [Text Block]",
        "documentation": "The entire disclosure for impact of changes in the scope of consolidation due to acquisitions and divestments."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of impairment loss and reversal of impairment loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Intangible Assets",
        "label": "Disclosure Of Impairment Of Intangible Assets And Property Plant And Equipment Explanatory [Text Block]",
        "documentation": "The entire disclosure for impairment of intangible assets and property, plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Expense",
        "label": "Disclosure of income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]",
        "label": "Disclosure of information about credit exposures designated as measured at fair value through profit or loss [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Table]",
        "label": "Disclosure of information about credit exposures designated as measured at fair value through profit or loss [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to credit exposures designated as measured at fair value through profit or loss."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of information about major customers and credit risk [line items]",
        "label": "Disclosure Of Information About Major Customers And Credit Risk [Line Items]",
        "documentation": "Disclosure of information about major customers and credit risk."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Information About Major Customers and Credit Risk [Table]",
        "label": "Disclosure Of Information About Major Customers And Credit Risk [Table]",
        "documentation": "Disclosure of information about major customers and credit risk."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]",
        "label": "Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Table]",
        "label": "Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the terms and conditions of hedging instruments and how they affect future cash flows."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of initial application of standards or interpretations [line items]",
        "label": "Disclosure of initial application of standards or interpretations [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of initial application of standards or interpretations [table]",
        "label": "Disclosure of initial application of standards or interpretations [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the initial application of standards or interpretations."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Other Intangible Assets",
        "label": "Disclosure of intangible assets and goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets [line items]",
        "label": "Disclosure of detailed information about intangible assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsTable",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets [table]",
        "label": "Disclosure of detailed information about intangible assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Instruments",
        "label": "Disclosure Of Interest Rates Hedging Instruments With Notional Amount By Expiry Date Explanatory [Table Text Block]",
        "documentation": "The disclosure of interest rates hedging instruments with notional amount by expiry date."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethod"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments Accounted for Using the Equity Method",
        "label": "Disclosure of investments accounted for using equity method [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Investments in Associates and Joint Ventures",
        "label": "Disclosure Of Investments In Associates And Joint Ventures [Table Text Block]",
        "documentation": "The entire disclosure of investments in associates and joint ventures explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLegalAndArbitralProceedingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfLegalAndArbitralProceedingsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Legal and Arbitral Proceedings [Line Items]",
        "label": "Disclosure Of Legal And Arbitral Proceedings [Line Items]",
        "documentation": "Disclosure of legal and arbitral proceedings."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLegalAndArbitralProceedingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfLegalAndArbitralProceedingsTable",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Legal and Arbitral Proceedings [Table]",
        "label": "Disclosure Of Legal And Arbitral Proceedings [Table]",
        "documentation": "Disclosure of legal and arbitral proceedings."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLegalAndArbitralProceedingsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfLegalAndArbitralProceedingsTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation and Arbitration Proceedings",
        "label": "Disclosure Of Legal And Arbitral Proceedings [Text Block]",
        "documentation": "Disclosure Of Legal And Arbitral Proceedings [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities Related to Business Combinations and to Non-Controlling Interests",
        "label": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests Explanatory [Text Block]",
        "documentation": "The entire disclosure for liabilities related to business combination and to non-controlling interests."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]",
        "label": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]",
        "documentation": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Table]",
        "label": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Table]",
        "documentation": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests Table"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfMarketValueOfNetDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfMarketValueOfNetDebtTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Market Value of Net Debt",
        "label": "Disclosure Of Market Value Of Net Debt [Table Text Block]",
        "documentation": "Disclosure of market value of net debt [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetLineItems",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of net defined benefit liability (asset) [Line Items]",
        "label": "Disclosure of net defined benefit liability (asset) [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetTable",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of net defined benefit liability (asset) [Table]",
        "label": "Disclosure of net defined benefit liability (asset) [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the net defined benefit liability (asset)."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Net Sales by Segment and Geographical Area",
        "label": "Disclosure Of Net Sales By Segment And Geographical Area [Table Text Block]",
        "documentation": "Disclosure of net sales by segment and geographical area."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfNonCurrentProvisionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfNonCurrentProvisionsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Non-current Provisions [Line Items]",
        "label": "Disclosure Of Non-Current Provisions [Line Items]",
        "documentation": "Disclosure Of Non-current Provisions [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfNonCurrentProvisionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfNonCurrentProvisionsTable",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Noncurrent Provisions [Table]",
        "label": "Disclosure Of Non-Current Provisions [Table]",
        "documentation": "Disclosure Of Noncurrent Provisions [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfNonCurrentProvisionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfNonCurrentProvisionsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Movements in Non-Current Provisions",
        "label": "Disclosure Of Non-Current Provisions [Table Text Block]",
        "documentation": "Disclosure of noncurrent provisions explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [line items]",
        "label": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [table]",
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Number of Restricted Shares Not Yet Fully Vested",
        "label": "Disclosure Of Number Of Restricted Share Plans Not Yet Fully Vested [Table Text Block]",
        "documentation": "Disclosure of number of restricted share plans Not yet fully vested."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Off Balance Sheet Commitments",
        "label": "Disclosure Of Off-Balance Sheet Commitments Explanatory [Text Block]",
        "documentation": "Disclosure of off-balance sheet commitments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOffBalanceSheetCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfOffBalanceSheetCommitmentsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Off Balance Sheet Commitments [Line Items]",
        "label": "Disclosure Of Off-Balance Sheet Commitments [Line Items]",
        "documentation": "[Line Items] for Disclosure Of Off Balance Sheet Commitments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOffBalanceSheetCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfOffBalanceSheetCommitmentsTable",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Off Balance Sheet Commitments [Table]",
        "label": "Disclosure Of Off-Balance Sheet Commitments [Table]",
        "documentation": "Disclosure Of Off Balance Sheet Commitments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Operating Currency Hedging Instruments",
        "label": "Disclosure Of Operating Currency Hedging Instruments With Notional Amount Translated In To Euros At Closing Exchange Rate [Table Text Block]",
        "documentation": "The disclosure of operating currency hedging instruments with notional amount translated in to euros at closing exchange rate."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Results",
        "label": "Disclosure of operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "ifrs-full_DisclosureOfOperatingSegmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of operating segments [Line Items]",
        "label": "Disclosure of operating segments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method",
        "label": "Disclosure Of Operating Segments Reconciling Items [Table Text Block]",
        "documentation": "The disclosure of operating segments reconciling items."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsTable",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of operating segments [Table]",
        "label": "Disclosure of operating segments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to operating segments."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfOtherGainsAndLossesAndLitigationTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/OtherGainsandLossesandLitigation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Gains and Losses, and Litigation",
        "label": "Disclosure Of Other Gains And Losses, And Litigation [Text Block]",
        "documentation": "The entire disclosure of other gains and losses, and litigation."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOtherNonCurrentAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfOtherNonCurrentAssetsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Other Non Current Assets [Line Items]",
        "label": "Disclosure Of Other Non-Current Assets [Line Items]",
        "documentation": "Disclosure of other non-current assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOtherNonCurrentAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfOtherNonCurrentAssetsTable",
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Other Non-current Assets [Table]",
        "label": "Disclosure Of Other Non-Current Assets [Table]",
        "documentation": "Schedule disclosing information related to other non-current assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherNoncurrentAssetsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Non-Current Assets",
        "label": "Disclosure of other non-current assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other non-current assets. [Refer: Other non-current assets]"
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherOperatingIncomeExpenseExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Operating Income and Expenses",
        "label": "Disclosure of other operating income (expense) [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other operating income or expense. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "sny_DisclosureOfOtherOperatingIncomeExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfOtherOperatingIncomeExpensesLineItems",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Other Operating Income Expenses [Line Items]",
        "label": "Disclosure Of Other Operating Income Expenses [Line Items]",
        "documentation": "Disclosure of other operating income (expenses)."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOtherOperatingIncomeExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfOtherOperatingIncomeExpensesTable",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Other Operating Income Expenses [Table]",
        "label": "Disclosure Of Other Operating Income Expenses [Table]",
        "documentation": "Disclosure of other operating income expenses."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfOverdueReceivablesGrossValueTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Gross Value of Overdue Receivables",
        "label": "Disclosure Of Overdue Receivables Gross Value [Table Text Block]",
        "documentation": "The disclosure of overdue receivables gross value."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfPrincipalAgreementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfPrincipalAgreementsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Principal Agreements [Line Items]",
        "label": "Disclosure Of Principal Agreements [Line Items]",
        "documentation": "Disclosure Of Principal Agreements [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfPrincipalAgreementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfPrincipalAgreementsTable",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Principal Agreements [Table]",
        "label": "Disclosure Of Principal Agreements [Table]",
        "documentation": "Disclosure Of Principal Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment",
        "label": "Disclosure of property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]",
        "label": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]",
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Non-Current Provisions and Other Non-Current Liabilities",
        "label": "Disclosure Of Provisions And Other Non Current Liabilities Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Provisions And Other Non Current Liabilities Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Current Provisions And Other Non-Current Liabilities",
        "label": "Disclosure Of Provisions And Other Non-Current Liabilities [Text Block]",
        "documentation": "Disclosure Of Provisions And Other Non-Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate",
        "label": "Disclosure Of Reconciliation Of Average Effective Tax Rate And Applicable Tax Rate Explanatory [Table Text Block]",
        "documentation": "Disclosure of reconciliation of average effective tax rate and applicable tax rate."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of carrying amount to value on redemption [line items]",
        "label": "Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Line Items]",
        "documentation": "Disclosure of reconciliation of carrying amount to value on redemption."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of carrying amount to value on redemption [Table]",
        "label": "Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Table]",
        "documentation": "Disclosure of reconciliation of carrying amount to value on redemption [table]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Reconciliation of Carrying Amount to Value on Redemption",
        "label": "Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Table Text Block]",
        "documentation": "Disclosure of reconciliation of carrying amount to value on redemption [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInGoodwillLineItems",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of changes in goodwill [line items]",
        "label": "Disclosure of reconciliation of changes in goodwill [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInGoodwillTable",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of changes in goodwill [table]",
        "label": "Disclosure of reconciliation of changes in goodwill [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of changes in goodwill."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Movements in Other Intangible Assets",
        "label": "Disclosure Of Reconciliation Of Changes In Other Intangible Assets [Table Text Block]",
        "documentation": "Disclosure of reconciliation of changes in other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Remeasurement of Net Defined Benefit Liability Asset",
        "label": "Disclosure Of Remeasurement Of Net Defined Benefit Liability Asset [Table Text Block]",
        "documentation": "Disclosure Of Remeasurement Of Net Defined Benefit Liability Asset"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItems"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Costs and Similar Items",
        "label": "Disclosure Of Restructuring Costs And Similar Items [Text Block]",
        "documentation": "The entire disclosure of restructuring costs and similar items."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfRestructuringCostsDetailsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfRestructuringCostsDetailsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restructuring Costs and Similar Items",
        "label": "Disclosure Of Restructuring Costs Details [Table Text Block]",
        "documentation": "The disclosure of restructuring costs details."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Options Outstanding and Exercisable",
        "label": "Disclosure Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table Text Block]",
        "documentation": "The disclosure of share based compensation shares authorized under stock option plans by exercise price range."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Shareholders' Equity",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Number of Shares Used to Compute Diluted Earnings Per Share",
        "label": "Disclosure Of Shares Used To Compute Diluted Earnings Per Share [Table Text Block]",
        "documentation": "The disclosure of shares used to compute diluted earnings per share."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "sny_DisclosureOfTradeReceivablesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DisclosureOfTradeReceivablesTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Disclosure Of Trade Receivables [Text Block]",
        "documentation": "The disclosure of trade receivables."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Principal Transactions and Balances with Related Parties",
        "label": "Disclosure of transactions between related parties [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of transactions between related parties [line items]",
        "label": "Disclosure of transactions between related parties [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of transactions between related parties [table]",
        "label": "Disclosure of transactions between related parties [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisposalsAndRetirementsIntangibleAssetsAndGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Disposals and other decreases",
        "label": "Disposals and retirements, intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets and goodwill resulting from disposals and retirements. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposals and retirements, intangible assets other than goodwill",
        "label": "Disposals and retirements, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets other than goodwill resulting from disposals and retirements. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "sny_DividendsPaidAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DividendsPaidAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends paid:",
        "label": "Dividends Paid [Abstract]",
        "documentation": "Dividends Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DividendsPaidOrdinarySharesPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DividendsPaidOrdinarySharesPerShare",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend paid per share (in euros per share)",
        "label": "Dividends paid, ordinary shares per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of dividends paid per ordinary share."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends paid to equity holders of Sanofi",
        "label": "Dividends paid to equity holders of parent, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for dividends paid to equity holders of the parent, classified as financing activities."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends paid to non-controlling interests",
        "label": "Dividends paid to non-controlling interests, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for dividends paid to non-controlling interests, classified as financing activities. [Refer: Non-controlling interests; Dividends paid to non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends received from non-consolidated entities",
        "label": "Dividends Received From Nonconsolidated Entities Classified As Operating Activities",
        "documentation": "Dividends received from non-consolidated entities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DividendsRecognisedAsDistributionsToNoncontrollingInterests",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of dividends to non-controlling interests",
        "label": "Dividends recognised as distributions to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of dividends recognised as distributions to non-controlling interests. [Refer: Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DividendsRecognisedAsDistributionsToOwnersOfParent",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividend paid out of earnings",
        "label": "Dividends recognised as distributions to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of dividends recognised as distributions to owners of the parent. [Refer: Parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DupixentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "DupixentMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dupixent",
        "label": "Dupixent [Member]",
        "documentation": "Dupixent [member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EUROZONEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "EUROZONEMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eurozone",
        "label": "EUROZONE [Member]",
        "documentation": "EUROZONE"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of exchange rates on cash and cash equivalents",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123"
     ]
    },
    "sny_EloctateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "EloctateMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eloctate",
        "label": "Eloctate [Member]",
        "documentation": "Eloctate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EmployeeShareOwnershipPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "EmployeeShareOwnershipPlanMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees share ownership plan",
        "label": "Employee Share Ownership Plan [Member]",
        "documentation": "Employees share ownership plan."
       }
      }
     },
     "auth_ref": []
    },
    "sny_EnjaymoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "EnjaymoMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Enjaymo",
        "label": "Enjaymo [Member]",
        "documentation": "Enjaymo"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "ifrs-full_EntitysTotalForAssociatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForAssociatesMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for associates [Member]",
        "label": "Entity's total for associates [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r85",
      "r152"
     ]
    },
    "ifrs-full_EntitysTotalForBusinessCombinationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForBusinessCombinationsMember",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for business combinations [Member]",
        "label": "Entity's total for business combinations [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r190"
     ]
    },
    "ifrs-full_EntitysTotalForJointVenturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForJointVenturesMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for joint ventures [Member]",
        "label": "Entity's total for joint ventures [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Joint ventures' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r85",
      "r151"
     ]
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForRelatedPartiesMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for related parties [Member]",
        "label": "Entity's total for related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ifrs-full_EntitysTotalForSegmentConsolidationItemsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForSegmentConsolidationItemsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for segment consolidation items [Member]",
        "label": "Entity's total for segment consolidation items [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Segment consolidation items' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "ifrs-full_EntitysTotalForSubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForSubsidiariesMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for subsidiaries [member]",
        "label": "Entity's total for subsidiaries [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r85",
      "r150"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r30",
      "r133",
      "r135",
      "r153",
      "r154",
      "r157"
     ]
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL EQUITY AND LIABILITIES",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity and liabilities",
        "label": "Equity and liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity attributable to equity holders of Sanofi",
        "label": "Equity attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ifrs-full_EquityAttributableToOwnersOfParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParentMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributable to equity holders of Sanofi",
        "label": "Equity attributable to owners of parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity attributable to the owners of the parent."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "sny_EquityInstrumentsIncludedInFinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "EquityInstrumentsIncludedInFinancialAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity instruments included in financial assets",
        "label": "Equity Instruments Included In Financial Assets [Member]",
        "documentation": "Equity Instruments Included In Financial Assets[member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [member]",
        "label": "Equity [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity risk hedging instruments designated as fair value hedges",
        "label": "Equity Risk Hedging Instruments Designated At Fair Value Hedges",
        "documentation": "Equity Risk Hedging Instruments Designated At Fair Value Hedges"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EuroapiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "EuroapiMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Euroapi",
        "verboseLabel": "EUROAPI",
        "label": "Euroapi [Member]",
        "documentation": "Euroapi"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EuropeMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe",
        "label": "Europe [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExceptionalSupplementaryDividendPercentageOfShareCapital": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ExceptionalSupplementaryDividendPercentageOfShareCapital",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exceptional supplementary dividend, in percentage",
        "label": "Exceptional Supplementary Dividend, Percentage Of Share Capital",
        "documentation": "Exceptional Supplementary Dividend, Percentage Of Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Effect of the distribution of an exceptional supplementary dividend of 58% of the shares of EUROAPI to the equity holders of Sanofi",
        "label": "Exceptional Supplementary Dividends Recognised As Distributions To Owners Of Parent",
        "documentation": "Exceptional Supplementary Dividends Recognised As Distributions To Owners Of Parent"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExcludingChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ExcludingChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excluding General Director",
        "label": "Excluding Chief Executive Officer [Member]",
        "documentation": "Excluding Chief Executive Officer"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of outstanding options (in euros per share)",
        "label": "Exercise price of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "sny_ExercisePriceRangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ExercisePriceRangeFourMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "From \u20ac80.00 to \u20ac90.00 per share",
        "label": "Exercise Price Range Four [Member]",
        "documentation": "Exercise Price Range Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExercisePriceRangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ExercisePriceRangeThreeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "From \u20ac70.00 to \u20ac80.00 per share",
        "label": "Exercise Price Range Three [Member]",
        "documentation": "Exercise Price Range Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExercisePriceRangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ExercisePriceRangeTwoMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "From \u20ac60.00 to \u20ac70.00 per share",
        "label": "Exercise Price Range Two [Member]",
        "documentation": "Exercise Price Range Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ExpenseArisingFromTheImpactOfAcquisitionsOnInventories",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expense arising from the impact of acquisitions on inventories",
        "label": "Expense Arising From The Impact Of Acquisitions On Inventories",
        "documentation": "Expenses arising from the impact of acquisitions on inventories."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseDueToUnwindingOfDiscountOnProvisions",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unwinding of discounting of provisions",
        "label": "Expense arising from passage of time on other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense recognised due to the unwinding of the discount on provisions other than provisions for employee benefits, resulting from the effect of the passage of time. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense recognized",
        "netLabel": "Total expense for restricted share plans",
        "label": "Expense from equity-settled share-based payment transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "ifrs-full_ExpenseOfRestructuringActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseOfRestructuringActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      },
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restructuring costs and similar items",
        "totalLabel": "Total",
        "label": "Expense of restructuring activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "sny_ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ExpenseOfRestructuringActivitiesCompensationForEarlyTerminationOfContracts",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": "ifrs-full_ExpenseOfRestructuringActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation for early termination of contracts (other than contracts of employment)",
        "label": "Expense Of Restructuring Activities Compensation For Early Termination Of Contracts",
        "documentation": "Compensation for early termination of contracts (other than contracts of employment)."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": "ifrs-full_ExpenseOfRestructuringActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee-related expenses",
        "label": "Expense Of Restructuring Activities Employee Related Expenses",
        "documentation": "Employee related expenses."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": "ifrs-full_ExpenseOfRestructuringActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charges, gains or losses on assets",
        "label": "Expense Of Restructuring Activities Related To Property Plant And Equipment And To Inventories",
        "documentation": "Expense of restructuring activities related to property plant and equipment to inventories."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ExpenseOfRestructuringActivitiesTransformationProgramsCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": "ifrs-full_ExpenseOfRestructuringActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs of transformation programs",
        "label": "Expense Of Restructuring Activities, Transformation Programs Costs",
        "documentation": "Expense Of Restructuring Activities, Transformation Programs Costs"
       }
      }
     },
     "auth_ref": []
    },
    "country_FR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "FR",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "France",
        "label": "FRANCE"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FabrazymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "FabrazymeMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fabrazyme",
        "label": "Fabrazyme [Member]",
        "documentation": "Fabrazyme [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FairValueHedgesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FairValueHedgesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value hedges",
        "label": "Fair value hedges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedges of the exposure to changes in fair value of a recognised asset or liability or an unrecognised firm commitment, or an identified portion of such an asset, liability or firm commitment, that is attributable to a particular risk and could affect profit or loss. [Refer: Hedges [member]]"
       }
      }
     },
     "auth_ref": [
      "r111",
      "r194",
      "r195",
      "r196"
     ]
    },
    "sny_FairValueOfPlanAtDateOfGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "FairValueOfPlanAtDateOfGrant",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of plan at the date of grant",
        "label": "Fair Value Of Plan At Date Of Grant",
        "documentation": "Fair value of plan at the date of grant."
       }
      }
     },
     "auth_ref": []
    },
    "sny_FairValuePerShareAwardedForThreeYearServicePeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "FairValuePerShareAwardedForThreeYearServicePeriod",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value per share awarded (in euros per share)",
        "label": "Fair Value Per Share Awarded For Three Year Service Period",
        "documentation": "Fair value per share awarded to a three year service period."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Financial expenses",
        "label": "Finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial income",
        "terseLabel": "Financial income",
        "label": "Finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "ifrs-full_FinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net financial income/(expenses)",
        "label": "Finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income or cost associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "ifrs-full_FinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets, class [Member]",
        "label": "Financial assets, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r174",
      "r204",
      "r205",
      "r222",
      "r223"
     ]
    },
    "sny_FinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "FinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Abstract]",
        "label": "Financial Instruments [Abstract]",
        "documentation": "Financial Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FirmOrdersOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "FirmOrdersOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Firm orders of property, plant and equipment",
        "label": "Firm Orders Of Property Plant And Equipment",
        "documentation": "Firm orders of property plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "sny_FixedRateBondMaturingApril2024Redeemed2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "FixedRateBondMaturingApril2024Redeemed2024Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed Rate Bond Maturing April2024 Redeemed2024",
        "label": "Fixed Rate Bond Maturing April2024 Redeemed2024 [Member]",
        "documentation": "Fixed Rate Bond Maturing April2024 Redeemed2024"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForeignCurrencyTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForeignCurrencyTranslationMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation",
        "label": "Foreign Currency Translation [Member]",
        "documentation": "Foreign Currency Translation"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInCanadianDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencyPurchasesInCanadianDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in Canadian dollar",
        "label": "Forward Currency Purchases In Canadian Dollar [Member]",
        "documentation": "Forward Currency Purchases In Canadian Dollar"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencyPurchasesInChineseYuanRenminbiMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in Chinese yuan renminbi",
        "label": "Forward Currency Purchases In Chinese Yuan Renminbi [Member]",
        "documentation": "Forward Currency Purchases In Chinese Yuan Renminbi"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInHungarianFlorintMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencyPurchasesInHungarianFlorintMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward Currency Purchases In Hungarian florint",
        "label": "Forward Currency Purchases In Hungarian florint [Member]",
        "documentation": "Forward Currency Purchases In Hungarian florint"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInJapaneseYenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencyPurchasesInJapaneseYenMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in Japanese Yen",
        "label": "Forward Currency Purchases In Japanese Yen [Member]",
        "documentation": "Forward Currency Purchased In Japanese yen [member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInKoreanWonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencyPurchasesInKoreanWonMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in Korean won",
        "label": "Forward Currency Purchases In Korean Won [Member]",
        "documentation": "Forward Currency Purchases In Korean Won"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInRussianRoubleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencyPurchasesInRussianRoubleMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward Currency Purchases In Russian rouble",
        "label": "Forward Currency Purchases In Russian rouble [Member]",
        "documentation": "Forward Currency Purchases In Russian rouble"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInSingaporeDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencyPurchasesInSingaporeDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in Singapore dollar",
        "label": "Forward Currency Purchases In Singapore Dollar [Member]",
        "documentation": "Forward currency purchases in Singapore Dollar."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInTurkishLiraMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencyPurchasesInTurkishLiraMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward Currency Purchases In Turkish lira",
        "label": "Forward Currency Purchases In Turkish lira [Member]",
        "documentation": "Forward Currency Purchases In Turkish lira"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInUSDollarCommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencyPurchasesInUSDollarCommercialPaperMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in US dollar, commercial paper",
        "label": "Forward Currency Purchases In US Dollar, Commercial Paper [Member]",
        "documentation": "Forward Currency Purchases In US Dollar, Commercial Paper"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInUSDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencyPurchasesInUSDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in US dollar",
        "label": "Forward Currency Purchases In US Dollar [Member]",
        "documentation": "Forward currency purchases in USD."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInUSDollarUSBondMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencyPurchasesInUSDollarUSBondMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in US dollar, US bond",
        "label": "Forward Currency Purchases In US Dollar, US Bond [Member]",
        "documentation": "Forward Currency Purchases In US Dollar, US Bond"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencyPurchasesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases",
        "label": "Forward Currency Purchases [Member]",
        "documentation": "Forward currency purchases."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInCanadianDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencySalesInCanadianDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward Currency Sales In Canadian Dollar",
        "label": "Forward Currency Sales In Canadian Dollar [Member]",
        "documentation": "Forward Currency Sales In Canadian Dollar"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInChineseYuanRenminbiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencySalesInChineseYuanRenminbiMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales in Chinese yuan renminbi",
        "label": "Forward Currency Sales In Chinese Yuan Renminbi [member]",
        "documentation": "Forward currency sales in Chinese Yuan Renminbi."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInJapaneseYenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencySalesInJapaneseYenMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales in Japanese yen",
        "label": "Forward Currency Sales In Japanese Yen [Member]",
        "documentation": "Forward currency sales in Japanese Yen."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInMexicanPesoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencySalesInMexicanPesoMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales in Mexican peso",
        "label": "Forward Currency Sales In Mexican Peso [Member]",
        "documentation": "Forward Currency Sales In Mexican Peso"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInPoundSterlingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencySalesInPoundSterlingMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales in Pound sterling",
        "label": "Forward Currency Sales In Pound Sterling [Member]",
        "documentation": "Forward Currency Sales In Pound Sterling"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInRussianRoubleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencySalesInRussianRoubleMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward Currency Sales In Russian rouble",
        "label": "Forward Currency Sales In Russian rouble [Member]",
        "documentation": "Forward Currency Sales In Russian rouble"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInSingaporeDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencySalesInSingaporeDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales in Singapore dollar",
        "label": "Forward Currency Sales In Singapore Dollar [member]",
        "documentation": "Forward currency sales in Singapore Dollar."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInUSDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencySalesInUSDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales in US dollar",
        "label": "Forward Currency Sales In US Dollar [Member]",
        "documentation": "Forward currency sales in USD."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ForwardCurrencySalesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales",
        "label": "Forward Currency Sales [Member]",
        "documentation": "Forward currency sales."
       }
      }
     },
     "auth_ref": []
    },
    "sny_FulcrumTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "FulcrumTherapeuticsMember",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fulcrum Therapeutics",
        "label": "Fulcrum Therapeutics [Member]",
        "documentation": "Fulcrum Therapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FutureRoyaltiesReceivableValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "FutureRoyaltiesReceivableValue",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future royalties receivable, value",
        "label": "Future Royalties Receivable, Value",
        "documentation": "Future Royalties Receivable, Value"
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "GB",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United Kingdom",
        "label": "UNITED KINGDOM"
       }
      }
     },
     "auth_ref": []
    },
    "sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "GainLossOnDerivativesUsedToManageCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on derivatives used to manage cash and cash equivalents",
        "label": "Gain (Loss) On Derivatives Used To Manage Cash And Cash Equivalents",
        "documentation": "Gain (loss) on derivatives used to manage cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "sny_GainLossOnDerivativesUsedToManageDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "GainLossOnDerivativesUsedToManageDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on derivatives used to manage debt",
        "label": "Gain (Loss) On Derivatives Used To Manage Debt",
        "documentation": "Gain (loss) on derivatives used to manage debt."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial gains/(losses) on benefit obligations",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnAvailableforsaleFinancialAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains/(losses) on disposals of financial assets",
        "label": "Gains (losses) on available-for-sale financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) on available-for-sale financial assets. [Refer: Financial assets available-for-sale]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnCashFlowHedgesBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of cash flow hedges",
        "label": "Gains (losses) on cash flow hedges, before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on cash flow hedges, before tax, before reclassification adjustments. [Refer: Cash flow hedges [member]]"
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in currency translation differences",
        "label": "Gains (losses) on exchange differences on translation of foreign operations, before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange gain (loss)",
        "label": "Foreign exchange gain (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r75"
     ]
    },
    "sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "GainsLossesOnRemeasuringDebtInstrumentsBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of debt instruments included in financial assets",
        "label": "Gains (Losses) On Remeasuring Debt Instruments, Before Tax",
        "documentation": "Gains (Losses) On Remeasuring Debt Instruments, Before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of equity instruments included in financial assets and financial liabilities",
        "label": "Gains (losses) recognised in other comprehensive income including exchange differences, fair value measurement, entity's own equity instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) including exchange differences recognised in other comprehensive income on the fair value measurement of the entity's own equity instruments. [Refer: At fair value [member]; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)",
        "label": "Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "sny_GainsOnDivestmentOfProducts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "GainsOnDivestmentOfProducts",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains on divestment of some mature products",
        "label": "Gains On Divestment Of Products",
        "documentation": "Gains on divestment of products."
       }
      }
     },
     "auth_ref": []
    },
    "sny_GeneralInformationAboutFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "GeneralInformationAboutFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General Information About Financial Statements [Abstract]",
        "label": "General Information About Financial Statements [Abstract]",
        "documentation": "General Information About Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_GeneralMedicinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "GeneralMedicinesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General Medicines [Member]",
        "label": "General Medicines [Member]",
        "documentation": "General Medicines"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical areas [Axis]",
        "label": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r237",
      "r256",
      "r259"
     ]
    },
    "ifrs-full_GeographicalAreasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeographicalAreasMember",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical areas [Member]",
        "label": "Geographical areas [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r237",
      "r256",
      "r259"
     ]
    },
    "sny_GlobalPenaltyFeeIncurredByDefendantsAmountVacated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "GlobalPenaltyFeeIncurredByDefendantsAmountVacated",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Global penalty fee incurred by defendants, amount vacated",
        "label": "Global Penalty Fee Incurred By Defendants, Amount Vacated",
        "documentation": "Global Penalty Fee Incurred By Defendants, Amount Vacated"
       }
      }
     },
     "auth_ref": []
    },
    "sny_GoldBondProductLitigationInTheUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "GoldBondProductLitigationInTheUSMember",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gold Bond Product Litigation In The US",
        "label": "Gold Bond Product Litigation In The US [Member]",
        "documentation": "Gold Bond Product Litigation In The US"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r94",
      "r95",
      "r189"
     ]
    },
    "sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government grant recognised as deduction from development expenses",
        "label": "Government Grant Recognised As Deduction From Development Expenses",
        "documentation": "Government Grant Recognised As Deduction From Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossCarryingAmountMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofAccountsReceivableDetails",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross value",
        "label": "Gross carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r60",
      "r101",
      "r115",
      "r118",
      "r189",
      "r200",
      "r202",
      "r263"
     ]
    },
    "ifrs-full_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross profit"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]"
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrs-full_HedgedItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "HedgedItemsAxis",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedged items [Axis]",
        "label": "Hedged items [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "ifrs-full_HedgedItemsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "HedgedItemsMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedged items [Member]",
        "label": "Hedged items [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedged items. A hedged item can be a recognised asset or liability, an unrecognised firm commitment, a forecast transaction or a net investment in a foreign operation. The hedged item can be: (a) a single item; or (b) a group of items (subject to paragraphs 6.6.1\u20136.6.6 and B6.6.1\u2013B6.6.16 of IFRS 9). A hedged item can also be a component of such an item or group of items (see paragraphs 6.3.7 and B6.3.7\u2013B6.3.25 of IFRS 9). This member also represents the standard value for the 'Hedged items' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "ifrs-full_HedgingInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "HedgingInstrumentsAxis",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Instruments [Axis]",
        "label": "Hedging instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r194"
     ]
    },
    "ifrs-full_HedgingInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "HedgingInstrumentsMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging instruments [Member]",
        "label": "Hedging instruments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedging instruments. A hedging instrument can be a designated: (a) derivative measured at fair value through profit or loss, except for some written options (see paragraph B6.2.4 of IFRS 9); (b) non-derivative financial asset or non-derivative financial liability measured at fair value through profit or loss, unless it is a financial liability designated as at fair value through profit or loss for which the amount of its change in fair value that is attributable to changes in the credit risk of that liability is presented in other comprehensive income in accordance with paragraph 5.7.7 of IFRS 9. For a hedge of foreign currency risk, the foreign currency risk component of a non-derivative financial asset or a non-derivative financial liability may be designated as a hedging instrument provided that it is not an investment in an equity instrument for which an entity has elected to present changes in fair value in other comprehensive income in accordance with paragraph 5.7.5 of IFRS 9. This member also represents the standard value for the 'Hedging instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r194"
     ]
    },
    "ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Identifiable intangible assets recognised as of acquisition date",
        "label": "Identifiable intangible assets recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262"
     ]
    },
    "sny_ImmunoOncologyAllianceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ImmunoOncologyAllianceMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Immuno-Oncology Alliance",
        "label": "Immuno-Oncology Alliance [Member]",
        "documentation": "Immuno-oncology Alliance [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ImmunoOncologyCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ImmunoOncologyCollaborationAgreementMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Immuno Oncology Collaboration Agreement",
        "label": "Immuno Oncology Collaboration Agreement [Member]",
        "documentation": "Immuno oncology collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of the workdown of acquired inventories remeasured at fair value",
        "label": "Impact Of The Workdown Of Acquired Inventories Remeasured At Fair Value",
        "documentation": "Impact of the workdown of acquired inventories remeasured at fair value arising from business combination in accordance with IFRS 3."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ImpairmentLossOnIntangibleAssetOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment Loss on Intangible Asset Other Than Goodwill",
        "label": "Impairment Loss on Intangible Asset Other Than Goodwill",
        "documentation": "Impairment Loss on Intangible Asset Other Than Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Impairment losses, net of reversals",
        "label": "Impairment loss recognised in other comprehensive income, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in other comprehensive income for intangible assets other than goodwill. [Refer: Impairment loss recognised in other comprehensive income; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss recognised in profit or loss",
        "label": "Impairment loss recognised in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r90",
      "r92"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/ImpairmentofIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment of intangible assets",
        "terseLabel": "Impairment loss on other intangible assets",
        "label": "Impairment loss recognised in profit or loss, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables",
        "label": "Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss or reversal of impairment loss recognised in profit or loss for trade receivables. [Refer: Impairment loss recognised in profit or loss; Reversal of impairment loss recognised in profit or loss; Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements_1": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before tax and investments accounted for using the equity method",
        "terseLabel": "Income before tax and investments accounted for using the equity method",
        "label": "Income Before Tax And Investments Accounted For Equity Method Investments",
        "documentation": "Income before tax and investments accounted for equity method investments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncomeResultingFromOutLicensing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "IncomeResultingFromOutLicensing",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income from out-licensing",
        "label": "Income Resulting From Out-Licensing",
        "documentation": "Income Resulting From Out-Licensing"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements_1": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "negatedTotalLabel": "Total",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r43",
      "r52",
      "r54",
      "r55",
      "r81",
      "r148",
      "r211"
     ]
    },
    "sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax effects",
        "label": "Income Tax Relating To Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Equity Investments",
        "documentation": "Income Tax Relating To Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Equity Investments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax effects",
        "label": "Income tax relating to cash flow hedges included in other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income in relation to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r44",
      "r53"
     ]
    },
    "sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax effects",
        "label": "Income Tax Relating To Change In Fair Value Of Debt Instrument Excluding Equity Investments",
        "documentation": "Income Tax Relating To Change In Fair Value Of Debt Instrument Excluding Equity Investments"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax effects",
        "label": "Income Tax Relating To Change In Fair Value Of Equity Instruments Excluding Equity Method",
        "documentation": "Income Tax Relating To Change In Fair Value Of Equity Instruments Excluding Equity Method"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax effects",
        "label": "Income tax relating to components of other comprehensive income that will be reclassified to profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income that will be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax effects",
        "label": "Income tax relating to components of other comprehensive income that will not be reclassified to profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income that will not be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_IncomeTaxesPaidRefundAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxesPaidRefundAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax paid",
        "label": "Income taxes paid (refund), classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]"
       }
      }
     },
     "auth_ref": [
      "r125",
      "r244"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInContingentConsiderationAssetLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fair value remeasurement of contingent consideration",
        "label": "Increase (decrease) in contingent consideration asset (liability)"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in a contingent consideration asset (liability) relating to a business combination."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "sny_IncreaseDecreaseInTotalExpenseOfRestructuringActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "IncreaseDecreaseInTotalExpenseOfRestructuringActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in total expense of restructuring activities",
        "label": "Increase (Decrease) In Total Expense Of Restructuring Activities",
        "documentation": "Increase (Decrease) In Total Expense Of Restructuring Activities"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net interest related to employee benefits, and unwinding of discount",
        "label": "Increase Decrease Of Unused Provision Reversed, Other Provisions",
        "documentation": "Increase Decrease Of Unused Provision Reversed, Other Provisions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial gains and losses on defined-benefit plans (B.12.1.)",
        "label": "Increase (Decrease) Through Actuarial Gains And Losses On Defined Benefit Plans, Other Provisions",
        "documentation": "Actuarial gains and losses on defined-benefit plans."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Increase (decrease) through exercise of options, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other changes arising from issuance of restricted shares",
        "label": "Increase (Decrease) Through Issuance Of Restricted Shares, Equity",
        "documentation": "Increase (decrease) through issuance of restricted shares, equity."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences",
        "label": "Increase (Decrease) Through Net Exchange Differences Business Combinations And Noncontrolling Interests",
        "documentation": "Increase decrease through net exchange differences business combinations and noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Currency translation differences",
        "label": "Increase (decrease) through net exchange differences, intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets and goodwill resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) through net exchange differences, intangible assets other than goodwill",
        "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences",
        "label": "Increase (decrease) through net exchange differences, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net interest related to employee benefits, and unwinding of discount",
        "label": "Increase (Decrease) Through Net Interest Related To Employees Benefits And Unwinding Of Discount, Other Provisions",
        "documentation": "Net interest related to employees benefits and unwinding of discount."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase through remeasurement of financial liability",
        "label": "Increase (Decrease) Through Remeasurement, Other Current Liabilities",
        "documentation": "Increase (Decrease) Through Remeasurement, Other Non-Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee share ownership plan",
        "label": "Increase (Decrease) Through Share-Based Payment Plans Employee Share Ownership Plans",
        "documentation": "Employee share ownership plans."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of restricted shares and vesting of existing restricted shares",
        "label": "Increase (Decrease) Through Share-Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares",
        "documentation": "Increase (decrease) through share-based payment plans issuance of restricted shares and vesting of existing restricted shares."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax effects of share-based payments",
        "label": "Increase (Decrease) Through Share-Based Payment Plans Tax Effects Of The Exercise Of Stock Options",
        "documentation": "Tax effects of the exercise of stock options."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of services obtained from employees",
        "label": "Increase (Decrease) Through Share-Based Payment Plans Value Of Services Obtained From Employees",
        "documentation": "Value of services obtained from employees."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other movements (b)",
        "label": "Increase (decrease) through other changes, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers",
        "label": "Increase (decrease) through transfers and other changes, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers",
        "label": "Increase (decrease) through transfers, intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets and goodwill resulting from transfers. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) through transfers, intangible assets other than goodwill",
        "label": "Increase (decrease) through transfers, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "sny_IndustrialSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "IndustrialSalesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "of which",
        "label": "Industrial Sales [Member]",
        "documentation": "Industrial Sales"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InfluenzaVaccinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "InfluenzaVaccinesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Influenza Vaccines",
        "label": "Influenza Vaccines [Member]",
        "documentation": "Influenza Vaccines."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InfraservGmbhAndCoHochstKGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "InfraservGmbhAndCoHochstKGMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Infraserv GmbH &amp; Co. H\u00f6chst KG",
        "label": "Infraserv Gmbh And Co Hochst KG [member]",
        "documentation": "Infraserv GmbH and Co. Hochst KG."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InhibrxIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "InhibrxIncMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inhibrx, Inc",
        "label": "Inhibrx, Inc [Member]",
        "documentation": "Inhibrx, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsAndGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets and goodwill [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other intangible assets",
        "terseLabel": "Carrying amount of intangible assets",
        "label": "Intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r108"
     ]
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwillMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets other than goodwill [member]",
        "label": "Intangible assets other than goodwill [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r109",
      "r242",
      "r257"
     ]
    },
    "ifrs-full_InterestCostsCapitalised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestCostsCapitalised",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest costs capitalised",
        "label": "Interest costs capitalised"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "ifrs-full_InterestExpenseOnBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestExpenseOnBorrowings",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails": {
       "parentTag": "sny_CostOfDebtNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of debt",
        "label": "Interest expense on borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestExpenseOnLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net interest expense on lease liabilities",
        "label": "Interest expense on lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "sny_InterestIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "InterestIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails": {
       "parentTag": "sny_CostOfDebtNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest Income",
        "documentation": "Interest Income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid",
        "label": "Interest paid, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "sny_InterestRateAndCurrencyDerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "InterestRateAndCurrencyDerivativesMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate and currency derivatives used to hedge debt",
        "label": "Interest Rate And Currency Derivatives [Member]",
        "documentation": "Interest rate and currency derivatives used to hedge debt."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "sny_DebtNetOfCashAndCashEquivalents",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest rate and currency derivatives used to manage cash and cash equivalents",
        "label": "Interest Rate And Currency Derivatives Used To Manage Cash And Cash Equivalent",
        "documentation": "Interest rate and currency derivatives used to manage cash and cash equivalent."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateAndCurrencyDerivativesUsedToManageDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "InterestRateAndCurrencyDerivativesUsedToManageDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest rate and currency derivatives used to manage debt",
        "label": "Interest Rate And Currency Derivatives Used To Manage Debt",
        "documentation": "Interest rate and currency derivatives used to manage debt."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "InterestRateSwapsInterestRate",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Interest Rate Swaps, Interest Rate",
        "documentation": "Interest Rate Swaps, Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedEsterReceive069Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "InterestRateSwapsPayCapitalizedEsterReceive069Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "pay capitalized Ester / receive 0.69%",
        "label": "Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized Ester / Receive 0.69%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedEsterReceive092Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "InterestRateSwapsPayCapitalizedEsterReceive092Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "pay capitalized Ester / receive 0.92%",
        "label": "Interest Rate Swaps Pay Capitalized Ester / Receive 0.92% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized Ester / Receive 0.92%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedEsterReceive3.56Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "InterestRateSwapsPayCapitalizedEsterReceive3.56Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Swaps Pay Capitalized Ester / Receive 3.56%",
        "label": "Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized Ester / Receive 3.56%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedEsterReceive343Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "InterestRateSwapsPayCapitalizedEsterReceive343Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "pay capitalized Ester / receive 3.56%",
        "label": "Interest Rate Swaps Pay Capitalized Ester / Receive 3.43% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized Ester / Receive 3.43%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02%",
        "label": "Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "pay capitalized SOFR USD / receive 1.02%",
        "label": "Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.03% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.03%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "pay capitalized SOFR USD / receive 1.32%",
        "label": "Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.32% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.32%"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest received",
        "label": "Interest received, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "sny_InterestsInOtherEntitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "InterestsInOtherEntitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interests In Other Entities [Abstract]",
        "label": "Interests In Other Entities [Abstract]",
        "documentation": "Interests In Other Entities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Current inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r74",
      "r229"
     ]
    },
    "ifrs-full_InvestmentAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InvestmentAccountedForUsingEquityMethod",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 8.0
      },
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments accounted for using the equity method",
        "totalLabel": "Investments accounted for using the equity method",
        "label": "Investments accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r149",
      "r213"
     ]
    },
    "ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InvestmentsInAssociatesAccountedForUsingEquityMethod",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails": {
       "parentTag": "ifrs-full_InvestmentAccountedForUsingEquityMethod",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in associates",
        "label": "Investments in associates accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments in associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, ownership percentage",
        "label": "Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income, Ownership Percentage",
        "documentation": "Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income, Ownership Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InvestmentsInJointVenturesAccountedForUsingEquityMethod",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails": {
       "parentTag": "ifrs-full_InvestmentAccountedForUsingEquityMethod",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in joint ventures",
        "label": "Investments in joint ventures accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments in joint ventures accounted for using the equity method. [Refer: Joint ventures [member]; Investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "sny_IssuanceOfFurtherSharesAsAnEmployersContribution": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "IssuanceOfFurtherSharesAsAnEmployersContribution",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued immediately for employer's contribution (in shares)",
        "label": "Issuance Of Further Shares As An Employers Contribution",
        "documentation": "Further shares as an employers contribution."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ItemsNotSubsequentlyReclassifiableToProfitOrLossMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Items not subsequently reclassifiable to profit or loss",
        "label": "Items Not Subsequently Reclassifiable To Profit Or Loss [Member]",
        "documentation": "Items not subsequently reclassifiable to profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ItemsSubsequentlyReclassifiableToProfitOrLossMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Items subsequently reclassifiable to profit or loss",
        "label": "Items Subsequently Reclassifiable To Profit Or Loss [Member]",
        "documentation": "Items subsequently reclassifiable to profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "sny_JevtanaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "JevtanaMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jevtana",
        "label": "Jevtana [Member]",
        "documentation": "Jevtana."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_JointVenturesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "JointVenturesAxis",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Joint ventures [Axis]",
        "label": "Joint ventures [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r85",
      "r151"
     ]
    },
    "sny_LantusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "LantusMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lantus",
        "label": "Lantus [Member]",
        "documentation": "Lantus."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanFiveYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r173",
      "r267",
      "r272",
      "r274"
     ]
    },
    "ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanFourYearsAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028 and beyond",
        "label": "Later than four years and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than four years and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r173",
      "r267",
      "r274",
      "r280"
     ]
    },
    "ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneMonthAndNotLaterThanThreeMonthsMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Overdue by 1-3 months",
        "label": "Later than one month and not later than three months [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one month and not later than three months."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r269",
      "r274"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Later than one year and not later than five years [member]",
        "label": "Later than one year and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r274"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Later than one year and not later than two years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than two years."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r173",
      "r267",
      "r274",
      "r280"
     ]
    },
    "ifrs-full_LaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Overdue by > 12 months",
        "label": "Later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanSixMonthsAndNotLaterThanOneYearMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Overdue by 6-12 months",
        "label": "Later than six months and not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than six months and not later than one year."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r271",
      "r274"
     ]
    },
    "ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanThreeMonthsAndNotLaterThanSixMonthsMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Overdue by 3-6 months",
        "label": "Later than three months and not later than six months [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three months and not later than six months."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r270",
      "r274"
     ]
    },
    "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Later than three years and not later than four years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years and not later than four years."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r173",
      "r267",
      "r274",
      "r280"
     ]
    },
    "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Later than two years and not later than three years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than two years and not later than three years."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r173",
      "r267",
      "r274",
      "r280"
     ]
    },
    "sny_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, cost",
        "label": "Lease, Cost",
        "documentation": "Lease, Cost"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LeaseExtensionOptionsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "LeaseExtensionOptionsNumber",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, extension options, number",
        "label": "Lease, Extension Options, Number",
        "documentation": "Lease, Extension Options, Number"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LeaseExtensionOptionsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "LeaseExtensionOptionsTerm",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, extension options, term",
        "label": "Lease, Extension Options, Term",
        "documentation": "Lease, Extension Options, Term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "sny_LeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "LeaseTerm",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, term",
        "label": "Lease, Term",
        "documentation": "Lease, Term"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LegalAndArbitralProceedingsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "LegalAndArbitralProceedingsAxis",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal And Arbitral Proceedings [Axis]",
        "label": "Legal And Arbitral Proceedings [Axis]",
        "documentation": "Legal And Arbitral Proceedings [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LegalAndArbitralProceedingsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "LegalAndArbitralProceedingsDomain",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal And Arbitral Proceedings [Domain]",
        "label": "Legal And Arbitral Proceedings [Domain]",
        "documentation": "[Domain] for Legal And Arbitral Proceedings [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities related to assets held for sale or exchange",
        "label": "Liabilities included in disposal groups classified as held for sale"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities included in disposal groups classified as held for sale. [Refer: Liabilities; Disposal groups classified as held for sale [member]]"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r191"
     ]
    },
    "sny_LiabilityRecognisedForEstimatedFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "LiabilityRecognisedForEstimatedFutureRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Recognised For Estimated Future Royalties",
        "label": "Liability Recognised For Estimated Future Royalties",
        "documentation": "Liability Recognised For Estimated Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LineItemsByFunctionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LineItemsByFunctionMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line items by function [member]",
        "label": "Line items by function [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r280"
     ]
    },
    "sny_LongTermPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "LongTermPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term prepaid expenses",
        "label": "Long Term Prepaid Expenses",
        "documentation": "Long term prepaid expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LongtermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LongtermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "label": "Non-current portion of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "sny_LovenoxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "LovenoxMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lovenox",
        "label": "Lovenox [Member]",
        "documentation": "Lovenox."
       }
      }
     },
     "auth_ref": []
    },
    "sny_MCMVaccineBVMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "MCMVaccineBVMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MCM Vaccine BV",
        "label": "MCM Vaccine BV [Member]",
        "documentation": "MCM Vaccine BV"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "MSDContingentConsiderationEuropeanVaccinesBusinessMember",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MSD contingent consideration (European Vaccines business)",
        "label": "MSD Contingent Consideration European Vaccines Business [Member]",
        "documentation": "MSD contingent consideration European vaccines business."
       }
      }
     },
     "auth_ref": []
    },
    "sny_MSPVaccineCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "MSPVaccineCompanyMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MSP Vaccine Company",
        "label": "MSP Vaccine Company [Member]",
        "documentation": "MSP Vaccine Company"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorBusinessCombinationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorBusinessCombinationMember",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major business combination",
        "label": "Major business combination [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for major business combinations. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "sny_MajorCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "MajorCollaborationAgreementMember",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major collaboration agreement",
        "label": "Major Collaboration Agreement [Member]",
        "documentation": "Major Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major customers [Axis]",
        "label": "Major customers [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "ifrs-full_MajorCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorCustomersMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customers [Member]",
        "label": "Customers [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "sny_MajorFinancialLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "MajorFinancialLiabilityMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major financial liability",
        "label": "Major Financial Liability [Member]",
        "documentation": "Major Financial Liability"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MajorTerritoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "MajorTerritoriesMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major territories",
        "label": "Major Territories [Member]",
        "documentation": "Major Territories"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ManufacturingAndSupplyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ManufacturingAndSupplyMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing &amp; Supply",
        "label": "Manufacturing And Supply [Member]",
        "documentation": "Manufacturing and supply"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MarketConditionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "MarketConditionAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Condition [Axis]",
        "label": "Market Condition [Axis]",
        "documentation": "Market Condition"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MarketConditionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "MarketConditionDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Condition [Domain]",
        "label": "Market Condition [Domain]",
        "documentation": "Market Condition [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MarketedProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "MarketedProductsMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketed products",
        "label": "Marketed Products [Member]",
        "documentation": "Marketed products."
       }
      }
     },
     "auth_ref": []
    },
    "sny_MarketedProductsTrademarksAndOtherRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "MarketedProductsTrademarksAndOtherRightsMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketed Products Trademarks And Other Rights",
        "label": "Marketed Products Trademarks And Other Rights [Member]",
        "documentation": "Marketed Products Trademarks And Other Rights"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaterialReconcilingItemsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaterialReconcilingItemsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material reconciling items",
        "label": "Material reconciling items [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for material adjustments used to reconcile items in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity [Axis]",
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r162",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r193",
      "r203",
      "r239",
      "r267"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MazeTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "MazeTherapeuticsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maze Therapeutics",
        "label": "Maze Therapeutics [Member]",
        "documentation": "Maze Therapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MeasurementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MeasurementAxis",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement [Axis]",
        "label": "Measurement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r117",
      "r153"
     ]
    },
    "sny_MeningitisTravelAndEndemicVaccinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "MeningitisTravelAndEndemicVaccinesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Meningitis Travel And Endemic Vaccines",
        "label": "Meningitis Travel And Endemic Vaccines [Member]",
        "documentation": "Meningitis Travel And Endemic Vaccines"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MiscellaneousOtherOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MiscellaneousOtherOperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other operating expenses",
        "terseLabel": "Other operating expense",
        "label": "Miscellaneous other operating expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "ifrs-full_MiscellaneousOtherOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MiscellaneousOtherOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income",
        "label": "Miscellaneous other operating income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "sny_MiscellaneousOtherOperatingIncomeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "MiscellaneousOtherOperatingIncomeExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income and expenses",
        "label": "Miscellaneous Other Operating Income (Expenses)",
        "documentation": "Other operating income and expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MiscellaneousOtherProvisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MiscellaneousOtherProvisionsMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other provisions",
        "label": "Miscellaneous other provisions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for miscellaneous other provisions. [Refer: Other provisions [member]]"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "sny_MyozymeLumizymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "MyozymeLumizymeMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Myozyme/Lumizyme",
        "label": "Myozyme/Lumizyme [Member]",
        "documentation": "Myozyme/Lumizyme"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NameOfAcquiree": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NameOfAcquiree",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of acquiree",
        "label": "Name of acquiree"
       }
      },
      "en": {
       "role": {
        "documentation": "The name of the business or businesses that the acquirer obtains control of in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in other current assets and other current liabilities",
        "label": "Net Change In Other Current Assets And Other Current Liabilities",
        "documentation": "Adjustments for decrease (increase) in other current assets and increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetChangeInOtherNonCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NetChangeInOtherNonCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in other non-current assets",
        "label": "Net Change In Other Non-Current Assets",
        "documentation": "Net change in other non-current assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetDefinedBenefitLiabilityAssetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NetDefinedBenefitLiabilityAssetAxis",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net defined benefit liability (asset) [Axis]",
        "label": "Net defined benefit liability (asset) [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ifrs-full_NetDefinedBenefitLiabilityAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NetDefinedBenefitLiabilityAssetMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net defined benefit liability (asset) [Member]",
        "label": "Net defined benefit liability (asset) [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the net defined benefit liability (asset). It also represents the standard value for the 'Net defined benefit liability (asset)' axis if no other member is used. [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "sny_NetInterestCostRelatedToEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NetInterestCostRelatedToEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net interest cost related to employee benefits",
        "label": "Net Interest Cost Related To Employee Benefits",
        "documentation": "Net interest cost related to employee benefits."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetReversalOfImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NetReversalOfImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Reversal of Impairment Loss",
        "label": "Net Reversal of Impairment Loss",
        "documentation": "Net Reversal of Impairment Loss"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NexviazymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NexviazymeMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nexviazyme",
        "label": "Nexviazyme [Member]",
        "documentation": "Nexviazyme"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCoreAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NonCoreAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Core Assets [Member]",
        "label": "Non-Core Assets [Member]",
        "documentation": "Non-Core Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NonCurrentAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "non-current",
        "label": "Non-Current Assets [Member]",
        "documentation": "Non-current assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NonCurrentLiabilitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "non-current",
        "label": "Non-Current Liabilities [Member]",
        "documentation": "Non-current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities related to business combinations and to non-controlling interests",
        "verboseLabel": "Non-current portion",
        "label": "Non-Current Liabilities Related To Business Combinations And To Non-Controlling Interests",
        "documentation": "This account includes non-current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes non-current portion of liabilities related to non-controlling interests."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NonCurrentProvisionsAndOtherNonCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current provisions and other non-current liabilities",
        "totalLabel": "Non-current provisions",
        "label": "Non-Current Provisions And Other Non-Current Liabilities",
        "documentation": "The amount of non-current provisions and non-current other liabilities that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentRestructuringProvisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NonCurrentRestructuringProvisionMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring provisions",
        "label": "Non-Current Restructuring Provision [Member]",
        "documentation": "Restructuring provisions."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonOperatingForeignExchangeGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NonOperatingForeignExchangeGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-operating foreign exchange gains/(losses)",
        "label": "Non-Operating Foreign Exchange Gains/(Losses)",
        "documentation": "Non-operating foreign exchange gains/(losses)."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [Axis]",
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ifrs-full_NonadjustingEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsMember",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [Member]",
        "label": "Non-adjusting events after reporting period [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ifrs-full_NoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity attributable to non-controlling interests",
        "label": "Non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r21",
      "r137",
      "r139"
     ]
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncontrollingInterestsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributable to\u00a0non-controlling interests",
        "label": "Non-controlling interests [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Non-current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r28",
      "r143",
      "r250"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets:",
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets held for sale or exchange",
        "label": "Non-current assets or disposal groups classified as held for sale"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]]"
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Instruments at fair value through other comprehensive income",
        "label": "Non-current financial assets at fair value through other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets at fair value through other comprehensive income. [Refer: Financial assets at fair value through other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current lease liabilities",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Non-current liabilities",
        "label": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r29",
      "r144",
      "r250"
     ]
    },
    "ifrs-full_NoncurrentLoansAndReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLoansAndReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term loans and advances and other non-current receivables",
        "label": "Non-current loans and receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current loans and receivables. [Refer: Loans and receivables]"
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_NoncurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentProvisions",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails": {
       "parentTag": "sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Non-current provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "sny_NotEligibleForHedgeAccountingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NotEligibleForHedgeAccountingMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Not eligible for hedge accounting",
        "label": "Not Eligible For Hedge Accounting [Member]",
        "documentation": "Not eligible for hedge accounting."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotLaterThanOneMonthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotLaterThanOneMonthMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Overdue by less than 1 month",
        "label": "Not later than one month [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one month."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r268",
      "r274"
     ]
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r168",
      "r169",
      "r173",
      "r267",
      "r274"
     ]
    },
    "ifrs-full_NotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotionalAmount",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional amount",
        "label": "Notional amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "sny_NovavaxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NovavaxMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novavax",
        "label": "Novavax [Member]",
        "documentation": "Novavax"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfBondIssuesRedeemed": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NumberOfBondIssuesRedeemed",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of bond issues redeemed",
        "label": "Number Of Bond Issues Redeemed",
        "documentation": "Number Of Bond Issues Redeemed"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfCases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NumberOfCases",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number Of Cases",
        "label": "Number Of Cases",
        "documentation": "Number Of Cases"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfClassActionLawsuits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NumberOfClassActionLawsuits",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number Of Class Action Lawsuits",
        "label": "Number Of Class Action Lawsuits",
        "documentation": "Number Of Class Action Lawsuits"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfDismissals": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NumberOfDismissals",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number Of Dismissals",
        "label": "Number Of Dismissals",
        "documentation": "Number Of Dismissals"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Total number of shares awarded (in shares)",
        "label": "Number of other equity instruments granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r300"
     ]
    },
    "sny_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationAdditionalInformationDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number Of Operating Segments",
        "documentation": "Number of operating segments."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of other equity instruments exercised or vested in share-based payment arrangement",
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOutstandingShareOptions",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Outstanding, number\u00a0of options (in shares)",
        "label": "Number of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r178"
     ]
    },
    "sny_NumberOfPlaintiffs": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NumberOfPlaintiffs",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number Of Plaintiffs",
        "label": "Number Of Plaintiffs",
        "documentation": "Number Of Plaintiffs"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfRestrictedSharesAlloted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NumberOfRestrictedSharesAlloted",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of restricted shares alloted (in shares)",
        "label": "Number Of Restricted Shares Alloted",
        "documentation": "Number Of Restricted Shares Alloted"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of restricted shares alloted in regards of capital increase",
        "label": "Number of restricted shares alloted in regards of capital increase",
        "documentation": "Number of restricted shares alloted in regards of capital increase"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital increase by issuance of restricted shares (in shares)",
        "label": "Number Of Restricted Shares Issued In Regards Of Capital Increase",
        "documentation": "Number of restricted shares issued in regards of capital increase."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfRestrictedSharesNotYetFullyVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NumberOfRestrictedSharesNotYetFullyVested",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares not yet fully vested (in shares)",
        "label": "Number Of Restricted Shares Not Yet Fully Vested",
        "documentation": "Number of restricted shares not yet fully vested."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of restricted shares vested (in shares)",
        "label": "Number Of Restricted Shares Vested In Regards Of Capital Increase",
        "documentation": "Number Of Restricted Shares Vested In Regards Of Capital Increase"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, number of options (in shares)",
        "label": "Number of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "sny_NumberOfSharesHeld": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NumberOfSharesHeld",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofTreasurySharesHeldDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares (in shares)",
        "label": "Number Of Shares Held",
        "documentation": "Number of shares held."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares (in shares)",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital\u00a0increase\u00a0by\u00a0exercise\u00a0of stock subscription options (in shares)",
        "label": "Number Of Shares Issued In Regards Of Capital Increase By Exercise Of Stock Subscription Options",
        "documentation": "Number of shares issued in regards of capital increase by exercise of stock subscription options."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfSharesRepurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NumberOfSharesRepurchased",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares repurchased (in shares)",
        "label": "Number Of Shares Repurchased",
        "documentation": "Number of shares repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfSharesSubscribed": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NumberOfSharesSubscribed",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares subscribed (in shares)",
        "label": "Number Of Shares Subscribed",
        "documentation": "Number of shares subscribed."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfYearsServicePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "NumberOfYearsServicePeriod",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service period",
        "label": "Number Of Years, Service Period",
        "documentation": "Number Of Years, Service Period"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OffBalanceSheetCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OffBalanceSheetCommitmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Off-Balance Sheet Commitments [Abstract]",
        "documentation": "Off-Balance Sheet Commitments"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OneBillionBondsMaturingJune2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OneBillionBondsMaturingJune2023Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u20ac1 billion bonds maturing June 2023",
        "label": "One Billion Bonds Maturing June 2023 [Member]",
        "documentation": "One Billion Bonds Maturing June 2023"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u20ac1.75 billion bonds maturing March 2023",
        "label": "One Billion Seven Hundred Fifty Million Bonds Maturing March 2023 [Member]",
        "documentation": "One Billion Seven Hundred Fifty Million Bonds Maturing March 2023"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OpellaMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella",
        "label": "Opella [Member]",
        "documentation": "Opella"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating segments",
        "label": "Operating segments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for operating segments. An operating segment is a component of an entity: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity); (b) whose operating results are regularly reviewed by the entity\u2019s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance; and (c) for which discrete financial information is available. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "ifrs-full_OtherAdjustmentsToReconcileProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherAdjustmentsToReconcileProfitLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other profit or loss items with no cash effect on cash flows generated by operating activities",
        "label": "Other adjustments to reconcile profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Adjustments to reconcile profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "sny_OtherBankBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OtherBankBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other bank borrowings",
        "label": "Other Bank Borrowings",
        "documentation": "Other bank borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other borrowings",
        "label": "Other borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income for the period, net of taxes",
        "terseLabel": "Other comprehensive income for the period",
        "label": "Other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r35",
      "r45",
      "r146"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income:",
        "label": "Other comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Items subsequently reclassifiable to profit or loss",
        "terseLabel": "Other comprehensive income that will be reclassified to profit or loss, net of tax",
        "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Items not subsequently reclassifiable to profit or loss",
        "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234"
     ]
    },
    "sny_OtherCountriesExcludingEuropeAndNorthAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OtherCountriesExcludingEuropeAndNorthAmericaMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other countries",
        "label": "Other Countries, Excluding Europe And North America [Member]",
        "documentation": "Other Countries, Excluding Europe And North America"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherCountriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OtherCountriesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other countries",
        "label": "Other Countries [member]",
        "documentation": "Other countries."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ifrs-full_OtherFinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherFinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OtherFinancialAssetsAtFairValueThroughProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial assets at fair value through profit or loss",
        "label": "Other Financial Assets At Fair Value Through Profit Or Loss",
        "documentation": "Other Financial Assets At Fair Value Through Profit Or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherGainsLossesAndLitigation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OtherGainsLossesAndLitigation",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/OtherGainsandLossesandLitigationDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other gains and losses, and litigation",
        "negatedNetLabel": "Other gains and litigation",
        "label": "Other Gains, (Losses) And Litigation",
        "documentation": "The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Other intangible assets, beginning balance",
        "periodEndLabel": "Other intangible assets, ending balance",
        "label": "Other intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "sny_OtherIntangibleAssetsExcludingSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OtherIntangibleAssetsExcludingSoftwareMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets excluding software",
        "label": "Other Intangible Assets Excluding Software [Member]",
        "documentation": "Intangible assets excluding software."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets",
        "label": "Other intangible assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "sny_OtherLiabilities1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OtherLiabilities1Member",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Liabilities1 [member]",
        "documentation": "Other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other movements",
        "label": "Other Movements, Contingent Liabilities Recognised In Business Combination",
        "documentation": "Other movements."
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherNonCoreAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OtherNonCoreAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Non-Core Assets [Member]",
        "label": "Other Non-Core Assets [Member]",
        "documentation": "Other Non-Core Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "totalLabel": "Total",
        "label": "Other non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails": {
       "parentTag": "sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "sny_OtherOperatingExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OtherOperatingExpensesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Operating Expenses",
        "label": "Other Operating Expenses [Table Text Block]",
        "documentation": "Other Operating Expenses [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherOperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherOperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income/(expenses), net related to Regeneron",
        "label": "Other operating income (expense)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of operating income (expense) that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "sny_OtherOperatingIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OtherOperatingIncomeExpenseMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income (expense)",
        "label": "Other Operating Income (Expense) [Member]",
        "documentation": "Other Operating Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherProductsSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OtherProductsSegmentMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Products Segment",
        "label": "Other Products Segment [Member]",
        "documentation": "Other Products Segment"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]",
        "label": "Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]",
        "documentation": "Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherProvisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherProvisionsMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other provisions [Member]",
        "label": "Other provisions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ifrs-full_OtherRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherRelatedPartiesMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other related parties",
        "label": "Other related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for related parties that the entity does not separately disclose in the same statement or note. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "sny_OtherRestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OtherRestructuringCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": "ifrs-full_ExpenseOfRestructuringActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RestructuringCostsandSimilarItemsSummaryofRestructuringCostsandSimilarItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other restructuring costs",
        "label": "Other Restructuring Costs",
        "documentation": "Other restructuring costs."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails",
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues",
        "label": "Other revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome",
     "calculation": {
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (d)",
        "label": "Other tax rate effects for reconciliation between accounting profit and tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "Tax rate effects, in aggregate, on the reconciliation between the average effective tax rate and the applicable tax rate that the entity does not separately disclose in the reconciliation. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "sny_OtherTerritoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OtherTerritoriesMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other territories",
        "label": "Other Territories [Member]",
        "documentation": "Other Territories"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OthersCounterpartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OthersCounterpartyMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (mainly Zaltrap and Libtayo)",
        "label": "Others Counterparty [Member]",
        "documentation": "Others Counterparty [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OthersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OthersMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Others [Member]",
        "documentation": "Others"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OverdueReceivablesGrossValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "OverdueReceivablesGrossValue",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/AccountsReceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Overdue receivables gross value",
        "label": "Overdue Receivables Gross Value",
        "documentation": "Overdue receivables gross value."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PainCareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "PainCareMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wellness brands",
        "label": "Pain Care [Member]",
        "documentation": "Pain [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Par value per share (in euros per share)",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "sny_PaymentToSaleOfBusinessPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "PaymentToSaleOfBusinessPeriod",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment to sale of business period",
        "label": "Payment To Sale Of Business Period",
        "documentation": "Payment to sale of business period."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsFromChangesInOwnershipInterestsInSubsidiaries",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments received/(made) on changes of ownership interest in a subsidiary without loss of control",
        "label": "Payments from changes in ownership interests in subsidiaries that do not result in loss of control"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for changes in ownership interests in subsidiaries that do not result in a loss of control. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128"
     ]
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of lease liabilities",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "ifrs-full_PaymentsToAcquireOrRedeemEntitysShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsToAcquireOrRedeemEntitysShares",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisitions of treasury shares",
        "label": "Payments to acquire or redeem entity's shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to acquire or redeem entity's shares."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "sny_PenaltyFeeIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "PenaltyFeeIncurred",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Penalty Fee Incurred",
        "label": "Penalty Fee Incurred",
        "documentation": "Penalty Fee Incurred"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PenaltyFeeIncurredByDefendantsInterestsAmountVacated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "PenaltyFeeIncurredByDefendantsInterestsAmountVacated",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Penalty fee incurred by defendants, interests, amount vacated",
        "label": "Penalty Fee Incurred By Defendants, Interests, Amount Vacated",
        "documentation": "Penalty Fee Incurred By Defendants, Interests, Amount Vacated"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PensionsAndOtherPostEmploymentBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "PensionsAndOtherPostEmploymentBenefitsMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pensions and other post-employment benefits",
        "label": "Pensions And Other Post-Employment Benefits [Member]",
        "documentation": "Pensions and other post-employment benefits."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageIncreaseInFairValueLiabilities": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "PercentageIncreaseInFairValueLiabilities",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in fair value of liability",
        "label": "Percentage Increase In Fair Value Liabilities",
        "documentation": "Percentage increase in fair value liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "PercentageOfDevelopmentCostsArisingFromCommercialOperations",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of development costs arising from commercial operations",
        "label": "Percentage Of Development Costs Arising From Commercial Operations",
        "documentation": "Percentage Of Development Costs Arising From Commercial Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PercentageOfEntitysRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PercentageOfEntitysRevenue",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of entity's revenue",
        "label": "Percentage of entity's revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of the entity's revenue. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "sny_PercentageOfNetSalesArisingFromCommercialOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "PercentageOfNetSalesArisingFromCommercialOperations",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of net sales arising from commercial operations",
        "label": "Percentage Of Net Sales Arising From Commercial Operations",
        "documentation": "Percentage Of Net Sales Arising From Commercial Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfProfitsArisingFromCommercialOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "PercentageOfProfitsArisingFromCommercialOperations",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of profits arising from commercial operations",
        "label": "Percentage Of Profits Arising From Commercial Operations",
        "documentation": "Percentage Of Profits Arising From Commercial Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleDecreaseInActuarialAssumption",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease in actuarial assumption",
        "label": "Percentage of reasonably possible decrease in actuarial assumption"
       }
      },
      "en": {
       "role": {
        "documentation": "The reasonably possible percentage of the decrease in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleIncreaseInActuarialAssumption",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in actuarial assumption",
        "label": "Percentage of reasonably possible increase in actuarial assumption"
       }
      },
      "en": {
       "role": {
        "documentation": "The reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "sny_PercentageOfShareCapitalForThePeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "PercentageOfShareCapitalForThePeriod",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofTreasurySharesHeldDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "% of share capital for the period",
        "label": "Percentage Of Share Capital For The Period",
        "documentation": "Percentage of share capital for the period."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PeriodOfShareRepurchaseProgram": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "PeriodOfShareRepurchaseProgram",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of share repurchase program",
        "label": "Period Of Share Repurchase Program",
        "documentation": "Period of share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PharmaLaunchesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "PharmaLaunchesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharma Launches",
        "label": "Pharma Launches [Member]",
        "documentation": "Pharma Launches"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PharmaSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "PharmaSegmentMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharma Segment",
        "label": "Pharma Segment [Member]",
        "documentation": "Pharma Segment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PlanAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PlanAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan assets",
        "label": "Plan assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for defined benefit plan assets. Plan assets comprise: (a) assets held by a long-term employee benefit fund; and (b) qualifying insurance policies."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "sny_PlavixAttorneyGeneralActionInHawaiiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "PlavixAttorneyGeneralActionInHawaiiMember",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plavix Attorney General action in Hawaii",
        "label": "Plavix Attorney General Action In Hawaii [Member]",
        "documentation": "Plavix Attorney General Action In Hawaii"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PlavixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "PlavixMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plavix",
        "label": "Plavix [Member]",
        "documentation": "Plavix [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PolioPertussisHibVaccinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "PolioPertussisHibVaccinesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Polio/Pertussis/ Hib Vaccines",
        "label": "Polio Pertussis Hib Vaccines [Member]",
        "documentation": "Polio Pertussis Hib Vaccines."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PotentialPaymentsRelatedToPercentageOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "PotentialPaymentsRelatedToPercentageOfSales",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentiel payments related to percentage of sales of alemtuzumab",
        "label": "Potential Payments Related To Percentage Of Sales",
        "documentation": "Potential payments related to percentage of sales."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PreFundedPensionObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "PreFundedPensionObligations",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded pension obligations",
        "label": "Pre-Funded Pension Obligations",
        "documentation": "Pre-funded pension obligations."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipalAlliancesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "PrincipalAlliancesAxis",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Alliances [Axis]",
        "label": "Principal Alliances [Axis]",
        "documentation": "Principal Alliances"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipalAlliancesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "PrincipalAlliancesDomain",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Alliances [Domain]",
        "label": "Principal Alliances [Domain]",
        "documentation": "Principal Alliances [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax",
        "label": "Proceeds from disposals of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the disposal of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Sanofi shares",
        "label": "Proceeds from issuing shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "ifrs-full_ProceedsFromNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromNoncurrentBorrowings",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional long-term debt contracted",
        "label": "Proceeds from non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from non-current borrowings obtained. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "sny_ProductLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ProductLiabilitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Liabilities",
        "label": "Product Liabilities [Member]",
        "documentation": "Product Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProductsAndServicesAxis",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and services [axis]",
        "label": "Products and services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r255"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProductsAndServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProductsAndServicesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and services [member]",
        "label": "Products and services [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r255"
     ]
    },
    "sny_ProductsTrademarksAndOtherRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ProductsTrademarksAndOtherRightsMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products, trademarks and other rights",
        "label": "Products, Trademarks And Other Rights [Member]",
        "documentation": "Products, trademarks and other rights"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income",
        "verboseLabel": "Net income for the period",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r34",
      "r120",
      "r134",
      "r136",
      "r212",
      "r214",
      "r250",
      "r258"
     ]
    },
    "ifrs-full_ProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit (loss) [abstract]",
        "label": "Profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income attributable to non-controlling interests",
        "terseLabel": "Attributable to non-controlling interests",
        "netLabel": "Non-controlling interests",
        "label": "Profit (loss), attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r138"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income attributable to equity holders of Sanofi",
        "label": "Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) attributable to ordinary equity holders of the parent entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income attributable to equity holders of Sanofi",
        "terseLabel": "Attributable to equity holders of Sanofi",
        "label": "Profit (loss), attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating income",
        "label": "Profit (loss) from operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r284"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets",
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment owned",
        "verboseLabel": "property, plant and equipment",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r62"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment [abstract]",
        "label": "Property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment [Member]",
        "label": "Property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r63",
      "r242",
      "r257"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of ownership interest in associate",
        "label": "Proportion of ownership interest in associate"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r82",
      "r84",
      "r141"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInJointVenture": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInJointVenture",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of ownership interest in joint venture",
        "label": "Proportion of ownership interest in joint venture"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a joint venture attributable to the entity. [Refer: Joint ventures [member]]"
       }
      }
     },
     "auth_ref": [
      "r82",
      "r84",
      "r141"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of ownership interest in subsidiary",
        "label": "Proportion of ownership interest in subsidiary"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r82",
      "r84",
      "r140"
     ]
    },
    "sny_ProventionBioIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ProventionBioIncMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provention Bio",
        "label": "Provention Bio, Inc [Member]",
        "documentation": "Provention Bio, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProvisionUsedOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProvisionUsedOtherProvisions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Provisions utilized",
        "label": "Provision used, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "sny_ProvisionsForOtherLongTermBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ProvisionsForOtherLongTermBenefitsMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions for other long-term benefits",
        "label": "Provisions For Other Long Term Benefits [member]",
        "documentation": "Provisions for other long term benefits."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ProvisionsForPensionsAndOtherPostemploymentBenefitsMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions for pensions &amp; other post-employment benefits",
        "label": "Provisions For Pensions And Other Postemployment Benefits [member]",
        "documentation": "Provisions for pensions and other post-employment benefits."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisitions of other equity investments",
        "label": "Purchase of financial instruments, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions of other intangible assets",
        "label": "Purchase of intangible assets, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions of property, plant and equipment",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisitions of property, plant and equipment and intangible assets",
        "label": "Purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ifrs-full_PurchaseOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfTreasuryShares",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share repurchase program",
        "label": "Purchase of treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "ifrs-full_PurchasesOfGoodsRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchasesOfGoodsRelatedPartyTransactions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of goods and services",
        "label": "Purchases of goods, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of goods purchased by the entity in related party transactions. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "sny_QRIBIntermediateHoldingsLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "QRIBIntermediateHoldingsLLCMember",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "QRIB intermediate Holdings, LLC",
        "label": "QRIB intermediate Holdings, LLC [Member]",
        "documentation": "QRIB intermediate Holdings, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RSVVaccinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "RSVVaccinesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSV Vaccines",
        "label": "RSV Vaccines [Member]",
        "documentation": "RSV Vaccines"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Axis]",
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r172",
      "r178",
      "r252",
      "r254",
      "r301"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges [Member]",
        "label": "Ranges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r172",
      "r178",
      "r252",
      "r254",
      "r301"
     ]
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges of exercise prices for outstanding share options [axis]",
        "label": "Ranges of exercise prices for outstanding share options [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges of exercise prices for outstanding share options [member]",
        "label": "Ranges of exercise prices for outstanding share options [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Ranges [member]]"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "ifrs-full_ReclassifiedItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReclassifiedItemsAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassified items [Axis]",
        "label": "Reclassified items [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ifrs-full_ReclassifiedItemsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReclassifiedItemsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassified items [Member]",
        "label": "Reclassified items [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for items that have been reclassified when the entity changes their presentation or classification in its financial statements. It also represents the standard value for the 'Reclassified items' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "sny_RecludixPharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "RecludixPharmaMember",
     "presentation": [
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recludix Pharma",
        "label": "Recludix Pharma [Member]",
        "documentation": "Recludix Pharma"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReconciliationOfChangesInOtherProvisionsAbstract",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of changes in other provisions [abstract]",
        "label": "Reconciliation of changes in other provisions [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RedemptionOfDebtInstrumentIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "RedemptionOfDebtInstrumentIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value on redemption",
        "label": "Redemption Of Debt Instrument Issued",
        "documentation": "Redemption of debt instrument issued."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReductionOfIssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReductionOfIssuedCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reductions in share capital",
        "label": "Reduction of issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in equity resulting from a reduction in issued capital. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "sny_RegeneronMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "RegeneronMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regeneron",
        "label": "Regeneron [Member]",
        "documentation": "Regeneron"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RegeneronPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "RegeneronPharmaceuticalsIncMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regeneron Pharmaceuticals, Inc",
        "label": "Regeneron Pharmaceuticals, Inc [Member]",
        "documentation": "Regeneron Pharmaceuticals, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "RegularMilestonePaymentsForProjectsUnderCollaborationAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regular milestone payments",
        "label": "Regular Milestone Payments For Projects Under Collaboration Agreements",
        "documentation": "Regular Milestone Payments For Projects Under Collaboration Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RepaymentsOfNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RepaymentsOfNoncurrentBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of long-term debt",
        "label": "Repayments of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "sny_ReportableGeographicalZonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ReportableGeographicalZonesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Reportable Geographical Zones [Member]",
        "documentation": "Reportable geographical zones."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReportableSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReportableSegmentsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "Reportable segments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for operating segments for which IFRS 8 requires information to be disclosed. The entity shall report separately information about an operating segment that meets any of the following quantitative thresholds: (a) reported revenue, including both sales to external customers and intersegment sales or transfers, is 10 per cent or more of the combined revenue, internal and external, of all operating segments; (b) the absolute amount of its reported profit or loss is 10 per cent or more of the greater, in absolute amount, of (i) the combined reported profit of all operating segments that did not report a loss and (ii) the combined reported loss of all operating segments that reported a loss; or (c) assets are 10 per cent or more of the combined assets of all operating segments. Additionally operating segments that do not meet any of the quantitative thresholds may be considered reportable, and separately disclosed, if management believes that information about the segment would be useful to users of the financial statements. [Refer: Operating segments [member]]"
       }
      }
     },
     "auth_ref": [
      "r161",
      "r212",
      "r238",
      "r260"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development expenses",
        "negatedTerseLabel": "Research and development expense",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options and other share-based payments",
        "label": "Reserve of share-based payments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "sny_RestrictedSharePlan2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "RestrictedSharePlan2020Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share plan 2020",
        "label": "Restricted Share Plan 2020 [Member]",
        "documentation": "Restricted Share Plan 2020"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "RestrictedSharePlan2021Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share plan 2021",
        "label": "Restricted Share Plan 2021 [Member]",
        "documentation": "Restricted Share Plan 2021"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "RestrictedSharePlan2022Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share plan 2022",
        "label": "Restricted Share Plan 2022 [Member]",
        "documentation": "Restricted Share Plan 2022"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2023AdditionalSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "RestrictedSharePlan2023AdditionalSharesMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share plan 2023, additional shares",
        "label": "Restricted Share Plan 2023, Additional Shares [Member]",
        "documentation": "Restricted Share Plan 2023, Additional Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "RestrictedSharePlan2023Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share plan 2023",
        "label": "Restricted Share Plan 2023 [Member]",
        "documentation": "Restricted Share Plan 2023"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2024AdditionalSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "RestrictedSharePlan2024AdditionalSharesMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Share Plan 2024, Additional Shares",
        "label": "Restricted Share Plan 2024, Additional Shares [Member]",
        "documentation": "Restricted Share Plan 2024, Additional Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "RestrictedSharePlan2024Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Share Plan 2024",
        "label": "Restricted Share Plan 2024 [Member]",
        "documentation": "Restricted Share Plan 2024"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "RestrictedSharesMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted shares",
        "label": "Restricted Shares [Member]",
        "documentation": "Restricted shares."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserves and retained earnings",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r228"
     ]
    },
    "ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Actuarial gains/(losses) on plan assets",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [member]; Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ifrs-full_RevenueFromSaleOfGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromSaleOfGoods",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sales",
        "label": "Revenue from sale of goods"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from the sale of goods. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromSaleOfGoodsRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales",
        "label": "Revenue from sale of goods, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from the sale of goods in related party transactions. [Refer: Revenue; Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss recognised in profit or loss, intangible assets other than goodwill, reversal amount",
        "label": "Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of reversal of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Reversal of impairment loss recognised in profit or loss; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "RevisionsToTaxExposuresAndSettlementsOfTaxDisputes",
     "calculation": {
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revisions to tax exposures and settlements of tax disputes",
        "label": "Revisions To Tax Exposures And Settlements Of Tax Disputes",
        "documentation": "Revisions to tax exposures and settlements of tax disputes."
       }
      }
     },
     "auth_ref": []
    },
    "sny_RezurockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "RezurockMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rezurock",
        "label": "Rezurock [Member]",
        "documentation": "Rezurock"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r166"
     ]
    },
    "sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "RoyaltiesAndOtherIncomeRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties and other income",
        "label": "Royalties And Other Income, Related Party Transactions",
        "documentation": "Royalties and other income, related party transactions."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SAR44425Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "SAR44425Member",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SAR44425",
        "label": "SAR44425 [Member]",
        "documentation": "SAR44425"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiEuroMediumTermNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "SanofiEuroMediumTermNotesMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Euro Medium Term Notes",
        "label": "Sanofi Euro Medium Term Notes [Member]",
        "documentation": "Sanofi Euro Medium Term Notes"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "SanofiMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi",
        "label": "Sanofi [member]",
        "documentation": "Sanofi."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SarclisaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "SarclisaMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sarclisa",
        "label": "Sarclisa [Member]",
        "documentation": "Sarclisa"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsPrincipalChangesinScopeofConsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ScribeTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ScribeTherapeuticsMember",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scribe Therapeutics",
        "label": "Scribe Therapeutics [Member]",
        "documentation": "Scribe Therapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SeasonalSymptomsAndPainReliefMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "SeasonalSymptomsAndPainReliefMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Seasonal Symptoms And Pain Relief",
        "label": "Seasonal Symptoms And Pain Relief [Member]",
        "documentation": "Seasonal Symptoms And Pain Relief"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Seasonal Trends",
        "label": "Seasonality Or Cyclicality Of Interim Operations [Policy Text Block]",
        "documentation": "Seasonality Or Cyclicality Of Interim Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SegmentConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SegmentConsolidationItemsAxis",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment consolidation items [Axis]",
        "label": "Segment consolidation items [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "ifrs-full_SegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SegmentsAxis",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r161",
      "r212",
      "r238",
      "r260"
     ]
    },
    "ifrs-full_SegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SegmentsMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyPlantandEquipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Member]",
        "label": "Segments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r161",
      "r217",
      "r238",
      "r260"
     ]
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Selling and general expenses",
        "negatedTerseLabel": "Selling, general and administrative expense",
        "label": "Selling, general and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling, general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments made",
        "label": "Settled liabilities, contingent liabilities recognised in business combination"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contingent liabilities recognised in a business combination that were settled. [Refer: Contingent liabilities recognised in business combination]"
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "sny_ShareBasedPaymentPlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ShareBasedPaymentPlansAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment plans:",
        "label": "Share Based Payment Plans [abstract]",
        "documentation": "Share based payment plans."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareCapitalReservesAndOtherEquityInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ShareCapitalReservesAndOtherEquityInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital, Reserves And Other Equity Interest [Abstract]",
        "label": "Share Capital, Reserves And Other Equity Interest [Abstract]",
        "documentation": "Share Capital, Reserves And Other Equity Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements_1": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of profit/(loss) from investments accounted for using the equity method",
        "label": "Share of profit (loss) of associates accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentInformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of profit/(loss) from investments accounted for using the equity method",
        "label": "Share of profit (loss) of associates and joint ventures accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r42",
      "r210",
      "r216"
     ]
    },
    "sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income &amp; expense related to profit/loss sharing under the Monoclonal Antibody Alliance",
        "label": "Share Of Profit Or Loss From Commercialization Of Monoclonal Antibodies [Member]",
        "documentation": "Share of profit or loss from commercialization of monoclonal antibodies member."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ShareOfProfitOrLossFromCommercializationOfZaltrapMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional share of profit paid by Regeneron towards development costs",
        "label": "Share Of Profit Or Loss From Commercialization Of Zaltrap [Member]",
        "documentation": "Share of profit or loss from commercialization of Zaltrap."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ShareProgramAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Program [Axis]",
        "label": "Share Program [Axis]",
        "documentation": "Share Program [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ShareProgramDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Program [Domain]",
        "label": "Share Program [Domain]",
        "documentation": "Share Program [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareRepurchase2022ProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ShareRepurchase2022ProgramMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase 2022 program",
        "label": "Share Repurchase 2022 Program [Member]",
        "documentation": "Share Repurchase 2022 Program"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareRepurchase2023ProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ShareRepurchase2023ProgramMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase 2023 program",
        "label": "Share Repurchase 2023 Program [Member]",
        "documentation": "Share Repurchase 2023 Program"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareRepurchase2024ProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ShareRepurchase2024ProgramMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase 2024 Program",
        "label": "Share Repurchase 2024 Program [Member]",
        "documentation": "Share Repurchase 2024 Program"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharebasedPaymentArrangementsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options and other share-based payment [Member]",
        "label": "Share-based payment arrangements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shire contingent consideration arising from acquisition of Translate Bio",
        "label": "Shire Contingent Consideration Arising From Acquisition Of Translate Bio [Member]",
        "documentation": "Shire Contingent Consideration Arising From Acquisition Of Translate Bio"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SignificantInvestmentsInAssociatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SignificantInvestmentsInAssociatesAxis",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtherOperatingIncomeAndExpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Associates [Axis]",
        "label": "Associates [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r85",
      "r152"
     ]
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiaries [axis]",
        "label": "Subsidiaries [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r85",
      "r150"
     ]
    },
    "sny_SpecialtyCareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "SpecialtyCareMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Pharma launches",
        "label": "Specialty Care [Member]",
        "documentation": "Specialty Care."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of cash flows [abstract]",
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [abstract]",
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [line items]",
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity",
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [table]",
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of comprehensive income [abstract]",
        "label": "Statement of comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of financial position [abstract]",
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfIFRSCompliance": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfIFRSCompliance",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International Financial Reporting Standards (IFRS)",
        "label": "Statement of IFRS compliance [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "An explicit and unreserved statement of compliance with all the requirements of IFRSs."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "sny_StockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "StockOptionPlanMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option Plan",
        "label": "Stock Option Plan [member]",
        "documentation": "Stock Option Plan [member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_StockPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "StockPrice",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price (in euro per share)",
        "label": "Stock Price",
        "documentation": "Stock Price"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subclassifications of assets, liabilities and equities [abstract]",
        "label": "Subclassifications of assets, liabilities and equities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SubordinatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SubordinatedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsAccountedforUsingtheEquityMethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subordinated liabilities",
        "label": "Subordinated liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are subordinate to other liabilities with respect to claims."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "sny_SubscriptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "SubscriptionPricePerShare",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription price (in euros per share)",
        "label": "Subscription Price Per Share",
        "documentation": "Subscription price per share."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SwedishOrphanBiovitrumABMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "SwedishOrphanBiovitrumABMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/PrincipalChangesinScopeofConsolidationinthePeriodandAmendmentstoPrincipalAgreementsAmendmentstoPrincipalAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Swedish Orphan Biovitrum AB",
        "label": "Swedish Orphan Biovitrum AB [Member]",
        "documentation": "Swedish Orphan Biovitrum AB"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SyndicatedCreditFacilityCanceledMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "SyndicatedCreditFacilityCanceledMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Syndicated credit facility canceled",
        "label": "Syndicated Credit Facility Canceled [Member]",
        "documentation": "Syndicated Credit Facility Canceled"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SyndicatedCreditFacilityOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "SyndicatedCreditFacilityOneMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Syndicated credit facility, expires in 2027",
        "label": "Syndicated Credit Facility One [Member]",
        "documentation": "Syndicated credit facility one."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SyndicatedCreditFacilityTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "SyndicatedCreditFacilityTwoMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Syndicated credit facility, expires in 2028",
        "label": "Syndicated Credit Facility Two [Member]",
        "documentation": "Syndicated credit facility two."
       }
      }
     },
     "auth_ref": []
    },
    "country_TR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "TR",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Turkey",
        "label": "T\u00dcRKIYE"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations",
     "calculation": {
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value remeasurement of contingent consideration liabilities",
        "label": "Tax Rate Effect Of Fair Value Remeasurement Of Contingent Considerations",
        "documentation": "Tax Rate Effect Of Fair Value Remeasurement Of Contingent Considerations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxRateEffectOfForeignTaxRates": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxRateEffectOfForeignTaxRates",
     "calculation": {
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Difference between the standard French tax rate and the rates applicable to Sanofi",
        "label": "Tax rate effect of foreign tax rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the application of foreign tax rates. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments",
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Rate Effect Of Reversal Of Temporary Difference On Investments",
        "label": "Tax Rate Effect Of Reversal Of Temporary Difference On Investments",
        "documentation": "Tax Rate Effect Of Reversal Of Temporary Difference On Investments"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TaxotereProductLitigationInTheUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "TaxotereProductLitigationInTheUSMember",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxotere Product Litigation In The US",
        "label": "Taxotere Product Litigation In The US [Member]",
        "documentation": "Taxotere Product Litigation In The US"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TechnologicalPlatformsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "TechnologicalPlatformsMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technological platforms",
        "label": "Technological Platforms [Member]",
        "documentation": "Technological Platforms"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]",
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember",
     "presentation": [
      "http://www.sanofi.com/role/IncomeTaxExpenseDetailsSummaryofEffectiveTaxRateandStandardCorporateIncomeTaxRateParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [member]",
        "label": "Temporary difference, unused tax losses and unused tax credits [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Domain]",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/LiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top of range",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r172",
      "r178",
      "r252",
      "r254",
      "r301"
     ]
    },
    "sny_TotalMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "TotalMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Milestone Payments",
        "label": "Total Milestone Payments",
        "documentation": "Total Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ToujeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ToujeoMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Toujeo",
        "label": "Toujeo [Member]",
        "documentation": "Toujeo."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Current trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r230",
      "r283"
     ]
    },
    "ifrs-full_TradeAndOtherReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other receivables [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradingEquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradingEquitySecuritiesMember",
     "presentation": [
      "http://www.sanofi.com/role/OtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading equity securities",
        "label": "Trading equity securities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that (a) are acquired or incurred principally for the purpose of selling or repurchasing it in the near term; or (b) on initial recognition are part of a portfolio of identified financial instruments that are managed together and for which there is evidence of a recent actual pattern of short-term profit-taking."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r253"
     ]
    },
    "ifrs-full_TreasurySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TreasurySharesMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedStatementsofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury shares",
        "label": "Treasury shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "sny_TypesOfAgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "TypesOfAgreementAxis",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types Of Agreement [Axis]",
        "label": "Types Of Agreement [Axis]",
        "documentation": "Types Of Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TypesOfAgreementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "TypesOfAgreementDomain",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types Of Agreement [Domain]",
        "label": "Types Of Agreement [Domain]",
        "documentation": "Types Of Agreement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfHedgesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfHedgesAxis",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of Hedges [Axis]",
        "label": "Types of hedges [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196"
     ]
    },
    "ifrs-full_TypesOfHedgesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfHedgesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedges [Member]",
        "label": "Hedges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of hedges. It also represents the standard value for the 'Types of hedges' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of share-based payment arrangements [Axis]",
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "sny_TzieldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "TzieldMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tzield",
        "label": "Tzield [Member]",
        "documentation": "Tzield"
       }
      }
     },
     "auth_ref": []
    },
    "sny_UKZONEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "UKZONEMember",
     "presentation": [
      "http://www.sanofi.com/role/NonCurrentProvisionsAndOtherNonCurrentLiabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UKZONE",
        "label": "UKZONE [Member]",
        "documentation": "UKZONE"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "verboseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "sny_USGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "USGovernmentMember",
     "presentation": [
      "http://www.sanofi.com/role/BasisofPreparationoftheHalfYearFinancialStatementsandAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Government",
        "label": "US Government [Member]",
        "documentation": "US Government"
       }
      }
     },
     "auth_ref": []
    },
    "sny_UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "UnwindingOfDiscountAndGainsLossesArisingFromRevisionsOfExpectedCashFlowsOnFinancialIncomeExpenseRelatedToLiabilitiesAtAmortizedCost",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/FinancialExpensesandIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unwinding of discount and gains (losses) arising from revisions of expected cash flows",
        "label": "Unwinding Of Discount And Gains (Losses) Arising From Revisions Of Expected Cash Flows On Financial Income (Expense) Related To Liabilities At Amortized Cost",
        "documentation": "Unwinding Of Discount And Gains (Losses) Arising From Revisions Of Expected Cash Flows On Financial Income (Expense) Related To Liabilities At Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "sny_UpfrontPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "UpfrontPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/EventsSubsequenttoJune302023Details",
      "http://www.sanofi.com/role/OffBalanceSheetCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment",
        "label": "Upfront Payments",
        "documentation": "Upfront payments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "UpfrontPaymentsForProjectsUnderCollaborationAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payments",
        "label": "Upfront Payments For Projects Under Collaboration Agreements",
        "documentation": "Upfront Payments For Projects Under Collaboration Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average amortization period",
        "label": "Useful life measured as period of time, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "sny_VaccinesCoExclusiveLicensingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "VaccinesCoExclusiveLicensingAgreementMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vaccines Co-exclusive licensing agreement",
        "label": "Vaccines Co-exclusive licensing agreement [Member]",
        "documentation": "Vaccines Co-exclusive licensing agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_VaccinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "VaccinesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Vaccines",
        "label": "Vaccines [Member]",
        "documentation": "Vaccines."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ValueOfHedgeRecognizedInEquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ValueOfHedgeRecognizedInEquityMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativeFinancialInstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of hedge recognized in equity",
        "label": "Value Of Hedge Recognized In Equity [Member]",
        "documentation": "Value Of Hedge Recognized In Equity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ValueOnRedemptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ValueOnRedemptionMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofMarketValueofNetDebtDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtCashandCashEquivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value on redemption",
        "label": "Value On Redemption [Member]",
        "documentation": "Value on redemption."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise\u00a0price per share, options exercisable (in euros per share)",
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)",
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176"
     ]
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average residual life (years)",
        "label": "Weighted average remaining contractual life of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageShares",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails": {
       "parentTag": "ifrs-full_AdjustedWeightedAverageShares",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedIncomeStatements",
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average number of shares outstanding (in shares)",
        "verboseLabel": "Average number of shares outstanding (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "sny_WellnessBrandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "WellnessBrandsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wellness Brands",
        "label": "Wellness Brands [Member]",
        "documentation": "Wellness Brands"
       }
      }
     },
     "auth_ref": []
    },
    "sny_WithMarketConditionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "WithMarketConditionMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "With market condition",
        "label": "With Market Condition [Member]",
        "documentation": "With Market Condition"
       }
      }
     },
     "auth_ref": []
    },
    "sny_WithoutMarketConditionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "WithoutMarketConditionMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedShareholdersEquitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Without market condition",
        "label": "Without Market Condition [Member]",
        "documentation": "Without Market Condition"
       }
      }
     },
     "auth_ref": []
    },
    "sny_XenpozymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "XenpozymeMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentInformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Xenpozyme",
        "label": "Xenpozyme [Member]",
        "documentation": "Xenpozyme"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ZantacProductLitigationInTheUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20240630",
     "localname": "ZantacProductLitigationInTheUSMember",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandArbitrationProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zantac Product Litigation in the US",
        "label": "Zantac Product Litigation in the US [Member]",
        "documentation": "Zantac Product Litigation in the US"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "41",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_41&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "l",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_l&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "p",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_p&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_q&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "90",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_90&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "98",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2023-03-23"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "ab",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_ab&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2023-03-23"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2023-03-23"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "140",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_140_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "140",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_140_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "141",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "141",
   "Subparagraph": "c",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_c_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "145",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_145_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "145",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_145&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "29",
   "IssueDate": "2023-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=29&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS29_g39-40_TI",
   "URIDate": "2023-03-23"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "34",
   "IssueDate": "2023-01-01",
   "Paragraph": "16A",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=34&code=ifrs-tx-2023-en-r&anchor=para_16A_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "129",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_129_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "134",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "135",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_135_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "86",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_86&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "88",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_88&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_v&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "39",
   "IssueDate": "2023-01-01",
   "Paragraph": "86",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=39&code=ifrs-tx-2023-en-r&anchor=para_86_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "39",
   "IssueDate": "2023-01-01",
   "Paragraph": "86",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=39&code=ifrs-tx-2023-en-r&anchor=para_86_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "32A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42B&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "12",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "12",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_21_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B16&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B4",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B4",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2023-03-23"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "p",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_p_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2023-01-01",
   "Paragraph": "38",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_38&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "23A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "24A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_24A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "24B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_24B&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "24C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_24C&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "24G",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_24G&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2023-03-23"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2023-01-01",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2023-01-01",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_20_a_ii&doctype=Standard&book=b",
   "URIDate": "2023-03-23"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37&doctype=Standard&book=b",
   "URIDate": "2023-03-23"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_c&doctype=Standard&book=b",
   "URIDate": "2023-03-23"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "22",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_21_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "119",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "14",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2023-03-23"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE60",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE60&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE72",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_IE72&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_c&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "145",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_145&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "14",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>124
<FILENAME>0001121404-24-000016-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001121404-24-000016-xbrl.zip
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M@0ZPL@@3.LTB%P!95@NP?'F0',P_S(' 0L JZ<&Q,,^8" +W  O#,+F'%&?
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ME9J>%^Q&!'@OW;02U0^!;LA=*C9M'=(BI*'8G<Q#3I'=0]( +&W#7P*$%G7
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MK.2 \R40 *L"EGB .1X0<$%6AZ!Y*1"  59VX+NTC-+0*F2] YJ7R@H#K%)
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M .9]WN:_*!J 6WMDIF8+L!@%86KNZI)?O90\T^JI-WT^I/R:N5MEA,L#R $
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MUZ$1SZC[($.P0Z,A8+7?F*9B.&$;0=Z$9,5E!#9@0=Z$9#H3SZC_)B0#0$/
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MV># 7]#LKP$6W%X$1X7H^$/SHF8]8.'M$& O:K8#EMR*%L2*FHE:"F)8P3@
MN0HK-(#%I*)-5U'>!+"J5)SI*@H,P*(.%--5%#1H%);-]VW?5]"LM^OI5.IH
MQ(_-]P,Z#WE,KGRJ.3: E0D@LZ8@>U8'+!Z F35%80,XP\<X:RR[[%CI( ,X
MT<<Y:U+$!G#>OQKY3AA$H<\\$HOMO9C.'H'5%UT66X.)YG$!8"$ +%9%>2/
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M#J'D@Q#>$_=A#[P)D&YX@3O[P.]]-HXB8UVW%HH604=U!&4@)68DT%$!=:3
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MS@'UM>$]CY5"'FC890PCU8Q9K1Z0%DT-Q48!52EP"[BC$N =PI=D)I,EPTW
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MCG#(G43[V2.34<WW$?MWPC"ORL])P([V#_</CZPP; )(A\QW#<6Z@CHJP&(
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M6F'96Y$RG*+\IC';'@J9#%,_3Y!UYF[12K.,,Y,S[S9-:KH1]8XX39;\6:M
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M*\IZJ7(F6"C>RAUE&-R7]D[)K4;M6=1,;4[]O2GPA+&G>+/C7SI)(.MPR;0
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MM-W6E,!MNVFO"BLOA0T/^,(OVALFWY3/"M4Z,:RM+06:[G+$&ON^B#?JVF4
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M;-7$J[J\KML8BJJX4T^B;QHF0/#>*QV$/&=)YJ3AA.$*_3J4%[)(I?\B>'O
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M6"'#6'D7((I2_2O'#8F]D#GV!ITGB!V6V]P%?EIRJR&(WLZF'\F@.MN*^N1
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MF H$D0PO&*RWNK]BW-O4M3!2EV'Z<4Q;?@LB?YO-\I<Q?<*%X+F)Q AI'6T
MV3DN%@:21<Y59M()UZ/I^@2YP_*8#D+3?>9G2V8U/#7OYK-SG"^_O9L$6NHT
M5^_KO-ZI&=GHM<\AD7 (-3\@ D0RC2%G@=DRGTN/9NF#9 [+#6J,FC;,Z2;-
MMUF@]U&:X@JD$EP5]@8"&@>6$.N54C;I_@*H=\@;EMO2&!V',:,A*M[7W9N5
MB\5&N(VD=LDB61,Q< N*%@9!)0-HN%%:L("NOT3>;>J&Y5HTQL1!K&CM<=Y9
MFTA,R>KTBE*EELL)7")OV =MLQ=2L-R?L+B7Q&&Y (W!<3A3.HR&;:4'T2@,
M!3D90)D<"&,CQ&PRQ*@M#\FQPO71 F+/R^,>(SG7!"N-V-,0,%>6<A$E6E8L
MR& T*$P< G?$/5V\$,):Y?N#QW.\%_N]@F&OK6^<CUDLJ^'[,J79Q72)-:3Q
MC\5X^K&:Q,MOO^+RTRR/7%8JY&3!,4[V3U$2G!$>BD81:L9(Q/X\_AV)W@4X
M[GL%3A>,:XBKS1JSBP*C4, B,EHC8^"DS2"<YRJPS(+I+YW<*CQTAY/!5.YQ
M2<Y![5G!Z@6G%,EO1"92RMEX=HSJNMWMKOZ"/WO@XK$BNCT8\'W5M=!>T#DE
MOU/H0L?7U;N@G+Z2.H5ZP5B8T'O;@][J6HX=<VH"UH&!I,.TP(ZKJ55H(FF+
MX(1=6;FU](047PA21)&X*[:_"YA[+F)8X:].I&H7[&R(OK65\W*:MRLFHTXJ
MAGI[1Y.-H]#5M%O)9$6;P*HF*%GV!JW[*&RU[E&4.M.V8[U/74!),B&]LP4,
M,NNS=(6\Q9Y7.BQ+XV!\W#TA>VQ]YW<U+<_9ZUP@Q5K\0M*>3)^4R/2QAANR
M](7NKSQ_A[N:Q];I'<#B<,9TT/6@[17IC(DYSQ(PM(IDO"SK6RI<>_K7H7:V
M]T*Z+MN7'5NA=X#2XP.CY7V3_2E63&K:1,*5XV0D94;2FRE#QS2X@$IBMCW>
M2^D4K_WEVCK :T\L;FZ1CD+,4F7NP'ARQ)0SDI:M/3@>0_%*V"#ZBWG=9YGM
M:WS<=WN>*\U23!JT<1J4R&3\,U1@C$]5W46;^U,,#Q Y1+OT62BYW^0XE!WM
M?;'E.C11:Q4O8Q,GY5U8I;:"9T[3XL!P36=2N41+-1&X2FA4"59@?Q5S3],[
M1*/U0,PT9M(M^/SYQ]L[]9:^/[PU,<G^V1E^6-+79ZO;7S=>_^SNQ'<>U[9!
M\>/4-NM1_&Y.%"S?SA:+4>"!QTQPB%F01THP('4;Z5OM2><Q'U2/U[.OZ6I2
M/KEYUDW(/B3Z@K0FQ1) )D66*/>U,">2)$0E7-*%-J2_J.(SB1^6AMH37?<6
M67;&PK:%NO>2>5LX*K(?%68P3JZ*[S6XE$D.<QFY$BI@Z;5J=P>:AZ7%.L?5
M 0QKTMEI+?U?89G-L9;W3/-UEGZQG:;?SM!O?62D7."LIC MKQY3+++6_SC(
M+EA52X_3;2/IWD9/A]+1\DC]0D X.<<Y063Z\65:CC]O>N2X9"TS-3RFB24F
M(SA''B)3&AE+(=C<7ZG1D^0.04#WCK#'#EX+MC84X;^,IW4PQ$^S=2]%QDIT
M$00G4U8Q6R 8%*1&'(LLRN1"?Q&>;<J>*8[A]PJCO;G5'C'KG1BQ&)(GYQFL
M% 1;QCSX+!Q$C]G;XD4QO4-F3=H0XM+#@<P>[&I9)SLGR;>6@:-LI72"O.02
MDJ[+*>"+(SIB9DR8[+WK+].\15B#.R?X&:<76"7\JOBDU!K5Q<@&&;U2 51&
M^H^2!CR3Q$GIN7>UN,#W>//D7AJ'H*4/1\L]5T\.YTCK"R@;DD8Z):FX18C<
M&% V9UI3<D"'VN20<_2BOS*$;<J&Y?JTP\+>N]\RQTR*^Z14*"Y&Y*3[)$CV
M:BX8J% [OK!Z*<H);[+F*8<>;Y1<$_9,O=F-K=4% /;=_$X")@^Y 8R@9Z(-
MP*/())"B)=$4.00GHC98K!?'B$KNY-WMLR._CA<))Y,PQ=G%.J]^]9J?OY[C
M=(&C++W/+@=PS/M:G*? 92DABQAX<$RBZ4]2/DWO,W5IU^>G+>3NGJK&#&QZ
M0R?-:ZO8U[C^]\VJC3G1159U33V,\XK.V;JD^#)K_FV$LIK!JN:)).U'R!&\
MCQK02I:-5CRK/KNK[;6(03C,_8&P#U:WS/JN#\9)>4].WOPB+2_F-W<C2&&*
M4 Y**62@!B8@!%, D9%R\CPZT]_EA:>H'9C!T#76FC*O(:@>$<0;Y]\YS(:9
M"%BRK3-;-$1"/W"7(D>KK."#4*2[QV_ZJ],ZHAK=@WM-DC(K*OX6QM-%738N
M5D5JR_''U8:-@HDZ)\E!E-HV,"DRGF-UHYCPJ$76D=]JGG9OQN71EPRK\T$W
M$&B[TRW-I[/S,)[7$&0EZCVFV<?I>%$K-=8;<3*O/W^ZB93GQ=#Z'6!4B7!;
MR4^:G.Y@F5?9!=7C'<]&BWIFFX7O7>4= PHM>P'A NE!M9GS:_R,D]FJ7]6E
M=\)M\(&+ BS4RC\5 @0A25U+TM8153(]-D!_E-1G]G/XWE'7CFT=93)*+%AG
MC!"2:U6A=98$L_! X Y)!U%\CU;Z@YF,8[=OZ!HF^W*D(2@^X*H>ZV\XI<5-
M"*\O\]EX6B\<TU(_XU4<)#*56!'D7CH/2A-NG70*M!:H/7KC8NP-+[O1O N4
M_.]'Y'3 R):M0<[JM.#%:JN>5K::SH&0R@*2XU!36Z+>+K80DDP2HR&)V9^W
M]RS2=XJ@LM\/ZKKCZY%*S4>W-._!Q>;TP&[+S6]3W$G!.3GO-A4/5J$$Q9T
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M'2YT8(5" Q"L0T%5RP39]H&NLW-_F<R^_!WS1US<T Q)AUA ^M4UI! @D@M
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MQCU'A*)D'=#,:A%C")!X\5JKX&+L=9KQ3E3W=L,Z9V$UL1!0U\! KB-1M4I
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M24=OMMXA^],V:G_/6T\_A>4_QY/)*T)%NFIU=#K;]DA^P]J"('P=<2$Q8##
MC2#/1&$$)U4$6T)F/#)_)[S4=9#_P!4=U%YC_;;P]3U.5O6HI[/+ULQ7[MU)
M>8UQ>=U.[>>O:7*1KS)?6WFRD8O:)ZD]H+%UTI5UX+.CTQ^]9\8X'G>:DM"6
MJF<:E5U?$.P=Q#=Z<1R/WVWO#]Q9Q:82\>^8:]57>3#4S8O663@B.3D+*I<$
M3AL&R:/-7)D0>7]]'@]8R,!::!\-U?VCHHFQ>WGJUCGO].UT'J:+-0/7UX16
MS;XV!V^K^N!6I=J(850ZZP36$?6J#C/WA7N0M)A@?3:LR!TD;B-RAF4.'U72
M'H/!39%YK0^F-X_1+E1SEP(F8\&;U6A*R2#X+,!%YTR=X<#0/@.6A] RP*S-
ML3'9&VN[ N1- ^418E-RBGE1(#%;A^U(DNL8,SB6M9!!"R^>(Q[W(&& >:$!
MP:\31G:MH$^FE_8$;<F-,L%?2*Z//VY=^1UY.B!"L #,2EOMXE@S8@*$-B:C
MT#[P>)A^?@8UP^HO- @L]LC>KF%YN2<GTT?.44[**XD&$$6M]"D2O&/T;1:,
MTRG2.AZ(QUW(>&;/GG]3(#9G:/>"L1JUJS#Q8E18(M*" I[J@#U>'+E4*8%T
MK@3-."L^'2KYKE_WS*XYOUMWN"L.]6/)[6)_"I9-"+6FOI;4JI@*1,LT9(WT
M8YY*#+OD>UK0,JS&.(/ 7&^L[<?7W4D$FVRE2TF2",X15(YDF]9,:5(B)19T
M84SLA\CG$S.P?CA#PV3'W&W=3.R1G?MMMMQM\X(R=*0LR%A;_ C:01+R#HJ)
M11GKI2JW4I='3'?MN*B#^MJFY468C\-DU1UIW2CIY7Q<;W+5)@97W9FVRQTO
MSM;9;GK_:RSC*>97.,7:\6O3&O_;JB9R)SA)3:),8 *.6.TU9.!RY""#X0$E
M8P5W:F![W&4,JU#K&&?E1MO:[PA3;9I#=[?@G6+B6:((FD,(J\[K(8.K3CAQ
M+<GH.8GF713N<5<QK/*SW_$1:HVH)B=HG4M_/U[\JYHBJ[D"5^/J7N-B_'%:
M"W*VBNS7%LM(IB(#%@'H"EDC=+CKX)\(B2.S/BMI=H+^GJ__OO)[76.V#QYV
MY>9<UG)<$?S+;/Y8=^C3FQU5KO;.1EMB=!HT*MJ[%!0$GCDDQK65R<FL]7Z^
M3R,*OZ_T7]>0'0@2VHR&VJF6Z<[R;I4S;1HW(#>)2YE <'+U5!TXY+S)M>-_
MR:0)F%;M*M=VHVE@<UR/#=VCL;LKL/9A\MPMV4M,>!UT@)0M*1^;3!W.;$'Q
M:(J.]#_G]P/Z4=;SS)3FO^$A&3[,>K-Q=O($C+#.8P1AK0)5E*XU!@R"U0Q]
M$*G<'BR[MT'3R$D<3J)T"-9+:QYW>#6E)DAJ0#K<Z4YY=>UB<SK'UZ?SW6PQ
MKJ_=_R9*D]<>?O&D_>J;W3-Y-9O/9U_JQ>610J&*(X/6TIDAJY9)"&0\ ,$W
M.(>L>']K@FB'X?-KN@[/+]3>14N<GVVM528?LT<-R?)5$U8+7E@#UK.@=<(<
M6.IMK7?I&U;,>4^,W"U;/Y 1+9MSKYM%7!-2V^9NY@/7T6NSZ?8(B2UZM54,
M-2V[6"R@'/,0N2#Q*I1(2NLZ"J4WX.R[BF'%8YO!JQ>F-G*1UI-5:_?F*R+3
MM]<X)\50+Z"N6DR<SGX-T_ 1J_H8T4$P+%L//-4[RIYH](YQ$+DXAB8[&W<I
M[WW^FY\9".W:[3@0+3WL?IL;XO36E1'Y0$]OSD2VEF5(/ 7RZHL SZ4"*Q5S
M3AA.'L@.<'CB-8<+VBUV&:>,KN/UBB87J;9_ &>S!.--,%RZD'J<P#0L7=N:
MXW=EXYY\:#P/XYYEN8B&D80%;8*O#HH$K\E+\E('8Z53.?8[_V*_00.=WS_L
M'B(-&'0$Y7@OU:/DF4G>"\!L70UZ5HR31F=<6I6=5G:GT$8#4@:A/KL"SS'8
M==PHQ2I,&)?QVRF140,SJU?.RGO,N(XD=AJMV/WUO40M]MR-3J(7R1<=B@,=
MC:R.I()8;^T)+Q1:&2+3_0WM:AF]>#6;YL6;Q>("\\BB]$KE ,YS#DIS,D-E
M21 <4SI[\J-9?][G%F%#L*$.1L5]1M-^6]^N(^BK,/W7MNG&0I!6>Y(;D62T
M=@)B0@>!*<F2BHR;G5M^WGST<$,">W"PQ?:UKF_>(D,00RP9VN 54:"2,."*
M\F",)')(\9H>Y[?<(FY894_-3O(A+&B(A(K'D\\XS_-0EHN?KI)'+Q>WK;$8
M=8F,>9"U_%\5[R"B)N/,HG'1,IMX?\WI=R9[6!5([?1 )VP[5B11!!.9"0B!
MK.XZ$\[6:&=M;1!HHT561K,=E$@WD<0>JWP:*)F.=[]#5^=Z!LV[^>SSN+;/
MK^'R6_-I+FL@QKAE\]_SE^&QO]S?(3H"D8>[3<?>V0.=JPKK9R^!Y)X0SE@/
M.D@$LI,+Q.(S.))^*066<]BEU.K9+VXYL>'ZE:-2DI0^U<8;U3S H"%:9&!M
M5"&&PI/J;Q[A?10.P>'J'BF/36W8DUNMS?JM,1);BTS.:1># EW0DZ,A/1 =
M&FS&H@UG-O38,/IA.H?@]!T#18TXUZ%Z7K48ODC+BSG9)S_-%LNJ"#Z,S\:3
M,']#^WBM-)[\Y/[JMP,B#E>O7>],L]CD9D3:R4TZMD:%8Q#*U6:B3-2(4O )
M0HCD@RIE@W$L&=/?=>6GJ#WH M@3S_Z9L#C[AK@JY,7KV7)&"I$-K_?3-)G*
MN@;?&*?CGAUG17H?_"Y)G#U?/P05VQ&:;MSLZH$Y;:X1/D%H+=:E#ZRV\Y?9
M_.<PGWRK$PO'TW4[F/+3;+J<A]H-)BCNJK]'6*E7(+/RX(W6$!(7H:2,\K9Y
MMQ>P=J=H"(IX %CKB(7MPO%W5<H(M4/.6 ;.N:R1Q$)[H<EJ8&@P)Z,R/J5G
M'WG\L,*QG0&CQ>;V(F0V4G!5['^.\^6W=Y,P79*M6H. YZO&CE/Z;;T>,J6W
MU#WQQ4EC+8)TM6-!" ZBC+SN29(J"HU\E^9@[2D;5K#V:$*G8Y;V LM5V[,R
MFZ_WFA;R<1[.%NLSE%GTA5L!3I%\5.@M$6L9"!V4SS(P6W8)]QY PK#ZPAX-
M:*V8U*';>77YY-+,(X_IT&DP3S_S<*?PF70W\_'6[]U<#:N<'&'21M2TC]&*
M[!)+MK$OV4'0V7GMM8CFEL_2H5-WA[S#@UZ;1ZY1Z[AR.0<-/D9%J$T%'$H2
MAEQJQH6@ ]-?F&N;LH'-03D,)G?C5WLSH6'T\\::1M&Y',CG VT*R4Q!2W&B
M-OO0DCLABF"ZOY*&&Z0-R[7J" E[<*'-361:P7J&SF^X'/F,]()L07-? P&,
MD:&NB!II:1G1URZ].U@:-Q[:8H+..D=[J9ZG6WG?Z#"1'Y$@.UF -*V"*)R$
MDA0+.M)Z8I\3<AXD= BQJ,/X?=\,FS9\:5I&L3E((F?KDD[@HB29*@H=RN04
M&&&%+2ZR<ONJRJ,E$@,:8]2&BP=NV3$MV!'OPH:EI_9@Q=ZFO4,[-FO+$Z_7
MZARO%?E9@N>U'ZRILU"XL5'U=QF\F1V[2C;620=KZ-9'7;G_EX'N3?N/Q2B(
M@*4H!2S6GN&FY-HUP8)%*;64BANW2_^Y7=\W>)OU.9#8%A2=;'@'Y@O3J',R
MKAK2I'1TI*]JB3"S9)HE7:?([C3(Z6'SY>BCZ]HQ=?^M:^B#;+7Y.9F^_$PB
M,L1)G3BV"!/<;O*#A"[OI.66<4!!BU3,DI_$0P23G?#"<5%ZO#OQ',J'E0-H
M Z$>>-AT".<M4_4MA@5NEXV0",ADH$;(JI 1Y3&#5XDD64F1[*%B;.Y/73Y)
M[C,C_]^'5.J*70UQM"'H]06>SOXQ)5>G-F\B*3I>K!I/GDRWBMIRTKZ0X 2>
MZ[@EQFM^/1/>A4K2\Q1MZD]</8/P@15YM\965RQL8L_\-KL<V#7]N!G@]?/7
MM.HLM25F1V1422+-@",'C^PL;L%+#)"2#3:*4#S;I97(;F\;UB"VAE9M^[UN
M79MZ=['2!,UC)KG':YHIU<1E[0K*G+(%.2;.>QX(_X1K=^PV@*W%1P.^=!@\
MN6JIN9%R5Z64+R<KT*WN=M_^T"M<?D&\+-(-T_P:"]+7F3YRR.6/#HDY/%33
MUTXUB_#<IJ564HVG%U5Y78]XM-8%F0SYWKZ6VWA>ZQJ\!EERD>34V9CZ$P^[
M4-RL$=SU:S;A3!5U*B$GX"RLKFD)B$70M\*4G#-S+/97G/L D4/("G2(L <;
MO!W$K(9*=NOXWJ1'*R=%<@B<R"*E3PL,61%C&8]>&18UBM[ \Q"5PTJ,]H">
M)NPZAO9]/2Y$.9+)L-$@ZZF6X\^K[M=AB?5>0]4G89Y_FLW/9[1?>/6T^H$.
MM' [HCK4QAWM7#.M_/(S8?LCWJ9JQ(JS@:&'K&IU,]<"O,":3!.%>1644OTU
MLWF R,/EY\OS\\DXU7#?U;J5*5%8#XA8FZS(VJB:CB,/QJ-/6MD>!><=\H:E
M;UM@YZZ0/(PGK3W8#0V;*;[D9K_'-)NF\62\VJ/-H=[,;2%=L6[!7NMU;\OX
M+%+"$!5)=FU!6=J:X+0B7TM+:RQC_G9#N*X]WV9K&Y8B[P:61T1#0TS?6,!)
MV82--C]=C%+,D=L2:S%YI:IVH<A2@[=%>BZ4$$;VAM'':1U63JH;S#7D5I/H
M[FUZ+B=#O,<S#(N+.=:["NL[4@1^^IJ^6HSSE?7LA;$^F 2>DS17*G+RDA2#
M7+C22A:-;I=QK >2,:Q;)RV1TS>/FH#J/6ZR%:>SM92<52KK[?L/N%Q.5O0N
M5J-,7H\7YQ<5^,7[HDL*4+P@&IDF:BW1Z&2Q6L6H NYRH>3Y;Q[6/9+6T.F8
M$QTZKA_P8R7NS?3J<LN'] GSQ01G9?.[][BXF"P/B 8__QV'NY4'KJM!(YY7
M%XOQ%!>+JTS3QG[QQ7@=!($J(^D>S00$5F^_\LIRP8RSNV3P'GC\X88.81FG
M%UB';GT($SPI?YO-,JE,J51V)-ALK/T7G?=D=N4,+/DB3"D2=7\=X.^G<0@^
M7BO.WS5I&O"EM8NW(6EDD8Y*=3.=KT$X7A1])4CS68U)94E2M;]ZAVW*AN!>
M=8>(O7G0<C+ JI:P G(QLBX71&6!HZO3*H,'[Q&A.".=*5PRWU_GK2W"!M/&
MO1L8[,N"AB@@58KTH-H=_C7A<3);W;W>^.TC9U GGB)DIFO#)Q,@HE>@94[>
M9"VU[2\?]RBI@RBNZU*%M&)30^Q\P G]\N/?<$I+G1!I+_/9>#I>+.>K+IR7
MU-5X99&NIG<\R3>A%'A6;QEQ:\B,#E+E_F:-[$;S(,KIND-3!XQKXA;_.EXD
M(BU,<7:Q6.G(6^N^ZH.4DE6N: :UMR\H:Q \6@[DQ0NG5+'![W+I<><7#J&>
MKC4>NMOQEC+F4YB3Q;P.*M?JOI/R\-S5.Z/D;XSDCJ)$'T6&7&*D/2J6-&PT
M@!8#!HX%>S1RVJUK"*5['8JJX_"_(8*O27^Y7,['\6*YRO/-:B?,VEAKMI+%
ME]7S=;!U#+F0,YA\K5]&F:%6QX,Q&(W3/C'37P_Z9Q*_"Q;==XO%+CEYI$#A
MO;F\!W:/_IP4Q.9IU[=D7]5?U#CLZB=7 ]JOSF+9G$7ZV^WCV$U0\OCKZ38
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M;4!IP:58 QR!1RPIF-M7?^]5KX?0,(@@=A]*N#=&-6U'D.;U1OMK7/_[9OI
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MKG%)R N6Q&QA-\BQ.;Z,+!XFO:!(.DRP4AB6%-,E!L6F-58OKCDF9L3U(1/
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M./#6SFL_P=@<]^GV\ND"Q)'M$!J:EHM>S?$,PS%E>'!)0.J[,UJ?!ENF\6R
M!_3B>0&;"=CSD&DO5[6-0V1:B\KJO$N&3MW_.WM=F-['6]*%3[COO-B6AP<M
MFV[;;Y=W[2VZ:;\G0/T#</H[-KV92ZLGF[9/X.IUWNQ@W'UK@=LDO2@&9=AI
MU2(/L1XTH'IX/$BE^A';XIQ+^/5PP=;#(T0NU8V,)S/<83I'AZEKOB,\'.*^
MSUT;[MJLT4^!VB%0>:(M&NR7K@-JR;%!O72&Z_14=V3Z_[+&X[;C?\5$L8V)
M<VT-+3SH.L'Q4L<-DE/C^@F2,>*M_+A'<QA ;'5I#@\(-1,@N#MSU+#0X>&A
M)7F\1:'C(DZ9GV<]W_'-\36R?#SQH,$<\F8]#_]W1K@X_D#NG$%1 M>4,@DY
M+H*3-/2ED=O0P!/)"V>G-F2K2=]3!MO8[PR)@"?)(LSDTTZF<N1R3[O80>M6
M?Z- M.JENAX_(644K/P0[>BXWL]36ALT+A#A1JE>B\=Z6#PTXUE2[ 6(UIVH
M#7#/3WV>QE.J>$I5SN=MT'1^*6[>L9_PA(;#"57N"#:7 N!?\=!Q<;)VU(52
M/6[^,P>:SM];9.M(98W'F!<HQ%(]:Q$K=\U.#D1KXEAY@0BJH5G*DN,'<*?D
M7_5-;X2&8^<-C?#@A2<>\=.Y+(E''?N6X.>>P.<;1<]&125G"9[SL[:C90]E
M8BJ,YN Y0.R(<?I0T*X<5Y,X?J0S,.Y,'-F9Z,]<%]O]#^2[Y#O&='0)&EC#
M(8:7N3MQ3NY$K@>#*]JG^=ZGB+I; *=C=Q>(6M)'V;JMP#P<L2PH?.@W6XD^
MZ8Q2<;"H45BHZ8\KN-/"H--2'#YTP(>:H#:XGW-)?@[/6N:.3&K5M&<V8L94
M1-THU7,KN>=N#9/YRQDA80BENLX]&B:@473N<E9H))XT\L3E'!.7,R8M?^5)
MRR>;M)PN0R[;EL.0Z)94BV])&<T1O=P4%882/],'5HZ":3D(LZ1W2GAZRXD!
M,+_,XT( J- X3D*3V(M)2SXX?-:W#07FT4'O4W)K9U!&-@YFOYOO&,JX_G_N
M$YV>3Y19).'XN"S)?'H:]W,.Z><D05&#[B094I*X<W):J-G?.<FLW>C!HB8P
M JJ+<#AN$UP-[D>PZD?D(60Z'=MD\-KO"W<A<CVKR0.8=#*PHI^,;\L=FI/"
M\-9#I?TQ+ ETFK!^.ONS"_"?<CG;I+?D(UE9.&;.R(JB_:\<QQM*@DA]LX3N
MZ=Q%.DU$[>(XY8HH.NU7T;+F.G'?Y@S MXO'DROXZ(1@/:'K.;-.R9GY'7Q:
MZVFY#ZD'-TJ"0A0[SV!E"P#[6_L, ("CP'AN""\>9@<.^]O?#'" <;X'GB<1
MVM+H=A&=:/$',S,_^3U6[T&9=D7Q%=7C+-4Y34SWQ;(K/<?WG<FUNBJ@_YEY
MOC7\"(6Q_DO/O:JO5O;L=J<<Q5K?'A630(R[(XS,/N39F/8'>$:VXV,/$8&>
MFDM]7 )':I7.Y"G'YM3#U]$O-P/+FX[-CVO+IE]$/W037_\G.:+D"-Z^>;,&
M_NA:JNJZ##HF]$_#[PW>%*ODN:_BKQMZU1"2WQ*JXM_R]WD)SE9KXY:N[V-0
M44>K3#(/7?A&ETYTO./2DDE0O;B$1B[H_Y\L&0\U21RJ-7D@*%B6>HJL]:6>
MW#/TOB;+XK]E)9@)9=83"N16!/5(8N([QY$$N2KJ&I>$O&!)/'[LPE4LR,CB
M8=(+B@2M"&2%84DQ76)0;+K!?G'-,3$C;I">20P-<>$&Q,?# S0RQ\/*!S8A
MQ=.FAMKT\?(00\\G+]"N=56TUK2&7ZP*584\V]3Q+$I8E]9"O>)0AD*=N/2Y
M4 *%Q4?,'GF(F;_^(RFM^&&U@V%4)57,K!Z4:JTF;E0/:6\E5P7).*"B"5:_
M5M=0-WTG59-2KF.'K]+B9)'_Y#_Y3_[S6#^?&^W.?0MMR*\(=\*).A 4'U&"
M6?T:JO\D05*.U76#/@#ZUGBXK_S9;#RA^U:[T;YM-1[04_.Q\]0MO.%&[E[O
M7J9(W>85AJ\O_80%0.PLA?,IE:(/C=P%W5YPI>=B\T?%')(U7YOC-_/# ]N_
M[#X1SR9\T)I$5K*GFW4DWQ9]<D7G!-PA$"0"&<*7(&)EK&N<DUUJ12U[3)>N
M[[;3?NX\M.X:W>8=>NZ2?WYOMKO/J'./;K\UVK\VGU&KC9K_^[W5_3/E,N5U
MJ\PG:G9P?UM7]:S^MB15%57+Q=]6JS59S^5.>E6L;0X1I+U3C>Q!\GFF/.^D
M:_E0/+]GRH_B>E63\EF=5I4.&BB:[]\.7_'S]Y]T65-"7XG<?4RV_6D*13>L
MD+$<X.<1Q%[ZYA3T_5FMK$$>%,(T-)QD#2K0,?8,E]EUZ>"&#^0!)[.DIK"_
MMB=,/OF*/63: ^1BWR17#! V79L\_WDM]=EW^C^0,P7$!NMU:#$[Y6JE9T+\
M<VI^T.#F62U\?<W^62TSRDRHY)#4?L*KSB.ECOUE=Z$Y5\CAE84=:3C@$4CP
MU1R;=A\CTT>_F?;,) 9*+"-)@"R;C<$57FL%N4Z;,Y^:%%F9$XIKD,VN2A(O
MK^*0^P2Y6EK(Q5$%_:H3<FDYILX14YEZ8.BI>V"L1Q=,]A48Z:%U ?S-PEZC
M&#,E"J6ZII5KD+#"=0K'W&J1B% 0Z,1272EK">TB.>8N'G-;*Y-VQ!QMNZNH
M\7IECKGH*QDIO6<(C%)!8)2)HZ64:_K)6-W++=MG"(WRSOM&42G598W;6Z[[
MTJ-M:X7HCKI/);I/+8OJR43&CJ+[6 I>%U\.E;J7-*OQ[$/,3M.)$WO#G.+D
M=.9TYG1FE\Z9;/[6-@#INVY+HE:JZZPV<SICAG/!8G!,G!@[9BZZ1;DDAK./
MT\^VO>!]%VMPB1T1YS '01+U4MU(Z*^W%@^7&_5A#0_I3W>SX,'(,D>4:P=6
MT%#$D!1)$C(.26$Q+')ZD8\V]O>,=)PBW-/XJ!?5Z8]3BU/K#,(#P2S'8#9U
MMMV*%/03ES,VX.6,Y+ _+6J=6A/B_+3'UK3G/;2'M)/VX%V&\^5P;)>ZB<-Q
M)LJE>L($7RZCA^/@UC/_/414H2*J9F1P82+*R,B?PX],7+?/9.8LO5B2A):?
MT5R3LP^L<N9RYG+F<N86&X?(X?A44L%?445>;'D9 .3:Y8R96U2N1AYZ1N-I
M&HR@)-]H5A[8J*T;B<BHFKK<A!&&D+DU"I<R(4!/G-K%*/*X3CP^\G:9*9=9
M)1I4)>HG,[:<Q329,ZL>NK->K0&V![3U)')F=)J))$C2O'LABIJ+;H+S(W9I
M@\Z-L&ZU[^.XCA[ >R0/T'$)^4SW@][+6]PTA+(PA[(LD!UF-2$@#I'9H!?A
MSZFS@,XN(XZGL7,Z<SIS.A>;5[TUDCA7[4^X[[S8EH<'#>_.\H)6F] _=M_1
MXS+MAJ.H\5X0+ 4 S@TF7!POF\Z,;-Y8TX=;HUH'T(=29GUXN6$G+L!<@#.%
M8 X@O_)IR.^6&$DTD8C.25X[T)Q?M=]5!=5S'450'X.)$1!\&D12MEL;_M-.
M&>:5")Q:G%J<6IQ:G%J\.N.@%51IO/NV8R]Y(ZW(&5EU\X?6.QY4_L*ND^3A
M*TOI<DP4<YR/6.W9%B170,09KY*MG9%Z7\?%G\'-?09N:YFX?:Q*K=/+5PC&
M@+IX.G/[(]/#:.HZ+ZXYV309?I^G4JIJFDR6FZGCT2&>URX>F[[UBF\@\E*1
MJHHRC0^*)0\.=R 8-M.G*9RBC'*_D%.+"?TO;AT"]!AJE,XPFE0;9"$E:?<:
MM(1/W^^)\XPCG%/K?*EUN6YUBL8D&=2JGDVM\BTQEPD&96)[(Y ,(F$P(A+\
MQ)>!J\[IQ)="O@([8:@]"$Y_R6)M[SK#A'4!UKF>?F=PV5:!/O37%!=1^G2+
M"EQ_+>K132Q[0#!R78%7CF=.#4W96.A>]#/<K%)'K1HJD*/YCMV^Y6%(H/!\
MI_\#.5,:M#SKZ%(6JRQM'<C:LOM@CO$=#O[MCHA O(PBTG:&G8"D&4Y[%&''
MTQ[NP>[$XZT#4-/S.,Y+,;&FE[.1\8T(IQ:G%J<6"]0ZJY! OE&R?>R2E-TN
M\<@9%Q/VQ&1KX&P?*9$9DA*^AV9Q#]WRO)EI]^D>&O)Z7*OOXT'03,)#ICU
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MO-YS6.2GQB4%<!U2YOF\2&:&>!3/<,CLCB=VLS;IH^>X ^Q68 <(=_><L35
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MY[45W*<$?<'9&Y6<B',I[N55GKU231\*#;?5/=^T;*C^([=QG7%G^#SK>=;
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M/C8TAUJR<U<#&V:&S;D1:0!H*PLS=Y<XT0P9D2G>-;3>\:#R%W:=N-)0!0$
MJDLB #07:Y]1Y/.-FEXLL#9,&LL56'$ B32G*A-T.$+8\4 .@! X=<GHEA0-
MD:0TL$_Y3KOF;]5_Z;E7]553>?89_GA34G3MG/*?Y:I$,_SO'9=FXWO6>Y@Y
M BT(B+.TDBA4)M<D5Y' 9^UH:(HS\X=CYVV>Z4_=,+C"7$R*@TS_ECVR>NY[
MF?S2KZX6F9#__5Q%J9Y*7GFJO1[HT75>P3LD?WVUG."QHF?XP*8;?GLLX:9,
MJ+''5WO)WTVK&_[WJ?7U^*4+QQ3&X29AU,])&)6JIJ0IMYFZ3A]CLM&A8(+D
M4<<C=A!0],7Z.:SOH^CIS0CH,"V[&<PP+>QR7'](C(\#O?MI/8WU%_VE3#_P
MQ2(W@$XD_@?]FPZ/7BJON6PHOFR"HG%.4(SJ8K+;A1A:3?A]@EU:>SHUB9,%
M 'YQ33 ?].;?B9]';OGLTVD29+.'R!Y.UI2;+ YA36!X.K$JR-#U1-#B9[F!
MXT@X/*9""'0SW:"$;1<JL#S&6Q44FHDBQZF 0@)$D-AL\:EJVH4Z:WK<'&HB
ML2JHI;JAQ#N+?5[^)F>CBA;V@:S#63@>&8HP-XULV5AR68X$G KN,QI #8-;
MCBHQR3:'W 9*X!:5F!/3-LDSD ],TIH/7EY7E50Q:R&'H51KM>32B*PE$W)5
MD#877^1[#+U<;I907D?WOX>OK@MT,__)?_*?_.>Q?O)JV)35L.=<Z&UDK_Z%
M!8#?:<EXJ$GB4*W) T'!LM139*TO]>2>H?<U61;_+>DE7C(<+QE>^_APX'RS
M%.(PUD4IL@NFJ.T8G&AWNLUGU.V@[K<FNNVT[YKMY^;=D@"1UYX[#ZV[1I>\
MO)"FYRYYX?=FN_N,&L^H<X]^^]YN!HIG7A^:J^H1 Z=^EPA%;!\ Q*^H52WN
M4_?(?@UN4*I_$7^.'U^DDPM9+&W%0N;3DV#KUR9[1-?JQP_4/V?2W%E>GVS:
M9B[N#'_%-G9ACQELNPDI&CUGYL\WGS2"0O>>S7>R#[%-WW$_%IM/L@_%9$LZ
M!8WFSO I[(/TJ@*5VQGW07K5$#87M*=+] G"E84V4R8W.;KJ:+6[3YV[[[?=
M5J<=KQ?>UBZ0494>W*^,?.<%0X0&O5D^M(+RD#?K>=; ,EWH(/4%,(OAP!>/
M/R"F)$G$XZ*?I7^(-^7H58AX_.HZLVGX!@H"E=%;MQ"YLS_"-W\N(PMBGR]C
MIV>.T0B;8W_4-UV,QM@DZ$'8?B$&=A!%?%SL8=/MC\IH@,FC.%/:#@NB*H3,
M/[ ?CH6!E1 !GA$((1K8H,='0Z=/@RV.C:9$+< G;3@@J*)M![=,,P_1,)?G
M!U1ZA",T]*4Y<QV;/.HU(G[QSY1";?P6&*P_'?<'^M(VO8'Y7_)^^\^?3Y8"
M78()8AL&V ;&KN2O+3HY>G-]3Z/FVP/UZ V[@+57"[^1]WI!&"]\]J^.Z=*N
M\W>62R3"<0E^?7I!\,X$AS"TR4V)L$#<'VY:_>0[K1BXO/,.4AINI92#N?UJ
M>I;7&3ZZ>&H&IV6=85I;6_O<.@U>@R_D%IA;X)BT-Z[0U\9SB_K?CV1_VWAJ
M@#&&/\&=3]H%+_OM[3O4N+WM?&]W6^U?T2/Q\F];S>>DUA^? NQRT*0H7<^;
M!&\@HW#-9:8S;-T_/8/%'%M$G/!";O0$N=&SR(V\NC4+<H.YT!Q*:':+@= -
M]?8@2*,J5A'Q5IM/;2H?1 P^AX5  (AHM.\:3W?/Z O +*$'SHGZM. 4C,SQ
ML$+/![<[!2/S%:,>QL0MI#:,7 ?^TA2<33MTJQ9.1K"IA-?,?I]@!00S\)I;
MC6<D*X2:$/NR)FAN!-$3AH02 IR?X5@2TT]2-Q@<!3C<H^E0+H83242W[30+
M!49H6D.")^*IXE?ZK/!@ODNH$QR)>J&W&X[ "0X8O9$S&Q.W!6YE1D__G_"8
M,GA4/_";4GI+F\]93]AU!#[,;.JN30DI:+-<ND4(MQO3A4\3$7H[U4S*%' H
MY_&AX!?J6@+CB5<8;+, *':88+1T,S>""]S6'A"OT@ME%&Y.&$&<SH5?"J[^
M%!,:?K?A.0$!Y"K+\V:+:UHKW]18+/MY_@6!]_J%@/@K02E\6YHOFZ]UX3S#
M[LU\-:TQ-2:OEDD_."36@R8#$.>Z!\?R/ZY/%3F0L>2%*4MXZ)HO-&>I&5 *
M,'"BZUHG$>:4^!]0$30<!B$ ])MISZ#WM+C$<D@FI[8/-)<_<CR\JD%S5#DG
M2M^.33SBJ4\7$VH$B:Y(*@="2D0ODEOR@,0KM <TOD$("O(8?$;4T)<'R+/Q
M?@Y,!?"*7#&&UXA@F3UK3+/RJ8E"GCG&%2+C%?H^%/ 0;KF0[@*W+@?]G&D0
M!KC<IS)+$R9C/"9Z943,B>T@B]BNO@\[W(!$__ 2F7G"? H7'W))IB00XEP*
MXUI1>41_;BD>EMA =&28$ 6AL/9BV,0\<A9C=B/B=6#0R=>2N]K!:YV^[\P!
M%(J$].F!EKYDY5&HU;F%#&KB4GB+[T?#F4NC?VL>(_1:HC>]"#94U2?C9KZ
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M&_'O!3:=^"9[K)85#LCQ@A^ZITYDH>J1,W*PTKFELDKGNH<>!3YY N\).$G
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M-FBCA!$'"E@)KR'4(!\YP!MCO:.SK8_*]AK&K@,E.FT6O^X4OW=UKY^\[P2
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M_04%Q;&@B4V"AXOH00LVP8W(R7+81S#4'0Q7:'0^Z!^O4ZJ>T,=JCRWLZ$$
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M"1:/TG&/^08I%B!DWPQ%=[NV#7XL^#..-;>(4%&X,SC8!RV^:T38Z>(A"*2
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M"[Y_+1W7F*R\MPQS3"AS>^-_S\/"Q+)<TW*Q1P?S!BQ00(%A+O&XZ_KOW0A
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M)4'.!VSM1H?GPMEB:["=JV+\2CGP.@JP<5'I8=L Z2ZEWPS_PC/X%/XQM6:
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MH3Y9)UGS,@X/##GNZ*WB%EIV E677C*8^$6*P?2U,89.F921$R% L]TF($=
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MY?O(_1>S;RLE6+WKZ.=P5Z,<_U6Y5/G;]E7P_:'N70C?LR?Q0L9_7"RZ$$P
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M/2#P>+YXS*//M[[&YRNP>KY8S6-:=WUM-UF!U7/%ZF$<[-9T?#6PO2O_U;&
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M:JIRH5DI-F),S7D4^U*C*U8C@^91VDNY./!R/T\;,S\G^B<-\(#+7NV>@>4
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M@+5_Q1=,8('L 4N_F>BN)\&*O1M]?)SKW8;'$%,2=MW[D9TZ1F_JT3LFNC'
M3" [6 EI.,4+\;7P(9M[W] =@[BW[-,1"5:9OGYSY:UUH\'S2PGXM:<;)NT/
M7X2)>I[I-XO'%P)_MP;TS]*28R6T54X?Z;&,H;(K8[CH74H_=,,R_5A)6J<!
MZ(&XHG3RJ<LB*KWXYB>^G%UL@A(FBD_Y&+H! WR<CF%I^BE3KOF?/>>ZN3B
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ME?_%TM_^32-GOG!OY*H'2NJO*WT(D[[1S0_]TT7A']:?0+7Q1UH'"VM?/>M
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M!*K6R#;]FF&8[\:2E]EH_,(_<->8>'R2_(3^()C\&B;_/ZW';NONG%A\!RM
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MUEK&&/P\U1\\#W9RK,?O<DEZ;G7C&]>(T_<\(.L,!=7S2^O[3\"D= %CQOH
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M'6]DZBP[WBKQ;K<YZ_@!K(/ _K2(/77C>$>L+TXK-&N5^FI?G"\^H[5CI M
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MP#I@?9%Y"!=5V&8Y<*CFT5HD%[1"!1<-\'(6$^AZ\)ON(*-R)C9]3RBXC-5
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MM#3&A^&-I$[KM2(7)7VA!U.HGSDVKG9FO=<1<S23V^>H\?&]@&5:SB,:Y[L
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ML[/_$-]+!: 9Y6Q(\D>$8-?5MSN$3;TIL4;%*J.1T"8^6]'\/IG>"M'^SX_
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M;VS@D_F2CO$F@/2JE@ _O3I(^*( GHP::D;.Z)AXOA/2V?)B@YN_VX^KCU_
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M(4^4HQ)1/QPGWA;7R14E+F@2_/8>?WL;<W+K=G<2+:S--389%5:1!)1_T^O
MM4KK<,2KHRG+^L<#JW/=:5J[R2?Z2&<VSE>,DEG2V9'@4<=2W<SL5+=]">S%
M&0%DJ(N4$A2M_CS=4$[7T)+9/X0C6LS!6!OJ4OL]91 3!S&1+?[,#Q/68*P,
M1:-HC0MBHF%,9*L^<\.$+ [&\E QRA5C("8:PT1V 0\_3$B "=DHIP3>2@@
M=Q3-[2@>/&_VY"R7U3</QS]K,_<'7^/!+#Y)94KPQ*%H%NT9Q[=B-6O5/GX3
M9Y+Z=!//G5]D=O8?XGNIUE6B^2_)'YLH5D<K9M+P4E94T8K=(LZEK*BA%;M%
M=4M946_)BLV6L"&SK<!LL_0EJD;).=>$]VE.Y^B>O5L)SG)[[Q:V6YXA&Z"&
M-M0UI=/%WSGC'B>,G1QMM[ECAX7/):T3S= 0(979>T&$9% )JR250'AT=%O
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M:Z"$@#X+SK35G5A,=X;][@G>7Y@/V=5=L'NC<F_I;V8GROG,Z'0 H0,'I<@
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MMCMO&U5@#Z$/H0S&^2)<,5!X38MEWH"70H$AUT5GR93EPYWD0RC!D^%J_>G
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M'_*F<C]R>ND3N;9U:AM4?W0'WX/)=AV@=Z%AN.[@5B:?@T$0M0R%DB*#"Z6
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M 7;XA'D?RY5^MD&S_M![DM9#''#[2WP#=7N(J^O-\B$JC\B<LQ%*T+3)>,O
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MF11@%II.\%BJCU8@*>8$:JWQ?M?-M2;04^,<XM&K<VJ:GN3:RS/J]:E]OTU
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M 3$+E^.(Q3NVH7R1%D<3R@9Y/MN$[%+1NV ;W_+8BO=0AD<;;CNIS![$#&.
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M7-7WK?PUI_KKM12X5YAI^S$H"RA6$QU]#)!8=&1P"M31=""^[[A'H >#BGJ
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M)Z6K7S.:,MV#=]SW1ONQ,;R"K*/U.H :_=IH ]!#71CM2>/#:K$'!X,8XIO
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MUX[+;<%V;>1ZZ."YU<8^GTSCY!N>O:(C VN*TD5,A)>IE!#!D6,#2B<&3KH
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MBX ^<A \H[4N>FWD:!K3#_LA+)1&Q-]3J %9&\1XV8J,9^T]-XZ@&$GKJAC
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M5HP..$$3,9J.NEH@W1FGC LJ,2T[&(VWO_K<F=I33HV=@#__[PT<7FAE8O;
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M7JY!K N:=8#1P0#NQ?4A;-D]A'^7OCTD-\12O80C;&8RJNJ7T\ZD OVC6E/
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MZ=,4__!C? _&5\T8/[M=H_S"!S_&:^4K3 ?1#^]OI54=1L<$'5S$T2?##JP
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M+Q>UPWE5V:7QLP]COT)*9AF4\YS0TBU74H]RE!TEUB675(HB^M "M@?+OES
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MGB!..\T2TJ6$L>4T0Q/;9D8X6MO,!J \N9>'^H9N+'V"O@-?*R?HK.LUQZW
MBTE2(HU-N$&34:E/D3B!!CJ =8JW2K4Z9E.^B@S?TIEO%VY5;KQR0\XO?C:*
M7^]4#A&  U!2LFY+_I$EGJ)I[I..J.7A#F.K@HLU:Y\&? ?PJXML\?4M B$$
MZK1&JDJ_9,E%)+:D0%LCL^)9 +=M4'P.G16[P;(2[SII>_L1OL%H!C\C"TI&
M-.J+39,FYY8;/"BR(HJ5=KR.2^*YDD0+ 1(4I8_B+QVV/%M/X[''M78V@; "
M))4/[]]FA3'O\WNT0OQT,+I8]AT]UV" .FJ(4=P1&= R]\ LX9XR&6VDN94S
M>N,#3@SD>LRL/4-@-BG^TLDM4>]&L;F$\PQ&IVP9<;KD8PNCB8.(YYY3(D+6
M%EKU=-JP_ FB6X.1G1ST\TMH<;2<)\L@BM)Z17M;KAV'U!A4*9)F6<@0E>YO
M;M J92<F$178WTF3W#?-9/H^STN@SHWE,JB820CS>Z644F4E")3DCQR$D0^G
M2W0H"RN$G:PH[,O\BIZS565C KCD5]1V?T+I'#97Y2Y:3((_-YXZIFTF6H*\
MF?MN.<L$E)+%F/0^]#?]X$E23U9:Z@'427OV3S#$'UXLRC21R+-TB:R?3,OM
M]PV6="8E#64F$LU+&_E &?'&2!(H&DU64RF2[$V0VM%\LA+5 625T]M_13:4
MV3 C:&:3^<WY0)U:T(B<"%0;B_<G@,7KE =%O(^LE-,#J,SPEFT35&W]P!,3
MBNZ873%Y?D5RO_K"A _C)@^FOS2H9>>SR:2) S^%XJ_Y>X-,_@<>C\BKR5F<
MCUZ%]',S_H)*^<7;?\T&T^M?8?JU22C=*-P6M2\^'R[CR_ WC]+-<O320K:@
M3'\'4K5]G9A\'AWZBL4$]V+PBTV<3:?C09A-2TCV<_-;@^_;:(K<'\Y?OBG@
M7J:3<RN3I3I)DHT7^-XA^T*00'C2TI=D49-];[*Z(_$G*Y!=@KBQ'.)__O"
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MQW<U>%-R7',&ON7U+:AO.?C/HOQ;_A6#3UM<BZ*\@_#?F]?>%/>/97YS6X/
M"U#_6/_7\I^QYP>"!@RR4 B(:(QA%GD<>AG%@GN$Q)YX=?////%]%J8$HD3X
M$(5!!@F-4NBG/HX#DJ 0BZ;1;;[[VS^K_Q!<<2#5VU7-/__M#[=U??_/O_SR
M[=NW/WXGY?:/17GS2^!YX2_]TW_H'O_^[/EO8?.TGV79+\U?]X]6^:D'9;/^
M+__[MP]?Z"V_PS#?537>426@RO^Y:G[YH:"X;EB?Q 7./J'^!?O'H/H5] ,8
M^G_\7K$__/L_ -#2419;_ID+H/[_SY\OSXK,?E%/_++C-ZIO/_$R+]B7&I?U
M!TSX5J)O6JL?[_F__:'*[^ZWO/_=;<G%Z6:W97G4JD*9*91^K%#^XSEAO\R
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M027:YL^;E))81 F!<9AZ$*%0P#1#%*8H\GV4!6GFASH&<F%<CBWF'BDH.ZA
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M8=+R8(Z\R LB$1.M+-VV !R;G.,P2\9KG&^;K1*YX+WKDK^0XJ%625<;I*^
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MI^1@$="H"?9Z@H.BS0%GHRKH=?V[^6@,SI#_;CX>RT/K8]L!]K8#=Q^1FK,
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M":F(.2,^ACZ-&$0DSF"&$($DH4D<$!0DF78M%RV)CKWZ?_K'-(S1O_B M$@
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M(H \"VG(<>+1+-,/:IR%Q7F$8X,.W/7P^JO>1L%W\]B>MN$K<FAFT7OZ]LA
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M>N0A!E',8FG5600CFDKC'M$P1=YFQV]4J@)=XVZ,0LM:9*VU&&+1-AH7M'[
MI;(*-SC?5;\TU0-Y]3-0=<ODDY;;=^9TZUIC-Q3:&=S3Y1U5-B?6 @*D1;3W
MQA_!3PVA/P/9[L.V283:S(=EH]83UE52*.D=M=E2Y7C@U7YG59KI+G'JLLE0
M+,E=(1^**;+54Z)84G<J*XIM4^;QO?_!OTJCB_NB9&E""<48IHAQB,(H@@2E
M')* LS067D0R[7PH1RT[]D,[6?H!J\=JC]N>6<J8691.C$4$[K%"^B&WUHK9
MQ=AVXA8*U#\)?B2(]OCYU:)F3\(<ALF>?L#6U1E4(9:KYGZ2ZI/"7>XN=U_E
MWXI2%5W&/@U#*ET;RJE*@(1]V&1@$T)@'"/"<:*5%-]*NF.C\%,O].=?]H68
MY?2<'P"8>C4FS.KZ,X[X,K,[FH6K=:BS\#HL*'#N;YA@6MG3L*#KN8]ATXCU
MGML@N_Q;N:++MVJ_3WYG=VTV8%(\U*^+LBR^24^WNE:;1)N,L2@,?&F.,I%*
M3\3',",IA6&:<2X"/^2"&VZLF:-P;*".-VQ8ATF.LCTH@!4J0/:PP.\-,.,Z
M7S9=H+T_YI;8.9M@FIS6XYS:;&W9<^)^_\H"V]J;5/;TG=B)FM&818HF=<CQ
M/M_A'54[7&U.W?H]SLN_X.U#GXOW4UG(5=Q5^:&HJDV ,&$I]Z"'XQ@B*CR8
M$B:@CXC@& 4^S6+MM$S&XAT;N;:2CN@1[=-8UT!(4."K0K5/A'W?X%*;&VH;
MRB!7D#GITVL^MU2:F;66Q3T8T*(!%S50>$ #"'2(0 L)7)7@@VL6#;(L.673
M,K.2 U;-<BI9DS*61\F\T?5R)UDK?)0OR;Z595.9;S+,LHQ&,4R0_ ]"$8/$
MRS@4,6?"9XP1%"R1LMSY.6[=1'PLE)Y\9AIR=V;T?+IQ]RG%5]PJ/RG^AT@1
M/K;I/?J\I2/VL=B]*<JNM$&W.1I$G(?$IU DDD$DQRC,?,&A-*,49Y$?>(EV
M%IIS0E9QJE2>)"6XG[<L<BR>XTC3.YJIN8T/Y%!I0V=FIO)S7)8G)"SHC(PH
M->5RG'IU7<=B!/PS]V'LV24VNBYV>/M8Y5574/%$%=S7CZJ4XH=]K<\@8HB'
M&8:,!0*B)/ AIH1"G_$H#J-4H'3&EI<QGE4WOW"'[E H]&3E9_((<HG-HOSJ
M4IUDLRGFE/HYVV.FK&\5Z_DXZS,WRZRY6G7;S!SE"VZ@65,ZOI5FWZRY+R>7
M<NHX0B7"S0O9^-Z3(QX6F8 4AP@B&F!(PBR W$/<\Z/4C_3RUIX7X=@('H0"
M*57?A3G#Q[37-E]+,WMSK. K54?;PF,[HZZ^OS9?;3MO[83ZR_AJXPJ->&IG
M7ES-3QL'/O32)IZT]=$^X+J]A/!>VJG_PW'9>_\XB*-,^ A&,5/NEY] PB(,
M0YQA+\:"1X'A%>QSHAP;E6MU=\O4*SI+BZ[#LX2R9K:ED=A>=A+*6WE40IU<
MW9S2S;GO<1; RF[%%!'//8;)-VS'\76)&;_8L<;Y^,PIS[^JD[OJ@E1UB:E^
M0/%40^X^X$9R<SNF=;[+@W#P.^[$+_HAZ^KJ_(.>!++RAZU+S/,/7/M-\S27
MO^'O^=W#73\_)6F0IIZJSR!\B#*:PC2(4^A[-(V].(DC3RL+W;.6'4]'G2S]
MW)3':D_XM'.4,1NMG9AI]]4HL^1)\#.R1QZWMUJ&R)-J#+- GG[ ?"7XF<MA
ME:N[1$WJ+Q4B+_4/NH\E0G(4D Q!P7P*D0JG(%F ((N8X+[/_=C7\N$F)3D>
M,P?976*^YE*($J^_:!IG:GJIN)C^9L-LH'HC%WSJ5;=8.(YSH+]^7(P+NV7D
M>4Z664UJJ3>RJ!Q_?[6UI98:PR6FW@N61X_5,,MM]\41GWA1A CT@^:Z.(D@
MYI3!@'K<QW)RIZ%VPOQS0E8Y>OQ))>S=/H+_#V^EEW/?.+$?<E+CQ\*@-NA9
MGJ:MTQ+:FQFF5B(X2C5M>?AX2F7#P\>9JL\X?#2EP/P,<D2WJ3/(4Z^N>P8Y
M O[9&>38L^969[@Y_X'?X*U<E5R4))<#=/NI+"CGZB9I]>%PX(A%%#"Y0HLR
M3WI+$>$P]2F%) W]4,1A2"-M;\E4^*JGBPV@-@U%!PD,,%F<)EK1/6W47))H
M9NP&_%WU_%V\,'_Z%M(ECW:6\_A[W.Z_1]SS>7^ M=#E2%L21DRL<9.KF5Y;
M98<FV;J-)<)%7C]4JC:]G!'N2+YKDUX8;V7J-KA6?,'8]9L.GHHXZ/$YVO0T
M96752()10"\8-*!#U'A\@%8+9D.'\7SSMK._U_+5C8B]Q&-9 %$@,$2IRKR8
M13$D-&,QIY1QKA5^_;1AU]Y))PHH67HSYC/5QVW"'(4,1[R6+MK#]ASPD<*V
M\I5V1U3^<-@,?=;0*H/I'/Q^J)S]N^T<\FM95%5[TV'#O 3[B73@?9$RZ<_S
M &(AD'3J24!IZ@<A\\WRD Y:-QH2YME#&TG=_2_3L^LA![I3I:5F9F-#2RF+
M&>T$>.>3UE#FRO/2"76?3SVG'C)?0[\ORF^X9&WN2OJH;B+T@1"1'T=9E,20
MB42H:P,1)+'@,/%]Z@F$&<WTSM]&Q3B>>3K!769Z^FARZV>"G^GE[3):FPW!
M7N%>*&BD6FS<C6BNOS!=A@&[)>CIKE]HL3FMV,BR<N3EU1:0TPH,EXH:3YO;
MGH\/JH&NV%&3]';C9S3V4>!#GZB"V3'W(?92!#,YHZ=9*K(TU YP?=Z\8UO3
M"MP7%ZN:VF_MCP9G!"=8F;8T\W0ULS"=FE>B/9NK@!(W2S]]>S)/3SL[\JQ;
M5<[PA<S(>7U&S,>)EU8S&^<!#\W%R%.V?G]S?C!(XG-=?.8*;[[EK1/47,_/
M:(9$R&.8JHI"<I%,81J$&>0>%RIM=2BP84RKEMQ5CB"/<T6TUU+ M[R^!;L"
M4%71@PO!5>;C7?M/5>"C C=\QTN5)U5=:RGNU<\JOR:F=?[5JFB!7D_HKDL6
MY]?,F+74XD$ZL+I0<8DM@I[S)DGL>1MNL:(Q4MOY6D</S<JK(".*GJ^/S%XW
M]UXNZH^%FD?P]N).G6IVOG&(.(T1":$OD%PU!4Q(6R3-$!>,QV'B,RY"70_F
MM C77DPG$N!&IO[$?H:0:>=EOIIF8_ZB!GLE6XG30?2ZVNJ[,O.UMG-GI/:[
MXRY>R)<95VC$GSGSXFH^S3CPH5\S\>2\$(;++N/U9SE95ZH*E)RF+W=573:=
M7/VGG.F/I;]^?/?]/B\?W\H7Y$^REU7O/#8)O:[Y]_JU*F"PH4&&1:92G*99
MJ(X,I$&B,8>1G^!,L-A+L7;V!_=P5PV3&,"U.\9WU&73)O/'Z@C# Y2C4(L>
M/6C@@P[_L&N TN"9Q7[]"%HM@%(##/3H4D8"I0IX/5[$XR5ZURZLX^5[V6ZZ
MN;[EJ@378-3M,_N738_?=CV>#WJ\6]4<S5)J^<+;'F?R10=!(VXIU@PS<03B
M10)3W!)Z+I3%L=0E@E_>[>J\?JP^\_NB;'*Q?N$W#;B!^$U$!)>S-8-^%E&Y
MDH@83#%+(2*(9SQ)B!^9EMHRA.!X,NXD@D%NTCFY3;1(U=V6<$F5]72IJEPU
M6/YG-=C)J3HT[LI667*Q:ER1%K 7C"\R(6X\SLBH)5MKU2:;Y&^*JJXV*!,1
MX2F'S&\R!:0!3'F$(8^"C,3(0SP0?66H:Q.#-)2B-8*.*S]=6YP'[W.?=M6$
MC+<_CYC1-2?&BMJ=_;92 %5BEK0 I^ [']U'0E<>N:<4?CXJ3SXUZX#CJK?J
M;4*A=^TWNHF0P&F499"GJDQ1I 8@BQ#TTM!/$A$'@FHES-:2MLIAQF'Z:G-N
M_?)3/QY_?M44%"OYMCFTJ OPF3=G&.;>P1BE1N<3\XFR.95XRA'H.5K^)&)<
MP77.'\Y@>(E3AW$ZSIPU3+PT/W^/_%J:A"(7.R87,&<3V*"(AID?IS#F@306
M:1C!3(0QQ)DO4N)Y.$!:-<WL(3BV(/(S2IO+)(0_%CO-T(,9A.J:"I<TF=F/
M8:8@^4R7*4A1MBMJL'V!/$)FC*R87T@3V(OE'3(C;BP?D6%+L^W5M>Q%?E)B
MCZ0_,TM]#]$@@6G$Y?*"9Q02&E/(4>"S0/B$<L,\L,88W%NLQ-I,:?-H;*=<
ML&-MJ&H%9L12'>R84TMERLEZIDH;V4O9*E/J1HR5<5.VUJJ/5+MZJ)N2\-)]
M:X+6KII"WM4F2"(6D@!!'Z$,(I]SB",_AD*P,$$I$TG*-U]Y20I]ZS0ATV2T
M#27KKRX.<N5:JP'S3__HQ]Z_J*S(+0;ST%5]2G7-U((TF1FE)P&?>TZ* Q#0
MTP,)KN0J]1X_-EO9N"QE2US]O*1UTJ3"N2V:PK&RY=&DY;F=T7W1/(7=F]N<
MBW??.7VHI5]U)41.>=G-SQZ/TC11Q@-%"40!3B")$8,$41Y2'%,_U;J\.2''
ML2_32 9[T:"3K9_N;HRB<=NPH.)F%N&,S@NGQM-0;4:BO+'65TN;IZ'B,(F>
MSN.V,_\A"/2BKLN</#1G*=?%1ZE%L:NE1MMF+Z<]3*XVR$]B1C,,@XA+3R 5
M'L1Q&D(1IFGFJ;C..#+U! PQ./<,5%FL;J\1#P"I3=A=L8,#3/LH#N/S$U/>
M21"F'(D(^FF&( I#"C%)Y$\B#3))O2\"PXK=#EFWL*<7/PK17HSBC% Y*=$P
MEM-3G$&2<<D[E_,5QJE'0[[9\?HE:=Z?_]6&'_9+D:KK[#K\)LVFND_#&P^O
M%C #%NZN)1G.W5]37"N[PY:T/7>/;1NRN'Z.28G_6ZZ=>A>9>BCQ2 013@.(
M.&%0NLP8BD"0E <H2'RB?>?\N&W'9GPOS>"&]1/E)YS?>2J968&]()N+XT_4
M,K@M;J^>Y15Q?37-;H>?5F3L2OB3-]:[!WX:ZM'E[S./S+ONT-XEKYMT\H,T
M\D^"I7VN<DYPZ6L3&JL$UW*YS)(4^A&*PC -L*#:22B,I3LV&5\>[NYP^:@V
MFBXH59&H%3A@L8M9UV-UVM(XY<K,%AW?%^C @+:6Q.=A!8F%PO[U*+2+XE^<
MRJ6"\FE':]W0.BC,X2#.WH@$S;!YO39?) K>2-US0>UFC9A;YC>W:M_Z<K>O
M*7ZU>_=?#WG].(B<?_>=;A_47NE%514T5^'U%SOV'X5< _Q%_EWBK#8H8ED:
M4@1]5:8.A0F5#AQGD*&4>B1+:$BT4^PNA,GY?JA"J0X$A,0)OBJ@*E*KPR7_
M\)7W=\MQ:^8Y Z(H@<H7> -J.19YHQ:XX_5MP0QRA2S5:]/SP0OTA>D6;=,-
MESN@(((&([C:@1;ET7VR/4YP -HD^VV@@A[K^MV@/Z>\0'?8S30K=HO1?+0P
M@2.SU%*25IN[%J9F.*,MW?02=[$^E2K.MGY4Q3!J*4D!NE=(AM>&>."E38%J
MBGR5:9)X*IS2AXCRE!(6"B_0JF-A#\'Q+-9#>-646JF;")P]C#FWLK3HU=TE
M=4F:]:)$>L_W>_;N]^SQ'L\J][),V%CU7I86L!>\EV5"W/B]+*.6G%JN9E6P
MR5B N9]$,/*E X[2F,#4SZ0KWI3>(7'"TLR!S6J$.[96VEG7IP:FPJJY36#5
M!XL:-F-FYY@T9Z2Z,G1'[/P8)JZ%]",:MR.R+,W:<1M+&+2/Q:[-Q":]OW>J
M%G9U(6I59%3==)6_^\3+O&#MR,)^F(5-)&9,,H@RG$(<!#'T<$H]P5 FR SK
M9H!D55.GCE_WP #_VNXJ*&B@[+&!^P;<$M;-I$-L3)TCFN?8O249GFGJ+-A9
MU>Z9X'M!(VA!X[A%M&G0UCS^)N7RK?Q>>?%0-=<,I3W^FE<J3+4_,T]#%(<8
M0TI#7U5!\"'&-($H2>(@"W#"0L/+P=-"'1N]?<+33JBI#=-@3==<+<N%F64Z
MDMW53#^0XN0>C+ZZSDV-!I25K8H^.<\-B,&[YJ<W7QYW+*?JOOR;DK.\?H]I
MOLWKQS<J/8%TXGM+$224QG$$1:0R"D4X48G5*4P$IV$2A\3'VM$U>B)=GZ#O
M00#:H "B@P%HAT-_%U^3Q.FSDN6I,3,; U9: *!' 'H(%F$]FO3HGV$L3Y/=
M$84&7<N<.9@I/'*DH-G0:B<&9HH-#P0,WS2WC!\XKIH$+9LTB3U5SP:2#'&(
M!"$P38D/DU!DOB<\GE%?U_CM6W5LWQHYKYI\/OH#]:#RM*FR4L3,&G4ZO+'4
M0=^>6.EB9S)T=#(R#<^PCXS^P[.K#?!G\(9C^/D?7=4';3<:4)+%"0H]&""L
M:B!Z'&+D9\J+\1,2^RSSA/W.SUFY/\J6]NE"HO/W>LX3;K.SLPB-CO:OK1AT
M4(?UY79NSJ/YP2JP&NS*3+]N:Y:NB_LK\5E%+O25\5+,D@!GT(^87$>)@,+4
M9PE$)(YI(-*81H8)2YZ*<&QLI#@U1IJ[ZJ8VXQD;NN9ACHYFEF"HGI-=DG.J
M.!_$SP2O/%[/*?Y\:)Y]<E9^Q"X,]J*J>%UMDC1@8482Z!&5G .' F9",!CR
MC$@'GWK<U!-X+F25G<X^^AHW(JW2'!XSHSLFY^EK-BJ-5+5-9'A2EW7R%QZ+
M?HFTA2>5/Y.M\/2SMH-S4&?I?5%>[FBI%@5O>?O_E[LF;KV[Y/()/[8GN*GO
M>1Y&D#.!(**>@(3ZOG3F.4DY0LR/L-GHM4#A>'CW&'[YB74H?E:1XKB_[G/?
MHC =\39TZYH$QR2:V8P!F"9D/N_@@&,^VULKVJQ:&)<9K#BW/C;85C9/,^A[
M;K_F-+9,A>S+W9=\=X/OBY*_+;9;W*>OX5&2(A+(A4&0$(C\R(=9PF,8HR#R
MA%P=!%PK3-A0KF,C=KJ0LAIW>S2 -7#F59<^Q^KT-J8CKLQLU9G*VY=#FEHD
M%N7F3/B:5YY[ =Z6K-=]_)FUB!S6\)[0WK"H][G67K3*]X2*4V6_IUXWM[#O
MOO.2YA7_5.:4-TO&ZV]%?V3M,9X&W(,1CQ.(8N3#E"$,O91FB$8>SC+M4YL1
M.:XMJ.P4\$__F(8Q^I?8^Z/GJ50JW;^3YM_W<FG4)!34-PECM$V;S(7(,#.1
MO5#02 6-6"#E6AQ'CVFO;P 78L'.X-FS863F-'0<,6MC;Z]FQC14&)HMG<>7
M.*,:2?L_O-W$<)KA@(401>K*F,\#F(8L@:$?^Q'Q$(HBK1P6<T"LLHVU1P$N
MNR1RZA:999T="Z)M#JJ6IV_.J54Q4?ACE;MD9I2L>G"E">T%3[',R!L_TC)L
MR]:D]8F\NJ:O=LV)_H<<$Q6+D_-J$R4H#;Q$>F$I]B B*8(D"^0_69C& 9).
M&/&M"H!-BM8:>+.K@K5Y+[NRI-U8 \4.;)N]INT!CJD1FZ96UV8MPY25B;J<
MQ8R%,=+6U;GMF4:RLJG1IN:Y9=%_U7P)-ZRY^N4;OJ\^X<<W^#ZO\3;_;\Z^
M7+W__.<O;]O$-=SWPKY441)1+XH%9"3Q58E3JDH5,2CB,,E$E 4LT<KM:@_!
ML5]TCU4D\AX$4"B A %^Z7(L<>#_T0O^A_ZZQY+IZ06A>_XLK8X"!!I$0$("
M;T[3^?E 9_@_+-:3EKSJ+S7=\VNW"IW#\S(+U'G,C*Q=+1M>;5D[3_'ABG=F
M2^8&OSU#5B<LI9PY]CE;WCVHV\)-S9:ROKVXXW(%CKNA0M,XY8$@, [5/34>
M9A!3(F <,(*RR L#_=1@YN+7B>/H$>G;'0LBIVVY6WK,['C+S![,JT&>IQ9/
MD^.I000Z2!;FVX)&?=/MEDX[LVU!ZS+6VIZ,$4MMT>AJ5MI>X:&%GM'*$EN5
M<H*07T].MKR-^)$2?RT*]BW?;H<[:&$8)"3T"0P33^6,$3%,$X(A0MC'09KP
M%!O&Y)B#<&RI>XG-YF0[B@ZXP(55!)X%TS9[E<OS-V>O,C^PU@;S-8S>]/2N
ML5-I1LBJ.Y6:T%YPI]*,O/&=2L.VS/W-W][\]A=,:;[CK__2'PUG:2BB((!)
M(+CT)ZF .,X0%!$72>B'+,1:4?BGFW=LA:1 T$D$K_^B[^><X&':'9RGG9F-
M.%;,PI,[H:&^IS9/4SM/3+,KC9RL\WJ,.%$G7EK-23H/>.@$C3RUC).S3[5\
MT6=:?E^4?U9YEML\H[\U&9://)Z()800'_)$NCTHR A,&9%&A7,L"/%B%FJM
M2A=#Y-CP#!"!BZ-TU'_>IZ/NDO.VT.;Y0N8=8N<8.:5YGI<TGO[[*/7W2DZ3
M-5DK>U#F.%_4G;*F=<JWLF_8W-'ZU%:RO2Y4L-_A5F6;TVK#6$P]WR.0>7X,
M48@"N3[D C)!$Q[[/ SULNY-2G)L!3O9*@Q/19FJ@;J_%=PF=]-W6,89F_;.
M%N/!S$SU%%P73:"RJJW2BP:?%J5 WWU;C H[3V[ZJU@H\EA+SQ%/;_S]U9P^
M+36&_I_>"^9&JUMT4FD-JUQU>;=P"#E2-5L3R*C TEQ%".*PJ2*:>'X0X#@-
MM*.'S\AP;*A:J6 @5G]4GF-EVB0MH*N9,7JNIL7*\9R^^O9G ;WM+(]!-QL9
MF@F%1DS,N3=7,RX3T(=F9>I1V[7E!RQ'[/4MWEWM^/_AN&RVZ>O];Z^_%>JW
M?49)(B@.Y/^DB0DY1!C[,".A#Z,D"L- A-P3AF&^1O(=&R+Y@42F2T$S_G07
M?LY8,3-9C4"Y7,8[4.PX>)0RFPWP75&#[>%O];>B^9N;=)U67#A?Q9FA6GG-
M9D79\Q6:73/FKLVO.-]5JA0OKZYVG_D=QW)5*%=^;SFI!U5S7G-1E/P:?]_X
MF*?8HUQVBPC4AI8'58)@Z/DH\'@4^4&6Z/H\IL(=VZ"3I=::7$]$Q>\>2DGE
M.W6\VB1_ B+?X1W-\=8HNX85]=..E4M"S<Q7@P3\U&+Y697D&L !"L^P.-<K
MT$("$I-# O4]-9=$VKEP#@@U<O5L&1GQ 8V;7,TYM%5VZ#5:MV%HQ,MZT]Q!
MN_B>5YL4BQBG208#'*KDA?(_J:HKAK$0"1*8QTPK6?M1JX[-[A<U$JHZI]*&
M_M:PQ-M*+TJV[OKLB(4)0VFKFYD%M%1+?U">4N.$[R5P11I%Y N-V_4+W]:5
M^I<:D:UO==S6.L/L%/S]^#GY1_L+2$]3>+S!U:WTJ-3_J2UN.=.KH;@A#/DD
M00221"7>0RR&) H$C+$O71N14)_YF[JH\59WB:4KVFB([0%H?XOJ A+=>S=4
MRF[6$LT/_(#"_/J1)K&Z:R\7=)F-VLO3&8#.4M;5;N%"<%HK9Y%_[X@N5;Q[
M^_/"MY?,.%KA$I,FH-7O,ID1=>I*DV$+-C>;U*U+.?U_YMOF&N9U<4'K!US*
M%<7 @[@H<W4>IQ(]M*N4ZG+WOE]Y7%35P]U]DY%4#O2W7"Y).'O-=_*'NK]_
M]=AL8AWB0KNRJ/NCOTV6$<3")((A9Y%<UTFSA[ER'Y!<V:& "1J;W,'\D733
MLA:S+WE*/3LS8+ &_%$HTKK ]6- =6K[U6UXU9&]CNKX<J\E>+(&ZU0%3?J5
M3MFF%/5^2V"@+U!S<*<QZ%0&>YW;P.!AD'U?P'JO]]_A1V5R>^W'@.Q^'?]W
M^I$9WKC[L7IS] [?#P)UQ5N!/XC&)_9,?CALY@Y='W3P)*_&AI(TY"04D&<,
M092(#&(A_:N8>B+ (:<LU=XW/R/#\3[-/GSG:?X8_9GI'#F,1QE)? &C*/4A
M2GT/9IG/88"B()1^*6$\T%EX+T6.^0K;(3G3KMD"*IMY2GMMGZ9D6N!3T/89
M%M#:;@H_V]<+A6]-*#8RFYU[<[7)90+ZT-9//;I$Q/Z?'E5<W4YLFP[&Y>.^
MB.I1C'X6B2QF%/J4)'+IZP4PI7X,":9!&(89(T(K3<@,#*Y/-N5D6&QSUI6I
MV3'POBAY?K,[9).]+O&N:C&J;2P5IW]P,=5>-F_//N7?OCR0*F<Y5C=-U>;8
M,PW!.ZJVE2P2&IEWGN[6HM,N,;.>3R/XGQ80NGW&YZ$T]!H1_$;TK!JSKX?L
M!:/TC:@;C\LW:\K66GXJ"^472[?ZHJ[+G#PT=:JNBZMO.VEFKL0GK,HX;#+L
M^YBE 61(91Y'LJ/2C'@P]C.4>8%TVP*^^<I+4N@;23W1)L-P",#H;*3+@X@'
M.%24=G=YYK;82DI;TX=W$K2I5=,DF;,,!QD+81S'0MTXC2&F?@@CC!%+0NKQ
M4&N)X))BFQCCEV55=X)8GBNS6:&5#WZ2X[_Z^=6S;[%H8"BV[AL@2QI_,]6=
M6WQ-."N;>3.2GMMVP_>MCI*.3JNN;\OBX>96VK=]^B:UJ\+9=?'N[GY;/')>
M=?LBZD+]GW??\IW:#;D2:AI2%\&>U!'?$!%[2) 04A1*1SF- T@"GD*6B"3E
MA*<BT;Z>Y1RM8ZMVE-.S;*$VUJT#"T@']E7C;S_T>)N P@ZQT9:^X[[5.@#Z
M<7K,]E3_[?Y4OX/?;)D?DM1U'7E=@+T._49ZU:0\VJNA;K3UBKSJ,KT<=/F1
MNM;H&.;'Z6*[S9FI<5GM!^;Y<;G0/LYJ;(Z?;SC&L.;!Q3IT/CF16$FH^83_
M64HO<RJ%?U&E/3[)<2#[W^_SUS B5(X:& <J^:WG4YAB^5.8^#'VU;^QUGVA
M24F.)]J#[+:""5"+7Z#$Z]O8<::FI[[%]#>;M@:J-W+!IUYUB^N+XQSHSQ&+
M<6%GW\]SLHS1UE)OQ.".O[^:L=128VCH]%Y8;%5R?*PK+64?*?]_N7NSY<AQ
M)&WT57@S]E>9):JX@"1XJ=RJ-5.5RI.IZCG_U(4,J\3N$*D.4LI4/_T!N$0P
M%!$D !)4SAD;JU9*)-S] ^%P!WPYO+!5;%0O[1F!$$4PI<KO" ',4@&RB$*0
M2HV68"1(3+2O4I=GS_5IRBY0Y+8)%%%&S*9A3M7-9RU[H+-Q&EU9>3^]_24(
M?PE^^7FV53IGVJP]C)4F8SF7XF4PC_(;6IY5WL[+^)R&;P<>Q)RYFNTRK#1G
MENGPYFO(K4NP %KF/L <HJ]M]"\ F(:5OP25I3K"OL,%9CDN#EIQ9@@EH4K!
M#0-, 614 ))A!A 3@1\$D":Q=HU*?;*.=[CSC4Y[9KH^G7/;FYZ$='J7<@.4
MV>ZCC9&%HV  UMQ6L'-!F]<)UOX#6Z /[)CHQFU@3P[VREU@QP2<;@([^K:Y
M3OU4UA\V>5-!6-+[&V>W?0?OO+CM/F:,$QB'&0=9FC( 5:QF%D,D=6N$$YXE
M* Q#766J0<_U_419>[QCH:D'>:>8Z&M$2B[T%8(.>--J<V%(S/2E0J.GKF*?
MO(:^MV? 0D_JP**O(!>&Q_+P?.JC6<@,-A!V1!?JC+*:$C00::C]3%XS5WOM
M4<ZVO-WB^R8S/H21#P7+0)AB58Z8IM)@) CX,8F2+.!I!(FNCGLYN&.%UIWV
MM?3,B@.<0F):8<V1STP[+2R:OM*9(Z*=AC$2U4BGG)-E1($<O;*:MCC'[% U
MG'W&-M;O77G_\"A7WM=2U-+DXGUAN315 6<4Q!D* 4Q2 3#B' 00T<!'28RQ
MEDZ8(N1:/W3$3,/(SJ RKA^6E-5,5_3TO*HCZ*3PV[A4SB/ SI!?.>)K'(3C
M"*^)Y\VW[V$X\._\%F\N"G:Q)7F]Q1NI&"CGZFJYNE:!9#<^"9F(?;\-'(5A
MP@ )DPC$?D0I%W$$XTAW:S<A['A9'P;+-\PTY[4].]Z '^^OAB.#O=,(X6F3
MP15N9BIB -E5#]G%ZT"F;XJX@L[.3#G\ZC:[KP[W$#[L65K()[(!8,2V,1IN
M-;O'1LBA363UOKGB?5<V_I?\;/[(-[RJRX)WM<6KFX3'7 1RX\K\. +0YUC^
MA#@0H2]B%":!3[7U[ @=QVIU3]G;D?9ZVOK*8 RH:76YD/BF!I1SR?6UWD((
MV"DY.R2,E)J&?",Z;.SMU526A@A##:7SN*T#IPHCX)I_:*H,78DNA[/[;743
M93@B$6) \(P#B' L+4!$ 0]1&B+&,DBUBC_J$G1N^4FRZDY Q=+7WS@OFJS4
MJI8;L;J^^:C^=N=)AZ.MM:;V9_6 ^D?EX8>'34[[[!F[#*,)O'5=Q.50---T
MUSTR^^ITHDO[[4%;M#*=GIS.G<<)-E9V(O5 .78F-=\S+Q;;- GFVP>\K9\_
MX?NV8BH-@RAC/ .$1M*#A&FF;L'D3QB1B 6<<.CKUHT]1<"Y-;,GZ2F:QL5C
M3Z(R8<$L(*NIZ6(HIE$QV3%99M25/3GL:B5FQX0:5IL=?<YVO_Y4%IC]X[%J
MDK:?E G0'2X*&H49CS&(42IWZBA!@&0) QG$,0])G%!BV,OC'"GGM\P%V-'U
M^-.@).J^9D';V\KPAE4#1=W]=PELS!:J$2P.CF^G)':^!Y]E8.7==PJ(XWUW
M\@WSTX1=G;%W=SD7'[YS^ECG3_Q*B)SR/I0J27$0$8P!$KY4"5D2@"R1QGO*
M1<PC&.(@U:O<KDG0L6+8%QG\C1=<G9B]S[?2DBD-HO:T<)L^95@:#3-5L >B
M(>_MZ'L= Q:1)UK Z!]"+ V0W6G$)%#+G$B8"#MR-*$US&IG%"9"#0\KC-ZS
M25"\58M_URDOII@G:9( A+((P$!$ !,A0!+ZF. T2&# ]%,2#\9VK,YVU$SR
M[0Z%GU94,T0RTTD[0E9IA(=BF20.6HMGFRHX-6F&F8$G^1_-!3Q\8\7LOY.L
M'N;[G7[$UM>YV&R:%(BO_/9^8*/C2(@,$96<  , (11R\0=RW0=8KGE*(\:A
MF:=SFI#C]=\F9U4M25,'Y@PT$6'2YXLI""*. 0Q%"$@B_YEQ%-$$XHP1:%I3
M:SXX5C6T&IH+P:+KU<T7U4QI2GI>.?P,W+1<'!?+N>-VAOS*;MLX",=.V\3S
M\R)OY.!JWN3.<R5V!:K?MC<2;=9"?5&P]UQP^3.3?^/M_?,U_UZ_584:;P+F
MLY1D"4A%FDJ[1UE $?5!' >9" G'/-;V[1;ES+'6_/IX?Z_*5Y;"V[.J_C4H
M@O_A^P,O*NYU;'=).75SF]-S[C6LVX6HS)^]:</MU>;$3(,=Q@4-9N3J8$9>
MSL3%T4QT04.>XME[.UZ+U/'DV 48K3I)=L;K]1UOZA'MHY#PP1+J2E:JB[S^
M=I0.E@[K)ZQ6S#L(45H,0LT8IOGT7B7(:3&8SD5!+4? ?)<<B<!Z7][CO+C!
M849QE"8@"V(B=SX2 RQ0!% <8Y)1$L%(.T%YDIKCW6PJD+)EPD 33L,WO?4L
M"HK9=O(*>.AK^T5QL=/@/0!-(MT46 LFPFB+/J)YI\=839MJBS/4D/HOV02'
MWM_SK:J+_QD_-#4?5(;.9?'GUXO^>I<('T(2@@A*4Q\BAD &(PH$0FD@?P^#
M2+OTVB0UYZ$5/7WO03&@(I^;W*V\\"0/)@&34[!-:[M%P3#3=@,<&MJ['+;+
M!@>+D]1I0$SB2!<$QC::=/1#6<@$U19T-*QT:HP5@TLUQ3D,,=5]R?8P]PNG
M&UQ5N<@YNZSY?7\V1Q@/,L0XB,,@EN8<5&%B@@!,812@IKNXECDW2<GY=<Z>
MJI<KLM;1*>>@TCW&7   T\N?8]D=G&-.R.7\(/,<_95/,B=@.#[*G'IA9A9A
MUP OY]6N;FW?B$FJ%9(7C=)7M:ZNRT]2R+*HI<";ICU36^^V&K0?V9_#) )E
M,(RE9F 8 ABR%&#.**!1RA%-*$80664?.F+8M:^X9WM74[PNO5WGL"'K;>!Z
MZ:F@L7=[]G=%R2T//IU-M=EYZ(\P@7..24_-Y/6YF53^W74SD_341'H#0;R_
M9I^>.IMARZS-'V"F[<]:Y4OY]N#(5;GMF\'L#XK)DW[VZ5ZN?AD7<AD/9[\O
M1N\D3]0QY+KYI:[8>)V\5,>@GLUG=4W7HG[0-RX7Q-W5]N$.%V_S\BFOMX_W
M%V]W)>:S0/!$@"3PH:J8AE7E20:2A,($9U#^0ZMQXC0IUQ>5+7&OI>[MR'L7
M;PWJ\(R#-;UM+@>!V88W(KW%L<8$# ;%B1:#P[)4D<5'85:Q2$O L?I%XP.L
M5\U(2Y"#VD9Z;\QS=O;5>*7*;.)#I-;L[L0&RG9O]X0T0JG4:"".&%;!:@D@
M612#5,0PY@%C"=6N #F'$<?:KG$TNKOB/6N-\=K&N0T?&/!G9Z4:SX*9?^$2
MVSE^@PFP"_@"QBC;V?@NT9Y=J<40]>7-<5MT-,ULX^%?Q7RV!>&<66P]GOGF
M<<%8WC3;W?R.'PMZ)PDVY8B/*WRD2912'Q+@"^8#Z$<"D"B* .89ARQ.119J
M9S)H4W6\+>SY\%I&FB74UL:>4RE%']5IS>\$*S,U__HPZ:MN)W!9]MQ8!C8C
MW6PL_H@BUA]K-:UK+-Y0Q9J_;'N9.%3FNPBUP4'%C:\J:26AU*,DCE7E0@1P
MX'/ &4'*YF:!,.Q[/472L28]#F\VO56<Q$SW>G%))*S-X<-PU;]J9>R2<6/7
MXL915U3G5X^3C*Q\!ZD+S/%EI/:;B_6%:XH>OY7_9IW^:9KK7%;5(Y;27HD7
M;>J43?AWWB3K7XD/W_/FIY?/W$0DX52@ ,1,ZA:( P0(BA+ !6-^&D:8^-J7
MDROR[5I+=<RIY;E]T62SO91\:CE4#_".Q^,G9_<I<S+ETZ;D#SJ19DIVK M=
M0QLTHO1V5=MKSMO-O/287_;3;!WG3B3U0"_4\9,_YLS/;EWWVE^ G7V]_Q+8
M[DNHNR^A6:B -%_"0_<EM)TA\V5T@-ON>"XGQ+QMGA-N7KN?GDN(-1KM.25O
M$>'-M_S?DH\^ZM%G,&6, A'XF3KLB0%.> HR^6_**)=?3J8=SGTPM.O8[8Z8
M04SRH>33NZB]/&8;74_')L[Z4":#H&IKV2PCJ#MZ2X5*GV1_+"[Z\(7U@J!/
M,GH0\7SZ"8O>FGDA-4J.-Y=%I6X<U0''!9$_8EK?\(#0+!1RB;,D!E"H@GP<
M9M)K8(F?Q"++N-#NICE"R/&JWY'V!K2]OWKJ)IT@Q]":U@U+86"F*582WZ#U
MY4(P6#:[M(7#K,>EAHQC72W'7E^OCZ6&$ >=*W6>MSTU_?"OQ[Q^O@D(CU$<
M(D##. "0JQ KHAK^IC1(_)3X"4$W=5FK8UR]$\%V8",=M!M>/Z)2O>+QAI3I
MV6<G.8J2, D#"N)821ZQ!* L)2 B\L<TP4D<L9NVAN;7&F]K=_*_)**-PEM^
MFQ>%\I@(WBA+UA(*S$06^82##'$H=R<2 \0E%$*P+ UPDJ8)[:#X4##70/0D
MM&&0+\S'0/? VUPJL^WEP_@W;7%N?<BQ\]/ICMS*9]"'0AZ?-+_X^]S KUSJ
MY0>\N;C=<M[HY=_S@C?I-#=AD 8D\#'P!9=67@13@)@$*H(93"BF, FP79#7
M>:*.+;Z7,3 =(]Z>$^\OQ8O7,&,=830"ZK0QZ (JZPNI5T+)-N9J&;26B:^R
M16U&4-6T^-H!5"-#O5*PU+1PYP.C--Z=ITBOY(Z/U>%:7UCM"U<"YAN5<Z#H
MO*C&Q F.0HY3X/N82T/%CP%)LP $6!JM68J0KY<?/),/Q^KV*[WC[''3')KO
M&&ES@/K:6;OTL!WG?84ME56DNM3TDC2'[-W?WG+5GZ6)&VA_JP[?VZ>ZIM"<
M-0/\6:D1U3#MONG]P>N[DMFI+--)-M/U#J=NCOK?S\MN(@:,M<ILL3)GI@C;
M[1,.D5ZJA%FY0WU70W,[0+W)1G>0)F>)C.:N8CKZJVPTEA"<VWMLA[..(9.>
MYQ-6M<EWARX75<55,"1)29P&'."$) #RA !"> #"A!"<X# -]&([-&BYMN)W
M=#VQ.[3##67C\+&S<.FZT8N 8*B@+>2W"1.;DLQ]?-A9#M8.#)N"XD1$V.0K
M-@6UJOI*O.>D_L3K&XXR&L40 P$S+!<TETL["%(0(,1YC*%TW;.;@M^V";*3
M!Y]'!+0^X*S]@(_(Z-_E29)JQRMX[3%)V*0LU!"-:6/+7#C+^E=2(&DX*4*>
MI&0KD$E-*TO!;.M7M3.F9DM-VV(%JTY(,5J<:OC\BH6H3K!Y6'3JU .V^_F[
M\OZA+)3A<"5:%Z9IN)<B0@E..4 BEOYCX M 0N&#*.51G&$_$-1P,S]-R'7<
MQ8YH$S;5NFA_8?V.A)- Z6[C\\4WU1+FDEOLX>-B.=_ SY!?>?<>!^%XZYYX
M?F:1?"I'K)J,DJK)V9,.0OVLPKA4^6%%[N&^+47<I/!=2NU<W.;21VBM!_G[
M=WB[?9;NP\6].NA0\>:[TX_+0CY52ENC;D*__K/,B_KO\@^2<O7V^:4O\K+X
M/@]8XD,$L,#200A#'R!,*>""IHPS*.*86!7?_U$E7O'T:X!!6]:_E]%KA7SC
M];B\:4*/V]KD.VSL3KD\\MP?VEA6G?]19\ZTU<"/*L=:AWA# +KL[P:"[EN[
M./C6]OG@1Y]I\[<>"Z\%HVV*L/\T+PMO#TCS0@.)UV/BO7T^/E1<KE'"CSK5
MM@T8?E1Y7N-4% \_8_GOA_XS?MBI3'Z@,MLV1/G^,VY/29J_T?XSQNUGW.3>
M[3_CO% /]Y^Q>N$?S6?\U'_&4KD>G=*Z:!_QHW\ NFTI?E@Y7J?=Q0\+Q\2!
M]H_/N*VK_1O.B^KW4K)9717O<'7W<5-^^QMGMY)V<]]XC;_?Q+$?(2R8ZM,1
M )C" * 0I2#+XC F#$6AKU7)S8RL:S?\3OZ+*Y4G<+[UGO#FL=&W5'+C"<F.
M=]?P8^J3:R&JZZ$OC9.9/=50]W[:-/1_]J09_Q*<-QYI;Z6EY[RD"V\BMW.'
M7HN9E=U[$X".G7VCMVV.[#?RQW+;F#Z[^)/_SNN[W[[^5Y\VE<4PBE &PCA5
M.14^ IDO?^(P"[. LHSZ6F4=-.DY/],;<+"/?O*^21X\R83)>?@T=CK'_HLB
M8GK,=QJ,_^[ L.J&,8V*R=W!HNC8WBB,H[34!8.VJ*/7#M.CK'@9H2W2X16%
M_FLVS<P9OW]H&ZVI:Y!]TH?*4^7L)A H"T0< 8HP!C"1-E1&(0$I)('P$YQ$
M*-#O;CY.S+&R^WMK*A7>=L>'28?P":"FE=N2XIMIMCWEW67GGKC74E\0"I/N
MZ<M!8MM.?0=-?TV:[Z')&RX6.BG0%7:T]_K$$"LV8]<3YK [N^8[AGIL6]]<
MY_6F*>?#\J></>)-<Z&811&)2,* +Q+I (J, X1\!GC,,A2'-,2:+8K/47"L
ML1J:[1U$3W6JJ9XF,A/::@EYS524A:CZBV]*G!.NF, 5:022+S=>V*]\4U?J
M7VI5MJ[6^7'768938NW6WN2#YH;#YPU^RK]W)FP4$$&(R$#$HU2N,VDIH 1"
M$'(*<808C_0B'%X.['AYM:3T-[X#F:?W>UM)S!9.2\7"-SF01G_+MI7*;GO6
ME<YH(SXEPLBF>_#X:AOL*2:'F^G)OR_:[;C9*&(>^ &##% LG0"812' -,H
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MM\=XS/5<'UMQ#]P?ZT%F5H(6XFW;O^'K'>>UW%'N\_IE97T<AG[B2Q='!!A
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M?"&UY0*W5>^N+%E]Q<NK>>".WU[-''MUI=RFQ02Q\!$B$4CC6  8409(0D-
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M!\2(.C<<<#6U;2?H4#U;CF![\-V%>E_C[X/SM?W)VTTD AI2D8$HCB, !4$
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MU!/EP*74?,5<@?U>/O&B_-ZGCL ,HR3E0(@$ D@# DA,!4 A3K(P"!!/M$\
M#T9VK)PZ6OJ+[U#L::5C+8R9BNG(6&B30X'T=8>U8'::HB.WD%(XR?R("CA\
M?K4%?Y+-X?(^_8!%^^+G@N7->=*[+6=Y_1%3%1[R?/VM[#Z,F&4PX6D 2*+*
MEV,?2N\FC@$6%$(_ACXE3+N5\10UUT[-CKY'&P8\T7'PQN/?'_)M<PCAR:\
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M>_Y1VP7Z>U[PRYK?5V^?/SX6S;%0GU['(YQDJJAP"E43G)@!1"$&*0\2FI(
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M+[(,EKJ(6@XY37/=ELJK6.\S(3EGS,\=UGSGZI+I'XMZ*_?%SK?U242"D/L
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M6PZ:O*_V5P;Y7E,03M^T+0B,V2KM,+D2WIZTU]+V.N++X6#0/W Y/"S;"<[
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MVI'.IM0=*]##XHAXQ]!;N=![EKR'GB=I'35,&<1G&J,]?5IWBJ&9>CR$[V(
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M/C3F/ MK!\-,@G$B_&7Z'>M4G<VF_*DN6SZ5U?N*LWS;=C?K<O:AGR9R>0>
MT4@ B'$$,$LS$/DX"'TDUSS3RGK6)>AXX>^(&]\B3>"DN]"7D]YLL>_H-F'S
MM*'LM:T5G=0]T)/3??+..!MKI_!H@7(BD4?O/5L5<#(]L(EP9Q'#62)-83^5
MA\1,$) AN?@#D20P1AEGV+#FZCE2CI?]Z:QLN]#WLVCIJH E,#!;_"?3DQW$
MQT])YGRYGV5@Y84^!<3Q$I]\8XF0E+8[*3^HP#X,>. 9S<(HC%7IQ A B&*
M([GRD;3Z:1+Z21H9.H4,J#M6 ;O.K+LV:DVD2<O-G)"2*5!UU8(CJ,PTQ6'@
M2-M:F?<]%-ZHIJB_K1(IH@G JL$A4SR]8CR()ESC(2"Z@RRAB?["R[L*/][G
M%$N4..[*DG,_C05/(I"%, 0PC5) PE!:'0+#!(8I@[YOKX!.$W6L=PY7U-V
M!0\K'B:KF-NC::-YYF,T1^%8P#-3T8S+NZI^.</**ZJ5<7#&M<G$N^9Q#,/!
M5:,NN9EO\JYY[GM<5<]Y<7?QH))_;\J_J;HZ5\57SGC;A+U=$)0CPH)(M8_@
M@?P_7YYLY"D&A#A&G(4<8;WZ \NPLZKBJ0Y8;*H?=4QZN.%2%0EJRQ&5*CBT
MY]2L!\5"\S2NN-9'WUJE-?'\!\#+W_3\>2V#JC!8PZ)W57A?7Q=X_6"*=2?
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MNW4/M[ZW[H>]_VTPU"KK^YCU?F6?^,N\@_67LNCN^:^K\D=>JX/>"Y,:P9!
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M5=?_>V:[2JR6Z6Q+3M*TCOLS0&^F*U]D'.[GX.K$'#2'UIYQK^&\^=6.=V_
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MM61T[VH>9V-ME[(6*"=<QWKOF1_3KA[Y9H/[2AG"3TF*?" BB.7B9Q$@)$E
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M!#^QA9][TGPC_^-1LE)LK_%ST^?A-@DH347,01IPJLX*&) D9(!QGZ,D0)Q
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M)'%*U7\W[JQG+-6SG>IP@.\'(#K*1&]P6RSMGM;B4-2<SVD#YH4E.WO6$S3
M\&;O@ P9<JF[9TR51>$''Y0YEH,PI6ZA0A&VFH^5CS!^UWI%)6S5.RHU8?VP
M>T_QMA7J57G!_N>A4!OO76ND/VSKHGZJFL[(U;7(1)+&(88QBW6%/HEA'J09
M# 0)2(AD)I/@>BMN=-\'TZ-$,]%&WWW>?O=# .9A;%IX5>BITAQ6U;NF;]!3
MVY/;^@30D%#3D[X%27)L4][*;YIYM AT_X[6,P:B ?%_JBFNG!J8VRB^0EMS
M(SBK-SNW(>E4"W2KYQ<(*?PJ6'FS+2K=D.)<=\M]6;]!!Z\.T.7WKC[7H-G/
M=29Y* .&E(^'U?\$,H($!PED"&5I2%B$B'L0H@? OGW$II*9=@OE40G*KD3=
ML.?6L)?,\W"\YDKD\(^;0TN1&8&./H;?U)3^/(-J9X*?!5/N]MCUJ)UO"=P-
MKK[-ZKLM 5Y(*79"MU]X,_PZ[@XJOCD8]?+[]L1'XRE,T^.0K!G8Z4.-UPL%
M]3@HH\&C/N6Z-#8J'Y6'J/S#C^6N@?.YW-Y<B=W=6[$5LJC[;5^"XBS(6 YS
M(F.H_A)"2IB <1!%),X1)JGQ4:BI4,^+R0%&TTFL-3<;A02JE]T!VF&Q:0AD
M2.;T<8,/BBR]XP,["D(74:5! (T"]# <RDD:TV331VEYNES[*IWYJ,#11[50
M1)2MWJ,]EPQ?M6(/)COECGLR63[K7-1)]YH3U:5L8Z2Z+S>3E$010E"@A$$4
MX0"27" 8(DY2D@6"IM2RKM,I.9X-9!\S:76:.$6-J4L[6V$[<]?KZB$ ?E03
M_W6=3DI?N[33& 4GJCN-_GQ.OZ+B?QMS_K5MX_KAQ[URN_9'VPDE"<\HAV'$
M0XAH)&&N9BMD(<U2)O-4Y X=B\9$>I[ 7T5Q1Q_48TW>>EV"K^)&F;]=&ZM6
MB<VFW4*UD/2N2L=[6ER-&A)K<+VR.%V6=RO/Y8,. .@1S&IF-,J.2SNCI5B:
MV]"H9ZOOB]Q_2XLW-#)1V*BET>B+7J&ID8EBI]L:&3UI;RR_"K6Q+)B^C=%'
MI+K[B%Y<^C!!E@NU \P@#G2Y&9H(M2,,8X@9B;DB';/0.#=G5))WT]C+;@_X
MVRXV6KSY_!YG:MKH+::_G:T;J-[(;5L::<D.-FZ< W/3MA@7;A;M/"?+&#(C
M]4;LU_CSJYDM(S6&ULKL@2522/J4%39,61DF(,0!SR(:!S#.=58AHP*2.,8P
M9S$5+,="8"/+Y2;>LSF;ET'HR*CI5LX73W9F[SB!8Y^I!H]3U59)UC E8=74
MC$E0KYB(84K8>-J%\5L<@HCWN7*'DZ>++7^61_?Y<-%XG> PPUA'G.!80)0Q
MY4BA!,$P)*$@6209"J\?Q8Z61M'%MO)MYMD0A?%T^WTPM>X/AZ+ZYO7EW+.^
M@77CG&<AQ3)%$"6)5$L 2B&.<@J#'"NV\U@&>7Y=ES79O#+C!PPS^?;)YK2#
MZY4C.^L_7!H'9_0*S8ED\<\K?8[FT>,^B71/!2=W3;5KM9QNS\_VX7_JKD,.
M.'4%DK9S:'LU#WBI_E$7**G:W#BQ>>HSSD4?#ER1.W'(K]0Q6^J!I9I\.5,]
M%M]N_<[UPMY=U3V*AG=^B?U*V[ST;^5CFR+YKFR2FH_?/KQB/U&C]QI'$:8D
MC6#*)-+GO %4[G\&(\'#+*6)C +21WQ>F1UES$?E$ QZY;I/N.N!FENW!6B?
M7B]68M%I 6F9VX-[ P[PANL%. #4 >8]1/#.MLSY0J2;KS'KDN^VZ#S[?!<R
M^<MI/K(&+"!DM45A.4*&J\2";UWBP.C35HDDFZ[*:)N$WY>\K2YWGYK^,CO1
M?J'59X7EDW(XU,8M8IE$:0PYP;K]BUX](DYAA+.0XRRB&!OE7BV*RO/QTO'9
M2=%B[,L!][4OJAZF]LB*8Z#@3R5(.7 :JW4@P1*CYG)6M<)8S#G"\C8,,T^W
M9M*VZJ&7*]97/ N;2>_X$=G<ESN'475;!-UO<[A%CB1-",H0%#3/]2D9@A@G
M,=3Y]U$>Y2*FEE74STCR;$#[DX5-TWYV1L+!.:),[=L"ZMO9+'O-74*LQK7R
M'V1U1O[:85;C-)P(M)IX8 D_Z[VR%L5&>W2RW-TUAN."E@_UVW*W*[\K%W"P
M2H<QX3)+&.09"2!",H$Y9PRF4<H8BO.0!)9%C!V1K.I/\0Z76JWWP #1R #=
M0P-_:G#@TVP/RF8\7+PF3RS/\90,"5[!-W(@9U5_R ;?*_I #C2.^STN+W0O
M-=3FGGX5]^KKO56FEU]3G*5ADC*8X#S5U=<XS)G ZJ]9&',N28",&@&/2O%L
MU Z%AMJ4:; [B :_%-ONGW^UK[SSDB^#NZ<E6+"\8]K7V6F%@H'4)92VKS8T
M2_E9Q89.?@5+7=%,:6=0:NCELZM7&CH+_U2AH?,_MC=#OY6/8K?50_O;CFSK
MPZ';1?5>Z")K:KP_*LCOQ:/8E/=-]F$777HMTUAD/!40A2B"*,9,;<BXA(R%
MRGF+,*7<./YS!@[/INR #-QH:,/,9%(I?Z)#!_3(JK_N\>T#H,WG^YS1F#:#
M*W%L9R@']#:HAI<F%Q78 P,:&1A VT?CKT.ON<%=B68WD^R1;BN[O0!)(Y9]
MSMM7L_T+4#!<'99XG4-O#T'K0?IY%^N-<!9A3!,H)4(0B3R#. T9C#(14!UP
M%<1&.8]G)?C>DRN9QA5$++I&G"1KVG#/IL!RPZRU'\AS2 4XK:E%YXNY&KM9
MQ^>:+]6L8DR;L384)Y];K\'$&.RCUA&C/[0W*A=55:H)5@L=.?1O9;&M_T.]
M5VW.]]F9$0UXH+;(,0\81$F:0QSG"-(T4'OG*$<1,_8\IX1Y-C4'\4V$W']K
M ."Q0V ^X28IF[8R2Q)A9W &'.@@S$8VZ(4[6)]),LP-T9*DN-FD9Q_(,3D+
M&2A3+4=LU>0K5C-;ILH,+9CQ,_;&[-/=W<.VO-RR<E/>/%UL-H5NE=Q]B)1S
MQA,N8)HG:A^=<@I)%*4P)&&..0\31(UJNDT)\FS$6M&PEPUZX38-Y$=8FK9=
M2^EN9[?.J>U@LD;U-S=72_'@9JHZ/DI[/JRLE8F2H^WN1QY?L;7]M!+';>P-
M?N]^#?%E0Y31*Z2LKIFD,>%80AX'NEN],DPX"C&4+*=89"A-@\#V_N'P^G4N
M'BXE.(BT/V\?L&%^N^"FH^NUPD+JV=\CN*DYMUN!@;I.]P8OM3&X,!@\M/I-
MP4O IZX(3OQJ7M_63W?WA-67LJVZVM;I_L;*^Z99X+8J-P5OAO;]@^BJ[':U
MII4_];YX%%7]O(W5H2$FRC,N2);#2&2IVLU1!@G*0BB("$F>,B&%46#7BI@]
M6[$ONV++BGNR 1UV?>[40->7:4?@^T2H+V)7E+QM\*=@\WTYZ\.[+FYVPC;7
M8ZUOP. 0[.<;6<MCM:,FM:T*3;O:;HB['@3M,%\^'V:E"K@JP5$9=[U9'J@#
M!OJ /V?WM?4YW&X]<'^287=/DM2)C;NCMKFZ,&31?@JZ@^YAMC?)C?V,9T>?
M@NY[W]>I[S\%/>_Y044/7797(-^P(Z]/)*_2O7<%:L]U^EU#])P2"DW1F =6
M/ZA5[&:?4=H? R<Y#61*(25)"%$L= Y_%NBZQ#A*8BQD9-SZR$RDYW7_2/3,
MU/U1Y@QV-8OS8;G3&>3@'].RA^!PS&)(CTLV_E(TS2A:=>++63P3WD1-H_3W
MT1>]0LZ[B6*G$]V-GG3.AB'5[<=-^;W2=_=_M*7B[X7N%+R]N6!U\=A$Z5]0
M!4$9\FLI9<S3,(59S)1)U,V+\H#&4(H <XP#&5*CNJ6N #P;2 T&2(VF#;?Z
MY:%M$/$K*'M,RB_J08$_20?+OF"Q'>WC]G0-,NVLZ_(\NF3J.)'A/X''#M;:
M>3U.I)U(]W%[CZL9^[VL/Q,UX:^4GWFY%?\ER*Y;:QG- QR+4(U%IBQ6%F>0
M1"B!F&04)4% (V:90WU6EF?CI!<[6SMSGA=3D[*(MK:^60UTH=F=+MFS!>56
M@"<EUDO%]$GUO-N#\PA6GOJ35+R<Y=./S#L6WIN,UA5B3W\5_$;]=1 -])]%
M?:M@*(^(;"Z:(E%7.[*MFD+%:KM9?GC8E=5%_4Z]4CWXH>OA]%7]YRM"-^)P
M9B2SE$<!)3")I( (A1SFB2 PE4D0A8)(%ANWG7DE'3P;H&\/=W=D]Z1/C/9*
M@5XKT*DUC&]S.QA<<]#MSH5_TJ&<<TYL-I! JP5ZO4"K&#AHUAPNEZ!1#ES4
MH%,/]/H!K2#XLU$1S#XY7O,#<3M)_DD_%/>397Z4Y'IPXEG_T=QV'\TPJOF[
M_FBV_4?35?"K#Q^-/H8N@6@^&E(#UGTT^SY[NB:?AY/F5Q@<PY/G-9&]RDGT
M*U!_[F3Z-:"X[F[.N/ X2Q*29A+F5&*(4L(@YH)!P4.*,B)(GC"SNKY3HFR,
MC%,)WTOUE+YWHD_@GV_J?P5A!.[*;7UK7;1DYFYG[:W.YY6V.:^\Q_DY-CBV
MNYM%MS;GBB =%P%XMQ.\T(E3S7^OWHNJN-EJ>W-1=0TZ^46][]EY=;LK'VYN
MO^Q*6=27.]WU\_.^H$:.LS2C:@/#(VT=\@Q#PIJFSGDH<QGDB%@VAEL'N.=-
MS'&YCD\OJG2TBH"])N"@BL['[971#HM6!S3Z@$XAT&JDRZ%IG18KI.+Q,S&U
MC#_?X#MO>YJ"=L_'G;7C+O;CSH_&_6XP[H.6SW4W[O?[<=\TX[Y9H_:=[T%8
MN3R>-W5>M8*>[T&:*K+G7;[K,GC!Z@>RTQ4 J^KA[KXM *A3AG4+'^U$5PW\
M30.^3_R5&><BRF$6I!RB1'U7.<UC&*8RD(0)0L/,;DUS0.%Y@=HCTOF_'21M
MLD0'JMD65YT1VUB4>9Y'O>DZX9E0.Z/OP*47]WL&*=Z-L NVE2WJ#/I>FL<Y
M+W.^GA3U>R&5Z>1=3^B^ N)3TQGHXD>A_'5&48YI"H5,4MTQ!D&2\@#F<1(G
M/!!I2BQ#*PRD>K9E"H'RHQH(?3_R?5W.)_!+4^#@5_"G1F+M'YMP:GS)N2Q3
MEM>=9B2149)<KC[-E?9_"6J 9>WK4'-Z3ER,6CP\[XJTK=:E(RRNRG?EW?U#
M+=X7FP?=II7LMKJ<X!>Q:W[T[&8#1YGD1!*8AY&R-WF*($99!*F,2101&<:(
MN]QWN@):[_+R4#>N*YZGP>JKB XNZ/""'K#.?FE_ZW9AY3Q&=M>3:S _YZYQ
MR/:5"=N+W1@Z#X#;]=\: ['475Y7.O&AFP*L&Q3>#8KH!^5>#4KS6P\W<G/Y
M,KQ><Q;S*G=E<TDY=_$U^[WVZ]7_\_73VZ:>_YW@N@K&7\L-;PK=?G[7[2X#
M%J=(*N> 4$0ABED"22S4QAYGB(1A'F6),%V,)J5Y7FFT_+8;1@< ] C> (7!
MW()-TS:]/BQ*AIWQG^#!(;UBFA!S>[TH,6[&V/5#L;*SQGJ.&-'I=ZQF(8W5
M&9H_\X?L;=L?V^_%5K_M4FHKJZ,$+K;\-U)L*WU>*JJ+7:'# W0<]%?1I<T<
M#ASV<=*7VX]]X;]/6[4*BZYZXE?1Q!M<E8.F"1?UQ5VYJXO_5<^757T=1U(?
M$60P91A!1$BN P$H3%'&$26I8-BXI,9/H(]G^[S7L*G7W^G89+C>:"W!+YM&
MSU\!:35M4QAVO:Y'YX=LG^A@;L5^ H8-%HZ? *6_I>GP":AM2:]>D^_^6_L)
M?.X^@4[)MESM7DW]5*\H:')=&E7!Y1;LE06MMN"73M]?0:>QWOH,NSA>U&"O
M-=!J_V-]2>8K[D^ UO^:_H_Y95EY%#_1.([X+#\#RM6\HI]!V1-^U\\$R_7J
MIFDEV@GZ0G9:1+?72&40)&'$(,5A!E$4AY"*@$!.U(XU(Q$/$;&[L#DKR[-'
MU/:ZW756Y+Z5;'L?<YXHTUN81=2W<P1.:N[E"GA2.>]W+.<1K'RS,DG%R_N4
MZ4><RD"+NAH4'7E?WBG3=(U9CK D$:1Y&D,44@E)3@BD29*R5,WLE!O7"SLC
MPW<(22-U6,P)_-D*MJMR?)*>Z:W# DI;AGGXU->JF/-<O9UK.%OK;UO >4RS
M\;K-)Y]<LUSS&/1G59I'?[I$P/>[C;[/K[IC^'?DOJC)ICEHOXY2RE(B&,QS
MW8"69A+2, H@IZ'$RO9@;-N UDSPJ@'7K(6QOWD"K$4"_JPUEEE1TB/<FKH@
MRS/F?&$ZAZR9H<73FJ\:&CP"YQ5#>Z=)&@_--7C>WJ=I_*1]:MO19JESQN,L
MQP'*..2L*6J6)9 $40I)%@0!YK&D+#'U;B:EK;)O.62C%MW!2-<9S:+]XS1O
MTV[/HFRX;&,.N=PO3HCL[]JF&3%WC!9EQLU%FF)H&3_)6-$1CVGZ':OY3L;J
M#+TH\X><:Y;UEO.3^@JV-X4RF:WKUHC6"7N_E27_7FPV31"H9"&+9(I@D,4,
M(I)S2)&0:LWA*(TRB5D06]8LLP+@V0B^.S@)Q1Y.USL,E,UGW^27WG20IB))
MER'=U.'R1Z6=!5V:19=Z94Y4^*]79@=K[7IE3J2=J%?F]IY9I\K[6H[[$V6<
MY#Q*)4SB+%*6"C-(&>>0Y'&*2:QVA,PH)'="SBI>V:%&J*7S,462U6GR'-5=
M7+"AUKX.D<_IM,X!\@OIKW%X?(Z",P?'9W_NT&YK*W>D$KO'W^[H[<66ORO_
M6K+;JO[WWWJOF*$H%%3 -(FDVE^E N),[:]XD+ L1ES-8^/>@5/"/$_DO7B@
MY/\5_#.YN_]7\*[\%_#7?_Z_(I3^JX8"_OTWBRY44^1-;[*6I,1N@A^Q<=M<
MZ;\K02M=L3 ]WQV^)?/&7 O2XMB<Z_AC(0T]_W+@9Z&P<5-%QQIT3;UBO29=
MALH<->HR?<;5-3EJ3]CX\CS):9:$& 8\0+KH<PIQJ!P4F49!EDN99H'E1?<+
M&9XMV;\=M3UU3#A\28RI*S)+73LK]5S3Q7<I9W7Q[GZ\E+RRZW%6]9=NQ_F?
MND[+;P]4/5 TQ1H&X2[7 8]R2A,&&0K4GD&H_\G#,(*8Q[E$,4K5#^PFYQE)
MGJ?H4.H^_=4A#.4<3Z9S=0'M[6:LM>(.DW9"*>]3]YS\E2?P! TOI_'4 W.Z
M+C2U!*78[02_EDJ?C :ZDA^6NO9P" DA"+*$DS1"&<J14>WALQ)\GT'J2-7Z
M(,ZE'<*0#^/30W<M+8\'315T[%-P0HE5&A$,Y;Y"IX$3:I]N)7#JA_:;]W?E
M1OVQW+7UD/;M"O^X5_BV]1?RI/]ZC7G&8]TJ&\>20"0#]2=&!&0B#>,\XCD*
MC KG&4OT/3F'& #9@W@#'EH8X+[%8;YS-2-R>C>_.#V6L_J(F8L!,QT"\,4/
M,^8;^\49<MO=SV?*:I=OI?7(5M_L/:OM]ZW4&F[Z[1Z<TQ"OO?381[CG><)P
M M.8),H2\@C2)*)0Y"+G:1CDB=G&_[P(SZ9O6VYA6Z+<8@J?(6/:FLU7T<Y\
M#7O8=2&@<UK6'6GKTJ+.56O'YMV'L>WN:1=O1G=*(:/F<T</OD*SN5/ 3S>7
M._E+AXI$0HHM)]NZ"YHF2<RC/,(PC92]0(F(( ZY@%(Q)C@.LT08%3,[\6[/
M)F,OS2&$_#D+TR9CAFYVMF))M2R*XKBKYV84+-2TJU9S6I&QPC//GEBOALQI
MJ$?E8,[\Q'[>?U._WA05Z58-*F.9I"&'09#FNH9A K%( H@)9@F*49Y)HU"K
MEZ_V??K8"3.?%,\TGY[J[OI8GB=V<AQ\@6<ZF<]S=]W<IOGD<%E-[M/H1^;V
MLP=6F]JG@0YG]IE?V$_LMP]5L155]:Z\H_K\4XW.[^6=^M.FJ0Q]G3/"<YGD
M,!=80)3E!.8X#R"B*(X2%DL2&H<Y3,CR//5[Z6 @'G3RV^K^YA-HBK5I*[$@
M%W9F8TT:S W+@G2X69H9M%C9($-%1XS2U!M6LU*&J@S-ENDCKO<M@Y(#E]N^
M4=/[0DJA6S_I?^P[.RG);X4L=?&[']=Q&J6$1 G,44P@BG@*\XP*R"(>J?\3
M,0HLKV7<@/@^(&[;K17;0SNW^H "\ ,\VWL=1]['S>2:;-K9T-^.ZT<I[O:]
M[ 8DZG\?\EM*H)$5-]L^E:G<5F\ ;?""FOQ8\K)I'F7>[Z0<X:U\=36/Q)<W
M7#/?9^_=?155O2MTC96V&N@^=A4C'B0QI%FJ,V6(LGP!Y9!D"#/.!9'2J%?V
M>1&>+=E!:%?7UMQG.4/)M,<V7U$[(S/0L2NH;+_1.S?^QG[9?*7=W+$7 [S0
MF>^X/B->UYD'5W.VQH$/?:R)7[JZ5E?JP>I2ZNZ9^^\HBC,1I6D"998G:G/(
M*,0!0A#G2+(08Y2&1M5\1Z5X-B6M*.?<E5.TF+HU,Y6U,R>]GAZR54;T\.Y(
MG)*]LI<PHOY+%V#LQZY3\].6[02IQ'O1_O]/VW?E5B?E*K.K_E05O/,VFTN@
M?8>*:R(1CS#A,,CUV0Z5@9J^0O\IBU(L4DP(N]Z*FR8JSO";=L1B]-WG[7<_
M1&3\^7\\]/+;B:[)GUZ6FO(;>X3ZCP>(MK; =1Q,[85/;AU395H@X!?>0?JU
MV5V>X;.]OE7[IA[9 MGXB['CW5*YXEO9FLVD\:7%F_O"V;N>+^J;5:,2=*MS
MR&4H=>LM3G5O018IJR>0,H(\Y0F),HIRX\(HHY)6W@.!>_6?@1;OO#]XQI3U
MGLA=_WE;(_"E5WW^'ND9!\Y;)7<N9N^8GG'B9>=T6CWS#=2SYU]K'W5:C9'M
MU)D'EB@9-ZA]JT0VGT#55C5#'-,\BR2,LUCMLQ"*("$A@GF0<HI9FL>996*>
MD5S?$3A'-="XJ$FQ45_ORY;-<E\1NS@@7**0W'G&35VRQ7FT,X2>*9Q97FZ2
MD%6KRYU'\XK%Y28I&J\M-_VXO??TL=C=7>K?JFWJEYV^J:B?M-73);T__,]#
M<=]$MD=9RI5]3V$H:0Z1+F>)$RDARE#$1":H-,MD,I;HV1AI#"U%36V@^P[&
MF\:K:KN&B!Z*N6]AQN6TG[4X0W9FIB&GE:\;%_0(&A>C;7KPP1<WYO[7XARY
M^6%G/J13W]%"9]I6BH]X:&;O6<U3LU)KZ+'9/>A@(!\V3-G:JUNU;[T7#W7!
M^H/?7#*)4X(@CX7RTY(\@91P 47 HQ!'&>+"N#_362F^#6$K%PP%6TSJL]P8
M&+DE-+8T;">4==A"GM?:PGPMH;VCR;(9<CO3-*74F#DZ^^QZ)F@*_I'9F?SQ
MK")RNH7G3MR*;54\BK;:YM4MJ?^SV&Q^+^NWXJMHJD@7LM"-4I3=DT5]N=/!
M!K^+^E+J<)M,"DHQYC"+XT#Y;$D*B9 1%#@C,>=AR'!^79<UV9AN(Q="9F72
M]OC,CZEK<5>!;5F#ZH%6:OE5,V3S!'9[7$WSX;K4B[5NRE[N@ [M<2ICM\ P
MF>X]7X%\.^O:ELIC0X1]Z>9:801-?4T]+%0,!J/M3WP\%&_ 5C17-0M'22U,
MX3J5^1; ^QJU_):C^4SUOP4%N%KJMV3[]\M'L>,[(NOJW5[<1:6+&VCG\Y%L
M]";].A ,I9ER%5&JFT!PG7(;YQQB%$4DC&,A$\LF$,:R/3N0&@=@.\'5]*5$
M_2>'>%)S'DV-I1=V[,QA0TRYQ["D';/6SKNE,D>TLBVRINJEM;%_A7-D!U>O
MZ1R4YP6+E3DK;[9%I>5>RF$W&U*+ZXAF2<[3%"8X4?9%.WR4R 3B5$8D0#)!
M'-G9%V<LGNW-$->)FMZ[/33U+]J%((/N25S!LX[R<!X34UNU"M-VMLL;R2Z!
M'G/I\1_JX8QP[6"/N52>"/>8_4J'J@2#*Y$+UO0?U;*$LL-*=GNCIWMNY9@2
MF'/&=;<_#&G.,B@0$9P(E*7<N-J3@;Q5[TY[#.   OQY97$]:DKB]"'>PM0X
M7X=>KLB*19V$9=EQK)UP^MO9'5AJ@"QT.V&A\EB5!8.WK%=YP5REHVH,%H\Y
M%YQ\N0>^J.M=01^:J_ZK\O+[MKT8(;HJS'6"J6 YSF'(HJSM$D8S)*#@DF<I
M0DDD+=U$2P2>[>10M#Y6TG=O]1.X+3?]!=TWLBUE85W(TI)G4]?/(WMVIO3=
MB5.[-X \H[-LT#3WG&2T^)9+N4PW*OR7T[3$M7:Y33?:3I3C='R1J^GJNK)N
MAP5XNUNT0. 8A2R .288(DI#B,.(PRS(LY30*(RY4;ZBB3#?!JG=,.DX@$$-
M:.?THQ'23$W.,E3869=S+'A(3II6S[O%&(&PLG&8)N.E'3!XQK%_Z:%=SR$C
M8""D:7K1_WN'@E;UCK#Z&@N>(LQSR((H@B@3"*IM7 ICEO!0)BA,D7'O]IE8
M/!N,]A+M .\-.  ! X1=HYK]?^H+1?8P;5N"SAB<Z5WBBI2[7%G^0[%MV9YU
M'=;G-&_UR;Y]E]?Y?$WU@)TA8=T.L?.I>-$_=H%7SCLNU$>26Z;$-5^JVI@_
MBAVY$1^D%*Q6CN\5^?&5U$(!N;B_WQ2LW:HW__;AAX[IU-_/4[-YOQ(_ZK>*
ML+]?$\*C, L9Q"1,E;^:Z]4I(>JO))-9@A*<&\<!^@;K>?GZ]G!W1W9/>HMX
M*'0"WHKZNQ!;L$<.%$R@<38^X;=:_2_9Z3F^N]?5L$7?Q[G_F=L!GI?!MCL3
M?>TAG'.@>HR].6)MT9\:1VVB#RH<_GV@17<:"[0BH-'$\6#6R[BZG>J^]O@N
M<22\.QYG?9W7C;/8C[/:&(%=/U_)89S[?_=P>NR36L.C9R\07N7<VB>9YPZ]
MO<JT=P,N6/U =@79#,IR7>R4-[*]^:AX:ZOE59^V^R0KY8 \W-TW9=M^%_5[
M(8NMX&_%5OWAD+?>>"E]0-FE3FHOU;-UX\L<=8N[SG+&$Y8SY1M$&*( *P<A
M" F4*6,XR4D69,9%E%]9%]^'9KUVX$:K]Y=#Y3W=Q?U15'6;STC:6Q7!=:$]
MH&M-W@#E9?:G_G>BOBWY,);4IG#8:W\NTW[&/]!'8'E<N!__KO+BYV[\.^V
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MG#"CKWE.&<=>L,WFS8 CTUB)67H[]_/J%5;FOY$)?FGCL18MGSBEFO]:/><
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M?\%(0@BG.90AH1"E.%>FAW,8,,)%(A.22Z-F ]:2/=OV Y:V*$%35QMH.&\
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MM]I65E<[M66[([N_ZZ963<3&U^+FMNZ]ZB@-LBBF(>1!&B@_),L@YAA#1K(
MA7&0A:%Q!JJ92,\FI@?Q!M1[&(-@YUV#Q":[R8C&:5=F>7+LS,F!EP."IA1
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MWM>*!+\4V[Z$J++K6[7F\A;0GMA-#PG\TG17^%4'&#YL&L.MYW@S)J 9DF9
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M)&:,D__6$KZ8,VPT,5O<5=I.^"+I4A,*;\]WO2QR*O2K+S[*# M40**2 R"
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MH)IPA WC<0)*\=+NL+T6E)#^\LP>N#ZK5<*WN_I1XAKVJKUGF.(TBPE@(DL
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MQ@'2D]("[Q1T=J*YL9LF9WIE\:JRW7)Q$!T-94=:N,-U[30=Y@;=*RUN5GI
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M?^#MGW=?F\WSP]>_\MV';U17%_^A%H*K6%L58SOE1V9IFH@XB0$N*BRW,X0
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M)C0Q"$BM H2W]ZQHT9E'I1@$P<F/LS% S!Y!BH!66^-*Z>Y(X#%]^P'IM1R
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MJT<OV8J:$:Z1?MF9>>IOHM^3KQ@5%8)B@H/,=2"H,04"RP6D=B%P^E<4UIF
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M\A3S*>V51$Z1PSX5)D\\?D  .$9EST'@"/D-XCCO)4-Y=SVKF77!E%7>4IU
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M"WT)#!W3GLLTSUBX1[<\]Q/JV 9K>+DU <<'RX'.O#72LY0AA51KW*6&(%6
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MR6%VTP^%+_*A;R:1M=F+_/L52G>/S<=W%^_SJ0/T"S]X\X-U +^%SENW4-M
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M'NX=US'?$,2KV%W>:!VY>P,J%%%%PP,DXA0HQSTXY!E,T"[)8"PA;C(&'4'
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M&:$(YGHS3XH8AY8!<RB,-=9FR3NUPM_LE>K0S9OA&+;1%-+N M8WVN"6E(7
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M=^'[R_!UM@[GLW]A_O#V]?L_/_SZ'A.2R<*9O*)0,"Y3\!Q\J943CCRJX)2
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M"[!H#G38!7A-?D'DQ4VI4P=MN34V1P?+OG \0')= +)ZII<WSG6C0)^,<BQ
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M'.SUK)35F0G99BL%L%);?Z+R0*8GHXM 2S0Z"2'9 $#=_W+W#M[Q<#F2G9V
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M+,C$C2_":6G% .#LO7 ?"3:GN0Y/+XDN;L+?B40\/P]S7%RL=M%XEEC,IL@
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MGX ,_QM2*CH2-YD.#58S[6I)G><A@"DIN23)CO'3Q3 ?IK5UQL^D^!M0;;.
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M3@7IA'*0E:X#:DP!%VGE&OH\ZYB+X:+'9G5* 5/[5D1/TF.? J8G"'466]6
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M,C0P-C,P+FAT;5!+ 0(4 Q0    ( %53^5@0^V15XS,  -9U @ 0
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M2P$"% ,4    " !54_E8-#R06+>M 0 <C1  %               @ %RU0(
M<VYY+3(P,C0P-C,P7VQA8BYX;6Q02P$"% ,4    " !54_E8SCQ)L0(. 0!E
M*0P %               @ %;@P0 <VYY+3(P,C0P-C,P7W!R92YX;6Q02P4&
2      < !P#% 0  CY$%

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>sny-20240630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sny="http://www.sanofi.com/20240630"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sny-20240630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-07</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-07</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-07</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-07</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:TR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AssetsAcquisitionAxis">sny:AssetsAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AssetsAcquisitionAxis">sny:AssetsAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:OtherIntangibleAssetsExcludingSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:VaccinesCoExclusiveLicensingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:OtherIntangibleAssetsExcludingSoftwareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:NovavaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-10</startDate>
            <endDate>2024-05-10</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:MCMVaccineBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:ShareProgramAxis">sny:ShareRepurchase2023ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:ShareProgramAxis">sny:ShareRepurchase2023ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:ShareProgramAxis">sny:ShareRepurchase2024ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-30</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithoutMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sny:ExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sny:ExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024AdditionalSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-24</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-02</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-23</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:EquityInstrumentsIncludedInFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:EquityInstrumentsIncludedInFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:EquityInstrumentsIncludedInFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AmortizedCostNettingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AdjustmentToDebtMeasuredAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:NonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:NonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondMaturingApril2024Redeemed2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:SyndicatedCreditFacilityOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtMarketValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtMarketValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInCanadianDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInCanadianDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInCanadianDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInHungarianFlorintMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInHungarianFlorintMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarUSBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarUSBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1.02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive3.56Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ContingentConsiderationArisingFromAcquisitionOfAmunixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ContingentConsiderationArisingFromAcquisitionOfAmunixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ContingentConsiderationArisingFromAcquisitionOfAmunixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:UKZONEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:EUROZONEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:NovavaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-10</startDate>
            <endDate>2024-05-10</endDate>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:FulcrumTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-13</startDate>
            <endDate>2024-05-13</endDate>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:TaxotereProductLitigationInTheUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:ZantacProductLitigationInTheUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:GoldBondProductLitigationInTheUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:PlavixAttorneyGeneralActionInHawaiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-22</startDate>
            <endDate>2024-05-21</endDate>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:OthersCounterpartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:OthersCounterpartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:OthersCounterpartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:InterestRateAndCurrencyDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:InterestRateAndCurrencyDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:InterestRateAndCurrencyDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaLaunchesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaLaunchesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaLaunchesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaLaunchesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaLaunchesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaLaunchesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaLaunchesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:PharmaLaunchesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CabliviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:XenpozymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EnjaymoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EnjaymoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EnjaymoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EnjaymoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EnjaymoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EnjaymoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EnjaymoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EnjaymoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:TzieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OtherProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SeasonalSymptomsAndPainReliefMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SeasonalSymptomsAndPainReliefMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:WellnessBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:WellnessBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CertainWholesalersInTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="proceeding">
        <measure>sny:proceeding</measure>
    </unit>
    <unit id="segment">
        <measure>sny:segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-3">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-4">0001121404</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-5">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-6">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-7">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-8">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="c-1" id="f-1">6-K</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="c-1" id="f-2">SANOFI</dei:EntityRegistrantName>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-2" decimals="-6" id="f-9" unitRef="eur">10264000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-3" decimals="-6" id="f-10" unitRef="eur">10160000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets contextRef="c-2" decimals="-6" id="f-11" unitRef="eur">1616000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-3" decimals="-6" id="f-12" unitRef="eur">1654000000</ifrs-full:RightofuseAssets>
    <ifrs-full:Goodwill contextRef="c-2" decimals="-6" id="f-13" unitRef="eur">50080000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-3" decimals="-6" id="f-14" unitRef="eur">49404000000</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-2" decimals="-6" id="f-15" unitRef="eur">26653000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-3" decimals="-6" id="f-16" unitRef="eur">24319000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-2" decimals="-6" id="f-17" unitRef="eur">315000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-3" decimals="-6" id="f-18" unitRef="eur">424000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-2" decimals="-6" id="f-19" unitRef="eur">3333000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-3" decimals="-6" id="f-20" unitRef="eur">3218000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:CurrentTaxAssetsNoncurrent contextRef="c-2" decimals="-6" id="f-21" unitRef="eur">129000000</ifrs-full:CurrentTaxAssetsNoncurrent>
    <ifrs-full:CurrentTaxAssetsNoncurrent contextRef="c-3" decimals="-6" id="f-22" unitRef="eur">188000000</ifrs-full:CurrentTaxAssetsNoncurrent>
    <ifrs-full:DeferredTaxAssets contextRef="c-2" decimals="-6" id="f-23" unitRef="eur">7284000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="c-3" decimals="-6" id="f-24" unitRef="eur">6427000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-2" decimals="-6" id="f-25" unitRef="eur">99674000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-3" decimals="-6" id="f-26" unitRef="eur">95794000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Inventories contextRef="c-2" decimals="-6" id="f-27" unitRef="eur">10609000000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-3" decimals="-6" id="f-28" unitRef="eur">9666000000</ifrs-full:Inventories>
    <ifrs-full:CurrentTradeReceivables contextRef="c-2" decimals="-6" id="f-29" unitRef="eur">8510000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-3" decimals="-6" id="f-30" unitRef="eur">8433000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:OtherCurrentAssets contextRef="c-2" decimals="-6" id="f-31" unitRef="eur">3870000000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c-3" decimals="-6" id="f-32" unitRef="eur">3455000000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CurrentTaxAssetsCurrent contextRef="c-2" decimals="-6" id="f-33" unitRef="eur">295000000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentTaxAssetsCurrent contextRef="c-3" decimals="-6" id="f-34" unitRef="eur">391000000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CashAndCashEquivalents contextRef="c-2" decimals="-6" id="f-35" unitRef="eur">6795000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-6" id="f-36" unitRef="eur">8710000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners contextRef="c-2" decimals="-6" id="f-37" unitRef="eur">30079000000</ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners contextRef="c-3" decimals="-6" id="f-38" unitRef="eur">30655000000</ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale contextRef="c-2" decimals="-6" id="f-39" unitRef="eur">2000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale contextRef="c-3" decimals="-6" id="f-40" unitRef="eur">15000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:Assets contextRef="c-2" decimals="-6" id="f-41" unitRef="eur">129755000000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c-3" decimals="-6" id="f-42" unitRef="eur">126464000000</ifrs-full:Assets>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c-2" decimals="-6" id="f-43" unitRef="eur">72690000000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c-3" decimals="-6" id="f-44" unitRef="eur">74040000000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NoncontrollingInterests contextRef="c-2" decimals="-6" id="f-45" unitRef="eur">307000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="c-3" decimals="-6" id="f-46" unitRef="eur">313000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity contextRef="c-2" decimals="-6" id="f-47" unitRef="eur">72997000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-3" decimals="-6" id="f-48" unitRef="eur">74353000000</ifrs-full:Equity>
    <ifrs-full:LongtermBorrowings contextRef="c-2" decimals="-6" id="f-49" unitRef="eur">12503000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-3" decimals="-6" id="f-50" unitRef="eur">14347000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-2" decimals="-6" id="f-51" unitRef="eur">1733000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-3" decimals="-6" id="f-52" unitRef="eur">1755000000</ifrs-full:NoncurrentLeaseLiabilities>
    <sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-2" decimals="-6" id="f-53" unitRef="eur">527000000</sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-3" decimals="-6" id="f-54" unitRef="eur">501000000</sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-2" decimals="-6" id="f-55" unitRef="eur">8219000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-3" decimals="-6" id="f-56" unitRef="eur">7602000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent contextRef="c-2" decimals="-6" id="f-57" unitRef="eur">1949000000</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent contextRef="c-3" decimals="-6" id="f-58" unitRef="eur">1842000000</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-2" decimals="-6" id="f-59" unitRef="eur">1800000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-3" decimals="-6" id="f-60" unitRef="eur">1857000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-2" decimals="-6" id="f-61" unitRef="eur">26731000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-3" decimals="-6" id="f-62" unitRef="eur">27904000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c-2" decimals="-6" id="f-63" unitRef="eur">7433000000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c-3" decimals="-6" id="f-64" unitRef="eur">7328000000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-2" decimals="-6" id="f-65" unitRef="eur">201000000</sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-3" decimals="-6" id="f-66" unitRef="eur">208000000</sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:CurrentProvisionsAndOtherCurrentLiabilities contextRef="c-2" decimals="-6" id="f-67" unitRef="eur">12746000000</sny:CurrentProvisionsAndOtherCurrentLiabilities>
    <sny:CurrentProvisionsAndOtherCurrentLiabilities contextRef="c-3" decimals="-6" id="f-68" unitRef="eur">13741000000</sny:CurrentProvisionsAndOtherCurrentLiabilities>
    <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="c-2" decimals="-6" id="f-69" unitRef="eur">132000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="c-3" decimals="-6" id="f-70" unitRef="eur">597000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-2" decimals="-6" id="f-71" unitRef="eur">279000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-3" decimals="-6" id="f-72" unitRef="eur">275000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-2" decimals="-6" id="f-73" unitRef="eur">9236000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-3" decimals="-6" id="f-74" unitRef="eur">2045000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="c-2" decimals="-6" id="f-75" unitRef="eur">30027000000</ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="c-3" decimals="-6" id="f-76" unitRef="eur">24194000000</ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="c-2" decimals="-6" id="f-77" unitRef="eur">0</ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="c-3" decimals="-6" id="f-78" unitRef="eur">13000000</ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:EquityAndLiabilities contextRef="c-2" decimals="-6" id="f-79" unitRef="eur">129755000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-3" decimals="-6" id="f-80" unitRef="eur">126464000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-1" decimals="-6" id="f-81" unitRef="eur">21209000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-4" decimals="-6" id="f-82" unitRef="eur">20187000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-5" decimals="-6" id="f-83" unitRef="eur">43070000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:OtherRevenue contextRef="c-1" decimals="-6" id="f-84" unitRef="eur">1289000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-4" decimals="-6" id="f-85" unitRef="eur">1358000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-5" decimals="-6" id="f-86" unitRef="eur">3374000000</ifrs-full:OtherRevenue>
    <ifrs-full:CostOfSales contextRef="c-1" decimals="-6" id="f-87" unitRef="eur">6849000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-4" decimals="-6" id="f-88" unitRef="eur">6347000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-5" decimals="-6" id="f-89" unitRef="eur">14236000000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit contextRef="c-1" decimals="-6" id="f-90" unitRef="eur">15649000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="c-4" decimals="-6" id="f-91" unitRef="eur">15198000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="c-5" decimals="-6" id="f-92" unitRef="eur">32208000000</ifrs-full:GrossProfit>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-6" id="f-93" unitRef="eur">3423000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-4" decimals="-6" id="f-94" unitRef="eur">3193000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-6" id="f-95" unitRef="eur">6728000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-6" id="f-96" unitRef="eur">5260000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-4" decimals="-6" id="f-97" unitRef="eur">5182000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-5" decimals="-6" id="f-98" unitRef="eur">10692000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-1" decimals="-6" id="f-99" unitRef="eur">617000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-4" decimals="-6" id="f-100" unitRef="eur">617000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-5" decimals="-6" id="f-101" unitRef="eur">1292000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-1" decimals="-6" id="f-102" unitRef="eur">2010000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-4" decimals="-6" id="f-103" unitRef="eur">1422000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-5" decimals="-6" id="f-104" unitRef="eur">3516000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-6" id="f-105" unitRef="eur">1061000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-4" decimals="-6" id="f-106" unitRef="eur">1035000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-5" decimals="-6" id="f-107" unitRef="eur">2172000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-6" id="f-108" unitRef="eur">-371000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-4" decimals="-6" id="f-109" unitRef="eur">15000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-5" decimals="-6" id="f-110" unitRef="eur">896000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability contextRef="c-1" decimals="-6" id="f-111" unitRef="eur">66000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability contextRef="c-4" decimals="-6" id="f-112" unitRef="eur">26000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability contextRef="c-5" decimals="-6" id="f-113" unitRef="eur">93000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-1" decimals="-6" id="f-114" unitRef="eur">1331000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-4" decimals="-6" id="f-115" unitRef="eur">547000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-5" decimals="-6" id="f-116" unitRef="eur">1490000000</ifrs-full:ExpenseOfRestructuringActivities>
    <sny:OtherGainsLossesAndLitigation contextRef="c-1" decimals="-6" id="f-117" unitRef="eur">-442000000</sny:OtherGainsLossesAndLitigation>
    <sny:OtherGainsLossesAndLitigation contextRef="c-4" decimals="-6" id="f-118" unitRef="eur">-73000000</sny:OtherGainsLossesAndLitigation>
    <sny:OtherGainsLossesAndLitigation contextRef="c-5" decimals="-6" id="f-119" unitRef="eur">-38000000</sny:OtherGainsLossesAndLitigation>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-1" decimals="-6" id="f-120" unitRef="eur">3044000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-4" decimals="-6" id="f-121" unitRef="eur">4322000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-5" decimals="-6" id="f-122" unitRef="eur">7875000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-6" id="f-123" unitRef="eur">586000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-4" decimals="-6" id="f-124" unitRef="eur">370000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-5" decimals="-6" id="f-125" unitRef="eur">1313000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-6" id="f-126" unitRef="eur">281000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-4" decimals="-6" id="f-127" unitRef="eur">286000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-5" decimals="-6" id="f-128" unitRef="eur">591000000</ifrs-full:FinanceIncome>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-129" unitRef="eur">2739000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-4" decimals="-6" id="f-130" unitRef="eur">4238000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-5" decimals="-6" id="f-131" unitRef="eur">7153000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-6" id="f-132" unitRef="eur">463000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-4" decimals="-6" id="f-133" unitRef="eur">730000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-5" decimals="-6" id="f-134" unitRef="eur">1602000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod contextRef="c-1" decimals="-6" id="f-135" unitRef="eur">-13000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod contextRef="c-4" decimals="-6" id="f-136" unitRef="eur">-52000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod contextRef="c-5" decimals="-6" id="f-137" unitRef="eur">-115000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-6" id="f-138" unitRef="eur">2263000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-4" decimals="-6" id="f-139" unitRef="eur">3456000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-5" decimals="-6" id="f-140" unitRef="eur">5436000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-141" unitRef="eur">17000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-4" decimals="-6" id="f-142" unitRef="eur">26000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-5" decimals="-6" id="f-143" unitRef="eur">36000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-1" decimals="-6" id="f-144" unitRef="eur">2246000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-4" decimals="-6" id="f-145" unitRef="eur">3430000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-5" decimals="-6" id="f-146" unitRef="eur">5400000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="-5" id="f-147" unitRef="shares">1249400000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-4" decimals="-5" id="f-148" unitRef="shares">1249900000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-5" decimals="-5" id="f-149" unitRef="shares">1251700000</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-1" decimals="-5" id="f-150" unitRef="shares">1253800000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-4" decimals="-5" id="f-151" unitRef="shares">1254500000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-5" decimals="-5" id="f-152" unitRef="shares">1256400000</ifrs-full:AdjustedWeightedAverageShares>
    <sny:BasicEarningsLossPerShareAttributableToOwnersOfParent
      contextRef="c-1"
      decimals="2"
      id="f-153"
      unitRef="eurPerShare">1.80</sny:BasicEarningsLossPerShareAttributableToOwnersOfParent>
    <sny:BasicEarningsLossPerShareAttributableToOwnersOfParent
      contextRef="c-4"
      decimals="2"
      id="f-154"
      unitRef="eurPerShare">2.74</sny:BasicEarningsLossPerShareAttributableToOwnersOfParent>
    <sny:BasicEarningsLossPerShareAttributableToOwnersOfParent
      contextRef="c-5"
      decimals="2"
      id="f-155"
      unitRef="eurPerShare">4.31</sny:BasicEarningsLossPerShareAttributableToOwnersOfParent>
    <sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent
      contextRef="c-1"
      decimals="2"
      id="f-156"
      unitRef="eurPerShare">1.79</sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent>
    <sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent
      contextRef="c-4"
      decimals="2"
      id="f-157"
      unitRef="eurPerShare">2.73</sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent>
    <sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent
      contextRef="c-5"
      decimals="2"
      id="f-158"
      unitRef="eurPerShare">4.30</sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-6" id="f-159" unitRef="eur">2263000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-4" decimals="-6" id="f-160" unitRef="eur">3456000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-5" decimals="-6" id="f-161" unitRef="eur">5436000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-1" decimals="-6" id="f-162" unitRef="eur">2246000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-4" decimals="-6" id="f-163" unitRef="eur">3430000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-5" decimals="-6" id="f-164" unitRef="eur">5400000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-165" unitRef="eur">17000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-4" decimals="-6" id="f-166" unitRef="eur">26000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-5" decimals="-6" id="f-167" unitRef="eur">36000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1" decimals="-6" id="f-168" unitRef="eur">-235000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-4" decimals="-6" id="f-169" unitRef="eur">-141000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-5" decimals="-6" id="f-170" unitRef="eur">171000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments contextRef="c-1" decimals="-6" id="f-171" unitRef="eur">-10000000</ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments>
    <ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments contextRef="c-4" decimals="-6" id="f-172" unitRef="eur">3000000</ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments>
    <ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments contextRef="c-5" decimals="-6" id="f-173" unitRef="eur">97000000</ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss contextRef="c-1" decimals="-6" id="f-174" unitRef="eur">59000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss contextRef="c-4" decimals="-6" id="f-175" unitRef="eur">59000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss contextRef="c-5" decimals="-6" id="f-176" unitRef="eur">3000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-1" decimals="-6" id="f-177" unitRef="eur">166000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-4" decimals="-6" id="f-178" unitRef="eur">85000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-5" decimals="-6" id="f-179" unitRef="eur">-77000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax contextRef="c-1" decimals="-6" id="f-180" unitRef="eur">-5000000</sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax>
    <sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax contextRef="c-4" decimals="-6" id="f-181" unitRef="eur">6000000</sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax>
    <sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax contextRef="c-5" decimals="-6" id="f-182" unitRef="eur">21000000</sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax contextRef="c-1" decimals="-6" id="f-183" unitRef="eur">-3000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax contextRef="c-4" decimals="-6" id="f-184" unitRef="eur">1000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax contextRef="c-5" decimals="-6" id="f-185" unitRef="eur">-1000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax contextRef="c-1" decimals="-6" id="f-186" unitRef="eur">1040000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax contextRef="c-4" decimals="-6" id="f-187" unitRef="eur">-1057000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax contextRef="c-5" decimals="-6" id="f-188" unitRef="eur">-1540000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss contextRef="c-1" decimals="-6" id="f-189" unitRef="eur">-35000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss contextRef="c-4" decimals="-6" id="f-190" unitRef="eur">8000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss contextRef="c-5" decimals="-6" id="f-191" unitRef="eur">6000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-1" decimals="-6" id="f-192" unitRef="eur">1067000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-4" decimals="-6" id="f-193" unitRef="eur">-1058000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-5" decimals="-6" id="f-194" unitRef="eur">-1526000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-1" decimals="-6" id="f-195" unitRef="eur">1233000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-4" decimals="-6" id="f-196" unitRef="eur">-973000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-5" decimals="-6" id="f-197" unitRef="eur">-1603000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-6" id="f-198" unitRef="eur">3496000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-4" decimals="-6" id="f-199" unitRef="eur">2483000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-5" decimals="-6" id="f-200" unitRef="eur">3833000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="c-1" decimals="-6" id="f-201" unitRef="eur">3471000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="c-4" decimals="-6" id="f-202" unitRef="eur">2465000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="c-5" decimals="-6" id="f-203" unitRef="eur">3810000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-204" unitRef="eur">25000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="c-4" decimals="-6" id="f-205" unitRef="eur">18000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="c-5" decimals="-6" id="f-206" unitRef="eur">23000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:Equity contextRef="c-6" decimals="-6" id="f-207" unitRef="eur">2522000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-7" decimals="-6" id="f-208" unitRef="eur">125000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-8" decimals="-6" id="f-209" unitRef="eur">-706000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-9" decimals="-6" id="f-210" unitRef="eur">66734000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-10" decimals="-6" id="f-211" unitRef="eur">4658000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-11" decimals="-6" id="f-212" unitRef="eur">1451000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-12" decimals="-6" id="f-213" unitRef="eur">74784000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-13" decimals="-6" id="f-214" unitRef="eur">368000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-14" decimals="-6" id="f-215" unitRef="eur">75152000000</ifrs-full:Equity>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-15" decimals="-6" id="f-216" unitRef="eur">85000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-16" decimals="-6" id="f-217" unitRef="eur">-1050000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-17" decimals="-6" id="f-218" unitRef="eur">-965000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-18" decimals="-6" id="f-219" unitRef="eur">-8000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-4" decimals="-6" id="f-220" unitRef="eur">-973000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ProfitLoss contextRef="c-15" decimals="-6" id="f-221" unitRef="eur">3430000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-17" decimals="-6" id="f-222" unitRef="eur">3430000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-18" decimals="-6" id="f-223" unitRef="eur">26000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-4" decimals="-6" id="f-224" unitRef="eur">3456000000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome contextRef="c-15" decimals="-6" id="f-225" unitRef="eur">3515000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-16" decimals="-6" id="f-226" unitRef="eur">-1050000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-17" decimals="-6" id="f-227" unitRef="eur">2465000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-18" decimals="-6" id="f-228" unitRef="eur">18000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-4" decimals="-6" id="f-229" unitRef="eur">2483000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="c-4"
      decimals="INF"
      id="f-230"
      unitRef="eurPerShare">3.56</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-15" decimals="-6" id="f-231" unitRef="eur">4454000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-17" decimals="-6" id="f-232" unitRef="eur">4454000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-4" decimals="-6" id="f-233" unitRef="eur">4454000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-17" decimals="-6" id="f-234" unitRef="eur">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-18" decimals="-6" id="f-235" unitRef="eur">49000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-4" decimals="-6" id="f-236" unitRef="eur">49000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-19" decimals="-6" id="f-237" unitRef="eur">363000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-17" decimals="-6" id="f-238" unitRef="eur">363000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-4" decimals="-6" id="f-239" unitRef="eur">363000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-20" decimals="-6" id="f-240" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-21" decimals="-6" id="f-241" unitRef="eur">18000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-17" decimals="-6" id="f-242" unitRef="eur">18000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-4" decimals="-6" id="f-243" unitRef="eur">18000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-20" decimals="-6" id="f-244" unitRef="eur">3000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-21" decimals="-6" id="f-245" unitRef="eur">-3000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-19" decimals="-6" id="f-246" unitRef="eur">112000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-15" decimals="-6" id="f-247" unitRef="eur">-112000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-17" decimals="-6" id="f-248" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-4" decimals="-6" id="f-249" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-22" decimals="-6" id="f-250" unitRef="eur">160000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-17" decimals="-6" id="f-251" unitRef="eur">160000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-4" decimals="-6" id="f-252" unitRef="eur">160000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-22" decimals="-6" id="f-253" unitRef="eur">8000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-17" decimals="-6" id="f-254" unitRef="eur">8000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-4" decimals="-6" id="f-255" unitRef="eur">8000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-15" decimals="-6" id="f-256" unitRef="eur">2000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-17" decimals="-6" id="f-257" unitRef="eur">2000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-4" decimals="-6" id="f-258" unitRef="eur">2000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="c-15" decimals="-6" id="f-259" unitRef="eur">9000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="c-17" decimals="-6" id="f-260" unitRef="eur">9000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="c-18" decimals="-6" id="f-261" unitRef="eur">-19000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="c-4" decimals="-6" id="f-262" unitRef="eur">-10000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:Equity contextRef="c-23" decimals="-6" id="f-263" unitRef="eur">2525000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-24" decimals="-6" id="f-264" unitRef="eur">140000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-25" decimals="-6" id="f-265" unitRef="eur">-957000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-26" decimals="-6" id="f-266" unitRef="eur">65694000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-27" decimals="-6" id="f-267" unitRef="eur">4826000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-28" decimals="-6" id="f-268" unitRef="eur">401000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-29" decimals="-6" id="f-269" unitRef="eur">72629000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-30" decimals="-6" id="f-270" unitRef="eur">318000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-31" decimals="-6" id="f-271" unitRef="eur">72947000000</ifrs-full:Equity>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-32" decimals="-6" id="f-272" unitRef="eur">-162000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-33" decimals="-6" id="f-273" unitRef="eur">-463000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-34" decimals="-6" id="f-274" unitRef="eur">-625000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-35" decimals="-6" id="f-275" unitRef="eur">-5000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-36" decimals="-6" id="f-276" unitRef="eur">-630000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ProfitLoss contextRef="c-32" decimals="-6" id="f-277" unitRef="eur">1970000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-34" decimals="-6" id="f-278" unitRef="eur">1970000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-35" decimals="-6" id="f-279" unitRef="eur">10000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-36" decimals="-6" id="f-280" unitRef="eur">1980000000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome contextRef="c-32" decimals="-6" id="f-281" unitRef="eur">1808000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-33" decimals="-6" id="f-282" unitRef="eur">-463000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-34" decimals="-6" id="f-283" unitRef="eur">1345000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-35" decimals="-6" id="f-284" unitRef="eur">5000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-36" decimals="-6" id="f-285" unitRef="eur">1350000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-35" decimals="-6" id="f-286" unitRef="eur">10000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-36" decimals="-6" id="f-287" unitRef="eur">10000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-37" decimals="-6" id="f-288" unitRef="eur">230000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-34" decimals="-6" id="f-289" unitRef="eur">230000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-36" decimals="-6" id="f-290" unitRef="eur">230000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-38" decimals="-6" id="f-291" unitRef="eur">1000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-39" decimals="-6" id="f-292" unitRef="eur">18000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-34" decimals="-6" id="f-293" unitRef="eur">19000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-36" decimals="-6" id="f-294" unitRef="eur">19000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-40" decimals="-6" id="f-295" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-41" decimals="-6" id="f-296" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-42" decimals="-6" id="f-297" unitRef="eur">3000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-43" decimals="-6" id="f-298" unitRef="eur">-3000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-44" decimals="-6" id="f-299" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-38" decimals="-6" id="f-300" unitRef="eur">4000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-39" decimals="-6" id="f-301" unitRef="eur">155000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-34" decimals="-6" id="f-302" unitRef="eur">159000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-36" decimals="-6" id="f-303" unitRef="eur">159000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-45" decimals="-6" id="f-304" unitRef="eur">123000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-34" decimals="-6" id="f-305" unitRef="eur">123000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-36" decimals="-6" id="f-306" unitRef="eur">123000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-45" decimals="-6" id="f-307" unitRef="eur">-5000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-34" decimals="-6" id="f-308" unitRef="eur">-5000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-36" decimals="-6" id="f-309" unitRef="eur">-5000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <ifrs-full:Equity contextRef="c-46" decimals="-6" id="f-310" unitRef="eur">2530000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-47" decimals="-6" id="f-311" unitRef="eur">313000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-48" decimals="-6" id="f-312" unitRef="eur">-1184000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-49" decimals="-6" id="f-313" unitRef="eur">67499000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-50" decimals="-6" id="f-314" unitRef="eur">4944000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-51" decimals="-6" id="f-315" unitRef="eur">-62000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-52" decimals="-6" id="f-316" unitRef="eur">74040000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-53" decimals="-6" id="f-317" unitRef="eur">313000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-3" decimals="-6" id="f-318" unitRef="eur">74353000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-46" decimals="-6" id="f-319" unitRef="eur">2530000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-47" decimals="-6" id="f-320" unitRef="eur">313000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-48" decimals="-6" id="f-321" unitRef="eur">-1184000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-49" decimals="-6" id="f-322" unitRef="eur">67499000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-50" decimals="-6" id="f-323" unitRef="eur">4944000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-51" decimals="-6" id="f-324" unitRef="eur">-62000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-52" decimals="-6" id="f-325" unitRef="eur">74040000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-53" decimals="-6" id="f-326" unitRef="eur">313000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-3" decimals="-6" id="f-327" unitRef="eur">74353000000</ifrs-full:Equity>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-54" decimals="-6" id="f-328" unitRef="eur">166000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-55" decimals="-6" id="f-329" unitRef="eur">1059000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-56" decimals="-6" id="f-330" unitRef="eur">1225000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-57" decimals="-6" id="f-331" unitRef="eur">8000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-1" decimals="-6" id="f-332" unitRef="eur">1233000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ProfitLoss contextRef="c-54" decimals="-6" id="f-333" unitRef="eur">2246000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-56" decimals="-6" id="f-334" unitRef="eur">2246000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-57" decimals="-6" id="f-335" unitRef="eur">17000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-6" id="f-336" unitRef="eur">2263000000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome contextRef="c-54" decimals="-6" id="f-337" unitRef="eur">2412000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-55" decimals="-6" id="f-338" unitRef="eur">1059000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-56" decimals="-6" id="f-339" unitRef="eur">3471000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-57" decimals="-6" id="f-340" unitRef="eur">25000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-6" id="f-341" unitRef="eur">3496000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="c-1"
      decimals="INF"
      id="f-342"
      unitRef="eurPerShare">3.76</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-54" decimals="-6" id="f-343" unitRef="eur">4704000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-56" decimals="-6" id="f-344" unitRef="eur">4704000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-1" decimals="-6" id="f-345" unitRef="eur">4704000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-56" decimals="-6" id="f-346" unitRef="eur">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-57" decimals="-6" id="f-347" unitRef="eur">31000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-348" unitRef="eur">31000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-58" decimals="-6" id="f-349" unitRef="eur">302000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-56" decimals="-6" id="f-350" unitRef="eur">302000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-1" decimals="-6" id="f-351" unitRef="eur">302000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-59" decimals="-6" id="f-352" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-60" decimals="-6" id="f-353" unitRef="eur">7000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-56" decimals="-6" id="f-354" unitRef="eur">7000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-1" decimals="-6" id="f-355" unitRef="eur">7000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-59" decimals="-6" id="f-356" unitRef="eur">3000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-60" decimals="-6" id="f-357" unitRef="eur">-3000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-58" decimals="-6" id="f-358" unitRef="eur">115000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-54" decimals="-6" id="f-359" unitRef="eur">-115000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-56" decimals="-6" id="f-360" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-1" decimals="-6" id="f-361" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-61" decimals="-6" id="f-362" unitRef="eur">173000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-56" decimals="-6" id="f-363" unitRef="eur">173000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-1" decimals="-6" id="f-364" unitRef="eur">173000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-61" decimals="-6" id="f-365" unitRef="eur">4000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-56" decimals="-6" id="f-366" unitRef="eur">4000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-1" decimals="-6" id="f-367" unitRef="eur">4000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-54" decimals="-6" id="f-368" unitRef="eur">1000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-56" decimals="-6" id="f-369" unitRef="eur">1000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-1" decimals="-6" id="f-370" unitRef="eur">1000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <ifrs-full:Equity contextRef="c-62" decimals="-6" id="f-371" unitRef="eur">2533000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-63" decimals="-6" id="f-372" unitRef="eur">317000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-64" decimals="-6" id="f-373" unitRef="eur">-1371000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-65" decimals="-6" id="f-374" unitRef="eur">65093000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-66" decimals="-6" id="f-375" unitRef="eur">5121000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-67" decimals="-6" id="f-376" unitRef="eur">997000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-68" decimals="-6" id="f-377" unitRef="eur">72690000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-69" decimals="-6" id="f-378" unitRef="eur">307000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-2" decimals="-6" id="f-379" unitRef="eur">72997000000</ifrs-full:Equity>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c-1" decimals="-6" id="f-380" unitRef="eur">2246000000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c-4" decimals="-6" id="f-381" unitRef="eur">3430000000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c-5" decimals="-6" id="f-382" unitRef="eur">5400000000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-383" unitRef="eur">17000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-4" decimals="-6" id="f-384" unitRef="eur">26000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-5" decimals="-6" id="f-385" unitRef="eur">36000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod contextRef="c-1" decimals="-6" id="f-386" unitRef="eur">-110000000</ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod contextRef="c-4" decimals="-6" id="f-387" unitRef="eur">-196000000</ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod contextRef="c-5" decimals="-6" id="f-388" unitRef="eur">-295000000</ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod>
    <sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset contextRef="c-1" decimals="-6" id="f-389" unitRef="eur">1445000000</sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset>
    <sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset contextRef="c-4" decimals="-6" id="f-390" unitRef="eur">1838000000</sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset>
    <sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset contextRef="c-5" decimals="-6" id="f-391" unitRef="eur">4792000000</sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c-1" decimals="-6" id="f-392" unitRef="eur">-279000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c-4" decimals="-6" id="f-393" unitRef="eur">-307000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c-5" decimals="-6" id="f-394" unitRef="eur">-509000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForDeferredTaxExpense contextRef="c-1" decimals="-6" id="f-395" unitRef="eur">-780000000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <ifrs-full:AdjustmentsForDeferredTaxExpense contextRef="c-4" decimals="-6" id="f-396" unitRef="eur">-446000000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <ifrs-full:AdjustmentsForDeferredTaxExpense contextRef="c-5" decimals="-6" id="f-397" unitRef="eur">-970000000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-1" decimals="-6" id="f-398" unitRef="eur">1087000000</sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-4" decimals="-6" id="f-399" unitRef="eur">-716000000</sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-5" decimals="-6" id="f-400" unitRef="eur">-136000000</sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-1" decimals="-6" id="f-401" unitRef="eur">173000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-4" decimals="-6" id="f-402" unitRef="eur">160000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-5" decimals="-6" id="f-403" unitRef="eur">283000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue contextRef="c-1" decimals="-6" id="f-404" unitRef="eur">19000000</sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue>
    <sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue contextRef="c-4" decimals="-6" id="f-405" unitRef="eur">5000000</sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue>
    <sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue contextRef="c-5" decimals="-6" id="f-406" unitRef="eur">20000000</sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="c-1" decimals="-6" id="f-407" unitRef="eur">26000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="c-4" decimals="-6" id="f-408" unitRef="eur">196000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="c-5" decimals="-6" id="f-409" unitRef="eur">283000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-1" decimals="-6" id="f-410" unitRef="eur">4064000000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-4" decimals="-6" id="f-411" unitRef="eur">4382000000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-5" decimals="-6" id="f-412" unitRef="eur">9494000000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c-1" decimals="-6" id="f-413" unitRef="eur">-886000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c-4" decimals="-6" id="f-414" unitRef="eur">-1174000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c-5" decimals="-6" id="f-415" unitRef="eur">-840000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-1" decimals="-6" id="f-416" unitRef="eur">14000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-4" decimals="-6" id="f-417" unitRef="eur">-215000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-5" decimals="-6" id="f-418" unitRef="eur">-397000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c-1" decimals="-6" id="f-419" unitRef="eur">82000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c-4" decimals="-6" id="f-420" unitRef="eur">497000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c-5" decimals="-6" id="f-421" unitRef="eur">402000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities contextRef="c-1" decimals="-6" id="f-422" unitRef="eur">-1851000000</sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities>
    <sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities contextRef="c-4" decimals="-6" id="f-423" unitRef="eur">73000000</sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities>
    <sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities contextRef="c-5" decimals="-6" id="f-424" unitRef="eur">1599000000</sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-1" decimals="-6" id="f-425" unitRef="eur">1423000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-4" decimals="-6" id="f-426" unitRef="eur">3563000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-5" decimals="-6" id="f-427" unitRef="eur">10258000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-1" decimals="-6" id="f-428" unitRef="eur">1886000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-4" decimals="-6" id="f-429" unitRef="eur">930000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-5" decimals="-6" id="f-430" unitRef="eur">3024000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-1" decimals="-6" id="f-431" unitRef="eur">1885000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-4" decimals="-6" id="f-432" unitRef="eur">2465000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-5" decimals="-6" id="f-433" unitRef="eur">3870000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-1" decimals="-6" id="f-434" unitRef="eur">208000000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-4" decimals="-6" id="f-435" unitRef="eur">56000000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-5" decimals="-6" id="f-436" unitRef="eur">134000000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-1" decimals="-6" id="f-437" unitRef="eur">607000000</ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-4" decimals="-6" id="f-438" unitRef="eur">578000000</ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-5" decimals="-6" id="f-439" unitRef="eur">1015000000</ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-1" decimals="-6" id="f-440" unitRef="eur">0</ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-4" decimals="-6" id="f-441" unitRef="eur">15000000</ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-5" decimals="-6" id="f-442" unitRef="eur">42000000</ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <sny:NetChangeInOtherNonCurrentAssets contextRef="c-1" decimals="-6" id="f-443" unitRef="eur">-41000000</sny:NetChangeInOtherNonCurrentAssets>
    <sny:NetChangeInOtherNonCurrentAssets contextRef="c-4" decimals="-6" id="f-444" unitRef="eur">-215000000</sny:NetChangeInOtherNonCurrentAssets>
    <sny:NetChangeInOtherNonCurrentAssets contextRef="c-5" decimals="-6" id="f-445" unitRef="eur">-229000000</sny:NetChangeInOtherNonCurrentAssets>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-1" decimals="-6" id="f-446" unitRef="eur">-3413000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-4" decimals="-6" id="f-447" unitRef="eur">-3073000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-5" decimals="-6" id="f-448" unitRef="eur">-6200000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-1" decimals="-6" id="f-449" unitRef="eur">21000000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-4" decimals="-6" id="f-450" unitRef="eur">31000000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-5" decimals="-6" id="f-451" unitRef="eur">195000000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="c-1" decimals="-6" id="f-452" unitRef="eur">4704000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="c-4" decimals="-6" id="f-453" unitRef="eur">4454000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="c-5" decimals="-6" id="f-454" unitRef="eur">4454000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities contextRef="c-1" decimals="-6" id="f-455" unitRef="eur">31000000</ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities contextRef="c-4" decimals="-6" id="f-456" unitRef="eur">49000000</ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities contextRef="c-5" decimals="-6" id="f-457" unitRef="eur">61000000</ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries contextRef="c-1" decimals="-6" id="f-458" unitRef="eur">0</ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries>
    <ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries contextRef="c-4" decimals="-6" id="f-459" unitRef="eur">3000000</ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries>
    <ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries contextRef="c-5" decimals="-6" id="f-460" unitRef="eur">3000000</ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries>
    <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="c-1" decimals="-6" id="f-461" unitRef="eur">0</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="c-4" decimals="-6" id="f-462" unitRef="eur">0</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="c-5" decimals="-6" id="f-463" unitRef="eur">48000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="c-1" decimals="-6" id="f-464" unitRef="eur">637000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="c-4" decimals="-6" id="f-465" unitRef="eur">2680000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="c-5" decimals="-6" id="f-466" unitRef="eur">3684000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-1" decimals="-6" id="f-467" unitRef="eur">144000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-4" decimals="-6" id="f-468" unitRef="eur">127000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-5" decimals="-6" id="f-469" unitRef="eur">265000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments contextRef="c-1" decimals="-6" id="f-470" unitRef="eur">5886000000</sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments>
    <sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments contextRef="c-4" decimals="-6" id="f-471" unitRef="eur">2431000000</sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments>
    <sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments contextRef="c-5" decimals="-6" id="f-472" unitRef="eur">765000000</sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="c-1" decimals="-6" id="f-473" unitRef="eur">302000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="c-4" decimals="-6" id="f-474" unitRef="eur">363000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="c-5" decimals="-6" id="f-475" unitRef="eur">593000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-1" decimals="-6" id="f-476" unitRef="eur">89000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-4" decimals="-6" id="f-477" unitRef="eur">-5214000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-5" decimals="-6" id="f-478" unitRef="eur">-8052000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-1" decimals="-6" id="f-479" unitRef="eur">-14000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-4" decimals="-6" id="f-480" unitRef="eur">-19000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-5" decimals="-6" id="f-481" unitRef="eur">-32000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-1" decimals="-6" id="f-482" unitRef="eur">-1915000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-4" decimals="-6" id="f-483" unitRef="eur">-4743000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-5" decimals="-6" id="f-484" unitRef="eur">-4026000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-6" id="f-485" unitRef="eur">8710000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-14" decimals="-6" id="f-486" unitRef="eur">12736000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-14" decimals="-6" id="f-487" unitRef="eur">12736000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-2" decimals="-6" id="f-488" unitRef="eur">6795000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-31" decimals="-6" id="f-489" unitRef="eur">7993000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-6" id="f-490" unitRef="eur">8710000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="c-1" decimals="-6" id="f-491" unitRef="eur">1434000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="c-4" decimals="-6" id="f-492" unitRef="eur">1431000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="c-5" decimals="-6" id="f-493" unitRef="eur">2623000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c-1" decimals="-6" id="f-494" unitRef="eur">320000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c-4" decimals="-6" id="f-495" unitRef="eur">234000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c-5" decimals="-6" id="f-496" unitRef="eur">559000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c-1" decimals="-6" id="f-497" unitRef="eur">261000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c-4" decimals="-6" id="f-498" unitRef="eur">262000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c-5" decimals="-6" id="f-499" unitRef="eur">547000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities contextRef="c-1" decimals="-6" id="f-500" unitRef="eur">0</sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities>
    <sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities contextRef="c-4" decimals="-6" id="f-501" unitRef="eur">8000000</sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities>
    <sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities contextRef="c-5" decimals="-6" id="f-502" unitRef="eur">17000000</sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities>
    <sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments contextRef="c-70" decimals="-6" id="f-503" unitRef="eur">6060000000</sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments>
    <sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments contextRef="c-71" decimals="-6" id="f-504" unitRef="eur">2630000000</sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments>
    <sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments contextRef="c-72" decimals="-6" id="f-505" unitRef="eur">946000000</sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="c-1" id="f-506">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%"&gt;INTRODUCTION&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi, together with its subsidiaries (collectively &#x201c;Sanofi&#x201d;, &#x201c;the Group&#x201d; or &#x201c;the Company&#x201d;), is a global healthcare leader engaged in the research, development and marketing of therapeutic solutions focused on patient needs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi is listed in Paris (Euronext: SAN) and New&#160;York (Nasdaq: SNY). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements for the six months ended June 30, 2024 were reviewed by the Sanofi Board of Directors at the Board meeting on July 24, 2024.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="c-1" id="f-507">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%"&gt;A/ BASIS OF PREPARATION OF THE HALF-YEAR FINANCIAL STATEMENTS AND ACCOUNTING POLICIES&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;A.1. INTERNATIONAL FINANCIAL REPORTING STANDARDS (IFRS)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS 34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The accounting policies used in the preparation of the consolidated financial statements as of June&#160;30,&#160;2024 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2024 are available via the following web link: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;https://www.efrag.org/Endorsement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The accounting policies applied effective January 1, 2024 are identical to those presented in the consolidated financial statements for the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On September&#160;22, 2022, the IASB issued an amendment to IFRS&#160;16 (Leases) relating to lease liabilities in a sale-and-leaseback arrangement, which is applicable from January 1, 2024 and had no impact on Sanofi's financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On January&#160;23, 2020, the IASB issued &#x201c;Classification of Liabilities as Current or Non-current&#x201d;, an amendment to IAS&#160;1, and then on&#160;October&#160;31, 2022 issued &#x201c;Non-current Liabilities with Covenants&#x201d;, a further amendment to IAS&#160;1. The amendments, which are applicable from January&#160;1, 2024, had no impact on Sanofi's financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On May&#160;25, 2023, the IASB issued "Supplier Finance Arrangements", an amendment to IAS&#160;7 and IFRS&#160;7, applicable from January&#160;1, 2024. The &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;amendment relates to disclosures of information about such arrangements; it had no impact on the 2024 half-year financial statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As a reminder, in its 2023 consolidated financial statements Sanofi applied &#x201c;International Tax Reform &#x2013; Pillar Two Model Rules&#x201d;, an amendment to&#160;IAS&#160;12 issued by the IASB on May 23, 2023, and did not recognize any deferred tax on temporary differences related to Pillar 2 rules. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In its 2024 half-year financial statements, Sanofi has used an average effective tax rate that takes into account the top-up tax applicable from January 1, 2024 (see Note B.19.). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;A.2. USE OF ESTIMATES&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;impairment of property, plant and equipment and intangible assets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the valuation of goodwill and the valuation and useful life of acquired intangible assets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the measurement of contingent consideration receivable in connection with asset divestments and of contingent consideration payable;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the measurement of financial assets and financial liabilities at amortized cost;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the amount of post-employment benefit obligations;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Actual results could differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For half-year financial reporting purposes, and as allowed under IAS 34, Sanofi has determined income tax expense on the basis of an estimate of the effective tax rate for the full financial year. That rate is applied to business operating income plus financial income and minus financial expenses, and before (i) the share of profit/loss of investments accounted for using the equity method and (ii) net income attributable to non-controlling interests. The estimated full-year effective tax rate is based on the tax rates that will be applicable to projected pre-tax profits or losses arising in the various tax jurisdictions in which Sanofi operates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;A.3. SEASONAL TRENDS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi&#x2019;s activities are not subject to significant seasonal fluctuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;A.4. CONSOLIDATION AND FOREIGN CURRENCY TRANSLATION OF THE FINANCIAL STATEMENTS OF SUBSIDIARIES IN HYPERINFLATIONARY ECONOMIES&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2024, Sanofi continues to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS&#160;10 (Consolidated Financial Statements) are still met.The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since July&#160;1, 2018 treated Argentina as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In Turkey, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since January&#160;1, 2022 treated Turkey as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;A.5. FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;Level 3: valuation techniques in which not all important inputs are derived from observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.161%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.814%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.880%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.880%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.880%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.885%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:0.85pt;padding-right:0.85pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Type of financial&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:0.85pt;padding-right:0.85pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;instrument&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;principle&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level in fair value hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Method used to determine fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Market data&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Volatilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value (quoted equity instruments)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value (quoted debt instruments)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value (unquoted equity instruments)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost/ Peer comparison (primarily)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets at fair value (contingent consideration receivable)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2021.&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term loans and advances and other non-current receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value held to meet obligations under post-employment benefit plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Financial assets designated at fair value held to meet obligations under deferred compensation plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments in mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net asset value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Negotiable debt instruments, commercial paper, instant access deposits and term deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;br/&gt;B.12.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial Debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Amortized cost &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Future lease payments are discounted using the incremental borrowing rate.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid Money Market&lt;br/&gt;&amp;gt;&#160;1 year:&#160;Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&amp;lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&amp;gt;&#160;1 year: Mid Zero Coupon&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&amp;lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&amp;gt;&#160;1 year: Mid Zero Coupon&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.11.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;A.6. NEW PRONOUNCEMENTS ISSUED BY THE IASB AND APPLICABLE FROM 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On August&#160;15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS&#160;21 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(The Effects of Changes in Foreign Exchange Rates), relating to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; how to determine the exchange rate when a currency is not exchangeable. The amendment is applicable from January&#160;1, 2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; (subject to endorsement by the European Union); it&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; will not have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027 (subject to endorsement by the European Union). An impact assessment is currently under way. Sanofi will not early adopt this new standard.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments, applicable no earlier than January 1, 2026 (subject to endorsement by the European Union). Sanofi does not expect any material impact, and will not early adopt these amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On July 18, 2024, the IASB issued Volume 11 of &#x201c;Annual Improvements to IFRS&#x201d;, applicable from January 1, 2026 (subject to endorsement by the European Union). Sanofi does not expect any material impact from those improvements to various standards, which are essentially in the nature of clarifications, and will not early adopt them.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:StatementOfIFRSCompliance contextRef="c-1" id="f-508">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;A.1. INTERNATIONAL FINANCIAL REPORTING STANDARDS (IFRS)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS 34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The accounting policies used in the preparation of the consolidated financial statements as of June&#160;30,&#160;2024 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2024 are available via the following web link: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;https://www.efrag.org/Endorsement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The accounting policies applied effective January 1, 2024 are identical to those presented in the consolidated financial statements for the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On September&#160;22, 2022, the IASB issued an amendment to IFRS&#160;16 (Leases) relating to lease liabilities in a sale-and-leaseback arrangement, which is applicable from January 1, 2024 and had no impact on Sanofi's financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On January&#160;23, 2020, the IASB issued &#x201c;Classification of Liabilities as Current or Non-current&#x201d;, an amendment to IAS&#160;1, and then on&#160;October&#160;31, 2022 issued &#x201c;Non-current Liabilities with Covenants&#x201d;, a further amendment to IAS&#160;1. The amendments, which are applicable from January&#160;1, 2024, had no impact on Sanofi's financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On May&#160;25, 2023, the IASB issued "Supplier Finance Arrangements", an amendment to IAS&#160;7 and IFRS&#160;7, applicable from January&#160;1, 2024. The &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;amendment relates to disclosures of information about such arrangements; it had no impact on the 2024 half-year financial statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As a reminder, in its 2023 consolidated financial statements Sanofi applied &#x201c;International Tax Reform &#x2013; Pillar Two Model Rules&#x201d;, an amendment to&#160;IAS&#160;12 issued by the IASB on May 23, 2023, and did not recognize any deferred tax on temporary differences related to Pillar 2 rules. &lt;/span&gt;&lt;/div&gt;In its 2024 half-year financial statements, Sanofi has used an average effective tax rate that takes into account the top-up tax applicable from January 1, 2024 (see Note B.19.).</ifrs-full:StatementOfIFRSCompliance>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="c-1" id="f-509">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;A.2. USE OF ESTIMATES&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;impairment of property, plant and equipment and intangible assets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the valuation of goodwill and the valuation and useful life of acquired intangible assets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the measurement of contingent consideration receivable in connection with asset divestments and of contingent consideration payable;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the measurement of financial assets and financial liabilities at amortized cost;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the amount of post-employment benefit obligations;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Actual results could differ from these estimates.&lt;/span&gt;&lt;/div&gt;For half-year financial reporting purposes, and as allowed under IAS 34, Sanofi has determined income tax expense on the basis of an estimate of the effective tax rate for the full financial year. That rate is applied to business operating income plus financial income and minus financial expenses, and before (i) the share of profit/loss of investments accounted for using the equity method and (ii) net income attributable to non-controlling interests. The estimated full-year effective tax rate is based on the tax rates that will be applicable to projected pre-tax profits or losses arising in the various tax jurisdictions in which Sanofi operates.</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <sny:SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock contextRef="c-1" id="f-510">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;A.3. SEASONAL TRENDS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi&#x2019;s activities are not subject to significant seasonal fluctuations.&lt;/span&gt;&lt;/div&gt;</sny:SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock>
    <ifrs-full:DisclosureOfHyperinflationaryReportingExplanatory contextRef="c-1" id="f-511">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;A.4. CONSOLIDATION AND FOREIGN CURRENCY TRANSLATION OF THE FINANCIAL STATEMENTS OF SUBSIDIARIES IN HYPERINFLATIONARY ECONOMIES&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2024, Sanofi continues to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS&#160;10 (Consolidated Financial Statements) are still met.The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since July&#160;1, 2018 treated Argentina as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In Turkey, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since January&#160;1, 2022 treated Turkey as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfHyperinflationaryReportingExplanatory>
    <sny:CumulativeConsumerPriceInflationRateOverTheLastThreeYears contextRef="c-73" decimals="2" id="f-512" unitRef="number">1</sny:CumulativeConsumerPriceInflationRateOverTheLastThreeYears>
    <sny:CumulativeConsumerPriceInflationRateOverTheLastThreeYears contextRef="c-74" decimals="2" id="f-513" unitRef="number">1</sny:CumulativeConsumerPriceInflationRateOverTheLastThreeYears>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="c-1" id="f-514">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;A.5. FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;Level 3: valuation techniques in which not all important inputs are derived from observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.161%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.814%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.880%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.880%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.880%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.885%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:0.85pt;padding-right:0.85pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Type of financial&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:0.85pt;padding-right:0.85pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;instrument&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;principle&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level in fair value hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Method used to determine fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Market data&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Volatilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value (quoted equity instruments)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value (quoted debt instruments)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value (unquoted equity instruments)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost/ Peer comparison (primarily)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets at fair value (contingent consideration receivable)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2021.&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term loans and advances and other non-current receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value held to meet obligations under post-employment benefit plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Financial assets designated at fair value held to meet obligations under deferred compensation plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments in mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net asset value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Negotiable debt instruments, commercial paper, instant access deposits and term deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;br/&gt;B.12.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial Debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Amortized cost &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Future lease payments are discounted using the incremental borrowing rate.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid Money Market&lt;br/&gt;&amp;gt;&#160;1 year:&#160;Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&amp;lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&amp;gt;&#160;1 year: Mid Zero Coupon&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&amp;lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&amp;gt;&#160;1 year: Mid Zero Coupon&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.11.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory contextRef="c-1" id="f-515">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.161%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.814%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.880%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.880%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.880%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.885%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:0.85pt;padding-right:0.85pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Type of financial&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:0.85pt;padding-right:0.85pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;instrument&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;principle&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level in fair value hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Method used to determine fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Market data&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Volatilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value (quoted equity instruments)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value (quoted debt instruments)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value (unquoted equity instruments)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost/ Peer comparison (primarily)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets at fair value (contingent consideration receivable)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2021.&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term loans and advances and other non-current receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value held to meet obligations under post-employment benefit plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:1.7pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Financial assets designated at fair value held to meet obligations under deferred compensation plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments in mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net asset value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Negotiable debt instruments, commercial paper, instant access deposits and term deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;br/&gt;B.12.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial Debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Amortized cost &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:5.35pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Future lease payments are discounted using the incremental borrowing rate.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid Money Market&lt;br/&gt;&amp;gt;&#160;1 year:&#160;Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&amp;lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&amp;gt;&#160;1 year: Mid Zero Coupon&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&amp;lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-right:-1.62pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&amp;gt;&#160;1 year: Mid Zero Coupon&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.11.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations contextRef="c-1" id="f-516">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;A.6. NEW PRONOUNCEMENTS ISSUED BY THE IASB AND APPLICABLE FROM 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On August&#160;15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS&#160;21 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(The Effects of Changes in Foreign Exchange Rates), relating to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; how to determine the exchange rate when a currency is not exchangeable. The amendment is applicable from January&#160;1, 2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; (subject to endorsement by the European Union); it&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; will not have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027 (subject to endorsement by the European Union). An impact assessment is currently under way. Sanofi will not early adopt this new standard.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments, applicable no earlier than January 1, 2026 (subject to endorsement by the European Union). Sanofi does not expect any material impact, and will not early adopt these amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On July 18, 2024, the IASB issued Volume 11 of &#x201c;Annual Improvements to IFRS&#x201d;, applicable from January 1, 2026 (subject to endorsement by the European Union). Sanofi does not expect any material impact from those improvements to various standards, which are essentially in the nature of clarifications, and will not early adopt them.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
    <sny:AgreementsRelatingToTheRecombinantCOVID19VaccineCandidatePolicyPolicyTextBlock contextRef="c-1" id="f-517" xsi:nil="true"/>
    <sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock contextRef="c-1" id="f-518">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.1. PRINCIPAL CHANGES IN SCOPE OF CONSOLIDATION IN THE PERIOD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of Inhibrx, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On May 30, 2024, Sanofi completed the acquisition of Inhibrx, Inc (&#x201c;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Inhibrx&#x201d;), adding &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;SAR447537 (formerly INBRX-101) to Sanofi&#x2019;s rare disease pipeline. SAR447537 is a human recombinant protein that holds the promise of allowing alpha-1 antitrypsin deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing. AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lungs with progressive tissue deterioration. SAR447537 may help to reduce inflammation and prevent further deterioration of lung function in affected individuals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The transaction did not meet the criteria for a business combination under IFRS 3, and consequently was accounted for as an acquisition of a group of assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The acquisition price was $2,035&#160;million. Of that amount (plus acquisition-related costs), $1,908&#160;million was allocated to in-process development in respect of SAR447537, and recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in accordance with IAS 38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed in the transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In addition, Sanofi awarded the former shareholders of Inhibrx an unquoted, non-negotiable Contingent Value Right (CVR) certificate that entitles them to a deferred cash payment of $5.00 per Inhibrx share, subject to attainment of a regulatory milestone before June 30, 2027. The nominal value of that commitment is $300&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The impact of this acquisition, as reflected within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions of consolidated undertakings and investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the consolidated statement of cash flows, is a net cash outflow of $2,035&#160;million.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock>
    <ifrs-full:NameOfAcquiree contextRef="c-1" id="f-519">Inhibrx, Inc</ifrs-full:NameOfAcquiree>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="c-75" decimals="-6" id="f-520" unitRef="usd">2035000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="c-75" decimals="-6" id="f-521" unitRef="usd">1908000000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <sny:AssetsAcquisitionPurchasePricePerShare
      contextRef="c-75"
      decimals="INF"
      id="f-522"
      unitRef="usdPerShare">5.00</sny:AssetsAcquisitionPurchasePricePerShare>
    <sny:AssetsAcquisitionNominalValue contextRef="c-75" decimals="-6" id="f-523" unitRef="eur">300000000</sny:AssetsAcquisitionNominalValue>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-76" decimals="-6" id="f-524" unitRef="usd">2035000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-525">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.2. PROPERTY, PLANT AND EQUIPMENT&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;591&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,693&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Biopharma &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;Of which Manufacturing &amp;amp; Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Of which Manufacturing &amp;amp; Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:700;line-height:100%"&gt;Of which capitalized interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:700;line-height:100%"&gt;26&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Firm orders for property, plant and equipment stood at &#x20ac;659&#160;million as of June 30, 2024.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock contextRef="c-1" id="f-526">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;591&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,693&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Biopharma &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;Of which Manufacturing &amp;amp; Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Of which Manufacturing &amp;amp; Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:700;line-height:100%"&gt;Of which capitalized interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:700;line-height:100%"&gt;26&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-527" unitRef="eur">591000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-5" decimals="-6" id="f-528" unitRef="eur">1693000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-77" decimals="-6" id="f-529" unitRef="eur">535000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-78" decimals="-6" id="f-530" unitRef="eur">1592000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-79" decimals="-6" id="f-531" unitRef="eur">366000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-80" decimals="-6" id="f-532" unitRef="eur">1188000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-81" decimals="-6" id="f-533" unitRef="eur">56000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-82" decimals="-6" id="f-534" unitRef="eur">101000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-83" decimals="-6" id="f-535" unitRef="eur">41000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-84" decimals="-6" id="f-536" unitRef="eur">90000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:InterestCostsCapitalised contextRef="c-1" decimals="-6" id="f-537" unitRef="eur">22000000</ifrs-full:InterestCostsCapitalised>
    <ifrs-full:InterestCostsCapitalised contextRef="c-5" decimals="-6" id="f-538" unitRef="eur">26000000</ifrs-full:InterestCostsCapitalised>
    <sny:FirmOrdersOfPropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-539" unitRef="eur">659000000</sny:FirmOrdersOfPropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory contextRef="c-1" id="f-540">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.3. GOODWILL AND OTHER INTANGIBLE ASSETS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Goodwill amounted to &#x20ac;50,080&#160;million as of June 30, 2024, versus &#x20ac;49,404 million as of December&#160;31, 2023. The movement during the period was mainly due to the impact of changes in exchange rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements in other intangible assets during the first half of 2024 were as follows:&lt;br/&gt;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.267%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.058%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.058%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.058%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.059%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Acquired R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Products, trademarks and other rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross value at January&#160;1, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;9,772&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;73,733&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,808&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;85,313&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross value at June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;12,298&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;74,969&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,848&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;89,115&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Accumulated amortization and impairment at January&#160;1, 2024 &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(3,734)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(55,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(60,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,136)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment losses, net of reversals &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(701)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(775)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Accumulated amortization and impairment at June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(3,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(57,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(62,462)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Carrying amount at January&#160;1, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;6,038&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;17,825&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;456&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;24,319&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Carrying amount at June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;8,530&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;17,678&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;445&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;26,653&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Impact of the acquisition of Inhibrx, Inc (see Note B.1.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;See Note B.4. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Acquisitions of other intangible assets (excluding software) in the first half of 2024 totale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;d &#x20ac;772 million, including &#x20ac;463 million&#160;related to the agreements entered into between Sanofi and Novavax in May 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x201c;Products, trademarks and other products&#x201d; mainly comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;marketed products, with a carrying amount of &#x20ac;16.3 bil&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;lion as of June 30, 2024 (versus &#x20ac;16.6 billion as of December 31, 2023) and a weighted average amortization period of approximately 11 years; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;technological platforms brought into service, with a carrying amou&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;nt of &#x20ac;1.4 billion as&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; (versus &#x20ac;1.2 billion as of December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) and a weighted average amortization period of approximately 18 years.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory>
    <ifrs-full:Goodwill contextRef="c-2" decimals="-6" id="f-541" unitRef="eur">50080000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-3" decimals="-6" id="f-542" unitRef="eur">49404000000</ifrs-full:Goodwill>
    <sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock contextRef="c-1" id="f-543">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements in other intangible assets during the first half of 2024 were as follows:&lt;br/&gt;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.267%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.058%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.058%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.058%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.059%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Acquired R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Products, trademarks and other rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross value at January&#160;1, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;9,772&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;73,733&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,808&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;85,313&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross value at June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;12,298&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;74,969&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,848&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;89,115&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Accumulated amortization and impairment at January&#160;1, 2024 &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(3,734)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(55,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(60,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,136)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment losses, net of reversals &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(701)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(775)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Accumulated amortization and impairment at June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(3,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(57,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(62,462)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Carrying amount at January&#160;1, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;6,038&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;17,825&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;456&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;24,319&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Carrying amount at June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;8,530&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;17,678&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;445&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;26,653&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Impact of the acquisition of Inhibrx, Inc (see Note B.1.).&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;See Note B.4.</sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-85" decimals="-6" id="f-544" unitRef="eur">9772000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-86" decimals="-6" id="f-545" unitRef="eur">73733000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-87" decimals="-6" id="f-546" unitRef="eur">1808000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-88" decimals="-6" id="f-547" unitRef="eur">85313000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-89" decimals="-6" id="f-548" unitRef="eur">1766000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-90" decimals="-6" id="f-549" unitRef="eur">0</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-91" decimals="-6" id="f-550" unitRef="eur">0</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-92" decimals="-6" id="f-551" unitRef="eur">1766000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-89" decimals="-6" id="f-552" unitRef="eur">571000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-90" decimals="-6" id="f-553" unitRef="eur">201000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-91" decimals="-6" id="f-554" unitRef="eur">41000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-92" decimals="-6" id="f-555" unitRef="eur">813000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-89" decimals="-6" id="f-556" unitRef="eur">-49000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-90" decimals="-6" id="f-557" unitRef="eur">-27000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-91" decimals="-6" id="f-558" unitRef="eur">-7000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-92" decimals="-6" id="f-559" unitRef="eur">-83000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-89" decimals="-6" id="f-560" unitRef="eur">236000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-90" decimals="-6" id="f-561" unitRef="eur">1050000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-91" decimals="-6" id="f-562" unitRef="eur">7000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-92" decimals="-6" id="f-563" unitRef="eur">1293000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-89" decimals="-6" id="f-564" unitRef="eur">2000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-90" decimals="-6" id="f-565" unitRef="eur">12000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-91" decimals="-6" id="f-566" unitRef="eur">-1000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-92" decimals="-6" id="f-567" unitRef="eur">13000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-93" decimals="-6" id="f-568" unitRef="eur">12298000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-94" decimals="-6" id="f-569" unitRef="eur">74969000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-95" decimals="-6" id="f-570" unitRef="eur">1848000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-96" decimals="-6" id="f-571" unitRef="eur">89115000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-97" decimals="-6" id="f-572" unitRef="eur">-3734000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-98" decimals="-6" id="f-573" unitRef="eur">-55908000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-99" decimals="-6" id="f-574" unitRef="eur">-1352000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-100" decimals="-6" id="f-575" unitRef="eur">-60994000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-101" decimals="-6" id="f-576" unitRef="eur">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-102" decimals="-6" id="f-577" unitRef="eur">-1084000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-103" decimals="-6" id="f-578" unitRef="eur">-52000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-104" decimals="-6" id="f-579" unitRef="eur">-1136000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-101" decimals="-6" id="f-580" unitRef="eur">-13000000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-102" decimals="-6" id="f-581" unitRef="eur">379000000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-103" decimals="-6" id="f-582" unitRef="eur">0</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-104" decimals="-6" id="f-583" unitRef="eur">366000000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-101" decimals="-6" id="f-584" unitRef="eur">49000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-102" decimals="-6" id="f-585" unitRef="eur">27000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-103" decimals="-6" id="f-586" unitRef="eur">6000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-104" decimals="-6" id="f-587" unitRef="eur">82000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-101" decimals="-6" id="f-588" unitRef="eur">-70000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-102" decimals="-6" id="f-589" unitRef="eur">-701000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-103" decimals="-6" id="f-590" unitRef="eur">-4000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-104" decimals="-6" id="f-591" unitRef="eur">-775000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-101" decimals="-6" id="f-592" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-102" decimals="-6" id="f-593" unitRef="eur">-4000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-103" decimals="-6" id="f-594" unitRef="eur">-1000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-104" decimals="-6" id="f-595" unitRef="eur">-5000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-105" decimals="-6" id="f-596" unitRef="eur">-3768000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-106" decimals="-6" id="f-597" unitRef="eur">-57291000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-107" decimals="-6" id="f-598" unitRef="eur">-1403000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-108" decimals="-6" id="f-599" unitRef="eur">-62462000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-109" decimals="-6" id="f-600" unitRef="eur">6038000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-110" decimals="-6" id="f-601" unitRef="eur">17825000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-111" decimals="-6" id="f-602" unitRef="eur">456000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-3" decimals="-6" id="f-603" unitRef="eur">24319000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:OtherIntangibleAssets contextRef="c-105" decimals="-6" id="f-604" unitRef="eur">8530000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-106" decimals="-6" id="f-605" unitRef="eur">17678000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-107" decimals="-6" id="f-606" unitRef="eur">445000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-108" decimals="-6" id="f-607" unitRef="eur">26653000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-112" decimals="-6" id="f-608" unitRef="eur">772000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-113" decimals="-6" id="f-609" unitRef="eur">463000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-114" decimals="-8" id="f-610" unitRef="eur">16300000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-115" decimals="-8" id="f-611" unitRef="eur">16600000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-116" id="f-612">P11Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-117" decimals="-8" id="f-613" unitRef="eur">1400000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-118" decimals="-8" id="f-614" unitRef="eur">1200000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-119" id="f-615">P18Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock contextRef="c-1" id="f-616">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.4. IMPAIRMENT OF INTANGIBLE ASSETS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The monitoring of impairment indicators for other intangible assets led to the recognition of a net reversal of impairment losses amounting to &#x20ac;366&#160;million in the first half of 2024, mainly due to an increase in the recoverable amounts of certain marketed products and other rights in the Biopharma segment.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock>
    <sny:ImpairmentLossOnIntangibleAssetOtherThanGoodwill contextRef="c-120" decimals="-6" id="f-617" unitRef="eur">366000000</sny:ImpairmentLossOnIntangibleAssetOtherThanGoodwill>
    <ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory contextRef="c-1" id="f-618">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.5. INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2023), and comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;% interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;EUROAPI &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Infraserv GmbH &amp;amp; Co. H&#xf6;chst KG &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;MSP Vaccine Company &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;315&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;424&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (&#x20ac;2.55 as of June 30, 2024, and &#x20ac;5.73 as of December 31, 2023). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Joint venture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Joint venture MSP Vaccine Company owns 100% of MCM Vaccine BV.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;157&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Royalties and other income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accounts receivable and other receivables&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;213&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;249&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Purchases of goods and services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;302&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;642&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accounts payable and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Subject to certain conditions, Sanofi could raise its investment in EUROAPI by &#x20ac;200 million in the form of a perpetual subordinated hybrid bond.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory>
    <sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock contextRef="c-1" id="f-619">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2023), and comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;% interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;EUROAPI &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Infraserv GmbH &amp;amp; Co. H&#xf6;chst KG &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;MSP Vaccine Company &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;315&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;424&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (&#x20ac;2.55 as of June 30, 2024, and &#x20ac;5.73 as of December 31, 2023). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Joint venture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Joint venture MSP Vaccine Company owns 100% of MCM Vaccine BV.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c-121" decimals="3" id="f-620" unitRef="number">0.298</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod contextRef="c-122" decimals="-6" id="f-621" unitRef="eur">72000000</ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod contextRef="c-123" decimals="-6" id="f-622" unitRef="eur">162000000</ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture contextRef="c-124" decimals="3" id="f-623" unitRef="number">0.312</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-125" decimals="-6" id="f-624" unitRef="eur">89000000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-126" decimals="-6" id="f-625" unitRef="eur">90000000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture contextRef="c-127" decimals="3" id="f-626" unitRef="number">0.500</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-128" decimals="-6" id="f-627" unitRef="eur">90000000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-129" decimals="-6" id="f-628" unitRef="eur">96000000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture contextRef="c-130" decimals="3" id="f-629" unitRef="number">0</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-131" decimals="-6" id="f-630" unitRef="eur">64000000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-132" decimals="-6" id="f-631" unitRef="eur">76000000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-2" decimals="-6" id="f-632" unitRef="eur">315000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-3" decimals="-6" id="f-633" unitRef="eur">424000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <sny:StockPrice
      contextRef="c-133"
      decimals="INF"
      id="f-634"
      unitRef="eurPerShare">2.55</sny:StockPrice>
    <sny:StockPrice
      contextRef="c-134"
      decimals="INF"
      id="f-635"
      unitRef="eurPerShare">5.73</sny:StockPrice>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-135" decimals="2" id="f-636" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="c-1" id="f-637">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;157&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Royalties and other income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accounts receivable and other receivables&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;213&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;249&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Purchases of goods and services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;302&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;642&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accounts payable and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions contextRef="c-136" decimals="-6" id="f-638" unitRef="eur">59000000</ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions>
    <ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions contextRef="c-137" decimals="-6" id="f-639" unitRef="eur">64000000</ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions>
    <ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions contextRef="c-138" decimals="-6" id="f-640" unitRef="eur">157000000</ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions>
    <sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions contextRef="c-136" decimals="-6" id="f-641" unitRef="eur">61000000</sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions>
    <sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions contextRef="c-137" decimals="-6" id="f-642" unitRef="eur">32000000</sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions>
    <sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions contextRef="c-138" decimals="-6" id="f-643" unitRef="eur">63000000</sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-139" decimals="-6" id="f-644" unitRef="eur">278000000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-140" decimals="-6" id="f-645" unitRef="eur">213000000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-141" decimals="-6" id="f-646" unitRef="eur">249000000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:PurchasesOfGoodsRelatedPartyTransactions contextRef="c-136" decimals="-6" id="f-647" unitRef="eur">345000000</ifrs-full:PurchasesOfGoodsRelatedPartyTransactions>
    <ifrs-full:PurchasesOfGoodsRelatedPartyTransactions contextRef="c-137" decimals="-6" id="f-648" unitRef="eur">302000000</ifrs-full:PurchasesOfGoodsRelatedPartyTransactions>
    <ifrs-full:PurchasesOfGoodsRelatedPartyTransactions contextRef="c-138" decimals="-6" id="f-649" unitRef="eur">642000000</ifrs-full:PurchasesOfGoodsRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-139" decimals="-6" id="f-650" unitRef="eur">63000000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-140" decimals="-6" id="f-651" unitRef="eur">97000000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-141" decimals="-6" id="f-652" unitRef="eur">71000000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:SubordinatedLiabilities contextRef="c-2" decimals="-6" id="f-653" unitRef="eur">200000000</ifrs-full:SubordinatedLiabilities>
    <ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory contextRef="c-1" id="f-654">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.6. OTHER NON-CURRENT ASSETS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Other non-current assets comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity instruments at fair value through other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Debt instruments at fair value through other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other financial assets at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Pre-funded pension obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term prepaid expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term loans and advances and other non-current receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,333&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,218&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory>
    <sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock contextRef="c-1" id="f-655">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Other non-current assets comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity instruments at fair value through other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Debt instruments at fair value through other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other financial assets at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Pre-funded pension obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term prepaid expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term loans and advances and other non-current receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,333&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,218&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-142" decimals="-6" id="f-656" unitRef="eur">1161000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-143" decimals="-6" id="f-657" unitRef="eur">1088000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-144" decimals="-6" id="f-658" unitRef="eur">347000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-145" decimals="-6" id="f-659" unitRef="eur">346000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c-2" decimals="-6" id="f-660" unitRef="eur">817000000</sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss>
    <sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c-3" decimals="-6" id="f-661" unitRef="eur">808000000</sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss>
    <sny:PreFundedPensionObligations contextRef="c-2" decimals="-6" id="f-662" unitRef="eur">325000000</sny:PreFundedPensionObligations>
    <sny:PreFundedPensionObligations contextRef="c-3" decimals="-6" id="f-663" unitRef="eur">271000000</sny:PreFundedPensionObligations>
    <sny:LongTermPrepaidExpenses contextRef="c-2" decimals="-6" id="f-664" unitRef="eur">95000000</sny:LongTermPrepaidExpenses>
    <sny:LongTermPrepaidExpenses contextRef="c-3" decimals="-6" id="f-665" unitRef="eur">114000000</sny:LongTermPrepaidExpenses>
    <ifrs-full:NoncurrentLoansAndReceivables contextRef="c-2" decimals="-6" id="f-666" unitRef="eur">587000000</ifrs-full:NoncurrentLoansAndReceivables>
    <ifrs-full:NoncurrentLoansAndReceivables contextRef="c-3" decimals="-6" id="f-667" unitRef="eur">591000000</ifrs-full:NoncurrentLoansAndReceivables>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-2" decimals="-6" id="f-668" unitRef="eur">3333000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-3" decimals="-6" id="f-669" unitRef="eur">3218000000</ifrs-full:OtherNoncurrentAssets>
    <sny:DisclosureOfTradeReceivablesTextBlock contextRef="c-1" id="f-670">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.7. ACCOUNTS RECEIVABLE&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Accounts receivable break down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gross value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;8,510&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;8,433&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The impact of allowances against accounts receivable in the first half of 2024 was a net expense of &#x20ac;3 million (versus a net expense of &#x20ac;2 million for the first half of 2023).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the ageing profile of overdue accounts receivable, based on gross value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.058%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.058%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.058%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.058%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.058%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Overdue accounts gross value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Overdue by &amp;lt;1 month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Overdue by 1-3 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Overdue by 3-6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Overdue by 6-12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Overdue by    &amp;gt; 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Some Sanofi subsidiaries have assigned receivables to factoring companies or banks without recourse. The amount of receivables that met the conditions described in Note B.8.6. to the consolidated financial statements for the year ended December 31, 2023 and hence were derecognized was &#x20ac;503 million as of June&#160;30, 2024 (versus &#x20ac;761 million as of December 31, 2023). The residual guarantees relating to those transfers were immaterial as of June 30, 2024.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfTradeReceivablesTextBlock>
    <sny:DisclosureOfCurrentTradeReceivablesTableTextBlock contextRef="c-1" id="f-671">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Accounts receivable break down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gross value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;8,510&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;8,433&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfCurrentTradeReceivablesTableTextBlock>
    <ifrs-full:CurrentTradeReceivables contextRef="c-96" decimals="-6" id="f-672" unitRef="eur">8602000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-88" decimals="-6" id="f-673" unitRef="eur">8528000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-146" decimals="-6" id="f-674" unitRef="eur">92000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-147" decimals="-6" id="f-675" unitRef="eur">95000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-2" decimals="-6" id="f-676" unitRef="eur">8510000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-3" decimals="-6" id="f-677" unitRef="eur">8433000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables contextRef="c-1" decimals="-6" id="f-678" unitRef="eur">-3000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables contextRef="c-4" decimals="-6" id="f-679" unitRef="eur">-2000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables>
    <sny:DisclosureOfOverdueReceivablesGrossValueTableTextBlock contextRef="c-1" id="f-680">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the ageing profile of overdue accounts receivable, based on gross value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.058%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.058%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.058%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.058%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.058%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Overdue accounts gross value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Overdue by &amp;lt;1 month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Overdue by 1-3 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Overdue by 3-6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Overdue by 6-12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Overdue by    &amp;gt; 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfOverdueReceivablesGrossValueTableTextBlock>
    <sny:OverdueReceivablesGrossValue contextRef="c-2" decimals="-6" id="f-681" unitRef="eur">646000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-148" decimals="-6" id="f-682" unitRef="eur">264000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-149" decimals="-6" id="f-683" unitRef="eur">105000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-150" decimals="-6" id="f-684" unitRef="eur">137000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-151" decimals="-6" id="f-685" unitRef="eur">69000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-152" decimals="-6" id="f-686" unitRef="eur">71000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-3" decimals="-6" id="f-687" unitRef="eur">689000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-153" decimals="-6" id="f-688" unitRef="eur">269000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-154" decimals="-6" id="f-689" unitRef="eur">154000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-155" decimals="-6" id="f-690" unitRef="eur">123000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-156" decimals="-6" id="f-691" unitRef="eur">62000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-157" decimals="-6" id="f-692" unitRef="eur">81000000</sny:OverdueReceivablesGrossValue>
    <sny:DerecognizedReceivables contextRef="c-2" decimals="-6" id="f-693" unitRef="eur">503000000</sny:DerecognizedReceivables>
    <sny:DerecognizedReceivables contextRef="c-3" decimals="-6" id="f-694" unitRef="eur">761000000</sny:DerecognizedReceivables>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c-1" id="f-696">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.8. CONSOLIDATED SHAREHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.1. SHARE CAPITAL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2024, the share capital was &#x20ac;2,532,725,512 and consisted of 1,266,362,756 shares (the total number of shares outstanding) with a par value of &#x20ac;2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Treasury shares held by Sanofi are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;br/&gt;(million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;% of share capital&lt;br/&gt;for the period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15.33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A total of 91,355 shares were issued in the first half of 2024 as a result of the exercise of Sanofi stock subscription options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In addition, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2,803,637&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; shares &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;vested under Sanofi restricted share plans during the first half of 2024, of which 1,471,432&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;were fulfilled by issuance of new shares and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1,332,205&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; by allotment of existing shares free of charge&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.2. REPURCHASE OF SANOFI SHARES&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On May 25, 2023, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of 18 months. Under that program, Sanofi repurchased 3,215,460 of its own shares during the first half of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; for a total amount of &#x20ac;302&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April 30, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of 18 months. Sanofi did n&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;ot use that authorization during the first half of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.3. REDUCTIONS IN SHARE CAPITAL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;No decision to cancel treasury shares was made by the Sanofi Board of Directors during the first half of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.4. RESTRICTED SHARE PLANS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2023. The principal features of the plans awarded in 2024 are set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.270%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.161%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.169%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Type of plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Performance share plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Date of Board meeting approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total number of shares subject to a 3-year service period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,505,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which with no market condition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,888,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;81.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which with market conditions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,616,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded other than to the Chief Executive Officer (1,394,478 shares in total) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;72.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Fair value per share awarded other than to the Chief Executive Officer (139,665 additional shares) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;13.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Fair value per share awarded to the Chief Executive Officer (82,500 shares) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;72.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value of plan at the date of grant (&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;346&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c) Additional tranche subject to a higher level of market conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.089%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total expense for restricted share plans (&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Number of shares not yet fully vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,192,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,127,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2024 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4,498,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2023 plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,652,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,837,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2022 plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,031,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,226,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2021 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;11,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,996,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2020 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;67,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.5. CAPITAL INCREASES&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On January 31, 2024, the Sanofi Board of Directors approved a capital increase reserved for employees, offering the opportunity for them to subscribe for new Sanofi shares at a price of &#x20ac;72.87 per share. The subscription period was open from June&#160;4 through June&#160;24, 2024. Sanofi employees subscribed for a total of 2,124,445 shares, and this capital increase was supplemented by the immediate issuance of a further 119,951 shares for the employer&#x2019;s contribution. The total expense recognized for this capital increase in the first half of 2024 was &#x20ac;45 million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On February&#160;2, 2023, the Sanofi Board of Directors approved a capital increase reserved for employees, offering the opportunity for them to subscribe for new Sanofi shares at a price of &#x20ac;79.58 per share. The subscription period was open from June&#160;5 through June&#160;23, 2023. Sanofi employees subscribed for a total of 2,009,306 shares, and this capital increase was supplemented by the immediate issuance of a further 119,417 shares for the employer&#x2019;s contribution. The total expense recognized for this capital increase in the first half of 2023 was &#x20ac;52 million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.6. STOCK SUBSCRIPTION OPTION PLANS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;No stock subscription option plans were awarded in the first half of 2024 or in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;No more expenses have been recognized through equity for stock option plans in either 2024 or 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below provides summary information about options outstanding and exercisable as of June&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.257%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Range of exercise prices per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:38pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Weighted average residual life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price per share (&#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price per share (&#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;60.00 to &#x20ac;70.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;70.00 to &#x20ac;80.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;478,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;478,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;80.00 to &#x20ac;90.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;594,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;594,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,241,658&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,241,658&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.7. NUMBER OF SHARES USED TO COMPUTE DILUTED EARNINGS PER SHARE&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.554%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023 (12 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Average number of shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,249.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,249.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,251.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Adjustment for stock options with dilutive effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Adjustment for restricted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Average number of shares used to compute diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,253.8&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,254.5&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,256.4&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2024, December 31, 2023 and June 30, 2023 all stock options were taken into account in computing diluted earnings per share because they all had a dilutive effect. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.8. OTHER COMPREHENSIVE INCOME&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements within other comprehensive income are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.554%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.674%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.857%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.857%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.857%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.564%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024 (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023 (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023 (12 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="padding-right:2.1pt;text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Actuarial gains/(losses) excluding investments accounted for using the equity method&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity instruments included in financial assets and financial liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (excluding investments accounted for using the equity method)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Equity risk hedging instruments designated as fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Items not subsequently reclassifiable to profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;166&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;85&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Debt instruments included in financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="padding-right:2.1pt;text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (excluding investments accounted for using the equity method) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash flow hedges and fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (excluding investments accounted for using the equity method) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Change in currency translation differences:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Currency translation differences (investments accounted for using the equity method) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Hedges of net investments in foreign operations &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Items subsequently reclassifiable to profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,067&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Includes reclassifications to profit or loss: immaterial over all periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes reclassifications to profit or loss: immaterial over all periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes a reclassification to profit or loss: immaterial in the first half of 2024 , &#x20ac;(56) million in 2023 and &#x20ac;(14) million in the first half of 2023.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c-1" id="f-695">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.8. CONSOLIDATED SHAREHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.1. SHARE CAPITAL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2024, the share capital was &#x20ac;2,532,725,512 and consisted of 1,266,362,756 shares (the total number of shares outstanding) with a par value of &#x20ac;2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Treasury shares held by Sanofi are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;br/&gt;(million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;% of share capital&lt;br/&gt;for the period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15.33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A total of 91,355 shares were issued in the first half of 2024 as a result of the exercise of Sanofi stock subscription options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In addition, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2,803,637&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; shares &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;vested under Sanofi restricted share plans during the first half of 2024, of which 1,471,432&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;were fulfilled by issuance of new shares and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1,332,205&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; by allotment of existing shares free of charge&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:IssuedCapital contextRef="c-2" decimals="0" id="f-697" unitRef="eur">2532725512</ifrs-full:IssuedCapital>
    <ifrs-full:NumberOfSharesIssued contextRef="c-2" decimals="INF" id="f-698" unitRef="shares">1266362756</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ParValuePerShare
      contextRef="c-2"
      decimals="INF"
      id="f-699"
      unitRef="eurPerShare">2</ifrs-full:ParValuePerShare>
    <sny:NumberOfSharesHeld contextRef="c-2" decimals="-4" id="f-700" unitRef="shares">15330000</sny:NumberOfSharesHeld>
    <sny:PercentageOfShareCapitalForThePeriod contextRef="c-2" decimals="5" id="f-701" unitRef="number">0.01211</sny:PercentageOfShareCapitalForThePeriod>
    <sny:NumberOfSharesHeld contextRef="c-3" decimals="-4" id="f-702" unitRef="shares">13450000</sny:NumberOfSharesHeld>
    <sny:PercentageOfShareCapitalForThePeriod contextRef="c-3" decimals="5" id="f-703" unitRef="number">0.01063</sny:PercentageOfShareCapitalForThePeriod>
    <sny:NumberOfSharesHeld contextRef="c-31" decimals="-4" id="f-704" unitRef="shares">10900000</sny:NumberOfSharesHeld>
    <sny:PercentageOfShareCapitalForThePeriod contextRef="c-31" decimals="5" id="f-705" unitRef="number">0.00864</sny:PercentageOfShareCapitalForThePeriod>
    <sny:NumberOfSharesHeld contextRef="c-14" decimals="-4" id="f-706" unitRef="shares">8200000</sny:NumberOfSharesHeld>
    <sny:PercentageOfShareCapitalForThePeriod contextRef="c-14" decimals="5" id="f-707" unitRef="number">0.00650</sny:PercentageOfShareCapitalForThePeriod>
    <sny:NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions
      contextRef="c-158"
      decimals="INF"
      id="f-708"
      unitRef="shares">91355</sny:NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions>
    <sny:NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease contextRef="c-1" decimals="INF" id="f-709" unitRef="shares">2803637</sny:NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease>
    <sny:NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease
      contextRef="c-158"
      decimals="INF"
      id="f-710"
      unitRef="shares">1471432</sny:NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease>
    <sny:NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease contextRef="c-2" decimals="INF" id="f-711" unitRef="shares">1332205</sny:NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease>
    <sny:PeriodOfShareRepurchaseProgram contextRef="c-159" id="f-712">P18M</sny:PeriodOfShareRepurchaseProgram>
    <sny:NumberOfSharesRepurchased
      contextRef="c-160"
      decimals="INF"
      id="f-713"
      unitRef="shares">3215460</sny:NumberOfSharesRepurchased>
    <sny:AmountOfSharesRepurchased contextRef="c-160" decimals="-6" id="f-714" unitRef="eur">302000000</sny:AmountOfSharesRepurchased>
    <sny:PeriodOfShareRepurchaseProgram contextRef="c-161" id="f-715">P18M</sny:PeriodOfShareRepurchaseProgram>
    <sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock contextRef="c-1" id="f-716">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2023. The principal features of the plans awarded in 2024 are set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.270%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.161%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.169%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Type of plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Performance share plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Date of Board meeting approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total number of shares subject to a 3-year service period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,505,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which with no market condition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,888,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;81.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which with market conditions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,616,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded other than to the Chief Executive Officer (1,394,478 shares in total) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;72.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Fair value per share awarded other than to the Chief Executive Officer (139,665 additional shares) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;13.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Fair value per share awarded to the Chief Executive Officer (82,500 shares) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;72.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value of plan at the date of grant (&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;346&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c) Additional tranche subject to a higher level of market conditions.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock>
    <sny:NumberOfYearsServicePeriod contextRef="c-162" id="f-717">P3Y</sny:NumberOfYearsServicePeriod>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-162"
      decimals="INF"
      id="f-718"
      unitRef="shares">4505145</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-163"
      decimals="INF"
      id="f-719"
      unitRef="shares">2888502</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-163"
      decimals="2"
      id="f-720"
      unitRef="eurPerShare">81.84</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-164"
      decimals="INF"
      id="f-721"
      unitRef="shares">1616643</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-165"
      decimals="INF"
      id="f-722"
      unitRef="shares">1394478</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-165"
      decimals="2"
      id="f-723"
      unitRef="eurPerShare">72.79</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-166"
      decimals="INF"
      id="f-724"
      unitRef="shares">139665</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-166"
      decimals="2"
      id="f-725"
      unitRef="eurPerShare">13.50</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-167"
      decimals="INF"
      id="f-726"
      unitRef="shares">82500</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-167"
      decimals="2"
      id="f-727"
      unitRef="eurPerShare">72.38</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <sny:FairValueOfPlanAtDateOfGrant contextRef="c-162" decimals="-6" id="f-728" unitRef="eur">346000000</sny:FairValueOfPlanAtDateOfGrant>
    <sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock contextRef="c-1" id="f-729">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.089%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total expense for restricted share plans (&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Number of shares not yet fully vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,192,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,127,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2024 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4,498,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2023 plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,652,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,837,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2022 plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,031,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,226,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2021 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;11,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,996,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2020 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;67,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-168" decimals="-6" id="f-730" unitRef="eur">128000000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-169" decimals="-6" id="f-731" unitRef="eur">108000000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-170"
      decimals="INF"
      id="f-732"
      unitRef="shares">11192984</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-171"
      decimals="INF"
      id="f-733"
      unitRef="shares">10127545</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-172"
      decimals="INF"
      id="f-734"
      unitRef="shares">4498109</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-173"
      decimals="INF"
      id="f-735"
      unitRef="shares">0</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-174"
      decimals="INF"
      id="f-736"
      unitRef="shares">3652352</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-175"
      decimals="INF"
      id="f-737"
      unitRef="shares">3837974</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-176"
      decimals="INF"
      id="f-738"
      unitRef="shares">3031060</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-177"
      decimals="INF"
      id="f-739"
      unitRef="shares">3226321</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-178"
      decimals="INF"
      id="f-740"
      unitRef="shares">11463</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-179"
      decimals="INF"
      id="f-741"
      unitRef="shares">2996101</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-180"
      decimals="INF"
      id="f-742"
      unitRef="shares">0</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-181"
      decimals="INF"
      id="f-743"
      unitRef="shares">67149</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:SubscriptionPricePerShare
      contextRef="c-182"
      decimals="2"
      id="f-744"
      unitRef="eurPerShare">72.87</sny:SubscriptionPricePerShare>
    <sny:NumberOfSharesSubscribed
      contextRef="c-183"
      decimals="INF"
      id="f-745"
      unitRef="shares">2124445</sny:NumberOfSharesSubscribed>
    <sny:IssuanceOfFurtherSharesAsAnEmployersContribution
      contextRef="c-183"
      decimals="INF"
      id="f-746"
      unitRef="shares">119951</sny:IssuanceOfFurtherSharesAsAnEmployersContribution>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-184" decimals="-6" id="f-747" unitRef="eur">45000000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <sny:SubscriptionPricePerShare
      contextRef="c-185"
      decimals="2"
      id="f-748"
      unitRef="eurPerShare">79.58</sny:SubscriptionPricePerShare>
    <sny:NumberOfSharesSubscribed
      contextRef="c-186"
      decimals="INF"
      id="f-749"
      unitRef="shares">2009306</sny:NumberOfSharesSubscribed>
    <sny:IssuanceOfFurtherSharesAsAnEmployersContribution
      contextRef="c-186"
      decimals="INF"
      id="f-750"
      unitRef="shares">119417</sny:IssuanceOfFurtherSharesAsAnEmployersContribution>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-187" decimals="-6" id="f-751" unitRef="eur">52000000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <sny:DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock contextRef="c-1" id="f-752">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below provides summary information about options outstanding and exercisable as of June&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.257%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Range of exercise prices per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:38pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Weighted average residual life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price per share (&#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price per share (&#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;60.00 to &#x20ac;70.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;70.00 to &#x20ac;80.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;478,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;478,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;80.00 to &#x20ac;90.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;594,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;594,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,241,658&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,241,658&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-188"
      decimals="INF"
      id="f-753"
      unitRef="eurPerShare">60.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-189"
      decimals="INF"
      id="f-754"
      unitRef="eurPerShare">70.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-190"
      decimals="INF"
      id="f-755"
      unitRef="shares">168784</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-191" id="f-756">P3Y10M2D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-190"
      decimals="2"
      id="f-757"
      unitRef="eurPerShare">65.84</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-190"
      decimals="INF"
      id="f-758"
      unitRef="shares">168784</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-190"
      decimals="2"
      id="f-759"
      unitRef="eurPerShare">65.84</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-192"
      decimals="INF"
      id="f-760"
      unitRef="eurPerShare">70.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-193"
      decimals="INF"
      id="f-761"
      unitRef="eurPerShare">80.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-194"
      decimals="INF"
      id="f-762"
      unitRef="shares">478150</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-195" id="f-763">P3Y2M4D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-194"
      decimals="2"
      id="f-764"
      unitRef="eurPerShare">76.26</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-194"
      decimals="INF"
      id="f-765"
      unitRef="shares">478150</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-194"
      decimals="2"
      id="f-766"
      unitRef="eurPerShare">76.26</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-196"
      decimals="INF"
      id="f-767"
      unitRef="eurPerShare">80.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-197"
      decimals="INF"
      id="f-768"
      unitRef="eurPerShare">90.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-198"
      decimals="INF"
      id="f-769"
      unitRef="shares">594724</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-199" id="f-770">P1Y9M14D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-198"
      decimals="2"
      id="f-771"
      unitRef="eurPerShare">89.20</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-198"
      decimals="INF"
      id="f-772"
      unitRef="shares">594724</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-198"
      decimals="2"
      id="f-773"
      unitRef="eurPerShare">89.20</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-200"
      decimals="INF"
      id="f-774"
      unitRef="shares">1241658</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-200"
      decimals="INF"
      id="f-775"
      unitRef="shares">1241658</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <sny:DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock contextRef="c-1" id="f-776">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.554%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023 (12 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Average number of shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,249.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,249.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,251.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Adjustment for stock options with dilutive effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Adjustment for restricted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Average number of shares used to compute diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,253.8&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,254.5&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,256.4&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="-5" id="f-777" unitRef="shares">1249400000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-4" decimals="-5" id="f-778" unitRef="shares">1249900000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-5" decimals="-5" id="f-779" unitRef="shares">1251700000</ifrs-full:WeightedAverageShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares contextRef="c-1" decimals="-5" id="f-780" unitRef="shares">100000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares contextRef="c-4" decimals="-5" id="f-781" unitRef="shares">300000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares contextRef="c-5" decimals="-5" id="f-782" unitRef="shares">200000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares contextRef="c-1" decimals="-5" id="f-783" unitRef="shares">4300000</sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares>
    <sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares contextRef="c-4" decimals="-5" id="f-784" unitRef="shares">4300000</sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares>
    <sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares contextRef="c-5" decimals="-5" id="f-785" unitRef="shares">4500000</sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-1" decimals="-5" id="f-786" unitRef="shares">1253800000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-4" decimals="-5" id="f-787" unitRef="shares">1254500000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-5" decimals="-5" id="f-788" unitRef="shares">1256400000</ifrs-full:AdjustedWeightedAverageShares>
    <sny:DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock contextRef="c-1" id="f-789">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements within other comprehensive income are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.554%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.674%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.857%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.857%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.857%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.564%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024 (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023 (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023 (12 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="padding-right:2.1pt;text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Actuarial gains/(losses) excluding investments accounted for using the equity method&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity instruments included in financial assets and financial liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (excluding investments accounted for using the equity method)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Equity risk hedging instruments designated as fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Items not subsequently reclassifiable to profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;166&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;85&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Debt instruments included in financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="padding-right:2.1pt;text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (excluding investments accounted for using the equity method) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash flow hedges and fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (excluding investments accounted for using the equity method) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Change in currency translation differences:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Currency translation differences (investments accounted for using the equity method) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Hedges of net investments in foreign operations &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Items subsequently reclassifiable to profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,067&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Includes reclassifications to profit or loss: immaterial over all periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes reclassifications to profit or loss: immaterial over all periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes a reclassification to profit or loss: immaterial in the first half of 2024 , &#x20ac;(56) million in 2023 and &#x20ac;(14) million in the first half of 2023.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock>
    <sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures contextRef="c-201" decimals="-6" id="f-790" unitRef="eur">235000000</sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures>
    <sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures contextRef="c-202" decimals="-6" id="f-791" unitRef="eur">133000000</sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures>
    <sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures contextRef="c-203" decimals="-6" id="f-792" unitRef="eur">-171000000</sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures>
    <sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures contextRef="c-201" decimals="-6" id="f-793" unitRef="eur">0</sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures>
    <sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures contextRef="c-202" decimals="-6" id="f-794" unitRef="eur">8000000</sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures>
    <sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures contextRef="c-203" decimals="-6" id="f-795" unitRef="eur">0</sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures>
    <sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments contextRef="c-201" decimals="-6" id="f-796" unitRef="eur">57000000</sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments>
    <sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments contextRef="c-202" decimals="-6" id="f-797" unitRef="eur">60000000</sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments>
    <sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments contextRef="c-203" decimals="-6" id="f-798" unitRef="eur">-18000000</sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments>
    <sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures contextRef="c-204" decimals="-6" id="f-799" unitRef="eur">-10000000</sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures contextRef="c-205" decimals="-6" id="f-800" unitRef="eur">3000000</sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures contextRef="c-206" decimals="-6" id="f-801" unitRef="eur">97000000</sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax contextRef="c-204" decimals="-6" id="f-802" unitRef="eur">0</sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax>
    <sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax contextRef="c-205" decimals="-6" id="f-803" unitRef="eur">0</sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax>
    <sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax contextRef="c-206" decimals="-6" id="f-804" unitRef="eur">0</sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax>
    <sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges contextRef="c-204" decimals="-6" id="f-805" unitRef="eur">0</sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges>
    <sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges contextRef="c-205" decimals="-6" id="f-806" unitRef="eur">0</sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges>
    <sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges contextRef="c-206" decimals="-6" id="f-807" unitRef="eur">0</sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges>
    <sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod contextRef="c-204" decimals="-6" id="f-808" unitRef="eur">2000000</sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod>
    <sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod contextRef="c-205" decimals="-6" id="f-809" unitRef="eur">-1000000</sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod>
    <sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod contextRef="c-206" decimals="-6" id="f-810" unitRef="eur">21000000</sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-201" decimals="-6" id="f-811" unitRef="eur">166000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-202" decimals="-6" id="f-812" unitRef="eur">85000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-203" decimals="-6" id="f-813" unitRef="eur">-77000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures contextRef="c-207" decimals="-6" id="f-814" unitRef="eur">-5000000</sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures contextRef="c-208" decimals="-6" id="f-815" unitRef="eur">6000000</sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures contextRef="c-209" decimals="-6" id="f-816" unitRef="eur">21000000</sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures contextRef="c-207" decimals="-6" id="f-817" unitRef="eur">0</sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures contextRef="c-208" decimals="-6" id="f-818" unitRef="eur">0</sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures contextRef="c-209" decimals="-6" id="f-819" unitRef="eur">0</sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures>
    <sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments contextRef="c-207" decimals="-6" id="f-820" unitRef="eur">-1000000</sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments>
    <sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments contextRef="c-208" decimals="-6" id="f-821" unitRef="eur">1000000</sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments>
    <sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments contextRef="c-209" decimals="-6" id="f-822" unitRef="eur">4000000</sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments>
    <sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures contextRef="c-210" decimals="-6" id="f-823" unitRef="eur">-4000000</sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures contextRef="c-211" decimals="-6" id="f-824" unitRef="eur">1000000</sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures contextRef="c-212" decimals="-6" id="f-825" unitRef="eur">1000000</sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures contextRef="c-210" decimals="-6" id="f-826" unitRef="eur">1000000</sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures contextRef="c-211" decimals="-6" id="f-827" unitRef="eur">0</sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures contextRef="c-212" decimals="-6" id="f-828" unitRef="eur">-2000000</sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome contextRef="c-210" decimals="-6" id="f-829" unitRef="eur">-1000000</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome contextRef="c-211" decimals="-6" id="f-830" unitRef="eur">0</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome contextRef="c-212" decimals="-6" id="f-831" unitRef="eur">0</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures contextRef="c-210" decimals="-6" id="f-832" unitRef="eur">1167000000</sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures>
    <sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures contextRef="c-211" decimals="-6" id="f-833" unitRef="eur">-1089000000</sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures>
    <sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures contextRef="c-212" decimals="-6" id="f-834" unitRef="eur">-1551000000</sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures>
    <sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures contextRef="c-210" decimals="-6" id="f-835" unitRef="eur">-1000000</sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures>
    <sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures contextRef="c-211" decimals="-6" id="f-836" unitRef="eur">6000000</sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures>
    <sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures contextRef="c-212" decimals="-6" id="f-837" unitRef="eur">3000000</sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures>
    <sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations contextRef="c-210" decimals="-6" id="f-838" unitRef="eur">-126000000</sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations>
    <sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations contextRef="c-211" decimals="-6" id="f-839" unitRef="eur">26000000</sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations>
    <sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations contextRef="c-212" decimals="-6" id="f-840" unitRef="eur">8000000</sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations>
    <sny:ChangeInCurrencyTranslationOnTaxEffects contextRef="c-210" decimals="-6" id="f-841" unitRef="eur">-33000000</sny:ChangeInCurrencyTranslationOnTaxEffects>
    <sny:ChangeInCurrencyTranslationOnTaxEffects contextRef="c-211" decimals="-6" id="f-842" unitRef="eur">7000000</sny:ChangeInCurrencyTranslationOnTaxEffects>
    <sny:ChangeInCurrencyTranslationOnTaxEffects contextRef="c-212" decimals="-6" id="f-843" unitRef="eur">2000000</sny:ChangeInCurrencyTranslationOnTaxEffects>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-210" decimals="-6" id="f-844" unitRef="eur">1067000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-211" decimals="-6" id="f-845" unitRef="eur">-1058000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-212" decimals="-6" id="f-846" unitRef="eur">-1526000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-213" decimals="-6" id="f-847" unitRef="eur">-56000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-214" decimals="-6" id="f-848" unitRef="eur">-14000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock contextRef="c-1" id="f-849">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.9. DEBT, CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Changes in financial position during the period were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.089%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21,918&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;16,531&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net debt (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;15,112&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,793&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Net debt does not include lease liabilities, which amounted to &#x20ac;2,012 million as of June 30, 2024 and &#x20ac;2,030 million as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x201c;Net debt&#x201d; is a financial indicator used by management and investors to measure Sanofi&#x2019;s overall net indebtedness.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.9.1. NET DEBT AT VALUE ON REDEMPTION&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2024 is shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.450%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.665%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.949%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Value on redemption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Carrying amount at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Adjustment to debt measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21,918&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21,952&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;16,573&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net debt (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;15,112&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;15,146&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,835&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Net debt does not include lease liabilities, which amounted to &#x20ac;2,012 million as of June 30, 2024 and &#x20ac;2,030 million as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows an analysis of net debt by type, at value on redemption:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.626%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #661de8;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bond issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbe5f1;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other bank borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbe5f1;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbe5f1;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bank credit balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbe5f1;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbe5f1;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;12,688&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;9,264&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21,952&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;14,546&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,027&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;16,573&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;12,688&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,458&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;15,146&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;14,546&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(6,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,835&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) As of June 30, 2024, current other bank borrowings includ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;e &#x20ac;6,955&#160;million related to the US Commercial Paper program and &#x20ac;0&#160;million related to the Negotiable European Commercial Paper program in France.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principal financing and debt reduction transactions during the period&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi did not carry out any bond issues in the first half of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;An April&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; 2016 fixed-rate bond issue of &#x20ac;600&#160;million, which matured on April 5, 2024, was redeemed during the first half of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2024, Sanofi had two syndicated credit facilities linked to social and environmental criteria in place to manage its liquidity in connection with current operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:14.14pt"&gt;a syndicated credit facility of &#x20ac;4&#160;billion, drawable in euros and US dollars and expiring on December 6, 2027, for which no further extension options are available; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.27pt"&gt;a syndicated credit facility of &#x20ac;4&#160;billion, drawable in euros and US dollars and expiring on March 7, 2029, for which a further one-year extension option remains available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2024, neither facility was drawn down.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi also has two short-term debt programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:14.14pt"&gt; a &#x20ac;6 billion Negotiable European Commercial Paper program in France; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.27pt"&gt;a $10&#160;billion Commercial Paper program in the United States. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;During the first half of 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:14.14pt"&gt; the average drawdown under the US Commercial Paper program was $5.8 billion; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.27pt"&gt;the average drawdown under the Negotiable European Commercial Paper program in France was &#x20ac;0.1 billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The financing in place as of June 30, 2024 at the level of the holding company (which manages most of Sanofi&#x2019;s financing needs centrally) is not subject to any financial covenants, and contains no clauses linking credit spreads or fees to the credit rating.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.9.2. MARKET VALUE OF NET DEBT&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The market value of Sanofi&#x2019;s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.644%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.130%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Value on redemption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock>
    <sny:DisclosureOfChangesInFinancialPositionTableTextBlock contextRef="c-1" id="f-850">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Changes in financial position during the period were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.089%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21,918&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;16,531&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net debt (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;15,112&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,793&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Net debt does not include lease liabilities, which amounted to &#x20ac;2,012 million as of June 30, 2024 and &#x20ac;2,030 million as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfChangesInFinancialPositionTableTextBlock>
    <ifrs-full:LongtermBorrowings contextRef="c-2" decimals="-6" id="f-851" unitRef="eur">12503000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-3" decimals="-6" id="f-852" unitRef="eur">14347000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-2" decimals="-6" id="f-853" unitRef="eur">9236000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-3" decimals="-6" id="f-854" unitRef="eur">2045000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-2" decimals="-6" id="f-855" unitRef="eur">-179000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-3" decimals="-6" id="f-856" unitRef="eur">-139000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <ifrs-full:Borrowings contextRef="c-2" decimals="-6" id="f-857" unitRef="eur">21918000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-3" decimals="-6" id="f-858" unitRef="eur">16531000000</ifrs-full:Borrowings>
    <ifrs-full:CashAndCashEquivalents contextRef="c-2" decimals="-6" id="f-859" unitRef="eur">6795000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-6" id="f-860" unitRef="eur">8710000000</ifrs-full:CashAndCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-2" decimals="-6" id="f-861" unitRef="eur">11000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-3" decimals="-6" id="f-862" unitRef="eur">28000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-2" decimals="-6" id="f-863" unitRef="eur">15112000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-3" decimals="-6" id="f-864" unitRef="eur">7793000000</sny:DebtNetOfCashAndCashEquivalents>
    <ifrs-full:LeaseLiabilities contextRef="c-2" decimals="-6" id="f-865" unitRef="eur">2012000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-3" decimals="-6" id="f-866" unitRef="eur">2030000000</ifrs-full:LeaseLiabilities>
    <sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock contextRef="c-1" id="f-867">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2024 is shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.450%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.665%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.949%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Value on redemption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Carrying amount at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Adjustment to debt measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21,918&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21,952&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;16,573&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net debt (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;15,112&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;15,146&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,835&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Net debt does not include lease liabilities, which amounted to &#x20ac;2,012 million as of June 30, 2024 and &#x20ac;2,030 million as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock>
    <ifrs-full:LongtermBorrowings contextRef="c-2" decimals="-6" id="f-868" unitRef="eur">12503000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-215" decimals="-6" id="f-869" unitRef="eur">35000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-216" decimals="-6" id="f-870" unitRef="eur">150000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-217" decimals="-6" id="f-871" unitRef="eur">12688000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-218" decimals="-6" id="f-872" unitRef="eur">14546000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-2" decimals="-6" id="f-873" unitRef="eur">9236000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-215" decimals="-6" id="f-874" unitRef="eur">0</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-216" decimals="-6" id="f-875" unitRef="eur">18000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-217" decimals="-6" id="f-876" unitRef="eur">9254000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-218" decimals="-6" id="f-877" unitRef="eur">2045000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-2" decimals="-6" id="f-878" unitRef="eur">-179000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-215" decimals="-6" id="f-879" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-216" decimals="-6" id="f-880" unitRef="eur">169000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-217" decimals="-6" id="f-881" unitRef="eur">-10000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-218" decimals="-6" id="f-882" unitRef="eur">18000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <ifrs-full:Borrowings contextRef="c-2" decimals="-6" id="f-883" unitRef="eur">21918000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-215" decimals="-6" id="f-884" unitRef="eur">35000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-216" decimals="-6" id="f-885" unitRef="eur">-1000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-217" decimals="-6" id="f-886" unitRef="eur">21952000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-218" decimals="-6" id="f-887" unitRef="eur">16573000000</ifrs-full:Borrowings>
    <ifrs-full:CashAndCashEquivalents contextRef="c-2" decimals="-6" id="f-888" unitRef="eur">6795000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-215" decimals="-6" id="f-889" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-216" decimals="-6" id="f-890" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-217" decimals="-6" id="f-891" unitRef="eur">6795000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-218" decimals="-6" id="f-892" unitRef="eur">8710000000</ifrs-full:CashAndCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-2" decimals="-6" id="f-893" unitRef="eur">11000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-215" decimals="-6" id="f-894" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-216" decimals="-6" id="f-895" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-217" decimals="-6" id="f-896" unitRef="eur">11000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-218" decimals="-6" id="f-897" unitRef="eur">28000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-2" decimals="-6" id="f-898" unitRef="eur">15112000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-215" decimals="-6" id="f-899" unitRef="eur">35000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-216" decimals="-6" id="f-900" unitRef="eur">-1000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-217" decimals="-6" id="f-901" unitRef="eur">15146000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-218" decimals="-6" id="f-902" unitRef="eur">7835000000</sny:DebtNetOfCashAndCashEquivalents>
    <ifrs-full:LeaseLiabilities contextRef="c-2" decimals="-6" id="f-903" unitRef="eur">2012000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-3" decimals="-6" id="f-904" unitRef="eur">2030000000</ifrs-full:LeaseLiabilities>
    <sny:DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock contextRef="c-1" id="f-905">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows an analysis of net debt by type, at value on redemption:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.626%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #661de8;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bond issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbe5f1;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other bank borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbe5f1;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbe5f1;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bank credit balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbe5f1;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbe5f1;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;12,688&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;9,264&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21,952&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;14,546&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,027&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;16,573&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;12,688&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,458&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;15,146&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;14,546&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(6,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,835&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) As of June 30, 2024, current other bank borrowings includ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;e &#x20ac;6,955&#160;million related to the US Commercial Paper program and &#x20ac;0&#160;million related to the Negotiable European Commercial Paper program in France.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock>
    <ifrs-full:BondsIssued contextRef="c-219" decimals="-6" id="f-906" unitRef="eur">12593000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-220" decimals="-6" id="f-907" unitRef="eur">1916000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-217" decimals="-6" id="f-908" unitRef="eur">14509000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-221" decimals="-6" id="f-909" unitRef="eur">14416000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-222" decimals="-6" id="f-910" unitRef="eur">718000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-218" decimals="-6" id="f-911" unitRef="eur">15134000000</ifrs-full:BondsIssued>
    <sny:OtherBankBorrowings contextRef="c-219" decimals="-6" id="f-912" unitRef="eur">95000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-220" decimals="-6" id="f-913" unitRef="eur">7118000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-217" decimals="-6" id="f-914" unitRef="eur">7213000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-221" decimals="-6" id="f-915" unitRef="eur">130000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-222" decimals="-6" id="f-916" unitRef="eur">1118000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-218" decimals="-6" id="f-917" unitRef="eur">1248000000</sny:OtherBankBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-219" decimals="-6" id="f-918" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-220" decimals="-6" id="f-919" unitRef="eur">5000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-217" decimals="-6" id="f-920" unitRef="eur">5000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-221" decimals="-6" id="f-921" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-222" decimals="-6" id="f-922" unitRef="eur">6000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-218" decimals="-6" id="f-923" unitRef="eur">6000000</ifrs-full:OtherBorrowings>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-219" decimals="-6" id="f-924" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-220" decimals="-6" id="f-925" unitRef="eur">215000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-217" decimals="-6" id="f-926" unitRef="eur">215000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-221" decimals="-6" id="f-927" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-222" decimals="-6" id="f-928" unitRef="eur">203000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-218" decimals="-6" id="f-929" unitRef="eur">203000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-219" decimals="-6" id="f-930" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-220" decimals="-6" id="f-931" unitRef="eur">-10000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-217" decimals="-6" id="f-932" unitRef="eur">-10000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-221" decimals="-6" id="f-933" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-222" decimals="-6" id="f-934" unitRef="eur">18000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-218" decimals="-6" id="f-935" unitRef="eur">18000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <ifrs-full:Borrowings contextRef="c-219" decimals="-6" id="f-936" unitRef="eur">12688000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-220" decimals="-6" id="f-937" unitRef="eur">9264000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-217" decimals="-6" id="f-938" unitRef="eur">21952000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-221" decimals="-6" id="f-939" unitRef="eur">14546000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-222" decimals="-6" id="f-940" unitRef="eur">2027000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-218" decimals="-6" id="f-941" unitRef="eur">16573000000</ifrs-full:Borrowings>
    <ifrs-full:CashAndCashEquivalents contextRef="c-223" decimals="-6" id="f-942" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-224" decimals="-6" id="f-943" unitRef="eur">6795000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-217" decimals="-6" id="f-944" unitRef="eur">6795000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-225" decimals="-6" id="f-945" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-226" decimals="-6" id="f-946" unitRef="eur">8710000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-218" decimals="-6" id="f-947" unitRef="eur">8710000000</ifrs-full:CashAndCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-223" decimals="-6" id="f-948" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-224" decimals="-6" id="f-949" unitRef="eur">11000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-217" decimals="-6" id="f-950" unitRef="eur">11000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-225" decimals="-6" id="f-951" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-226" decimals="-6" id="f-952" unitRef="eur">28000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-218" decimals="-6" id="f-953" unitRef="eur">28000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-223" decimals="-6" id="f-954" unitRef="eur">12688000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-224" decimals="-6" id="f-955" unitRef="eur">2458000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-217" decimals="-6" id="f-956" unitRef="eur">15146000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-225" decimals="-6" id="f-957" unitRef="eur">14546000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-226" decimals="-6" id="f-958" unitRef="eur">-6711000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-218" decimals="-6" id="f-959" unitRef="eur">7835000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:OtherBankBorrowings contextRef="c-227" decimals="-6" id="f-960" unitRef="eur">6955000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-228" decimals="-6" id="f-961" unitRef="eur">0</sny:OtherBankBorrowings>
    <ifrs-full:NotionalAmount contextRef="c-229" decimals="-8" id="f-962" unitRef="eur">600000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-230" decimals="-9" id="f-963" unitRef="eur">4000000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-230" decimals="-9" id="f-964" unitRef="eur">4000000000</ifrs-full:NotionalAmount>
    <ifrs-full:CommercialPapersIssued contextRef="c-231" decimals="-9" id="f-965" unitRef="eur">6000000000</ifrs-full:CommercialPapersIssued>
    <ifrs-full:CommercialPapersIssued contextRef="c-232" decimals="-9" id="f-966" unitRef="usd">10000000000</ifrs-full:CommercialPapersIssued>
    <sny:BorrowingAverageDrawdown contextRef="c-233" decimals="-8" id="f-967" unitRef="usd">5800000000</sny:BorrowingAverageDrawdown>
    <sny:BorrowingAverageDrawdown contextRef="c-234" decimals="-8" id="f-968" unitRef="eur">100000000</sny:BorrowingAverageDrawdown>
    <sny:DisclosureOfMarketValueOfNetDebtTableTextBlock contextRef="c-1" id="f-969">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The market value of Sanofi&#x2019;s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.644%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.130%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Value on redemption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfMarketValueOfNetDebtTableTextBlock>
    <ifrs-full:Borrowings contextRef="c-235" decimals="-6" id="f-970" unitRef="eur">14214000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-236" decimals="-6" id="f-971" unitRef="eur">7086000000</ifrs-full:Borrowings>
    <sny:RedemptionOfDebtInstrumentIssued contextRef="c-237" decimals="-6" id="f-972" unitRef="eur">15146000000</sny:RedemptionOfDebtInstrumentIssued>
    <sny:RedemptionOfDebtInstrumentIssued contextRef="c-238" decimals="-6" id="f-973" unitRef="eur">7835000000</sny:RedemptionOfDebtInstrumentIssued>
    <ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory contextRef="c-1" id="f-975">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.10. DERIVATIVE FINANCIAL INSTRUMENTS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.10.1 CURRENCY DERIVATIVES USED TO MANAGE OPERATING RISK EXPOSURES&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows operating currency hedging instruments in place as of June&#160;30, 2024. The notional amount is translated into euros at the relevant closing exchange rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.634%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.228%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Of which derivatives designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Of which derivatives not eligible for hedge accounting&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Of which recognized in equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,120&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,120&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Russian rouble&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,195&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,195&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Russian rouble&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Turkish lira&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Canadian dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;8,315&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;8,315&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The above positions mainly hedge material foreign currency cash flows arising after the end of the reporting period in relation to transactions carried out during the six months ended June&#160;30, 2024 and recognized in the balance sheet at that date. Gains and losses on hedging in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;struments (forward contracts) are calculated and recognized in parallel with the recognition of gains and losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange difference on those items (hedging instruments and hedged transactions) will be immaterial in the second half of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.10.2. CURRENCY AND INTEREST RATE DERIVATIVES USED TO MANAGE FINANCIAL EXPOSURE&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The cash pooling arrangements for foreign subsidiaries outside the eurozone, and some of Sanofi&#x2019;s financing activities, expose certain Sanofi entities to financial foreign exchange risk (i.e.&#160;the risk of changes in the value of loans and borrowings denominated in a currency other than the functional currency of the lender or borrower).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;That foreign exchange exposure is hedged using derivative instruments (currency swaps or forward contracts) that alter the currency split of Sanofi&#x2019;s debt once those instruments are taken into account.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows financial currency hedging instruments in place as of June&#160;30, 2024. The notional amount is translated into euros at the relevant closing exchange rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:1.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Maximum expiry date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,190&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Canadian dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,656&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b) (c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Hungarian forint&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;14,846&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Includes forward sales with a notional amount of $3,615 million expiring in 2024, designated as a hedge of Sanofi&#x2019;s net investment in Bioverativ. As of June&#160;30, 2024, the fair value of these forward contracts represented a liability of &#x20ac;26 million; the opposite entry was recognized in &#x201c;Other comprehensive income&#x201d;, with the impact on financial income and expense being immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)  Includes forward purchases with a notional amount of $1,000 million expiring in 2024, designated as a fair value hedge of the exposure of $1,000 million of bond issues to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; fluctuations in the EUR/USD spot rate. As of June 30, 2024, the fair value of these contracts represented an asset of &#x20ac;2 million, with &#x20ac;0 million&#160;credited to &#x201c;Other comprehensive income&#x201d; to recognize the hedging cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)  Includes forward purchases with a notional amount of $1,080 million expiring in 2024 , designated as a fair value hedge of $1,080 million of commercial paper. As of June 30, 2024, the fair value of these contracts represented an asset of &#x20ac;16 million, with &#x20ac;0&#160;million credited to &#x201c;Other comprehensive income&#x201d; to recognize the hedging cost. .&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;To optimize the cost of debt or reduce the volatility of debt, Sanofi uses derivative instruments (interest rate swaps and cross currency swaps) to alter the fixed/floating rate split of its net debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows instruments of this type in place as of June 30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.279%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.279%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.279%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.834%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.873%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.255%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Of which designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Of which designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2028 and beyond&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Of which recognized in equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized SOFR USD / receive 1.02%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;pay capitalized SOFR USD / receive  1.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester / receive 0.69%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester / receive 0.92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;pay capitalized Ester / receive 3.56%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;997&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;850&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,584&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,431&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,431&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory contextRef="c-1" id="f-974">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.10. DERIVATIVE FINANCIAL INSTRUMENTS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.10.1 CURRENCY DERIVATIVES USED TO MANAGE OPERATING RISK EXPOSURES&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows operating currency hedging instruments in place as of June&#160;30, 2024. The notional amount is translated into euros at the relevant closing exchange rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.634%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.228%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Of which derivatives designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Of which derivatives not eligible for hedge accounting&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Of which recognized in equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,120&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,120&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Russian rouble&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,195&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,195&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Russian rouble&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Turkish lira&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Canadian dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;8,315&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;8,315&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The above positions mainly hedge material foreign currency cash flows arising after the end of the reporting period in relation to transactions carried out during the six months ended June&#160;30, 2024 and recognized in the balance sheet at that date. Gains and losses on hedging in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;struments (forward contracts) are calculated and recognized in parallel with the recognition of gains and losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange difference on those items (hedging instruments and hedged transactions) will be immaterial in the second half of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.10.2. CURRENCY AND INTEREST RATE DERIVATIVES USED TO MANAGE FINANCIAL EXPOSURE&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The cash pooling arrangements for foreign subsidiaries outside the eurozone, and some of Sanofi&#x2019;s financing activities, expose certain Sanofi entities to financial foreign exchange risk (i.e.&#160;the risk of changes in the value of loans and borrowings denominated in a currency other than the functional currency of the lender or borrower).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;That foreign exchange exposure is hedged using derivative instruments (currency swaps or forward contracts) that alter the currency split of Sanofi&#x2019;s debt once those instruments are taken into account.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows financial currency hedging instruments in place as of June&#160;30, 2024. The notional amount is translated into euros at the relevant closing exchange rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:1.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Maximum expiry date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,190&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Canadian dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,656&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b) (c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Hungarian forint&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;14,846&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Includes forward sales with a notional amount of $3,615 million expiring in 2024, designated as a hedge of Sanofi&#x2019;s net investment in Bioverativ. As of June&#160;30, 2024, the fair value of these forward contracts represented a liability of &#x20ac;26 million; the opposite entry was recognized in &#x201c;Other comprehensive income&#x201d;, with the impact on financial income and expense being immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)  Includes forward purchases with a notional amount of $1,000 million expiring in 2024, designated as a fair value hedge of the exposure of $1,000 million of bond issues to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; fluctuations in the EUR/USD spot rate. As of June 30, 2024, the fair value of these contracts represented an asset of &#x20ac;2 million, with &#x20ac;0 million&#160;credited to &#x201c;Other comprehensive income&#x201d; to recognize the hedging cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)  Includes forward purchases with a notional amount of $1,080 million expiring in 2024 , designated as a fair value hedge of $1,080 million of commercial paper. As of June 30, 2024, the fair value of these contracts represented an asset of &#x20ac;16 million, with &#x20ac;0&#160;million credited to &#x201c;Other comprehensive income&#x201d; to recognize the hedging cost. .&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;To optimize the cost of debt or reduce the volatility of debt, Sanofi uses derivative instruments (interest rate swaps and cross currency swaps) to alter the fixed/floating rate split of its net debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows instruments of this type in place as of June 30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.279%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.279%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.279%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.834%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.873%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.255%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Of which designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Of which designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2028 and beyond&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Of which recognized in equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized SOFR USD / receive 1.02%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;pay capitalized SOFR USD / receive  1.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester / receive 0.69%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester / receive 0.92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;pay capitalized Ester / receive 3.56%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;997&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;850&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,584&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,431&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,431&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory>
    <sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock contextRef="c-1" id="f-976">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows operating currency hedging instruments in place as of June&#160;30, 2024. The notional amount is translated into euros at the relevant closing exchange rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.634%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.228%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Of which derivatives designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Of which derivatives not eligible for hedge accounting&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Of which recognized in equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,120&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,120&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Russian rouble&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,195&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,195&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Russian rouble&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Turkish lira&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Canadian dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;8,315&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;8,315&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The above positions mainly hedge material foreign currency cash flows arising after the end of the reporting period in relation to transactions carried out during the six months ended June&#160;30, 2024 and recognized in the balance sheet at that date. Gains and losses on hedging in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;struments (forward contracts) are calculated and recognized in parallel with the recognition of gains and losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange difference on those items (hedging instruments and hedged transactions) will be immaterial in the second half of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock>
    <sny:DerivativeFinancialInstruments contextRef="c-239" decimals="-6" id="f-977" unitRef="eur">5120000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-240" decimals="-6" id="f-978" unitRef="eur">-45000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-241" decimals="-6" id="f-979" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-242" decimals="-6" id="f-980" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-243" decimals="-6" id="f-981" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-244" decimals="-6" id="f-982" unitRef="eur">5120000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-245" decimals="-6" id="f-983" unitRef="eur">-45000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-246" decimals="-6" id="f-984" unitRef="eur">2152000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-247" decimals="-6" id="f-985" unitRef="eur">-17000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-248" decimals="-6" id="f-986" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-249" decimals="-6" id="f-987" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-250" decimals="-6" id="f-988" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-251" decimals="-6" id="f-989" unitRef="eur">2152000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-252" decimals="-6" id="f-990" unitRef="eur">-17000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-253" decimals="-6" id="f-991" unitRef="eur">608000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-254" decimals="-6" id="f-992" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-255" decimals="-6" id="f-993" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-256" decimals="-6" id="f-994" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-257" decimals="-6" id="f-995" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-258" decimals="-6" id="f-996" unitRef="eur">608000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-259" decimals="-6" id="f-997" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-260" decimals="-6" id="f-998" unitRef="eur">252000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-261" decimals="-6" id="f-999" unitRef="eur">-31000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-262" decimals="-6" id="f-1000" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-263" decimals="-6" id="f-1001" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-264" decimals="-6" id="f-1002" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-265" decimals="-6" id="f-1003" unitRef="eur">252000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-266" decimals="-6" id="f-1004" unitRef="eur">-31000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-267" decimals="-6" id="f-1005" unitRef="eur">269000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-268" decimals="-6" id="f-1006" unitRef="eur">5000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-269" decimals="-6" id="f-1007" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-270" decimals="-6" id="f-1008" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-271" decimals="-6" id="f-1009" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-272" decimals="-6" id="f-1010" unitRef="eur">269000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-273" decimals="-6" id="f-1011" unitRef="eur">5000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-274" decimals="-6" id="f-1012" unitRef="eur">197000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-275" decimals="-6" id="f-1013" unitRef="eur">-1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-276" decimals="-6" id="f-1014" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-277" decimals="-6" id="f-1015" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-278" decimals="-6" id="f-1016" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-279" decimals="-6" id="f-1017" unitRef="eur">197000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-280" decimals="-6" id="f-1018" unitRef="eur">-1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-281" decimals="-6" id="f-1019" unitRef="eur">3195000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-282" decimals="-6" id="f-1020" unitRef="eur">21000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-283" decimals="-6" id="f-1021" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-284" decimals="-6" id="f-1022" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-285" decimals="-6" id="f-1023" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-286" decimals="-6" id="f-1024" unitRef="eur">3195000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-287" decimals="-6" id="f-1025" unitRef="eur">21000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-288" decimals="-6" id="f-1026" unitRef="eur">1733000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-289" decimals="-6" id="f-1027" unitRef="eur">2000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-290" decimals="-6" id="f-1028" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-291" decimals="-6" id="f-1029" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-292" decimals="-6" id="f-1030" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-293" decimals="-6" id="f-1031" unitRef="eur">1733000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-294" decimals="-6" id="f-1032" unitRef="eur">2000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-295" decimals="-6" id="f-1033" unitRef="eur">398000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-296" decimals="-6" id="f-1034" unitRef="eur">1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-297" decimals="-6" id="f-1035" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-298" decimals="-6" id="f-1036" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-299" decimals="-6" id="f-1037" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-300" decimals="-6" id="f-1038" unitRef="eur">398000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-301" decimals="-6" id="f-1039" unitRef="eur">1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-302" decimals="-6" id="f-1040" unitRef="eur">203000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-303" decimals="-6" id="f-1041" unitRef="eur">12000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-304" decimals="-6" id="f-1042" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-305" decimals="-6" id="f-1043" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-306" decimals="-6" id="f-1044" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-307" decimals="-6" id="f-1045" unitRef="eur">203000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-308" decimals="-6" id="f-1046" unitRef="eur">12000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-309" decimals="-6" id="f-1047" unitRef="eur">108000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-310" decimals="-6" id="f-1048" unitRef="eur">7000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-311" decimals="-6" id="f-1049" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-312" decimals="-6" id="f-1050" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-313" decimals="-6" id="f-1051" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-314" decimals="-6" id="f-1052" unitRef="eur">108000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-315" decimals="-6" id="f-1053" unitRef="eur">7000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-316" decimals="-6" id="f-1054" unitRef="eur">100000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-317" decimals="-6" id="f-1055" unitRef="eur">1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-318" decimals="-6" id="f-1056" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-319" decimals="-6" id="f-1057" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-320" decimals="-6" id="f-1058" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-321" decimals="-6" id="f-1059" unitRef="eur">100000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-322" decimals="-6" id="f-1060" unitRef="eur">1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-323" decimals="-6" id="f-1061" unitRef="eur">8315000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-324" decimals="-6" id="f-1062" unitRef="eur">-24000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-325" decimals="-6" id="f-1063" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-326" decimals="-6" id="f-1064" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-327" decimals="-6" id="f-1065" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-328" decimals="-6" id="f-1066" unitRef="eur">8315000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-329" decimals="-6" id="f-1067" unitRef="eur">-24000000</sny:DerivativeFinancialInstruments>
    <sny:DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock contextRef="c-1" id="f-1068">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows financial currency hedging instruments in place as of June&#160;30, 2024. The notional amount is translated into euros at the relevant closing exchange rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:1.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Maximum expiry date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,190&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Canadian dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,656&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b) (c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Hungarian forint&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;14,846&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Includes forward sales with a notional amount of $3,615 million expiring in 2024, designated as a hedge of Sanofi&#x2019;s net investment in Bioverativ. As of June&#160;30, 2024, the fair value of these forward contracts represented a liability of &#x20ac;26 million; the opposite entry was recognized in &#x201c;Other comprehensive income&#x201d;, with the impact on financial income and expense being immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)  Includes forward purchases with a notional amount of $1,000 million expiring in 2024, designated as a fair value hedge of the exposure of $1,000 million of bond issues to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; fluctuations in the EUR/USD spot rate. As of June 30, 2024, the fair value of these contracts represented an asset of &#x20ac;2 million, with &#x20ac;0 million&#160;credited to &#x201c;Other comprehensive income&#x201d; to recognize the hedging cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)  Includes forward purchases with a notional amount of $1,080 million expiring in 2024 , designated as a fair value hedge of $1,080 million of commercial paper. As of June 30, 2024, the fair value of these contracts represented an asset of &#x20ac;16 million, with &#x20ac;0&#160;million credited to &#x201c;Other comprehensive income&#x201d; to recognize the hedging cost. .&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-239" decimals="-6" id="f-1069" unitRef="eur">7190000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-240" decimals="-6" id="f-1070" unitRef="eur">-30000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-330" decimals="-6" id="f-1071" unitRef="eur">5797000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-331" decimals="-6" id="f-1072" unitRef="eur">-28000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-332" decimals="-6" id="f-1073" unitRef="eur">301000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-333" decimals="-6" id="f-1074" unitRef="eur">-1000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-334" decimals="-6" id="f-1075" unitRef="eur">190000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-335" decimals="-6" id="f-1076" unitRef="eur">-1000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-281" decimals="-6" id="f-1077" unitRef="eur">7656000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-282" decimals="-6" id="f-1078" unitRef="eur">42000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-336" decimals="-6" id="f-1079" unitRef="eur">5242000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-337" decimals="-6" id="f-1080" unitRef="eur">37000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-338" decimals="-6" id="f-1081" unitRef="eur">1768000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-339" decimals="-6" id="f-1082" unitRef="eur">7000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-340" decimals="-6" id="f-1083" unitRef="eur">182000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-341" decimals="-6" id="f-1084" unitRef="eur">-1000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-323" decimals="-6" id="f-1085" unitRef="eur">14846000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-324" decimals="-6" id="f-1086" unitRef="eur">12000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <ifrs-full:NotionalAmount contextRef="c-342" decimals="-6" id="f-1087" unitRef="usd">3615000000</ifrs-full:NotionalAmount>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-342" decimals="-6" id="f-1088" unitRef="eur">26000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:NotionalAmount contextRef="c-343" decimals="-6" id="f-1089" unitRef="usd">1000000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-343" decimals="-6" id="f-1090" unitRef="usd">1000000000</ifrs-full:NotionalAmount>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-343" decimals="-6" id="f-1091" unitRef="eur">2000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax contextRef="c-344" decimals="-6" id="f-1092" unitRef="eur">0</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:NotionalAmount contextRef="c-345" decimals="-6" id="f-1093" unitRef="usd">1080000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-345" decimals="-6" id="f-1094" unitRef="usd">1080000000</ifrs-full:NotionalAmount>
    <ifrs-full:DerivativeFinancialAssets contextRef="c-345" decimals="-6" id="f-1095" unitRef="eur">16000000</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax contextRef="c-346" decimals="-6" id="f-1096" unitRef="eur">0</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <sny:DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock contextRef="c-1" id="f-1097">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows instruments of this type in place as of June 30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.279%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.279%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.279%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.834%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.873%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.255%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Of which designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Of which designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2028 and beyond&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Of which recognized in equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized SOFR USD / receive 1.02%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;pay capitalized SOFR USD / receive  1.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester / receive 0.69%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester / receive 0.92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;pay capitalized Ester / receive 3.56%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;997&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;850&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,584&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,431&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,431&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock>
    <sny:InterestRateSwapsInterestRate
      contextRef="c-347"
      decimals="INF"
      id="f-1098"
      unitRef="number">0.0102</sny:InterestRateSwapsInterestRate>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-348" decimals="-6" id="f-1099" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-348" decimals="-6" id="f-1100" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-349" decimals="-6" id="f-1101" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-349" decimals="-6" id="f-1102" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-350" decimals="-6" id="f-1103" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-350" decimals="-6" id="f-1104" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-351" decimals="-6" id="f-1105" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-351" decimals="-6" id="f-1106" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-352" decimals="-6" id="f-1107" unitRef="eur">467000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-352" decimals="-6" id="f-1108" unitRef="eur">467000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-353" decimals="-6" id="f-1109" unitRef="eur">467000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-353" decimals="-6" id="f-1110" unitRef="eur">467000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-354" decimals="-6" id="f-1111" unitRef="eur">-53000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-354" decimals="-6" id="f-1112" unitRef="eur">-53000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-355" decimals="-6" id="f-1113" unitRef="eur">467000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-355" decimals="-6" id="f-1114" unitRef="eur">467000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-356" decimals="-6" id="f-1115" unitRef="eur">-53000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-356" decimals="-6" id="f-1116" unitRef="eur">-53000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-357" decimals="-6" id="f-1117" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-357" decimals="-6" id="f-1118" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-358" decimals="-6" id="f-1119" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-358" decimals="-6" id="f-1120" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-359" decimals="-6" id="f-1121" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-359" decimals="-6" id="f-1122" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:InterestRateSwapsInterestRate
      contextRef="c-360"
      decimals="INF"
      id="f-1123"
      unitRef="number">0.0132</sny:InterestRateSwapsInterestRate>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-361" decimals="-6" id="f-1124" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-362" decimals="-6" id="f-1125" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-363" decimals="-6" id="f-1126" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-364" decimals="-6" id="f-1127" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-365" decimals="-6" id="f-1128" unitRef="eur">467000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-366" decimals="-6" id="f-1129" unitRef="eur">467000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-367" decimals="-6" id="f-1130" unitRef="eur">-48000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-368" decimals="-6" id="f-1131" unitRef="eur">467000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-369" decimals="-6" id="f-1132" unitRef="eur">-48000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-370" decimals="-6" id="f-1133" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-371" decimals="-6" id="f-1134" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-372" decimals="-6" id="f-1135" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:InterestRateSwapsInterestRate
      contextRef="c-373"
      decimals="INF"
      id="f-1136"
      unitRef="number">0.0069</sny:InterestRateSwapsInterestRate>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-374" decimals="-6" id="f-1137" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-375" decimals="-6" id="f-1138" unitRef="eur">850000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-376" decimals="-6" id="f-1139" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-377" decimals="-6" id="f-1140" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-378" decimals="-6" id="f-1141" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-379" decimals="-6" id="f-1142" unitRef="eur">850000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-380" decimals="-6" id="f-1143" unitRef="eur">-24000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-381" decimals="-6" id="f-1144" unitRef="eur">850000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-382" decimals="-6" id="f-1145" unitRef="eur">-24000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-383" decimals="-6" id="f-1146" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-384" decimals="-6" id="f-1147" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-385" decimals="-6" id="f-1148" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:InterestRateSwapsInterestRate
      contextRef="c-386"
      decimals="INF"
      id="f-1149"
      unitRef="number">0.0092</sny:InterestRateSwapsInterestRate>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-387" decimals="-6" id="f-1150" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-388" decimals="-6" id="f-1151" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-389" decimals="-6" id="f-1152" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-390" decimals="-6" id="f-1153" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-391" decimals="-6" id="f-1154" unitRef="eur">650000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-392" decimals="-6" id="f-1155" unitRef="eur">650000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-393" decimals="-6" id="f-1156" unitRef="eur">-56000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-394" decimals="-6" id="f-1157" unitRef="eur">650000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-395" decimals="-6" id="f-1158" unitRef="eur">-56000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-396" decimals="-6" id="f-1159" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-397" decimals="-6" id="f-1160" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-398" decimals="-6" id="f-1161" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:InterestRateSwapsInterestRate
      contextRef="c-399"
      decimals="INF"
      id="f-1162"
      unitRef="number">0.0356</sny:InterestRateSwapsInterestRate>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-400" decimals="-6" id="f-1163" unitRef="eur">997000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-401" decimals="-6" id="f-1164" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-402" decimals="-6" id="f-1165" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-403" decimals="-6" id="f-1166" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-404" decimals="-6" id="f-1167" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-405" decimals="-6" id="f-1168" unitRef="eur">997000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-406" decimals="-6" id="f-1169" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-407" decimals="-6" id="f-1170" unitRef="eur">997000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-408" decimals="-6" id="f-1171" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-409" decimals="-6" id="f-1172" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-410" decimals="-6" id="f-1173" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-411" decimals="-6" id="f-1174" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-412" decimals="-6" id="f-1175" unitRef="eur">997000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-413" decimals="-6" id="f-1176" unitRef="eur">850000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-414" decimals="-6" id="f-1177" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-415" decimals="-6" id="f-1178" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-416" decimals="-6" id="f-1179" unitRef="eur">1584000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-323" decimals="-6" id="f-1180" unitRef="eur">3431000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-324" decimals="-6" id="f-1181" unitRef="eur">-181000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-417" decimals="-6" id="f-1182" unitRef="eur">3431000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-418" decimals="-6" id="f-1183" unitRef="eur">-181000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-325" decimals="-6" id="f-1184" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-326" decimals="-6" id="f-1185" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-327" decimals="-6" id="f-1186" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock contextRef="c-1" id="f-1187">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.11. LIABILITIES RELATED TO BUSINESS COMBINATIONS AND TO NON-CONTROLLING INTERESTS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For a description of the nature of the liabilities reported in the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, refer to Note B.8.4. to the consolidated financial statements for the year ended December 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The liabilities related to business combinations and to non-controlling interests shown in the table below are level&#160;3 instruments under the IFRS 13 and IFRS 7 fair value hierarchy (see Note A.5.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2024 are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;MSD contingent consideration (European Vaccines business)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Shire contingent consideration arising from acquisition of Translate Bio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Contingent consideration arising from acquisition of Amunix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt; (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Balance at January 1, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;441&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;709&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other movements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Balance at June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;61&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;526&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;140&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;728&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Of which:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt;text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt;text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt;text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;padding-left:33.44pt"&gt;Current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;201&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;padding-left:33.44pt"&gt;Non-current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;527&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;As of January 1, 2024, this comprised a non-current portion of &#x20ac;501 million and a current portion of &#x20ac;208 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Amounts mainly reported within the income statement line item &#x201c;Fair value remeasurement of contingent consideration&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2024,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;mainly comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.18pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.28pt"&gt;The MSD contingent consideration liability arising from the 2016 acquisition of the Sanofi Pasteur activities carried on within the former Sanofi Pasteur MSD joint venture, which amounted to &#x20ac;61 million as of June&#160;30, 2024 versus &#x20ac;127 million as of December 31, 2023. The fair value of this contingent consideration is determined by applying the royalty percentage stipulated in the contract to discounted projections of sales by Sanofi through December 31, 2024 of products previously commercialized by the joint venture. If the discount rate were to fall by one percentage point, the fair value of the MSD contingent consideration would increase by approximately 1%;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;The contingent consideration liability towards Shire Human Genetic Therapies Inc. (Shire) arising from Sanofi's acquisition of Translate Bio in September 2021. The fair value of the Shire liability is determined by applying the contractual terms to development and sales projections that are weighted to reflect the probability of success, and discounted. The liability was measured at &#x20ac;526 million as of June&#160;30, 2024, compared with &#x20ac;441 million as of December 31, 2023. If the discount rate were to fall by one percentage point, the fair value of the Shire liability would increase by approximately 14%; and&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;The contingent consideration liability arising from the 2022 acquisition of Amunix. The fair value of the liability is determined on&#160;the basis of the nominal value of payments due subject to the attainment of specified&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; development milestones&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. The liability was measured at &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x20ac;140 million&lt;/span&gt; as of June 30, 2024, versus &#x20ac;137 million as of December 31, 2023.</sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock>
    <sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock contextRef="c-1" id="f-1188">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2024 are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;MSD contingent consideration (European Vaccines business)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Shire contingent consideration arising from acquisition of Translate Bio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Contingent consideration arising from acquisition of Amunix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt; (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Balance at January 1, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;441&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;709&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other movements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Balance at June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;61&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;526&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;140&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;728&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Of which:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt;text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt;text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt;text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;padding-left:33.44pt"&gt;Current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;201&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;padding-left:33.44pt"&gt;Non-current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;527&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;As of January 1, 2024, this comprised a non-current portion of &#x20ac;501 million and a current portion of &#x20ac;208 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Amounts mainly reported within the income statement line item &#x201c;Fair value remeasurement of contingent consideration&#x201d;.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-419" decimals="-6" id="f-1189" unitRef="eur">127000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-420" decimals="-6" id="f-1190" unitRef="eur">441000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-421" decimals="-6" id="f-1191" unitRef="eur">137000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-422" decimals="-6" id="f-1192" unitRef="eur">4000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-3" decimals="-6" id="f-1193" unitRef="eur">709000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-423" decimals="-6" id="f-1194" unitRef="eur">71000000</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-424" decimals="-6" id="f-1195" unitRef="eur">0</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-425" decimals="-6" id="f-1196" unitRef="eur">0</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-426" decimals="-6" id="f-1197" unitRef="eur">0</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1" decimals="-6" id="f-1198" unitRef="eur">71000000</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-423" decimals="-6" id="f-1199" unitRef="eur">4000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-424" decimals="-6" id="f-1200" unitRef="eur">71000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-425" decimals="-6" id="f-1201" unitRef="eur">0</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-426" decimals="-6" id="f-1202" unitRef="eur">0</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-1" decimals="-6" id="f-1203" unitRef="eur">75000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <sny:OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-423" decimals="-6" id="f-1204" unitRef="eur">0</sny:OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination>
    <sny:OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-424" decimals="-6" id="f-1205" unitRef="eur">0</sny:OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination>
    <sny:OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-425" decimals="-6" id="f-1206" unitRef="eur">0</sny:OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination>
    <sny:OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-426" decimals="-6" id="f-1207" unitRef="eur">3000000</sny:OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination>
    <sny:OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1" decimals="-6" id="f-1208" unitRef="eur">3000000</sny:OtherMovementsContingentLiabilitiesRecognisedInBusinessCombination>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests contextRef="c-423" decimals="-6" id="f-1209" unitRef="eur">1000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests contextRef="c-424" decimals="-6" id="f-1210" unitRef="eur">14000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests contextRef="c-425" decimals="-6" id="f-1211" unitRef="eur">3000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests contextRef="c-426" decimals="-6" id="f-1212" unitRef="eur">0</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-1213" unitRef="eur">18000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-427" decimals="-6" id="f-1214" unitRef="eur">61000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-428" decimals="-6" id="f-1215" unitRef="eur">526000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-429" decimals="-6" id="f-1216" unitRef="eur">140000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-430" decimals="-6" id="f-1217" unitRef="eur">1000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-2" decimals="-6" id="f-1218" unitRef="eur">728000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-2" decimals="-6" id="f-1219" unitRef="eur">201000000</sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-2" decimals="-6" id="f-1220" unitRef="eur">527000000</sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-3" decimals="-6" id="f-1221" unitRef="eur">501000000</sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-3" decimals="-6" id="f-1222" unitRef="eur">208000000</sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-427" decimals="-6" id="f-1223" unitRef="eur">61000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-419" decimals="-6" id="f-1224" unitRef="eur">127000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <sny:PercentageIncreaseInFairValueLiabilities
      contextRef="c-427"
      decimals="2"
      id="f-1225"
      unitRef="number">0.01</sny:PercentageIncreaseInFairValueLiabilities>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-428" decimals="-6" id="f-1226" unitRef="eur">526000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-420" decimals="-6" id="f-1227" unitRef="eur">441000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <sny:PercentageIncreaseInFairValueLiabilities
      contextRef="c-428"
      decimals="2"
      id="f-1228"
      unitRef="number">0.14</sny:PercentageIncreaseInFairValueLiabilities>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-429" decimals="-6" id="f-1229" unitRef="eur">140000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-421" decimals="-6" id="f-1230" unitRef="eur">137000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock contextRef="c-1" id="f-1231">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.12. NON-CURRENT PROVISIONS AND OTHER NON-CURRENT LIABILITIES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-current provisions and other non-current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; comprises the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023 (12 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;8,219&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,088&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,602&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Includes &#x20ac;1,970 million at June 30, 2024 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States. Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#x20ac;1,147&#160;million; the nominal value of payments estimated to be due after more than five years is &#x20ac;2,679 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows movements in provisions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.717%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.450%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.450%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.450%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.450%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.452%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Provisions for pensions &amp;amp; other post-employment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Provisions for other long-term benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Restructuring provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Balance at January&#160;1, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,214&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;718&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;554&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,776&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,262&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Increases in provisions and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions utilized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Reversals of unutilized provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest related to employee benefits, and unwinding of discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains and losses on defined-benefit plans (B.12.1.)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Balance at June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,040&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;759&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;909&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,210&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,918&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;In the case of &#x201c;Provisions for pensions and other post-employment benefits&#x201d;, the &#x201c;Increases in provisions&#x201d; line corresponds to rights vesting in employees during the period, and past service cost; the &#x201c;Provisions utilized&#x201d; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#x201c;Reversals of unutilized provisions&#x201d; line corresponds to plan curtailments, settlements and amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) Mainly transfers to the line &#x201c;Current provisions and other current liabilities&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provisions for pensions and other post-employment benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For an analysis of the sensitivity of obligations in respect of pensions and other employee benefits as of December 31, 2023, and of the assumptions used as of that date, see Note D.19.1. to the consolidated financial statements for the year ended December 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The principal assumptions used (in particular, changes in discount and inflation rates and in the market value of plan assets) for the eurozone, the United States and the United Kingdom were reviewed as of June 30, 2024 to take into account changes during the first half of the year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.827%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.973%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024 (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023 (12 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses) on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses) on benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Includes the effects of (i) the change in discount rates (in a range between +0.40% and +0.65%) and (ii) the change in the inflation rate in the United Kingdom (+0.10%) in the first half of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes the effects of (i) the change in discount rates (in a range between -0.15% and +0.40%) and (ii) the change in the inflation rate in the eurozone (-0.10%) in the first half of 2023.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock>
    <sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock contextRef="c-1" id="f-1232">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-current provisions and other non-current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; comprises the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023 (12 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;8,219&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,088&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,602&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Includes &#x20ac;1,970 million at June 30, 2024 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States. Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#x20ac;1,147&#160;million; the nominal value of payments estimated to be due after more than five years is &#x20ac;2,679 million.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock>
    <ifrs-full:NoncurrentProvisions contextRef="c-2" decimals="-6" id="f-1233" unitRef="eur">5918000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-31" decimals="-6" id="f-1234" unitRef="eur">5018000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-3" decimals="-6" id="f-1235" unitRef="eur">5262000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-2" decimals="-6" id="f-1236" unitRef="eur">2301000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-31" decimals="-6" id="f-1237" unitRef="eur">2070000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-3" decimals="-6" id="f-1238" unitRef="eur">2340000000</ifrs-full:OtherNoncurrentLiabilities>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-2" decimals="-6" id="f-1239" unitRef="eur">8219000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-31" decimals="-6" id="f-1240" unitRef="eur">7088000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-3" decimals="-6" id="f-1241" unitRef="eur">7602000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-431" decimals="-6" id="f-1242" unitRef="eur">1970000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-432" decimals="-6" id="f-1243" unitRef="eur">1147000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-433" decimals="-6" id="f-1244" unitRef="eur">2679000000</ifrs-full:OtherNoncurrentLiabilities>
    <sny:DisclosureOfNonCurrentProvisionsTableTextBlock contextRef="c-1" id="f-1245">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows movements in provisions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.717%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.450%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.450%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.450%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.450%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.452%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Provisions for pensions &amp;amp; other post-employment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Provisions for other long-term benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Restructuring provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Balance at January&#160;1, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,214&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;718&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;554&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,776&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,262&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Increases in provisions and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions utilized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Reversals of unutilized provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest related to employee benefits, and unwinding of discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains and losses on defined-benefit plans (B.12.1.)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Balance at June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,040&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;759&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;909&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,210&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,918&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;In the case of &#x201c;Provisions for pensions and other post-employment benefits&#x201d;, the &#x201c;Increases in provisions&#x201d; line corresponds to rights vesting in employees during the period, and past service cost; the &#x201c;Provisions utilized&#x201d; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#x201c;Reversals of unutilized provisions&#x201d; line corresponds to plan curtailments, settlements and amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) Mainly transfers to the line &#x201c;Current provisions and other current liabilities&#x201d;.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfNonCurrentProvisionsTableTextBlock>
    <ifrs-full:NoncurrentProvisions contextRef="c-434" decimals="-6" id="f-1246" unitRef="eur">2214000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-435" decimals="-6" id="f-1247" unitRef="eur">718000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-436" decimals="-6" id="f-1248" unitRef="eur">554000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-437" decimals="-6" id="f-1249" unitRef="eur">1776000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-3" decimals="-6" id="f-1250" unitRef="eur">5262000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-438" decimals="-6" id="f-1251" unitRef="eur">-72000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-439" decimals="-6" id="f-1252" unitRef="eur">-89000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-440" decimals="-6" id="f-1253" unitRef="eur">-581000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-441" decimals="-6" id="f-1254" unitRef="eur">-559000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-1" decimals="-6" id="f-1255" unitRef="eur">-1301000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-438" decimals="-6" id="f-1256" unitRef="eur">-78000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-439" decimals="-6" id="f-1257" unitRef="eur">-65000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-440" decimals="-6" id="f-1258" unitRef="eur">-11000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-441" decimals="-6" id="f-1259" unitRef="eur">-76000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-1" decimals="-6" id="f-1260" unitRef="eur">-230000000</ifrs-full:ProvisionUsedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-438" decimals="-6" id="f-1261" unitRef="eur">-63000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-439" decimals="-6" id="f-1262" unitRef="eur">1000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-440" decimals="-6" id="f-1263" unitRef="eur">-4000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-441" decimals="-6" id="f-1264" unitRef="eur">-53000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-1" decimals="-6" id="f-1265" unitRef="eur">-119000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-438" decimals="-6" id="f-1266" unitRef="eur">75000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-439" decimals="-6" id="f-1267" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-440" decimals="-6" id="f-1268" unitRef="eur">-173000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-441" decimals="-6" id="f-1269" unitRef="eur">-24000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-1" decimals="-6" id="f-1270" unitRef="eur">-122000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions contextRef="c-438" decimals="-6" id="f-1271" unitRef="eur">37000000</sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions>
    <sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions contextRef="c-439" decimals="-6" id="f-1272" unitRef="eur">3000000</sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions>
    <sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions contextRef="c-440" decimals="-6" id="f-1273" unitRef="eur">9000000</sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions>
    <sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions contextRef="c-441" decimals="-6" id="f-1274" unitRef="eur">11000000</sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions>
    <sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions contextRef="c-1" decimals="-6" id="f-1275" unitRef="eur">60000000</sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-438" decimals="-6" id="f-1276" unitRef="eur">18000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-439" decimals="-6" id="f-1277" unitRef="eur">13000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-440" decimals="-6" id="f-1278" unitRef="eur">-47000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-441" decimals="-6" id="f-1279" unitRef="eur">17000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-1" decimals="-6" id="f-1280" unitRef="eur">1000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions contextRef="c-438" decimals="-6" id="f-1281" unitRef="eur">-235000000</sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions>
    <sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions contextRef="c-439" decimals="-6" id="f-1282" unitRef="eur">0</sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions>
    <sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions contextRef="c-440" decimals="-6" id="f-1283" unitRef="eur">0</sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions>
    <sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions contextRef="c-441" decimals="-6" id="f-1284" unitRef="eur">0</sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions>
    <sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions contextRef="c-1" decimals="-6" id="f-1285" unitRef="eur">-235000000</sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-442" decimals="-6" id="f-1286" unitRef="eur">2040000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-443" decimals="-6" id="f-1287" unitRef="eur">759000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-444" decimals="-6" id="f-1288" unitRef="eur">909000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-445" decimals="-6" id="f-1289" unitRef="eur">2210000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-2" decimals="-6" id="f-1290" unitRef="eur">5918000000</ifrs-full:NoncurrentProvisions>
    <sny:DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock contextRef="c-1" id="f-1291">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.827%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.973%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024 (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023 (12 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses) on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses) on benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Includes the effects of (i) the change in discount rates (in a range between +0.40% and +0.65%) and (ii) the change in the inflation rate in the United Kingdom (+0.10%) in the first half of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes the effects of (i) the change in discount rates (in a range between -0.15% and +0.40%) and (ii) the change in the inflation rate in the eurozone (-0.10%) in the first half of 2023.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset contextRef="c-446" decimals="-6" id="f-1292" unitRef="eur">138000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset contextRef="c-447" decimals="-6" id="f-1293" unitRef="eur">-34000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset contextRef="c-448" decimals="-6" id="f-1294" unitRef="eur">208000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-449" decimals="-6" id="f-1295" unitRef="eur">373000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-450" decimals="-6" id="f-1296" unitRef="eur">99000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-451" decimals="-6" id="f-1297" unitRef="eur">379000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="c-452"
      decimals="4"
      id="f-1298"
      unitRef="number">-0.0040</ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="c-453"
      decimals="4"
      id="f-1299"
      unitRef="number">0.0065</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="c-454"
      decimals="4"
      id="f-1300"
      unitRef="number">0.0010</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="c-455"
      decimals="4"
      id="f-1301"
      unitRef="number">-0.0015</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="c-456"
      decimals="4"
      id="f-1302"
      unitRef="number">0.0040</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="c-457"
      decimals="4"
      id="f-1303"
      unitRef="number">-0.0010</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock contextRef="c-1" id="f-1304">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.13. OFF BALANCE SHEET COMMITMENTS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Off balance sheet commitments to third parties as of December&#160;31, 2023 are presented in Note D.21.1. to the consolidated financial statements for the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The principal commitments entered into, amended or discontinued during the period are described below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.18pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.28pt"&gt;On May, 2024, Sanofi entered into a co-exclusive licensing agreement with Novavax. The terms of the agreement include (i)&#160;a co-exclusive license to co-commercialize Novavax&#x2019;s current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements and in India, Japan, and South Korea, where Novavax has existing partnership agreements); (ii) a sole license to Novavax&#x2019;s adjuvanted COVID-19 vaccine for use in combination with Sanofi&#x2019;s flu vaccines; and (iii) a non-exclusive license to use the Matrix-M adjuvant in vaccine products. Novavax received an upfront payment of $500 million and up to $700 million in development, regulatory and launch milestones, representing up to $1.2&#160;billion in total. Starting in 2025, Sanofi will book sales of Novavax&#x2019;s adjuvanted COVID-19 vaccine and will support certain R&amp;amp;D, regulatory, and commercial expenses. Novavax will receive double-digit tiered royalties on sales of COVID-19 vaccines and combined influenza/COVID-19 vaccines made by Sanofi. Novavax is also entitled to additional launch and sales milestones opportunities of up to $200 million, plus single-digit royalties for each additional Sanofi vaccine product developed under a non-exclusive license with Novavax&#x2019;s Matrix-M adjuvant technology. In addition, Sanofi took a minority (&amp;lt;5%) equity investment in Novavax. This agreement will provide patients with broader access from 2025 onwards to a protein-based non-mRNA adjuvanted COVID-19 vaccine. Outside of the collaboration, each party may develop and commercialize their own flu and COVID-19 vaccines and their own adjuvanted products at their own cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.18pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.69pt"&gt;On May, 2024, Sanofi entered into a collaboration and license agreement with Fulcrum Therapeutics for the development and commercialization of losmapimod, an investigational oral therapy for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The agreement combines Fulcrum&#x2019;s FSHD expertise with Sanofi&#x2019;s global reach and commitment to treating people with rare diseases. Under the terms of the agreement, Sanofi obtained exclusive commercialization rights outside of the United States, while Fulcrum retained the US rights. Fulcrum will receive an upfront payment of $80 million, and could receive up to $975 million contingent on the attainment of specified milestones, plus royalties on non-US sales. The two parties will share worldwide development costs equally. Losmapimod, currently in worldwide Phase 3 clinical trials, has demonstrated promising results in slowing the progression of FSHD; data from the Phase 3 trial are expected by end 2024. If the results are positive, Fulcrum and Sanofi intend to file for marketing approval in the United States, Europe, Japan, and other regions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi has also entered into power purchase agreements in furtherance of its ESG strategy. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The characteristics of the principal power purchase agreements in place as of June 30, 2024 are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.190%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Country&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Type of Energy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Annual Volume&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Start Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Type of Contract&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Accounting Treatment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Solar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8 GWh&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;PPA &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Own use&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;procurement contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Wind&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;46 GWh&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Wind&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29 GWh&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Power Purchase Agreement (PPA): long-term renewable energy contract resulting in physical supply of electricity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) At the current stage of analysis, with reference to the own use exception permitted by paragraph 2.4 of IFRS 9.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;These contracts help secure the objective of 100% green electricity supply across all operations of the Group by 2030.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock>
    <sny:UpfrontPayments contextRef="c-458" decimals="-6" id="f-1305" unitRef="usd">500000000</sny:UpfrontPayments>
    <sny:DevelopmentRegulatoryAndLaunchMilestonePayments contextRef="c-458" decimals="-6" id="f-1306" unitRef="usd">700000000</sny:DevelopmentRegulatoryAndLaunchMilestonePayments>
    <sny:TotalMilestonePayments contextRef="c-458" decimals="-8" id="f-1307" unitRef="usd">1200000000</sny:TotalMilestonePayments>
    <sny:AdditionalLaunchAndSalesMilestonePayments contextRef="c-458" decimals="-6" id="f-1308" unitRef="usd">200000000</sny:AdditionalLaunchAndSalesMilestonePayments>
    <sny:UpfrontPayments contextRef="c-459" decimals="-6" id="f-1309" unitRef="usd">80000000</sny:UpfrontPayments>
    <sny:ContingentMilestonePayments contextRef="c-459" decimals="-6" id="f-1310" unitRef="usd">975000000</sny:ContingentMilestonePayments>
    <sny:DisclosureOfLegalAndArbitralProceedingsTextBlock contextRef="c-1" id="f-1311">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.14. LITIGATION AND ARBITRATION PROCEEDINGS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi and its affiliates are involved in litigation, arbitration and other legal proceedings. These proceedings typically are related to product liability claims, intellectual property rights (particularly claims against generic companies seeking to limit the patent protection of Sanofi products), competition law and trade practices, commercial claims, employment and wrongful discharge claims, tax assessment claims, waste disposal and pollution claims, and claims under warranties or indemnification arrangements relating to business divestitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The matters discussed below constitute the most significant developments since publication of the financial statements for the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.14.1. PRODUCTS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;TAXOTERE PRODUCT LITIGATION IN THE US&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2024, there were approximately 6,770 ingesting plaintiffs cases remaining in courts across the country. Throughout the first half of 2024, Sanofi entered into a number of settlement agreements or agreements in principle with many plaintiffs&#x2019; firms encompassing nearly all the remaining cases. These agreements require the consent of the individual plaintiffs and will take some time to conclude, in order to ensure that certain threshold participation requirements are met. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ZANTAC PRODUCT LITIGATION IN THE US&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In March 2024, Sanofi reached agreement in principle with a number of plaintiffs&#x2019; lawyers to resolve Zantac personal injury cases pending against it in all US state courts outside of Delaware. This agreement would resolve approximately 75% of nearly 4,400 cases. The agreement requires the consent of individual plaintiffs and will take some time to conclude.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the State court cases pending in Delaware, the State of Delaware court decided in May 2024 not to exclude plaintiffs&#x2019; experts from the cases. Sanofi is appealing this decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;GOLD BOND PRODUCT LITIGATION IN THE US&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2024, Sanofi is named as a defendant in approximately 600 product liability ongoing actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;DEPAKINE PRODUCT LITIGATION IN FRANCE&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Civil Proceedings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Several questions on the Product Liability Directive have been referred to the European Court of Justice (ECJ), which will have an impact on the pending Depakine cases. A ruling from the ECJ is expected between September and December 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As a result, several stays in the proceedings have been requested including in the class action, the anxiety damage claim, and several individual proceedings. Similar requests will be made in the remaining proceedings (in particular, on appeal), depending on the timescales determined by the Courts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the class action, a hearing is scheduled for September 2024 for this question to be tried. As regards the anxiety damage cases, the ruling is expected on August 2, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;DENGVAXIA PRODUCT LITIGATION IN THE PHILIPPINES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On July 16, 2024, the Court dismissed the first eight criminal cases, ruling the prosecution failed to establish the elements of &#x201c;reckless imprudence&#x201d; resulting in homicide. Remaining cases are still pending at various stages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.14.2. PATENTS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;PRALUENT (alirocumab)-RELATED AMGEN PATENT LITIGATION IN EUROPE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the revocation action filed by Sanofi against Amgen before the Munich Central Division of the Unified Patent Court, a decision on the Amgen patent&#x2019;s validity was issued on July 16, 2024. This decision revokes Amgen&#x2019;s patent, hence supporting Sanofi/Regeneron&#x2019;s position. The decision can be appealed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi and Regeneron have also attacked the validity of the same EP 3 666 797 patent at the European Patent Office. These proceedings are ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.14.3. OTHER LITIGATION&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;PLAVIX (clopidogrel) - ATTORNEY GENERAL ACTION IN HAWAII&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On May 21, 2024, the Court issued a new decision against Sanofi and BMS, imposing penalties in the total amount of $916 million, with $458 million attributed to Sanofi. Sanofi and BMS will appeal the decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;PLAVIX (clopidogrel)-RELATED LITIGATION IN FRANCE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the claim filed by the CNAM, the final expert report was issued in March 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;340B DRUG PRICING PROGRAM IN THE UNITED STATES&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In May 2024, Sanofi filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and Services Administration (HRSA) under the Freedom of Information Act (FOIA) seeking an order declaring that Sanofi is entitled to covered entities&#x2019; pharmacy contracts, requiring HRSA to produce the contracts and enjoining HRSA from withholding pharmacy contracts from Sanofi pursuant to its FOIA request. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Mosaic Health in the United States &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In February 2024, plaintiffs filed a notice of appeal of the dismissal of the complaint by the Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Adventist Health System/West in the United States &lt;/span&gt;&lt;/div&gt;In March 2024, the Court dismissed the action in its entirety, without granting the plaintiff leave to amend its complaint. The plaintiff filed its appeal in April 2024. A decision on the appeal could be delivered during 2025.</sny:DisclosureOfLegalAndArbitralProceedingsTextBlock>
    <sny:NumberOfPlaintiffs
      contextRef="c-460"
      decimals="INF"
      id="f-1312"
      unitRef="proceeding">6770</sny:NumberOfPlaintiffs>
    <sny:NumberOfCases
      contextRef="c-461"
      decimals="INF"
      id="f-1313"
      unitRef="proceeding">4400</sny:NumberOfCases>
    <sny:NumberOfClassActionLawsuits
      contextRef="c-462"
      decimals="INF"
      id="f-1314"
      unitRef="proceeding">600</sny:NumberOfClassActionLawsuits>
    <sny:GlobalPenaltyFeeIncurredByDefendantsAmountVacated contextRef="c-463" decimals="-6" id="f-1315" unitRef="usd">916000000</sny:GlobalPenaltyFeeIncurredByDefendantsAmountVacated>
    <sny:PenaltyFeeIncurred contextRef="c-463" decimals="-6" id="f-1316" unitRef="usd">458000000</sny:PenaltyFeeIncurred>
    <ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory contextRef="c-1" id="f-1317">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.15. OTHER OPERATING INCOME AND EXPENSES&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; amounted to &#x20ac;617 million in the first half of 2024 (versus &#x20ac;617 million in the first half of 2023), and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; to &#x20ac;2,010 million (versus &#x20ac; 1,422 million in the first half of 2023).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The main items included in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; were: in the first half of 2024, (i) income from pharmaceutical partners of &#x20ac;118&#160;million (versus &#x20ac;160 million in the first half of 2023), of which &#x20ac;96 million came from Regeneron (versus &#x20ac;102 million in the first half of 2023, see table below) and (ii) gains on disposals of assets and operations of &#x20ac;389 million, primarily on divestments of non strategic products (versus &#x20ac;413 million in the first half of 2023). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;for the first half of 2024 included &#x20ac;1,841 million of expenses related to Regeneron (compared with &#x20ac;1,423 million in the first half of 2023), as shown in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(12 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Income &amp;amp; expense related to profit/loss sharing under the Monoclonal Antibody Alliance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Additional share of profit paid by Regeneron towards development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Reimbursement to Regeneron of selling expenses incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(543)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total: Monoclonal Antibody Alliance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(3,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other (mainly Zaltrap and Libtayo)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;92&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;97&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;217&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other operating income/(expenses), net related to Regeneron &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(2,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;of which amount presented in &#x201c;Other operating income&#x201d; &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;102&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;227&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-1" decimals="-6" id="f-1318" unitRef="eur">617000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-4" decimals="-6" id="f-1319" unitRef="eur">617000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-1" decimals="-6" id="f-1320" unitRef="eur">2010000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-4" decimals="-6" id="f-1321" unitRef="eur">1422000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-464" decimals="-6" id="f-1322" unitRef="eur">118000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-465" decimals="-6" id="f-1323" unitRef="eur">160000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-466" decimals="-6" id="f-1324" unitRef="eur">96000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-467" decimals="-6" id="f-1325" unitRef="eur">102000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <sny:GainsOnDivestmentOfProducts contextRef="c-464" decimals="-6" id="f-1326" unitRef="eur">389000000</sny:GainsOnDivestmentOfProducts>
    <sny:GainsOnDivestmentOfProducts contextRef="c-465" decimals="-6" id="f-1327" unitRef="eur">413000000</sny:GainsOnDivestmentOfProducts>
    <sny:OtherOperatingExpensesTableTextBlock contextRef="c-1" id="f-1328">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;for the first half of 2024 included &#x20ac;1,841 million of expenses related to Regeneron (compared with &#x20ac;1,423 million in the first half of 2023), as shown in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(12 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Income &amp;amp; expense related to profit/loss sharing under the Monoclonal Antibody Alliance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Additional share of profit paid by Regeneron towards development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Reimbursement to Regeneron of selling expenses incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(543)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total: Monoclonal Antibody Alliance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(3,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other (mainly Zaltrap and Libtayo)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;92&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;97&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;217&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other operating income/(expenses), net related to Regeneron &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(2,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;of which amount presented in &#x201c;Other operating income&#x201d; &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;102&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;227&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:OtherOperatingExpensesTableTextBlock>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-468" decimals="-6" id="f-1329" unitRef="eur">1841000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-469" decimals="-6" id="f-1330" unitRef="eur">1423000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-470" decimals="-6" id="f-1331" unitRef="eur">1934000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-471" decimals="-6" id="f-1332" unitRef="eur">1449000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-472" decimals="-6" id="f-1333" unitRef="eur">3321000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-473" decimals="-6" id="f-1334" unitRef="eur">389000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-474" decimals="-6" id="f-1335" unitRef="eur">291000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-475" decimals="-6" id="f-1336" unitRef="eur">668000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-476" decimals="-6" id="f-1337" unitRef="eur">292000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-477" decimals="-6" id="f-1338" unitRef="eur">260000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-478" decimals="-6" id="f-1339" unitRef="eur">543000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-479" decimals="-6" id="f-1340" unitRef="eur">1837000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-480" decimals="-6" id="f-1341" unitRef="eur">1418000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-481" decimals="-6" id="f-1342" unitRef="eur">3196000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-482" decimals="-6" id="f-1343" unitRef="eur">92000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-483" decimals="-6" id="f-1344" unitRef="eur">97000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-484" decimals="-6" id="f-1345" unitRef="eur">217000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-1" decimals="-6" id="f-1346" unitRef="eur">-1745000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-4" decimals="-6" id="f-1347" unitRef="eur">-1321000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-5" decimals="-6" id="f-1348" unitRef="eur">-2979000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-466" decimals="-6" id="f-1349" unitRef="eur">96000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-467" decimals="-6" id="f-1350" unitRef="eur">102000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-485" decimals="-6" id="f-1351" unitRef="eur">227000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock contextRef="c-1" id="f-1353">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.16. RESTRUCTURING COSTS AND SIMILAR ITEMS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring costs and similar items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;comprise the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(12 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Employee-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Charges, gains or losses on assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Costs of transformation programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,331&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;547&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,490&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Restructuring and similar costs increased by &#x20ac;784 million between June 30, 2023 and June 30, 2024. They mainly comprise costs relating to severance plans announced in the first half of 2024. For the six months ended June 30, 2023 and the year ended December 31, 2023, they included the impact of pension reform in France on future annuities under the rules of each severance plan. Restructuring costs also include Sanofi's ongoing transformation projects, mainly those relating to the separation of the Opella business.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock>
    <sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock contextRef="c-1" id="f-1352">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.16. RESTRUCTURING COSTS AND SIMILAR ITEMS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring costs and similar items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;comprise the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(12 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Employee-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Charges, gains or losses on assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Costs of transformation programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,331&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;547&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,490&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Restructuring and similar costs increased by &#x20ac;784 million between June 30, 2023 and June 30, 2024. They mainly comprise costs relating to severance plans announced in the first half of 2024. For the six months ended June 30, 2023 and the year ended December 31, 2023, they included the impact of pension reform in France on future annuities under the rules of each severance plan. Restructuring costs also include Sanofi's ongoing transformation projects, mainly those relating to the separation of the Opella business.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock>
    <sny:DisclosureOfRestructuringCostsDetailsTableTextBlock contextRef="c-1" id="f-1354">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring costs and similar items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;comprise the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(12 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Employee-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Charges, gains or losses on assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Costs of transformation programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,331&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;547&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,490&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfRestructuringCostsDetailsTableTextBlock>
    <sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses contextRef="c-1" decimals="-6" id="f-1355" unitRef="eur">849000000</sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses>
    <sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses contextRef="c-4" decimals="-6" id="f-1356" unitRef="eur">185000000</sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses>
    <sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses contextRef="c-5" decimals="-6" id="f-1357" unitRef="eur">489000000</sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses>
    <sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories contextRef="c-1" decimals="-6" id="f-1358" unitRef="eur">-31000000</sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories>
    <sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories contextRef="c-4" decimals="-6" id="f-1359" unitRef="eur">86000000</sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories>
    <sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories contextRef="c-5" decimals="-6" id="f-1360" unitRef="eur">293000000</sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories>
    <sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts contextRef="c-1" decimals="-6" id="f-1361" unitRef="eur">347000000</sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts>
    <sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts contextRef="c-4" decimals="-6" id="f-1362" unitRef="eur">265000000</sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts>
    <sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts contextRef="c-5" decimals="-6" id="f-1363" unitRef="eur">676000000</sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts>
    <sny:OtherRestructuringCosts contextRef="c-1" decimals="-6" id="f-1364" unitRef="eur">166000000</sny:OtherRestructuringCosts>
    <sny:OtherRestructuringCosts contextRef="c-4" decimals="-6" id="f-1365" unitRef="eur">11000000</sny:OtherRestructuringCosts>
    <sny:OtherRestructuringCosts contextRef="c-5" decimals="-6" id="f-1366" unitRef="eur">32000000</sny:OtherRestructuringCosts>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-1" decimals="-6" id="f-1367" unitRef="eur">1331000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-4" decimals="-6" id="f-1368" unitRef="eur">547000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-5" decimals="-6" id="f-1369" unitRef="eur">1490000000</ifrs-full:ExpenseOfRestructuringActivities>
    <sny:IncreaseDecreaseInTotalExpenseOfRestructuringActivities contextRef="c-486" decimals="-6" id="f-1370" unitRef="eur">-784000000</sny:IncreaseDecreaseInTotalExpenseOfRestructuringActivities>
    <sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock contextRef="c-1" id="f-1371">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.17. OTHER GAINS AND LOSSES, AND LITIGATION&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For the first half of 2024, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; is a charge of &#x20ac;442 million, mainly comprising a &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;provision recognized in respect of the litigation related to Plavix (clopidogrel) in the US state of Hawaii (see note B.14.)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. That compares with a charge of &#x20ac;73&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; million in the first half of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2023, which comprised costs related to the settlement of a dispute with shareholders of Bioverativ.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock>
    <sny:OtherGainsLossesAndLitigation contextRef="c-1" decimals="-6" id="f-1372" unitRef="eur">-442000000</sny:OtherGainsLossesAndLitigation>
    <sny:OtherGainsLossesAndLitigation contextRef="c-4" decimals="-6" id="f-1373" unitRef="eur">-73000000</sny:OtherGainsLossesAndLitigation>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="c-1" id="f-1374">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.18. FINANCIAL EXPENSES AND INCOME&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;An analysis of financial expenses and income is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(12 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of debt &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(555)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Cost of net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-operating foreign exchange gains/(losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Unwinding of discounting of provisions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest cost related to employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gains/(losses) on disposals of financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net financial income/(expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;comprising: Financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(586)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(370)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;286&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;591&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: &#x20ac;(24) million in the first half of 2024, &#x20ac;(25) million in the first half of 2023, and &#x20ac;(67) million over the whole of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: &#x20ac;(18) million in the first half of 2024, &#x20ac;(4)&#160;million in the first half of 2023, and &#x20ac;(13) million over the whole of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes a financial expense of &#x20ac;176&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;million for the six months ended June 30, 2024 (&#x20ac;541 million for the year ended December 31, 2023, &#x20ac;35 million for the six months ended June 30, 2023) for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the US.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;The impact of the ineffective portion of hedging relationships was not material in either 2024 or 2023.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock contextRef="c-1" id="f-1375">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;An analysis of financial expenses and income is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(12 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of debt &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(555)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Cost of net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-operating foreign exchange gains/(losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Unwinding of discounting of provisions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest cost related to employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gains/(losses) on disposals of financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net financial income/(expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;comprising: Financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(586)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(370)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;286&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;591&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: &#x20ac;(24) million in the first half of 2024, &#x20ac;(25) million in the first half of 2023, and &#x20ac;(67) million over the whole of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: &#x20ac;(18) million in the first half of 2024, &#x20ac;(4)&#160;million in the first half of 2023, and &#x20ac;(13) million over the whole of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes a financial expense of &#x20ac;176&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;million for the six months ended June 30, 2024 (&#x20ac;541 million for the year ended December 31, 2023, &#x20ac;35 million for the six months ended June 30, 2023) for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the US.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock>
    <ifrs-full:InterestExpenseOnBorrowings contextRef="c-1" decimals="-6" id="f-1376" unitRef="eur">309000000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings contextRef="c-4" decimals="-6" id="f-1377" unitRef="eur">232000000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings contextRef="c-5" decimals="-6" id="f-1378" unitRef="eur">555000000</ifrs-full:InterestExpenseOnBorrowings>
    <sny:InterestIncome contextRef="c-1" decimals="-6" id="f-1379" unitRef="eur">243000000</sny:InterestIncome>
    <sny:InterestIncome contextRef="c-4" decimals="-6" id="f-1380" unitRef="eur">257000000</sny:InterestIncome>
    <sny:InterestIncome contextRef="c-5" decimals="-6" id="f-1381" unitRef="eur">533000000</sny:InterestIncome>
    <sny:CostOfDebtNet contextRef="c-1" decimals="-6" id="f-1382" unitRef="eur">66000000</sny:CostOfDebtNet>
    <sny:CostOfDebtNet contextRef="c-4" decimals="-6" id="f-1383" unitRef="eur">-25000000</sny:CostOfDebtNet>
    <sny:CostOfDebtNet contextRef="c-5" decimals="-6" id="f-1384" unitRef="eur">22000000</sny:CostOfDebtNet>
    <sny:NonOperatingForeignExchangeGainsLosses contextRef="c-1" decimals="-6" id="f-1385" unitRef="eur">1000000</sny:NonOperatingForeignExchangeGainsLosses>
    <sny:NonOperatingForeignExchangeGainsLosses contextRef="c-4" decimals="-6" id="f-1386" unitRef="eur">-3000000</sny:NonOperatingForeignExchangeGainsLosses>
    <sny:NonOperatingForeignExchangeGainsLosses contextRef="c-5" decimals="-6" id="f-1387" unitRef="eur">-2000000</sny:NonOperatingForeignExchangeGainsLosses>
    <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="c-1" decimals="-6" id="f-1388" unitRef="eur">17000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
    <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="c-4" decimals="-6" id="f-1389" unitRef="eur">22000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
    <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="c-5" decimals="-6" id="f-1390" unitRef="eur">59000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
    <sny:NetInterestCostRelatedToEmployeeBenefits contextRef="c-1" decimals="-6" id="f-1391" unitRef="eur">40000000</sny:NetInterestCostRelatedToEmployeeBenefits>
    <sny:NetInterestCostRelatedToEmployeeBenefits contextRef="c-4" decimals="-6" id="f-1392" unitRef="eur">41000000</sny:NetInterestCostRelatedToEmployeeBenefits>
    <sny:NetInterestCostRelatedToEmployeeBenefits contextRef="c-5" decimals="-6" id="f-1393" unitRef="eur">73000000</sny:NetInterestCostRelatedToEmployeeBenefits>
    <ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets contextRef="c-1" decimals="-6" id="f-1394" unitRef="eur">0</ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets>
    <ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets contextRef="c-4" decimals="-6" id="f-1395" unitRef="eur">0</ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets>
    <ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets contextRef="c-5" decimals="-6" id="f-1396" unitRef="eur">-1000000</ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-1" decimals="-6" id="f-1397" unitRef="eur">22000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-4" decimals="-6" id="f-1398" unitRef="eur">21000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-5" decimals="-6" id="f-1399" unitRef="eur">39000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:OtherFinanceIncomeCost contextRef="c-1" decimals="-6" id="f-1400" unitRef="eur">-161000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="c-4" decimals="-6" id="f-1401" unitRef="eur">-22000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="c-5" decimals="-6" id="f-1402" unitRef="eur">-526000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c-1" decimals="-6" id="f-1403" unitRef="eur">-305000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c-4" decimals="-6" id="f-1404" unitRef="eur">-84000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c-5" decimals="-6" id="f-1405" unitRef="eur">-722000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-6" id="f-1406" unitRef="eur">586000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-4" decimals="-6" id="f-1407" unitRef="eur">370000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-5" decimals="-6" id="f-1408" unitRef="eur">1313000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-6" id="f-1409" unitRef="eur">281000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-4" decimals="-6" id="f-1410" unitRef="eur">286000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-5" decimals="-6" id="f-1411" unitRef="eur">591000000</ifrs-full:FinanceIncome>
    <sny:GainLossOnDerivativesUsedToManageDebt contextRef="c-487" decimals="-6" id="f-1412" unitRef="eur">-24000000</sny:GainLossOnDerivativesUsedToManageDebt>
    <sny:GainLossOnDerivativesUsedToManageDebt contextRef="c-488" decimals="-6" id="f-1413" unitRef="eur">-25000000</sny:GainLossOnDerivativesUsedToManageDebt>
    <sny:GainLossOnDerivativesUsedToManageDebt contextRef="c-489" decimals="-6" id="f-1414" unitRef="eur">-67000000</sny:GainLossOnDerivativesUsedToManageDebt>
    <sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents contextRef="c-487" decimals="-6" id="f-1415" unitRef="eur">-18000000</sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents>
    <sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents contextRef="c-488" decimals="-6" id="f-1416" unitRef="eur">-4000000</sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents>
    <sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents contextRef="c-489" decimals="-6" id="f-1417" unitRef="eur">-13000000</sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents>
    <sny:LiabilityRecognisedForEstimatedFutureRoyalties contextRef="c-1" decimals="-6" id="f-1418" unitRef="eur">-176000000</sny:LiabilityRecognisedForEstimatedFutureRoyalties>
    <sny:LiabilityRecognisedForEstimatedFutureRoyalties contextRef="c-5" decimals="-6" id="f-1419" unitRef="eur">-541000000</sny:LiabilityRecognisedForEstimatedFutureRoyalties>
    <sny:LiabilityRecognisedForEstimatedFutureRoyalties contextRef="c-4" decimals="-6" id="f-1420" unitRef="eur">-35000000</sny:LiabilityRecognisedForEstimatedFutureRoyalties>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c-1" id="f-1421">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.19. INCOME TAX EXPENSE&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi has elected for tax consolidations in a number of countries, principally France, Germany, the United Kingdom and the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the allocation of income tax expense between current and deferred taxes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(12 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,739&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,238&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,153&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(as a percentage)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6 months)&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023  (6 months)&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(12 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Standard tax rate applicable in France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Difference between the standard French tax rate and the rates applicable to Sanofi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(14.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(13.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Probable reversal of temporary differences on investments in Opella subsidiaries &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revisions to tax exposures and settlements of tax disputes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurement of contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;16.9&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;17.3&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;22.4&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;In accordance with IAS12, a deferred tax liability was recognised in 2023 on the temporary differences arising on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Opella business, as announced in October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;For the six months ended June 30, 2024, this line includes a tax expense of &#x20ac;52 million, representing the estimated impact of Pillar 2 based on Sanofi&#x2019;s current understanding of Pillar Two rules.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock contextRef="c-1" id="f-1422">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the allocation of income tax expense between current and deferred taxes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(12 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,739&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,238&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,153&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c-1" decimals="-6" id="f-1423" unitRef="eur">1243000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c-4" decimals="-6" id="f-1424" unitRef="eur">1171000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c-5" decimals="-6" id="f-1425" unitRef="eur">2560000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="c-1" decimals="-6" id="f-1426" unitRef="eur">-780000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="c-4" decimals="-6" id="f-1427" unitRef="eur">-441000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="c-5" decimals="-6" id="f-1428" unitRef="eur">-958000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-6" id="f-1429" unitRef="eur">463000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-4" decimals="-6" id="f-1430" unitRef="eur">730000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-5" decimals="-6" id="f-1431" unitRef="eur">1602000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-1432" unitRef="eur">2739000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-4" decimals="-6" id="f-1433" unitRef="eur">4238000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-5" decimals="-6" id="f-1434" unitRef="eur">7153000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock contextRef="c-1" id="f-1435">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(as a percentage)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6 months)&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023  (6 months)&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(12 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Standard tax rate applicable in France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Difference between the standard French tax rate and the rates applicable to Sanofi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(14.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(13.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Probable reversal of temporary differences on investments in Opella subsidiaries &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revisions to tax exposures and settlements of tax disputes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurement of contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;16.9&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;17.3&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;22.4&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;In accordance with IAS12, a deferred tax liability was recognised in 2023 on the temporary differences arising on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Opella business, as announced in October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;For the six months ended June 30, 2024, this line includes a tax expense of &#x20ac;52 million, representing the estimated impact of Pillar 2 based on Sanofi&#x2019;s current understanding of Pillar Two rules.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock>
    <ifrs-full:ApplicableTaxRate contextRef="c-1" decimals="3" id="f-1436" unitRef="number">0.258</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c-4" decimals="3" id="f-1437" unitRef="number">0.258</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c-5" decimals="3" id="f-1438" unitRef="number">0.258</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxRateEffectOfForeignTaxRates contextRef="c-1" decimals="3" id="f-1439" unitRef="number">-0.143</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <ifrs-full:TaxRateEffectOfForeignTaxRates contextRef="c-4" decimals="3" id="f-1440" unitRef="number">-0.082</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <ifrs-full:TaxRateEffectOfForeignTaxRates contextRef="c-5" decimals="3" id="f-1441" unitRef="number">-0.136</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <sny:TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments contextRef="c-1" decimals="3" id="f-1442" unitRef="number">0</sny:TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments>
    <sny:TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments contextRef="c-4" decimals="3" id="f-1443" unitRef="number">0</sny:TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments>
    <sny:TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments contextRef="c-5" decimals="3" id="f-1444" unitRef="number">0.051</sny:TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments>
    <sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes contextRef="c-1" decimals="3" id="f-1445" unitRef="number">0.032</sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes>
    <sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes contextRef="c-4" decimals="3" id="f-1446" unitRef="number">0.005</sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes>
    <sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes contextRef="c-5" decimals="3" id="f-1447" unitRef="number">0.027</sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes>
    <sny:TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations contextRef="c-1" decimals="3" id="f-1448" unitRef="number">0</sny:TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations>
    <sny:TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations contextRef="c-4" decimals="3" id="f-1449" unitRef="number">0</sny:TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations>
    <sny:TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations contextRef="c-5" decimals="3" id="f-1450" unitRef="number">0.001</sny:TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-1" decimals="3" id="f-1451" unitRef="number">0.022</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-4" decimals="3" id="f-1452" unitRef="number">-0.008</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-5" decimals="3" id="f-1453" unitRef="number">0.023</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-1" decimals="3" id="f-1454" unitRef="number">0.169</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-4" decimals="3" id="f-1455" unitRef="number">0.173</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-5" decimals="3" id="f-1456" unitRef="number">0.224</ifrs-full:AverageEffectiveTaxRate>
    <sny:CurrentTaxExpenseRelatedToPillarTwo contextRef="c-1" decimals="-6" id="f-1457" unitRef="eur">52000000</sny:CurrentTaxExpenseRelatedToPillarTwo>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="c-1" id="f-1458">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;B.20. SEGMENT INFORMATION&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi reports two operating segments: Biopharma and Opella (formerly Consumer Healthcare &#x2013; CHC).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises, for all geographical territories. The segment&#x2019;s results include the costs of global support functions that are not within the managerial responsibility of the Opella GBU.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The Opella operating segment comprises commercial operations relating to consumer healthcare products, and research, development and production activities and global support functions (as listed above) dedicated to the segment, for all geographical territories. The Opella GBU segment&#x2019;s results reflect all incurred costs of global support functions attributable to its business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The &#x201c;Other&#x201d; category comprises reconciling items, primarily but not limited to (i)&#160;gains and losses on centralized foreign exchange risk hedging transactions that cannot be allocated to the operating segments and (ii)&#160;gains and losses on retained commitments in respect of previously divested operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.20.1. SEGMENT RESULTS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.20.1.1. Analysis of net sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth net sales for the six months ended June 30, 2024 and June 30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#d9c6f9;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,074&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;8,294&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;6,010&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;18,378&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,194&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,366&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,907&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;17,467&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total Pharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,692&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,550&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,817&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;16,059&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,624&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;6,709&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,744&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;15,077&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:1pt solid #deb3ff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Dupixent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;770&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,437&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;931&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;6,138&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;587&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,682&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;609&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,878&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total Pharma launches&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;249&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;868&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;178&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,295&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;168&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;460&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;87&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;715&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Nexviazyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sarclisa&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;ALTUVIIIO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Rezurock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cablivi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Xenpozyme&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Enjaymo&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Tzield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total other products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,673&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,245&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,708&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;8,626&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,869&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,567&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,048&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;9,484&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Industrial sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;382&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;744&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,193&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,319&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;570&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;657&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,163&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,390&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Influenza Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Polio/Pertussis/&lt;br/&gt;Hib Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;RSV vaccines (Beyfortus)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Meningitis, travel and endemics vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total Opella&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;808&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;773&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,250&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,831&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;840&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;622&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,258&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,720&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Seasonal symptoms &amp;amp; pain relief&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Wellness brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Others&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,882&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;9,067&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,260&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21,209&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,034&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,988&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,165&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;20,187&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.20.1.2. Business operating income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi reports segment results on the basis of &#x201c;Business operating income&#x201d;, a non-IFRS financial measure used internally by the chief operating decision maker to measure the performance of each operating segment and to allocate resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x201c;Business operating income&#x201d; is derived from&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, adjusted as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the amounts reported in the line items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring costs and similar items, Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; relating to business combinations (IFRS 3) or divestments and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;expenses arising from the remeasurement of inventories following a business combination (IFRS 3) are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature) are eliminated; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the share of profits/losses from investments accounted for using the equity method is added for joint ventures and associates with which Sanofi has entered into a strategic partnership agreement; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;net income attributable to non-controlling interests is deducted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Segment results are shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.340%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.702%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.949%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.949%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.949%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.951%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024 (6 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Opella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;18,378&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,831&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21,209&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,756)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,417)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,931&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;739&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,656&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) &#160;&#160;&#160;&#160;The &#x201c;Other&#x201d; column reconciles segmental results to the total per the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.403%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.235%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.781%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023 (6 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Opella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;17,467&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,720&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;20,187&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(949)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,082)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(936)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(897)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,220&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;850&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;6,059&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;The &#x201c;Other&#x201d; column reconciles segmental results to the total per the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.554%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.210%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.906%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.125%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023 (12 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Opella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;37,890&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,180&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;43,070&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12,282)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,933)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(14,216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;11,247&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,438&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;12,670&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;The &#x201c;Other&#x201d; column reconciles segmental results to the total per the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below, presented in compliance with IFRS 8, shows a reconciliation between &#x201c;Business operating income&#x201d; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024 ( 6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023 ( 6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023 (12 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,656&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;6,059&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;12,670&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Share of profit/(loss) from investments accounted for using the equity method &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Net income attributable to non-controlling interests &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortization and impairment of intangible assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Expense arising from the impact of acquisitions on inventories &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Restructuring costs and similar items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(547)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other gains and losses, and litigation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(442)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,044&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,322&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,875&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,739&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,238&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,153&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Joint ventures and associates with which Sanofi has entered into a strategic alliance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;As of June 30, 2024, this line includes a net reversal of impairment losses amounting to of &#x20ac;371&#160;million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights in the Biopharma segment. For 2023, this amount mainly comprises an impairment loss of &#x20ac;833&#160;million, reflecting the impact of the strategic decision to de-prioritize certain R&amp;amp;D programs, in particular those related to the NK Cell and PRO-XTEN technology platforms. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt"&gt;See note B.16.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt"&gt;See note B.17.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.20.2. OTHER SEGMENT INFORMATION&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The tables below show the split by operating segment of (i)&#160;the carrying amount of investments accounted for using the equity method for which Sanofi has entered into a strategic partnership agreement, (ii)&#160;acquisitions of property, plant and equipment, and (iii)&#160;acquisitions of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Investments accounted for using the equity method in the Biopharma segment mainly comprise MSP Vaccine Company and Infraserv GmbH &amp;amp; Co. H&#xf6;chst&#160;KG (see Note B.5.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024 (6 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Opella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments accounted for using the equity method &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Carrying amount at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023 (6 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Opella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments accounted for using the equity method &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of other intangible assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Carrying amount at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023 (12 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Opella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments accounted for using the equity method &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Carrying amount at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.20.3. INFORMATION BY GEOGRAPHICAL REGION&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The geographical information on net sales provided below is based on the geographical location of the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.188%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;of which France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other countries&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21,209&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,882&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,082&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;9,067&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,260&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt"&gt;property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt"&gt;goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt"&gt;other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.266%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.230%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;of which France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other countries&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;20,187&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,034&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,174&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,988&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,165&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt"&gt;property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt"&gt;goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt"&gt;other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.266%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.230%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023  (12 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;of which France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other countries&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;43,070&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;10,392&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,379&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;18,512&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;14,166&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt"&gt;property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt"&gt;goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt"&gt;other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As stated in Note D.5. to the consolidated financial statements for the year ended December 31, 2023, goodwill is not allocated by geographical region.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <sny:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1459"
      unitRef="segment">2</sny:NumberOfOperatingSegments>
    <sny:DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock contextRef="c-1" id="f-1460">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth net sales for the six months ended June 30, 2024 and June 30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#d9c6f9;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,074&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;8,294&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;6,010&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;18,378&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,194&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,366&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,907&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;17,467&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total Pharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,692&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,550&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,817&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;16,059&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,624&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;6,709&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,744&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;15,077&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:1pt solid #deb3ff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Dupixent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;770&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,437&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;931&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;6,138&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;587&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,682&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;609&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,878&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total Pharma launches&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;249&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;868&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;178&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,295&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;168&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;460&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;87&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;715&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Nexviazyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sarclisa&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;ALTUVIIIO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Rezurock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cablivi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Xenpozyme&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Enjaymo&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Tzield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total other products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,673&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,245&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,708&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;8,626&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,869&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,567&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,048&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;9,484&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #deb3ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Industrial sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #deb3ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #deb3ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;382&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;744&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,193&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,319&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;570&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;657&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,163&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,390&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Influenza Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Polio/Pertussis/&lt;br/&gt;Hib Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;RSV vaccines (Beyfortus)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Meningitis, travel and endemics vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total Opella&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;808&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;773&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,250&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,831&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;840&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;622&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,258&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,720&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d9c6f9;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Seasonal symptoms &amp;amp; pain relief&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Wellness brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Others&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,882&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;9,067&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,260&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21,209&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,034&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,988&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,165&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;20,187&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-490" decimals="-6" id="f-1461" unitRef="eur">4074000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-491" decimals="-6" id="f-1462" unitRef="eur">8294000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-492" decimals="-6" id="f-1463" unitRef="eur">6010000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-77" decimals="-6" id="f-1464" unitRef="eur">18378000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-493" decimals="-6" id="f-1465" unitRef="eur">4194000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-494" decimals="-6" id="f-1466" unitRef="eur">7366000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-495" decimals="-6" id="f-1467" unitRef="eur">5907000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-496" decimals="-6" id="f-1468" unitRef="eur">17467000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-497" decimals="-6" id="f-1469" unitRef="eur">3692000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-498" decimals="-6" id="f-1470" unitRef="eur">7550000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-499" decimals="-6" id="f-1471" unitRef="eur">4817000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-500" decimals="-6" id="f-1472" unitRef="eur">16059000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-501" decimals="-6" id="f-1473" unitRef="eur">3624000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-502" decimals="-6" id="f-1474" unitRef="eur">6709000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-503" decimals="-6" id="f-1475" unitRef="eur">4744000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-504" decimals="-6" id="f-1476" unitRef="eur">15077000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-505" decimals="-6" id="f-1477" unitRef="eur">770000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-506" decimals="-6" id="f-1478" unitRef="eur">4437000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-507" decimals="-6" id="f-1479" unitRef="eur">931000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-508" decimals="-6" id="f-1480" unitRef="eur">6138000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-509" decimals="-6" id="f-1481" unitRef="eur">587000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-510" decimals="-6" id="f-1482" unitRef="eur">3682000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-511" decimals="-6" id="f-1483" unitRef="eur">609000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-512" decimals="-6" id="f-1484" unitRef="eur">4878000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-513" decimals="-6" id="f-1485" unitRef="eur">249000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-514" decimals="-6" id="f-1486" unitRef="eur">868000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-515" decimals="-6" id="f-1487" unitRef="eur">178000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-516" decimals="-6" id="f-1488" unitRef="eur">1295000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-517" decimals="-6" id="f-1489" unitRef="eur">168000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-518" decimals="-6" id="f-1490" unitRef="eur">460000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-519" decimals="-6" id="f-1491" unitRef="eur">87000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-520" decimals="-6" id="f-1492" unitRef="eur">715000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-521" decimals="-6" id="f-1493" unitRef="eur">95000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-522" decimals="-6" id="f-1494" unitRef="eur">174000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-523" decimals="-6" id="f-1495" unitRef="eur">51000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-524" decimals="-6" id="f-1496" unitRef="eur">320000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-525" decimals="-6" id="f-1497" unitRef="eur">42000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-526" decimals="-6" id="f-1498" unitRef="eur">123000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-527" decimals="-6" id="f-1499" unitRef="eur">19000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-528" decimals="-6" id="f-1500" unitRef="eur">184000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-529" decimals="-6" id="f-1501" unitRef="eur">64000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-530" decimals="-6" id="f-1502" unitRef="eur">100000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-531" decimals="-6" id="f-1503" unitRef="eur">63000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-532" decimals="-6" id="f-1504" unitRef="eur">227000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-533" decimals="-6" id="f-1505" unitRef="eur">56000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-534" decimals="-6" id="f-1506" unitRef="eur">76000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-535" decimals="-6" id="f-1507" unitRef="eur">49000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-536" decimals="-6" id="f-1508" unitRef="eur">181000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-537" decimals="-6" id="f-1509" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-538" decimals="-6" id="f-1510" unitRef="eur">259000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-539" decimals="-6" id="f-1511" unitRef="eur">21000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-540" decimals="-6" id="f-1512" unitRef="eur">280000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-541" decimals="-6" id="f-1513" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-542" decimals="-6" id="f-1514" unitRef="eur">17000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-543" decimals="-6" id="f-1515" unitRef="eur">2000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-544" decimals="-6" id="f-1516" unitRef="eur">19000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-545" decimals="-6" id="f-1517" unitRef="eur">12000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-546" decimals="-6" id="f-1518" unitRef="eur">188000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-547" decimals="-6" id="f-1519" unitRef="eur">7000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-548" decimals="-6" id="f-1520" unitRef="eur">207000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-549" decimals="-6" id="f-1521" unitRef="eur">2000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-550" decimals="-6" id="f-1522" unitRef="eur">140000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-551" decimals="-6" id="f-1523" unitRef="eur">-1000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-552" decimals="-6" id="f-1524" unitRef="eur">141000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-553" decimals="-6" id="f-1525" unitRef="eur">43000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-554" decimals="-6" id="f-1526" unitRef="eur">60000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-555" decimals="-6" id="f-1527" unitRef="eur">10000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-556" decimals="-6" id="f-1528" unitRef="eur">113000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-557" decimals="-6" id="f-1529" unitRef="eur">49000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-558" decimals="-6" id="f-1530" unitRef="eur">58000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-559" decimals="-6" id="f-1531" unitRef="eur">6000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-560" decimals="-6" id="f-1532" unitRef="eur">113000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-561" decimals="-6" id="f-1533" unitRef="eur">24000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-562" decimals="-6" id="f-1534" unitRef="eur">37000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-563" decimals="-6" id="f-1535" unitRef="eur">11000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-564" decimals="-6" id="f-1536" unitRef="eur">72000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-565" decimals="-6" id="f-1537" unitRef="eur">15000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-566" decimals="-6" id="f-1538" unitRef="eur">21000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-567" decimals="-6" id="f-1539" unitRef="eur">2000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-568" decimals="-6" id="f-1540" unitRef="eur">38000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-569" decimals="-6" id="f-1541" unitRef="eur">10000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-570" decimals="-6" id="f-1542" unitRef="eur">30000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-571" decimals="-6" id="f-1543" unitRef="eur">15000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-572" decimals="-6" id="f-1544" unitRef="eur">55000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-573" decimals="-6" id="f-1545" unitRef="eur">4000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-574" decimals="-6" id="f-1546" unitRef="eur">19000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-575" decimals="-6" id="f-1547" unitRef="eur">10000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-576" decimals="-6" id="f-1548" unitRef="eur">33000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-577" decimals="-6" id="f-1549" unitRef="eur">1000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-578" decimals="-6" id="f-1550" unitRef="eur">20000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-579" decimals="-6" id="f-1551" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-580" decimals="-6" id="f-1552" unitRef="eur">21000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-581" decimals="-6" id="f-1553" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-582" decimals="-6" id="f-1554" unitRef="eur">6000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-579" decimals="-6" id="f-1555" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-583" decimals="-6" id="f-1556" unitRef="eur">6000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-584" decimals="-6" id="f-1557" unitRef="eur">2673000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-585" decimals="-6" id="f-1558" unitRef="eur">2245000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-586" decimals="-6" id="f-1559" unitRef="eur">3708000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-587" decimals="-6" id="f-1560" unitRef="eur">8626000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-588" decimals="-6" id="f-1561" unitRef="eur">2869000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-589" decimals="-6" id="f-1562" unitRef="eur">2567000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-590" decimals="-6" id="f-1563" unitRef="eur">4048000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-591" decimals="-6" id="f-1564" unitRef="eur">9484000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-592" decimals="-6" id="f-1565" unitRef="eur">274000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-593" decimals="-6" id="f-1566" unitRef="eur">3000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-594" decimals="-6" id="f-1567" unitRef="eur">1000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-595" decimals="-6" id="f-1568" unitRef="eur">278000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-596" decimals="-6" id="f-1569" unitRef="eur">264000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-597" decimals="-6" id="f-1570" unitRef="eur">3000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-598" decimals="-6" id="f-1571" unitRef="eur">13000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-599" decimals="-6" id="f-1572" unitRef="eur">280000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-600" decimals="-6" id="f-1573" unitRef="eur">382000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-601" decimals="-6" id="f-1574" unitRef="eur">744000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-602" decimals="-6" id="f-1575" unitRef="eur">1193000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-603" decimals="-6" id="f-1576" unitRef="eur">2319000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-604" decimals="-6" id="f-1577" unitRef="eur">570000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-605" decimals="-6" id="f-1578" unitRef="eur">657000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-606" decimals="-6" id="f-1579" unitRef="eur">1163000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-607" decimals="-6" id="f-1580" unitRef="eur">2390000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-608" decimals="-6" id="f-1581" unitRef="eur">30000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-609" decimals="-6" id="f-1582" unitRef="eur">16000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-610" decimals="-6" id="f-1583" unitRef="eur">142000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-611" decimals="-6" id="f-1584" unitRef="eur">188000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-612" decimals="-6" id="f-1585" unitRef="eur">37000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-613" decimals="-6" id="f-1586" unitRef="eur">19000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-614" decimals="-6" id="f-1587" unitRef="eur">106000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-615" decimals="-6" id="f-1588" unitRef="eur">162000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-616" decimals="-6" id="f-1589" unitRef="eur">248000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-617" decimals="-6" id="f-1590" unitRef="eur">311000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-618" decimals="-6" id="f-1591" unitRef="eur">789000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-619" decimals="-6" id="f-1592" unitRef="eur">1348000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-620" decimals="-6" id="f-1593" unitRef="eur">231000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-621" decimals="-6" id="f-1594" unitRef="eur">347000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-622" decimals="-6" id="f-1595" unitRef="eur">850000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-623" decimals="-6" id="f-1596" unitRef="eur">1428000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-624" decimals="-6" id="f-1597" unitRef="eur">7000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-625" decimals="-6" id="f-1598" unitRef="eur">116000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-626" decimals="-6" id="f-1599" unitRef="eur">77000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-627" decimals="-6" id="f-1600" unitRef="eur">200000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-628" decimals="-6" id="f-1601" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-629" decimals="-6" id="f-1602" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-630" decimals="-6" id="f-1603" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-631" decimals="-6" id="f-1604" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-632" decimals="-6" id="f-1605" unitRef="eur">97000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-633" decimals="-6" id="f-1606" unitRef="eur">301000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-634" decimals="-6" id="f-1607" unitRef="eur">184000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-635" decimals="-6" id="f-1608" unitRef="eur">582000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-636" decimals="-6" id="f-1609" unitRef="eur">72000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-637" decimals="-6" id="f-1610" unitRef="eur">291000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-638" decimals="-6" id="f-1611" unitRef="eur">206000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-639" decimals="-6" id="f-1612" unitRef="eur">569000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-640" decimals="-6" id="f-1613" unitRef="eur">808000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-641" decimals="-6" id="f-1614" unitRef="eur">773000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-642" decimals="-6" id="f-1615" unitRef="eur">1250000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-81" decimals="-6" id="f-1616" unitRef="eur">2831000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-643" decimals="-6" id="f-1617" unitRef="eur">840000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-644" decimals="-6" id="f-1618" unitRef="eur">622000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-645" decimals="-6" id="f-1619" unitRef="eur">1258000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-646" decimals="-6" id="f-1620" unitRef="eur">2720000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-647" decimals="-6" id="f-1621" unitRef="eur">1216000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-648" decimals="-6" id="f-1622" unitRef="eur">1261000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-649" decimals="-6" id="f-1623" unitRef="eur">1258000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-650" decimals="-6" id="f-1624" unitRef="eur">1112000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-651" decimals="-6" id="f-1625" unitRef="eur">357000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-652" decimals="-6" id="f-1626" unitRef="eur">347000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-653" decimals="-6" id="f-1627" unitRef="eur">4882000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-654" decimals="-6" id="f-1628" unitRef="eur">9067000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-655" decimals="-6" id="f-1629" unitRef="eur">7260000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-1" decimals="-6" id="f-1630" unitRef="eur">21209000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-656" decimals="-6" id="f-1631" unitRef="eur">5034000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-657" decimals="-6" id="f-1632" unitRef="eur">7988000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-658" decimals="-6" id="f-1633" unitRef="eur">7165000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-4" decimals="-6" id="f-1634" unitRef="eur">20187000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="c-1" id="f-1635">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Segment results are shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.340%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.702%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.949%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.949%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.949%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.951%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024 (6 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Opella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;18,378&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,831&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21,209&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,756)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,417)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,931&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;739&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,656&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) &#160;&#160;&#160;&#160;The &#x201c;Other&#x201d; column reconciles segmental results to the total per the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.403%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.235%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.781%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023 (6 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Opella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;17,467&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,720&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;20,187&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(949)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,082)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(936)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(897)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,220&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;850&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;6,059&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;The &#x201c;Other&#x201d; column reconciles segmental results to the total per the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.554%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.210%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.906%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.125%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023 (12 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Opella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;37,890&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,180&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;43,070&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12,282)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,933)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(14,216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;11,247&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,438&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;12,670&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;The &#x201c;Other&#x201d; column reconciles segmental results to the total per the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-77" decimals="-6" id="f-1636" unitRef="eur">18378000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-81" decimals="-6" id="f-1637" unitRef="eur">2831000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-659" decimals="-6" id="f-1638" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-660" decimals="-6" id="f-1639" unitRef="eur">21209000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:OtherRevenue contextRef="c-77" decimals="-6" id="f-1640" unitRef="eur">1257000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-81" decimals="-6" id="f-1641" unitRef="eur">32000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-659" decimals="-6" id="f-1642" unitRef="eur">0</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-660" decimals="-6" id="f-1643" unitRef="eur">1289000000</ifrs-full:OtherRevenue>
    <ifrs-full:CostOfSales contextRef="c-77" decimals="-6" id="f-1644" unitRef="eur">5756000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-81" decimals="-6" id="f-1645" unitRef="eur">1077000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-659" decimals="-6" id="f-1646" unitRef="eur">-3000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-660" decimals="-6" id="f-1647" unitRef="eur">6830000000</ifrs-full:CostOfSales>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-77" decimals="-6" id="f-1648" unitRef="eur">3331000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-81" decimals="-6" id="f-1649" unitRef="eur">92000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-659" decimals="-6" id="f-1650" unitRef="eur">0</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-660" decimals="-6" id="f-1651" unitRef="eur">3423000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-77" decimals="-6" id="f-1652" unitRef="eur">4260000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-81" decimals="-6" id="f-1653" unitRef="eur">1002000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-659" decimals="-6" id="f-1654" unitRef="eur">-2000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-660" decimals="-6" id="f-1655" unitRef="eur">5260000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-77" decimals="-6" id="f-1656" unitRef="eur">-1417000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-81" decimals="-6" id="f-1657" unitRef="eur">43000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-659" decimals="-6" id="f-1658" unitRef="eur">-19000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-660" decimals="-6" id="f-1659" unitRef="eur">-1393000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-77" decimals="-6" id="f-1660" unitRef="eur">66000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-81" decimals="-6" id="f-1661" unitRef="eur">9000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-659" decimals="-6" id="f-1662" unitRef="eur">0</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-660" decimals="-6" id="f-1663" unitRef="eur">75000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-77" decimals="-6" id="f-1664" unitRef="eur">-6000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-81" decimals="-6" id="f-1665" unitRef="eur">-5000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-659" decimals="-6" id="f-1666" unitRef="eur">0</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-660" decimals="-6" id="f-1667" unitRef="eur">-11000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <sny:BusinessOperatingIncome contextRef="c-77" decimals="-6" id="f-1668" unitRef="eur">4931000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-81" decimals="-6" id="f-1669" unitRef="eur">739000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-659" decimals="-6" id="f-1670" unitRef="eur">-14000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-660" decimals="-6" id="f-1671" unitRef="eur">5656000000</sny:BusinessOperatingIncome>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-496" decimals="-6" id="f-1672" unitRef="eur">17467000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-646" decimals="-6" id="f-1673" unitRef="eur">2720000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-661" decimals="-6" id="f-1674" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-662" decimals="-6" id="f-1675" unitRef="eur">20187000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:OtherRevenue contextRef="c-496" decimals="-6" id="f-1676" unitRef="eur">1331000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-646" decimals="-6" id="f-1677" unitRef="eur">27000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-661" decimals="-6" id="f-1678" unitRef="eur">0</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-662" decimals="-6" id="f-1679" unitRef="eur">1358000000</ifrs-full:OtherRevenue>
    <ifrs-full:CostOfSales contextRef="c-496" decimals="-6" id="f-1680" unitRef="eur">5388000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-646" decimals="-6" id="f-1681" unitRef="eur">949000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-661" decimals="-6" id="f-1682" unitRef="eur">5000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-662" decimals="-6" id="f-1683" unitRef="eur">6342000000</ifrs-full:CostOfSales>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-496" decimals="-6" id="f-1684" unitRef="eur">3082000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-646" decimals="-6" id="f-1685" unitRef="eur">111000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-661" decimals="-6" id="f-1686" unitRef="eur">0</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-662" decimals="-6" id="f-1687" unitRef="eur">3193000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-496" decimals="-6" id="f-1688" unitRef="eur">4248000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-646" decimals="-6" id="f-1689" unitRef="eur">936000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-661" decimals="-6" id="f-1690" unitRef="eur">-2000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-662" decimals="-6" id="f-1691" unitRef="eur">5182000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-496" decimals="-6" id="f-1692" unitRef="eur">-897000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-646" decimals="-6" id="f-1693" unitRef="eur">100000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-661" decimals="-6" id="f-1694" unitRef="eur">-8000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-662" decimals="-6" id="f-1695" unitRef="eur">-805000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-496" decimals="-6" id="f-1696" unitRef="eur">48000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-646" decimals="-6" id="f-1697" unitRef="eur">7000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-661" decimals="-6" id="f-1698" unitRef="eur">0</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-662" decimals="-6" id="f-1699" unitRef="eur">55000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-496" decimals="-6" id="f-1700" unitRef="eur">-11000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-646" decimals="-6" id="f-1701" unitRef="eur">-8000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-661" decimals="-6" id="f-1702" unitRef="eur">0</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-662" decimals="-6" id="f-1703" unitRef="eur">-19000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <sny:BusinessOperatingIncome contextRef="c-496" decimals="-6" id="f-1704" unitRef="eur">5220000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-646" decimals="-6" id="f-1705" unitRef="eur">850000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-661" decimals="-6" id="f-1706" unitRef="eur">-11000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-662" decimals="-6" id="f-1707" unitRef="eur">6059000000</sny:BusinessOperatingIncome>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-78" decimals="-6" id="f-1708" unitRef="eur">37890000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-82" decimals="-6" id="f-1709" unitRef="eur">5180000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-663" decimals="-6" id="f-1710" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-664" decimals="-6" id="f-1711" unitRef="eur">43070000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:OtherRevenue contextRef="c-78" decimals="-6" id="f-1712" unitRef="eur">3322000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-82" decimals="-6" id="f-1713" unitRef="eur">52000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-663" decimals="-6" id="f-1714" unitRef="eur">0</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-664" decimals="-6" id="f-1715" unitRef="eur">3374000000</ifrs-full:OtherRevenue>
    <ifrs-full:CostOfSales contextRef="c-78" decimals="-6" id="f-1716" unitRef="eur">12282000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-82" decimals="-6" id="f-1717" unitRef="eur">1933000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-663" decimals="-6" id="f-1718" unitRef="eur">1000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-664" decimals="-6" id="f-1719" unitRef="eur">14216000000</ifrs-full:CostOfSales>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-78" decimals="-6" id="f-1720" unitRef="eur">6509000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-82" decimals="-6" id="f-1721" unitRef="eur">219000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-663" decimals="-6" id="f-1722" unitRef="eur">0</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-664" decimals="-6" id="f-1723" unitRef="eur">6728000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-78" decimals="-6" id="f-1724" unitRef="eur">8868000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-82" decimals="-6" id="f-1725" unitRef="eur">1828000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-663" decimals="-6" id="f-1726" unitRef="eur">-4000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-664" decimals="-6" id="f-1727" unitRef="eur">10692000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-78" decimals="-6" id="f-1728" unitRef="eur">-2387000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-82" decimals="-6" id="f-1729" unitRef="eur">181000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-663" decimals="-6" id="f-1730" unitRef="eur">-18000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-664" decimals="-6" id="f-1731" unitRef="eur">-2224000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-78" decimals="-6" id="f-1732" unitRef="eur">101000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-82" decimals="-6" id="f-1733" unitRef="eur">21000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-663" decimals="-6" id="f-1734" unitRef="eur">0</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-664" decimals="-6" id="f-1735" unitRef="eur">122000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-78" decimals="-6" id="f-1736" unitRef="eur">-20000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-82" decimals="-6" id="f-1737" unitRef="eur">-16000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-663" decimals="-6" id="f-1738" unitRef="eur">0</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-664" decimals="-6" id="f-1739" unitRef="eur">-36000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <sny:BusinessOperatingIncome contextRef="c-78" decimals="-6" id="f-1740" unitRef="eur">11247000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-82" decimals="-6" id="f-1741" unitRef="eur">1438000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-663" decimals="-6" id="f-1742" unitRef="eur">-15000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-664" decimals="-6" id="f-1743" unitRef="eur">12670000000</sny:BusinessOperatingIncome>
    <sny:DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock contextRef="c-1" id="f-1744">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below, presented in compliance with IFRS 8, shows a reconciliation between &#x201c;Business operating income&#x201d; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024 ( 6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023 ( 6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023 (12 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,656&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;6,059&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;12,670&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Share of profit/(loss) from investments accounted for using the equity method &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Net income attributable to non-controlling interests &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortization and impairment of intangible assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Expense arising from the impact of acquisitions on inventories &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Restructuring costs and similar items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(547)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other gains and losses, and litigation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(442)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,044&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,322&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,875&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,739&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,238&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,153&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Joint ventures and associates with which Sanofi has entered into a strategic alliance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;As of June 30, 2024, this line includes a net reversal of impairment losses amounting to of &#x20ac;371&#160;million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights in the Biopharma segment. For 2023, this amount mainly comprises an impairment loss of &#x20ac;833&#160;million, reflecting the impact of the strategic decision to de-prioritize certain R&amp;amp;D programs, in particular those related to the NK Cell and PRO-XTEN technology platforms. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt"&gt;See note B.16.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt"&gt;See note B.17.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock>
    <sny:BusinessOperatingIncome contextRef="c-665" decimals="-6" id="f-1745" unitRef="eur">5656000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-666" decimals="-6" id="f-1746" unitRef="eur">6059000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-667" decimals="-6" id="f-1747" unitRef="eur">12670000000</sny:BusinessOperatingIncome>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-668" decimals="-6" id="f-1748" unitRef="eur">-75000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-669" decimals="-6" id="f-1749" unitRef="eur">-55000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-670" decimals="-6" id="f-1750" unitRef="eur">-122000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-668" decimals="-6" id="f-1751" unitRef="eur">11000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-669" decimals="-6" id="f-1752" unitRef="eur">19000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-670" decimals="-6" id="f-1753" unitRef="eur">36000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill contextRef="c-668" decimals="-6" id="f-1754" unitRef="eur">690000000</sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill>
    <sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill contextRef="c-669" decimals="-6" id="f-1755" unitRef="eur">1050000000</sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill>
    <sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill contextRef="c-670" decimals="-6" id="f-1756" unitRef="eur">3068000000</sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability contextRef="c-668" decimals="-6" id="f-1757" unitRef="eur">66000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability contextRef="c-669" decimals="-6" id="f-1758" unitRef="eur">26000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability contextRef="c-670" decimals="-6" id="f-1759" unitRef="eur">93000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories contextRef="c-668" decimals="-6" id="f-1760" unitRef="eur">19000000</sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories>
    <sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories contextRef="c-669" decimals="-6" id="f-1761" unitRef="eur">5000000</sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories>
    <sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories contextRef="c-670" decimals="-6" id="f-1762" unitRef="eur">20000000</sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-668" decimals="-6" id="f-1763" unitRef="eur">1331000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-669" decimals="-6" id="f-1764" unitRef="eur">547000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-670" decimals="-6" id="f-1765" unitRef="eur">1490000000</ifrs-full:ExpenseOfRestructuringActivities>
    <sny:OtherGainsLossesAndLitigation contextRef="c-668" decimals="-6" id="f-1766" unitRef="eur">-442000000</sny:OtherGainsLossesAndLitigation>
    <sny:OtherGainsLossesAndLitigation contextRef="c-669" decimals="-6" id="f-1767" unitRef="eur">-73000000</sny:OtherGainsLossesAndLitigation>
    <sny:OtherGainsLossesAndLitigation contextRef="c-670" decimals="-6" id="f-1768" unitRef="eur">-38000000</sny:OtherGainsLossesAndLitigation>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-1" decimals="-6" id="f-1769" unitRef="eur">3044000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-4" decimals="-6" id="f-1770" unitRef="eur">4322000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-5" decimals="-6" id="f-1771" unitRef="eur">7875000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-6" id="f-1772" unitRef="eur">586000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-4" decimals="-6" id="f-1773" unitRef="eur">370000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-5" decimals="-6" id="f-1774" unitRef="eur">1313000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-6" id="f-1775" unitRef="eur">281000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-4" decimals="-6" id="f-1776" unitRef="eur">286000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-5" decimals="-6" id="f-1777" unitRef="eur">591000000</ifrs-full:FinanceIncome>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-1778" unitRef="eur">2739000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-4" decimals="-6" id="f-1779" unitRef="eur">4238000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-5" decimals="-6" id="f-1780" unitRef="eur">7153000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:NetReversalOfImpairmentLoss contextRef="c-1" decimals="-6" id="f-1781" unitRef="eur">371000000</sny:NetReversalOfImpairmentLoss>
    <sny:NetReversalOfImpairmentLoss contextRef="c-4" decimals="-6" id="f-1782" unitRef="eur">833000000</sny:NetReversalOfImpairmentLoss>
    <sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock contextRef="c-1" id="f-1783">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024 (6 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Opella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments accounted for using the equity method &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Carrying amount at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023 (6 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Opella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments accounted for using the equity method &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of other intangible assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Carrying amount at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.706%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023 (12 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Opella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments accounted for using the equity method &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-671" decimals="-6" id="f-1784" unitRef="eur">229000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-672" decimals="-6" id="f-1785" unitRef="eur">14000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-673" decimals="-6" id="f-1786" unitRef="eur">243000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-77" decimals="-6" id="f-1787" unitRef="eur">882000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-81" decimals="-6" id="f-1788" unitRef="eur">68000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-660" decimals="-6" id="f-1789" unitRef="eur">950000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-77" decimals="-6" id="f-1790" unitRef="eur">922000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-81" decimals="-6" id="f-1791" unitRef="eur">14000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-660" decimals="-6" id="f-1792" unitRef="eur">936000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-674" decimals="-6" id="f-1793" unitRef="eur">231000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-675" decimals="-6" id="f-1794" unitRef="eur">10000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-676" decimals="-6" id="f-1795" unitRef="eur">241000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-496" decimals="-6" id="f-1796" unitRef="eur">751000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-677" decimals="-6" id="f-1797" unitRef="eur">31000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-662" decimals="-6" id="f-1798" unitRef="eur">782000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-496" decimals="-6" id="f-1799" unitRef="eur">132000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-677" decimals="-6" id="f-1800" unitRef="eur">16000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-662" decimals="-6" id="f-1801" unitRef="eur">148000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-678" decimals="-6" id="f-1802" unitRef="eur">234000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-679" decimals="-6" id="f-1803" unitRef="eur">28000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-680" decimals="-6" id="f-1804" unitRef="eur">262000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-78" decimals="-6" id="f-1805" unitRef="eur">1619000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-82" decimals="-6" id="f-1806" unitRef="eur">100000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-664" decimals="-6" id="f-1807" unitRef="eur">1719000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-78" decimals="-6" id="f-1808" unitRef="eur">1287000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-82" decimals="-6" id="f-1809" unitRef="eur">18000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-664" decimals="-6" id="f-1810" unitRef="eur">1305000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:DisclosureOfGeographicalAreasExplanatory contextRef="c-1" id="f-1811">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.188%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2024  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;of which France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other countries&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21,209&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,882&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,082&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;9,067&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,260&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt"&gt;property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt"&gt;goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt"&gt;other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.266%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.230%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;June 30, 2023  (6 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;of which France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other countries&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;20,187&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,034&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,174&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,988&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;7,165&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt"&gt;property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt"&gt;goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt"&gt;other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.266%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.230%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023  (12 months)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;of which France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other countries&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;43,070&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;10,392&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,379&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;18,512&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;14,166&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt"&gt;property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt"&gt;goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.61pt"&gt;other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e8eaf6;border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeographicalAreasExplanatory>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-681" decimals="-6" id="f-1812" unitRef="eur">21209000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-653" decimals="-6" id="f-1813" unitRef="eur">4882000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-682" decimals="-6" id="f-1814" unitRef="eur">1082000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-654" decimals="-6" id="f-1815" unitRef="eur">9067000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-683" decimals="-6" id="f-1816" unitRef="eur">7260000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-684" decimals="-6" id="f-1817" unitRef="eur">10264000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-685" decimals="-6" id="f-1818" unitRef="eur">5611000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-686" decimals="-6" id="f-1819" unitRef="eur">3079000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-687" decimals="-6" id="f-1820" unitRef="eur">2377000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-688" decimals="-6" id="f-1821" unitRef="eur">2276000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:Goodwill contextRef="c-684" decimals="-6" id="f-1822" unitRef="eur">50080000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-685" decimals="-6" id="f-1823" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-686" decimals="-6" id="f-1824" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-687" decimals="-6" id="f-1825" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-688" decimals="-6" id="f-1826" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-684" decimals="-6" id="f-1827" unitRef="eur">26653000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-685" decimals="-6" id="f-1828" unitRef="eur">5156000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-686" decimals="-6" id="f-1829" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-687" decimals="-6" id="f-1830" unitRef="eur">20726000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-688" decimals="-6" id="f-1831" unitRef="eur">771000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-689" decimals="-6" id="f-1832" unitRef="eur">20187000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-656" decimals="-6" id="f-1833" unitRef="eur">5034000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-690" decimals="-6" id="f-1834" unitRef="eur">1174000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-657" decimals="-6" id="f-1835" unitRef="eur">7988000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-691" decimals="-6" id="f-1836" unitRef="eur">7165000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-692" decimals="-6" id="f-1837" unitRef="eur">9804000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-693" decimals="-6" id="f-1838" unitRef="eur">5462000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-694" decimals="-6" id="f-1839" unitRef="eur">2921000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-695" decimals="-6" id="f-1840" unitRef="eur">2364000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-696" decimals="-6" id="f-1841" unitRef="eur">1978000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:Goodwill contextRef="c-692" decimals="-6" id="f-1842" unitRef="eur">49243000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-693" decimals="-6" id="f-1843" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-694" decimals="-6" id="f-1844" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-695" decimals="-6" id="f-1845" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-696" decimals="-6" id="f-1846" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-692" decimals="-6" id="f-1847" unitRef="eur">24590000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-693" decimals="-6" id="f-1848" unitRef="eur">5961000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-694" decimals="-6" id="f-1849" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-695" decimals="-6" id="f-1850" unitRef="eur">17595000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-696" decimals="-6" id="f-1851" unitRef="eur">1034000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-697" decimals="-6" id="f-1852" unitRef="eur">43070000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-698" decimals="-6" id="f-1853" unitRef="eur">10392000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-699" decimals="-6" id="f-1854" unitRef="eur">2379000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-700" decimals="-6" id="f-1855" unitRef="eur">18512000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-701" decimals="-6" id="f-1856" unitRef="eur">14166000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-702" decimals="-6" id="f-1857" unitRef="eur">10160000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-703" decimals="-6" id="f-1858" unitRef="eur">5659000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-704" decimals="-6" id="f-1859" unitRef="eur">3085000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-705" decimals="-6" id="f-1860" unitRef="eur">2322000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-706" decimals="-6" id="f-1861" unitRef="eur">2179000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:Goodwill contextRef="c-702" decimals="-6" id="f-1862" unitRef="eur">49404000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-703" decimals="-6" id="f-1863" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-704" decimals="-6" id="f-1864" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-705" decimals="-6" id="f-1865" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-706" decimals="-6" id="f-1866" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-702" decimals="-6" id="f-1867" unitRef="eur">24319000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-703" decimals="-6" id="f-1868" unitRef="eur">5566000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-704" decimals="-6" id="f-1869" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-705" decimals="-6" id="f-1870" unitRef="eur">17850000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-706" decimals="-6" id="f-1871" unitRef="eur">903000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-707"
      decimals="2"
      id="f-1872"
      unitRef="number">0.29</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-708"
      decimals="2"
      id="f-1873"
      unitRef="number">0.13</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-709"
      decimals="2"
      id="f-1874"
      unitRef="number">0.09</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-710"
      decimals="2"
      id="f-1875"
      unitRef="number">0.07</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-711"
      decimals="2"
      id="f-1876"
      unitRef="number">0.11</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-712"
      decimals="2"
      id="f-1877"
      unitRef="number">0.09</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-713"
      decimals="2"
      id="f-1878"
      unitRef="number">0.07</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c-1" id="f-1879">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.492%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #7802e6;border-top:1pt solid #7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:12pt;margin-top:9pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%"&gt;C/ EVENTS SUBSEQUENT TO JUNE 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;No significant events occurred between the end of the reporting period and the date on which the condensed consolidated financial statements were signed off by the Board of Directors.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
